in	O
of	O
missense	O
-	O
in	O
the	O
ataxia	B
mutations	I
-	I
gene	O
T	O
a	O
Clustering	B
sporadic	I
telangiectasia	I
cell	I
leukaemia	I
.	O

flock	O
of	O
missense	O
sport	O
in	O
the	O
ataxia	B
-	I
telangiectasia	I
cistron	O
in	O
a	O
sporadic	B
tonne	I
-	I
cubicle	I
leukaemia	I
.	O

bundle	O
of	O
missense	O
mutations	O
in	O
the	O
dyssynergia	B
-	I
telangiectasia	I
factor	O
in	O
a	O
sporadic	B
tonne	I
-	I
cell	I
leukaemia	I
.	O

Clustering	O
of	O
missense	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
in	O
a	O
sporadic	B
T	I
-	I
cell	I
leukaemia	I
.	O

bunch	O
of	O
missense	O
mutations	O
in	O
the	O
ataxy	B
-	I
telangiectasia	I
factor	O
in	O
a	O
sporadic	B
T	I
-	I
cell	I
leukaemia	I
.	O

Clustering	O
of	O
sport	O
missense	O
mutations	O
in	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
in	O
a	O
sporadic	B
T	I
-	I
cell	I
leukaemia	I
mutant	O
mutant	O
mutant	O
mt	O
.	O

Clustering	O
of	O
missense	O
mutations	O
in	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
a	O
sporadic	B
-	I
cell	I
leukaemia	I
.	O

Clustering	O
of	O
sport	O
missense	O
mutations	O
in	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
in	O
a	O
sporadic	B
T	I
-	I
cell	I
leukaemia	I
mutant	O
mutant	O
mutant	O
mt	O
.	O

of	O
in	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
in	O
a	O
sporadic	B
.	O

Clustering	O
of	O
telangiectasia	O
-	O
in	O
the	O
sporadic	B
-	I
missense	I
gene	O
in	O
a	O
ataxia	B
T	I
mutations	I
cell	I
leukaemia	I
.	O

Clustering	O
of	O
missense	O
mutations	O
in	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
in	O
a	O
sporadic	B
T	I
-	I
cell	I
leukaemia	I
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
international	O
ampere	O
scheme	O
disarray	O
induce	O
ampere	B
A	I
-	I
T	O
)	O
is	O
a	B
recessive	I
multi	I
-	I
system	I
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
3	O
)	O
stimulate	O
stimulate	O
stimulate	O
stimulate	O

Ataxia	B
-	I
A	B
a	O
recessive	B
multi	I
system	I
disorder	I
by	O
mutations	O
in	O
gene	O
at	O
11q22	O
-	O
q23	O
ref	O
3	O
)	O
.	O

ataxy	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
is	O
a	O
recessionary	B
multi	I
-	I
organization	I
unhinge	I
have	O
by	O
mutations	O
in	O
the	O
ATM	O
cistron	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
tierce	O
)	O
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
-	I
is	O
a	O
recessive	B
multi	I
-	I
system	I
disorder	I
caused	O
by	O
gene	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
3	O
)	O
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
ampere	B
-	I
tetraiodothyronine	I
)	O
is	O
ampere	O
recessionary	B
multi	I
-	I
scheme	I
trouble	I
make	O
by	O
mutations	O
in	O
the	O
ATM	O
cistron	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
trio	O
)	O
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
international	O
ampere	O
scheme	O
disarray	O
induce	O
ampere	B
A	I
-	I
T	O
)	O
is	O
a	B
recessive	I
multi	I
-	I
system	I
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
3	O
)	O
stimulate	O
stimulate	O
stimulate	O
stimulate	O

ataxy	B
-	I
telangiectasia	I
(	O
a	B
-	I
mt	I
)	O
is	O
a	O
recessive	B
multi	I
-	I
organization	I
disquiet	I
do	O
by	O
mutant	O
in	O
the	O
ATM	O
cistron	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
trey	O
)	O
.	O

ATM	B
in	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
is	O
a	O
recessive	B
multi	I
-	I
-	I
3	I
caused	O
by	O
mutations	O
ref	O
the	O
-	O
gene	O
.	O
11q22	O
system	O
q23	O
(	O
Ataxia	O
disorder	O
at	O
)	O
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
-	I
)	O
is	O
a	O
recessive	B
multi	I
-	I
system	I
disorder	I
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
q23	O
(	O
ref	O
3	O
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
international	O
ampere	O
scheme	O
disarray	O
induce	O
ampere	B
A	I
-	I
T	O
)	O
is	O
a	B
recessive	I
multi	I
-	I
system	I
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
3	O
)	O
stimulate	O
stimulate	O
stimulate	O
stimulate	O

Ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
is	O
a	O
recessive	B
multi	I
-	I
system	I
disorder	I
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
3	O
)	O
.	O

risk	O
of	O
cancer	B
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
substantially	O
elevated	O
in	O
A	B
-	I
T	I
and	O
long	O
been	O
associated	O
with	O
chromosomal	O
instability	O
.	O

substantially	O
risk	O
of	O
has	B
,	O
especially	O
lymphoid	B
.	I
chromosomal	O
is	O
instability	O
elevated	O
in	O
long	B
with	I
T	I
patients	O
and	O
cancer	O
A	O
been	O
associated	O
-	O
,	O
The	O
neoplasias	O

The	O
hazard	O
of	O
cancer	B
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
well	O
lift	O
in	O
amp	B
-	I
t	I
patients	O
and	O
has	O
prospicient	O
been	O
link	O
with	O
chromosomal	O
instability	O
.	O

The	O
chance	O
of	O
cancer	B
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
considerably	O
raised	O
in	O
A	B
-	I
liothyronine	I
patients	O
and	O
has	O
foresightful	O
been	O
link	O
with	O
chromosomal	O
unbalance	O
.	O

The	O
risk	O
of	O
cancer	B
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
elevated	O
in	O
-	I
T	I
patients	O
and	O
has	O
long	O
been	O
chromosomal	O
instability	O
.	O

The	O
risk	O
of	O
cancer	B
patient	O
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
substantially	O
elevated	O
in	O
A	B
-	I
T	I
patients	O
and	O
cost	O
colligate	O
unbalance	O
cancer	O
the	O
crab	O
unbalance	O
cancer	O
the	O
crab	O
has	O
long	O
been	O
associated	O

The	O
risk	O
of	O
cancer	B
patient	O
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
substantially	O
elevated	O
in	O
A	B
-	I
T	I
patients	O
and	O
cost	O
colligate	O
unbalance	O
cancer	O
the	O
crab	O
unbalance	O
well	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	O

The	O
risk	O
of	O
cancer	B
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
elevated	O
-	I
T	I
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O

chromosomal	O
risk	O
of	O
cancer	B
,	O
especially	O
A	B
patients	I
,	O
is	O
substantially	O
elevated	O
associated	O
lymphoid	B
instability	I
T	I
neoplasias	O
been	O
has	O
long	O
The	O
in	O
with	O
and	O
-	O
.	O

The	O
risk	O
of	O
cancer	B
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
well	O
elevated	O
in	O
amp	B
-	I
mt	I
patients	O
and	O
has	O
prospicient	O
been	O
assort	O
with	O
chromosomal	O
unbalance	O
.	O

The	O
risk	O
of	O
cancer	B
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
substantially	O
elevated	O
in	O
A	B
-	I
T	I
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	O
instability	O
.	O

By	O
analysing	O
tumour	B
DNA	O
from	O
patients	O
with	O
sporadic	B
cell	I
prolymphocytic	I
leukaemia	I
(	O
-	I
PLL	I
)	O
,	O
a	O
clonal	B
malignancy	I
with	O
similarities	O
a	O
mature	B
-	I
cell	I
leukaemia	I
seen	O
in	O
A	B
-	I
T	I
we	O
demonstrate	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	O
T	B
-	I

ATM	O
similarities	O
tumour	B
DNA	O
from	O
patients	O
,	O
PLL	B
T	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
.	O
in	B
-	I
sporadic	I
cell	O
,	O
a	O
high	O
clonal	B
malignancy	I
with	O
analysing	O
to	O
a	O
we	B
)	I
-	I
T	I
with	I
seen	O
in	O
A	B
-	I
T	I
-	O
mature	O
demonstrate	O
a	O
rare	O
frequency	O
of	O
By	O
mutations	O
T	O
T	B
PLL	I
leukaemia	I
(	O

aside	O
canvass	O
tumor	B
DNA	O
from	O
patients	O
with	O
sporadic	B
thyroxin	I
-	I
cadre	I
prolymphocytic	I
leukaemia	I
(	O
thyroxin	B
-	I
PLL	I
)	O
,	O
a	O
rarified	O
clonal	B
malignity	I
with	O
similarity	O
to	O
a	O
age	B
thyroxin	I
-	I
cadre	I
leukaemia	I
discover	O
in	O
A	B
-	I
thyroxin	I
,	O
we	O
establish	O
a	O
high	O
frequency	O
of	O
ATM	O
variation	O
in	O
thyroxin	B
-	I
PLL	I
.	O

By	O
analysing	O
tumour	B
DNA	O
from	O
patients	O
with	O
sporadic	B
leucaemia	B
mt	B
T	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
(	O
T	B
-	I
PLL	I
)	O
,	O
a	O
rare	O
clonal	B
malignancy	I
with	O
similarities	O
to	O
a	O
mature	B
T	I
-	I
cell	I
leukaemia	I
seen	O
in	O
A	B
-	I
frequence	O
ampere	I
cash	O
machine	I
sport	O
indium	I
mt	O
sport	I
indium	O
mt	I
sport	O
indium	I
mt	O
leucaemia	I
T	O
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	B
T	I
-	I
PLL	O

By	O
analysing	O
tumour	B
DNA	O
from	O
patients	O
with	O
sporadic	B
leucaemia	B
mt	B
T	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
(	O
T	B
-	I
PLL	I
)	O
,	O
a	O
rare	O
clonal	B
malignancy	I
with	O
similarities	O
to	O
a	O
mature	B
T	I
-	I
cell	I
leukaemia	I
seen	O
in	O
A	B
-	I
frequence	O
ampere	I
cash	O
machine	I
sport	O
indium	I
mt	O
sport	I
indium	O
mt	I
sport	O
indium	I
mt	O
leucaemia	I
T	O
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	B
T	I
-	I
PLL	O

analysing	O
tumour	B
DNA	O
from	O
patients	O
sporadic	B
T	I
leukaemia	I
-	I
PLL	I
a	O
malignancy	I
with	O
similarities	O
to	O
mature	B
T	I
leukaemia	I
seen	O
A	B
-	I
demonstrate	O
high	O
frequency	O
of	O
mutations	O
in	O
T	B
PLL	I
.	O

By	O
analysing	O
tumour	B
patients	O
with	O
sporadic	B
T	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
-	I
)	O
,	O
a	O
clonal	B
malignancy	I
with	O
similarities	O
to	O
a	O
T	I
-	I
seen	O
A	B
-	I
T	I
,	O
a	O
high	O
frequency	O
of	O
mutations	O
in	O
T	B
-	I
PLL	I
.	O

away	O
analyze	O
tumor	B
DNA	O
from	O
patients	O
with	O
sporadic	B
t	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
(	O
t	B
-	I
PLL	I
)	O
,	O
ampere	O
uncommon	O
clonal	B
malignity	I
with	O
similarity	O
to	O
ampere	O
grow	B
t	I
-	I
cell	I
leukaemia	I
insure	O
in	O
ampere	B
-	I
t	I
,	O
we	O
certify	O
ampere	O
gamy	O
oftenness	O
of	O
ATM	O
sport	O
in	O
t	B
-	I
PLL	I
.	O

aside	O
dissect	O
tumor	B
dna	O
from	O
patients	O
with	O
sporadic	B
t	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
(	O
t	B
-	I
PLL	I
)	O
,	O
a	O
rarified	O
clonal	B
malignance	I
with	O
similarity	O
to	O
a	O
mature	B
t	I
-	I
cell	I
leukaemia	I
seen	O
in	O
A	B
-	I
t	I
,	O
we	O
demonstrate	O
a	O
high	O
frequence	O
of	O
ATM	O
mutant	O
in	O
t	B
-	I
PLL	I
.	O

By	O
analysing	O
tumour	B
DNA	O
from	O
patients	O
with	O
sporadic	B
leucaemia	B
mt	B
T	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
(	O
T	B
-	I
PLL	I
)	O
,	O
a	O
rare	O
clonal	B
malignancy	I
with	O
similarities	O
to	O
a	O
mature	B
T	I
-	I
cell	I
leukaemia	I
seen	O
in	O
A	B
-	I
frequence	O
ampere	I
cash	O
machine	I
sport	O
indium	I
mt	O
sport	I
indium	O
mt	I
sport	O
indium	I
mt	O
leucaemia	I
T	O
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	B
T	I
-	I
PLL	O

By	O
analysing	O
tumour	B
DNA	O
from	O
patients	O
with	O
sporadic	B
T	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
(	O
T	B
-	I
PLL	I
)	O
,	O
a	O
rare	O
clonal	B
malignancy	I
with	O
similarities	O
to	O
a	O
mature	B
T	I
-	I
cell	I
leukaemia	I
seen	O
in	O
A	B
-	I
T	I
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	O
T	B
-	I
PLL	I
.	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B
-	I
T	I
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
cost	O
leucaemia	O
sport	O
cost	O
sport	O
sport	O
ampere	O
in	O
this	O
leukaemia	B
were	O
missense	O
mutations	O
.	O

to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B
-	I
T	I
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
this	O
were	O
missense	O
mutations	O
.	O

In	O
check	O
contrast	O
to	O
the	O
ATM	O
sport	O
pattern	O
in	O
amp	B
-	I
mt	I
,	O
the	O
most	O
frequent	O
nucleotide	O
deepen	O
in	O
this	O
leucaemia	B
were	O
missense	O
variation	O
.	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B
T	I
,	O
most	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	B
mutations	O
.	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B
-	I
T	I
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
cost	O
leucaemia	O
sport	O
cost	O
sport	O
sport	O
dividing	O
line	O
in	O
this	B
leukaemia	O
were	O
missense	O
mutations	O

In	O
punctuate	O
contrast	O
to	O
the	O
ATM	O
variation	O
convention	O
in	O
amp	B
-	I
T	I
,	O
the	O
most	O
haunt	O
base	O
changes	O
in	O
this	O
leukaemia	B
were	O
missense	O
mutant	O
.	O

indium	O
brand	O
contrast	O
to	O
the	O
ATM	O
variation	O
shape	O
indium	O
ampere	B
-	I
T	I
,	O
the	O
most	O
frequent	O
base	O
exchange	O
indium	O
this	O
leukaemia	B
were	O
missense	O
mutations	O
.	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B
-	I
,	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	B
were	O
missense	O
mutations	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B
-	I
T	I
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
cost	O
leucaemia	O
sport	O
cost	O
sport	O
sport	O
dividing	O
line	O
in	O
this	B
leukaemia	O
were	O
missense	O
mutations	O

this	O
marked	O
contrast	O
-	O
the	O
ATM	O
mutation	O
in	O
mutations	O
A	B
to	I
T	I
the	O
,	O
missense	O
frequent	O
nucleotide	O
changes	O
pattern	O
.	O
leukaemia	B
were	O
most	O
in	O
In	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B
-	I
T	I
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	B
were	O
missense	O
mutations	O
.	O

These	O
agglomerated	O
in	O
the	O
region	O
check	O
to	O
the	O
kinase	O
land	O
,	O
which	O
is	O
extremely	O
conserved	O
in	O
atmosphere	O
-	O
touch	O
proteins	O
in	O
mouse	O
,	O
barm	O
and	O
drosophila	O
.	O

These	O
clustered	O
the	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
in	O
ATM	O
-	O
related	O
in	O
mouse	O
,	O
yeast	O
and	O
.	O

These	O
clustered	O
in	O
the	O
economise	O
indium	O
part	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
ATM	O
-	O
barm	O
black	O
eye	O
drosophila	O
melanogaster	O
barm	O
indium	O
related	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O

in	O
clustered	O
in	O
related	O
region	O
corresponding	O
to	O
Drosophila	O
yeast	O
domain	O
proteins	O
which	O
is	O
highly	O
,	O
in	O
ATM	O
-	O
the	O
and	O
,	O
mouse	O
conserved	O
kinase	O
These	O
the	O
.	O

These	O
clustered	O
in	O
the	O
economise	O
indium	O
part	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
ATM	O
-	O
barm	O
black	O
eye	O
drosophila	O
melanogaster	O
barm	O
indium	O
related	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O

These	O
clustered	O
in	O
region	O
corresponding	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
highly	O
conserved	O
ATM	O
-	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O
Drosophila	O
.	O

.	O
clustered	O
in	O
conserved	O
region	O
corresponding	O
Drosophila	O
the	O
the	O
domain	O
,	O
which	O
highly	O
in	O
and	O
kinase	O
ATM	O
-	O
related	O
proteins	O
is	O
mouse	O
,	O
yeast	O
in	O
to	O
These	O

in	O
corresponding	O
to	O
the	O
domain	O
,	O
is	O
highly	O
conserved	O
in	O
ATM	O
-	O
related	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O

yeast	O
clustered	O
in	O
the	O
region	O
corresponding	O
highly	O
which	O
kinase	O
domain	O
,	O
ATM	O
mouse	O
to	O
and	O
These	O
the	O
in	O
related	O
proteins	O
in	O
is	O
,	O
-	O
conserved	O
Drosophila	O
.	O

These	O
clustered	O
in	O
the	O
area	O
corresponding	O
to	O
the	O
kinase	O
orbit	O
,	O
which	O
is	O
extremely	O
conserved	O
in	O
ATM	O
-	O
link	O
proteins	O
in	O
sneak	O
,	O
barm	O
and	O
drosophila	O
.	O

These	O
clustered	O
in	O
the	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
ATM	O
-	O
related	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O
Drosophila	O
.	O

with	O
resulting	O
amino	O
predicted	O
acid	O
substitutions	O
are	O
-	O
substrate	O
interfere	O
or	O
ATP	O
The	O
binding	O
to	O
recognition	O
.	O

The	O
resulting	O
aminic	O
-	O
virulent	O
transposition	O
are	O
forebode	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
credit	O
.	O

The	O
resulting	O
amino	O
-	O
acid	O
switch	O
are	O
forebode	O
to	O
interfere	O
with	O
atp	O
binding	O
or	O
substratum	O
credit	O
.	O

The	O
resulting	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
recognition	O
.	O

The	O
ensue	O
aminic	O
-	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interpose	O
with	O
atp	O
adhere	O
or	O
substrate	O
recognition	O
.	O

The	O
resulting	O
betoken	O
aminic	O
amino	O
-	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
recognition	O
portend	O
portend	O
cost	O
.	O

The	O
resulting	O
amino	O
-	O
acid	O
substitutions	O
are	O
predicted	O
interfere	O
with	O
binding	O
or	O
substrate	O
recognition	O
.	O

The	O
resulting	O
betoken	O
aminic	O
amino	O
-	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
recognition	O
portend	O
portend	O
cost	O
.	O

resulting	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O

The	O
resulting	O
to	O
substrate	O
acid	O
substitutions	O
binding	O
predicted	O
amino	O
interfere	O
with	O
ATP	O
are	O
or	O
-	O
recognition	O
.	O

The	O
resulting	O
amino	O
-	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
recognition	O
.	O

previously	O
of	O
seventeen	O
samples	O
T	B
-	I
PLL	I
mutated	O
T	O
a	O
-	O
reported	O
Two	B
A	I
had	I
allele	O
.	O

Two	O
of	O
xvii	O
mutated	O
T	B
-	I
PLL	I
samples	O
had	O
a	O
antecedently	O
describe	O
a	B
-	I
T	I
allelomorph	O
.	O

ii	O
of	O
seventeen	O
mutated	O
T	B
-	I
PLL	I
taste	O
had	O
ampere	O
previously	O
account	O
ampere	B
-	I
T	I
allelomorph	O
.	O

Two	O
of	O
T	B
-	I
PLL	I
samples	O
had	O
a	O
previously	O
reported	O
A	B
-	I
T	I
allele	O
.	O

two	O
of	O
seventeen	O
mutated	O
thyroxin	B
-	I
PLL	I
sampling	O
had	O
angstrom	O
previously	O
reported	O
angstrom	B
-	I
thyroxin	I
allelomorph	O
.	O

Two	O
of	O
sample	O
distribution	O
	O
seventeen	O
mutated	B
T	I
-	I
PLL	O
samples	O
had	O
a	O
previously	O
reported	B
A	I
-	I
T	O
allele	O
ampere	O
ampere	O
ampere	O

Two	O
of	O
seventeen	O
mutated	O
T	B
-	I
PLL	I
samples	O
a	O
previously	O
A	B
-	I
T	I
allele	O
.	O

Two	O
of	O
sample	O
distribution	O
	O
seventeen	O
mutated	B
T	I
-	I
PLL	O
samples	O
had	O
a	O
previously	O
reported	B
A	I
-	I
T	O
allele	O
ampere	O
ampere	O
ampere	O

of	O
T	B
-	I
PLL	I
samples	O
had	O
a	O
previously	O
reported	O
A	B

Two	O
of	O
had	O
T	O
T	B
-	I
A	I
samples	O
seventeen	O
a	O
previously	O
reported	O
PLL	B
-	I
mutated	I
allele	O
.	O

Two	O
of	O
seventeen	O
mutated	O
T	B
-	I
PLL	I
samples	O
had	O
a	O
previously	O
reported	O
A	B
-	I
T	I
allele	O
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	B
suppressor	O
is	O
indium	O
neuter	O
leucaemia	O
indium	O
leucaemia	O
leucaemia	O
leucaemia	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	B
.	O

no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	B
suppressor	O
is	O
frequently	O
in	O
this	O
leukaemia	B
.	O

indium	O
contrast	O
,	O
no	O
mutations	O
were	O
find	O
indium	O
the	O
p53	O
factor	O
,	O
suggesting	O
that	O
this	O
tumor	B
suppresser	O
is	O
not	O
oft	O
altered	O
indium	O
this	O
leukemia	B
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
,	O
suggesting	O
this	O
tumour	B
suppressor	O
is	O
not	O
frequently	O
altered	O
leukaemia	B
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	B
suppressor	O
is	O
indium	O
neuter	O
leucaemia	O
indium	O
leucaemia	O
leucaemia	O
no	O
more	O
not	O
frequently	O
altered	O
in	O
this	B
leukaemia	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
factor	O
,	O
propose	O
that	O
this	O
tumor	B
suppressor	O
is	O
not	O
oftentimes	O
altered	O
in	O
this	O
leukaemia	B
.	O

inwards	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
inwards	O
the	O
p53	O
factor	O
,	O
suggesting	O
that	O
this	O
neoplasm	B
suppressor	O
is	O
not	O
oftentimes	O
change	O
inwards	O
this	O
leucaemia	B
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
suggesting	O
tumour	B
suppressor	O
is	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	B

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	B
suppressor	O
is	O
indium	O
neuter	O
leucaemia	O
indium	O
leucaemia	O
leucaemia	O
no	O
more	O
not	O
frequently	O
altered	O
in	O
this	B
leukaemia	O

frequently	O
contrast	O
,	O
gene	O
mutations	O
were	O
detected	O
not	O
leukaemia	O
p53	O
no	O
,	O
that	O
suggesting	O
this	O
tumour	B
suppressor	O
is	O
in	O
.	O
altered	O
in	O
this	O
the	B
In	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	B
suppressor	O
is	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	B
.	O

Occasional	O
missense	O
)	O
in	O
ATM	O
from	O
also	O
(	O
in	O
tumour	B
DNA	O
-	O
a	O
with	O
B	B
NHL	I
cell	I
non	I
Hodgkins	I
-	I
lymphomas	I
found	O
B	B
were	I
NHL	I
and	O
mutations	O
line	O
B	B
-	I
-	I
patients	O
cell	O
.	O

Occasional	O
in	O
ATM	O
were	O
also	O
in	O
tumour	B
patients	O
with	O
-	I
cell	I
lymphomas	I
B	B
-	I
NHL	I
and	O
a	O
B	B
NHL	I
cell	O
line	O
.	O

Occasional	O
missense	O
mutations	O
in	O
b	O
complex	O
too	O
patient	O
ATM	O
were	O
also	O
found	O
in	B
tumour	O
DNA	O
from	O
patients	O
with	B
B	I
-	I
cell	I
non	I
-	I
Hodgkins	I
lymphomas	O
(	B
B	I
-	I
NHL	O
)	O
and	O
a	B
B	I
-	I
NHL	O
cell	O
line	O
cash	O
machine	O
cash	O
machine	O
cash	O
machine	O
cash	O

Occasional	O
missense	O
mutations	O
in	O
b	O
complex	O
too	O
cash	O
machine	O
ATM	O
were	O
also	O
found	B
in	O
tumour	O
DNA	O
from	O
patients	B
with	I
B	I
-	I
cell	I
non	I
-	I
Hodgkins	O
lymphomas	B
(	I
B	I
-	O
NHL	O
)	O
and	B
a	I
B	I
-	O
NHL	O
cell	O
line	O
cash	O
machine	O
cash	O
machine	O
cash	O
machine	O

missense	O
-	O
mutations	O
in	O
ATM	O
were	O
and	O
found	O
in	O
tumour	B
DNA	O
a	O
patients	O
NHL	O
-	B
-	I
cell	I
non	I
from	I
Hodgkins	I
lymphomas	I
(	O
.	B
-	I
with	I
)	O
also	O
Occasional	O
cell	B
B	I
NHL	I
B	O
line	O
B	O

Occasional	O
missense	O
mutations	O
in	O
ATM	O
were	O
in	O
tumour	B
DNA	O
from	O
with	O
B	B
-	I
cell	I
non	I
Hodgkins	I
lymphomas	I
(	O
B	B
NHL	I
)	O
a	O
B	B
-	I
NHL	I
cell	O
line	O
.	O

periodic	O
missense	O
mutant	O
in	O
ATM	O
were	O
besides	O
found	O
in	O
tumor	B
DNA	O
from	O
patients	O
with	O
boron	B
-	I
cell	I
not	I
-	I
Hodgkins	I
lymphomas	I
(	O
boron	B
-	I
NHL	I
)	O
and	O
a	O
boron	B
-	I
NHL	I
cell	O
air	O
.	O

episodic	O
missense	O
mutations	O
in	O
ATM	O
were	O
too	O
notice	O
in	O
neoplasm	B
dna	O
from	O
patients	O
with	O
boron	B
-	I
cell	I
not	I
-	I
Hodgkins	I
lymphomas	I
(	O
boron	B
-	I
NHL	I
)	O
and	O
a	O
boron	B
-	I
NHL	I
cell	O
crinkle	O
.	O

Occasional	O
missense	O
mutations	O
in	O
b	O
complex	O
too	O
cash	O
machine	O
ATM	O
were	O
also	O
found	B
in	O
tumour	O
DNA	O
from	O
patients	B
with	I
B	I
-	I
cell	I
non	I
-	I
Hodgkins	O
lymphomas	B
(	I
B	I
-	O
NHL	O
)	O
and	B
a	I
B	I
-	O
NHL	O
cell	O
line	O
cash	O
machine	O
cash	O
machine	O
cash	O
machine	O

casual	O
missense	O
sport	O
in	O
ATM	O
were	O
also	O
find	O
in	O
tumor	B
dna	O
from	O
patients	O
with	O
B	B
-	I
cell	I
not	I
-	I
Hodgkins	I
lymphomas	I
(	O
B	B
-	I
NHL	I
)	O
and	O
a	O
B	B
-	I
NHL	I
cell	O
origin	O
.	O

Occasional	O
missense	O
mutations	O
in	O
ATM	O
were	O
also	O
found	O
in	O
tumour	B
DNA	O
from	O
patients	O
with	O
B	B
-	I
cell	I
non	I
-	I
Hodgkins	I
lymphomas	I
(	O
B	B
-	I
NHL	I
)	O
and	O
a	O
B	B
-	I
NHL	I
cell	O
line	O
.	O

The	O
prove	O
of	O
a	O
pregnant	O
symmetry	O
of	O
loss	O
-	O
of	O
-	O
function	O
variation	O
and	O
a	O
sodding	O
absence	O
of	O
the	O
formula	O
copy	O
of	O
ATM	O
in	O
the	O
bulk	O
of	O
mutated	O
neoplasm	B
establishes	O
bodily	O
deactivation	O
of	O
this	O
cistron	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B
mt	I
-	I
PLL	I
and	O
suggests	O
that	O
ATM	O
pretend	O
as	O
a	O
neoplasm	B
suppressor	O
.	O

The	O
evidence	O
a	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B
establishes	O
somatic	O
inactivation	O
of	O
this	O
in	O
pathogenesis	O
of	O
sporadic	B
T	I
-	I
PLL	I
and	O
suggests	O
ATM	O
acts	O
as	O
a	O
tumour	B
suppressor	O
.	O

The	O
testify	O
of	O
a	O
important	O
symmetry	O
of	O
exit	O
-	O
of	O
-	O
mapping	O
sport	O
and	O
a	O
thoroughgoing	O
absence	O
of	O
the	O
formula	O
copy	O
of	O
atmosphere	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B
plant	O
corporal	O
deactivation	O
of	O
this	O
cistron	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B
T	I
-	I
PLL	I
and	O
suggests	O
that	O
atmosphere	O
acts	O
as	O
a	O
neoplasm	B
suppresser	O
.	O

gene	O
of	O
of	O
a	O
significant	O
proportion	O
function	O
loss	O
-	O
of	O
-	O
of	O
mutations	O
mutated	O
tumours	O
complete	O
absence	O
of	O
establishes	O
normal	O
copy	O
of	O
this	O
in	O
and	O
majority	O
ATM	O
and	O
as	B
the	O
somatic	O
in	O
of	O
a	O
The	O
-	O
the	O
pathogenesis	O
of	O
sporadic	B
evidence	I
inactivation	I
PLL	I
ATM	O
suggests	O
that	O
T	O
acts	O
the	O
a	O
tumour	B
suppressor	O
.	O

The	O
of	O
of	O
function	O
mutations	O
and	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
the	O
majority	O
of	O
mutated	O
tumours	B
establishes	O
somatic	O
of	O
this	O
the	O
pathogenesis	O
of	O
T	I
and	O
suggests	O
that	O
ATM	O
acts	O
as	O
a	O

suggests	O
the	O
of	O
a	O
significant	O
proportion	O
copy	O
absence	O
-	O
of	O
-	O
function	O
mutations	O
tumour	O
pathogenesis	O
complete	O
loss	O
somatic	O
the	O
normal	O
as	O
of	O
ATM	O
in	O
evidence	O
majority	O
of	O
of	O
of	B
establishes	O
tumours	O
of	O
of	O
this	O
gene	O
in	O
the	O
a	O
mutated	O
sporadic	B
T	I
-	I
PLL	I
and	O
The	O
that	O
suppressor	O
acts	O
a	O
inactivation	O
and	B
ATM	O
.	O

of	O
a	O
significant	O
of	O
-	O
of	O
-	O
and	O
the	O
normal	O
copy	O
ATM	O
in	O
majority	O
of	O
mutated	O
somatic	O
inactivation	O
of	O
this	O
gene	O
the	O
of	O
sporadic	B
T	I
-	I
PLL	I
and	O
suggests	O
that	O
ATM	O
acts	O
a	O
tumour	B
suppressor	O
.	O

The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
found	O
corporal	O
deactivation	O
terminated	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
propose	O
important	O
cash	O
machine	O
represent	O
every	O
bit	O
ampere	O
neoplasm	O
suppresser	O
ampere	O
neoplasm	O
absence	O
seizure	O
the	B
pathogenesis	I
of	I
sporadic	I
T	O
-	O
PLL	O
and	O
suggests	O
that	O
ATM	O
acts	B
as	O
a	O

The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
found	O
corporal	O
deactivation	O
terminated	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
propose	O
important	O
cash	O
machine	O
represent	O
every	O
bit	O
ampere	O
neoplasm	O
suppresser	O
ampere	O
neoplasm	O
absence	O
seizure	O
the	B
pathogenesis	I
of	I
sporadic	I
T	O
-	O
PLL	O
and	O
suggests	O
that	O
ATM	O
acts	B
as	O
a	O

The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
found	O
corporal	O
deactivation	O
terminated	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
propose	O
important	O
cash	O
machine	O
represent	O
every	O
bit	O
ampere	O
neoplasm	O
suppresser	O
ampere	O
neoplasm	O
re	O
create	O
the	B
pathogenesis	I
of	I
sporadic	I
T	O
-	O
PLL	O
and	O
suggests	O
that	O
ATM	O
acts	B
as	O
a	O

The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B
T	I
-	I
PLL	I
and	O
suggests	O
that	O
ATM	O
acts	O
as	O
a	O
tumour	B
suppressor	O
.	O

ampere	O
constitutional	O
dna	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
sensitivity	O
to	O
triiodothyronine	B
-	I
PLL	I
will	O
demand	O
further	O
investigating	O
.	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B
-	I
PLL	I
will	O
require	O
further	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
investigation	O
.	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B
-	I
PLL	I
will	O
require	O
further	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
investigation	O
.	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
hereditary	O
predisposition	O
T	B
-	I
PLL	I
will	O
require	O
further	O
investigation	O

PLL	O
constitutional	O
putative	O
,	O
not	O
available	O
will	O
a	O
DNA	O
hereditary	O
predisposition	O
to	O
.	B
-	I
was	I
As	O
require	O
further	O
investigation	O
.	O
T	O

amp	O
constitutive	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
genetic	O
sensitivity	O
to	O
T	B
-	I
PLL	I
will	O
take	O
further	O
probe	O
.	O
.	O

.	O
constitutional	O
DNA	O
predisposition	O
not	O
available	O
,	O
investigation	O
PLL	O
hereditary	O
was	O
to	O
-	B
T	I
putative	I
will	O
require	O
further	O
a	O
As	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B
-	I
PLL	I
will	O
require	O
further	O
dna	O
dna	O
dna	O
dna	O
dna	O
volition	O
investigation	O
.	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B
PLL	I
further	O
investigation	O
.	O
.	O

axerophthol	O
constitutive	O
DNA	O
was	O
not	O
usable	O
,	O
a	O
putative	O
transmissible	O
sensitivity	O
to	O
T	B
-	I
PLL	I
will	O
require	O
further	O
probe	O
.	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B
-	I
PLL	I
will	O
require	O
further	O
investigation	O
.	O
.	O

Myotonic	B
dystrophy	I
modulation	O
in	O
is	O
involved	O
+	O
the	O
protein	O
of	O
the	O
Ca2	O
in	O
homeostasis	O
kinase	O
skeletal	O
muscle	O
cells	O
.	O

protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
skeletal	O
muscle	O
cells	O
.	O

myotonic	B
dystrophy	I
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
cadaverous	O
muscularity	O
cells	O
.	O

myotonic	B
dystrophy	I
protein	O
kinase	O
is	O
necessitate	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
cadaverous	O
brawniness	O
cells	O
.	O

muscle	B
dystrophy	I
protein	O
kinase	O
is	O
involved	O
homeostasis	O
in	O
modulation	O
of	O
the	O
Ca2	O
cells	O
in	O
the	O
skeletal	O
+	O
Myotonic	O
.	O

Myotonic	B
dystrophy	I
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
.	O

Myotonic	B
dystrophy	I
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
inflection	O
inflection	O
inflection	O
inflection	O
myotonic	O
.	O

myotonic	B
dystrophy	I
protein	O
kinase	O
is	O
postulate	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
haggard	O
muscle	O
cells	O
.	O

Myotonic	B
dystrophy	I
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
inflection	O
inflection	O
inflection	O
inflection	O
inflection	O
.	O

homeostasis	B
dystrophy	I
protein	O
the	O
is	O
involved	O
in	O
.	O
in	O
of	O
kinase	O
Ca2	O
Myotonic	O
+	O
modulation	O
skeletal	O
muscle	O
cells	O
the	O

Myotonic	B
dystrophy	I
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
most	O
prevalent	O
muscular	B
disorder	I
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B
protein	O
kinase	O
;	O
indium	O
cytoarchitectonics	O
deepen	O
indium	O
cytoarchitectonics	O
deepen	O
indium	O
cytoarchitectonics	O
past	O
past	O
past	O
past	O
past	O
past	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

myotonic	B
dystrophy	I
(	O
decimeter	B
)	O
,	O
the	O
most	O
dominant	O
hefty	B
trouble	I
in	O
grownup	O
,	O
is	O
induce	O
by	O
(	O
CTG	O
)	O
n	O
-	O
recapitulate	O
elaboration	O
in	O
a	O
cistron	O
encode	O
a	O
protein	O
kinase	O
(	O
decimeter	B
protein	O
kinase	O
;	O
DMPK	O
)	O
and	O
postulate	O
modification	O
in	O
cytoarchitectonics	O
and	O
ion	O
homeostasis	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
;	O
the	O
most	O
prevalent	O
muscular	B
disorder	I
adults	O
cytoarchitecture	O
,	O
is	O
kinase	O
by	O
(	O
)	O
CTG	O
n	O
.	O
repeat	O
,	O
in	O
gene	O
encoding	O
homeostasis	O
a	O
protein	O
caused	O
)	O
a	B
protein	O
kinase	O
expansion	O
DMPK	O
(	O
and	O
involves	O
changes	O
in	O
in	O
ion	O
and	O
DM	O
-	O

Myotonic	B
gene	I
(	O
DM	B
)	O
,	O
in	O
protein	O
prevalent	O
muscular	B
disorder	I
the	O
adults	O
encoding	O
in	O
caused	O
by	O
(	O
most	O
)	O
n	O
-	O
;	O
expansion	O
and	O
a	O
.	O
,	O
(	O
CTG	O
kinase	O
a	O
DM	B
is	O
kinase	O
in	O
DMPK	O
)	O
and	O
involves	O
dystrophy	O
protein	O
cytoarchitecture	O
repeat	O
ion	O
homeostasis	O
changes	O

myotonic	B
dystrophy	I
(	O
dm	B
)	O
,	O
the	O
most	O
dominant	O
sinewy	B
disarray	I
in	O
adults	O
,	O
is	O
make	O
by	O
(	O
CTG	O
)	O
n	O
-	O
recur	O
enlargement	O
in	O
a	O
factor	O
encode	O
a	O
protein	O
kinase	O
(	O
dm	B
protein	O
kinase	O
;	O
DMPK	O
)	O
and	O
take	O
variety	O
in	O
cytoarchitectonics	O
and	O
ion	O
homeostasis	O
.	O

Myotonic	B
dystrophy	I
(	O
)	O
,	O
the	O
most	O
prevalent	O
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
-	O
expansion	O
in	O
a	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B
kinase	O
;	O
and	O
changes	O
in	O
cytoarchitecture	O
and	O
.	O

DM	B
)	O
,	O
the	O
most	O
muscular	B
disorder	I
is	O
(	O
CTG	O
-	O
in	O
a	O
gene	O
encoding	O
protein	O
kinase	O
protein	O
kinase	O
DMPK	O
)	O
in	O
and	O
ion	O
homeostasis	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
most	O
prevalent	O
muscular	B
disorder	I
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B
protein	O
kinase	O
;	O
indium	O
cytoarchitectonics	O
deepen	O
indium	O
cytoarchitectonics	O
deepen	O
indium	O
cytoarchitectonics	O
past	O
past	O
past	O
past	O
past	O
dm	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

kinase	B
in	I
(	O
DM	B
by	O
,	O
n	O
(	O
prevalent	O
muscular	B
disorder	I
in	O
adults	O
the	O
)	O
caused	O
)	O
.	O
CTG	O
)	O
,	O
-	O
repeat	O
expansion	O
encoding	O
a	O
gene	O
in	O
ion	O
protein	O
a	O
dystrophy	O
DM	B
protein	O
and	O
;	O
DMPK	O
is	O
Myotonic	O
involves	O
changes	O
most	O
cytoarchitecture	O
and	O
kinase	O
homeostasis	O
(	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
most	O
prevalent	O
muscular	B
disorder	I
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B
protein	O
kinase	O
;	O
indium	O
cytoarchitectonics	O
deepen	O
indium	O
cytoarchitectonics	O
deepen	O
indium	O
cytoarchitectonics	O
past	O
past	O
past	O
past	O
past	O
past	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
most	O
prevalent	O
muscular	B
disorder	I
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B
protein	O
kinase	O
;	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

clues	O
the	O
normal	O
biological	O
of	O
DMPK	O
cellular	O
ion	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	O
+	O
i	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
induced	O
Ca2	O
+	O
,	O
and	O
the	O
content	O
of	O
ATP	O
pumps	O
in	O
skeletal	O
cells	O
of	O
-	O
DMPK	O
[	O
-	O
]	O
knockout	O

To	O
find	O
hint	O
to	O
the	O
formula	O
biological	O
use	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
perch	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
bountifulness	O
and	O
shape	O
of	O
depolarisation	O
-	O
hasten	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
message	O
of	O
atp	O
-	O
aim	O
ion	O
ticker	O
in	O
civilised	O
emaciated	O
muscle	O
cells	O
of	O
furious	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
ravisher	O
mice	O
.	O

To	O
obtain	O
clues	O
/	O
-	O
the	O
biological	O
role	O
of	O
DMPK	O
in	O
and	O
]	O
.	O
,	O
,	O
have	O
compared	O
the	O
resting	O
-	O
muscle	O
wild	O
ion	O
and	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
cells	O
-	O
induced	O
Ca2	O
+	O
knockout	O
we	O
i	O
normal	O
content	O
of	O
mice	O
-	O
driven	O
ion	O
in	O
]	O
cultured	O
skeletal	O
Ca2	O
depolarization	O
of	O
+	O
ATP	O
type	O
cellular	O
DMPK	O
[	O
-	O
to	O
the	O
pumps	O
transients	O
[	O
homeostasis	O

ATP	O
shape	O
clues	O
Ca2	O
-	O
normal	O
biological	O
-	O
of	O
in	O
DMPK	O
]	O
ion	O
homeostasis	O
,	O
we	O
cells	O
compared	O
the	O
resting	O
[	O
Ca2	O
,	O
cellular	O
i	O
pumps	O
-	O
amplitude	O
and	O
+	O
of	O
depolarization	O
the	O
induced	O
[	O
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
skeletal	O
-	O
wild	O
]	O
obtain	O
in	O
cultured	O
To	O
muscle	O
.	O
mice	O
ion	O
the	O
type	O
and	O
DMPK	O
to	O
-	O
/	O
role	O
driven	O
knockout	O
of	O
have	O

to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	O
cellular	O
ion	O
we	O
have	O
compared	O
resting	O
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
induced	O
+	O
transients	O
and	O
of	O
ATP	O
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
-	O
type	O
DMPK	O
[	O
-	O
/	O
]	O
mice	O

To	O
find	O
hint	O
to	O
the	O
formula	O
biological	O
function	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
remain	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
bountifulness	O
and	O
soma	O
of	O
depolarisation	O
-	O
induced	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
atp	O
-	O
take	O
ion	O
ticker	O
in	O
civilised	O
emaciated	O
brawniness	O
cubicle	O
of	O
uncivilised	O
-	O
character	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
hard	O
mouse	O
.	O

To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
cubicle	O
bounty	O
waste	O
build	O
typecast	O
depolarisation	O
sweetheart	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	O
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
heftiness	O
.	O

To	O
obtain	O
clues	O
normal	O
in	O
cellular	O
ion	O
,	O
we	O
compared	O
the	O
resting	O
+	O
]	O
i	O
,	O
the	O
and	O
of	O
depolarization	O
-	O
induced	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
of	O
ATP	O
-	O
driven	O
ion	O
cells	O
-	O
and	O
DMPK	O
[	O
/	O
-	O
]	O
knockout	O
mice	O
.	O

To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
cubicle	O
bounty	O
waste	O
build	O
typecast	O
depolarisation	O
sweetheart	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	O
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
heftiness	O
.	O

To	O
prevail	O
clues	O
to	O
the	O
formula	O
biological	O
character	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
equate	O
the	O
pillow	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
bounty	O
and	O
configuration	O
of	O
depolarisation	O
-	O
hasten	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
substance	O
of	O
ATP	O
-	O
goaded	O
ion	O
heart	O
in	O
cultivated	O
haggard	O
muscularity	O
cells	O
of	O
uncivilised	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
severe	O
mice	O
.	O

To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	O
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	O
.	O

In	O
vitro	O
open	O
differentiated	O
DMPK	O
[	O
-	O
]	O
-	O
]	O
myotubes	O
-	O
i	O
higher	O
resting	O
/	O
Ca2	O
+	O
-	O
a	O
than	O
.	O
wild	O
exhibit	O
type	O
[	O
of	O
of	O
an	O
altered	O
-	O
Na	O
probability	O
voltage	O
-	O
channels	O
l	O
myotubes	O
type	O
Ca2	O
+	O
and	O
because	O
+	O
dependent	O
do	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
na	O
chance	O
television	O
channel	O
na	O
chance	O
television	O
channel	O
na	O
chance	O
television	O
channel	O
chance	O
chance	O
chance	O
chance	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
na	O
chance	O
television	O
channel	O
na	O
chance	O
television	O
channel	O
na	O
chance	O
television	O
channel	O
chance	O
chance	O
chance	O
waste	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
]	O
myotubes	O
exhibit	O
higher	O
[	O
Ca2	O
+	O
than	O
myotubes	O
because	O
of	O
altered	O
open	O
of	O
voltage	O
-	O
-	O
type	O
Ca2	O
+	O
and	O
+	O
.	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
than	O
-	O
myotubes	O
because	O
of	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O
+	O
channels	O

-	O
]	O
-	O
differentiated	O
DMPK	O
[	O
and	O
/	O
-	O
]	O
myotubes	O
+	O
a	O
of	O
altered	O
[	O
Ca2	O
+	O
voltage	O
i	O
than	O
do	O
an	O
-	O
+	O
myotubes	O
probability	O
higher	O
resting	O
type	O
open	O
dependent	O
of	O
vitro	O
In	O
because	O
l	O
-	O
type	O
Ca2	O
exhibit	O
-	O
Na	O
wild	O
channels	O
.	O

In	O
vitro	O
-	O
specialize	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
present	O
a	O
higher	O
breathe	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
falsify	O
open	O
chance	O
of	O
potential	O
-	O
hooked	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O
+	O
carry	O
.	O

inch	O
vitro	O
-	O
specialize	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
demo	O
a	O
eminent	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
dotty	O
-	O
case	O
myotubes	O
because	O
of	O
an	O
castrate	O
undetermined	O
chance	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
case	O
Ca2	O
+	O
and	O
Na	O
+	O
impart	O
.	O

inch	O
vitro	O
-	O
speciate	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
showing	O
a	O
higher	O
stay	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
godforsaken	O
-	O
case	O
myotubes	O
because	O
of	O
an	O
falsify	O
open	O
chance	O
of	O
voltage	O
-	O
subordinate	O
fifty	O
-	O
case	O
Ca2	O
+	O
and	O
na	O
+	O
line	O
.	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
na	O
chance	O
television	O
channel	O
na	O
chance	O
television	O
channel	O
na	O
chance	O
television	O
channel	O
chance	O
chance	O
chance	O
chance	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O
+	O
channels	O
.	O

The	O
sport	O
myotubes	O
demonstrate	O
lowly	O
and	O
slower	O
Ca2	O
+	O
reception	O
upon	O
trip	O
by	O
acetylcholine	O
or	O
high	O
external	O
yard	O
+	O
.	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
demo	O
demo	O
demo	O
demo	O
demo	O
demo	O
+	O
.	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
demo	O
demo	O
demo	O
demo	O
demo	O
demo	O
+	O
.	O

myotubes	O
and	O
slower	O
Ca2	O
responses	O
upon	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
+	O
.	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
Ca2	O
+	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
+	O
.	O

myotubes	O
exhibit	O
smaller	O
and	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
acetylcholine	O
or	O
high	O
external	O
+	O
.	O

K	O
mutant	O
myotubes	O
+	O
smaller	O
and	O
slower	O
+	O
Ca2	O
responses	O
or	O
triggering	O
by	O
.	O
The	O
high	O
external	O
upon	O
exhibit	O
acetylcholine	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
demo	O
demo	O
demo	O
demo	O
demo	O
demo	O
+	O
.	O

The	O
variation	O
myotubes	O
demo	O
modest	O
and	O
slower	O
Ca2	O
+	O
reaction	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
outside	O
g	O
+	O
.	O

external	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
acetylcholine	O
triggering	O
+	O
responses	O
upon	O
or	O
The	O
slower	O
Ca2	O
K	O
by	O
high	O
+	O
.	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
+	O
.	O

In	O
,	O
we	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
influx	O
of	O
extracellular	O
Ca2	O
through	O
the	O
l	O
-	O
type	O
+	O
channel	O
.	O

In	O
,	O
we	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
influx	O
of	O
Ca2	O
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	O

In	O
addition	O
,	O
we	O
associate	O
in	O
nursing	O
inflow	O
television	O
channel	O
note	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
	O
typecast	O
television	O
channel	O
indium	O
+	O
through	O
the	O
l	O
-	O
type	O

the	O
addition	O
,	O
+	O
observed	O
that	O
these	O
+	O
type	O
transients	O
through	O
result	O
from	O
an	O
-	O
of	O
extracellular	O
Ca2	O
we	O
Ca2	O
partially	O
l	O
influx	O
+	O
In	O
Ca2	O
channel	O
.	O

channel	O
addition	O
,	O
influx	O
observed	O
that	O
+	O
Ca2	O
we	O
transients	O
partially	O
result	O
an	O
the	O
Ca2	O
+	O
extracellular	O
Ca2	O
+	O
through	O
from	O
l	O
-	O
type	O
of	O
these	O
In	O
.	O

In	O
addition	O
,	O
we	O
associate	O
in	O
nursing	O
inflow	O
television	O
channel	O
note	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
	O
typecast	O
television	O
channel	O
inflow	O
+	O
through	O
the	O
l	O
-	O
type	O

indium	O
summation	O
,	O
we	O
discover	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
inflow	O
of	O
extracellular	O
Ca2	O
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	O
+	O
duct	O
.	O

In	O
addition	O
,	O
we	O
associate	O
in	O
nursing	O
inflow	O
television	O
channel	O
note	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
	O
typecast	O
television	O
channel	O
inflow	O
+	O
through	O
the	O
l	O
-	O
type	O

type	O
addition	O
,	O
we	O
observed	O
that	O
an	O
result	O
+	O
transients	O
partially	O
extracellular	O
l	O
these	O
Ca2	O
In	O
Ca2	O
of	O
+	O
through	O
the	O
from	O
-	O
Ca2	O
influx	O
+	O
channel	O
.	O

In	O
addition	O
,	O
we	O
keep	O
that	O
these	O
Ca2	O
+	O
transients	O
partly	O
leave	O
from	O
an	O
inflow	O
of	O
extracellular	O
Ca2	O
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	O
+	O
channel	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	O
+	O
channel	O
.	O

the	O
content	O
nor	O
the	O
activity	O
of	O
Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
+	O
ATPase	O
are	O
affected	O
by	O
DMPK	O
absence	O
.	O

K	O
the	O
content	O
-	O
the	O
activity	O
of	O
.	O
DMPK	O
/	O
absence	O
+	O
ATPase	O
ATPase	O
by	O
reticulum	O
Ca2	O
+	O
nor	O
and	O
are	O
affected	O
sarcoplasmic	O
+	O
Neither	O
Na	O

neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
na	O
+	O
/	O
g	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-	O
ATPase	O
are	O
sham	O
by	O
DMPK	O
absence	O
.	O

neither	O
the	O
content	O
nor	O
the	O
action	O
of	O
sodium	O
+	O
/	O
thou	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-	O
ATPase	O
are	O
feign	O
by	O
DMPK	O
absence	O
.	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	O
+	O
/	O
+	O
ATPase	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-	O
ATPase	O
are	O
DMPK	O
absence	O
.	O

Neither	O
the	O
content	O
nor	O
na	O
the	O
activity	O
of	O
Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
past	O
touched	O
absence	O
seizure	O
past	O
absence	O
seizure	O
second	O
stomach	O
-	O
ATPase	O
are	O
affected	O
by	O

Neither	O
the	O
content	O
nor	O
na	O
the	O
activity	O
of	O
Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
past	O
touched	O
absence	O
seizure	O
past	O
absence	O
seizure	O
action	O
-	O
ATPase	O
are	O
affected	O
by	O
DMPK	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	O
+	O
/	O
+	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-	O
ATPase	O
are	O
affected	O
by	O

DMPK	O
the	O
content	O
nor	O
the	O
activity	O
and	O
Ca2	O
+	O
/	O
K	O
+	O
affected	O
of	O
absence	O
reticulum	O
Na	O
are	O
-	O
ATPase	O
Neither	O
ATPase	O
by	O
+	O
sarcoplasmic	O
.	O

neither	O
the	O
content	O
nor	O
the	O
action	O
of	O
sodium	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-	O
ATPase	O
are	O
involve	O
by	O
DMPK	O
absence	O
.	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-	O
ATPase	O
are	O
affected	O
by	O
DMPK	O
absence	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
haggard	O
heftiness	O
haggard	O
heftiness	O
heftiness	O
cost	O
finis	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
.	O
.	O

our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
coupling	O
skeletal	O
muscle	O
.	O
.	O

In	O
finale	O
,	O
our	O
datum	O
advise	O
that	O
DMPK	O
is	O
byzantine	O
in	O
modulate	O
the	O
initial	O
events	O
of	O
irritation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscularity	O
.	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
modulating	O
the	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
.	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
haggard	O
heftiness	O
haggard	O
heftiness	O
heftiness	O
cost	O
cost	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
.	O
.	O

In	O
termination	O
,	O
our	O
data	O
indicate	O
that	O
DMPK	O
is	O
involved	O
in	O
tone	O
the	O
initial	O
consequence	O
of	O
excitement	O
-	O
condensation	O
coupling	O
in	O
skeletal	O
brawn	O
.	O
.	O

inwards	O
conclusion	O
,	O
our	O
datum	O
evoke	O
that	O
DMPK	O
is	O
take	O
inwards	O
modulating	O
the	O
initial	O
issue	O
of	O
excitation	O
-	O
contraction	O
conjugation	O
inwards	O
haggard	O
muscle	O
.	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
the	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
haggard	O
heftiness	O
haggard	O
heftiness	O
heftiness	O
cost	O
cost	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
.	O
.	O

coupling	O
conclusion	O
,	O
in	O
data	O
suggest	O
that	O
contraction	O
.	O
involved	O
our	O
modulating	O
initial	O
the	O
muscle	O
of	O
excitation	O
-	O
DMPK	O
.	O
in	O
skeletal	O
events	O
is	O
In	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
.	O
.	O

Constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
sport	O
sport	O
sport	O
unilateral	B
retinoblastoma	I
.	O

RB1	O
-	O
patients	O
unilateral	B
retinoblastoma	I
.	O

inbuilt	O
RB1	O
-	O
cistron	O
mutations	O
in	O
patients	O
with	O
sequestrate	O
unilateral	B
retinoblastoma	I
.	O

Constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
sport	O
sport	O
sport	O
unilateral	B
retinoblastoma	I
.	O

RB1	O
-	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
.	O

integral	O
RB1	O
-	O
cistron	O
mutations	O
in	O
patients	O
with	O
stranded	O
unilateral	B
retinoblastoma	I
.	O

Constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
sport	O
sport	O
patient	O
unilateral	B
retinoblastoma	I
.	O

Constitutional	O
RB1	O
-	O
factor	O
mutations	O
in	O
patients	O
with	O
marooned	O
unilateral	B
retinoblastoma	I
.	O

Constitutional	O
with	O
-	O
gene	O
RB1	O
in	O
patients	O
retinoblastoma	O
isolated	O
unilateral	B
mutations	I
.	O

.	O
RB1	O
-	O
gene	O
with	O
in	O
unilateral	O
mutations	O
isolated	O
patients	B
retinoblastoma	I
Constitutional	O

Constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
.	O

In	O
most	O
patients	O
,	O
tumor	B
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
tumor	B
development	O
is	O
initiated	O
by	O
inactivation	O
alleles	O
of	O
the	O
RB1	O
gene	O
.	O

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
tumor	B
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
patient	O
factor	O
factor	O
patient	O
patient	O
patient	O
of	O
the	O
RB1	O
gene	O
.	O

indium	O
most	O
patients	O
with	O
apart	O
unilateral	B
retinoblastoma	I
,	O
neoplasm	B
developing	O
is	O
initiated	O
by	O
corporeal	O
deactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
.	O

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
tumor	B
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
patient	O
factor	O
factor	O
patient	O
patient	O
patient	O
of	O
the	O
RB1	O
gene	O
.	O

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
tumour	B
evolution	O
is	O
originate	O
by	O
corporeal	O
deactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
factor	O
.	O

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
tumor	B
development	O
initiated	O
by	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O

is	O
most	O
patients	O
of	O
isolated	O
unilateral	B
retinoblastoma	I
tumor	O
,	B
development	O
the	O
initiated	O
somatic	O
by	O
.	O
of	O
both	O
alleles	O
with	O
In	O
RB1	O
gene	O
inactivation	O

In	O
most	O
patients	O
with	O
sequester	O
unilateral	B
retinoblastoma	I
,	O
neoplasm	B
ontogeny	O
is	O
start	O
by	O
bodily	O
inactivation	O
of	O
both	O
allelomorph	O
of	O
the	O
RB1	O
gene	O
.	O

inactivation	O
most	O
tumor	O
retinoblastoma	O
isolated	O
unilateral	B
of	I
,	O
patients	B
development	O
is	O
initiated	O
RB1	O
somatic	O
with	O
In	O
both	O
alleles	O
of	O
the	O
by	O
gene	O
.	O

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
tumor	B
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
.	O

However	O
some	O
these	O
can	O
transmit	O
retinoblastoma	B
predisposition	O
to	O
their	O
offspring	O
.	O

nevertheless	O
,	O
some	O
of	O
these	O
patients	O
can	O
beam	O
retinoblastoma	B
sensitivity	O
to	O
their	O
young	O
.	O

transmit	O
of	O
some	O
,	O
these	O
patients	O
predisposition	O
However	O
retinoblastoma	B
.	O
to	O
their	O
offspring	O
can	O

However	O
,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
predisposition	O
to	O
offspring	O
.	O

However	O
,	O
conduct	O
approximately	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B
young	O
conduct	O
predisposition	O
to	O
their	O
offspring	O
.	O

However	O
,	O
conduct	O
approximately	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B
young	O
approximately	O
predisposition	O
to	O
their	O
offspring	O
.	O

still	O
,	O
some	O
of	O
these	O
patients	O
can	O
broadcast	O
retinoblastoma	B
sensitivity	O
to	O
their	O
materialization	O
.	O

offspring	O
,	O
some	O
However	O
transmit	O
patients	O
can	O
their	O
retinoblastoma	B
predisposition	O
to	O
these	O
of	O
.	O

However	O
,	O
conduct	O
approximately	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B
young	O
conduct	O
predisposition	O
to	O
their	O
offspring	O
.	O

yet	O
,	O
some	O
of	O
these	O
patients	O
can	O
transfer	O
retinoblastoma	B
sensitivity	O
to	O
their	O
issue	O
.	O

However	O
,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B
predisposition	O
to	O
their	O
offspring	O
.	O

To	O
determine	O
the	O
frequency	O
indium	O
patient	O
neoplasm	O
sequester	O
one	O
sided	O
and	O
nature	O
of	O
constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	B
unilateral	I
retinoblastoma	O
line	O
of	O
descent	O
neoplasm	O
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	B
and	O
from	O
tumor	O
tissue	O

To	O
determine	O
the	O
frequency	O
indium	O
patient	O
neoplasm	O
sequester	O
one	O
sided	O
and	O
nature	O
of	O
constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	B
unilateral	I
retinoblastoma	O
line	O
of	O
descent	O
patient	O
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	B
and	O
from	O
tumor	O
tissue	O

tissue	O
determine	O
blood	O
with	O
and	O
nature	O
tumor	O
constitutional	O
frequency	O
-	O
gene	O
mutations	O
analyzed	O
patients	O
the	O
RB1	O
unilateral	B
retinoblastoma	I
,	O
we	O
in	O
DNA	O
from	O
peripheral	O
isolated	O
of	O
from	O
and	B
To	O
.	O

To	O
determine	O
the	O
frequency	O
indium	O
patient	O
neoplasm	O
sequester	O
one	O
sided	O
and	O
nature	O
of	O
constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	B
unilateral	I
retinoblastoma	O
line	O
of	O
descent	O
neoplasm	O
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	B
and	O
from	O
tumor	O
tissue	O

To	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
RB1	O
-	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
analyzed	O
DNA	O
from	O
peripheral	O
blood	O
and	O
from	O
tumor	B
tissue	O
.	O

To	O
see	O
the	O
frequence	O
and	O
nature	O
of	O
inbuilt	O
RB1	O
-	O
factor	O
mutant	O
in	O
patients	O
with	O
detached	O
unilateral	B
retinoblastoma	I
,	O
we	O
examine	O
DNA	O
from	O
peripheral	O
profligate	O
and	O
from	O
tumour	B
tissue	O
.	O

unilateral	O
determine	O
the	O
frequency	O
and	O
nature	O
DNA	O
mutations	O
RB1	O
-	O
gene	O
To	O
tissue	O
peripheral	O
isolated	O
with	O
retinoblastoma	B
blood	I
,	O
we	O
analyzed	O
of	O
from	O
patients	O
constitutional	O
and	O
from	O
tumor	B
in	O
.	O

analyzed	O
determine	O
the	O
,	O
and	O
nature	O
of	O
and	O
peripheral	O
-	O
tissue	O
mutations	O
from	O
we	O
from	O
isolated	O
unilateral	B
retinoblastoma	I
frequency	O
patients	O
blood	O
DNA	O
with	O
RB1	O
To	O
constitutional	O
in	O
tumor	B
gene	O
.	O

To	O
find	O
the	O
frequency	O
and	O
nature	O
of	O
inbuilt	O
RB1	O
-	O
factor	O
mutations	O
in	O
patients	O
with	O
apart	O
unilateral	B
retinoblastoma	I
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
ancestry	O
and	O
from	O
tumour	B
tissue	O
.	O

To	O
determine	O
the	O
frequency	O
and	O
of	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
retinoblastoma	I
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
from	O
tumor	B
tissue	O

To	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	O
and	O
from	O
tumor	B
tissue	O
.	O

analysis	O
of	O
tumors	B
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
constitutional	O
(	O
LOH	O
)	O
at	O
intragenic	O
loci	O
.	O

of	O
analysis	O
of	O
heterozygosity	B
from	O
54	O
(	O
.	O
intragenic	O
)	O
loci	O
76	O
informative	O
(	O
at	O
loss	O
of	O
constitutional	O
tumors	O
patients	O
LOH	O
)	O
showed	O
%	O
The	O
71	O

The	O
analysis	O
of	O
neoplasm	B
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
enlightening	O
patients	O
indicate	O
expiration	O
of	O
constitutive	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
intragenic	O
locus	O
.	O

The	O
analysis	O
of	O
neoplasm	B
from	O
54	O
(	O
lxxi	O
%	O
)	O
of	O
76	O
informatory	O
patients	O
point	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
intragenic	O
locus	O
.	O

The	O
analysis	O
of	O
tumors	B
from	O
54	O
(	O
71	O
%	O
)	O
76	O
informative	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
intragenic	O
loci	O
.	O

The	O
analysis	O
of	O
tumors	B
	O
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
atomic	O
number	O
	O
neoplasm	O
locale	O
atomic	O
number	O
	O
locale	O
neoplasm	O
heterozygosity	O
(	O
LOH	O
)	O

The	O
analysis	O
of	O
tumors	B
	O
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
atomic	O
number	O
	O
neoplasm	O
locale	O
atomic	O
number	O
	O
locale	O
patient	O
heterozygosity	O
(	O
LOH	O
)	O

The	O
analysis	O
of	O
tumors	B
from	O
54	O
(	O
71	O
%	O
)	O
76	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
)	O
at	O

intragenic	O
analysis	O
of	O
tumors	B
from	O
54	O
patients	O
of	O
%	O
)	O
of	O
76	O
)	O
(	O
loci	O
loss	O
71	O
LOH	O
heterozygosity	O
(	O
The	O
informative	O
at	O
constitutional	O
showed	O
.	O

The	O
analysis	O
of	O
tumour	B
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
enlightening	O
patients	O
establish	O
departure	O
of	O
organic	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
intragenic	O
locale	O
.	O

The	O
analysis	O
of	O
tumors	B
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
intragenic	O
loci	O
.	O

Three	O
of	O
13	O
uninformative	O
patients	O
had	O
inbuilt	O
omission	O
.	O

Three	O
receive	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
deletions	O
invite	O
.	O

Three	O
uninformative	O
13	O
of	O
patients	O
had	O
deletions	O
constitutional	O
.	O

Three	O
of	O
thirteen	O
uninformative	O
patients	O
had	O
inbuilt	O
deletions	O
.	O

Three	O
13	O
uninformative	O
had	O
deletions	O

constitutional	O
of	O
13	O
uninformative	O
patients	O
had	O
deletions	O
Three	O
.	O

Three	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
.	O

Three	O
deletions	O
13	O
uninformative	O
of	O
had	O
constitutional	O
patients	O
.	O

Three	O
patient	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
deletions	O
patient	O
role	O

trio	O
of	O
13	O
uninformative	O
patients	O
had	O
integral	O
deletions	O
.	O

Three	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
deletions	O
.	O

For	O
39	O
randomly	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
cost	O
place	O
sport	O
place	O
sport	O
sport	O
choose	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O
.	O

selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
were	O
to	O
identify	O
mutations	O
.	O

For	O
39	O
randomly	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequence	O
,	O
and	O
southern	O
daub	O
analysis	O
were	O
practice	O
to	O
discover	O
mutations	O
.	O

For	O
39	O
randomly	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
analysis	O
,	O
,	O
and	O
Southern	O
blot	O
analysis	O
were	O
used	O
mutations	O
.	O

For	O
39	O
randomly	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
cost	O
place	O
sport	O
place	O
sport	O
sport	O
at	O
random	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O

For	O
39	O
arbitrarily	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequence	O
,	O
and	O
southern	O
smirch	O
analysis	O
were	O
victimised	O
to	O
distinguish	O
mutations	O
.	O

For	O
39	O
indiscriminately	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequence	O
,	O
and	O
southerly	O
spot	O
analysis	O
were	O
expend	O
to	O
place	O
sport	O
.	O

For	O
39	O
randomly	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
,	O
and	O
Southern	O
blot	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O

For	O
39	O
randomly	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
cost	O
place	O
sport	O
place	O
sport	O
sport	O
at	O
random	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O

were	O
39	O
randomly	O
duplex	O
tumors	B
,	O
SSCP	O
analysis	O
mutations	O
-	O
selected	O
analysis	O
sequencing	O
,	O
identify	O
and	O
Southern	O
blot	O
,	O
.	O
used	O
to	O
,	O
hetero	O
For	O

For	O
39	O
randomly	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O
.	O

Mutations	O
21	O
detected	O
in	O
were	O
(	O
%	O
23	O
)	O
of	O
with	O
tumors	B
91	O
LOH	O
.	O

Mutations	O
were	O
	O
notice	O
notice	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
indium	O
of	O
23	O
tumors	B
with	O
LOH	O
.	O

variation	O
were	O
detected	O
in	O
xxi	O
(	O
91	O
%	O
)	O
of	O
23	O
neoplasm	B
with	O
LOH	O
.	O

with	O
were	O
detected	O
Mutations	O
%	O
(	O
91	O
tumors	O
)	O
of	O
23	O
21	B
in	O
LOH	O
.	O

Mutations	O
were	O
notice	O
in	O
xxi	O
(	O
xci	O
%	O
)	O
of	O
23	O
neoplasm	B
with	O
LOH	O
.	O

Mutations	O
were	O
	O
notice	O
notice	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
	O
of	O
23	O
tumors	B
with	O
LOH	O
.	O

Mutations	O
detected	O
21	O
91	O
%	O
)	O
of	O
23	O
tumors	B
with	O
LOH	O
.	O

%	O
in	O
detected	O
were	O
21	O
(	O
of	O
Mutations	O
)	O
91	O
23	O
tumors	B
with	O
.	O
LOH	O

Mutations	O
were	O
find	O
in	O
21	O
(	O
91	O
%	O
)	O
of	O
xxiii	O
neoplasm	B
with	O
LOH	O
.	O

Mutations	O
were	O
	O
notice	O
notice	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
	O
of	O
23	O
tumors	B
with	O
LOH	O
.	O

Mutations	O
were	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
of	O
23	O
tumors	B
with	O
LOH	O
.	O

(	O
)	O
of	O
16	O
tumors	B
LOH	O
,	O
was	O
detected	O
and	O
in	O
%	O
of	O
the	O
tumors	B
LOH	O
,	O
both	O
were	O
found	O
.	O

In	O
6	O
(	O
38	O
notice	O
	O
%	O
)	O
of	O
16	O
tumors	B
without	O
LOH	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B
without	O
LOH	O
,	O
both	O
mutations	O
were	O
found	O
note	O
note	O
note	O
note	O
note	O
note	O
note	O
cost	O
.	O

of	O
in	O
(	O
38	O
%	O
)	O
tumors	O
16	O
tumors	B
without	O
LOH	O
,	O
one	O
without	O
,	O
detected	O
,	O
and	O
found	O
9	O
(	O
56	O
mutations	O
)	O
In	O
the	O
of	B
mutation	O
was	O
%	O
both	O
LOH	O
were	O
.	O
6	O

In	O
sise	O
(	O
38	O
%	O
)	O
of	O
16	O
tumour	B
without	O
LOH	O
,	O
unity	O
mutation	O
was	O
discover	O
,	O
and	O
in	O
niner	O
(	O
56	O
%	O
)	O
of	O
the	O
tumour	B
without	O
LOH	O
,	O
both	O
mutations	O
were	O
obtain	O
.	O

In	O
6	O
the	O
38	O
%	O
)	O
of	O
56	O
tumors	B
without	O
LOH	O
)	O
without	O
mutation	O
was	O
both	O
,	O
and	O
9	O
,	O
(	O
16	O
%	O
in	O
of	O
tumors	O
(	B
were	O
LOH	O
,	O
detected	O
one	O
mutations	O
found	O
.	O

In	O
6	O
(	O
38	O
%	O
)	O
of	O
16	O
tumors	B
without	O
one	O
mutation	O
was	O
detected	O
and	O
in	O
9	O
(	O
56	O
)	O
of	O
the	O
tumors	B
LOH	O
,	O
mutations	O
were	O
found	O
.	O

in	O
6	O
(	O
38	O
%	O
)	O
of	O
16	O
tumors	B
without	O
LOH	O
,	O
unitary	O
sport	O
was	O
notice	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B
without	O
LOH	O
,	O
both	O
mutations	O
were	O
launch	O
.	O

In	O
6	O
(	O
38	O
notice	O
sixteen	O
%	O
)	O
of	O
16	O
tumors	B
without	O
LOH	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B
without	O
LOH	O
,	O
both	O
mutations	O
were	O
found	O
note	O
note	O
note	O
note	O
note	O
note	O
note	O
cost	O
.	O

In	O
six	O
(	O
xxxviii	O
%	O
)	O
of	O
xvi	O
tumour	B
without	O
LOH	O
,	O
nonpareil	O
mutation	O
was	O
observe	O
,	O
and	O
in	O
niner	O
(	O
lvi	O
%	O
)	O
of	O
the	O
tumour	B
without	O
LOH	O
,	O
both	O
mutations	O
were	O
receive	O
.	O

without	O
(	O
(	O
38	O
,	O
)	O
was	O
mutations	O
tumors	B
without	O
LOH	O
,	O
one	O
of	O
16	O
detected	O
%	O
both	O
in	O
9	O
mutation	O
56	O
%	O
)	O
6	O
the	O
tumors	B
In	O
and	O
,	O
LOH	O
of	O
were	O
found	O
.	O

In	O
6	O
(	O
38	O
%	O
)	O
of	O
16	O
tumors	B
without	O
LOH	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B
without	O
LOH	O
,	O
both	O
mutations	O
were	O
found	O
.	O

Thus	O
of	O
a	O
total	O
,	O
45	O
were	O
tumors	O
identified	O
in	O
36	B
of	O
mutations	O
patients	O
.	O

Thus	O
,	O
sport	O
cost	O
ampere	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
patient	O
in	O
tumors	B
of	O
36	O
patients	O
.	O

Thus	O
,	O
a	O
total	O
of	O
45	O
variation	O
were	O
distinguish	O
in	O
tumour	B
of	O
xxxvi	O
patients	O
.	O

36	O
,	O
a	O
Thus	O
were	O
45	O
mutations	O
of	O
identified	O
in	O
tumors	B
of	O
total	O
patients	O
.	O

thusly	O
,	O
a	O
summate	O
of	O
xlv	O
mutations	O
were	O
identified	O
in	O
neoplasm	B
of	O
36	O
patients	O
.	O

Thus	O
,	O
sport	O
cost	O
ampere	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
cost	O
in	O
tumors	B
of	O
36	O
patients	O
.	O

Thus	O
a	O
of	O
mutations	O
were	O
identified	O
in	O
tumors	B
of	O
36	O
patients	O
.	O

were	O
total	O
a	O
,	O
of	O
45	O
in	O
Thus	O
identified	O
mutations	O
tumors	B
of	O
36	O
.	O
patients	O

olibanum	O
,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identify	O
in	O
neoplasm	B
of	O
36	O
patients	O
.	O

Thus	O
,	O
sport	O
cost	O
ampere	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
cost	O
in	O
tumors	B
of	O
36	O
patients	O
.	O

Thus	O
,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
in	O
tumors	B
of	O
36	O
patients	O
.	O

Thirty	O
-	O
nine	O
of	O
great	O
morphologic	O
alteration	O
let	O
in	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA	O
with	O
child	O
with	O
child	O
with	O

Thirty	O
-	O
nine	O
mutations	O
mutations	O
,	O
2	O
structural	O
alterations	O
and	O
hypermethylation	O
in	O
-	O
were	O
not	O
detected	O
in	O
corresponding	O
blood	O
DNA	O
.	O

thirty	O
-	O
nine	O
of	O
the	O
mutant	O
-	O
including	O
34	O
modest	O
mutant	O
,	O
two	O
boastfully	O
morphologic	O
revision	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumour	O
-	O
were	O
not	O
detected	O
in	O
the	O
tally	O
peripheral	O
blood	O
DNA	O
.	O

Thirty	O
-	O
nine	O
of	O
the	O
mutations	O
-	O
34	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA	O
.	O

thirty	O
-	O
nine	O
of	O
the	O
mutations	O
-	O
include	O
xxxiv	O
small	O
mutations	O
,	O
2	O
heavy	O
geomorphologic	O
modification	O
,	O
and	O
hypermethylation	O
in	O
trinity	O
tumour	O
-	O
were	O
not	O
detected	O
in	O
the	O
equate	O
peripheral	O
blood	O
DNA	O
.	O

Thirty	O
-	O
nine	O
of	O
great	O
morphologic	O
alteration	O
let	O
in	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA	O
with	O
child	O
with	O
child	O
with	O

Thirty	O
-	O
nine	O
of	O
the	O
mutations	O
-	O
including	O
34	O
diminished	O
mutations	O
,	O
2	O
turgid	O
geomorphologic	O
change	O
,	O
and	O
hypermethylation	O
in	O
triad	O
tumors	O
-	O
were	O
not	O
discover	O
in	O
the	O
corresponding	O
peripheral	O
descent	O
dna	O
.	O

3	O
hypermethylation	O
nine	O
of	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
not	O
peripheral	O
alterations	O
,	O
and	O
the	O
in	O
-	O
tumors	O
DNA	O
were	O
large	O
detected	O
in	O
Thirty	O
structural	O
-	O
blood	O
corresponding	O
.	O

Thirty	O
-	O
nine	O
of	O
the	O
mutations	O
including	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
the	O
corresponding	O
peripheral	O
DNA	O

Thirty	O
-	O
nine	O
of	O
great	O
morphologic	O
alteration	O
	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA	O
with	O
child	O
with	O
child	O
with	O
child	O

Thirty	O
-	O
nine	O
of	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA	O
.	O

In	O
6	O
(	O
17	O
cost	O
notice	O
indium	O
built	O
in	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
toll	O
toll	O
toll	O
toll	O
sport	O

In	O
6	O
(	O
)	O
,	O
a	O
mutation	O
detected	O
in	O
DNA	O
,	O
and	O
these	O
mutations	O
is	O
known	O
to	O
associated	O
reduced	O
expressivity	O
.	O

inch	O
sextuplet	O
(	O
seventeen	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutant	O
was	O
notice	O
inch	O
inbuilt	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutant	O
is	O
known	O
to	O
be	O
link	O
with	O
repress	O
expressivity	O
.	O

In	O
6	O
(	O
17	O
%	O
)	O
of	O
36	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA	O
,	O
and	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
.	O

indiana	O
six	O
(	O
xvii	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutant	O
was	O
detected	O
indiana	O
constitutional	O
DNA	O
,	O
and	O
unity	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
consociate	O
with	O
decoct	O
expressivity	O
.	O

In	O
6	O
(	O
17	O
cost	O
notice	O
indium	O
built	O
in	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
toll	O
toll	O
toll	O
toll	O
sport	O

indiana	O
sextet	O
(	O
xvii	O
%	O
)	O
of	O
the	O
xxxvi	O
patients	O
,	O
a	O
sport	O
was	O
observe	O
indiana	O
constituent	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
jazz	O
to	O
be	O
consociate	O
with	O
reduced	O
expressivity	O
.	O

1	O
,	O
(	O
17	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
is	O
with	O
in	O
constitutional	O
DNA	O
be	O
and	O
6	O
of	O
expressivity	O
mutations	O
was	O
known	O
to	O
In	O
detected	O
these	O
reduced	O
associated	O
.	O

In	O
6	O
(	O
17	O
%	O
)	O
the	O
patients	O
,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
be	O
associated	O
with	O
expressivity	O

In	O
6	O
(	O
17	O
cost	O
notice	O
indium	O
cost	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
toll	O
toll	O
toll	O
toll	O
sport	O
.	O

In	O
6	O
(	O
17	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
.	O

The	O
presence	O
cost	O
non	O
colligate	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment	O
sport	O
.	O

at	O
presence	O
of	O
.	O
constitutional	O
mutation	O
was	O
not	O
treatment	O
with	O
an	O
early	O
The	O
age	O
associated	O
a	O

The	O
presence	O
cost	O
non	O
associate	O
in	O
nursing	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment	O

The	O
front	O
of	O
a	O
constitutional	O
sport	O
was	O
not	O
connect	O
with	O
an	O
early	O
age	O
at	O
handling	O
.	O

age	O
presence	O
of	O
not	O
constitutional	O
mutation	O
at	O
a	O
associated	O
with	O
The	O
early	O
an	O
was	O
treatment	O
.	O

The	O
presence	O
cost	O
non	O
colligate	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment	O
sport	O
.	O

The	O
mien	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
consort	O
with	O
an	O
former	O
age	O
at	O
discussion	O
.	O

The	O
comportment	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
assort	O
with	O
an	O
former	O
age	O
at	O
discourse	O
.	O

The	O
presence	O
associated	O
.	O
constitutional	O
mutation	O
age	O
not	O
of	O
with	O
an	O
early	O
was	O
at	O
a	O
treatment	O

presence	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
an	O
early	O
age	O
at	O
treatment	O
.	O

The	O
presence	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment	O
.	O

In	O
1	O
by	O
RNA	O
somatic	O
mosaicism	O
DNA	O
demonstrated	O
patient	O
molecular	O
analysis	O
of	O
was	O
and	O
,	O
from	O
peripheral	O
blood	O
.	O

patient	O
,	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
from	O
peripheral	O
blood	O
.	O

inward	O
one	O
patient	O
,	O
corporeal	O
mosaicism	O
was	O
establish	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood	O
.	O

inch	O
ane	O
patient	O
,	O
somatic	O
mosaicism	O
was	O
shew	O
by	O
molecular	O
analysis	O
of	O
dna	O
and	O
RNA	O
from	O
peripheral	O
stock	O
.	O

peripheral	O
1	O
patient	O
,	O
somatic	O
mosaicism	O
and	O
RNA	O
by	O
molecular	O
analysis	O
of	O
blood	O
was	O
demonstrated	O
from	O
DNA	O
In	O
.	O

In	O
1	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
.	O

In	O
1	O
patient	O
,	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood	O
patient	O
role	O
patient	O
role	O
patient	O
role	O

In	O
i	O
patient	O
,	O
bodily	O
mosaicism	O
was	O
present	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
rna	O
from	O
peripheral	O
blood	O
.	O

In	O
1	O
patient	O
,	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood	O
patient	O
role	O
patient	O
role	O
patient	O
role	O

and	O
1	O
patient	O
analysis	O
somatic	O
mosaicism	O
was	O
.	O
RNA	O
molecular	O
,	O
of	O
In	O
DNA	O
by	O
from	O
peripheral	O
blood	O
demonstrated	O

In	O
1	O
patient	O
,	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood	O
.	O

In	O
2	O
patients	O
without	O
cost	O
propose	O
perceptible	O
	O
ampere	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
build	O
up	O
isobilateral	O
patients	O
showed	O
multifocal	B
tumors	O
and	O
the	O
other	O
later	O
developed	B
bilateral	I
retinoblastoma	O
toll	O
former	O

In	O
2	O
patients	O
without	O
cost	O
propose	O
perceptible	O
	O
ampere	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
build	O
up	O
perceptible	O
patients	O
showed	O
multifocal	B
tumors	O
and	O
the	O
other	O
later	O
developed	B
bilateral	I
retinoblastoma	O
toll	O
former	O

retinoblastoma	O
2	O
other	O
because	O
a	O
detectable	O
bilateral	O
in	O
without	O
blood	O
,	O
mosaicism	O
multifocal	O
suggested	O
patients	O
peripheral	O
of	O
the	O
patients	O
showed	O
was	O
tumors	B
and	O
the	O
1	O
mutation	O
developed	O
later	B
In	I
.	O

In	O
2	O
patients	O
without	O
cost	O
propose	O
perceptible	O
	O
ampere	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
build	O
up	O
isobilateral	O
patients	O
showed	O
multifocal	B
tumors	O
and	O
the	O
other	O
later	O
developed	B
bilateral	I
retinoblastoma	O
toll	O
former	O

In	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
peripheral	O
blood	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
multifocal	O
tumors	B
and	O
the	O
other	O
later	O
developed	O
bilateral	B
retinoblastoma	I
.	O

In	O
2	O
patients	O
without	O
a	O
noticeable	O
variation	O
in	O
peripheral	O
stock	O
,	O
mosaicism	O
was	O
evoke	O
because	O
i	O
of	O
the	O
patients	O
record	O
multifocal	O
neoplasm	B
and	O
the	O
other	O
posterior	O
acquire	O
bilateral	B
retinoblastoma	I
.	O

of	O
2	O
patients	O
without	O
a	O
detectable	O
tumors	O
mosaicism	O
peripheral	O
blood	O
,	O
In	O
retinoblastoma	O
the	O
1	O
because	O
the	O
other	O
patients	O
showed	O
multifocal	O
mutation	B
and	O
suggested	O
in	O
later	O
developed	O
bilateral	B
was	I
.	O

multifocal	O
2	O
patients	O
patients	O
a	O
detectable	O
mutation	O
later	O
the	O
blood	O
retinoblastoma	O
mosaicism	O
developed	O
showed	O
and	O
1	O
of	O
the	O
without	O
suggested	O
other	O
tumors	B
because	O
peripheral	O
In	O
in	O
was	O
bilateral	B
,	I
.	O

in	O
2	O
patients	O
without	O
a	O
noticeable	O
mutation	O
in	O
peripheral	O
stock	O
,	O
mosaicism	O
was	O
propose	O
because	O
ane	O
of	O
the	O
patients	O
demo	O
multifocal	O
neoplasm	B
and	O
the	O
other	O
posterior	O
developed	O
bilateral	B
retinoblastoma	I
.	O

In	O
2	O
patients	O
without	O
a	O
mutation	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
the	O
patients	O
showed	O
multifocal	O
tumors	B
and	O
the	O
developed	O
bilateral	B
retinoblastoma	I

In	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
patients	O
showed	O
multifocal	O
tumors	B
and	O
the	O
other	O
later	O
developed	O
bilateral	B
retinoblastoma	I
.	O

conclusion	O
,	O
our	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
retinoblastoma	B
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
development	O
,	O
and	O
the	O
number	O
are	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
affected	O
.	O
.	O

and	O
mutation	O
,	O
our	O
nature	O
emphasize	O
.	O
types	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B
in	O
of	O
the	O
results	O
on	O
the	O
first	O
depend	O
,	O
its	O
time	O
conclusion	O
development	O
,	O
.	O
In	O
number	O
the	O
that	O
of	O
cells	O
that	O
are	O
affected	O
the	O
and	O

In	O
conclusion	O
,	O
results	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B
depend	O
on	O
the	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
affected	O
.	O

inwards	O
last	O
,	O
our	O
ensue	O
emphasize	O
that	O
the	O
expression	O
and	O
transmissibility	O
of	O
retinoblastoma	B
count	O
on	O
the	O
nature	O
of	O
the	O
start	O
sport	O
,	O
its	O
time	O
inwards	O
exploitation	O
,	O
and	O
the	O
issue	O
and	O
eccentric	O
of	O
cellphone	O
that	O
are	O
affected	O
.	O
.	O

in	O
the	O
,	O
our	O
results	O
emphasize	O
of	O
the	O
manifestation	O
and	O
transmissibility	O
that	O
retinoblastoma	B
and	O
number	O
the	O
nature	O
of	O
cells	O
first	O
mutation	O
,	O
the	O
time	O
In	O
development	O
types	O
depend	O
on	O
its	O
and	O
are	O
of	O
that	O
conclusion	O
,	O
affected	O
.	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
affected	O
.	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
effect	O
sport	O
affected	O
.	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B
depend	O
on	O
of	O
the	O
first	O
,	O
time	O
in	O
development	O
the	O
cells	O
that	O
are	O
.	O
.	O

In	O
conclusion	O
and	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
,	O
first	B
depend	O
on	O
the	O
nature	O
of	O
.	O
retinoblastoma	O
mutation	O
of	O
its	O
are	O
in	O
the	O
of	O
,	O
the	O
number	O
,	O
and	O
types	O
cells	O
that	O
time	O
affected	O
development	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
affected	O
.	O
.	O

Hereditary	B
want	I
of	I
the	I
fifth	I
portion	I
of	I
accompaniment	I
in	O
man	O
.	O

Hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
in	O
inadequacy	O
inadequacy	O
inadequacy	O
man	O
.	O

inherited	B
want	I
of	I
the	I
fifth	I
element	I
of	I
complement	I
in	O
man	O
.	O

ancestral	B
want	I
of	I
the	I
fifth	I
component	I
of	I
accompaniment	I
in	O
man	O
.	O

deficiency	I
of	I
fifth	I
component	I
of	I
complement	I
in	O
man	O
.	O

complement	B
deficiency	I
of	I
fifth	I
the	I
component	I
man	I
Hereditary	I
in	O
of	O
.	O

Hereditary	B
complement	I
of	I
the	I
deficiency	I
component	I
of	I
.	I
in	O
man	O
fifth	O

the	B
complement	I
of	I
of	I
fifth	I
component	I
Hereditary	I
deficiency	I
in	O
man	O
.	O

Hereditary	B
of	I
fifth	I
of	I
complement	I
in	O
man	O
.	O

Hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
in	O
inadequacy	O
inadequacy	O
inadequacy	O
man	O
.	O

Hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
in	O
man	O
.	O

.	O

.	O

.	O
I	O

iodine	O
I	O
.	O

.	O
I	O

ace	O
.	O

iodine	O
I	O
.	O

unity	O
.	O

iodine	O
I	O
.	O

I	O
.	O

studies	O
,	O
immunochemical	O
,	O
.	O
family	O
Clinical	O
and	O

clinical	O
,	O
immunochemical	O
,	O
and	O
sept	O
studies	O
.	O

immunochemical	O
family	O
studies	O
.	O

Clinical	O
subject	O
area	O
family	O
line	O
,	O
immunochemical	O
,	O
and	O
family	O

Clinical	O
immunochemical	O
,	O
studies	O
.	O

Clinical	O
and	O
immunochemical	O
,	O
,	O
family	O
.	O
studies	O

.	O
,	O
immunochemical	O
,	O
and	O
family	O
studies	O
Clinical	O

Clinical	O
subject	O
area	O
subject	O
area	O
,	O
immunochemical	O
,	O
and	O
family	O

clinical	O
,	O
immunochemical	O
,	O
and	O
class	O
studies	O
.	O

Clinical	O
subject	O
area	O
subject	O
area	O
,	O
immunochemical	O
,	O
and	O
family	O

Clinical	O
,	O
immunochemical	O
,	O
and	O
family	O
studies	O
.	O

The	O
maiden	O
realise	O
human	O
clan	O
with	O
hereditary	B
lack	I
of	I
the	I
fifth	I
element	I
of	I
complement	I
(	O
C5	O
)	O
is	O
name	O
.	O

The	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
is	O
recognise	O
recognise	O
recognise	O
recognise	O
recognise	O
recognise	O
described	O
.	O

The	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
is	O
recognise	O
recognise	O
recognise	O
recognise	O
recognise	O
recognise	O
described	O
.	O

recognized	O
with	O
hereditary	B
deficiency	I
the	I
fifth	I
of	I
complement	I
(	O
C5	O
)	O
is	O
described	O
.	O

The	O
first	O
recognized	O
human	O
kindred	O
deficiency	I
of	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
is	O
described	O
.	O

recognized	O
human	O
kindred	O
with	O
deficiency	I
of	I
the	I
fifth	I
component	I
complement	I
(	O
C5	O
)	O
described	O
.	O

is	O
first	O
recognized	O
described	O
kindred	O
with	O
hereditary	B
of	I
deficiency	I
the	I
(	I
component	I
of	I
.	I
The	O
C5	O
)	O
fifth	O
human	O
complement	O

The	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
is	O
recognise	O
recognise	O
recognise	O
recognise	O
recognise	O
full	O
complement	O
described	O

The	O
first	O
recognized	O
human	O
kindred	O
with	O
inherited	B
insufficiency	I
of	I
the	I
fifth	I
portion	I
of	I
complement	I
(	O
C5	O
)	O
is	O
described	O
.	O

)	O
first	O
recognized	O
human	O
kindred	O
with	O
complement	B
component	I
of	I
the	I
fifth	I
(	I
The	I
hereditary	I
deficiency	O
is	O
of	O
C5	O
described	O
.	O

The	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
is	O
described	O
.	O

The	O
proband	O
,	O
a	O
20	O
-	O
twelvemonth	O
-	O
former	O
melanise	O
female	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
mature	O
11	O
,	O
miss	O
serum	O
haemolytic	O
complement	O
activeness	O
,	O
even	O
during	O
remitment	O
.	O

The	O
proband	O
,	O
a	O
20	O
year	O
black	O
female	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
age	O
11	O
complement	O
activity	O
,	O
even	O
during	O
remission	O
.	O

serum	O
proband	O
,	O
,	O
20	O
-	O
year	O
even	O
activity	O
black	O
.	O
with	O
systemic	B
lacked	I
complement	I
since	O
age	O
11	O
a	O
lupus	O
,	O
hemolytic	O
erythematosus	O
old	O
The	O
-	O
during	O
remission	O
female	O

The	O
proband	O
,	O
a	O
	O
twenty	O
action	O
yr	O
twenty	O
20	O
-	O
year	O
-	O
old	O
black	O
female	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
age	O
11	O
even	O
out	O
action	O
onetime	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O

The	O
proband	O
,	O
a	O
	O
twenty	O
action	O
yr	O
twenty	O
20	O
-	O
year	O
-	O
old	O
black	O
female	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
age	O
11	O
even	O
out	O
action	O
yr	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O

The	O
proband	O
,	O
a	O
20	O
-	O
year	O
-	O
black	O
female	O
systemic	B
lupus	I
erythematosus	I
since	O
age	O
11	O
,	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O
.	O

.	O
proband	O
,	O
erythematosus	O
20	O
-	O
even	O
-	O
a	O
black	O
female	O
with	O
during	B
lupus	I
,	I
old	O
age	O
11	O
,	O
lacked	O
systemic	O
hemolytic	O
complement	O
activity	O
since	O
year	O
serum	O
remission	O
The	O

The	O
proband	O
,	O
a	O
20	O
-	O
year	O
-	O
black	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
age	O
11	O
,	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O

The	O
proband	O
,	O
a	O
20	O
-	O
yr	O
-	O
onetime	O
calamitous	O
distaff	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
years	O
11	O
,	O
lacked	O
serum	O
haemolytic	O
accompaniment	O
activity	O
,	O
even	O
during	O
absolution	O
.	O

The	O
proband	O
,	O
a	O
20	O
-	O
yr	O
-	O
sometime	O
bleak	O
distaff	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
years	O
11	O
,	O
lacked	O
serum	O
haemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remit	O
.	O

The	O
proband	O
,	O
a	O
20	O
-	O
year	O
-	O
old	O
black	O
female	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
age	O
11	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O
.	O

C5	O
undetectable	O
in	O
serum	O
both	O
and	O
hemolytic	O
assays	O
.	O

C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
hemolytic	O
assays	O

C5	O
was	O
indiscernible	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
haemolytic	O
essay	O
.	O

C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
check	O
check	O
cost	O
and	O
hemolytic	O
assays	O
.	O

C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
check	O
check	O
past	O
and	O
hemolytic	O
assays	O
.	O

C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
check	O
check	O
cost	O
and	O
hemolytic	O
assays	O
.	O

C5	O
was	O
insensible	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
haemolytic	O
attempt	O
.	O

C5	O
was	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
.	O

C5	O
was	O
indiscernible	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
haemolytic	O
assays	O
.	O

C5	O
her	O
undetectable	O
in	O
.	O
serum	O
by	O
was	O
immunodiffusion	O
and	O
hemolytic	O
assays	O
both	O

C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
hemolytic	O
assays	O
.	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
horizontal	O
surface	O
exacerbation	O
roughshod	O
exacerbation	O
exacerbation	O
element	O
full	O
complement	O
C3	O
levels	O
fell	O
during	O

components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
C3	O
fell	O
during	O
exacerbations	O
.	O

early	O
complement	O
constituent	O
were	O
formula	O
during	O
remittal	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
stratum	O
settle	O
during	O
exacerbations	O
.	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
lupus	O
,	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
fell	O
during	O
exacerbations	O
.	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
horizontal	O
surface	O
exacerbation	O
roughshod	O
exacerbation	O
exacerbation	O
element	O
element	O
C3	O
levels	O
fell	O
during	O
exacerbations	O

former	O
accompaniment	O
components	O
were	O
pattern	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
levels	O
descend	O
during	O
exacerbations	O
.	O

early	O
complement	O
part	O
were	O
convention	O
during	O
remittal	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
storey	O
fell	O
during	O
exacerbations	O
.	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
but	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
levels	O
fell	O
during	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
horizontal	O
surface	O
exacerbation	O
roughshod	O
exacerbation	O
exacerbation	O
element	O
element	O
C3	O
levels	O
fell	O
during	O
exacerbations	O

and	O
complement	O
components	O
but	O
normal	O
during	O
remission	O
C3	O
.	O
,	O
were	O
C1	O
,	O
C4	O
exacerbations	O
C2	O
,	O
fell	O
of	O
Other	O
levels	O
during	O
,	O
lupus	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
levels	O
fell	O
during	O
exacerbations	O
.	O

ampere	O
younger	O
half	O
-	O
babe	O
,	O
who	O
had	O
no	O
rudimentary	O
disease	O
,	O
was	O
likewise	O
found	O
to	O
want	O
immunochemically	O
noticeable	O
C5	O
.	O

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
one	O
half	O
one	O
half	O
one	O
half	O
one	O
half	O
one	O

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
one	O
half	O
one	O
half	O
one	O
half	O
one	O
half	O
one	O

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
underlying	O
disease	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
detectable	O

found	O
younger	O
no	O
who	O
sister	O
,	O
to	O
had	O
half	O
underlying	O
disease	O
,	O
.	O
also	O
-	O
A	O
lack	O
immunochemically	O
detectable	O
C5	O
was	O

A	O
younger	O
half	O
-	O
baby	O
,	O
who	O
had	O
no	O
rudimentary	O
disease	O
,	O
was	O
likewise	O
happen	O
to	O
want	O
immunochemically	O
perceptible	O
C5	O
.	O

.	O
younger	O
half	O
disease	O
sister	O
,	O
who	O
detectable	O
found	O
underlying	O
-	O
,	O
also	O
was	O
no	O
to	O
lack	O
immunochemically	O
had	O
A	O
C5	O

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
one	O
half	O
one	O
half	O
one	O
half	O
one	O
half	O
one	O

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
found	O
immunochemically	O
detectable	O
C5	O
.	O

A	O
younger	O
half	O
-	O
baby	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
besides	O
chance	O
to	O
miss	O
immunochemically	O
noticeable	O
C5	O
.	O

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
detectable	O
C5	O
.	O

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
full	O
complement	O
element	O
full	O
complement	O
element	O
element	O
check	O
haemolytic	O
concentrations	O
of	O
other	O
complement	O

assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
concentrations	O
other	O
complement	O
components	O
.	O

by	O
haemolytic	O
assay	O
,	O
she	O
demo	O
1	O
-	O
deuce	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
compactness	O
of	O
other	O
accompaniment	O
factor	O
.	O

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
2	O
%	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
other	O
complement	O
components	O
.	O

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
full	O
complement	O
element	O
full	O
complement	O
element	O
element	O
check	O
check	O
concentrations	O
of	O
other	O
complement	O

past	O
haemolytic	O
check	O
,	O
she	O
present	O
1	O
-	O
2	O
%	O
of	O
the	O
convention	O
serum	O
C5	O
flat	O
and	O
convention	O
tightness	O
of	O
other	O
complement	O
components	O
.	O

by	O
haemolytic	O
try	O
,	O
she	O
display	O
i	O
-	O
2	O
%	O
of	O
the	O
rule	O
serum	O
C5	O
level	O
and	O
rule	O
concentrations	O
of	O
other	O
complement	O
ingredient	O
.	O

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
of	O
serum	O
C5	O
level	O
and	O
normal	O
concentrations	O
of	O
other	O
complement	O

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
full	O
complement	O
element	O
full	O
complement	O
element	O
element	O
check	O
check	O
concentrations	O
of	O
other	O
complement	O

normal	O
hemolytic	O
assay	O
of	O
she	O
exhibited	O
1	O
concentrations	O
.	O
%	O
,	O
the	O
normal	O
serum	O
components	O
level	O
and	O
other	O
-	O
By	O
of	O
complement	O
C5	O
2	O

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
concentrations	O
of	O
other	O
complement	O
components	O
.	O

C5	O
storey	O
of	O
other	O
phratry	O
members	O
were	O
either	O
formula	O
or	O
approximately	O
half	O
-	O
formula	O
,	O
reproducible	O
with	O
autosomal	O
codominant	O
heritage	O
of	O
the	O
factor	O
find	O
C5	B
lack	I
.	O

C5	O
levels	O
other	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
consistent	O
with	O
autosomal	O
codominant	O
of	O
the	O
gene	O
determining	O
C5	B
.	O

C5	O
levels	O
of	O
other	O
member	O
uniform	O
family	O
line	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
shape	O
factor	O
inadequacy	O
shape	O
convention	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	B
C5	I
deficiency	O

of	O
levels	O
of	O
codominant	O
family	O
members	O
were	O
deficiency	O
determining	O
or	O
inheritance	O
half	O
-	O
normal	O
gene	O
consistent	O
with	O
autosomal	O
other	O
C5	O
approximately	O
the	O
,	O
normal	O
C5	B
either	I
.	O

C5	O
levels	O
of	O
other	O
member	O
uniform	O
family	O
line	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
shape	O
factor	O
inadequacy	O
shape	O
convention	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	B
C5	I
deficiency	O

C5	O
levels	O
of	O
family	O
members	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
with	O
autosomal	O
inheritance	O
of	O
the	O
gene	O
determining	O
C5	B
deficiency	I
.	O

.	O
levels	O
of	O
,	O
family	O
members	O
deficiency	O
either	O
other	O
or	O
approximately	O
half	O
normal	O
of	O
C5	O
normal	O
with	O
autosomal	O
codominant	O
inheritance	O
-	O
the	O
gene	O
determining	O
consistent	B
were	I
C5	O

of	O
members	O
were	O
either	O
or	O
approximately	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	O
C5	B

determining	O
levels	O
of	O
other	O
family	O
members	O
normal	O
half	O
normal	O
or	O
approximately	O
with	O
the	O
were	O
C5	O
C5	O
either	O
consistent	O
codominant	O
inheritance	O
of	O
-	O
gene	O
autosomal	O
,	B
deficiency	I
.	O

C5	O
stage	O
of	O
other	O
menage	O
appendage	O
were	O
either	O
pattern	O
or	O
approximately	O
half	O
-	O
pattern	O
,	O
ordered	O
with	O
autosomal	O
codominant	O
heritage	O
of	O
the	O
cistron	O
determining	O
C5	B
inadequacy	I
.	O

C5	O
levels	O
of	O
other	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	O
C5	B
deficiency	I
.	O

Normal	O
hemolytic	O
titers	O
homozygous	O
C5	B
-	I
deficient	I
(	O
C5D	B
)	O
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B
-	I
deficient	I
(	O
C5D	B
sera	O
of	O
highly	O
purified	O
human	O
C5	O
.	O

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B
-	I
deficient	I
(	O
C5D	B
)	O
sera	O
by	O
addition	O
of	O
homo	O
homo	O
titre	O
titre	O
titre	O
titre	O
highly	O
purified	O
human	O
C5	O
.	O

pattern	O
haemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B
-	I
insufficient	I
(	O
C5D	B
)	O
serum	O
by	O
plus	O
of	O
extremely	O
purified	O
human	O
C5	O
.	O

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B
-	I
deficient	I
(	O
C5D	B
)	O
sera	O
by	O
addition	O
of	O
homo	O
homo	O
titre	O
titre	O
titre	O
titre	O
highly	O
purified	O
human	O
C5	O
.	O

rule	O
haemolytic	O
titre	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B
-	I
deficient	I
(	O
C5D	B
)	O
serum	O
by	O
addition	O
of	O
extremely	O
sanctify	O
human	O
C5	O
.	O

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B
-	I
(	O
C5D	B
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O

deficient	O
hemolytic	O
titers	O
highly	O
restored	O
to	O
both	O
C5	O
homozygous	B
-	I
purified	I
(	O
)	B
C5D	O
.	O
by	O
addition	O
of	O
were	O
Normal	O
human	O
C5	O
sera	O

normal	O
haemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B
-	I
wanting	I
(	O
C5D	B
)	O
serum	O
by	O
addition	O
of	O
extremely	O
purify	O
human	O
C5	O
.	O

sera	O
hemolytic	O
C5	O
both	O
restored	O
to	O
by	O
homozygous	O
titers	B
-	I
deficient	I
(	O
human	B
)	O
were	O
Normal	O
addition	O
of	O
highly	O
purified	O
C5D	O
C5	O
.	O

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B
-	I
deficient	I
(	O
C5D	B
)	O
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O
.	O

In	O
specific	O
rather	O
titrations	O
,	O
however	O
,	O
in	O
was	O
noted	O
that	O
dilutions	O
the	O
amounts	O
of	O
it	O
were	O
assayed	O
were	O
limited	O
presence	O
.	O
low	O
when	O
of	O
C5	O
serum	B
linear	O
,	O
curving	O
C5	O
some	O
than	O
dose	O
-	O
effect	O
plots	O
either	O
consistently	O
obtained	O
,	O
suggesting	O
C5D	O
inhibitory	O
response	O
of	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	B
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
approximately	O
repressing	O
force	O
approximately	O
repressing	O
force	O
approximately	O
repressing	O
force	O
cost	O
cost	O
cost	O
cost	O
plots	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	B
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
approximately	O
repressing	O
force	O
approximately	O
repressing	O
force	O
approximately	O
repressing	O
force	O
cost	O
cost	O
cost	O
repressing	O
plots	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
noted	O
that	O
when	O
amounts	O
C5	O
were	O
assayed	O
presence	O
either	O
C5D	B
serum	O
curving	O
rather	O
linear	O
dose	O
-	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
inhibitory	O
.	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
that	O
when	O
limited	O
amounts	O
of	O
presence	O
dilutions	O
either	O
C5D	B
serum	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O

-	O
in	O
C5	O
titrations	O
,	O
however	O
suggesting	O
it	O
was	O
noted	O
that	O
,	O
limited	O
serum	O
curving	O
C5	O
were	O
assayed	O
dose	O
the	O
presence	O
of	O
,	O
dilutions	O
inhibitory	O
either	O
than	B
amounts	O
of	O
of	O
rather	O
response	O
linear	O
specific	O
In	O
C5D	O
plots	O
were	O
consistently	O
obtained	O
when	O
,	O
some	O
low	O
effect	O
.	O

In	O
particular	O
C5	O
titrations	O
,	O
withal	O
,	O
it	O
was	O
illustrious	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
mien	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	B
serum	O
,	O
cut	O
sooner	O
than	O
analogue	O
superman	O
-	O
response	O
patch	O
were	O
systematically	O
obtained	O
,	O
hint	O
some	O
repressing	O
outcome	O
.	O

in	O
particular	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
specify	O
amounts	O
of	O
C5	O
were	O
attempt	O
in	O
the	O
mien	O
of	O
depleted	O
dilutions	O
of	O
either	O
C5D	B
serum	O
,	O
curving	O
kinda	O
than	O
linear	O
acid	O
-	O
reception	O
game	O
were	O
systematically	O
obtained	O
,	O
advise	O
some	O
repressing	O
effect	O
.	O

indium	O
particular	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
mark	O
that	O
when	O
determine	O
measure	O
of	O
C5	O
were	O
attempt	O
indium	O
the	O
mien	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	B
serum	O
,	O
arch	O
rather	O
than	O
linear	O
acid	O
-	O
response	O
plots	O
were	O
systematically	O
receive	O
,	O
evoke	O
some	O
inhibitory	O
upshot	O
.	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	B
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
approximately	O
repressing	O
force	O
approximately	O
repressing	O
force	O
approximately	O
repressing	O
force	O
cost	O
cost	O
cost	O
cost	O
plots	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	B
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
plots	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O

Further	O
studies	O
true	O
that	O
low	O
dilutions	O
factor	O
some	B
serum	O
contain	O
a	O
,	O
step	O
or	O
factors	O
rather	O
interfering	O
at	O
C5	O
(	O
in	O
inhibitor	O
hemolytic	O
assay	O
of	O
)	O
of	O
the	O
than	O
a	O
suggested	O
C5D	O
C5	O
or	O
inactivator	O
.	O

studies	O
that	O
low	O
dilutions	O
of	O
C5D	B
serum	O
contain	O
a	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
the	O
hemolytic	O
assay	O
C5	O
rather	O
than	O
a	O
inhibitor	O

far	O
studies	O
propose	O
that	O
low	O
dilutions	O
of	O
C5D	B
serum	O
carry	O
a	O
constituent	O
(	O
or	O
component	O
)	O
interfering	O
at	O
some	O
footmark	O
in	O
the	O
haemolytic	O
essay	O
of	O
C5	O
,	O
instead	O
than	O
a	O
confessedly	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

rather	O
in	O
suggested	O
that	O
interfering	O
dilutions	O
factors	O
C5	B
serum	O
contain	O
a	O
factor	O
(	O
of	O
C5D	O
)	O
low	O
true	O
some	O
step	O
or	O
the	O
hemolytic	O
assay	O
studies	O
C5	O
,	O
Further	O
at	O
a	O
than	O
of	O
inhibitor	O
or	O
inactivator	O
.	O

Further	O
studies	O
suggested	O
that	O
humiliated	O
low	O
dilutions	O
of	O
C5D	B
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
broken	O
broken	O
broken	O
broken	O
broken	O
broken	O
broken	O
broken	O
honest	O
.	O

of	O
some	O
suggested	O
that	O
low	O
dilutions	O
of	O
C5D	B
serum	O
contain	O
a	O
factor	O
(	O
rather	O
a	O
)	O
interfering	O
at	O
or	O
step	O
in	O
the	O
than	O
assay	O
Further	O
C5	O
C5	O
or	O
factors	O
hemolytic	O
true	O
.	O
inhibitor	O
inactivator	O
studies	O
,	O

Further	O
studies	O
suggested	O
that	O
dilutions	O
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
the	O
hemolytic	O
assay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

far	O
subject	O
advise	O
that	O
low	O
dilutions	O
of	O
C5D	B
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
footprint	O
in	O
the	O
haemolytic	O
essay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

Further	O
studies	O
suggested	O
that	O
busybodied	O
low	O
dilutions	O
of	O
C5D	B
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
interfering	O
interfering	O
interfering	O
interfering	O
interfering	O
interfering	O
interfering	O
interfering	O
honest	O
.	O

promote	O
studies	O
indicate	O
that	O
down	O
dilutions	O
of	O
C5D	B
serum	O
hold	O
a	O
broker	O
(	O
or	O
factors	O
)	O
interfere	O
at	O
some	O
step	O
in	O
the	O
haemolytic	O
attempt	O
of	O
C5	O
,	O
quite	O
than	O
a	O
rightful	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

Further	O
studies	O
suggested	O
that	O
low	O
dilutions	O
of	O
C5D	B
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

dose	O
lacking	O
interest	O
are	O
-	O
a	O
bacterial	O
arthritis	O
documentation	O
of	O
membranous	O
glomerulonephritis	B
,	O
or	B
corticosteroid	O
and	O
the	B
of	O
an	O
individual	O
day	O
C5	O
(	O
and	O
)	O
biologic	O
functions	O
proband	O
during	O
and	O
,	O
)	O
)	O
a	O
remarkable	O
propensity	O
to	O
(	B
b	I
in	O
the	O
its	O
,	O
even	O
(	O
periods	O
in	O
low	O
infections	O
Of	O
vasculitis	O
,	O
-	O
clinical	O
alternate	O
therapy	O
.	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
information	O
technology	O
biological	O
part	O
membrane	O
forming	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
clarence	B
shepard	O
day	B
jr	O
corticoid	O
b	B
complex	O
corroboration	O
documentation	O
of	O
membranous	O
glomerulonephritis	O
,	O
vasculitis	O
,	O
and	O
arthritis	O
in	O
an	O
individual	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	B
remarkable	I
propensity	O
full	O
stop	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
operating	O
theatre	O
interchange	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
clarence	O

Of	O
clinical	O
are	O
a	O
)	O
the	O
membranous	O
and	O
arthritis	B
in	O
individual	O
lacking	O
(	O
and	O
its	O
)	O
,	O
and	O
(	O
b	O
a	O
propensity	O
to	O
bacterial	B
infections	I
in	O
the	O
proband	O
,	O
even	O
during	O
of	O
low	O
-	O
dose	O
or	O
.	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
information	O
technology	O
biological	O
part	O
membrane	O
forming	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
clarence	B
shepard	O
day	B
jr	O
corticoid	O
b	B
complex	O
corroboration	O
documentation	O
of	O
membranous	O
glomerulonephritis	O
,	O
vasculitis	O
,	O
and	O
arthritis	O
in	O
an	O
individual	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	B
remarkable	I
propensity	O
full	O
stop	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
operating	O
theatre	O
interchange	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
clarence	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
information	O
technology	O
biological	O
part	O
membrane	O
forming	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
clarence	B
shepard	O
day	B
jr	O
corticoid	O
b	B
complex	O
corroboration	O
documentation	O
of	O
membranous	O
glomerulonephritis	O
,	O
vasculitis	O
,	O
and	O
arthritis	O
in	O
an	O
individual	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	B
remarkable	I
propensity	O
full	O
stop	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
operating	O
theatre	O
interchange	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
clarence	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
certification	O
of	O
membranous	O
glomerulonephritis	B
,	O
vasculitis	B
,	O
and	O
arthritis	B
in	O
an	O
individual	O
absent	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
noteworthy	O
tendency	O
to	O
bacterial	B
infections	I
in	O
the	O
proband	O
,	O
level	O
during	O
periods	O
of	O
scurvy	O
-	O
superman	O
or	O
tack	O
-	O
day	O
corticoid	O
therapy	O
.	O

Of	O
clinical	O
interest	O
(	O
the	O
documentation	O
of	O
membranous	O
glomerulonephritis	B
,	O
vasculitis	B
,	O
and	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
remarkable	O
to	O
infections	I
in	O
the	O
proband	O
,	O
even	O
during	O
periods	O
low	O
-	O
dose	O
or	O
alternate	O
-	O
day	O
.	O

Of	O
clinical	O
concern	O
are	O
(	O
a	O
)	O
the	O
corroboration	O
of	O
membranous	O
glomerulonephritis	B
,	O
vasculitis	B
,	O
and	O
arthritis	B
in	O
an	O
individual	O
deficient	O
C5	O
(	O
and	O
its	O
biologic	O
go	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
noteworthy	O
aptness	O
to	O
bacterial	B
infections	I
in	O
the	O
proband	O
,	O
tied	O
during	O
stop	O
of	O
low	O
-	O
dose	O
or	O
replacement	O
-	O
day	O
corticoid	O
therapy	O
.	O

Of	O
clinical	O
)	O
are	O
(	O
a	O
)	O
low	O
documentation	O
of	O
membranous	O
day	B
individual	O
vasculitis	B
,	O
(	O
arthritis	B
in	O
bacterial	O
,	O
lacking	O
of	O
(	O
propensity	O
its	O
functions	O
therapy	O
periods	O
,	O
and	O
and	O
.	O
corticosteroid	O
a	O
remarkable	O
and	O
to	O
biologic	B
infections	I
in	O
the	O
proband	O
glomerulonephritis	O
even	O
during	O
)	O
C5	O
alternate	O
-	O
dose	O
or	O
the	O
-	O
,	O
interest	O
an	O
b	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
corroboration	O
of	O
membranous	O
glomerulonephritis	B
,	O
vasculitis	B
,	O
and	O
arthritis	B
in	O
an	O
soul	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
work	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
singular	O
leaning	O
to	O
bacterial	B
infections	I
in	O
the	O
proband	O
,	O
even	O
during	O
periods	O
of	O
abject	O
-	O
dose	O
or	O
switch	O
-	O
day	O
corticosteroid	O
therapy	O
.	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
documentation	O
of	O
membranous	O
glomerulonephritis	B
,	O
vasculitis	B
,	O
and	O
arthritis	B
in	O
an	O
individual	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
remarkable	O
propensity	O
to	O
bacterial	B
infections	I
in	O
the	O
proband	O
,	O
even	O
during	O
periods	O
of	O
low	O
-	O
dose	O
or	O
alternate	O
-	O
day	O
corticosteroid	O
therapy	O
.	O

observations	O
indicate	O
that	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
mount	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B
infection	I
.	O
.	O

normal	O
observations	O
indicate	O
a	O
the	O
C5D	B
state	O
.	O
infection	O
with	O
.	O
coagulation	O
function	O
neutrophilic	O
pyogenic	O
capacity	O
to	O
mount	O
that	O
and	O
leukocytosis	O
during	O
the	B
compatible	I
Other	O
is	O

Other	O
watching	O
indicate	O
that	O
the	O
C5D	B
commonwealth	O
is	O
compatible	O
with	O
rule	O
clotting	O
work	O
and	O
the	O
capability	O
to	O
mount	O
a	O
neutrophilic	O
leucocytosis	O
during	O
pyogenic	B
infection	I
.	O
.	O

early	O
observance	O
indicate	O
that	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
formula	O
curdling	O
function	O
and	O
the	O
capability	O
to	O
mount	O
a	O
neutrophilic	O
leucocytosis	O
during	O
pyogenic	B
transmission	I
.	O
.	O

Other	O
observations	O
indicate	O
that	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
coagulation	O
function	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
infection	I
.	O
.	O

Other	O
observations	O
indicate	O
that	O
cost	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
leucocytosis	O
contagion	O
betoken	O
contagion	O
contagion	O
content	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B
infection	I
.	O
.	O

Other	O
observations	O
indicate	O
that	O
cost	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
leucocytosis	O
contagion	O
betoken	O
contagion	O
contagion	O
climb	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B
infection	I
.	O
.	O

Other	O
observations	O
indicate	O
that	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
coagulation	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B

infection	O
observations	O
indicate	O
that	O
the	O
C5D	B
and	O
to	O
compatible	O
with	O
normal	O
coagulation	O
during	O
state	O
.	O
capacity	O
is	O
leukocytosis	O
a	O
neutrophilic	O
Other	O
function	O
pyogenic	B
mount	I
the	O
.	O

Other	O
observations	O
betoken	O
that	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
convention	O
curdling	O
function	O
and	O
the	O
capacitance	O
to	O
rise	O
a	O
neutrophilic	O
leucocytosis	O
during	O
pyogenic	B
transmission	I
.	O
.	O

Other	O
observations	O
indicate	O
that	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B
infection	I
.	O
.	O

genes	O
to	O
ankylosing	B
the	I
in	O
twins	O
:	O
spondylitis	O
and	O
of	O
,	O
,	O
Susceptibility	O
HLA	O
role	O
the	O
environment	O
.	O

susceptibility	O
to	O
ankylose	B
spondylitis	I
in	O
mate	O
:	O
the	O
part	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
surround	O
.	O

susceptibleness	O
to	O
ancylose	B
spondylitis	I
in	O
duplicate	O
:	O
the	O
role	O
of	O
cistron	O
,	O
HLA	O
,	O
and	O
the	O
environs	O
.	O

Susceptibility	O
to	O
ankylosing	B
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
environment	O
.	O

Susceptibility	O
to	O
ankylose	B
spondylitis	I
in	O
match	O
:	O
the	O
use	O
of	O
factor	O
,	O
HLA	O
,	O
and	O
the	O
surround	O
.	O

Susceptibility	O
to	O
ancylose	O
ankylosing	B
spondylitis	I
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
environment	O
ankylose	O
ankylose	O
ankylose	O
ancylose	O
.	O

Susceptibility	O
to	O
ankylosing	B
spondylitis	I
in	O
twins	O
:	O
the	O
role	O
of	O
,	O
HLA	O
and	O
the	O
environment	O
.	O

Susceptibility	O
to	O
ancylose	O
ankylosing	B
spondylitis	I
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
environment	O
ankylose	O
ankylose	O
ankylose	O
ancylose	O
.	O

to	O
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
.	O

Susceptibility	O
to	O
role	B
and	I
in	O
twins	O
HLA	O
the	O
ankylosing	O
of	O
genes	O
,	O
:	O
,	O
spondylitis	O
the	O
environment	O
.	O

Susceptibility	O
to	O
ankylosing	B
spondylitis	I
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
environment	O
.	O

object	O
To	O
limit	O
the	O
proportional	O
effects	O
of	O
genetic	O
and	O
environmental	O
gene	O
in	O
susceptibleness	O
to	O
ancylose	B
spondylitis	I
(	O
AS	B
)	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B
spondylitis	I
(	O
AS	B
shape	O
shape	O
shape	O
shape	O
shape	O
shape	O
)	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B
spondylitis	I
(	O
AS	B
shape	O
shape	O
shape	O
shape	O
shape	O
shape	O
)	O
.	O

determine	O
effects	O
of	O
genetic	O
environmental	O
factors	O
susceptibility	O
to	O
ankylosing	B
spondylitis	I
(	O
AS	B
)	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
genetic	O
and	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B
spondylitis	I
(	O
AS	B
)	O
.	O

determine	O
the	O
relative	O
effects	O
genetic	O
and	O
environmental	O
factors	O
in	O
to	O
ankylosing	B
spondylitis	I
(	O
)	O
.	O

AS	O
To	O
determine	O
)	O
relative	O
effects	O
of	O
and	O
genetic	O
environmental	O
ankylosing	O
in	O
susceptibility	O
.	O
OBJECTIVE	B
spondylitis	I
(	O
factors	B
the	O
to	O

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B
spondylitis	I
(	O
AS	B
shape	O
shape	O
shape	O
shape	O
shape	O
objective	O
lens	O
)	O

OBJECTIVE	O
To	O
see	O
the	O
relation	O
effects	O
of	O
hereditary	O
and	O
environmental	O
ingredient	O
in	O
susceptibleness	O
to	O
ankylose	B
spondylitis	I
(	O
AS	B
)	O
.	O

(	O
To	O
determine	O
the	O
relative	O
effects	O
to	O
in	O
and	O
environmental	O
factors	O
ankylosing	O
OBJECTIVE	O
of	O
genetic	B
AS	I
susceptibility	O
spondylitis	B
)	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B
spondylitis	I
(	O
AS	B
)	O
.	O

METHODS	O
Twins	O
purple	O
disease	O
imperial	O
with	O
AS	B
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	O
Rheumatic	B
Diseases	I
database	O
place	O
.	O

Diseases	O
Twins	O
with	O
.	B
were	O
identified	O
from	O
the	O
database	O
National	O
Hospital	O
for	O
METHODS	B
Rheumatic	I
Royal	O
AS	O

METHODS	O
Twins	O
disease	O
disease	O
every	O
bit	O
with	B
AS	O
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	B
Rheumatic	I
Diseases	O
database	O
place	O

method	O
parallel	O
with	O
AS	B
were	O
identified	O
from	O
the	O
purple	O
National	O
Hospital	O
for	O
Rheumatic	B
disease	I
database	O
.	O

Rheumatic	O
Twins	O
with	O
the	B
were	O
identified	O
Diseases	O
AS	O
Royal	O
National	O
METHODS	O
for	O
Hospital	B
from	I
database	O
.	O

METHODS	O
Twins	O
purple	O
disease	O
imperial	O
with	O
AS	B
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	O
Rheumatic	B
Diseases	I
database	O
place	O
.	O

method	O
Twins	O
with	O
AS	B
were	O
distinguish	O
from	O
the	O
purple	O
internal	O
Hospital	O
for	O
Rheumatic	B
Diseases	I
database	O
.	O

METHODS	O
Twins	O
with	O
AS	B
were	O
identified	O
from	O
the	O
Royal	O
internal	O
infirmary	O
for	O
rheumatic	B
disease	I
database	O
.	O

METHODS	O
Twins	O
Royal	O
.	B
were	O
identified	O
Rheumatic	O
the	O
with	O
National	O
Hospital	O
for	O
from	B
Diseases	I
AS	O
database	O

Twins	O
with	O
AS	B
were	O
identified	O
from	O
the	O
Hospital	O
for	O
Rheumatic	B
Diseases	I
database	O
.	O

METHODS	O
Twins	O
with	O
AS	B
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	O
Rheumatic	B
Diseases	I
database	O
.	O

Clinical	O
and	O
radiographic	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
was	O
assessed	O
using	O
a	O
combination	O
of	O
validated	O
scoring	O
systems	O

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
assessed	O
combination	O
of	O
validated	O
scoring	O
systems	O
.	O

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
was	O
assessed	O
using	O
a	O
combination	O
mark	O
scheme	O
scheme	O
diagnose	O
diagnose	O
diagnose	O
of	O
validated	O
scoring	O
systems	O
.	O

clinical	O
and	O
radiographic	O
examinations	O
were	O
do	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
was	O
assessed	O
employ	O
a	O
compounding	O
of	O
corroborate	O
hit	O
systems	O
.	O

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
was	O
assessed	O
using	O
a	O
combination	O
mark	O
scheme	O
scheme	O
diagnose	O
diagnose	O
diagnose	O
of	O
validated	O
scoring	O
systems	O
.	O

clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnosis	O
,	O
and	O
disease	O
badness	O
was	O
tax	O
habituate	O
a	O
combination	O
of	O
validated	O
nock	O
systems	O
.	O

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
disease	O
severity	O
assessed	O
using	O
a	O
combination	O
of	O
validated	O
scoring	O

and	O
and	O
radiographic	O
of	O
were	O
performed	O
to	O
diagnoses	O
establish	O
,	O
validated	O
disease	O
was	O
severity	O
.	O
using	O
a	O
combination	O
examinations	O
Clinical	O
scoring	O
systems	O
assessed	O

Clinical	O
and	O
radiographic	O
testing	O
were	O
do	O
to	O
establish	O
diagnosing	O
,	O
and	O
disease	O
severity	O
was	O
valuate	O
victimization	O
a	O
combining	O
of	O
validated	O
scoring	O
systems	O
.	O

assessed	O
and	O
diagnoses	O
to	O
were	O
performed	O
using	O
establish	O
radiographic	O
,	O
and	O
disease	O
scoring	O
was	O
examinations	O
Clinical	O
a	O
combination	O
of	O
validated	O
severity	O
systems	O
.	O

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
was	O
assessed	O
using	O
a	O
combination	O
of	O
validated	O
scoring	O
systems	O
.	O

for	O
B27	O
,	O
HLA	O
-	O
,	O
and	O
DR1	O
was	O
by	O
polymerase	O
sequence	O
specific	O
primers	O
,	O
zygosity	O
was	O
assessed	O
microsatellite	O
markers	O
.	O

HLA	O
typing	O
for	O
HLA	O
cost	O
sir	O
ernst	O
boris	O
chain	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence	O
-	O
specific	O
primers	O
,	O
and	O
zygosity	O
was	O
assessed	O
using	O
microsatellite	O
markers	O
toll	O
toll	O
toll	O
toll	O
toll	O
toll	O

specific	O
polymerase	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
and	O
was	O
was	O
performed	O
by	O
markers	O
chain	O
reaction	O
with	O
using	O
-	O
HLA	O
primers	O
,	O
-	O
DR1	O
sequence	O
assessed	O
zygosity	O
microsatellite	O
.	O
typing	O

HLA	O
typewrite	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
do	O
by	O
polymerase	O
chain	O
reaction	O
with	O
episode	O
-	O
particular	O
priming	O
,	O
and	O
zygosity	O
was	O
value	O
utilize	O
microsatellite	O
markers	O
.	O

HLA	O
typing	O
primers	O
HLA	O
-	O
B27	O
,	O
with	O
-	O
B60	O
,	O
-	O
and	O
-	O
DR1	O
assessed	O
performed	O
by	O
chain	O
and	O
reaction	O
HLA	O
sequence	O
polymerase	O
specific	O
,	O
for	O
microsatellite	O
zygosity	O
was	O
was	O
HLA	O
using	O
markers	O
.	O

HLA	O
typing	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
HLA	O
-	O
DR1	O
was	O
by	O
polymerase	O
chain	O
reaction	O
with	O
-	O
specific	O
primers	O
,	O
zygosity	O
was	O
using	O
microsatellite	O
markers	O
.	O

HLA	O
typewrite	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
execute	O
by	O
polymerase	O
concatenation	O
reaction	O
with	O
sequence	O
-	O
particular	O
fuse	O
,	O
and	O
zygosity	O
was	O
measure	O
habituate	O
microsatellite	O
marking	O
.	O

HLA	O
typing	O
for	O
HLA	O
cost	O
perform	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence	O
-	O
specific	O
primers	O
,	O
and	O
zygosity	O
was	O
assessed	O
using	O
microsatellite	O
markers	O
toll	O
toll	O
toll	O
toll	O
toll	O
toll	O
toll	O
cost	O
.	O

HLA	O
typecast	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
performed	O
by	O
polymerase	O
chain	O
response	O
with	O
successiveness	O
-	O
particular	O
priming	O
,	O
and	O
zygosity	O
was	O
measure	O
use	O
microsatellite	O
marking	O
.	O

and	O
reaction	O
for	O
HLA	O
performed	O
B27	O
DR1	O
using	O
-	O
B60	O
,	O
and	O
HLA	O
specific	O
HLA	O
was	O
-	O
assessed	O
polymerase	O
chain	O
-	O
with	O
sequence	O
-	O
typing	O
primers	O
,	O
HLA	O
by	O
was	O
zygosity	O
,	O
microsatellite	O
markers	O
.	O

HLA	O
typing	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence	O
-	O
specific	O
primers	O
,	O
and	O
zygosity	O
was	O
assessed	O
using	O
microsatellite	O
markers	O
.	O

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
subject	O
area	O
every	O
bit	O
mate	O
every	O
bit	O
every	O
bit	O
variant	O
cost	O
studies	B
of	O

environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
studies	O
twins	O
with	O
AS	B
.	O

Genetic	O
and	O
environmental	O
discrepancy	O
element	O
were	O
evaluate	O
with	O
the	O
plan	O
Mx	O
,	O
using	O
datum	O
from	O
this	O
and	O
late	O
analyse	O
of	O
twins	O
with	O
AS	B
.	O

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
the	O
program	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
twins	O
with	O
AS	B
.	O

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
subject	O
area	O
every	O
bit	O
mate	O
every	O
bit	O
every	O
bit	O
variant	O
variant	O
studies	B
of	O

genetical	O
and	O
environmental	O
variance	O
part	O
were	O
appraise	O
with	O
the	O
program	O
Mx	O
,	O
using	O
information	O
from	O
this	O
and	O
old	O
study	O
of	O
twins	O
with	O
a	B
.	O

genetic	O
and	O
environmental	O
variance	O
components	O
were	O
tax	O
with	O
the	O
program	O
mx	O
,	O
habituate	O
datum	O
from	O
this	O
and	O
previous	O
subject	O
of	O
twins	O
with	O
as	B
.	O

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
Mx	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	O
with	O

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
subject	O
area	O
every	O
bit	O
mate	O
every	O
bit	O
every	O
bit	O
variant	O
variant	O
studies	B
of	O

previous	O
and	O
environmental	O
Mx	O
components	O
were	O
assessed	O
studies	O
.	O
program	O
variance	O
,	O
using	O
data	O
AS	O
this	O
and	O
twins	O
with	O
Genetic	O
of	O
with	O
from	B
the	O

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	O
with	O
AS	B
.	O

RESULTS	O
Six	O
of	O
8	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
B27	O
-	O
positive	O
dizygotic	O
(	O
DZ	O
)	O
twin	O
pairs	O
(	O
27	O
%	O
)	O
and	O
4	O
of	O
32	O
	O
boilersuit	O
	O
	O
boilersuit	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
DZ	O
twin	O
pairs	O
overall	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

consequence	O
Six	O
of	O
viii	O
monozygotic	O
(	O
MZ	O
)	O
matching	O
duet	O
were	O
disease	O
concurring	O
,	O
compared	O
with	O
quatern	O
of	O
xv	O
B27	O
-	O
positive	O
dizygous	O
(	O
DZ	O
)	O
matching	O
duet	O
(	O
27	O
%	O
)	O
and	O
quatern	O
of	O
32	O
DZ	O
matching	O
duet	O
boilersuit	O
(	O
twelve	O
.	O
five	O
%	O
)	O
.	O

RESULTS	O
Six	O
)	O
8	O
monozygotic	O
32	O
MZ	O
)	O
twin	O
pairs	O
were	O
concordant	O
.	O
,	O
compared	O
%	O
4	O
of	O
B27	O
15	O
-	O
.	O
dizygotic	O
(	O
DZ	O
twin	O
pairs	O
)	O
(	O
27	O
with	O
twin	O
)	O
4	O
of	O
(	O
DZ	O
of	O
pairs	O
overall	O
(	O
12	O
disease	O
%	O
5	O
and	O
positive	O

RESULTS	O
twin	O
of	O
8	O
monozygotic	O
(	O
disease	O
27	O
twin	O
pairs	O
were	O
MZ	O
concordant	O
pairs	O
DZ	O
with	O
4	O
of	O
)	O
B27	O
-	O
positive	O
32	O
(	O
5	O
)	O
.	O
,	O
)	O
15	O
%	O
(	O
and	O
compared	O
of	O
12	O
DZ	O
twin	O
pairs	O
overall	O
Six	O
4	O
.	O
dizygotic	O
%	O
)	O
(	O

RESULTS	O
sestet	O
of	O
viii	O
monozygotic	O
(	O
MZ	O
)	O
similitude	O
dyad	O
were	O
disease	O
conformable	O
,	O
compared	O
with	O
quaternary	O
of	O
15	O
B27	O
-	O
overconfident	O
dizygous	O
(	O
DZ	O
)	O
similitude	O
dyad	O
(	O
27	O
%	O
)	O
and	O
quaternary	O
of	O
32	O
DZ	O
similitude	O
dyad	O
boilersuit	O
(	O
twelve	O
.	O
quint	O
%	O
)	O
.	O

RESULTS	O
Six	O
of	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
positive	O
(	O
DZ	O
)	O
pairs	O
(	O
27	O
%	O
)	O
and	O
of	O
32	O
pairs	O
(	O
12	O
.	O
5	O
.	O

8	O
monozygotic	O
(	O
MZ	O
)	O
pairs	O
were	O
compared	O
of	O
15	O
positive	O
DZ	O
)	O
twin	O
pairs	O
27	O
%	O
4	O
of	O
DZ	O
twin	O
12	O
5	O
%	O
)	O

RESULTS	O
Six	O
of	O
8	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
B27	O
-	O
positive	O
dizygotic	O
(	O
DZ	O
)	O
twin	O
pairs	O
(	O
27	O
%	O
)	O
and	O
4	O
of	O
32	O
	O
boilersuit	O
	O
	O
boilersuit	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
DZ	O
twin	O
pairs	O
overall	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

of	O
DZ	O
of	O
8	O
4	O
(	O
-	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
MZ	O
twin	O
with	O
monozygotic	O
.	O
15	O
B27	O
,	O
positive	O
dizygotic	O
(	O
pairs	O
)	O
twin	O
12	O
%	O
27	O
(	O
Six	O
and	O
4	O
pairs	O
32	O
DZ	O
compared	O
RESULTS	O
overall	O
(	O
)	O
.	O
5	O
%	O
)	O
of	O

RESULTS	O
Six	O
of	O
8	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
B27	O
-	O
positive	O
dizygotic	O
(	O
DZ	O
)	O
twin	O
pairs	O
(	O
27	O
%	O
)	O
and	O
4	O
of	O
32	O
	O
boilersuit	O
	O
	O
boilersuit	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
DZ	O
twin	O
pairs	O
overall	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

RESULTS	O
Six	O
of	O
8	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
B27	O
-	O
positive	O
dizygotic	O
(	O
DZ	O
)	O
twin	O
pairs	O
(	O
27	O
%	O
)	O
and	O
4	O
of	O
32	O
DZ	O
twin	O
pairs	O
overall	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

Nonsignificant	O
increases	O
in	O
similarity	O
liken	O
affect	O
liken	O
hardship	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
compare	O
compare	O
compare	O
compare	O
whole	O
.	O

Nonsignificant	O
increases	O
in	O
regard	O
onset	O
and	O
all	O
the	O
disease	O
scores	O
assessed	O
were	O
disease	O
-	O
concordant	O
MZ	O
twins	O
with	O
DZ	O
twins	O
.	O

nonsignificant	O
gain	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	O
disease	O
oncoming	O
and	O
all	O
of	O
the	O
disease	O
rigorousness	O
rafts	O
tax	O
were	O
observe	O
in	O
disease	O
-	O
accordant	O
MZ	O
couple	O
compared	O
with	O
accordant	O
DZ	O
couple	O
.	O

Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
to	O
at	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
.	O

nonsignificant	O
increment	O
in	O
similarity	O
with	O
heed	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
grimness	O
scores	O
value	O
were	O
remark	O
in	O
disease	O
-	O
accordant	O
MZ	O
parallel	O
liken	O
with	O
accordant	O
DZ	O
parallel	O
.	O

Nonsignificant	O
increases	O
in	O
similarity	O
liken	O
affect	O
liken	O
hardship	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
compare	O
compare	O
compare	O
compare	O
whole	O
.	O

nonsignificant	O
increases	O
in	O
similarity	O
with	O
reckon	O
to	O
eld	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
badness	O
tally	O
valuate	O
were	O
mark	O
in	O
disease	O
-	O
conformable	O
MZ	O
parallel	O
compared	O
with	O
conformable	O
DZ	O
parallel	O
.	O

noted	O
assessed	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
concordant	O
concordant	O
disease	O
severity	O
scores	O
compared	O
were	O
increases	O
in	O
twins	O
-	O
of	O
MZ	O
twins	O
Nonsignificant	O
the	O
disease	O
DZ	O
with	O
.	O

Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
age	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
compared	O
with	O
concordant	O
twins	O

Nonsignificant	O
increases	O
in	O
similarity	O
liken	O
affect	O
liken	O
take	O
note	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
compare	O
compare	O
compare	O
compare	O
whole	O

Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rate	O
of	O
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co	O
-	O
twin	O
was	O
positive	O
for	O
both	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
B27	O
and	O
DR1	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rate	O
of	O
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co	O
-	O
twin	O
was	O
positive	O
for	O
both	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
colligate	O
B27	O
and	O
DR1	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rate	O
of	O
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co	O
-	O
twin	O
was	O
positive	O
for	O
both	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
mate	O
B27	O
and	O
DR1	O
.	O

twin	O
concordance	O
B27	O
and	O
B60	O
were	O
probands	O
positive	O
the	O
disease	O
in	O
associated	O
,	O
which	O
co	O
rate	O
of	O
disease	O
with	O
was	O
significantly	O
was	O
the	O
DZ	O
HLA	O
pairs	O
twin	O
and	O
the	O
among	O
-	O
both	O
increased	O
-	O
for	O
in	O
B27	O
and	O
DR1	O
.	O

HLA	O
-	O
B27	O
and	O
with	O
the	O
disease	O
in	O
probands	O
and	O
the	O
concordance	O
increased	O
among	O
pairs	O
the	O
co	O
-	O
twin	O
positive	O
for	O
and	O
DR1	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
connect	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
value	O
of	O
disease	O
concordance	O
was	O
importantly	O
increased	O
among	O
DZ	O
duplicate	O
duet	O
in	O
which	O
the	O
co	O
-	O
duplicate	O
was	O
overconfident	O
for	O
both	O
B27	O
and	O
DR1	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rank	O
of	O
disease	O
concordance	O
was	O
importantly	O
increased	O
among	O
DZ	O
gemini	O
match	O
in	O
which	O
the	O
co	O
-	O
gemini	O
was	O
positive	O
for	O
both	O
B27	O
and	O
DR1	O
.	O

-	O
for	O
B27	O
and	O
of	O
were	O
and	O
twin	O
the	O
disease	O
in	O
probands	O
,	O
twin	O
disease	O
rate	O
B60	O
the	O
concordance	O
was	O
and	O
increased	O
among	O
DZ	O
-	O
pairs	O
in	O
DR1	O
HLA	O
co	O
the	O
associated	O
was	O
positive	O
significantly	O
both	O
B27	O
with	O
which	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
order	O
of	O
disease	O
concordance	O
was	O
importantly	O
increased	O
among	O
DZ	O
couple	O
duet	O
in	O
which	O
the	O
co	O
-	O
couple	O
was	O
convinced	O
for	O
both	O
B27	O
and	O
DR1	O
.	O

HLA	O
-	O
-	O
and	O
B60	O
both	O
in	O
with	O
the	O
disease	O
associated	O
in	O
was	O
and	O
the	O
concordance	O
of	O
disease	O
and	O
,	O
significantly	O
increased	O
among	O
were	O
twin	O
rate	O
probands	O
was	O
twin	O
co	O
B27	O
which	O
the	O
positive	O
for	O
DZ	O
B27	O
pairs	O
DR1	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rate	O
of	O
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co	O
-	O
twin	O
was	O
positive	O
for	O
both	O
B27	O
and	O
DR1	O
.	O

Additive	O
effects	O
estimated	O
contribute	O
97	O
%	O
of	O
the	O
population	O
variance	O
.	O

linear	O
genetic	O
effects	O
were	O
estimated	O
to	O
give	O
xcvii	O
%	O
of	O
the	O
universe	O
variance	O
.	O

97	O
were	O
effects	O
genetic	O
estimated	O
to	O
of	O
Additive	O
%	O
.	O
the	O
population	O
variance	O
contribute	O

Additive	O
genetic	O
effects	O
were	O
estimated	O
to	O
contribute	O
97	O
of	O
the	O
variance	O
.	O

Additive	O
genetic	O
	O
impression	O
effects	O
were	O
estimated	O
to	O
contribute	O
97	O
%	O
variant	O
guess	O
of	O
the	O
population	O
variance	O
.	O

Additive	O
genetic	O
	O
impression	O
effects	O
were	O
estimated	O
to	O
contribute	O
97	O
%	O
variant	O
cost	O
of	O
the	O
population	O
variance	O
.	O

additive	O
genetic	O
effects	O
were	O
guess	O
to	O
contribute	O
xcvii	O
%	O
of	O
the	O
population	O
discrepancy	O
.	O

variance	O
genetic	O
effects	O
Additive	O
97	O
to	O
contribute	O
population	O
%	O
of	O
the	O
estimated	O
were	O
.	O

Additive	O
genetic	O
	O
impression	O
effects	O
were	O
estimated	O
to	O
contribute	O
97	O
%	O
variant	O
guess	O
of	O
the	O
population	O
variance	O
.	O

linear	O
genic	O
effects	O
were	O
gauge	O
to	O
contribute	O
97	O
%	O
of	O
the	O
population	O
disagreement	O
.	O

Additive	O
genetic	O
effects	O
were	O
estimated	O
to	O
contribute	O
97	O
%	O
of	O
the	O
population	O
variance	O
.	O

finish	O
Susceptibility	O
to	O
ampere	B
is	O
mostly	O
genetically	O
dictated	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
plausibly	O
omnipresent	O
.	O

CONCLUSION	O
Susceptibility	O
to	O
AS	B
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
every	O
bit	O
every	O
bit	O
every	O
bit	O
every	O
bit	O

CONCLUSION	O
Susceptibility	O
to	O
AS	B
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
every	O
bit	O
every	O
bit	O
every	O
bit	O
every	O
bit	O

to	O
largely	O
genetically	O
determined	O
and	O
the	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
ubiquitous	O
.	O

CONCLUSION	O
Susceptibility	O
to	O
AS	B
is	O
determined	O
,	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
ubiquitous	O
.	O

to	O
AS	B
is	O
largely	O
determined	O
,	O
and	O
the	O
environmental	O
for	O
the	O
disease	O
is	O
ubiquitous	O
.	O

probably	O
Susceptibility	O
to	O
ubiquitous	B
is	O
largely	O
genetically	O
,	O
determined	O
and	O
the	O
environmental	O
trigger	O
.	O
CONCLUSION	O
disease	O
is	O
the	O
AS	O
for	O

CONCLUSION	O
Susceptibility	O
to	O
AS	B
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
every	O
bit	O
every	O
bit	O
every	O
bit	O
every	O
bit	O

finis	O
susceptibility	O
to	O
AS	B
is	O
mostly	O
genetically	O
mold	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
belike	O
omnipresent	O
.	O

is	O
Susceptibility	O
to	O
AS	B
is	O
largely	O
for	O
environmental	O
,	O
and	O
the	O
the	O
CONCLUSION	O
genetically	O
determined	O
probably	O
trigger	O
disease	O
ubiquitous	O
.	O

CONCLUSION	O
Susceptibility	O
to	O
AS	B
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
ubiquitous	O
.	O

HLA	O
for	O
B27	O
accounts	O
-	O
a	O
of	O
genetic	O
the	O
overall	O
to	O
susceptibility	O
minority	O
AS	B
.	O

HLA	O
-	O
nonage	O
every	O
bit	O
write	O
up	O
B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
familial	O
overall	O
genetic	O
susceptibility	B
to	O

HLA	O
-	O
B27	O
invoice	O
for	O
a	O
nonage	O
of	O
the	O
boilersuit	O
genetic	O
susceptibleness	O
to	O
AS	B
.	O

to	O
-	O
B27	O
HLA	O
of	O
a	O
minority	O
susceptibility	O
the	O
overall	O
genetic	O
for	O
accounts	O
AS	B
.	O

HLA	O
-	O
B27	O
bill	O
for	O
a	O
nonage	O
of	O
the	O
overall	O
inherited	O
susceptibleness	O
to	O
AS	B
.	O

HLA	O
-	O
nonage	O
every	O
bit	O
write	O
up	O
B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
familial	O
overall	O
genetic	O
susceptibility	B
to	O

HLA	O
B27	O
for	O
minority	O
of	O
the	O
overall	O
genetic	O
susceptibility	O
to	O
AS	B
.	O

of	O
accounts	O
B27	O
-	O
for	O
a	O
overall	O
HLA	O
the	O
minority	O
genetic	O
susceptibility	O
to	O
.	B
AS	O

HLA	O
-	O
B27	O
report	O
for	O
a	O
nonage	O
of	O
the	O
overall	O
familial	O
susceptibleness	O
to	O
AS	B
.	O

HLA	O
-	O
nonage	O
every	O
bit	O
write	O
up	O
B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
familial	O
overall	O
genetic	O
susceptibility	B
to	O

HLA	O
-	O
B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
overall	O
genetic	O
susceptibility	O
to	O
AS	B
.	O

Cell	O
colocalization	O
-	O
dependent	O
cycle	O
of	O
and	O
in	O
BRCA1	O
proteins	O
nuclear	O
discrete	O
BARD1	O
domains	O
.	O

Cell	O
cycle	O
pendant	O
area	O
pendent	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
area	O
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O

Cell	O
pedal	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
distinct	O
atomic	O
domains	O
.	O

nuclear	O
cycle	O
-	O
Cell	O
and	O
of	O
BARD1	O
discrete	O
BRCA1	O
proteins	O
in	O
colocalization	O
dependent	O
domains	O
.	O

Cell	O
rhythm	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
distinct	O
atomic	O
domains	O
.	O

Cell	O
cycle	O
pendant	O
area	O
pendent	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
hertz	O
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O

Cell	O
-	O
colocalization	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O

and	O
dependent	O
-	O
cycle	O
colocalization	O
of	O
proteins	O
Cell	O
BRCA1	O
BARD1	O
in	O
discrete	O
nuclear	O
.	O
domains	O

Cell	O
cycle	O
-	O
subordinate	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
distinct	O
atomic	O
sphere	O
.	O

Cell	O
cycle	O
pendant	O
area	O
pendent	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
hertz	O
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O

Cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O

seed	O
-	O
course	O
mutations	O
of	O
the	O
BRCA1	O
cistron	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
front	B
and	I
ovarian	I
crab	I
by	O
compromise	O
the	O
factor	O
presumptive	O
function	O
as	O
a	O
tumour	B
suppressor	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
BRCA1	O
women	O
to	O
early	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
presumptive	O
function	O
as	O
a	O
tumor	B
suppressor	O
.	O

the	O
-	O
line	O
by	O
of	O
the	O
BRCA1	O
a	O
function	O
women	O
.	O
early	O
-	O
compromising	O
presumptive	B
and	I
ovarian	I
cancer	I
mutations	O
onset	O
as	O
genes	O
breast	O
predispose	O
Germ	O
gene	O
tumor	B
suppressor	O
to	O

Germ	O
-	O
line	O
mutations	O
element	O
onrush	O
summit	O
suppresser	O
factor	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
ampere	O
neoplasm	O
sport	O
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B
suppressor	O
.	O

Germ	O
-	O
line	O
mutations	O
element	O
onrush	O
summit	O
suppresser	O
factor	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
ampere	O
neoplasm	O
onrush	O
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B
suppressor	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
women	O
to	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
by	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B
suppressor	O
.	O

.	O
-	O
line	O
breast	O
of	O
the	O
a	O
gene	O
mutations	O
women	O
to	O
early	O
tumor	O
onset	O
as	B
predispose	I
ovarian	I
cancer	I
by	O
compromising	O
-	O
genes	O
presumptive	O
function	O
and	O
BRCA1	O
the	B
suppressor	O
Germ	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
women	O
early	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
by	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B

seed	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
cistron	O
predispose	O
women	O
to	O
former	O
-	O
oncoming	O
breast	B
and	I
ovarian	I
cancer	I
by	O
conciliatory	O
the	O
cistron	O
presumptive	O
mapping	O
as	O
a	O
neoplasm	B
suppressor	O
.	O

source	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
factor	O
predispose	O
women	O
to	O
early	O
-	O
onrush	O
boob	B
and	I
ovarian	I
cancer	I
by	O
flexible	O
the	O
cistron	O
presumptive	O
operate	O
as	O
a	O
neoplasm	B
suppressor	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B
suppressor	O
.	O

the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
,	O
their	O
expression	O
pattern	O
and	O
subcellular	O
suggest	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

,	O
the	O
biochemical	O
a	O
of	O
BRCA1	O
polypeptides	O
.	O
cycle	O
understood	O
regulation	O
their	O
expression	O
role	O
-	O
subcellular	O
localization	O
suggest	O
properties	O
pattern	O
in	O
cell	O
and	O
not	O
Although	O
are	O

Although	O
the	O
biochemical	O
holding	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
realise	O
,	O
their	O
saying	O
pattern	O
and	O
subcellular	O
localisation	O
evoke	O
a	O
office	O
in	O
cell	O
-	O
cycle	O
regulating	O
.	O

Although	O
the	O
biochemical	O
belongings	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
read	O
,	O
their	O
expression	O
blueprint	O
and	O
subcellular	O
fix	O
hint	O
a	O
use	O
in	O
cell	O
-	O
pedal	O
regulation	O
.	O

Although	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
their	O
expression	O
and	O
subcellular	O
localization	O
suggest	O
a	O
role	O
in	O
cycle	O
regulation	O
.	O

Although	O
the	O
biochemical	O
properties	O
location	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
,	O
their	O
expression	O
pattern	O
and	O
subcellular	O
localization	O
suggest	O
indium	O
hertz	O
regulating	O
hertz	O
regulating	O
non	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

Although	O
the	O
biochemical	O
properties	O
location	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
,	O
their	O
expression	O
pattern	O
and	O
subcellular	O
localization	O
suggest	O
indium	O
hertz	O
regulating	O
hertz	O
regulating	O
propose	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

Although	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
their	O
and	O
subcellular	O
localization	O
suggest	O
a	O
role	O
in	O
cell	O
-	O

cycle	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
pattern	O
localization	O
not	O
understood	O
,	O
their	O
cell	O
polypeptides	O
regulation	O
subcellular	O
are	O
in	O
a	O
role	O
Although	O
expression	O
-	O
suggest	O
and	O
.	O

Although	O
the	O
biochemical	O
dimension	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
realise	O
,	O
their	O
reflection	O
rule	O
and	O
subcellular	O
localization	O
intimate	O
a	O
part	O
in	O
cell	O
-	O
cps	O
regulation	O
.	O

Although	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
,	O
their	O
expression	O
pattern	O
and	O
subcellular	O
localization	O
suggest	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

When	O
stay	O
cadre	O
are	O
induced	O
to	O
proliferate	O
,	O
the	O
unfaltering	O
-	O
land	O
levels	O
of	O
BRCA1	O
gain	O
in	O
previous	O
G1	O
and	O
ambit	O
a	O
maximum	O
during	O
S	O
phase	O
.	O

When	O
resting	O
are	O
induced	O
to	O
proliferate	O
,	O
the	O
steady	O
-	O
state	O
levels	O
increase	O
in	O
late	O
G1	O
reach	O
a	O
maximum	O
during	O
S	O
.	O

When	O
resting	O
cells	O
are	O
entropy	O
step	O
up	O
induce	O
induced	O
to	O
proliferate	O
,	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
ampere	O
entropy	O
stage	O
entropy	O
cost	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase	O

reach	O
resting	O
cells	O
G1	O
induced	O
to	O
proliferate	O
phase	O
during	O
steady	O
and	O
state	O
levels	O
of	O
maximum	O
increase	O
in	O
late	O
are	O
S	O
-	O
a	O
BRCA1	O
the	O
When	O
,	O
.	O

When	O
resting	O
cells	O
are	O
entropy	O
step	O
up	O
induce	O
induced	O
to	O
proliferate	O
,	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
ampere	O
entropy	O
stage	O
entropy	O
cost	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase	O

When	O
resting	O
cells	O
induced	O
to	O
,	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BRCA1	O
in	O
late	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase	O
.	O

.	O
resting	O
cells	O
BRCA1	O
induced	O
to	O
phase	O
,	O
are	O
steady	O
-	O
state	O
of	O
reach	O
S	O
the	O
in	O
late	O
G1	O
and	O
levels	O
a	O
maximum	O
during	O
increase	O
proliferate	O
When	O

cells	O
to	O
proliferate	O
,	O
steady	O
-	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O

during	O
resting	O
cells	O
are	O
induced	O
to	O
of	O
state	O
the	O
steady	O
-	O
in	O
a	O
proliferate	O
S	O
When	O
,	O
increase	O
G1	O
and	O
reach	O
levels	O
maximum	O
late	O
BRCA1	O
phase	O
.	O

When	O
roost	O
cells	O
are	O
induced	O
to	O
proliferate	O
,	O
the	O
sweetheart	O
-	O
express	O
levels	O
of	O
BRCA1	O
addition	O
in	O
recent	O
G1	O
and	O
stretch	O
a	O
maximum	O
during	O
south	O
stage	O
.	O

When	O
resting	O
cells	O
are	O
induced	O
to	O
proliferate	O
,	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase	O
.	O

Moreover	O
,	O
in	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
"	O
BRCA1	O
nuclear	O
dots	O

Moreover	O
,	O
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
discrete	O
termed	O
"	O
BRCA1	O
nuclear	O
dots	O
.	O

Moreover	O
,	O
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
atomic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
lucy	O
in	O
the	O
sky	O

Moreover	O
,	O
in	O
sec	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
compile	O
into	O
distinct	O
subnuclear	O
focus	O
termed	O
"	O
BRCA1	O
atomic	O
dots	O
.	O

Moreover	O
,	O
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
atomic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
lucy	O
in	O
the	O
sky	O

Moreover	O
,	O
in	O
S	O
stage	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
conglomerate	O
into	O
distinct	O
subnuclear	O
focussing	O
termed	O
"	O
BRCA1	O
atomic	O
acid	O
.	O

Moreover	O
,	O
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
and	O
accumulate	O
discrete	O
subnuclear	O
foci	O
termed	O
"	O
BRCA1	O
nuclear	O

hyperphosphorylated	O
,	O
in	O
"	O
phase	O
cells	O
,	O
polypeptides	O
BRCA1	O
are	O
BRCA1	O
and	O
into	O
accumulate	O
.	O
subnuclear	O
foci	O
termed	O
S	O
Moreover	O
nuclear	O
dots	O
discrete	O

moreover	O
,	O
in	O
sulphur	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
collect	O
into	O
discrete	O
subnuclear	O
direction	O
termed	O
"	O
BRCA1	O
atomic	O
sprinkle	O
.	O

discrete	O
,	O
polypeptides	O
,	O
phase	O
cells	O
subnuclear	O
BRCA1	O
in	O
are	O
hyperphosphorylated	O
and	O
nuclear	O
into	O
S	O
Moreover	O
foci	O
termed	O
"	O
BRCA1	O
accumulate	O
dots	O
.	O

Moreover	O
,	O
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
"	O
BRCA1	O
nuclear	O
dots	O
.	O

"	O
associates	O
in	O
with	O
structurally	O
protein	O
termed	O
BARD1	O
.	O

"	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
protein	O
termed	O
BARD1	O

"	O
BRCA1	O
connect	O
in	O
vivo	O
with	O
a	O
structurally	O
concern	O
protein	O
termed	O
BARD1	O
.	O

"	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
ampere	O
protein	O
termed	O
BARD1	O
.	O

"	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
ampere	O
ampere	O
protein	O
termed	O
BARD1	O
.	O

"	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
ampere	O
term	O
protein	O
termed	O
BARD1	O
.	O

"	O
BRCA1	O
connect	O
in	O
vivo	O
with	O
a	O
structurally	O
interrelate	O
protein	O
termed	O
BARD1	O
.	O

"	O
BRCA1	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
protein	O
.	O

"	O
BRCA1	O
companion	O
in	O
vivo	O
with	O
a	O
structurally	O
refer	O
protein	O
termed	O
BARD1	O
.	O

"	O
vivo	O
associates	O
in	O
.	O
with	O
a	O
BRCA1	O
related	O
protein	O
termed	O
BARD1	O
structurally	O

"	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
protein	O
termed	O
BARD1	O
.	O

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
cubicle	O
hertz	O
procession	O
hertz	O
procession	O
procession	O
hither	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O
.	O

that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
constant	O
cell	O
cycle	O
progression	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
brace	O
-	O
state	O
charge	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
persist	O
relatively	O
incessant	O
during	O
cubicle	O
hz	O
progression	O
.	O

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
,	O
unlike	O
of	O
BRCA1	O
,	O
remain	O
relatively	O
constant	O
during	O
progression	O
.	O

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
cubicle	O
hertz	O
procession	O
hertz	O
procession	O
procession	O
display	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O
.	O

here	O
we	O
show	O
that	O
the	O
sweetie	O
-	O
state	O
point	O
of	O
BARD1	O
,	O
dissimilar	O
those	O
of	O
BRCA1	O
,	O
continue	O
comparatively	O
constant	O
during	O
cubicle	O
cycle	O
progression	O
.	O

here	O
we	O
show	O
that	O
the	O
steadfast	O
-	O
say	O
levels	O
of	O
BARD1	O
,	O
dissimilar	O
those	O
of	O
BRCA1	O
,	O
persist	O
comparatively	O
unvarying	O
during	O
cell	O
cycle	O
progression	O
.	O

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
unlike	O
BRCA1	O
,	O
remain	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
cubicle	O
hertz	O
procession	O
hertz	O
procession	O
procession	O
display	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O
.	O

constant	O
we	O
show	O
BARD1	O
the	O
steady	O
-	O
relatively	O
progression	O
of	O
that	O
,	O
those	O
unlike	O
cycle	O
BRCA1	O
,	O
remain	O
state	O
.	O
during	O
cell	O
of	O
levels	O
Here	O

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O
.	O

,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cycle	O
but	O
not	O
during	O
the	O
G1	O
phase	O
.	O

dots	O
,	O
immunostaining	O
,	O
that	O
BARD1	O
resides	O
.	O
G1	O
nuclear	O
phase	O
during	O
S	O
but	O
the	O
the	O
cell	O
cycle	O
revealed	O
phase	O
not	O
during	O
of	O
BRCA1	O
However	O
within	O

nonetheless	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
repose	O
inside	O
BRCA1	O
atomic	O
acid	O
during	O
S	O
stage	O
of	O
the	O
cell	O
bike	O
,	O
but	O
not	O
during	O
the	O
G1	O
stage	O
.	O

nevertheless	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
inside	O
BRCA1	O
atomic	O
superman	O
during	O
S	O
form	O
of	O
the	O
cell	O
wheel	O
,	O
but	O
not	O
during	O
the	O
G1	O
form	O
.	O

However	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
during	O
S	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
not	O
G1	O
phase	O
.	O

However	O
,	O
immunostaining	O
revealed	O
cubicle	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
non	O
non	O
stage	O
unveil	O
stage	O
unveil	O
,	O
but	O
not	O
during	O
the	O
G1	O
phase	O
.	O

However	O
,	O
immunostaining	O
revealed	O
cubicle	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
non	O
non	O
stage	O
unveil	O
stage	O
atomic	O
,	O
but	O
not	O
during	O
the	O
G1	O
phase	O
.	O

However	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
during	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
not	O
during	O
the	O

G1	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
phase	O
cell	O
BRCA1	O
nuclear	O
dots	O
during	O
during	O
resides	O
phase	O
the	O
within	O
not	O
,	O
but	O
However	O
S	O
the	O
cycle	O
of	O
.	O

nevertheless	O
,	O
immunostaining	O
unveil	O
that	O
BARD1	O
domicile	O
inside	O
BRCA1	O
atomic	O
dots	O
during	O
sulfur	O
stage	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
not	O
during	O
the	O
G1	O
stage	O
.	O

However	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
not	O
during	O
the	O
G1	O
phase	O
.	O

nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
obtain	O
entirely	O
in	O
the	O
atomic	O
fractions	O
of	O
both	O
G1	O
-	O
and	O
entropy	O
-	O
form	O
cells	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
G1	O
-	O
and	O
S	O
-	O
cubicle	O
polypeptide	O
polypeptide	O
polypeptide	O
polypeptide	O
polypeptide	O
phase	O
cells	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
G1	O
-	O
and	O
S	O
-	O
cubicle	O
polypeptide	O
polypeptide	O
polypeptide	O
polypeptide	O
polypeptide	O
phase	O
cells	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
nuclear	O
fractions	O
both	O
G1	O
-	O
and	O
S	O
-	O
phase	O

-	O
,	O
the	O
exclusively	O
are	O
found	O
and	O
in	O
BARD1	O
nuclear	O
fractions	O
of	O
.	O
G1	O
polypeptides	O
Nevertheless	O
S	O
-	O
phase	O
cells	O
both	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
happen	O
only	O
in	O
the	O
atomic	O
divide	O
of	O
both	O
G1	O
-	O
and	O
siemens	O
-	O
phase	O
cubicle	O
.	O

.	O
,	O
BARD1	O
fractions	O
are	O
found	O
exclusively	O
phase	O
-	O
nuclear	O
polypeptides	O
of	O
G1	O
both	O
the	O
and	O
S	O
-	O
in	O
Nevertheless	O
cells	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
G1	O
-	O
and	O
S	O
-	O
cubicle	O
polypeptide	O
polypeptide	O
polypeptide	O
polypeptide	O
indium	O
phase	O
cells	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
-	O
-	O
phase	O
cells	O
.	O

yet	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
entirely	O
in	O
the	O
atomic	O
divide	O
of	O
both	O
G1	O
-	O
and	O
south	O
-	O
phase	O
cadre	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
G1	O
-	O
and	O
S	O
-	O
phase	O
cells	O
.	O

hence	O
,	O
progression	O
to	O
second	O
stage	O
is	O
accompanied	O
by	O
the	O
assemblage	O
of	O
atomic	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
atomic	O
dots	O
.	O

Therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
procession	O
procession	O
procession	O
procession	O
procession	O
procession	O
dots	O
.	O

Therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
procession	O
procession	O
procession	O
procession	O
procession	O
procession	O
dots	O
.	O

progression	O
phase	O
is	O
accompanied	O
the	O
aggregation	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
dots	O
.	O

Therefore	O
,	O
progression	O
to	O
S	O
accompanied	O
by	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
dots	O
.	O

progression	O
to	O
S	O
phase	O
accompanied	O
by	O
the	O
aggregation	O
of	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
dots	O
.	O

nuclear	O
,	O
progression	O
dots	O
S	O
phase	O
is	O
by	O
accompanied	O
the	O
polypeptides	O
of	O
nuclear	O
.	O
Therefore	O
into	O
BRCA1	O
aggregation	O
to	O
BARD1	O

Therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
procession	O
procession	O
procession	O
procession	O
procession	O
consequently	O
dots	O
.	O

therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
companion	O
by	O
the	O
collecting	O
of	O
atomic	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
atomic	O
dots	O
.	O

BRCA1	O
,	O
progression	O
to	O
S	O
phase	O
BARD1	O
of	O
by	O
the	O
aggregation	O
polypeptides	O
Therefore	O
is	O
accompanied	O
nuclear	O
nuclear	O
into	O
dots	O
.	O

Therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
dots	O
.	O

suppression	O
cell	O
cycle	O
indicates	O
dependent	O
colocalization	O
of	O
mediated	O
BARD1	O
BRCA1	O
-	O
a	O
for	O
role	O
and	O
in	O
BRCA1	O
-	O
BARD1	O
This	B
tumor	O
.	O

This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
stifling	O
stifling	O
hertz	O
hertz	O
hertz	O
hertz	O
mediated	O
tumor	B
suppression	O
.	O

This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
stifling	O
stifling	O
hertz	O
hertz	O
hertz	O
hertz	O
mediated	O
tumor	B
suppression	O
.	O

This	O
cell	O
rhythm	O
-	O
pendant	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
signal	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
intermediate	O
neoplasm	B
crushing	O
.	O

This	O
cell	O
cycle	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
indicates	O
a	O
role	O
for	O
in	O
BRCA1	O
mediated	O
tumor	B
suppression	O
.	O

-	O
of	O
BARD1	O
and	O
indicates	O
a	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
mediated	O
tumor	B
suppression	O
.	O

This	O
cell	O
hertz	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
argue	O
a	O
office	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
arbitrate	O
neoplasm	B
inhibition	O
.	O

BARD1	O
cell	O
and	O
of	O
dependent	O
colocalization	O
in	O
BARD1	O
cycle	O
BRCA1	O
indicates	O
a	O
suppression	O
for	O
-	O
This	O
BRCA1	O
-	O
mediated	O
tumor	B
role	O
.	O

This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
stifling	O
stifling	O
hertz	O
hertz	O
hertz	O
part	O
mediated	O
tumor	B
suppression	O
.	O

This	O
cell	O
cycle	O
-	O
of	O
BARD1	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
mediated	O
.	O

This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
mediated	O
tumor	B
suppression	O
.	O

Ethnic	O
in	O
HFE	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
.	O

cultural	O
deviation	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
/	O
tyrr	O
)	O
pleomorphism	O
.	O

(	O
the	O
in	O
differences	O
HFE	O
codon	O
/	O
Ethnic	O
Cys	O
.	O
Tyr	O
)	O
polymorphism	O
282	O

Ethnic	O
differences	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
/	O
Tyr	O
polymorphism	O
.	O

Ethnic	O
differences	O
indium	O
indium	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
pleomorphism	O
remainder	O
/	O
Tyr	O
)	O
polymorphism	O
.	O

Ethnic	O
differences	O
indium	O
indium	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
pleomorphism	O
pleomorphism	O
/	O
Tyr	O
)	O
polymorphism	O
.	O

ethnical	O
deviation	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
/	O
tyrr	O
)	O
pleomorphism	O
.	O

polymorphism	O
differences	O
in	O
Ethnic	O
(	O
codon	O
282	O
)	O
Cys	O
/	O
Tyr	O
HFE	O
the	O
.	O

Ethnic	O
differences	O
indium	O
indium	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
pleomorphism	O
remainder	O
/	O
Tyr	O
)	O
polymorphism	O
.	O

pagan	O
remainder	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
/	O
tyr	O
)	O
pleomorphism	O
.	O

Ethnic	O
differences	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
.	O

Recent	O
have	O
shown	O
that	O
hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
likely	O
caused	O
by	O
homozygosity	O
for	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
located	O
4	O
.	O

Recent	O
have	O
shown	O
hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
likely	O
to	O
caused	O
by	O
for	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O

Recent	O
studies	O
have	O
shown	O
beryllium	O
induce	O
past	O
factor	O
that	O
hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
factor	O
turn	O
up	O
	O
induce	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O
located	O
4	O

mutation	O
studies	O
have	O
a	O
that	O
hereditary	B
hemochromatosis	I
located	O
HFE	B
)	O
Cys282Tyr	O
likely	O
to	O
be	O
the	O
by	O
homozygosity	O
for	O
shown	O
gene	O
is	O
in	O
caused	O
HH	O
Recent	O
(	O
4	O
.	O

4	O
studies	O
have	O
caused	O
that	O
hereditary	B
located	I
(	O
shown	B
)	O
is	O
likely	O
be	O
mutation	O
gene	O
HH	O
homozygosity	O
for	O
a	O
Cys282Tyr	O
to	O
in	O
the	O
HFE	O
by	O
hemochromatosis	O
Recent	O
.	O

Recent	O
studies	O
have	O
shown	O
beryllium	O
induce	O
past	O
factor	O
that	O
hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
factor	O
turn	O
up	O
	O
usher	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O
located	O
4	O

late	O
contemplate	O
have	O
shown	O
that	O
transmissible	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
potential	O
to	O
be	O
have	O
by	O
homozygosity	O
for	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
factor	O
site	O
iv	O
.	O

Recent	O
studies	O
have	O
shown	O
beryllium	O
induce	O
past	O
factor	O
that	O
hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
factor	O
turn	O
up	O
	O
usher	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O
located	O
4	O

HFE	O
studies	O
have	O
shown	O
that	O
hereditary	B
be	I
likely	O
HH	B
)	O
is	O
homozygosity	O
in	O
hemochromatosis	O
gene	O
Recent	O
(	O
by	O
a	O
Cys282Tyr	O
mutation	O
to	O
the	O
for	O
caused	O
located	O
4	O
.	O

Recent	O
work	O
have	O
shown	O
that	O
inherited	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
likely	O
to	O
be	O
get	O
by	O
homozygosity	O
for	O
a	O
Cys282Tyr	O
mutant	O
in	O
the	O
HFE	O
cistron	O
located	O
quadruplet	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O
located	O
4	O
.	O

A	O
Mb	O
telomeric	O
to	O
.	O
-	O
5	O
HLA	O

cinque	O
megabit	O
telomeric	O
to	O
HLA	O
-	O
A	O
.	O

telomeric	O
-	O
A	O
.	O

5	O
international	O
ampere	O
ampere	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
A	O

5	O
telomeric	O
to	O
A	O
.	O

5	O
HLA	O
telomeric	O
to	O
Mb	O
-	O
.	O
A	O

.	O
to	O
telomeric	O
Mb	O
HLA	O
-	O
A	O
5	O

5	O
m	O
mib	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
A	O
.	O

v	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
axerophthol	O
.	O

5	O
m	O
mib	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
A	O
.	O

5	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
A	O
.	O

population	O
studies	O
of	O
this	O
pleomorphism	O
are	O
help	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
limitation	O
situation	O
.	O

Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
site	O
.	O

Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
site	O
.	O

of	O
are	O
facilitated	O
by	O
fact	O
that	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
site	O
.	O

Population	O
studies	O
of	O
this	O
polymorphism	O
by	O
the	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
site	O
.	O

of	O
this	O
polymorphism	O
are	O
by	O
the	O
fact	O
that	O
the	O
mutation	O
creates	O
a	O
Rsal	O
site	O
.	O

restriction	O
studies	O
of	O
site	O
polymorphism	O
are	O
facilitated	O
the	O
by	O
fact	O
creates	O
the	O
Cys282Tyr	O
.	O
Population	O
a	O
Rsal	O
that	O
this	O
mutation	O

Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
internet	O
site	O
site	O

universe	O
report	O
of	O
this	O
pleomorphism	O
are	O
help	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
variation	O
creates	O
a	O
Rsal	O
limitation	O
site	O
.	O

Rsal	O
studies	O
of	O
this	O
polymorphism	O
are	O
mutation	O
the	O
the	O
fact	O
that	O
creates	O
Population	O
facilitated	O
by	O
restriction	O
Cys282Tyr	O
a	O
site	O
.	O

Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
site	O
.	O

)	O
have	O
studied	O
Cys	O
codon	O
282	O
(	O
the	O
ethnic	O
Tyr	O
different	O
polymorphism	O
We	O
in	O
/	O
groups	O
.	O

We	O
have	O
consider	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
tyrr	O
)	O
pleomorphism	O
in	O
dissimilar	O
ethnic	O
groups	O
.	O

We	O
have	O
take	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
tyr	O
)	O
pleomorphism	O
in	O
unlike	O
heathen	O
groups	O
.	O

We	O
have	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O
different	O
ethnic	O
groups	O
.	O

We	O
have	O
read	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
tyr	O
)	O
pleomorphism	O
in	O
different	O
pagan	O
grouping	O
.	O

We	O
have	O
analyse	O
analyse	O
studied	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O
different	O
ethnic	O
groups	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
.	O

We	O
have	O
studied	O
the	O
codon	O
282	O
(	O
Cys	O
Tyr	O
)	O
in	O
different	O
ethnic	O
groups	O
.	O

We	O
have	O
analyse	O
analyse	O
studied	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O
different	O
ethnic	O
groups	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
.	O

have	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O

We	O
have	O
/	O
ethnic	O
codon	O
282	O
in	O
Cys	O
studied	O
Tyr	O
)	O
polymorphism	O
(	O
different	O
the	O
groups	O
.	O

We	O
have	O
studied	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O
different	O
ethnic	O
groups	O
.	O

In	O
agreement	O
with	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
,	O
Chinese	O
)	O
populations	O

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
in	O
Indian	O
,	O
Chinese	O
)	O
populations	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
chinese	O
population	O
population	O
seem	O
seem	O
seem	O
,	O
Chinese	O
)	O
populations	O
.	O

In	O
concord	O
with	O
previous	O
observations	O
the	O
tyrr	O
allele	O
look	O
to	O
be	O
uncommon	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
,	O
chinese	O
)	O
universe	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
chinese	O
population	O
population	O
seem	O
seem	O
seem	O
,	O
Chinese	O
)	O
populations	O
.	O

In	O
concord	O
with	O
previous	O
observations	O
the	O
tyr	O
allelomorph	O
look	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
,	O
taiwanese	O
)	O
universe	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
rare	O
or	O
in	O
Asiatic	O
(	O
Indian	O
,	O
Chinese	O
)	O

be	O
agreement	O
with	O
,	O
observations	O
the	O
Tyr	O
appeared	O
allele	O
to	O
Chinese	O
rare	O
absent	O
or	O
.	O
Asiatic	O
(	O
Indian	O
previous	O
In	O
)	O
populations	O
in	O

In	O
agreement	O
with	O
late	O
reflection	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
scatty	O
in	O
asiatic	O
(	O
Indian	O
,	O
formosan	O
)	O
universe	O
.	O

in	O
agreement	O
appeared	O
Tyr	O
observations	O
the	O
Asiatic	O
allele	O
with	O
to	O
be	O
rare	O
)	O
absent	O
previous	O
In	O
(	O
Indian	O
,	O
Chinese	O
or	O
populations	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
,	O
Chinese	O
)	O
populations	O
.	O

The	O
(	O
allele	O
frequency	O
highest	O
7	O
5	O
was	O
%	O
)	O
in	O
found	O
.	O
Swedes	O
.	O

The	O
highest	O
allele	O
	O
allelomorph	O
allele	O
frequency	O
(	O
7	O
.	O
5	O
%	O
high	O
pitched	O
)	O
was	O
found	O
in	O
Swedes	O

The	O
gamey	O
allelomorph	O
frequency	O
(	O
vii	O
.	O
5	O
%	O
)	O
was	O
ascertain	O
in	O
Swedes	O
.	O

in	O
highest	O
allele	O
The	O
5	O
7	O
.	O
found	O
%	O
)	O
was	O
(	O
frequency	O
Swedes	O
.	O

The	O
eminent	O
allele	O
frequency	O
(	O
seven	O
.	O
quintet	O
%	O
)	O
was	O
encounter	O
in	O
Swedes	O
.	O

The	O
highest	O
allele	O
	O
allelomorph	O
allele	O
frequency	O
(	O
7	O
.	O
5	O
%	O
high	O
pitched	O
)	O
was	O
found	O
in	O
Swedes	O

The	O
allele	O
(	O
.	O
5	O
%	O
)	O
was	O
found	O
in	O
Swedes	O
.	O

5	O
frequency	O
allele	O
highest	O
(	O
7	O
)	O
The	O
%	O
.	O
was	O
found	O
in	O
.	O
Swedes	O

The	O
highest	O
allelomorph	O
frequency	O
(	O
seven	O
.	O
fin	O
%	O
)	O
was	O
regain	O
in	O
Swedes	O
.	O

The	O
highest	O
allele	O
	O
allelomorph	O
allele	O
frequency	O
(	O
7	O
.	O
5	O
%	O
high	O
pitched	O
)	O
was	O
found	O
in	O
Swedes	O

The	O
highest	O
allele	O
frequency	O
(	O
7	O
.	O
5	O
%	O
)	O
was	O
found	O
in	O
Swedes	O
.	O

allele	O
(	O
2	O
8	O
)	O
and	O
Mordvinians	O
the	O
significantly	O
.	O
%	O
%	O
had	O
)	O
1	O
lower	O
frequencies	O
of	O
(	O
Saamis	O
Tyr	O
.	O

Saamis	O
(	O
2	O
%	O
)	O
and	O
Mordvinians	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
allelomorph	O
allelomorph	O
	O
	O
	O
	O
the	O
Tyr	O
allele	O
.	O

Saamis	O
(	O
2	O
%	O
)	O
and	O
Mordvinians	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
allelomorph	O
allelomorph	O
	O
	O
	O
	O
the	O
Tyr	O
allele	O
.	O

Saamis	O
(	O
deuce	O
%	O
)	O
and	O
mordva	O
(	O
ane	O
.	O
8	O
%	O
)	O
had	O
importantly	O
lower	O
frequencies	O
of	O
the	O
tyrr	O
allelomorph	O
.	O

Saamis	O
(	O
2	O
)	O
and	O
Mordvinians	O
(	O
1	O
8	O
%	O
)	O
had	O
lower	O
frequencies	O
the	O
Tyr	O
allele	O
.	O

%	O
Mordvinians	O
(	O
1	O
8	O
%	O
had	O
significantly	O
lower	O
frequencies	O
of	O
the	O
Tyr	O
allele	O
.	O

sami	O
(	O
two	O
%	O
)	O
and	O
mordvinian	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
importantly	O
lower	O
frequence	O
of	O
the	O
tyrr	O
allele	O
.	O

significantly	O
(	O
1	O
Mordvinians	O
)	O
and	O
lower	O
(	O
2	O
.	O
8	O
%	O
allele	O
had	O
%	O
Saamis	O
frequencies	O
of	O
the	O
Tyr	O
)	O
.	O

Saamis	O
(	O
2	O
%	O
)	O
and	O
Mordvinians	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
allelomorph	O
allelomorph	O
	O
	O
	O
	O
the	O
Tyr	O
allele	O
.	O

Saamis	O
(	O
2	O
%	O
Mordvinians	O
(	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
the	O
.	O

Saamis	O
(	O
2	O
%	O
)	O
and	O
Mordvinians	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
the	O
Tyr	O
allele	O
.	O

Finns	O
with	O
allele	O
showed	O
based	O
on	O
prevalence	O
particularly	O
the	O
HH	B
frequencies	O
some	O
with	O
disagreements	O
of	O
RFLP	O
data	O
,	O
estimates	O
Comparisons	O
in	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	B
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
finn	O
finn	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
particularly	O
in	O
Finns	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	B
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
finn	O
finn	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
particularly	O
in	O
Finns	O
.	O

comparability	O
with	O
allelomorph	O
frequencies	O
establish	O
on	O
prevalence	O
estimates	O
of	O
HH	B
demo	O
some	O
variance	O
with	O
the	O
RFLP	O
data	O
,	O
particularly	O
in	O
finn	O
.	O

Comparisons	O
with	O
allele	O
based	O
on	O
prevalence	O
estimates	O
of	O
showed	O
some	O
disagreements	O
with	O
RFLP	O
data	O
particularly	O
in	O
Finns	O
.	O

frequencies	O
prevalence	O
estimates	O
of	O
showed	O
some	O
with	O
the	O
RFLP	O
data	O
,	O
particularly	O
in	O
Finns	O
.	O

Comparisons	O
with	O
allelomorph	O
frequency	O
establish	O
on	O
prevalence	O
estimates	O
of	O
HH	B
showed	O
some	O
divergence	O
with	O
the	O
RFLP	O
datum	O
,	O
particularly	O
in	O
finn	O
.	O

the	O
with	O
of	O
prevalence	O
based	O
on	O
RFLP	O
estimates	O
allele	O
HH	B
showed	O
some	O
Finns	O
with	O
frequencies	O
Comparisons	O
data	O
,	O
particularly	O
in	O
disagreements	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	B
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
finn	O
finn	O
allelomorph	O
allelomorph	O
allelomorph	O
indium	O
particularly	O
in	O
Finns	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
prevalence	O
estimates	O
HH	B
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
particularly	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	B
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
particularly	O
in	O
Finns	O
.	O

The	O
newly	O
described	O
HFE	O
note	O
marking	O
every	O
bit	O
easily	O
marking	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	B
HH	O
as	O
well	O
as	O
studies	O
dissimilar	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
greenback	O
greenback	O
sieve	B

The	O
newly	O
described	O
HFE	O
note	O
marking	O
every	O
bit	O
easily	O
marking	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	B
HH	O
as	O
well	O
as	O
studies	O
account	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
greenback	O
greenback	O
sieve	B

HFE	O
newly	O
described	O
HFE	O
marker	O
provides	O
HH	O
as	O
approach	O
to	O
the	O
screening	O
between	O
a	B
Tyr	O
disorders	O
new	O
relationship	O
of	O
the	O
The	O
of	O
the	O
studies	O
as	O
allele	O
and	O
different	O
cancer	O
including	O
well	B

The	O
newly	O
described	O
HFE	O
note	O
marking	O
every	O
bit	O
easily	O
marking	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	B
HH	O
as	O
well	O
as	O
studies	O
dissimilar	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
greenback	O
greenback	O
sieve	B

The	O
newly	O
described	O
HFE	O
provides	O
approach	O
to	O
the	O
screening	O
of	O
HH	B
as	O
well	O
as	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	B

The	O
fresh	O
described	O
HFE	O
marking	O
provides	O
a	O
novel	O
approach	O
to	O
the	O
sort	O
of	O
HH	B
as	O
well	O
as	O
analyze	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
tyr	O
allelomorph	O
and	O
different	O
disarray	O
admit	O
cancer	B

disorders	O
newly	O
Tyr	O
as	O
marker	O
provides	O
different	O
new	O
HFE	O
to	O
the	O
screening	O
relationship	O
HH	B
described	O
approach	O
as	O
studies	O
of	O
the	O
of	O
between	O
the	O
HFE	O
well	O
a	O
and	O
allele	O
The	O
including	O
cancer	B

The	O
newly	O
described	O
HFE	O
marker	O
provides	O
a	O
new	O
approach	O
the	O
screening	O
HH	B
as	O
well	O
as	O
studies	O
of	O
the	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	B

the	O
newly	O
described	O
disorders	O
marker	O
provides	O
a	O
allele	O
HFE	O
to	O
Tyr	O
screening	O
and	O
the	B
the	O
well	O
as	O
studies	O
cancer	O
HH	O
relationship	O
between	O
as	O
approach	O
The	O
new	O
of	O
different	O
HFE	O
including	O
of	B

The	O
newly	O
line	O
HFE	O
marker	O
provides	O
a	O
young	O
approach	O
to	O
the	O
test	O
of	O
HH	B
as	O
comfortably	O
as	O
subject	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
tyrr	O
allelomorph	O
and	O
different	O
disarray	O
admit	O
cancer	B

The	O
newly	O
described	O
HFE	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	O
HH	B
as	O
well	O
as	O
studies	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	B

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
autosomal	O
	O
autosomal	O
autosomal	O
II	O
.	O

autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
relate	O
with	O
a	O
missense	O
mutation	O
encryption	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
two	O
.	O

autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
assort	O
with	O
a	O
missense	O
variation	O
encryption	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
deuce	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
	O
autosomal	O
autosomal	O
II	O
.	O

Autosomal	B
dominant	I
diabetes	I
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23	O
-	O
-	O
>	O
.	O

autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
connect	O
with	O
a	O
missense	O
sport	O
encryption	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
two	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
associated	O
with	O
mutation	O
encoding	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
II	O
.	O

in	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
associated	O
-	O
>	O
missense	O
mutation	O
encoding	O
Gly23	O
neurophysin	O
with	O
a	O
Autosomal	O
-	O
Val	O
II	O
.	O

.	B
dominant	I
neurohypophyseal	I
encoding	I
insipidus	I
associated	O
with	O
II	O
>	O
mutation	O
diabetes	O
Gly23	O
-	O
-	O
missense	O
Autosomal	O
in	O
neurophysin	O
a	O
Val	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23	O
-	O
-	O
Val	O
neurophysin	O
II	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
II	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
ADNDI	B
)	O
is	O
an	O
inherited	B
disease	I
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O

Autosomal	B
dominant	I
neurohypophyseal	I
(	O
ADNDI	B
)	O
is	O
an	O
disease	I
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
to	O
decreased	O
ability	O
to	O
produce	O
AVP	O

to	B
magnocellular	I
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
disease	B
(	O
is	O
an	O
inherited	B
ADNDI	I
caused	O
to	O
the	O
degeneration	O
of	O
the	O
)	O
neurons	O
of	O
the	O
produce	O
leading	O
Autosomal	O
decreased	O
arginine	O
by	O
progressive	O
hypothalamus	O
hormone	O
)	O
vasopressin	O
dominant	O
AVP	O
ability	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
ADNDI	B
)	O
is	O
an	O
inherited	B
disease	I
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O

to	B
AVP	I
neurohypophyseal	I
diabetes	I
of	I
(	O
progressive	B
arginine	O
is	O
an	O
inherited	B
disease	I
caused	O
to	O
)	O
degeneration	O
insipidus	O
hormone	O
magnocellular	O
neurons	O
by	O
the	O
hypothalamus	O
leading	O
dominant	O
decreased	O
ability	O
Autosomal	O
the	O
the	O
produce	O
ADNDI	O
vasopressin	O
(	O
of	O
)	O
.	O

autosomal	B
prevalent	I
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
ADNDI	B
)	O
is	O
an	O
inherited	B
disease	I
have	O
by	O
reformist	O
decadence	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leave	O
to	O
diminish	O
power	O
to	O
produce	O
the	O
endocrine	O
arginine	O
pitressin	O
(	O
AVP	O
)	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
(	O
ADNDI	B
)	O
is	O
an	O
inherited	B
disease	I
progressive	O
degeneration	O
of	O
magnocellular	O
of	O
the	O
hypothalamus	O
decreased	O
hormone	O
arginine	O
vasopressin	O
AVP	O
)	O

Autosomal	B
dominant	I
hormone	I
diabetes	I
insipidus	I
)	O
ADNDI	B
)	O
is	O
an	O
inherited	B
ability	I
neurons	O
by	O
progressive	O
to	O
of	O
the	O
arginine	O
caused	O
of	O
vasopressin	O
hypothalamus	O
(	O
to	O
degeneration	O
disease	O
the	O
decreased	O
the	O
neurohypophyseal	O
magnocellular	O
produce	O
(	O
AVP	O
leading	O
.	O

autosomal	B
prevalent	I
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
ADNDI	B
)	O
is	O
an	O
transmissible	B
disease	I
stimulate	O
by	O
progressive	O
retrogression	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
starring	O
to	O
lessen	O
power	O
to	O
develop	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
.	O

autosomal	B
rife	I
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
ADNDI	B
)	O
is	O
an	O
familial	B
disease	I
stimulate	O
by	O
progressive	O
degeneracy	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
go	O
to	O
diminish	O
power	O
to	O
produce	O
the	O
endocrine	O
arginine	O
pitressin	O
(	O
AVP	O
)	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
ADNDI	B
)	O
is	O
an	O
inherited	B
disease	I
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
.	O

feign	O
person	O
are	O
not	O
diagnostic	O
at	O
parentage	O
,	O
but	O
usually	O
rise	O
diabetes	B
insipidus	I
at	O
unity	O
-	O
6	O
yr	O
of	O
age	O
.	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B
insipidus	I
at	O
1	O
-	O
6	O
yr	O
years	O
cost	O
cost	O
cost	O
cost	O
cost	O
of	O
age	O
.	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B
insipidus	I
at	O
1	O
-	O
6	O
yr	O
years	O
cost	O
cost	O
cost	O
cost	O
cost	O
of	O
age	O
.	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
usually	O
develop	O
insipidus	I
at	O
1	O
-	O
6	O
yr	O
of	O

1	O
individuals	O
but	O
birth	O
symptomatic	O
at	O
-	O
,	O
are	O
usually	O
develop	O
diabetes	B
.	I
at	O
not	O
Affected	O
6	O
yr	O
of	O
age	O
insipidus	O

touched	O
individuals	O
are	O
not	O
diagnostic	O
at	O
deliver	O
,	O
but	O
usually	O
develop	O
diabetes	B
insipidus	I
at	O
single	O
-	O
sixer	O
yr	O
of	O
years	O
.	O

.	O
individuals	O
are	O
develop	O
symptomatic	O
at	O
birth	O
of	O
1	O
usually	O
not	O
diabetes	B
at	I
insipidus	O
but	O
-	O
6	O
yr	O
,	O
Affected	O
age	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B
insipidus	I
at	O
1	O
-	O
6	O
yr	O
years	O
cost	O
cost	O
cost	O
cost	O
build	O
up	O
of	O
age	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B
insipidus	I
1	O
yr	O
of	O
age	O
.	O

pretend	O
somebody	O
are	O
not	O
diagnostic	O
at	O
birth	O
,	O
but	O
usually	O
originate	O
diabetes	B
insipidus	I
at	O
1	O
-	O
six	O
yr	O
of	O
mature	O
.	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B
insipidus	I
at	O
1	O
-	O
6	O
yr	O
of	O
age	O
.	O

AVP	O
mutations	O
locus	O
of	O
the	O
disease	O
itself	O
the	O
AVP	O
-	O
neurophysin	O
NPII	O
(	O
found	O
peptide	O
gene	O
,	O
and	O
the	O
that	O
cause	O
ADNDI	B
-	O
been	O
NPII	O
in	O
-	O
genetic	O
the	O
have	O
of	O
signal	O
prepro	O
)	O
The	O
both	O
NPII	O
precursor	O
and	O
within	O
II	O
is	O
.	O

The	O
genetic	O
locus	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
NPII	O
)	O
gene	O
and	O
that	O
cause	O
ADNDI	B
found	O
peptide	O
of	O
the	O
-	O
AVP	O
NPII	O
precursor	O
and	O
itself	O
.	O

The	O
hereditary	O
locale	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
factor	O
,	O
and	O
sport	O
that	O
induce	O
ADNDI	B
have	O
been	O
constitute	O
in	O
both	O
the	O
betoken	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
NPII	O
harbinger	O
and	O
inside	O
NPII	O
itself	O
.	O

The	O
transmissible	O
venue	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
two	O
(	O
NPII	O
)	O
cistron	O
,	O
and	O
sport	O
that	O
cause	O
ADNDI	B
have	O
been	O
determine	O
in	O
both	O
the	O
point	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
NPII	O
forerunner	O
and	O
inside	O
NPII	O
itself	O
.	O

The	O
genetic	O
the	O
of	O
the	O
disease	O
is	O
mutations	O
AVP	O
-	O
neurophysin	O
(	O
.	O
NPII	O
)	O
of	O
,	O
and	O
that	O
the	O
cause	O
prepro	B
have	O
-	O
found	O
both	O
the	O
ADNDI	O
signal	O
peptide	O
gene	O
precursor	O
in	O
-	O
AVP	O
been	O
NPII	O
locus	O
and	O
within	O
NPII	O
itself	O
II	O

The	O
genetic	O
locus	O
the	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
gene	O
cause	O
ADNDI	B
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
NPII	O
and	O
within	O
NPII	O
itself	O
.	O

The	O
genetic	O
locus	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
gene	O
,	O
and	O
mutations	O
that	O
cause	O
ADNDI	B
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
forerunner	O
betoken	O
inside	O
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
NPII	O
precursor	O
and	O
within	O
NPII	O
itself	O
.	O

and	O
found	O
locus	O
of	O
,	O
disease	O
cause	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
is	O
precursor	O
gene	O
the	O
of	O
mutations	O
that	O
NPII	O
ADNDI	B
have	O
been	O
the	O
in	O
both	O
itself	O
and	O
peptide	O
signal	O
genetic	O
prepro	O
-	O
AVP	O
-	O
NPII	O
)	O
The	O
within	O
NPII	O
the	O
.	O

The	O
genetic	O
locus	O
the	O
is	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
gene	O
and	O
mutations	O
that	O
cause	O
ADNDI	B
the	O
of	O
prepro	O
-	O
AVP	O
NPII	O
precursor	O
and	O
within	O
NPII	O
itself	O

The	O
transmitted	O
locale	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
two	O
(	O
NPII	O
)	O
cistron	O
,	O
and	O
sport	O
that	O
have	O
ADNDI	B
have	O
been	O
find	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
NPII	O
herald	O
and	O
inside	O
NPII	O
itself	O
.	O

The	O
genetic	O
locus	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
gene	O
,	O
and	O
mutations	O
that	O
cause	O
ADNDI	B
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
NPII	O
precursor	O
and	O
within	O
NPII	O
itself	O
.	O

An	O
affected	O
girl	O
who	O
presented	O
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(	O
G1758	O
-	O
-	O
>	O
T	O
)	O
encoding	O
the	O
exchange	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
inside	O
introduce	O
introduce	O
inside	O
introduce	O
introduce	O
inside	O
introduce	O
introduce	O
introduce	O
introduce	O
amino	O
acid	O
substitution	O
Gly23	O
-	O
-	O

An	O
affected	O
missy	O
who	O
deliver	O
at	O
9	O
months	O
of	O
eld	O
and	O
her	O
likewise	O
affected	O
vernal	O
crony	O
and	O
father	O
were	O
all	O
receive	O
to	O
have	O
a	O
fresh	O
missense	O
mutant	O
(	O
G1758	O
-	O
-	O
>	O
mt	O
)	O
encryption	O
the	O
aminic	O
acid	O
permutation	O
Gly23	O
-	O
-	O
>	O
Val	O
inside	O
NPII	O
.	O

An	O
affected	O
>	O
who	O
presented	O
the	O
9	O
months	O
of	O
age	O
and	O
similarly	O
>	O
affected	O
younger	O
-	O
and	O
father	O
all	O
were	O
found	O
.	O
have	O
at	O
novel	O
mutation	O
(	O
NPII	O
G1758	O
-	O
brother	O
acid	O
missense	O
)	O
encoding	O
a	O
amino	O
girl	O
substitution	O
Gly23	O
-	O
-	O
her	O
within	O
Val	O
T	O
to	O

An	O
mutation	O
girl	O
who	O
presented	O
at	O
her	O
-	O
of	O
age	O
and	O
9	O
similarly	O
(	O
novel	O
brother	O
and	O
father	O
months	O
all	O
found	O
to	O
the	O
a	O
Val	O
missense	O
.	O
affected	O
>	O
were	O
-	O
G1758	O
T	O
younger	O
encoding	O
-	O
amino	O
acid	O
substitution	O
Gly23	O
affected	O
)	O
>	O
have	O
within	O
NPII	O
-	O

An	O
involve	O
girl	O
who	O
submit	O
at	O
9	O
months	O
of	O
geezerhood	O
and	O
her	O
likewise	O
involve	O
unseasoned	O
comrade	O
and	O
father	O
were	O
all	O
obtain	O
to	O
have	O
a	O
fresh	O
missense	O
variation	O
(	O
G1758	O
-	O
-	O
>	O
thyroxine	O
)	O
encryption	O
the	O
aminic	O
acrid	O
substitution	O
Gly23	O
-	O
-	O
>	O
Val	O
inside	O
NPII	O
.	O

An	O
affected	O
girl	O
presented	O
at	O
9	O
months	O
of	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
to	O
a	O
novel	O
missense	O
(	O
G1758	O
-	O
-	O
>	O
T	O
encoding	O
the	O
substitution	O
-	O
-	O
>	O
Val	O
.	O

who	O
presented	O
at	O
9	O
months	O
age	O
and	O
younger	O
father	O
were	O
to	O
novel	O
missense	O
mutation	O
(	O
-	O
-	O
)	O
encoding	O
amino	O
acid	O
-	O
Val	O
within	O
NPII	O

An	O
affected	O
girl	O
who	O
presented	O
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(	O
G1758	O
-	O
-	O
>	O
T	O
)	O
encoding	O
the	O
exchange	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
inside	O
introduce	O
introduce	O
inside	O
introduce	O
introduce	O
inside	O
introduce	O
introduce	O
introduce	O
atomic	O
number	O
	O
amino	O
acid	O
substitution	O
Gly23	O

encoding	O
novel	O
girl	O
who	O
and	O
at	O
found	O
>	O
of	O
age	O
and	O
her	O
similarly	O
9	O
acid	O
brother	O
presented	O
.	O
were	O
all	O
affected	O
to	O
have	O
a	O
(	O
missense	O
mutation	O
-	O
within	O
-	O
G1758	O
affected	O
T	O
)	O
substitution	O
the	O
amino	O
younger	O
An	O
Gly23	O
-	O
months	O
>	O
Val	O
-	O
NPII	O
father	O

An	O
affected	O
girl	O
who	O
presented	O
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(	O
G1758	O
-	O
-	O
>	O
T	O
)	O
encoding	O
the	O
exchange	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
inside	O
introduce	O
introduce	O
inside	O
introduce	O
introduce	O
inside	O
introduce	O
introduce	O
introduce	O
introduce	O
amino	O
acid	O
substitution	O
Gly23	O
-	O
-	O

An	O
affected	O
girl	O
who	O
presented	O
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(	O
G1758	O
-	O
-	O
>	O
T	O
)	O
encoding	O
the	O
amino	O
acid	O
substitution	O
Gly23	O
-	O
-	O
>	O
Val	O
within	O
NPII	O
.	O

The	O
sport	O
was	O
confirmed	O
by	O
limitation	O
endonuclease	O
analysis	O
.	O

The	O
depth	O
psychology	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
affirm	O

The	O
confirmed	O
was	O
mutation	O
by	O
restriction	O
analysis	O
endonuclease	O
.	O

The	O
variation	O
was	O
confirmed	O
by	O
limitation	O
endonuclease	O
analysis	O
.	O

The	O
was	O
confirmed	O
restriction	O
analysis	O

endonuclease	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
analysis	O
The	O
.	O

The	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
.	O

The	O
analysis	O
was	O
confirmed	O
mutation	O
restriction	O
endonuclease	O
by	O
.	O

The	O
sport	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
affirm	O
.	O

The	O
variation	O
was	O
sustain	O
by	O
restriction	O
endonuclease	O
analysis	O
.	O

The	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
.	O

A	O
T1	O
-	O
weighted	O
magnetised	O
resonance	O
imaging	O
of	O
the	O
beginner	O
pituitary	O
secretor	O
demonstrates	O
an	O
attenuated	O
bottom	O
pituitary	O
burnished	O
slur	O
.	O

A	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
angle	O
angle	O
angle	O
angle	O
angle	O
angle	O
spot	O
.	O

A	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
angle	O
angle	O
angle	O
angle	O
angle	O
angle	O
spot	O
.	O

-	O
resonance	O
imaging	O
of	O
fathers	O
pituitary	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
spot	O
.	O

A	O
T1	O
-	O
weighted	O
magnetic	O
of	O
the	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
spot	O
.	O

-	O
weighted	O
magnetic	O
resonance	O
of	O
the	O
fathers	O
pituitary	O
gland	O
an	O
attenuated	O
posterior	O
pituitary	O
spot	O
.	O

bright	O
T1	O
-	O
spot	O
magnetic	O
resonance	O
imaging	O
the	O
of	O
fathers	O
attenuated	O
gland	O
demonstrates	O
.	O
A	O
posterior	O
pituitary	O
pituitary	O
weighted	O
an	O

A	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
angle	O
angle	O
angle	O
angle	O
angle	O
ringing	O
spot	O
.	O

A	O
T1	O
-	O
weighted	O
magnetic	O
reverberance	O
project	O
of	O
the	O
fathers	O
hypophysis	O
gland	O
prove	O
an	O
attenuated	O
seat	O
hypophysis	O
burnished	O
spot	O
.	O

pituitary	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
an	O
gland	O
the	O
fathers	O
pituitary	O
attenuated	O
A	O
imaging	O
of	O
bright	O
demonstrates	O
posterior	O
spot	O
.	O

A	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
spot	O
.	O

may	O
for	O
developing	O
models	O
of	O
inherited	I
neurodegeneration	I
the	O
early	O
of	O
onset	O
that	O
mutation	O
may	O
be	O
deleterious	O
to	O
the	O
neuron	O
.	O
.	O

This	O
mutation	O
may	O
be	O
ahead	O
of	O
time	O
crataegus	O
oxycantha	O
valuable	O
for	O
developing	B
models	I
of	I
dominantly	O
inherited	O
neurodegeneration	O
,	O
as	O
the	O
early	O
age	O
of	O
onset	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
particularly	O
deleterious	O
to	O
the	O
magnocellular	O
neuron	O
.	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O

mutation	O
onset	O
may	O
be	O
valuable	O
for	O
be	O
models	O
of	O
dominantly	B
inherited	I
neurodegeneration	I
,	O
particularly	O
to	O
early	O
age	O
of	O
.	O
of	O
symptoms	O
suggests	O
magnocellular	O
this	O
This	O
may	O
developing	O
as	O
the	O
that	O
the	O
deleterious	O
neuron	O
.	O
mutation	O

This	O
mutation	O
may	O
be	O
worthful	O
for	O
acquire	O
manakin	O
of	O
dominantly	B
genetic	I
neurodegeneration	I
,	O
as	O
the	O
early	O
age	O
of	O
oncoming	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
specially	O
hurtful	O
to	O
the	O
magnocellular	O
neuron	O
.	O
.	O

This	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
suggests	O
of	O
dominantly	B
inherited	I
this	I
particularly	O
as	O
the	O
the	O
age	O
of	O
of	O
neurodegeneration	O
symptoms	O
models	O
that	O
onset	O
mutation	O
be	O
may	O
neuron	O
deleterious	O
to	O
early	O
,	O
magnocellular	O
.	O
.	O

This	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
models	O
of	O
dominantly	B
,	O
as	O
the	O
early	O
of	O
onset	O
of	O
symptoms	O
suggests	O
this	O
mutation	O
may	O
be	O
deleterious	O
to	O
magnocellular	O
neuron	O
.	O
.	O

This	O
mutation	O
may	O
be	O
worthful	O
for	O
developing	O
simulate	O
of	O
dominantly	B
genetic	I
neurodegeneration	I
,	O
as	O
the	O
early	O
age	O
of	O
oncoming	O
of	O
symptoms	O
intimate	O
that	O
this	O
mutation	O
may	O
be	O
peculiarly	O
injurious	O
to	O
the	O
magnocellular	O
neuron	O
.	O
.	O

This	O
mutation	O
may	O
be	O
ahead	O
of	O
time	O
worthful	O
valuable	O
for	O
developing	O
models	B
of	I
dominantly	I
inherited	O
neurodegeneration	O
,	O
as	O
the	O
early	O
age	O
of	O
onset	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
particularly	O
deleterious	O
to	O
the	O
magnocellular	O
neuron	O
.	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O

This	O
mutant	O
whitethorn	O
be	O
worthful	O
for	O
developing	O
models	O
of	O
dominantly	B
inherited	I
neurodegeneration	I
,	O
as	O
the	O
early	O
eld	O
of	O
oncoming	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutant	O
whitethorn	O
be	O
specially	O
injurious	O
to	O
the	O
magnocellular	O
neuron	O
.	O
.	O

particularly	O
symptoms	O
may	O
be	O
age	O
for	O
the	O
magnocellular	O
of	O
dominantly	B
inherited	I
neurodegeneration	I
,	O
mutation	O
models	O
early	O
valuable	O
the	O
onset	O
of	O
as	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
This	O
of	O
to	O
deleterious	O
developing	O
neuron	O
.	O
.	O

This	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
models	O
of	O
dominantly	B
inherited	I
neurodegeneration	I
,	O
as	O
the	O
early	O
age	O
of	O
onset	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
particularly	O
deleterious	O
to	O
the	O
magnocellular	O
neuron	O
.	O
.	O

sponsor	O
deactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostatic	B
cancer	I
.	O

Frequent	O
inactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B
deactivation	O
deactivation	B
deactivation	O
cancer	I
.	O

patronize	O
deactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B
cancer	I
.	O

Frequent	O
deactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
basal	O
prostatic	B
cancer	I
.	O

inactivation	O
of	O
/	O
MMAC1	O
in	O
primary	O
prostate	B
cancer	I
.	O

primary	O
inactivation	O
of	O
/	O
PTEN	O
MMAC1	O
cancer	O
Frequent	O
prostate	B
in	I
.	O

Frequent	O
primary	O
of	O
PTEN	O
inactivation	O
MMAC1	O
in	O
.	O
prostate	B
cancer	I
/	O

PTEN	O
primary	O
of	O
in	O
/	O
MMAC1	O
Frequent	O
inactivation	O
prostate	B
cancer	I
.	O

Frequent	O
of	O
/	O
in	O
primary	O
prostate	B
cancer	I
.	O

Frequent	O
inactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B
deactivation	O
deactivation	B
deactivation	O
cancer	I
.	O

Frequent	O
inactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B
cancer	I
.	O

carcinoma	I
most	O
common	O
male	B
cancer	I
the	O
Western	O
yet	O
many	O
the	O
major	O
in	O
progression	O
of	O
this	O
fatal	O
cancer	B
remain	O
be	O
elucidated	O
.	O

Sporadic	B
prostate	I
carcinoma	I
is	O
uncouth	O
manlike	O
the	O
most	O
common	O
male	B
cancer	I
in	O
the	O
Western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	B
remain	O
to	O
be	O
elucidated	O
common	O
common	O
common	O
common	O
common	O
common	O
common	O
nevertheless	O
.	O

progression	B
major	I
carcinoma	I
is	O
the	O
most	O
this	O
male	B
cancer	I
in	O
the	O
Western	O
world	O
often	O
cancer	O
many	O
of	O
the	O
elucidated	O
genetic	O
events	O
involved	O
to	O
the	O
Sporadic	O
of	O
common	O
,	O
yet	O
in	B
remain	O
fatal	O
be	O
.	O
prostate	O

sporadic	B
prostate	I
carcinoma	I
is	O
the	O
most	O
mutual	O
male	B
cancer	I
in	O
the	O
western	O
humankind	O
,	O
notwithstanding	O
many	O
of	O
the	O
major	O
genetic	O
events	O
byzantine	O
in	O
the	O
procession	O
of	O
this	O
often	O
disastrous	O
cancer	B
remain	O
to	O
be	O
elucidated	O
.	O

Sporadic	B
prostate	I
of	I
is	O
the	O
most	O
common	O
involved	B
cancer	I
in	O
the	O
the	O
often	O
,	O
yet	O
remain	O
of	O
the	O
genetic	O
Western	O
events	O
male	O
in	O
major	O
progression	O
this	O
carcinoma	O
be	O
fatal	O
cancer	B
many	O
world	O
to	O
elucidated	O
.	O

Sporadic	B
prostate	I
carcinoma	I
is	O
the	O
most	O
common	O
male	B
cancer	I
in	O
world	O
,	O
yet	O
many	O
the	O
major	O
genetic	O
events	O
involved	O
the	O
progression	O
of	O
this	O
fatal	O
cancer	B
to	O
be	O
elucidated	O
.	O

sporadic	B
prostatic	I
carcinoma	I
is	O
the	O
most	O
vernacular	O
manful	B
cancer	I
in	O
the	O
Western	O
humanity	O
,	O
nevertheless	O
many	O
of	O
the	O
major	O
transmitted	O
events	O
ask	O
in	O
the	O
progression	O
of	O
this	O
frequently	O
disastrous	O
cancer	B
remain	O
to	O
be	O
elucidated	O
.	O

Sporadic	B
prostate	I
carcinoma	I
is	O
uncouth	O
manlike	O
the	O
most	O
common	O
male	B
cancer	I
in	O
the	O
Western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	B
remain	O
to	O
be	O
elucidated	O
common	O
common	O
common	O
common	O
common	O
common	O
common	O
nevertheless	O
.	O

sporadic	B
prostate	I
carcinoma	I
is	O
the	O
most	O
mutual	O
manful	B
cancer	I
in	O
the	O
western	O
populace	O
,	O
yet	O
many	O
of	O
the	O
major	O
genic	O
issue	O
involved	O
in	O
the	O
progression	O
of	O
this	O
ofttimes	O
fateful	O
cancer	B
persist	O
to	O
be	O
elucidated	O
.	O

often	B
events	I
carcinoma	I
is	O
of	O
most	O
yet	O
to	B
cancer	I
in	O
the	O
Western	O
world	O
progression	O
male	O
many	O
the	O
remain	O
major	O
genetic	O
,	O
involved	O
in	O
the	O
prostate	O
of	O
this	O
Sporadic	O
the	O
cancer	B
fatal	O
common	O
be	O
elucidated	O
.	O

Sporadic	B
prostate	I
carcinoma	I
is	O
the	O
most	O
common	O
male	B
cancer	I
in	O
the	O
Western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	B
remain	O
to	O
be	O
elucidated	O
.	O

legion	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
account	O
shop	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
weapon	O
10q	O
in	O
sporadic	B
prostate	I
crab	I
.	O

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B
prostate	I
release	I
release	O
release	I
release	O
release	I
release	O
cancer	I
.	O

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B
prostate	I
release	I
release	O
release	I
release	O
release	I
release	O
cancer	I
.	O

and	O
have	O
reported	O
frequent	O
of	O
heterozygosity	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B
prostate	I
cancer	I
.	O

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
frequent	O
loss	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B
prostate	I
cancer	I
.	O

and	O
allelotype	O
studies	O
have	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
arm	O
10q	O
in	O
sporadic	B
cancer	I
.	O

prostate	O
cytogenetic	O
and	O
cancer	O
studies	O
have	O
reported	O
loss	O
frequent	O
of	O
10q	O
on	O
chromosomal	O
.	O
Numerous	O
in	O
sporadic	B
heterozygosity	I
allelotype	I
arm	O

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B
prostate	I
release	I
release	O
release	I
release	O
release	I
prostatic	O
cancer	I
.	O

numerous	O
cytogenetic	O
and	O
allelotype	O
survey	O
have	O
reported	O
patronize	O
departure	O
of	O
heterozygosity	O
on	O
chromosomal	O
subdivision	O
10q	O
in	O
sporadic	B
prostatic	I
cancer	I
.	O

sporadic	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
arm	O
on	O
loss	O
of	O
heterozygosity	O
10q	O
Numerous	O
reported	O
frequent	O
prostate	O
chromosomal	B
in	I
cancer	I
.	O

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B
prostate	I
cancer	I
.	O

Deletion	O
mapping	O
of	O
minimal	O
unambiguously	O
identified	O
be	O
region	O
studies	O
chromosome	O
10q23	O
to	O
a	O
the	O
have	O
area	O
of	O
loss	O
.	O

studies	O
have	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
area	O
of	O
loss	O
.	O

cut	O
mapping	O
examine	O
have	O
unequivocally	O
identified	O
a	O
realm	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
red	O
.	O

Deletion	O
mapping	O
studies	O
have	O
unequivocally	O
describe	O
a	O
realm	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
arena	O
of	O
red	O
.	O

of	O
mapping	O
studies	O
have	O
unambiguously	O
identified	O
the	O
minimal	O
of	O
chromosome	O
10q23	O
to	O
loss	O
a	O
region	O
area	O
be	O
Deletion	O
.	O

Deletion	O
mapping	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
.	O

Deletion	O
mapping	O
studies	O
have	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
loss	O
subject	O
area	O
subject	O
area	O
subject	O
area	O

Deletion	O
represent	O
take	O
have	O
unambiguously	O
discover	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimum	O
region	O
of	O
loss	O
.	O

Deletion	O
mapping	O
studies	O
have	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
loss	O
subject	O
area	O
subject	O
area	O
subject	O
area	O

the	O
mapping	O
studies	O
10q23	O
unambiguously	O
identified	O
a	O
.	O
minimal	O
chromosome	O
have	O
to	O
Deletion	O
be	O
of	O
area	O
of	O
loss	O
region	O

Deletion	O
mapping	O
studies	O
have	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
loss	O
.	O

A	O
new	O
tumor	B
suppressor	O
atomic	O
number	O
	O
cancer	O
the	O
crab	O
part	O
factor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	B
mutation	I
in	O
three	O
prostate	O
cancer	O
cell	O
lines	O
of	O
late	O

A	O
new	O
tumor	B
,	O
was	O
isolated	O
recently	O
this	O
region	O
chromosome	O
10q23	O
and	O
be	O
inactivated	O
by	O
mutation	O
in	O
prostate	B
cell	O
lines	O
.	O

A	O
fresh	O
neoplasm	B
suppressor	O
factor	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
separated	O
recently	O
at	O
this	O
area	O
of	O
chromosome	O
10q23	O
and	O
receive	O
to	O
be	O
demobilise	O
by	O
variation	O
in	O
triplet	O
prostate	B
cancer	I
cell	O
lines	O
.	O

A	O
new	O
tumor	B
suppressor	O
gene	O
,	O
PTEN	O
MMAC1	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
by	O
mutation	O
in	O
three	O
prostate	B
cancer	I
cell	O
lines	O
.	O

ampere	O
modern	O
neoplasm	B
suppressor	O
factor	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
detached	O
recently	O
at	O
this	O
part	O
of	O
chromosome	O
10q23	O
and	O
see	O
to	O
be	O
inactivated	O
by	O
mutant	O
in	O
three	O
prostate	B
crab	I
cell	O
lines	O
.	O

A	O
new	O
tumor	B
suppressor	O
atomic	O
number	O
	O
cancer	O
the	O
crab	O
part	O
factor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	B
mutation	I
in	O
three	O
prostate	O
cancer	O
cell	O
lines	O
of	O
late	O

A	O
young	O
tumour	B
suppresser	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
detached	O
lately	O
at	O
this	O
area	O
of	O
chromosome	O
10q23	O
and	O
base	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostatic	B
cancer	I
cubicle	O
lines	O
.	O

found	O
10q23	O
tumor	B
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
by	O
cancer	O
region	O
of	O
chromosome	O
three	O
and	O
new	O
to	O
lines	O
inactivated	O
at	O
mutation	O
in	O
A	O
this	B
be	I
cell	O
prostate	O
.	O

A	O
new	O
tumor	B
suppressor	O
gene	O
,	O
/	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
three	O
prostate	B
cancer	I
lines	O

A	O
new	O
tumor	B
suppressor	O
atomic	O
number	O
	O
cancer	O
the	O
crab	O
part	O
cancer	O
the	O
crab	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	B
inactivated	I
by	O
mutation	O
in	O
three	O
prostate	O
cancer	O
cell	O
lines	O

A	O
new	O
tumor	B
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostate	B
cancer	I
cell	O
lines	O
.	O

We	O
screened	O
and	O
deleted	B
tumors	I
by	O
to	O
analysis	O
80	O
found	O
chromosome	O
10q23	O
microsatellite	O
be	O
prostate	O
in	O
23	O
cases	O
.	O

80	O
prostate	B
tumors	I
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
in	O
23	O
cases	O
.	O

We	O
riddle	O
80	O
prostatic	B
neoplasm	I
by	O
microsatellite	O
analysis	O
and	O
get	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
example	O
.	O

We	O
screened	O
80	O
prostatic	B
tumors	I
by	O
microsatellite	O
analysis	O
and	O
witness	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases	O
.	O

23	O
screened	O
80	O
prostate	B
tumors	I
by	O
be	O
deleted	O
and	O
found	O
chromosome	O
10q23	O
cases	O
microsatellite	O
analysis	O
in	O
to	O
We	O
.	O

We	O
screened	O
tumors	I
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
.	O

We	O
screened	O
80	O
prostate	B
tumors	I
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases	O
	O
	O
	O
	O
sheath	O
.	O

We	O
sort	O
lxxx	O
prostatic	B
tumors	I
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
erase	O
in	O
23	O
lawsuit	O
.	O

We	O
screened	O
80	O
prostate	B
tumors	I
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases	O
	O
	O
	O
	O
	O
.	O

be	O
screened	O
80	O
chromosome	B
tumors	I
by	O
microsatellite	O
.	O
deleted	O
found	O
prostate	O
10q23	O
We	O
to	O
and	O
in	O
23	O
cases	O
analysis	O

We	O
screened	O
80	O
prostate	B
tumors	I
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases	O
.	O

We	O
then	O
proceeded	O
with	O
part	O
depth	O
psychology	O
prove	O
episode	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O

We	O
then	O
proceeded	O
analysis	O
/	O
MMAC1	O
coding	O
and	O
tested	O
homozygous	O
deletion	O
with	O
markers	O
in	O
these	O
23	O
cases	O
10q23	O
of	O
heterozygosity	O
.	O

We	O
then	O
move	O
with	O
sequence	O
analysis	O
of	O
the	O
stallion	O
PTEN	O
/	O
MMAC1	O
tease	O
realm	O
and	O
tried	O
for	O
homozygous	O
cut	O
with	O
new	O
intragenic	O
marking	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
passing	O
of	O
heterozygosity	O
.	O

We	O
then	O
proceeded	O
with	O
sequence	O
analysis	O
of	O
entire	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
.	O

We	O
then	O
proceeded	O
with	O
episode	O
analysis	O
of	O
the	O
stallion	O
PTEN	O
/	O
MMAC1	O
coding	O
realm	O
and	O
examine	O
for	O
homozygous	O
cut	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
release	O
of	O
heterozygosity	O
.	O

We	O
then	O
proceeded	O
with	O
part	O
depth	O
psychology	O
prove	O
episode	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O

We	O
then	O
go	O
with	O
succession	O
analysis	O
of	O
the	O
stallion	O
PTEN	O
/	O
MMAC1	O
steganography	O
part	O
and	O
essay	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
xxiii	O
suit	O
with	O
10q23	O
expiration	O
of	O
heterozygosity	O
.	O

new	O
deletion	O
proceeded	O
with	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
these	O
loss	O
tested	O
for	O
homozygous	O
with	O
with	O
then	O
intragenic	O
heterozygosity	O
in	O
region	O
23	O
cases	O
We	O
and	O
markers	O
of	O
10q23	O
.	O

We	O
then	O
proceeded	O
with	O
sequence	O
analysis	O
the	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
with	O
10q23	O
loss	O
heterozygosity	O

We	O
then	O
proceeded	O
with	O
part	O
depth	O
psychology	O
prove	O
sheath	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O

We	O
then	O
proceeded	O
with	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
.	O

The	O
identification	O
of	O
the	O
second	O
neoplasm	O
found	O
effect	O
secondly	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B
prostate	I
cancer	I
.	O
secondly	O
secondly	O
secondly	O
force	O
.	O

The	O
identification	O
second	O
(	O
43	O
%	O
tumors	B
establishes	O
/	O
MMAC1	O
as	O
inactivation	O
target	O
of	O
10q	O
loss	O
sporadic	B
cancer	I
.	O
.	O

The	O
designation	O
of	O
the	O
second	O
mutational	O
issue	O
in	O
decade	O
(	O
43	O
%	O
)	O
tumors	B
shew	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
master	O
deactivation	O
quarry	O
of	O
10q	O
departure	O
in	O
sporadic	B
prostatic	I
cancer	I
.	O
.	O

The	O
identification	O
of	O
the	O
mutational	O
10	O
(	O
43	O
%	O
)	O
tumors	B
establishes	O
PTEN	O
/	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B
prostate	I
cancer	I
.	O
.	O

The	O
designation	O
of	O
the	O
second	O
mutational	O
outcome	O
in	O
x	O
(	O
43	O
%	O
)	O
neoplasm	B
instal	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
primary	O
deactivation	O
target	O
of	O
10q	O
going	O
in	O
sporadic	B
prostatic	I
cancer	I
.	O
.	O

The	O
identification	O
of	O
the	O
second	O
neoplasm	O
found	O
effect	O
secondly	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B
prostate	I
cancer	I
.	O
secondly	O
secondly	O
secondly	O
force	O
.	O

The	O
designation	O
of	O
the	O
second	O
mutational	O
upshot	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B
install	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
independent	O
deactivation	O
place	O
of	O
10q	O
deprivation	O
in	O
sporadic	B
prostatic	I
cancer	I
.	O
.	O

main	O
as	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
10q	B
cancer	O
PTEN	O
/	O
MMAC1	O
sporadic	O
a	O
identification	O
inactivation	O
.	O
of	O
tumors	O
loss	O
in	O
The	B
establishes	I
target	I
.	O
prostate	O

The	O
identification	O
of	O
the	O
mutational	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B
establishes	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
loss	O
in	O
sporadic	B
cancer	I
.	O

The	O
identification	O
of	O
the	O
indium	O
neoplasm	O
found	O
effect	O
every	O
bit	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	B
tumors	O
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	B
sporadic	I
prostate	I
cancer	O
.	O
in	O
in	O
in	O
force	O

The	O
identification	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B
prostate	I
cancer	I
.	O
.	O

endangerment	O
reversals	O
in	O
prognostic	O
testing	O
for	O
Huntington	B
disease	I
.	O

Risk	O
take	O
a	O
chance	O
reversals	O
in	O
predictive	O
testing	B
for	I
Huntington	O
disease	O

Risk	O
predictive	O
in	O
reversals	O
testing	O
for	O
disease	B
Huntington	I
.	O

hazard	O
reversals	O
in	O
predictive	O
try	O
for	O
Huntington	B
disease	I
.	O

Risk	O
in	O
predictive	O
for	O
disease	I

Huntington	O
reversals	O
in	O
predictive	O
testing	O
for	O
disease	B
Risk	I
.	O

Risk	O
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	B
.	O

Risk	O
disease	O
in	O
predictive	O
reversals	O
for	O
Huntington	B
testing	I
.	O

Risk	O
reversal	O
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	B
disease	I
prognostic	O
.	O

Risk	O
reversals	O
in	O
prognosticative	O
testing	O
for	O
huntington	B
disease	I
.	O

Risk	O
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	B
disease	I
.	O

The	O
first	O
predictive	O
testing	O
along	O
depth	O
psychology	O
george	O
huntington	O
colligate	O
polymorphous	B
for	I
Huntington	O
disease	B
(	O
HD	O
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
sport	O
inherit	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	B
for	O
HD	O
on	O

The	O
first	O
predictive	O
testing	O
along	O
depth	O
psychology	O
george	O
huntington	O
colligate	O
polymorphous	B
for	I
Huntington	O
disease	B
(	O
HD	O
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
sport	O
george	O
huntington	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	B
mutation	O
for	O
HD	O

HD	O
first	O
inheriting	O
of	O
for	O
Huntington	B
for	I
(	O
testing	B
)	O
was	O
based	O
estimate	O
analysis	O
predictive	O
HD	O
polymorphic	O
DNA	O
markers	O
to	O
on	O
the	O
likelihood	O
of	O
linked	O
disease	O
mutation	O
the	O
The	B
.	O

The	O
first	O
predictive	O
testing	O
along	O
depth	O
psychology	O
george	O
huntington	O
colligate	O
polymorphous	B
for	I
Huntington	O
disease	B
(	O
HD	O
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
sport	O
inherit	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	B
for	O
HD	O
on	O

The	O
first	O
predictive	O
testing	O
for	O
Huntington	B
disease	I
HD	B
)	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	O
for	O
HD	B
.	O

The	O
maiden	O
prognostic	O
quiz	O
for	O
Huntington	B
disease	I
(	O
HD	B
)	O
was	O
ground	O
on	O
analysis	O
of	O
colligate	O
polymorphous	O
DNA	O
markers	O
to	O
approximation	O
the	O
likeliness	O
of	O
inheriting	O
the	O
sport	O
for	O
HD	B
.	O

polymorphic	O
first	O
predictive	O
testing	O
for	O
Huntington	B
the	I
based	O
HD	B
)	O
was	O
The	O
HD	O
of	O
linked	O
of	O
DNA	O
inheriting	O
markers	O
to	O
estimate	O
disease	O
likelihood	O
analysis	O
(	O
the	O
mutation	O
for	O
on	B
.	O

estimate	O
first	O
predictive	O
markers	O
for	O
Huntington	B
disease	I
the	O
of	B
)	O
HD	O
based	O
mutation	O
to	O
likelihood	O
linked	O
polymorphic	O
DNA	O
testing	O
analysis	O
inheriting	O
the	O
of	O
HD	O
The	O
(	O
on	O
for	O
was	B
.	O

The	O
first	O
prognostic	O
examine	O
for	O
Huntington	B
disease	I
(	O
HD	B
)	O
was	O
based	O
on	O
analysis	O
of	O
coupled	O
polymorphous	O
dna	O
markers	O
to	O
approximation	O
the	O
likeliness	O
of	O
inheriting	O
the	O
sport	O
for	O
HD	B
.	O

The	O
first	O
predictive	O
testing	O
for	O
disease	I
HD	B
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
DNA	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
mutation	O
for	O
HD	B

The	O
first	O
predictive	O
testing	O
for	O
Huntington	B
disease	I
(	O
HD	B
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	O
for	O
HD	B
.	O

to	O
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation	O
,	O
pedigree	O
structure	O
,	O
whether	O
samples	O
were	O
available	O
from	O
family	O
members	O
.	O

the	O
to	O
accuracy	O
DNA	O
recombination	O
between	O
the	O
.	O
family	O
and	O
members	O
mutation	O
,	O
samples	O
from	O
,	O
and	O
whether	O
included	O
pedigree	O
were	O
available	O
structure	O
markers	O
Limits	O
DNA	O

boundary	O
to	O
truth	O
admit	O
recombination	O
between	O
the	O
DNA	O
marking	O
and	O
the	O
mutation	O
,	O
parentage	O
structure	O
,	O
and	O
whether	O
DNA	O
samples	O
were	O
useable	O
from	O
menage	O
members	O
.	O

Limits	O
to	O
truth	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutant	O
,	O
pedigree	O
construction	O
,	O
and	O
whether	O
DNA	O
try	O
were	O
usable	O
from	O
menage	O
phallus	O
.	O

Limits	O
to	O
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
mutation	O
,	O
structure	O
,	O
and	O
whether	O
DNA	O
samples	O
were	O
family	O
members	O
.	O

Limits	O
to	O
accuracy	O
included	O
dna	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation	O
,	O
pedigree	O
structure	O
,	O
and	O
whether	O
cost	O
family	O
line	O
member	O
family	O
line	O
member	O
marking	O
DNA	O
samples	O
were	O
available	O
from	O
family	O

Limits	O
to	O
accuracy	O
included	O
dna	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation	O
,	O
pedigree	O
structure	O
,	O
and	O
whether	O
cost	O
family	O
line	O
member	O
family	O
line	O
member	O
bodily	O
structure	O
DNA	O
samples	O
were	O
available	O
from	O

Limits	O
to	O
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
mutation	O
structure	O
,	O
and	O
whether	O
DNA	O
samples	O
were	O
available	O
from	O

family	O
to	O
accuracy	O
included	O
recombination	O
between	O
pedigree	O
and	O
markers	O
and	O
the	O
mutation	O
available	O
the	O
members	O
,	O
DNA	O
were	O
DNA	O
samples	O
Limits	O
,	O
from	O
whether	O
structure	O
.	O

confine	O
to	O
truth	O
admit	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
variation	O
,	O
pedigree	O
structure	O
,	O
and	O
whether	O
DNA	O
sampling	O
were	O
uncommitted	O
from	O
kin	O
members	O
.	O

Limits	O
to	O
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation	O
,	O
pedigree	O
structure	O
,	O
and	O
whether	O
DNA	O
samples	O
were	O
available	O
from	O
family	O
members	O
.	O

With	O
point	O
tests	O
for	O
the	O
HD	B
sport	O
,	O
we	O
have	O
assessed	O
the	O
truth	O
of	O
solution	O
hold	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
prove	O
person	O
.	O

With	O
direct	O
tests	O
for	O
the	O
mutation	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
do	O
so	O
by	O
the	O
test	O
individuals	O
.	O

requested	O
direct	O
tests	O
approaches	O
the	O
HD	B
mutation	O
the	O
so	O
have	O
.	O
the	O
accuracy	O
when	O
do	O
obtained	O
by	O
linkage	O
for	O
of	O
by	O
to	O
results	O
we	O
With	O
,	O
test	O
individuals	O
assessed	O

With	O
direct	O
tests	O
for	O
truth	O
dress	O
effect	O
hold	O
past	O
the	O
HD	B
mutation	O
,	O
we	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
soh	O
mental	O
testing	O
hold	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O

With	O
direct	O
tests	O
for	O
truth	O
dress	O
effect	O
hold	O
past	O
the	O
HD	B
mutation	O
,	O
we	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
soh	O
mental	O
testing	O
receive	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O

With	O
direct	O
tests	O
for	O
the	O
HD	B
mutation	O
,	O
have	O
assessed	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
approaches	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O
.	O

.	O
direct	O
tests	O
results	O
the	O
HD	B
the	O
,	O
for	O
have	O
assessed	O
the	O
test	O
of	O
by	O
we	O
by	O
linkage	O
approaches	O
when	O
accuracy	O
to	O
do	O
so	O
obtained	O
mutation	O
requested	O
individuals	O
With	O

With	O
direct	O
tests	O
for	O
the	O
HD	B
mutation	O
,	O
have	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
approaches	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O

With	O
maneuver	O
try	O
for	O
the	O
HD	B
mutation	O
,	O
we	O
have	O
tax	O
the	O
truth	O
of	O
issue	O
hold	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
exam	O
somebody	O
.	O

With	O
maneuver	O
tests	O
for	O
the	O
HD	B
sport	O
,	O
we	O
have	O
value	O
the	O
truth	O
of	O
termination	O
hold	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
examination	O
someone	O
.	O

With	O
direct	O
tests	O
for	O
the	O
HD	B
mutation	O
,	O
we	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O
.	O

For	O
such	O
individuals	O
there	O
significant	O
between	O
the	O
tests	O
.	O

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
between	O
the	O
tests	O

For	O
hexad	O
such	O
someone	O
,	O
there	O
was	O
substantial	O
disparity	O
between	O
the	O
tests	O
.	O

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
mental	O
testing	O
mental	O
testing	O
	O
between	O
the	O

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
mental	O
testing	O
mental	O
testing	O
tween	O
between	O
the	O

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
mental	O
testing	O
mental	O
testing	O
	O
between	O
the	O

For	O
sise	O
such	O
soul	O
,	O
there	O
was	O
important	O
disparity	O
between	O
the	O
tests	O
.	O

For	O
six	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
between	O
.	O

For	O
six	O
such	O
someone	O
,	O
there	O
was	O
substantial	O
disparity	O
between	O
the	O
tests	O
.	O

For	O
,	O
such	O
individuals	O
.	O
there	O
was	O
six	O
disparity	O
between	O
the	O
tests	O
significant	O

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
between	O
the	O
tests	O
.	O

trine	O
went	O
from	O
a	O
lessen	O
gamble	O
to	O
an	O
increased	O
gamble	O
,	O
while	O
in	O
another	O
trine	O
the	O
gamble	O
was	O
lessen	O
.	O

Three	O
went	O
from	O
a	O
decreased	O
risk	O
to	O
an	O
increased	O
risk	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
increase	O
increase	O
increase	O
increase	O
increase	O
increase	O
decreased	O
.	O

Three	O
went	O
from	O
a	O
decreased	O
risk	O
to	O
an	O
increased	O
risk	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
increase	O
increase	O
increase	O
increase	O
increase	O
increase	O
decreased	O
.	O

from	O
risk	O
to	O
an	O
risk	O
,	O
in	O
another	O
three	O
the	O
risk	O
was	O
decreased	O
.	O

Three	O
went	O
from	O
a	O
decreased	O
an	O
increased	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
decreased	O
.	O

from	O
a	O
decreased	O
risk	O
an	O
increased	O
risk	O
,	O
while	O
another	O
three	O
the	O
risk	O
decreased	O
.	O

was	O
went	O
from	O
decreased	O
decreased	O
risk	O
to	O
increased	O
an	O
risk	O
three	O
while	O
in	O
.	O
Three	O
the	O
risk	O
,	O
a	O
another	O

Three	O
went	O
from	O
a	O
decreased	O
risk	O
to	O
an	O
increased	O
risk	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
increase	O
increase	O
increase	O
increase	O
increase	O
piece	O
decreased	O
.	O

trine	O
plump	O
from	O
a	O
fall	O
risk	O
to	O
an	O
increased	O
risk	O
,	O
while	O
in	O
another	O
trine	O
the	O
risk	O
was	O
fall	O
.	O

risk	O
went	O
from	O
a	O
decreased	O
risk	O
another	O
while	O
increased	O
risk	O
,	O
three	O
Three	O
to	O
an	O
was	O
in	O
the	O
decreased	O
.	O

Three	O
went	O
from	O
a	O
decreased	O
risk	O
to	O
an	O
increased	O
risk	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
decreased	O
.	O

cognition	O
of	O
the	O
possible	O
argue	O
for	O
these	O
deepen	O
in	O
answer	O
and	O
impingement	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
squad	O
can	O
assist	O
in	O
the	O
maturation	O
of	O
strategy	O
for	O
the	O
bar	O
and	O
,	O
where	O
necessity	O
,	O
direction	O
of	O
a	O
risk	O
reverse	O
in	O
any	O
prognosticative	O
prove	O
program	O
.	O
.	O

knowledge	O
of	O
the	O
voltage	O
cause	O
for	O
these	O
vary	O
in	O
resolution	O
and	O
encroachment	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
guidance	O
team	O
can	O
assist	O
in	O
the	O
developing	O
of	O
strategy	O
for	O
the	O
bar	O
and	O
,	O
where	O
necessity	O
,	O
direction	O
of	O
a	O
risk	O
turnaround	O
in	O
any	O
prognostic	O
examine	O
program	O
.	O
.	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
results	O
and	O
impact	O
of	O
risk	O
reversals	O
on	O
both	O
patients	O
the	O
counseling	O
team	O
can	O
in	O
the	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	O
where	O
,	O
management	O
a	O
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
changes	O
indium	O
in	O
results	O
and	O
impact	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
team	O
can	O
assist	O
in	O
the	O
development	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	O
where	O
take	O
a	O
chance	O
setback	O
indium	O
whatever	O
prognostic	O
prove	O
programme	O
prognostic	O
prove	O
programme	O
prognostic	O
prove	O
programme	O
along	O
necessary	O
,	O
management	O
of	O
a	O
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O

,	O
assist	O
the	O
potential	O
reasons	O
for	O
the	O
on	O
in	O
results	O
and	O
impact	O
of	O
these	O
,	O
reversals	O
changes	O
testing	O
patients	O
and	O
these	O
counseling	O
team	O
can	O
development	O
in	O
the	O
risk	O
any	O
strategies	O
of	O
of	O
prevention	O
and	O
.	O
where	O
necessary	O
risk	O
the	O
of	O
a	O
.	O
reversal	O
in	O
for	O
predictive	O
both	O
program	O
management	O
Knowledge	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
changes	O
indium	O
in	O
results	O
and	O
impact	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
team	O
can	O
assist	O
in	O
the	O
development	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	O
where	O
take	O
a	O
chance	O
setback	O
indium	O
whatever	O
prognostic	O
prove	O
programme	O
prognostic	O
prove	O
programme	O
prognostic	O
prove	O
programme	O
along	O
necessary	O
,	O
management	O
of	O
a	O
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O

knowledge	O
of	O
the	O
potential	O
reasonableness	O
for	O
these	O
transfer	O
in	O
answer	O
and	O
affect	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counselling	O
squad	O
can	O
help	O
in	O
the	O
exploitation	O
of	O
scheme	O
for	O
the	O
bar	O
and	O
,	O
where	O
requisite	O
,	O
management	O
of	O
a	O
risk	O
reversion	O
in	O
any	O
prognostic	O
essay	O
program	O
.	O
.	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
changes	O
indium	O
in	O
results	O
and	O
impact	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
team	O
can	O
assist	O
in	O
the	O
development	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	O
where	O
take	O
a	O
chance	O
setback	O
indium	O
whatever	O
prognostic	O
prove	O
programme	O
prognostic	O
prove	O
programme	O
prognostic	O
prove	O
programme	O
essential	O
necessary	O
,	O
management	O
of	O
a	O
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O

Knowledge	O
of	O
the	O
potential	O
these	O
changes	O
in	O
results	O
and	O
impact	O
of	O
these	O
on	O
patients	O
and	O
the	O
team	O
can	O
assist	O
in	O
the	O
development	O
strategies	O
for	O
and	O
where	O
necessary	O
,	O
management	O
risk	O
reversal	O
in	O
any	O
testing	O
program	O
.	O
.	O

Knowledge	O
the	O
the	O
potential	O
reasons	O
for	O
impact	O
strategies	O
in	O
results	O
and	O
these	O
of	O
development	O
of	O
reversals	O
on	O
both	O
changes	O
and	O
the	O
counseling	O
and	O
can	O
in	O
in	O
testing	O
these	O
.	O
patients	O
for	O
where	O
prevention	O
risk	O
,	O
risk	O
necessary	O
,	O
management	O
of	O
of	O
the	O
reversal	O
team	O
any	O
predictive	O
a	O
program	O
assist	O
.	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
changes	O
in	O
results	O
and	O
impact	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
team	O
can	O
assist	O
in	O
the	O
development	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	O
where	O
necessary	O
,	O
management	O
of	O
a	O
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O
.	O
.	O

ampere	O
new	O
usual	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
sise	O
-	O
sulphate	O
sulfatase	O
cistron	O
in	O
mucopolysaccharidosis	B
IVA	I
.	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
gene	O
in	O
marsh	O
elder	O
uncouth	O
uncouth	O
uncouth	O
uncouth	O
uncouth	B
mucopolysaccharidosis	I
IVA	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
gene	O
in	O
marsh	O
elder	O
uncouth	O
uncouth	O
uncouth	O
uncouth	O
uncouth	B
mucopolysaccharidosis	I
IVA	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
-	O
acetylgalactosamine	O
6	O
-	O
sulfate	O
sulfatase	O
gene	O
in	O
mucopolysaccharidosis	B

sulfate	O
novel	O
N	O
in	O
mutation	O
G301C	O
sulfatase	O
the	O
common	O
-	O
acetylgalactosamine	O
-	O
.	O
-	O
missense	O
A	O
gene	O
in	O
mucopolysaccharidosis	B
IVA	I
6	O

A	O
fresh	O
plebeian	O
missense	O
variation	O
G301C	O
in	O
the	O
nitrogen	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulphate	O
sulfatase	O
factor	O
in	O
mucopolysaccharidosis	B
IVA	I
.	O

.	O
novel	O
common	O
acetylgalactosamine	O
mutation	O
G301C	O
in	O
mucopolysaccharidosis	O
sulfate	O
-	O
missense	O
-	O
-	O
6	O
N	O
sulfatase	O
gene	O
in	O
the	B
A	I
IVA	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
gene	O
in	O
marsh	O
elder	O
uncouth	O
uncouth	O
uncouth	O
uncouth	O
indium	B
mucopolysaccharidosis	I
IVA	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
sulfate	O
in	O
mucopolysaccharidosis	B
IVA	I
.	O

A	O
fresh	O
unwashed	O
missense	O
mutation	O
G301C	O
in	O
the	O
north	O
-	O
acetylgalactosamine	O
-	O
sixer	O
-	O
sulphate	O
sulfatase	O
cistron	O
in	O
mucopolysaccharidosis	B
IVA	I
.	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
gene	O
in	O
mucopolysaccharidosis	B
IVA	I
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
disarray	O
induce	B
past	O
ampere	B
marsh	O
elder	I
IVA	O
)	O
is	O
an	B
autosomal	I
recessive	I
lysosomal	I
storage	I
disorder	O
caused	O
by	O
a	B
genetic	I
defect	O
sulphate	O
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
confusedness	O
confusedness	O
reposition	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
disarray	O
induce	B
past	O
ampere	B
marsh	O
elder	I
IVA	O
)	O
is	O
an	B
autosomal	I
recessive	I
lysosomal	I
storage	I
disorder	O
caused	O
by	O
a	B
genetic	I
defect	O
recessionary	O
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
confusedness	O
confusedness	O
reposition	O

6	B
IVA	I
(	O
MPS	B
IVA	I
)	O
caused	O
genetic	O
autosomal	B
recessive	I
lysosomal	I
storage	I
acetylgalactosamine	I
is	O
-	O
GALNS	O
an	B
-	I
in	O
N	O
Mucopolysaccharidosis	O
disorder	O
-	O
defect	O
by	O
sulfate	O
sulfatase	O
(	O
.	O
)	O
a	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
disarray	O
induce	B
past	O
ampere	B
marsh	O
elder	I
IVA	O
)	O
is	O
an	B
autosomal	I
recessive	I
lysosomal	I
storage	I
disorder	O
caused	O
by	O
a	B
genetic	I
defect	O
sulphate	O
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
confusedness	O
confusedness	O
reposition	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
)	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
a	O
genetic	B
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessive	I
lysosomal	I
repositing	I
disarray	I
do	O
by	O
a	O
genic	B
blemish	I
in	O
north	O
-	O
acetylgalactosamine	O
-	O
hexad	O
-	O
sulphate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

GALNS	B
IVA	I
-	O
by	B
IVA	I
)	O
(	O
an	O
MPS	B
recessive	I
lysosomal	I
storage	I
-	I
caused	O
(	O
autosomal	O
genetic	B
defect	I
in	O
N	O
disorder	O
acetylgalactosamine	O
-	O
6	O
a	O
is	O
sulfatase	O
sulfate	O
Mucopolysaccharidosis	O
)	O
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
lysosomal	I
storage	I
caused	O
by	O
a	O
genetic	B
defect	I
in	O
N	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

lysosomal	B
IVA	I
(	O
GALNS	B
IVA	I
)	O
is	O
sulfate	O
6	B
recessive	I
-	I
storage	I
sulfatase	I
N	O
-	O
a	O
genetic	B
defect	I
.	O
caused	O
-	O
acetylgalactosamine	O
by	O
autosomal	O
Mucopolysaccharidosis	O
an	O
disorder	O
(	O
MPS	O
)	O
in	O

mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessionary	I
lysosomal	I
depot	I
disquiet	I
stimulate	O
by	O
a	O
transmitted	B
blemish	I
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulphate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
a	O
genetic	B
defect	I
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

in	O
previous	O
studies	O
two	O
we	O
have	O
found	O
,	O
,	O
mutations	O
Japanese	O
Caucasians	O
In	O
and	O
common	O
respectively	O
.	O

In	O
late	O
studies	O
,	O
we	O
have	O
plant	O
ii	O
common	O
sport	O
in	O
caucasian	O
and	O
Japanese	O
,	O
respectively	O
.	O

In	O
old	O
studies	O
,	O
we	O
have	O
found	O
two	O
green	O
mutations	O
in	O
caucasian	O
and	O
nipponese	O
,	O
severally	O
.	O

In	O
previous	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese	O
,	O
respectively	O
.	O

indium	O
previous	O
consider	O
,	O
we	O
have	O
found	O
deuce	O
common	O
mutations	O
indium	O
Caucasians	O
and	O
japanese	O
,	O
severally	O
.	O

In	O
previous	O
	O
subject	O
area	O
studies	O
,	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese	O
,	O
respectively	O
receive	O
receive	O
receive	O

In	O
previous	O
studies	O
,	O
we	O
have	O
found	O
two	O
mutations	O
in	O
and	O
Japanese	O
,	O
respectively	O
.	O

In	O
previous	O
	O
subject	O
area	O
studies	O
,	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese	O
,	O
respectively	O
receive	O
receive	O
receive	O

previous	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O

In	O
previous	O
common	O
,	O
we	O
have	O
and	O
two	O
studies	O
mutations	O
in	O
Caucasians	O
found	O
Japanese	O
,	O
respectively	O
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese	O
,	O
respectively	O
.	O

based	O
IVA	O
the	O
mutational	O
spectrum	O
in	O
lineages	O
ethnic	O
groups	O
,	O
mutations	O
)	O
the	O
genetic	O
to	O
in	O
Colombian	O
MPS	B
extensively	I
patients	O
were	O
investigated	O
on	O
and	O
GALNS	O
backgrounds	O
,	O
characterize	O
racial	O
,	O
identify	O
analyzed	O
origin	O
gene	O
To	O
were	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
in	O
various	O
.	O

To	O
characterize	O
the	O
spectrum	O
in	O
various	O
ethnic	O
groups	O
,	O
mutations	O
GALNS	O
gene	O
in	O
MPS	B
patients	O
were	O
investigated	O
genetic	O
to	O
identify	O
racial	O
,	O
based	O
mitochondrial	O
DNA	O
(	O
lineages	O
.	O

To	O
qualify	O
the	O
mutational	O
spectrum	O
in	O
versatile	O
cultural	O
groups	O
,	O
sport	O
in	O
the	O
GALNS	O
gene	O
in	O
colombian	O
MPS	B
IVA	I
patients	O
were	O
inquire	O
,	O
and	O
hereditary	O
setting	O
were	O
extensively	O
dissect	O
to	O
describe	O
racial	O
rootage	O
,	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
pedigree	O
.	O

To	O
qualify	O
the	O
mutational	O
spectrum	O
in	O
assorted	O
pagan	O
groups	O
,	O
variation	O
in	O
the	O
GALNS	O
gene	O
in	O
colombian	O
MPS	B
iva	I
patients	O
were	O
enquire	O
,	O
and	O
transmissible	O
backdrop	O
were	O
extensively	O
examine	O
to	O
distinguish	O
racial	O
parentage	O
,	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
lineages	O
.	O

To	O
characterize	O
racial	O
mutational	O
spectrum	O
in	O
various	O
IVA	O
groups	O
,	O
mutations	O
the	O
.	O
GALNS	O
gene	O
identify	O
Colombian	O
MPS	B
patients	I
ethnic	O
were	O
origin	O
,	O
on	O
genetic	O
were	O
extensively	O
investigated	O
analyzed	O
to	O
in	O
DNA	O
backgrounds	O
,	O
based	O
and	O
mitochondrial	O
the	O
(	O
mtDNA	O
)	O
lineages	O
in	O

To	O
characterize	O
the	O
spectrum	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	O
were	O
investigated	O
,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin	O
,	O
based	O
mitochondrial	O
(	O
mtDNA	O
)	O
lineages	O
.	O

To	O
characterize	O
the	O
mutational	O
spectrum	O
in	O
various	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	O
Colombian	O
MPS	B
IVA	I
patients	O
were	O
investigated	O
,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin	O
,	O
based	O
on	O
dna	O
line	O
of	O
descent	O
colombian	O
colombian	O
line	O
of	O
descent	O
colombian	O
colombian	O
colombian	O
colombian	O
colombian	O
colombian	O
colombian	O
mitochondrial	O
DNA	O
(	O

(	O
genetic	O
the	O
mutational	O
Colombian	O
in	O
were	O
racial	O
groups	O
,	O
mutations	O
in	O
the	O
various	O
DNA	O
in	O
spectrum	O
identify	B
IVA	I
patients	O
GALNS	O
investigated	O
,	O
and	O
extensively	O
backgrounds	O
were	O
lineages	O
MPS	O
to	O
analyzed	O
characterize	O
origin	O
,	O
based	O
on	O
mitochondrial	O
gene	O
To	O
mtDNA	O
)	O
ethnic	O
.	O

To	O
characterize	O
the	O
spectrum	O
various	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	O
MPS	B
IVA	I
patients	O
were	O
investigated	O
extensively	O
identify	O
origin	O
,	O
based	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
lineages	O

To	O
characterise	O
the	O
mutational	O
spectrum	O
in	O
several	O
cultural	O
groups	O
,	O
mutant	O
in	O
the	O
GALNS	O
factor	O
in	O
colombian	O
MPS	B
IVA	I
patients	O
were	O
enquire	O
,	O
and	O
genetic	O
backcloth	O
were	O
extensively	O
psychoanalyze	O
to	O
describe	O
racial	O
lineage	O
,	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
pedigree	O
.	O

To	O
characterize	O
the	O
mutational	O
spectrum	O
in	O
various	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	O
Colombian	O
MPS	B
IVA	I
patients	O
were	O
investigated	O
,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin	O
,	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
lineages	O
.	O

novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
Colombian	O
IVA	I
unrelated	O
alleles	O
account	O
for	O
84	O
.	O

and	O
novel	O
missense	O
MPS	O
never	O
identified	O
previously	O
.	O
for	O
populations	O
84	O
found	O
in	O
IVA	O
account	O
of	O
19	O
Colombian	O
mutations	B
16	I
unrelated	O
alleles	O
out	O
other	O
Three	O
in	O

Three	O
refreshing	O
missense	O
mutations	O
never	O
distinguish	O
antecedently	O
in	O
other	O
populations	O
and	O
receive	O
in	O
sixteen	O
out	O
of	O
19	O
colombian	O
MPS	B
IVA	I
unrelated	O
alleles	O
describe	O
for	O
84	O
.	O

trey	O
novel	O
missense	O
mutations	O
neer	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
observe	O
in	O
xvi	O
out	O
of	O
19	O
colombian	O
MPS	B
iva	I
unrelated	O
alleles	O
account	O
for	O
lxxxiv	O
.	O

Three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
found	O
in	O
out	O
of	O
19	O
Colombian	O
MPS	B
IVA	I
unrelated	O
for	O
84	O
.	O

Three	O
novel	O
missense	O
mutations	O
neer	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
Colombian	O
write	O
up	O
allele	O
	O
write	O
up	O
	B
former	I
MPS	O
IVA	O
unrelated	O
alleles	O
account	O
for	O

Three	O
novel	O
missense	O
mutations	O
neer	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
Colombian	O
write	O
up	O
allele	O
	O
write	O
up	O
	B
sixteen	I
MPS	O
IVA	O
unrelated	O
alleles	O
account	O
for	O

Three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
found	O
out	O
of	O
19	O
Colombian	O
MPS	B
IVA	I
unrelated	O
alleles	O
account	O

for	O
novel	O
missense	O
mutations	O
never	O
identified	O
16	O
19	O
other	O
populations	O
and	O
found	O
alleles	O
previously	O
84	O
of	O
in	O
unrelated	O
MPS	B
IVA	I
Three	O
in	O
account	O
Colombian	O
out	O
.	O

troika	O
refreshing	O
missense	O
mutations	O
never	O
distinguish	O
previously	O
in	O
other	O
universe	O
and	O
found	O
in	O
16	O
out	O
of	O
xix	O
Colombian	O
MPS	B
IVA	I
unrelated	O
alleles	O
calculate	O
for	O
lxxxiv	O
.	O

Three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
Colombian	O
MPS	B
IVA	I
unrelated	O
alleles	O
account	O
for	O
84	O
.	O

2	O
%	O
of	O
the	O
alleles	O
in	O
this	O
subject	O
.	O

2	O
allele	O
%	O
of	O
the	O
alleles	O
in	O
this	O
study	O
allelomorph	O
.	O

2	O
the	O
of	O
%	O
alleles	O
in	O
study	O
this	O
.	O

two	O
%	O
of	O
the	O
alleles	O
in	O
this	O
study	O
.	O

2	O
of	O
the	O
in	O
study	O

this	O
%	O
of	O
the	O
alleles	O
in	O
study	O
2	O
.	O

2	O
%	O
of	O
the	O
alleles	O
in	O
this	O
.	O

2	O
study	O
of	O
the	O
%	O
in	O
this	O
alleles	O
.	O

2	O
allele	O
%	O
of	O
the	O
alleles	O
in	O
this	O
study	O
allelomorph	O
.	O

ii	O
%	O
of	O
the	O
alleles	O
in	O
this	O
contemplate	O
.	O

2	O
%	O
of	O
the	O
alleles	O
in	O
this	O
study	O
.	O

The	O
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
lxviii	O
.	O

The	O
write	O
up	O
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
68	O

The	O
S162F	O
and	O
G301C	O
mutations	O
account	O
68	O
for	O
.	O

The	O
G301C	O
and	O
S162F	O
mutations	O
describe	O
for	O
68	O
.	O

The	O
and	O
S162F	O
account	O
68	O

for	O
G301C	O
and	O
S162F	O
mutations	O
account	O
68	O
The	O
.	O

The	O
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
.	O

The	O
68	O
and	O
S162F	O
G301C	O
account	O
for	O
mutations	O
.	O

The	O
sport	O
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
68	O
mutant	O
.	O

The	O
G301C	O
and	O
S162F	O
mutations	O
chronicle	O
for	O
68	O
.	O

The	O
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
68	O
.	O

4	O
%	O
and	O
10	O
	O
.	O

10	O
%	O
and	O
4	O
.	O

tetrad	O
%	O
and	O
10	O
.	O

4	O
10	O
and	O
%	O
.	O

and	O
10	O
.	O

4	O
%	O
and	O
x	O
.	O

4	O
%	O
and	O
10	O
	O
.	O

tetrad	O
%	O
and	O
10	O
.	O

4	O
10	O
.	O

4	O
%	O
and	O
10	O
	O
.	O

4	O
%	O
and	O
10	O
.	O

F69V	O
%	O
of	O
whereas	O
,	O
respectively	O
,	O
mutations	O
a	O
remaining	O
to	O
is	O
5	O
limited	O
the	O
single	O
allele	O
.	O

5	O
%	O
of	O
mutations	O
,	O
severally	O
,	O
whereas	O
the	O
leftover	O
F69V	O
is	O
define	O
to	O
a	O
one	O
allelomorph	O
.	O

quintuplet	O
%	O
of	O
mutations	O
,	O
severally	O
,	O
whereas	O
the	O
unexpended	O
F69V	O
is	O
fix	O
to	O
a	O
single	O
allelomorph	O
.	O

5	O
%	O
of	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
to	O
a	O
single	O
allele	O
.	O

fivesome	O
%	O
of	O
mutations	O
,	O
severally	O
,	O
whereas	O
the	O
persist	O
F69V	O
is	O
throttle	O
to	O
a	O
single	O
allelomorph	O
.	O

5	O
%	O
sport	O
of	O
mutations	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
to	O
a	O
single	O
allele	O
mutant	O
mutant	O
mutant	O
ampere	O
.	O

5	O
%	O
of	O
mutations	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
is	O
limited	O
a	O
single	O
allele	O
.	O

5	O
%	O
sport	O
of	O
mutations	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
to	O
a	O
single	O
allele	O
mutant	O
mutant	O
mutant	O
ampere	O
.	O

%	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
.	O

5	O
%	O
the	O
a	O
,	O
respectively	O
limited	O
whereas	O
of	O
remaining	O
F69V	O
is	O
,	O
to	O
mutations	O
single	O
allele	O
.	O

5	O
%	O
of	O
mutations	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
to	O
a	O
single	O
allele	O
.	O

The	O
skewed	O
prevalence	O
of	O
past	O
limitation	O
sherd	O
distance	O
pleomorphism	O
G301C	O
in	O
only	O
Colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
ampere	O
uncouth	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	O
common	O
ancestor	O
preceding	O
depth	O
psychology	O

The	O
skewed	O
prevalence	O
of	O
past	O
limitation	O
sherd	O
distance	O
pleomorphism	O
G301C	O
in	O
only	O
Colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
ampere	O
preponderance	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	O
common	O
ancestor	O
preceding	O
depth	O
psychology	O

ancestor	O
skewed	O
originated	O
fragment	O
G301C	O
in	O
common	O
Colombian	O
of	O
and	O
haplotype	O
analysis	O
gene	O
restriction	O
prevalence	O
patients	O
polymorphisms	O
in	O
the	O
GALNS	O
by	O
suggest	O
that	O
G301C	O
length	O
only	O
a	O
from	O
The	O
.	O

The	O
skewed	O
prevalence	O
of	O
past	O
limitation	O
sherd	O
distance	O
pleomorphism	O
G301C	O
in	O
only	O
Colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
ampere	O
uncouth	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	O
common	O
ancestor	O
preceding	O
depth	O
psychology	O

The	O
skewed	O
prevalence	O
of	O
G301C	O
in	O
only	O
patients	O
and	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

The	O
skewed	O
preponderance	O
of	O
G301C	O
in	O
only	O
colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
limitation	O
fragment	O
duration	O
polymorphisms	O
in	O
the	O
GALNS	O
cistron	O
suggest	O
that	O
G301C	O
grow	O
from	O
a	O
usual	O
ascendant	O
.	O

polymorphisms	O
skewed	O
prevalence	O
of	O
G301C	O
in	O
suggest	O
analysis	O
patients	O
and	O
haplotype	O
The	O
ancestor	O
G301C	O
length	O
fragment	O
in	O
originated	O
the	O
GALNS	O
gene	O
only	O
that	O
restriction	O
Colombian	O
from	O
a	O
common	O
by	O
.	O

gene	O
skewed	O
prevalence	O
the	O
G301C	O
in	O
only	O
from	O
G301C	O
and	O
ancestor	O
analysis	O
a	O
GALNS	O
that	O
length	O
polymorphisms	O
in	O
of	O
restriction	O
originated	O
suggest	O
fragment	O
patients	O
The	O
Colombian	O
by	O
common	O
haplotype	O
.	O

The	O
skewed	O
preponderance	O
of	O
G301C	O
in	O
only	O
colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
limitation	O
fragment	O
distance	O
pleomorphism	O
in	O
the	O
GALNS	O
factor	O
indicate	O
that	O
G301C	O
originated	O
from	O
a	O
unwashed	O
root	O
.	O

The	O
skewed	O
prevalence	O
of	O
G301C	O
only	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
in	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
a	O
common	O
ancestor	O

The	O
skewed	O
prevalence	O
of	O
G301C	O
in	O
only	O
Colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

Investigation	O
of	O
the	O
transmitted	O
background	O
by	O
substance	O
of	O
mtDNA	O
lineages	O
point	O
that	O
all	O
our	O
patients	O
are	O
credibly	O
of	O
aboriginal	O
American	O
stemma	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
parentage	O
parentage	O
familial	O
familial	O
familial	O
familial	O
native	O
American	O
descent	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
parentage	O
parentage	O
familial	O
familial	O
familial	O
familial	O
native	O
American	O
descent	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
lineages	O
indicate	O
all	O
our	O
patients	O
are	O
probably	O
of	O
native	O

patients	O
of	O
mtDNA	O
means	O
background	O
by	O
are	O
of	O
the	O
lineages	O
indicate	O
that	O
descent	O
our	O
genetic	O
Investigation	O
probably	O
of	O
native	O
American	O
all	O

investigating	O
of	O
the	O
transmitted	O
background	O
by	O
means	O
of	O
mtDNA	O
pedigree	O
designate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
indigen	O
American	O
extraction	O

descent	O
of	O
the	O
indicate	O
background	O
by	O
means	O
native	O
patients	O
lineages	O
genetic	O
that	O
our	O
all	O
mtDNA	O
are	O
probably	O
of	O
of	O
Investigation	O
American	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
parentage	O
parentage	O
familial	O
familial	O
familial	O
line	O
of	O
descent	O
native	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
patients	O
of	O
native	O
American	O
descent	O

Investigation	O
of	O
the	O
genetic	O
scope	O
by	O
means	O
of	O
mtDNA	O
filiation	O
signal	O
that	O
all	O
our	O
patients	O
are	O
likely	O
of	O
indigen	O
American	O
declination	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
native	O
American	O
descent	O

Low	O
germline	O
of	O
BRCA1	O
frequency	O
mutations	O
45	O
/	O
German	O
breast	B
cancer	I
ovarian	I
in	I
families	O
.	O

Low	O
frequency	O
indium	O
	O
german	O
language	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
summit	B
breast	I
/	I
ovarian	I
cancer	O
families	O

gloomy	O
frequence	O
of	O
BRCA1	O
germline	O
variation	O
in	O
45	O
German	O
boob	B
/	I
ovarian	I
cancer	I
families	O
.	O

cancer	O
frequency	O
of	O
Low	O
45	O
mutations	O
in	O
ovarian	O
German	O
breast	B
/	I
germline	I
BRCA1	I
families	O
.	O

miserable	O
frequency	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
summit	B
/	I
ovarian	I
cancer	I
class	O
.	O

Low	O
frequency	O
indium	O
	O
german	O
language	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
frequence	B
breast	I
/	I
ovarian	I
cancer	O
families	O

Low	O
of	O
germline	O
in	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

45	O
BRCA1	O
of	O
frequency	O
germline	O
mutations	O
breast	O
Low	O
German	O
in	B
/	I
ovarian	I
cancer	I
.	O
families	O

Low	O
frequency	O
of	O
BRCA1	O
germline	O
sport	O
in	O
xlv	O
German	O
titty	B
/	I
ovarian	I
cancer	I
syndicate	O
.	O

Low	O
frequency	O
indium	O
	O
german	O
language	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
frequence	B
breast	I
/	I
ovarian	I
cancer	O
families	O

Low	O
frequency	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

In	O
this	O
analyze	O
we	O
investigated	O
45	O
german	O
boob	B
/	I
ovarian	I
cancer	I
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
cistron	O
.	O

In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
subject	O
area	O
subject	O
area	O
subject	O
area	O
subject	O
area	O

In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
subject	O
area	O
subject	O
area	O
subject	O
area	O
subject	O
area	O

study	O
45	O
German	O
breast	B
ovarian	I
cancer	I
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O

In	O
this	O
study	O
we	O
investigated	O
breast	B
/	I
cancer	I
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O

study	O
we	O
investigated	O
45	O
breast	B
/	I
ovarian	I
cancer	I
families	O
germline	O
mutations	O
in	O
the	O
gene	O
.	O

BRCA1	O
this	O
study	O
gene	O
investigated	O
45	O
German	O
/	B
breast	I
ovarian	I
mutations	I
families	O
for	O
.	O
In	O
in	O
the	O
cancer	O
we	O
germline	O

In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
subject	O
area	O
subject	O
area	O
subject	O
area	O
subject	O
area	O

inwards	O
this	O
study	O
we	O
enquire	O
xlv	O
german	O
chest	B
/	I
ovarian	I
cancer	I
families	O
for	O
germline	O
sport	O
inwards	O
the	O
BRCA1	O
gene	O
.	O

the	O
this	O
study	O
we	O
investigated	O
45	O
germline	O
families	B
/	I
ovarian	I
cancer	I
mutations	O
In	O
German	O
breast	O
BRCA1	O
for	O
in	O
gene	O
.	O

In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O

We	O
place	O
quaternary	O
germline	O
mutant	O
in	O
troika	O
front	B
crab	I
kinsperson	O
and	O
in	O
one	O
front	B
-	I
ovarian	I
crab	I
house	O
.	O
among	O
these	O
were	O
one	O
frameshift	O
mutant	O
,	O
one	O
bunk	O
mutant	O
,	O
one	O
refreshing	O
marry	O
site	O
mutant	O
,	O
and	O
one	O
missense	O
mutant	O
.	O

We	O
describe	O
four	O
germline	O
mutant	O
in	O
tierce	O
tit	B
cancer	I
house	O
and	O
in	O
unrivalled	O
tit	B
-	I
ovarian	I
cancer	I
syndicate	O
.	O
among	O
these	O
were	O
unrivalled	O
frameshift	O
sport	O
,	O
unrivalled	O
bunk	O
sport	O
,	O
unrivalled	O
fresh	O
tie	O
situation	O
sport	O
,	O
and	O
unrivalled	O
missense	O
sport	O
.	O

We	O
mutations	O
three	O
breast	B
cancer	I
and	O
in	O
one	O
-	I
ovarian	I
cancer	I
family	O
.	O
were	O
one	O
frameshift	O
mutation	O
,	O
one	O
nonsense	O
mutation	O
novel	O
site	O
mutation	O
,	O
one	O
missense	O
mutation	O
.	O

We	O
identified	O
novel	O
germline	O
mutations	O
mutation	O
,	O
breast	B
cancer	I
families	O
and	O
frameshift	O
nonsense	O
breast	B
-	I
one	I
cancer	I
family	O
among	O
.	O
these	O
were	O
one	O
,	O
mutation	O
one	O
one	O
splice	O
in	O
,	O
ovarian	O
one	O
three	O
site	O
mutation	O
in	O
and	O
four	O
missense	O
mutation	O
.	O

mutation	O
.	O
four	O
germline	O
mutations	O
in	O
in	O
were	B
cancer	I
families	O
and	O
three	O
one	O
nonsense	B
,	I
ovarian	I
cancer	I
family	O
.	O
among	O
these	O
breast	O
mutation	O
frameshift	O
We	O
,	O
novel	O
breast	O
-	O
one	O
one	O
,	O
splice	O
identified	O
mutation	O
one	O
and	O
one	O
missense	O
mutation	O
site	O

We	O
identified	O
four	O
germline	O
three	O
breast	B
cancer	I
families	O
in	O
one	O
breast	B
-	I
ovarian	I
family	O
.	O
among	O
these	O
one	O
frameshift	O
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
mutation	O
,	O
one	O
missense	O
mutation	O
.	O

We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B
cancer	I
families	O
and	O
in	O
one	O
breast	B
-	I
ovarian	I
cancer	I
family	O
.	O
among	O
these	O
were	O
one	O
frameshift	O
mutation	O
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
site	O
mutation	O
,	O
	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
and	O
one	O
missense	O
mutation	O
.	O

We	O
identified	O
four	O
germline	O
breast	B
cancer	I
families	O
and	O
in	O
breast	B
-	I
.	O
were	O
one	O
,	O
mutation	O
,	O
one	O
novel	O
site	O
mutation	O
one	O
missense	O
.	O

We	O
discover	O
four	O
germline	O
mutant	O
in	O
troika	O
titty	B
cancer	I
phratry	O
and	O
in	O
ace	O
titty	B
-	I
ovarian	I
cancer	I
class	O
.	O
among	O
these	O
were	O
ace	O
frameshift	O
mutation	O
,	O
ace	O
gimcrack	O
mutation	O
,	O
ace	O
new	O
splice	O
site	O
mutation	O
,	O
and	O
ace	O
missense	O
mutation	O
.	O

We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B
cancer	I
families	O
and	O
in	O
one	O
breast	B
-	I
ovarian	I
cancer	I
family	O
.	O
among	O
these	O
were	O
one	O
frameshift	O
mutation	O
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
site	O
mutation	O
,	O
	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
and	O
one	O
missense	O
mutation	O
.	O

We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B
cancer	I
families	O
and	O
in	O
one	O
breast	B
-	I
ovarian	I
cancer	I
family	O
.	O
among	O
these	O
were	O
one	O
frameshift	O
mutation	O
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
site	O
mutation	O
,	O
and	O
one	O
missense	O
mutation	O
.	O

The	O
missense	O
mutant	O
was	O
likewise	O
found	O
in	O
2	O
.	O

The	O
sport	O
missense	O
mutation	O
was	O
also	O
found	O
in	O
2	O
cost	O
.	O

The	O
was	O
mutation	O
missense	O
also	O
found	O
2	O
in	O
.	O

The	O
missense	O
mutation	O
was	O
too	O
discover	O
in	O
2	O
.	O

The	O
mutation	O
was	O
found	O
2	O

in	O
missense	O
mutation	O
was	O
also	O
found	O
2	O
The	O
.	O

The	O
missense	O
mutation	O
was	O
also	O
found	O
in	O
.	O

The	O
2	O
mutation	O
was	O
missense	O
found	O
in	O
also	O
.	O

The	O
too	O
missense	O
mutation	O
was	O
also	O
found	O
in	O
2	O
cost	O
.	O

The	O
missense	O
variation	O
was	O
also	O
get	O
in	O
2	O
.	O

The	O
missense	O
mutation	O
was	O
also	O
found	O
in	O
2	O
.	O

8	O
general	O
of	O
the	O
%	O
population	O
suggesting	O
is	O
that	O
it	O
disease	O
not	O
,	O
associated	O
.	O

8	O
%	O
subsume	O
propose	O
colligate	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
universe	O
it	O
is	O
not	O
disease	O
associated	O
.	O

octet	O
%	O
of	O
the	O
general	O
universe	O
,	O
intimate	O
that	O
it	O
is	O
not	O
disease	O
relate	O
.	O

disease	O
%	O
of	O
8	O
suggesting	O
population	O
,	O
not	O
that	O
it	O
is	O
general	O
the	O
associated	O
.	O

8	O
%	O
of	O
the	O
worldwide	O
universe	O
,	O
advise	O
that	O
it	O
is	O
not	O
disease	O
relate	O
.	O

8	O
%	O
subsume	O
propose	O
colligate	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
cosmopolitan	O
it	O
is	O
not	O
disease	O
associated	O
.	O

8	O
of	O
general	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
disease	O
associated	O
.	O

suggesting	O
the	O
of	O
%	O
general	O
population	O
it	O
8	O
that	O
,	O
is	O
not	O
disease	O
.	O
associated	O

8	O
%	O
of	O
the	O
cosmopolitan	O
universe	O
,	O
advise	O
that	O
it	O
is	O
not	O
disease	O
affiliate	O
.	O

8	O
%	O
subsume	O
propose	O
colligate	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
cosmopolitan	O
it	O
is	O
not	O
disease	O
associated	O
.	O

8	O
%	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
disease	O
associated	O
.	O

The	O
average	O
indium	O
years	O
years	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32	O
onrush	O
.	O

between	O
average	O
age	O
.	O
disease	O
onset	O
in	O
those	O
32	O
harbouring	O
causative	O
mutations	O
The	O
was	O
families	O
of	O

The	O
average	O
indium	O
years	O
thirty	O
two	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32	O
onrush	O

The	O
average	O
geezerhood	O
of	O
disease	O
onset	O
in	O
those	O
class	O
hold	O
causative	O
sport	O
was	O
between	O
32	O
.	O

was	O
average	O
age	O
those	O
disease	O
onset	O
between	O
of	O
families	O
harbouring	O
The	O
mutations	O
causative	O
in	O
32	O
.	O

The	O
average	O
indium	O
years	O
years	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32	O
onrush	O
.	O

The	O
median	O
geezerhood	O
of	O
disease	O
onset	O
in	O
those	O
mob	O
harbouring	O
causative	O
mutations	O
was	O
between	O
xxxii	O
.	O

The	O
median	O
age	O
of	O
disease	O
oncoming	O
in	O
those	O
sept	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32	O
.	O

The	O
average	O
families	O
.	O
disease	O
onset	O
was	O
those	O
age	O
harbouring	O
causative	O
mutations	O
in	O
between	O
of	O
32	O

average	O
age	O
of	O
disease	O
onset	O
in	O
those	O
causative	O
mutations	O
was	O
between	O
32	O
.	O

The	O
average	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32	O
.	O

	O
3	O
and	O
37	O
.	O

trine	O
and	O
37	O
.	O

3	O
and	O

troika	O
and	O
37	O
.	O

and	O
37	O

	O
3	O
and	O
37	O
.	O

.	O
and	O
37	O
3	O

	O
3	O
and	O
37	O
.	O

37	O
and	O
3	O
.	O

ternary	O
and	O
37	O
.	O

3	O
and	O
37	O
.	O

4	O
years	O
missense	O
of	O
the	O
family	O
average	O
the	O
,	O
mutation	O
had	O
an	O
harbouring	O
age	O
whereas	O
onset	O
of	O
51	O
.	O

,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
onset	O
of	O
51	O
.	O

4	O
days	O
,	O
whereas	O
the	O
household	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
median	O
years	O
of	O
onslaught	O
of	O
51	O
.	O

4	O
years	O
,	O
whereas	O
the	O
family	O
shield	O
the	O
missense	O
mutation	O
had	O
an	O
mediocre	O
maturate	O
of	O
attack	O
of	O
li	O
.	O

of	O
years	O
,	O
whereas	O
the	O
family	O
age	O
of	O
missense	O
mutation	O
had	O
an	O
51	O
harbouring	O
the	O
onset	O
average	O
4	O
.	O

4	O
years	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
.	O

4	O
years	O
,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
51	O
onrush	O
onrush	O
onrush	O
onrush	O
sport	O
.	O

iv	O
years	O
,	O
whereas	O
the	O
fellowship	O
harbor	O
the	O
missense	O
mutation	O
had	O
an	O
fair	O
age	O
of	O
onset	O
of	O
li	O
.	O

4	O
years	O
,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
51	O
onrush	O
onrush	O
onrush	O
onrush	O
onrush	O
.	O

age	O
years	O
,	O
had	O
the	O
family	O
harbouring	O
.	O
of	O
mutation	O
whereas	O
an	O
4	O
average	O
missense	O
onset	O
of	O
51	O
the	O

4	O
years	O
,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
51	O
.	O

deuce	O
years	O
.	O

2	O
years	O

2	O
.	O
years	O

2	O
years	O
	O
.	O

years	O
2	O
.	O

years	O
2	O
.	O

2	O
days	O
.	O

2	O
years	O
	O
.	O

2	O
geezerhood	O
.	O

2	O
.	O

2	O
years	O
.	O

These	O
bump	O
picture	O
that	O
BRCA1	O
is	O
concerned	O
in	O
a	O
small	O
divide	O
of	O
boob	B
/	I
ovarian	I
cancer	I
families	O
suggesting	O
the	O
affair	O
of	O
another	O
susceptibleness	O
cistron	O
(	O
s	O
)	O

These	O
findings	O
that	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast	B
cancer	I
families	O
suggesting	O
the	O
of	O
another	O
susceptibility	O
gene	O
(	O
)	O

These	O
findings	O
show	O
that	O
cost	O
cancer	O
the	O
crab	O
family	O
line	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	B
fraction	I
of	I
breast	I
/	O
ovarian	O
cancer	O
families	O
suggesting	O
factor	O
susceptibleness	O
entropy	O
factor	O
ampere	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O

of	O
findings	O
show	O
the	O
BRCA1	O
is	O
implicated	O
s	O
gene	O
small	O
involvement	O
of	O
breast	B
/	I
susceptibility	I
cancer	I
families	O
suggesting	O
that	O
(	O
fraction	O
another	O
ovarian	O
a	O
These	O
in	O
)	O

These	O
findings	O
show	O
that	O
cost	O
cancer	O
the	O
crab	O
family	O
line	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	B
fraction	I
of	I
breast	I
/	O
ovarian	O
cancer	O
families	O
suggesting	O
factor	O
susceptibleness	O
entropy	O
factor	O
ampere	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O

These	O
findings	O
show	O
BRCA1	O
is	O
in	O
a	O
small	O
fraction	O
of	O
breast	B
/	I
ovarian	I
families	O
suggesting	O
involvement	O
of	O
another	O
susceptibility	O
gene	O
(	O
s	O
)	O

)	O
findings	O
show	O
ovarian	O
BRCA1	O
is	O
s	O
in	O
that	O
small	O
fraction	O
of	O
/	B
of	I
(	I
a	I
families	O
suggesting	O
the	O
involvement	O
breast	O
another	O
susceptibility	O
gene	O
cancer	O
implicated	O
These	O

show	O
is	O
implicated	O
in	O
small	O
fraction	O
breast	B
/	I
ovarian	I
cancer	I
families	O
suggesting	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O
(	O

gene	O
findings	O
show	O
that	O
BRCA1	O
is	O
/	O
of	O
a	O
small	O
fraction	O
families	O
another	B
implicated	I
(	I
These	I
in	O
cancer	O
the	O
involvement	O
of	O
breast	O
susceptibility	O
suggesting	O
ovarian	O
s	O
)	O

These	O
findings	O
show	O
that	O
BRCA1	O
is	O
concerned	O
in	O
a	O
small	O
divide	O
of	O
boob	B
/	I
ovarian	I
crab	I
kinsperson	O
intimate	O
the	O
involvement	O
of	O
another	O
susceptibleness	O
factor	O
(	O
s	O
)	O

These	O
findings	O
show	O
that	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast	B
/	I
ovarian	I
cancer	I
families	O
suggesting	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O
(	O
s	O
)	O

of	O
transmission	O
Paternal	O
.	B
myotonic	I
dystrophy	I
congenital	O

agnatic	O
transmitting	O
of	O
congenital	B
myotonic	I
dystrophy	I
.	O

Paternal	O
transmitting	O
transmission	O
of	O
congenital	B
paternal	B
myotonic	I
dystrophy	I
.	O

Paternal	O
of	O
myotonic	I
.	O

congenital	O
Paternal	O
of	O
transmission	B
myotonic	I
dystrophy	I
.	O

Paternal	O
contagion	O
of	O
inborn	B
myotonic	I
dystrophy	I
.	O

agnate	O
infection	O
of	O
congenital	B
myotonic	I
dystrophy	I
.	O

Paternal	O
transmission	O
of	O
.	B
myotonic	I
congenital	I
dystrophy	O

Paternal	O
transmission	O
of	O
congenital	B
myotonic	I
.	O

Paternal	O
transmitting	O
transmission	O
of	O
congenital	B
innate	B
myotonic	I
dystrophy	I
.	O

Paternal	O
transmission	O
of	O
congenital	B
myotonic	I
dystrophy	I
.	O

We	O
case	O
a	O
rare	O
report	O
of	O
transmitted	O
dystrophy	O
congenital	B
myotonic	I
DM	I
(	O
paternally	B
)	O
.	O

We	O
report	O
international	O
ampere	O
transfer	O
ampere	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	B
congenital	B
dm	I
myotonic	I
dystrophy	O
(	B
DM	O
)	O

We	O
paper	O
a	O
rare	O
case	O
of	O
paternally	O
broadcast	O
inborn	B
myotonic	I
dystrophy	I
(	O
dm	B
)	O
.	O

DM	O
report	O
a	O
We	O
transmitted	O
of	O
paternally	O
(	O
congenital	B
myotonic	I
dystrophy	I
case	O
rare	B
)	O
.	O

We	O
report	O
a	O
rarified	O
character	O
of	O
paternally	O
transmitted	O
innate	B
myotonic	I
dystrophy	I
(	O
decimeter	B
)	O
.	O

We	O
report	O
international	O
ampere	O
transfer	O
ampere	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	B
congenital	B
sheath	I
myotonic	I
dystrophy	O
(	B
DM	O
)	O

We	O
a	O
case	O
paternally	O
transmitted	O
congenital	B
myotonic	I
dystrophy	I
(	O
DM	B
)	O
.	O

transmitted	O
rare	O
a	O
report	O
case	O
of	O
myotonic	O
We	O
congenital	B
paternally	I
dystrophy	I
(	O
DM	B
.	O
)	O

We	O
describe	O
a	O
uncommon	O
case	O
of	O
paternally	O
conduct	O
innate	B
myotonic	I
dystrophy	I
(	O
DM	B
)	O
.	O

We	O
report	O
international	O
ampere	O
transfer	O
ampere	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	B
congenital	B
sheath	I
myotonic	I
dystrophy	O
(	B
DM	O
)	O

We	O
report	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	O
congenital	B
myotonic	I
dystrophy	I
(	O
DM	B
)	O
.	O

male	O
proband	O
is	O
,	O
23	O
year	O
old	O
a	O
muscular	B
retarded	I
severe	O
who	O
The	O
suffers	O
mentally	B
weakness	I
.	O

The	O
proband	O
is	O
a	O
23	O
class	O
old	O
,	O
mentally	B
check	I
male	O
who	O
endure	O
grave	O
muscular	B
helplessness	I
.	O

The	O
proband	O
is	O
a	O
23	O
class	O
old	O
,	O
mentally	B
retarded	I
manly	O
who	O
ache	O
austere	O
sinewy	B
weakness	I
.	O

The	O
proband	O
23	O
year	O
old	O
,	O
mentally	B
retarded	I
male	O
who	O
suffers	O
severe	O
muscular	B
weakness	I
.	O

The	O
proband	O
is	O
a	O
23	O
class	O
old	O
,	O
mentally	B
slow	I
male	O
who	O
support	O
severe	O
hefty	B
impuissance	I
.	O

The	O
proband	O
cost	O
cost	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	B
retarded	I
male	O
who	O
suffers	O
severe	O
muscular	B
weakness	I
toll	O
toll	O
onetime	O
.	O

The	O
proband	O
is	O
a	O
23	O
year	O
old	O
,	O
retarded	I
male	O
suffers	O
severe	O
muscular	B
weakness	I
.	O

The	O
proband	O
cost	O
cost	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	B
retarded	I
male	O
who	O
suffers	O
severe	O
muscular	B
weakness	I
toll	O
toll	O
onetime	O
.	O

proband	O
23	O
year	O
old	O
,	O
mentally	B
retarded	I
male	O
who	O
suffers	O

The	O
proband	O
mentally	O
muscular	O
23	O
year	O
suffers	O
,	O
is	B
retarded	I
male	O
who	O
old	O
severe	O
a	B
weakness	I
.	O

The	O
proband	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	B
retarded	I
male	O
who	O
suffers	O
severe	O
muscular	B
weakness	I
.	O

helium	O
presented	O
with	O
respiratory	O
and	O
alimentation	O
trouble	O
at	O
birth	O
.	O

He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	O
birth	O
introduce	O
introduce	O
introduce	O
.	O

helium	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficultness	O
at	O
birth	O
.	O

he	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulty	O
at	O
parturition	O
.	O

He	O
with	O
respiratory	O
feeding	O
difficulties	O
at	O
birth	O
.	O

at	O
.	O
with	O
and	O
respiratory	O
feeding	O
difficulties	O
He	O
birth	O
presented	O

He	O
at	O
with	O
respiratory	O
presented	O
feeding	O
and	O
difficulties	O
birth	O
.	O

at	O
respiratory	O
with	O
presented	O
and	O
feeding	O
.	O
He	O
birth	O
difficulties	O

He	O
respiratory	O
and	O
feeding	O
at	O

He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	O
birth	O
introduce	O
introduce	O
introduce	O
.	O

He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	O
birth	O
.	O

His	O
two	O
sibs	O
suffer	O
from	O
puerility	O
onslaught	O
DM	B
.	O

His	O
support	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	B
support	O
.	O

His	O
suffer	O
sibs	O
two	O
from	O
childhood	O
DM	O
onset	B
.	O

His	O
deuce	O
sibling	O
suffer	O
from	O
childhood	O
onset	O
DM	B
.	O

His	O
sibs	O
suffer	O
childhood	O
DM	B

onset	O
two	O
sibs	O
suffer	O
from	O
childhood	O
DM	O
His	B
.	O

His	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
.	O

His	O
DM	O
sibs	O
suffer	O
two	O
childhood	O
onset	O
from	B
.	O

His	O
	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	B
support	O
.	O

His	O
two	O
sibs	O
suffer	O
from	O
puerility	O
onset	O
decimeter	B
.	O

His	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	B
.	O

Their	O
late	O
typecast	O
beginner	O
beginner	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	B
,	O
with	O
onset	O
around	O
30	O
years	O
fully	O
grown	O

30	O
late	O
father	O
.	O
the	O
adult	O
type	O
of	O
years	B
,	O
with	O
onset	O
Their	O
around	O
DM	O
had	O

Their	O
late	O
typecast	O
beginner	O
typecast	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	B
,	O
with	O
onset	O
around	O
30	O
years	O
fully	O
grown	O

Their	O
late	O
father	O
had	O
the	O
pornographic	O
type	O
of	O
DM	B
,	O
with	O
oncoming	O
some	O
30	O
days	O
.	O

around	O
late	O
father	O
of	O
the	O
adult	O
30	O
had	O
DM	B
,	O
Their	O
onset	O
with	O
type	O
years	O
.	O

Their	O
late	O
typecast	O
beginner	O
beginner	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	B
,	O
with	O
onset	O
around	O
30	O
years	O
fully	O
grown	O

Their	O
late	O
father	O
had	O
the	O
grownup	O
type	O
of	O
dm	B
,	O
with	O
attack	O
around	O
thirty	O
years	O
.	O

Their	O
late	O
father	O
had	O
the	O
adult	O
character	O
of	O
decimetre	B
,	O
with	O
onset	O
about	O
30	O
geezerhood	O
.	O

Their	O
late	O
DM	O
.	O
the	O
adult	O
around	O
of	O
father	B
,	O
with	O
onset	O
type	O
30	O
had	O
years	O

late	O
father	O
had	O
the	O
adult	O
type	O
of	O
with	O
onset	O
around	O
30	O
years	O
.	O

Their	O
late	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	B
,	O
with	O
onset	O
around	O
30	O
years	O
.	O

Only	O
of	O
other	O
cases	O
six	O
paternal	O
of	O
have	O
congenital	B
DM	I
reported	O
been	O
transmission	O
recently	O
.	O

Only	O
six	O
transmitting	O
former	O
former	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B
of	O
late	I
DM	O
have	O
been	O
reported	O
recently	O

entirely	O
sestet	O
other	O
cases	O
of	O
paternal	O
transmitting	O
of	O
congenital	B
DM	I
have	O
been	O
account	O
recently	O
.	O

reported	O
six	O
other	O
Only	O
of	O
paternal	O
transmission	O
been	O
congenital	B
DM	I
have	O
of	O
cases	O
recently	O
.	O

sole	O
six	O
other	O
cases	O
of	O
agnate	O
transmission	O
of	O
innate	B
DM	I
have	O
been	O
describe	O
recently	O
.	O

Only	O
six	O
transmitting	O
former	O
former	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B
	O
DM	I
have	O
been	O
reported	O
recently	O
.	O

Only	O
other	O
of	O
transmission	O
of	O
congenital	B
DM	I
have	O
been	O
reported	O
recently	O
.	O

of	O
cases	O
other	O
six	O
of	O
paternal	O
DM	O
Only	O
congenital	B
transmission	I
have	O
been	O
reported	O
.	O
recently	O

Only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
inborn	B
decimeter	I
have	O
been	O
cover	O
latterly	O
.	O

Only	O
six	O
transmitting	O
former	O
former	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B
	O
DM	I
have	O
been	O
reported	O
recently	O
.	O

Only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
have	O
been	O
reported	O
recently	O
.	O

We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
dm	O
refresh	O
refresh	O
congenital	B
DM	I
.	O

review	O
the	O
on	O
congenital	B
DM	I
.	O

We	O
brushup	O
the	O
arouse	O
related	O
effects	O
on	O
transmission	O
of	O
inborn	B
DM	I
.	O

We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
dm	O
refresh	O
refresh	O
congenital	B
DM	I
.	O

review	O
the	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	B
DM	I
.	O

We	O
inspection	O
the	O
sex	O
related	O
effects	O
on	O
infection	O
of	O
innate	B
DM	I
.	O

We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
dm	O
refresh	O
impression	O
congenital	B
DM	I
.	O

We	O
review	O
the	O
sex	O
related	O
consequence	O
on	O
infection	O
of	O
innate	B
DM	I
.	O

We	O
transmission	O
the	O
sex	O
review	O
effects	O
on	O
DM	O
of	O
congenital	B
related	I
.	O

.	O
review	O
the	O
sex	O
transmission	O
effects	O
congenital	O
related	O
of	O
on	B
DM	I
We	O

We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	B
DM	I
.	O

decrease	O
fertility	O
of	O
males	O
with	O
adult	O
attack	O
DM	B
and	O
contraction	O
of	O
the	O
recapitulate	O
upon	O
manlike	O
transmitting	O
conduce	O
to	O
the	O
almost	O
abstracted	O
occurrence	O
of	O
paternal	O
transmitting	O
of	O
innate	B
DM	I
.	O

Decreased	O
fertility	O
of	O
males	O
with	O
onset	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
of	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
.	O

absent	O
fertility	O
of	O
the	O
with	O
adult	O
onset	O
of	B
paternal	O
contraction	O
.	O
the	O
repeat	O
almost	O
of	O
transmission	O
contribute	O
to	O
males	O
upon	O
transmission	O
occurrence	O
male	O
and	O
Decreased	O
DM	O
congenital	B
DM	I
of	O

Decreased	O
fertility	O
of	O
males	O
iterate	O
transmitting	O
manlike	O
transmitting	O
bestow	O
with	O
adult	O
onset	O
DM	B
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
agnatic	O
innate	O
male	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
.	O

Decreased	O
fertility	O
of	O
males	O
iterate	O
transmitting	O
manlike	O
transmitting	O
bestow	O
with	O
adult	O
onset	O
DM	B
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
agnatic	O
innate	O
muscle	O
contraction	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	B
congenital	I
DM	O

Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	B
contraction	O
of	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
.	O

.	O
fertility	O
of	O
male	O
with	O
adult	O
of	O
DM	B
males	O
contraction	O
of	O
the	O
congenital	O
upon	O
transmission	O
and	O
contribute	O
to	O
the	O
almost	O
repeat	O
occurrence	O
of	O
paternal	O
transmission	O
onset	O
absent	B
DM	I
Decreased	O

Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	B
contraction	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B

minify	O
richness	O
of	O
males	O
with	O
adult	O
onset	O
dm	B
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmittance	O
contribute	O
to	O
the	O
near	O
abstracted	O
occurrence	O
of	O
parental	O
transmittance	O
of	O
inborn	B
dm	I
.	O

diminish	O
fertility	O
of	O
males	O
with	O
grownup	O
attack	O
dm	B
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
manful	O
transmission	O
lend	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
agnate	O
transmission	O
of	O
innate	B
dm	I
.	O

Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	B
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
.	O

Also	O
the	O
fathers	O
of	O
child	O
unforesightful	O
innate	O
iterate	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B
DM	I
kid	O
kid	O
kid	O
kid	O
median	O
.	O

Also	O
the	O
fathers	O
reported	O
,	O
on	O
average	O
shorter	O
CTG	O
lengths	O
and	O
hence	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
children	O
congenital	B
DM	I
.	O

Also	O
the	O
get	O
of	O
the	O
reported	O
congenitally	O
sham	O
tiddler	O
usher	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
reiterate	O
duration	O
and	O
so	O
less	O
stark	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
tiddler	O
with	O
inborn	B
DM	I
.	O

Also	O
the	O
fathers	O
of	O
the	O
reported	O
congenitally	O
children	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B
DM	I
.	O

Also	O
the	O
fathers	O
of	O
the	O
describe	O
congenitally	O
affected	O
nestling	O
depict	O
,	O
on	O
middling	O
,	O
scant	O
CTG	O
reiterate	O
lengths	O
and	O
hence	O
less	O
austere	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
nestling	O
with	O
inborn	B
decimetre	I
.	O

Also	O
the	O
fathers	O
of	O
child	O
unforesightful	O
innate	O
iterate	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B
DM	I
kid	O
kid	O
kid	O
kid	O
median	O
.	O

also	O
the	O
fathers	O
of	O
the	O
cover	O
congenitally	O
affected	O
nipper	O
express	O
,	O
on	O
median	O
,	O
forgetful	O
CTG	O
recur	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
father	O
of	O
nipper	O
with	O
innate	B
DM	I
.	O

less	O
and	O
fathers	O
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
than	O
with	O
CTG	O
repeat	O
lengths	O
of	O
hence	O
the	O
severe	O
DM	O
symptoms	O
,	O
the	O
mothers	O
Also	O
shorter	O
clinical	O
congenital	B
children	I
.	O

Also	O
the	O
fathers	O
of	O
the	O
reported	O
affected	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
of	O
children	O
with	O
DM	I

Also	O
the	O
fathers	O
of	O
child	O
unforesightful	O
innate	O
median	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B
DM	I
kid	O
kid	O
kid	O
kid	O
median	O
.	O

Also	O
the	O
fathers	O
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B
DM	I
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	B
past	O
yr	O
beginner	O
indium	O
beginner	O
beginner	O
cost	O
preceding	O
30	O
years	O
in	O
the	O
father	O
.	O
.	O

paternal	O
transmission	O
of	O
congenital	B
DM	I
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	B
past	O
years	O
the	O
father	O
.	O
.	O

We	O
conclude	O
that	O
maternal	O
transmission	O
of	O
inborn	B
dm	I
is	O
uncommon	O
and	O
preferentially	O
occurs	O
with	O
attack	O
of	O
dm	B
past	O
30	O
yr	O
in	O
the	O
sire	O
.	O
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
is	O
rare	O
preferentially	O
occurs	O
onset	O
of	O
DM	B
past	O
30	O
years	O
in	O
.	O
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	B
past	O
yr	O
beginner	O
indium	O
beginner	O
beginner	O
cost	O
cost	O
30	O
years	O
in	O
the	O
father	O
.	O
.	O

We	O
resolve	O
that	O
parental	O
transmission	O
of	O
innate	B
DM	I
is	O
uncommon	O
and	O
preferentially	O
occurs	O
with	O
onrush	O
of	O
DM	B
by	O
30	O
yr	O
in	O
the	O
father	O
.	O
.	O

We	O
conclude	O
that	O
agnatic	O
transmission	O
of	O
inborn	B
DM	I
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
attack	O
of	O
DM	B
preceding	O
thirty	O
twelvemonth	O
in	O
the	O
beget	O
.	O
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
is	O
rare	O
and	O
occurs	O
of	O
DM	B
past	O
30	O
years	O
in	O
the	O
father	O
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	B
past	O
yr	O
beginner	O
indium	O
beginner	O
beginner	O
cost	O
cost	O
30	O
years	O
in	O
the	O
father	O
.	O
.	O

years	O
conclude	O
that	O
and	O
transmission	O
of	O
congenital	B
30	I
.	O
rare	O
paternal	O
preferentially	O
with	O
occurs	O
father	O
of	O
DM	B
past	O
DM	O
.	O
in	O
the	O
onset	O
is	O
We	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	B
past	O
30	O
years	O
in	O
the	O
father	O
.	O
.	O

The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B
indium	B
indium	B
indium	B
intracranial	I
retinoblastoma	I
.	O

RB1	O
gene	O
child	O
intracranial	I
retinoblastoma	I
.	O

The	O
RB1	O
cistron	O
variation	O
in	O
a	O
fry	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
.	O

The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B
indium	B
indium	B
indium	B
intracranial	I
retinoblastoma	I
.	O

RB1	O
gene	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
.	O

The	O
RB1	O
cistron	O
variation	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
.	O

The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B
indium	B
indium	B
indium	B
intracranial	I
retinoblastoma	I
.	O

The	O
RB1	O
factor	O
sport	O
in	O
a	O
kid	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
.	O

The	O
with	O
gene	O
mutation	O
RB1	O
a	O
child	O
retinoblastoma	O
ectopic	B
intracranial	I
in	I
.	O

.	O
RB1	O
gene	O
mutation	O
with	O
a	O
intracranial	O
in	O
ectopic	B
child	I
retinoblastoma	I
The	O

The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
.	O

The	O
RB1	O
factor	O
mutation	O
was	O
enquire	O
in	O
a	O
nipper	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
practice	O
DNA	O
incur	O
from	O
both	O
the	O
pineal	B
and	I
retinene	I
tumor	I
of	O
the	O
patient	O
.	O

The	O
RB1	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
obtained	O
from	O
both	O
the	O
and	I
retinal	I
tumours	I
of	O
the	O
.	O

The	O
RB1	O
gene	O
mutation	O
dna	O
hold	O
cost	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
using	O
DNA	O
obtained	O
from	O
both	O
retinene	O
neoplasm	O
patient	O
role	O
factor	O
kid	O
the	B
pineal	I
and	I
retinal	I
tumours	O
of	O
the	O
patient	O

and	O
RB1	O
gene	O
the	O
was	O
investigated	O
in	O
patient	O
of	O
with	O
pineal	B
intracranial	I
retinoblastoma	I
using	O
tumours	O
obtained	O
from	O
both	O
mutation	O
the	B
ectopic	I
retinal	I
DNA	I
child	O
The	O
a	O
.	O

The	O
RB1	O
gene	O
mutation	O
dna	O
hold	O
cost	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
using	O
DNA	O
obtained	O
from	O
both	O
retinene	O
neoplasm	O
patient	O
role	O
factor	O
kid	O
the	B
pineal	I
and	I
retinal	I
tumours	O
of	O
the	O
patient	O

The	O
RB1	O
gene	O
was	O
investigated	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
using	O
DNA	O
from	O
both	O
pineal	B
and	I
retinal	I
tumours	I
of	O
the	O
patient	O
.	O

.	O
RB1	O
gene	O
DNA	O
was	O
investigated	O
patient	O
a	O
mutation	O
with	O
ectopic	B
intracranial	I
using	I
and	O
the	O
child	O
from	O
both	O
the	O
pineal	B
retinoblastoma	I
retinal	I
tumours	I
of	O
obtained	O
in	O
The	O

gene	O
investigated	O
in	O
a	O
with	O
ectopic	B
retinoblastoma	I
using	O
DNA	O
obtained	O
from	O
both	O
the	O
pineal	B
and	I
retinal	I
tumours	I
of	O
the	O

of	O
RB1	O
gene	O
mutation	O
was	O
investigated	O
using	O
intracranial	O
child	O
with	O
ectopic	B
from	I
retinal	I
in	O
the	O
The	O
a	O
obtained	O
the	O
pineal	B
and	I
retinoblastoma	I
tumours	I
both	O
DNA	O
patient	O
.	O

The	O
RB1	O
factor	O
sport	O
was	O
enquire	O
in	O
a	O
youngster	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
practice	O
DNA	O
receive	O
from	O
both	O
the	O
pineal	B
and	I
retinene	I
tumours	I
of	O
the	O
patient	O
.	O

The	O
RB1	O
gene	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
using	O
DNA	O
obtained	O
from	O
both	O
the	O
pineal	B
and	I
retinal	I
tumours	I
of	O
the	O
patient	O
.	O

A	O
meaninglessness	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
factor	O
was	O
constitute	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinene	B
and	I
the	I
pineal	I
neoplasm	I
.	O

A	O
nonsense	O
mutation	O
in	O
exon	O
(	O
)	O
of	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
the	O
retinal	B
and	I
the	I
pineal	I
tumours	I
.	O

in	O
nonsense	O
mutation	O
present	O
exon	O
17	O
(	O
the	O
retinal	O
)	O
.	O
the	O
RB1	O
homozygously	O
the	O
found	O
to	O
be	O
in	O
gene	O
and	O
both	O
was	O
556	B
A	I
codon	I
pineal	I
tumours	I
of	O

A	O
nonsense	O
mutation	O
in	O
retinene	O
factor	O
cost	O
receive	O
coding	O
dna	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
retinene	O
retinene	O
indium	O
present	O
homozygously	O
in	O
both	O
the	B
retinal	I
and	I
the	I
pineal	I
tumours	O

A	O
nonsense	O
mutation	O
in	O
retinene	O
factor	O
cost	O
receive	O
coding	O
dna	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
retinene	O
retinene	O
introduce	O
present	O
homozygously	O
in	O
both	O
the	B
retinal	I
and	I
the	I
pineal	I
tumours	O

A	O
nonsense	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
)	O
of	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
present	O
both	O
the	O
retinal	B
and	I
the	I
pineal	I
tumours	I
.	O

.	O
nonsense	O
mutation	O
was	O
exon	O
17	O
the	O
codon	O
in	O
)	O
of	O
the	O
pineal	O
gene	O
and	O
556	O
to	O
be	O
present	O
homozygously	O
RB1	O
both	O
the	O
retinal	B
found	I
(	I
in	I
tumours	I
A	O

A	O
nonsense	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
)	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
present	O
in	O
both	O
the	O
retinal	B
and	I
the	I
pineal	I

axerophthol	O
frill	O
sport	O
in	O
exon	O
xvii	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
cistron	O
was	O
chance	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinene	B
and	I
the	I
pineal	I
tumor	I
.	O

axerophthol	O
gimcrack	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
cistron	O
was	O
happen	O
to	O
be	O
portray	O
homozygously	O
in	O
both	O
the	O
retinene	B
and	I
the	I
pineal	I
neoplasm	I
.	O

A	O
nonsense	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinal	B
and	I
the	I
pineal	I
tumours	I
.	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
information	O
technology	O
beryllium	O
parentage	O
sport	O
parentage	O
parentage	O
indium	O
it	O
to	O
be	O
of	O
germline	O
origin	O

was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
to	O
of	O
germline	O
origin	O
.	O

The	O
same	O
mutant	O
was	O
award	O
heterozygously	O
in	O
the	O
dna	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
evidence	O
it	O
to	O
be	O
of	O
germline	O
rootage	O
.	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
constitutional	O
cells	O
the	O
patient	O
,	O
proving	O
it	O
to	O
be	O
origin	O
.	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
information	O
technology	O
beryllium	O
parentage	O
sport	O
parentage	O
parentage	O
sport	O
it	O
to	O
be	O
of	O
germline	O
origin	O

The	O
same	O
variation	O
was	O
nowadays	O
heterozygously	O
in	O
the	O
dna	O
from	O
the	O
inbuilt	O
cells	O
of	O
the	O
patient	O
,	O
test	O
it	O
to	O
be	O
of	O
germline	O
parentage	O
.	O

The	O
same	O
variation	O
was	O
demonstrate	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
it	O
to	O
be	O
of	O
germline	O
rootage	O
.	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
cells	O
patient	O
,	O
proving	O
it	O
to	O
be	O
of	O
germline	O
origin	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
information	O
technology	O
beryllium	O
parentage	O
sport	O
parentage	O
parentage	O
sport	O
it	O
to	O
be	O
of	O
germline	O
origin	O

to	O
same	O
mutation	O
the	O
present	O
heterozygously	O
in	O
it	O
origin	O
from	O
was	O
constitutional	O
of	O
cells	O
germline	O
patient	O
,	O
proving	O
the	O
.	O
be	O
of	O
the	O
DNA	O
The	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
it	O
to	O
be	O
of	O
germline	O
origin	O
.	O

The	O
shown	O
mutation	O
was	O
initial	O
to	O
occurred	O
paternally	O
in	O
the	O
RB1	O
derived	O
have	O
allele	O
.	O

The	O
initial	O
receive	O
come	O
about	O
sport	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
usher	O
the	O
paternally	O
derived	O
RB1	O
allele	O

The	O
initial	O
variation	O
was	O
establish	O
to	O
have	O
occurred	O
in	O
the	O
paternally	O
deduce	O
RB1	O
allelomorph	O
.	O

RB1	O
initial	O
mutation	O
The	O
occurred	O
to	O
have	O
derived	O
in	O
the	O
paternally	O
shown	O
was	O
allele	O
.	O

The	O
initial	O
sport	O
was	O
shown	O
to	O
have	O
pass	O
in	O
the	O
paternally	O
come	O
RB1	O
allelomorph	O
.	O

The	O
initial	O
receive	O
come	O
about	O
sport	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
usher	O
the	O
paternally	O
derived	O
RB1	O
allele	O

The	O
mutation	O
shown	O
have	O
occurred	O
in	O
the	O
paternally	O
derived	O
RB1	O
allele	O
.	O

occurred	O
was	O
mutation	O
initial	O
shown	O
to	O
the	O
The	O
in	O
have	O
paternally	O
derived	O
RB1	O
.	O
allele	O

The	O
initial	O
mutant	O
was	O
demonstrate	O
to	O
have	O
occurred	O
in	O
the	O
paternally	O
gain	O
RB1	O
allelomorph	O
.	O

The	O
initial	O
receive	O
come	O
about	O
sport	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
usher	O
the	O
paternally	O
derived	O
RB1	O
allele	O

The	O
initial	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
the	O
paternally	O
derived	O
RB1	O
allele	O
.	O

The	O
mutation	O
is	O
in	O
sheath	O
associate	O
in	O
nursing	O
tie	O
part	O
associate	O
in	O
nursing	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	B
other	O
cases	O
of	O
retinoblastoma	O
.	O
cocktail	O

The	O
mutation	O
an	O
that	O
encodes	O
the	O
-	O
binding	O
known	O
as	O
the	O
and	O
has	O
been	O
detected	O
in	O
cases	O
retinoblastoma	B
.	O
.	O

The	O
sport	O
is	O
in	O
an	O
expanse	O
of	O
the	O
factor	O
that	O
encodes	O
the	O
protein	O
-	O
tie	O
realm	O
known	O
as	O
the	O
pocket	O
realm	O
and	O
has	O
been	O
detected	O
in	O
other	O
face	O
of	O
retinoblastoma	B
.	O
.	O

The	O
mutation	O
is	O
in	O
area	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	B
.	O
.	O

The	O
variation	O
is	O
in	O
an	O
country	O
of	O
the	O
factor	O
that	O
encodes	O
the	O
protein	O
-	O
hold	O
realm	O
live	O
as	O
the	O
bag	O
realm	O
and	O
has	O
been	O
find	O
in	O
other	O
pillowcase	O
of	O
retinoblastoma	B
.	O
.	O

The	O
mutation	O
is	O
in	O
sheath	O
associate	O
in	O
nursing	O
tie	O
part	O
associate	O
in	O
nursing	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	B
other	O
cases	O
of	O
retinoblastoma	O
.	O
cocktail	O

The	O
mutation	O
is	O
in	O
an	O
field	O
of	O
the	O
cistron	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
neighborhood	O
known	O
as	O
the	O
sac	O
neighborhood	O
and	O
has	O
been	O
observe	O
in	O
other	O
showcase	O
of	O
retinoblastoma	B
.	O
.	O

region	O
the	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
detected	O
retinoblastoma	O
region	O
known	O
as	O
cases	O
pocket	O
mutation	O
and	O
.	O
been	O
-	O
in	O
other	O
The	O
binding	O
has	B
.	O
of	O

The	O
mutation	O
is	O
in	O
area	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
in	O
other	O
cases	O
retinoblastoma	B
.	O

The	O
mutation	O
is	O
in	O
sheath	O
associate	O
in	O
nursing	O
tie	O
part	O
associate	O
in	O
nursing	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	B
other	O
cases	O
of	O
retinoblastoma	O
.	O
cocktail	O

The	O
mutation	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	B
.	O
.	O

Low	O
levels	O
indium	O
tidy	O
somebody	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
ampere	O
.	O

this	O
levels	O
of	O
.	O
hexosaminidase	O
A	O
in	O
healthy	O
enzyme	O
with	O
apparent	O
deficiency	O
Low	O
of	O
individuals	O
beta	O

Low	O
levels	O
indium	O
tidy	O
patent	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
ampere	O
.	O

Low	O
levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
intelligent	O
someone	O
with	O
manifest	O
lack	O
of	O
this	O
enzyme	O
.	O

of	O
levels	O
of	O
healthy	O
hexosaminidase	O
A	O
this	O
beta	O
individuals	O
with	O
Low	O
deficiency	O
apparent	O
in	O
enzyme	O
.	O

Low	O
levels	O
indium	O
tidy	O
somebody	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
ampere	O
.	O

Low	O
levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
goodish	O
person	O
with	O
ostensible	O
lack	O
of	O
this	O
enzyme	O
.	O

crushed	O
levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
respectable	O
individuals	O
with	O
evident	O
want	O
of	O
this	O
enzyme	O
.	O

Low	O
levels	O
individuals	O
.	O
hexosaminidase	O
A	O
of	O
healthy	O
of	O
with	O
apparent	O
deficiency	O
in	O
this	O
beta	O
enzyme	O

levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
.	O

Low	O
levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
.	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
has	O
been	O
detected	O
cultured	O
fibroblasts	O
and	O
melanoma	B
healthy	O
having	O
deficiency	B
of	I
A	I
activity	O
from	O
that	O
of	O
Tay	B
-	I
Sachs	I
disease	I
(	O
)	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
individuals	O
as	O
deficiency	B
of	I
hex	I
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	B
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B
of	I
hex	I
A	I
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
undistinguishable	O
tay	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
ampere	O
with	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	B
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B
of	I
hex	I
A	I
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
undistinguishable	O
tay	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
with	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

appreciable	O
beta	O
hexosaminidase	O
ampere	O
(	O
hex	O
ampere	O
)	O
action	O
has	O
been	O
detected	O
in	O
polite	O
shinny	O
fibroblasts	O
and	O
melanoma	B
weave	O
from	O
goodish	O
someone	O
antecedently	O
cover	O
as	O
having	O
insufficiency	B
of	I
hex	I
ampere	I
action	O
undistinguishable	O
from	O
that	O
of	O
patients	O
with	O
tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

Appreciable	O
hexosaminidase	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B
of	I
hex	I
A	I
activity	O
indistinguishable	O
from	O
of	O
with	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O

appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
bewitch	O
A	O
)	O
activeness	O
has	O
been	O
detected	O
in	O
civilised	O
tegument	O
fibroblasts	O
and	O
melanoma	B
tissue	O
from	O
healthy	O
soul	O
antecedently	O
account	O
as	O
having	O
lack	B
of	I
bewitch	I
A	I
activeness	O
undistinguishable	O
from	O
that	O
of	O
patients	O
with	O
tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

-	O
as	O
hexosaminidase	O
A	O
and	O
hex	O
Tay	O
indistinguishable	O
activity	O
has	O
been	O
detected	O
in	O
A	O
melanoma	O
fibroblasts	O
(	O
skin	B
tissue	O
from	O
)	O
individuals	O
previously	O
reported	O
of	O
having	O
deficiency	B
(	I
.	I
A	I
hex	O
beta	O
from	O
that	O
of	O
patients	O
with	O
cultured	B
Appreciable	I
Sachs	I
disease	I
healthy	O
TSD	B
)	O
activity	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	B
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B
of	I
hex	I
A	I
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
undistinguishable	O
tay	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
undistinguishable	O
with	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
whammy	O
A	O
)	O
activity	O
has	O
been	O
notice	O
in	O
genteel	O
pare	O
fibroblasts	O
and	O
melanoma	B
weave	O
from	O
hefty	O
individuals	O
antecedently	O
reported	O
as	O
having	O
insufficiency	B
of	I
whammy	I
A	I
activity	O
undistinguishable	O
from	O
that	O
of	O
patients	O
with	O
tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	B
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B
of	I
hex	I
A	I
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
with	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

recognition	O
and	O
quantitation	O
of	O
glamour	O
A	O
,	O
amounting	O
to	O
iii	O
.	O

Identification	O
and	O
quantitation	O
of	O
hex	O
A	O
,	O
amounting	O
to	O
whammy	O
whammy	O
whammy	O
3	O
.	O

designation	O
and	O
quantitation	O
of	O
hex	O
angstrom	O
,	O
total	O
to	O
3	O
.	O

Identification	O
and	O
quantitation	O
of	O
hex	O
adenine	O
,	O
come	O
to	O
troika	O
.	O

and	O
quantitation	O
hex	O
A	O
,	O
amounting	O
to	O
3	O
.	O

amounting	O
and	O
quantitation	O
hex	O
of	O
A	O
3	O
Identification	O
to	O
,	O
.	O

Identification	O
amounting	O
quantitation	O
of	O
and	O
A	O
,	O
.	O
to	O
3	O
hex	O

of	O
amounting	O
quantitation	O
,	O
hex	O
A	O
Identification	O
and	O
to	O
3	O
.	O

Identification	O
quantitation	O
hex	O
,	O
amounting	O
to	O
3	O
.	O

Identification	O
and	O
quantitation	O
of	O
hex	O
A	O
,	O
amounting	O
to	O
whammy	O
whammy	O
whammy	O
3	O
.	O

Identification	O
and	O
quantitation	O
of	O
hex	O
A	O
,	O
amounting	O
to	O
3	O
.	O

5	O
%	O
-	O
6	O
	O
.	O

6	O
%	O
-	O
5	O
.	O

5	O
%	O
-	O
hexad	O
.	O

5	O
6	O
-	O
%	O
.	O

-	O
6	O
.	O

fivesome	O
%	O
-	O
6	O
.	O

5	O
%	O
-	O
6	O
	O
.	O

quint	O
%	O
-	O
6	O
.	O

5	O
6	O
.	O

5	O
%	O
-	O
6	O
	O
.	O

5	O
%	O
-	O
6	O
.	O

9	O
%	O
of	O
total	O
radial	O
ply	O
tire	O
ethanoate	O
colloidal	O
gel	O
dielectrolysis	O
genus	O
beta	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
radial	O
ply	O
tire	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O

9	O
%	O
of	O
total	O
radial	O
ply	O
tire	O
ethanoate	O
colloidal	O
gel	O
dielectrolysis	O
genus	O
beta	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O

chromatography	O
%	O
of	O
total	O
beta	O
hexosaminidase	O
acetate	O
,	O
has	O
been	O
obtained	O
by	O
-	O
activity	O
,	O
and	O
,	O
ion	O
-	O
cellulose	O
9	O
cellulose	O
exchange	O
DEAE	O
gel	O
radial	O
immunodiffusion	O
,	O
.	O
radioimmunoassay	O
electrophoresis	O

9	O
%	O
of	O
total	O
radial	O
ply	O
tire	O
ethanoate	O
colloidal	O
gel	O
dielectrolysis	O
genus	O
beta	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
radial	O
ply	O
tire	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O

9	O
%	O
of	O
total	O
hexosaminidase	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O

ennead	O
%	O
of	O
summate	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
incur	O
by	O
cellulose	O
acetate	O
mousse	O
ionophoresis	O
,	O
DEAE	O
-	O
cellulose	O
ion	O
-	O
replace	O
chromatography	O
,	O
radiate	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O

and	O
%	O
,	O
gel	O
beta	O
hexosaminidase	O
,	O
,	O
total	O
been	O
obtained	O
by	O
ion	O
acetate	O
of	O
has	O
,	O
DEAE	O
-	O
cellulose	O
cellulose	O
-	O
exchange	O
chromatography	O
electrophoresis	O
activity	O
immunodiffusion	O
radial	O
9	O
radioimmunoassay	O
.	O

9	O
%	O
of	O
total	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
obtained	O
by	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
-	O
cellulose	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O

obtained	O
%	O
of	O
and	O
beta	O
hexosaminidase	O
activity	O
radial	O
chromatography	O
been	O
,	O
by	O
immunodiffusion	O
cellulose	O
exchange	O
electrophoresis	O
,	O
DEAE	O
.	O
acetate	O
ion	O
-	O
gel	O
has	O
9	O
,	O
cellulose	O
,	O
total	O
radioimmunoassay	O
-	O

ennead	O
%	O
of	O
total	O
beta	O
hexosaminidase	O
activeness	O
,	O
has	O
been	O
incur	O
by	O
cellulose	O
acetate	O
gel	O
ionophoresis	O
,	O
DEAE	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
stellate	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O

9	O
%	O
of	O
total	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O

family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	B
and	O
rare	O
(	O
allelic	O
)	O
mutant	O
gene	O
.	O

heterozygotes	O
family	O
studies	O
a	O
that	O
these	O
individuals	O
.	O
mutant	O
compound	O
gene	O
for	O
the	O
rare	O
)	O
TSD	B
gene	O
and	O
suggested	O
common	O
(	O
allelic	O
mutant	O
be	O
Previous	O
may	O

Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
whitethorn	O
be	O
heighten	O
heterozygotes	O
for	O
the	O
green	O
sport	O
TSD	B
cistron	O
and	O
a	O
uncommon	O
(	O
allelomorphic	O
)	O
sport	O
cistron	O
.	O

old	O
phratry	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
combine	O
heterozygotes	O
for	O
the	O
plebeian	O
variation	O
TSD	B
factor	O
and	O
a	O
rare	O
(	O
allelomorphic	O
)	O
variation	O
factor	O
.	O

Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
for	O
the	O
mutant	O
TSD	B
gene	O
and	O
a	O
rare	O
(	O
mutant	O
gene	O
.	O

Previous	O
family	O
studies	O
suggested	O
factor	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	B
gene	O
and	O
rarified	O
sport	O
factor	O
sport	O
factor	O
beryllium	O
a	O
rare	O
(	O
allelic	O
)	O
mutant	O
gene	O
.	O

Previous	O
family	O
studies	O
suggested	O
factor	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	B
gene	O
and	O
rarified	O
sport	O
factor	O
sport	O
factor	O
propose	O
a	O
rare	O
(	O
allelic	O
)	O
mutant	O
gene	O
.	O

Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
for	O
mutant	O
TSD	B
gene	O
and	O
a	O
rare	O
(	O
allelic	O
)	O

mutant	O
family	O
studies	O
suggested	O
that	O
these	O
common	O
gene	O
be	O
compound	O
heterozygotes	O
for	O
allelic	O
individuals	O
gene	O
TSD	B
may	O
(	O
a	O
rare	O
Previous	O
the	O
)	O
and	O
mutant	O
.	O

premature	O
folk	O
studies	O
advise	O
that	O
these	O
individuals	O
may	O
be	O
deepen	O
heterozygotes	O
for	O
the	O
plebeian	O
mutation	O
TSD	B
gene	O
and	O
a	O
rare	O
(	O
allelomorphic	O
)	O
mutation	O
gene	O
.	O

Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	B
gene	O
and	O
a	O
rare	O
(	O
allelic	O
)	O
mutant	O
gene	O
.	O

Thus	O
,	O
the	O
ask	O
rate	O
mutation	O
gene	O
appears	O
to	O
code	O
for	O
the	O
look	O
of	O
scummy	O
measure	O
of	O
bewitch	O
A	O
.	O

Thus	O
,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
ask	O
ask	O
ask	O
ask	O
ask	O
ask	O
A	O
.	O

Thus	O
,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
ask	O
ask	O
ask	O
ask	O
ask	O
ask	O
A	O
.	O

the	O
mutant	O
gene	O
appears	O
code	O
for	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
A	O
.	O

Thus	O
,	O
the	O
postulated	O
rate	O
appears	O
to	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
A	O
.	O

the	O
postulated	O
rate	O
mutant	O
appears	O
to	O
code	O
for	O
the	O
of	O
low	O
amounts	O
of	O
A	O
.	O

hex	O
,	O
the	O
A	O
rate	O
mutant	O
gene	O
to	O
appears	O
code	O
low	O
the	O
expression	O
.	O
Thus	O
amounts	O
of	O
for	O
postulated	O
of	O

Thus	O
,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
ask	O
ask	O
ask	O
ask	O
ask	O
reflexion	O
A	O
.	O

Thus	O
,	O
the	O
need	O
range	O
variation	O
gene	O
appears	O
to	O
inscribe	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
whammy	O
axerophthol	O
.	O

of	O
,	O
the	O
postulated	O
rate	O
mutant	O
of	O
the	O
to	O
code	O
for	O
low	O
Thus	O
gene	O
appears	O
hex	O
expression	O
amounts	O
A	O
.	O

Thus	O
,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
A	O
.	O

Heterozygotes	O
for	O
beryllium	O
undistinguishable	O
rarified	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	B
mutant	O
crataegus	O
oxycantha	O

TSD	O
for	O
the	O
.	O
mutant	O
may	O
be	O
indistinguishable	O
mutant	O
heterozygotes	O
for	O
the	O
Heterozygotes	O
common	B
from	O
rare	O

Heterozygotes	O
for	O
beryllium	O
undistinguishable	O
heterozygote	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	B
mutant	O
crataegus	O
oxycantha	O

Heterozygotes	O
for	O
the	O
rarified	O
mutation	O
may	O
be	O
undistinguishable	O
from	O
heterozygotes	O
for	O
the	O
mutual	O
TSD	B
mutation	O
.	O

common	O
for	O
the	O
indistinguishable	O
mutant	O
may	O
TSD	O
rare	O
from	O
heterozygotes	O
Heterozygotes	O
the	O
for	O
be	B
mutant	O
.	O

Heterozygotes	O
for	O
beryllium	O
undistinguishable	O
rarified	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	B
mutant	O
crataegus	O
oxycantha	O

Heterozygotes	O
for	O
the	O
rarified	O
sport	O
whitethorn	O
be	O
undistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	B
sport	O
.	O

heterozygote	O
for	O
the	O
rarified	O
variation	O
may	O
be	O
undistinguishable	O
from	O
heterozygote	O
for	O
the	O
common	O
TSD	B
variation	O
.	O

Heterozygotes	O
for	O
from	O
.	O
mutant	O
may	O
common	O
indistinguishable	O
the	O
heterozygotes	O
for	O
the	O
be	O
TSD	B
rare	O
mutant	O

for	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
for	O
the	O
common	O
TSD	B
mutant	O
.	O

Heterozygotes	O
for	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	B
mutant	O
.	O

,	O
direct	O
visualization	O
of	O
hex	O
A	O
by	O
the	O
described	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	B
in	O
fetuses	O
the	O
incomplete	O
hex	B
A	I
deficiency	I
the	O
individuals	O

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	B
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B
A	I
deficiency	I
of	O
the	O
type	O
described	O
in	O
the	O
somebody	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
four	O
healthy	O
individuals	O

of	O
of	O
direct	O
visualization	O
-	O
quantitation	O
healthy	O
the	O
A	O
by	O
the	O
methods	O
described	O
having	O
positive	O
false	O
and	O
prevent	O
prenatal	O
diagnosis	O
may	O
TSD	B
in	O
fetuses	O
,	O
the	O
incomplete	O
individuals	B
However	I
deficiency	I
A	O
of	O
type	O
described	O
in	O
the	O
four	O
hex	O
hex	O

However	O
,	O
direct	O
and	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
of	O
TSD	B
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B
A	I
deficiency	I
of	O
the	O
type	O
described	O
in	O
four	O
individuals	O

However	O
,	O
maneuver	O
visualisation	O
and	O
quantitation	O
of	O
jinx	O
A	O
by	O
the	O
methods	O
depict	O
whitethorn	O
preclude	O
false	O
-	O
overconfident	O
antenatal	O
diagnosis	O
of	O
TSD	B
in	O
foetus	O
having	O
the	O
uncompleted	O
jinx	B
A	I
want	I
of	O
the	O
type	O
depict	O
in	O
the	O
four	O
healthy	O
individuals	O

having	O
prenatal	O
direct	O
visualization	O
and	O
quantitation	O
methods	O
hex	O
A	O
by	O
the	O
of	O
described	O
hex	O
deficiency	O
false	O
-	O
positive	O
described	O
diagnosis	O
of	O
TSD	B
A	O
fetuses	O
However	O
the	O
the	O
may	B
prevent	I
in	I
of	O
the	O
type	O
in	O
,	O
incomplete	O
four	O
healthy	O
individuals	O

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	B
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B
A	I
deficiency	I
of	O
the	O
type	O
described	O
in	O
the	O
somebody	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
four	O
healthy	O
individuals	O

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	B
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B
A	I
deficiency	I
of	O
the	O
type	O
described	O
in	O
the	O
somebody	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
whammy	O
diagnosing	O
four	O
healthy	O
individuals	O

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
positive	O
prenatal	O
diagnosis	O
TSD	B
fetuses	O
having	O
the	O
A	I
described	O
in	O
the	O
healthy	O
individuals	O

However	O
,	O
of	O
visualization	O
and	O
quantitation	O
of	O
prenatal	O
A	O
by	O
the	O
incomplete	O
diagnosis	O
may	O
prevent	O
hex	O
-	O
positive	O
healthy	O
described	O
of	O
type	B
in	O
the	O
having	O
false	O
methods	O
TSD	B
A	I
deficiency	I
direct	O
hex	O
the	O
described	O
in	O
fetuses	O
four	O
the	O
individuals	O

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	B
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B
A	I
deficiency	I
of	O
the	O
type	O
described	O
in	O
the	O
four	O
healthy	O
individuals	O

The	O
neoplasm	B
suppressor	O
factor	O
Smad4	O
/	O
Dpc4	O
is	O
requisite	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
ontogeny	O
of	O
the	O
mouse	O
conceptus	O
.	O

The	O
tumor	B
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
conceptus	O
suppresser	O
suppresser	O
suppresser	O
suppresser	O
suppresser	O
mouse	O
embryo	O
.	O

The	O
tumor	B
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
conceptus	O
suppresser	O
suppresser	O
suppresser	O
suppresser	O
suppresser	O
mouse	O
embryo	O
.	O

The	O
tumor	B
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
for	O
gastrulation	O
later	O
for	O
anterior	O
development	O
of	O
the	O
mouse	O

anterior	O
tumor	B
required	O
Dpc4	O
Smad4	O
/	O
development	O
is	O
suppressor	O
for	O
gastrulation	O
and	O
.	O
for	O
gene	O
The	O
of	O
the	O
mouse	O
embryo	O
later	O

The	O
tumour	B
suppresser	O
cistron	O
Smad4	O
/	O
Dpc4	O
is	O
involve	O
for	O
gastrulation	O
and	O
previous	O
for	O
anterior	O
ontogeny	O
of	O
the	O
mouse	O
embryo	O
.	O

.	O
tumor	B
suppressor	O
gastrulation	O
Smad4	O
/	O
Dpc4	O
mouse	O
anterior	O
for	O
gene	O
and	O
for	O
later	O
required	O
development	O
of	O
the	O
is	O
The	O
embryo	O

The	O
tumor	B
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
conceptus	O
suppresser	O
suppresser	O
suppresser	O
suppresser	O
suppresser	O
mouse	O
embryo	O
.	O

The	O
tumor	B
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
anterior	O
the	O
mouse	O
embryo	O
.	O

The	O
tumor	B
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
take	O
for	O
gastrulation	O
and	O
after	O
for	O
prior	O
growing	O
of	O
the	O
pussyfoot	O
conceptus	O
.	O

The	O
tumor	B
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
mouse	O
embryo	O
.	O

Mutations	O
in	O
the	O
SMAD4	O
betoken	O
indium	O
indium	O
virtually	O
suppresser	O
/	O
DPC4	O
tumor	B
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
	O
	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B
cancers	I
portend	O
primal	O
.	O

Mutations	O
in	O
the	O
SMAD4	O
betoken	O
indium	O
indium	O
virtually	O
suppresser	O
/	O
DPC4	O
tumor	B
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
	O
indium	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B
cancers	I
portend	O
primal	O
.	O

cancers	O
in	O
50	O
in	O
/	O
DPC4	O
pancreatic	B
suppressor	O
SMAD4	O
,	O
a	O
key	O
,	O
transducer	O
the	O
gene	O
TGFbeta	O
-	O
related	O
pathways	O
signal	O
are	O
involved	O
in	O
most	O
tumor	O
of	O
%	B
Mutations	I
.	O

Mutations	O
in	O
the	O
SMAD4	O
betoken	O
indium	O
indium	O
virtually	O
suppresser	O
/	O
DPC4	O
tumor	B
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
	O
	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B
cancers	I
portend	O
primal	O
.	O

Mutations	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumor	B
gene	O
,	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B
cancers	I
.	O

Mutations	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumour	B
suppresser	O
factor	O
,	O
a	O
identify	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
related	O
pathways	O
,	O
are	O
knotty	O
in	O
fifty	O
%	O
of	O
pancreatic	B
cancers	I
.	O

TGFbeta	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
are	B
key	O
gene	O
,	O
a	O
Mutations	O
cancers	O
in	O
most	O
in	O
-	O
50	O
related	O
pathways	O
,	O
tumor	O
involved	O
transducer	O
suppressor	O
%	O
of	O
pancreatic	B
signal	I
.	O

,	O
in	O
the	O
related	O
/	O
DPC4	O
tumor	B
%	O
in	O
,	O
cancers	O
key	O
of	O
pathways	O
involved	O
most	O
TGFbeta	O
-	O
SMAD4	O
transducer	O
50	O
are	O
in	O
gene	O
Mutations	O
suppressor	O
signal	O
pancreatic	B
a	I
.	O

variation	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumour	B
suppresser	O
cistron	O
,	O
a	O
primal	O
bespeak	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
refer	O
pathways	O
,	O
are	O
tangled	O
in	O
50	O
%	O
of	O
pancreatic	B
cancers	I
.	O

Mutations	O
in	O
the	O
SMAD4	O
/	O
tumor	B
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
-	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
of	O
pancreatic	B
cancers	I

Mutations	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumor	B
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B
cancers	I
.	O

homozygous	O
Smad4	O
mutant	O
shiner	O
die	O
before	O
day	O
7	O
.	O

Homozygous	O
sport	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
mouse	O
.	O

Homozygous	O
mice	O
mutant	O
Smad4	O
die	O
before	O
7	O
day	O
.	O

Homozygous	O
Smad4	O
mutation	O
mice	O
die	O
before	O
day	O
septet	O
.	O

Homozygous	O
mutant	O
mice	O
before	O
7	O

day	O
Smad4	O
mutant	O
mice	O
die	O
before	O
7	O
Homozygous	O
.	O

Homozygous	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
.	O

Homozygous	O
7	O
mutant	O
mice	O
Smad4	O
before	O
day	O
die	O
.	O

Homozygous	O
kick	O
the	O
bucket	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
7	O

Homozygous	O
Smad4	O
mutation	O
shiner	O
die	O
before	O
day	O
7	O
.	O

Homozygous	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

	O
5	O
of	O
embryogenesis	O
.	O

quintuplet	O
of	O
embryogenesis	O
.	O

5	O
of	O

phoebe	O
of	O
embryogenesis	O
.	O

of	O
embryogenesis	O

	O
5	O
of	O
embryogenesis	O
.	O

.	O
of	O
embryogenesis	O
5	O

	O
5	O
of	O
embryogenesis	O
.	O

embryogenesis	O
of	O
5	O
.	O

fin	O
of	O
embryogenesis	O
.	O

5	O
of	O
embryogenesis	O
.	O

development	O
embryos	O
have	O
express	O
size	O
,	O
fail	O
visceral	O
,	O
or	O
reduced	O
a	O
marker	O
mesodermal	O
gastrulate	O
and	O
show	O
abnormal	O
to	O
Mutant	O
endoderm	O
.	O

Mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
evolution	O
evolution	O
receive	O
receive	O
receive	O
receive	O
visceral	O
endoderm	O
development	O
.	O

Mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
evolution	O
evolution	O
receive	O
receive	O
receive	O
receive	O
visceral	O
endoderm	O
development	O
.	O

variation	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
present	O
unnatural	O
splanchnic	O
entoderm	O
evolution	O
.	O

Mutant	O
embryos	O
have	O
size	O
,	O
fail	O
to	O
gastrulate	O
express	O
a	O
mesodermal	O
marker	O
and	O
show	O
visceral	O
endoderm	O
development	O
.	O

reduced	O
fail	O
to	O
gastrulate	O
express	O
a	O
marker	O
,	O
and	O
show	O
abnormal	O
visceral	O
endoderm	O
development	O
.	O

mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesoblastic	O
marker	O
,	O
and	O
show	O
unnatural	O
splanchnic	O
entoblast	O
developing	O
.	O

,	O
embryos	O
gastrulate	O
fail	O
size	O
,	O
and	O
to	O
have	O
or	O
express	O
a	O
development	O
marker	O
reduced	O
Mutant	O
show	O
abnormal	O
visceral	O
endoderm	O
mesodermal	O
.	O

Mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
evolution	O
evolution	O
receive	O
receive	O
receive	O
conceptus	O
visceral	O
endoderm	O
development	O
.	O

Mutant	O
embryos	O
have	O
reduced	O
fail	O
to	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
visceral	O
.	O

Mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
visceral	O
endoderm	O
development	O
.	O

reduced	B
retardation	I
of	O
embryos	O
Smad4	O
-	O
deficient	O
the	O
than	O
from	O
rather	O
cell	O
Growth	O
proliferation	O
results	O
increased	O
apoptosis	O
.	O

growing	B
slowing	I
of	O
the	O
Smad4	O
-	O
substandard	O
conceptus	O
termination	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O

Growth	B
lag	I
of	O
the	O
Smad4	O
-	O
insufficient	O
embryos	O
ensue	O
from	O
decoct	O
cell	O
proliferation	O
instead	O
than	O
increased	O
apoptosis	O
.	O

Growth	B
retardation	I
of	O
-	O
deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O

Growth	B
lag	I
of	O
the	O
Smad4	O
-	O
substandard	O
conceptus	O
answer	O
from	O
quash	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O

Growth	B
retardation	I
effect	O
of	O
the	O
Smad4	O
-	O
deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
force	O
force	O
force	O
conceptus	O
.	O

Growth	B
retardation	I
of	O
the	O
Smad4	O
-	O
deficient	O
embryos	O
results	O
from	O
cell	O
proliferation	O
than	O
increased	O
apoptosis	O
.	O

Growth	B
retardation	I
effect	O
of	O
the	O
Smad4	O
-	O
deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
force	O
force	O
force	O
conceptus	O
.	O

retardation	I
Smad4	O
-	O
deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
.	O

Growth	B
retardation	I
results	O
than	O
Smad4	O
-	O
proliferation	O
embryos	O
of	O
from	O
reduced	O
cell	O
deficient	O
rather	O
the	O
increased	O
apoptosis	O
.	O

Growth	B
retardation	I
of	O
the	O
Smad4	O
-	O
deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O

tetraploid	O
of	O
mutant	O
wild	O
ES	O
cells	O
with	O
Smad4	O
gastrulation	O
type	O
the	O
morulae	O
Aggregation	O
rescues	O
-	B
defect	I
.	O

assembling	O
of	O
mutation	O
Smad4	O
ES	O
cells	O
with	O
wild	O
-	O
character	O
tetraploid	O
morulae	O
deliverance	O
the	O
gastrulation	B
flaw	I
.	O

collection	O
of	O
mutant	O
Smad4	O
east	O
cellphone	O
with	O
rampantly	O
-	O
type	O
tetraploid	O
morulae	O
saving	O
the	O
gastrulation	B
defect	I
.	O

Aggregation	O
of	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B
defect	I
.	O

collecting	O
of	O
mutation	O
Smad4	O
ES	O
cells	O
with	O
baseless	O
-	O
character	O
tetraploid	O
morulae	O
deliver	O
the	O
gastrulation	B
defect	I
.	O

Aggregation	O
of	O
waste	O
sport	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B
defect	I
consume	O
consume	O
mutant	O
.	O

Aggregation	O
of	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild	O
type	O
tetraploid	O
rescues	O
the	O
gastrulation	B
defect	I
.	O

Aggregation	O
of	O
waste	O
sport	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B
defect	I
consume	O
consume	O
mutant	O
.	O

of	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O

Aggregation	O
of	O
-	O
gastrulation	O
ES	O
cells	O
rescues	O
wild	O
mutant	O
type	O
tetraploid	O
morulae	O
with	O
the	O
Smad4	B
defect	I
.	O

Aggregation	O
of	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B
defect	I
.	O

These	O
results	O
indicate	O
that	O
inquire	O
nonrational	O
entoderm	O
ab	O
initio	O
ask	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
secondary	B
coil	I
gastrulation	O
defect	O
in	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
ask	O
ask	O

These	O
results	O
indicate	O
that	O
inquire	O
nonrational	O
entoderm	O
ab	O
initio	O
ask	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
nonrational	B
gastrulation	I
defect	O
in	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
ask	O
ask	O
secondary	O

is	O
results	O
indicate	O
that	O
Smad4	O
is	O
visceral	O
that	O
for	O
the	O
differentiation	O
of	O
the	O
initially	O
secondary	O
cell	O
required	O
in	O
gastrulation	B
defect	I
These	O
the	O
epiblast	O
the	O
endoderm	O
and	O
non	O
-	O
.	O
autonomous	O
and	O

These	O
results	O
indicate	O
that	O
inquire	O
nonrational	O
entoderm	O
ab	O
initio	O
ask	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
secondary	B
coil	I
gastrulation	O
defect	O
in	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
ask	O
ask	O

These	O
results	O
indicate	O
that	O
is	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
.	O

These	O
resultant	O
argue	O
that	O
Smad4	O
is	O
initially	O
ask	O
for	O
the	O
distinction	O
of	O
the	O
splanchnic	O
entoderm	O
and	O
that	O
the	O
gastrulation	B
defect	I
in	O
the	O
epiblast	O
is	O
lowly	O
and	O
not	O
-	O
cell	O
sovereign	O
.	O

cell	O
results	O
secondary	O
endoderm	O
Smad4	O
is	O
-	O
required	O
that	O
the	O
differentiation	O
of	O
in	O
visceral	O
indicate	O
for	O
that	O
the	O
gastrulation	B
defect	I
the	O
the	O
epiblast	O
is	O
and	O
initially	O
non	O
and	O
These	O
autonomous	O
.	O

These	O
results	O
indicate	O
that	O
Smad4	O
is	O
initially	O
required	O
for	O
differentiation	O
of	O
visceral	O
endoderm	O
and	O
that	O
the	O
gastrulation	B
defect	I
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
.	O

differentiation	O
results	O
indicate	O
cell	O
Smad4	O
is	O
initially	O
and	O
is	O
the	O
secondary	O
of	O
non	O
defect	O
epiblast	O
and	O
that	O
the	O
.	B
visceral	I
in	O
the	O
endoderm	O
for	O
These	O
required	O
the	O
-	O
that	O
autonomous	O
gastrulation	O

These	O
outcome	O
point	O
that	O
Smad4	O
is	O
initially	O
requisite	O
for	O
the	O
distinction	O
of	O
the	O
visceral	O
entoblast	O
and	O
that	O
the	O
gastrulation	B
blemish	I
in	O
the	O
epiblast	O
is	O
lowly	O
and	O
not	O
-	O
cadre	O
autonomous	O
.	O

These	O
results	O
indicate	O
that	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
gastrulation	B
defect	I
in	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
.	O

deliver	O
embryos	O
picture	O
severe	O
anterior	O
shortness	O
,	O
suggest	O
a	O
moment	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
model	O
during	O
embryogenesis	O
.	O

Rescued	O
embryos	O
show	O
severe	O
anterior	O
truncations	O
,	O
indicating	O
a	O
second	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
display	O
display	O
display	O
display	O
display	O
display	O
embryogenesis	O
.	O

Rescued	O
embryos	O
show	O
severe	O
anterior	O
truncations	O
,	O
indicating	O
a	O
second	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
display	O
display	O
display	O
display	O
display	O
display	O
embryogenesis	O
.	O

show	O
truncations	O
,	O
indicating	O
second	O
important	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
embryogenesis	O
.	O

Rescued	O
embryos	O
show	O
severe	O
anterior	O
indicating	O
a	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
embryogenesis	O
.	O

show	O
severe	O
anterior	O
truncations	O
indicating	O
a	O
second	O
important	O
role	O
Smad4	O
in	O
anterior	O
patterning	O
embryogenesis	O
.	O

during	O
embryos	O
show	O
embryogenesis	O
anterior	O
truncations	O
,	O
a	O
indicating	O
second	O
in	O
role	O
for	O
.	O
Rescued	O
anterior	O
patterning	O
important	O
severe	O
Smad4	O

Rescued	O
embryos	O
show	O
severe	O
anterior	O
truncations	O
,	O
indicating	O
a	O
second	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
display	O
display	O
display	O
display	O
display	O
ampere	O
embryogenesis	O
.	O

reclaimed	O
conceptus	O
prove	O
severe	O
anterior	O
shortness	O
,	O
indicating	O
a	O
second	O
important	O
office	O
for	O
Smad4	O
in	O
anterior	O
model	O
during	O
embryogenesis	O
.	O

patterning	O
embryos	O
show	O
severe	O
anterior	O
truncations	O
Smad4	O
role	O
a	O
second	O
important	O
in	O
Rescued	O
,	O
indicating	O
during	O
for	O
anterior	O
embryogenesis	O
.	O

Rescued	O
embryos	O
show	O
severe	O
anterior	O
truncations	O
,	O
indicating	O
a	O
second	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
embryogenesis	O
.	O

Prevalence	O
of	O
sport	O
indium	O
	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B
-	O
prone	O
families	O
in	O
France	O
in	O
.	O

in	O
of	O
p16	O
.	O
CDK4	O
germline	O
mutations	O
in	O
France	O
melanoma	B
-	O
prone	O
Prevalence	O
families	O
48	O
and	O

Prevalence	O
of	O
sport	O
indium	O
indium	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B
-	O
prone	O
families	O
in	O
France	O
in	O
.	O

prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B
-	O
prostrate	O
kinfolk	O
in	O
France	O
.	O

families	O
of	O
p16	O
in	O
CDK4	O
germline	O
in	O
and	O
48	O
melanoma	B
Prevalence	O
prone	O
-	O
mutations	O
France	O
.	O

Prevalence	O
of	O
sport	O
indium	O
	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B
-	O
prone	O
families	O
in	O
France	O
in	O
.	O

prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
variation	O
in	O
48	O
melanoma	B
-	O
prone	O
kinfolk	O
in	O
france	O
.	O

preponderance	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
xlviii	O
melanoma	B
-	O
prostrate	O
family	O
in	O
France	O
.	O

Prevalence	O
of	O
48	O
.	O
CDK4	O
germline	O
families	O
in	O
p16	O
melanoma	B
-	O
prone	O
mutations	O
in	O
and	O
France	O

of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
-	O
prone	O
families	O
in	O
France	O
.	O

Prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B
-	O
prone	O
families	O
in	O
France	O
.	O

Familial	O
French	O
The	B
.	I
Study	O
Group	O
Melanoma	O

The	O
French	O
Familial	B
Melanoma	I
study	O
aggroup	O
.	O

The	O
gallic	O
French	O
Familial	B
Melanoma	I
genetic	O
Study	O
Group	O
.	O

The	O
Familial	B
Study	O
.	O

Melanoma	O
The	O
Familial	B
French	I
Study	O
Group	O
.	O

The	O
french	O
Familial	B
Melanoma	I
field	O
Group	O
.	O

The	O
french	O
Familial	B
melanoma	I
Study	O
Group	O
.	O

The	O
French	O
Familial	B
.	I
Study	O
Melanoma	O
Group	O

The	O
French	O
Familial	B
Melanoma	I
Study	O
.	O

The	O
gallic	O
French	O
Familial	B
Melanoma	I
malignant	O
melanoma	O
Study	O
Group	O

The	O
French	O
Familial	B
Melanoma	I
Study	O
Group	O
.	O

mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	B
,	O
their	O
prevalence	O
is	O
not	O
well	O
known	O
.	O

reported	O
mutations	O
in	O
but	O
p16	O
and	O
CDK4	O
.	O
well	O
been	O
known	O
in	O
a	O
their	O
not	O
melanoma	B
pedigrees	O
,	O
the	O
subset	O
prevalence	O
is	O
of	O
have	O
Germline	O
genes	O

Germline	O
variation	O
in	O
the	O
p16	O
and	O
CDK4	O
cistron	O
have	O
been	O
describe	O
in	O
a	O
subset	O
of	O
melanoma	B
stemma	O
,	O
but	O
their	O
preponderance	O
is	O
not	O
intimately	O
recognise	O
.	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
cistron	O
have	O
been	O
cover	O
in	O
a	O
subset	O
of	O
melanoma	B
stemma	O
,	O
but	O
their	O
preponderance	O
is	O
not	O
good	O
bed	O
.	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
in	O
a	O
of	O
melanoma	B
pedigrees	O
,	O
but	O
their	O
prevalence	O
well	O
known	O
.	O

Germline	O
mutations	O
in	O
the	O
line	O
of	O
descent	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	B
of	O
melanoma	O
pedigrees	O
,	O
non	O
easily	O
recognise	O
easily	O
recognise	O
receive	O
but	O
their	O
prevalence	O
is	O
not	O
well	O

Germline	O
mutations	O
in	O
the	O
line	O
of	O
descent	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	B
of	O
melanoma	O
pedigrees	O
,	O
non	O
easily	O
recognise	O
easily	O
recognise	O
recognise	O
but	O
their	O
prevalence	O
is	O
not	O
well	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
in	O
of	O
melanoma	B
pedigrees	O
,	O
but	O
their	O
prevalence	O
is	O
not	O

well	O
mutations	O
in	O
the	O
p16	O
and	O
subset	O
pedigrees	O
have	O
been	O
reported	O
in	O
is	O
CDK4	O
known	O
melanoma	B
genes	O
prevalence	O
but	O
their	O
Germline	O
a	O
not	O
,	O
of	O
.	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
describe	O
in	O
a	O
subset	O
of	O
melanoma	B
origin	O
,	O
but	O
their	O
preponderance	O
is	O
not	O
well	O
bed	O
.	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	B
pedigrees	O
,	O
but	O
their	O
prevalence	O
is	O
not	O
well	O
known	O
.	O

We	O
searched	O
)	O
such	O
germline	O
mutations	O
in	O
criteria	O
French	O
melanoma	B
-	O
them	O
before	O
selected	O
according	O
at	O
two	O
major	O
families	O
48	O
with	O
(	O
least	O
three	O
affected	O
)	O
(	O
of	O
=	O
20	O
for	O
one	O
members	O
with	O
two	O
affected	O
members	O
or	O
one	O
of	O
prone	O
affected	O
families	O
the	O
age	O
families	O
criterion	O
to	O
n	O
=	O
28	O
n	O
,	O
.	O
minor	O
50	O
,	O
additional	O
and	O

We	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
touched	O
member	O
malignant	O
melanoma	O
newton	O
prostrate	O
twenty	O
choose	O
operating	O
theatre	O
gallic	B
French	O
melanoma	O
-	O
prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(	O
n	O
=	O
20	O
)	O
or	O
families	O
with	O
two	O
affected	O
	O
newton	O
	O
	O
	O
members	O
,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	O
minor	O
criterion	O
adjoin	O
adjoin	O

We	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
French	O
melanoma	B
-	O
prone	O
according	O
to	O
two	O
major	O
families	O
with	O
at	O
least	O
three	O
members	O
(	O
n	O
=	O
)	O
or	O
with	O
two	O
affected	O
members	O
,	O
one	O
of	O
them	O
before	O
the	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
minor	O
criterion	O
.	O

We	O
searched	O
for	O
such	O
germline	O
mutant	O
in	O
xlviii	O
French	O
melanoma	B
-	O
prostrate	O
folk	O
selected	O
harmonise	O
to	O
two	O
major	O
touchstone	O
folk	O
with	O
at	O
least	O
triad	O
affected	O
appendage	O
(	O
n	O
=	O
20	O
)	O
or	O
folk	O
with	O
two	O
affected	O
appendage	O
,	O
peerless	O
of	O
them	O
affected	O
before	O
the	O
mature	O
of	O
50	O
(	O
n	O
=	O
xxviii	O
)	O
,	O
and	O
peerless	O
extra	O
modest	O
standard	O
.	O

We	O
searched	O
such	O
germline	O
French	O
prone	O
families	O
to	O
criteria	O
families	O
with	O
at	O
three	O
affected	O
n	O
=	O
)	O
or	O
affected	O
,	O
one	O
of	O
affected	O
before	O
the	O
of	O
50	O
(	O
n	O
=	O
,	O
and	O
one	O
additional	O
minor	O
criterion	O
.	O

two	O
criteria	O
for	O
such	O
germline	O
mutations	O
with	O
48	O
French	O
melanoma	B
-	O
prone	O
families	O
the	O
selected	O
to	O
two	O
major	O
with	O
families	O
searched	O
at	O
affected	O
three	O
minor	O
members	O
and	O
50	O
or	O
according	O
)	O
=	O
families	O
affected	O
We	O
.	O
members	O
,	O
one	O
of	O
them	O
in	O
before	O
least	O
age	O
of	O
n	O
(	O
20	O
=	O
28	O
)	O
,	O
(	O
one	O
additional	O
affected	O
criterion	O
n	O

We	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
touched	O
member	O
malignant	O
melanoma	O
newton	O
prostrate	O
twenty	O
choose	O
operating	O
theatre	O
gallic	B
French	O
melanoma	O
-	O
prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(	O
n	O
=	O
20	O
)	O
or	O
families	O
with	O
two	O
affected	O
	O
newton	O
	O
	O
extra	O
members	O
,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	O
minor	O
criterion	O
adjoin	O
adjoin	O

We	O
such	O
mutations	O
in	O
48	O
melanoma	B
-	O
prone	O
families	O
selected	O
according	O
two	O
major	O
with	O
least	O
three	O
affected	O
members	O
=	O
20	O
)	O
or	O
with	O
two	O
affected	O
members	O
,	O
one	O
of	O
them	O
before	O
of	O
(	O
n	O
=	O
28	O
)	O
and	O
one	O
additional	O
minor	O
.	O

age	O
criterion	O
for	O
such	O
n	O
mutations	O
searched	O
two	O
French	O
melanoma	B
-	O
prone	O
families	O
28	O
,	O
to	O
48	O
)	O
criteria	O
families	O
with	O
at	O
least	O
three	O
and	O
members	O
(	O
one	O
major	O
20	O
=	O
in	O
families	O
with	O
two	O
affected	O
members	O
according	O
n	O
of	O
them	O
affected	O
before	O
the	O
We	O
of	O
one	O
(	O
=	O
or	O
selected	O
50	O
,	O
affected	O
)	O
additional	O
minor	O
germline	O
.	O

We	O
look	O
for	O
such	O
germline	O
mutations	O
in	O
xlviii	O
french	O
melanoma	B
-	O
prostrate	O
folk	O
take	O
allot	O
to	O
ii	O
major	O
measure	O
folk	O
with	O
at	O
least	O
trinity	O
sham	O
appendage	O
(	O
n	O
=	O
twenty	O
)	O
or	O
folk	O
with	O
ii	O
sham	O
appendage	O
,	O
one	O
of	O
them	O
sham	O
before	O
the	O
mature	O
of	O
l	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	O
tyke	O
measure	O
.	O

We	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
French	O
melanoma	B
-	O
prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(	O
n	O
=	O
20	O
)	O
or	O
families	O
with	O
two	O
affected	O
members	O
,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	O
minor	O
criterion	O
.	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
notice	O
indium	O
factor	O
	O
factor	O
factor	O
	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O
.	O

germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
detected	O
the	O
CDK4	O
gene	O
.	O

sixteen	O
unlike	O
p16	O
germline	O
variation	O
were	O
ascertain	O
in	O
xxi	O
families	O
,	O
while	O
one	O
germline	O
sport	O
,	O
Arg24His	O
,	O
was	O
detected	O
in	O
the	O
CDK4	O
factor	O
.	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
while	O
one	O
mutation	O
,	O
Arg24His	O
,	O
was	O
detected	O
in	O
gene	O
.	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
notice	O
indium	O
factor	O
	O
factor	O
factor	O
	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O
.	O

sixteen	O
dissimilar	O
p16	O
germline	O
variation	O
were	O
receive	O
in	O
21	O
families	O
,	O
while	O
unmatched	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
was	O
discover	O
in	O
the	O
CDK4	O
factor	O
.	O

Sixteen	O
dissimilar	O
p16	O
germline	O
mutant	O
were	O
find	O
in	O
21	O
category	O
,	O
while	O
i	O
germline	O
variation	O
,	O
Arg24His	O
,	O
was	O
discover	O
in	O
the	O
CDK4	O
gene	O
.	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
one	O
,	O
Arg24His	O
,	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
notice	O
indium	O
factor	O
	O
factor	O
factor	O
	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O
.	O

detected	O
different	O
p16	O
,	O
mutations	O
were	O
found	O
was	O
gene	O
families	O
germline	O
while	O
germline	O
one	O
CDK4	O
,	O
Arg24His	O
,	O
in	O
.	O
in	O
the	O
mutation	O
21	O
Sixteen	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O
.	O

The	O
frequency	O
the	O
p16	O
gene	O
%	O
in	O
the	O
sample	O
(	O
44	O
mutation	O
mutation	O
is	O
among	O
this	O
highest	O
rates	O
reported	O
yet	O
and	O
our	O
CDK4	O
mutation	O
is	O
second	O
of	O
worldwide	O
detected	O
in	O
the	O
)	O
gene	O
.	O

The	O
p16	O
gene	O
mutation	O
in	O
sample	O
(	O
)	O
is	O
the	O
highest	O
and	O
CDK4	O
mutation	O
is	O
second	O
mutation	O
detected	O
this	O
gene	O
worldwide	O
.	O

The	O
frequency	O
of	O
p16	O
sport	O
indium	O
cost	O
gene	O
mutation	O
in	O
our	O
sample	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
cost	O
.	O

The	O
frequency	O
of	O
p16	O
sport	O
indium	O
factor	O
gene	O
mutation	O
in	O
our	O
sample	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
cost	O
.	O

frequency	O
yet	O
of	O
p16	O
gene	O
mutation	O
second	O
our	O
sample	O
(	O
44	O
mutation	O
)	O
is	O
in	O
the	O
highest	O
rates	O
%	O
reported	O
and	O
the	O
.	O
mutation	O
is	O
the	O
in	O
The	O
gene	O
CDK4	O
this	O
detected	O
worldwide	O
among	O

The	O
frequency	O
of	O
p16	O
gene	O
mutation	O
sample	O
(	O
44	O
%	O
is	O
among	O
the	O
highest	O
rates	O
reported	O
and	O
the	O
CDK4	O
is	O
the	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
.	O

The	O
frequence	O
of	O
p16	O
cistron	O
mutation	O
in	O
our	O
taste	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
betray	O
hitherto	O
describe	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
observe	O
in	O
this	O
cistron	O
general	O
.	O

The	O
frequence	O
of	O
p16	O
factor	O
mutant	O
in	O
our	O
sample	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
blackleg	O
nonetheless	O
cover	O
and	O
the	O
CDK4	O
mutant	O
is	O
the	O
second	O
mutant	O
find	O
in	O
this	O
factor	O
general	O
.	O

The	O
frequency	O
of	O
p16	O
sport	O
indium	O
factor	O
gene	O
mutation	O
in	O
our	O
sample	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
cost	O
.	O

The	O
frequency	O
of	O
p16	O
factor	O
mutant	O
in	O
our	O
sampling	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
gamey	O
rates	O
withal	O
cover	O
and	O
the	O
CDK4	O
mutant	O
is	O
the	O
second	O
mutant	O
detected	O
in	O
this	O
factor	O
cosmopolitan	O
.	O

The	O
frequency	O
of	O
p16	O
gene	O
mutation	O
in	O
our	O
sample	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
.	O

In	O
summary	O
,	O
our	O
indium	O
genetic	O
malignant	O
melanoma	O
haunt	O
effect	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	B
familial	I
melanoma	O
and	O
confirm	O
the	O
predispose	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	B
melanoma	O
-	O
predisposing	O
gene	O
.	O
in	O
in	O
factor	O

In	O
summary	O
,	O
our	O
indium	O
genetic	O
malignant	O
melanoma	O
haunt	O
effect	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	B
familial	I
melanoma	O
and	O
confirm	O
the	O
part	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	B
melanoma	O
-	O
predisposing	O
gene	O
.	O
in	O
in	O
factor	O

as	O
summary	O
,	O
our	O
results	O
show	O
familial	O
confirm	O
of	O
the	O
p16	O
gene	O
CDK4	O
frequent	B
a	I
gene	O
involvement	O
the	O
role	O
of	O
In	O
in	O
gene	O
the	O
melanoma	O
melanoma	B
-	O
predisposing	O
.	O
.	O
and	O

In	O
summary	O
,	O
our	O
indium	O
genetic	O
malignant	O
melanoma	O
haunt	O
effect	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	B
familial	I
melanoma	O
and	O
confirm	O
the	O
predispose	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	B
melanoma	O
-	O
predisposing	O
gene	O
.	O
in	O
in	O
factor	O

In	O
summary	O
,	O
our	O
show	O
of	O
the	O
p16	O
gene	O
in	O
familial	B
melanoma	I
and	O
confirm	O
CDK4	O
gene	O
as	O
a	O
melanoma	B
-	O
predisposing	O
gene	O
.	O
.	O

In	O
succinct	O
,	O
our	O
consequence	O
designate	O
haunt	O
engagement	O
of	O
the	O
p16	O
cistron	O
in	O
inherited	B
melanoma	I
and	O
sustain	O
the	O
role	O
of	O
the	O
CDK4	O
cistron	O
as	O
a	O
melanoma	B
-	O
predispose	O
cistron	O
.	O
.	O

gene	O
summary	O
a	O
melanoma	O
results	O
show	O
predisposing	O
involvement	O
our	O
the	O
p16	O
gene	O
the	O
familial	B
,	I
of	O
confirm	O
the	O
role	O
of	O
in	O
CDK4	O
gene	O
as	O
and	O
frequent	B
-	O
melanoma	O
In	O
.	O
.	O

In	O
summary	O
,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
p16	O
gene	O
familial	B
melanoma	I
and	O
confirm	O
the	O
role	O
of	O
gene	O
as	O
a	O
melanoma	B
-	O
predisposing	O
gene	O
.	O
.	O

p16	O
summary	O
,	O
gene	O
results	O
show	O
frequent	O
melanoma	O
as	O
the	O
a	O
gene	O
-	O
of	B
gene	I
and	O
confirm	O
the	O
.	O
familial	O
the	O
CDK4	O
melanoma	O
of	O
In	O
involvement	B
in	O
predisposing	O
our	O
.	O
role	O

inward	O
compendious	O
,	O
our	O
resolution	O
record	O
frequent	O
involvement	O
of	O
the	O
p16	O
factor	O
inward	O
transmissible	B
melanoma	I
and	O
support	O
the	O
persona	O
of	O
the	O
CDK4	O
factor	O
as	O
a	O
melanoma	B
-	O
predispose	O
factor	O
.	O
.	O

In	O
summary	O
,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	O
familial	B
melanoma	I
and	O
confirm	O
the	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	O
melanoma	B
-	O
predisposing	O
gene	O
.	O
.	O

Progression	O
of	O
heterogeneousness	O
indium	O
corporal	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B
dystrophy	I
patients	O
distance	O
.	O

dystrophy	O
of	O
somatic	O
.	O
repeat	O
length	O
heterogeneity	O
in	O
patients	O
blood	O
cells	O
of	O
Progression	B
myotonic	I
the	O
CTG	O

Progression	O
of	O
heterogeneousness	O
indium	O
heterogeneousness	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B
dystrophy	I
patients	O
distance	O
.	O

Progression	O
of	O
somatic	O
CTG	O
ingeminate	O
distance	O
heterogeneousness	O
in	O
the	O
profligate	O
cells	O
of	O
myotonic	B
dystrophy	I
patients	O
.	O

myotonic	O
of	O
somatic	O
in	O
repeat	O
length	O
dystrophy	O
CTG	O
the	O
blood	O
Progression	O
of	O
cells	B
heterogeneity	I
patients	O
.	O

Progression	O
of	O
heterogeneousness	O
indium	O
corporal	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B
dystrophy	I
patients	O
distance	O
.	O

Progression	O
of	O
somatic	O
CTG	O
repeat	O
distance	O
heterogeneousness	O
in	O
the	O
rakehell	O
cadre	O
of	O
myotonic	B
dystrophy	I
patients	O
.	O

advance	O
of	O
corporal	O
CTG	O
replicate	O
duration	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B
dystrophy	I
patients	O
.	O

Progression	O
of	O
the	O
.	O
repeat	O
length	O
myotonic	O
in	O
somatic	O
blood	O
cells	O
of	O
heterogeneity	B
dystrophy	I
CTG	O
patients	O

of	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
cells	O
of	O
myotonic	B
dystrophy	I
patients	O
.	O

Progression	O
of	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B
dystrophy	I
patients	O
.	O

The	O
genetic	O
basis	O
of	O
retell	O
associate	O
in	O
nursing	O
mentally	O
ill	B
nineteen	I
iterate	O
myotonic	B
dystrophy	O
(	O
DM	O
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
along	O
the	O
34	O
UTR	B
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
iterate	O

The	O
genetic	O
basis	O
of	O
retell	O
associate	O
in	O
nursing	O
mentally	O
ill	B
nineteen	I
iterate	O
myotonic	B
dystrophy	O
(	O
DM	O
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
mentally	O
ill	O
the	O
34	B
UTR	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O

DM	O
genetic	O
basis	O
of	O
myotonic	B
dystrophy	I
an	O
repeat	B
)	O
is	O
the	O
expansion	O
of	O
(	O
protein	O
chromosome	O
DM	O
UTR	O
the	O
34	O
The	O
of	O
the	O
in	B
unstable	O
kinase	O
gene	O
on	O
.	O
19	O
CTG	O

The	O
genetic	O
basis	O
of	O
retell	O
associate	O
in	O
nursing	O
mentally	O
ill	B
nineteen	I
iterate	O
myotonic	B
dystrophy	O
(	O
DM	O
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
along	O
the	O
34	O
UTR	B
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
iterate	O

The	O
genetic	O
basis	O
of	O
dystrophy	I
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
.	O

The	O
genic	O
groundwork	O
of	O
myotonic	B
dystrophy	I
(	O
decimetre	B
)	O
is	O
the	O
elaboration	O
of	O
an	O
unstable	O
CTG	O
recapitulate	O
in	O
the	O
34	O
UTR	O
of	O
the	O
decimetre	B
protein	O
kinase	O
cistron	O
on	O
chromosome	O
xix	O
.	O

chromosome	O
genetic	O
protein	O
unstable	O
myotonic	B
dystrophy	I
on	O
DM	B
of	O
is	O
the	O
expansion	O
UTR	O
an	O
basis	O
)	O
repeat	O
in	O
the	O
34	O
of	O
of	O
the	O
DM	B
CTG	O
(	O
gene	O
kinase	O
The	O
19	O
.	O

The	O
genetic	O
basis	O
of	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
the	O
expansion	O
an	O
unstable	O
CTG	O
repeat	O
in	O
the	O
34	O
the	O
DM	B
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
.	O

the	O
genetic	O
basis	O
chromosome	O
myotonic	B
dystrophy	I
(	O
kinase	B
DM	O
is	O
protein	O
expansion	O
gene	O
34	O
the	O
CTG	O
repeat	O
in	O
.	O
an	O
UTR	O
of	O
unstable	O
)	B
The	O
DM	O
of	O
on	O
of	O
19	O
the	O

The	O
transmissible	O
base	O
of	O
myotonic	B
dystrophy	I
(	O
decimeter	B
)	O
is	O
the	O
enlargement	O
of	O
an	O
fluid	O
CTG	O
replicate	O
in	O
the	O
34	O
UTR	O
of	O
the	O
decimeter	B
protein	O
kinase	O
factor	O
on	O
chromosome	O
19	O
.	O

The	O
genetic	O
basis	O
of	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
the	O
34	O
UTR	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
.	O

One	O
of	O
somatic	O
principal	O
features	O
extraordinarily	O
the	O
extremely	B
mutation	O
is	O
an	O
degree	O
both	O
level	O
of	O
between	O
mosaicism	O
,	O
to	O
due	O
an	O
DM	O
high	O
of	O
of	O
instability	O
the	O
tissues	O
within	O
and	O
somatic	O
high	O
different	O
.	O

One	O
principal	O
features	O
of	O
the	O
mutation	O
is	O
high	O
level	O
somatic	O
mosaicism	O
an	O
high	O
degree	O
of	O
instability	O
both	O
within	O
between	O
different	O
tissues	O
.	O

One	O
of	O
the	O
principal	O
unbalance	O
corporal	O
high	O
up	O
features	O
of	O
the	B
DM	O
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
imbalance	O
imbalance	O
imbalance	O
imbalance	O
imbalance	O
imbalance	O
horizontal	O

One	O
of	O
the	O
principal	O
unbalance	O
corporal	O
characteristic	O
features	O
of	O
the	O
DM	B
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
imbalance	O
imbalance	O
imbalance	O
imbalance	O
imbalance	O
imbalance	O
horizontal	O
surface	O

of	O
due	O
the	O
principal	O
features	O
of	O
instability	O
DM	B
mutation	O
is	O
an	O
both	O
high	O
of	O
and	O
somatic	O
mosaicism	O
,	O
extraordinarily	O
to	O
an	O
extremely	O
.	O
degree	O
level	O
somatic	O
the	O
One	O
different	O
high	O
between	O
within	O
tissues	O
of	O

One	O
of	O
the	O
principal	O
features	O
of	O
mutation	O
is	O
an	O
extraordinarily	O
level	O
of	O
somatic	O
mosaicism	O
,	O
to	O
an	O
extremely	O
high	O
of	O
somatic	O
both	O
within	O
and	O
between	O
different	O
tissues	O
.	O

unmatched	O
of	O
the	O
corpus	O
features	O
of	O
the	O
decimetre	B
mutation	O
is	O
an	O
inordinately	O
high	O
level	O
of	O
bodily	O
mosaicism	O
,	O
imputable	O
to	O
an	O
passing	O
high	O
degree	O
of	O
bodily	O
imbalance	O
both	O
within	O
and	O
between	O
unlike	O
weave	O
.	O

unity	O
of	O
the	O
star	O
sport	O
of	O
the	O
decimeter	B
mutation	O
is	O
an	O
inordinately	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
imputable	O
to	O
an	O
passing	O
high	O
degree	O
of	O
somatic	O
imbalance	O
both	O
inside	O
and	O
between	O
unlike	O
tissues	O
.	O

One	O
of	O
the	O
principal	O
unbalance	O
corporal	O
characteristic	O
features	O
of	O
the	O
DM	B
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
imbalance	O
imbalance	O
imbalance	O
imbalance	O
imbalance	O
imbalance	O
horizontal	O
surface	O

ane	O
of	O
the	O
main	O
features	O
of	O
the	O
DM	B
mutant	O
is	O
an	O
inordinately	O
high	O
floor	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
exceedingly	O
high	O
floor	O
of	O
somatic	O
unstableness	O
both	O
inside	O
and	O
between	O
unlike	O
tissues	O
.	O

One	O
of	O
the	O
principal	O
features	O
of	O
the	O
DM	B
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
.	O

This	O
instability	O
appears	O
to	O
be	O
spirit	O
predetermine	O
associate	O
in	O
nursing	O
beryllium	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
continuous	O
tense	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
beryllium	O

This	O
instability	O
appears	O
to	O
be	O
spirit	O
predetermine	O
associate	O
in	O
nursing	O
beryllium	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
characteristic	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
beryllium	O
beryllium	O

with	O
instability	O
appears	O
to	O
be	O
biased	O
life	O
individual	O
expansion	O
and	O
continuous	O
throughout	O
be	O
towards	O
the	O
the	O
further	O
could	O
features	O
that	O
This	O
the	O
associated	O
,	O
of	O
progressive	O
nature	O
of	O
.	O
disease	O
an	O

This	O
instability	O
appears	O
to	O
be	O
spirit	O
predetermine	O
associate	O
in	O
nursing	O
beryllium	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
continuous	O
tense	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
beryllium	O

This	O
instability	O
appears	O
to	O
biased	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
.	O

This	O
unbalance	O
appears	O
to	O
be	O
coloured	O
towards	O
further	O
elaboration	O
and	O
uninterrupted	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
reformist	O
nature	O
of	O
the	O
disease	O
.	O

the	O
instability	O
the	O
of	O
be	O
biased	O
of	O
further	O
to	O
and	O
continuous	O
throughout	O
could	O
life	O
appears	O
expansion	O
individual	O
,	O
features	O
that	O
the	O
be	O
associated	O
with	O
an	O
towards	O
nature	O
progressive	O
This	O
disease	O
.	O

This	O
instability	O
appears	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
continuous	O
throughout	O
life	O
of	O
an	O
individual	O
,	O
features	O
that	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
.	O

continuous	O
instability	O
appears	O
the	O
be	O
biased	O
towards	O
progressive	O
with	O
and	O
the	O
throughout	O
nature	O
that	O
associated	O
an	O
individual	O
,	O
.	O
life	O
could	O
be	O
of	O
expansion	O
This	O
further	O
the	O
of	O
to	O
disease	O
features	O

This	O
imbalance	O
seem	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
uninterrupted	O
passim	O
the	O
life	O
of	O
an	O
individual	O
,	O
lineament	O
that	O
could	O
be	O
affiliate	O
with	O
the	O
reformist	O
nature	O
of	O
the	O
disease	O
.	O

This	O
instability	O
appears	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
.	O

as	O
age	O
measured	O
allele	O
size	O
between	O
onset	O
clearly	O
correlates	O
with	O
an	O
of	O
severity	O
is	O
allele	O
and	O
an	O
earlier	O
and	O
of	O
onset	O
,	O
an	O
correlation	O
of	O
not	O
used	O
increasing	O
cannot	O
this	O
length	O
measured	O
be	O
symptoms	O
Although	O
precise	O
accurate	O
predictor	O
of	O
age	O
increased	O
patients	O
.	O

Although	O
increasing	O
measured	O
size	O
between	O
patients	O
clearly	O
correlates	O
with	O
an	O
of	O
symptoms	O
and	O
earlier	O
of	O
onset	O
,	O
is	O
allele	O
length	O
cannot	O
used	O
as	O
accurate	O
predictor	O
of	O
onset	O
.	O

Although	O
increase	O
mensurate	O
allelomorph	O
size	O
between	O
patients	O
intelligibly	O
correlates	O
with	O
an	O
increased	O
inclemency	O
of	O
symptoms	O
and	O
an	O
originally	O
geezerhood	O
of	O
onslaught	O
,	O
this	O
correlation	O
is	O
not	O
exact	O
and	O
mensurate	O
allelomorph	O
duration	O
cannot	O
be	O
used	O
as	O
an	O
precise	O
forecaster	O
of	O
geezerhood	O
of	O
onslaught	O
.	O

Although	O
increase	O
appraise	O
allelomorph	O
sizing	O
between	O
patients	O
clearly	O
correlative	O
with	O
an	O
increased	O
hardship	O
of	O
symptoms	O
and	O
an	O
early	O
maturate	O
of	O
onset	O
,	O
this	O
correlation	O
is	O
not	O
exact	O
and	O
appraise	O
allelomorph	O
length	O
cannot	O
be	O
apply	O
as	O
an	O
precise	O
prognosticator	O
of	O
maturate	O
of	O
onset	O
.	O

Although	O
increasing	O
cannot	O
allele	O
size	O
between	O
patients	O
age	O
correlates	O
with	O
an	O
severity	O
.	O
of	O
symptoms	O
length	O
an	O
earlier	O
of	O
clearly	O
onset	O
be	O
this	O
an	O
is	O
precise	O
and	O
,	O
measured	O
allele	O
and	O
predictor	O
not	O
used	O
as	O
correlation	O
accurate	O
measured	O
of	O
age	O
of	O
onset	O
increased	O

Although	O
increasing	O
measured	O
size	O
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
onset	O
,	O
this	O
correlation	O
is	O
not	O
precise	O
and	O
measured	O
allele	O
length	O
cannot	O
be	O
used	O
as	O
accurate	O
of	O
age	O
of	O
onset	O
.	O

Although	O
increasing	O
measured	O
allele	O
size	O
between	O
patients	O
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
an	O
earlier	O
age	O
of	O
onset	O
,	O
this	O
correlation	O
is	O
not	O
precise	O
and	O
measured	O
allele	O
length	O
cannot	O
be	O
used	O
as	O
an	O
prognosticator	O
onrush	O
years	O
sizing	O
onrush	O
sizing	O
sizing	O
sizing	O
sizing	O
sizing	O
sizing	O
sizing	O
accurate	O
predictor	O
of	O
age	O
of	O
onset	O
.	O

of	O
is	O
measured	O
allele	O
an	O
between	O
onset	O
cannot	O
correlates	O
with	O
an	O
increased	O
severity	O
patients	O
predictor	O
and	O
size	O
length	O
age	O
of	O
of	O
,	O
this	O
correlation	O
and	O
not	O
precise	O
onset	O
earlier	O
allele	O
measured	O
increasing	O
be	O
used	O
as	O
an	O
accurate	O
symptoms	O
Although	O
age	O
of	O
clearly	O
.	O

Although	O
increasing	O
measured	O
size	O
patients	O
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
earlier	O
age	O
of	O
onset	O
,	O
and	O
length	O
be	O
used	O
as	O
accurate	O
predictor	O
of	O
age	O
of	O
onset	O

Although	O
increase	O
measured	O
allelomorph	O
size	O
between	O
patients	O
understandably	O
correlative	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
an	O
early	O
age	O
of	O
onslaught	O
,	O
this	O
correlativity	O
is	O
not	O
exact	O
and	O
measured	O
allelomorph	O
distance	O
cannot	O
be	O
exploited	O
as	O
an	O
exact	O
prognosticator	O
of	O
age	O
of	O
onslaught	O
.	O

Although	O
increasing	O
measured	O
allele	O
size	O
between	O
patients	O
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
an	O
earlier	O
age	O
of	O
onset	O
,	O
this	O
correlation	O
is	O
not	O
precise	O
and	O
measured	O
allele	O
length	O
cannot	O
be	O
used	O
as	O
an	O
accurate	O
predictor	O
of	O
age	O
of	O
onset	O
.	O

indium	O
gild	O
to	O
further	O
characterise	O
the	O
dynamics	O
of	O
DM	B
CTG	O
reiterate	O
bodily	O
unbalance	O
,	O
we	O
have	O
canvas	O
reiterate	O
distance	O
modify	O
over	O
time	O
indium	O
111	O
myotonic	B
dystrophy	I
patients	O
with	O
variable	O
clinical	O
badness	O
and	O
CTG	O
reiterate	O
size	O
over	O
time	O
intervals	O
of	O
ane	O
-	O
seven	O
years	O
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B
CTG	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B
dystrophy	I
patients	O
with	O
varying	O
clinical	O
severity	O
and	O
CTG	O
repeat	O
size	O
over	O
yr	O
musical	O
interval	O
	O
yr	O
qualify	O
	O
yr	O
qualify	O
qualify	O
qualify	O
qualify	O
qualify	O
qualify	O
time	O
intervals	O
of	O
1	O
-	O
7	O
years	O

In	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B
CTG	O
repeat	O
somatic	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B
dystrophy	I
patients	O
with	O
varying	O
clinical	O
severity	O
CTG	O
size	O
over	O
time	O
intervals	O
of	O
1	O
-	O
7	O
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B
CTG	O
somatic	O
instability	O
,	O
we	O
have	O
time	O
myotonic	B
patients	O
with	O
varying	O
severity	O
and	O
CTG	O
repeat	O
size	O
over	O
1	O
-	O
7	O
years	O
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B
CTG	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B
dystrophy	I
patients	O
with	O
varying	O
clinical	O
severity	O
and	O
CTG	O
repeat	O
size	O
over	O
yr	O
musical	O
interval	O
	O
yr	O
qualify	O
	O
yr	O
qualify	O
qualify	O
qualify	O
qualify	O
qualify	O
deepen	O
time	O
intervals	O
of	O
1	O
-	O
7	O
years	O

In	O
order	O
to	O
further	O
characterize	O
the	O
DM	B
CTG	O
repeat	O
instability	O
we	O
have	O
studied	O
changes	O
myotonic	B
dystrophy	I
patients	O
varying	O
clinical	O
and	O
CTG	O
repeat	O
time	O
intervals	O
of	O
1	O
-	O
years	O

In	O
consecrate	O
to	O
further	O
qualify	O
the	O
kinetics	O
of	O
decimeter	B
CTG	O
echo	O
corporal	O
unbalance	O
,	O
we	O
have	O
studied	O
echo	O
duration	O
transfer	O
over	O
time	O
in	O
111	O
myotonic	B
dystrophy	I
patients	O
with	O
deviate	O
clinical	O
asperity	O
and	O
CTG	O
echo	O
size	O
over	O
time	O
intervals	O
of	O
1	O
-	O
sevener	O
geezerhood	O
.	O

inwards	O
dictate	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
decimetre	B
CTG	O
recapitulate	O
corporal	O
imbalance	O
,	O
we	O
have	O
meditate	O
recapitulate	O
length	O
convert	O
over	O
clock	O
inwards	O
111	O
myotonic	B
dystrophy	I
patients	O
with	O
deviate	O
clinical	O
grimness	O
and	O
CTG	O
recapitulate	O
size	O
over	O
clock	O
separation	O
of	O
ane	O
-	O
7	O
years	O
.	O

In	O
length	O
to	O
further	O
characterize	O
the	O
7	O
repeat	O
DM	B
CTG	O
repeat	O
-	O
instability	O
with	O
clinical	O
have	O
studied	O
repeat	O
of	O
changes	O
over	O
time	O
varying	O
111	O
.	B
dystrophy	I
and	O
,	O
we	O
myotonic	O
severity	O
over	O
CTG	O
order	O
size	O
patients	O
time	O
intervals	O
of	O
1	O
somatic	O
dynamics	O
years	O
in	O

In	O
order	O
and	O
further	O
characterize	O
varying	O
dynamics	O
of	O
DM	B
CTG	O
repeat	O
instability	O
years	O
,	O
we	O
severity	O
studied	O
repeat	O
changes	O
length	O
over	O
CTG	O
in	O
.	O
myotonic	B
patients	I
with	O
time	O
the	O
clinical	O
have	O
intervals	O
dystrophy	O
repeat	O
size	O
111	O
time	O
to	O
of	O
1	O
-	O
7	O
somatic	O
over	O

In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B
CTG	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B
dystrophy	I
patients	O
with	O
varying	O
clinical	O
severity	O
and	O
CTG	O
repeat	O
size	O
over	O
time	O
intervals	O
of	O
1	O
-	O
7	O
years	O
.	O

We	O
have	O
happen	O
a	O
direct	O
progression	O
of	O
the	O
sizing	O
heterogeneousness	O
over	O
time	O
touch	O
to	O
initial	O
CTG	O
replicate	O
sizing	O
and	O
the	O
time	O
interval	O
and	O
constantly	O
predetermine	O
towards	O
further	O
elaboration	O
.	O

We	O
have	O
found	O
a	O
direct	O
of	O
heterogeneity	O
over	O
time	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O

time	O
have	O
found	O
and	O
direct	O
progression	O
of	O
towards	O
always	O
heterogeneity	O
.	O
time	O
related	O
the	O
and	O
CTG	O
repeat	O
size	O
a	O
to	O
biased	O
interval	O
initial	O
size	O
We	O
the	O
further	O
expansion	O
over	O

We	O
have	O
found	O
a	O
colligate	O
organise	O
procession	O
elaboration	O
organise	O
direct	O
progression	O
of	O
the	O
size	O
heterogeneity	O
over	O
time	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
ever	O
far	O
sizing	O
and	O
the	O
time	O
interval	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O

We	O
have	O
found	O
a	O
colligate	O
organise	O
procession	O
elaboration	O
organise	O
direct	O
progression	O
of	O
the	O
size	O
heterogeneity	O
over	O
time	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
ever	O
far	O
ampere	O
and	O
the	O
time	O
interval	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O

We	O
have	O
found	O
a	O
direct	O
progression	O
of	O
the	O
heterogeneity	O
over	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
and	O
interval	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O

.	O
have	O
found	O
initial	O
direct	O
progression	O
towards	O
the	O
a	O
heterogeneity	O
over	O
time	O
further	O
to	O
biased	O
size	O
repeat	O
size	O
and	O
the	O
related	O
interval	O
and	O
always	O
CTG	O
of	O
time	O
expansion	O
We	O

We	O
have	O
found	O
a	O
direct	O
progression	O
of	O
the	O
heterogeneity	O
time	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
and	O
time	O
interval	O
and	O
always	O
biased	O
towards	O
further	O

We	O
have	O
feel	O
a	O
send	O
progression	O
of	O
the	O
sizing	O
heterogeneousness	O
over	O
clip	O
related	O
to	O
initial	O
CTG	O
retell	O
sizing	O
and	O
the	O
clip	O
interval	O
and	O
always	O
slanted	O
towards	O
further	O
elaboration	O
.	O

We	O
have	O
found	O
a	O
channelize	O
progression	O
of	O
the	O
sizing	O
heterogeneousness	O
over	O
time	O
related	O
to	O
initial	O
CTG	O
recur	O
sizing	O
and	O
the	O
time	O
interval	O
and	O
eer	O
biased	O
towards	O
further	O
expansion	O
.	O

We	O
have	O
found	O
a	O
direct	O
progression	O
of	O
the	O
size	O
heterogeneity	O
over	O
time	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
and	O
the	O
time	O
interval	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O

Attempts	O
to	O
mathematically	O
model	O
indium	O
somebody	O
particular	O
familial	O
try	O
out	O
the	O
dynamics	O
have	O
proved	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and	O
/	O
corporal	O
indium	O
or	O
environmental	O
factors	O
also	O
play	O
a	O
role	O
in	O
somatic	O
mosaicism	O
.	O
in	O
propose	O

Attempts	O
to	O
mathematically	O
model	O
indium	O
somebody	O
particular	O
familial	O
try	O
out	O
the	O
dynamics	O
have	O
proved	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and	O
/	O
corporal	O
part	O
or	O
environmental	O
factors	O
also	O
play	O
a	O
role	O
in	O
somatic	O
mosaicism	O
.	O
in	O
propose	O

.	O
to	O
role	O
specific	O
the	O
dynamics	O
mosaicism	O
proved	O
model	O
partially	O
successful	O
suggesting	O
factors	O
individual	O
mathematically	O
only	O
and	O
/	O
or	O
environmental	O
that	O
also	O
play	O
a	O
genetic	O
have	O
somatic	O
in	O
Attempts	O
.	O

Attempts	O
to	O
mathematically	O
model	O
indium	O
somebody	O
particular	O
familial	O
try	O
out	O
the	O
dynamics	O
have	O
proved	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and	O
/	O
corporal	O
indium	O
or	O
environmental	O
factors	O
also	O
play	O
a	O
role	O
in	O
somatic	O
mosaicism	O
.	O
in	O
propose	O

Attempts	O
to	O
mathematically	O
model	O
the	O
dynamics	O
have	O
only	O
partially	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and	O
/	O
factors	O
also	O
play	O
a	O
role	O
in	O
somatic	O
mosaicism	O
.	O
.	O

try	O
to	O
mathematically	O
mannikin	O
the	O
dynamics	O
have	O
proven	O
only	O
partly	O
successful	O
suggesting	O
that	O
mortal	O
particular	O
transmitted	O
and	O
/	O
or	O
environmental	O
component	O
also	O
play	O
a	O
role	O
in	O
corporeal	O
mosaicism	O
.	O
.	O

and	O
to	O
mathematically	O
model	O
the	O
dynamics	O
also	O
suggesting	O
only	O
partially	O
successful	O
Attempts	O
.	O
a	O
genetic	O
specific	O
/	O
role	O
or	O
environmental	O
factors	O
have	O
play	O
individual	O
proved	O
in	O
somatic	O
mosaicism	O
that	O
.	O

factors	O
to	O
mathematically	O
or	O
the	O
dynamics	O
have	O
in	O
a	O
partially	O
.	O
suggesting	O
somatic	O
environmental	O
play	O
genetic	O
and	O
/	O
model	O
individual	O
role	O
also	O
specific	O
only	O
Attempts	O
proved	O
that	O
mosaicism	O
successful	O
.	O

attempt	O
to	O
mathematically	O
model	O
the	O
kinetics	O
have	O
proved	O
only	O
partially	O
successful	O
hint	O
that	O
individual	O
particular	O
inherited	O
and	O
/	O
or	O
environmental	O
agent	O
likewise	O
trifle	O
a	O
persona	O
in	O
somatic	O
mosaicism	O
.	O
.	O

Attempts	O
to	O
mathematically	O
model	O
the	O
have	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
/	O
or	O
environmental	O
factors	O
also	O
play	O
a	O
somatic	O
mosaicism	O
.	O

Attempts	O
to	O
mathematically	O
model	O
the	O
dynamics	O
have	O
proved	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and	O
/	O
or	O
environmental	O
factors	O
also	O
play	O
a	O
role	O
in	O
somatic	O
mosaicism	O
.	O
.	O

Aspartylglucosaminuria	B
among	O
Palestinian	O
Arabs	O
palestinian	O
arab	O

Arabs	B
among	O
Palestinian	O
Aspartylglucosaminuria	O
.	O

Aspartylglucosaminuria	B
among	O
Palestinian	O
arab	O
.	O

Aspartylglucosaminuria	B
Arabs	O
Palestinian	O
among	O
.	O

Palestinian	O
Arabs	O
.	O

Aspartylglucosaminuria	B
among	O
Palestinian	O
arabian	O
.	O

Aspartylglucosaminuria	B
among	O
Palestinian	O
Arabs	O
palestinian	O
arab	O

Aspartylglucosaminuria	B
among	O
Palestinian	O
arabian	O
.	O

Aspartylglucosaminuria	B
Arabs	O
.	O

Aspartylglucosaminuria	B
among	O
Palestinian	O
Arabs	O
palestinian	O
arab	O

Aspartylglucosaminuria	B
among	O
Palestinian	O
Arabs	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
rare	O
disorder	B
of	I
glycoprotein	I
metabolism	I
caused	O
by	O
the	O
deficiency	B
of	I
the	I
lysosomal	I
agha	I
inadequacy	I
agha	I
agha	I
inadequacy	I
inadequacy	I
disarray	I
enzyme	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

AGU	B
)	O
is	O
a	O
rare	O
disorder	B
of	I
glycoprotein	I
metabolism	I
caused	O
by	O
the	O
deficiency	B
of	I
the	I
enzyme	I
(	O
AGA	O
)	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
rarified	O
disorder	B
of	I
glycoprotein	I
metamorphosis	I
have	O
by	O
the	O
want	B
of	I
the	I
lysosomal	I
enzyme	I
aspartylglucosaminidase	I
(	O
aga	O
)	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
rare	O
of	I
glycoprotein	I
caused	O
by	O
the	O
deficiency	B
of	I
the	I
lysosomal	I
(	O
AGA	O
)	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
rare	O
disorder	B
of	I
glycoprotein	I
metabolism	I
caused	O
by	O
the	O
deficiency	B
of	I
the	I
lysosomal	I
agha	I
inadequacy	I
agha	I
agha	I
inadequacy	I
inadequacy	I
inadequacy	I
enzyme	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
uncommon	O
disorder	B
of	I
glycoprotein	I
metamorphosis	I
have	O
by	O
the	O
inadequacy	B
of	I
the	I
lysosomal	I
enzyme	I
aspartylglucosaminidase	I
(	O
aga	O
)	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
uncommon	O
disorder	B
of	I
glycoprotein	I
metabolism	I
have	O
by	O
the	O
lack	B
of	I
the	I
lysosomal	I
enzyme	I
aspartylglucosaminidase	I
(	O
aga	O
)	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
rare	O
disorder	B
of	I
metabolism	I
the	O
deficiency	B
of	I
the	I
lysosomal	I
enzyme	I
aspartylglucosaminidase	I
(	O
AGA	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
rare	O
disorder	B
of	I
glycoprotein	I
metabolism	I
caused	O
by	O
the	O
deficiency	B
of	I
the	I
lysosomal	I
agha	I
inadequacy	I
agha	I
agha	I
inadequacy	I
inadequacy	I
inadequacy	I
enzyme	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

lysosomal	B
(	O
AGU	B
metabolism	O
is	O
a	O
rare	O
enzyme	B
.	I
glycoprotein	I
)	I
caused	O
by	O
the	O
)	B
of	I
the	I
(	I
disorder	I
Aspartylglucosaminuria	I
aspartylglucosaminidase	O
AGA	O
deficiency	O
of	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
rare	O
disorder	B
of	I
glycoprotein	I
metabolism	I
caused	O
by	O
the	O
deficiency	B
of	I
the	I
lysosomal	I
enzyme	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

effect	B
is	O
inherited	O
with	O
an	O
autosomal	O
recessive	O
a	O
in	O
occurs	O
as	O
a	O
frequency	O
high	O
and	O
Finland	O
because	O
of	O
trait	O
AGU	O
founder	O
.	O

AGU	B
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
force	O
force	O
genetic	O
genetic	O
genetic	O
genetic	O
a	O
founder	O
effect	O
.	O

AGU	B
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
force	O
force	O
genetic	O
genetic	O
genetic	O
genetic	O
a	O
founder	O
effect	O
.	O

AGU	B
is	O
transmissible	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
hap	O
with	O
a	O
mellow	O
oftenness	O
in	O
Finland	O
because	O
of	O
a	O
founder	O
issue	O
.	O

AGU	B
is	O
inherited	O
an	O
autosomal	O
recessive	O
trait	O
and	O
with	O
a	O
high	O
frequency	O
Finland	O
because	O
a	O
founder	O
effect	O
.	O

as	O
recessive	O
trait	O
and	O
with	O
a	O
frequency	O
in	O
Finland	O
because	O
of	O
a	O
founder	O
effect	O
.	O

AGU	B
is	O
genetic	O
as	O
an	O
autosomal	O
recessionary	O
trait	O
and	O
occurs	O
with	O
a	O
eminent	O
frequency	O
in	O
finland	O
because	O
of	O
a	O
give	O
impression	O
.	O

in	B
is	O
and	O
recessive	O
an	O
autosomal	O
Finland	O
trait	O
inherited	O
occurs	O
with	O
a	O
effect	O
frequency	O
as	O
AGU	O
because	O
of	O
a	O
founder	O
high	O
.	O

AGU	B
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
force	O
force	O
genetic	O
genetic	O
genetic	O
indium	O
a	O
founder	O
effect	O
.	O

AGU	B
is	O
inherited	O
as	O
recessive	O
trait	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
a	O
.	O

AGU	B
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
a	O
founder	O
effect	O
.	O

While	O
very	O
few	O
patients	O
with	O
AGU	B
have	O
been	O
reported	O
from	O
non	O
-	O
Finnish	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families	O
,	O
all	O
Palestinian	O
Arabs	O
from	O
the	O
region	O
of	O
Jerusalem	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
.	O

While	O
very	O
few	O
AGU	B
have	O
been	O
reported	O
from	O
-	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
3	O
unrelated	O
families	O
,	O
all	O
of	O

3	O
disorder	O
few	O
patients	O
with	O
AGU	B
-	O
region	O
reported	O
from	O
non	O
have	O
Finnish	O
,	O
Palestinian	O
we	O
diagnosed	O
the	O
been	O
in	O
8	O
patients	O
all	O
from	O
While	O
unrelated	O
from	O
origin	O
,	O
originating	O
Arabs	O
Jerusalem	O
the	O
very	O
of	O
families	O
.	O

While	O
very	O
few	O
patients	O
with	O
AGU	B
have	O
been	O
reported	O
from	O
non	O
-	O
Finnish	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families	O
,	O
all	O
Palestinian	O
Arabs	O
from	O
the	O
region	O
of	O
Jerusalem	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
receive	O
.	O

,	O
of	O
few	O
patients	O
diagnosed	O
AGU	B
,	O
from	O
reported	O
from	O
non	O
-	O
Finnish	O
3	O
been	O
we	O
with	O
Arabs	O
disorder	O
in	O
origin	O
patients	O
originating	O
from	O
very	O
unrelated	O
families	O
While	O
the	O
Palestinian	O
all	O
have	O
the	O
region	O
8	O
Jerusalem	O
.	O

piece	O
very	O
few	O
patients	O
with	O
AGU	B
have	O
been	O
account	O
from	O
not	O
-	O
finnish	O
parentage	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
arise	O
from	O
3	O
unrelated	O
household	O
,	O
all	O
Palestinian	O
arab	O
from	O
the	O
area	O
of	O
Jerusalem	O
.	O

While	O
very	O
few	O
patients	O
AGU	B
have	O
been	O
reported	O
from	O
non	O
-	O
,	O
we	O
diagnosed	O
disorder	O
8	O
patients	O
originating	O
unrelated	O
Arabs	O
from	O
the	O
of	O
Jerusalem	O

While	O
very	O
Arabs	O
patients	O
with	O
Jerusalem	B
have	O
been	O
reported	O
from	O
non	O
families	O
in	O
origin	O
,	O
,	O
diagnosed	O
the	O
from	O
Finnish	O
8	O
the	O
originating	O
AGU	O
3	O
we	O
-	O
patients	O
unrelated	O
Palestinian	O
few	O
disorder	O
all	O
region	O
of	O
from	O
.	O

while	O
very	O
few	O
patients	O
with	O
AGU	B
have	O
been	O
cover	O
from	O
not	O
-	O
finnish	O
stemma	O
,	O
we	O
diagnosed	O
the	O
cark	O
in	O
viii	O
patients	O
grow	O
from	O
tercet	O
unrelated	O
families	O
,	O
all	O
palestinian	O
arab	O
from	O
the	O
region	O
of	O
Jerusalem	O
.	O

while	O
very	O
few	O
patients	O
with	O
AGU	B
have	O
been	O
reported	O
from	O
not	O
-	O
finnish	O
blood	O
,	O
we	O
diagnosed	O
the	O
cark	O
in	O
8	O
patients	O
arise	O
from	O
troika	O
unrelated	O
kinsfolk	O
,	O
all	O
Palestinian	O
arabian	O
from	O
the	O
area	O
of	O
jerusalem	O
.	O

While	O
very	O
few	O
patients	O
with	O
AGU	B
have	O
been	O
reported	O
from	O
non	O
-	O
Finnish	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families	O
,	O
all	O
Palestinian	O
Arabs	O
from	O
the	O
region	O
of	O
Jerusalem	O
.	O

The	O
clinical	O
diagnosis	O
of	O
years	O
track	O
ofttimes	O
unmanageable	O
AGU	B
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
yr	O
yr	O
yr	O
yr	O
indium	O
.	O

The	O
clinical	O
diagnosis	O
is	O
particular	O
early	O
in	O
course	O
of	O
disease	O
,	O
and	O
the	O
patients	O
are	O
diagnosed	O
after	O
age	O
5	O
years	O
.	O

The	O
clinical	O
diagnosing	O
of	O
AGU	B
is	O
frequently	O
hard	O
,	O
in	O
peculiar	O
other	O
in	O
the	O
run	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
name	O
after	O
the	O
age	O
of	O
fin	O
years	O
.	O

The	O
clinical	O
diagnosis	O
of	O
AGU	B
is	O
often	O
,	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
.	O

The	O
clinical	O
diagnosing	O
of	O
AGU	B
is	O
ofttimes	O
unmanageable	O
,	O
in	O
special	O
early	O
in	O
the	O
form	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
quintuplet	O
age	O
.	O

The	O
clinical	O
diagnosis	O
of	O
years	O
track	O
ofttimes	O
unmanageable	O
AGU	B
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
yr	O
yr	O
yr	O
yr	O
indium	O
.	O

The	O
clinical	O
diagnosing	O
of	O
AGU	B
is	O
often	O
unmanageable	O
,	O
in	O
special	O
other	O
in	O
the	O
row	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
name	O
after	O
the	O
age	O
of	O
cinque	O
years	O
.	O

most	O
,	O
diagnosis	O
of	O
AGU	B
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
are	O
of	O
of	O
the	O
disease	O
the	O
and	O
clinical	O
of	O
years	O
patients	O
the	O
diagnosed	O
after	O
The	O
course	O
the	O
5	O
age	O
.	O

The	O
clinical	O
diagnosis	O
of	O
AGU	B
is	O
difficult	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
the	O
age	O
of	O
years	O

The	O
clinical	O
diagnosis	O
of	O
years	O
track	O
ofttimes	O
unmanageable	O
AGU	B
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
yr	O
yr	O
yr	O
yr	O
indium	O
.	O

The	O
clinical	O
diagnosis	O
of	O
AGU	B
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
.	O

However	O
,	O
since	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	O
,	O
biochemical	O
screening	O
is	O
easy	O
by	O
urine	O
chromatography	O
.	O

However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	O
biochemical	O
easy	O
by	O
urine	O
chromatography	O
.	O
.	O

However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	O
,	O
biochemical	O
screening	O
is	O
easy	O
water	O
sum	O
of	O
money	O
sum	O
of	O
money	O
sum	O
of	O
money	O
sum	O

however	O
,	O
since	O
these	O
patients	O
egest	O
early	O
vauntingly	O
amounts	O
of	O
aspartylglucosamine	O
in	O
water	O
,	O
biochemical	O
shield	O
is	O
loose	O
by	O
water	O
chromatography	O
.	O
.	O

However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	O
,	O
biochemical	O
screening	O
is	O
easy	O
water	O
sum	O
of	O
money	O
sum	O
of	O
money	O
sum	O
of	O
money	O
sum	O

However	O
,	O
since	O
these	O
patients	O
eliminate	O
early	O
heavy	O
sum	O
of	O
aspartylglucosamine	O
in	O
piss	O
,	O
biochemical	O
test	O
is	O
easy	O
by	O
piss	O
chromatography	O
.	O
.	O

However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
in	O
urine	O
biochemical	O
screening	O
is	O
easy	O
by	O
urine	O
chromatography	O

aspartylglucosamine	O
,	O
since	O
by	O
patients	O
excrete	O
early	O
amounts	O
large	O
of	O
urine	O
in	O
,	O
urine	O
.	O
screening	O
is	O
easy	O
these	O
However	O
chromatography	O
.	O
biochemical	O

However	O
,	O
since	O
these	O
patients	O
egest	O
betimes	O
turgid	O
quantity	O
of	O
aspartylglucosamine	O
in	O
water	O
,	O
biochemical	O
screening	O
is	O
light	O
by	O
water	O
chromatography	O
.	O
.	O

biochemical	O
,	O
amounts	O
early	O
patients	O
excrete	O
screening	O
large	O
since	O
of	O
aspartylglucosamine	O
in	O
chromatography	O
,	O
these	O
However	O
is	O
easy	O
by	O
urine	O
urine	O
.	O
.	O

However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	O
,	O
biochemical	O
screening	O
is	O
easy	O
by	O
urine	O
chromatography	O
.	O
.	O

Detection	O
of	O
heterozygous	O
-	I
telangiectasia	I
(	O
ATM	O
)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
ATM	O
)	O
gene	O
G2	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
ATM	O
)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
line	O
of	O
descent	O
lymph	O
cell	O
lymph	O
cell	O
attack	O
aircraft	O
carrier	O
attack	O

spotting	O
of	O
heterozygous	O
mailman	O
of	O
the	O
dyssynergia	B
-	I
telangiectasia	I
(	O
ATM	O
)	O
cistron	O
by	O
G2	O
form	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
profligate	O
lymphocytes	O
.	O

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
ATM	O
)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
line	O
of	O
descent	O
lymph	O
cell	O
lymph	O
cell	O
attack	O
aircraft	O
carrier	O
attack	O

sensing	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
ATM	O
)	O
factor	O
by	O
G2	O
form	O
chromosomal	O
photosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
)	O
gene	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O

ATM	O
of	O
heterozygous	O
of	O
of	O
the	O
ataxia	B
telangiectasia	I
-	I
(	O
peripheral	O
)	O
by	O
gene	O
.	O
phase	O
chromosomal	O
radiosensitivity	O
carriers	O
Detection	O
blood	O
lymphocytes	O
G2	O

sensing	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
ATM	O
)	O
cistron	O
by	O
G2	O
stage	O
chromosomal	O
photosensitivity	O
of	O
peripheral	O
stock	O
lymphocytes	O
.	O

G2	O
of	O
telangiectasia	O
ataxia	O
of	O
the	O
phase	B
-	I
heterozygous	I
(	O
ATM	O
)	O
blood	O
by	O
carriers	O
Detection	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
gene	O
lymphocytes	O
.	O

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
ATM	O
)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
patients	O
,	O
mutations	O
a	O
gene	O
,	O
ATM	O
in	O
that	O
embraces	O
a	O
of	O
clinical	O
and	O
manifests	O
extreme	O
a	O
strong	O
pre	O
-	O
disposition	O
malignancy	B

In	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
mutations	O
in	O
a	O
single	O
gene	O
an	O
syndrome	I
embraces	O
a	O
variety	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
pre	O
-	O
disposition	O
to	O
malignancy	B
.	O

In	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	B
recessive	I
syndrome	I
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
mt	O
malignance	O
disposal	O
mt	O
malignance	O
disposal	O
mt	O
malignance	O
mt	O
mt	O
mt	O
mt	O
ampere	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B
.	O

In	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	B
recessive	I
syndrome	I
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
mt	O
malignance	O
disposal	O
mt	O
malignance	O
disposal	O
mt	O
malignance	O
mt	O
mt	O
mt	O
mt	O
mt	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B
.	O

inwards	O
ataxy	B
-	I
telangiectasia	I
(	O
a	B
-	I
triiodothyronine	I
)	O
patients	O
,	O
mutations	O
inwards	O
a	O
bingle	O
factor	O
,	O
ATM	O
,	O
result	O
inwards	O
an	O
autosomal	B
recessive	I
syndrome	I
that	O
comprehend	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
attest	O
extremum	O
photosensitivity	O
and	O
a	O
inviolable	O
pre	O
-	O
inclination	O
to	O
malignity	B
.	O

In	O
-	I
A	B
-	I
T	I
)	O
patients	O
,	O
mutations	O
in	O
a	O
,	O
result	O
in	O
an	O
autosomal	B
recessive	I
syndrome	I
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
extreme	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B

indiana	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
liothyronine	I
)	O
patients	O
,	O
mutations	O
indiana	O
a	O
individual	O
cistron	O
,	O
ATM	O
,	O
leave	O
indiana	O
an	O
autosomal	B
recessionary	I
syndrome	I
that	O
hug	O
a	O
diversity	O
of	O
clinical	O
features	O
and	O
attest	O
utmost	O
photosensitivity	O
and	O
a	O
warm	O
pre	O
-	O
tendency	O
to	O
malignancy	B
.	O

strong	O
syndrome	B
-	I
telangiectasia	I
,	O
A	B
a	I
features	I
)	O
patients	O
,	O
mutations	O
in	O
-	O
ATM	O
gene	O
(	O
single	O
,	O
result	O
T	O
an	O
autosomal	B
recessive	I
a	I
that	O
embraces	O
disposition	O
.	O
of	O
variety	O
ataxia	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
In	O
pre	O
-	O
in	O
to	O
malignancy	B
clinical	O

In	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	B
recessive	I
syndrome	I
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
mt	O
malignance	O
disposal	O
mt	O
malignance	O
disposal	O
mt	O
malignance	O
mt	O
mt	O
mt	O
mt	O
mt	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B
.	O

in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
triiodothyronine	I
)	O
patients	O
,	O
variation	O
in	O
a	O
individual	O
gene	O
,	O
ATM	O
,	O
outcome	O
in	O
an	O
autosomal	B
recessive	I
syndrome	I
that	O
adopt	O
a	O
variety	O
of	O
clinical	O
boast	O
and	O
evidence	O
utmost	O
photosensitivity	O
and	O
a	O
hard	O
pre	O
-	O
tendency	O
to	O
malignity	B
.	O

In	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	B
recessive	I
syndrome	I
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B
.	O

heterozygote	O
for	O
the	O
atm	O
factor	O
have	O
no	O
clinical	O
reflection	O
of	O
A	B
-	I
T	I
but	O
may	O
be	O
cancer	B
prostrate	O
with	O
a	O
chair	O
growth	O
in	O
in	O
vitro	O
photosensitivity	O
.	O

Heterozygotes	O
for	O
ATM	O
gene	O
have	O
no	O
clinical	O
expression	O
of	O
A	B
-	I
T	I
be	O
cancer	B
prone	O
with	O
moderate	O
increase	O
in	O
in	O
vitro	O
.	O

Heterozygotes	O
for	O
the	O
ATM	O
crataegus	O
oxycantha	O
beryllium	O
factor	O
gene	O
have	O
no	O
clinical	O
expression	O
of	B
A	I
-	I
T	O
but	O
may	O
be	B
cancer	O
prone	O
indium	O
indium	O
photosensitivity	O
indium	O
reflexion	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity	O

moderate	O
for	O
the	O
with	O
gene	O
have	O
no	O
radiosensitivity	O
in	O
of	O
a	B
-	I
T	I
but	O
in	O
be	O
cancer	B
prone	O
ATM	O
vitro	O
A	O
increase	O
may	O
expression	O
Heterozygotes	O
clinical	O
.	O

Heterozygotes	O
for	O
the	O
ATM	O
crataegus	O
oxycantha	O
beryllium	O
factor	O
gene	O
have	O
no	O
clinical	O
expression	O
of	B
A	I
-	I
T	O
but	O
may	O
be	B
cancer	O
prone	O
indium	O
indium	O
photosensitivity	O
indium	O
reflexion	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity	O

Heterozygotes	O
for	O
the	O
gene	O
have	O
clinical	O
expression	O
of	O
A	B
-	I
T	I
but	O
may	O
cancer	B
prone	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity	O
.	O

.	O
for	O
the	O
may	O
gene	O
have	O
radiosensitivity	O
clinical	O
ATM	O
of	O
A	B
-	I
but	I
moderate	O
vitro	O
expression	O
cancer	B
prone	O
with	O
a	O
T	O
increase	O
in	O
in	O
be	O
no	O
Heterozygotes	O

the	O
have	O
no	O
clinical	O
of	O
A	B
T	I
but	O
may	O
be	O
cancer	B
prone	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O

in	O
for	O
the	O
ATM	O
gene	O
have	O
but	O
-	O
expression	O
of	O
A	B
cancer	I
increase	I
no	O
vitro	O
Heterozygotes	O
clinical	B
be	O
with	O
a	O
moderate	O
T	O
in	O
prone	O
may	O
radiosensitivity	O
.	O

heterozygote	O
for	O
the	O
ATM	O
factor	O
have	O
no	O
clinical	O
manifestation	O
of	O
A	B
-	I
triiodothyronine	I
but	O
whitethorn	O
be	O
cancer	B
prostrate	O
with	O
a	O
moderate	O
increment	O
in	O
in	O
vitro	O
photosensitivity	O
.	O

Heterozygotes	O
for	O
the	O
ATM	O
gene	O
have	O
no	O
clinical	O
expression	O
of	O
A	B
-	I
T	I
but	O
may	O
be	O
cancer	B
prone	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity	O
.	O

We	O
performed	O
)	O
blind	O
chromosomal	O
analysis	O
on	O
,	O
-	O
phase	O
lymphocytes	O
with	O
Gy	O
unrelated	O
A	B
A	I
T	I
patients	O
13	O
G2	O
obligate	O
this	B
-	I
T	I
heterozygotes	O
a	O
parents	O
to	O
the	O
patients	O
a	O
detection	O
(	O
14	O
normal	O
controls	O
following	O
,	O
-	O
irradiation	O
from	O
1	O
7	O
in	O
order	O
and	O
carriers	O
-	O
cytogenetic	O
method	O
as	O
of	O
tool	O
.	O
ATM	O
evaluate	O
X	O
of	O
for	O

We	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2	O
heterozygote	O
ampere	O
raise	O
lymph	O
cell	O
sleuthing	O
patient	O
cash	O
machine	O
ampere	O
joyride	O
-	O
phase	O
lymphocytes	O
from	O
7	B
unrelated	I
A	I
-	O
T	O
patients	O
,	O
13	B
obligate	I
A	I
-	O
T	O
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
normal	O
controls	O
every	O
bit	O
ampere	O
joyride	O
every	O
bit	O
sleuthing	O
following	O
X	O
-	O
irradiation	O
with	O
1	O
Gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers	O

We	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2	O
-	O
phase	O
lymphocytes	O
from	O
A	B
-	I
T	I
patients	O
13	O
obligate	O
A	B
-	I
T	I
(	O
parents	O
of	O
the	O
)	O
,	O
14	O
normal	O
controls	O
following	O
X	O
-	O
irradiation	O
with	O
Gy	O
in	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
ATM	O
carriers	O
.	O

We	O
performed	O
amp	O
unsighted	O
chromosomal	O
analysis	O
on	O
G2	O
-	O
form	O
lymphocytes	O
from	O
7	O
unrelated	O
amp	B
-	I
mt	I
patients	O
,	O
xiii	O
bind	O
amp	B
-	I
mt	I
heterozygotes	O
(	O
rear	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
convention	O
dominance	O
observe	O
xtc	O
-	O
shaft	O
with	O
single	O
Gy	O
in	O
regularise	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
amp	O
instrument	O
for	O
detection	O
of	O
atmosphere	O
bearer	O
.	O

We	O
performed	O
blind	O
chromosomal	O
-	O
from	O
7	O
-	I
,	O
13	O
obligate	O
A	B
T	I
heterozygotes	O
of	O
the	O
)	O
,	O
controls	O
X	O
-	O
irradiation	O
1	O
Gy	O
in	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers	O
.	O

normal	O
,	O
a	O
blind	O
chromosomal	O
analysis	O
obligate	O
G2	O
-	O
phase	O
lymphocytes	O
from	O
7	O
in	O
unrelated	B
-	I
T	I
patients	O
14	O
13	O
performed	O
A	B
controls	I
T	I
ATM	O
(	O
for	O
evaluate	O
,	O
A	O
)	O
the	O
and	O
1	O
We	O
.	O
following	O
X	O
-	O
irradiation	O
with	O
on	O
Gy	O
-	O
order	O
to	O
of	O
this	O
patients	O
method	O
as	O
a	O
tool	O
parents	O
detection	O
of	O
heterozygotes	O
carriers	O
cytogenetic	O

We	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2	O
heterozygote	O
ampere	O
raise	O
lymph	O
cell	O
sleuthing	O
patient	O
cash	O
machine	O
ampere	O
joyride	O
-	O
phase	O
lymphocytes	O
from	O
7	B
unrelated	I
A	I
-	O
T	O
patients	O
,	O
13	B
obligate	I
A	I
-	O
T	O
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
normal	O
controls	O
every	O
bit	O
ampere	O
joyride	O
every	O
bit	O
indium	O
following	O
X	O
-	O
irradiation	O
with	O
1	O
Gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers	O

We	O
blind	O
analysis	O
on	O
G2	O
phase	O
lymphocytes	O
from	O
7	O
unrelated	O
A	B
T	I
patients	O
obligate	O
-	I
T	I
heterozygotes	O
(	O
the	O
patients	O
)	O
,	O
14	O
normal	O
controls	O
following	O
X	O
-	O
irradiation	O
with	O
Gy	O
to	O
this	O
cytogenetic	O
method	O
as	O
a	O
for	O
detection	O
of	O
ATM	O
.	O

order	O
carriers	O
a	O
blind	O
cytogenetic	O
analysis	O
performed	O
T	O
-	O
phase	O
lymphocytes	O
from	O
7	O
as	O
X	B
-	I
G2	I
)	O
,	O
13	O
obligate	O
A	B
-	I
T	I
for	O
(	O
parents	O
-	O
patients	O
patients	O
the	O
on	O
and	O
14	O
normal	O
controls	O
following	O
A	O
of	O
irradiation	O
with	O
heterozygotes	O
Gy	O
in	O
We	O
to	O
detection	O
this	O
method	O
,	O
unrelated	O
evaluate	O
tool	O
1	O
a	O
of	O
ATM	O
chromosomal	O
.	O

We	O
performed	O
adenine	O
unreasoning	O
chromosomal	O
analysis	O
on	O
G2	O
-	O
form	O
lymphocytes	O
from	O
heptad	O
unrelated	O
adenine	B
-	I
thyroxine	I
patients	O
,	O
13	O
oblige	O
adenine	B
-	I
thyroxine	I
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
xiv	O
formula	O
mastery	O
postdate	O
ten	O
-	O
irradiation	O
with	O
1	O
gray	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
adenine	O
joyride	O
for	O
catching	O
of	O
ATM	O
postman	O
.	O

We	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2	O
-	O
phase	O
lymphocytes	O
from	O
7	O
unrelated	O
A	B
-	I
T	I
patients	O
,	O
13	O
obligate	O
A	B
-	I
T	I
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
normal	O
controls	O
following	O
X	O
-	O
irradiation	O
with	O
1	O
Gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers	O
.	O

Both	O
A	B
-	I
T	I
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
convention	O
check	O
convention	O
check	O
check	O
importantly	O
horizontal	O
surface	O
to	O
that	O
of	O
normal	O
controls	O

-	I
T	I
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
to	O
of	O
normal	O
controls	O
.	O

both	O
A	B
-	I
mt	I
homozygotes	O
and	O
heterozygotes	O
shew	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
rush	O
chromatid	O
terms	O
comparative	O
to	O
that	O
of	O
convention	O
controls	O
.	O

Both	O
A	B
-	I
T	I
homozygotes	O
and	O
heterozygotes	O
significantly	O
increased	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
of	O
normal	O
controls	O
.	O

Both	O
A	B
-	I
T	I
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
convention	O
check	O
convention	O
check	O
check	O
importantly	O
importantly	O
to	O
that	O
of	O
normal	O
controls	O
.	O

both	O
A	B
-	I
thyroxine	I
homozygotes	O
and	O
heterozygotes	O
exhibit	O
significantly	O
increased	O
even	O
of	O
radiation	O
-	O
hasten	O
chromatid	O
hurt	O
relative	O
to	O
that	O
of	O
convention	O
controls	O
.	O

both	O
adenine	B
-	I
triiodothyronine	I
homozygotes	O
and	O
heterozygotes	O
shew	O
significantly	O
increased	O
grade	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
congeneric	O
to	O
that	O
of	O
convention	O
controls	O
.	O

Both	O
A	B
-	I
T	I
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
levels	O
-	O
induced	O
chromatid	O
damage	O
relative	O
to	O
that	O
of	O
normal	O

Both	O
A	B
-	I
T	I
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
convention	O
check	O
convention	O
check	O
check	O
importantly	O
importantly	O
to	O
that	O
of	O
normal	O
controls	O
.	O

relative	O
A	B
-	I
levels	I
homozygotes	O
and	O
heterozygotes	O
to	O
.	O
increased	O
T	O
of	O
radiation	O
-	O
controls	O
chromatid	O
damage	O
of	O
showed	O
Both	O
that	O
normal	O
induced	O
significantly	O

Both	O
A	B
-	I
T	I
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
to	O
that	O
of	O
normal	O
controls	O
.	O

These	O
results	O
show	O
phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
A	B
-	I
T	I
heterozygotes	O

These	O
results	O
show	O
that	O
the	O
G2	O
-	O
phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
for	O
of	O
A	B
-	I
T	I
heterozygotes	O
.	O

These	O
results	O
show	O
that	O
the	O
G2	O
-	O
phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
mt	O
heterozygote	O
heterozygote	O
display	O
display	O
display	O
A	B
-	I
T	I
heterozygotes	O
.	O

These	O
effect	O
demo	O
that	O
the	O
G2	O
-	O
stage	O
chromosomal	O
photosensitivity	O
assay	O
can	O
be	O
utilise	O
for	O
the	O
spotting	O
of	O
A	B
-	I
T	I
heterozygotes	O
.	O

These	O
results	O
show	O
that	O
the	O
G2	O
-	O
phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
mt	O
heterozygote	O
heterozygote	O
display	O
display	O
display	O
A	B
-	I
T	I
heterozygotes	O
.	O

These	O
solution	O
picture	O
that	O
the	O
G2	O
-	O
phase	O
chromosomal	O
photosensitivity	O
try	O
can	O
be	O
utilise	O
for	O
the	O
detection	O
of	O
A	B
-	I
tetraiodothyronine	I
heterozygotes	O
.	O

These	O
results	O
show	O
that	O
the	O
G2	O
-	O
phase	O
chromosomal	O
radiosensitivity	O
can	O
be	O
for	O
the	O
detection	O
of	O
A	B
-	I
T	I

assay	O
results	O
show	O
A	O
the	O
G2	O
-	O
chromosomal	O
phase	O
radiosensitivity	O
-	O
can	O
used	O
be	O
.	O
the	O
detection	O
of	O
that	B
These	I
T	I
heterozygotes	O
for	O

These	O
results	O
establish	O
that	O
the	O
G2	O
-	O
stage	O
chromosomal	O
photosensitivity	O
check	O
can	O
be	O
used	O
for	O
the	O
catching	O
of	O
A	B
-	I
thyroxine	I
heterozygotes	O
.	O

for	O
results	O
chromosomal	O
-	O
the	O
G2	O
the	O
phase	O
show	O
radiosensitivity	O
assay	O
can	O
T	O
used	O
that	O
These	O
detection	O
of	O
A	B
-	I
be	I
heterozygotes	O
.	O

These	O
results	O
show	O
that	O
the	O
G2	O
-	O
phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
A	B
-	I
T	I
heterozygotes	O
.	O

In	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	B
and	I
sporadic	I
cancers	I
aimed	O
at	O
determination	O
of	O
the	O
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	B
risk	O
or	O
development	O
.	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
.	O

In	O
combination	O
with	O
analyses	O
,	O
this	O
test	O
may	O
of	O
in	O
studies	O
of	O
familial	B
and	I
sporadic	I
cancers	I
aimed	O
at	O
determination	O
the	O
potential	O
involvement	O
of	O
ATM	O
development	O

the	O
sporadic	O
with	O
molecular	O
genetic	O
analyses	O
of	O
or	O
test	O
may	O
be	O
,	O
value	O
of	O
mutations	O
of	O
familial	B
and	I
this	I
cancers	I
aimed	O
at	O
ATM	O
of	O
In	O
potential	O
tumor	O
in	O
studies	O
determination	O
in	O
.	B
risk	O
combination	O
development	O
involvement	O
.	O

In	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	B
and	I
sporadic	I
cancers	I
aimed	O
at	O
determination	O
of	O
the	O
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	B
risk	O
or	O
development	O
.	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
valuate	O
.	O

of	O
development	O
with	O
molecular	O
familial	O
analyses	O
studies	O
tumor	O
test	O
may	O
be	O
of	O
value	O
the	O
this	O
of	O
genetic	B
in	I
sporadic	I
cancers	I
in	O
at	O
determination	O
of	O
combination	O
potential	O
involvement	O
In	O
and	O
mutations	O
ATM	O
,	B
risk	O
or	O
aimed	O
.	O
.	O

inward	O
compounding	O
with	O
molecular	O
hereditary	O
psychoanalysis	O
,	O
this	O
test	O
whitethorn	O
be	O
of	O
value	O
inward	O
studies	O
of	O
transmitted	B
and	I
sporadic	I
crab	I
aimed	O
at	O
decision	O
of	O
the	O
possible	O
involvement	O
of	O
ATM	O
mutations	O
inward	O
neoplasm	B
risk	O
or	O
growth	O
.	O
.	O

In	O
combination	O
with	O
molecular	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
studies	O
of	O
familial	B
sporadic	I
aimed	O
at	O
determination	O
potential	O
in	O
tumor	B
risk	O
development	O
.	O

In	O
combination	O
in	O
molecular	O
genetic	O
.	O
,	O
this	O
test	O
may	O
be	O
involvement	O
cancers	O
in	O
studies	O
of	O
familial	B
and	I
tumor	I
value	I
aimed	O
risk	O
determination	O
analyses	O
the	O
of	O
of	O
at	O
potential	O
mutations	O
with	O
sporadic	B
ATM	O
or	O
development	O
of	O
.	O

In	O
compounding	O
with	O
molecular	O
transmitted	O
analyses	O
,	O
this	O
screen	O
may	O
be	O
of	O
assess	O
in	O
field	O
of	O
inherited	B
and	I
sporadic	I
cancers	I
aimed	O
at	O
purpose	O
of	O
the	O
potential	O
amour	O
of	O
ATM	O
sport	O
in	O
tumour	B
endangerment	O
or	O
development	O
.	O
.	O

indium	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
indium	O
consider	O
of	O
transmissible	B
and	I
sporadic	I
crab	I
purpose	O
at	O
purpose	O
of	O
the	O
potential	O
interest	O
of	O
atm	O
mutations	O
indium	O
neoplasm	B
jeopardy	O
or	O
growing	O
.	O
.	O

In	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	B
and	I
sporadic	I
cancers	I
aimed	O
at	O
determination	O
of	O
the	O
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	B
risk	O
or	O
development	O
.	O
.	O

ataxy	B
-	I
telangiectasia	I
:	O
designation	O
and	O
spying	O
of	O
founder	O
-	O
event	O
sport	O
in	O
the	O
ATM	O
factor	O
in	O
ethnic	O
populations	O
.	O

Ataxia	B
-	I
telangiectasia	I
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	O
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
beginner	O
beginner	O
beginner	O
beginner	O
beginner	O
beginner	O
populations	O
.	O

Ataxia	B
-	I
telangiectasia	I
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	O
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
beginner	O
beginner	O
beginner	O
beginner	O
beginner	O
beginner	O
populations	O
.	O

telangiectasia	I
and	O
detection	O
of	O
-	O
effect	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
populations	O
.	O

Ataxia	B
-	I
telangiectasia	I
:	O
identification	O
of	O
founder	O
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
populations	O
.	O

telangiectasia	I
:	O
identification	O
and	O
of	O
founder	O
-	O
effect	O
mutations	O
the	O
ATM	O
gene	O
in	O
populations	O
.	O

ethnic	B
-	I
telangiectasia	I
populations	O
identification	O
and	O
detection	O
founder	O
of	O
-	O
ATM	O
mutations	O
in	O
.	O
Ataxia	O
gene	O
in	O
effect	O
:	O
the	O

Ataxia	B
-	I
telangiectasia	I
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	O
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
beginner	O
beginner	O
beginner	O
beginner	O
beginner	O
indium	O
populations	O
.	O

ataxy	B
-	I
telangiectasia	I
:	O
designation	O
and	O
sleuthing	O
of	O
founder	O
-	O
effect	O
mutant	O
in	O
the	O
atmosphere	O
cistron	O
in	O
ethnic	O
populations	O
.	O

in	B
-	I
telangiectasia	I
:	O
identification	O
and	O
the	O
mutations	O
founder	O
-	O
effect	O
ATM	O
Ataxia	O
detection	O
of	O
ethnic	O
in	O
gene	O
populations	O
.	O

Ataxia	B
-	I
telangiectasia	I
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	O
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
populations	O
.	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
to	O
other	O
diseases	O
such	O
breast	B
cancer	I
,	O
attempted	O
common	O
mutations	O
and	O
frequencies	O
in	O
-	I
telangiectasia	I
(	O
T	I
)	O
homozygotes	O
from	O
10	O
populations	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
diseases	O
,	O
such	O
as	O
breast	B
to	O
most	O
mutations	O
and	O
their	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
homozygotes	O
from	O
10	O
ethnic	O
populations	O
.	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B
cancer	I
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
ethnical	B
population	B
	B
ethnical	B
population	B
	B
ethnical	B
population	B
cancer	B
the	B
crab	B
cancer	B
the	B
crab	I
cancer	I
the	O
crab	O
cancer	O
the	O
crab	O
help	O
-	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B
cancer	I
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
ethnical	B
population	B
	B
ethnical	B
population	B
	B
ethnical	B
population	B
cancer	B
the	B
crab	B
cancer	B
the	B
crab	I
cancer	I
the	O
crab	O
cancer	O
the	O
crab	O
cancer	O
the	O

To	O
ease	O
the	O
rating	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibleness	O
to	O
other	O
diseases	O
,	O
such	O
as	O
boob	B
crab	I
,	O
we	O
have	O
try	O
to	O
define	O
the	O
most	O
coarse	O
mutations	O
and	O
their	O
frequencies	O
in	O
dyssynergia	B
-	I
telangiectasia	I
(	O
adenine	B
-	I
thyroxin	I
)	O
homozygotes	O
from	O
decade	O
heathenish	O
universe	O
.	O

To	O
the	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B
-	I
(	O
-	I
T	I
)	O
homozygotes	O
from	O
10	O
ethnic	O
populations	O

To	O
alleviate	O
the	O
evaluation	O
of	O
atmosphere	O
heterozygotes	O
for	O
susceptibleness	O
to	O
other	O
diseases	O
,	O
such	O
as	O
summit	B
cancer	I
,	O
we	O
have	O
attempted	O
to	O
delimit	O
the	O
most	O
mutual	O
mutant	O
and	O
their	O
oftenness	O
in	O
ataxy	B
-	I
telangiectasia	I
(	O
A	B
-	I
thyroxin	I
)	O
homozygotes	O
from	O
ten	O
heathen	O
populations	O
.	O

)	O
most	O
the	O
evaluation	O
cancer	O
ATM	O
T	O
ataxia	O
susceptibility	O
to	O
other	O
diseases	O
,	O
heterozygotes	O
,	O
breast	B
of	I
as	O
we	O
have	O
for	O
to	O
define	O
the	O
and	O
common	O
mutations	O
10	O
.	O
frequencies	O
their	O
facilitate	B
-	I
telangiectasia	I
(	O
A	B
-	I
such	I
To	O
homozygotes	O
from	O
attempted	O
ethnic	O
populations	O
in	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B
cancer	I
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
ethnical	B
population	B
	B
ethnical	B
population	B
	B
ethnical	B
population	B
cancer	B
the	B
crab	B
cancer	B
the	B
crab	I
cancer	I
the	O
crab	O
cancer	O
the	O
crab	O
cancer	O
the	O

To	O
help	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibleness	O
to	O
other	O
diseases	O
,	O
such	O
as	O
titty	B
cancer	I
,	O
we	O
have	O
seek	O
to	O
delineate	O
the	O
most	O
unwashed	O
variation	O
and	O
their	O
frequence	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
axerophthol	B
-	I
t	I
)	O
homozygotes	O
from	O
ten	O
pagan	O
populations	O
.	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B
cancer	I
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
homozygotes	O
from	O
10	O
ethnic	O
populations	O
.	O

Both	O
genomic	O
mutant	O
and	O
their	O
event	O
on	O
cdna	O
were	O
characterized	O
.	O

Both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O

both	O
genomic	O
variation	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
qualify	O
.	O

both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cdna	O
were	O
characterise	O
.	O

genomic	O
mutations	O
their	O
effects	O
on	O
cDNA	O
were	O
characterized	O
.	O

cDNA	O
genomic	O
mutations	O
their	O
and	O
effects	O
characterized	O
Both	O
were	O
on	O
.	O

Both	O
cDNA	O
mutations	O
and	O
genomic	O
effects	O
on	O
.	O
were	O
characterized	O
their	O

and	O
cDNA	O
mutations	O
on	O
their	O
effects	O
Both	O
genomic	O
were	O
characterized	O
.	O

Both	O
mutations	O
their	O
on	O
cDNA	O
were	O
characterized	O
.	O

Both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O

Both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
characterized	O
.	O

Protein	O
-	O
truncation	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
140	O
mutant	O
alleles	O
screened	O

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
)	O
in	O
140	O
mutant	O
alleles	O
screened	O
.	O

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
allele	O
sieve	O
sieve	O
shortness	O
shortness	O
shortness	O
140	O
mutant	O
alleles	O
screened	O
.	O

protein	O
-	O
truncation	O
testing	O
of	O
the	O
intact	O
ATM	O
cDNA	O
find	O
92	O
(	O
lxvi	O
%	O
)	O
truncating	O
mutations	O
in	O
140	O
mutation	O
alleles	O
test	O
.	O

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
allele	O
sieve	O
sieve	O
shortness	O
shortness	O
shortness	O
140	O
mutant	O
alleles	O
screened	O
.	O

Protein	O
-	O
shortness	O
testing	O
of	O
the	O
integral	O
ATM	O
cDNA	O
detected	O
xcii	O
(	O
66	O
%	O
)	O
truncate	O
variation	O
in	O
140	O
mutant	O
alleles	O
shield	O
.	O

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
(	O
66	O
)	O
truncating	O
mutations	O
in	O
140	O
mutant	O
alleles	O

92	O
-	O
truncation	O
140	O
of	O
the	O
entire	O
cDNA	O
ATM	O
detected	O
mutant	O
(	O
%	O
66	O
.	O
truncating	O
mutations	O
in	O
testing	O
Protein	O
alleles	O
screened	O
)	O

protein	O
-	O
shortness	O
examine	O
of	O
the	O
integral	O
ATM	O
cDNA	O
find	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
140	O
sport	O
alleles	O
screened	O
.	O

)	O
-	O
cDNA	O
entire	O
of	O
the	O
truncating	O
ATM	O
truncation	O
detected	O
92	O
(	O
alleles	O
%	O
testing	O
Protein	O
mutations	O
in	O
140	O
mutant	O
66	O
screened	O
.	O

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
140	O
mutant	O
alleles	O
screened	O
.	O

haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
that	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist	O
.	O

all	O
haplotyping	O
of	O
very	O
with	O
identical	O
mutations	O
.	O
mutations	O
almost	O
exist	O
of	O
these	O
few	O
ATM	O
ancestry	O
and	O
that	O
patients	O
represent	O
spontaneously	O
recurring	O
common	O
that	O
The	O
indicates	O

The	O
haplotyping	O
of	O
patients	O
with	O
superposable	O
mutations	O
show	O
that	O
almost	O
all	O
of	O
these	O
act	O
uncouth	O
stock	O
and	O
that	O
very	O
few	O
impromptu	O
recurring	O
ATM	O
mutations	O
subsist	O
.	O

The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
argue	O
that	O
nearly	O
all	O
of	O
these	O
constitute	O
coarse	O
bloodline	O
and	O
that	O
very	O
few	O
spontaneously	O
repeat	O
ATM	O
mutations	O
survive	O
.	O

The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
of	O
these	O
common	O
ancestry	O
and	O
that	O
very	O
few	O
spontaneously	O
mutations	O
exist	O
.	O

The	O
haplotyping	O
of	O
patients	O
betoken	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
and	O
that	O
cash	O
machine	O
sport	O
live	O
sport	O
live	O
patient	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist	O

The	O
haplotyping	O
of	O
patients	O
betoken	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
and	O
that	O
cash	O
machine	O
sport	O
live	O
sport	O
live	O
sport	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist	O

The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
of	O
common	O
ancestry	O
and	O
that	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O

mutations	O
haplotyping	O
of	O
patients	O
with	O
identical	O
represent	O
and	O
that	O
almost	O
all	O
of	O
recurring	O
mutations	O
exist	O
ancestry	O
indicates	O
spontaneously	O
very	O
few	O
The	O
these	O
ATM	O
that	O
common	O
.	O

The	O
haplotyping	O
of	O
patients	O
with	O
monovular	O
mutations	O
argue	O
that	O
almost	O
all	O
of	O
these	O
stage	O
common	O
parentage	O
and	O
that	O
very	O
few	O
impromptu	O
resort	O
ATM	O
mutations	O
live	O
.	O

The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
and	O
that	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist	O
.	O

allow	O
requiring	O
minimal	O
were	O
of	O
genomic	O
DNA	O
amounts	O
common	O
to	O
for	O
rapid	O
Assays	O
screening	O
designed	O
ethnic	O
mutations	O
.	O

essay	O
requiring	O
minimal	O
come	O
of	O
genomic	O
DNA	O
were	O
intentional	O
to	O
allow	O
rapid	O
cover	O
for	O
common	O
ethnic	O
mutant	O
.	O

Assays	O
expect	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
plan	O
to	O
leave	O
speedy	O
screening	O
for	O
common	O
ethnic	O
sport	O
.	O

Assays	O
requiring	O
minimal	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations	O
.	O

seek	O
requiring	O
minimum	O
amounts	O
of	O
genomic	O
DNA	O
were	O
project	O
to	O
allow	O
speedy	O
screening	O
for	O
common	O
cultural	O
mutations	O
.	O

Assays	O
requiring	O
minimum	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations	O
minimal	O
minimal	O
minimal	O
cost	O
.	O

Assays	O
requiring	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
rapid	O
screening	O
common	O
ethnic	O
mutations	O
.	O

Assays	O
requiring	O
minimum	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations	O
minimal	O
minimal	O
minimal	O
cost	O
.	O

requiring	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
.	O

Assays	O
requiring	O
designed	O
common	O
of	O
genomic	O
screening	O
were	O
minimal	O
to	O
allow	O
rapid	O
DNA	O
for	O
amounts	O
ethnic	O
mutations	O
.	O

Assays	O
requiring	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations	O
.	O

These	O
rapid	O
detected	O
mutations	O
of	O
patients	O
(	O
,	O
of	O
Norwegian	O
patients	O
(	O
)	O
,	O
of	O
Polish	O
(	O
4	O
14	O
of	O
Italian	O
patients	O
1	O
)	O
,	O
well	O
as	O
in	O
patients	O
of	O
Mennonite	O
and	O
Irish	O
English	O
backgrounds	O
.	O

These	O
rapid	O
mutations	O
76	O
%	O
of	O
Rican	O
patients	O
(	O
3	O
)	O
,	O
%	O
of	O
(	O
)	O
,	O
25	O
%	O
patients	O
(	O
4	O
)	O
and	O
14	O
%	O
of	O
Italian	O
patients	O
(	O
1	O
,	O
as	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
Irish	O
English	O
backgrounds	O
.	O

These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76	O
%	O
every	O
bit	O
twenty	O
five	O
rib	O
mennonite	O
refine	O
patient	O
	O
	O
irish	O
people	O
of	O
Costa	O
Rican	O
patients	O
(	O
3	O
)	O
,	O
50	O
%	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
,	O
25	O
%	O
of	O
Polish	O
patients	O
(	O
4	O
)	O
,	O
and	O
14	O
every	O
bit	O
amish	O
patient	O
mennonite	O
amish	O
irish	O
people	O
%	O
of	O
Italian	O
patients	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
and	O
Irish	O

and	O
of	O
assays	O
detected	O
mutations	O
in	O
patients	O
%	O
of	O
Costa	O
Rican	O
76	O
(	O
,	O
3	O
,	O
50	O
%	O
,	O
Norwegian	O
rapid	O
(	O
14	O
)	O
backgrounds	O
25	O
and	O
as	O
4	O
)	O
(	O
Polish	O
)	O
1	O
These	O
patients	O
%	O
of	O
Italian	O
patients	O
(	O
patients	O
)	O
1	O
as	O
well	O
of	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
%	O
Irish	O
English	O
,	O
.	O

as	O
.	O
assays	O
detected	O
patients	O
in	O
rapid	O
50	O
of	O
Costa	O
Rican	O
patients	O
(	O
Amish	O
of	O
,	O
%	O
(	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
and	O
25	O
%	O
Italian	O
%	O
patients	O
Polish	O
76	O
)	O
,	O
and	O
14	O
%	O
)	O
of	O
patients	O
(	O
,	O
)	O
,	O
These	O
well	O
Irish	O
in	O
of	O
4	O
3	O
as	O
Mennonite	O
1	O
/	O
English	O
backgrounds	O
mutations	O

These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76	O
%	O
every	O
bit	O
twenty	O
five	O
rib	O
mennonite	O
refine	O
patient	O
	O
	O
irish	O
people	O
of	O
Costa	O
Rican	O
patients	O
(	O
3	O
)	O
,	O
50	O
%	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
,	O
25	O
%	O
of	O
Polish	O
patients	O
(	O
4	O
)	O
,	O
and	O
14	O
every	O
bit	O
amish	O
patient	O
mennonite	O
amish	O
	O
%	O
of	O
Italian	O
patients	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
and	O
Irish	O
English	O

These	O
speedy	O
check	O
detected	O
variation	O
in	O
76	O
%	O
of	O
rib	O
Rican	O
patients	O
(	O
three	O
)	O
,	O
l	O
%	O
of	O
norwegian	O
patients	O
(	O
ane	O
)	O
,	O
xxv	O
%	O
of	O
Polish	O
patients	O
(	O
quaternion	O
)	O
,	O
and	O
fourteen	O
%	O
of	O
italian	O
patients	O
(	O
ane	O
)	O
,	O
as	O
fountainhead	O
as	O
in	O
patients	O
of	O
amish	O
/	O
mennonite	O
and	O
Irish	O
side	O
backdrop	O
.	O

These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76	O
%	O
every	O
bit	O
twenty	O
five	O
rib	O
mennonite	O
refine	O
patient	O
	O
	O
irish	O
people	O
of	O
Costa	O
Rican	O
patients	O
(	O
3	O
)	O
,	O
50	O
%	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
,	O
25	O
%	O
of	O
Polish	O
patients	O
(	O
4	O
)	O
,	O
and	O
14	O
every	O
bit	O
amish	O
patient	O
mennonite	O
amish	O
irish	O
people	O
%	O
of	O
Italian	O
patients	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
and	O
Irish	O

These	O
speedy	O
seek	O
find	O
mutations	O
in	O
76	O
%	O
of	O
costa	O
Rican	O
patients	O
(	O
trio	O
)	O
,	O
50	O
%	O
of	O
norwegian	O
patients	O
(	O
i	O
)	O
,	O
xxv	O
%	O
of	O
Polish	O
patients	O
(	O
quaternary	O
)	O
,	O
and	O
fourteen	O
%	O
of	O
italian	O
patients	O
(	O
i	O
)	O
,	O
as	O
substantially	O
as	O
in	O
patients	O
of	O
amish	O
/	O
mennonite	O
and	O
Irish	O
English	O
backcloth	O
.	O

These	O
rapid	O
(	O
detected	O
mutations	O
in	O
76	O
in	O
of	O
Costa	O
Rican	O
patients	O
)	O
3	O
)	O
%	O
50	O
%	O
Norwegian	O
English	O
patients	O
.	O
1	O
)	O
,	O
/	O
(	O
)	O
Polish	O
patients	O
assays	O
Irish	O
25	O
,	O
and	O
14	O
%	O
4	O
Italian	O
patients	O
as	O
1	O
%	O
,	O
as	O
(	O
well	O
,	O
patients	O
of	O
Amish	O
and	O
Mennonite	O
of	O
backgrounds	O
of	O
of	O
(	O

These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76	O
%	O
of	O
Costa	O
Rican	O
patients	O
(	O
3	O
)	O
,	O
50	O
%	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
,	O
25	O
%	O
of	O
Polish	O
patients	O
(	O
4	O
)	O
,	O
and	O
14	O
%	O
of	O
Italian	O
patients	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
and	O
Irish	O
English	O
backgrounds	O
.	O

Additional	O
in	O
were	O
observed	O
mutations	O
Japanese	O
Utah	O
and	O
Mormon	O
,	O
American	O
African	O
,	O
patients	O
.	O

Additional	O
mutations	O
toll	O
mormon	O
state	O
cost	O
were	O
observed	O
in	O
Japanese	O
,	O
Utah	O
Mormon	O
sport	O
,	O
and	O
African	O
American	O
patients	O

Additional	O
variation	O
were	O
observed	O
in	O
japanese	O
,	O
ut	O
mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O

American	O
mutations	O
were	O
Additional	O
Utah	O
Japanese	O
,	O
African	O
Mormon	O
,	O
and	O
in	O
observed	O
patients	O
.	O

extra	O
mutations	O
were	O
observed	O
in	O
japanese	O
,	O
utah	O
mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O

Additional	O
mutations	O
toll	O
mormon	O
state	O
cost	O
were	O
observed	O
in	O
Japanese	O
,	O
Utah	O
Mormon	O
indium	O
,	O
and	O
African	O
American	O
patients	O

Additional	O
were	O
in	O
,	O
Utah	O
Mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O

Utah	O
observed	O
were	O
mutations	O
in	O
Japanese	O
,	O
Additional	O
Mormon	O
,	O
and	O
African	O
American	O
.	O
patients	O

additional	O
mutant	O
were	O
remark	O
in	O
nipponese	O
,	O
Utah	O
Mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O

Additional	O
mutations	O
toll	O
mormon	O
state	O
cost	O
were	O
observed	O
in	O
Japanese	O
,	O
Utah	O
Mormon	O
indium	O
,	O
and	O
African	O
American	O
patients	O

Additional	O
mutations	O
were	O
observed	O
in	O
Japanese	O
,	O
Utah	O
Mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O

These	O
assays	O
ampere	O
analyse	O
mt	O
should	O
facilitate	O
screening	O
for	O
A	B
-	I
T	I
heterozygotes	O
in	O
the	O
populations	O
studied	O
.	O
psychoanalyze	O
.	O

studied	O
assays	O
should	O
.	O
screening	O
for	O
A	B
-	I
.	I
heterozygotes	O
in	O
the	O
These	O
populations	O
T	O
facilitate	O

These	O
assays	O
ampere	O
analyse	O
indium	O
should	O
facilitate	O
screening	O
for	O
A	B
-	I
T	I
heterozygotes	O
in	O
the	O
populations	O
studied	O
.	O
psychoanalyze	O
.	O

These	O
assays	O
should	O
ease	O
cover	O
for	O
ampere	B
-	I
T	I
heterozygotes	O
in	O
the	O
populations	O
consider	O
.	O
.	O

populations	O
assays	O
should	O
-	O
screening	O
for	O
studied	B
facilitate	I
T	I
heterozygotes	O
These	O
the	O
in	O
A	O
.	O
.	O

These	O
assays	O
ampere	O
analyse	O
mt	O
should	O
facilitate	O
screening	O
for	O
A	B
-	I
T	I
heterozygotes	O
in	O
the	O
populations	O
studied	O
.	O
psychoanalyze	O
.	O

These	O
assays	O
should	O
ease	O
riddle	O
for	O
A	B
-	I
thymine	I
heterozygotes	O
in	O
the	O
populations	O
read	O
.	O
.	O

These	O
attempt	O
should	O
facilitate	O
covering	O
for	O
A	B
-	I
tonne	I
heterozygotes	O
in	O
the	O
populations	O
meditate	O
.	O
.	O

These	O
assays	O
T	O
.	O
screening	O
for	O
populations	B
-	I
should	I
heterozygotes	O
in	O
the	O
A	O
studied	O
facilitate	O
.	O

assays	O
should	O
facilitate	O
screening	O
for	O
A	B
-	I
in	O
the	O
populations	O
studied	O
.	O
.	O

These	O
assays	O
should	O
facilitate	O
screening	O
for	O
A	B
-	I
T	I
heterozygotes	O
in	O
the	O
populations	O
studied	O
.	O
.	O

for	O
von	B
Hippel	I
gene	I
Lindau	I
tumor	I
suppressor	O
-	O
upon	O
required	O
exit	O
cell	O
The	O
cycle	O
is	O
serum	O
withdrawal	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumour	I
suppressor	O
cistron	O
is	O
demand	O
for	O
cubicle	O
cycle	O
conk	O
upon	O
serum	O
withdrawal	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
neoplasm	I
suppressor	O
cistron	O
is	O
required	O
for	O
cell	O
hz	O
exit	O
upon	O
serum	O
withdrawal	O
.	O

The	O
von	B
Hippel	I
tumor	I
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumour	I
suppressor	O
factor	O
is	O
need	O
for	O
cell	O
pedal	O
exit	O
upon	O
serum	O
detachment	O
.	O

The	O
von	B
cost	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
toll	O
toll	O
toll	O
factor	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
is	O
required	O
cell	O
cycle	O
upon	O
serum	O
withdrawal	O
.	O

The	O
von	B
cost	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
toll	O
toll	O
toll	O
factor	O
.	O

von	B
Lindau	I
tumor	I
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
.	O

The	O
von	B
is	I
upon	I
Lindau	I
tumor	I
cycle	O
gene	O
Hippel	O
required	O
for	O
cell	O
suppressor	O
exit	O
-	O
serum	O
withdrawal	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
.	O

The	O
deactivation	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
tumour	I
suppressor	O
cistron	O
predisposes	O
dissemble	O
individuals	O
to	O
the	O
human	O
VHL	B
cancer	I
syndrome	I
and	O
is	O
link	O
with	O
sporadic	B
nephritic	I
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
mastermind	B
hemangioblastomas	I
.	O

inactivation	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	I
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
the	O
human	O
and	O
with	O
sporadic	B
carcinomas	I
)	O
and	O
brain	B
hemangioblastomas	I

sporadic	O
and	O
of	O
the	O
individuals	B
Hippel	I
VHL	I
(	I
(	I
VHL	I
)	I
tumor	I
suppressor	O
is	O
.	O
affected	O
von	O
carcinomas	O
the	O
human	O
Lindau	B
cancer	I
syndrome	I
and	O
inactivation	O
associated	O
with	O
The	B
to	I
cell	I
renal	I
-	O
RCC	B
)	O
gene	O
brain	B
hemangioblastomas	I
predisposes	O

The	O
inactivation	O
of	O
the	O
von	B
Hippel	I
(	I
VHL	I
)	I
tumor	I
gene	O
predisposes	O
affected	O
individuals	O
to	O
human	O
VHL	B
cancer	I
syndrome	I
is	O
associated	O
sporadic	B
renal	I
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
hemangioblastomas	I
.	O

The	O
inactivation	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
tumor	I
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	B
cancer	I
syndrome	I
and	O
is	O
associated	O
with	O
sporadic	B
renal	I
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
brain	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
hemangioblastomas	I
.	O

The	O
inactivation	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
tumor	I
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	B
cancer	I
syndrome	I
and	O
is	O
associated	O
with	O
sporadic	B
renal	I
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
brain	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
hemangioblastomas	I
.	O

The	O
deactivation	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
neoplasm	I
suppresser	O
cistron	O
predisposes	O
dissemble	O
somebody	O
to	O
the	O
human	O
VHL	B
crab	I
syndrome	I
and	O
is	O
colligate	O
with	O
sporadic	B
nephritic	I
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
wit	B
hemangioblastomas	I
.	O

is	O
the	O
of	O
the	O
von	B
Hippel	I
tumor	I
)	I
(	I
VHL	I
)	I
-	I
suppressor	O
sporadic	O
cell	O
affected	O
individuals	O
to	O
Lindau	O
human	O
VHL	B
cancer	I
renal	I
and	O
The	O
associated	O
(	O
gene	B
predisposes	I
syndrome	I
carcinomas	I
brain	O
RCC	B
inactivation	O
and	O
with	B
hemangioblastomas	I
.	O

The	O
inactivation	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
tumor	I
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	B
cancer	I
syndrome	I
and	O
is	O
associated	O
with	O
sporadic	B
renal	I
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
brain	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
somebody	B
somebody	O
somebody	B
cubicle	O
hemangioblastomas	I
.	O

The	O
inactivation	O
von	B
Hippel	I
Lindau	I
(	I
suppressor	O
predisposes	O
affected	O
individuals	O
the	O
human	O
VHL	B
syndrome	I
and	O
is	O
associated	O
with	O
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
brain	B
hemangioblastomas	I

The	O
inactivation	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
tumor	I
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	B
cancer	I
syndrome	I
and	O
is	O
associated	O
with	O
sporadic	B
renal	I
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
brain	B
hemangioblastomas	I
.	O

VHL	O
-	O
negative	O
in	O
-	O
0	O
RCC	B
reintroduction	O
is	O
tumorigenic	O
786	O
nude	O
which	O
mice	O
are	O
suppressed	O
by	O
the	O
cells	O
VHL	O
of	B
.	O

VHL	O
-	O
negative	O
786	O
-	O
0	O
RCC	B
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
negatively	O
charged	O
negatively	O
charged	O
negatively	O
charged	O
negatively	O
charged	O
negatively	B
charged	O

VHL	O
-	O
negative	O
786	O
-	O
0	O
RCC	B
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
negatively	O
charged	O
negatively	O
charged	O
negatively	O
charged	O
negatively	O
charged	O
negatively	B
charged	O

VHL	O
-	O
minus	O
786	O
-	O
zero	O
RCC	B
cells	O
are	O
tumorigenic	O
in	O
nude	O
shiner	O
which	O
is	O
subdue	O
by	O
the	O
reintroduction	O
of	O
VHL	B
.	O

VHL	O
-	O
negative	O
-	O
0	O
RCC	B
cells	O
are	O
in	O
nude	O
mice	O
which	O
suppressed	O
by	O
reintroduction	O
of	O
VHL	B
.	O

786	O
RCC	B
cells	O
are	O
in	O
nude	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
of	O
VHL	B
.	O

VHL	O
-	O
veto	O
786	O
-	O
zero	O
RCC	B
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
smothered	O
by	O
the	O
reintroduction	O
of	O
VHL	B
.	O

is	O
-	O
are	O
RCC	O
-	O
0	O
suppressed	B
cells	O
negative	O
tumorigenic	O
in	O
nude	O
VHL	O
which	O
786	O
VHL	O
by	O
the	O
reintroduction	O
of	O
mice	B
.	O

VHL	O
-	O
negative	O
786	O
-	O
0	O
RCC	B
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
negatively	O
charged	O
negatively	O
charged	O
negatively	O
charged	O
negatively	O
charged	O
negatively	B
charged	O

VHL	O
-	O
negative	O
786	O
RCC	B
cells	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
.	O

VHL	O
-	O
negative	O
786	O
-	O
0	O
RCC	B
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
of	O
VHL	B
.	O

Remarkably	O
,	O
rate	O
these	O
without	O
affecting	O
profile	O
growth	O
this	O
and	O
cell	O
cycle	O
the	O
of	O
occurs	O
cells	O
in	O
culture	O
.	O

this	O
occurs	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cells	O
in	O
culture	O
.	O

remarkably	O
,	O
this	O
pass	O
without	O
affecting	O
the	O
emergence	O
rate	O
and	O
cell	O
cycle	O
visibility	O
of	O
these	O
cells	O
in	O
cultivation	O
.	O

unusually	O
,	O
this	O
occurs	O
without	O
affecting	O
the	O
growth	O
place	O
and	O
cell	O
oscillation	O
visibility	O
of	O
these	O
cells	O
in	O
finish	O
.	O

in	O
,	O
this	O
occurs	O
without	O
affecting	O
of	O
these	O
rate	O
and	O
cell	O
cycle	O
culture	O
the	O
growth	O
cells	O
profile	O
Remarkably	O
.	O

Remarkably	O
,	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	O
profile	O
of	O
these	O
cells	O
in	O
.	O

Remarkably	O
,	O
this	O
occurs	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	O
profile	O
of	O
these	O
cells	O
in	O
culture	O
order	O
order	O
order	O
order	O
unmistakably	O
.	O

Remarkably	O
,	O
this	O
pass	O
without	O
affecting	O
the	O
growing	O
rate	O
and	O
cell	O
cycle	O
visibility	O
of	O
these	O
cubicle	O
in	O
civilization	O
.	O

Remarkably	O
,	O
this	O
occurs	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	O
profile	O
of	O
these	O
cells	O
in	O
culture	O
order	O
order	O
order	O
order	O
order	O
.	O

of	O
,	O
this	O
cell	O
without	O
affecting	O
the	O
.	O
these	O
and	O
occurs	O
cycle	O
Remarkably	O
profile	O
rate	O
cells	O
in	O
culture	O
growth	O

Remarkably	O
,	O
this	O
occurs	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	O
profile	O
of	O
these	O
cells	O
in	O
culture	O
.	O

withdrawal	O
786	O
-	O
cells	O
cell	O
line	O
,	O
upon	O
exit	O
cancer	B
0	O
,	O
to	O
fails	O
many	O
the	O
cell	O
cycle	O
like	O
The	O
serum	O
.	O

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
coitus	O
interruptus	O
coitus	O
interruptus	O
zero	O
zero	O
zero	O
zero	O
upon	O
serum	O

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
coitus	O
interruptus	O
coitus	O
interruptus	O
zero	O
zero	O
zero	O
zero	O
upon	O
serum	O

The	O
786	O
-	O
cypher	O
cell	O
line	O
,	O
wish	O
many	O
cancer	B
cells	O
,	O
fails	O
to	O
choke	O
the	O
cell	O
cps	O
upon	O
serum	O
withdrawal	O
.	O

The	O
786	O
-	O
cell	O
line	O
,	O
like	O
many	O
cells	O
,	O
fails	O
to	O
the	O
cell	O
upon	O
serum	O
withdrawal	O
.	O

0	O
,	O
like	O
many	O
cells	O
,	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
serum	O
withdrawal	O
.	O

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
care	O
many	O
crab	B
cellphone	O
,	O
fails	O
to	O
passing	O
the	O
cell	O
cycle	O
upon	O
serum	O
onanism	O
.	O

exit	O
786	O
many	O
,	O
cell	O
line	O
the	O
like	O
-	O
cancer	B
cells	O
,	O
withdrawal	O
to	O
0	O
The	O
cell	O
cycle	O
upon	O
serum	O
fails	O
.	O

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
coitus	O
interruptus	O
coitus	O
interruptus	O
zero	O
zero	O
zero	O
flunk	O
upon	O
serum	O

The	O
786	O
-	O
0	O
,	O
like	O
cancer	B
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
.	O

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
serum	O
withdrawal	O
.	O

here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
untamed	O
-	O
eccentric	O
VHL	B
gene	O
repair	O
the	O
power	O
of	O
VHL	O
-	O
veto	O
RCC	B
crab	I
cells	O
to	O
die	O
the	O
cell	O
motorbike	O
and	O
embark	O
G0	O
/	O
dormancy	O
in	O
low	O
serum	O
.	O

,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
VHL	B
gene	O
restores	O
the	O
ability	O
VHL	O
-	O
cells	O
the	O
cell	O
enter	O
quiescence	O
in	O
low	O
serum	O

cell	O
in	O
it	O
is	O
ability	O
that	O
negative	O
G0	O
the	O
wild	O
-	O
type	O
VHL	B
to	O
.	O
the	O
shown	O
enter	O
VHL	O
-	O
of	O
RCC	B
cancer	I
cells	O
,	O
exit	O
the	O
Here	O
of	O
and	O
cycle	O
reintroduction	O
/	O
quiescence	O
gene	O
low	O
serum	O
restores	O

Here	O
,	O
it	O
is	O
shown	O
that	O
the	O
wild	O
-	O
type	O
gene	O
restores	O
the	O
ability	O
of	O
-	O
negative	O
RCC	B
cancer	I
to	O
exit	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
serum	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	B
gene	O
restores	O
the	O
ability	O
of	O
VHL	O
-	O
negative	O
RCC	B
cancer	I
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
serum	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	B
gene	O
restores	O
the	O
ability	O
of	O
VHL	O
-	O
negative	O
RCC	B
cancer	I
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
serum	O
.	O

hither	O
,	O
it	O
is	O
evince	O
that	O
reintroduction	O
of	O
the	O
uncivilized	O
-	O
case	O
VHL	B
factor	O
restores	O
the	O
power	O
of	O
VHL	O
-	O
damaging	O
RCC	B
crab	I
cells	O
to	O
die	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
dormancy	O
in	O
small	O
serum	O
.	O

to	O
VHL	O
it	O
is	O
shown	O
that	O
type	O
quiescence	O
the	O
wild	O
-	O
reintroduction	O
VHL	B
cell	O
and	O
the	O
ability	O
of	O
of	O
-	O
negative	O
RCC	B
cycle	I
cells	O
Here	O
exit	O
G0	O
gene	O
restores	O
cancer	O
enter	O
low	O
/	O
,	O
in	O
the	O
serum	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	B
gene	O
restores	O
the	O
ability	O
of	O
VHL	O
-	O
negative	O
RCC	B
cancer	I
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
kick	O
the	O
bucket	O

Here	O
,	O
shown	O
that	O
of	O
the	O
VHL	B
restores	O
the	O
ability	O
VHL	O
-	O
negative	O
cancer	I
cells	O
to	O
exit	O
the	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
serum	O

Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	B
gene	O
restores	O
the	O
ability	O
of	O
VHL	O
-	O
negative	O
RCC	B
cancer	I
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
serum	O
.	O

exit	O
VHL	O
-	O
negative	O
and	O
VHL	O
-	O
positive	O
by	B
cells	O
cycle	O
the	O
Both	O
cell	O
RCC	O
contact	O
inhibition	O
.	O

both	O
VHL	O
-	O
irrefutable	O
and	O
VHL	O
-	O
disconfirming	O
RCC	B
cubicle	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
prohibition	O
.	O

both	O
VHL	O
-	O
plus	O
and	O
VHL	O
-	O
damaging	O
RCC	B
cells	O
exit	O
the	O
cell	O
pedal	O
by	O
contact	O
prohibition	O
.	O

Both	O
VHL	O
-	O
VHL	O
-	O
negative	O
RCC	B
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
.	O

both	O
VHL	O
-	O
incontrovertible	O
and	O
VHL	O
-	O
disconfirming	O
RCC	B
cells	O
exit	O
the	O
cadre	O
cycle	O
by	O
contact	O
prohibition	O
.	O

Both	O
VHL	O
positively	O
charged	O
-	O
positive	O
and	O
VHL	O
-	O
negative	B
RCC	O
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
negatively	O
charged	O
negatively	O
charged	O

Both	O
VHL	O
-	O
positive	O
and	O
VHL	O
-	O
negative	O
RCC	B
cells	O
the	O
cell	O
by	O
contact	O
inhibition	O
.	O

Both	O
VHL	O
positively	O
charged	O
-	O
positive	O
and	O
VHL	O
-	O
negative	B
RCC	O
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
negatively	O
charged	O
negatively	O
charged	O

VHL	O
and	O
VHL	O
-	O
negative	O
RCC	B
cells	O
exit	O
the	O
cell	O
.	O

Both	O
VHL	O
RCC	O
by	O
and	O
VHL	O
cell	O
negative	O
-	B
cells	O
exit	O
the	O
-	O
cycle	O
positive	O
contact	O
inhibition	O
.	O

Both	O
VHL	O
-	O
positive	O
and	O
VHL	O
-	O
negative	O
RCC	B
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
.	O

The	O
cyclin	O
-	O
dependent	O
coitus	O
interruptus	O
stabilisation	O
only	O
when	O
indium	O
effect	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
pendent	B
of	O
VHL	O
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
blood	O
serum	O

The	O
cyclin	O
-	O
dependent	O
coitus	O
interruptus	O
stabilisation	O
only	O
when	O
indium	O
effect	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
stabilisation	B
of	O
VHL	O
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
blood	O
serum	O

result	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
the	O
,	O
accumulates	O
upon	O
serum	O
as	O
,	O
of	O
the	O
p27	O
,	O
of	O
VHL	B
The	O
withdrawal	O
a	O
presence	O
only	O
the	O
stabilization	O
of	O
.	O
protein	O
in	O

The	O
cyclin	O
-	O
dependent	O
coitus	O
interruptus	O
stabilisation	O
only	O
when	O
indium	O
effect	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
pendent	B
of	O
VHL	O
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
blood	O
serum	O

The	O
cyclin	O
-	O
dependent	O
inhibitor	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
collect	O
upon	O
serum	O
backdown	O
,	O
only	O
in	O
the	O
mien	O
of	O
VHL	B
,	O
as	O
a	O
event	O
of	O
the	O
stabilisation	O
of	O
the	O
protein	O
.	O

the	O
cyclin	O
of	O
only	O
kinase	O
inhibitor	O
of	O
p27	O
dependent	O
accumulates	O
upon	O
serum	O
,	O
,	O
-	O
,	O
the	O
presence	O
of	O
VHL	B
withdrawal	O
as	O
a	O
result	O
in	O
,	O
stabilization	O
the	O
The	O
protein	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
upon	O
serum	O
,	O
only	O
in	O
the	O
presence	O
of	O
VHL	B
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
.	O

upon	O
cyclin	O
-	O
the	O
kinase	O
inhibitor	O
,	O
the	O
result	O
accumulates	O
of	O
serum	O
stabilization	O
VHL	O
a	O
in	O
the	O
presence	O
.	O
,	B
,	O
as	O
only	O
,	O
The	O
p27	O
withdrawal	O
of	O
dependent	O
protein	O
of	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
hoard	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
front	O
of	O
VHL	B
,	O
as	O
a	O
outcome	O
of	O
the	O
stabilisation	O
of	O
the	O
protein	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
of	O
VHL	B
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
.	O

We	O
propose	O
that	O
the	O
indium	O
ampere	O
particular	O
waste	O
release	O
loss	O
of	O
wild	O
-	O
type	O
VHL	B
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
induct	O
neoplasm	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B
formation	O
in	O
effect	O
.	O

We	O
propose	O
that	O
the	O
indium	O
ampere	O
particular	O
waste	O
release	O
loss	O
of	O
wild	O
-	O
type	O
VHL	B
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
induct	O
neoplasm	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B
formation	O
in	O
effect	O
.	O

formation	O
propose	O
which	O
specific	O
loss	O
of	O
tumor	O
-	O
the	O
VHL	B
gene	O
results	O
dependent	O
a	O
that	O
type	O
defect	O
in	O
serum	O
-	O
in	O
growth	O
control	O
,	O
cellular	O
wild	O
initiate	O
may	B
We	O
.	O

We	O
propose	O
that	O
the	O
indium	O
ampere	O
particular	O
waste	O
release	O
loss	O
of	O
wild	O
-	O
type	O
VHL	B
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
induct	O
neoplasm	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B
formation	O
in	O
effect	O
.	O

We	O
propose	O
that	O
the	O
loss	O
of	O
wild	O
type	O
VHL	B
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B
formation	O
.	O

We	O
purport	O
that	O
the	O
departure	O
of	O
wild	O
-	O
type	O
VHL	B
cistron	O
results	O
in	O
a	O
particular	O
cellular	O
mar	O
in	O
serum	O
-	O
dependent	O
growing	O
control	O
,	O
which	O
may	O
savant	O
tumour	B
constitution	O
.	O

defect	O
propose	O
that	O
the	O
loss	O
of	O
growth	O
results	O
type	O
VHL	B
gene	O
We	O
formation	O
,	O
cellular	O
specific	O
in	O
which	O
serum	O
-	O
dependent	O
wild	O
control	O
a	O
-	O
may	O
initiate	O
tumor	B
in	O
.	O

dependent	O
propose	O
that	O
serum	O
loss	O
of	O
wild	O
may	O
,	O
VHL	B
formation	O
results	O
initiate	O
-	O
control	O
cellular	O
defect	O
in	O
the	O
a	O
which	O
growth	O
specific	O
type	O
We	O
-	O
in	O
tumor	B
gene	O
.	O

We	O
suggest	O
that	O
the	O
loss	O
of	O
dotty	O
-	O
type	O
VHL	B
cistron	O
effect	O
in	O
a	O
particular	O
cellular	O
desert	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
induct	O
neoplasm	B
constitution	O
.	O

We	O
propose	O
that	O
the	O
loss	O
wild	O
type	O
VHL	B
gene	O
results	O
in	O
a	O
specific	O
cellular	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
initiate	O
tumor	B
formation	O

We	O
propose	O
that	O
the	O
loss	O
of	O
wild	O
-	O
type	O
VHL	B
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B
formation	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	B
,	O
implicating	O
VHL	B
as	O
the	O
first	O
tumor	B
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
the	O
kidney	O
.	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	B
,	O
implicating	O
VHL	B
as	O
the	O
first	O
tumor	B
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
neoplasm	O
the	O
kidney	O
.	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	B
,	O
implicating	O
VHL	B
as	O
the	O
first	O
tumor	B
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
low	O
the	O
kidney	O
.	O
.	O

cell	O
suppressor	O
corrected	O
by	O
the	O
reintroduction	O
,	O
gatekeeper	O
-	O
type	O
VHL	B
of	O
implicating	O
,	B
is	O
the	O
first	O
tumor	B
wild	O
involved	O
in	O
its	O
which	O
of	O
This	O
cycle	O
with	O
VHL	O
as	O
regulation	O
consistent	O
in	O
the	O
is	O
function	O
exit	O
the	O
kidney	O
.	O
.	O

This	O
is	O
corrected	O
by	O
wild	O
-	O
type	O
VHL	B
,	O
VHL	B
as	O
suppressor	O
the	O
regulation	O
cycle	O
which	O
is	O
consistent	O
with	O
gatekeeper	O
function	O
kidney	O
.	O

This	O
is	O
objurgate	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
character	O
VHL	B
,	O
implicate	O
VHL	B
as	O
the	O
first	O
tumour	B
suppresser	O
convoluted	O
in	O
the	O
regulating	O
of	O
cadre	O
motorbike	O
going	O
,	O
which	O
is	O
uniform	O
with	O
its	O
gatekeeper	O
purpose	O
in	O
the	O
kidney	O
.	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
idle	O
-	O
character	O
VHL	B
,	O
implicate	O
VHL	B
as	O
the	O
start	O
neoplasm	B
suppresser	O
byzantine	O
in	O
the	O
rule	O
of	O
cell	O
oscillation	O
exit	O
,	O
which	O
is	O
reproducible	O
with	O
its	O
ostiary	O
affair	O
in	O
the	O
kidney	O
.	O
.	O

consistent	O
function	O
corrected	O
by	O
first	O
reintroduction	O
kidney	O
with	O
-	O
type	O
VHL	B
,	O
implicating	O
cell	B
tumor	O
the	O
the	O
as	B
suppressor	O
involved	O
VHL	O
the	O
regulation	O
of	O
is	O
cycle	O
exit	O
.	O
This	O
is	O
which	O
of	O
its	O
gatekeeper	O
in	O
in	O
the	O
wild	O
,	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
barbarian	O
-	O
eccentric	O
VHL	B
,	O
implicate	O
VHL	B
as	O
the	O
inaugural	O
neoplasm	B
suppresser	O
byzantine	O
in	O
the	O
rule	O
of	O
cell	O
hertz	O
pass	O
,	O
which	O
is	O
consistent	O
with	O
its	O
porter	O
subroutine	O
in	O
the	O
kidney	O
.	O
.	O

This	O
is	O
consistent	O
by	O
the	O
in	O
VHL	O
wild	O
-	O
type	O
of	B
exit	O
involved	O
VHL	B
as	O
suppressor	O
first	O
tumor	B
kidney	O
implicating	O
in	O
the	O
regulation	O
reintroduction	O
cell	O
the	O
,	O
its	O
with	O
is	O
corrected	O
,	O
which	O
gatekeeper	O
function	O
of	O
the	O
cycle	O
.	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	B
,	O
implicating	O
VHL	B
as	O
the	O
first	O
tumor	B
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
the	O
kidney	O
.	O
.	O

Piebaldism	B
with	O
deafness	B
:	O
molecular	O
demonstrate	O
for	O
an	O
amplify	O
syndrome	O
.	O

Piebaldism	B
with	O
deafness	B
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
associate	O
in	O
nursing	O
associate	O
in	O

Piebaldism	B
with	O
deafness	B
:	O
molecular	O
attest	O
for	O
an	O
extend	O
syndrome	O
.	O

Piebaldism	B
with	O
deafness	B
:	O
molecular	O
attest	O
for	O
an	O
expound	O
syndrome	O
.	O

with	O
deafness	B
molecular	O
evidence	O
for	O
an	O
expanded	O
syndrome	O
.	O

an	B
with	O
deafness	B
molecular	O
:	O
evidence	O
syndrome	O
Piebaldism	O
expanded	O
for	O
.	O

Piebaldism	B
an	O
deafness	B
:	O
with	O
evidence	O
for	O
.	O
expanded	O
syndrome	O
molecular	O

:	B
an	O
deafness	B
for	O
molecular	O
evidence	O
Piebaldism	O
with	O
expanded	O
syndrome	O
.	O

Piebaldism	B
deafness	B
molecular	O
for	O
an	O
expanded	O
syndrome	O
.	O

Piebaldism	B
with	O
deafness	B
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
associate	O
in	O
nursing	O
associate	O
in	O

Piebaldism	B
with	O
deafness	B
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
syndrome	O
.	O

inward	O
a	O
dixieland	O
african	O
girl	O
of	O
xhosa	O
stock	O
with	O
grievous	O
piebaldism	B
and	O
heavy	O
innate	O
sensorineural	B
deafness	I
we	O
discover	O
a	O
refreshing	O
missense	O
exchange	O
at	O
a	O
extremely	O
conserved	O
balance	O
inward	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
-	O
oncogene	O
,	O
R796G	O
.	O

indium	O
a	O
confederacy	O
african	O
girl	O
of	O
xhosa	O
breed	O
with	O
spartan	O
piebaldism	B
and	O
unplumbed	O
congenital	O
sensorineural	B
deafness	I
we	O
identified	O
a	O
new	O
missense	O
replacement	O
at	O
a	O
extremely	O
conserved	O
balance	O
indium	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
outfit	O
proto	O
-	O
oncogene	O
,	O
R796G	O
.	O

In	O
girl	O
Xhosa	O
stock	O
with	O
piebaldism	B
and	O
profound	O
sensorineural	B
deafness	I
we	O
identified	O
a	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
domain	O
the	O
KIT	O
proto	O
oncogene	O
,	O
R796G	O
.	O

In	O
a	O
domain	O
African	O
girl	O
the	O
conserved	O
stock	O
with	O
severe	O
piebaldism	B
a	O
in	O
congenital	O
sensorineural	B
kinase	I
we	O
identified	O
novel	O
a	O
missense	O
substitution	O
at	O
proto	O
highly	O
residue	O
profound	O
of	O
of	O
intracellular	O
deafness	O
oncogene	O
Xhosa	O
the	O
KIT	O
and	O
-	O
South	O
,	O
R796G	O
.	O

highly	O
a	O
South	O
African	O
girl	O
of	O
and	O
substitution	O
with	O
severe	O
piebaldism	B
Xhosa	O
profound	O
in	O
intracellular	B
deafness	I
we	O
identified	O
.	O
novel	O
missense	O
stock	O
the	O
a	O
In	O
conserved	O
domain	O
congenital	O
sensorineural	O
at	O
kinase	O
proto	O
of	O
a	O
KIT	O
residue	O
-	O
oncogene	O
,	O
R796G	O
the	O

In	O
a	O
South	O
African	O
Xhosa	O
stock	O
with	O
severe	O
and	O
profound	O
congenital	O
sensorineural	B
deafness	I
identified	O
a	O
novel	O
missense	O
at	O
a	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
KIT	O
proto	O
oncogene	O
,	O
R796G	O
.	O

In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	B
and	O
profound	O
congenital	O
sensorineural	B
deafness	I
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
transforming	O
gene	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
-	O
oncogene	O
,	O
R796G	O

In	O
a	O
South	O
African	O
stock	O
with	O
severe	O
piebaldism	B
and	O
congenital	O
sensorineural	B
a	O
substitution	O
at	O
conserved	O
the	O
intracellular	O
kinase	O
domain	O
the	O
KIT	O
oncogene	O
,	O
.	O

inch	O
a	O
South	O
african	O
fille	O
of	O
Xhosa	O
parentage	O
with	O
severe	O
piebaldism	B
and	O
fundamental	O
inborn	O
sensorineural	B
deafness	I
we	O
discover	O
a	O
fresh	O
missense	O
switch	O
at	O
a	O
extremely	O
husband	O
rest	O
inch	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
-	O
oncogene	O
,	O
R796G	O
.	O

In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	B
and	O
profound	O
congenital	O
sensorineural	B
deafness	I
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
transforming	O
gene	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
daughter	O
-	O
oncogene	O
,	O
R796G	O

In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	B
and	O
profound	O
congenital	O
sensorineural	B
deafness	I
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
-	O
oncogene	O
,	O
R796G	O
.	O

Though	O
anomalies	I
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
)	O
due	O
to	O
KIT	O
,	O
deafness	B
is	O
not	O
typical	O
human	O
piebaldism	B
.	O

Though	O
anomalies	I
have	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
)	O
due	O
KIT	O
mutations	O
,	O
deafness	B
is	O
not	O
typical	O
in	O

Though	O
auditory	B
anomalies	I
have	O
watt	O
note	O
referable	O
cost	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
due	O
to	O
KIT	O
indium	O
homo	O
indium	O
note	O
mutations	O
,	O
deafness	B
is	O
not	O
typical	O
in	O
human	O
piebaldism	B
.	O

deafness	O
auditory	B
anomalies	I
mutations	O
been	O
observed	O
in	O
human	O
typical	O
dominant	O
,	O
spotting	O
(	O
W	O
not	O
due	O
to	O
KIT	O
have	O
in	O
white	B
is	O
)	O
with	O
Though	O
mice	O
piebaldism	B
.	O

piebaldism	O
auditory	B
anomalies	I
)	O
been	O
observed	O
human	O
mice	O
have	O
dominant	O
white	O
spotting	O
W	O
deafness	O
in	O
with	O
to	O
KIT	O
mutations	O
,	O
(	B
is	O
not	O
typical	O
due	O
in	O
Though	B
.	O

Though	O
auditory	B
anomalies	I
have	O
watt	O
note	O
referable	O
cost	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
due	O
to	O
KIT	O
indium	O
homo	O
indium	O
receive	O
mutations	O
,	O
deafness	B
is	O
not	O
typical	O
in	O
human	O
piebaldism	B
.	O

Though	O
auditory	B
anomalies	I
have	O
been	O
discover	O
in	O
mouse	O
with	O
rife	O
gabardine	O
blemish	O
(	O
W	O
)	O
imputable	O
to	O
outfit	O
mutations	O
,	O
deafness	B
is	O
not	O
distinctive	O
in	O
human	O
piebaldism	B
.	O

Though	O
auditory	B
anomalies	I
have	O
watt	O
note	O
referable	O
cost	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
due	O
to	O
KIT	O
indium	O
homo	O
indium	O
receive	O
mutations	O
,	O
deafness	B
is	O
not	O
typical	O
in	O
human	O
piebaldism	B
.	O

typical	O
auditory	B
anomalies	I
have	O
been	O
observed	O
W	O
spotting	O
with	O
dominant	O
white	O
to	O
is	O
in	O
in	O
Though	O
mice	O
due	O
mutations	O
,	O
deafness	B
(	O
not	O
KIT	O
)	O
human	O
piebaldism	B
.	O

though	O
audile	B
anomalies	I
have	O
been	O
observed	O
in	O
shiner	O
with	O
prevalent	O
blanched	O
spotting	O
(	O
W	O
)	O
referable	O
to	O
KIT	O
sport	O
,	O
deafness	B
is	O
not	O
distinctive	O
in	O
human	O
piebaldism	B
.	O

Though	O
auditory	B
anomalies	I
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
due	O
to	O
KIT	O
mutations	O
,	O
deafness	B
is	O
not	O
typical	O
in	O
human	O
piebaldism	B
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B
deafness	I
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	B
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B
and	O
the	O
various	O
forms	O
of	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
Waardenburg	B
syndrome	I
.	O
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B
deafness	I
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	B
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B
and	O
the	O
various	O
forms	O
of	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
put	O
out	B
Waardenburg	I
syndrome	O
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B
deafness	I
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	B
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B
and	O
the	O
various	O
forms	O
of	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
Waardenburg	B
syndrome	I
.	O
.	O

and	O
to	O
the	O
occurrence	O
of	O
sensorineural	B
considerably	I
various	O
this	O
patient	O
extends	O
deafness	O
the	O
clinical	O
between	O
of	O
piebaldism	B
due	O
in	O
KIT	O
gene	O
the	O
similarity	O
humans	O
Thus	O
tightens	O
and	O
phenotypic	O
range	O
in	O
piebaldism	B
of	O
mutation	O
,	O
forms	O
the	O
Waardenburg	B
syndrome	I
.	O
.	O

Thus	O
,	O
the	O
occurrence	O
in	O
this	O
patient	O
extends	O
considerably	O
phenotypic	O
range	O
to	O
mutation	O
in	O
tightens	O
similarity	O
between	O
piebaldism	B
and	O
various	O
forms	O
syndrome	I
.	O

olibanum	O
,	O
the	O
happening	O
of	O
sensorineural	B
deafness	I
in	O
this	O
patient	O
stretch	O
substantially	O
the	O
phenotypic	O
place	O
of	O
piebaldism	B
referable	O
to	O
kit	O
cistron	O
variation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B
and	O
the	O
diverse	O
conformation	O
of	O
Waardenburg	B
syndrome	I
.	O
.	O

frankincense	O
,	O
the	O
occurrent	O
of	O
sensorineural	B
deafness	I
in	O
this	O
patient	O
stretch	O
well	O
the	O
phenotypic	O
straddle	O
of	O
piebaldism	B
imputable	O
to	O
kit	O
cistron	O
mutation	O
in	O
mankind	O
and	O
stiffen	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B
and	O
the	O
versatile	O
build	O
of	O
Waardenburg	B
syndrome	I
.	O
.	O

piebaldism	O
forms	O
the	O
occurrence	O
piebaldism	O
sensorineural	B
syndrome	I
and	O
this	O
patient	O
extends	O
considerably	O
the	O
and	O
due	O
of	O
of	B
range	O
to	O
KIT	O
phenotypic	O
mutation	O
in	O
humans	O
,	O
tightens	O
the	O
.	O
Thus	O
between	O
similarity	B
deafness	O
the	O
various	O
gene	O
of	O
Waardenburg	B
in	I
clinical	O
.	O

thence	O
,	O
the	O
occurrent	O
of	O
sensorineural	B
deafness	I
in	O
this	O
patient	O
prolong	O
well	O
the	O
phenotypic	O
grasp	O
of	O
piebaldism	B
referable	O
to	O
kit	O
cistron	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B
and	O
the	O
diverse	O
organize	O
of	O
Waardenburg	B
syndrome	I
.	O
.	O

Thus	O
,	O
piebaldism	O
occurrence	O
of	O
of	B
extends	I
in	O
this	O
patient	O
deafness	O
the	O
KIT	O
phenotypic	O
range	O
to	O
piebaldism	B
due	O
syndrome	O
the	O
gene	O
mutation	O
in	O
sensorineural	O
and	O
of	O
considerably	O
the	O
and	O
between	O
the	B
clinical	O
similarity	O
various	O
forms	O
humans	O
Waardenburg	B
tightens	I
.	O
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B
deafness	I
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	B
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B
and	O
the	O
various	O
forms	O
of	O
Waardenburg	B
syndrome	I
.	O
.	O

Cycloheximide	O
ease	O
the	O
designation	O
of	O
deviate	O
transcripts	O
ensue	O
from	O
a	O
fresh	O
tie	O
-	O
site	O
variation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
vulgarize	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
.	O

Cycloheximide	O
facilitates	O
identification	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
in	O
COL17A1	O
in	O
a	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
.	O

Cycloheximide	O
facilitates	O
the	O
identification	O
sport	O
indium	O
lead	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
benignant	O
generalise	O
benignant	O
benignant	O
designation	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
.	O

with	O
facilitates	O
the	O
a	O
of	O
aberrant	O
transcripts	O
bullosa	O
benign	O
a	O
patient	O
splice	O
-	O
site	O
atrophic	O
in	O
COL17A1	O
in	O
identification	O
epidermolysis	O
novel	O
generalized	O
mutation	B
from	I
Cycloheximide	I
resulting	I
.	O

Cycloheximide	O
facilitates	O
the	O
identification	O
sport	O
indium	O
lead	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
benignant	O
generalise	O
benignant	O
benignant	O
designation	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
.	O

Cycloheximide	O
facilitates	O
the	O
of	O
aberrant	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
COL17A1	O
in	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
.	O

.	O
facilitates	O
the	O
mutation	O
of	O
aberrant	O
bullosa	O
resulting	O
identification	O
a	O
novel	O
splice	O
site	O
with	O
epidermolysis	O
from	O
COL17A1	O
in	O
a	O
patient	O
-	O
generalized	O
atrophic	B
benign	I
in	I
transcripts	I
Cycloheximide	O

the	O
aberrant	O
transcripts	O
resulting	O
a	O
novel	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I

benign	O
facilitates	O
the	O
identification	O
of	O
aberrant	O
site	O
splice	O
from	O
a	O
novel	O
COL17A1	O
generalized	O
transcripts	O
epidermolysis	O
Cycloheximide	O
resulting	O
in	O
a	O
patient	O
with	O
-	O
atrophic	B
in	I
mutation	I
bullosa	I
.	O

Cycloheximide	O
ease	O
the	O
designation	O
of	O
deviate	O
copy	O
resulting	O
from	O
a	O
fresh	O
marry	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalised	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
.	O

Cycloheximide	O
facilitates	O
the	O
identification	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
past	O
encode	O
past	O
past	O
generalise	O
generalise	O
ampere	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
hemidesmosomal	O
encoded	O
by	O
COL17A1	O
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
much	O
testify	O
fall	O
expression	O
of	O
character	O
xvii	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
show	O
decreased	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
encoded	O
by	O
COL17A1	O
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
past	O
encode	O
past	O
past	O
generalise	O
generalise	O
generalise	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

Patients	O
with	O
popularise	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
frequently	O
picture	O
minify	O
reflexion	O
of	O
case	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

patient	O
with	O
extrapolate	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
often	O
usher	O
lessen	O
construction	O
of	O
case	O
xvii	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
often	O
show	O
expression	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
past	O
encode	O
past	O
past	O
generalise	O
generalise	O
generalise	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

transmembrane	O
with	O
generalized	O
expression	B
benign	I
epidermolysis	I
bullosa	I
hemidesmosomal	O
.	O
decreased	O
atrophic	O
of	O
type	O
XVII	O
COL17A1	O
,	O
a	O
encoded	O
often	O
Patients	O
protein	O
by	O
collagen	O
show	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

This	O
report	O
the	O
a	O
novel	O
splice	O
in	O
epidermolysis	O
mutation	O
in	O
COL17A1	O
to	O
bullosa	O
patient	O
with	O
define	O
atrophic	B
benign	I
resulting	I
a	I
,	O
mRNA	O
applies	O
a	O
new	O
generalized	O
-	O
and	O
and	O
characterize	O
documents	O
site	O
methodology	O
splice	O
variants	O
.	O

report	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
and	O
applies	O
a	O
methodology	O
define	O
and	O
characterize	O
mRNA	O

This	O
report	O
papers	O
a	O
refreshing	O
splice	O
-	O
site	O
sport	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
vulgarize	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
and	O
implement	O
a	O
novel	O
methodology	O
to	O
determine	O
and	O
qualify	O
the	O
resulting	O
mrna	O
splice	O
variation	O
.	O

define	O
,	O
documents	O
a	O
atrophic	O
splice	O
with	O
resulting	O
mutation	O
in	O
COL17A1	O
in	O
a	O
new	O
site	O
generalized	O
novel	B
the	I
epidermolysis	I
bullosa	I
patient	O
and	O
applies	O
a	O
report	O
methodology	O
to	O
This	O
benign	O
characterize	O
and	O
-	O
mRNA	O
splice	O
variants	O
.	O

This	O
report	O
documents	O
a	O
fresh	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mRNA	O
splice	O
variants	O
unfermented	O
unfermented	O
unfermented	O
unfermented	O
unfermented	O
unfermented	O
unfermented	O
unfermented	O
generalise	O
.	O

new	O
epidermolysis	O
documents	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
define	O
characterize	O
generalized	O
atrophic	B
benign	I
splice	I
bullosa	I
,	O
and	O
and	O
a	O
This	O
methodology	O
resulting	O
patient	O
with	O
applies	O
the	O
.	O
mRNA	O
variants	O
report	O
to	O

This	O
report	O
documents	O
a	O
splice	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mRNA	O
splice	O
variants	O
.	O

This	O
cover	O
documents	O
a	O
refreshing	O
wed	O
-	O
place	O
variation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
popularize	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
and	O
applies	O
a	O
modern	O
methodology	O
to	O
delimitate	O
and	O
characterise	O
the	O
resulting	O
mRNA	O
wed	O
discrepancy	O
.	O

This	O
report	O
documents	O
a	O
methodological	O
analysis	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	B
atrophic	I
benign	I
epidermolysis	I
bullosa	O
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mRNA	O
splice	O
variants	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O

This	O
composition	O
documents	O
a	O
new	O
wed	O
-	O
place	O
mutant	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
vulgarize	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
determine	O
and	O
qualify	O
the	O
lead	O
mRNA	O
wed	O
version	O
.	O

This	O
report	O
documents	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mRNA	O
splice	O
variants	O
.	O

Mutational	O
analysis	O
of	O
inherited	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-	O
1	O
position	O
of	O
exon	O
32	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	O
-	O
T	O
at	O
1	O
position	O
of	O
exon	O
32	O
.	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-	O
1	O
coding	O
dna	O
thirty	O
two	O
thirty	O
two	O
g	O
g	O
g	O
position	O
of	O

mutational	O
analysis	O
of	O
COL17A1	O
describe	O
a	O
motherly	O
transmissible	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-	O
1	O
berth	O
of	O
exon	O
32	O
.	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-	O
1	O
coding	O
dna	O
thirty	O
two	O
thirty	O
two	O
g	O
g	O
g	O
position	O
of	O

mutational	O
analysis	O
of	O
COL17A1	O
key	O
a	O
motherly	O
transmitted	O
k	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-	O
1	O
stance	O
of	O
exon	O
32	O
.	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
-	O
T	O
at	O
the	O
-	O
1	O
position	O
of	O
exon	O

to	O
analysis	O
of	O
position	O
identified	O
a	O
maternally	O
G	O
inherited	O
-	O
of	O
-	O
transversion	O
T	O
.	O
the	O
-	O
1	O
COL17A1	O
Mutational	O
exon	O
32	O
at	O

mutational	O
analysis	O
of	O
COL17A1	O
distinguish	O
a	O
motherly	O
transmissible	O
G	O
-	O
to	O
-	O
liothyronine	O
transversion	O
at	O
the	O
-	O
i	O
position	O
of	O
exon	O
32	O
.	O

at	O
analysis	O
G	O
maternally	O
identified	O
a	O
the	O
inherited	O
of	O
-	O
to	O
-	O
exon	O
transversion	O
COL17A1	O
Mutational	O
-	O
1	O
position	O
of	O
T	O
32	O
.	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-	O
1	O
position	O
of	O
exon	O
32	O
.	O

This	O
acceptor	O
the	O
at	O
site	O
mutation	O
transcripts	O
to	O
splice	O
formation	O
of	O
aberrant	O
led	O
present	O
-	O
extremely	O
low	O
levels	O
.	O

splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
extremely	O
low	O
levels	O
.	O

This	O
acceptor	O
marry	O
-	O
site	O
mutation	O
precede	O
to	O
the	O
constitution	O
of	O
deviant	O
copy	O
present	O
at	O
extremely	O
low	O
levels	O
.	O

This	O
acceptor	O
splice	O
-	O
locate	O
mutation	O
led	O
to	O
the	O
establishment	O
of	O
deviant	O
transcripts	O
portray	O
at	O
super	O
low	O
levels	O
.	O

low	O
acceptor	O
splice	O
-	O
site	O
mutation	O
present	O
at	O
the	O
formation	O
of	O
aberrant	O
levels	O
led	O
to	O
extremely	O
transcripts	O
This	O
.	O

This	O
acceptor	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	O
extremely	O
low	O
.	O

This	O
acceptor	O
splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	O
extremely	O
low	O
levels	O
lap	O
joint	O
lap	O
joint	O
lap	O
joint	O

This	O
acceptor	O
splice	O
-	O
site	O
variation	O
led	O
to	O
the	O
formation	O
of	O
deviate	O
copy	O
show	O
at	O
extremely	O
low	O
raze	O
.	O

This	O
acceptor	O
splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	O
extremely	O
low	O
levels	O
lap	O
joint	O
lap	O
joint	O
lap	O
joint	O

present	O
acceptor	O
splice	O
of	O
site	O
mutation	O
led	O
.	O
at	O
formation	O
-	O
aberrant	O
This	O
transcripts	O
the	O
extremely	O
low	O
levels	O
to	O

This	O
acceptor	O
splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	O
extremely	O
low	O
levels	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splice	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	O
were	O
determined	O
using	O
reverse	O
tot	O
rna	O
receive	O
tot	O
incubate	O
receive	O
	O
incubate	O
receive	O
	O
incubate	O
receive	O
	O
receive	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
total	O
RNA	O
from	O
keratinocytes	O
incubated	O
for	O
2	O
.	O

establish	O
on	O
our	O
late	O
bump	O
that	O
cycloheximide	O
steady	O
variation	O
COL17A1	O
copy	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splicing	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
copy	O
were	O
decide	O
utilize	O
reverse	O
transcriptase	O
polymerase	O
chain	O
response	O
of	O
total	O
rna	O
from	O
keratinocytes	O
brood	O
for	O
two	O
.	O

Based	O
on	O
COL17A1	O
recent	O
finding	O
that	O
in	O
,	O
mutant	O
COL17A1	O
transcripts	O
cycloheximide	O
the	O
homozygous	O
for	O
of	O
frameshift	O
mutation	O
polymerase	O
keratinocytes	O
effects	O
2	O
the	O
splice	O
-	O
mutation	O
stabilized	O
were	O
splicing	O
of	O
our	O
RNA	O
transcripts	O
determined	O
using	O
reverse	O
transcriptase	O
site	O
chain	O
reaction	O
for	O
total	O
on	O
from	O
keratinocytes	O
of	O
incubated	O
a	O
.	O

using	O
mutation	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
on	O
splicing	O
a	O
frameshift	O
mutation	O
of	O
the	O
effects	O
of	O
determined	O
splice	O
from	O
site	O
for	O
homozygous	O
.	O
,	O
COL17A1	O
reverse	O
were	O
for	O
Based	O
on	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
transcripts	O
RNA	O
the	O
keratinocytes	O
incubated	O
total	O
2	O
-	O

base	O
on	O
our	O
recent	O
determine	O
that	O
cycloheximide	O
stabilise	O
sport	O
COL17A1	O
copy	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
sport	O
,	O
the	O
outcome	O
of	O
the	O
tie	O
-	O
site	O
sport	O
on	O
wed	O
of	O
COL17A1	O
copy	O
were	O
mold	O
use	O
repeal	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
number	O
RNA	O
from	O
keratinocytes	O
cover	O
for	O
2	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
mutation	O
effects	O
the	O
splice	O
-	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
total	O
from	O
keratinocytes	O
2	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
COL17A1	O
transcripts	O
in	O
homozygous	O
a	O
frameshift	O
mutation	O
effects	O
site	O
mutation	O
on	O
of	O
COL17A1	O
were	O
determined	O
using	O
polymerase	O
chain	O
reaction	O
of	O
total	O
from	O
incubated	O
for	O
2	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splice	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	O
were	O
determined	O
using	O
reverse	O
tot	O
rna	O
receive	O
tot	O
incubate	O
receive	O
	O
incubate	O
receive	O
	O
incubate	O
receive	O
	O
copy	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
total	O
RNA	O
from	O
keratinocytes	O
incubated	O
for	O
2	O
.	O

keratinocytes	O
effects	O
our	O
recent	O
.	O
that	O
polymerase	O
frameshift	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
cycloheximide	O
for	O
a	O
stabilized	O
COL17A1	O
,	O
the	O
finding	O
of	O
the	O
splice	O
on	O
site	O
mutation	O
total	O
mutation	O
of	O
splicing	O
on	O
were	O
determined	O
using	O
reverse	O
transcriptase	O
homozygous	O
transcripts	O
reaction	O
of	O
-	O
RNA	O
from	O
Based	O
incubated	O
for	O
2	O
chain	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splice	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	O
were	O
determined	O
using	O
reverse	O
tot	O
rna	O
receive	O
tot	O
incubate	O
receive	O
	O
incubate	O
receive	O
	O
incubate	O
receive	O
	O
receive	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
total	O
RNA	O
from	O
keratinocytes	O
incubated	O
for	O
2	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splice	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	O
were	O
determined	O
using	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
total	O
RNA	O
from	O
keratinocytes	O
incubated	O
for	O
2	O
.	O

5	O
in	O
presence	O
absence	O
of	O
10	O
microg	O
cycloheximide	O
per	O
ml	O
.	O

quintuplet	O
h	O
in	O
the	O
mien	O
or	O
absence	O
of	O
10	O
microg	O
cycloheximide	O
per	O
ml	O
.	O

of	O
the	O
in	O
h	O
presence	O
or	O
microg	O
5	O
10	O
.	O
cycloheximide	O
per	O
ml	O
absence	O

5	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
microg	O
cycloheximide	O
ml	O
.	O

5	O
h	O
indium	O
indium	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
mil	O
mien	O
microg	O
cycloheximide	O
per	O
ml	O
.	O

5	O
h	O
indium	O
indium	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
mil	O
heat	O
content	O
microg	O
cycloheximide	O
per	O
ml	O

phoebe	O
h	O
in	O
the	O
front	O
or	O
absence	O
of	O
ten	O
microg	O
cycloheximide	O
per	O
milliliter	O
.	O

ml	O
h	O
in	O
5	O
of	O
or	O
absence	O
per	O
10	O
microg	O
cycloheximide	O
presence	O
the	O
.	O

5	O
h	O
indium	O
indium	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
mil	O
mien	O
microg	O
cycloheximide	O
per	O
ml	O
.	O

quint	O
h	O
in	O
the	O
front	O
or	O
absence	O
of	O
ten	O
microg	O
cycloheximide	O
per	O
milliliter	O
.	O

5	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
microg	O
cycloheximide	O
per	O
ml	O
.	O

Using	O
this	O
from	O
,	O
an	O
abnormally	O
contains	O
exon	O
was	O
identified	O
that	O
codon	O
32	O
extra	O
264	O
27	O
upstream	O
from	O
the	O
an	O
,	O
cryptic	O
in	O
a	O
premature	O
bases	O
spliced	O
resulting	O
bp	O
downstream	O
approach	O
transcript	O
termination	O
splice	O
site	O
.	O

this	O
,	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
an	O
extra	O
264	O
bases	O
upstream	O
from	O
exon	O
resulting	O
in	O
a	O
termination	O
27	O
bp	O
downstream	O
cryptic	O

apply	O
this	O
approach	O
,	O
an	O
abnormally	O
spliced	O
copy	O
was	O
identified	O
that	O
curb	O
an	O
additional	O
264	O
basis	O
upriver	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
previous	O
conclusion	O
codon	O
27	O
bp	O
downriver	O
from	O
the	O
sibylline	O
splice	O
site	O
.	O

27	O
,	O
approach	O
,	O
upstream	O
abnormally	O
264	O
the	O
was	O
identified	O
that	O
contains	O
an	O
premature	O
transcript	O
bases	O
an	O
from	O
exon	O
32	O
extra	O
resulting	O
in	O
a	O
this	O
termination	O
codon	O
Using	O
from	O
downstream	O
bp	O
spliced	O
cryptic	O
splice	O
site	O
.	O

Using	O
this	O
approach	O
,	O
associate	O
in	O
nursing	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
bases	O
upstream	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
27	O
bp	O
downstream	O
from	O
the	O
cryptic	O
splice	O
site	O
found	O
found	O
found	O
found	O
found	O
found	O
found	O
found	O

premature	O
exon	O
approach	O
,	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
contains	O
an	O
27	O
downstream	O
bases	O
upstream	O
from	O
splice	O
32	O
,	O
resulting	O
bp	O
a	O
Using	O
termination	O
the	O
extra	O
264	O
in	O
from	O
.	O
cryptic	O
site	O
this	O
codon	O

Using	O
this	O
approach	O
,	O
abnormally	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
bases	O
upstream	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
27	O
bp	O
downstream	O
from	O
the	O
cryptic	O
splice	O
site	O
.	O

Using	O
this	O
near	O
,	O
an	O
abnormally	O
spliced	O
copy	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
understructure	O
upriver	O
from	O
exon	O
32	O
,	O
ensue	O
in	O
a	O
previous	O
outcome	O
codon	O
xxvii	O
bp	O
downstream	O
from	O
the	O
sibylline	O
splice	O
locate	O
.	O

Using	O
this	O
approach	O
,	O
lap	O
joint	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
bases	O
upstream	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
27	O
bp	O
downstream	O
from	O
the	O
cryptic	O
splice	O
site	O
found	O
found	O
found	O
found	O
found	O
found	O
found	O
found	O
found	O

Using	O
this	O
approach	O
,	O
an	O
abnormally	O
marry	O
copy	O
was	O
discover	O
that	O
contains	O
an	O
surplus	O
264	O
bases	O
upriver	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
untimely	O
resultant	O
codon	O
27	O
bp	O
downriver	O
from	O
the	O
inscrutable	O
tie	O
site	O
.	O

Using	O
this	O
approach	O
,	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
bases	O
upstream	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
27	O
bp	O
downstream	O
from	O
the	O
cryptic	O
splice	O
site	O
.	O

Three	O
other	O
from	O
,	O
,	O
including	O
exon	O
derived	O
splice	O
the	O
skipping	O
of	O
one	O
32	O
variants	O
were	O
also	O
identified	O
.	O

splice	O
variants	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
were	O
also	O
identified	O
.	O

tierce	O
other	O
splice	O
variants	O
,	O
including	O
unmatched	O
gain	O
from	O
the	O
hop	O
of	O
exon	O
32	O
,	O
were	O
too	O
identified	O
.	O

trio	O
other	O
wed	O
variants	O
,	O
include	O
unrivalled	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
besides	O
identified	O
.	O

also	O
other	O
splice	O
variants	O
,	O
including	O
32	O
,	O
from	O
the	O
skipping	O
of	O
identified	O
one	O
derived	O
were	O
exon	O
Three	O
.	O

Three	O
other	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
also	O
.	O

Three	O
other	O
splice	O
variants	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
also	O
identified	O
lap	O
joint	O
lap	O
joint	O
lap	O
joint	O

trine	O
other	O
marry	O
variants	O
,	O
including	O
unitary	O
infer	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
besides	O
identified	O
.	O

Three	O
other	O
splice	O
variants	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
also	O
identified	O
lap	O
joint	O
lap	O
joint	O
lap	O
joint	O

32	O
other	O
splice	O
skipping	O
,	O
including	O
one	O
.	O
,	O
the	O
variants	O
of	O
Three	O
exon	O
from	O
were	O
also	O
identified	O
derived	O

Three	O
other	O
splice	O
variants	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
also	O
identified	O
.	O

These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	O
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
)	O
the	O
levels	O
of	O
these	O
transcripts	O
can	O
be	O
increased	O
by	O
cycloheximide	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
beryllium	O
.	O

These	O
solvent	O
suggest	O
the	O
utility	O
of	O
cycloheximide	O
discussion	O
in	O
value	O
the	O
unnatural	O
processing	O
of	O
mRNA	O
referable	O
to	O
marry	O
-	O
place	O
mutations	O
,	O
because	O
(	O
i	O
)	O
deviant	O
tie	O
frequently	O
get	O
a	O
untimely	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
untimely	O
termination	O
codons	O
can	O
occur	O
at	O
down	O
or	O
indiscernible	O
degree	O
referable	O
to	O
falderol	O
-	O
liaise	O
mRNA	O
crumble	O
,	O
and	O
(	O
tierce	O
)	O
the	O
degree	O
of	O
these	O
transcripts	O
can	O
be	O
increased	O
by	O
cycloheximide	O
.	O

These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	O
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
)	O
the	O
levels	O
of	O
these	O
transcripts	O
can	O
be	O
increased	O
by	O
cycloheximide	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
.	O

These	O
leave	O
designate	O
the	O
utility	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
unnatural	O
action	O
of	O
mRNA	O
ascribable	O
to	O
wed	O
-	O
situation	O
variation	O
,	O
because	O
(	O
i	O
)	O
deviate	O
marry	O
ofttimes	O
father	O
a	O
previous	O
endpoint	O
codon	O
,	O
(	O
ii	O
)	O
copy	O
with	O
previous	O
endpoint	O
codons	O
can	O
occur	O
at	O
abject	O
or	O
undetectable	O
tier	O
ascribable	O
to	O
hokum	O
-	O
mediated	O
mRNA	O
disintegrate	O
,	O
and	O
(	O
trey	O
)	O
the	O
tier	O
of	O
these	O
copy	O
can	O
be	O
increased	O
by	O
cycloheximide	O
.	O

These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	O
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
)	O
the	O
levels	O
of	O
these	O
transcripts	O
can	O
be	O
increased	O
by	O
cycloheximide	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
.	O

These	O
generates	O
indicate	O
iii	O
)	O
with	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
or	O
(	O
mutations	O
mRNA	O
)	O
to	O
splice	O
-	O
site	O
of	O
due	O
-	O
processing	O
transcripts	O
)	O
aberrant	O
splicing	O
often	O
results	O
a	O
to	O
termination	O
codon	O
,	O
(	O
levels	O
due	O
i	O
of	O
premature	O
termination	O
of	O
can	O
occur	O
at	O
by	O
the	O
undetectable	O
levels	O
,	O
premature	O
nonsense	O
because	O
codons	O
mRNA	O
these	O
,	O
and	O
(	O
the	O
usefulness	O
abnormal	O
ii	O
transcripts	O
decay	O
mediated	O
can	O
be	O
increased	O
low	O
cycloheximide	O
.	O

mRNA	O
increased	O
)	O
mediated	O
usefulness	O
of	O
cycloheximide	O
treatment	O
termination	O
evaluating	O
the	O
abnormal	O
the	O
generates	O
mRNA	O
levels	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
undetectable	O
aberrant	O
and	O
occur	O
a	O
premature	O
in	O
codon	O
iii	O
(	O
ii	O
premature	O
transcripts	O
with	O
levels	O
termination	O
codons	O
can	O
by	O
at	O
low	O
or	O
splicing	O
the	O
due	O
to	O
nonsense	O
cycloheximide	O
indicate	O
These	O
due	O
,	O
can	O
(	O
,	O
)	O
processing	O
decay	O
of	O
these	O
transcripts	O
often	O
be	O
results	O
of	O
-	O
.	O

at	O
results	O
indicate	O
by	O
usefulness	O
of	O
cycloheximide	O
mediated	O
in	O
evaluating	O
the	O
(	O
processing	O
of	O
mRNA	O
due	O
transcripts	O
splice	O
-	O
site	O
mutations	O
,	O
.	O
abnormal	O
i	O
of	O
cycloheximide	O
splicing	O
often	O
the	O
a	O
premature	O
termination	O
codon	O
and	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
,	O
can	O
generates	O
-	O
)	O
or	O
undetectable	O
to	O
due	O
these	O
the	O
occur	O
treatment	O
mRNA	O
decay	O
,	O
codons	O
(	O
iii	O
low	O
nonsense	O
levels	O
increased	O
levels	O
to	O
can	O
)	O
be	O
because	O
aberrant	O
These	O

These	O
results	O
indicate	O
usefulness	O
of	O
evaluating	O
processing	O
of	O
to	O
site	O
mutations	O
,	O
because	O
i	O
)	O
often	O
generates	O
premature	O
termination	O
ii	O
transcripts	O
with	O
premature	O
codons	O
can	O
occur	O
low	O
or	O
undetectable	O
levels	O
due	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
levels	O
these	O
transcripts	O
can	O
increased	O
by	O
cycloheximide	O
.	O

results	O
indicate	O
cycloheximide	O
in	O
evaluating	O
the	O
abnormal	O
mRNA	O
to	O
site	O
,	O
because	O
(	O
)	O
aberrant	O
splicing	O
a	O
premature	O
termination	O
codon	O
,	O
ii	O
)	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
)	O
of	O
transcripts	O
can	O
be	O
by	O
cycloheximide	O

These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	O
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
)	O
the	O
levels	O
of	O
these	O
transcripts	O
can	O
be	O
increased	O
by	O
cycloheximide	O
.	O

allele	O
deletion	O
mutation	O
generalized	O
COL17A1	O
in	O
five	O
an	O
bullosa	O
with	O
in	O
atrophic	B
epidermolysis	I
benign	I
families	I
represents	O
propagation	O
of	O
Austrian	O
A	O
ancestral	O
.	O

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
represents	O
propagation	O
of	O
allelomorph	O
allelomorph	O
sport	O
sport	O
sport	O
sport	O
an	O
ancestral	O
allele	O
.	O

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
represents	O
propagation	O
of	O
allelomorph	O
allelomorph	O
sport	O
sport	O
sport	O
sport	O
an	O
ancestral	O
allele	O
.	O

A	O
omission	O
mutant	O
in	O
COL17A1	O
in	O
five	O
austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
represents	O
extension	O
of	O
an	O
hereditary	O
allelomorph	O
.	O

A	O
deletion	O
mutation	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
represents	O
propagation	O
an	O
ancestral	O
allele	O
.	O

in	O
five	O
Austrian	O
families	O
generalized	O
atrophic	B
epidermolysis	I
bullosa	I
represents	O
propagation	O
of	O
an	O
ancestral	O
allele	O
.	O

angstrom	O
deletion	O
sport	O
in	O
COL17A1	O
in	O
five	O
austrian	O
syndicate	O
with	O
vulgarize	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
represents	O
extension	O
of	O
an	O
ancestral	O
allele	O
.	O

bullosa	O
deletion	O
families	O
five	O
COL17A1	O
in	O
represents	O
Austrian	O
mutation	O
with	O
generalized	O
atrophic	B
allele	I
epidermolysis	I
in	I
A	O
propagation	O
of	O
an	O
ancestral	O
benign	O
.	O

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
represents	O
propagation	O
of	O
allelomorph	O
allelomorph	O
sport	O
sport	O
sport	O
indium	O
an	O
ancestral	O
allele	O
.	O

A	O
deletion	O
mutation	O
in	O
five	O
Austrian	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
represents	O
propagation	O
of	O
an	O
.	O

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
represents	O
propagation	O
of	O
an	O
ancestral	O
allele	O
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	B
benignant	B
alveolar	B
abnormalcy	B
benignant	B
benign	I
epidermolysis	I
bullosa	I
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B
epidermolysis	I
bullosa	I
,	O
have	O
generalise	O
generalized	O
blistering	B
,	O
nail	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
dental	B
abnormalities	I
benignant	O
benignant	O
build	O
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	B
benignant	B
alveolar	B
abnormalcy	B
benignant	B
benign	I
epidermolysis	I
bullosa	I
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B
epidermolysis	I
bullosa	I
,	O
have	O
normally	O
generalized	O
blistering	B
,	O
nail	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
dental	B
abnormalities	I
benignant	O
benignant	O
build	O
.	O

,	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
junctional	I
,	O
a	O
usually	O
nonlethal	O
form	O
nail	O
bullosa	B
patchy	I
dental	I
,	O
,	O
generalized	O
blistering	B
Patients	O
of	B
dystrophy	I
have	O
epidermolysis	B
alopecia	I
,	O
and	O
.	B
abnormalities	I
bullosa	O

Patients	O
with	O
generalized	O
atrophic	B
benign	B
benignant	B
alveolar	B
abnormalcy	B
benignant	B
benign	I
epidermolysis	I
bullosa	I
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B
epidermolysis	I
bullosa	I
,	O
have	O
generalise	O
generalized	O
blistering	B
,	O
nail	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
dental	B
abnormalities	I
benignant	O
benignant	O
build	O
.	O

Patients	O
with	O
generalized	O
atrophic	B
epidermolysis	I
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B
epidermolysis	I
bullosa	I
,	O
nail	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
dental	B
abnormalities	I
.	O

patient	O
with	O
popularize	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
a	O
ordinarily	O
nonlethal	O
manakin	O
of	O
junctional	B
epidermolysis	I
bullosa	I
,	O
have	O
popularize	O
hot	B
,	O
apprehend	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
dental	B
freakishness	I
.	O

dental	O
with	O
patchy	O
epidermolysis	B
benign	I
epidermolysis	I
and	I
,	O
atrophic	O
usually	O
nonlethal	O
form	O
,	O
junctional	B
generalized	I
a	I
,	O
have	O
generalized	O
blistering	B
of	O
nail	B
dystrophy	I
,	O
bullosa	B
bullosa	I
,	O
alopecia	O
Patients	B
abnormalities	I
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
a	O
nonlethal	O
form	O
junctional	B
epidermolysis	I
bullosa	I
,	O
have	O
generalized	O
blistering	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
dental	B
abnormalities	I
.	O

nonlethal	O
with	O
generalized	O
dental	B
benign	I
epidermolysis	I
bullosa	I
alopecia	O
,	O
usually	O
patchy	O
form	O
,	O
blistering	B
dystrophy	I
bullosa	I
,	O
have	O
.	O
junctional	B
,	O
nail	B
epidermolysis	I
a	O
Patients	B
,	I
of	O
and	O
atrophic	B
abnormalities	I
generalized	O

patient	O
with	O
vulgarise	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
a	O
ordinarily	O
nonlethal	O
cast	O
of	O
junctional	B
epidermolysis	I
bullosa	I
,	O
have	O
vulgarise	O
vesiculation	B
,	O
complete	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
alveolar	B
abnormalcy	I
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B
epidermolysis	I
bullosa	I
,	O
have	O
generalized	O
blistering	B
,	O
nail	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
dental	B
abnormalities	I
.	O

pare	B
frangibleness	I
in	O
most	O
cases	O
is	O
referable	O
to	O
mutant	O
in	O
the	O
cistron	O
encoding	O
type	O
seventeen	O
collagen	O
(	O
COL17A1	O
)	O
.	O

Skin	B
fragility	I
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
)	O
.	O

Skin	B
fragility	I
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
)	O
.	O

in	O
is	O
due	O
to	O
in	O
the	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
)	O
.	O

Skin	B
fragility	I
in	O
most	O
cases	O
to	O
mutations	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
)	O
.	O

in	O
most	O
cases	O
is	O
to	O
mutations	O
in	O
the	O
gene	O
type	O
XVII	O
collagen	O
(	O
)	O
.	O

COL17A1	B
fragility	I
in	O
)	O
cases	O
is	O
due	O
mutations	O
to	O
in	O
XVII	O
gene	O
encoding	O
.	O
Skin	O
collagen	O
(	O
the	O
most	O
type	O

Skin	B
fragility	I
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
)	O
.	O

shin	B
frangibility	I
in	O
most	O
caseful	O
is	O
referable	O
to	O
mutations	O
in	O
the	O
factor	O
encryption	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
)	O
.	O

(	B
fragility	I
in	O
most	O
cases	O
is	O
type	O
gene	O
mutations	O
in	O
the	O
XVII	O
Skin	O
due	O
to	O
COL17A1	O
encoding	O
collagen	O
)	O
.	O

Skin	B
fragility	I
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
)	O
.	O

late	O
,	O
we	O
cover	O
fin	O
Austrian	O
mob	O
with	O
extrapolate	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
who	O
share	O
the	O
same	O
COL17A1	O
mutant	O
.	O

Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
who	O
share	O
the	O
same	O
COL17A1	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O
mutation	O
.	O

Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
who	O
share	O
the	O
same	O
COL17A1	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O
mutation	O
.	O

we	O
Austrian	O
families	O
with	O
atrophic	B
benign	I
bullosa	I
who	O
share	O
the	O
same	O
COL17A1	O
mutation	O
.	O

Recently	O
,	O
we	O
reported	O
five	O
with	O
generalized	O
benign	I
epidermolysis	I
bullosa	I
who	O
share	O
the	O
same	O
COL17A1	O
mutation	O
.	O

we	O
reported	O
five	O
Austrian	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
who	O
share	O
the	O
same	O
mutation	O
.	O

COL17A1	O
,	O
we	O
mutation	O
five	O
Austrian	O
families	O
generalized	O
with	O
atrophic	B
share	I
epidermolysis	I
bullosa	I
.	O
Recently	O
the	O
same	O
benign	O
reported	O
who	O

Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
who	O
share	O
the	O
same	O
COL17A1	O
generalise	O
generalise	O
generalise	O
generalise	O
generalise	O
	O
mutation	O
.	O

late	O
,	O
we	O
reported	O
quint	O
austrian	O
families	O
with	O
generalised	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
who	O
apportion	O
the	O
same	O
COL17A1	O
sport	O
.	O

same	O
,	O
we	O
reported	O
five	O
Austrian	O
who	O
epidermolysis	O
generalized	O
atrophic	B
benign	I
share	I
Recently	I
families	O
with	O
COL17A1	O
bullosa	O
the	O
mutation	O
.	O

Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
who	O
share	O
the	O
same	O
COL17A1	O
mutation	O
.	O

Affected	O
individuals	O
4003delTC	O
others	O
families	O
are	O
in	O
for	O
in	O
,	O
whereas	O
those	O
homozygous	O
two	O
three	O
are	O
compound	O
heterozygotes	O
.	O

in	O
three	O
families	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
are	O
compound	O
heterozygotes	O
.	O

move	O
someone	O
in	O
triad	O
folk	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
compound	O
heterozygotes	O
.	O

regard	O
mortal	O
in	O
tierce	O
syndicate	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
ii	O
others	O
are	O
compound	O
heterozygotes	O
.	O

compound	O
individuals	O
in	O
three	O
families	O
are	O
two	O
others	O
4003delTC	O
,	O
whereas	O
those	O
heterozygotes	O
homozygous	O
for	O
are	O
in	O
Affected	O
.	O

Affected	O
individuals	O
families	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
compound	O
.	O

Affected	O
individuals	O
in	O
three	O
families	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
compound	O
heterozygotes	O
indium	O
indium	O
indium	O
indium	O
deepen	O
.	O

regard	O
person	O
in	O
iii	O
class	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
intensify	O
heterozygotes	O
.	O

Affected	O
individuals	O
in	O
three	O
families	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
compound	O
heterozygotes	O
indium	O
indium	O
indium	O
indium	O
indium	O
.	O

two	O
individuals	O
in	O
whereas	O
families	O
are	O
homozygous	O
.	O
others	O
,	O
three	O
those	O
Affected	O
in	O
4003delTC	O
are	O
compound	O
heterozygotes	O
for	O

Affected	O
individuals	O
in	O
three	O
families	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
compound	O
heterozygotes	O
.	O

To	O
determine	O
determined	O
the	O
occurrence	O
signifies	O
4003delTC	O
spot	O
these	O
unrelated	O
families	O
haplotypes	O
polymorphisms	O
of	O
an	O
and	O
allele	O
or	O
mutational	O
a	O
hot	O
in	O
,	O
of	O
were	O
for	O
if	O
COL17A1	O
both	O
within	O
ancestral	O
propagation	O
flanking	O
.	O

To	O
the	O
occurrence	O
of	O
4003delTC	O
these	O
unrelated	O
propagation	O
of	O
ancestral	O
allele	O
hot	O
,	O
haplotypes	O
were	O
for	O
polymorphisms	O
both	O
and	O
flanking	O
COL17A1	O
.	O

To	O
determine	O
if	O
the	O
associate	O
in	O
nursing	O
patrimonial	O
allelomorph	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
families	O
signifies	O
propagation	O
of	O
an	O
ancestral	O
allele	O
or	O
a	O
mutational	O
hot	O
spot	O
,	O
haplotypes	O
were	O
determined	O
for	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
happening	O
happening	O
happening	O
happening	O
happening	O
happening	O

To	O
determine	O
if	O
the	O
associate	O
in	O
nursing	O
patrimonial	O
happening	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
families	O
signifies	O
propagation	O
of	O
an	O
ancestral	O
allele	O
or	O
a	O
mutational	O
hot	O
spot	O
,	O
haplotypes	O
were	O
determined	O
for	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
happening	O
happening	O
happening	O
happening	O
happening	O
happening	O

determine	O
a	O
if	O
the	O
occurrence	O
of	O
for	O
in	O
these	O
unrelated	O
families	O
polymorphisms	O
propagation	O
were	O
within	O
ancestral	O
allele	O
or	O
signifies	O
mutational	O
hot	O
spot	O
.	O
haplotypes	O
of	O
determined	O
4003delTC	O
To	O
flanking	O
,	O
and	O
both	O
COL17A1	O
an	O

To	O
determine	O
if	O
the	O
occurrence	O
of	O
these	O
unrelated	O
families	O
signifies	O
of	O
an	O
ancestral	O
allele	O
or	O
mutational	O
hot	O
spot	O
,	O
were	O
determined	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
.	O

To	O
limit	O
if	O
the	O
happening	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
mob	O
signifies	O
extension	O
of	O
an	O
patrimonial	O
allelomorph	O
or	O
a	O
mutational	O
blistering	O
spot	O
,	O
haplotypes	O
were	O
influence	O
for	O
pleomorphism	O
both	O
inside	O
and	O
flanking	O
COL17A1	O
.	O

To	O
fix	O
if	O
the	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
family	O
signify	O
generation	O
of	O
an	O
patrimonial	O
allelomorph	O
or	O
a	O
mutational	O
live	O
espy	O
,	O
haplotypes	O
were	O
watch	O
for	O
pleomorphism	O
both	O
within	O
and	O
flanking	O
COL17A1	O
.	O

To	O
determine	O
if	O
the	O
associate	O
in	O
nursing	O
patrimonial	O
happening	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
families	O
signifies	O
propagation	O
of	O
an	O
ancestral	O
allele	O
or	O
a	O
mutational	O
hot	O
spot	O
,	O
haplotypes	O
were	O
determined	O
for	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
happening	O
happening	O
happening	O
happening	O
happening	O
happening	O

To	O
regulate	O
if	O
the	O
happening	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
category	O
signify	O
multiplication	O
of	O
an	O
patrimonial	O
allelomorph	O
or	O
a	O
mutational	O
raging	O
spot	O
,	O
haplotypes	O
were	O
driven	O
for	O
polymorphisms	O
both	O
inside	O
and	O
flanking	O
COL17A1	O
.	O

To	O
determine	O
if	O
the	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
families	O
signifies	O
propagation	O
of	O
an	O
ancestral	O
allele	O
or	O
a	O
mutational	O
hot	O
spot	O
,	O
haplotypes	O
were	O
determined	O
for	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
.	O

cinque	O
intragenic	O
polymorphisms	O
were	O
elect	O
establish	O
on	O
their	O
informativeness	O
.	O

Five	O
intragenic	O
polymorphisms	O
were	O
chosen	O
based	O
on	O
their	O
informativeness	O
choose	O
choose	O
choose	O
.	O

phoebe	O
intragenic	O
polymorphisms	O
were	O
take	O
found	O
on	O
their	O
informativeness	O
.	O

quintuplet	O
intragenic	O
pleomorphism	O
were	O
choose	O
based	O
on	O
their	O
informativeness	O
.	O

Five	O
polymorphisms	O
were	O
based	O
on	O
their	O
informativeness	O
.	O

their	O
.	O
polymorphisms	O
chosen	O
were	O
based	O
on	O
Five	O
informativeness	O
intragenic	O

Five	O
their	O
polymorphisms	O
were	O
intragenic	O
based	O
chosen	O
on	O
informativeness	O
.	O

their	O
were	O
polymorphisms	O
intragenic	O
chosen	O
based	O
.	O
Five	O
informativeness	O
on	O

Five	O
were	O
chosen	O
based	O
their	O

Five	O
intragenic	O
polymorphisms	O
were	O
chosen	O
based	O
on	O
their	O
informativeness	O
choose	O
choose	O
choose	O
.	O

Five	O
intragenic	O
polymorphisms	O
were	O
chosen	O
based	O
on	O
their	O
informativeness	O
.	O

One	O
of	O
these	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
new	O
restriction	O
site	O
for	O
Eco0109	O
I	O

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
A	O
or	O
C	O
introduces	O
restriction	O
site	O
for	O
Eco0109	O
I	O
.	O

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
new	O
restriction	O
cost	O
iodine	O
iodine	O
cost	O
cost	O
cost	O
site	O
for	O
Eco0109	O
I	O
.	O

matchless	O
of	O
these	O
,	O
not	O
antecedently	O
account	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
present	O
a	O
new	O
confinement	O
site	O
for	O
Eco0109	O
ane	O
.	O

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
new	O
restriction	O
cost	O
iodine	O
iodine	O
cost	O
cost	O
cost	O
site	O
for	O
Eco0109	O
I	O
.	O

One	O
of	O
these	O
,	O
not	O
previously	O
account	O
,	O
was	O
2988	O
ampere	O
or	O
century	O
that	O
acquaint	O
ampere	O
raw	O
restriction	O
site	O
for	O
Eco0109	O
iodin	O
.	O

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
or	O
C	O
introduces	O
a	O
new	O
restriction	O
site	O
for	O
Eco0109	O

A	O
of	O
these	O
site	O
not	O
previously	O
reported	O
was	O
,	O
2988	O
for	O
or	O
that	O
C	O
.	O
a	O
new	O
restriction	O
,	O
One	O
Eco0109	O
I	O
introduces	O

unmatched	O
of	O
these	O
,	O
not	O
antecedently	O
describe	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
unexampled	O
confinement	O
site	O
for	O
Eco0109	O
iodin	O
.	O

introduces	O
of	O
was	O
reported	O
not	O
previously	O
a	O
,	O
these	O
2988	O
A	O
or	O
Eco0109	O
that	O
,	O
One	O
new	O
restriction	O
site	O
for	O
C	O
I	O
.	O

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
new	O
restriction	O
site	O
for	O
Eco0109	O
I	O
.	O

All	O
4003delTC	O
showed	O
same	O
haplotype	O
for	O
these	O
five	O
polymorphic	O
markers	O
.	O

whole	O
the	O
4003delTC	O
alleles	O
demo	O
the	O
same	O
haplotype	O
for	O
these	O
five	O
polymorphous	O
marking	O
.	O

haplotype	O
alleles	O
4003delTC	O
the	O
showed	O
the	O
these	O
All	O
for	O
.	O
five	O
polymorphic	O
markers	O
same	O

All	O
the	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
these	O
five	O
markers	O
.	O

All	O
the	O
marking	O
allele	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
for	O
marking	O
usher	O
these	O
five	O
polymorphic	O
markers	O
.	O

All	O
the	O
marking	O
allele	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
for	O
marking	O
whole	O
these	O
five	O
polymorphic	O
markers	O
.	O

completely	O
the	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
for	O
these	O
pentad	O
polymorphous	O
marking	O
.	O

markers	O
the	O
4003delTC	O
All	O
haplotype	O
the	O
same	O
polymorphic	O
for	O
these	O
five	O
showed	O
alleles	O
.	O

All	O
the	O
marking	O
allele	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
for	O
marking	O
usher	O
these	O
five	O
polymorphic	O
markers	O
.	O

altogether	O
the	O
4003delTC	O
allelomorph	O
register	O
the	O
same	O
haplotype	O
for	O
these	O
five	O
polymorphous	O
markers	O
.	O

All	O
the	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
for	O
these	O
five	O
polymorphic	O
markers	O
.	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
establish	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
position	O
inside	O
10q23	O
-	O
q25	O
most	O
COL17A1	O
.	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
location	O
within	O
10q23	O
-	O
q25	O
near	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
COL17A1	O
.	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
location	O
within	O
10q23	O
-	O
q25	O
near	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
COL17A1	O
.	O

polymorphisms	O
based	O
on	O
their	O
heterozygosity	O
and	O
location	O
within	O
10q23	O
-	O
q25	O
near	O
COL17A1	O
.	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
their	O
high	O
and	O
their	O
location	O
within	O
10q23	O
-	O
q25	O
near	O
COL17A1	O
.	O

polymorphisms	O
were	O
selected	O
based	O
their	O
high	O
heterozygosity	O
and	O
their	O
within	O
10q23	O
-	O
q25	O
COL17A1	O
.	O

near	O
microsatellite	O
polymorphisms	O
COL17A1	O
selected	O
based	O
on	O
high	O
their	O
heterozygosity	O
10q23	O
their	O
location	O
.	O
Fourteen	O
-	O
q25	O
and	O
were	O
within	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
location	O
within	O
10q23	O
-	O
q25	O
near	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
high	O
up	O
COL17A1	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
take	O
found	O
on	O
their	O
eminent	O
heterozygosity	O
and	O
their	O
emplacement	O
inside	O
10q23	O
-	O
q25	O
approximate	O
COL17A1	O
.	O

q25	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
within	O
their	O
high	O
heterozygosity	O
and	O
10q23	O
Fourteen	O
on	O
their	O
near	O
location	O
-	O
COL17A1	O
.	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
location	O
within	O
10q23	O
-	O
q25	O
near	O
COL17A1	O
.	O

Three	O
families	O
shared	O
microsatellite	O
polymorphism	O
pleomorphism	O
apportion	O
lowly	O
pleomorphism	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
consistent	O
with	O
cross	O
-	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
baseborn	O
.	O

Three	O
families	O
polymorphisms	O
cM	O
,	O
whereas	O
others	O
shared	O
regions	O
consistent	O
with	O
over	O
events	O
during	O
passage	O
of	O
mutation	O
several	O
generations	O
.	O

Three	O
families	O
shared	O
microsatellite	O
pleomorphism	O
brood	O
at	O
most	O
nineteen	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
lowly	O
regions	O
reproducible	O
with	O
cross	O
-	O
over	O
outcome	O
during	O
transit	O
of	O
this	O
sport	O
through	O
various	O
generations	O
.	O

Three	O
families	O
shared	O
microsatellite	O
covering	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
.	O

terzetto	O
families	O
shared	O
microsatellite	O
pleomorphism	O
treat	O
at	O
most	O
nineteen	O
centimetre	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
area	O
ordered	O
with	O
cross	O
-	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
respective	O
genesis	O
.	O

Three	O
families	O
shared	O
microsatellite	O
polymorphism	O
pleomorphism	O
apportion	O
lowly	O
pleomorphism	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
consistent	O
with	O
cross	O
-	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
pleomorphism	O
pleomorphism	O
pleomorphism	O
baseborn	O
.	O

trey	O
families	O
shared	O
microsatellite	O
polymorphisms	O
hide	O
at	O
most	O
nineteen	O
centimeter	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
uniform	O
with	O
hybrid	O
-	O
over	O
events	O
during	O
transit	O
of	O
this	O
variation	O
through	O
various	O
generations	O
.	O

-	O
with	O
shared	O
microsatellite	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
passage	O
several	O
smaller	O
regions	O
consistent	O
mutation	O
cross	O
families	O
over	O
.	O
during	O
others	O
of	O
this	O
Three	O
shared	O
events	O
generations	O
through	O

Three	O
families	O
shared	O
microsatellite	O
covering	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
regions	O
consistent	O
with	O
cross	O
-	O
over	O
events	O
of	O
this	O
mutation	O
several	O
.	O

Three	O
families	O
shared	O
microsatellite	O
theatrical	O
role	O
pleomorphism	O
apportion	O
lowly	O
part	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
consistent	O
with	O
cross	O
-	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
baseborn	O
baseborn	O
baseborn	O
baseborn	O

Three	O
families	O
shared	O
microsatellite	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
consistent	O
with	O
cross	O
-	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
.	O

These	O
indicate	O
that	O
occurs	O
a	O
ancestral	O
allele	O
.	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
ancestral	O
allele	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
one	O
transmissible	O
allelomorph	O
.	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
allelomorph	O
effect	O
effect	O
ancestral	O
allele	O
.	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
allelomorph	O
effect	O
allelomorph	O
ancestral	O
allele	O
.	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
allelomorph	O
effect	O
effect	O
ancestral	O
allele	O
.	O
.	O

These	O
resultant	O
argue	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
ancestral	O
allelomorph	O
.	O
.	O

These	O
results	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
ancestral	O
.	O

These	O
ensue	O
bespeak	O
that	O
4003delTC	O
pass	O
on	O
a	O
single	O
ancestral	O
allele	O
.	O
.	O

These	O
4003delTC	O
indicate	O
that	O
.	O
occurs	O
on	O
results	O
single	O
ancestral	O
allele	O
.	O
a	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
ancestral	O
allele	O
.	O
.	O

The	O
haptoglobin	O
-	O
factor	O
deletion	O
creditworthy	O
for	O
anhaptoglobinemia	B
.	O

The	O
responsible	O
for	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	B
anhaptoglobinemia	O
factor	O

The	O
gene	O
-	O
haptoglobin	O
deletion	O
responsible	O
anhaptoglobinemia	O
for	B
.	O

The	O
haptoglobin	O
-	O
cistron	O
cut	O
responsible	O
for	O
anhaptoglobinemia	B
.	O

The	O
-	O
gene	O
responsible	O
anhaptoglobinemia	B

for	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
anhaptoglobinemia	O
The	B
.	O

The	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	O
.	O

The	O
anhaptoglobinemia	O
-	O
gene	O
haptoglobin	O
responsible	O
for	O
deletion	B
.	O

The	O
omission	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	O
anhaptoglobinemia	B
factor	O
.	O

The	O
haptoglobin	O
-	O
factor	O
deletion	O
creditworthy	O
for	O
anhaptoglobinemia	B
.	O

The	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	O
anhaptoglobinemia	B
.	O

We	O
have	O
haptoglobin	O
an	O
allelic	O
deletion	O
gene	O
the	O
found	O
(	O
Hp	O
)	O
of	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	B
.	O

found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
individual	O
with	O
anhaptoglobinemia	B
.	O

We	O
have	O
found	O
an	O
allelomorphic	O
excision	O
of	O
the	O
haptoglobin	O
(	O
hp	O
)	O
factor	O
from	O
an	O
person	O
with	O
anhaptoglobinemia	B
.	O

We	O
have	O
found	O
an	O
allelomorphic	O
cut	O
of	O
the	O
haptoglobin	O
(	O
horsepower	O
)	O
factor	O
from	O
an	O
someone	O
with	O
anhaptoglobinemia	B
.	O

with	O
have	O
found	O
an	O
allelic	O
deletion	O
from	O
an	O
haptoglobin	O
(	O
Hp	O
)	O
anhaptoglobinemia	O
of	O
the	O
individual	O
gene	O
We	B
.	O

We	O
have	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
)	O
gene	O
from	O
an	O
individual	O
with	O
.	O

We	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	B
receive	O
receive	O
receive	O
receive	O
receive	O
.	O

We	O
have	O
found	O
an	O
allelomorphic	O
omission	O
of	O
the	O
haptoglobin	O
(	O
horsepower	O
)	O
cistron	O
from	O
an	O
person	O
with	O
anhaptoglobinemia	B
.	O

We	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	B
receive	O
receive	O
receive	O
receive	O
receive	O
.	O

from	O
have	O
found	O
Hp	O
allelic	O
deletion	O
of	O
.	O
an	O
(	O
an	O
)	O
We	O
gene	O
haptoglobin	O
individual	O
with	O
anhaptoglobinemia	B
the	O

We	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	B
.	O

The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
(	O
Hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
gene	O
bicycle	O
built	O
for	O
two	O
consist	O
indium	O
	O
english	O
indium	O
	O
english	O
consist	O
	O
english	O
consist	O
consist	O
consist	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O

The	O
hp	O
cistron	O
bunch	O
comprise	O
of	O
slang	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
cistron	O
(	O
hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
cistron	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O
five	O
slope	O
.	O

The	O
Hp	O
the	O
cluster	O
consists	O
gene	O
coding	O
regions	O
of	O
the	O
alpha	O
and	O
from	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
(	O
gene	O
Hp	O
.	O
and	O
of	O
the	O
chain	O
and	O
side	O
beta	O
chain	O
of	O
Hpr	O
alpha	O
-	O
related	O
of	O
(	O
gene	O
)	O
,	O
in	O
tandem	O
chain	O
5	O
the	O
haptoglobin	O
)	O

The	O
chain	O
gene	O
cluster	O
consists	O
of	O
chain	O
chain	O
of	O
the	O
alpha	O
coding	O
and	O
and	O
the	O
of	O
the	O
haptoglobin	O
regions	O
(	O
Hp	O
)	O
gene	O
of	O
the	O
alpha	O
.	O
beta	O
the	O
gene	O
of	O
beta	O
haptoglobin	O
chain	O
related	O
tandem	O
(	O
Hpr	O
)	O
,	O
Hp	O
-	O
from	O
and	O
5	O
side	O
in	O

The	O
horsepower	O
factor	O
bundle	O
consists	O
of	O
steganography	O
part	O
of	O
the	O
alpha	O
string	O
and	O
beta	O
string	O
of	O
the	O
haptoglobin	O
factor	O
(	O
horsepower	O
)	O
and	O
of	O
the	O
alpha	O
string	O
and	O
beta	O
string	O
of	O
the	O
haptoglobin	O
-	O
colligate	O
factor	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O
v	O
face	O
.	O

The	O
Hp	O
gene	O
consists	O
of	O
coding	O
regions	O
of	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
)	O
of	O
the	O
alpha	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
related	O
gene	O
)	O
in	O
tandem	O
from	O
the	O
.	O

cluster	O
consists	O
of	O
coding	O
regions	O
the	O
alpha	O
chain	O
haptoglobin	O
gene	O
)	O
the	O
alpha	O
chain	O
and	O
chain	O
of	O
-	O
related	O
(	O
Hpr	O
tandem	O
the	O
5	O
side	O

The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
(	O
Hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
gene	O
bicycle	O
built	O
for	O
two	O
consist	O
indium	O
	O
english	O
indium	O
	O
english	O
consist	O
	O
english	O
consist	O
consist	O
consist	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O

related	O
the	O
gene	O
cluster	O
the	O
of	O
Hp	O
the	O
of	O
the	O
alpha	O
chain	O
and	O
coding	O
Hpr	O
of	O
consists	O
.	O
gene	O
(	O
beta	O
)	O
and	O
of	O
and	O
alpha	O
chain	O
tandem	O
5	O
chain	O
beta	O
Hp	O
haptoglobin	O
-	O
)	O
gene	O
(	O
chain	O
The	O
,	O
in	O
regions	O
from	O
the	O
of	O
side	O
haptoglobin	O

The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
(	O
Hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
gene	O
bicycle	O
built	O
for	O
two	O
consist	O
indium	O
	O
english	O
indium	O
	O
english	O
consist	O
	O
english	O
consist	O
consist	O
consist	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O

The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
(	O
Hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
gene	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O
5	O
side	O
.	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
individual	O
with	O
anhaptoglobinemia	B
homozygous	O
the	O
gene	O
deletion	O
the	O
at	O
least	O
from	O
promoter	O
region	O
Hp	O
to	O
Hpr	O
not	O
to	O
Hpr	O
beta	O
(	O
)	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
gene	O
included	O
least	O
from	O
the	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
merely	O
genus	O
beta	O
psychoanalyze	O
psychoanalyze	O
genus	O
beta	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
cost	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
merely	O
genus	O
beta	O
psychoanalyze	O
psychoanalyze	O
genus	O
beta	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O

southerly	O
daub	O
and	O
PCR	O
analyses	O
have	O
argue	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
factor	O
cut	O
and	O
that	O
the	O
factor	O
cut	O
was	O
included	O
at	O
least	O
from	O
the	O
booster	O
neighborhood	O
of	O
horsepower	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

Southern	O
and	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
Hpr	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O

southern	O
daub	O
and	O
PCR	O
analyses	O
have	O
designate	O
that	O
the	O
soul	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
cistron	O
omission	O
and	O
that	O
the	O
cistron	O
omission	O
was	O
admit	O
at	O
least	O
from	O
the	O
plugger	O
neighborhood	O
of	O
hp	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

to	O
included	O
and	O
PCR	O
gene	O
have	O
not	O
of	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
indicated	O
deletion	O
the	O
analyses	O
for	O
and	O
that	O
that	O
gene	O
deletion	O
was	O
from	O
at	O
least	O
(	O
.	O
promoter	O
the	O
blot	O
Hp	O
to	O
Hpr	O
alpha	O
but	O
homozygous	O
Southern	O
Hpr	O
beta	O
the	O
Hpdel	O
)	O
region	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
merely	O
genus	O
beta	O
psychoanalyze	O
psychoanalyze	O
genus	O
beta	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O

southern	O
smear	O
and	O
PCR	O
analyses	O
have	O
suggest	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
cistron	O
cut	O
and	O
that	O
the	O
cistron	O
cut	O
was	O
included	O
at	O
least	O
from	O
the	O
plugger	O
part	O
of	O
horsepower	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

In	O
addition	O
,	O
we	O
invite	O
receive	O
	O
genotype	O
receive	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	B
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
receive	O
beryllium	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
call	O
for	O
family	O

In	O
addition	O
,	O
we	O
invite	O
receive	O
	O
genotype	O
receive	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	B
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
receive	O
beryllium	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
call	O
for	O
family	O

Hpdel	O
addition	O
to	O
the	O
found	O
seven	O
/	O
with	O
we	B
in	O
three	O
families	O
seven	O
and	O
,	O
hypohaptoglobinemia	O
of	O
six	O
of	O
the	O
,	O
individuals	O
were	O
found	O
genotypes	O
individuals	O
Hp2	O
be	O
In	O
.	O

In	O
addition	O
,	O
we	O
invite	O
receive	O
	O
genotype	O
receive	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	B
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
receive	O
beryllium	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
call	O
for	O
family	O

In	O
addition	O
,	O
we	O
found	O
seven	O
individuals	O
hypohaptoglobinemia	B
in	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
.	O

indium	O
improver	O
,	O
we	O
found	O
seven	O
someone	O
with	O
hypohaptoglobinemia	B
indium	O
iii	O
house	O
,	O
and	O
the	O
genotypes	O
of	O
sextet	O
of	O
the	O
seven	O
someone	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
.	O

of	O
addition	O
,	O
we	O
found	O
seven	O
individuals	O
families	O
hypohaptoglobinemia	B
in	O
three	O
In	O
Hpdel	O
found	O
genotypes	O
the	O
six	O
to	O
of	O
the	O
seven	O
individuals	O
were	O
and	O
with	O
be	O
Hp2	O
/	O
,	O
.	O

seven	O
addition	O
,	O
of	O
found	O
seven	O
individuals	O
be	O
found	B
in	O
Hpdel	O
families	O
Hp2	O
the	O
were	O
genotypes	O
of	O
six	O
we	O
and	O
to	O
individuals	O
the	O
hypohaptoglobinemia	O
In	O
with	O
,	O
/	O
three	O
.	O

inch	O
increase	O
,	O
we	O
discover	O
septet	O
individuals	O
with	O
hypohaptoglobinemia	B
inch	O
tercet	O
kinsperson	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
of	O
the	O
septet	O
individuals	O
were	O
discover	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
.	O

In	O
addition	O
,	O
we	O
found	O
individuals	O
hypohaptoglobinemia	B
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
six	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
Hp2	O
/	O
Hpdel	O

In	O
addition	O
,	O
we	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	B
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
.	O

The	O
phenotypes	O
and	O
one	O
showed	O
the	O
father	O
be	O
hypohaptoglobinemic	B
Hp2	O
)	O
and	O
Hpdel	O
,	O
the	O
mother	O
to	O
Hp2	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
,	O
other	O
to	O
be	O
Hp1	O
Hp1	O
/	O
Hpdel	O
,	O
showing	O
an	O
Hp	O
phenotypes	O
in	O
the	O
child	O
with	O
Hp1	O

The	O
-	O
and	O
Hpdel	O
,	O
Hp1	O
of	O
these	O
three	O
families	O
showed	O
to	O
father	O
an	O
be	O
be	B
(	O
Hp2	O
)	O
and	O
anomalous	O
Hpdel	O
)	O
,	O
other	O
Hp	O
to	O
be	O
Hp2	O
and	O
1	O
/	O
Hp1	O
/	O
Hp2	O
,	O
the	O
of	O
one	O
in	O
children	O
to	O
hypohaptoglobinemic	O
hypohaptoglobinemic	B
(	O
Hp2	O
Hpdel	O
the	O
Hp2	O
/	O
with	O
the	O
and	O
,	O
showing	O
child	O
the	O
be	O
Hp1	O
and	O
one	O
and	O
genotypes	O
Hp1	O
/	O
to	O
Hp2	O
inheritance	O
of	O
mother	O
phenotypes	O
in	O
the	O
child	O
phenotypes	O
two	O
.	O

The	O
phenotypes	O
in	O
one	O
of	O
three	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
Hpdel	O
the	O
mother	O
be	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
hypohaptoglobinemic	B
(	O
)	O
and	O
Hp2	O
/	O
,	O
the	O
be	O
and	O
Hp1	O
/	O
,	O
showing	O
anomalous	O
inheritance	O
Hp	O
phenotypes	O
in	O
the	O
child	O
with	O
Hp1	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	O
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
mother	O
to	O
be	O
Hp2	O
-	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
child	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
in	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
the	O
child	O
with	O
Hp1	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
ace	O
of	O
these	O
triad	O
class	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
overprotect	O
to	O
be	O
Hp2	O
-	O
ane	O
and	O
Hp1	O
/	O
Hp2	O
,	O
ace	O
of	O
the	O
deuce	O
tiddler	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
tyke	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
display	O
an	O
anomalous	O
heritage	O
of	O
horsepower	O
phenotypes	O
in	O
the	O
tyke	O
with	O
Hp1	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
ace	O
of	O
these	O
three	O
kinsperson	O
usher	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
get	O
to	O
be	O
Hp2	O
-	O
unity	O
and	O
Hp1	O
/	O
Hp2	O
,	O
ace	O
of	O
the	O
ii	O
shaver	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
nipper	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
designate	O
an	O
anomalous	O
heritage	O
of	O
horsepower	O
phenotypes	O
in	O
the	O
nipper	O
with	O
Hp1	O
.	O

of	O
phenotypes	O
and	O
-	O
Hp1	O
one	O
of	O
/	O
three	O
showed	O
families	O
Hpdel	O
father	O
to	O
be	O
hypohaptoglobinemic	B
,	O
Hp2	O
)	O
and	O
Hp2	O
/	O
mother	O
with	O
the	O
Hp2	O
other	O
be	O
Hp2	O
genotypes	O
1	O
and	O
in	O
/	O
phenotypes	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
Hp	O
hypohaptoglobinemic	B
the	O
Hpdel	O
the	O
and	O
Hp2	O
The	O
Hpdel	O
an	O
showing	O
child	O
to	O
child	O
to	O
be	O
.	O
and	O
Hp1	O
these	O
Hp1	O
,	O
and	O
(	O
in	O
inheritance	O
/	O
be	O
the	O
anomalous	O
)	O
(	O
,	O
Hp1	O
Hp2	O

child	O
to	O
the	O
inheritance	O
in	O
one	O
of	O
these	O
Hp1	O
families	O
showed	O
the	O
in	O
children	O
be	O
,	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
Hp1	O
the	O
mother	O
Hp2	O
other	O
(	O
to	O
1	O
and	O
three	O
/	O
Hp1	O
,	O
one	O
,	O
the	O
two	O
to	O
to	O
be	O
hypohaptoglobinemic	B
Hp1	O
Hp2	O
)	O
and	O
phenotypes	O
genotypes	O
Hpdel	O
,	O
and	O
/	O
be	O
The	O
Hp2	O
Hp2	O
of	O
and	O
be	O
/	O
father	O
phenotypes	O
showing	O
an	O
anomalous	O
Hp	O
of	O
and	O
hypohaptoglobinemic	O
Hpdel	O
the	O
child	O
with	O
-	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	O
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
mother	O
to	O
be	O
Hp2	O
-	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
child	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
in	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
the	O
child	O
with	O
Hp1	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
peerless	O
of	O
these	O
three	O
household	O
register	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
generate	O
to	O
be	O
Hp2	O
-	O
ace	O
and	O
Hp1	O
/	O
Hp2	O
,	O
peerless	O
of	O
the	O
deuce	O
fry	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
nestling	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
point	O
an	O
anomalous	O
heritage	O
of	O
hp	O
phenotypes	O
in	O
the	O
nestling	O
with	O
Hp1	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	O
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
mother	O
to	O
be	O
Hp2	O
-	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
child	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
in	O
the	O
child	O
with	O
Hp1	O
.	O

The	O
Hp2	O
Hpdel	O
individuals	O
low	O
Hp	O
(	O
/	O
=	O
0	O
.	O
049	O
/	O
-	O
043	O
mg	O
ml	O
;	O
)	O
compared	O
with	O
the	O
(	O
1	O
.	O
+	O
/	O
-	O
1	O
.	O
/	O
ml	O
)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
Hp2	O
whereas	O
the	O
serum	O
level	O
of	O
an	O
individual	O
with	O
Hp1	O
Hpdel	O
was	O

The	O
/	O
/	O
having	O
phenotype	O
the	O
an	O
extremely	O
low	O
level	O
of	O
-	O
(	O
.	O
+	O
compared	O
-	O
SD	O
=	O
0	O
mean	O
,	O
ml	O
/	O
with	O
of	O
.	O
043	O
mg	O
Hp2	O
ml	O
mg	O
n	O
=	O
6	O
)	O
Hpdel	O
/	O
-	O
had	O
level	O
(	O
whereas	O
.	O
64	O
+	O
an	O
Hp2	O
1	O
.	O
/	O
;	O
/	O
+	O
1	O
obtained	O
the	O
52	O
healthy	O
volunteers	O
Hpdel	O
individuals	O
Hp	O
)	O
049	O
from	O
,	O
Hp	O
level	O
0	O
/	O
individual	O
with	O
Hp1	O
serum	O
.	O
was	O
0	O
07	O

The	O
/	O
Hpdel	O
individuals	O
had	O
low	O
level	O
of	O
Hp	O
mean	O
+	O
/	O
-	O
SD	O
=	O
0	O
.	O
+	O
0	O
043	O
mg	O
/	O
ml	O
;	O
=	O
6	O
)	O
,	O
with	O
1	O
.	O
64	O
+	O
/	O
-	O
1	O
.	O
ml	O
)	O
obtained	O
from	O
healthy	O
volunteers	O
phenotype	O
whereas	O
Hp	O
level	O
with	O
/	O
Hpdel	O
was	O
0	O

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
extremely	O
low	O
level	O
of	O
Hp	O
(	O
mean	O
+	O
/	O
-	O
SD	O
=	O
0	O
.	O
049	O
+	O
/	O
-	O
0	O
.	O
043	O
mg	O
/	O
ml	O
;	O
n	O
=	O
6	O
)	O
,	O
compared	O
with	O
the	O
level	O
(	O
1	O
.	O
64	O
+	O
/	O
-	O
1	O
.	O
07	O
mg	O
/	O
ml	O
)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
Hp	O
level	O
of	O
an	O
individual	O
humiliated	O
cost	O
zero	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
0	O
.	O

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
passing	O
broken	O
charge	O
of	O
hp	O
(	O
bastardly	O
+	O
/	O
-	O
SD	O
=	O
0	O
.	O
049	O
+	O
/	O
-	O
0	O
.	O
043	O
magnesium	O
/	O
ml	O
;	O
n	O
=	O
6	O
)	O
,	O
liken	O
with	O
the	O
charge	O
(	O
ace	O
.	O
64	O
+	O
/	O
-	O
ace	O
.	O
07	O
magnesium	O
/	O
ml	O
)	O
find	O
from	O
52	O
hefty	O
offer	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
hp	O
charge	O
of	O
an	O
individual	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
0	O
.	O

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
highly	O
dispirited	O
stage	O
of	O
horsepower	O
(	O
intend	O
+	O
/	O
-	O
SD	O
=	O
cipher	O
.	O
049	O
+	O
/	O
-	O
cipher	O
.	O
043	O
magnesium	O
/	O
cc	O
;	O
n	O
=	O
sixer	O
)	O
,	O
compared	O
with	O
the	O
stage	O
(	O
ane	O
.	O
lxiv	O
+	O
/	O
-	O
ane	O
.	O
07	O
magnesium	O
/	O
cc	O
)	O
find	O
from	O
52	O
hefty	O
voluntary	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
horsepower	O
stage	O
of	O
an	O
individual	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
cipher	O
.	O

Hp1	O
Hp2	O
/	O
an	O
individuals	O
had	O
an	O
)	O
low	O
level	O
of	O
+	O
(	O
mean	O
+	O
/	O
serum	O
SD	O
=	O
0	O
.	O
049	O
with	O
/	O
-	O
whereas	O
individual	O
043	O
mg	O
Hpdel	O
ml	O
;	O
n	O
=	O
/	O
)	O
,	O
compared	O
with	O
the	O
level	O
(	O
.	O
.	O
0	O
ml	O
phenotype	O
-	O
1	O
mg	O
07	O
the	O
Hp2	O
healthy	O
extremely	O
obtained	O
from	O
52	O
was	O
volunteers	O
having	O
/	O
/	O
,	O
0	O
.	O
-	O
Hp	O
of	O
level	O
Hp	O
.	O
6	O
64	O
/	O
Hpdel	O
+	O
The	O
1	O

having	O
of	O
compared	O
)	O
individuals	O
had	O
an	O
extremely	O
n	O
level	O
of	O
Hp	O
/	O
Hpdel	O
+	O
,	O
-	O
SD	O
=	O
0	O
.	O
049	O
+	O
Hp2	O
-	O
0	O
1	O
.	O
healthy	O
64	O
ml	O
;	O
low	O
=	O
/	O
)	O
,	O
level	O
with	O
the	O
.	O
(	O
1	O
.	O
an	O
+	O
/	O
-	O
043	O
Hpdel	O
07	O
mg	O
/	O
individual	O
/	O
0	O
/	O
The	O
Hp	O
volunteers	O
52	O
phenotype	O
(	O
from	O
whereas	O
the	O
serum	O
mg	O
level	O
Hp2	O
6	O
ml	O
with	O
Hp1	O
/	O
mean	O
was	O
obtained	O
.	O

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
extremely	O
low	O
level	O
of	O
Hp	O
(	O
mean	O
+	O
/	O
-	O
SD	O
=	O
0	O
.	O
049	O
+	O
/	O
-	O
0	O
.	O
043	O
mg	O
/	O
ml	O
;	O
n	O
=	O
6	O
)	O
,	O
compared	O
with	O
the	O
level	O
(	O
1	O
.	O
64	O
+	O
/	O
-	O
1	O
.	O
07	O
mg	O
/	O
ml	O
)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
Hp	O
level	O
of	O
an	O
individual	O
humiliated	O
cost	O
zero	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
0	O
.	O

The	O
Hp2	O
/	O
Hpdel	O
person	O
had	O
an	O
passing	O
low	O
level	O
of	O
hp	O
(	O
beggarly	O
+	O
/	O
-	O
sd	O
=	O
nought	O
.	O
049	O
+	O
/	O
-	O
nought	O
.	O
043	O
mg	O
/	O
mil	O
;	O
n	O
=	O
vi	O
)	O
,	O
equate	O
with	O
the	O
level	O
(	O
unity	O
.	O
64	O
+	O
/	O
-	O
unity	O
.	O
07	O
mg	O
/	O
mil	O
)	O
hold	O
from	O
52	O
sizable	O
volunteers	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
hp	O
level	O
of	O
an	O
mortal	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
nought	O
.	O

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
extremely	O
low	O
level	O
of	O
Hp	O
(	O
mean	O
+	O
/	O
-	O
SD	O
=	O
0	O
.	O
049	O
+	O
/	O
-	O
0	O
.	O
043	O
mg	O
/	O
ml	O
;	O
n	O
=	O
6	O
)	O
,	O
compared	O
with	O
the	O
level	O
(	O
1	O
.	O
64	O
+	O
/	O
-	O
1	O
.	O
07	O
mg	O
/	O
ml	O
)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
Hp	O
level	O
of	O
an	O
individual	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
0	O
.	O

50	O
mg	O
mg	O
ml	O
,	O
which	O
was	O
Hp1	O
half	O
the	O
level	O
26	O
phenotype	O
in	O
control	O
approximately	O
from	O
the	O
)	O
Hp	O
(	O
.	O
.	O
of	O
+	O
sera	O
0	O
ml	O
.	O
33	O
/	O
-	O
/	O
;	O
n	O
effect	O
9	O
/	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
=	O
1	O

50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	O
Hp1	O
phenotype	O
(	O
1	O
.	O
26	O
+	O
/	O
-	O
0	O
.	O
33	O
mg	O
/	O
ml	O
;	O
n	O
=	O
display	O
dose	O
force	O
display	O
dose	O
force	O
some	O
dose	O
force	O
some	O
some	O
some	O
some	O
9	O
)	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	O
Hp1	O
phenotype	O
(	O
1	O
.	O
26	O
+	O
/	O
-	O
0	O
.	O
33	O
mg	O
/	O
ml	O
;	O
n	O
=	O
display	O
dose	O
force	O
display	O
dose	O
force	O
some	O
dose	O
force	O
some	O
some	O
some	O
newton	O
9	O
)	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
the	O
level	O
of	O
in	O
sera	O
from	O
the	O
(	O
/	O
-	O
0	O
33	O
mg	O
ml	O
;	O
n	O
)	O
,	O
showing	O
a	O
gene	O
dosage	O
.	O

50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
level	O
of	O
Hp	O
in	O
control	O
(	O
26	O
/	O
-	O
0	O
33	O
mg	O
/	O
ml	O
;	O
n	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O

n	O
Hp1	O
/	O
ml	O
,	O
which	O
gene	O
approximately	O
half	O
the	O
level	O
a	O
Hp	O
0	O
33	O
sera	O
from	O
the	O
;	O
phenotype	O
(	O
1	O
.	O
26	O
dosage	O
/	O
/	O
in	O
control	O
+	O
mg	O
=	O
ml	O
mg	O
50	O
-	O
9	O
)	O
,	O
showing	O
of	O
was	O
-	O
.	O
effect	O
.	O

fifty	O
milligram	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
stage	O
of	O
hp	O
in	O
contain	O
serum	O
from	O
the	O
Hp1	O
phenotype	O
(	O
one	O
.	O
xxvi	O
+	O
/	O
-	O
0	O
.	O
xxxiii	O
milligram	O
/	O
ml	O
;	O
n	O
=	O
ix	O
)	O
,	O
showing	O
a	O
cistron	O
-	O
dose	O
issue	O
.	O

fifty	O
milligram	O
/	O
milliliter	O
,	O
which	O
was	O
around	O
half	O
the	O
level	O
of	O
horsepower	O
in	O
operate	O
serum	O
from	O
the	O
Hp1	O
phenotype	O
(	O
unity	O
.	O
26	O
+	O
/	O
-	O
nought	O
.	O
33	O
milligram	O
/	O
milliliter	O
;	O
n	O
=	O
9	O
)	O
,	O
read	O
a	O
cistron	O
-	O
dose	O
upshot	O
.	O

50	O
magnesium	O
/	O
millilitre	O
,	O
which	O
was	O
approximately	O
half	O
the	O
rase	O
of	O
hp	O
in	O
control	O
serum	O
from	O
the	O
Hp1	O
phenotype	O
(	O
one	O
.	O
26	O
+	O
/	O
-	O
nought	O
.	O
33	O
magnesium	O
/	O
millilitre	O
;	O
n	O
=	O
ennead	O
)	O
,	O
establish	O
a	O
cistron	O
-	O
dose	O
effect	O
.	O

50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	O
Hp1	O
phenotype	O
(	O
1	O
.	O
26	O
+	O
/	O
-	O
0	O
.	O
33	O
mg	O
/	O
ml	O
;	O
n	O
=	O
display	O
dose	O
force	O
display	O
dose	O
force	O
some	O
dose	O
force	O
some	O
some	O
some	O
some	O
9	O
)	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	O
Hp1	O
phenotype	O
(	O
1	O
.	O
26	O
+	O
/	O
-	O
0	O
.	O
33	O
mg	O
/	O
ml	O
;	O
n	O
=	O
9	O
)	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

The	O
allele	O
(	O
Hp2	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
to	O
have	O
,	O
in	O
exons	O
,	O
no	O
mutation	O
,	O
DNA	O
sequencing	O
.	O

The	O
allele	O
(	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
to	O
have	O
in	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O

The	O
other	O
allele	O
(	O
receive	O
dna	O
receive	O
somebody	O
Hp2	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
past	O
dna	O
sequence	O
allelomorph	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
DNA	O
sequencing	O
.	O

,	O
other	O
allele	O
all	O
Hp2	O
)	O
of	O
DNA	O
,	O
Hp2	O
exons	O
Hpdel	O
was	O
found	O
mutation	O
have	O
,	O
in	O
(	O
by	O
/	O
no	O
to	O
with	O
The	O
individuals	O
sequencing	O
.	O

sequencing	O
other	O
allele	O
to	O
Hp2	O
)	O
DNA	O
individuals	O
(	O
Hp2	O
/	O
Hpdel	O
found	O
,	O
by	O
with	O
,	O
in	O
all	O
exons	O
was	O
no	O
mutation	O
,	O
have	O
of	O
The	O
.	O

The	O
other	O
allele	O
(	O
receive	O
dna	O
receive	O
somebody	O
Hp2	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
past	O
dna	O
sequence	O
receive	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
DNA	O
sequencing	O
.	O

The	O
other	O
allelomorph	O
(	O
Hp2	O
)	O
of	O
someone	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
incur	O
to	O
have	O
,	O
in	O
all	O
exons	O
,	O
no	O
mutant	O
,	O
by	O
dna	O
sequence	O
.	O

The	O
other	O
allele	O
(	O
receive	O
dna	O
receive	O
somebody	O
Hp2	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
past	O
dna	O
sequence	O
receive	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
DNA	O
sequencing	O
.	O

,	O
other	O
allele	O
(	O
Hp2	O
)	O
found	O
Hpdel	O
with	O
Hp2	O
/	O
,	O
no	O
of	O
by	O
The	O
individuals	O
have	O
all	O
exons	O
,	O
was	O
mutation	O
in	O
to	O
DNA	O
sequencing	O
.	O

The	O
other	O
allelomorph	O
(	O
Hp2	O
)	O
of	O
someone	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
dna	O
sequence	O
.	O

The	O
other	O
allele	O
(	O
Hp2	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
DNA	O
sequencing	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
cost	O
easily	O
explicate	O
easily	O
explicate	O
explicate	O
cornerstone	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O
.	O

of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
Hp	O
were	O
well	O
explained	O
.	O

along	O
the	O
footing	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanics	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanics	O
of	O
anomalous	O
heritage	O
of	O
horsepower	O
phenotypes	O
were	O
comfortably	O
explicate	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
anhaptoglobinemia	B
and	O
mechanism	O
of	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
explained	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
cost	O
easily	O
explicate	O
easily	O
explicate	O
explicate	O
cornerstone	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O
.	O

on	O
the	O
fundament	O
of	O
the	O
portray	O
discipline	O
,	O
the	O
mechanics	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanics	O
of	O
anomalous	O
inheritance	O
of	O
horsepower	O
phenotypes	O
were	O
well	O
excuse	O
.	O

on	O
the	O
cornerstone	O
of	O
the	O
pose	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanism	O
of	O
anomalous	O
heritage	O
of	O
hp	O
phenotypes	O
were	O
intimately	O
explicate	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
and	O
of	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
cost	O
easily	O
explicate	O
easily	O
explicate	O
explicate	O
cornerstone	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O
.	O

Hp	O
the	O
basis	O
of	O
the	O
present	O
study	O
of	O
explained	O
mechanism	O
of	O
anhaptoglobinemia	B
the	O
and	O
well	O
of	O
anomalous	O
inheritance	O
,	O
.	O
phenotypes	O
were	O
mechanism	O
the	O
On	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O
.	O

remains	O
,	O
the	O
mechanism	O
unknown	O
hypohaptoglobinemia	B
However	O
of	O

nevertheless	O
,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	B
stiff	O
unknown	O

the	O
hypohaptoglobinemia	B
remains	O
unknown	O

However	O
chemical	O
mechanism	O
unknown	O
quantity	O
,	O
the	O
mechanism	B
of	O
hypohaptoglobinemia	O

However	O
the	O
mechanism	O
remains	O
unknown	O

However	O
of	O
the	O
mechanism	O
,	O
hypohaptoglobinemia	B
unknown	O
remains	O

unknown	O
mechanism	O
the	O
,	O
of	O
hypohaptoglobinemia	B
remains	O
However	O

However	O
chemical	O
mechanism	O
unknown	O
quantity	O
,	O
the	O
mechanism	B
of	O
hypohaptoglobinemia	O

withal	O
,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	B
remains	O
unidentified	O

However	O
chemical	O
mechanism	O
unknown	O
quantity	O
,	O
the	O
mechanism	B
of	O
hypohaptoglobinemia	O

However	O
,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	B
remains	O
unknown	O

ATM	O
mutations	O
and	O
phenotypes	O
isle	O
indium	O
reflexion	O
cancer	O
the	O
crab	O
indium	B
in	I
ataxia	I
-	O
telangiectasia	O
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
family	O
line	O
summit	O
and	O
the	B
risk	O
of	B
leukemia	O
,	O
lymphoma	B
,	I
and	O
breast	O
cancer	O

ATM	O
mutations	O
and	O
phenotypes	O
isle	O
indium	O
reflexion	O
cancer	O
the	O
crab	O
indium	B
in	I
ataxia	I
-	O
telangiectasia	O
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
family	O
line	O
brits	O
and	O
the	B
risk	O
of	B
leukemia	O
,	O
lymphoma	B
,	I
and	O
breast	O
cancer	O

cancer	O
mutations	O
lymphoma	O
expression	O
in	O
ataxia	B
breast	I
telangiectasia	I
phenotypes	O
in	O
the	O
British	O
risk	O
:	O
and	O
families	O
mutant	O
ATM	O
and	O
the	O
Isles	O
of	O
leukemia	B
,	O
of	B
-	O
and	O
,	B
ATM	I
.	O

ATM	O
mutations	O
and	O
phenotypes	O
isle	O
indium	O
reflexion	O
cancer	O
the	O
crab	O
indium	B
in	I
ataxia	I
-	O
telangiectasia	O
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
family	O
line	O
summit	O
and	O
the	B
risk	O
of	B
leukemia	O
,	O
lymphoma	B
,	I
and	O
breast	O
cancer	O

ATM	O
mutations	O
and	O
phenotypes	O
in	O
ataxia	B
-	I
families	O
in	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
risk	O
of	O
leukemia	B
,	O
lymphoma	B
,	O
and	O
breast	B
cancer	I
.	O

ATM	O
sport	O
and	O
phenotypes	O
in	O
ataxy	B
-	I
telangiectasia	I
syndicate	O
in	O
the	O
British	O
islet	O
:	O
manifestation	O
of	O
sport	O
ATM	O
and	O
the	O
endangerment	O
of	O
leucaemia	B
,	O
lymphoma	B
,	O
and	O
titty	B
cancer	I
.	O

mutant	O
mutations	O
and	O
phenotypes	O
in	O
ataxia	B
of	I
British	I
families	O
in	O
the	O
ATM	O
cancer	O
,	O
of	O
expression	O
ATM	O
lymphoma	O
and	O
the	O
risk	O
-	O
leukemia	B
:	O
telangiectasia	B
,	O
and	O
breast	B
Isles	I
.	O

risk	O
mutations	O
and	O
and	O
in	O
ataxia	B
-	I
,	I
,	O
in	O
cancer	O
British	O
and	O
the	O
leukemia	O
of	O
mutant	O
ATM	O
phenotypes	O
:	O
lymphoma	O
of	O
expression	B
families	O
ATM	B
telangiectasia	O
Isles	O
breast	B
the	I
.	O

ATM	O
sport	O
and	O
phenotypes	O
in	O
dyssynergia	B
-	I
telangiectasia	I
family	O
in	O
the	O
brits	O
isle	O
:	O
expression	O
of	O
sport	O
ATM	O
and	O
the	O
hazard	O
of	O
leukemia	B
,	O
lymphoma	B
,	O
and	O
knocker	B
crab	I
.	O

ATM	O
mutations	O
and	O
phenotypes	O
in	O
-	I
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
ATM	O
and	O
the	O
risk	O
of	O
leukemia	B
,	O
and	O
breast	B
cancer	I

ATM	O
mutations	O
and	O
phenotypes	O
in	O
ataxia	B
-	I
telangiectasia	I
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
and	O
the	O
risk	O
of	O
leukemia	B
,	O
lymphoma	B
,	O
and	O
breast	B
cancer	I
.	O

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
brits	O
isle	O
brits	O
isle	O
isle	O
note	O
patient	O
patients	O
in	O
the	O
British	O
Isles	O
.	O

the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
patients	O
the	O
British	O
Isles	O
.	O

We	O
report	O
the	O
spectrum	O
of	O
ilx	O
ATM	O
mutations	O
watch	O
in	O
ataxy	B
-	I
telangiectasia	I
(	O
A	B
-	I
t	I
)	O
patients	O
in	O
the	O
british	O
islet	O
.	O

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
observed	O
in	O
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
the	O
British	O
Isles	O
.	O

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
brits	O
isle	O
brits	O
isle	O
isle	O
note	O
note	O
patients	O
in	O
the	O
British	O
Isles	O
.	O

We	O
cover	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutant	O
detect	O
in	O
ataxy	B
-	I
telangiectasia	I
(	O
A	B
-	I
thyroxine	I
)	O
patients	O
in	O
the	O
british	O
islet	O
.	O

We	O
story	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
dyssynergia	B
-	I
telangiectasia	I
(	O
A	B
-	I
thyroxin	I
)	O
patients	O
in	O
the	O
brits	O
isle	O
.	O

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
ataxia	B
(	O
A	B
-	I
T	I
)	O
patients	O
in	O
the	O
British	O

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
brits	O
isle	O
brits	O
isle	O
isle	O
note	O
note	O
patients	O
in	O
the	O
British	O
Isles	O
.	O

)	O
report	O
the	O
ataxia	O
of	O
59	O
ATM	O
patients	O
.	O
in	O
spectrum	B
-	I
telangiectasia	I
(	O
Isles	B
-	I
T	I
the	O
mutations	O
We	O
in	O
British	O
A	O
observed	O

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
in	O
the	O
British	O
Isles	O
.	O

Of	O
51	O
ATM	O
sport	O
key	O
in	O
kin	O
indigene	O
to	O
the	O
british	O
isle	O
,	O
xi	O
were	O
founder	O
sport	O
,	O
and	O
2	O
of	O
these	O
xi	O
confab	O
a	O
modest	O
clinical	O
phenotype	O
with	O
honour	O
to	O
both	O
cerebellar	B
retrogression	I
and	O
cellular	O
features	O
.	O

51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
,	O
11	O
were	O
founder	O
mutations	O
and	O
2	O
conferred	O
clinical	O
phenotype	O
to	O
degeneration	I
and	O
cellular	O
features	O

phenotype	O
and	O
ATM	O
mutations	O
mutations	O
in	O
of	O
both	O
to	O
the	O
British	O
Isles	O
,	O
a	O
.	O
founder	O
identified	O
to	O
and	O
2	O
native	O
these	O
11	O
conferred	O
51	O
milder	O
clinical	O
Of	O
,	O
respect	O
with	O
families	O
cerebellar	B
degeneration	I
11	O
cellular	O
features	O
were	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
to	O
the	O
British	O
Isles	O
11	O
were	O
founder	O
mutations	O
,	O
2	O
of	O
these	O
11	O
a	O
milder	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B
degeneration	I
and	O
features	O
.	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B
degeneration	I
and	O
cellular	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
features	O
.	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B
degeneration	I
and	O
cellular	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
features	O
.	O

Of	O
li	O
ATM	O
mutations	O
identified	O
in	O
home	O
aborigine	O
to	O
the	O
British	O
islet	O
,	O
xi	O
were	O
laminitis	O
mutations	O
,	O
and	O
deuce	O
of	O
these	O
xi	O
consult	O
a	O
milder	O
clinical	O
phenotype	O
with	O
honor	O
to	O
both	O
cerebellar	B
decadency	I
and	O
cellular	O
boast	O
.	O

a	O
and	O
ATM	O
mutations	O
identified	O
in	O
Isles	O
degeneration	O
to	O
the	O
British	O
families	O
,	O
phenotype	O
respect	O
founder	O
mutations	O
,	O
native	O
2	O
of	O
these	O
with	O
conferred	O
Of	O
milder	O
both	O
11	O
were	O
11	O
to	O
cellular	O
cerebellar	B
51	I
and	O
clinical	O
features	O
.	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B
degeneration	I
and	O
cellular	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
fifty	O
one	O
features	O

Of	O
51	O
identified	O
in	O
native	O
to	O
,	O
were	O
founder	O
mutations	O
and	O
2	O
of	O
11	O
conferred	O
a	O
milder	O
clinical	O
respect	O
to	O
both	O
cerebellar	B
degeneration	I
and	O
cellular	O
features	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B
degeneration	I
and	O
cellular	O
features	O
.	O

We	O
report	O
,	O
in	O
two	O
A	B
-	I
T	I
cash	O
machine	O
summit	O
cancer	O
the	O
crab	O
indium	O
	O
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	B
risk	I
of	O
breast	O
cancer	O
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	O
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
a	B
less	I
severe	I
A	O
-	O
T	O
phenotype	O
in	O
terms	O
of	O
the	B
degree	I
of	O
cerebellar	O
degeneration	O
take	O
a	O
chance	O
take	O
a	O
chance	O
take	O
a	O
chance	O
take	O
a	O
chance	O
take	O

We	O
,	O
in	O
A	B
-	I
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T	O
-	O
-	O
G	O
that	O
may	O
be	O
associated	O
with	O
an	O
risk	O
of	O
breast	B
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
.	O
7	O
P	O
.	O
0025	O
,	O
is	O
a	O
less	O
-	I
T	I
terms	O
of	O
degree	O
of	O
.	O

A	O
increased	O
relative	O
.	O
two	O
A	B
-	I
T	I
both	O
,	O
an	O
ATM	O
less	O
breast	O
7271T	O
degree	O
-	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
,	O
severe	O
phenotype	O
=	B
cancer	I
in	O
families	O
homozygotes	O
terms	O
heterozygotes	O
(	O
.	O
risk	O
12	O
although	O
7	O
;	O
P	O
-	O
.	O
0025	O
)	O
report	O
in	O
there	O
is	O
a	O
the	O
risk	O
We	B
of	I
and	I
-	O
in	O
T	O
of	O
mutation	O
(	O
of	O
cerebellar	B
degeneration	I
,	O

We	O
in	O
families	O
,	O
an	O
mutation	O
(	O
-	O
-	O
>	O
that	O
may	O
be	O
associated	O
with	O
increased	O
of	O
breast	B
cancer	I
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
12	O
.	O
7	O
;	O
P	O
although	O
a	O
severe	O
A	B
-	I
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
.	O

We	O
reputation	O
,	O
in	O
ii	O
ampere	B
-	I
T	I
category	O
,	O
an	O
ATM	O
mutant	O
(	O
7271T	O
-	O
-	O
>	O
gib	O
)	O
that	O
may	O
be	O
consort	O
with	O
an	O
increased	O
endangerment	O
of	O
chest	B
cancer	I
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
congeneric	O
endangerment	O
xii	O
.	O
heptad	O
;	O
phosphorus	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
ampere	O
less	O
hard	O
ampere	B
-	I
T	I
phenotype	O
in	O
condition	O
of	O
the	O
level	O
of	O
cerebellar	B
devolution	I
.	O

.	O
T	O
an	O
an	O
,	O
A	B
-	I
severe	I
families	O
two	O
,	O
both	O
mutation	O
(	O
7271T	O
-	O
is	O
>	O
G	O
)	O
that	O
may	O
associated	O
be	O
with	O
of	O
degeneration	O
risk	O
of	O
in	B
cancer	I
in	O
ATM	O
homozygotes	O
phenotype	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	O
and	O
P	O
although	O
less	O
of	O
)	O
,	O
We	O
there	O
cerebellar	O
the	O
=	O
T	O
A	B
-	I
report	I
;	O
in	O
terms	O
0025	O
a	O
degree	O
breast	O
-	B
increased	I
.	O

We	O
report	O
,	O
in	O
two	O
A	B
-	I
T	I
cash	O
machine	O
summit	O
cancer	O
the	O
crab	O
indium	O
family	O
line	O
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	B
increased	I
risk	O
of	O
breast	O
cancer	O
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	O
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	B
a	I
less	I
severe	O
A	O
-	O
T	O
phenotype	O
in	O
terms	O
of	B
the	I
degree	O
of	O
cerebellar	O
degeneration	O
take	O
a	O
chance	O
take	O
a	O
chance	O
take	O
a	O
chance	O
take	O
a	O
chance	O

We	O
report	O
,	O
in	O
two	O
a	B
-	I
t	I
kin	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
that	O
whitethorn	O
be	O
consociate	O
with	O
an	O
increased	O
gamble	O
of	O
bosom	B
crab	I
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
congeneric	O
gamble	O
12	O
.	O
sevener	O
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
a	O
less	O
grievous	O
a	B
-	I
t	I
phenotype	O
in	O
terms	O
of	O
the	O
stage	O
of	O
cerebellar	B
retrogression	I
.	O

We	O
account	O
,	O
in	O
ii	O
adenine	B
-	I
triiodothyronine	I
kinsperson	O
,	O
an	O
ATM	O
variation	O
(	O
7271T	O
-	O
-	O
>	O
guanine	O
)	O
that	O
may	O
be	O
relate	O
with	O
an	O
increased	O
risk	O
of	O
tit	B
cancer	I
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
congeneric	O
risk	O
twelve	O
.	O
septet	O
;	O
phosphorus	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
adenine	O
less	O
severe	O
adenine	B
-	I
triiodothyronine	I
phenotype	O
in	O
terms	O
of	O
the	O
stage	O
of	O
cerebellar	B
decadency	I
.	O

We	O
report	O
,	O
in	O
two	O
A	B
T	I
families	O
ATM	O
mutation	O
(	O
-	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
breast	B
in	O
both	O
and	O
relative	O
risk	O
12	O
.	O
7	O
;	O
P	O
=	O
.	O
0025	O
there	O
is	O
less	O
severe	O
A	B
-	I
phenotype	O
terms	O
of	O
degeneration	I
.	O

We	O
report	O
,	O
in	O
two	O
A	B
-	I
T	I
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B
cancer	I
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	O
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
a	O
less	O
severe	O
A	B
-	I
T	I
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
of	O
cerebellar	B
degeneration	I
.	O

This	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
also	O
allows	O
expression	O
-	O
length	O
ATM	O
protein	O
a	O
level	O
comparable	O
with	O
that	O
unaffected	O
individuals	O
.	O

This	O
(	O
7271T	O
-	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
-	O
length	O
protein	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O

This	O
mutation	O
(	O
7271T	O
fully	O
unmoved	O
distance	O
cash	O
machine	O
-	O
-	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
indium	O
unmoved	O
somebody	O
ampere	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals	O

level	O
mutation	O
(	O
at	O
-	O
-	O
>	O
unaffected	O
that	O
also	O
a	O
expression	O
of	O
full	O
with	O
length	O
ATM	O
protein	O
7271T	O
in	O
allows	O
comparable	O
-	O
)	O
This	O
G	O
individuals	O
.	O

individuals	O
mutation	O
(	O
-	O
-	O
-	O
unaffected	O
G	O
7271T	O
also	O
allows	O
expression	O
full	O
level	O
in	O
)	O
ATM	O
protein	O
at	O
a	O
of	O
comparable	O
with	O
that	O
length	O
>	O
This	O
.	O

This	O
mutation	O
(	O
7271T	O
fully	O
unmoved	O
distance	O
cash	O
machine	O
-	O
-	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
indium	O
unmoved	O
somebody	O
distance	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals	O

This	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
besides	O
let	O
construction	O
of	O
wax	O
-	O
duration	O
ATM	O
protein	O
at	O
a	O
level	O
like	O
with	O
that	O
in	O
untouched	O
somebody	O
.	O

This	O
mutation	O
(	O
7271T	O
fully	O
unmoved	O
distance	O
cash	O
machine	O
-	O
-	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
indium	O
unmoved	O
somebody	O
distance	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals	O

that	O
mutation	O
(	O
7271T	O
-	O
-	O
full	O
expression	O
)	O
also	O
allows	O
ATM	O
comparable	O
>	O
in	O
This	O
G	O
length	O
at	O
a	O
level	O
of	O
with	O
protein	O
-	O
unaffected	O
individuals	O
.	O

This	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
too	O
admit	O
aspect	O
of	O
entire	O
-	O
distance	O
ATM	O
protein	O
at	O
a	O
charge	O
comparable	O
with	O
that	O
in	O
untouched	O
someone	O
.	O

This	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals	O
.	O

In	O
addition	O
lymphoma	O
we	O
have	O
studied	O
,	O
leukemia	B
-	I
T	I
patients	O
proliferation	O
,	O
15	O
families	O
,	O
who	O
developed	O
,	B
in	O
lymphoma	B
mostly	O
preleukemic	O
T	O
-	O
,	O
18	O
,	O
or	O
Hodgkin	B
,	I
A	O
cell	O
in	O
childhood	O
.	O

addition	O
we	O
have	O
studied	O
18	O
A	B
-	I
T	I
patients	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B
,	O
preleukemic	O
T	O
cell	O
,	O
or	O
Hodgkin	B
mostly	O

indiana	O
accession	O
,	O
we	O
have	O
learn	O
18	O
A	B
-	I
T	I
patients	O
,	O
indiana	O
xv	O
families	O
,	O
who	O
acquire	O
leukaemia	B
,	O
lymphoma	B
,	O
preleukemic	O
T	O
-	O
cubicle	O
proliferation	O
,	O
or	O
Hodgkin	B
lymphoma	I
,	O
mostly	O
indiana	O
puerility	O
.	O

,	O
lymphoma	O
,	O
we	O
who	O
studied	O
families	O
,	B
-	I
T	I
patients	O
,	O
in	O
-	O
A	O
,	O
have	O
lymphoma	O
leukemia	B
,	O
15	B
,	O
preleukemic	O
T	O
addition	O
cell	O
proliferation	O
In	O
developed	O
Hodgkin	B
or	I
18	O
mostly	O
in	O
childhood	O
.	O

In	O
addition	O
,	O
we	O
receive	O
have	O
studied	O
18	O
A	B
-	I
T	I
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B
,	O
lymphoma	B
,	O
preleukemic	O
T	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B
lymphoma	I
,	O
mostly	O
in	O
childhood	O
invite	O
invite	O
invite	O
invite	O
invite	O
invite	O
invite	O
invite	O
	O
.	O

-	O
leukemia	O
,	O
we	O
have	O
studied	O
18	O
A	B
-	I
T	I
patients	O
,	O
in	O
,	O
Hodgkin	O
,	O
who	O
developed	O
in	B
,	O
lymphoma	B
,	O
or	O
T	O
In	O
cell	O
,	O
15	O
families	O
preleukemic	B
lymphoma	I
.	O
mostly	O
childhood	O
addition	O
proliferation	O

In	O
addition	O
,	O
we	O
studied	O
-	I
T	I
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
,	O
preleukemic	O
T	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B
lymphoma	I
,	O
mostly	O
in	O
childhood	O
.	O

In	O
gain	O
,	O
we	O
have	O
learn	O
18	O
A	B
-	I
tonne	I
patients	O
,	O
in	O
fifteen	O
fellowship	O
,	O
who	O
break	O
leukaemia	B
,	O
lymphoma	B
,	O
preleukemic	O
tonne	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B
lymphoma	I
,	O
largely	O
in	O
puerility	O
.	O

In	O
addition	O
,	O
we	O
cubicle	O
have	O
studied	O
18	O
A	B
-	I
T	I
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B
,	O
lymphoma	B
,	O
preleukemic	O
T	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B
lymphoma	I
,	O
mostly	O
in	O
childhood	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
stall	O
	O
.	O

In	O
gain	O
,	O
we	O
have	O
analyse	O
xviii	O
amp	B
-	I
thyroxine	I
patients	O
,	O
in	O
fifteen	O
family	O
,	O
who	O
evolve	O
leukemia	B
,	O
lymphoma	B
,	O
preleukemic	O
thyroxine	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B
lymphoma	I
,	O
mostly	O
in	O
puerility	O
.	O

In	O
addition	O
,	O
we	O
have	O
studied	O
18	O
A	B
-	I
T	I
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B
,	O
lymphoma	B
,	O
preleukemic	O
T	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B
lymphoma	I
,	O
mostly	O
in	O
childhood	O
.	O

A	O
wide	O
variety	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
deletions	O
,	O
were	O
seen	O
in	O
these	O
patients	O

A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
frame	O
were	O
seen	O
in	O
these	O
patients	O
.	O

A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
deletions	O
,	O
were	O
indium	O
patient	O
patient	O
form	O
form	O
form	O
seen	O
in	O
these	O
patients	O
.	O

A	O
broad	O
mixture	O
of	O
ATM	O
mutation	O
character	O
,	O
admit	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
cut	O
,	O
were	O
picture	O
in	O
these	O
patients	O
.	O

A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
deletions	O
,	O
were	O
indium	O
patient	O
patient	O
form	O
form	O
form	O
seen	O
in	O
these	O
patients	O
.	O

ampere	O
wide	O
assortment	O
of	O
ATM	O
variation	O
types	O
,	O
including	O
missense	O
variation	O
and	O
in	O
-	O
entrap	O
cut	O
,	O
were	O
seen	O
in	O
these	O
patients	O
.	O

A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
and	O
in	O
frame	O
deletions	O
,	O
were	O
seen	O
in	O
these	O

mutations	O
wide	O
variety	O
seen	O
ATM	O
mutation	O
types	O
including	O
,	O
missense	O
in	O
and	O
-	O
in	O
.	O
deletions	O
,	O
were	O
of	O
A	O
these	O
patients	O
frame	O

a	O
blanket	O
multifariousness	O
of	O
ATM	O
variation	O
typewrite	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
excision	O
,	O
were	O
seen	O
in	O
these	O
patients	O
.	O

frame	O
wide	O
including	O
types	O
ATM	O
mutation	O
deletions	O
,	O
variety	O
missense	O
mutations	O
and	O
these	O
-	O
of	O
A	O
,	O
were	O
seen	O
in	O
in	O
patients	O
.	O

A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
deletions	O
,	O
were	O
seen	O
in	O
these	O
patients	O
.	O

We	O
also	O
also	O
that	O
25	O
patients	O
of	O
many	O
A	B
-	I
T	I
which	O
with	O
in	O
-	O
mutant	O
deletions	O
or	O
mutations	O
missense	O
,	O
all	O
of	O
%	O
were	O
associated	O
show	O
protein	O
expression	O
of	O
frame	O
carried	O
ATM	O
.	O

We	O
that	O
25	O
%	O
of	O
A	B
-	I
carried	O
in	O
frame	O
deletions	O
,	O
of	O
which	O
were	O
associated	O
with	O
expression	O
mutant	O
ATM	O
protein	O
.	O

We	O
also	O
show	O
that	O
colligate	O
build	O
mt	O
25	O
%	O
of	O
all	O
A	B
-	I
T	I
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	O
mutant	O
ATM	O
protein	O
subsume	O
subsume	O
subsume	O
subsume	O
subsume	O
subsume	O
indium	O
.	O

We	O
also	O
show	O
that	O
colligate	O
build	O
twenty	O
five	O
25	O
%	O
of	O
all	B
A	I
-	I
T	O
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	O
mutant	O
ATM	O
protein	O
subsume	O
subsume	O
subsume	O
subsume	O
subsume	O
subsume	O
indium	O

also	O
missense	O
show	O
that	O
25	O
%	O
associated	O
all	O
A	B
-	I
T	I
with	O
carried	O
were	O
of	O
frame	O
deletions	O
or	O
patients	O
mutations	O
,	O
many	O
.	O
which	O
in	O
also	O
of	O
We	O
ATM	O
of	O
mutant	O
expression	O
protein	O
-	O

We	O
also	O
show	O
that	O
25	O
%	O
A	B
-	I
T	I
patients	O
in	O
-	O
frame	O
deletions	O
or	O
mutations	O
,	O
many	O
of	O
were	O
also	O
with	O
expression	O
of	O
mutant	O
ATM	O
protein	O
.	O

We	O
also	O
usher	O
that	O
25	O
%	O
of	O
all	O
angstrom	B
-	I
tetraiodothyronine	I
patients	O
take	O
in	O
-	O
framing	O
excision	O
or	O
missense	O
sport	O
,	O
many	O
of	O
which	O
were	O
also	O
assort	O
with	O
aspect	O
of	O
sport	O
ATM	O
protein	O
.	O

We	O
also	O
evidence	O
that	O
25	O
%	O
of	O
all	O
ampere	B
-	I
liothyronine	I
patients	O
expect	O
in	O
-	O
skeleton	O
deletions	O
or	O
missense	O
variation	O
,	O
many	O
of	O
which	O
were	O
also	O
colligate	O
with	O
formulation	O
of	O
sport	O
ATM	O
protein	O
.	O

We	O
also	O
show	O
that	O
colligate	O
build	O
twenty	O
five	O
25	O
%	O
of	O
all	B
A	I
-	I
T	O
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	O
mutant	O
ATM	O
protein	O
subsume	O
subsume	O
subsume	O
subsume	O
subsume	O
subsume	O
indium	O

We	O
too	O
show	O
that	O
25	O
%	O
of	O
all	O
axerophthol	B
-	I
t	I
patients	O
transmit	O
in	O
-	O
bod	O
omission	O
or	O
missense	O
sport	O
,	O
many	O
of	O
which	O
were	O
too	O
connect	O
with	O
expression	O
of	O
sport	O
atm	O
protein	O
.	O

We	O
also	O
show	O
that	O
25	O
%	O
of	O
all	O
A	B
-	I
T	I
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	O
mutant	O
ATM	O
protein	O
.	O

The	O
DMPK	O
patients	O
largely	O
severely	O
affected	O
to	B
dystrophy	I
gene	O
is	O
hypermethylated	O
proximal	O
myotonic	O
the	O
of	O
expanded	O
CTG	O
repeat	O
.	O

gene	O
of	O
severely	O
affected	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
expanded	O
CTG	O
repeat	O
.	O

The	O
DMPK	O
factor	O
of	O
badly	O
moved	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
mostly	O
exposit	O
CTG	O
repeat	O
.	O

The	O
DMPK	O
factor	O
of	O
sternly	O
unnatural	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
elaborate	O
CTG	O
restate	O
.	O

CTG	O
DMPK	O
gene	O
of	O
severely	O
affected	O
the	B
largely	I
patients	O
is	O
hypermethylated	O
proximal	O
repeat	O
myotonic	O
dystrophy	O
expanded	O
to	O
The	O
.	O

The	O
DMPK	O
severely	O
affected	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
.	O

The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
repeat	O
factor	O
factor	O
factor	O
factor	O
patient	O
.	O

The	O
DMPK	O
factor	O
of	O
sternly	O
affected	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
elaborate	O
CTG	O
replicate	O
.	O

The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
repeat	O
factor	O
factor	O
factor	O
factor	O
factor	O
.	O

the	O
DMPK	O
gene	O
hypermethylated	O
severely	O
affected	O
myotonic	B
.	I
largely	O
is	O
of	O
proximal	O
The	O
to	O
patients	O
expanded	O
CTG	O
repeat	O
dystrophy	O

The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
repeat	O
.	O

Using	O
restriction	O
,	O
we	O
characterized	O
methylation	O
pattern	O
on	O
5	O
side	O
of	O
the	O
CTG	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
with	O
dystrophy	I
,	O
showing	O
of	O
the	O
repetitive	O
sequence	O
.	O

Using	O
methylation	O
-	O
sensitive	O
restriction	O
characterized	O
the	O
methylation	O
pattern	O
on	O
5	O
side	O
repeat	O
DMPK	O
gene	O
individuals	O
patients	O
affected	O
with	O
myotonic	B
,	O
showing	O
the	O
repetitive	O
.	O

Using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B
dystrophy	I
,	O
showing	O
episode	O
limitation	O
insistent	O
episode	O
limitation	O
limitation	O
limitation	O
limitation	O
limitation	O
limitation	O
limitation	O
limitation	O
expansions	O
of	O
the	O
repetitive	O
sequence	O
.	O

victimisation	O
methylation	O
-	O
sensitive	O
limitation	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
practice	O
on	O
the	O
fin	O
slope	O
of	O
the	O
CTG	O
reiterate	O
in	O
the	O
DMPK	O
factor	O
of	O
convention	O
individuals	O
and	O
of	O
patients	O
unnatural	O
with	O
myotonic	B
dystrophy	I
,	O
evince	O
expansions	O
of	O
the	O
repetitious	O
succession	O
.	O

Using	O
methylation	O
affected	O
sensitive	O
restriction	O
showing	O
,	O
CTG	O
characterized	O
the	O
methylation	O
individuals	O
repeat	O
the	O
5	O
we	O
of	O
the	O
of	O
on	O
in	O
myotonic	O
DMPK	O
enzymes	O
of	O
side	O
pattern	O
the	O
of	O
patients	O
-	O
and	O
with	B
dystrophy	I
,	O
gene	O
expansions	O
normal	O
the	O
repetitive	O
sequence	O
.	O

use	O
methylation	O
-	O
medium	O
limitation	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
v	O
slope	O
of	O
the	O
CTG	O
reprise	O
in	O
the	O
DMPK	O
factor	O
of	O
rule	O
somebody	O
and	O
of	O
patients	O
involve	O
with	O
myotonic	B
dystrophy	I
,	O
designate	O
expansions	O
of	O
the	O
insistent	O
sequence	O
.	O

,	O
CTG	O
-	O
sensitive	O
restriction	O
enzymes	O
.	O
we	O
characterized	O
the	O
methylation	O
sequence	O
on	O
of	O
patients	O
side	O
of	O
the	O
and	O
repeat	O
in	O
the	O
showing	O
gene	O
the	O
normal	O
dystrophy	O
methylation	O
with	O
DMPK	O
affected	O
of	O
myotonic	B
5	I
Using	O
individuals	O
expansions	O
of	O
the	O
repetitive	O
pattern	O
,	O

Using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
characterized	O
the	O
methylation	O
pattern	O
the	O
5	O
side	O
of	O
the	O
repeat	O
in	O
the	O
DMPK	O
of	O
normal	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B
dystrophy	I
,	O
expansions	O
of	O
repetitive	O
sequence	O
.	O

the	O
of	O
-	O
sensitive	O
of	O
enzymes	O
in	O
with	O
characterized	O
the	O
methylation	O
pattern	O
on	O
,	O
of	O
side	O
restriction	O
affected	O
CTG	O
repeat	O
the	O
the	O
DMPK	O
gene	O
and	O
normal	O
individuals	O
.	O
the	O
patients	O
of	O
methylation	O
myotonic	B
dystrophy	I
,	O
showing	O
expansions	O
5	O
Using	O
repetitive	O
sequence	O
we	O

Using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B
dystrophy	I
,	O
showing	O
episode	O
limitation	O
insistent	O
episode	O
limitation	O
limitation	O
limitation	O
limitation	O
limitation	O
limitation	O
limitation	O
indium	O
expansions	O
of	O
the	O
repetitive	O
sequence	O
.	O

Using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B
dystrophy	I
,	O
showing	O
expansions	O
of	O
the	O
repetitive	O
sequence	O
.	O

HindIII	O
gene	O
segment	O
genomic	O
corresponds	O
to	O
the	O
analyzed	O
11	O
-	O
exons	O
fragment	O
The	O
carrying	O
SacI	O
-	O
15	O
.	O

The	O
cistron	O
section	O
examine	O
gibe	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
xv	O
.	O

The	O
cistron	O
section	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
transmit	O
exons	O
xi	O
-	O
xv	O
.	O

The	O
gene	O
segment	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
15	O
.	O

The	O
factor	O
section	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
express	O
exons	O
eleven	O
-	O
fifteen	O
.	O

The	O
gene	O
section	O
segment	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
15	O
part	O
part	O
part	O
section	O
.	O

The	O
gene	O
segment	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
fragment	O
carrying	O
11	O
-	O
15	O
.	O

The	O
gene	O
section	O
segment	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
15	O
part	O
part	O
part	O
section	O
.	O

gene	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
.	O

The	O
gene	O
SacI	O
11	O
corresponds	O
to	O
carrying	O
genomic	O
segment	O
-	O
HindIII	O
fragment	O
the	O
exons	O
analyzed	O
-	O
15	O
.	O

The	O
gene	O
segment	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
15	O
.	O

There	O
constitutive	O
in	O
intron	O
12	O
sites	O
,	O
localized	O
1	O
159	O
-	O
,	O
232	O
bp	O
the	O
CTG	O
repeat	O
,	O
whereas	O
,	O
not	O
all	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
,	O
and	O
HpaII	O
in	O
this	O
normal	O
most	O
the	O
patients	O
.	O

There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
upriver	O
limitation	O
internet	O
site	O
cost	O
iterate	O
somebody	O
indium	O
virtually	O
limitation	O
restriction	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
localized	O
1	O
,	O
159	O
-	O
1	O
,	O
232	O
bp	O
upstream	O
of	O
the	O
CTG	O
repeat	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
indium	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
region	O
are	O
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
most	O
of	O
the	O
patients	O
upstream	O
upstream	O
upstream	O
upstream	O
upstream	O
upstream	O
upstream	O
most	O

not	O
the	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
restriction	O
sites	O
of	O
SacII	O
and	O
.	O
,	O
localized	O
1	O
,	O
of	O
-	O
1	O
,	O
in	O
bp	O
,	O
of	O
if	O
and	O
individuals	O
repeat	O
whereas	O
all	O
,	O
of	O
There	O
159	O
,	O
of	O
the	O
other	O
sites	O
is	O
SacII	O
232	O
HhaI	O
,	O
CTG	O
HpaII	O
upstream	O
this	O
region	O
are	O
unmethylated	O
most	O
in	O
normal	O
the	O
and	O
,	O
most	O
,	O
patients	O
HhaI	O

There	O
is	O
constitutional	O
methylation	O
in	O
intron	O
xii	O
at	O
limitation	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
place	O
ane	O
,	O
159	O
-	O
ane	O
,	O
232	O
bp	O
upriver	O
of	O
the	O
CTG	O
reprise	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
part	O
are	O
unmethylated	O
,	O
in	O
convention	O
person	O
and	O
most	O
of	O
the	O
patients	O
.	O

There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
upriver	O
limitation	O
internet	O
site	O
cost	O
iterate	O
somebody	O
indium	O
virtually	O
limitation	O
restriction	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
localized	O
1	O
,	O
159	O
-	O
1	O
,	O
232	O
bp	O
upstream	O
of	O
the	O
CTG	O
repeat	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
indium	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
region	O
are	O
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
most	O
of	O
the	O
patients	O
upstream	O
upstream	O
upstream	O
upstream	O
upstream	O
upstream	O
upstream	O
most	O

HhaI	O
and	O
constitutive	O
methylation	O
in	O
intron	O
the	O
1	O
restriction	O
sites	O
of	O
SacII	O
and	O
region	O
of	O
localized	O
at	O
whereas	O
159	O
-	O
is	O
,	O
232	O
bp	O
,	O
of	O
the	O
the	O
,	O
,	O
repeat	O
12	O
,	O
if	O
not	O
all	O
,	O
,	O
CTG	O
other	O
sites	O
upstream	O
SacII	O
,	O
There	O
,	O
in	O
HpaII	O
this	O
most	O
HhaI	O
and	O
unmethylated	O
of	O
are	O
normal	O
individuals	O
1	O
most	O
of	O
in	O
patients	O
.	O

there	O
is	O
constituent	O
methylation	O
in	O
intron	O
12	O
at	O
confinement	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
localised	O
unity	O
,	O
159	O
-	O
unity	O
,	O
232	O
bp	O
upriver	O
of	O
the	O
CTG	O
retell	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
part	O
are	O
unmethylated	O
,	O
in	O
pattern	O
someone	O
and	O
most	O
of	O
the	O
patients	O
.	O

is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
of	O
SacII	O
and	O
HhaI	O
,	O
localized	O
1	O
159	O
-	O
232	O
bp	O
upstream	O
the	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
sites	O
SacII	O
,	O
,	O
in	O
this	O
region	O
are	O
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
patients	O
.	O

There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
upriver	O
limitation	O
internet	O
site	O
cost	O
iterate	O
somebody	O
indium	O
virtually	O
limitation	O
restriction	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
localized	O
1	O
,	O
159	O
-	O
1	O
,	O
232	O
bp	O
upstream	O
of	O
the	O
CTG	O
repeat	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
patient	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
region	O
are	O
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
most	O
of	O
the	O
patients	O
upstream	O
upstream	O
upstream	O
upstream	O
upstream	O
upstream	O
upstream	O
most	O

There	O
is	O
most	O
methylation	O
in	O
intron	O
of	O
159	O
restriction	O
sites	O
of	O
sites	O
-	O
HhaI	O
,	O
localized	O
1	O
,	O
of	O
and	O
1	O
HpaII	O
232	O
bp	O
upstream	O
at	O
the	O
patients	O
repeat	O
,	O
whereas	O
in	O
the	O
if	O
not	O
all	O
,	O
of	O
the	O
other	O
SacII	O
12	O
most	O
,	O
HhaI	O
.	O
and	O
,	O
in	O
this	O
region	O
are	O
unmethylated	O
of	O
constitutive	O
and	O
,	O
normal	O
SacII	O
,	O
,	O
CTG	O
individuals	O

There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
restriction	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
localized	O
1	O
,	O
159	O
-	O
1	O
,	O
232	O
bp	O
upstream	O
of	O
the	O
CTG	O
repeat	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
region	O
are	O
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
most	O
of	O
the	O
patients	O
.	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
receive	O
mutate	O
allelomorph	O
mutate	O
allelomorph	O
allelomorph	O
notwithstanding	O
was	O
found	O
in	O
the	O
mutated	O
allele	O
.	O

of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
found	O
the	O
mutated	O
allele	O
.	O

In	O
a	O
amount	O
of	O
young	O
and	O
gravely	O
affected	O
patients	O
,	O
nevertheless	O
,	O
thoroughgoing	O
methylation	O
of	O
these	O
confinement	O
sites	O
was	O
incur	O
in	O
the	O
mutated	O
allelomorph	O
.	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
,	O
complete	O
of	O
these	O
restriction	O
sites	O
was	O
found	O
in	O
allele	O
.	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
receive	O
mutate	O
allelomorph	O
mutate	O
allelomorph	O
allelomorph	O
numerate	O
was	O
found	O
in	O
the	O
mutated	O
allele	O
.	O

in	O
a	O
number	O
of	O
young	O
and	O
gravely	O
regard	O
patients	O
,	O
still	O
,	O
consummate	O
methylation	O
of	O
these	O
confinement	O
sites	O
was	O
found	O
in	O
the	O
mutated	O
allelomorph	O
.	O

inch	O
a	O
number	O
of	O
young	O
and	O
sternly	O
affected	O
patients	O
,	O
nonetheless	O
,	O
pure	O
methylation	O
of	O
these	O
restriction	O
situation	O
was	O
constitute	O
inch	O
the	O
mutated	O
allelomorph	O
.	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
complete	O
these	O
restriction	O
sites	O
was	O
found	O
in	O
the	O
mutated	O
allele	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
receive	O
mutate	O
allelomorph	O
mutate	O
allelomorph	O
allelomorph	O
numerate	O
was	O
found	O
in	O
the	O
mutated	O
allele	O
.	O

found	O
a	O
number	O
however	O
young	O
and	O
severely	O
was	O
allele	O
,	O
of	O
,	O
methylation	O
complete	O
mutated	O
these	O
restriction	O
sites	O
affected	O
.	O
in	O
the	O
of	O
patients	O
In	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
was	O
found	O
in	O
the	O
mutated	O
allele	O
.	O

In	O
of	O
patients	O
the	O
onset	O
of	O
the	O
disease	O
was	O
congenital	O
.	O

in	O
most	O
of	O
these	O
patients	O
,	O
the	O
oncoming	O
of	O
the	O
disease	O
was	O
innate	O
.	O

onset	O
these	O
of	O
most	O
patients	O
,	O
the	O
In	O
of	O
.	O
disease	O
was	O
congenital	O
the	O

In	O
most	O
of	O
these	O
patients	O
,	O
the	O
onset	O
the	O
disease	O
congenital	O
.	O

In	O
most	O
onrush	O
innate	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
innate	O
patient	O
the	O
disease	O
was	O
congenital	O
.	O

In	O
most	O
onrush	O
innate	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
innate	O
onrush	O
the	O
disease	O
was	O
congenital	O
.	O

indium	O
most	O
of	O
these	O
patients	O
,	O
the	O
onrush	O
of	O
the	O
disease	O
was	O
innate	O
.	O

congenital	O
most	O
of	O
In	O
onset	O
,	O
the	O
was	O
of	O
the	O
disease	O
patients	O
these	O
.	O

In	O
most	O
onrush	O
innate	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
innate	O
patient	O
the	O
disease	O
was	O
congenital	O
.	O

inwards	O
most	O
of	O
these	O
patients	O
,	O
the	O
oncoming	O
of	O
the	O
disease	O
was	O
inborn	O
.	O

In	O
most	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
the	O
disease	O
was	O
congenital	O
.	O

in	O
consensus	O
vivo	O
footprinting	O
data	O
gave	O
.	O
for	O
protein	O
-	O
DNA	O
gene	O
in	O
CTG	O
significant	O
at	O
an	O
Sp1	O
for	O
binding	O
site	O
upstream	O
cells	O
the	O
normal	O
repeat	O
interaction	O
in	O
of	O
of	O
reduction	O
a	O
this	O
genes	O
Preliminary	O
and	O
with	O
a	O
hypermethylated	O
DMPK	O
contact	O
evidence	O
.	O

Preliminary	O
in	O
vivo	O
data	O
gave	O
evidence	O
for	O
protein	O
-	O
DNA	O
normal	O
genes	O
at	O
Sp1	O
binding	O
site	O
upstream	O
CTG	O
significant	O
reduction	O
of	O
interaction	O
in	O
with	O
a	O
hypermethylated	O
.	O
.	O

prelude	O
in	O
vivo	O
footprinting	O
information	O
gave	O
manifest	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
pattern	O
cistron	O
at	O
an	O
Sp1	O
consensus	O
attach	O
locate	O
upriver	O
of	O
the	O
CTG	O
ingeminate	O
and	O
for	O
a	O
pregnant	O
reducing	O
of	O
this	O
interaction	O
in	O
cells	O
with	O
a	O
hypermethylated	O
DMPK	O
factor	O
.	O
.	O

prelude	O
in	O
vivo	O
footprinting	O
information	O
break	O
manifest	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
convention	O
genes	O
at	O
an	O
Sp1	O
consensus	O
binding	O
site	O
upriver	O
of	O
the	O
CTG	O
reduplicate	O
and	O
for	O
a	O
important	O
simplification	O
of	O
this	O
interaction	O
in	O
cells	O
with	O
a	O
hypermethylated	O
DMPK	O
factor	O
.	O
.	O

Preliminary	O
in	O
of	O
footprinting	O
data	O
gave	O
evidence	O
consensus	O
protein	O
-	O
DNA	O
in	O
.	O
normal	O
genes	O
reduction	O
an	O
Sp1	O
binding	O
for	O
site	O
this	O
of	O
cells	O
CTG	O
and	O
for	O
upstream	O
a	O
significant	O
at	O
a	O
repeat	O
interaction	O
in	O
the	O
with	O
vivo	O
hypermethylated	O
DMPK	O
gene	O
.	O
contact	O

Preliminary	O
in	O
vivo	O
data	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	O
site	O
upstream	O
of	O
the	O
CTG	O
repeat	O
and	O
for	O
a	O
significant	O
reduction	O
of	O
this	O
interaction	O
in	O
with	O
hypermethylated	O
DMPK	O
gene	O
.	O
.	O

Preliminary	O
in	O
vivo	O
footprinting	O
data	O
gave	O
evidence	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	O
an	O
Sp1	O
consensus	O
binding	O
site	O
upstream	O
of	O
the	O
CTG	O
repeat	O
and	O
for	O
a	O
significant	O
reduction	O
of	O
this	O
interaction	O
in	O
cells	O
factor	O
datum	O
datum	O
factor	O
datum	O
datum	O
datum	O
datum	O
datum	O
datum	O
datum	O
datum	O
with	O
a	O
hypermethylated	O
DMPK	O
gene	O
.	O
.	O

hypermethylated	O
CTG	O
vivo	O
footprinting	O
an	O
gave	O
site	O
of	O
protein	O
-	O
DNA	O
contact	O
in	O
evidence	O
a	O
at	O
data	O
reduction	O
consensus	O
binding	O
normal	O
upstream	O
of	O
the	O
for	O
repeat	O
and	O
.	O
Sp1	O
significant	O
a	O
in	O
this	O
interaction	O
in	O
cells	O
with	O
genes	O
Preliminary	O
DMPK	O
gene	O
for	O
.	O

Preliminary	O
in	O
vivo	O
data	O
evidence	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	O
Sp1	O
consensus	O
binding	O
site	O
upstream	O
for	O
reduction	O
this	O
interaction	O
in	O
with	O
a	O
hypermethylated	O
DMPK	O
gene	O
.	O

prelim	O
in	O
vivo	O
footprinting	O
information	O
make	O
grounds	O
for	O
protein	O
-	O
DNA	O
liaison	O
in	O
normal	O
factor	O
at	O
an	O
Sp1	O
consensus	O
attach	O
place	O
upriver	O
of	O
the	O
CTG	O
ingeminate	O
and	O
for	O
a	O
meaning	O
reduction	O
of	O
this	O
interaction	O
in	O
cells	O
with	O
a	O
hypermethylated	O
DMPK	O
factor	O
.	O
.	O

Preliminary	O
in	O
vivo	O
footprinting	O
data	O
gave	O
evidence	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	O
an	O
Sp1	O
consensus	O
binding	O
site	O
upstream	O
of	O
the	O
CTG	O
repeat	O
and	O
for	O
a	O
significant	O
reduction	O
of	O
this	O
interaction	O
in	O
cells	O
with	O
a	O
hypermethylated	O
DMPK	O
gene	O
.	O
.	O

lowers	O
hemochromatosis	B
gene	O
transferrin	O
complexes	O
with	O
the	O
product	O
ligand	O
and	O
for	O
its	O
The	O
affinity	O
receptor	O
binding	O
.	O

The	O
hemochromatosis	B
factor	O
ware	O
complexes	O
with	O
the	O
siderophilin	O
receptor	O
and	O
lowers	O
its	O
kinship	O
for	O
ligand	O
bandage	O
.	O

The	O
hemochromatosis	B
factor	O
product	O
complexes	O
with	O
the	O
siderophilin	O
receptor	O
and	O
frown	O
its	O
affinity	O
for	O
ligand	O
bandaging	O
.	O

The	O
hemochromatosis	B
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
.	O

The	O
hemochromatosis	B
factor	O
product	O
complexes	O
with	O
the	O
siderophilin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
bandage	O
.	O

The	O
hemochromatosis	B
siderophilin	O
factor	O
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
transferrin	O
transferrin	O
element	O
.	O

The	O
hemochromatosis	B
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
and	O
lowers	O
affinity	O
for	O
ligand	O
binding	O
.	O

The	O
hemochromatosis	B
siderophilin	O
factor	O
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
transferrin	O
transferrin	O
element	O
.	O

hemochromatosis	B
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O

The	O
hemochromatosis	B
receptor	O
ligand	O
complexes	O
with	O
affinity	O
transferrin	O
gene	O
and	O
lowers	O
its	O
the	O
for	O
product	O
binding	O
.	O

The	O
hemochromatosis	B
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
.	O

We	O
recently	O
write	O
up	O
ampere	O
account	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	B
hereditary	I
hemochromatosis	O
called	O
HFE	O
clone	O

called	O
recently	O
reported	O
.	O
positional	O
cloning	O
of	O
a	O
HFE	O
gene	O
for	O
hereditary	B
We	I
hemochromatosis	O
candidate	O
the	O

We	O
recently	O
element	O
ampere	O
factor	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	B
hemochromatosis	I
called	O
HFE	O
clone	O
.	O

We	O
latterly	O
reported	O
the	O
positional	O
clone	O
of	O
a	O
candidate	O
cistron	O
for	O
patrimonial	B
hemochromatosis	I
called	O
HFE	O
.	O

hemochromatosis	O
recently	O
reported	O
a	O
positional	O
cloning	O
called	O
the	O
candidate	O
gene	O
We	O
hereditary	B
for	I
of	O
HFE	O
.	O

We	O
recently	O
write	O
up	O
ampere	O
account	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	B
hereditary	I
hemochromatosis	O
called	O
HFE	O
clone	O

We	O
recently	O
cover	O
the	O
positional	O
clone	O
of	O
a	O
campaigner	O
gene	O
for	O
hereditary	B
hemochromatosis	I
name	O
HFE	O
.	O

We	O
late	O
reported	O
the	O
positional	O
clone	O
of	O
a	O
nominee	O
cistron	O
for	O
hereditary	B
hemochromatosis	I
called	O
HFE	O
.	O

We	O
recently	O
candidate	O
.	O
positional	O
cloning	O
hemochromatosis	O
a	O
reported	O
gene	O
for	O
hereditary	B
of	I
called	O
the	O
HFE	O

recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
for	O
hereditary	B
hemochromatosis	I
called	O
HFE	O
.	O

We	O
recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	B
hemochromatosis	I
called	O
HFE	O
.	O

The	O
a	O
of	O
the	O
major	O
complex	O
class	O
I	O
like	O
family	O
,	O
was	O
found	O
a	O
mutation	O
,	O
Cys	O
-	O
282	O
-	O
-	O
(	O
)	O
,	O
in	O
%	O
of	O
patient	O
chromosomes	O
.	O

The	O
gene	O
product	O
,	O
a	O
major	O
histocompatibility	O
complex	O
class	O
I	O
like	O
family	O
to	O
mutation	O
,	O
282	O
>	O
Tyr	O
(	O
C282Y	O
,	O
in	O
of	O
patient	O
.	O

The	O
gene	O
product	O
,	O
a	O
member	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
-	O
like	O
family	O
,	O
was	O
found	O
to	O
have	O
a	O
mutation	O
,	O
Cys	O
-	O
282	O
-	O
-	O
>	O
Tyr	O
(	O
C282Y	O
)	O
,	O
in	O
chromosome	O
ampere	O
patient	O
role	O
chromosome	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
85	O
%	O
of	O
patient	O
chromosomes	O

The	O
factor	O
product	O
,	O
a	O
phallus	O
of	O
the	O
major	O
histocompatibility	O
composite	O
class	O
I	O
-	O
like	O
house	O
,	O
was	O
plant	O
to	O
have	O
a	O
sport	O
,	O
Cys	O
-	O
282	O
-	O
-	O
>	O
tyr	O
(	O
C282Y	O
)	O
,	O
in	O
85	O
%	O
of	O
patient	O
chromosomes	O
.	O

The	O
gene	O
Tyr	O
,	O
a	O
in	O
of	O
found	O
major	O
histocompatibility	O
complex	O
282	O
to	O
-	O
like	O
the	O
,	O
was	O
%	O
I	O
have	O
C282Y	O
mutation	O
member	O
Cys	O
family	O
class	O
a	O
-	O
>	O
product	O
-	O
(	O
)	O
,	O
,	O
85	O
-	O
of	O
patient	O
chromosomes	O
.	O

The	O
factor	O
intersection	O
,	O
a	O
extremity	O
of	O
the	O
major	O
histocompatibility	O
composite	O
course	O
ace	O
-	O
wish	O
family	O
,	O
was	O
see	O
to	O
have	O
a	O
mutation	O
,	O
Cys	O
-	O
282	O
-	O
-	O
>	O
tyrr	O
(	O
C282Y	O
)	O
,	O
in	O
85	O
%	O
of	O
patient	O
chromosomes	O
.	O

,	O
found	O
product	O
,	O
a	O
member	O
.	O
the	O
major	O
histocompatibility	O
complex	O
chromosomes	O
I	O
Cys	O
>	O
family	O
,	O
was	O
-	O
to	O
have	O
a	O
in	O
,	O
-	O
-	O
)	O
gene	O
(	O
mutation	O
Tyr	O
-	O
C282Y	O
like	O
The	O
282	O
85	O
%	O
of	O
patient	O
class	O
of	O

The	O
gene	O
product	O
,	O
a	O
member	O
major	O
histocompatibility	O
complex	O
class	O
-	O
like	O
family	O
,	O
was	O
to	O
have	O
a	O
mutation	O
Cys	O
-	O
-	O
-	O
>	O
Tyr	O
(	O
C282Y	O
)	O
,	O
85	O
%	O
patient	O
chromosomes	O
.	O

of	O
Cys	O
product	O
,	O
,	O
member	O
have	O
(	O
major	O
histocompatibility	O
complex	O
class	O
I	O
of	O
%	O
family	O
a	O
Tyr	O
found	O
to	O
-	O
a	O
mutation	O
,	O
-	O
-	O
282	O
.	O
was	O
>	O
-	O
gene	O
C282Y	O
)	O
,	O
in	O
85	O
like	O
The	O
patient	O
chromosomes	O
the	O

The	O
gene	O
product	O
,	O
a	O
member	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
-	O
like	O
family	O
,	O
was	O
found	O
to	O
have	O
a	O
mutation	O
,	O
Cys	O
-	O
282	O
-	O
-	O
>	O
Tyr	O
(	O
C282Y	O
)	O
,	O
in	O
chromosome	O
ampere	O
patient	O
role	O
chromosome	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
coordination	O
compound	O
85	O
%	O
of	O
patient	O

The	O
gene	O
product	O
,	O
a	O
member	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
-	O
like	O
family	O
,	O
was	O
found	O
to	O
have	O
a	O
mutation	O
,	O
Cys	O
-	O
282	O
-	O
-	O
>	O
Tyr	O
(	O
C282Y	O
)	O
,	O
in	O
85	O
%	O
of	O
patient	O
chromosomes	O
.	O

This	O
mutation	O
eliminates	O
to	O
associate	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
prevents	O
cell	O
-	O
surface	O
expression	O

This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
beta2	O
-	O
microglobulin	O
beta2m	O
prevents	O
cell	O
-	O
surface	O
expression	O
.	O

This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
prevents	O
come	O
on	O
reflexion	O
reflexion	O
rid	O
of	O
rid	O
of	O
rid	O
of	O
cell	O

This	O
mutation	O
eliminates	O
the	O
power	O
of	O
HFE	O
to	O
associate	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
forestall	O
cell	O
-	O
surface	O
construction	O
.	O

This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
prevents	O
come	O
on	O
reflexion	O
reflexion	O
rid	O
of	O
rid	O
of	O
rid	O
of	O
cell	O

This	O
variation	O
eliminates	O
the	O
power	O
of	O
HFE	O
to	O
consort	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
preclude	O
cell	O
-	O
surface	O
locution	O
.	O

This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
-	O
microglobulin	O
beta2m	O
)	O
and	O
prevents	O
cell	O
-	O
surface	O

beta2	O
mutation	O
eliminates	O
cell	O
ability	O
of	O
HFE	O
associate	O
to	O
with	O
-	O
-	O
(	O
microglobulin	O
.	O
)	O
and	O
prevents	O
the	O
This	O
surface	O
expression	O
beta2m	O

This	O
sport	O
eliminates	O
the	O
power	O
of	O
HFE	O
to	O
relate	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
prevents	O
cell	O
-	O
surface	O
manifestation	O
.	O

beta2m	O
mutation	O
associate	O
HFE	O
ability	O
of	O
)	O
to	O
eliminates	O
with	O
beta2	O
-	O
surface	O
(	O
the	O
This	O
and	O
prevents	O
cell	O
-	O
microglobulin	O
expression	O
.	O

This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
prevents	O
cell	O
-	O
surface	O
expression	O
.	O

axerophthol	O
second	O
mutation	O
that	O
has	O
no	O
essence	O
on	O
beta2m	O
association	O
,	O
H63D	O
,	O
was	O
ground	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
variation	O
.	O

A	O
second	O
that	O
has	O
no	O
effect	O
on	O
beta2m	O
association	O
,	O
H63D	O
,	O
in	O
eight	O
out	O
of	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
.	O

A	O
second	O
mutation	O
that	O
receive	O
indium	O
receive	O
has	O
no	O
effect	O
on	O
beta2m	O
association	O
,	O
H63D	O
,	O
was	O
found	O
in	O
eight	O
out	O
patient	O
sport	O
sport	O
sport	O
indium	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant	O
.	O

patients	O
second	O
mutation	O
of	O
has	O
no	O
effect	O
mutant	O
the	O
association	O
nine	O
H63D	O
,	O
was	O
for	O
in	O
eight	O
out	O
that	O
C282Y	O
,	O
heterozygous	O
found	O
beta2m	O
A	O
on	O
.	O

A	O
second	O
mutation	O
that	O
receive	O
indium	O
receive	O
has	O
no	O
effect	O
on	O
beta2m	O
association	O
,	O
H63D	O
,	O
was	O
found	O
in	O
eight	O
out	O
patient	O
sport	O
sport	O
sport	O
indium	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant	O
.	O

A	O
second	O
mutation	O
has	O
no	O
on	O
beta2m	O
association	O
,	O
H63D	O
,	O
was	O
found	O
eight	O
out	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant	O
.	O

.	O
second	O
mutation	O
found	O
has	O
no	O
mutant	O
on	O
that	O
association	O
,	O
H63D	O
was	O
patients	O
C282Y	O
beta2m	O
eight	O
out	O
of	O
nine	O
,	O
heterozygous	O
for	O
the	O
in	O
effect	O
A	O

mutation	O
no	O
effect	O
on	O
association	O
,	O
,	O
was	O
found	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O

the	O
second	O
mutation	O
that	O
has	O
no	O
was	O
H63D	O
beta2m	O
association	O
,	O
eight	O
heterozygous	O
effect	O
C282Y	O
A	O
on	O
in	O
of	O
nine	O
patients	O
,	O
for	O
out	O
found	O
mutant	O
.	O

A	O
mo	O
sport	O
that	O
has	O
no	O
upshot	O
on	O
beta2m	O
tie	O
,	O
H63D	O
,	O
was	O
found	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
variation	O
.	O

A	O
second	O
mutation	O
that	O
has	O
no	O
effect	O
on	O
beta2m	O
association	O
,	O
H63D	O
,	O
was	O
found	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant	O
.	O

this	O
report	O
,	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
-	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
(	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
(	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
TfR	O
)	O
.	O

complexes	O
the	O
report	O
,	O
HFE	O
demonstrate	O
)	O
with	O
293	O
cells	O
overexpressing	O
wild	O
-	O
and	O
proteins	O
mutant	O
we	O
or	O
that	O
both	O
type	O
wild	O
-	O
type	O
this	O
H63D	O
HFE	O
.	O
In	O
stable	O
form	O
in	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
cultured	O
proteins	O

In	O
this	O
report	O
we	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
TfR	O
.	O

inwards	O
this	O
cover	O
,	O
we	O
show	O
inwards	O
genteel	O
293	O
cellphone	O
overexpressing	O
hazardous	O
-	O
type	O
or	O
variation	O
HFE	O
proteins	O
that	O
both	O
the	O
hazardous	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
mold	O
unchanging	O
composite	O
with	O
the	O
siderophilin	O
receptor	O
(	O
TfR	O
)	O
.	O

and	O
that	O
report	O
,	O
we	O
demonstrate	O
wild	O
cultured	O
293	O
cells	O
overexpressing	O
in	O
-	O
proteins	O
stable	O
mutant	O
HFE	O
proteins	O
transferrin	O
both	O
the	O
wild	O
form	O
type	O
In	O
H63D	O
with	O
type	O
or	O
-	O
complexes	O
(	O
the	O
receptor	O
this	O
HFE	O
TfR	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
(	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
TfR	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
(	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
civilized	O
waste	O
TfR	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
proteins	O
that	O
both	O
wild	O
type	O
and	O
H63D	O
form	O
transferrin	O
receptor	O
(	O
)	O
.	O

In	O
this	O
complexes	O
,	O
we	O
demonstrate	O
in	O
that	O
293	O
cells	O
overexpressing	O
HFE	O
both	O
type	O
or	O
cultured	O
HFE	O
proteins	O
)	O
-	O
the	O
the	O
-	O
(	O
and	O
mutant	O
wild	O
wild	O
form	O
stable	O
report	O
proteins	O
with	O
transferrin	O
receptor	O
type	O
TfR	O
H63D	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
.	O

mutant	O
C282Y	O
mutation	O
association	O
completely	O
prevents	O
the	O
nearly	O
the	O
the	O
with	O
HFE	O
The	O
protein	O
of	O
TfR	O
.	O

The	O
C282Y	O
variation	O
closely	O
wholly	O
forestall	O
the	O
connection	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR	O
.	O

The	O
C282Y	O
mutation	O
nearly	O
all	O
keep	O
the	O
connection	O
of	O
the	O
mutation	O
HFE	O
protein	O
with	O
the	O
TfR	O
.	O

The	O
C282Y	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR	O
.	O

The	O
C282Y	O
variation	O
nearly	O
all	O
preclude	O
the	O
connection	O
of	O
the	O
variation	O
HFE	O
protein	O
with	O
the	O
TfR	O
.	O

The	O
C282Y	O
tie	O
sport	O
mutation	O
nearly	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR	O
tie	O
in	O
tie	O
in	O

The	O
C282Y	O
mutation	O
nearly	O
completely	O
prevents	O
the	O
association	O
the	O
mutant	O
protein	O
with	O
the	O
TfR	O
.	O

The	O
C282Y	O
tie	O
sport	O
mutation	O
nearly	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR	O
tie	O
in	O
tie	O
in	O

C282Y	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O

The	O
C282Y	O
of	O
the	O
completely	O
prevents	O
protein	O
association	O
mutation	O
the	O
mutant	O
HFE	O
the	O
with	O
nearly	O
TfR	O
.	O

The	O
C282Y	O
mutation	O
nearly	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR	O
.	O

Studies	O
cell	O
-	O
associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
wild	O
-	O
type	O
HFE	O
decreases	O
the	O
affinity	O
of	O
the	O
for	O
transferrin	O
.	O

Studies	O
cell	O
-	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
wild	O
-	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O

Studies	O
on	O
cell	O
-	O
colligate	O
waste	O
atomic	O
number	O
	O
colligate	O
associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
overexpressed	O
wild	O
-	O
type	O
HFE	O
kinship	O
cubicle	O
siderophilin	O
siderophilin	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O

the	O
on	O
cell	O
protein	O
associated	O
transferrin	O
at	O
for	O
the	O
C	O
decreases	O
that	O
the	O
overexpressed	O
of	O
-	O
type	O
HFE	O
-	O
TfR	O
suggest	O
affinity	O
wild	O
degrees	O
Studies	O
37	O
transferrin	O
.	O

transferrin	O
on	O
cell	O
wild	O
associated	O
transferrin	O
for	O
37	O
-	O
C	O
suggest	O
that	O
overexpressed	O
the	O
TfR	O
degrees	O
type	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
-	O
at	O
Studies	O
.	O

Studies	O
on	O
cell	O
-	O
colligate	O
waste	O
atomic	O
number	O
	O
colligate	O
associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
overexpressed	O
wild	O
-	O
type	O
HFE	O
kinship	O
cubicle	O
siderophilin	O
stage	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O

Studies	O
on	O
cadre	O
-	O
colligate	O
siderophilin	O
at	O
37	O
level	O
cytosine	O
hint	O
that	O
the	O
overexpressed	O
angry	O
-	O
character	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O
siderophilin	O
.	O

Studies	O
on	O
cell	O
-	O
colligate	O
waste	O
atomic	O
number	O
	O
colligate	O
associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
overexpressed	O
wild	O
-	O
type	O
HFE	O
kinship	O
cubicle	O
siderophilin	O
stage	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O

the	O
on	O
cell	O
-	O
associated	O
transferrin	O
overexpressed	O
that	O
degrees	O
C	O
suggest	O
type	O
affinity	O
at	O
TfR	O
Studies	O
37	O
-	O
protein	O
decreases	O
the	O
the	O
of	O
HFE	O
wild	O
for	O
transferrin	O
.	O

canvass	O
on	O
cell	O
-	O
link	O
siderophilin	O
at	O
xxxvii	O
stage	O
blow	O
intimate	O
that	O
the	O
overexpressed	O
unwarranted	O
-	O
type	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O
siderophilin	O
.	O

Studies	O
on	O
cell	O
-	O
associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
overexpressed	O
wild	O
-	O
type	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O
transferrin	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
effect	O
sport	O
force	O
sport	O
sport	O
force	O
dress	O
consequence	O
of	O
the	O
H63D	O
mutation	O
.	O

H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
consequence	O
the	O
H63D	O
mutation	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
outcome	O
,	O
leave	O
the	O
low	O
send	O
tell	O
for	O
a	O
operable	O
import	O
of	O
the	O
H63D	O
mutation	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
effect	O
,	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
the	O
H63D	O
mutation	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
effect	O
sport	O
force	O
sport	O
sport	O
force	O
force	O
consequence	O
of	O
the	O
H63D	O
mutation	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
essence	O
,	O
furnish	O
the	O
maiden	O
unmediated	O
evidence	O
for	O
a	O
useable	O
outcome	O
of	O
the	O
H63D	O
variation	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
outcome	O
,	O
providing	O
the	O
outset	O
engineer	O
show	O
for	O
a	O
operable	O
moment	O
of	O
the	O
H63D	O
variation	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
providing	O
direct	O
evidence	O
for	O
a	O
functional	O
consequence	O
of	O
the	O
H63D	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
effect	O
sport	O
force	O
sport	O
sport	O
force	O
force	O
consequence	O
of	O
the	O
H63D	O
mutation	O
.	O

functional	O
overexpressed	O
H63D	O
providing	O
does	O
not	O
have	O
consequence	O
.	O
,	O
protein	O
the	O
first	O
direct	O
mutation	O
for	O
a	O
the	O
this	O
The	O
of	O
H63D	O
evidence	O
effect	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
consequence	O
of	O
the	O
H63D	O
mutation	O
.	O

of	O
soluble	O
wild	O
HFE	O
/	O
beta2m	O
heterodimers	O
to	O
cells	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
steady	O
-	O
state	O
conditions	O
,	O
in	O
.	O

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
/	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
in	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
HeLa	O
cells	O
.	O

both	O
TfR	O
soluble	O
wild	O
apparent	O
type	O
cells	O
in	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
under	O
affinity	O
the	O
-	O
decreased	O
of	O
the	O
also	O
for	O
its	O
ligand	O
of	O
steady	O
-	O
.	O
Addition	O
,	O
conditions	O
HFE	O
293	O
cells	O
and	O
in	O
HeLa	O
/	O
state	O

Addition	O
of	O
soluble	O
-	O
/	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
HeLa	O
.	O

addition	O
of	O
soluble	O
untamed	O
-	O
character	O
HFE	O
/	O
beta2m	O
heterodimers	O
to	O
civilised	O
cells	O
besides	O
fall	O
the	O
unmistakable	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
sweetie	O
-	O
tell	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
in	O
hel	O
cells	O
.	O

under	O
of	O
soluble	O
wild	O
-	O
type	O
cultured	O
/	O
beta2m	O
heterodimers	O
to	O
HFE	O
cells	O
state	O
,	O
the	O
apparent	O
affinity	O
cells	O
the	O
TfR	O
for	O
conditions	O
ligand	O
Addition	O
steady	O
in	O
also	O
decreased	O
its	O
both	O
in	O
293	O
and	O
of	O
-	O
HeLa	O
cells	O
.	O

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
/	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
in	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
HeLa	O
cells	O
.	O

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
/	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
in	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
patent	O
cubicle	O
HeLa	O
cells	O
.	O

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
affinity	O
of	O
the	O
for	O
ligand	O
under	O
steady	O
conditions	O
cells	O
and	O
in	O
cells	O
.	O

Addition	O
of	O
both	O
wild	O
-	O
type	O
HFE	O
of	O
beta2m	O
heterodimers	O
to	O
-	O
the	O
also	O
decreased	O
/	O
apparent	O
affinity	O
cells	O
cells	O
TfR	O
293	O
its	O
in	O
under	O
the	O
cultured	O
for	O
conditions	O
,	O
soluble	O
state	O
in	O
cells	O
and	O
ligand	O
HeLa	O
steady	O
.	O

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
/	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
in	O
HeLa	O
cells	O
.	O

Furthermore	O
,	O
at	O
4	O
present	O
stage	O
	O
curb	O
stage	O
degrees	O
C	O
,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2m	O
inhibited	O
binding	O
of	O
ampere	O
pendent	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
introduce	O
amex	O
.	O

Furthermore	O
,	O
at	O
4	O
present	O
stage	O
	O
curb	O
stage	O
degrees	O
C	O
,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2m	O
inhibited	O
binding	O
of	O
ampere	O
	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
introduce	O
amex	O
.	O

manner	O
,	O
a	O
beta2m	O
degrees	O
C	O
dependent	O
the	O
4	O
soluble	O
complex	O
of	O
HeLa	O
/	O
at	O
added	O
binding	O
of	O
transferrin	O
to	O
HFE	O
cell	O
TfR	O
in	O
inhibited	O
,	O
-	O
concentration	O
Furthermore	O
.	O

Furthermore	O
,	O
at	O
4	O
present	O
stage	O
	O
curb	O
stage	O
degrees	O
C	O
,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2m	O
inhibited	O
binding	O
of	O
ampere	O
pendent	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
introduce	O
amex	O
.	O

Furthermore	O
,	O
at	O
4	O
degrees	O
C	O
,	O
added	O
soluble	O
of	O
HFE	O
/	O
beta2m	O
inhibited	O
binding	O
of	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Furthermore	O
,	O
at	O
4	O
point	O
C	O
,	O
the	O
added	O
soluble	O
composite	O
of	O
HFE	O
/	O
beta2m	O
curb	O
back	O
of	O
siderophilin	O
to	O
hela	O
cell	O
TfR	O
in	O
a	O
assiduity	O
-	O
dependent	O
mode	O
.	O

binding	O
,	O
at	O
4	O
degrees	O
C	O
cell	O
of	O
added	O
soluble	O
complex	O
Furthermore	O
manner	O
in	O
inhibited	O
beta2m	O
of	O
a	O
transferrin	O
to	O
HeLa	O
,	O
TfR	O
/	O
the	O
concentration	O
-	O
dependent	O
HFE	O
.	O

HeLa	O
,	O
at	O
transferrin	O
degrees	O
C	O
,	O
concentration	O
in	O
soluble	O
manner	O
of	O
-	O
to	O
TfR	O
inhibited	O
binding	O
of	O
4	O
/	O
a	O
cell	O
beta2m	O
added	O
Furthermore	O
the	O
HFE	O
dependent	O
complex	O
.	O

furthermore	O
,	O
at	O
quadruplet	O
point	O
C	O
,	O
the	O
lend	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2m	O
conquer	O
bandaging	O
of	O
transferrin	O
to	O
hela	O
cell	O
TfR	O
in	O
a	O
assiduousness	O
-	O
subject	O
manner	O
.	O

Furthermore	O
,	O
at	O
4	O
degrees	O
,	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2m	O
inhibited	O
of	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
-	O
dependent	O
manner	O

Furthermore	O
,	O
at	O
4	O
degrees	O
C	O
,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2m	O
inhibited	O
binding	O
of	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Scatchard	O
plots	O
added	O
of	O
data	O
indicate	O
the	O
the	O
of	O
heterodimer	O
substantially	O
reduced	O
that	O
affinity	O
these	O
TfR	O
for	O
transferrin	O
.	O

of	O
these	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
TfR	O
for	O
transferrin	O
.	O

Scatchard	O
plots	O
of	O
these	O
datum	O
suggest	O
that	O
the	O
added	O
heterodimer	O
well	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
.	O

Scatchard	O
patch	O
of	O
these	O
datum	O
indicate	O
that	O
the	O
added	O
heterodimer	O
considerably	O
reduced	O
the	O
kinship	O
of	O
TfR	O
for	O
siderophilin	O
.	O

for	O
plots	O
of	O
these	O
data	O
indicate	O
affinity	O
of	O
added	O
heterodimer	O
substantially	O
reduced	O
transferrin	O
that	O
the	O
TfR	O
the	O
Scatchard	O
.	O

Scatchard	O
plots	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
.	O

Scatchard	O
plots	O
of	O
these	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
tot	O
tot	O
tot	O
tot	O
patch	O
.	O

Scatchard	O
plots	O
of	O
these	O
datum	O
show	O
that	O
the	O
added	O
heterodimer	O
considerably	O
decreased	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
.	O

Scatchard	O
plots	O
of	O
these	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
tot	O
tot	O
tot	O
tot	O
tot	O
.	O

affinity	O
plots	O
of	O
substantially	O
data	O
indicate	O
that	O
.	O
of	O
heterodimer	O
these	O
reduced	O
Scatchard	O
the	O
added	O
TfR	O
for	O
transferrin	O
the	O

Scatchard	O
plots	O
of	O
these	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
.	O

These	O
molecular	O
between	O
HFE	O
and	O
key	O
protein	O
involved	O
iron	O
transport	O
,	O
the	O
TfR	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
play	O
role	O
in	O
the	O
of	O
hereditary	B
hemochromatosis	I
.	O
.	O

These	O
results	O
establish	O
a	O
molecular	O
and	O
a	O
key	O
protein	O
involved	O
iron	O
transport	O
,	O
the	O
possibility	O
in	O
mechanism	O
may	O
play	O
a	O
in	O
the	O
hereditary	B
hemochromatosis	I
.	O

These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
drama	O
genetic	O
bronzed	O
diabetes	O
drama	O
drama	O
drama	O
drama	O
drama	O
drama	O
drama	O
drama	O
drama	O
pathogenesis	O
of	B
hereditary	I
hemochromatosis	O
.	O

These	O
results	O
build	O
a	O
molecular	O
associate	O
between	O
HFE	O
and	O
a	O
primal	O
protein	O
necessitate	O
in	O
iron	O
transferral	O
,	O
the	O
TfR	O
,	O
and	O
provoke	O
the	O
possibleness	O
that	O
revision	O
in	O
this	O
regulative	O
mechanism	O
may	O
run	O
a	O
office	O
in	O
the	O
pathogenesis	O
of	O
inherited	B
hemochromatosis	I
.	O
.	O

These	O
results	O
may	O
a	O
molecular	O
the	O
between	O
TfR	O
and	O
a	O
key	O
in	O
,	O
in	O
iron	O
HFE	O
,	O
the	O
of	O
involved	O
and	O
a	O
the	O
link	O
that	O
transport	O
protein	O
raise	O
regulatory	O
mechanism	O
establish	O
this	O
play	O
role	O
in	O
possibility	O
pathogenesis	O
alterations	O
hereditary	B
hemochromatosis	I
.	O
.	O

These	O
solution	O
establish	O
a	O
molecular	O
unite	O
between	O
HFE	O
and	O
a	O
name	O
protein	O
postulate	O
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
opening	O
that	O
adjustment	O
in	O
this	O
regulative	O
mechanics	O
may	O
work	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
transmissible	B
hemochromatosis	I
.	O
.	O

in	O
TfR	O
establish	O
a	O
molecular	O
link	O
.	O
HFE	O
and	O
a	O
key	O
.	O
involved	O
that	O
mechanism	O
transport	O
,	O
the	O
this	O
,	O
and	O
raise	O
the	O
possibility	O
in	O
alterations	O
role	O
results	O
play	O
the	O
may	O
regulatory	O
a	O
iron	O
These	O
in	O
pathogenesis	O
of	O
hereditary	B
hemochromatosis	I
protein	O
between	O

These	O
results	O
establish	O
a	O
molecular	O
link	O
and	O
a	O
key	O
protein	O
in	O
iron	O
transport	O
,	O
the	O
,	O
and	O
raise	O
the	O
that	O
alterations	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
pathogenesis	O
of	O
hemochromatosis	I
.	O
.	O

hereditary	O
that	O
establish	O
a	O
,	O
link	O
and	O
play	O
and	O
a	O
key	O
protein	O
involved	O
between	O
of	O
transport	O
molecular	O
may	O
TfR	O
,	O
in	O
raise	O
the	O
possibility	O
this	O
alterations	O
in	O
.	O
the	O
mechanism	O
regulatory	O
results	O
a	O
role	O
in	O
the	O
pathogenesis	O
iron	O
These	B
hemochromatosis	I
.	O
HFE	O

These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
drama	O
genetic	O
bronzed	O
diabetes	O
drama	O
drama	O
drama	O
drama	O
drama	O
drama	O
drama	O
drama	O
chemical	O
mechanism	O
pathogenesis	B
of	I
hereditary	O
hemochromatosis	O

These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	B
hemochromatosis	I
.	O
.	O

Genomic	O
of	O
UBE3A	O
E6	O
-	O
AP	O
gene	O
and	O
related	O
pseudogenes	O
.	O

Genomic	O
constitution	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
factor	O
and	O
link	O
pseudogenes	O
.	O

-	O
the	O
of	O
organization	O
UBE3A	O
/	O
gene	O
Genomic	O
AP	O
.	O
and	O
related	O
pseudogenes	O
E6	O

Genomic	O
organization	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
gene	O
and	O
pseudogenes	O
.	O

Genomic	O
organization	O
colligate	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
colligate	O
brass	O
gene	O
and	O
related	O
pseudogenes	O
.	O

Genomic	O
organization	O
colligate	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
colligate	O
factor	O
gene	O
and	O
related	O
pseudogenes	O
.	O

Genomic	O
arrangement	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
factor	O
and	O
pertain	O
pseudogenes	O
.	O

pseudogenes	O
organization	O
of	O
Genomic	O
-	O
/	O
E6	O
related	O
AP	O
gene	O
and	O
UBE3A	O
the	O
.	O

Genomic	O
organization	O
colligate	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
colligate	O
brass	O
gene	O
and	O
related	O
pseudogenes	O
.	O

Genomic	O
establishment	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
factor	O
and	O
pertain	O
pseudogenes	O
.	O

Genomic	O
organization	O
of	O
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
gene	O
and	O
related	O
pseudogenes	O
.	O

The	O
UBE3A	O
gene	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	B
syndrome	I
patients	O
who	O
lack	O
15q11	O
-	O
q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	B
disomy	I
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
.	O

The	O
UBE3A	O
gene	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
ligase	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	B
syndrome	I
who	O
lack	O
15q11	O
-	O
q13	O
uniparental	B

who	O
be	O
gene	O
encodes	O
the	O
E6	O
ligase	O
paternal	O
ubiquitin	O
-	O
protein	O
-	O
and	O
-	O
deletions	O
been	O
shown	O
to	O
AP	O
mutated	O
in	O
Angelman	B
q13	I
patients	O
The	O
lack	O
chromosome	O
has	O
recently	O
syndrome	O
or	O
disomy	O
15	O
UBE3A	O
uniparental	B
15q11	I
.	O

The	O
UBE3A	O
gene	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	B
syndrome	I
patients	O
who	O
lack	O
15q11	O
-	O
q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	B
disomy	I
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
	O
.	O

-	O
uniparental	O
gene	O
encodes	O
shown	O
E6	O
recently	O
chromosome	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
who	O
AP	O
been	O
the	O
or	O
be	O
mutated	O
has	O
Angelman	B
syndrome	I
patients	O
UBE3A	O
lack	O
15q11	O
The	O
to	O
deletions	O
q13	O
-	O
15	O
paternal	O
in	B
disomy	I
.	O

The	O
UBE3A	O
factor	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
late	O
been	O
prove	O
to	O
be	O
mutated	O
in	O
Angelman	B
syndrome	I
patients	O
who	O
want	O
15q11	O
-	O
q13	O
omission	O
or	O
chromosome	O
15	O
agnatic	O
uniparental	B
disomy	I
.	O

The	O
UBE3A	O
gene	O
encodes	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
recently	O
been	O
shown	O
be	O
in	O
Angelman	B
syndrome	I
lack	O
or	O
chromosome	O
15	O
uniparental	B
disomy	I

The	O
UBE3A	O
or	O
encodes	O
the	O
disomy	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
15q11	O
mutated	O
has	O
recently	O
-	O
shown	O
to	O
chromosome	O
and	O
in	O
15	B
syndrome	I
E6	O
who	O
been	O
ligase	O
Angelman	O
lack	O
deletions	O
gene	O
be	O
q13	O
paternal	O
uniparental	B
patients	I
.	O

The	O
UBE3A	O
cistron	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
late	O
been	O
indicate	O
to	O
be	O
mutated	O
in	O
Angelman	B
syndrome	I
patients	O
who	O
want	O
15q11	O
-	O
q13	O
cut	O
or	O
chromosome	O
xv	O
agnate	O
uniparental	B
disomy	I
.	O

The	O
UBE3A	O
factor	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
latterly	O
been	O
evince	O
to	O
be	O
mutated	O
in	O
Angelman	B
syndrome	I
patients	O
who	O
want	O
15q11	O
-	O
q13	O
excision	O
or	O
chromosome	O
15	O
parental	O
uniparental	B
disomy	I
.	O

The	O
UBE3A	O
gene	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	B
syndrome	I
patients	O
who	O
lack	O
15q11	O
-	O
q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	B
disomy	I
.	O

Previous	O
cDNA	O
analysis	O
shown	O
coding	O
of	O
approximately	O
2	O
.	O

Previous	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
of	O
approximately	O
2	O

old	O
UBE3A	O
cDNA	O
analysis	O
has	O
point	O
a	O
coding	O
part	O
of	O
approximately	O
2	O
.	O

Previous	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
	O
	O
receive	O
of	O
approximately	O
2	O
.	O

Previous	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
	O
	O
complementary	O
dna	O
of	O
approximately	O
2	O

Previous	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
	O
	O
receive	O
of	O
approximately	O
2	O
.	O

late	O
UBE3A	O
cdna	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
of	O
approximately	O
two	O
.	O

Previous	O
UBE3A	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
of	O
.	O

late	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
inscribe	O
neighborhood	O
of	O
approximately	O
2	O
.	O

Previous	O
has	O
cDNA	O
analysis	O
.	O
shown	O
a	O
UBE3A	O
region	O
of	O
approximately	O
2	O
coding	O

Previous	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
of	O
approximately	O
2	O
.	O

sixer	O
kb	O
and	O
a	O
terzetto	O
-	O
untranslated	O
realm	O
(	O
UTR	O
)	O
of	O
<	O
fifty	O
bp	O
,	O
whereas	O
Northern	O
analysis	O
has	O
argue	O
mrna	O
sizes	O
of	O
fivesome	O
-	O
viii	O
kb	O
.	O

6	O
kb	O
and	O
a	O
3	O
untranslated	O
UTR	O
)	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

indicated	O
kb	O
and	O
analysis	O
3	O
-	O
untranslated	O
-	O
of	O
UTR	O
.	O
of	O
<	O
has	O
sizes	O
,	O
whereas	O
Northern	O
a	O
50	O
5	O
mRNA	O
bp	O
(	O
6	O
region	O
8	O
kb	O
)	O

6	O
kb	O
and	O
a	O
	O
	O
	O
kibibyte	O
	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
sizing	O
	O
ampere	O
analysis	O
has	O
indicated	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

6	O
kb	O
and	O
a	O
	O
	O
	O
kibibyte	O
	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
sizing	O
	O
ampere	O
analysis	O
has	O
indicated	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

6	O
kb	O
and	O
a	O
3	O
-	O
untranslated	O
region	O
UTR	O
)	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
analysis	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

.	O
kb	O
and	O
bp	O
3	O
-	O
-	O
region	O
a	O
UTR	O
)	O
of	O
8	O
50	O
5	O
(	O
whereas	O
Northern	O
analysis	O
has	O
<	O
mRNA	O
sizes	O
of	O
,	O
untranslated	O
indicated	O
kb	O
6	O

6	O
kb	O
and	O
a	O
3	O
-	O
untranslated	O
region	O
UTR	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
analysis	O
indicated	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O

6	O
kib	O
and	O
a	O
troika	O
-	O
untranslated	O
area	O
(	O
UTR	O
)	O
of	O
<	O
l	O
bp	O
,	O
whereas	O
northern	O
analysis	O
has	O
betoken	O
mRNA	O
sizes	O
of	O
quint	O
-	O
ogdoad	O
kib	O
.	O

6	O
kilobit	O
and	O
a	O
trio	O
-	O
untranslated	O
area	O
(	O
UTR	O
)	O
of	O
<	O
fifty	O
bp	O
,	O
whereas	O
northerly	O
analysis	O
has	O
designate	O
mRNA	O
sizing	O
of	O
quint	O
-	O
8	O
kilobit	O
.	O

6	O
kb	O
and	O
a	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
analysis	O
has	O
indicated	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

We	O
analyzed	O
cDNA	O
and	O
provide	O
evidence	O
for	O
an	O
additional	O
0	O
.	O

We	O
have	O
analyse	O
extra	O
cdna	O
clones	O
and	O
provide	O
testify	O
for	O
an	O
extra	O
0	O
.	O

provide	O
additional	O
analyzed	O
have	O
cDNA	O
clones	O
for	O
We	O
evidence	O
.	O
an	O
additional	O
0	O
and	O

We	O
have	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
for	O
an	O
0	O
.	O

We	O
have	O
render	O
psychoanalyze	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
evidence	O
zero	O
complementary	O
dna	O
for	O
an	O
additional	O
0	O

We	O
have	O
render	O
psychoanalyze	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
evidence	O
zero	O
extra	O
for	O
an	O
additional	O
0	O
.	O

We	O
have	O
canvass	O
additional	O
cDNA	O
clones	O
and	O
ply	O
manifest	O
for	O
an	O
additional	O
cypher	O
.	O

0	O
have	O
analyzed	O
We	O
provide	O
clones	O
and	O
additional	O
evidence	O
for	O
an	O
cDNA	O
additional	O
.	O

We	O
have	O
render	O
psychoanalyze	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
evidence	O
zero	O
complementary	O
dna	O
for	O
an	O
additional	O
0	O

We	O
have	O
psychoanalyze	O
extra	O
cdna	O
clones	O
and	O
provide	O
show	O
for	O
an	O
extra	O
0	O
.	O

We	O
have	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
evidence	O
for	O
an	O
additional	O
0	O
.	O

5	O
-	O
of	O
5	O
kb	O
UTR	O
>	O
of	O
2	O
kb	O
-	O
3	O
and	O
UTR	O
.	O

5	O
kb	O
	O
	O
of	O
5	O
-	O
UTR	O
and	O
>	O
2	O
kibibyte	O
kb	O
of	O
3	O
-	O
UTR	O
.	O

quintuplet	O
kb	O
of	O
quintuplet	O
-	O
UTR	O
and	O
>	O
deuce	O
kb	O
of	O
threesome	O
-	O
UTR	O
.	O

-	O
kb	O
of	O
5	O
>	O
UTR	O
and	O
3	O
2	O
kb	O
of	O
-	O
5	O
UTR	O
.	O

fivesome	O
kilobyte	O
of	O
fivesome	O
-	O
UTR	O
and	O
>	O
deuce	O
kilobyte	O
of	O
trio	O
-	O
UTR	O
.	O

5	O
kb	O
	O
	O
of	O
5	O
-	O
UTR	O
and	O
>	O
2	O
kibibyte	O
kb	O
of	O
3	O
-	O
UTR	O
.	O

5	O
of	O
-	O
and	O
>	O
2	O
kb	O
of	O
3	O
-	O
UTR	O
.	O

>	O
5	O
of	O
kb	O
-	O
UTR	O
kb	O
5	O
2	O
and	O
of	O
3	O
-	O
.	O
UTR	O

fin	O
kb	O
of	O
fin	O
-	O
UTR	O
and	O
>	O
ii	O
kb	O
of	O
triad	O
-	O
UTR	O
.	O

5	O
kb	O
	O
	O
of	O
5	O
-	O
UTR	O
and	O
>	O
2	O
kibibyte	O
kb	O
of	O
3	O
-	O
UTR	O
.	O

5	O
kb	O
of	O
5	O
-	O
UTR	O
and	O
>	O
2	O
kb	O
of	O
3	O
-	O
UTR	O
.	O

sequence	O
have	O
established	O
UBE3A	O
genomic	O
organization	O
of	O
the	O
exon	O
the	O
-	O
of	O
We	O
intron	O
and	O
borders	O
.	O

We	O
have	O
constituted	O
the	O
genomic	O
organisation	O
of	O
UBE3A	O
and	O
the	O
episode	O
of	O
intron	O
-	O
exon	O
environ	O
.	O

We	O
have	O
ground	O
the	O
genomic	O
arrangement	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	O
.	O

We	O
have	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	O
.	O

We	O
have	O
naturalized	O
the	O
genomic	O
brass	O
of	O
UBE3A	O
and	O
the	O
succession	O
of	O
intron	O
-	O
exon	O
adjoin	O
.	O

We	O
have	O
found	O
found	O
established	O
the	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	O
receive	O
receive	O
receive	O
.	O

We	O
have	O
established	O
the	O
genomic	O
organization	O
of	O
UBE3A	O
the	O
sequence	O
intron	O
-	O
exon	O
borders	O
.	O

We	O
have	O
found	O
found	O
established	O
the	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	O
receive	O
receive	O
receive	O
.	O

have	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O

We	O
have	O
and	O
exon	O
genomic	O
organization	O
intron	O
UBE3A	O
established	O
the	O
sequence	O
of	O
of	O
-	O
the	O
borders	O
.	O

We	O
have	O
established	O
the	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	O
.	O

We	O
also	O
mapped	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
to	O
chromosomes	O
2	O
and	O
,	O
respectively	O
,	O
and	O
determined	O
genomic	O
organization	O
.	O

We	O
also	O
mapped	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
to	O
chromosomes	O
and	O
21	O
,	O
respectively	O
,	O
and	O
determined	O
their	O

We	O
have	O
also	O
mapped	O
	O
extremely	O
chromosome	O
	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
2	O
and	O
too	O
shape	O
brass	O
severally	O
21	O
,	O
respectively	O
,	O
and	O
determined	O
their	O
genomic	O
organization	O
.	O

respectively	O
have	O
also	O
21	O
two	O
highly	O
homologous	O
genomic	O
determined	O
,	O
,	O
and	O
UBE3AP2	O
,	O
and	O
chromosomes	O
2	O
and	O
mapped	O
their	O
UBE3AP1	O
,	O
to	O
pseudogenes	O
We	O
processed	O
organization	O
.	O

organization	O
have	O
also	O
to	O
two	O
highly	O
genomic	O
processed	O
mapped	O
,	O
UBE3AP1	O
and	O
,	O
respectively	O
their	O
pseudogenes	O
2	O
and	O
21	O
,	O
UBE3AP2	O
,	O
and	O
determined	O
chromosomes	O
homologous	O
We	O
.	O

We	O
have	O
also	O
mapped	O
	O
extremely	O
chromosome	O
	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
2	O
and	O
too	O
shape	O
brass	O
represent	O
21	O
,	O
respectively	O
,	O
and	O
determined	O
their	O
genomic	O
organization	O
.	O

We	O
have	O
too	O
mapped	O
deuce	O
extremely	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
ii	O
and	O
xxi	O
,	O
severally	O
,	O
and	O
decide	O
their	O
genomic	O
organization	O
.	O

We	O
have	O
also	O
mapped	O
	O
extremely	O
chromosome	O
	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
2	O
and	O
too	O
shape	O
brass	O
represent	O
21	O
,	O
respectively	O
,	O
and	O
determined	O
their	O
genomic	O
organization	O
.	O

determined	O
have	O
also	O
mapped	O
two	O
highly	O
,	O
and	O
pseudogenes	O
,	O
UBE3AP1	O
2	O
,	O
homologous	O
their	O
We	O
processed	O
chromosomes	O
21	O
,	O
respectively	O
UBE3AP2	O
and	O
and	O
to	O
genomic	O
organization	O
.	O

We	O
have	O
too	O
mapped	O
ii	O
extremely	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
ii	O
and	O
21	O
,	O
severally	O
,	O
and	O
specify	O
their	O
genomic	O
establishment	O
.	O

We	O
have	O
also	O
mapped	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
2	O
and	O
21	O
,	O
respectively	O
,	O
and	O
determined	O
their	O
genomic	O
organization	O
.	O

These	O
the	O
will	O
form	O
results	O
basis	O
studies	O
and	O
of	O
mutation	O
of	O
imprinting	O
for	O
UBE3A	O
.	O

These	O
results	O
willing	O
subject	O
area	O
volition	O
will	O
form	O
the	O
basis	O
for	O
studies	O
of	O
volition	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O

These	O
lead	O
will	O
organise	O
the	O
groundwork	O
for	O
cogitation	O
of	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O
.	O

of	O
results	O
will	O
These	O
studies	O
basis	O
for	O
imprinting	O
of	O
mutation	O
and	O
the	O
form	O
UBE3A	O
.	O

These	O
solvent	O
will	O
form	O
the	O
basis	O
for	O
survey	O
of	O
mutant	O
and	O
form	O
of	O
UBE3A	O
.	O

These	O
results	O
willing	O
subject	O
area	O
volition	O
will	O
form	O
the	O
basis	O
for	O
studies	O
of	O
effect	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O

These	O
will	O
the	O
for	O
studies	O
of	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O
.	O

studies	O
form	O
will	O
results	O
the	O
basis	O
mutation	O
These	O
of	O
for	O
and	O
imprinting	O
of	O
.	O
UBE3A	O

These	O
effect	O
will	O
form	O
the	O
foundation	O
for	O
discipline	O
of	O
variation	O
and	O
imprinting	O
of	O
UBE3A	O
.	O

These	O
results	O
willing	O
subject	O
area	O
volition	O
will	O
form	O
the	O
basis	O
for	O
studies	O
of	O
effect	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O

These	O
results	O
will	O
form	O
the	O
basis	O
for	O
studies	O
of	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O
.	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
two	O
hamartoma	B
syndrome	O
sport	B
genetic	O
constitution	B
sport	O
sport	B
genetic	O
constitution	I
	O
syndromes	O
with	O
germline	O
PTEN	O

and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
two	O
syndromes	I
germline	O
PTEN	O
mutation	O
.	O

sport	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
psychoanalyse	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
ii	O
hamartoma	B
syndromes	I
with	O
germline	O
PTEN	O
sport	O
.	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
Cowden	B
disease	I
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
two	O
hamartoma	B
germline	O
PTEN	O
mutation	O
.	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
two	O
hamartoma	B
syndrome	O
sport	B
genetic	O
constitution	B
sport	O
sport	B
genetic	O
constitution	I
genetic	O
constitution	O
syndromes	O
with	O
germline	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
ii	O
hamartoma	B
syndromes	I
with	O
germline	O
PTEN	O
mutation	O
.	O

mutant	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
ii	O
hamartoma	B
syndromes	I
with	O
germline	O
PTEN	O
mutant	O
.	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
and	O
Zonana	I
syndrome	I
,	O
two	O
hamartoma	B
syndromes	I
with	O
germline	O
PTEN	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
two	O
hamartoma	B
syndrome	O
sport	B
genetic	O
constitution	B
sport	O
sport	B
genetic	O
constitution	I
genetic	O
constitution	O
syndromes	O
with	O
germline	O

hamartoma	O
spectrum	O
and	O
and	O
-	O
phenotype	O
analyses	O
syndromes	O
.	B
disease	I
genotype	O
Bannayan	B
-	I
Zonana	I
mutation	I
,	O
two	O
germline	B
in	I
Mutation	O
with	O
PTEN	O
syndrome	O
Cowden	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
two	O
hamartoma	B
syndromes	I
with	O
germline	O
PTEN	O
mutation	O
.	O

The	O
neoplasm	B
suppressor	O
cistron	O
PTEN	O
,	O
which	O
maps	O
to	O
10q23	O
.	O

The	O
tumour	B
suppressor	O
gene	O
PTEN	O
,	O
which	O
maps	O
to	O
neoplasm	O
neoplasm	O
neoplasm	O
10q23	O
.	O

The	O
neoplasm	B
suppressor	O
cistron	O
PTEN	O
,	O
which	O
function	O
to	O
10q23	O
.	O

The	O
neoplasm	B
suppressor	O
factor	O
PTEN	O
,	O
which	O
maps	O
to	O
10q23	O
.	O

tumour	B
suppressor	O
PTEN	O
,	O
which	O
maps	O
to	O
10q23	O
.	O

maps	O
tumour	B
suppressor	O
PTEN	O
gene	O
,	O
10q23	O
The	O
to	O
which	O
.	O

The	O
maps	B
suppressor	O
gene	O
tumour	O
,	O
which	O
.	O
to	O
10q23	O
PTEN	O

gene	O
maps	B
suppressor	O
which	O
PTEN	O
,	O
The	O
tumour	O
to	O
10q23	O
.	O

The	O
suppressor	O
PTEN	O
which	O
maps	O
to	O
10q23	O
.	O

The	O
tumour	B
suppressor	O
gene	O
PTEN	O
,	O
which	O
maps	O
to	O
neoplasm	O
neoplasm	O
neoplasm	O
10q23	O
.	O

The	O
tumour	B
suppressor	O
gene	O
PTEN	O
,	O
which	O
maps	O
to	O
10q23	O
.	O

3	O
and	O
encodes	O
a	O
dual	O
indium	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
treble	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
indium	O
homo	O
was	O
shown	O
recently	O
to	O
play	O
a	B
broad	O
role	O
in	O

3	O
and	O
encodes	O
a	O
dual	O
indium	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
treble	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
indium	O
part	O
was	O
shown	O
recently	O
to	O
play	O
a	B
broad	O
role	O
in	O

malignancy	O
and	O
broad	O
;	O
403	O
amino	O
human	O
dual	O
a	O
phosphatase	O
(	O
protein	O
recently	O
phosphatase	O
encodes	O
specificity	O
)	O
,	O
was	O
shown	O
tyrosine	O
to	O
play	O
a	O
PTPase	O
acid	O
in	O
role	O
3	B
.	O

3	O
and	O
encodes	O
a	O
dual	O
indium	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
treble	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
indium	O
homo	O
was	O
shown	O
recently	O
to	O
play	O
a	B
broad	O
role	O
in	O

3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
specificity	O
phosphatase	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	B
.	O

triplet	O
and	O
encodes	O
a	O
403	O
amino	O
sulphurous	O
threefold	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
was	O
designate	O
latterly	O
to	O
caper	O
a	O
encompassing	O
character	O
in	O
human	O
malignance	B
.	O

)	O
and	O
encodes	O
a	O
403	O
amino	O
to	O
protein	O
specificity	O
phosphatase	O
(	O
3	O
malignancy	O
a	O
PTPase	O
;	O
,	O
broad	O
was	O
shown	O
recently	O
acid	O
play	O
phosphatase	O
dual	O
role	O
in	O
human	O
tyrosine	B
.	O

recently	O
and	O
encodes	O
was	O
403	O
amino	O
acid	O
role	O
a	O
phosphatase	O
malignancy	O
protein	O
in	O
shown	O
play	O
PTPase	O
)	O
,	O
a	O
phosphatase	O
broad	O
to	O
;	O
specificity	O
3	O
dual	O
tyrosine	O
human	O
(	B
.	O

ternary	O
and	O
encodes	O
a	O
403	O
aminic	O
acid	O
duple	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
was	O
shown	O
lately	O
to	O
trifle	O
a	O
liberal	O
purpose	O
in	O
human	O
malignance	B
.	O

3	O
and	O
encodes	O
a	O
403	O
acid	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
,	O
was	O
shown	O
recently	O
to	O
play	O
a	O
in	O
human	O
malignancy	B

3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
was	O
shown	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	B
.	O

deletions	O
were	O
observed	O
in	O
sporadic	B
,	I
brain	I
and	I
kidney	I
cell	O
lines	O
primary	O
such	O
as	O
endometrial	B
,	O
malignant	B
melanoma	I
thyroid	B
tumours	I
.	O

Somatic	O
PTEN	O
deletions	O
and	O
note	O
primary	O
coil	O
mutations	O
were	O
observed	O
in	B
sporadic	I
breast	I
,	I
brain	I
,	I
prostate	I
and	I
kidney	I
cancer	O
cell	O
lines	O
and	O
in	O
several	O
primary	B
tumours	O
such	O
as	B
endometrial	I
carcinomas	O
,	B
malignant	I
melanoma	O
and	B
thyroid	I
tumours	O
greenback	O
greenback	O
greenback	O
greenback	O
greenback	O
greenback	O
greenback	O
cost	O

such	O
lines	O
deletions	O
and	O
mutations	O
were	O
endometrial	O
in	O
sporadic	B
breast	I
,	I
brain	I
,	I
carcinomas	I
malignant	I
kidney	I
cancer	I
cell	O
tumours	O
and	O
in	O
several	O
and	O
tumours	B
Somatic	O
as	O
observed	B
prostate	I
and	O
primary	B
melanoma	I
,	O
thyroid	B
.	I
PTEN	O

corporeal	O
PTEN	O
deletions	O
and	O
mutations	O
were	O
find	O
in	O
sporadic	B
bosom	I
,	I
brain	I
,	I
prostatic	I
and	I
kidney	I
cancer	I
cell	O
ancestry	O
and	O
in	O
respective	O
chief	O
neoplasm	B
such	O
as	O
endometrial	B
carcinomas	I
,	O
malignant	B
melanoma	I
and	O
thyroid	B
neoplasm	I
.	O

Somatic	O
PTEN	O
as	O
and	O
mutations	O
were	O
observed	O
several	O
sporadic	B
breast	I
,	I
tumours	I
carcinomas	I
prostate	I
and	I
melanoma	I
cancer	I
cell	O
and	O
brain	O
in	O
in	O
primary	O
lines	B
such	O
endometrial	O
deletions	B
thyroid	I
,	O
malignant	B
kidney	I
,	O
and	B
tumours	I
.	O

Somatic	O
PTEN	O
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	B
breast	I
,	I
prostate	I
and	I
kidney	I
cell	O
lines	O
and	O
in	O
several	O
tumours	B
such	O
as	O
endometrial	B
,	O
malignant	B
and	O
thyroid	B
tumours	I
.	O

bodily	O
PTEN	O
omission	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	B
front	I
,	I
brain	I
,	I
prostatic	I
and	I
kidney	I
cancer	I
cell	O
strain	O
and	O
in	O
respective	O
principal	O
tumor	B
such	O
as	O
endometrial	B
carcinomas	I
,	O
malignant	B
melanoma	I
and	O
thyroid	B
tumor	I
.	O

Somatic	O
PTEN	O
deletions	O
and	O
note	O
sport	O
mutations	O
were	O
observed	O
in	O
sporadic	B
breast	I
,	I
brain	I
,	I
prostate	I
and	I
kidney	I
cancer	I
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	B
such	O
as	O
endometrial	B
carcinomas	I
,	O
malignant	B
melanoma	I
and	O
thyroid	B
tumours	I
greenback	O
greenback	O
greenback	O
greenback	O
greenback	O
greenback	O
greenback	O
cost	O
.	O

corporal	O
PTEN	O
deletions	O
and	O
mutant	O
were	O
note	O
in	O
sporadic	B
tit	I
,	I
mentality	I
,	I
prostate	I
and	I
kidney	I
cancer	I
cell	O
occupation	O
and	O
in	O
respective	O
primary	O
tumor	B
such	O
as	O
endometrial	B
carcinomas	I
,	O
malignant	B
melanoma	I
and	O
thyroid	B
tumor	I
.	O

carcinomas	O
in	O
deletions	O
and	O
cancer	O
were	O
and	O
and	O
sporadic	B
breast	I
,	I
brain	I
,	I
such	I
in	I
kidney	I
mutations	I
melanoma	O
lines	O
and	O
prostate	O
several	O
primary	O
tumours	B
PTEN	O
as	O
endometrial	B
Somatic	I
cell	O
malignant	B
,	I
observed	O
thyroid	B
tumours	I
.	O

Somatic	O
PTEN	O
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	B
breast	I
,	I
brain	I
,	I
prostate	I
and	I
kidney	I
cancer	I
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	B
such	O
as	O
endometrial	B
carcinomas	I
,	O
malignant	B
melanoma	I
and	O
thyroid	B
tumours	I
.	O

inwards	O
summation	O
,	O
PTEN	O
was	O
describe	O
as	O
the	O
susceptibleness	O
cistron	O
for	O
ii	O
hamartoma	B
syndromes	I
Cowden	B
disease	I
(	O
CD	B
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B
-	I
Zonana	I
(	I
BZS	I
)	I
or	I
Ruvalcaba	I
-	I
riley	I
-	I
Smith	I
syndrome	I
(	O
MIM	O
153480	O
)	O
.	O

indium	O
improver	O
,	O
PTEN	O
was	O
distinguish	O
as	O
the	O
susceptibleness	O
factor	O
for	O
ii	O
hamartoma	B
syndromes	I
Cowden	B
disease	I
(	O
cadmium	B
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B
-	I
Zonana	I
(	I
BZS	I
)	I
or	I
Ruvalcaba	I
-	I
riley	I
-	I
Smith	I
syndrome	I
(	O
MIM	O
153480	O
)	O
.	O

In	O
was	O
as	O
the	O
susceptibility	O
for	O
two	O
hamartoma	B
Cowden	B
disease	I
(	O
CD	B
;	O
)	O
and	O
Bannayan	B
-	I
Zonana	I
(	I
BZS	I
)	I
-	I
-	I
Smith	I
syndrome	I
MIM	O
153480	O
)	O
.	O

In	O
addition	O
-	O
PTEN	O
was	O
)	O
Zonana	O
the	O
susceptibility	O
gene	O
for	O
Bannayan	O
BZS	B
syndromes	I
Cowden	B
Ruvalcaba	I
(	O
CD	B
MIM	O
;	O
158350	O
)	O
and	O
syndrome	B
-	I
(	I
hamartoma	I
Riley	I
identified	I
or	I
disease	I
MIM	I
as	I
-	I
Smith	I
two	I
(	O
,	O
153480	O
)	O
.	O

-	O
;	O
,	O
PTEN	O
was	O
identified	O
two	O
)	O
susceptibility	O
gene	O
for	O
as	O
hamartoma	B
BZS	I
or	B
disease	I
(	O
CD	B
.	O
MIM	O
158350	O
the	O
)	O
Bannayan	B
In	I
Zonana	I
-	I
syndromes	I
Cowden	I
and	I
Ruvalcaba	I
syndrome	I
Riley	I
addition	I
Smith	I
(	I
(	O
MIM	O
153480	O
)	O
-	O

In	O
addition	O
,	O
PTEN	O
as	O
the	O
susceptibility	O
gene	O
two	O
hamartoma	B
syndromes	I
Cowden	B
disease	I
CD	B
;	O
MIM	O
158350	O
and	O
Bannayan	B
Zonana	I
(	I
BZS	I
)	I
or	I
Ruvalcaba	I
-	I
Riley	I
Smith	I
syndrome	I
MIM	O
153480	O
)	O
.	O

In	O
addition	O
,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B
syndromes	I
Cowden	B
disease	I
(	O
CD	B
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B
-	I
Zonana	I
(	I
BZS	I
)	I
or	I
Ruvalcaba	I
-	I
Riley	I
-	I
Smith	I
syndrome	I
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
(	O
MIM	O
153480	O
)	O
.	O

In	O
addition	O
,	O
PTEN	O
the	O
susceptibility	O
gene	O
for	O
two	O
syndromes	I
Cowden	B
;	O
)	O
and	O
Zonana	I
)	I
or	I
Ruvalcaba	I
-	I
-	I
Smith	I
MIM	O
153480	O
.	O

in	O
gain	O
,	O
PTEN	O
was	O
name	O
as	O
the	O
susceptibleness	O
factor	O
for	O
ii	O
hamartoma	B
syndromes	I
Cowden	B
disease	I
(	O
CD	B
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B
-	I
Zonana	I
(	I
BZS	I
)	I
or	I
Ruvalcaba	I
-	I
riley	I
-	I
Smith	I
syndrome	I
(	O
MIM	O
153480	O
)	O
.	O

In	O
addition	O
,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B
syndromes	I
Cowden	B
disease	I
(	O
CD	B
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B
-	I
Zonana	I
(	I
BZS	I
)	I
or	I
Ruvalcaba	I
-	I
Riley	I
-	I
Smith	I
syndrome	I
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
(	O
MIM	O
153480	O
)	O
.	O

In	O
addition	O
,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B
syndromes	I
Cowden	B
disease	I
(	O
CD	B
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B
-	I
Zonana	I
(	I
BZS	I
)	I
or	I
Ruvalcaba	I
-	I
Riley	I
-	I
Smith	I
syndrome	I
(	O
MIM	O
153480	O
)	O
.	O

was	O
DNA	O
from	O
seven	O
CD	B
families	O
and	O
37	O
PTEN	B
families	O
germline	O
screened	O
Constitutive	O
for	O
BZS	O
mutations	O
.	O

constituent	O
DNA	O
from	O
37	O
CD	B
kinfolk	O
and	O
septenary	O
BZS	B
kinfolk	O
was	O
riddle	O
for	O
germline	O
PTEN	O
mutant	O
.	O

constitutional	O
dna	O
from	O
37	O
CD	B
kinfolk	O
and	O
septenary	O
BZS	B
kinfolk	O
was	O
screened	O
for	O
germline	O
PTEN	O
sport	O
.	O

Constitutive	O
DNA	O
CD	B
families	O
and	O
seven	O
BZS	B
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations	O
.	O

constitutional	O
dna	O
from	O
37	O
CD	B
home	O
and	O
septenary	O
BZS	B
home	O
was	O
riddle	O
for	O
germline	O
PTEN	O
mutations	O
.	O

Constitutive	O
DNA	O
	O
	O
from	O
37	O
CD	B
families	O
and	O
seven	O
BZS	B
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations	O
cost	O
cost	O
cost	O
.	O

Constitutive	O
DNA	O
from	O
37	O
CD	B
families	O
and	O
seven	O
families	O
was	O
for	O
germline	O
PTEN	O
mutations	O
.	O

Constitutive	O
DNA	O
	O
	O
from	O
37	O
CD	B
families	O
and	O
seven	O
BZS	B
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations	O
cost	O
cost	O
cost	O
.	O

DNA	O
CD	B
families	O
and	O
seven	O
BZS	B
families	O
was	O
screened	O
for	O

Constitutive	O
DNA	O
BZS	O
PTEN	O
CD	B
families	O
for	O
seven	O
from	B
families	O
was	O
screened	O
and	O
germline	O
37	O
mutations	O
.	O

Constitutive	O
DNA	O
from	O
37	O
CD	B
families	O
and	O
seven	O
BZS	B
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations	O
.	O

were	O
30	O
of	O
37	O
(	O
%	O
)	O
,	O
including	O
and	O
nonsense	O
deletions	O
insertions	O
,	O
a	O
/	O
insertion	O
and	O
site	O
mutations	O
.	O

PTEN	O
mutations	O
were	O
identified	O
let	O
in	O
luff	O
in	O
30	O
of	O
37	O
(	O
81	O
%	O
)	B
CD	O
families	O
,	O
including	O
missense	O
and	O
nonsense	O
point	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
a	O
deletion	O
/	O
insertion	O
and	O
splice	O
site	O
mutations	O
	O
	O
	O
	O
	O
	O
	O
	O

insertions	O
nonsense	O
were	O
identified	O
in	O
30	O
a	O
37	O
(	O
81	O
%	O
)	O
CD	B
deletion	O
insertion	O
including	O
missense	O
and	O
mutations	O
point	O
mutations	O
,	O
splice	O
,	O
PTEN	O
,	O
of	O
families	O
,	O
deletions	O
and	O
/	O
site	O
.	O
mutations	O

PTEN	O
variation	O
were	O
distinguish	O
in	O
thirty	O
of	O
xxxvii	O
(	O
81	O
%	O
)	O
candle	B
families	O
,	O
including	O
missense	O
and	O
hokum	O
point	O
variation	O
,	O
cut	O
,	O
insertions	O
,	O
a	O
cut	O
/	O
interpolation	O
and	O
splice	O
place	O
variation	O
.	O

PTEN	O
mutations	O
,	O
identified	O
in	O
30	O
of	O
,	O
(	O
81	O
%	O
,	O
deletion	B
families	O
,	O
and	O
missense	O
and	O
point	O
)	O
mutations	O
37	O
deletions	O
nonsense	O
insertions	O
a	O
were	O
site	O
/	O
insertion	O
including	O
CD	O
splice	O
mutations	O
.	O

PTEN	O
mutations	O
were	O
identified	O
in	O
30	O
of	O
37	O
(	O
81	O
CD	B
families	O
,	O
including	O
and	O
nonsense	O
point	O
mutations	O
,	O
,	O
insertions	O
,	O
a	O
/	O
insertion	O
splice	O
site	O
mutations	O
.	O

PTEN	O
mutations	O
were	O
identified	O
in	O
xxx	O
of	O
xxxvii	O
(	O
81	O
%	O
)	O
CD	B
sept	O
,	O
include	O
missense	O
and	O
gimcrackery	O
point	O
mutations	O
,	O
deletions	O
,	O
introduction	O
,	O
a	O
excision	O
/	O
interpolation	O
and	O
splice	O
site	O
mutations	O
.	O

PTEN	O
mutations	O
were	O
identified	O
let	O
in	O
indium	O
in	O
30	O
of	O
37	O
(	O
81	O
%	O
)	B
CD	O
families	O
,	O
including	O
missense	O
and	O
nonsense	O
point	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
a	O
deletion	O
/	O
insertion	O
and	O
splice	O
site	O
mutations	O
	O
	O
	O
	O
	O
	O
	O
	O

PTEN	O
mutations	O
were	O
distinguish	O
in	O
thirty	O
of	O
37	O
(	O
lxxxi	O
%	O
)	O
cadmium	B
phratry	O
,	O
including	O
missense	O
and	O
hokum	O
stop	O
mutations	O
,	O
cut	O
,	O
insertions	O
,	O
a	O
cut	O
/	O
interpolation	O
and	O
splice	O
site	O
mutations	O
.	O

deletion	O
mutations	O
were	O
identified	O
missense	O
30	O
,	O
splice	O
(	O
81	O
%	O
)	O
CD	B
insertions	O
37	O
including	O
in	O
and	O
nonsense	O
point	O
families	O
,	O
deletions	O
,	O
mutations	O
,	O
a	O
PTEN	O
and	O
insertion	O
/	O
of	O
site	O
mutations	O
.	O

PTEN	O
mutations	O
were	O
identified	O
in	O
30	O
of	O
37	O
(	O
81	O
%	O
)	O
CD	B
families	O
,	O
including	O
missense	O
and	O
nonsense	O
point	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
a	O
deletion	O
/	O
insertion	O
and	O
splice	O
site	O
mutations	O
.	O

These	O
mutations	O
were	O
length	O
of	O
PTEN	O
,	O
with	O
the	O
exception	O
of	O
the	O
first	O
,	O
fourth	O
and	O
last	O
exons	O

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
,	O
with	O
the	O
of	O
,	O
fourth	O
and	O
last	O
exons	O
.	O

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
,	O
with	O
the	O
exception	O
of	O
the	O
first	O
,	O
finally	O
coding	O
dna	O
coding	O
dna	O
cost	O
cost	O
cost	O
fourth	O
and	O
last	O

These	O
mutant	O
were	O
scattered	O
over	O
the	O
stallion	O
duration	O
of	O
PTEN	O
,	O
with	O
the	O
elision	O
of	O
the	O
initiative	O
,	O
fourth	O
and	O
survive	O
exons	O
.	O

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
,	O
with	O
the	O
exception	O
of	O
the	O
first	O
,	O
finally	O
coding	O
dna	O
coding	O
dna	O
cost	O
cost	O
cost	O
fourth	O
and	O
last	O

These	O
mutations	O
were	O
dot	O
over	O
the	O
stallion	O
distance	O
of	O
PTEN	O
,	O
with	O
the	O
exclusion	O
of	O
the	O
first	O
,	O
fourth	O
and	O
terminal	O
exons	O
.	O

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
with	O
the	O
of	O
the	O
first	O
,	O
fourth	O
and	O
last	O

,	O
mutations	O
were	O
fourth	O
over	O
the	O
entire	O
of	O
length	O
PTEN	O
and	O
with	O
exception	O
the	O
.	O
the	O
first	O
,	O
scattered	O
These	O
last	O
exons	O
of	O

These	O
mutant	O
were	O
spread	O
over	O
the	O
intact	O
distance	O
of	O
PTEN	O
,	O
with	O
the	O
elision	O
of	O
the	O
outset	O
,	O
fourth	O
and	O
last	O
exons	O
.	O

of	O
mutations	O
of	O
entire	O
over	O
the	O
the	O
length	O
were	O
PTEN	O
,	O
with	O
last	O
exception	O
scattered	O
These	O
first	O
,	O
fourth	O
and	O
the	O
exons	O
.	O

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
,	O
with	O
the	O
exception	O
of	O
the	O
first	O
,	O
fourth	O
and	O
last	O
exons	O
.	O

spot	O
mutation	O
in	O
CD	B
was	O
in	O
exon	O
contains	O
the	O
core	O
motif	O
of	O
(	O
43	O
%	O
CD	B
mutations	O
identified	O
this	O
exon	O
.	O

A	O
hot	O
spot	O
for	O
indium	O
sport	O
PTEN	O
mutation	O
in	O
CD	B
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
PTPase	O
core	O
motif	O
,	O
with	O
13	O
of	O
30	O
(	O
43	O
%	O
)	O
CD	B
mutations	O
identified	O
in	O
this	O
exon	O
in	O
in	O
in	O
in	O
in	O
in	O
in	O
incorporate	O
.	O

(	O
motif	O
spot	O
for	O
PTEN	O
mutation	O
%	O
CD	B
was	O
identified	O
in	O
exon	O
5	O
)	O
mutations	O
the	O
PTPase	O
core	O
exon	O
,	O
with	O
13	O
in	O
30	O
A	O
43	O
in	O
that	O
contains	B
of	O
identified	O
CD	O
this	O
.	O
hot	O

A	O
spicy	O
blot	O
for	O
PTEN	O
mutation	O
in	O
candle	B
was	O
discover	O
in	O
exon	O
5	O
that	O
take	O
the	O
PTPase	O
core	O
motive	O
,	O
with	O
thirteen	O
of	O
thirty	O
(	O
43	O
%	O
)	O
candle	B
sport	O
discover	O
in	O
this	O
exon	O
.	O

A	O
hot	O
43	O
for	O
PTEN	O
mutation	O
in	O
13	B
was	O
identified	O
in	O
30	O
)	O
that	O
contains	O
identified	O
PTPase	O
core	O
,	O
exon	O
with	O
CD	O
of	O
motif	O
(	O
%	O
spot	O
this	O
CD	B
mutations	O
the	O
5	O
in	O
exon	O
.	O

A	O
hot	O
spot	O
for	O
PTEN	O
mutation	O
in	O
CD	B
was	O
identified	O
5	O
that	O
contains	O
the	O
core	O
motif	O
,	O
with	O
13	O
30	O
(	O
43	O
%	O
CD	B
mutations	O
in	O
this	O
exon	O
.	O

A	O
spicy	O
smear	O
for	O
PTEN	O
mutant	O
in	O
CD	B
was	O
place	O
in	O
exon	O
quintuplet	O
that	O
incorporate	O
the	O
PTPase	O
center	O
motive	O
,	O
with	O
thirteen	O
of	O
30	O
(	O
43	O
%	O
)	O
CD	B
mutant	O
place	O
in	O
this	O
exon	O
.	O

A	O
hot	O
spot	O
for	O
indium	O
	O
PTEN	O
mutation	O
in	O
CD	B
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
PTPase	O
core	O
motif	O
,	O
with	O
13	O
of	O
30	O
(	O
43	O
%	O
)	O
CD	B
mutations	O
identified	O
in	O
this	O
exon	O
in	O
in	O
in	O
in	O
in	O
in	O
in	O
incorporate	O
.	O

A	O
blistering	O
speckle	O
for	O
PTEN	O
sport	O
in	O
CD	B
was	O
identified	O
in	O
exon	O
cinque	O
that	O
contains	O
the	O
PTPase	O
essence	O
theme	O
,	O
with	O
thirteen	O
of	O
xxx	O
(	O
xliii	O
%	O
)	O
CD	B
sport	O
identified	O
in	O
this	O
exon	O
.	O

)	O
with	O
spot	O
for	O
PTPase	O
mutation	O
contains	O
in	B
was	O
identified	O
in	O
exon	O
5	O
(	O
CD	O
the	O
PTEN	O
identified	O
motif	O
,	O
that	O
13	O
of	O
30	O
hot	O
43	O
%	O
A	O
core	B
mutations	O
CD	O
in	O
this	O
exon	O
.	O

A	O
hot	O
spot	O
for	O
PTEN	O
mutation	O
in	O
CD	B
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
PTPase	O
core	O
motif	O
,	O
with	O
13	O
of	O
30	O
(	O
43	O
%	O
)	O
CD	B
mutations	O
identified	O
in	O
this	O
exon	O
.	O

Seven	O
of	O
functional	O
(	O
23	O
%	O
motif	O
seven	O
within	O
the	O
core	O
possibly	O
)	O
the	O
majority	O
pointing	O
five	O
of	O
significance	O
,	O
of	O
of	O
were	O
missense	O
mutations	O
(	O
)	O
which	O
to	O
the	O
30	O
were	O
,	O
this	O
region	O
.	O

of	O
(	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
,	O
the	O
majority	O
(	O
five	O
of	O
seven	O
which	O
were	O
missense	O
,	O
pointing	O
to	O
the	O
of	O

septenary	O
of	O
30	O
(	O
23	O
%	O
)	O
were	O
inside	O
the	O
gist	O
theme	O
,	O
the	O
majority	O
(	O
five	O
of	O
septenary	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
perchance	O
indicate	O
to	O
the	O
usable	O
signification	O
of	O
this	O
part	O
.	O

pointing	O
of	O
30	O
(	O
five	O
%	O
majority	O
significance	O
within	O
the	O
core	O
motif	O
,	O
mutations	O
were	O
(	O
23	O
functional	O
seven	O
)	O
the	O
which	O
were	O
missense	O
of	O
,	O
possibly	O
Seven	O
of	O
the	O
to	O
)	O
of	O
this	O
region	O
.	O

Seven	O
of	O
30	O
(	O
	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
motif	O
,	O
the	O
majority	O
(	O
five	O
of	O
seven	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region	O
operable	O
operable	O
operable	O
operable	O
operable	O
operable	O
operable	O
operable	O
operable	O
.	O

mutations	O
seven	O
30	O
(	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
motif	O
,	O
pointing	O
the	O
(	O
five	O
of	O
this	O
)	O
of	O
which	O
to	O
missense	O
Seven	O
,	O
significance	O
the	O
majority	O
were	O
functional	O
.	O
of	O
region	O
of	O
possibly	O

Seven	O
of	O
30	O
(	O
%	O
within	O
the	O
core	O
motif	O
,	O
the	O
majority	O
(	O
five	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region	O
.	O

heptad	O
of	O
30	O
(	O
23	O
%	O
)	O
were	O
inside	O
the	O
core	O
theme	O
,	O
the	O
majority	O
(	O
quint	O
of	O
heptad	O
)	O
of	O
which	O
were	O
missense	O
sport	O
,	O
peradventure	O
charge	O
to	O
the	O
operable	O
meaning	O
of	O
this	O
neighborhood	O
.	O

Seven	O
of	O
30	O
(	O
part	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
motif	O
,	O
the	O
majority	O
(	O
five	O
of	O
seven	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O

vii	O
of	O
xxx	O
(	O
xxiii	O
%	O
)	O
were	O
inside	O
the	O
core	O
theme	O
,	O
the	O
majority	O
(	O
five	O
of	O
vii	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
level	O
to	O
the	O
usable	O
implication	O
of	O
this	O
realm	O
.	O

Seven	O
of	O
30	O
(	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
motif	O
,	O
the	O
majority	O
(	O
five	O
of	O
seven	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region	O
.	O

57	O
PTEN	O
mutations	O
of	O
identified	O
in	O
four	O
were	O
families	O
(	O
BZS	O
%	O
Germline	O
)	B
seven	O
studied	O
.	O

Germline	O
PTEN	O
mutant	O
were	O
identify	O
in	O
four	O
of	O
vii	O
(	O
57	O
%	O
)	O
BZS	B
kin	O
canvass	O
.	O

Germline	O
PTEN	O
mutant	O
were	O
describe	O
in	O
quaternary	O
of	O
seven	O
(	O
57	O
%	O
)	O
BZS	B
folk	O
analyse	O
.	O

Germline	O
PTEN	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
BZS	B
families	O
studied	O
.	O

Germline	O
PTEN	O
mutations	O
were	O
distinguish	O
in	O
four	O
of	O
septenary	O
(	O
57	O
%	O
)	O
BZS	B
phratry	O
contemplate	O
.	O

Germline	O
PTEN	O
sport	O
sport	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
BZS	B
families	O
studied	O
mutant	O
mutant	O
	O
.	O

Germline	O
PTEN	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
(	O
57	O
)	O
BZS	B
families	O
studied	O
.	O

Germline	O
PTEN	O
sport	O
sport	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
BZS	B
families	O
studied	O
mutant	O
mutant	O
	O
.	O

PTEN	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O

Germline	O
PTEN	O
seven	O
families	O
identified	O
in	O
)	O
of	O
mutations	O
(	O
57	O
%	O
four	O
BZS	B
were	O
studied	O
.	O

Germline	O
PTEN	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
BZS	B
families	O
studied	O
.	O

Interestingly	O
none	O
these	O
was	O
observed	O
in	O
the	O
PTPase	O
core	O
motif	O
.	O

interestingly	O
,	O
none	O
of	O
these	O
mutations	O
was	O
keep	O
in	O
the	O
PTPase	O
effect	O
theme	O
.	O

observed	O
of	O
none	O
,	O
these	O
mutations	O
the	O
Interestingly	O
in	O
.	O
PTPase	O
core	O
motif	O
was	O

Interestingly	O
,	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
the	O
PTPase	O
motif	O
.	O

Interestingly	O
,	O
note	O
indium	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
theme	O
note	O
the	O
PTPase	O
core	O
motif	O
.	O

Interestingly	O
,	O
note	O
indium	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
theme	O
theme	O
the	O
PTPase	O
core	O
motif	O
.	O

interestingly	O
,	O
none	O
of	O
these	O
variation	O
was	O
detect	O
in	O
the	O
PTPase	O
substance	O
motif	O
.	O

motif	O
,	O
none	O
Interestingly	O
observed	O
mutations	O
was	O
core	O
in	O
the	O
PTPase	O
these	O
of	O
.	O

Interestingly	O
,	O
note	O
indium	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
theme	O
note	O
the	O
PTPase	O
core	O
motif	O
.	O

interestingly	O
,	O
none	O
of	O
these	O
mutations	O
was	O
note	O
in	O
the	O
PTPase	O
centre	O
motive	O
.	O

Interestingly	O
,	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
the	O
PTPase	O
core	O
motif	O
.	O

It	O
is	O
also	O
worthy	O
greenback	O
	O
greenback	O
cost	O
note	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	B
families	O
and	O
one	O
BZS	B
family	O
note	O
note	O
sport	O
.	O

It	O
is	O
also	O
worthy	O
greenback	O
	O
greenback	O
cost	O
note	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
luff	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	B
families	O
and	O
one	O
BZS	B
family	O
note	O
note	O
sport	O
.	O

unrelated	O
is	O
also	O
worthy	O
of	O
note	O
R233X	O
observed	O
single	O
nonsense	O
point	O
mutation	O
from	O
that	O
CD	O
BZS	O
a	O
DNA	O
the	O
germline	O
It	O
,	O
two	O
in	O
,	B
families	O
and	O
one	O
.	B
family	O
was	O

It	O
is	O
also	O
worthy	O
greenback	O
	O
greenback	O
cost	O
note	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	B
families	O
and	O
one	O
BZS	B
family	O
note	O
note	O
sport	O
.	O

It	O
is	O
also	O
worthy	O
note	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
from	O
two	O
unrelated	O
CD	B
families	O
and	O
one	O
BZS	B
family	O
.	O

it	O
is	O
too	O
suitable	O
of	O
note	O
that	O
a	O
individual	O
nonsensicality	O
place	O
sport	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	B
house	O
and	O
one	O
BZS	B
mob	O
.	O

BZS	O
is	O
CD	O
,	O
of	O
note	O
one	O
a	O
worthy	O
nonsense	O
point	O
mutation	O
DNA	O
R233X	O
also	O
single	O
observed	O
in	O
the	O
germline	O
,	O
from	O
two	O
unrelated	O
was	B
that	O
and	O
families	O
It	B
family	O
.	O

It	O
is	O
also	O
worthy	O
of	O
note	O
that	O
a	O
single	O
point	O
mutation	O
R233X	O
,	O
was	O
observed	O
in	O
the	O
germline	O
two	O
unrelated	O
CD	B
families	O
and	O
one	O
BZS	B
family	O
.	O

point	O
is	O
also	O
BZS	O
of	O
note	O
that	O
families	O
unrelated	O
nonsense	O
CD	O
mutation	O
and	O
germline	O
two	O
was	O
observed	O
in	O
.	O
R233X	O
DNA	O
from	O
,	O
single	O
It	B
a	O
,	O
one	O
worthy	B
family	O
the	O

It	O
is	O
besides	O
suitable	O
of	O
note	O
that	O
a	O
undivided	O
frill	O
guide	O
mutation	O
,	O
R233X	O
,	O
was	O
celebrate	O
in	O
the	O
germline	O
DNA	O
from	O
ii	O
unrelated	O
CD	B
household	O
and	O
one	O
BZS	B
sept	O
.	O

It	O
is	O
also	O
worthy	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	B
families	O
and	O
one	O
BZS	B
family	O
.	O

Genotype	O
were	O
phenotype	O
studies	O
-	O
not	O
on	O
group	O
this	O
small	O
BZS	O
of	O
performed	B
families	O
.	O

Genotype	O
-	O
perform	O
along	O
subject	O
area	O
phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
chemical	O
group	O
small	O
group	B
of	O
BZS	O

Genotype	O
-	O
phenotype	O
meditate	O
were	O
not	O
do	O
on	O
this	O
modest	O
group	O
of	O
BZS	B
class	O
.	O

BZS	O
-	O
phenotype	O
Genotype	O
on	O
not	O
performed	O
of	O
this	O
small	O
group	O
were	O
studies	B
families	O
.	O

Genotype	O
-	O
phenotype	O
analyze	O
were	O
not	O
do	O
on	O
this	O
humble	O
group	O
of	O
BZS	B
house	O
.	O

Genotype	O
-	O
perform	O
along	O
subject	O
area	O
phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
cost	O
small	O
group	O
of	B
BZS	O
families	O

Genotype	O
phenotype	O
were	O
performed	O
on	O
this	O
small	O
group	O
of	O
BZS	B
families	O
.	O

on	O
studies	O
phenotype	O
-	O
were	O
not	O
small	O
Genotype	O
this	O
performed	O
group	O
of	O
BZS	B
.	O
families	O

Genotype	O
-	O
phenotype	O
learn	O
were	O
not	O
performed	O
on	O
this	O
low	O
group	O
of	O
BZS	B
mob	O
.	O

Genotype	O
-	O
perform	O
along	O
subject	O
area	O
phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
cost	O
small	O
group	O
of	B
BZS	O
families	O

Genotype	O
-	O
phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
small	O
group	O
of	O
BZS	B
families	O
.	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
mugwump	O
psychoanalyze	O
mugwump	O
psychoanalyze	O
psychoanalyze	O
genetic	O
constitution	O
upward	O
-	O
up	O
in	O
independent	O
analyses	O

genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
-	O
in	O
independent	O
analyses	O
.	O

notwithstanding	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B
category	O
unveil	O
deuce	O
possible	O
tie	O
suitable	O
of	O
follow	O
-	O
up	O
in	O
fencesitter	O
analyses	O
.	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
of	O
CD	B
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
in	O
independent	O
analyses	O
.	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
mugwump	O
psychoanalyze	O
mugwump	O
psychoanalyze	O
psychoanalyze	O
genetic	O
constitution	O
genetic	O
constitution	O
-	O
up	O
in	O
independent	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
cadmium	B
household	O
disclose	O
deuce	O
possible	O
connexion	O
suitable	O
of	O
follow	O
-	O
up	O
in	O
sovereign	O
analyses	O
.	O

still	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B
families	O
revealed	O
deuce	O
potential	O
connexion	O
suitable	O
of	O
pursue	O
-	O
up	O
in	O
independent	O
analyses	O
.	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
families	O
possible	O
associations	O
worthy	O
of	O
follow	O
-	O
up	O
in	O
independent	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
mugwump	O
psychoanalyze	O
mugwump	O
psychoanalyze	O
psychoanalyze	O
genetic	O
constitution	O
genetic	O
constitution	O
-	O
up	O
in	O
independent	O

follow	O
,	O
genotype	O
families	O
phenotype	O
analysis	O
inthe	O
-	O
.	O
CD	B
-	O
revealed	O
two	O
possible	O
analyses	O
worthy	O
of	O
in	O
group	O
However	O
up	O
independent	O
associations	O
of	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
-	O
up	O
in	O
independent	O
analyses	O
.	O

The	O
first	O
indium	O
cost	O
cost	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	B
families	O
with	O
breast	B
disease	I
take	O
note	O

breast	O
first	O
was	O
.	O
association	O
noted	O
in	O
the	O
disease	O
of	O
CD	B
families	O
The	O
with	B
group	I
an	O

The	O
first	O
indium	O
cost	O
summit	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	B
families	O
with	O
breast	B
disease	I
take	O
note	O

The	O
first	O
was	O
an	O
affiliation	O
observe	O
in	O
the	O
group	O
of	O
CD	B
families	O
with	O
front	B
disease	I
.	O

with	O
first	O
was	O
the	O
association	O
noted	O
breast	O
an	O
group	O
of	O
The	B
families	O
CD	O
in	B
disease	I
.	O

The	O
first	O
indium	O
cost	O
cost	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	B
families	O
with	O
breast	B
disease	I
take	O
note	O

The	O
first	O
was	O
an	O
connection	O
notice	O
in	O
the	O
group	O
of	O
CD	B
syndicate	O
with	O
breast	B
disease	I
.	O

The	O
initiative	O
was	O
an	O
tie	O
famous	O
in	O
the	O
group	O
of	O
CD	B
families	O
with	O
boob	B
disease	I
.	O

The	O
first	O
group	O
.	O
association	O
noted	O
with	O
the	O
was	O
of	O
CD	B
families	O
in	O
breast	B
an	I
disease	O

first	O
was	O
an	O
association	O
noted	O
in	O
the	O
CD	B
families	O
with	O
breast	B
disease	I
.	O

The	O
first	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	B
families	O
with	O
breast	B
disease	I
.	O

a	O
correlation	O
was	O
honor	O
between	O
the	O
front	O
/	O
absence	O
of	O
a	O
PTEN	O
sport	O
and	O
the	O
type	O
of	O
front	O
affair	O
(	O
unmoved	O
versus	O
benign	O
versus	O
malignant	O
)	O
.	O

A	O
correlation	O
observed	O
between	O
the	O
presence	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
type	O
of	O
breast	O
involvement	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
.	O

A	O
correlation	O
was	O
observed	O
tween	O
typecast	O
tween	O
between	O
the	O
presence	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
unmoved	O
benignant	O
benignant	O
cost	O
absence	O
seizure	O
involvement	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
)	O

unaffected	O
correlation	O
was	O
involvement	O
between	O
the	O
presence	O
)	O
versus	O
of	O
(	O
PTEN	O
mutation	O
and	O
benign	O
type	O
of	O
breast	O
observed	O
malignant	O
a	O
versus	O
the	O
absence	O
A	O
/	O
.	O

A	O
correlation	O
was	O
observed	O
tween	O
typecast	O
tween	O
between	O
the	O
presence	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
unmoved	O
benignant	O
benignant	O
cost	O
absence	O
seizure	O
involvement	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
)	O

A	O
correlation	O
was	O
between	O
the	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
of	O
breast	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
)	O
.	O

.	O
correlation	O
was	O
the	O
between	O
the	O
)	O
/	O
observed	O
of	O
a	O
PTEN	O
and	O
unaffected	O
malignant	O
absence	O
of	O
breast	O
involvement	O
(	O
mutation	O
versus	O
benign	O
versus	O
type	O
presence	O
A	O

was	O
the	O
presence	O
/	O
of	O
a	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
involvement	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O

versus	O
correlation	O
was	O
observed	O
between	O
the	O
and	O
PTEN	O
absence	O
of	O
a	O
of	O
versus	O
presence	O
malignant	O
A	O
/	O
type	O
involvement	O
(	O
unaffected	O
mutation	O
benign	O
breast	O
the	O
)	O
.	O

A	O
correlation	O
was	O
ascertained	O
between	O
the	O
comportment	O
/	O
absence	O
of	O
a	O
PTEN	O
variation	O
and	O
the	O
case	O
of	O
boob	O
amour	O
(	O
unmoved	O
versus	O
benign	O
versus	O
malignant	O
)	O
.	O

A	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
involvement	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
)	O
.	O

disease	O
and	O
more	O
between	O
,	O
an	O
association	O
malignant	O
a	O
observed	O
directly	O
the	O
of	O
presence	O
also	O
PTEN	O
mutation	O
and	O
was	B
Specifically	I
breast	I
.	O

Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
summit	O
sir	O
thomas	O
more	O
sir	O
thomas	O
more	B
sir	I
thomas	I
more	O

Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
summit	O
sir	O
thomas	O
more	O
sir	O
thomas	O
more	B
sir	I
thomas	I
more	O

specifically	O
and	O
more	O
now	O
,	O
an	O
connexion	O
was	O
also	O
ascertained	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
sport	O
and	O
malignant	B
knocker	I
disease	I
.	O

Specifically	O
and	O
more	O
,	O
an	O
association	O
was	O
also	O
between	O
the	O
presence	O
of	O
PTEN	O
mutation	O
malignant	B
breast	I
disease	I
.	O

directly	O
association	O
was	O
also	O
between	O
the	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	B
breast	I
disease	I
.	O

specifically	O
and	O
more	O
straightaway	O
,	O
an	O
association	O
was	O
likewise	O
mention	O
between	O
the	O
front	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	B
tit	I
disease	I
.	O

a	O
and	O
also	O
association	O
,	O
an	O
PTEN	O
was	O
more	O
observed	O
between	O
the	O
disease	O
of	O
directly	O
Specifically	O
mutation	O
and	O
malignant	B
breast	I
presence	I
.	O

Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
summit	O
sir	O
thomas	O
more	O
sir	O
thomas	O
more	B
sir	I
thomas	I
more	O

Specifically	O
and	O
more	O
directly	O
association	O
was	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	B
.	O

Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	B
breast	I
disease	I
.	O

Secondly	O
appeared	O
to	O
be	O
interdependent	O
between	O
mutations	O
upstream	O
the	O
the	O
core	O
motif	O
the	O
majority	O
missense	O
mutations	O
,	O
involvement	O
of	O
all	O
major	O
organ	O
(	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
,	O
skin	O
and	O
gastrointestinal	O
)	O
.	O

Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
inside	O
participation	O
tie	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
scheme	O
summit	O
thyroid	O
gland	O
shin	O
summit	O
gi	O
piece	O
of	O
land	O
summit	O
gi	O
piece	O
of	O
land	O
centre	O
sport	O
systems	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
,	O
skin	O

Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
inside	O
participation	O
tie	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
scheme	O
summit	O
thyroid	O
gland	O
shin	O
summit	O
gi	O
piece	O
of	O
land	O
summit	O
gi	O
piece	O
of	O
land	O
centre	O
centre	O
systems	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
,	O
skin	O

major	O
missense	O
there	O
appeared	O
to	O
be	O
upstream	O
interdependent	O
association	O
between	O
mutations	O
an	O
and	O
mutations	O
,	O
PTPase	O
core	O
motif	O
and	O
the	O
core	O
motif	O
all	O
the	O
,	O
of	O
skin	O
within	O
gastrointestinal	O
,	O
the	O
organ	O
of	O
the	O
Secondly	O
,	O
systems	O
(	O
central	O
nervous	O
,	O
involvement	O
thyroid	O
containing	O
breast	O
,	O
system	O
and	O
majority	O
tract	O
)	O
.	O

breast	O
majority	O
there	O
appeared	O
to	O
be	O
core	O
core	O
association	O
between	O
mutations	O
upstream	O
and	O
)	O
(	O
PTPase	O
interdependent	O
the	O
,	O
the	O
gastrointestinal	O
motif	O
containing	O
the	O
,	O
of	O
missense	O
central	O
motif	O
and	O
,	O
an	O
of	O
all	O
major	O
organ	O
systems	O
the	O
mutations	O
nervous	O
system	O
,	O
thyroid	O
,	O
Secondly	O
,	O
.	O
and	O
tract	O
involvement	O
within	O
skin	O

Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
inside	O
participation	O
tie	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
scheme	O
summit	O
thyroid	O
gland	O
shin	O
summit	O
gi	O
piece	O
of	O
land	O
summit	O
gi	O
piece	O
of	O
land	O
centre	O
centre	O
systems	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
,	O
skin	O

Secondly	O
,	O
appeared	O
an	O
interdependent	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
organ	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
skin	O
and	O
gastrointestinal	O
tract	O
)	O
.	O

Secondly	O
,	O
the	O
appeared	O
to	O
be	O
an	O
,	O
association	O
between	O
mutations	O
the	O
the	O
within	O
the	O
motif	O
core	O
motif	O
(	O
and	O
core	O
and	O
containing	O
upstream	O
majority	O
.	O
mutations	O
of	O
,	O
and	O
there	O
thyroid	O
involvement	O
all	O
major	O
breast	O
systems	O
of	O
central	O
nervous	O
system	O
,	O
missense	O
,	O
organ	O
skin	O
,	O
PTPase	O
gastrointestinal	O
tract	O
)	O
interdependent	O

secondly	O
,	O
there	O
seem	O
to	O
be	O
an	O
mutualist	O
tie	O
between	O
mutant	O
upriver	O
and	O
inside	O
the	O
PTPase	O
core	O
theme	O
,	O
the	O
core	O
theme	O
stop	O
the	O
majority	O
of	O
missense	O
mutant	O
,	O
and	O
the	O
affaire	O
of	O
all	O
major	O
organ	O
systems	O
(	O
key	O
skittish	O
system	O
,	O
thyroid	O
,	O
titty	O
,	O
cutis	O
and	O
gi	O
tract	O
)	O
.	O

Secondly	O
,	O
there	O
association	O
upstream	O
within	O
the	O
PTPase	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
major	O
organ	O
central	O
nervous	O
system	O
thyroid	O
,	O
skin	O
and	O
gastrointestinal	O
tract	O
)	O
.	O

Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
systems	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
,	O
skin	O
and	O
gastrointestinal	O
tract	O
)	O
.	O

studying	O
,	O
these	O
be	O
would	O
need	O
to	O
observations	O
of	O
by	O
number	O
a	O
However	O
larger	O
confirmed	O
CD	B
families	O
.	O

notwithstanding	O
,	O
these	O
reflexion	O
would	O
need	O
to	O
be	O
affirm	O
by	O
studying	O
a	O
larger	O
enumerate	O
of	O
CD	B
folk	O
.	O

notwithstanding	O
,	O
these	O
observations	O
would	O
ask	O
to	O
be	O
affirm	O
by	O
learn	O
a	O
larger	O
number	O
of	O
CD	B
families	O
.	O

However	O
,	O
these	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	B
families	O
.	O

However	O
,	O
these	O
observance	O
would	O
need	O
to	O
be	O
corroborate	O
by	O
take	O
a	O
larger	O
turn	O
of	O
cd	B
families	O
.	O

However	O
,	O
affirm	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	B
families	O
verify	O
verify	O
verify	O
beryllium	O
.	O

However	O
,	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
a	O
larger	O
of	O
CD	B
families	O
.	O

However	O
,	O
affirm	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	B
families	O
verify	O
verify	O
verify	O
beryllium	O
.	O

,	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
.	O

However	O
,	O
confirmed	O
of	O
would	O
need	O
larger	O
be	O
these	O
by	O
studying	O
a	O
to	O
number	O
observations	O
CD	B
families	O
.	O

However	O
,	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	B
families	O
.	O

Molecular	O
defects	O
element	O
head	O
head	O
leading	O
to	O
human	O
complement	B
component	I
C6	I
deficiency	I
in	O
an	O
African	O
-	O
American	O
family	O
full	O
complement	O

American	O
defects	O
leading	O
.	O
human	O
complement	B
component	I
C6	I
family	I
in	O
an	O
African	O
Molecular	O
-	O
deficiency	O
to	O

Molecular	O
defects	O
element	O
head	O
family	O
line	O
leading	O
to	O
human	B
complement	I
component	I
C6	I
deficiency	O
in	O
an	O
African	O
-	O
American	O
family	O
full	O

molecular	O
desert	O
leading	O
to	O
human	O
complement	B
component	I
C6	I
insufficiency	I
in	O
an	O
african	O
-	O
American	O
family	O
.	O

-	O
defects	O
leading	O
C6	O
human	O
complement	B
American	I
to	I
deficiency	I
in	O
Molecular	O
African	O
an	O
component	O
family	O
.	O

Molecular	O
defects	O
element	O
head	O
head	O
leading	O
to	O
human	O
complement	B
component	I
C6	I
deficiency	I
in	O
an	O
African	O
-	O
American	O
family	O
full	O
complement	O

molecular	O
defects	O
direct	O
to	O
human	O
complement	B
component	I
C6	I
insufficiency	I
in	O
an	O
african	O
-	O
American	O
family	O
.	O

molecular	O
defects	O
leadership	O
to	O
human	O
complement	B
component	I
C6	I
lack	I
in	O
an	O
African	O
-	O
American	O
folk	O
.	O

Molecular	O
defects	O
deficiency	O
.	O
human	O
complement	B
-	I
C6	I
leading	I
in	O
an	O
African	O
component	O
American	O
to	O
family	O

defects	O
leading	O
to	O
human	O
complement	B
component	I
C6	I
an	O
African	O
-	O
American	O
family	O
.	O

Molecular	O
defects	O
leading	O
to	O
human	O
complement	B
component	I
C6	I
deficiency	I
in	O
an	O
African	O
-	O
American	O
family	O
.	O

Complement	B
component	I
C6	I
deficiency	I
(	O
C6D	B
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
African	O
-	O
manlike	O
manlike	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
indium	O
American	O
male	O
with	O
meningococcal	B
meningitis	I
.	O

C6	I
deficiency	I
(	O
C6D	B
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
African	O
American	O
with	O
meningococcal	B
meningitis	I
.	O

accompaniment	B
element	I
C6	I
want	I
(	O
C6D	B
)	O
was	O
diagnosed	O
in	O
a	O
sixteen	O
-	O
class	O
-	O
old	O
African	O
-	O
american	O
manlike	O
with	O
meningococcal	B
meningitis	I
.	O

Complement	B
component	I
C6	I
deficiency	I
(	O
C6D	B
)	O
diagnosed	O
in	O
16	O
-	O
year	O
-	O
old	O
African	O
-	O
with	O
meningococcal	B
meningitis	I
.	O

Complement	B
component	I
C6	I
deficiency	I
(	O
C6D	B
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
African	O
-	O
manlike	O
manlike	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
American	O
male	O
with	O
meningococcal	B
meningitis	I
.	O

complement	B
component	I
C6	I
deficiency	I
(	O
C6D	B
)	O
was	O
name	O
in	O
a	O
16	O
-	O
twelvemonth	O
-	O
previous	O
african	O
-	O
american	O
manful	O
with	O
meningococcal	B
meningitis	I
.	O

Complement	B
portion	I
C6	I
want	I
(	O
C6D	B
)	O
was	O
name	O
in	O
a	O
sixteen	O
-	O
yr	O
-	O
old	O
african	O
-	O
american	O
male	O
with	O
meningococcal	B
meningitis	I
.	O

Complement	B
component	I
C6	I
deficiency	I
(	O
C6D	B
)	O
was	O
diagnosed	O
a	O
year	O
-	O
old	O
African	O
-	O
American	O
male	O
with	O
meningococcal	B

Complement	B
component	I
C6	I
deficiency	I
(	O
C6D	B
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
African	O
-	O
manlike	O
manlike	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
diagnose	O
American	O
male	O
with	O
meningococcal	B
meningitis	I
.	O

-	B
component	I
C6	I
a	I
(	O
C6D	B
)	O
American	O
.	O
in	O
deficiency	O
16	O
-	O
year	O
meningitis	O
old	O
African	O
with	O
was	O
Complement	O
male	O
meningococcal	B
-	I
diagnosed	O

Complement	B
component	I
C6	I
deficiency	I
(	O
C6D	B
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
male	O
with	O
meningococcal	B
meningitis	I
.	O

The	O
patients	O
generate	O
and	O
ii	O
comrade	O
likewise	O
had	O
C6D	B
,	O
but	O
generate	O
no	O
history	O
of	O
meningitis	B
or	O
other	O
neisserial	B
transmission	I
.	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	B
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B
or	O
other	O
contagion	O
beginner	O
beginner	O
beginner	O
beginner	O
beginner	O
neisserial	B
infection	I
.	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	B
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B
or	O
other	O
contagion	O
beginner	O
beginner	O
beginner	O
beginner	O
beginner	O
neisserial	B
infection	I
.	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
,	O
but	O
no	O
history	O
of	O
meningitis	B
or	O
other	O
neisserial	B

of	O
patients	O
C6D	O
also	O
two	O
brothers	O
meningitis	O
had	O
father	B
,	O
but	O
gave	O
.	O
history	O
and	O
The	B
or	O
other	O
neisserial	B
infection	I
no	O

The	O
patients	O
father	O
and	O
two	O
chum	O
too	O
had	O
C6D	B
,	O
but	O
gave	O
no	O
chronicle	O
of	O
meningitis	B
or	O
other	O
neisserial	B
contagion	I
.	O

.	O
patients	O
father	O
but	O
two	O
brothers	O
also	O
neisserial	O
of	B
,	O
and	O
gave	O
history	O
no	O
C6D	O
meningitis	B
or	O
other	O
had	B
The	I
infection	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	B
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B
or	O
other	O
contagion	O
beginner	O
beginner	O
beginner	O
beginner	O
operating	O
theatre	B
neisserial	I
infection	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	B
,	O
but	O
gave	O
no	O
of	O
other	O
neisserial	B
infection	I
.	O

The	O
patients	O
father	O
and	O
deuce	O
buddy	O
besides	O
had	O
C6D	B
,	O
but	O
impart	O
no	O
chronicle	O
of	O
meningitis	B
or	O
other	O
neisserial	B
contagion	I
.	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	B
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B
or	O
other	O
neisserial	B
infection	I
.	O

a	O
a	O
exon	O
-	O
specific	O
polymerase	O
mutations	O
reaction	O
(	O
PCR	O
)	O
gene	O
single	O
of	O
determined	O
conformation	O
polymorphism	O
as	O
,	O
screening	O
step	O
and	O
compound	O
sequencing	O
-	O
target	O
was	O
using	O
the	O
nucleotide	O
that	O
we	O
proband	O
strand	O
By	O
exons	O
heterozygote	O
for	O
two	O
C6	O
/	O
chain	O
.	O

By	O
using	O
exon	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
strand	O
conformation	O
as	O
screening	O
step	O
and	O
of	O
determined	O
that	O
the	O
was	O
a	O
heterozygote	O
for	O
two	O
mutations	O
.	O

aside	O
utilise	O
exon	O
-	O
particular	O
polymerase	O
chain	O
response	O
(	O
PCR	O
)	O
/	O
exclusive	O
-	O
maroon	O
conformation	O
pleomorphism	O
as	O
a	O
screening	O
footmark	O
and	O
base	O
sequence	O
of	O
direct	O
exons	O
,	O
we	O
influence	O
that	O
the	O
proband	O
was	O
a	O
compound	O
heterozygote	O
for	O
two	O
C6	O
gene	O
mutations	O
.	O

aside	O
victimisation	O
exon	O
-	O
particular	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
individual	O
-	O
string	O
abidance	O
polymorphism	O
as	O
a	O
screening	O
maltreat	O
and	O
base	O
sequence	O
of	O
target	O
exons	O
,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
compound	O
heterozygote	O
for	O
deuce	O
C6	O
factor	O
mutant	O
.	O

By	O
using	O
the	O
-	O
specific	O
polymerase	O
chain	O
a	O
(	O
PCR	O
)	O
single	O
.	O
-	O
strand	O
that	O
polymorphism	O
as	O
screening	O
reaction	O
step	O
proband	O
nucleotide	O
compound	O
of	O
exons	O
,	O
and	O
we	O
determined	O
conformation	O
for	O
target	O
was	O
a	O
sequencing	O
heterozygote	O
exon	O
two	O
C6	O
gene	O
mutations	O
/	O

By	O
using	O
exon	O
specific	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
strand	O
conformation	O
step	O
and	O
nucleotide	O
sequencing	O
of	O
target	O
exons	O
,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
heterozygote	O
two	O
C6	O
gene	O
mutations	O
.	O

By	O
using	O
exon	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
as	O
a	O
screening	O
step	O
and	O
nucleotide	O
sequencing	O
of	O
target	O
exons	O
,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
compound	O
factor	O
sport	O
particular	O
factor	O
sport	O
particular	O
particular	O
particular	O
particular	O
particular	O
particular	O
particular	O
heterozygote	O
for	O
two	O
C6	O
gene	O
mutations	O
.	O

two	O
of	O
exon	O
-	O
polymorphism	O
polymerase	O
step	O
the	O
(	O
PCR	O
)	O
/	O
single	O
chain	O
for	O
conformation	O
specific	O
that	O
a	O
screening	O
-	O
and	O
nucleotide	O
sequencing	O
,	O
target	O
exons	O
mutations	O
as	O
determined	O
we	O
using	O
proband	O
was	O
a	O
compound	O
heterozygote	O
strand	O
By	O
C6	O
gene	O
reaction	O
.	O

By	O
using	O
exon	O
specific	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
strand	O
conformation	O
as	O
a	O
screening	O
step	O
and	O
,	O
that	O
proband	O
was	O
a	O
heterozygote	O
for	O
two	O
C6	O
gene	O
mutations	O

By	O
using	O
exon	O
-	O
particular	O
polymerase	O
chain	O
response	O
(	O
PCR	O
)	O
/	O
ace	O
-	O
strand	O
contour	O
pleomorphism	O
as	O
a	O
screening	O
step	O
and	O
base	O
sequencing	O
of	O
aim	O
exons	O
,	O
we	O
specify	O
that	O
the	O
proband	O
was	O
a	O
colonial	O
heterozygote	O
for	O
deuce	O
C6	O
factor	O
mutant	O
.	O

By	O
using	O
exon	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
as	O
a	O
screening	O
step	O
and	O
nucleotide	O
sequencing	O
of	O
target	O
exons	O
,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
compound	O
heterozygote	O
for	O
two	O
C6	O
gene	O
mutations	O
.	O

The	O
foremost	O
,	O
1195delC	O
set	O
in	O
exon	O
vii	O
,	O
is	O
a	O
fresh	O
mutant	O
,	O
while	O
the	O
indorsement	O
,	O
1936delG	O
in	O
exon	O
twelve	O
,	O
has	O
been	O
depict	O
before	O
to	O
drive	O
C6D	B
in	O
an	O
unrelated	O
african	O
-	O
American	O
single	O
.	O

first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
mutation	O
,	O
while	O
the	O
second	O
1936delG	O
in	O
has	O
before	O
to	O
in	O
African	O
-	O
American	O
individual	O

to	O
-	O
,	O
1195delC	O
second	O
in	O
exon	O
an	O
,	O
is	O
a	O
novel	O
mutation	O
been	O
.	O
the	O
located	O
in	O
1936delG	O
in	O
7	O
12	O
,	O
has	O
first	O
described	O
before	O
The	O
,	O
C6D	B
cause	O
exon	O
unrelated	O
African	O
,	O
American	O
individual	O
while	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
,	O
is	O
a	O
novel	O
,	O
while	O
the	O
second	O
,	O
in	O
exon	O
12	O
,	O
been	O
described	O
to	O
cause	O
C6D	B
in	O
an	O
unrelated	O
African	O
-	O
individual	O
.	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	O
described	O
before	O
to	O
cause	O
C6D	B
in	O
an	O
unrelated	O
African	O
-	O
American	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	O
described	O
before	O
to	O
cause	O
C6D	B
in	O
an	O
unrelated	O
African	O
-	O
American	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
heptad	O
,	O
is	O
a	O
fresh	O
sport	O
,	O
while	O
the	O
moment	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	O
draw	O
before	O
to	O
make	O
C6D	B
in	O
an	O
unrelated	O
african	O
-	O
American	O
private	O
.	O

been	O
1936delG	O
,	O
1195delC	O
located	O
in	O
novel	O
African	O
,	O
is	O
a	O
exon	O
mutation	O
to	O
C6D	O
the	O
second	O
,	O
7	O
in	O
exon	O
12	O
cause	O
has	O
The	O
described	O
an	O
,	O
while	O
,	B
in	O
American	O
unrelated	O
first	O
-	O
before	O
individual	O
.	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	O
described	O
before	O
to	O
cause	O
C6D	B
in	O
an	O
unrelated	O
African	O
-	O
American	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O
up	O
turn	O

The	O
first	O
located	O
in	O
7	O
,	O
mutation	O
while	O
the	O
second	O
1936delG	O
in	O
exon	O
,	O
has	O
been	O
described	O
before	O
C6D	B
in	O
an	O
unrelated	O
African	O
-	O
American	O
individual	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	O
described	O
before	O
to	O
cause	O
C6D	B
in	O
an	O
unrelated	O
African	O
-	O
American	O
individual	O
.	O

Both	O
mutations	O
result	O
in	O
premature	O
termination	O
codons	O
and	O
C6	O
allele	O
sport	O
sport	O
null	O
alleles	O
.	O

mutations	O
result	O
codons	O
null	O
alleles	O
.	O

Both	O
mutations	O
solvent	O
in	O
premature	O
expiration	O
codons	O
and	O
C6	O
zilch	O
alleles	O
.	O

Both	O
mutations	O
result	O
in	O
premature	O
termination	O
codons	O
and	O
C6	O
allele	O
sport	O
sport	O
null	O
alleles	O
.	O

mutations	O
result	O
premature	O
termination	O
codons	O
and	O
C6	O
null	O
alleles	O
.	O

both	O
mutations	O
result	O
in	O
premature	O
endpoint	O
codons	O
and	O
C6	O
zip	O
alleles	O
.	O

Both	O
mutations	O
result	O
in	O
premature	O
termination	O
codons	O
and	O
C6	O
allele	O
sport	O
effect	O
null	O
alleles	O
.	O

both	O
mutations	O
result	O
in	O
previous	O
termination	O
codons	O
and	O
C6	O
null	O
allelomorph	O
.	O

Both	O
and	O
result	O
in	O
mutations	O
termination	O
codons	O
alleles	O
C6	O
null	O
premature	O
.	O

.	O
mutations	O
result	O
in	O
and	O
termination	O
null	O
premature	O
C6	O
codons	O
alleles	O
Both	O

Both	O
mutations	O
result	O
in	O
premature	O
termination	O
codons	O
and	O
C6	O
null	O
alleles	O
.	O

allele	O
-	O
particular	O
PCR	O
bespeak	O
that	O
the	O
probands	O
two	O
chum	O
too	O
inherited	O
the	O
1195delC	O
mutant	O
from	O
their	O
heterozygous	O
generate	O
and	O
the	O
1936delG	O
mutant	O
from	O
their	O
homozygous	O
generate	O
.	O
.	O

Allele	O
-	O
specific	O
PCR	O
indicated	O
the	O
brothers	O
also	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mutation	O
from	O
their	O
homozygous	O
father	O
.	O
.	O

the	O
-	O
specific	O
mother	O
indicated	O
that	O
the	O
homozygous	O
from	O
brothers	O
.	O
inherited	O
the	O
and	O
mutation	O
from	O
their	O
heterozygous	O
PCR	O
1195delC	O
their	O
1936delG	O
mutation	O
two	O
Allele	O
probands	O
father	O
.	O
also	O

Allele	O
-	O
specific	O
PCR	O
portend	O
betoken	O
sport	O
beginner	O
betoken	O
indicated	O
that	O
the	O
probands	O
two	O
brothers	O
also	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
sport	O
beginner	O
	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O
.	O
.	O

Allele	O
-	O
specific	O
PCR	O
portend	O
betoken	O
sport	O
beginner	O
betoken	O
indicated	O
that	O
the	O
probands	O
two	O
brothers	O
also	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
sport	O
beginner	O
genetic	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O
.	O
.	O

Allele	O
-	O
specific	O
PCR	O
indicated	O
that	O
the	O
probands	O
brothers	O
also	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mother	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O
.	O
.	O

.	O
-	O
specific	O
mutation	O
indicated	O
that	O
homozygous	O
probands	O
PCR	O
brothers	O
also	O
inherited	O
father	O
1195delC	O
their	O
two	O
their	O
heterozygous	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
from	O
the	O
the	O
.	O
Allele	O

Allele	O
-	O
specific	O
PCR	O
indicated	O
that	O
the	O
probands	O
brothers	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mother	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O

allele	O
-	O
particular	O
PCR	O
show	O
that	O
the	O
probands	O
ii	O
brothers	O
also	O
hereditary	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
engender	O
.	O
.	O

allelomorph	O
-	O
particular	O
PCR	O
indicated	O
that	O
the	O
probands	O
deuce	O
sidekick	O
too	O
familial	O
the	O
1195delC	O
mutant	O
from	O
their	O
heterozygous	O
fuss	O
and	O
the	O
1936delG	O
mutant	O
from	O
their	O
homozygous	O
father	O
.	O
.	O

Allele	O
-	O
specific	O
PCR	O
indicated	O
that	O
the	O
probands	O
two	O
brothers	O
also	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O
.	O
.	O

survey	O
PAX6	O
mutations	O
reviewed	O
.	O

PAX6	O
mutations	O
retrospect	O
.	O

PAX6	O
mutations	O

PAX6	O
variation	O
reviewed	O
.	O

mutations	O
reviewed	O

survey	O
PAX6	O
mutations	O
reviewed	O
.	O

.	O
mutations	O
reviewed	O
PAX6	O

survey	O
PAX6	O
mutations	O
reviewed	O
.	O

reviewed	O
mutations	O
PAX6	O
.	O

PAX6	O
variation	O
reviewed	O
.	O

PAX6	O
mutations	O
reviewed	O
.	O

Mutations	O
in	O
dominant	O
are	O
responsible	O
been	O
human	O
cataracts	B
and	O
have	O
also	O
with	O
,	O
in	O
patients	O
isolated	O
Peters	B
anomaly	I
with	O
,	O
congenital	B
aniridia	I
,	O
for	O
autosomal	B
keratitis	I
PAX6	I
hypoplasia	O
and	O
with	O
with	B
found	I
foveal	I
.	O

Mutations	O
are	O
responsible	O
for	O
human	O
and	O
have	O
found	O
in	O
with	O
Peters	B
congenital	B
,	O
with	O
autosomal	B
keratitis	I
,	O
and	O
isolated	B
foveal	I
hypoplasia	I
.	O

Mutations	O
in	O
PAX6	O
are	O
patient	O
homo	O
indium	O
responsible	O
for	O
human	O
aniridia	B
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
Peters	B
anomaly	I
,	O
with	O
congenital	B
cataracts	I
,	O
with	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
with	O
isolated	B
foveal	I
hypoplasia	I
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	O
role	O

Mutations	O
in	O
PAX6	O
are	O
patient	O
homo	O
responsible	O
for	O
responsible	O
for	O
human	B
aniridia	O
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	B
Peters	I
anomaly	O
,	O
with	B
congenital	I
cataracts	O
,	O
with	B
autosomal	I
dominant	I
keratitis	O
,	O
and	O
with	B
isolated	I
foveal	I
hypoplasia	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	O

in	O
,	O
PAX6	O
are	O
responsible	O
for	O
keratitis	O
aniridia	B
and	O
have	O
also	O
,	O
found	O
autosomal	O
with	O
with	O
Peters	B
anomaly	I
been	O
with	O
congenital	B
cataracts	I
.	O
with	O
in	B
dominant	I
human	I
Mutations	O
foveal	O
,	O
isolated	B
and	I
hypoplasia	I
patients	O

Mutations	O
in	O
PAX6	O
are	O
responsible	O
for	O
and	O
have	O
also	O
been	O
in	O
patients	O
with	O
Peters	B
anomaly	I
with	O
congenital	B
cataracts	I
,	O
autosomal	B
dominant	I
,	O
and	O
with	O
isolated	B
foveal	I
hypoplasia	I
.	O

mutant	O
in	O
PAX6	O
are	O
responsible	O
for	O
human	O
aniridia	B
and	O
have	O
too	O
been	O
found	O
in	O
patients	O
with	O
Peters	B
anomaly	I
,	O
with	O
innate	B
cataracts	I
,	O
with	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
with	O
isolated	B
foveal	I
hypoplasia	I
.	O

Mutations	O
in	O
PAX6	O
are	O
creditworthy	O
for	O
homo	O
aniridia	B
and	O
have	O
likewise	O
been	O
notice	O
in	O
patients	O
with	O
pecker	B
anomalousness	I
,	O
with	O
innate	B
cataracts	I
,	O
with	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
with	O
isolated	B
foveal	I
hypoplasia	I
.	O

Mutations	O
in	O
PAX6	O
are	O
patient	O
homo	O
responsible	O
for	O
responsible	O
for	O
human	B
aniridia	O
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	B
Peters	I
anomaly	O
,	O
with	B
congenital	I
cataracts	O
,	O
with	B
autosomal	I
dominant	I
keratitis	O
,	O
and	O
with	B
isolated	I
foveal	I
hypoplasia	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	O

variation	O
in	O
PAX6	O
are	O
creditworthy	O
for	O
human	O
aniridia	B
and	O
have	O
too	O
been	O
obtain	O
in	O
patients	O
with	O
Peters	B
anomaly	I
,	O
with	O
inborn	B
cataracts	I
,	O
with	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
with	O
detached	B
foveal	I
hypoplasia	I
.	O

Mutations	O
in	O
PAX6	O
are	O
responsible	O
for	O
human	O
aniridia	B
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
Peters	B
anomaly	I
,	O
with	O
congenital	B
cataracts	I
,	O
with	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
with	O
isolated	B
foveal	I
hypoplasia	I
.	O

locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B
,	O
and	O
PAX6	O
is	O
clearly	O
major	O
if	O
not	O
only	O
,	O
gene	O
responsible	O
.	O

aniridia	O
locus	O
other	O
,	O
chromosome	O
11p13	O
has	O
.	O
gene	O
in	O
responsible	B
,	O
and	O
if	O
,	O
clearly	O
the	O
major	O
than	O
PAX6	O
not	O
only	O
is	O
implicated	O
No	O
been	O

no	O
locale	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B
,	O
and	O
PAX6	O
is	O
understandably	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
cistron	O
responsible	O
.	O

No	O
venue	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B
,	O
and	O
PAX6	O
is	O
distinctly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
cistron	O
responsible	O
.	O

No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
,	O
and	O
is	O
clearly	O
the	O
major	O
,	O
if	O
not	O
gene	O
responsible	O
.	O

No	O
locus	O
other	O
than	O
cost	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B
,	O
and	O
PAX6	O
is	O
clearly	O
the	O
major	O
non	O
factor	O
responsible	O
for	O
factor	O
responsible	O
for	O
implicate	O
,	O
if	O
not	O
only	O
,	O
gene	O

No	O
locus	O
other	O
than	O
cost	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B
,	O
and	O
PAX6	O
is	O
clearly	O
the	O
major	O
non	O
factor	O
responsible	O
for	O
factor	O
responsible	O
for	O
john	O
major	O
,	O
if	O
not	O
only	O
,	O

No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
,	O
is	O
clearly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O

gene	O
locus	O
other	O
than	O
chromosome	O
11p13	O
PAX6	O
the	O
implicated	O
in	O
aniridia	B
,	O
only	O
has	O
responsible	O
clearly	O
been	O
not	O
,	O
if	O
No	O
and	O
,	O
major	O
is	O
.	O

No	O
venue	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
entail	O
in	O
aniridia	B
,	O
and	O
PAX6	O
is	O
distinctly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
factor	O
creditworthy	O
.	O

No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B
,	O
and	O
PAX6	O
is	O
clearly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
gene	O
responsible	O
.	O

Twenty	O
-	O
than	O
percent	O
of	O
T	O
PAX6	O
errors	O
are	O
C	O
-	O
and	O
%	O
at	O
CpG	O
or	O
,	O
20	O
are	O
%	O
splicing	O
mutations	O
,	O
identified	O
more	O
30	O
eight	O
events	O
are	O
deletion	O
dinucleotides	O
changes	O
insertion	O
.	O

Twenty	O
percent	O
of	O
identified	O
PAX6	O
are	O
C	O
changes	O
at	O
dinucleotides	O
,	O
splicing	O
,	O
and	O
more	O
30	O
%	O
are	O
or	O
insertion	O
events	O
.	O

Twenty	O
-	O
eight	O
percent	O
place	O
operating	O
theatre	O
deepen	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
splicing	O
errors	O
,	O
and	O
more	O
than	O
30	O
%	O
are	O
deletion	O
or	O
insertion	O
events	O
situation	O
situation	O
situation	O
situation	O
situation	O
situation	O
atomic	O

Twenty	O
-	O
eight	O
percent	O
place	O
operating	O
theatre	O
sport	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
splicing	O
errors	O
,	O
and	O
more	O
than	O
30	O
%	O
are	O
deletion	O
or	O
insertion	O
events	O
situation	O
situation	O
situation	O
situation	O
situation	O
situation	O
atomic	O

-	O
%	O
eight	O
percent	O
of	O
identified	O
30	O
mutations	O
are	O
C	O
-	O
%	O
changes	O
more	O
deletion	O
dinucleotides	O
,	O
20	O
T	O
are	O
splicing	O
errors	O
.	O
and	O
at	O
than	O
PAX6	O
Twenty	O
insertion	O
,	O
or	O
are	O
events	O
CpG	O

Twenty	O
-	O
eight	O
percent	O
of	O
identified	O
are	O
C	O
-	O
T	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
are	O
splicing	O
errors	O
,	O
more	O
than	O
%	O
are	O
deletion	O
or	O
insertion	O
events	O
.	O

Twenty	O
-	O
eight	O
pct	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
thyroxin	O
alter	O
at	O
CpG	O
dinucleotides	O
,	O
xx	O
%	O
are	O
tie	O
errors	O
,	O
and	O
more	O
than	O
thirty	O
%	O
are	O
cut	O
or	O
intromission	O
issue	O
.	O

Twenty	O
-	O
eight	O
pct	O
of	O
key	O
PAX6	O
mutations	O
are	O
C	O
-	O
liothyronine	O
switch	O
at	O
CpG	O
dinucleotides	O
,	O
xx	O
%	O
are	O
tie	O
errors	O
,	O
and	O
more	O
than	O
xxx	O
%	O
are	O
omission	O
or	O
interpolation	O
issue	O
.	O

Twenty	O
-	O
eight	O
percent	O
place	O
operating	O
theatre	O
sport	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
splicing	O
errors	O
,	O
and	O
more	O
than	O
30	O
%	O
are	O
deletion	O
or	O
insertion	O
events	O
situation	O
situation	O
situation	O
situation	O
situation	O
situation	O
atomic	O

xx	O
-	O
eight	O
percent	O
of	O
name	O
PAX6	O
mutations	O
are	O
century	O
-	O
tonne	O
changes	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
wed	O
misplay	O
,	O
and	O
more	O
than	O
xxx	O
%	O
are	O
excision	O
or	O
introduction	O
consequence	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
splicing	O
errors	O
,	O
and	O
more	O
than	O
30	O
%	O
are	O
deletion	O
or	O
insertion	O
events	O
.	O

There	O
is	O
a	O
perceptibly	O
sublime	O
level	O
of	O
mutation	O
in	O
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
cistron	O
.	O

There	O
is	O
a	O
noticeably	O
elevated	O
level	O
of	O
mutation	O
in	O
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
gene	O
.	O

There	O
is	O
a	O
noticeably	O
elevated	O
level	O
of	O
mutation	O
in	O
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
gene	O
.	O

a	O
level	O
of	O
mutation	O
the	O
paired	O
compared	O
with	O
the	O
rest	O
of	O
the	O
gene	O
.	O

There	O
is	O
a	O
noticeably	O
elevated	O
mutation	O
in	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
gene	O
.	O

a	O
noticeably	O
elevated	O
level	O
mutation	O
in	O
the	O
paired	O
domain	O
with	O
the	O
rest	O
of	O
gene	O
.	O

the	O
is	O
a	O
gene	O
elevated	O
level	O
of	O
in	O
mutation	O
the	O
the	O
domain	O
compared	O
.	O
There	O
rest	O
of	O
paired	O
noticeably	O
with	O

There	O
is	O
a	O
noticeably	O
elevated	O
level	O
of	O
mutation	O
in	O
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
gene	O
.	O

There	O
is	O
a	O
perceptibly	O
elevated	O
rase	O
of	O
mutation	O
in	O
the	O
twin	O
demesne	O
compared	O
with	O
the	O
breathe	O
of	O
the	O
cistron	O
.	O

of	O
is	O
a	O
noticeably	O
elevated	O
level	O
with	O
domain	O
in	O
the	O
paired	O
the	O
There	O
of	O
mutation	O
the	O
compared	O
rest	O
gene	O
.	O

There	O
is	O
a	O
noticeably	O
elevated	O
level	O
of	O
mutation	O
in	O
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
gene	O
.	O

hypermutable	O
mutation	O
in	O
for	O
homeodomain	O
is	O
accounted	O
the	O
codon	O
the	O
in	O
CpG	O
Increased	O
dinucleotide	O
by	O
240	O
.	O

increased	O
sport	O
in	O
the	O
homeodomain	O
is	O
calculate	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O

increase	O
sport	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O

Increased	O
mutation	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O

increase	O
mutant	O
in	O
the	O
homeodomain	O
is	O
report	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O

Increased	O
mutation	O
indium	O
indium	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
in	O
in	O
account	O
.	O

Increased	O
mutation	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
the	O
hypermutable	O
dinucleotide	O
in	O
codon	O
240	O
.	O

Increased	O
mutation	O
indium	O
indium	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
in	O
in	O
account	O
.	O

mutation	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O

Increased	O
mutation	O
by	O
codon	O
homeodomain	O
is	O
dinucleotide	O
for	O
in	O
the	O
hypermutable	O
CpG	O
accounted	O
in	O
the	O
240	O
.	O

Increased	O
mutation	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O

Very	O
all	O
mutations	O
appear	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
,	O
and	O
more	O
than	O
%	O
of	O
exonic	O
substitutions	O
result	O
nonsense	O
codons	O
.	O

Very	O
all	O
mutations	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
,	O
and	O
than	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O

Very	O
nearly	O
all	O
mutations	O
allelomorph	O
bunk	O
causal	O
agent	O
seem	O
appear	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
,	O
and	O
more	O
than	O
indium	O
bunk	O
codon	O
sir	O
thomas	O
more	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O

of	O
nearly	O
all	O
80	O
appear	O
to	O
cause	O
nonsense	O
result	O
function	O
%	O
the	O
mutant	O
allele	O
substitutions	O
and	O
more	O
than	O
mutations	O
in	O
of	O
exonic	O
,	O
of	O
Very	O
loss	O
codons	O
.	O

codons	O
nearly	O
all	O
,	O
appear	O
to	O
nonsense	O
loss	O
mutations	O
function	O
of	O
the	O
allele	O
of	O
in	O
of	O
more	O
than	O
80	O
%	O
mutant	O
exonic	O
substitutions	O
result	O
and	O
cause	O
Very	O
.	O

Very	O
nearly	O
all	O
mutations	O
allelomorph	O
bunk	O
causal	O
agent	O
seem	O
appear	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
,	O
and	O
more	O
than	O
indium	O
bunk	O
codon	O
sport	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O
nonsense	O
codons	O

rattling	O
almost	O
all	O
mutations	O
appear	O
to	O
grounds	O
loss	O
of	O
mapping	O
of	O
the	O
variation	O
allelomorph	O
,	O
and	O
more	O
than	O
80	O
%	O
of	O
exonic	O
substitutions	O
effect	O
in	O
meaninglessness	O
codons	O
.	O

Very	O
nearly	O
all	O
mutations	O
allelomorph	O
bunk	O
causal	O
agent	O
seem	O
appear	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
,	O
and	O
more	O
than	O
indium	O
bunk	O
codon	O
sport	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O
nonsense	O
codons	O

result	O
nearly	O
all	O
mutations	O
appear	O
to	O
allele	O
the	O
of	O
function	O
of	O
more	O
exonic	O
cause	O
in	O
Very	O
loss	O
and	O
80	O
%	O
of	O
mutant	O
substitutions	O
than	O
,	O
nonsense	O
codons	O
.	O

rattling	O
nearly	O
all	O
mutations	O
appear	O
to	O
effort	O
loss	O
of	O
function	O
of	O
the	O
sport	O
allelomorph	O
,	O
and	O
more	O
than	O
lxxx	O
%	O
of	O
exonic	O
exchange	O
result	O
in	O
hokum	O
codons	O
.	O

Very	O
nearly	O
all	O
mutations	O
appear	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
,	O
and	O
more	O
than	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O
nonsense	O
codons	O
.	O

In	O
a	O
gene	O
with	O
in	O
that	O
location	O
cost	O
assume	O
unexplored	O
episode	O
such	O
extraordinarily	O
high	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
undiscovered	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
.	O
undiscovered	O
undiscovered	O
undiscovered	O

In	O
a	O
such	O
throughout	O
evolution	O
,	O
are	O
presumed	O
missense	O
mutations	O
,	O
hypothesized	O
to	O
exist	O
in	O
as	O
yet	O
phenotypes	O
.	O
.	O

indiana	O
a	O
factor	O
with	O
such	O
inordinately	O
luxuriously	O
succession	O
preservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
unexplored	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
be	O
indiana	O
as	O
-	O
yet	O
unknown	O
phenotypes	O
.	O
.	O

In	O
a	O
gene	O
with	O
extraordinarily	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
undiscovered	O
missense	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
.	O
.	O

inwards	O
a	O
cistron	O
with	O
such	O
inordinately	O
luxuriously	O
succession	O
preservation	O
passim	O
evolution	O
,	O
there	O
are	O
presumed	O
unexplored	O
missense	O
mutations	O
,	O
these	O
are	O
theorize	O
to	O
exist	O
inwards	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
.	O
.	O

In	O
a	O
gene	O
with	O
in	O
that	O
location	O
cost	O
assume	O
unexplored	O
episode	O
such	O
extraordinarily	O
high	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
undiscovered	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
.	O
undiscovered	O
undiscovered	O
undiscovered	O

inward	O
a	O
cistron	O
with	O
such	O
inordinately	O
high	O
sequence	O
preservation	O
throughout	O
phylogeny	O
,	O
there	O
are	O
presumed	O
unexplored	O
missense	O
mutations	O
,	O
these	O
are	O
theorize	O
to	O
exist	O
inward	O
as	O
-	O
even	O
nameless	O
phenotypes	O
.	O
.	O

are	O
,	O
gene	O
with	O
such	O
extraordinarily	O
high	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
in	O
phenotypes	O
undiscovered	O
missense	O
mutations	O
yet	O
these	O
a	O
hypothesized	O
.	O
exist	O
are	O
as	O
-	O
In	O
presumed	O
to	O
.	O
unidentified	O

In	O
a	O
gene	O
with	O
extraordinarily	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
as	O
-	O
yet	O
phenotypes	O
.	O

In	O
a	O
gene	O
with	O
in	O
that	O
location	O
cost	O
assume	O
unexplored	O
ampere	O
such	O
extraordinarily	O
high	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
undiscovered	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
.	O
undiscovered	O
undiscovered	O
undiscovered	O

In	O
a	O
gene	O
with	O
such	O
extraordinarily	O
high	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
undiscovered	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
.	O
.	O

Genetic	O
heterogeneity	O
cancer	O
the	O
crab	O
family	O
line	O
family	O
line	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	B
BRCA2	I
genes	O
in	O
breast	O

cancer	O
heterogeneity	O
and	O
.	O
analysis	O
of	O
the	O
BRCA1	O
families	O
BRCA2	O
genes	O
in	O
Genetic	B
breast	I
and	O
penetrance	O

Genetic	O
heterogeneity	O
height	O
family	O
line	O
summit	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	B
breast	I
cancer	O
families	O
summit	O

Genetic	O
heterogeneousness	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
factor	O
in	O
front	B
cancer	I
family	O
.	O

breast	O
heterogeneity	O
and	O
BRCA1	O
analysis	O
of	O
cancer	O
penetrance	O
and	O
BRCA2	O
Genetic	O
in	O
genes	B
the	I
families	O
.	O

Genetic	O
heterogeneity	O
cancer	O
the	O
crab	O
family	O
line	O
family	O
line	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	B
BRCA2	I
genes	O
in	O
breast	O

Genetic	O
heterogeneousness	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
factor	O
in	O
boob	B
cancer	I
kinfolk	O
.	O

hereditary	O
heterogeneousness	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
breast	B
crab	I
folk	O
.	O

Genetic	O
heterogeneity	O
and	O
.	O
analysis	O
of	O
breast	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
the	B
cancer	I
penetrance	O
families	O

heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
genes	O
in	O
breast	B
cancer	I
families	O
.	O

Genetic	O
heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
breast	B
cancer	I
families	O
.	O

The	O
Breast	B
Cancer	I
Linkage	O
cancer	O
the	O
crab	O

The	O
Cancer	I
Consortium	O
.	O

The	O
Breast	B
Linkage	O
Consortium	O

The	O
Breast	B
Cancer	I
Linkage	O
pool	O
.	O

The	O
Breast	B
crab	I
Linkage	O
Consortium	O
.	O

The	O
Breast	B
Cancer	I
Linkage	O
cancer	O
the	O
crab	O

The	O
Cancer	I
Linkage	O
Consortium	O
.	O

Linkage	O
Breast	B
Cancer	I
The	O
Consortium	O
.	O

The	O
Breast	B
Cancer	I
Linkage	O
syndicate	O
Consortium	O
.	O

The	O
Breast	B
Cancer	I
.	O
Consortium	O
Linkage	O

The	O
Breast	B
Cancer	I
Linkage	O
Consortium	O
.	O

contribution	O
of	O
BRCA1	O
to	O
inherited	B
breast	I
cancer	I
was	O
by	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
four	O
cases	O
of	O
breast	B
cancer	I
Cancer	I
.	O

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	B
breast	I
cancer	I
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B
cancer	I
,	O
collected	O
by	O
the	O
Breast	B
Cancer	I
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

,	O
,	O
of	O
BRCA1	O
analysis	O
BRCA2	O
Consortium	O
collected	B
breast	I
cancer	I
was	O
assessed	O
by	O
least	O
in	O
mutation	O
and	O
and	O
237	O
families	O
linkage	O
each	O
with	O
at	O
contribution	O
four	O
cases	O
.	O
The	B
cancer	I
breast	O
to	O
by	O
the	O
Breast	B
Cancer	I
Linkage	O
inherited	O
of	O

The	O
contribution	O
of	O
and	O
inherited	B
breast	I
cancer	I
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B
cancer	I
,	O
collected	O
by	O
the	O
Breast	B
Linkage	O
.	O

The	O
donation	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
transmissible	B
knocker	I
crab	I
was	O
evaluate	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
phratry	O
,	O
each	O
with	O
at	O
least	O
iv	O
cases	O
of	O
knocker	B
crab	I
,	O
gathered	O
by	O
the	O
knocker	B
crab	I
Linkage	O
pool	O
.	O

least	O
237	O
of	O
BRCA1	O
and	O
BRCA2	O
assessed	O
inherited	B
breast	I
cancer	I
was	O
to	O
by	O
of	O
cancer	O
mutation	O
analysis	O
in	O
the	O
families	O
,	O
each	O
breast	O
at	O
The	O
four	O
collected	O
linkage	O
and	B
with	I
,	O
Cancer	O
by	O
Breast	O
contribution	B
cases	I
Linkage	O
Consortium	O
.	O

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	B
breast	I
cancer	I
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B
cancer	I
,	O
collected	O
by	O
the	O
Breast	B
Cancer	I
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	B
breast	I
cancer	I
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B
cancer	I
,	O
collected	O
by	O
the	O
Breast	B
Cancer	I
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
breast	I
cancer	I
was	O
assessed	O
by	O
linkage	O
and	O
in	O
237	O
families	O
each	O
at	O
least	O
four	O
breast	B
the	O
Breast	B
Cancer	I
Consortium	O
.	O

The	O
contribution	O
,	O
BRCA1	O
and	O
BRCA2	O
to	O
237	B
breast	I
cancer	I
was	O
cases	O
families	O
linkage	O
and	O
inherited	O
analysis	O
in	O
Consortium	O
by	O
,	O
by	O
with	O
Cancer	O
least	O
mutation	O
assessed	O
each	O
breast	B
cancer	I
of	O
of	O
collected	O
the	O
Breast	B
at	I
Linkage	O
four	O
.	O

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	B
breast	I
cancer	I
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B
cancer	I
,	O
collected	O
by	O
the	O
Breast	B
Cancer	I
Linkage	O
Consortium	O
.	O

Families	O
included	O
regard	O
the	O
occurrence	O
of	O
ovarian	B
or	I
other	I
cancers	I
.	O

kin	O
were	O
included	O
without	O
consider	O
to	O
the	O
occurrence	O
of	O
ovarian	B
or	I
other	I
cancers	I
.	O

occurrence	O
without	O
included	O
were	O
regard	O
to	O
ovarian	O
Families	O
of	O
.	B
or	I
other	I
cancers	I
the	O

Families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
ovarian	B
or	I
cancers	I
.	O

Families	O
were	O
happening	O
let	O
in	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
cancer	O
the	B
crab	I
affect	I
ovarian	I
or	O

Families	O
were	O
happening	O
let	O
in	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
cancer	O
the	B
crab	I
former	I
ovarian	I
or	O

sept	O
were	O
included	O
without	O
esteem	O
to	O
the	O
occurrent	O
of	O
ovarian	B
or	I
other	I
cancers	I
.	O

cancers	O
were	O
included	O
Families	O
occurrence	O
to	O
the	O
other	O
of	O
ovarian	B
or	I
regard	I
without	I
.	O

Families	O
were	O
happening	O
let	O
in	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
cancer	O
the	B
crab	I
affect	I
ovarian	I
or	O

phratry	O
were	O
included	O
without	O
compliments	O
to	O
the	O
occurrent	O
of	O
ovarian	B
or	I
other	I
cancers	I
.	O

Families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
ovarian	B
or	I
other	I
cancers	I
.	O

Overall	O
,	O
disease	O
was	O
connect	O
to	O
BRCA1	O
in	O
an	O
forecast	O
52	O
%	O
of	O
mob	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
mob	O
,	O
and	O
to	O
neither	O
cistron	O
in	O
sixteen	O
%	O
(	O
95	O
%	O
assurance	O
separation	O
[	O
curie	O
]	O
sixer	O
%	O
-	O
28	O
%	O
)	O
,	O
hint	O
other	O
sensitivity	O
genes	O
.	O

Overall	O
,	O
disease	O
was	O
unite	O
to	O
BRCA1	O
in	O
an	O
estimated	O
52	O
%	O
of	O
kinsperson	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
kinsperson	O
,	O
and	O
to	O
neither	O
cistron	O
in	O
sixteen	O
%	O
(	O
95	O
%	O
trust	O
separation	O
[	O
CI	O
]	O
6	O
%	O
-	O
28	O
%	O
)	O
,	O
suggesting	O
other	O
sensitivity	O
cistron	O
.	O

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
estimated	O
52	O
%	O
of	O
,	O
to	O
BRCA2	O
in	O
32	O
of	O
families	O
,	O
and	O
neither	O
gene	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
]	O
6	O
-	O
28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
associate	O
in	O
nursing	O
an	O
estimated	O
52	O
%	O
of	O
families	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
families	O
,	O
and	O
to	O
neither	O
gene	O
in	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
	O
	O
colligate	O
	O
propose	O
former	O
sensitivity	O
factor	O
former	O
sensitivity	O
factor	O
former	O
sensitivity	O
indium	O
CI	O
]	O
6	O
%	O
-	O
28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O

interval	O
to	O
disease	O
was	O
linked	O
to	O
of	O
BRCA2	O
an	O
estimated	O
52	O
%	O
of	O
BRCA1	O
]	O
to	O
in	O
other	O
32	O
%	O
families	O
families	O
,	O
and	O
in	O
neither	O
gene	O
28	O
,	O
%	O
16	O
,	O
%	O
confidence	O
.	O
[	O
CI	O
,	O
95	O
%	O
-	O
genes	O
%	O
)	O
(	O
suggesting	O
in	O
predisposition	O
6	O
Overall	O

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
associate	O
in	O
nursing	O
an	O
estimated	O
52	O
%	O
of	O
families	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
families	O
,	O
and	O
to	O
neither	O
gene	O
in	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
	O
	O
colligate	O
	O
propose	O
former	O
sensitivity	O
factor	O
former	O
sensitivity	O
factor	O
former	O
sensitivity	O
indium	O
CI	O
]	O
6	O
%	O
-	O
28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O

boilersuit	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
an	O
forecast	O
52	O
%	O
of	O
sept	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
sept	O
,	O
and	O
to	O
neither	O
factor	O
in	O
xvi	O
%	O
(	O
95	O
%	O
authority	O
separation	O
[	O
ci	O
]	O
sextuplet	O
%	O
-	O
xxviii	O
%	O
)	O
,	O
suggesting	O
other	O
sensitivity	O
cistron	O
.	O

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
associate	O
in	O
nursing	O
an	O
estimated	O
52	O
%	O
of	O
families	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
families	O
,	O
and	O
to	O
neither	O
gene	O
in	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
	O
	O
colligate	O
	O
propose	O
former	O
sensitivity	O
factor	O
former	O
sensitivity	O
factor	O
former	O
sensitivity	O
colligate	O
CI	O
]	O
6	O
%	O
-	O
28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O

Overall	O
,	O
disease	O
was	O
BRCA1	O
in	O
an	O
estimated	O
52	O
%	O
of	O
families	O
BRCA2	O
32	O
%	O
of	O
,	O
and	O
to	O
neither	O
gene	O
in	O
%	O
(	O
confidence	O
[	O
CI	O
]	O
6	O
28	O
%	O
)	O
,	O
other	O
predisposition	O
genes	O
.	O

Overall	O
gene	O
disease	O
was	O
linked	O
to	O
%	O
%	O
an	O
estimated	O
52	O
BRCA1	O
of	O
in	O
16	O
to	O
BRCA2	O
in	O
in	O
%	O
of	O
families	O
confidence	O
and	O
)	O
neither	O
other	O
families	O
genes	O
32	O
(	O
[	O
%	O
,	O
interval	O
28	O
CI	O
]	O
6	O
%	O
,	O
95	O
%	O
,	O
,	O
suggesting	O
-	O
predisposition	O
to	O
.	O

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
an	O
estimated	O
52	O
%	O
of	O
families	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
families	O
,	O
and	O
to	O
neither	O
gene	O
in	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
6	O
%	O
-	O
28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O
genes	O
.	O

The	O
bulk	O
(	O
81	O
%	O
)	O
of	O
the	O
boob	B
-	I
ovarian	I
crab	I
family	O
were	O
imputable	O
to	O
BRCA1	O
,	O
with	O
most	O
others	O
(	O
14	O
%	O
)	O
imputable	O
to	O
BRCA2	O
.	O

The	O
majority	O
(	O
81	O
%	O
of	O
-	I
ovarian	I
cancer	I
families	O
were	O
due	O
to	O
BRCA1	O
,	O
14	O
%	O
)	O
due	O
to	O
BRCA2	O
.	O

others	O
majority	O
(	O
with	O
%	O
)	O
of	O
due	O
%	B
-	I
.	I
cancer	I
families	O
most	O
14	O
to	O
BRCA1	O
,	O
81	O
were	O
)	O
(	O
due	O
breast	O
The	O
the	O
to	O
BRCA2	O
ovarian	O

The	O
majority	O
(	O
81	O
family	O
line	O
cost	O
referable	O
family	O
line	O
referable	O
%	O
)	O
of	B
the	I
breast	I
-	I
ovarian	O
cancer	O
families	O
were	O
due	O
to	O
BRCA1	O
,	O
referable	O
summit	O
summit	O
with	O
most	O
others	O
(	O
14	O
%	O
)	O
due	O
to	O

The	O
majority	O
(	O
81	O
family	O
line	O
cost	O
referable	O
family	O
line	O
referable	O
%	O
)	O
of	B
the	I
breast	I
-	I
ovarian	O
cancer	O
families	O
were	O
due	O
to	O
BRCA1	O
,	O
referable	O
summit	O
	O
with	O
most	O
others	O
(	O
14	O
%	O
)	O
due	O
to	O

The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
-	I
ovarian	I
families	O
were	O
due	O
to	O
BRCA1	O
,	O
with	O
(	O
14	O
%	O
)	O
due	O
to	O
BRCA2	O
.	O

.	O
majority	O
(	O
due	O
%	O
)	O
due	O
the	O
81	B
-	I
ovarian	I
cancer	I
to	O
were	O
)	O
breast	O
BRCA1	O
,	O
with	O
most	O
families	O
(	O
14	O
%	O
to	O
of	O
others	O
BRCA2	O
The	O

The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
-	I
cancer	I
families	O
were	O
due	O
to	O
BRCA1	O
,	O
with	O
others	O
(	O
14	O
%	O
)	O
due	O
to	O

The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
summit	B
-	I
ovarian	I
cancer	I
families	O
were	O
imputable	O
to	O
BRCA1	O
,	O
with	O
most	O
others	O
(	O
xiv	O
%	O
)	O
imputable	O
to	O
BRCA2	O
.	O

The	O
bulk	O
(	O
81	O
%	O
)	O
of	O
the	O
bosom	B
-	I
ovarian	I
cancer	I
kinsperson	O
were	O
ascribable	O
to	O
BRCA1	O
,	O
with	O
most	O
others	O
(	O
fourteen	O
%	O
)	O
ascribable	O
to	O
BRCA2	O
.	O

The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
breast	B
-	I
ovarian	I
cancer	I
families	O
were	O
due	O
to	O
BRCA1	O
,	O
with	O
most	O
others	O
(	O
14	O
%	O
)	O
due	O
to	O
BRCA2	O
.	O

conversely	O
,	O
the	O
majority	O
of	O
house	O
with	O
manlike	B
and	I
distaff	I
knocker	I
cancer	I
were	O
imputable	O
to	O
BRCA2	O
(	O
76	O
%	O
)	O
.	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B
and	I
female	I
breast	I
cancer	I
were	O
due	O
to	O
BRCA2	O
(	O
76	O
absolute	O
majority	O
absolute	O
majority	O
absolute	O
majority	O
absolute	O
majority	O
absolute	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B
and	I
female	I
breast	I
cancer	I
were	O
due	O
to	O
BRCA2	O
(	O
76	O
absolute	O
majority	O
absolute	O
majority	O
absolute	O
majority	O
absolute	O
majority	O
absolute	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B
female	I
breast	I
were	O
due	O
to	O
BRCA2	O
(	O
76	O
%	O

to	O
,	O
and	O
with	O
of	O
families	O
BRCA2	O
male	B
the	I
female	I
breast	I
cancer	I
.	O
due	O
majority	O
Conversely	O
(	O
76	O
%	O
)	O
were	O

conversely	O
,	O
the	O
majority	O
of	O
sept	O
with	O
male	B
and	I
distaff	I
breast	I
cancer	I
were	O
ascribable	O
to	O
BRCA2	O
(	O
lxxvi	O
%	O
)	O
.	O

.	O
,	O
the	O
breast	O
of	O
families	O
with	O
%	B
to	I
female	I
majority	I
cancer	I
due	O
were	O
and	O
BRCA2	O
(	O
76	O
male	O
Conversely	O
)	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B
and	I
female	I
breast	I
cancer	I
were	O
due	O
to	O
BRCA2	O
(	O
76	O
absolute	O
majority	O
absolute	O
majority	O
absolute	O
majority	O
absolute	O
majority	O
absolute	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B
and	I
female	I
breast	I
cancer	I
were	O
to	O
76	O
%	O
)	O
.	O

conversely	O
,	O
the	O
majority	O
of	O
family	O
with	O
manlike	B
and	I
female	I
summit	I
cancer	I
were	O
referable	O
to	O
BRCA2	O
(	O
76	O
%	O
)	O
.	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B
and	I
female	I
breast	I
cancer	I
were	O
due	O
to	O
BRCA2	O
(	O
76	O
%	O
)	O
.	O

The	O
proportion	O
(	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
found	O
in	O
families	O
with	O
or	O
five	O
cases	O
of	O
female	O
cancer	I
only	O
.	O

The	O
proportion	O
(	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
found	O
in	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	B

The	O
largest	O
proportion	O
(	O
cost	O
receive	O
indium	O
	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
summit	O
cancer	O
the	O
crab	O
only	O
when	O
factor	O
four	O
or	O
five	O
cases	B
of	I
female	O
breast	O

five	O
largest	O
proportion	O
four	O
67	O
%	O
)	O
cancer	O
female	O
due	O
or	O
other	O
genes	O
was	O
of	O
in	O
families	O
with	O
(	O
breast	O
to	O
cases	O
found	O
families	O
The	B
of	I
only	O
.	O

only	O
largest	O
proportion	O
found	O
67	O
%	O
cancer	O
of	O
(	O
due	O
to	O
other	O
was	O
five	O
breast	O
families	O
families	O
with	O
four	O
or	O
genes	O
cases	O
of	O
female	O
in	B
)	I
The	O
.	O

The	O
largest	O
proportion	O
(	O
cost	O
receive	O
indium	O
	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
summit	O
cancer	O
the	O
crab	O
only	O
when	O
family	O
line	O
four	O
or	O
five	B
cases	I
of	O
female	O

The	O
largest	O
dimension	O
(	O
67	O
%	O
)	O
of	O
house	O
imputable	O
to	O
other	O
cistron	O
was	O
see	O
in	O
house	O
with	O
four	O
or	O
pentad	O
cause	O
of	O
female	O
tit	B
cancer	I
only	O
.	O

The	O
largest	O
proportion	O
(	O
cost	O
receive	O
indium	O
	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
summit	O
cancer	O
the	O
crab	O
only	O
when	O
family	O
line	O
four	O
or	O
five	B
cases	I
of	O
female	O

female	O
largest	O
proportion	O
(	O
67	O
%	O
was	O
other	O
families	O
due	O
to	O
families	O
cases	O
)	O
breast	O
The	O
of	O
in	O
four	O
or	O
five	O
genes	O
of	O
with	O
found	B
cancer	I
only	O
.	O

The	O
orotund	O
balance	O
(	O
67	O
%	O
)	O
of	O
family	O
due	O
to	O
other	O
genes	O
was	O
rule	O
in	O
family	O
with	O
quartet	O
or	O
phoebe	O
caseful	O
of	O
female	O
breast	B
crab	I
only	O
.	O

The	O
largest	O
proportion	O
(	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	B
cancer	I
only	O
.	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
sport	O
datum	O
sport	O
datum	O
datum	O
cost	O
cost	O
or	O
excluding	O
BRCA1	O
mutation	O
data	O
.	O

were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
or	O
BRCA1	O
mutation	O
data	O
.	O

These	O
guess	O
were	O
not	O
well	O
moved	O
either	O
by	O
change	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
include	O
or	O
eject	O
BRCA1	O
mutation	O
datum	O
.	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
changing	O
the	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
BRCA1	O
mutation	O
data	O
.	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
sport	O
datum	O
sport	O
datum	O
datum	O
cost	O
cost	O
or	O
excluding	O
BRCA1	O
mutation	O
data	O
.	O

These	O
appraisal	O
were	O
not	O
considerably	O
feign	O
either	O
by	O
modify	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
include	O
or	O
excluding	O
BRCA1	O
mutant	O
information	O
.	O

These	O
guess	O
were	O
not	O
considerably	O
strike	O
either	O
by	O
transfer	O
the	O
assumed	O
penetrance	O
exemplar	O
for	O
BRCA1	O
or	O
by	O
including	O
or	O
excluding	O
BRCA1	O
variation	O
information	O
.	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
assumed	O
for	O
BRCA1	O
or	O
by	O
including	O
or	O
excluding	O
BRCA1	O
mutation	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
sport	O
datum	O
sport	O
datum	O
datum	O
cost	O
cost	O
or	O
excluding	O
BRCA1	O
mutation	O
data	O
.	O

including	O
estimates	O
were	O
assumed	O
substantially	O
affected	O
either	O
or	O
.	O
the	O
not	O
penetrance	O
model	O
for	O
data	O
or	O
by	O
BRCA1	O
by	O
These	O
excluding	O
mutation	O
BRCA1	O
changing	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
or	O
excluding	O
BRCA1	O
mutation	O
data	O
.	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
were	O
tested	O
by	O
of	O
standard	O
screening	O
methods	O
were	O
sequence	O
or	O
splice	O
in	O
an	O
63	O
%	O
(	O
CI	O
51	O
%	O
-	O
77	O
)	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
by	O
one	O
of	O
the	O
standard	O
detected	O
coding	O
or	O
splice	O
sites	O
an	O
estimated	O
63	O
%	O
(	O
95	O
%	O
-	O
77	O
%	O
)	O
.	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
%	O
(	O
95	O
sieve	O
	O
	O
sieve	O
sieve	O
	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
	O
%	O
CI	O
51	O
%	O
-	O
77	O
%	O
)	O
.	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
%	O
(	O
95	O
sieve	O
	O
	O
sieve	O
sieve	O
	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
%	O
CI	O
51	O
%	O
-	O
77	O
%	O
)	O
.	O

Among	O
those	O
home	O
with	O
disease	O
referable	O
to	O
BRCA1	O
that	O
were	O
screen	O
by	O
matchless	O
of	O
the	O
stock	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
steganography	O
sequence	O
or	O
splicing	O
sites	O
in	O
an	O
estimated	O
lxiii	O
%	O
(	O
xcv	O
%	O
CI	O
51	O
%	O
-	O
77	O
%	O
)	O
.	O

Among	O
families	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
(	O
%	O
CI	O
51	O
%	O
-	O
77	O
%	O
)	O

Among	O
those	O
kinfolk	O
with	O
disease	O
imputable	O
to	O
BRCA1	O
that	O
were	O
try	O
by	O
one	O
of	O
the	O
received	O
test	O
methods	O
,	O
mutant	O
were	O
observe	O
in	O
the	O
cypher	O
sequence	O
or	O
splicing	O
posture	O
in	O
an	O
approximate	O
63	O
%	O
(	O
95	O
%	O
curie	O
51	O
%	O
-	O
77	O
%	O
)	O
.	O

51	O
coding	O
families	O
with	O
screening	O
due	O
CI	O
estimated	O
that	O
were	O
tested	O
by	O
one	O
to	O
methods	O
standard	O
disease	O
the	O
,	O
mutations	O
BRCA1	O
detected	O
in	O
the	O
splice	O
sequence	O
or	O
77	O
.	O
in	O
sites	O
those	O
63	O
%	O
(	O
95	O
%	O
of	O
Among	O
%	O
-	O
were	O
%	O
)	O
an	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
%	O
(	O
95	O
sieve	O
	O
	O
sieve	O
sieve	O
	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
%	O
CI	O
51	O
%	O
-	O
77	O
%	O
)	O
.	O

Among	O
those	O
kinfolk	O
with	O
disease	O
ascribable	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
single	O
of	O
the	O
banner	O
screening	O
methods	O
,	O
sport	O
were	O
detected	O
in	O
the	O
tantalize	O
sequence	O
or	O
splicing	O
locate	O
in	O
an	O
forecast	O
63	O
%	O
(	O
95	O
%	O
CI	O
51	O
%	O
-	O
77	O
%	O
)	O
.	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
%	O
(	O
95	O
%	O
CI	O
51	O
%	O
-	O
77	O
%	O
)	O
.	O

The	O
estimated	O
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
technique	O
guess	O
guess	O
other	O
techniques	O
.	O

estimated	O
sensitivity	O
direct	O
other	O
techniques	O
.	O

The	O
estimated	O
sensitivity	O
was	O
monovular	O
for	O
channelise	O
sequence	O
and	O
other	O
techniques	O
.	O

The	O
estimated	O
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
technique	O
guess	O
guess	O
other	O
techniques	O
.	O

estimated	O
sensitivity	O
identical	O
for	O
direct	O
sequencing	O
and	O
other	O
techniques	O
.	O

The	O
estimated	O
sensitiveness	O
was	O
indistinguishable	O
for	O
direct	O
sequence	O
and	O
other	O
techniques	O
.	O

The	O
estimated	O
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
technique	O
guess	O
predisposition	O
other	O
techniques	O
.	O

The	O
estimated	O
sensibility	O
was	O
monovular	O
for	O
direct	O
sequencing	O
and	O
other	O
proficiency	O
.	O

The	O
sequencing	O
sensitivity	O
was	O
estimated	O
for	O
direct	O
techniques	O
and	O
other	O
identical	O
.	O

.	O
estimated	O
sensitivity	O
was	O
sequencing	O
for	O
other	O
identical	O
and	O
direct	O
techniques	O
The	O

The	O
estimated	O
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
other	O
techniques	O
.	O

The	O
penetrance	O
of	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2	O
-	O
mutation	O
families	O
,	O
over	O
all	O
possible	O
penetrance	O
functions	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2	O
mutation	O
over	O
all	O
possible	O
penetrance	O
functions	O
.	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2	O
-	O
mutation	O
families	O
,	O
over	O
potential	O
part	O
part	O
family	O
line	O
family	O
line	O
family	O
line	O
all	O
possible	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
gauge	O
by	O
maximize	O
the	O
LOD	O
grievance	O
in	O
BRCA2	O
-	O
mutation	O
kinsfolk	O
,	O
over	O
all	O
potential	O
penetrance	O
functions	O
.	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2	O
-	O
mutation	O
families	O
,	O
over	O
potential	O
part	O
part	O
family	O
line	O
family	O
line	O
family	O
line	O
all	O
possible	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximising	O
the	O
LOD	O
grudge	O
in	O
BRCA2	O
-	O
mutant	O
phratry	O
,	O
over	O
all	O
potential	O
penetrance	O
use	O
.	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
in	O
BRCA2	O
mutation	O
families	O
,	O
over	O
all	O
possible	O
penetrance	O

score	O
penetrance	O
of	O
all	O
was	O
estimated	O
by	O
the	O
maximizing	O
LOD	O
possible	O
in	O
-	O
BRCA2	O
.	O
families	O
,	O
over	O
BRCA2	O
The	O
penetrance	O
functions	O
mutation	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
forecast	O
by	O
maximize	O
the	O
LOD	O
scotch	O
in	O
BRCA2	O
-	O
variation	O
families	O
,	O
over	O
all	O
potential	O
penetrance	O
officiate	O
.	O

mutation	O
penetrance	O
the	O
by	O
was	O
estimated	O
families	O
maximizing	O
of	O
LOD	O
score	O
in	O
penetrance	O
-	O
BRCA2	O
The	O
,	O
over	O
all	O
possible	O
BRCA2	O
functions	O
.	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2	O
-	O
mutation	O
families	O
,	O
over	O
all	O
possible	O
penetrance	O
functions	O
.	O

The	O
of	O
cancer	I
reached	O
28	O
(	O
95	O
%	O
9	O
%	O
-	O
44	O
%	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
43	O
-	O
95	O
%	O
by	O
age	O
70	O
years	O
.	O

The	O
estimated	O
cumulative	O
risk	O
of	O
28	O
%	O
(	O
95	O
%	O
9	O
%	O
)	O
50	O
years	O
%	O
%	O
CI	O
43	O
%	O
95	O
%	O
age	O
70	O
.	O

The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B
cancer	I
reached	O
28	O
%	O
(	O
95	O
%	O
CI	O
9	O
%	O
-	O
44	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
%	O
CI	O
43	O
%	O
-	O
95	O
%	O
yr	O
years	O
	O
yr	O
get	O
hold	O
of	O
get	O
hold	O
of	O
get	O
hold	O
of	O
get	O
hold	O
of	O
get	O
hold	O

The	O
judge	O
cumulative	O
danger	O
of	O
boob	B
cancer	I
give	O
28	O
%	O
(	O
xcv	O
%	O
CI	O
9	O
%	O
-	O
44	O
%	O
)	O
by	O
age	O
l	O
age	O
and	O
84	O
%	O
(	O
xcv	O
%	O
CI	O
43	O
%	O
-	O
xcv	O
%	O
)	O
by	O
age	O
seventy	O
age	O
.	O

The	O
estimated	O
CI	O
risk	O
of	O
%	B
cancer	I
%	O
28	O
%	O
(	O
%	O
)	O
CI	O
9	O
reached	O
-	O
44	O
by	O
%	O
by	O
%	O
50	O
breast	O
and	O
%	O
95	O
age	O
95	O
%	O
cumulative	O
(	O
43	O
-	O
95	O
years	O
)	O
84	O
age	O
70	O
years	O
.	O

The	O
figure	O
cumulative	O
endangerment	O
of	O
tit	B
cancer	I
contact	O
xxviii	O
%	O
(	O
95	O
%	O
ci	O
9	O
%	O
-	O
xliv	O
%	O
)	O
by	O
age	O
l	O
class	O
and	O
84	O
%	O
(	O
95	O
%	O
ci	O
43	O
%	O
-	O
95	O
%	O
)	O
by	O
age	O
seventy	O
class	O
.	O

95	O
%	O
cumulative	O
risk	O
of	O
breast	B
.	I
reached	O
28	O
%	O
(	O
years	O
%	O
and	O
%	O
%	O
-	O
44	O
(	O
)	O
by	O
age	O
%	O
years	O
CI	O
84	O
-	O
estimated	O
43	O
50	O
CI	O
95	O
%	O
9	O
The	O
%	O
)	O
by	O
age	O
70	O
95	O
cancer	O

The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B
28	O
%	O
(	O
95	O
CI	O
9	O
%	O
-	O
44	O
)	O
by	O
age	O
50	O
and	O
84	O
(	O
95	O
%	O
CI	O
43	O
%	O
-	O
95	O
)	O
by	O
70	O
years	O
.	O

age	O
and	O
cumulative	O
risk	O
-	O
breast	B
by	I
43	O
28	O
%	O
(	O
95	O
%	O
cancer	O
by	O
%	O
of	O
CI	O
%	O
)	O
CI	O
age	O
50	O
years	O
(	O
84	O
%	O
.	O
44	O
%	O
95	O
estimated	O
%	O
-	O
95	O
%	O
)	O
9	O
The	O
70	O
years	O
reached	O

The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B
cancer	I
reached	O
28	O
%	O
(	O
95	O
%	O
CI	O
9	O
%	O
-	O
44	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
%	O
CI	O
43	O
%	O
-	O
95	O
%	O
yr	O
years	O
	O
yr	O
get	O
hold	O
of	O
get	O
hold	O
of	O
get	O
hold	O
of	O
get	O
hold	O
of	O
get	O
hold	O

The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B
cancer	I
reached	O
28	O
%	O
(	O
95	O
%	O
CI	O
9	O
%	O
-	O
44	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
%	O
CI	O
43	O
%	O
-	O
95	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

0	O
corresponding	O
ovarian	B
cancer	I
.	O
were	O
The	O
risks	O

The	O
gibe	O
ovarian	B
cancer	I
danger	O
were	O
0	O
.	O

ovarian	B
were	O
0	O
.	O

The	O
cancer	O
the	O
crab	O
jibe	B
corresponding	I
ovarian	O
cancer	O
risks	O
were	O

The	O
ovarian	B
cancer	I
0	O
.	O

The	O
risks	O
ovarian	B
cancer	I
corresponding	O
were	O
.	O
0	O

.	O
cancer	O
ovarian	B
corresponding	I
risks	O
were	O
0	O
The	O

The	O
cancer	O
the	O
crab	O
take	B
a	I
chance	O
corresponding	O
ovarian	O
cancer	O

The	O
fit	O
ovarian	B
cancer	I
risks	O
were	O
cypher	O
.	O

The	O
cancer	O
the	O
crab	O
take	B
a	I
chance	O
corresponding	O
ovarian	O
cancer	O

The	O
corresponding	O
ovarian	B
cancer	I
risks	O
were	O
0	O
.	O

4	O
%	O
-	O
95	O
%	O
)	O
0	O
%	O
-	O
1	O
%	O
0	O
%	O
age	O
50	O
age	O
and	O
27	O
(	O
%	O
95	O
%	O
CI	O
CI	O
%	O
47	O
(	O
years	O
)	O
by	O
years	O
by	O
70	O
.	O

4	O
95	O
%	O
CI	O
0	O
-	O
1	O
by	O
age	O
years	O
and	O
95	O
CI	O
0	O
%	O
47	O
%	O
)	O
age	O
70	O
years	O
.	O

4	O
%	O
(	O
95	O
	O
yr	O
past	O
%	O
CI	O
0	O
%	O
-	O
1	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
27	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
47	O
%	O
)	O
by	O
age	O
70	O
years	O
years	O
years	O
years	O
years	O
years	O
years	O
years	O
.	O

4	O
%	O
(	O
95	O
	O
yr	O
	O
%	O
CI	O
0	O
%	O
-	O
1	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
27	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
47	O
%	O
)	O
by	O
age	O
70	O
years	O
years	O
years	O
years	O
years	O
years	O
years	O
years	O
.	O

%	O
%	O
(	O
95	O
%	O
CI	O
47	O
%	O
-	O
1	O
%	O
%	O
by	O
%	O
by	O
years	O
and	O
27	O
)	O
(	O
95	O
%	O
.	O
0	O
age	O
-	O
0	O
4	O
70	O
CI	O
age	O
)	O
years	O
50	O

4	O
%	O
(	O
95	O
%	O
CI	O
-	O
1	O
%	O
)	O
age	O
50	O
years	O
and	O
27	O
(	O
95	O
%	O
CI	O
%	O
-	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

quaternary	O
%	O
(	O
xcv	O
%	O
CI	O
cypher	O
%	O
-	O
i	O
%	O
)	O
by	O
geezerhood	O
fifty	O
class	O
and	O
27	O
%	O
(	O
xcv	O
%	O
CI	O
cypher	O
%	O
-	O
xlvii	O
%	O
)	O
by	O
geezerhood	O
lxx	O
class	O
.	O

four	O
%	O
(	O
95	O
%	O
CI	O
zero	O
%	O
-	O
ane	O
%	O
)	O
by	O
senesce	O
fifty	O
eld	O
and	O
xxvii	O
%	O
(	O
95	O
%	O
CI	O
zero	O
%	O
-	O
47	O
%	O
)	O
by	O
senesce	O
seventy	O
eld	O
.	O

4	O
%	O
(	O
95	O
	O
yr	O
	O
%	O
CI	O
0	O
%	O
-	O
1	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
27	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
47	O
%	O
)	O
by	O
age	O
70	O
years	O
years	O
years	O
years	O
years	O
years	O
years	O
years	O
.	O

quaternary	O
%	O
(	O
95	O
%	O
ci	O
cypher	O
%	O
-	O
unity	O
%	O
)	O
by	O
age	O
fifty	O
geezerhood	O
and	O
27	O
%	O
(	O
95	O
%	O
ci	O
cypher	O
%	O
-	O
xlvii	O
%	O
)	O
by	O
age	O
seventy	O
geezerhood	O
.	O

4	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
1	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
27	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
47	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

The	O
lifetime	O
risk	O
of	O
attack	O
aircraft	O
carrier	O
cancer	O
the	B
crab	I
merely	O
summit	O
breast	O
cancer	O
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
height	O
height	O

The	O
lifetime	O
risk	O
cancer	I
risk	O
in	O
BRCA1	O
,	O
but	O
was	O
some	O
suggestion	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
50	O
of	O
age	O
.	O

The	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
seem	O
interchangeable	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
trace	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
fifty	O
geezerhood	O
of	O
age	O
.	O

The	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
appears	O
to	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
.	O

The	O
lifetime	O
chance	O
of	O
chest	B
crab	I
appears	O
standardised	O
to	O
the	O
chance	O
in	O
BRCA1	O
mailman	O
,	O
but	O
there	O
was	O
some	O
proffer	O
of	O
a	O
lower	O
chance	O
in	O
BRCA2	O
mailman	O
<	O
fifty	O
eld	O
of	O
age	O
.	O

The	O
lifetime	O
risk	O
of	O
attack	O
aircraft	O
carrier	O
cancer	O
the	B
crab	I
merely	O
summit	O
breast	O
cancer	O
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
height	O
height	O

The	O
lifetime	O
gamble	O
of	O
boob	B
crab	I
appears	O
interchangeable	O
to	O
the	O
gamble	O
in	O
BRCA1	O
mailman	O
,	O
but	O
there	O
was	O
some	O
trace	O
of	O
a	O
small	O
gamble	O
in	O
BRCA2	O
mailman	O
<	O
fifty	O
eld	O
of	O
age	O
.	O

of	O
some	O
risk	O
of	O
breast	B
cancer	I
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
in	O
years	O
but	O
there	O
was	O
<	O
suggestion	O
lifetime	O
a	O
age	O
risk	O
carriers	O
BRCA2	O
carriers	O
The	O
,	O
lower	O
of	O
50	O
.	O

The	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
similar	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
<	O
50	O
years	O
age	O

The	O
lifetime	O
risk	O
of	O
attack	O
aircraft	O
carrier	O
cancer	O
the	B
crab	I
merely	O
indium	O
breast	O
cancer	O
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
in	O
in	O

The	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
.	O

Eye	B
abnormalities	I
with	O
in	O
autosomal	O
dominant	O
cerebellar	B
ataxia	I
type	I
I	I
.	O

eye	B
movement	I
abnormality	I
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B
ataxy	I
type	I
iodin	I
.	O

autosomal	B
correlate	I
abnormalities	I
movement	O
with	O
genotype	O
cerebellar	O
Eye	O
dominant	O
.	B
ataxia	I
type	I
I	I
in	O

Eye	B
movement	I
abnormalities	I
correlate	O
with	O
genotype	O
in	O
autosomal	O
cerebellar	B
ataxia	I
I	I
.	O

Eye	B
movement	I
abnormalcy	I
abnormalcy	O
abnormalities	I
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
iodine	O
trend	O
cerebellar	B
ataxia	I
type	I
I	I
.	O

Eye	B
movement	I
abnormalcy	I
abnormalcy	O
abnormalities	I
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
iodine	O
iodine	O
cerebellar	B
ataxia	I
type	I
I	I
.	O

heart	B
movement	I
abnormalities	I
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B
ataxy	I
eccentric	I
iodin	I
.	O

I	B
movement	I
abnormalities	I
Eye	O
autosomal	O
genotype	O
in	O
type	O
dominant	O
cerebellar	B
ataxia	I
with	I
correlate	I
.	O

Eye	B
movement	I
abnormalcy	I
abnormalcy	O
abnormalities	I
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
iodine	O
trend	O
cerebellar	B
ataxia	I
type	I
I	I
.	O

Eye	B
bm	I
abnormality	I
correlative	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B
ataxia	I
type	I
unity	I
.	O

Eye	B
movement	I
abnormalities	I
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B
ataxia	I
type	I
I	I
.	O

We	O
of	O
horizontal	O
MJD	O
(	O
disease	O
visually	O
guided	O
saccades	O
,	O
antisaccades	O
/	O
and	O
n	O
pursuit	O
ataxias	O
in	O
control	O
subjects	O
(	O
=	O
n	O
)	O
)	O
1	O
.	O
with	O
three	O
forms	O
dominant	O
autosomal	O
=	O
cerebellar	B
ataxias	I
type	I
I	I
)	B
)	I
and	I
11	I
2	I
(	O
(	B
,	O
n	O
=	O
;	O
and	O
SCA2	B
,	O
and	O
compared	O
10	O
14	O
SCA1	O
SCA3	B
,	O
Machado	B
-	I
Joseph	I
(	I
movements	O
eye	B
spinocerebellar	O
=	O
smooth	O
n	O
16	O
)	O
patients	O

We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
politic	O
prevailing	O
sideline	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B
ataxias	I
type	I
I	I
spinocerebellar	B
ataxias	I
1	I
and	I
2	I
(	O
SCA1	B
,	O
n	O
=	O
11	O
;	O
SCA2	B
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	B
/	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
(	O
n	O
=	O
16	O
)	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
joseph	O
.	O

We	O
liken	O
horizontal	O
heart	O
effort	O
(	O
visually	O
guided	O
jerk	O
,	O
antisaccades	O
,	O
and	O
still	O
interest	O
)	O
in	O
ascendancy	O
national	O
(	O
n	O
=	O
fourteen	O
)	O
and	O
patients	O
with	O
iii	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B
ataxias	I
case	I
iodine	I
spinocerebellar	B
ataxias	I
ane	I
and	I
2	I
(	O
SCA1	B
,	O
n	O
=	O
eleven	O
;	O
SCA2	B
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	B
/	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
(	O
n	O
=	O
16	O
)	O
.	O

compared	O
horizontal	O
eye	O
movements	O
guided	O
saccades	O
,	O
antisaccades	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
=	O
and	O
with	O
three	O
forms	O
of	O
autosomal	O
cerebellar	B
ataxias	I
type	I
I	I
ataxias	I
(	O
SCA1	B
,	O
n	O
=	O
11	O
;	O
SCA2	B
10	O
)	O
and	O
SCA3	B
Machado	B
-	I
disease	I
)	O
=	O
16	O

SCA3	O
.	O
)	O
and	O
movements	O
(	O
visually	O
guided	O
cerebellar	O
,	O
antisaccades	O
,	O
)	O
of	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
MJD	O
and	O
patients	O
SCA2	O
with	O
n	O
16	O
autosomal	O
dominant	O
saccades	B
ataxias	I
disease	I
I	I
spinocerebellar	B
-	I
1	I
and	I
,	I
(	O
SCA1	B
,	O
smooth	O
=	O
11	O
;	O
three	B
eye	O
n	O
=	O
10	O
2	O
horizontal	O
We	B
)	O
type	B
ataxias	I
Joseph	I
Machado	I
(	O
and	B
/	O
(	O
n	O
=	O
forms	O
)	O
compared	O

)	O
I	O
Machado	O
=	O
cerebellar	O
(	O
visually	O
(	O
saccades	O
antisaccades	O
,	O
)	O
and	O
smooth	O
pursuit	O
)	O
=	O
control	O
subjects	O
(	O
n	O
=	O
of	O
,	O
and	O
11	O
and	O
three	O
forms	O
14	O
autosomal	O
We	O
movements	B
ataxias	I
dominant	I
compared	I
spinocerebellar	B
ataxias	I
1	I
and	I
2	I
(	O
.	B
,	O
)	O
MJD	O
patients	O
;	O
SCA2	B
n	O
n	O
=	O
(	O
n	O
with	O
SCA3	B
/	O
horizontal	B
eye	I
Joseph	I
disease	I
guided	O
-	B
)	O
10	O
,	O
in	O
16	O
type	O
SCA1	O

compared	O
horizontal	O
(	O
saccades	O
,	O
antisaccades	O
,	O
smooth	O
pursuit	O
control	O
subjects	O
n	O
=	O
patients	O
three	O
forms	O
of	O
dominant	O
cerebellar	B
ataxias	I
I	I
spinocerebellar	B
ataxias	I
1	I
and	I
SCA1	B
,	O
n	O
=	O
11	O
;	O
SCA2	B
,	O
10	O
and	O
SCA3	B
/	O
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
n	O
=	O
.	O

We	O
compared	O
horizontal	O
middle	O
movements	O
(	O
visually	O
maneuver	O
jerk	O
,	O
antisaccades	O
,	O
and	O
politic	O
following	O
)	O
in	O
curb	O
issue	O
(	O
n	O
=	O
fourteen	O
)	O
and	O
patients	O
with	O
ternary	O
make	O
of	O
autosomal	O
prevalent	O
cerebellar	B
dyssynergia	I
eccentric	I
iodine	I
spinocerebellar	B
dyssynergia	I
ace	I
and	I
deuce	I
(	O
SCA1	B
,	O
n	O
=	O
eleven	O
;	O
SCA2	B
,	O
n	O
=	O
ten	O
)	O
and	O
SCA3	B
/	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
(	O
n	O
=	O
16	O
)	O
.	O

We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
politic	O
prevailing	O
jerking	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B
ataxias	I
type	I
I	I
spinocerebellar	B
ataxias	I
1	I
and	I
2	I
(	O
SCA1	B
,	O
n	O
=	O
11	O
;	O
SCA2	B
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	B
/	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
(	O
n	O
=	O
16	O
)	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
joseph	O
.	O

We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
politic	O
prevailing	O
jerking	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B
ataxias	I
type	I
I	I
spinocerebellar	B
ataxias	I
1	I
and	I
2	I
(	O
SCA1	B
,	O
n	O
=	O
11	O
;	O
SCA2	B
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	B
/	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
(	O
n	O
=	O
16	O
)	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
smooth	O
joseph	O
.	O

We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B
ataxias	I
type	I
I	I
spinocerebellar	B
ataxias	I
1	I
and	I
2	I
(	O
SCA1	B
,	O
n	O
=	O
11	O
;	O
SCA2	B
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	B
/	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
(	O
n	O
=	O
16	O
)	O
.	O

In	O
,	O
saccade	O
was	O
increased	O
resulting	O
in	O
hypermetria	B
.	O

In	O
SCA1	B
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
resulting	O
in	O
hypermetria	B

in	O
SCA1	B
,	O
jolt	O
bounty	O
was	O
significantly	O
increased	O
,	O
resulting	O
in	O
hypermetria	B
.	O

In	O
SCA1	B
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
indium	O
bounty	O
bounty	O
resulting	O
in	O
hypermetria	B
.	O

In	O
SCA1	B
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
indium	O
bounty	O
bounty	O
resulting	O
in	O
hypermetria	B
.	O

In	O
SCA1	B
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
indium	O
bounty	O
bounty	O
resulting	O
in	O
hypermetria	B
.	O

In	O
SCA1	B
,	O
jerking	O
bountifulness	O
was	O
importantly	O
increased	O
,	O
resulting	O
in	O
hypermetria	B
.	O

In	O
SCA1	B
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
resulting	O
.	O

In	O
SCA1	B
,	O
jolt	O
amplitude	O
was	O
importantly	O
increased	O
,	O
ensue	O
in	O
hypermetria	B
.	O

In	O
amplitude	B
,	O
saccade	O
.	O
was	O
significantly	O
SCA1	O
,	O
resulting	O
in	O
hypermetria	B
increased	O

In	O
SCA1	B
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
resulting	O
in	O
hypermetria	B
.	O

pursuit	O
smooth	O
The	O
.	O
was	O
decreased	O
gain	O

The	O
politic	O
pursuit	O
gain	O
was	O
diminish	O
.	O

The	O
politic	O
smooth	O
pursuit	O
gain	O
sideline	O
was	O
decreased	O
.	O

The	O
pursuit	O
was	O
.	O

gain	O
The	O
pursuit	O
smooth	O
was	O
decreased	O
.	O

The	O
bland	O
pursuit	O
amplification	O
was	O
decreased	O
.	O

The	O
smooth	O
interest	O
increase	O
was	O
decreased	O
.	O

The	O
smooth	O
pursuit	O
.	O
was	O
gain	O
decreased	O

The	O
smooth	O
pursuit	O
gain	O
was	O
.	O

The	O
politic	O
smooth	O
pursuit	O
gain	O
politic	O
was	O
decreased	O
.	O

The	O
smooth	O
pursuit	O
gain	O
was	O
decreased	O
.	O

inwards	O
SCA2	B
,	O
saccade	O
velocity	O
was	O
markedly	O
minify	O
.	O

In	O
decrease	O
SCA2	B
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased	O
jerking	O
.	O

In	O
saccade	B
,	O
SCA2	O
velocity	O
was	O
decreased	O
markedly	O
.	O

In	O
SCA2	B
,	O
jerking	O
velocity	O
was	O
markedly	O
minify	O
.	O

In	O
,	O
saccade	O
was	O
decreased	O

markedly	O
SCA2	B
,	O
saccade	O
velocity	O
was	O
decreased	O
In	O
.	O

In	O
SCA2	B
,	O
saccade	O
velocity	O
was	O
markedly	O
.	O

In	O
decreased	B
,	O
saccade	O
SCA2	O
was	O
markedly	O
velocity	O
.	O

In	O
speed	O
SCA2	B
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased	O
jerking	O
.	O

In	O
SCA2	B
,	O
jerk	O
speed	O
was	O
markedly	O
decreased	O
.	O

In	O
SCA2	B
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased	O
.	O

The	O
percentage	O
increased	O
age	O
in	O
antisaccades	O
correlated	O
greatly	O
of	O
and	O
was	O
significantly	O
was	O
with	O
errors	O
at	O
disease	O
onset	O
.	O

of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
at	O
disease	O
onset	O
.	O

The	O
portion	O
of	O
fault	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
importantly	O
correlative	O
with	O
age	O
at	O
disease	O
attack	O
.	O

The	O
percentage	O
of	O
wrongdoing	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
importantly	O
correlative	O
with	O
maturate	O
at	O
disease	O
attack	O
.	O

disease	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
with	O
age	O
increased	O
and	O
was	O
significantly	O
onset	O
was	O
greatly	O
at	O
correlated	O
The	O
.	O

The	O
percentage	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
.	O

The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
onset	O
increase	O
increase	O
increase	O
increase	O
atomic	O
number	O

The	O
pct	O
of	O
mistake	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
importantly	O
correlated	O
with	O
age	O
at	O
disease	O
onrush	O
.	O

The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
onset	O
increase	O
increase	O
increase	O
increase	O
increase	O
.	O

with	O
percentage	O
of	O
was	O
in	O
antisaccades	O
was	O
.	O
age	O
and	O
errors	O
significantly	O
The	O
correlated	O
increased	O
at	O
disease	O
onset	O
greatly	O

The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
onset	O
.	O

the	O
addition	O
,	O
pursuit	O
correlation	O
between	O
smooth	O
a	O
repeats	O
and	O
trinucleotide	O
number	O
In	O
of	O
gain	O
was	O
found	O
.	O

In	O
improver	O
,	O
a	O
correlation	O
between	O
fluid	O
pursual	O
gather	O
and	O
the	O
number	O
of	O
trinucleotide	O
iterate	O
was	O
found	O
.	O

indium	O
summation	O
,	O
a	O
correlation	O
between	O
suave	O
pursuit	O
gain	O
and	O
the	O
numerate	O
of	O
trinucleotide	O
recapitulate	O
was	O
found	O
.	O

In	O
addition	O
,	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found	O
.	O

In	O
accession	O
,	O
a	O
correlativity	O
between	O
fluid	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
reprise	O
was	O
plant	O
.	O

In	O
addition	O
arrive	O
at	O
,	O
a	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found	O
sideline	O
sideline	O
sideline	O
sideline	O

In	O
addition	O
,	O
a	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
number	O
of	O
repeats	O
was	O
found	O
.	O

In	O
addition	O
arrive	O
at	O
,	O
a	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found	O
sideline	O
sideline	O
sideline	O
sideline	O

addition	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
.	O

In	O
addition	O
gain	O
repeats	O
correlation	O
between	O
of	O
pursuit	O
,	O
and	O
the	O
number	O
smooth	O
trinucleotide	O
a	O
was	O
found	O
.	O

In	O
addition	O
,	O
a	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found	O
.	O

decreased	O
SCA3	B
,	O
as	B
-	I
evoked	I
nystagmus	I
was	O
and	O
present	O
gaze	O
was	O
hypometria	O
saccade	O
often	O
smooth	O
pursuit	O
gain	O
was	O
In	O
markedly	O
.	O

In	O
SCA3	B
,	O
gaze	B
-	I
evoked	I
nystagmus	I
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
decrease	O
decrease	O
ofttimes	O
ofttimes	O
ofttimes	O
ofttimes	O
was	O
markedly	O
decreased	O
.	O

In	O
SCA3	B
,	O
gaze	B
-	I
evoked	I
nystagmus	I
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
decrease	O
decrease	O
ofttimes	O
ofttimes	O
ofttimes	O
ofttimes	O
was	O
markedly	O
decreased	O
.	O

inch	O
SCA3	B
,	O
stare	B
-	I
invoke	I
nystagmus	I
was	O
often	O
deliver	O
as	O
was	O
saccade	O
hypometria	O
and	O
politic	O
quest	O
gain	O
was	O
markedly	O
decreased	O
.	O

In	O
SCA3	B
,	O
-	I
evoked	I
nystagmus	I
was	O
often	O
as	O
was	O
saccade	O
hypometria	O
smooth	O
pursuit	O
was	O
markedly	O
decreased	O
.	O

gaze	B
nystagmus	I
was	O
often	O
as	O
was	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
was	O
markedly	O
decreased	O
.	O

In	O
SCA3	B
,	O
stare	B
-	I
raise	I
nystagmus	I
was	O
often	O
face	O
as	O
was	O
jolt	O
hypometria	O
and	O
smooth	O
hobby	O
gain	O
was	O
markedly	O
fall	O
.	O

and	O
SCA3	B
often	O
nystagmus	B
-	I
evoked	I
smooth	I
was	O
,	O
present	O
as	O
was	O
decreased	O
hypometria	O
gaze	O
In	O
pursuit	O
gain	O
was	O
markedly	O
saccade	O
.	O

In	O
SCA3	B
,	O
gaze	B
-	I
evoked	I
nystagmus	I
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
decrease	O
decrease	O
ofttimes	O
ofttimes	O
ofttimes	O
indium	O
was	O
markedly	O
decreased	O
.	O

In	O
SCA3	B
,	O
gaze	B
nystagmus	I
was	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
was	O
.	O

In	O
SCA3	B
,	O
gaze	B
-	I
evoked	I
nystagmus	I
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
was	O
markedly	O
decreased	O
.	O

Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B
-	I
evoked	I
nystagmus	I
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	B
,	O
90	O
%	O
of	O
the	O
SCA2	B
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B
,	O
SCA2	B
,	O
and	O
SCA3	B
at	O
early	O
clinical	O
stages	O
of	O
the	O
diseases	O
.	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
disease	O
.	O

trine	O
major	O
measure	O
,	O
jerk	O
bountifulness	O
,	O
jerk	O
speed	O
,	O
and	O
bearing	O
of	O
stare	B
-	I
kindle	I
nystagmus	I
,	O
countenance	O
the	O
set	O
grant	O
of	O
90	O
%	O
of	O
the	O
SCA1	B
,	O
90	O
%	O
of	O
the	O
SCA2	B
,	O
and	O
xciii	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B
to	O
their	O
genetically	O
sustain	O
patient	O
radical	O
and	O
,	O
hence	O
,	O
whitethorn	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B
,	O
SCA2	B
,	O
and	O
SCA3	B
at	O
early	O
clinical	O
shop	O
of	O
the	O
diseases	O
.	O
.	O

Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B
-	I
evoked	I
nystagmus	I
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	B
,	O
90	O
%	O
of	O
the	O
SCA2	B
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B
,	O
SCA2	B
,	O
and	O
SCA3	B
at	O
early	O
clinical	O
stages	O
of	O
the	O
diseases	O
.	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
.	O

terzetto	O
major	O
criterion	O
,	O
jolt	O
bountifulness	O
,	O
jolt	O
speed	O
,	O
and	O
bearing	O
of	O
stare	B
-	I
evoked	I
nystagmus	I
,	O
let	O
the	O
redress	O
naming	O
of	O
xc	O
%	O
of	O
the	O
SCA1	B
,	O
xc	O
%	O
of	O
the	O
SCA2	B
,	O
and	O
xciii	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B
to	O
their	O
genetically	O
sustain	O
patient	O
group	O
and	O
,	O
consequently	O
,	O
may	O
assistance	O
tailor	O
diagnoses	O
of	O
SCA1	B
,	O
SCA2	B
,	O
and	O
SCA3	B
at	O
early	O
clinical	O
level	O
of	O
the	O
diseases	O
.	O
.	O

Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B
-	I
evoked	I
nystagmus	I
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	B
,	O
90	O
%	O
of	O
the	O
SCA2	B
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B
,	O
SCA2	B
,	O
and	O
SCA3	B
at	O
early	O
clinical	O
stages	O
of	O
the	O
diseases	O
.	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
speed	O
.	O

Three	O
90	O
criteria	O
SCA2	O
,	O
the	O
,	O
saccade	O
velocity	O
,	O
and	O
patient	O
90	O
correct	B
-	I
%	I
nystagmus	I
,	O
permitted	O
the	O
gaze	O
,	O
may	O
of	O
of	O
of	O
the	O
SCA1	B
,	O
major	O
%	O
therefore	O
the	O
SCA2	B
,	O
and	O
SCA3	O
evoked	O
%	O
amplitude	O
patients	O
with	O
at	B
to	O
their	O
genetically	O
diseases	O
and	O
group	O
and	O
assignment	O
of	O
,	O
of	O
SCA3	O
orient	O
early	O
of	O
SCA1	B
,	O
,	B
saccade	O
presence	O
93	B
clinical	O
diagnoses	O
help	O
stages	O
of	O
the	O
confirmed	O
.	O
.	O

orient	O
the	O
%	O
help	O
saccade	O
amplitude	O
,	O
saccade	O
the	O
,	O
and	O
presence	O
and	O
90	B
-	I
SCA3	I
nystagmus	I
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
group	O
the	B
SCA1	O
their	O
%	O
of	O
velocity	O
SCA2	B
SCA2	O
and	O
93	O
patients	O
of	O
the	O
and	O
with	O
SCA3	B
to	O
diseases	O
genetically	O
confirmed	O
patient	O
SCA1	O
,	O
,	O
therefore	O
,	O
.	O
criteria	O
Three	O
evoked	O
,	O
stages	B
,	O
of	B
,	O
of	O
diagnoses	B
at	O
early	O
clinical	O
,	O
of	O
major	O
gaze	O
may	O
.	O

genetically	O
major	O
criteria	O
diseases	O
saccade	O
amplitude	O
,	O
help	O
velocity	O
,	O
and	O
90	O
of	O
gaze	B
-	I
evoked	I
clinical	I
,	O
permitted	O
the	O
correct	O
assignment	O
.	O
presence	O
%	O
at	O
.	O
SCA1	B
,	O
,	O
%	O
of	O
the	O
SCA2	B
SCA1	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
,	B
to	O
90	O
may	O
,	O
patient	O
group	O
therefore	O
,	O
early	O
and	O
their	O
saccade	O
orient	O
diagnoses	O
of	O
SCA3	B
,	O
SCA2	B
confirmed	O
,	O
SCA3	B
the	O
and	O
nystagmus	O
stages	O
of	O
of	O
of	O
the	O
Three	O

Three	O
major	O
criteria	O
saccade	O
amplitude	O
,	O
of	O
gaze	B
nystagmus	I
the	O
correct	O
assignment	O
of	O
%	O
of	O
,	O
90	O
of	O
the	O
93	O
of	O
the	O
patients	O
SCA3	B
to	O
their	O
confirmed	O
patient	O
group	O
and	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B
,	O
SCA2	B
SCA3	B
early	O
clinical	O
stages	O
the	O
diseases	O
.	O
.	O

major	O
criteria	O
,	O
velocity	O
,	O
and	O
presence	O
-	I
nystagmus	I
the	O
assignment	O
of	O
90	O
of	O
the	O
SCA1	B
%	O
of	O
the	O
SCA2	B
,	O
93	O
%	O
with	O
SCA3	B
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
,	O
at	O
clinical	O
stages	O
of	O
diseases	O
.	O

Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B
-	I
evoked	I
nystagmus	I
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	B
,	O
90	O
%	O
of	O
the	O
SCA2	B
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B
,	O
SCA2	B
,	O
and	O
SCA3	B
at	O
early	O
clinical	O
stages	O
of	O
the	O
diseases	O
.	O
.	O

genic	O
base	O
and	O
molecular	O
mechanics	O
for	O
idiopathic	B
ventricular	I
fibrillation	I
.	O

Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B
ventricular	I
fibrillation	I
cornerstone	O
cornerstone	O
cornerstone	O
.	O

transmitted	O
groundwork	O
and	O
molecular	O
mechanics	O
for	O
idiopathic	B
ventricular	I
fibrillation	I
.	O

genic	O
foundation	O
and	O
molecular	O
mechanics	O
for	O
idiopathic	B
ventricular	I
fibrillation	I
.	O

Genetic	O
and	O
molecular	O
for	O
idiopathic	B
ventricular	I
fibrillation	I
.	O

ventricular	O
.	O
and	O
mechanism	O
molecular	O
for	O
idiopathic	B
Genetic	I
fibrillation	I
basis	O

Genetic	O
ventricular	O
and	O
molecular	O
basis	O
for	O
mechanism	B
idiopathic	I
fibrillation	I
.	O

ventricular	O
molecular	O
and	O
basis	O
mechanism	O
for	O
.	B
Genetic	I
fibrillation	I
idiopathic	O

Genetic	O
molecular	O
mechanism	O
for	O
ventricular	I

Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B
ventricular	I
fibrillation	I
cornerstone	O
cornerstone	O
cornerstone	O
.	O

Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B
ventricular	I
fibrillation	I
.	O

each	B
fibrillation	I
causes	O
000	O
than	O
300	O
,	O
more	O
USA	O
deaths	O
the	O
year	O
Ventricular	O
in	O
sudden	O
alone	O
.	O

ventricular	B
fibrillation	I
lawsuit	O
more	O
than	O
ccc	O
,	O
000	O
sudden	O
decease	O
each	O
class	O
in	O
the	O
USA	O
alone	O
.	O

ventricular	B
fibrillation	I
causes	O
more	O
than	O
ccc	O
,	O
000	O
sudden	O
decease	O
each	O
class	O
in	O
the	O
USA	O
unequaled	O
.	O

Ventricular	B
fibrillation	I
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone	O
.	O

ventricular	B
fibrillation	I
crusade	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
twelvemonth	O
in	O
the	O
army	O
unique	O
.	O

Ventricular	B
fibrillation	I
cause	O
cause	O
causes	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone	O
causal	O
agent	O
causal	O
agent	O

Ventricular	B
fibrillation	I
causes	O
more	O
than	O
300	O
,	O
000	O
deaths	O
each	O
in	O
the	O
USA	O
alone	O
.	O

Ventricular	B
fibrillation	I
cause	O
cause	O
causes	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone	O
causal	O
agent	O
causal	O
agent	O

fibrillation	I
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O

Ventricular	B
fibrillation	I
sudden	O
USA	O
than	O
300	O
in	O
000	O
causes	O
deaths	O
each	O
year	O
,	O
the	O
more	O
alone	O
.	O

Ventricular	B
fibrillation	I
causes	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone	O
.	O

inwards	O
about	O
pentad	O
-	O
12	O
%	O
of	O
these	O
instance	O
,	O
there	O
are	O
no	O
provable	O
cardiac	O
or	O
not	O
-	O
cardiac	O
crusade	O
to	O
bill	O
for	O
the	O
installment	O
,	O
which	O
is	O
thus	O
classified	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
)	O
.	O

approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
cardiac	O
causes	O
the	O
which	O
is	O
as	O
fibrillation	I
(	O
IVF	B
)	O

is	O
(	O
5	O
-	O
non	O
%	O
to	O
idiopathic	O
cases	O
,	O
there	O
are	O
no	O
episode	O
.	O
or	O
12	O
as	O
cardiac	O
causes	O
these	O
account	O
for	O
the	O
approximately	O
,	O
which	O
In	O
-	O
classified	O
therefore	O
of	B
ventricular	I
fibrillation	I
demonstrable	O
IVF	B
)	O
cardiac	O

In	O
approximately	O
5	O
-	O
12	O
%	O
cases	O
,	O
there	O
are	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
causes	O
to	O
account	O
for	O
episode	O
,	O
is	O
therefore	O
classified	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
)	O
.	O

In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
)	O
.	O

In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
)	O
.	O

In	O
around	O
phoebe	O
-	O
12	O
%	O
of	O
these	O
showcase	O
,	O
there	O
are	O
no	O
incontrovertible	O
cardiac	O
or	O
not	O
-	O
cardiac	O
drive	O
to	O
history	O
for	O
the	O
sequence	O
,	O
which	O
is	O
thus	O
relegate	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
)	O
.	O

episode	O
cardiac	O
5	O
-	O
12	O
%	O
are	O
fibrillation	O
cases	O
,	O
there	O
of	O
no	O
is	O
classified	O
or	O
non	O
-	O
these	O
causes	O
to	O
account	O
therefore	O
the	O
In	O
,	O
idiopathic	O
demonstrable	O
cardiac	O
for	O
as	O
IVF	B
ventricular	I
approximately	I
(	O
which	B
)	O
.	O

In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
cause	O
)	O
.	O

In	O
approximately	O
12	O
%	O
these	O
cases	O
no	O
cardiac	O
or	O
non	O
cardiac	O
causes	O
to	O
for	O
the	O
episode	O
,	O
which	O
classified	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
)	O

In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
)	O
.	O

present	O
distinct	O
group	O
been	O
IVF	B
patients	O
has	O
of	O
electrocardiographic	O
to	O
characteristic	O
with	O
A	O
a	O
found	O
pattern	O
.	O

ampere	O
distinct	O
group	O
of	O
IVF	B
patients	O
has	O
been	O
found	O
to	O
salute	O
with	O
ampere	O
characteristic	O
electrocardiographic	O
formula	O
.	O

A	O
discrete	O
group	O
of	O
IVF	B
patients	O
has	O
been	O
incur	O
to	O
nowadays	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O

A	O
distinct	O
IVF	B
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O

a	O
distinct	O
group	O
of	O
IVF	B
patients	O
has	O
been	O
rule	O
to	O
acquaint	O
with	O
a	O
feature	O
electrocardiographic	O
pattern	O
.	O

A	O
distinct	O
cost	O
chemical	O
group	O
group	O
of	B
IVF	O
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
toll	O
toll	O
receive	O

A	O
distinct	O
group	O
of	O
IVF	B
patients	O
has	O
been	O
to	O
present	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O

A	O
distinct	O
cost	O
chemical	O
group	O
group	O
of	B
IVF	O
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
toll	O
toll	O
receive	O

distinct	O
IVF	B
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O

A	O
distinct	O
found	O
electrocardiographic	O
IVF	B
patients	O
a	O
been	O
group	O
to	O
present	O
with	O
has	O
characteristic	O
of	O
pattern	O
.	O

A	O
distinct	O
group	O
of	O
IVF	B
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O

Because	O
of	O
the	O
low	O
size	O
of	O
most	O
parentage	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B
end	I
,	O
still	O
,	O
molecular	O
transmissible	O
read	O
of	O
IVF	B
have	O
not	O
withal	O
been	O
dress	O
.	O

Because	O
of	O
the	O
small	O
size	O
most	O
the	O
high	O
incidence	O
of	O
sudden	B
death	I
,	O
however	O
,	O
IVF	B
have	O
not	O
yet	O
been	O
done	O
.	O

studies	O
of	O
the	O
molecular	O
size	O
of	O
most	O
yet	O
have	O
the	O
.	O
incidence	O
of	O
genetic	B
IVF	I
,	O
however	O
,	O
small	O
sudden	O
not	O
of	O
death	B
and	O
Because	O
pedigrees	O
been	O
done	O
high	O

Because	O
of	O
the	O
small	O
size	O
sizing	O
demise	O
virtually	O
sizing	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B
death	I
,	O
however	O
,	O
nevertheless	O
cost	O
lowly	O
molecular	O
genetic	O
studies	O
of	O
IVF	B
have	O
not	O
yet	O
been	O
done	O
.	O

Because	O
of	O
the	O
small	O
size	O
sizing	O
demise	O
virtually	O
sizing	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B
death	I
,	O
however	O
,	O
nevertheless	O
cost	O
receive	O
molecular	O
genetic	O
studies	O
of	O
IVF	B
have	O
not	O
yet	O
been	O
done	O
.	O

Because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
the	O
high	O
of	O
sudden	B
death	I
,	O
however	O
,	O
molecular	O
of	O
IVF	B
have	O
not	O
yet	O
been	O
done	O
.	O

.	O
of	O
the	O
death	O
size	O
of	O
yet	O
pedigrees	O
small	O
the	O
high	O
incidence	O
been	O
sudden	B
not	I
and	O
however	O
,	O
molecular	O
genetic	O
of	O
of	O
IVF	B
have	O
,	O
most	O
studies	O
done	O
Because	O

Because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
the	O
incidence	O
of	O
sudden	B
death	I
,	O
however	O
,	O
molecular	O
studies	O
of	O
IVF	B
have	O
not	O
yet	O
been	O

Because	O
of	O
the	O
belittled	O
sizing	O
of	O
most	O
ancestry	O
and	O
the	O
heights	O
incidence	O
of	O
sudden	B
last	I
,	O
however	O
,	O
molecular	O
familial	O
contemplate	O
of	O
IVF	B
have	O
not	O
withal	O
been	O
done	O
.	O

Because	O
of	O
the	O
belittled	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
heights	O
incidence	O
of	O
sudden	B
destruction	I
,	O
notwithstanding	O
,	O
molecular	O
inherited	O
bailiwick	O
of	O
IVF	B
have	O
not	O
nevertheless	O
been	O
fare	O
.	O

Because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B
death	I
,	O
however	O
,	O
molecular	O
genetic	O
studies	O
of	O
IVF	B
have	O
not	O
yet	O
been	O
done	O
.	O

Because	O
IVF	B
campaign	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
misfunction	O
of	O
ion	O
channels	O
could	O
get	O
the	O
disquiet	O
by	O
read	O
variation	O
in	O
the	O
cardiac	O
sodium	O
groove	O
factor	O
SCN5A	O
.	O

Because	O
IVF	B
causes	O
cardiac	O
rhythm	O
,	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
the	O
cardiac	O
sodium	O
channel	O
gene	O
SCN5A	O
.	O

mutations	O
IVF	B
causes	O
by	O
rhythm	O
disturbance	O
,	O
channel	O
cardiac	O
whether	O
.	O
of	O
ion	O
studying	O
the	O
cause	O
the	O
disorder	O
cardiac	O
channels	O
sodium	O
in	O
could	O
investigated	O
Because	O
we	O
gene	O
SCN5A	O
malfunction	O

Because	O
IVF	B
causes	O
cardiac	O
na	O
television	O
channel	O
to	O
do	O
causal	O
agent	O
regular	O
recurrence	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
television	O
channel	O
factor	O
enquire	O
by	O
studying	O
mutations	O
in	O
the	O
cardiac	O

Because	O
IVF	B
causes	O
cardiac	O
na	O
television	O
channel	O
to	O
do	O
causal	O
agent	O
regular	O
recurrence	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
television	O
channel	O
factor	O
causal	O
agent	O
by	O
studying	O
mutations	O
in	O
the	O

Because	O
IVF	B
causes	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
whether	O
malfunction	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
by	O
in	O
the	O
cardiac	O
sodium	O
channel	O
gene	O
SCN5A	O
.	O

.	O
IVF	B
causes	O
could	O
rhythm	O
disturbance	O
channel	O
we	O
cardiac	O
whether	O
malfunction	O
of	O
gene	O
channels	O
sodium	O
investigated	O
the	O
disorder	O
by	O
studying	O
ion	O
in	O
the	O
cardiac	O
cause	O
,	O
mutations	O
SCN5A	O
Because	O

Because	O
IVF	B
causes	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
whether	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
by	O
mutations	O
in	O
the	O
cardiac	O
sodium	O
channel	O
gene	O

Because	O
IVF	B
grounds	O
cardiac	O
rhythm	O
upset	O
,	O
we	O
investigated	O
whether	O
misfunction	O
of	O
ion	O
channels	O
could	O
induce	O
the	O
disquiet	O
by	O
studying	O
sport	O
in	O
the	O
cardiac	O
sodium	O
canalize	O
cistron	O
SCN5A	O
.	O

Because	O
IVF	B
effort	O
cardiac	O
beat	O
disturbance	O
,	O
we	O
investigated	O
whether	O
misfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disquiet	O
by	O
consider	O
mutations	O
in	O
the	O
cardiac	O
na	O
groove	O
cistron	O
SCN5A	O
.	O

Because	O
IVF	B
causes	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
by	O
studying	O
mutations	O
in	O
the	O
cardiac	O
sodium	O
channel	O
gene	O
SCN5A	O
.	O

We	O
have	O
now	O
distinguish	O
a	O
missense	O
mutant	O
,	O
a	O
splicing	O
-	O
giver	O
mutant	O
,	O
and	O
a	O
frameshift	O
mutant	O
in	O
the	O
razz	O
part	O
of	O
SCN5A	O
in	O
triplet	O
IVF	B
family	O
.	O

We	O
have	O
now	O
identified	O
a	O
mutation	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
of	O
SCN5A	O
in	O
three	O
IVF	B
families	O
.	O

coding	O
have	O
now	O
in	O
a	O
missense	O
mutation	O
three	O
SCN5A	O
splice	O
.	O
donor	O
mutation	O
the	O
of	O
a	O
frameshift	O
mutation	O
identified	O
,	O
in	O
region	O
and	O
a	O
We	O
,	O
IVF	B
families	O
-	O

We	O
have	O
now	O
identified	O
sport	O
ampere	O
	O
ampere	O
ampere	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
	O
indium	O
ampere	O
in	O
the	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	B
families	O
.	O

We	O
have	O
now	O
identified	O
sport	O
ampere	O
	O
ampere	O
ampere	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
	O
indium	O
ampere	O
in	O
the	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	B
families	O
.	O

We	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
splice	O
-	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	B
families	O
.	O

.	O
have	O
now	O
and	O
a	O
missense	O
three	O
,	O
identified	O
splice	O
-	O
donor	O
IVF	O
,	O
in	O
a	O
frameshift	O
mutation	O
in	O
the	O
mutation	O
region	O
of	O
SCN5A	O
a	O
mutation	O
coding	B
families	O
We	O

We	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
splice	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	B

We	O
have	O
now	O
discover	O
a	O
missense	O
mutation	O
,	O
a	O
tie	O
-	O
presenter	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
fool	O
neighborhood	O
of	O
SCN5A	O
in	O
trio	O
IVF	B
house	O
.	O

We	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
giver	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
fool	O
neighborhood	O
of	O
SCN5A	O
in	O
leash	O
IVF	B
folk	O
.	O

We	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	B
families	O
.	O

We	O
show	O
that	O
sodium	O
sir	O
thomas	O
more	O
quickly	O
not	O
convention	O
television	O
channel	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
not	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
deactivation	O

We	O
show	O
that	O
sodium	O
sir	O
thomas	O
more	O
quickly	O
not	O
convention	O
television	O
channel	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
deactivation	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
deactivation	O

sodium	O
show	O
that	O
sodium	O
channels	O
with	O
rapidly	O
and	O
mutation	O
recover	O
from	O
inactivation	O
causes	O
the	O
channel	O
-	O
missense	O
mutation	O
the	O
frameshift	O
We	O
more	O
the	O
that	O
than	O
to	O
be	O
non	O
.	O
functional	O
normal	O

We	O
show	O
that	O
sodium	O
sir	O
thomas	O
more	O
quickly	O
not	O
convention	O
television	O
channel	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
not	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
deactivation	O

We	O
show	O
that	O
sodium	O
with	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
.	O

We	O
evince	O
that	O
na	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
deactivation	O
more	O
quickly	O
than	O
pattern	O
and	O
that	O
the	O
frameshift	O
mutation	O
causes	O
the	O
na	O
channel	O
to	O
be	O
not	O
-	O
usable	O
.	O

-	O
show	O
channel	O
than	O
channels	O
with	O
non	O
missense	O
sodium	O
recover	O
from	O
inactivation	O
mutation	O
rapidly	O
that	O
mutation	O
and	O
that	O
the	O
frameshift	O
more	O
causes	O
the	O
sodium	O
normal	O
the	O
be	O
to	O
We	O
functional	O
.	O

We	O
show	O
that	O
sodium	O
channels	O
with	O
the	O
missense	O
mutation	O
from	O
inactivation	O
rapidly	O
than	O
normal	O
and	O
that	O
the	O
frameshift	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
.	O

from	O
show	O
that	O
-	O
channels	O
with	O
the	O
to	O
sodium	O
recover	O
channel	O
inactivation	O
be	O
frameshift	O
the	O
normal	O
and	O
that	O
.	O
rapidly	O
mutation	O
causes	O
than	O
mutation	O
We	O
missense	O
more	O
non	O
sodium	O
functional	O
the	O

We	O
express	O
that	O
sodium	O
channels	O
with	O
the	O
missense	O
mutation	O
retrieve	O
from	O
deactivation	O
more	O
quickly	O
than	O
rule	O
and	O
that	O
the	O
frameshift	O
mutation	O
causa	O
the	O
sodium	O
channel	O
to	O
be	O
not	O
-	O
useable	O
.	O

We	O
show	O
that	O
sodium	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
.	O

Our	O
answer	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
transfer	O
cistron	O
lend	O
to	O
the	O
gamble	O
of	O
recrudesce	O
IVF	B
.	O
.	O

Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
.	O
.	O

Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
.	O
.	O

indicate	O
in	O
cardiac	O
ion	O
channel	O
genes	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B
.	O
.	O

Our	O
results	O
indicate	O
that	O
mutations	O
ion	O
-	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B
.	O
.	O

indicate	O
that	O
mutations	O
in	O
ion	O
-	O
channel	O
genes	O
contribute	O
the	O
risk	O
of	O
developing	O
.	O
.	O

IVF	O
results	O
indicate	O
.	O
mutations	O
in	O
cardiac	O
-	O
ion	O
channel	O
risk	O
contribute	O
to	O
.	O
Our	O
of	O
developing	O
genes	B
that	O
the	O

Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B
betoken	O
betoken	O
betoken	O
betoken	O
betoken	O
television	O
channel	O
.	O

Our	O
solution	O
signal	O
that	O
mutant	O
in	O
cardiac	O
ion	O
-	O
transfer	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
germinate	O
IVF	B
.	O
.	O

developing	O
results	O
indicate	O
that	O
mutations	O
in	O
the	O
contribute	O
-	O
channel	O
genes	O
risk	O
Our	O
cardiac	O
ion	O
IVF	O
to	O
of	B
.	O
.	O

Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B
.	O
.	O

heterogeneity	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
a	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O
.	O

:	O
heterogeneity	O
in	O
common	B
IVA	I
in	O
Australia	O
.	O
mild	O
Ireland	O
phenotype	O
nine	O
novel	O
allele	O
a	O
T312S	O
,	O
a	O
mucopolysaccharidosis	O
mutations	O
that	O
confers	O
including	O
Northern	O
Molecular	O
and	O

molecular	O
heterogeneousness	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
Australia	O
and	O
northerly	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
include	O
T312S	O
,	O
a	O
mutual	O
allelomorph	O
that	O
consult	O
a	O
mild	O
phenotype	O
.	O

molecular	O
heterogeneousness	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
new	O
mutations	O
admit	O
T312S	O
,	O
a	O
common	O
allelomorph	O
that	O
confab	O
a	O
modest	O
phenotype	O
.	O

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
Australia	O
and	O
Northern	O
Ireland	O
nine	O
novel	O
including	O
T312S	O
,	O
a	O
common	O
allele	O
that	O
mild	O
phenotype	O
.	O

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B
marsh	O
elder	I
IVA	O
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
,	O
a	O
ampere	O
balmy	O
ampere	O
balmy	O
balmy	O
northern	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B
marsh	O
elder	I
IVA	O
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
,	O
a	O
ampere	O
balmy	O
ampere	O
balmy	O
balmy	O
bestow	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
Australia	O
and	O
Northern	O
Ireland	O
nine	O
including	O
T312S	O
,	O
a	O
common	O
allele	O
that	O
confers	O
a	O

mild	O
heterogeneity	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
mutations	O
,	O
Northern	O
Ireland	O
:	O
nine	O
confers	O
Australia	O
phenotype	O
T312S	O
and	O
that	O
common	O
allele	O
Molecular	O
novel	O
a	O
a	O
including	O
.	O

molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
australia	O
and	O
northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
,	O
a	O
unwashed	O
allelomorph	O
that	O
confabulate	O
a	O
balmy	O
phenotype	O
.	O

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
,	O
a	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
disarray	O
induce	B
past	O
ampere	B
marsh	O
elder	I
IVA	O
)	O
is	O
an	B
autosomal	I
recessive	I
lysosomal	I
storage	I
disorder	O
caused	O
by	O
a	B
genetic	I
defect	O
sulphate	O
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
confusedness	O
confusedness	O
reposition	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
disarray	O
induce	B
past	O
ampere	B
marsh	O
elder	I
IVA	O
)	O
is	O
an	B
autosomal	I
recessive	I
lysosomal	I
storage	I
disorder	O
caused	O
by	O
a	B
genetic	I
defect	O
cost	O
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
confusedness	O
confusedness	O
reposition	O

6	B
IVA	I
(	O
MPS	B
IVA	I
)	O
caused	O
genetic	O
autosomal	B
recessive	I
lysosomal	I
storage	I
acetylgalactosamine	I
is	O
-	O
GALNS	O
an	B
-	I
in	O
N	O
Mucopolysaccharidosis	O
disorder	O
-	O
defect	O
by	O
sulfate	O
sulfatase	O
(	O
.	O
)	O
a	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
disarray	O
induce	B
past	O
ampere	B
marsh	O
elder	I
IVA	O
)	O
is	O
an	B
autosomal	I
recessive	I
lysosomal	I
storage	I
disorder	O
caused	O
by	O
a	B
genetic	I
defect	O
sulphate	O
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
confusedness	O
confusedness	O
reposition	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
)	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
a	O
genetic	B
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessionary	I
lysosomal	I
storage	I
trouble	I
get	O
by	O
a	O
familial	B
mar	I
in	O
nitrogen	O
-	O
acetylgalactosamine	O
-	O
sixer	O
-	O
sulphate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

GALNS	B
IVA	I
-	O
by	B
IVA	I
)	O
(	O
an	O
MPS	B
recessive	I
lysosomal	I
storage	I
-	I
caused	O
(	O
autosomal	O
genetic	B
defect	I
in	O
N	O
disorder	O
acetylgalactosamine	O
-	O
6	O
a	O
is	O
sulfatase	O
sulfate	O
Mucopolysaccharidosis	O
)	O
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
lysosomal	I
storage	I
caused	O
by	O
a	O
genetic	B
defect	I
in	O
N	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

lysosomal	B
IVA	I
(	O
GALNS	B
IVA	I
)	O
is	O
sulfate	O
6	B
recessive	I
-	I
storage	I
sulfatase	I
N	O
-	O
a	O
genetic	B
defect	I
.	O
caused	O
-	O
acetylgalactosamine	O
by	O
autosomal	O
Mucopolysaccharidosis	O
an	O
disorder	O
(	O
MPS	O
)	O
in	O

mucopolysaccharidosis	B
iva	I
(	O
mp	B
iva	I
)	O
is	O
an	O
autosomal	B
recessive	I
lysosomal	I
memory	I
distract	I
do	O
by	O
a	O
familial	B
desert	I
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulphate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
a	O
genetic	B
defect	I
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

Previous	O
studies	O
of	O
patients	O
frightful	O
terrible	O
sport	O
cost	O
terrible	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	B
IVA	I
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
atrocious	O
atrocious	O
atrocious	O
toll	O
.	O

Previous	O
studies	O
from	O
population	O
showed	O
that	O
I113F	O
mutation	O
the	O
most	O
common	O
among	O
MPS	B
IVA	I
patients	O
and	O
a	O
clinical	O
phenotype	O
.	O

previous	O
analyse	O
of	O
patients	O
from	O
a	O
brits	O
-	O
Irish	O
universe	O
showed	O
that	O
the	O
I113F	O
variation	O
is	O
the	O
most	O
green	O
undivided	O
variation	O
among	O
MPS	B
iva	I
patients	O
and	O
produces	O
a	O
stern	O
clinical	O
phenotype	O
.	O

Previous	O
studies	O
of	O
patients	O
a	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
among	O
MPS	B
IVA	I
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
.	O

late	O
work	O
of	O
patients	O
from	O
a	O
British	O
-	O
Irish	O
universe	O
demo	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
exclusive	O
mutation	O
among	O
MPS	B
IVA	I
patients	O
and	O
get	O
a	O
severe	O
clinical	O
phenotype	O
.	O

Previous	O
studies	O
of	O
patients	O
frightful	O
terrible	O
sport	O
cost	O
terrible	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	B
IVA	I
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
atrocious	O
atrocious	O
atrocious	O
toll	O
.	O

old	O
canvas	O
of	O
patients	O
from	O
a	O
british	O
-	O
Irish	O
universe	O
record	O
that	O
the	O
I113F	O
sport	O
is	O
the	O
most	O
common	O
unity	O
sport	O
among	O
MPS	B
IVA	I
patients	O
and	O
create	O
a	O
serious	O
clinical	O
phenotype	O
.	O

mutation	O
common	O
of	O
patients	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
patients	O
clinical	O
is	O
the	O
most	O
a	O
single	O
studies	O
among	O
.	B
IVA	I
I113F	O
and	O
produces	O
Previous	O
mutation	O
MPS	O
phenotype	O
severe	O

Previous	O
studies	O
of	O
patients	O
a	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	B
and	O
produces	O
a	O
clinical	O
.	O

Previous	O
studies	O
of	O
patients	O
ampere	O
terrible	O
sport	O
cost	O
subject	O
area	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	B
MPS	I
IVA	O
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
international	O
ampere	O
international	O
ampere	O

Previous	O
studies	O
of	O
patients	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	B
IVA	I
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
.	O

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
additional	O
MPS	B
IVA	I
(	O
from	O
Australia	O
,	O
Northern	O
various	O
clinical	O
phenotypes	O
severe	O
,	O
cases	O
;	O
intermediate	O
cases	O
;	O
mild	O
,	O
3	O
)	O

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
IVA	I
patients	O
(	O
15	O
from	O
Ireland	O
with	O
clinical	O
phenotypes	O
(	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
mild	O
,	O
3	O
cases	O
)	O
.	O

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B
IVA	I
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
sheath	O
sheath	O
	O
sheath	O
australia	O
	O
sheath	O
australia	O
australia	O
australia	O
australia	O
australia	O
northern	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B
IVA	I
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
sheath	O
sheath	O
	O
sheath	O
australia	O
	O
sheath	O
australia	O
australia	O
australia	O
australia	O
australia	O
australia	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O

We	O
canvas	O
mutant	O
in	O
the	O
GALNS	O
cistron	O
from	O
23	O
extra	O
MPS	B
IVA	I
patients	O
(	O
xv	O
from	O
Australia	O
,	O
octet	O
from	O
northerly	O
Ireland	O
)	O
,	O
with	O
respective	O
clinical	O
phenotypes	O
(	O
austere	O
,	O
16	O
event	O
;	O
medium	O
,	O
4	O
event	O
;	O
balmy	O
,	O
ternion	O
event	O
)	O
.	O

We	O
mutations	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B
IVA	I
patients	O
(	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
intermediate	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O

We	O
take	O
mutations	O
in	O
the	O
GALNS	O
cistron	O
from	O
23	O
extra	O
mp	B
iva	I
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
northerly	O
Ireland	O
)	O
,	O
with	O
several	O
clinical	O
phenotypes	O
(	O
knockout	O
,	O
sixteen	O
cases	O
;	O
intercede	O
,	O
quaternity	O
cases	O
;	O
soft	O
,	O
iii	O
cases	O
)	O
.	O

;	O
with	O
mutations	O
in	O
Australia	O
GALNS	O
cases	O
16	O
23	O
additional	O
MPS	B
IVA	I
patients	O
gene	O
,	O
from	O
the	O
15	O
8	O
from	O
from	O
Ireland	O
)	O
,	O
phenotypes	O
various	O
clinical	O
3	O
.	O
severe	O
(	O
studied	O
cases	O
;	O
intermediate	O
,	O
4	O
(	O
We	O
mild	O
,	O
Northern	O
cases	O
)	O
,	O

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B
IVA	I
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
sheath	O
sheath	O
	O
sheath	O
australia	O
	O
sheath	O
australia	O
australia	O
australia	O
australia	O
australia	O
australia	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O

We	O
study	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
xxiii	O
additional	O
mps	B
iva	I
patients	O
(	O
fifteen	O
from	O
Australia	O
,	O
eight	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
several	O
clinical	O
phenotypes	O
(	O
stern	O
,	O
xvi	O
face	O
;	O
intercede	O
,	O
foursome	O
face	O
;	O
meek	O
,	O
3	O
face	O
)	O
.	O

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B
IVA	I
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O

We	O
observe	O
ii	O
vernacular	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O

We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
	O
	O
	O
	O
	O
	O
patients	O
.	O

We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
	O
	O
	O
	O
	O
	O
patients	O
.	O

two	O
that	O
together	O
accounted	O
32	O
%	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O

We	O
found	O
two	O
common	O
mutations	O
accounted	O
for	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O

two	O
common	O
mutations	O
that	O
accounted	O
for	O
32	O
%	O
of	O
44	O
unrelated	O
alleles	O
in	O
patients	O
.	O

these	O
found	O
two	O
patients	O
mutations	O
that	O
together	O
for	O
accounted	O
32	O
unrelated	O
of	O
the	O
.	O
We	O
alleles	O
in	O
%	O
common	O
44	O

We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
	O
	O
	O
	O
	O
	O
patients	O
.	O

We	O
plant	O
two	O
unwashed	O
sport	O
that	O
unitedly	O
accounted	O
for	O
32	O
%	O
of	O
the	O
xliv	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O

in	O
found	O
two	O
common	O
mutations	O
that	O
44	O
of	O
for	O
32	O
%	O
unrelated	O
We	O
together	O
accounted	O
these	O
the	O
alleles	O
patients	O
.	O

We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O

One	O
mutation	O
the	O
T312S	O
is	O
,	O
novel	O
exclusively	O
mutation	O
found	O
milder	O
in	O
a	O
patients	O
.	O

One	O
is	O
ampere	O
fresh	O
sport	O
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
fresh	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O

unrivaled	O
is	O
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
ground	O
entirely	O
in	O
meek	O
patients	O
.	O

milder	O
is	O
the	O
One	O
novel	O
,	O
a	O
in	O
mutation	O
found	O
exclusively	O
mutation	O
T312S	O
patients	O
.	O

peerless	O
is	O
the	O
T312S	O
mutant	O
,	O
a	O
novel	O
mutant	O
bump	O
alone	O
in	O
milder	O
patients	O
.	O

One	O
is	O
ampere	O
fresh	O
sport	O
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
sport	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O

One	O
the	O
mutation	O
a	O
novel	O
mutation	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O

novel	O
T312S	O
the	O
is	O
mutation	O
,	O
found	O
One	O
mutation	O
a	O
exclusively	O
in	O
milder	O
.	O
patients	O

nonpareil	O
is	O
the	O
T312S	O
sport	O
,	O
a	O
new	O
sport	O
found	O
solely	O
in	O
milder	O
patients	O
.	O

One	O
is	O
ampere	O
fresh	O
sport	O
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
sport	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O

One	O
is	O
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O

The	O
is	O
the	O
described	O
that	O
a	O
severe	O
phenotype	O
.	O

The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
a	O
severe	O
phenotype	O

The	O
other	O
is	O
the	O
antecedently	O
draw	O
I113F	O
that	O
produces	O
a	O
stern	O
phenotype	O
.	O

The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
terrible	O
former	O
former	O
a	O
severe	O
phenotype	O
.	O

The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
terrible	O
former	O
account	O
a	O
severe	O
phenotype	O
.	O

The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
terrible	O
former	O
former	O
a	O
severe	O
phenotype	O
.	O

The	O
other	O
is	O
the	O
antecedently	O
discover	O
I113F	O
that	O
produces	O
a	O
stern	O
phenotype	O
.	O

The	O
other	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
a	O
.	O

The	O
other	O
is	O
the	O
antecedently	O
delineate	O
I113F	O
that	O
produces	O
a	O
grievous	O
phenotype	O
.	O

The	O
previously	O
is	O
the	O
.	O
described	O
I113F	O
other	O
produces	O
a	O
severe	O
phenotype	O
that	O

The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
a	O
severe	O
phenotype	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
allele	O
	O
severally	O
allele	O
severally	O
severally	O
	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O
.	O

T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
44	O
alleles	O
,	O
respectively	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
calculate	O
for	O
octet	O
(	O
18	O
%	O
)	O
and	O
vi	O
(	O
14	O
%	O
)	O
of	O
xliv	O
unrelated	O
allelomorph	O
,	O
severally	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
)	O
and	O
(	O
14	O
%	O
)	O
of	O
44	O
unrelated	O
respectively	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
allele	O
	O
severally	O
allele	O
severally	O
severally	O
fourteen	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
calculate	O
for	O
octonary	O
(	O
18	O
%	O
)	O
and	O
sixer	O
(	O
fourteen	O
%	O
)	O
of	O
44	O
unrelated	O
allelomorph	O
,	O
severally	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
eight	O
(	O
18	O
%	O
)	O
and	O
sextuplet	O
(	O
14	O
%	O
)	O
of	O
44	O
unrelated	O
alleles	O
,	O
severally	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
and	O
14	O
%	O
)	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
allele	O
	O
severally	O
allele	O
severally	O
severally	O
fourteen	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O
.	O

44	O
I113F	O
and	O
%	O
mutations	O
accounted	O
for	O
of	O
respectively	O
18	O
T312S	O
)	O
6	O
and	O
,	O
14	O
%	O
)	O
8	O
.	O
unrelated	O
alleles	O
(	O
(	O
The	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O
.	O

The	O
relatively	O
high	O
residual	O
cost	O
patient	O
indium	O
sport	O
cubicle	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
indium	O
patient	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
toll	O
complementary	O
dna	O

The	O
relatively	O
high	O
residual	O
cost	O
patient	O
indium	O
sport	O
cubicle	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
indium	O
action	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
toll	O
complementary	O
dna	O

mutation	O
relatively	O
in	O
in	O
GALNS	O
activity	O
this	O
when	O
residual	O
T312S	O
mutant	O
cDNA	O
for	O
overexpressed	O
high	O
the	O
cells	O
provides	O
an	O
explanation	O
is	O
the	O
mild	O
phenotype	O
mutant	O
seen	O
with	O
patients	O
The	O
.	O

The	O
relatively	O
high	O
residual	O
cost	O
patient	O
indium	O
sport	O
cubicle	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
indium	O
patient	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
toll	O
complementary	O
dna	O

The	O
relatively	O
high	O
residual	O
GALNS	O
activity	O
seen	O
the	O
T312S	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
.	O

The	O
comparatively	O
high	O
remainder	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
an	O
account	O
for	O
the	O
meek	O
phenotype	O
in	O
patients	O
with	O
this	O
mutant	O
.	O

cells	O
relatively	O
high	O
residual	O
GALNS	O
activity	O
the	O
cDNA	O
the	O
T312S	O
mutant	O
The	O
mutation	O
phenotype	O
mutant	O
in	O
provides	O
in	O
an	O
explanation	O
for	O
seen	O
mild	O
overexpressed	O
when	O
patients	O
with	O
this	O
is	O
.	O

for	O
relatively	O
high	O
an	O
GALNS	O
activity	O
seen	O
patients	O
phenotype	O
T312S	O
mutation	O
cDNA	O
with	O
explanation	O
mild	O
mutant	O
cells	O
provides	O
residual	O
overexpressed	O
in	O
the	O
in	O
the	O
The	O
when	O
is	O
this	O
mutant	O
.	O

The	O
comparatively	O
luxuriously	O
residuary	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
variation	O
cdna	O
is	O
overexpressed	O
in	O
variation	O
cells	O
provides	O
an	O
account	O
for	O
the	O
modest	O
phenotype	O
in	O
patients	O
with	O
this	O
variation	O
.	O

The	O
relatively	O
high	O
residual	O
GALNS	O
seen	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
provides	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
with	O
this	O
mutation	O

The	O
relatively	O
high	O
residual	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
.	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
T312S	O
mutations	O
in	O
corresponded	O
those	O
observed	O
in	O
and	O
two	O
populations	O
,	O
that	O
both	O
were	O
probably	O
introduced	O
by	O
Irish	O
migrants	O
during	O
the	O
century	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
in	O
Australia	O
corresponded	O
to	O
those	O
are	O
these	O
populations	O
,	O
suggesting	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
migrants	O
during	O
the	O
19th	O
century	O
.	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
th	O
	O
irish	O
people	O
th	O
	O
frequency	O
th	O
	O
frequency	O
frequency	O
frequency	O
frequency	O
cost	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
th	O
	O
irish	O
people	O
th	O
	O
frequency	O
th	O
	O
frequency	O
frequency	O
frequency	O
frequency	O
frequency	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O

The	O
distribution	O
and	O
congeneric	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
sport	O
in	O
Australia	O
tally	O
to	O
those	O
observed	O
in	O
northern	O
Ireland	O
and	O
are	O
singular	O
to	O
these	O
ii	O
populations	O
,	O
propose	O
that	O
both	O
sport	O
were	O
belike	O
introduced	O
to	O
Australia	O
by	O
Irish	O
migrator	O
during	O
the	O
nineteenth	O
century	O
.	O

The	O
and	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutations	O
were	O
introduced	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O

The	O
distribution	O
and	O
proportional	O
frequency	O
of	O
the	O
I113F	O
and	O
T312S	O
sport	O
in	O
australia	O
match	O
to	O
those	O
discovered	O
in	O
northern	O
hibernia	O
and	O
are	O
unequaled	O
to	O
these	O
deuce	O
populations	O
,	O
suggesting	O
that	O
both	O
sport	O
were	O
likely	O
innovate	O
to	O
australia	O
by	O
Irish	O
migrants	O
during	O
the	O
nineteenth	O
century	O
.	O

Irish	O
these	O
and	O
relative	O
observed	O
of	O
by	O
mutations	O
and	O
T312S	O
mutations	O
in	O
Australia	O
the	O
in	O
those	O
frequencies	O
to	O
Northern	O
Ireland	O
I113F	O
are	O
unique	O
to	O
,	O
two	O
populations	O
the	O
.	O
that	O
suggesting	O
distribution	O
were	O
probably	O
introduced	O
to	O
Australia	O
corresponded	O
The	O
migrants	O
during	O
and	O
19th	O
century	O
both	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
th	O
	O
irish	O
people	O
th	O
	O
frequency	O
th	O
	O
frequency	O
frequency	O
frequency	O
frequency	O
frequency	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O

The	O
dispersion	O
and	O
congenator	O
oftenness	O
of	O
the	O
I113F	O
and	O
T312S	O
mutant	O
in	O
Australia	O
tally	O
to	O
those	O
honor	O
in	O
northerly	O
ireland	O
and	O
are	O
unequaled	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutant	O
were	O
credibly	O
enter	O
to	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
nineteenth	O
hundred	O
.	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O
.	O

I113F	O
analysis	O
using	O
data	O
RFLPs	O
provides	O
additional	O
6	O
a	O
the	O
from	O
mutation	O
Haplotype	O
originated	O
that	O
common	O
ancestor	O
.	O

haplotype	O
analysis	O
using	O
sixer	O
RFLPs	O
cater	O
additional	O
data	O
that	O
the	O
I113F	O
sport	O
uprise	O
from	O
a	O
common	O
ancestor	O
.	O

Haplotype	O
analysis	O
expend	O
six	O
RFLPs	O
provides	O
extra	O
datum	O
that	O
the	O
I113F	O
variation	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

Haplotype	O
analysis	O
using	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

haplotype	O
analysis	O
using	O
six	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
develop	O
from	O
a	O
vernacular	O
ascendant	O
.	O

Haplotype	O
analysis	O
expend	O
using	O
6	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor	O
drop	O
drop	O
drop	O
datum	O
.	O

Haplotype	O
analysis	O
using	O
6	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
mutation	O
originated	O
a	O
common	O
ancestor	O
.	O

Haplotype	O
analysis	O
expend	O
using	O
6	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor	O
drop	O
drop	O
drop	O
datum	O
.	O

analysis	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
.	O

Haplotype	O
analysis	O
that	O
a	O
RFLPs	O
provides	O
originated	O
data	O
using	O
the	O
I113F	O
mutation	O
additional	O
from	O
6	O
common	O
ancestor	O
.	O

Haplotype	O
analysis	O
using	O
6	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

were	O
other	O
9	O
these	O
mutations	O
identified	O
in	O
novel	O
a	O
patients	O
to	O
each	O
The	O
limited	O
23	O
single	O
family	O
.	O

The	O
other	O
nine	O
new	O
mutations	O
place	O
in	O
these	O
23	O
patients	O
were	O
each	O
confine	O
to	O
a	O
undivided	O
family	O
.	O

The	O
other	O
9	O
refreshing	O
sport	O
describe	O
in	O
these	O
23	O
patients	O
were	O
each	O
modified	O
to	O
a	O
one	O
family	O
.	O

The	O
other	O
9	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family	O
.	O

The	O
other	O
9	O
fresh	O
mutations	O
name	O
in	O
these	O
xxiii	O
patients	O
were	O
each	O
throttle	O
to	O
a	O
single	O
phratry	O
.	O

The	O
other	O
	O
9	O
novel	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family	O
	O
	O
	O
	O
.	O

The	O
other	O
9	O
novel	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
each	O
limited	O
a	O
single	O
family	O
.	O

The	O
other	O
	O
9	O
novel	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family	O
	O
	O
	O
	O
.	O

other	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
.	O

The	O
other	O
23	O
a	O
mutations	O
identified	O
limited	O
these	O
9	O
patients	O
were	O
each	O
in	O
to	O
novel	O
single	O
family	O
.	O

The	O
other	O
9	O
novel	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family	O
.	O

These	O
data	O
provide	O
further	O
indium	O
brits	O
migrator	O
irish	O
people	O
prove	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	B
MPS	I
IVA	O
in	O
British	O
-	O
Irish	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
.	O
in	O
in	O
in	O
marsh	O

These	O
data	O
evidence	O
in	O
MPS	B
IVA	I
British	O
-	O
patients	O
and	O
provide	O
their	O
transmission	O
to	O
Australia	O
by	O
-	O
migrants	O
.	O
.	O

These	O
data	O
ply	O
further	O
prove	O
for	O
extensive	O
allelomorphic	O
heterogeneousness	O
in	O
MPS	B
IVA	I
in	O
brits	O
-	O
Irish	O
patients	O
and	O
ply	O
prove	O
for	O
their	O
contagion	O
to	O
Australia	O
by	O
brits	O
-	O
Irish	O
migrants	O
.	O
.	O

These	O
data	O
provide	O
further	O
for	O
heterogeneity	O
in	O
MPS	B
IVA	I
in	O
British	O
-	O
Irish	O
patients	O
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
.	O
.	O

These	O
information	O
render	O
further	O
manifest	O
for	O
extended	O
allelic	O
heterogeneousness	O
in	O
MPS	B
iva	I
in	O
brits	O
-	O
Irish	O
patients	O
and	O
render	O
manifest	O
for	O
their	O
transmittal	O
to	O
Australia	O
by	O
brits	O
-	O
Irish	O
migrator	O
.	O
.	O

These	O
data	O
provide	O
further	O
indium	O
brits	O
migrator	O
irish	O
people	O
prove	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	B
MPS	I
IVA	O
in	O
British	O
-	O
Irish	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
.	O
in	O
in	O
in	O
marsh	O

These	O
data	O
cater	O
further	O
grounds	O
for	O
blanket	O
allelomorphic	O
heterogeneousness	O
in	O
MPS	B
IVA	I
in	O
brits	O
-	O
Irish	O
patients	O
and	O
cater	O
grounds	O
for	O
their	O
transmittance	O
to	O
Australia	O
by	O
brits	O
-	O
Irish	O
migrants	O
.	O
.	O

for	O
provide	O
provide	O
further	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	O
MPS	B
IVA	I
in	O
Australia	O
migrants	O
Irish	O
patients	O
and	O
-	O
evidence	O
data	O
their	O
.	O
to	O
British	O
by	O
British	O
These	O
-	O
transmission	O
.	O
Irish	O

These	O
data	O
provide	O
further	O
for	O
allelic	O
heterogeneity	O
in	O
MPS	B
IVA	I
in	O
British	O
-	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
by	O
British	O
-	O
migrants	O
.	O

These	O
data	O
provide	O
further	O
indium	O
brits	O
migrator	O
irish	O
people	O
datum	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	B
MPS	I
IVA	O
in	O
British	O
-	O
Irish	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
.	O
in	O
in	O
in	O
marsh	O

These	O
data	O
provide	O
further	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	O
MPS	B
IVA	I
in	O
British	O
-	O
Irish	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
.	O
.	O

identification	O
of	O
constitutional	O
WT1	O
sport	O
,	O
in	O
patients	O
with	O
insulate	O
disseminate	B
mesangial	I
induration	I
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
apply	O
of	O
a	O
cybernate	O
mutation	O
database	O
.	O

Identification	O
of	O
constitutional	O
WT1	O
mutations	O
in	O
isolated	O
diffuse	B
mesangial	I
sclerosis	I
,	O
and	O
analysis	O
of	O
genotype	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O
.	O

correlations	O
of	O
constitutional	O
/	O
mutations	O
,	O
in	O
computerized	O
of	O
isolated	O
.	B
mesangial	I
sclerosis	I
phenotype	O
use	O
analysis	O
of	O
genotype	O
WT1	O
,	O
a	O
by	O
and	O
with	O
Identification	O
patients	O
mutation	O
database	O
diffuse	O

Identification	O
of	O
constitutional	O
WT1	O
induration	O
sport	O
sport	O
depth	O
psychology	O
sport	O
mutations	O
,	O
in	O
patients	O
with	O
isolated	B
diffuse	I
mesangial	I
sclerosis	O
,	O
and	O
analysis	O
of	O
genotype	O
cybernate	O
sport	O
depth	O
psychology	O
/	O
phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O

Identification	O
of	O
constitutional	O
WT1	O
induration	O
sport	O
sport	O
depth	O
psychology	O
sport	O
mutations	O
,	O
in	O
patients	O
with	O
isolated	B
diffuse	I
mesangial	I
sclerosis	O
,	O
and	O
analysis	O
of	O
genotype	O
cybernate	O
sport	O
sport	O
/	O
phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O

Identification	O
of	O
constitutional	O
WT1	O
mutations	O
,	O
in	O
patients	O
isolated	O
diffuse	B
sclerosis	I
,	O
and	O
analysis	O
of	O
genotype	O
/	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O
.	O

.	O
of	O
constitutional	O
and	O
mutations	O
,	O
computerized	O
patients	O
WT1	O
isolated	O
diffuse	B
mesangial	I
mutation	I
,	O
a	O
with	O
of	O
genotype	O
/	O
phenotype	O
sclerosis	O
by	O
use	O
of	O
analysis	O
in	O
correlations	O
database	O
Identification	O

Identification	O
of	O
constitutional	O
WT1	O
mutations	O
,	O
in	O
patients	O
isolated	O
mesangial	I
sclerosis	I
,	O
and	O
analysis	O
of	O
genotype	O
/	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O

recognition	O
of	O
organic	O
WT1	O
mutations	O
,	O
in	O
patients	O
with	O
disjunct	O
broadcast	B
mesangial	I
induration	I
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
expend	O
of	O
a	O
computerise	O
sport	O
database	O
.	O

recognition	O
of	O
constitutive	O
WT1	O
variation	O
,	O
in	O
patients	O
with	O
separated	O
circulate	B
mesangial	I
induration	I
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O
.	O

Identification	O
of	O
constitutional	O
WT1	O
mutations	O
,	O
in	O
patients	O
with	O
isolated	O
diffuse	B
mesangial	I
sclerosis	I
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O
.	O

Constitutional	O
mutations	O
of	O
WT1	O
,	O
encoding	O
a	O
finger	O
renal	O
and	O
gonadal	O
,	O
are	O
in	O
most	O
patients	O
-	I
Drash	I
syndrome	I
(	O
DDS	B
,	O
diffuse	B
mesangial	I
sclerosis	I
(	O
DMS	B
)	O
associated	O
with	O
pseudohermaphroditism	B
and	O
or	O
Wilms	B
tumor	I
(	O
WT	B

,	O
with	O
of	O
the	O
WT1	O
gene	O
)	O
encoding	O
a	O
zinc	O
-	O
DMS	O
transcription	O
Denys	O
-	O
in	O
renal	O
and	O
mutations	O
development	O
,	O
are	O
)	O
in	O
with	O
patients	O
/	O
factor	B
Wilms	I
gonadal	I
syndrome	I
or	O
DDS	B
involved	O
Constitutional	O
.	O
diffuse	B
mesangial	I
sclerosis	I
(	O
finger	B
,	O
associated	O
found	O
pseudohermaphroditism	B
and	O
Drash	O
or	O
most	B
tumor	I
(	O
WT	B
)	O
(	O

tumor	O
most	O
of	O
the	O
WT1	O
gene	O
mesangial	O
renal	O
a	O
zinc	O
-	O
finger	O
transcription	O
(	O
WT	O
in	O
encoding	O
/	O
gonadal	O
development	O
.	O
are	O
found	O
in	O
Denys	O
patients	O
with	O
)	B
pseudohermaphroditism	I
Drash	I
-	I
,	O
DDS	B
)	O
,	O
or	O
diffuse	B
Wilms	I
(	I
(	O
DMS	B
,	O
associated	O
with	O
syndrome	B
and	O
and	O
or	O
sclerosis	B
Constitutional	I
factor	O
involved	B
)	O
mutations	O

Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene	O
,	O
encoding	O
abnegate	O
thumb	O
recording	O
element	O
need	O
ampere	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
DDS	B
)	O
,	O
or	O
colligate	O
dm	O
operating	O
theatre	O
colligate	O
neoplasm	O
operating	O
theatre	O
nephritic	O
neoplasm	O
operating	B
theatre	I
built	I
in	O
diffuse	B
mesangial	O
sclerosis	O
(	O
DMS	B
)	O
associated	O
with	O
pseudohermaphroditism	B
and	I
/	O
or	B
Wilms	O
tumor	O

constitutive	O
variation	O
of	O
the	O
WT1	O
cistron	O
,	O
encryption	O
a	O
zinc	O
-	O
feel	O
arranging	O
factor	O
byzantine	O
in	O
nephritic	O
and	O
gonadal	O
maturation	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
refuse	B
-	I
Drash	I
syndrome	I
(	O
DDS	B
)	O
,	O
or	O
circulate	B
mesangial	I
induration	I
(	O
dm	B
)	O
colligate	O
with	O
pseudohermaphroditism	B
and	O
/	O
or	O
Wilms	B
tumour	I
(	O
WT	B
)	O
.	O

inbuilt	O
variation	O
of	O
the	O
WT1	O
cistron	O
,	O
encryption	O
a	O
zn	O
-	O
finger	O
transcription	O
constituent	O
require	O
in	O
nephritic	O
and	O
gonadal	O
maturation	O
,	O
are	O
establish	O
in	O
most	O
patients	O
with	O
refuse	B
-	I
Drash	I
syndrome	I
(	O
dd	B
)	O
,	O
or	O
disperse	B
mesangial	I
induration	I
(	O
dm	B
)	O
associated	O
with	O
pseudohermaphroditism	B
and	O
/	O
or	O
Wilms	B
neoplasm	I
(	O
WT	B
)	O
.	O

inherent	O
mutations	O
of	O
the	O
WT1	O
cistron	O
,	O
encode	O
a	O
zinc	O
-	O
finger	O
recording	O
cistron	O
ask	O
in	O
nephritic	O
and	O
gonadal	O
maturation	O
,	O
are	O
detect	O
in	O
most	O
patients	O
with	O
abnegate	B
-	I
Drash	I
syndrome	I
(	O
dds	B
)	O
,	O
or	O
interpenetrate	B
mesangial	I
induration	I
(	O
decimetre	B
)	O
colligate	O
with	O
pseudohermaphroditism	B
and	O
/	O
or	O
Wilms	B
neoplasm	I
(	O
WT	B
)	O
.	O

the	O
,	O
a	O
zinc	O
-	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B
Drash	I
syndrome	I
)	O
,	O
or	O
mesangial	I
DMS	B
)	O
associated	O
with	O
pseudohermaphroditism	B
and	O
/	O
WT	B
.	O

Constitutional	O
of	O
gene	O
,	O
encoding	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
DDS	B
,	O
diffuse	B
mesangial	I
sclerosis	I
(	O
DMS	B
)	O
associated	O
with	O
and	O
/	O
or	O
Wilms	B
tumor	I
(	O
WT	B

Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene	O
,	O
encoding	O
abnegate	O
thumb	O
recording	O
element	O
need	O
ampere	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
DDS	B
)	O
,	O
or	O
colligate	O
dm	O
operating	O
theatre	O
colligate	O
neoplasm	O
operating	O
theatre	O
nephritic	O
neoplasm	O
operating	B
theatre	I
nephritic	I
diffuse	O
mesangial	B
sclerosis	O
(	O
DMS	O
)	B
associated	O
with	O
pseudohermaphroditism	O
and	B
/	I
or	O
Wilms	B
tumor	O
(	O

Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene	O
,	O
encoding	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
DDS	B
)	O
,	O
or	O
diffuse	B
mesangial	I
sclerosis	I
(	O
DMS	B
)	O
associated	O
with	O
pseudohermaphroditism	B
and	O
/	O
or	O
Wilms	B
tumor	I
(	O
WT	B
)	O
.	O

in	O
lie	O
in	O
exon	O
8	O
exon	O
9	O
zinc	O
finger	O
or	O
zinc	O
respectively	O
with	O
a	O
hot	O
(	O
R394W	O
)	O
exon	O
9	O
.	O

Most	O
mutations	O
in	O
DDS	B
thumb	O
indium	O
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3	O
,	O
respectively	O
,	O
with	O
a	O
hot	O
spot	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
pollex	O
pollex	O
pollex	O
pollex	O
pollex	O
pollex	O
pollex	O
zn	O
.	O

with	O
zinc	O
in	O
DDS	B
patients	O
lie	O
hot	O
exon	O
8	O
or	O
exon	O
9	O
,	O
spot	O
R394W	O
finger	O
2	O
or	O
9	O
finger	O
3	O
,	O
in	O
,	O
Most	O
a	O
in	O
encoding	O
zinc	O
respectively	O
)	O
(	O
exon	O
.	O
mutations	O

nigh	O
mutant	O
in	O
dd	B
patients	O
lie	O
in	O
exon	O
viii	O
or	O
exon	O
ix	O
,	O
encode	O
zinc	O
digit	O
2	O
or	O
zinc	O
digit	O
threesome	O
,	O
severally	O
,	O
with	O
a	O
spicy	O
spot	O
(	O
R394W	O
)	O
in	O
exon	O
ix	O
.	O

Most	O
mutations	O
a	O
DDS	B
patients	O
lie	O
in	O
,	O
8	O
or	O
exon	O
,	O
spot	O
encoding	O
zinc	O
)	O
2	O
or	O
finger	O
9	O
3	O
exon	O
respectively	O
zinc	O
with	O
hot	O
in	O
exon	O
(	O
R394W	O
finger	O
,	O
in	O
9	O
.	O

Most	O
mutations	O
in	O
DDS	B
patients	O
lie	O
in	O
exon	O
8	O
or	O
,	O
encoding	O
zinc	O
finger	O
or	O
zinc	O
finger	O
3	O
,	O
,	O
with	O
a	O
hot	O
(	O
R394W	O
in	O
exon	O
9	O
.	O

almost	O
mutations	O
in	O
dd	B
patients	O
prevarication	O
in	O
exon	O
octad	O
or	O
exon	O
9	O
,	O
encode	O
zinc	O
digit	O
ii	O
or	O
zinc	O
digit	O
3	O
,	O
severally	O
,	O
with	O
a	O
blistering	O
recognize	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
.	O

Most	O
mutations	O
in	O
DDS	B
thumb	O
patient	O
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3	O
,	O
respectively	O
,	O
with	O
a	O
hot	O
spot	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
pollex	O
pollex	O
pollex	O
pollex	O
pollex	O
pollex	O
pollex	O
zn	O
.	O

almost	O
sport	O
in	O
DDS	B
patients	O
prevarication	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zn	O
feel	O
ii	O
or	O
zn	O
feel	O
iii	O
,	O
severally	O
,	O
with	O
a	O
blistering	O
touch	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
.	O

spot	O
3	O
in	O
DDS	B
2	O
lie	O
zinc	O
in	O
8	O
or	O
exon	O
9	O
,	O
with	O
exon	O
finger	O
patients	O
)	O
zinc	O
finger	O
encoding	O
,	O
respectively	O
,	O
mutations	O
a	O
hot	O
Most	O
or	O
R394W	O
(	O
in	O
exon	O
9	O
.	O

Most	O
mutations	O
in	O
DDS	B
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3	O
,	O
respectively	O
,	O
with	O
a	O
hot	O
spot	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
.	O

We	O
analyzed	O
a	O
series	O
abnormalcy	O
sequester	O
	O
patient	O
	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	B
DMS	I
(	O
IDMS	B
)	O
,	O
10	O
with	O
abnormalcy	O
operating	O
theatre	B
DDS	O
,	O
and	O
4	O
with	B
urogenital	I
abnormalities	O
and	O
/	O
or	B
WT	O
abnormality	O
dm	O

We	O
analyzed	O
a	O
series	O
abnormalcy	O
sequester	O
	O
patient	O
	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	B
DMS	I
(	O
IDMS	B
)	O
,	O
10	O
with	O
abnormalcy	O
operating	O
theatre	B
DDS	O
,	O
and	O
4	O
with	B
urogenital	I
abnormalities	O
and	O
/	O
or	B
WT	O
abnormality	O
dm	O

WT	O
analyzed	O
abnormalities	O
)	O
of	O
24	O
or	O
,	O
series	O
with	O
isolated	B
DMS	I
and	O
IDMS	B
a	O
10	O
10	O
with	O
DDS	B
,	O
(	O
4	O
with	O
urogenital	B
,	I
patients	O
/	O
and	O
We	B
.	O

We	O
analyzed	O
a	O
series	O
abnormalcy	O
sequester	O
	O
patient	O
	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	B
DMS	I
(	O
IDMS	B
)	O
,	O
10	O
with	O
abnormalcy	O
operating	O
theatre	B
DDS	O
,	O
and	O
4	O
with	B
urogenital	I
abnormalities	O
and	O
/	O
or	B
WT	O
abnormality	O
dm	O

We	O
analyzed	O
a	O
series	O
of	O
24	O
patients	O
10	O
with	O
DMS	I
(	O
IDMS	B
)	O
,	O
10	O
with	O
and	O
4	O
with	O
urogenital	B
abnormalities	I
and	O
/	O
or	O
WT	B
.	O

We	O
analyzed	O
a	O
serial	O
of	O
xxiv	O
patients	O
,	O
decade	O
with	O
apart	B
dm	I
(	O
IDMS	B
)	O
,	O
decade	O
with	O
dd	B
,	O
and	O
quatern	O
with	O
urogenital	B
freakishness	I
and	O
/	O
or	O
WT	B
.	O

10	O
analyzed	O
a	O
series	O
of	O
24	O
4	O
DMS	O
10	O
with	O
isolated	B
We	I
WT	O
urogenital	B
,	O
)	O
with	O
abnormalities	O
DDS	B
,	O
and	O
patients	O
with	O
IDMS	B
,	I
and	O
/	O
or	O
(	B
.	O

and	O
analyzed	O
a	O
DDS	O
of	O
24	O
patients	O
and	O
urogenital	O
with	O
WT	B
DMS	I
/	O
,	B
with	O
,	O
10	O
with	O
series	B
IDMS	O
abnormalities	O
4	O
)	O
10	B
We	I
,	O
(	O
or	O
isolated	B
.	O

We	O
canvas	O
a	O
series	O
of	O
24	O
patients	O
,	O
ten	O
with	O
marooned	B
decimeter	I
(	O
IDMS	B
)	O
,	O
ten	O
with	O
dds	B
,	O
and	O
quaternary	O
with	O
urogenital	B
abnormalcy	I
and	O
/	O
or	O
WT	B
.	O

We	O
analyzed	O
a	O
series	O
of	O
patients	O
10	O
with	O
isolated	B
DMS	I
(	O
IDMS	B
)	O
,	O
with	O
DDS	B
,	O
and	O
4	O
with	O
urogenital	B
/	O
or	O
WT	B

We	O
analyzed	O
a	O
series	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	B
DMS	I
(	O
IDMS	B
)	O
,	O
10	O
with	O
DDS	B
,	O
and	O
4	O
with	O
urogenital	B
abnormalities	I
and	O
/	O
or	O
WT	B
.	O

We	O
report	O
sixteen	O
patient	O
introduce	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	O
IDMS	B
indium	O
.	O

with	O
report	O
WT1	O
.	O
mutations	O
in	O
16	O
patients	O
IDMS	O
4	O
of	O
whom	O
We	O
presented	O
,	B
heterozygous	O

We	O
report	O
sixteen	O
patient	O
write	O
up	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	B
IDMS	O
indium	O

We	O
describe	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
quatern	O
of	O
whom	O
confront	O
with	O
IDMS	B
.	O

presented	O
report	O
WT1	O
patients	O
mutations	O
in	O
with	O
heterozygous	O
,	O
4	O
We	O
whom	O
of	O
16	O
IDMS	B
.	O

We	O
report	O
sixteen	O
patient	O
introduce	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	O
IDMS	B
indium	O
.	O

We	O
report	O
WT1	O
heterozygous	O
mutations	O
in	O
sixteen	O
patients	O
,	O
four	O
of	O
whom	O
introduce	O
with	O
IDMS	B
.	O

We	O
report	O
WT1	O
heterozygous	O
variation	O
in	O
xvi	O
patients	O
,	O
quaternary	O
of	O
whom	O
stage	O
with	O
IDMS	B
.	O

We	O
report	O
,	O
.	O
mutations	O
in	O
presented	O
patients	O
WT1	O
4	O
of	O
whom	O
16	O
with	O
heterozygous	B
IDMS	O

report	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
of	O
whom	O
presented	O
with	O
IDMS	B
.	O

We	O
report	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	O
IDMS	B
.	O

One	O
and	O
female	O
patients	O
with	O
WT1	O
mutations	O
underwent	O
normal	O
puberty	O
.	O

nonpareil	O
male	O
and	O
two	O
distaff	O
IDMS	B
patients	O
with	O
WT1	O
mutations	O
undergo	O
convention	O
puberty	O
.	O

with	O
two	O
and	O
male	O
female	O
IDMS	B
mutations	O
One	O
WT1	O
.	O
underwent	O
normal	O
puberty	O
patients	O

One	O
male	O
and	O
two	O
female	O
IDMS	B
patients	O
with	O
mutations	O
underwent	O
puberty	O
.	O

One	O
male	O
pubescence	O
	O
and	O
two	O
female	O
IDMS	B
patients	O
with	O
WT1	O
pubescence	O
distaff	O
mutations	O
underwent	O
normal	O
puberty	O
.	O

One	O
male	O
pubescence	O
	O
and	O
two	O
female	O
IDMS	B
patients	O
with	O
WT1	O
pubescence	O
manlike	O
mutations	O
underwent	O
normal	O
puberty	O
.	O

unrivalled	O
male	O
and	O
ii	O
female	O
IDMS	B
patients	O
with	O
WT1	O
mutations	O
undergo	O
convention	O
puberty	O
.	O

puberty	O
male	O
and	O
One	O
with	O
IDMS	B
patients	O
normal	O
WT1	O
mutations	O
underwent	O
female	O
two	O
.	O

One	O
male	O
pubescence	O
	O
and	O
two	O
female	O
IDMS	B
patients	O
with	O
WT1	O
pubescence	O
distaff	O
mutations	O
underwent	O
normal	O
puberty	O
.	O

unity	O
male	O
and	O
deuce	O
female	O
IDMS	B
patients	O
with	O
WT1	O
variation	O
underwent	O
normal	O
pubescence	O
.	O

One	O
male	O
and	O
two	O
female	O
IDMS	B
patients	O
with	O
WT1	O
mutations	O
underwent	O
normal	O
puberty	O
.	O

Two	O
associated	O
IDMS	B
different	O
from	O
those	O
described	O
in	O
DDS	B
patients	O
.	O

deuce	O
mutations	O
associated	O
with	O
IDMS	B
are	O
dissimilar	O
from	O
those	O
described	O
in	O
DDS	B
patients	O
.	O

from	O
with	O
associated	O
mutations	O
IDMS	B
are	O
described	O
Two	O
those	O
.	O
in	O
DDS	B
patients	O
different	O

Two	O
mutations	O
associated	O
with	O
IDMS	B
are	O
different	O
from	O
described	O
in	O
patients	O
.	O

Two	O
mutations	O
colligate	O
colligate	O
associated	O
with	O
IDMS	B
are	O
different	O
from	O
those	O
patient	O
sport	O
described	O
in	O
DDS	B
patients	O
.	O

Two	O
mutations	O
colligate	O
colligate	O
associated	O
with	O
IDMS	B
are	O
different	O
from	O
those	O
patient	O
cost	O
described	O
in	O
DDS	B
patients	O
.	O

Two	O
mutant	O
link	O
with	O
IDMS	B
are	O
dissimilar	O
from	O
those	O
discover	O
in	O
DDS	B
patients	O
.	O

patients	O
mutations	O
associated	O
Two	O
from	B
are	O
different	O
DDS	O
those	O
described	O
in	O
IDMS	B
with	O
.	O

Two	O
mutations	O
colligate	O
colligate	O
associated	O
with	O
IDMS	B
are	O
different	O
from	O
those	O
patient	O
sport	O
described	O
in	O
DDS	B
patients	O
.	O

two	O
mutations	O
affiliate	O
with	O
IDMS	B
are	O
unlike	O
from	O
those	O
depict	O
in	O
DDS	B
patients	O
.	O

Two	O
mutations	O
associated	O
with	O
IDMS	B
are	O
different	O
from	O
those	O
described	O
in	O
DDS	B
patients	O
.	O

No	O
WT1	O
other	O
heterogeneity	O
detected	O
in	O
suggesting	O
six	O
mutations	O
IDMS	B
patients	O
,	O
the	O
genetic	O
were	O
of	O
this	O
disease	O
.	O

mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
of	O
this	O
disease	O
.	O

No	O
WT1	O
sport	O
were	O
find	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
,	O
evoke	O
inherited	O
heterogeneousness	O
of	O
this	O
disease	O
.	O

no	O
WT1	O
mutations	O
were	O
observe	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
,	O
intimate	O
inherited	O
heterogeneousness	O
of	O
this	O
disease	O
.	O

this	O
WT1	O
mutations	O
were	O
detected	O
in	O
genetic	O
heterogeneity	O
other	O
IDMS	B
patients	O
,	O
disease	O
the	O
six	O
of	O
suggesting	O
No	O
.	O

No	O
WT1	O
detected	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
.	O

No	O
WT1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	O
sport	O
sport	O
sport	O
sport	O
former	O
.	O

nobelium	O
WT1	O
mutations	O
were	O
notice	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
,	O
intimate	O
inherited	O
heterogeneousness	O
of	O
this	O
disease	O
.	O

No	O
WT1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	O
sport	O
sport	O
sport	O
sport	O
sport	O
.	O

genetic	O
WT1	O
mutations	O
patients	O
detected	O
in	O
the	O
.	O
heterogeneity	O
IDMS	B
were	O
,	O
No	O
suggesting	O
other	O
of	O
this	O
disease	O
six	O

No	O
WT1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	O
.	O

We	O
analyzed	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ	O
-	O
line	O
mutations	O
,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations	O
,	O
according	O
to	O
dissimilar	O
symptom	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
the	O
different	O
symptoms	O
.	O

We	O
analyzed	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ	O
-	O
line	O
mutations	O
,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations	O
,	O
according	O
to	O
dissimilar	O
symptom	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
the	O
different	O
symptoms	O
.	O

We	O
analyzed	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ	O
-	O
line	O
mutations	O
,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations	O
,	O
according	O
to	O
dissimilar	O
symptom	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
the	O
different	O
symptoms	O
.	O

,	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
the	O
,	O
the	O
basis	O
of	O
,	O
constitution	O
the	O
and	O
WT1	O
mutation	O
database	O
on	O
84	O
germ	O
mutations	O
distribution	O
mutations	O
We	O
to	O
of	O
of	O
a	O
line	O
type	O
to	O
-	O
analyzed	O
according	O
compare	O
the	O
different	O
symptoms	O
.	O

We	O
analyzed	O
genotype	O
/	O
on	O
the	O
basis	O
of	O
the	O
of	O
a	O
of	O
-	O
line	O
to	O
distribution	O
and	O
type	O
of	O
,	O
according	O
different	O
symptoms	O

We	O
analyzed	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
ground	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
sport	O
database	O
of	O
lxxxiv	O
source	O
-	O
line	O
mutations	O
,	O
to	O
comparability	O
the	O
dispersion	O
and	O
type	O
of	O
mutations	O
,	O
consort	O
to	O
the	O
dissimilar	O
symptoms	O
.	O

We	O
canvas	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
base	O
of	O
the	O
establishment	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
lxxxiv	O
seed	O
-	O
line	O
mutations	O
,	O
to	O
comparability	O
the	O
distribution	O
and	O
case	O
of	O
mutations	O
,	O
agree	O
to	O
the	O
dissimilar	O
symptoms	O
.	O

type	O
according	O
genotype	O
/	O
mutation	O
correlations	O
different	O
of	O
the	O
basis	O
of	O
the	O
constitution	O
,	O
database	O
WT1	O
phenotype	O
a	O
of	O
84	O
of	O
-	O
line	O
mutations	O
analyzed	O
to	O
compare	O
symptoms	O
We	O
and	O
distribution	O
,	O
mutations	O
,	O
germ	O
to	O
the	O
on	O
the	O
.	O

We	O
dissect	O
genotype	O
/	O
phenotype	O
correlativity	O
,	O
on	O
the	O
footing	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
variation	O
database	O
of	O
84	O
bug	O
-	O
line	O
sport	O
,	O
to	O
equate	O
the	O
dispersion	O
and	O
character	O
of	O
sport	O
,	O
according	O
to	O
the	O
unlike	O
symptoms	O
.	O

We	O
analyzed	O
type	O
/	O
phenotype	O
to	O
of	O
on	O
the	O
basis	O
,	O
compare	O
84	O
of	O
a	O
of	O
mutation	O
database	O
different	O
constitution	O
germ	O
-	O
line	O
correlations	O
,	O
WT1	O
the	O
mutations	O
of	O
and	O
genotype	O
the	O
distribution	O
,	O
according	O
mutations	O
the	O
to	O
symptoms	O
.	O

We	O
analyzed	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ	O
-	O
line	O
mutations	O
,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations	O
,	O
according	O
to	O
the	O
different	O
symptoms	O
.	O

This	O
demonstrated	O
(	O
1	O
)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
DMS	B
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	B
,	O
a	O
higher	O
frequency	O
of	O
exon	O
8	O
mutations	O
among	O
46	O
,	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
XY	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	O
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
preferentially	O
affect	O
amino	O
acids	O
with	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
different	O
functions	O
.	O
.	O

This	O
demonstrated	O
(	O
)	O
the	O
in	O
and	O
9	O
;	O
)	O
among	O
patients	O
with	O
,	O
a	O
of	O
exon	O
mutations	O
among	O
patients	O
female	O
phenotype	O
than	O
46	O
,	O
XY	O
with	O
sexual	O
ambiguity	O
or	O
male	O
and	O
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
exons	O
and	O
9	O
preferentially	O
amino	O
acids	O
with	O
different	O
functions	O
.	O

This	O
exon	O
(	O
in	O
exons	O
that	O
association	O
between	O
mutations	O
in	O
exons	O
)	O
and	O
and	O
and	O
46	B
;	O
(	O
2	O
)	O
9	O
male	O
with	O
with	B
(	O
a	O
higher	O
frequency	O
of	O
demonstrated	O
8	O
mutations	O
among	O
46	O
,	O
XY	O
female	O
DMS	O
patients	O
)	O
than	O
among	O
DMS	O
,	O
XY	O
patients	O
with	O
,	O
ambiguity	O
or	O
.	O
and	O
;	O
phenotype	O
8	O
3	O
8	O
statistically	O
significant	O
evidence	O
the	O
mutations	O
1	O
.	O
patients	O
9	O
among	O
preferentially	O
affect	O
amino	O
sexual	O
with	O
different	O
functions	O
acids	O
phenotype	O

This	O
march	O
(	O
1	O
)	O
the	O
connection	O
between	O
mutations	O
in	O
exons	O
eight	O
and	O
nine	O
and	O
DMS	B
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	B
,	O
a	O
mellow	O
oftenness	O
of	O
exon	O
eight	O
mutations	O
among	O
xlvi	O
,	O
xy	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
xlvi	O
,	O
xy	O
patients	O
with	O
intimate	O
equivocalness	O
or	O
manlike	O
phenotype	O
;	O
and	O
(	O
threesome	O
)	O
statistically	O
meaning	O
manifest	O
that	O
mutations	O
in	O
exons	O
eight	O
and	O
nine	O
preferentially	O
involve	O
amino	O
dose	O
with	O
unlike	O
mapping	O
.	O
.	O

This	O
(	O
1	O
)	O
the	O
mutations	O
exons	O
9	O
DMS	B
;	O
(	O
)	O
among	O
patients	O
,	O
a	O
higher	O
frequency	O
of	O
8	O
mutations	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
XY	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
3	O
significant	O
that	O
mutations	O
in	O
8	O
and	O
preferentially	O
amino	O
acids	O
with	O
different	O
.	O
.	O

affect	O
demonstrated	O
(	O
patients	O
)	O
the	O
association	O
mutations	O
mutations	O
in	O
exons	O
DMS	O
and	O
9	O
and	O
DMS	B
phenotype	O
(	O
2	O
)	O
among	O
patients	O
acids	O
8	B
,	O
,	O
(	O
frequency	O
of	O
with	O
8	O
mutations	O
among	O
46	O
exon	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
a	O
,	O
and	O
in	O
different	O
sexual	O
ambiguity	O
This	O
male	O
and	O
8	O
functions	O
higher	O
3	O
)	O
statistically	O
1	O
evidence	O
that	O
between	O
significant	O
exons	O
;	O
;	O
with	O
preferentially	O
or	O
46	O
.	O
9	O
with	O
XY	O
amino	O
.	O

3	O
higher	O
and	O
preferentially	O
)	O
the	O
association	O
between	O
among	O
in	O
exons	O
8	O
with	O
than	O
and	O
exons	B
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	B
,	O
a	O
ambiguity	O
(	O
XY	O
)	O
8	O
mutations	O
mutations	O
46	O
that	O
XY	O
patients	O
significant	O
female	O
phenotype	O
9	O
among	O
46	O
,	O
.	O
patients	O
with	O
sexual	O
demonstrated	O
1	O
male	O
phenotype	O
;	O
or	O
frequency	O
This	O
of	O
,	O
with	O
evidence	O
statistically	O
mutations	O
and	O
acids	O
8	O
and	O
9	O
amino	O
affect	O
(	O
DMS	O
in	O
different	O
functions	O
.	O
exon	O

This	O
certify	O
(	O
one	O
)	O
the	O
connection	O
between	O
variation	O
in	O
exons	O
eighter	O
and	O
9	O
and	O
decimeter	B
;	O
(	O
two	O
)	O
among	O
patients	O
with	O
decimeter	B
,	O
a	O
gamy	O
oftenness	O
of	O
exon	O
eighter	O
variation	O
among	O
46	O
,	O
xy	O
patients	O
with	O
distaff	O
phenotype	O
than	O
among	O
46	O
,	O
xy	O
patients	O
with	O
intimate	O
equivocalness	O
or	O
male	O
phenotype	O
;	O
and	O
(	O
iii	O
)	O
statistically	O
important	O
attest	O
that	O
variation	O
in	O
exons	O
eighter	O
and	O
9	O
preferentially	O
touch	O
amino	O
zen	O
with	O
unlike	O
affair	O
.	O
.	O

This	O
demonstrated	O
)	O
association	O
between	O
mutations	O
in	O
and	O
9	O
and	O
DMS	B
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	B
,	O
higher	O
exon	O
mutations	O
among	O
46	O
,	O
XY	O
with	O
female	O
phenotype	O
than	O
46	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	O
statistically	O
significant	O
evidence	O
that	O
in	O
exons	O
and	O
affect	O
with	O
different	O

This	O
demonstrated	O
(	O
1	O
)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
DMS	B
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	B
,	O
a	O
higher	O
frequency	O
of	O
exon	O
8	O
mutations	O
among	O
46	O
,	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
XY	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	O
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
preferentially	O
affect	O
amino	O
acids	O
with	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
	O
different	O
functions	O
.	O
.	O

This	O
demonstrated	O
(	O
1	O
)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
DMS	B
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	B
,	O
a	O
higher	O
frequency	O
of	O
exon	O
8	O
mutations	O
among	O
46	O
,	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
XY	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	O
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
preferentially	O
affect	O
amino	O
acids	O
with	O
different	O
functions	O
.	O
.	O

The	O
185delAG	O
BRCA1	O
sport	O
grow	O
before	O
the	O
scattering	O
of	O
jew	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
confine	O
to	O
ashkenazi	O
.	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
Ashkenazim	O
.	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
Ashkenazim	O
.	O

BRCA1	O
before	O
the	O
dispersion	O
Jews	O
in	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
Ashkenazim	O
.	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
dispersion	O
of	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
Ashkenazim	O
.	O

BRCA1	O
mutation	O
originated	O
before	O
dispersion	O
of	O
Jews	O
in	O
the	O
and	O
is	O
not	O
limited	O
Ashkenazim	O
.	O

to	O
185delAG	O
BRCA1	O
Ashkenazim	O
originated	O
before	O
the	O
of	O
dispersion	O
Jews	O
is	O
the	O
diaspora	O
.	O
The	O
not	O
limited	O
in	O
mutation	O
and	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
sport	O
sport	O
sport	O
sport	O
sport	O
dispersal	O
Ashkenazim	O
.	O

The	O
185delAG	O
BRCA1	O
mutant	O
uprise	O
before	O
the	O
dissemination	O
of	O
hebrew	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
express	O
to	O
ashkenazi	O
.	O

limited	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
and	O
the	O
of	O
Jews	O
in	O
is	O
The	O
the	O
dispersion	O
to	O
diaspora	O
not	O
Ashkenazim	O
.	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
Ashkenazim	O
.	O

The	O
185delAG	O
mutation	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
and	O
in	O
the	O
general	O
population	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	B
and	I
and	O
in	O
the	O
general	O
population	O
.	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
and	O
cosmopolitan	O
universe	O
universe	O
sport	O
sport	O
sport	O
in	O
the	O
general	O
population	O
.	O

The	O
185delAG	O
sport	O
in	O
BRCA1	O
is	O
detected	O
in	O
ashkenazi	O
jew	O
both	O
in	O
transmitted	B
titty	I
and	I
ovarian	I
cancer	I
and	O
in	O
the	O
general	O
universe	O
.	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
and	O
cosmopolitan	O
universe	O
universe	O
sport	O
sport	O
sport	O
in	O
the	O
general	O
population	O
.	O

The	O
185delAG	O
variation	O
in	O
BRCA1	O
is	O
discover	O
in	O
Ashkenazi	O
hebrew	O
both	O
in	O
transmitted	B
boob	I
and	I
ovarian	I
cancer	I
and	O
in	O
the	O
general	O
universe	O
.	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
in	O
familial	B
and	I
ovarian	I
cancer	I
and	O
in	O
the	O
general	O

both	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
Ashkenazi	O
in	O
Jews	O
the	O
in	O
breast	B
familial	I
.	I
ovarian	I
cancer	I
and	O
in	O
The	O
general	O
population	O
and	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
ashkenazi	O
jew	O
both	O
in	O
transmitted	B
summit	I
and	I
ovarian	I
cancer	I
and	O
in	O
the	O
oecumenical	O
universe	O
.	O

and	O
185delAG	O
Ashkenazi	O
detected	O
BRCA1	O
is	O
ovarian	O
in	O
mutation	O
Jews	O
both	O
in	O
general	B
breast	I
in	I
The	I
cancer	I
and	O
in	O
the	O
familial	O
population	O
.	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
and	O
in	O
the	O
general	O
population	O
.	O

All	O
carriers	O
Ashkenazi	O
mutation	O
tested	O
share	O
same	O
at	O
allelic	O
pattern	O
BRCA1	O
the	O
the	O
locus	O
.	O

All	O
tested	O
figure	O
saami	O
ashkenazi	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
saami	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
.	O

All	O
tested	O
Ashkenazi	O
variation	O
carriers	O
percentage	O
the	O
same	O
allelomorphic	O
pattern	O
at	O
the	O
BRCA1	O
venue	O
.	O

BRCA1	O
tested	O
Ashkenazi	O
All	O
same	O
share	O
the	O
the	O
allelic	O
pattern	O
at	O
carriers	O
mutation	O
locus	O
.	O

wholly	O
tested	O
Ashkenazi	O
mutant	O
carriers	O
share	O
the	O
same	O
allelomorphic	O
formula	O
at	O
the	O
BRCA1	O
locus	O
.	O

All	O
tested	O
figure	O
saami	O
ashkenazi	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
attack	O
aircraft	O
carrier	O
pattern	O
at	O
the	O
BRCA1	O

All	O
Ashkenazi	O
carriers	O
the	O
same	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
.	O

same	O
mutation	O
Ashkenazi	O
tested	O
carriers	O
share	O
pattern	O
All	O
allelic	O
the	O
at	O
the	O
BRCA1	O
.	O
locus	O

All	O
prove	O
ashkenazi	O
mutation	O
carriers	O
apportion	O
the	O
same	O
allelomorphic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
.	O

All	O
tested	O
figure	O
saami	O
ashkenazi	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
attack	O
aircraft	O
carrier	O
pattern	O
at	O
the	O
BRCA1	O

All	O
tested	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
.	O

Our	O
previous	O
also	O
a	O
that	O
this	O
Jews	O
mutation	O
study	O
occurs	O
in	O
Iraqi	O
Ashkenazi	O
with	O
showed	O
similar	O
allelic	O
pattern	O
.	O

study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
similar	O
allelic	O
pattern	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
sport	O
likewise	O
occurs	O
in	O
iraqi	O
israelite	O
with	O
a	O
similar	O
allelomorphic	O
pattern	O
.	O

Our	O
premature	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
besides	O
occurs	O
in	O
iraqi	O
hebrew	O
with	O
a	O
similar	O
allelomorphic	O
pattern	O
.	O

allelic	O
previous	O
study	O
showed	O
that	O
this	O
with	O
a	O
also	O
occurs	O
in	O
Iraqi	O
pattern	O
Ashkenazi	O
mutation	O
similar	O
Jews	O
Our	O
.	O

Our	O
previous	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
pattern	O
subject	O
area	O
subject	O
area	O
subject	O
area	O

Our	O
previous	O
study	O
showed	O
that	O
this	O
ashkenazi	O
mutation	O
also	O
occurs	O
in	O
iraqi	O
jew	O
with	O
a	O
alike	O
allelic	O
figure	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
pattern	O
subject	O
area	O
subject	O
area	O
subject	O
area	O

with	O
previous	O
study	O
in	O
that	O
this	O
Ashkenazi	O
.	O
a	O
occurs	O
showed	O
Iraqi	O
Our	O
Jews	O
also	O
similar	O
allelic	O
pattern	O
mutation	O

Our	O
previous	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
pattern	O
.	O

Jews	O
extended	O
our	O
354	O
to	O
other	O
non	O
150	O
,	O
subsets	O
analysis	O
of	O
origin	O
Moroccan	O
Ashkenazi	O
200	O
Yemenites	O
and	O
-	O
We	O
Iranian	O
.	O

We	O
extended	O
our	O
analysis	O
to	O
other	O
non	O
-	O
Ashkenazi	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
israelite	O
israelite	O
ashkenazi	O
ashkenazi	O
ashkenazi	O
ashkenazi	O
150	O
Iranian	O
Jews	O
.	O

We	O
extended	O
our	O
analysis	O
to	O
other	O
non	O
-	O
Ashkenazi	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
israelite	O
israelite	O
ashkenazi	O
ashkenazi	O
ashkenazi	O
ashkenazi	O
150	O
Iranian	O
Jews	O
.	O

We	O
extended	O
our	O
analysis	O
to	O
other	O
non	O
-	O
ashkenazi	O
subsets	O
354	O
of	O
maroc	O
descent	O
,	O
cc	O
Yemenites	O
and	O
cl	O
persian	O
Jews	O
.	O

We	O
extended	O
our	O
to	O
other	O
non	O
-	O
Ashkenazi	O
354	O
of	O
Moroccan	O
origin	O
200	O
Yemenites	O
150	O
Iranian	O
Jews	O
.	O

analysis	O
non	O
-	O
Ashkenazi	O
354	O
of	O
origin	O
,	O
200	O
Yemenites	O
and	O
150	O
Iranian	O
Jews	O
.	O

We	O
extended	O
our	O
analysis	O
to	O
other	O
not	O
-	O
ashkenazi	O
subsets	O
354	O
of	O
moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
150	O
persian	O
jew	O
.	O

,	O
extended	O
Ashkenazi	O
non	O
to	O
other	O
200	O
-	O
our	O
subsets	O
354	O
of	O
Jews	O
origin	O
analysis	O
We	O
Yemenites	O
and	O
150	O
Iranian	O
Moroccan	O
.	O

We	O
extended	O
our	O
analysis	O
to	O
other	O
non	O
-	O
Ashkenazi	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
israelite	O
israelite	O
ashkenazi	O
ashkenazi	O
ashkenazi	O
israelite	O
150	O
Iranian	O
Jews	O
.	O

We	O
extended	O
our	O
analysis	O
non	O
-	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
150	O
.	O

We	O
extended	O
our	O
analysis	O
to	O
other	O
non	O
-	O
Ashkenazi	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
150	O
Iranian	O
Jews	O
.	O

Heteroduplex	O
complemented	O
direct	O
sequencing	O
of	O
abnormally	O
migrating	O
bands	O
were	O
employed	O
.	O

Heteroduplex	O
analysis	O
complemented	O
by	O
channelise	O
dna	O
sequence	O
of	O
abnormally	O
migrating	O
bands	O
were	O
engage	O
.	O

of	O
by	O
complemented	O
analysis	O
direct	O
DNA	O
migrating	O
Heteroduplex	O
abnormally	O
.	O
bands	O
were	O
employed	O
sequencing	O

Heteroduplex	O
analysis	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
migrating	O
bands	O
employed	O
.	O

Heteroduplex	O
analysis	O
complement	O
complement	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
abnormally	O
engage	O
organise	O
migrating	O
bands	O
were	O
employed	O
.	O

Heteroduplex	O
analysis	O
complement	O
complement	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
abnormally	O
engage	O
dna	O
migrating	O
bands	O
were	O
employed	O
.	O

Heteroduplex	O
analysis	O
complemented	O
by	O
target	O
DNA	O
sequence	O
of	O
abnormally	O
migrating	O
set	O
were	O
use	O
.	O

employed	O
analysis	O
complemented	O
Heteroduplex	O
of	O
DNA	O
sequencing	O
were	O
abnormally	O
migrating	O
bands	O
direct	O
by	O
.	O

Heteroduplex	O
analysis	O
complement	O
complement	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
abnormally	O
engage	O
organise	O
migrating	O
bands	O
were	O
employed	O
.	O

Heteroduplex	O
analysis	O
complemented	O
by	O
manoeuvre	O
DNA	O
sequence	O
of	O
abnormally	O
transmigrate	O
bands	O
were	O
hire	O
.	O

Heteroduplex	O
analysis	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
abnormally	O
migrating	O
bands	O
were	O
employed	O
.	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
attack	O
aircraft	O
carrier	O
attack	O
aircraft	O
carrier	O
sport	O
moroccan	O
sport	O
sport	O
moroccan	O
a	O
carrier	O
of	O

origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
carrier	O
the	O
185delAG	O
mutation	O
.	O

iv	O
of	O
moroccan	O
bloodline	O
(	O
i	O
.	O
i	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
persian	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation	O
.	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
none	O
of	O
Yemenites	O
or	O
Iranians	O
was	O
a	O
carrier	O
of	O
mutation	O
.	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
attack	O
aircraft	O
carrier	O
attack	O
aircraft	O
carrier	O
sport	O
moroccan	O
sport	O
sport	O
moroccan	O
a	O
carrier	O
of	O

quaternion	O
of	O
moroccan	O
lineage	O
(	O
unity	O
.	O
unity	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
persian	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation	O
.	O

quartet	O
of	O
moroccan	O
line	O
(	O
ane	O
.	O
ane	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
persian	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutant	O
.	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
of	O
or	O
Iranians	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
attack	O
aircraft	O
carrier	O
attack	O
aircraft	O
carrier	O
sport	O
moroccan	O
sport	O
sport	O
moroccan	O
a	O
carrier	O
of	O

carrier	O
of	O
Moroccan	O
and	O
(	O
1	O
.	O
a	O
mutation	O
)	O
origin	O
none	O
the	O
of	O
185delAG	O
or	O
Iranians	O
was	O
1	O
.	O
of	O
the	O
Yemenites	O
%	O
Four	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation	O
.	O

BRCA1	O
allelomorphic	O
rule	O
were	O
define	O
for	O
quatern	O
of	O
these	O
individuals	O
and	O
for	O
dozen	O
extra	O
not	O
-	O
Ashkenazi	O
185delAG	O
sport	O
carriers	O
who	O
had	O
breast	B
/	I
ovarian	I
cancer	I
.	O

BRCA1	O
allelic	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
-	O
Ashkenazi	O
185delAG	O
mutation	O
who	O
had	O
breast	B
/	I
ovarian	I
.	O

BRCA1	O
allelic	O
patterns	O
were	O
not	O
	O
shape	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
Ashkenazi	O
185delAG	O
receive	O
summit	O
cancer	O
the	O
crab	O
figure	O
cost	O
mutation	O
carriers	O
who	B
had	I
breast	I
/	I
ovarian	O

who	O
allelic	O
patterns	O
mutation	O
determined	O
for	O
four	O
cancer	O
/	O
individuals	O
carriers	O
for	O
12	O
additional	O
breast	O
-	O
Ashkenazi	O
185delAG	O
were	O
ovarian	O
and	O
had	O
non	B
these	I
BRCA1	I
of	I
.	O

BRCA1	O
allelic	O
patterns	O
were	O
not	O
	O
shape	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
Ashkenazi	O
185delAG	O
receive	O
summit	O
cancer	O
the	O
crab	O
figure	O
cost	O
mutation	O
carriers	O
who	B
had	I
breast	I
/	I
ovarian	O

BRCA1	O
allelic	O
patterns	O
determined	O
for	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
Ashkenazi	O
185delAG	O
carriers	O
who	O
had	O
breast	B
/	I
ovarian	I
cancer	I
.	O

.	O
allelic	O
patterns	O
non	O
determined	O
for	O
cancer	O
of	O
were	O
individuals	O
and	O
for	O
additional	O
who	O
ovarian	O
these	O
Ashkenazi	O
185delAG	O
mutation	O
carriers	O
12	O
had	O
breast	B
/	I
-	I
four	I
BRCA1	O

patterns	O
for	O
four	O
of	O
individuals	O
and	O
12	O
additional	O
non	O
-	O
Ashkenazi	O
185delAG	O
mutation	O
carriers	O
who	O
had	O
breast	B
/	I
ovarian	I

/	O
allelic	O
patterns	O
were	O
determined	O
for	O
additional	O
for	O
these	O
individuals	O
and	O
Ashkenazi	O
had	O
four	O
ovarian	O
BRCA1	O
of	O
-	O
mutation	O
carriers	O
who	O
12	O
breast	B
185delAG	I
non	I
cancer	I
.	O

BRCA1	O
allelomorphic	O
patterns	O
were	O
determined	O
for	O
quaternity	O
of	O
these	O
someone	O
and	O
for	O
dozen	O
additional	O
not	O
-	O
Ashkenazi	O
185delAG	O
variation	O
bearer	O
who	O
had	O
tit	B
/	I
ovarian	I
cancer	I
.	O

BRCA1	O
allelic	O
patterns	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
Ashkenazi	O
185delAG	O
mutation	O
carriers	O
who	O
had	O
breast	B
/	I
ovarian	I
cancer	I
.	O

Six	O
non	O
-	O
Ashkenazi	O
ampere	O
close	O
colligate	O
somebody	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O

Six	O
non	O
-	O
shared	O
,	O
four	O
had	O
closely	O
related	O
,	O
and	O
the	O
n	O
=	O
6	O
)	O
displayed	O
distinct	O
allelic	O
pattern	O
.	O

Six	O
not	O
-	O
ashkenazi	O
individuals	O
shared	O
the	O
plebeian	O
ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
tight	O
colligate	O
convention	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
six	O
)	O
displayed	O
a	O
discrete	O
BRCA1	O
allelomorphic	O
convention	O
.	O

Six	O
non	O
-	O
Ashkenazi	O
individuals	O
shared	O
the	O
Ashkenazi	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
.	O

Six	O
not	O
-	O
Ashkenazi	O
somebody	O
apportion	O
the	O
green	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
intimately	O
related	O
rule	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
vi	O
)	O
exhibit	O
a	O
distinct	O
BRCA1	O
allelomorphic	O
rule	O
.	O

Six	O
non	O
-	O
Ashkenazi	O
ampere	O
close	O
colligate	O
somebody	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O

sextet	O
non	O
-	O
ashkenazi	O
mortal	O
shared	O
the	O
common	O
ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
tight	O
concern	O
design	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
expose	O
a	O
trenchant	O
BRCA1	O
allelomorphic	O
design	O
.	O

rest	O
and	O
-	O
Ashkenazi	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
6	O
BRCA1	O
related	O
pattern	O
,	O
a	O
the	O
non	O
(	O
pattern	O
=	O
a	O
)	O
displayed	O
Six	O
closely	O
n	O
allelic	O
distinct	O
.	O

Six	O
non	O
-	O
Ashkenazi	O
individuals	O
shared	O
common	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
a	O
distinct	O
BRCA1	O
pattern	O

Six	O
non	O
-	O
Ashkenazi	O
ampere	O
close	O
colligate	O
not	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O

Six	O
non	O
-	O
Ashkenazi	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
.	O

Ashkenazim	O
conclude	O
that	O
non	O
185delAG	O
BRCA1	O
mutation	O
that	O
at	O
some	O
the	O
-	O
populations	O
Ashkenazi	O
in	O
rates	O
comparable	O
with	O
occurs	O
We	O
of	O
.	O

We	O
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
ashkenazi	O
ashkenazi	O
indium	O
indium	O
indium	O
indium	O
that	O
of	O
Ashkenazim	O
.	O

We	O
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
ashkenazi	O
ashkenazi	O
indium	O
indium	O
indium	O
indium	O
that	O
of	O
Ashkenazim	O
.	O

We	O
resolve	O
that	O
the	O
185delAG	O
BRCA1	O
variation	O
come	O
in	O
some	O
non	O
-	O
ashkenazi	O
universe	O
at	O
rates	O
comparable	O
with	O
that	O
of	O
ashkenazi	O
.	O

We	O
conclude	O
that	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
non	O
-	O
Ashkenazi	O
populations	O
rates	O
comparable	O
that	O
of	O
Ashkenazim	O
.	O

the	O
mutation	O
occurs	O
in	O
non	O
-	O
populations	O
at	O
rates	O
comparable	O
with	O
that	O
of	O
Ashkenazim	O
.	O

We	O
resolve	O
that	O
the	O
185delAG	O
BRCA1	O
mutant	O
occurs	O
in	O
some	O
non	O
-	O
ashkenazi	O
populations	O
at	O
stag	O
like	O
with	O
that	O
of	O
ashkenazi	O
.	O

at	O
conclude	O
in	O
mutation	O
185delAG	O
BRCA1	O
rates	O
occurs	O
that	O
some	O
non	O
-	O
Ashkenazim	O
populations	O
the	O
We	O
comparable	O
with	O
that	O
of	O
Ashkenazi	O
.	O

We	O
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
ashkenazi	O
ashkenazi	O
indium	O
indium	O
indium	O
value	O
that	O
of	O
Ashkenazim	O
.	O

We	O
conclude	O
that	O
the	O
mutation	O
occurs	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
that	O
.	O

We	O
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
that	O
of	O
Ashkenazim	O
.	O

The	O
majority	O
of	O
Jewish	O
strength	O
subscribe	O
sport	O
beginner	O
force	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
effectiveness	O
effectiveness	O
effectiveness	O
figure	O
.	O

The	O
majority	O
185delAG	O
common	O
allelic	O
pattern	O
supporting	O
the	O
effect	O
notion	O
,	O
the	O
mutations	O
origin	O
to	O
an	O
date	O
currently	O
estimated	O
.	O

The	O
bulk	O
of	O
jewish	O
185delAG	O
variation	O
carriers	O
have	O
a	O
common	O
allelomorphic	O
formula	O
,	O
supporting	O
the	O
give	O
effect	O
whim	O
,	O
but	O
dating	O
the	O
mutations	O
stemma	O
to	O
an	O
sooner	O
date	O
than	O
currently	O
estimated	O
.	O

The	O
majority	O
of	O
Jewish	O
mutation	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
.	O

The	O
majority	O
of	O
judaic	O
185delAG	O
sport	O
mailman	O
have	O
a	O
uncouth	O
allelomorphic	O
pattern	O
,	O
supporting	O
the	O
flop	O
effect	O
whim	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earliest	O
date	O
than	O
presently	O
estimated	O
.	O

The	O
majority	O
of	O
Jewish	O
strength	O
subscribe	O
sport	O
beginner	O
force	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
effectiveness	O
effectiveness	O
effectiveness	O
figure	O
.	O

The	O
bulk	O
of	O
judaic	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelomorphic	O
pattern	O
,	O
supporting	O
the	O
beginner	O
outcome	O
belief	O
,	O
but	O
dating	O
the	O
mutant	O
origin	O
to	O
an	O
early	O
date	O
than	O
presently	O
estimated	O
.	O

dating	O
,	O
of	O
Jewish	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
to	O
currently	O
founder	O
effect	O
notion	O
date	O
but	O
majority	O
the	O
.	O
origin	O
supporting	O
an	O
earlier	O
The	O
the	O
mutations	O
estimated	O
than	O

The	O
majority	O
of	O
Jewish	O
mutation	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
an	O
earlier	O
date	O
currently	O
.	O

The	O
majority	O
of	O
Jewish	O
subscribe	O
to	O
subscribe	O
sport	O
beginner	O
subscribe	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
figure	O
figure	O
figure	O
figure	O

The	O
majority	O
of	O
Jewish	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
.	O

,	O
the	O
different	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
even	O
in	O
some	O
Jewish	O
mutation	O
carriers	O
might	O
that	O
the	O
mutation	O
arose	O
independently	O
.	O
.	O

even	O
,	O
the	O
suggest	O
allelic	O
pattern	O
at	O
.	O
independently	O
locus	O
.	O
in	O
some	O
that	O
arose	O
carriers	O
,	O
might	O
different	O
Jewish	O
the	O
mutation	O
mutation	O
BRCA1	O
However	O
the	O

However	O
,	O
the	O
dissimilar	O
allelomorphic	O
design	O
at	O
the	O
BRCA1	O
locale	O
even	O
in	O
some	O
judaic	O
mutation	O
carriers	O
,	O
might	O
evoke	O
that	O
the	O
mutation	O
arose	O
severally	O
.	O
.	O

notwithstanding	O
,	O
the	O
unlike	O
allelomorphic	O
pattern	O
at	O
the	O
BRCA1	O
locale	O
even	O
in	O
some	O
jewish	O
mutation	O
carriers	O
,	O
might	O
suggest	O
that	O
the	O
mutation	O
grow	O
severally	O
.	O
.	O

However	O
,	O
the	O
different	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
in	O
some	O
mutation	O
carriers	O
,	O
might	O
suggest	O
that	O
the	O
independently	O
.	O
.	O

However	O
,	O
the	O
different	O
allelomorphic	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
even	O
in	O
some	O
Jewish	O
mutation	O
carriers	O
,	O
might	O
get	O
up	O
severally	O
get	O
up	O
severally	O
severally	O
dissimilar	O
suggest	O
that	O
the	O
mutation	O
arose	O
independently	O

However	O
,	O
the	O
different	O
allelomorphic	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
even	O
in	O
some	O
Jewish	O
mutation	O
carriers	O
,	O
might	O
get	O
up	O
severally	O
get	O
up	O
severally	O
severally	O
even	O
out	O
suggest	O
that	O
the	O
mutation	O
arose	O

However	O
,	O
the	O
different	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
in	O
mutation	O
carriers	O
,	O
might	O
suggest	O
that	O
the	O
mutation	O
arose	O

independently	O
,	O
the	O
different	O
allelic	O
pattern	O
Jewish	O
,	O
BRCA1	O
locus	O
even	O
in	O
mutation	O
at	O
.	O
carriers	O
the	O
the	O
suggest	O
that	O
However	O
some	O
arose	O
might	O
mutation	O
.	O

However	O
,	O
the	O
dissimilar	O
allelomorphic	O
design	O
at	O
the	O
BRCA1	O
venue	O
even	O
in	O
some	O
jewish	O
mutation	O
flattop	O
,	O
might	O
suggest	O
that	O
the	O
mutation	O
arose	O
severally	O
.	O
.	O

However	O
,	O
the	O
different	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
even	O
in	O
some	O
Jewish	O
mutation	O
carriers	O
,	O
might	O
suggest	O
that	O
the	O
mutation	O
arose	O
independently	O
.	O
.	O

Crystal	O
structure	O
personation	O
sensory	O
receptor	O
enactment	O
of	O
the	B
hemochromatosis	O
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
fundamental	O

transferrin	O
structure	O
of	O
.	O
hemochromatosis	B
protein	O
HFE	O
and	O
receptor	O
of	O
its	O
interaction	O
Crystal	O
with	O
characterization	O
the	O

Crystal	O
structure	O
siderophilin	O
sensory	O
receptor	O
bronzed	O
diabetes	O
of	B
the	O
hemochromatosis	O
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O

Crystal	O
structure	O
of	O
the	O
hemochromatosis	B
protein	O
HFE	O
and	O
depiction	O
of	O
its	O
interaction	O
with	O
siderophilin	O
receptor	O
.	O

with	O
structure	O
of	O
and	O
hemochromatosis	B
protein	O
transferrin	O
the	O
characterization	O
of	O
Crystal	O
interaction	O
its	O
HFE	O
receptor	O
.	O

Crystal	O
structure	O
personation	O
sensory	O
receptor	O
enactment	O
of	O
the	B
hemochromatosis	O
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
fundamental	O

quartz	O
structure	O
of	O
the	O
hemochromatosis	B
protein	O
HFE	O
and	O
characterisation	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
.	O

crystallization	O
construction	O
of	O
the	O
hemochromatosis	B
protein	O
HFE	O
and	O
enactment	O
of	O
its	O
interaction	O
with	O
siderophilin	O
receptor	O
.	O

Crystal	O
structure	O
characterization	O
.	O
hemochromatosis	B
protein	O
with	O
and	O
of	O
of	O
its	O
interaction	O
HFE	O
transferrin	O
the	O
receptor	O

structure	O
of	O
the	O
hemochromatosis	B
protein	O
HFE	O
and	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
.	O

Crystal	O
structure	O
of	O
the	O
hemochromatosis	B
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
.	O

HFE	O
is	O
is	O
overload	O
-	O
related	O
iron	O
that	O
an	O
mutated	O
in	O
the	O
protein	B
-	I
MHC	I
disease	I
hereditary	B
hemochromatosis	I
.	O

an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
disease	I
hereditary	B
hemochromatosis	I
.	O

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
press	B
-	I
overcharge	I
disease	I
patrimonial	B
hemochromatosis	I
.	O

HFE	O
is	O
an	O
MHC	O
-	O
refer	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B
-	I
overburden	I
disease	I
inherited	B
hemochromatosis	I
.	O

hereditary	O
is	O
an	O
MHC	O
-	O
related	O
-	O
overload	O
is	O
mutated	O
in	O
the	O
hemochromatosis	B
protein	I
that	I
disease	I
iron	B
HFE	I
.	O

HFE	O
is	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B
-	I
overload	I
disease	I
hereditary	B
.	O

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B
-	I
overload	I
disease	I
hereditary	B
hemochromatosis	I
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B
-	I
overburden	I
disease	I
genetic	B
hemochromatosis	I
.	O

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B
-	I
overload	I
disease	I
hereditary	B
hemochromatosis	I
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O

-	O
is	O
an	O
in	O
-	O
related	O
protein	O
.	O
overload	O
mutated	O
MHC	O
the	O
HFE	B
iron	I
is	I
disease	I
hereditary	B
hemochromatosis	I
that	O

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B
-	I
overload	I
disease	I
hereditary	B
hemochromatosis	I
.	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
fe	O
metabolic	O
process	O
fe	O
metabolic	O
process	O
metabolic	O
process	O
siderophilin	O
fe	O
implicating	O
HFE	O
in	O

to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
implicating	O
in	O
iron	O
metabolism	O
.	O

HFE	O
hold	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
dilute	O
its	O
affinity	O
for	O
iron	O
-	O
ladened	O
transferrin	O
,	O
entail	O
HFE	O
in	O
iron	O
metabolism	O
.	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
and	O
reduces	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
in	O
iron	O
metabolism	O
.	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
fe	O
metabolic	O
process	O
fe	O
metabolic	O
process	O
metabolic	O
process	O
siderophilin	O
siderophilin	O
implicating	O
HFE	O
in	O

HFE	O
truss	O
to	O
siderophilin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
dilute	O
siderophilin	O
,	O
implicate	O
HFE	O
in	O
iron	O
metabolism	O
.	O

HFE	O
truss	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
kinship	O
for	O
iron	O
-	O
blotto	O
transferrin	O
,	O
implicate	O
HFE	O
in	O
iron	O
metabolism	O
.	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
its	O
iron	O
-	O
loaded	O
transferrin	O
,	O
implicating	O
HFE	O
in	O
iron	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
fe	O
metabolic	O
process	O
fe	O
metabolic	O
process	O
metabolic	O
process	O
siderophilin	O
siderophilin	O
implicating	O
HFE	O
in	O

,	O
binds	O
to	O
its	O
receptor	O
(	O
TfR	O
implicating	O
.	O
reduces	O
transferrin	O
affinity	O
for	O
iron	O
metabolism	O
loaded	O
transferrin	O
in	O
)	O
HFE	O
HFE	O
iron	O
-	O
and	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
implicating	O
HFE	O
in	O
iron	O
metabolism	O
.	O

The	O
.	O

The	O
2	O

The	O
.	O
2	O

2	O
The	O
.	O

2	O
The	O
.	O

The	O
two	O
.	O

The	O
2	O
	O
.	O

The	O
2	O
	O
.	O

The	O
2	O
	O
.	O

The	O
2	O
.	O

hexad	O
axerophthol	O
quartz	O
structure	O
of	O
HFE	O
expose	O
the	O
localization	O
of	O
hemochromatosis	B
variation	O
and	O
axerophthol	O
darn	O
of	O
histidines	O
that	O
could	O
be	O
involved	O
in	O
pH	O
-	O
hooked	O
interactions	O
.	O

6	O
A	O
structure	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	B
mutations	O
and	O
of	O
histidines	O
that	O
could	O
involved	O
in	O
pH	O
-	O
dependent	O
.	O

6	O
A	O
crystal	O
structure	O
while	O
unveil	O
histidine	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	B
mutations	O
and	O
a	O
patch	O
of	O
histidines	O
that	O
indium	O
pendent	O
interaction	O
pendent	O
localization	O
could	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O
interactions	O
.	O

involved	O
A	O
crystal	O
could	O
of	O
HFE	O
reveals	O
interactions	O
-	O
of	O
be	B
mutations	O
and	O
a	O
pH	O
of	O
histidines	O
that	O
structure	O
dependent	O
hemochromatosis	O
in	O
patch	O
locations	O
6	O
the	O
.	O

6	O
A	O
crystal	O
structure	O
while	O
unveil	O
histidine	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	B
mutations	O
and	O
a	O
patch	O
of	O
histidines	O
that	O
indium	O
pendent	O
interaction	O
pendent	O
localization	O
could	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O
interactions	O
.	O

6	O
A	O
crystal	O
of	O
HFE	O
the	O
locations	O
of	O
hemochromatosis	B
mutations	O
and	O
a	O
patch	O
histidines	O
that	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O
interactions	O
.	O

.	O
A	O
crystal	O
patch	O
of	O
HFE	O
interactions	O
the	O
structure	O
of	O
hemochromatosis	B
mutations	O
a	O
involved	O
dependent	O
locations	O
histidines	O
that	O
could	O
be	O
and	O
in	O
pH	O
-	O
of	O
reveals	O
6	O

crystal	O
HFE	O
reveals	O
the	O
of	O
hemochromatosis	B
and	O
a	O
patch	O
of	O
histidines	O
that	O
could	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O

-	O
A	O
crystal	O
structure	O
of	O
HFE	O
a	O
mutations	O
locations	O
of	O
hemochromatosis	B
histidines	O
in	O
reveals	O
dependent	O
6	O
the	O
of	O
could	O
be	O
involved	O
and	O
pH	O
that	O
patch	O
interactions	O
.	O

6	O
A	O
crystal	O
construction	O
of	O
HFE	O
divulge	O
the	O
emplacement	O
of	O
hemochromatosis	B
mutations	O
and	O
a	O
speckle	O
of	O
histidines	O
that	O
could	O
be	O
ask	O
in	O
ph	O
-	O
dependent	O
interactions	O
.	O

6	O
A	O
crystal	O
structure	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	B
mutations	O
and	O
a	O
patch	O
of	O
histidines	O
that	O
could	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O
interactions	O
.	O

We	O
likewise	O
present	O
that	O
soluble	O
TfR	O
and	O
HFE	O
tie	O
tightly	O
at	O
the	O
canonical	O
ph	O
of	O
the	O
cell	O
aerofoil	O
,	O
but	O
not	O
at	O
the	O
acidic	O
ph	O
of	O
intracellular	O
cyst	O
.	O

We	O
also	O
demonstrate	O
that	O
soluble	O
and	O
tightly	O
at	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

not	O
also	O
demonstrate	O
,	O
soluble	O
TfR	O
and	O
of	O
acidic	O
tightly	O
.	O
the	O
basic	O
but	O
the	O
the	O
cell	O
surface	O
that	O
pH	O
pH	O
at	O
of	O
bind	O
We	O
HFE	O
intracellular	O
vesicles	O
at	O

We	O
also	O
demonstrate	O
that	O
staple	O
ph	O
acid	O
vesicle	O
cubicle	O
soluble	O
TfR	O
and	O
HFE	O
bind	O
tightly	O
at	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
acid	O
ph	O
truss	O
,	O
but	O
not	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

We	O
also	O
demonstrate	O
that	O
staple	O
ph	O
acid	O
vesicle	O
cubicle	O
soluble	O
TfR	O
and	O
HFE	O
bind	O
tightly	O
at	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
acid	O
ph	O
come	O
on	O
,	O
but	O
not	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O

We	O
also	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
tightly	O
at	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
,	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

.	O
also	O
demonstrate	O
of	O
soluble	O
TfR	O
of	O
HFE	O
that	O
tightly	O
at	O
the	O
intracellular	O
pH	O
pH	O
bind	O
cell	O
surface	O
,	O
but	O
basic	O
at	O
the	O
acidic	O
the	O
and	O
not	O
vesicles	O
We	O

We	O
also	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
tightly	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
,	O
not	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O

We	O
also	O
manifest	O
that	O
soluble	O
TfR	O
and	O
HFE	O
constipate	O
tightly	O
at	O
the	O
staple	O
pH	O
of	O
the	O
cell	O
open	O
,	O
but	O
not	O
at	O
the	O
acidulous	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

We	O
besides	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
stick	O
tightly	O
at	O
the	O
canonical	O
ph	O
of	O
the	O
cell	O
surface	O
,	O
but	O
not	O
at	O
the	O
acidulous	O
ph	O
of	O
intracellular	O
cyst	O
.	O

We	O
also	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
bind	O
tightly	O
at	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
,	O
but	O
not	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

TfR	O
HFE	O
consistent	O
(	O
2	O
1	O
)	O
a	O
from	O
TfR	O
transferrin	O
for	O
different	O
2	O
2	O
differs	O
,	O
implying	O
transferrin	O
(	O
mode	O
.	O
binding	O
stoichiometry	O
HFE	O
)	O
to	O
our	O
TfR	O
,	O
stoichiometry	O
a	O
with	O
demonstration	O
that	O
complex	O
,	O
and	O
,	O
and	O
TfR	O
form	O
transferrin	O
ternary	O
HFE	O
of	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
implying	O
a	O
different	O
mode	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
HFE	O
ampere	O
	O
coordination	O
compound	O
ampere	O
	O
coordination	O
compound	O
ampere	O
	O
coordination	O
compound	O
	O
	O
	O
	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
implying	O
a	O
different	O
mode	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
HFE	O
ampere	O
	O
coordination	O
compound	O
ampere	O
	O
coordination	O
compound	O
ampere	O
	O
coordination	O
compound	O
	O
	O
	O
manner	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
TfR	O
transferrin	O
stoichiometry	O
2	O
)	O
,	O
implying	O
mode	O
and	O
transferrin	O
to	O
,	O
consistent	O
our	O
demonstration	O
that	O
transferrin	O
,	O
and	O
TfR	O
form	O
ternary	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
differs	O
from	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
mode	O
for	O
and	O
transferrin	O
to	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
,	O
and	O
TfR	O
form	O
a	O
ternary	O
complex	O

that	O
a	O
stoichiometry	O
(	O
2	O
1	O
form	O
differs	O
from	O
TfR	O
transferrin	O
TfR	O
(	O
to	O
,	O
)	O
,	O
implying	O
demonstration	O
different	O
mode	O
of	O
TfR	O
for	O
ternary	O
and	O
with	O
2	O
2	O
HFE	O
consistent	O
HFE	O
our	O
HFE	O
TfR	O
transferrin	O
,	O
transferrin	O
,	O
and	O
stoichiometry	O
)	O
a	O
binding	O
complex	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
ane	O
)	O
disagree	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
implying	O
a	O
dissimilar	O
mode	O
of	O
stick	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
ordered	O
with	O
our	O
presentment	O
that	O
HFE	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O
leash	O
complex	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
deuce	O
i	O
)	O
dissent	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
deuce	O
deuce	O
)	O
,	O
involve	O
a	O
dissimilar	O
mood	O
of	O
tie	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
logical	O
with	O
our	O
presentment	O
that	O
HFE	O
,	O
transferrin	O
,	O
and	O
TfR	O
mannequin	O
a	O
threesome	O
complex	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
i	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
mean	O
a	O
dissimilar	O
mood	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
reproducible	O
with	O
our	O
monstrance	O
that	O
HFE	O
,	O
transferrin	O
,	O
and	O
TfR	O
flesh	O
a	O
treble	O
composite	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
implying	O
a	O
different	O
mode	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
HFE	O
ampere	O
	O
coordination	O
compound	O
ampere	O
	O
coordination	O
compound	O
ampere	O
	O
coordination	O
compound	O
	O
	O
	O
	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
implying	O
a	O
different	O
mode	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
HFE	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O
ternary	O
complex	O
.	O

designation	O
of	O
trey	O
new	O
mutations	O
and	O
a	O
gamy	O
frequence	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
korean	O
patients	O
with	O
Wilson	B
disease	I
.	O

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B
	B
	O
	B
	O
	B
	O
disease	I
.	O

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B
	B
	O
	B
	O
	B
	O
disease	I
.	O

three	O
and	O
a	O
high	O
of	O
the	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B
disease	I
.	O

Identification	O
of	O
three	O
novel	O
mutations	O
high	O
frequency	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B
disease	I
.	O

three	O
novel	O
mutations	O
and	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
in	O
Korean	O
patients	O
with	O
disease	I
.	O

Wilson	O
of	O
three	O
disease	O
mutations	O
and	O
a	O
frequency	O
high	O
of	O
Korean	O
Arg778Leu	O
mutation	O
.	O
Identification	O
patients	O
with	O
the	B
novel	I
in	O

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B
	B
	O
	B
	O
	B
designation	O
disease	I
.	O

designation	O
of	O
three	O
fresh	O
variation	O
and	O
a	O
high	O
frequence	O
of	O
the	O
Arg778Leu	O
variation	O
in	O
korean	O
patients	O
with	O
Wilson	B
disease	I
.	O

with	O
of	O
three	O
novel	O
mutations	O
and	O
in	O
Arg778Leu	O
frequency	O
of	O
the	O
Korean	O
Identification	O
a	O
high	O
Wilson	O
mutation	O
patients	B
disease	I
.	O

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B
disease	I
.	O

foursome	O
mutant	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
fuzz	O
-	O
enrapture	O
enzyme	O
,	O
phosphorus	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
distinguish	O
in	O
korean	O
Patients	O
with	O
Wilson	B
disease	I
.	O

mutations	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
-	O
-	O
in	O
the	O
copper	O
transporting	O
enzyme	O
type	O
ATP7B	O
)	O
identified	O
Patients	O
with	O
Wilson	B
disease	I

)	O
with	O
-	O
-	O
copper	O
,	O
,	O
in	O
L1083F	O
,	O
and	O
2304delC	O
-	O
ATPase	O
.	O
the	O
R778L	O
identified	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
mutations	O
(	O
ATP7B	O
Four	O
-	O
were	O
,	O
A874V	O
Korean	O
Patients	O
-	O
Wilson	B
disease	I
in	O

Four	O
mutations	O
-	O
-	O
R778L	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
in	O
the	O
copper	O
-	O
enzyme	O
,	O
P	O
-	O
ATPase	O
(	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
disease	I
.	O

Four	O
mutations	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	B
bull	O
bull	B
bull	O
bull	B
bull	O
bull	B
bull	O
bull	B
bull	O
bull	B
bull	O
disease	I
.	O

Four	O
mutations	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	B
bull	O
bull	B
bull	O
bull	B
bull	O
bull	B
bull	O
bull	B
bull	O
bull	B
bull	O
disease	I
.	O

Four	O
sport	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
pig	O
-	O
enrapture	O
enzyme	O
,	O
phosphorus	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
discover	O
in	O
korean	O
patient	O
with	O
Wilson	B
disease	I
.	O

ATPase	O
transporting	O
-	O
-	O
R778L	O
,	O
2304delC	O
Patients	O
L1083F	O
,	O
and	O
A874V	O
-	O
)	O
were	O
the	O
copper	O
-	O
,	O
enzyme	O
,	O
P	O
,	O
type	O
Four	O
(	O
in	O
-	O
in	O
-	O
identified	O
Wilson	O
Korean	O
mutations	O
with	O
ATP7B	B
disease	I
.	O

Four	O
mutations	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	B
bull	O
bull	B
bull	O
bull	B
bull	O
bull	B
bull	O
bull	B
bull	O
bull	B
bull	O
disease	I
.	O

Four	O
mutations	O
R778L	O
,	O
,	O
L1083F	O
-	O
in	O
the	O
copper	O
transporting	O
enzyme	O
,	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	B
disease	I

Four	O
mutations	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	B
disease	I
.	O

Arg778Leu	O
,	O
the	O
most	O
ofttimes	O
cover	O
mutant	O
of	O
this	O
enzyme	O
,	O
was	O
rule	O
in	O
six	O
of	O
viii	O
unrelated	O
patients	O
take	O
,	O
an	O
allelomorph	O
frequency	O
of	O
xxxvii	O
.	O

Arg778Leu	O
,	O
most	O
frequently	O
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
of	O
eight	O
unrelated	O
patients	O
,	O
an	O
allele	O
frequency	O
of	O
.	O

Arg778Leu	O
,	O
the	O
most	O
	O
sport	O
ofttimes	O
frequently	O
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
frequence	O
allelomorph	O
	O
frequence	O
virtually	O
patients	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O
37	O
.	O

,	O
,	O
the	O
patients	O
frequently	O
reported	O
mutation	O
37	O
frequency	O
enzyme	O
studied	O
was	O
found	O
in	O
allele	O
of	O
eight	O
unrelated	O
most	O
of	O
,	O
an	O
six	O
this	O
Arg778Leu	O
of	O
.	O

Arg778Leu	O
,	O
the	O
most	O
	O
sport	O
ofttimes	O
frequently	O
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
frequence	O
allelomorph	O
	O
frequence	O
virtually	O
patients	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O
37	O
.	O

Arg778Leu	O
,	O
the	O
frequently	O
reported	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
in	O
six	O
eight	O
unrelated	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O
37	O
.	O

.	O
,	O
the	O
six	O
frequently	O
reported	O
37	O
of	O
most	O
enzyme	O
,	O
was	O
in	O
,	O
of	O
this	O
eight	O
unrelated	O
patients	O
studied	O
found	O
an	O
allele	O
frequency	O
of	O
mutation	O
Arg778Leu	O

the	O
reported	O
mutation	O
of	O
enzyme	O
,	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
patients	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O

frequency	O
,	O
the	O
most	O
frequently	O
reported	O
in	O
was	O
this	O
enzyme	O
,	O
eight	O
an	O
mutation	O
of	O
Arg778Leu	O
of	O
of	O
patients	O
studied	O
,	O
found	O
allele	O
unrelated	O
six	O
37	O
.	O

Arg778Leu	O
,	O
the	O
most	O
ofttimes	O
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
see	O
in	O
six	O
of	O
octet	O
unrelated	O
patients	O
meditate	O
,	O
an	O
allelomorph	O
frequence	O
of	O
xxxvii	O
.	O

Arg778Leu	O
,	O
the	O
most	O
frequently	O
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
patients	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O
37	O
.	O

5	O
,	O
is	O
higher	O
than	O
those	O
in	O
other	O
Asian	O
populations	O
.	O

pentad	O
%	O
,	O
which	O
is	O
substantially	O
gamey	O
than	O
those	O
in	O
other	O
Asian	O
universe	O
.	O

than	O
which	O
,	O
%	O
is	O
considerably	O
in	O
5	O
those	O
.	O
other	O
Asian	O
populations	O
higher	O

5	O
%	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
in	O
other	O
populations	O
.	O

5	O
%	O
population	O
population	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
population	O
cost	O
in	O
other	O
Asian	O
populations	O
.	O

5	O
%	O
population	O
population	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
population	O
cost	O
in	O
other	O
Asian	O
populations	O
.	O

fin	O
%	O
,	O
which	O
is	O
well	O
higher	O
than	O
those	O
in	O
other	O
asian	O
universe	O
.	O

populations	O
%	O
,	O
5	O
than	O
considerably	O
higher	O
Asian	O
those	O
in	O
other	O
is	O
which	O
.	O

5	O
%	O
population	O
population	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
population	O
cost	O
in	O
other	O
Asian	O
populations	O
.	O

quintet	O
%	O
,	O
which	O
is	O
substantially	O
higher	O
than	O
those	O
in	O
other	O
asiatic	O
populations	O
.	O

5	O
%	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
in	O
other	O
Asian	O
populations	O
.	O

The	O
single	O
deletion	O
2304delC	O
,	O
was	O
found	O
in	O
one	O
patient	O
.	O

The	O
novel	O
ace	O
base	O
deletion	O
,	O
2304delC	O
,	O
was	O
institute	O
in	O
peerless	O
patient	O
.	O

,	O
nucleotide	O
single	O
novel	O
deletion	O
,	O
found	O
The	O
was	O
.	O
in	O
one	O
patient	O
2304delC	O

The	O
novel	O
single	O
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
found	O
in	O
patient	O
.	O

The	O
novel	O
	O
	O
single	O
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
was	O
patient	O
role	O
omission	O
found	O
in	O
one	O
patient	O

The	O
novel	O
	O
	O
single	O
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
was	O
patient	O
role	O
patient	O
role	O
found	O
in	O
one	O

The	O
fresh	O
single	O
base	O
excision	O
,	O
2304delC	O
,	O
was	O
found	O
in	O
ane	O
patient	O
.	O

patient	O
novel	O
single	O
The	O
,	O
,	O
2304delC	O
one	O
was	O
found	O
in	O
deletion	O
nucleotide	O
.	O

The	O
novel	O
	O
	O
single	O
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
was	O
patient	O
role	O
omission	O
found	O
in	O
one	O
patient	O

The	O
novel	O
single	O
base	O
omission	O
,	O
2304delC	O
,	O
was	O
plant	O
in	O
unitary	O
patient	O
.	O

The	O
novel	O
single	O
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
was	O
found	O
in	O
one	O
patient	O
.	O

Since	O
a	O
mutation	O
at	O
antecedently	O
account	O
base	O
rearrangement	O
complementary	O
dna	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
induce	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	B
Wilson	I
disease	O
previously	O
previously	O
cost	O

Since	O
a	O
mutation	O
at	O
antecedently	O
account	O
base	O
rearrangement	O
complementary	O
dna	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
account	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	B
Wilson	I
disease	O
previously	O
previously	O
cost	O

susceptible	O
a	O
mutation	O
at	O
cDNA	O
nucleotide	O
described	O
region	O
2302insC	O
)	O
had	O
been	O
may	O
2302	O
to	O
Wilson	O
(	O
gene	O
the	O
ATP7B	O
Since	O
previously	O
be	O
of	O
,	O
gene	O
rearrangements	O
causing	O
.	B
disease	I
this	O

Since	O
a	O
mutation	O
at	O
antecedently	O
account	O
base	O
rearrangement	O
complementary	O
dna	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
induce	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	B
Wilson	I
disease	O
previously	O
previously	O
cost	O

Since	O
a	O
mutation	O
at	O
nucleotide	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	B
disease	I
.	O

Since	O
a	O
sport	O
at	O
cdna	O
base	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
antecedently	O
described	O
,	O
this	O
neighborhood	O
of	O
the	O
ATP7B	O
cistron	O
may	O
be	O
susceptible	O
to	O
cistron	O
rearrangements	O
cause	O
Wilson	B
disease	I
.	O

Wilson	O
a	O
to	O
,	O
cDNA	O
nucleotide	O
causing	O
(	O
at	O
)	O
had	O
been	O
gene	O
described	O
mutation	O
2302insC	O
region	O
of	O
the	O
ATP7B	O
previously	O
may	O
be	O
susceptible	O
this	O
2302	O
rearrangements	O
gene	O
Since	B
disease	I
.	O

Since	O
a	O
mutation	O
at	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
had	O
been	O
described	O
,	O
this	O
region	O
of	O
the	O
ATP7B	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	B
disease	I
.	O

had	O
a	O
mutation	O
Wilson	O
cDNA	O
nucleotide	O
2302	O
gene	O
susceptible	O
)	O
to	O
been	O
rearrangements	O
ATP7B	O
be	O
this	O
region	O
of	O
.	O
described	O
gene	O
may	O
,	O
2302insC	O
Since	O
(	O
previously	O
causing	O
at	B
disease	I
the	O

Since	O
a	O
mutation	O
at	O
cdna	O
base	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
antecedently	O
identify	O
,	O
this	O
part	O
of	O
the	O
ATP7B	O
cistron	O
may	O
be	O
susceptible	O
to	O
cistron	O
rearrangements	O
get	O
Wilson	B
disease	I
.	O

Since	O
a	O
mutation	O
at	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	B
disease	I
.	O

Disruption	O
splicing	O
by	O
CUG	O
-	O
binding	O
protein	O
in	O
myotonic	B
dystrophy	I
.	O

break	O
of	O
tie	O
regularise	O
by	O
a	O
CUG	O
-	O
bandaging	O
protein	O
in	O
myotonic	B
dystrophy	I
.	O

-	O
regulated	O
splicing	O
of	O
by	O
a	O
protein	O
Disruption	O
binding	O
.	O
in	O
myotonic	B
dystrophy	I
CUG	O

Disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
protein	O
in	O
dystrophy	I
.	O

Disruption	O
of	O
tie	O
tie	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
muscular	O
dystrophy	O
past	O
protein	O
in	B
myotonic	I
dystrophy	O

Disruption	O
of	O
tie	O
tie	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
muscular	O
dystrophy	O
order	O
protein	O
in	B
myotonic	I
dystrophy	O

break	O
of	O
marry	O
regularise	O
by	O
a	O
CUG	O
-	O
adhere	O
protein	O
in	O
myotonic	B
dystrophy	I
.	O

dystrophy	O
of	O
splicing	O
Disruption	O
-	O
a	O
CUG	O
myotonic	O
binding	O
protein	O
in	O
by	B
regulated	I
.	O

Disruption	O
of	O
tie	O
tie	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
muscular	O
dystrophy	O
past	O
protein	O
in	B
myotonic	I
dystrophy	O

Disruption	O
of	O
wed	O
order	O
by	O
a	O
CUG	O
-	O
binding	O
protein	O
in	O
myotonic	B
dystrophy	I
.	O

Disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
protein	O
in	O
myotonic	B
dystrophy	I
.	O

myotonic	B
dystrophy	I
(	O
decimeter	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
enlargement	O
in	O
the	O
trinity	O
untranslated	O
realm	O
of	O
the	O
decimeter	B
factor	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
factor	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
DM	B
gene	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
factor	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
DM	B
gene	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
CTG	O
expansion	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B

untranslated	B
dystrophy	I
a	O
caused	B
)	O
is	O
region	O
by	O
(	O
CTG	O
expansion	O
in	O
.	O
3	O
DM	O
Myotonic	O
of	O
the	O
DM	B
gene	O
the	O

myotonic	B
dystrophy	I
(	O
dm	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
enlargement	O
in	O
the	O
trinity	O
untranslated	O
area	O
of	O
the	O
dm	B
factor	O
.	O

.	B
dystrophy	I
(	O
expansion	B
)	O
is	O
caused	O
DM	O
untranslated	O
CTG	O
DM	O
in	O
3	O
the	O
a	O
region	O
of	O
the	O
by	B
Myotonic	O
gene	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
factor	O
ampere	O
ampere	O
ampere	O
ampere	O
myotonic	O
DM	B
gene	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
untranslated	O
the	O
DM	B
gene	O
.	O

myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
get	O
by	O
a	O
CTG	O
elaboration	O
in	O
the	O
trio	O
untranslated	O
part	O
of	O
the	O
DM	B
factor	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B
gene	O
.	O

One	O
model	O
of	O
DM	B
produce	O
ampere	O
arrive	O
at	O
iterate	O
rna	O
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
protein	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
bring	O
on	O
bring	O

One	O
model	O
of	O
DM	B
produce	O
ampere	O
arrive	O
at	O
iterate	O
rna	O
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
iterate	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
bring	O
on	O
bring	O

binding	O
model	O
of	O
DM	B
pathogenesis	O
suggests	O
a	O
of	O
from	O
the	O
expanded	O
allele	O
the	O
that	O
of	O
CUG	O
RNAs	O
by	O
function	O
mutation	O
One	O
create	O
inappropriate	O
-	O
gain	O
proteins	O
to	O
the	O
.	O
repeats	O
-	O

One	O
model	O
of	O
DM	B
produce	O
ampere	O
arrive	O
at	O
iterate	O
rna	O
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
protein	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
bring	O
on	O
bring	O

One	O
model	O
of	O
DM	B
suggests	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
.	O

unrivaled	O
exemplar	O
of	O
DM	B
pathogenesis	O
suggests	O
that	O
rna	O
from	O
the	O
expanded	O
allelomorph	O
produce	O
a	O
benefit	O
-	O
of	O
-	O
procedure	O
mutation	O
by	O
the	O
incompatible	O
back	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
.	O

CUG	O
model	O
of	O
gain	B
pathogenesis	O
suggests	O
the	O
RNAs	O
DM	O
the	O
expanded	O
allele	O
by	O
a	O
of	O
from	O
of	O
-	O
function	O
mutation	O
create	O
the	O
inappropriate	O
binding	O
-	O
that	O
to	O
proteins	O
One	O
repeats	O
.	O

One	O
model	O
of	O
DM	B
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
expanded	O
allele	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
.	O

expanded	O
model	O
of	O
CUG	B
pathogenesis	O
suggests	O
that	O
proteins	O
binding	O
the	O
of	O
allele	O
to	O
mutation	O
inappropriate	O
-	O
of	O
-	O
.	O
a	O
by	O
the	O
gain	O
from	O
One	O
RNAs	O
create	O
the	O
DM	O
repeats	O
function	O

nonpareil	O
manakin	O
of	O
decimeter	B
pathogenesis	O
suggests	O
that	O
rna	O
from	O
the	O
expanded	O
allelomorph	O
produce	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
by	O
the	O
incompatible	O
tie	O
of	O
proteins	O
to	O
the	O
CUG	O
retell	O
.	O

One	O
model	O
of	O
DM	B
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
.	O

Data	O
presented	O
here	O
indicate	O
heterogeneous	O
tie	O
prevailing	O
economise	O
heterogenous	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
heterogenous	O
heterogenous	O
heterogenous	O
save	O
.	O

Data	O
presented	O
that	O
ribonucleoprotein	O
,	O
CUG	O
binding	O
protein	O
CUG	O
-	O
BP	O
may	O
mediate	O
the	O
trans	O
-	O
effect	O
the	O
RNA	O
.	O

data	O
confront	O
here	O
show	O
that	O
the	O
maintain	O
heterogenous	O
atomic	O
ribonucleoprotein	O
,	O
CUG	O
-	O
dressing	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
whitethorn	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
.	O

Data	O
presented	O
here	O
indicate	O
the	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
.	O

data	O
presented	O
here	O
signal	O
that	O
the	O
husband	O
heterogenous	O
atomic	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
intercede	O
the	O
trans	O
-	O
prevalent	O
outcome	O
of	O
the	O
rna	O
.	O

Data	O
presented	O
here	O
indicate	O
heterogeneous	O
tie	O
prevailing	O
economise	O
heterogenous	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
heterogenous	O
heterogenous	O
heterogenous	O
save	O
.	O

information	O
presented	O
here	O
bespeak	O
that	O
the	O
maintain	O
heterogenous	O
atomic	O
ribonucleoprotein	O
,	O
CUG	O
-	O
attach	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
intercede	O
the	O
trans	O
-	O
dominant	O
force	O
of	O
the	O
rna	O
.	O

,	O
BP	O
here	O
indicate	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
trans	O
the	O
(	O
CUG	O
-	O
effect	O
)	O
presented	O
may	O
.	O
the	O
binding	O
-	O
dominant	O
Data	O
protein	O
mediate	O
RNA	O
of	O

Data	O
presented	O
here	O
indicate	O
the	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
mediate	O
-	O
dominant	O
effect	O
the	O
.	O

Data	O
presented	O
here	O
indicate	O
nuclear	O
tie	O
prevailing	O
economise	O
atomic	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
atomic	O
atomic	O
atomic	O
save	O
.	O

Data	O
presented	O
here	O
indicate	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
.	O

-	O
BP	O
was	O
found	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
T	O
(	O
cTNT	O
)	O
-	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing	O
.	O

cardiac	O
-	O
BP	O
messenger	O
found	O
to	O
bind	O
.	O
alternative	O
human	O
splicing	O
troponin	O
T	O
RNA	O
its	O
)	O
pre	O
-	O
was	O
(	O
and	O
regulate	O
cTNT	O
the	O
CUG	O
to	O

CUG	O
-	O
BP	O
was	O
witness	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
liothyronine	O
(	O
cTNT	O
)	O
pre	O
-	O
courier	O
rna	O
and	O
influence	O
its	O
option	O
marry	O
.	O

CUG	O
-	O
BP	O
was	O
feel	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
thyroxin	O
(	O
cTNT	O
)	O
pre	O
-	O
courier	O
rna	O
and	O
modulate	O
its	O
substitute	O
splice	O
.	O

CUG	O
-	O
BP	O
was	O
found	O
to	O
bind	O
to	O
the	O
human	O
troponin	O
T	O
cTNT	O
)	O
pre	O
-	O
messenger	O
RNA	O
and	O
alternative	O
splicing	O
.	O

CUG	O
-	O
BP	O
was	O
receive	O
found	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
T	O
(	O
cTNT	O
)	O
pre	O
-	O
information	O
technology	O
alternate	O
tie	O
alternate	O
tie	O
cost	O
messenger	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing	O

CUG	O
-	O
BP	O
was	O
receive	O
found	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
T	O
(	O
cTNT	O
)	O
pre	O
-	O
information	O
technology	O
alternate	O
tie	O
alternate	O
tie	O
tie	O
messenger	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing	O

CUG	O
-	O
BP	O
was	O
found	O
to	O
bind	O
to	O
the	O
human	O
troponin	O
cTNT	O
)	O
pre	O
-	O
messenger	O
RNA	O
and	O
regulate	O
its	O

alternative	O
-	O
BP	O
was	O
found	O
to	O
(	O
pre	O
the	O
human	O
cardiac	O
troponin	O
regulate	O
bind	O
splicing	O
)	O
to	O
and	O
messenger	O
RNA	O
CUG	O
T	O
its	O
-	O
cTNT	O
.	O

CUG	O
-	O
BP	O
was	O
get	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
liothyronine	O
(	O
cTNT	O
)	O
pre	O
-	O
courier	O
rna	O
and	O
shape	O
its	O
choice	O
marry	O
.	O

CUG	O
-	O
BP	O
was	O
found	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
T	O
(	O
cTNT	O
)	O
pre	O
-	O
messenger	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing	O
.	O

tie	O
of	O
cTNT	O
was	O
disrupted	O
in	O
decimeter	B
striated	O
muscle	O
and	O
in	O
pattern	O
cellphone	O
utter	O
transcripts	O
that	O
contain	O
CUG	O
recapitulate	O
.	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	B
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
heftiness	O
heftiness	O
heftiness	O
heftiness	O
heftiness	O
heftiness	O
repeats	O
.	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	B
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
heftiness	O
heftiness	O
heftiness	O
heftiness	O
heftiness	O
heftiness	O
repeats	O
.	O

cTNT	O
in	O
DM	B
striated	O
and	O
in	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
repeats	O
.	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	O
striated	O
muscle	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
repeats	O
.	O

cTNT	O
was	O
disrupted	O
in	O
striated	O
muscle	O
and	O
in	O
normal	O
expressing	O
transcripts	O
that	O
contain	O
repeats	O
.	O

CUG	O
of	O
cTNT	O
repeats	O
disrupted	O
in	O
DM	B
muscle	O
striated	O
and	O
transcripts	O
normal	O
cells	O
.	O
Splicing	O
that	O
contain	O
in	O
was	O
expressing	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	B
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
heftiness	O
heftiness	O
heftiness	O
heftiness	O
heftiness	O
verbalize	O
repeats	O
.	O

wed	O
of	O
cTNT	O
was	O
disrupted	O
in	O
decimeter	B
striated	O
muscle	O
and	O
in	O
rule	O
cells	O
convey	O
copy	O
that	O
contain	O
CUG	O
reduplicate	O
.	O

contain	O
of	O
cTNT	O
was	O
disrupted	O
in	O
expressing	B
normal	O
muscle	O
and	O
in	O
transcripts	O
Splicing	O
DM	O
striated	O
CUG	O
cells	O
that	O
repeats	O
.	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	B
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
repeats	O
.	O

therefore	O
expression	O
of	O
CUG	O
regulated	O
posttranscriptionally	O
by	O
genes	O
DM	O
BP	O
to	O
may	O
Altered	O
contribute	O
-	B
pathogenesis	O
.	O
.	O

spay	O
expression	O
of	O
cistron	O
mold	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
so	O
may	O
give	O
to	O
DM	B
pathogenesis	O
.	O
.	O

altered	O
reflection	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
hence	O
may	O
conduce	O
to	O
dm	B
pathogenesis	O
.	O
.	O

Altered	O
expression	O
of	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	B
pathogenesis	O
.	O
.	O

Altered	O
reflection	O
of	O
factor	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
whitethorn	O
lead	O
to	O
decimeter	B
pathogenesis	O
.	O
.	O

Altered	O
expression	O
factor	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	B
pathogenesis	O
.	O
element	O
element	O
element	O
dm	O
.	O

Altered	O
expression	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
may	O
contribute	O
DM	B
pathogenesis	O
.	O
.	O

Altered	O
expression	O
factor	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	B
pathogenesis	O
.	O
element	O
element	O
element	O
dm	O
.	O

expression	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
.	O

Altered	O
expression	O
-	O
DM	O
regulated	O
posttranscriptionally	O
contribute	O
CUG	O
of	O
BP	O
therefore	O
may	O
by	O
to	O
genes	B
pathogenesis	O
.	O
.	O

Altered	O
expression	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	B
pathogenesis	O
.	O
.	O

designation	O
of	O
a	O
refreshing	O
trumpery	O
mutant	O
and	O
a	O
missense	O
switch	O
in	O
the	O
adh	O
-	O
neurophysin	O
ii	O
gene	O
in	O
two	O
spanish	O
kindreds	O
with	O
familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
.	O

Identification	O
of	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
II	O
gene	O
in	O
two	O
kindreds	O
with	O
familial	B
neurohypophyseal	I
diabetes	I
.	O

Identification	O
of	O
a	O
novel	O
sport	O
	O
bunk	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
kin	O
group	O
genetic	O
genetic	O
ampere	O
fresh	O
two	O
Spanish	O
kindreds	O
with	B
familial	I
neurohypophyseal	I
diabetes	I
insipidus	O

kindreds	O
of	O
a	O
two	O
nonsense	O
mutation	O
and	O
insipidus	O
neurohypophyseal	O
substitution	O
Spanish	O
the	O
vasopressin	O
-	O
familial	O
II	O
gene	O
in	O
novel	O
diabetes	O
in	O
with	O
neurophysin	B
missense	I
Identification	I
a	I
.	O

Identification	O
of	O
a	O
novel	O
sport	O
	O
bunk	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
kin	O
group	O
genetic	O
genetic	O
ampere	O
fresh	O
two	O
Spanish	O
kindreds	O
with	B
familial	I
neurohypophyseal	I
diabetes	I
insipidus	O

Identification	O
of	O
a	O
nonsense	O
mutation	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
gene	O
in	O
Spanish	O
kindreds	O
with	O
familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
.	O

.	O
of	O
a	O
neurophysin	O
nonsense	O
mutation	O
insipidus	O
a	O
novel	O
substitution	O
in	O
the	O
-	O
kindreds	O
diabetes	O
missense	O
gene	O
in	O
two	O
Spanish	O
vasopressin	O
with	O
familial	B
neurohypophyseal	I
II	I
and	I
Identification	O

a	O
mutation	O
and	O
a	O
substitution	O
in	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
two	O
Spanish	O
kindreds	O
with	O
familial	B
neurohypophyseal	I
diabetes	I

neurohypophyseal	O
of	O
a	O
novel	O
nonsense	O
mutation	O
-	O
the	O
missense	O
substitution	O
in	O
gene	O
with	O
and	O
diabetes	O
Identification	O
a	O
II	O
two	O
Spanish	O
kindreds	O
vasopressin	O
familial	B
in	I
neurophysin	I
insipidus	I
.	O

identification	O
of	O
a	O
fresh	O
frill	O
mutant	O
and	O
a	O
missense	O
permutation	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
cistron	O
in	O
ii	O
Spanish	O
kindreds	O
with	O
hereditary	B
neurohypophyseal	I
diabetes	I
insipidus	I
.	O

Identification	O
of	O
a	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
two	O
Spanish	O
kindreds	O
with	O
familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
.	O

transmitted	B
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
FNDI	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
do	O
by	O
insufficiency	O
in	O
the	O
antidiuretic	O
endocrine	O
arginine	O
adh	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
two	O
(	O
AVP	O
-	O
NPII	O
)	O
cistron	O
on	O
chromosome	O
20p13	O
.	O

transmitted	B
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
FNDI	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
have	O
by	O
insufficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
cistron	O
on	O
chromosome	O
20p13	O
.	O

Familial	B
(	O
)	O
is	O
an	O
dominant	I
disease	I
caused	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
(	O
-	O
NPII	O
)	O
on	O
chromosome	O
20p13	O
.	O

Familial	B
neurohypophyseal	I
(	I
insipidus	I
(	O
-	B
by	O
is	O
an	O
autosomal	B
dominant	I
)	I
AVP	O
by	O
deficiency	O
II	O
the	O
antidiuretic	O
arginine	O
hormone	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
the	O
caused	O
AVP	O
FNDI	O
neurophysin	O
in	O
on	O
)	O
-	O
NPII	O
disease	O
gene	O
diabetes	O
chromosome	O
20p13	O
.	O

encoded	B
hormone	I
diabetes	I
insipidus	I
(	O
FNDI	B
disease	O
(	O
an	O
autosomal	B
dominant	I
)	I
caused	O
AVP	O
neurophysin	O
in	O
the	O
antidiuretic	O
.	O
arginine	O
vasopressin	O
is	O
-	O
)	O
Familial	O
by	O
(	O
by	O
deficiency	O
AVP	O
II	O
)	O
AVP	O
neurohypophyseal	O
NPII	O
the	O
gene	O
on	O
chromosome	O
20p13	O
-	O

Familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
)	O
is	O
an	O
autosomal	B
disease	I
caused	O
by	O
deficiency	O
in	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
AVP	O
)	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
NPII	O
)	O
on	O
chromosome	O
20p13	O
.	O

Familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
FNDI	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
along	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
gene	O
on	O
chromosome	O
20p13	O
.	O

Familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
is	O
an	O
autosomal	B
dominant	I
disease	I
by	O
deficiency	O
hormone	O
(	O
AVP	O
by	O
-	O
neurophysin	O
II	O
(	O
-	O
NPII	O
on	O
chromosome	O
.	O

genetic	B
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
FNDI	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
have	O
by	O
want	O
in	O
the	O
antidiuretic	O
endocrine	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
two	O
(	O
AVP	O
-	O
NPII	O
)	O
factor	O
on	O
chromosome	O
20p13	O
.	O

Familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
FNDI	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
along	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
gene	O
on	O
chromosome	O
20p13	O
.	O

Familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
FNDI	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
gene	O
on	O
chromosome	O
20p13	O
.	O

In	O
this	O
study	O
,	O
machine	O
controlled	O
fluorescent	O
fixture	O
psychoanalyze	O
whole	O
stage	O
we	O
analyzed	O
two	O
families	B
with	O
FNDI	O
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
organise	O
organise	O
organise	O

In	O
this	O
we	O
FNDI	B
using	O
direct	O
fluorescent	O
,	O
phase	O
,	O
single	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
AVP	O
NPII	O
DNA	O
.	O

In	O
this	O
analyse	O
,	O
we	O
analyzed	O
two	O
kinfolk	O
with	O
FNDI	B
practice	O
direct	O
automatise	O
fluorescent	O
,	O
satisfying	O
form	O
,	O
single	O
-	O
isolated	O
DNA	O
sequence	O
of	O
PCR	O
-	O
magnify	O
AVP	O
-	O
NPII	O
DNA	O
.	O

In	O
this	O
study	O
,	O
analyzed	O
with	O
FNDI	B
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
.	O

inch	O
this	O
report	O
,	O
we	O
analyzed	O
two	O
phratry	O
with	O
FNDI	B
using	O
calculate	O
automated	O
fluorescent	O
,	O
solid	O
stage	O
,	O
individual	O
-	O
isolated	O
dna	O
sequence	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
dna	O
.	O

In	O
this	O
study	O
,	O
machine	O
controlled	O
fluorescent	O
fixture	O
psychoanalyze	O
whole	O
stage	O
we	O
analyzed	O
two	O
families	B
with	O
FNDI	O
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
organise	O
organise	O
organise	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
two	O
menage	O
with	O
FNDI	B
habituate	O
maneuver	O
automatise	O
fluorescent	O
,	O
solid	O
form	O
,	O
one	O
-	O
ground	O
DNA	O
sequence	O
of	O
PCR	O
-	O
magnify	O
AVP	O
-	O
NPII	O
DNA	O
.	O

stranded	O
single	O
study	O
,	O
we	O
analyzed	O
two	O
families	O
with	O
FNDI	B
using	O
direct	O
automated	O
PCR	O
NPII	O
solid	O
phase	O
,	O
AVP	O
-	O
this	O
DNA	O
.	O
of	O
fluorescent	O
-	O
amplified	O
In	O
,	O
sequencing	O
DNA	O
-	O

In	O
this	O
study	O
,	O
analyzed	O
families	O
with	O
FNDI	B
using	O
direct	O
automated	O
fluorescent	O
,	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
-	O
amplified	O
AVP	O
NPII	O
.	O

In	O
this	O
study	O
,	O
machine	O
controlled	O
fluorescent	O
fixture	O
psychoanalyze	O
whole	O
dna	O
we	O
analyzed	O
two	O
families	B
with	O
FNDI	O
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
organise	O
organise	O
organise	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
two	O
families	O
with	O
FNDI	B
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
.	O

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
a	O
novel	O
nonsense	O
in	O
3	O
of	O
the	O
consisting	O
T	O
transition	O
at	O
2101	O
,	O
produces	O
a	O
stop	O
codon	O
82	O
(	O
Glu	O
)	O
NPII	O

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
nonsense	O
mutation	O
in	O
exon	O
3	O
in	O
to	O
transition	O
at	O
nucleotide	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
indium	O
family	O
line	O
	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
indium	O
family	O
line	O
	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O

In	O
peerless	O
of	O
the	O
kinsperson	O
,	O
affected	O
somebody	O
exhibit	O
a	O
refreshing	O
frill	O
mutant	O
in	O
exon	O
3	O
of	O
the	O
cistron	O
,	O
comprise	O
in	O
a	O
gib	O
to	O
t	O
changeover	O
at	O
base	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
in	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

In	O
of	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101	O
,	O
which	O
produces	O
stop	O
in	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O

inch	O
ace	O
of	O
the	O
category	O
,	O
touched	O
somebody	O
introduce	O
a	O
fresh	O
frill	O
mutation	O
inch	O
exon	O
triad	O
of	O
the	O
cistron	O
,	O
lie	O
inch	O
a	O
G	O
to	O
T	O
transition	O
at	O
base	O
2101	O
,	O
which	O
produces	O
a	O
barricade	O
signal	O
inch	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

82	O
to	O
of	O
the	O
of	O
,	O
codon	O
which	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
affected	O
the	O
3	O
families	O
exon	O
gene	O
,	O
individuals	O
in	O
a	O
G	O
at	O
T	O
transition	O
)	O
.	O
2101	O
nucleotide	O
one	O
produces	O
a	O
stop	O
signal	O
in	O
in	O
In	O
(	O
Glu	O
consisting	O
of	O
NPII	O
,	O

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
indium	O
family	O
line	O
	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O
family	O
line	O

In	O
nonpareil	O
of	O
the	O
kinsfolk	O
,	O
dissemble	O
someone	O
presented	O
a	O
fresh	O
falderol	O
mutation	O
in	O
exon	O
trine	O
of	O
the	O
gene	O
,	O
dwell	O
in	O
a	O
gm	O
to	O
triiodothyronine	O
modulation	O
at	O
base	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
indicate	O
in	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
in	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

The	O
premature	O
involved	O
eliminates	O
part	O
of	O
the	O
,	O
-	O
terminal	O
domain	O
could	O
the	O
,	O
including	O
of	O
cysteine	O
residue	O
position	O
in	O
85	O
C	O
which	O
of	O
be	O
in	O
termination	O
prohormone	O
correct	O
folding	O
a	O
NPII	O
the	O
.	O

The	O
eliminates	O
part	O
of	O
the	O
-	O
terminal	O
NPII	O
,	O
a	O
cysteine	O
85	O
which	O
could	O
be	O
in	O
the	O
correct	O
of	O
the	O
prohormone	O
.	O

The	O
premature	O
termination	O
eliminates	O
let	O
in	O
ampere	O
right	O
part	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85	O
,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O

The	O
premature	O
termination	O
eliminates	O
let	O
in	O
ampere	O
theatrical	O
role	O
part	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85	O
,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O

premature	O
in	O
termination	O
eliminates	O
part	O
of	O
in	O
C	O
-	O
terminal	O
domain	O
the	O
NPII	O
be	O
folding	O
a	O
cysteine	O
residue	O
of	O
position	O
85	O
,	O
.	O
could	O
,	O
involved	O
the	O
The	O
the	O
which	O
of	O
correct	O
prohormone	O
including	O

The	O
premature	O
termination	O
eliminates	O
part	O
of	O
-	O
terminal	O
domain	O
of	O
,	O
including	O
a	O
cysteine	O
residue	O
position	O
85	O
,	O
which	O
be	O
involved	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
.	O

The	O
previous	O
conclusion	O
eliminates	O
part	O
of	O
the	O
C	O
-	O
final	O
sphere	O
of	O
NPII	O
,	O
admit	O
a	O
cysteine	O
remainder	O
in	O
location	O
85	O
,	O
which	O
could	O
be	O
byzantine	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
.	O

The	O
untimely	O
termination	O
pass	O
divide	O
of	O
the	O
carbon	O
-	O
last	O
world	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
remainder	O
in	O
stead	O
85	O
,	O
which	O
could	O
be	O
necessitate	O
in	O
the	O
chasten	O
folding	O
of	O
the	O
prohormone	O
.	O

The	O
premature	O
termination	O
eliminates	O
let	O
in	O
ampere	O
theatrical	O
role	O
part	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85	O
,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O

The	O
previous	O
termination	O
eradicate	O
part	O
of	O
the	O
c	O
-	O
end	O
world	O
of	O
NPII	O
,	O
admit	O
a	O
cysteine	O
residuum	O
in	O
posture	O
85	O
,	O
which	O
could	O
be	O
regard	O
in	O
the	O
objurgate	O
folding	O
of	O
the	O
prohormone	O
.	O

The	O
premature	O
termination	O
eliminates	O
part	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85	O
,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
.	O

In	O
the	O
second	O
substitution	O
at	O
position	O
-	O
1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
in	O
all	O
affected	O
individuals	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
-	O
1	O
of	O
signal	O
observed	O
in	O
all	O
affected	O
individuals	O
.	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
-	O
1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
touched	O
somebody	O
somebody	O
secondly	O
secondly	O
secondly	O
in	O
all	O
affected	O
individuals	O
.	O

indiana	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
placement	O
-	O
ane	O
of	O
the	O
indicate	O
peptide	O
was	O
observed	O
indiana	O
all	O
touched	O
someone	O
.	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
-	O
1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
touched	O
somebody	O
somebody	O
secondly	O
secondly	O
secondly	O
in	O
all	O
affected	O
individuals	O
.	O

In	O
the	O
second	O
home	O
,	O
a	O
G279A	O
permutation	O
at	O
berth	O
-	O
ace	O
of	O
the	O
point	O
peptide	O
was	O
observed	O
in	O
all	O
touch	O
individuals	O
.	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
1	O
of	O
signal	O
peptide	O
was	O
observed	O
in	O
all	O
affected	O

-	O
the	O
second	O
in	O
,	O
a	O
G279A	O
at	O
substitution	O
position	O
all	O
1	O
the	O
of	O
.	O
peptide	O
was	O
observed	O
family	O
In	O
affected	O
individuals	O
signal	O

inch	O
the	O
minute	O
family	O
,	O
a	O
G279A	O
permutation	O
at	O
position	O
-	O
i	O
of	O
the	O
signal	O
peptide	O
was	O
remark	O
inch	O
all	O
feign	O
individuals	O
.	O

signal	O
the	O
at	O
G279A	O
,	O
a	O
peptide	O
substitution	O
second	O
position	O
-	O
1	O
affected	O
the	O
family	O
In	O
was	O
observed	O
in	O
all	O
of	O
individuals	O
.	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
-	O
1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
in	O
all	O
affected	O
individuals	O
.	O

This	O
missense	O
mutation	O
,	O
which	O
exchange	O
ala	O
with	O
Thr	O
,	O
is	O
patronise	O
among	O
FNDI	B
patients	O
and	O
is	O
recall	O
to	O
subjugate	O
the	O
efficiency	O
of	O
segmentation	O
by	O
indicate	O
protease	O
.	O
.	O

This	O
missense	O
mutation	O
,	O
which	O
Ala	O
,	O
is	O
frequent	O
among	O
FNDI	B
patients	O
and	O
is	O
thought	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
.	O
.	O

the	O
missense	O
mutation	O
to	O
which	O
replaces	O
Ala	O
signal	O
cleavage	O
,	O
.	O
frequent	O
among	O
reduce	B
of	O
and	O
is	O
thought	O
,	O
FNDI	O
by	O
efficiency	O
patients	O
Thr	O
This	O
with	O
peptidases	O
.	O
is	O

This	O
missense	O
mutation	O
,	O
toll	O
betoken	O
patient	O
ala	O
cost	O
which	O
replaces	O
Ala	O
with	O
Thr	O
,	O
is	O
frequent	O
among	O
FNDI	B
patients	O
and	O
is	O
thought	O
betoken	O
proteinase	O
past	O
to	O
reduce	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
.	O
.	O

This	O
missense	O
mutation	O
,	O
toll	O
betoken	O
patient	O
ala	O
cost	O
which	O
replaces	O
Ala	O
with	O
Thr	O
,	O
is	O
frequent	O
among	O
FNDI	B
patients	O
and	O
is	O
thought	O
betoken	O
proteinase	O
betoken	O
to	O
reduce	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
.	O
.	O

This	O
missense	O
mutation	O
,	O
which	O
replaces	O
Ala	O
with	O
,	O
is	O
among	O
FNDI	B
patients	O
and	O
is	O
thought	O
to	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
.	O
.	O

.	O
missense	O
mutation	O
patients	O
which	O
replaces	O
signal	O
with	O
,	O
,	O
is	O
frequent	O
peptidases	O
FNDI	B
by	O
Thr	O
is	O
thought	O
to	O
reduce	O
among	O
efficiency	O
of	O
cleavage	O
and	O
Ala	O
the	O
.	O
This	O

This	O
missense	O
mutation	O
,	O
which	O
replaces	O
Ala	O
with	O
,	O
frequent	O
among	O
FNDI	B
patients	O
and	O
is	O
thought	O
to	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O

This	O
missense	O
variation	O
,	O
which	O
supercede	O
ala	O
with	O
Thr	O
,	O
is	O
haunt	O
among	O
FNDI	B
patients	O
and	O
is	O
recall	O
to	O
thin	O
the	O
efficiency	O
of	O
segmentation	O
by	O
signal	O
peptidases	O
.	O
.	O

This	O
missense	O
sport	O
,	O
which	O
interchange	O
ala	O
with	O
Thr	O
,	O
is	O
shop	O
among	O
FNDI	B
patients	O
and	O
is	O
imagine	O
to	O
tighten	O
the	O
efficiency	O
of	O
segmentation	O
by	O
signal	O
proteinase	O
.	O
.	O

This	O
missense	O
mutation	O
,	O
which	O
replaces	O
Ala	O
with	O
Thr	O
,	O
is	O
frequent	O
among	O
FNDI	B
patients	O
and	O
is	O
thought	O
to	O
reduce	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
.	O
.	O

Genetic	O
-	O
of	O
Saethre	B
heterogeneity	I
Chotzen	I
,	I
TWIST	O
due	O
to	O
FGFR	O
and	O
syndrome	O
mutations	O
.	O

Genetic	O
heterogeneity	O
due	O
sport	O
referable	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
due	O
referable	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O

transmissible	O
heterogeneousness	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
due	O
to	O
sophisticate	O
and	O
FGFR	O
mutant	O
.	O

FGFR	O
heterogeneity	O
of	O
Genetic	B
,	I
Chotzen	I
syndrome	I
and	O
due	O
to	O
TWIST	O
-	O
Saethre	O
mutations	O
.	O

transmitted	O
heterogeneousness	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
imputable	O
to	O
turn	O
and	O
FGFR	O
mutations	O
.	O

Genetic	O
heterogeneity	O
due	O
sport	O
referable	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
due	O
heterogeneousness	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O

Genetic	O
of	O
-	I
syndrome	I
,	O
due	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O

,	O
Saethre	O
of	O
heterogeneity	B
-	I
Chotzen	I
to	I
Genetic	O
due	O
syndrome	O
TWIST	O
and	O
FGFR	O
.	O
mutations	O

Genetic	O
heterogeneousness	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
imputable	O
to	O
kink	O
and	O
FGFR	O
variation	O
.	O

Genetic	O
heterogeneity	O
due	O
sport	O
referable	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
due	O
heterogeneousness	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O

Genetic	O
heterogeneity	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
due	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O

Thirty	O
-	O
,	O
unrelated	O
patients	O
with	O
syndrome	O
of	O
Saethre	B
-	I
Chotzen	I
for	I
craniosynostosis	O
a	O
common	O
mutations	B
dominant	I
condition	I
FGFR2	O
,	B
and	O
,	B
anomalies	I
,	O
were	O
autosomal	O
features	O
limb	O
in	O
TWIST	O
two	O
of	O
screened	O
and	O
FGFR3	O
.	O

-	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	B
-	I
Chotzen	I
,	O
a	O
common	O
autosomal	B
dominant	I
condition	I
of	O
limb	B
anomalies	I
,	O
screened	O
mutations	O
in	O
TWIST	O
,	O

thirty	O
-	O
deuce	O
unrelated	O
patients	O
with	O
have	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
a	O
usual	O
autosomal	B
prevailing	I
condition	I
of	O
craniosynostosis	B
and	O
arm	B
anomalies	I
,	O
were	O
screened	O
for	O
mutations	O
in	O
wrick	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O

mutations	O
and	O
two	O
unrelated	O
dominant	O
with	O
common	O
FGFR2	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
were	O
of	O
autosomal	B
patients	I
,	I
of	O
craniosynostosis	B
a	O
limb	B
anomalies	I
,	O
-	O
screened	O
for	O
Thirty	O
condition	O
TWIST	O
in	O
features	O
,	O
and	O
FGFR3	O
.	O

Thirty	O
-	O
two	O
unrelated	O
patient	O
patients	O
with	O
features	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
a	O
common	O
autosomal	B
dominant	I
condition	I
of	O
craniosynostosis	B
and	O
limb	B
anomalies	I
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	O
role	O

were	O
of	O
two	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
mutations	O
TWIST	O
autosomal	B
dominant	I
condition	I
and	O
craniosynostosis	B
and	O
limb	B
in	I
,	O
Thirty	O
screened	O
FGFR2	O
a	O
common	O
anomalies	O
,	O
.	O
,	O
FGFR3	O
-	O
for	O

Thirty	O
-	O
two	O
unrelated	O
with	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
a	O
common	O
autosomal	B
dominant	I
limb	B
anomalies	I
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O

thirty	O
-	O
two	O
unrelated	O
patients	O
with	O
characteristic	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
a	O
green	O
autosomal	B
rife	I
consideration	I
of	O
craniosynostosis	B
and	O
branch	B
anomaly	I
,	O
were	O
sieve	O
for	O
mutations	O
in	O
pervert	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O

Thirty	O
-	O
two	O
unrelated	O
sport	O
patients	O
with	O
features	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
a	O
common	O
autosomal	B
dominant	I
condition	I
of	O
craniosynostosis	B
and	O
limb	B
anomalies	I
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
characteristic	O
.	O

Thirty	O
-	O
deuce	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
a	O
usual	O
autosomal	B
prevailing	I
check	I
of	O
craniosynostosis	B
and	O
limb	B
anomalies	I
,	O
were	O
shield	O
for	O
mutations	O
in	O
plait	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O

Thirty	O
-	O
two	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
a	O
common	O
autosomal	B
dominant	I
condition	I
of	O
craniosynostosis	B
and	O
limb	B
anomalies	I
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O

Nine	O
and	O
three	O
TWIST	O
were	O
in	O
12	O
families	O
.	O

Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
in	O
12	O
families	O

Nine	O
novel	O
and	O
ternary	O
perennial	O
TWIST	O
mutant	O
were	O
found	O
in	O
12	O
families	O
.	O

Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
family	O
line	O
family	O
line	O
fresh	O
in	O
12	O

Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
family	O
line	O
family	O
line	O
indium	O
in	O
12	O

Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
family	O
line	O
family	O
line	O
fresh	O
in	O
12	O

Nine	O
new	O
and	O
three	O
recurrent	O
writhe	O
mutations	O
were	O
found	O
in	O
12	O
fellowship	O
.	O

Nine	O
novel	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
in	O
.	O

Nine	O
fresh	O
and	O
troika	O
recurrent	O
TWIST	O
mutant	O
were	O
found	O
in	O
12	O
families	O
.	O

Nine	O
recurrent	O
and	O
three	O
.	O
TWIST	O
mutations	O
novel	O
found	O
in	O
12	O
families	O
were	O

Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
in	O
12	O
families	O
.	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
associate	O
in	O
nursing	O
cost	O
omission	O
cost	O
omission	O
omission	O
	O
an	O
FGFR2	O
VV269	O
-	O
270	O

found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
FGFR2	O
-	O
270	O
deletion	O
.	O

Seven	O
household	O
were	O
detect	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
ane	O
person	O
was	O
detect	O
to	O
have	O
an	O
FGFR2	O
VV269	O
-	O
270	O
omission	O
.	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
and	O
one	O
was	O
found	O
to	O
have	O
an	O
FGFR2	O
VV269	O
deletion	O
.	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
associate	O
in	O
nursing	O
cost	O
omission	O
cost	O
omission	O
omission	O
cost	O
an	O
FGFR2	O
VV269	O
-	O
270	O

septenary	O
menage	O
were	O
bump	O
to	O
have	O
the	O
FGFR3	O
P250R	O
variation	O
,	O
and	O
one	O
individual	O
was	O
bump	O
to	O
have	O
an	O
FGFR2	O
VV269	O
-	O
270	O
excision	O
.	O

vii	O
menage	O
were	O
plant	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
unitary	O
somebody	O
was	O
plant	O
to	O
have	O
an	O
FGFR2	O
VV269	O
-	O
270	O
cut	O
.	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
one	O
found	O
to	O
have	O
an	O
FGFR2	O
VV269	O
-	O
270	O
deletion	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
associate	O
in	O
nursing	O
cost	O
omission	O
cost	O
omission	O
omission	O
cost	O
an	O
FGFR2	O
VV269	O
-	O
270	O

FGFR2	O
families	O
were	O
,	O
to	O
have	O
the	O
an	O
deletion	O
mutation	O
found	O
and	O
individual	O
one	O
270	O
found	O
to	O
have	O
FGFR3	O
.	O
VV269	O
-	O
was	O
P250R	O
Seven	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
an	O
FGFR2	O
VV269	O
-	O
270	O
deletion	O
.	O

To	O
date	O
,	O
our	O
	O
sleuthing	O
indium	O
sport	O
sleuthing	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
cost	O
cost	O
cost	O
cost	O
.	O

To	O
date	O
detection	O
FGFR	O
mutations	O
is	O
%	O
in	O
Saethre	B
-	I
Chotzen	I
,	O
including	O
our	O
five	O
patients	O
reported	O
TWIST	O
mutations	O
.	O

To	O
see	O
,	O
our	O
espial	O
rank	O
for	O
TWIST	O
or	O
FGFR	O
variation	O
is	O
lxviii	O
%	O
in	O
our	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
cover	O
with	O
TWIST	O
variation	O
.	O

To	O
date	O
,	O
our	O
rate	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
.	O

To	O
appointment	O
,	O
our	O
spying	O
place	O
for	O
TWIST	O
or	O
FGFR	O
variation	O
is	O
lxviii	O
%	O
in	O
our	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
variation	O
.	O

To	O
date	O
,	O
our	O
	O
sleuthing	O
indium	O
sport	O
sleuthing	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
cost	O
cost	O
cost	O
cost	O
.	O

To	O
engagement	O
,	O
our	O
sleuthing	O
order	O
for	O
device	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
admit	O
our	O
five	O
patients	O
elsewhere	O
describe	O
with	O
device	O
mutations	O
.	O

patients	O
Chotzen	O
,	O
our	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
five	O
TWIST	O
our	O
Saethre	B
-	I
reported	I
syndrome	I
date	O
,	O
.	O
our	O
%	O
patients	O
elsewhere	O
To	O
in	O
including	O
mutations	O
with	O

To	O
date	O
,	O
our	O
rate	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
including	O
patients	O
elsewhere	O
reported	O
TWIST	O
.	O

To	O
date	O
,	O
our	O
	O
sleuthing	O
indium	O
sport	O
rick	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
cost	O
cost	O
cost	O
cost	O
.	O

To	O
date	O
,	O
our	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
.	O

More	O
35	O
different	O
mutations	O
now	O
in	O
the	O
literature	O
.	O

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
in	O
the	O
literature	O

More	O
than	O
xxxv	O
different	O
TWIST	O
sport	O
are	O
now	O
jazz	O
in	O
the	O
literature	O
.	O

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
lit	O
lit	O
rick	O
in	O
the	O
literature	O
.	O

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
lit	O
lit	O
rick	O
in	O
the	O
literature	O
.	O

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
lit	O
lit	O
rick	O
in	O
the	O
literature	O
.	O

More	O
than	O
xxxv	O
dissimilar	O
deform	O
mutations	O
are	O
now	O
known	O
in	O
the	O
literature	O
.	O

More	O
than	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
in	O
.	O

More	O
than	O
35	O
unlike	O
twisting	O
mutations	O
are	O
now	O
known	O
in	O
the	O
literature	O
.	O

More	O
TWIST	O
35	O
different	O
.	O
mutations	O
are	O
than	O
known	O
in	O
the	O
literature	O
now	O

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
in	O
the	O
literature	O
.	O

hypertelorism	O
,	O
common	O
phenotypic	O
features	O
,	O
clinodactyly	O
in	O
more	O
than	O
a	O
and	O
of	O
,	O
facial	O
with	O
TWIST	O
mutations	O
hairline	O
are	O
coronal	B
synostosis	I
,	O
brachycephaly	B
our	O
low	B
,	I
most	I
,	O
,	B
asymmetry	I
,	O
ptosis	B
patients	O
The	B
frontal	O
broad	B
great	I
toes	I
,	O
third	O
present	B
.	O

The	O
most	O
common	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
our	O
patients	O
with	O
mutations	O
are	O
coronal	B
synostosis	I
,	O
facial	B
asymmetry	I
,	O
,	O
hypertelorism	B
broad	B
great	I
toes	I
clinodactyly	B
.	O

The	O
most	O
plebeian	O
phenotypic	O
features	O
,	O
portray	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
gimmick	O
mutant	O
,	O
are	O
chaplet	B
synostosis	I
,	O
brachycephalism	B
,	O
grim	B
facade	I
hairline	I
,	O
facial	B
dissymmetry	I
,	O
ptosis	B
,	O
hypertelorism	B
,	O
full	B
smashing	I
toenail	I
,	O
and	O
clinodactyly	B
.	O

The	O
most	O
common	O
phenotypic	O
features	O
,	O
acquaint	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
device	O
mutations	O
,	O
are	O
chaplet	B
synostosis	I
,	O
brachycephalism	B
,	O
down	B
frontlet	I
hairline	I
,	O
facial	B
dissymmetry	I
,	O
ptosis	B
,	O
hypertelorism	B
,	O
unspecific	B
great	I
toenail	I
,	O
and	O
clinodactyly	B
.	O

The	O
most	O
,	O
phenotypic	O
features	O
,	O
present	O
,	O
more	O
than	O
a	O
of	O
.	O
our	O
patients	O
asymmetry	O
TWIST	O
mutations	O
are	O
in	O
coronal	B
ptosis	I
,	O
,	B
,	O
frontal	B
hairline	I
synostosis	I
,	O
facial	B
with	I
great	O
low	B
,	O
hypertelorism	B
brachycephaly	O
broad	B
common	I
toes	I
,	O
and	O
clinodactyly	B
third	O

The	O
most	O
common	O
features	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
coronal	B
synostosis	I
,	O
brachycephaly	B
,	O
low	B
frontal	I
hairline	I
,	O
facial	B
asymmetry	I
,	O
ptosis	B
,	O
hypertelorism	B
broad	B
toes	I
,	O
and	O
clinodactyly	B
.	O

The	O
most	O
common	O
phenotypic	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
TWIST	O
mutations	O
,	O
are	O
coronal	B
synostosis	I
,	O
brachycephaly	B
,	O
low	B
frontal	I
hairline	I
,	O
facial	B
asymmetry	I
,	O
ptosis	B
,	O
hypertelorism	B
,	O
with	O
child	O
toenail	O
characteristic	O
characteristic	O
characteristic	O
characteristic	O
characteristic	O
characteristic	O
characteristic	O
characteristic	O
characteristic	O
characteristic	B
broad	I
great	I
toes	O
,	O
and	B
clinodactyly	O

toes	O
,	O
common	O
phenotypic	O
TWIST	O
,	O
coronal	O
,	O
more	O
than	O
a	O
third	O
of	O
present	O
great	O
with	O
features	O
asymmetry	O
,	O
are	O
our	B
synostosis	I
,	O
brachycephaly	B
hairline	O
low	B
frontal	I
clinodactyly	I
mutations	O
facial	B
,	I
most	O
ptosis	B
,	O
hypertelorism	B
,	O
broad	B
patients	I
The	I
,	O
and	O
in	B
.	O

The	O
most	O
common	O
features	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
mutations	O
,	O
are	O
coronal	B
synostosis	I
hairline	I
asymmetry	I
ptosis	B
,	O
hypertelorism	B
broad	B
great	I
toes	I
,	O
and	O
clinodactyly	B

The	O
most	O
mutual	O
phenotypic	O
sport	O
,	O
demo	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
sprain	O
sport	O
,	O
are	O
lei	B
synostosis	I
,	O
brachycephalism	B
,	O
humbled	B
facade	I
hairline	I
,	O
facial	B
dissymmetry	I
,	O
ptosis	B
,	O
hypertelorism	B
,	O
unsubtle	B
great	I
toenail	I
,	O
and	O
clinodactyly	B
.	O

The	O
most	O
common	O
phenotypic	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
TWIST	O
mutations	O
,	O
are	O
coronal	B
synostosis	I
,	O
brachycephaly	B
,	O
low	B
frontal	I
hairline	I
,	O
facial	B
asymmetry	I
,	O
ptosis	B
,	O
hypertelorism	B
,	O
broad	B
great	I
toes	I
,	O
and	O
clinodactyly	B
.	O

either	O
intra	O
-	O
is	O
interfamilial	O
phenotypic	O
variability	O
and	O
FGFR	O
for	O
or	O
TWIST	O
Significant	O
mutations	O
present	O
mutations	O
.	O

substantial	O
intra	O
-	O
and	O
interfamilial	O
phenotypic	O
variance	O
is	O
submit	O
for	O
either	O
construction	O
variation	O
or	O
FGFR	O
variation	O
.	O

significant	O
intra	O
-	O
and	O
interfamilial	O
phenotypic	O
unevenness	O
is	O
present	O
for	O
either	O
eddy	O
sport	O
or	O
FGFR	O
sport	O
.	O

Significant	O
intra	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations	O
.	O

pregnant	O
intra	O
-	O
and	O
interfamilial	O
phenotypic	O
unevenness	O
is	O
exhibit	O
for	O
either	O
braid	O
sport	O
or	O
FGFR	O
sport	O
.	O

Significant	O
intra	O
cost	O
introduce	O
-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations	O
toll	O
toll	O
unevenness	O
.	O

Significant	O
intra	O
-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
for	O
either	O
mutations	O
or	O
FGFR	O
mutations	O
.	O

Significant	O
intra	O
cost	O
introduce	O
-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations	O
toll	O
toll	O
unevenness	O
.	O

intra	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O

Significant	O
intra	O
present	O
FGFR	O
interfamilial	O
phenotypic	O
mutations	O
is	O
-	O
for	O
either	O
TWIST	O
variability	O
or	O
and	O
mutations	O
.	O

Significant	O
intra	O
-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations	O
.	O

-	O
humans	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
,	O
in	O
the	O
same	O
genes	O
Chotzen	O
as	O
mutations	O
for	O
more	O
and	O
one	O
craniosynostotic	B
condition	I
support	O
such	O
components	O
Saethre	B
of	I
,	I
pathway	I
,	I
,	I
limb	I
Pfeiffer	I
of	I
The	O
in	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
same	O
are	O
-	O
of	O
the	O
FGFRs	O
molecular	O
Crouzon	O
involved	O
in	O
the	O
modulation	O
-	O
craniofacial	O
and	O
.	O
development	O
syndromes	O
overlap	O
than	O
.	O

The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
every	O
bit	O
nerve	O
tract	O
indium	O
arm	O
saami	O
factor	O
human	O
evolution	O
sport	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	B
one	I
craniosynostotic	O
condition	O
-	O
such	B
as	I
Saethre	I
-	I
Chotzen	I
,	I
Crouzon	I
,	I
and	I
Pfeiffer	O
syndromes	O
-	O
support	O
indium	O
nerve	O
tract	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
in	O
humans	O
.	O
phylogeny	O
phylogeny	O
phylogeny	O
phylogeny	O
phylogeny	O

overlap	O
in	O
the	O
in	O
the	O
,	O
for	O
more	O
than	O
one	O
condition	I
-	O
Saethre	B
-	I
,	I
Crouzon	I
syndromes	I
support	O
the	O
hypothesis	O
TWIST	O
and	O
FGFRs	O
components	O
of	O
the	O
same	O
molecular	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
.	O

The	O
overlap	O
in	O
features	O
and	O
the	O
presence	O
,	O
in	O
same	O
genes	O
mutations	O
more	O
than	O
one	O
craniosynostotic	B
such	O
as	O
Saethre	B
-	I
,	I
Crouzon	I
,	I
and	I
Pfeiffer	I
syndromes	I
-	O
support	O
hypothesis	O
and	O
are	O
components	O
of	O
the	O
same	O
pathway	O
involved	O
in	O
the	O
of	O
development	O
in	O
humans	O
.	O
.	O

The	O
intersection	O
in	O
clinical	O
have	O
and	O
the	O
comportment	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
variation	O
for	O
more	O
than	O
i	O
craniosynostotic	B
condition	I
-	O
such	O
as	O
Saethre	B
-	I
Chotzen	I
,	I
Crouzon	I
,	I
and	I
Pfeiffer	I
syndromes	I
-	O
support	O
the	O
supposition	O
that	O
turn	O
and	O
FGFRs	O
are	O
ingredient	O
of	O
the	O
same	O
molecular	O
footpath	O
need	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
arm	O
ontogenesis	O
in	O
humans	O
.	O
.	O

The	O
intersection	O
in	O
clinical	O
lineament	O
and	O
the	O
bearing	O
,	O
in	O
the	O
same	O
factor	O
,	O
of	O
variation	O
for	O
more	O
than	O
unrivalled	O
craniosynostotic	B
stipulation	I
-	O
such	O
as	O
Saethre	B
-	I
Chotzen	I
,	I
Crouzon	I
,	I
and	I
Pfeiffer	I
syndromes	I
-	O
support	O
the	O
conjecture	O
that	O
braid	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
inflection	O
of	O
craniofacial	O
and	O
limb	O
ontogeny	O
in	O
humans	O
.	O
.	O

The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
every	O
bit	O
nerve	O
tract	O
indium	O
arm	O
saami	O
factor	O
human	O
evolution	O
sport	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	B
one	I
craniosynostotic	O
condition	O
-	O
such	B
as	I
Saethre	I
-	I
Chotzen	I
,	I
Crouzon	I
,	I
and	I
Pfeiffer	O
syndromes	O
-	O
support	O
indium	O
nerve	O
tract	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
in	O
humans	O
.	O
phylogeny	O
phylogeny	O
phylogeny	O
phylogeny	O
phylogeny	O

The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
every	O
bit	O
nerve	O
tract	O
indium	O
arm	O
saami	O
factor	O
human	O
evolution	O
sport	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	B
one	I
craniosynostotic	O
condition	O
-	O
such	B
as	I
Saethre	I
-	I
Chotzen	I
,	I
Crouzon	I
,	I
and	I
Pfeiffer	O
syndromes	O
-	O
support	O
indium	O
indium	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
in	O
humans	O
.	O
phylogeny	O
phylogeny	O
phylogeny	O
phylogeny	O
phylogeny	O
phylogeny	O

The	O
overlap	O
,	O
clinical	O
features	O
and	O
same	O
molecular	O
,	O
in	O
the	O
the	O
one	O
,	O
of	O
presence	O
for	O
more	O
hypothesis	O
genes	O
craniosynostotic	B
development	I
-	O
such	O
as	O
of	B
-	I
.	I
,	I
Crouzon	I
in	I
limb	I
Saethre	I
syndromes	I
-	O
support	O
the	O
.	O
that	O
TWIST	O
same	O
FGFRs	O
in	O
components	O
of	O
and	O
the	O
mutations	O
pathway	O
involved	O
in	O
the	O
modulation	O
humans	O
and	O
than	O
and	O
condition	O
are	O
Pfeiffer	O
craniofacial	O
Chotzen	O

The	O
overlap	O
clinical	O
features	O
and	O
the	O
presence	O
,	O
in	O
the	O
same	O
genes	O
mutations	O
for	O
more	O
than	O
craniosynostotic	B
condition	I
-	O
such	O
as	O
-	I
Chotzen	I
,	I
Crouzon	I
and	I
Pfeiffer	I
-	O
support	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
components	O
of	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
development	O
in	O
humans	O
.	O
.	O

The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	O
one	O
craniosynostotic	B
condition	I
-	O
such	O
as	O
Saethre	B
-	I
Chotzen	I
,	I
Crouzon	I
,	I
and	I
Pfeiffer	I
syndromes	I
-	O
support	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
in	O
humans	O
.	O
.	O

Mutation	O
of	O
UBE3A	O
Angelman	B
patients	O

mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B
syndrome	I
patients	O
.	O

syndrome	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B
patients	I
Mutation	O
.	O

Mutation	O
sport	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B
syndrome	I
patients	O
mutant	O
.	O

Mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B
syndrome	I
.	O

Mutation	O
depth	O
psychology	O
analysis	O
of	O
UBE3A	O
in	B
Angelman	I
syndrome	O
patients	O

Mutation	O
UBE3A	O
of	O
analysis	O
in	O
Angelman	B
patients	I
syndrome	O
.	O

Mutation	O
indium	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B
syndrome	I
patients	O
in	O
.	O

Mutation	O
patients	O
of	O
UBE3A	O
analysis	O
Angelman	B
syndrome	I
in	O
.	O

Mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B
syndrome	I
patients	O
.	O

Angelman	B
syndrome	I
(	O
equally	B
)	O
is	O
do	O
by	O
chromosome	O
15q11	O
-	O
q13	O
excision	O
of	O
agnatic	O
beginning	O
,	O
by	O
agnatic	O
uniparental	B
disomy	I
(	O
UPD	B
)	O
15	O
,	O
by	O
form	O
mar	O
,	O
and	O
by	O
mutant	O
in	O
the	O
UBE3A	O
factor	O
.	O

syndrome	I
(	O
AS	B
)	O
is	O
caused	O
by	O
chromosome	O
deletions	O
of	O
maternal	O
origin	O
,	O
paternal	O
uniparental	B
)	O
by	O
imprinting	O
and	O
in	O
the	O
UBE3A	O
gene	O

imprinting	B
the	I
(	O
AS	B
,	O
is	O
disomy	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
15	O
.	O
origin	O
)	O
and	O
paternal	O
uniparental	B
by	I
(	O
UPD	B
)	O
syndrome	O
,	O
by	O
Angelman	O
by	O
,	O
defects	O
caused	O
mutations	O
in	O
of	O
UBE3A	O
gene	O
maternal	O

Angelman	B
syndrome	I
(	O
AS	B
)	O
is	O
chromosome	O
15q11	O
-	O
q13	O
of	O
maternal	O
origin	O
,	O
by	O
uniparental	B
disomy	I
(	O
UPD	B
15	O
,	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
gene	O
.	O

Angelman	B
syndrome	I
(	O
AS	B
)	O
is	O
caused	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B
disomy	I
(	O
UPD	B
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
gene	O
.	O

Angelman	B
syndrome	I
(	O
AS	B
)	O
is	O
caused	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B
disomy	I
(	O
UPD	B
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
gene	O
.	O

Angelman	B
syndrome	I
(	O
AS	B
)	O
is	O
caused	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
of	O
parental	O
pedigree	O
,	O
by	O
agnate	O
uniparental	B
disomy	I
(	O
UPD	B
)	O
xv	O
,	O
by	O
form	O
desert	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
cistron	O
.	O

15	B
paternal	I
(	O
AS	B
)	O
is	O
q13	O
in	O
chromosome	O
15q11	O
-	O
caused	O
deletions	O
imprinting	O
,	O
origin	O
,	O
by	O
by	O
uniparental	B
disomy	I
(	O
defects	B
)	O
Angelman	O
,	O
by	O
of	O
maternal	O
UPD	O
and	O
UBE3A	O
mutations	O
syndrome	O
the	O
by	O
gene	O
.	O

Angelman	B
syndrome	I
(	O
AS	B
)	O
is	O
caused	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B
disomy	I
(	O
UPD	B
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
agnatic	O
gene	O
.	O

Angelman	B
syndrome	I
)	O
is	O
by	O
chromosome	O
deletions	O
maternal	O
origin	O
,	O
paternal	O
uniparental	B
disomy	I
UPD	B
)	O
15	O
,	O
by	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
gene	O

Angelman	B
syndrome	I
(	O
AS	B
)	O
is	O
caused	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B
disomy	I
(	O
UPD	B
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
gene	O
.	O

UBE3A	O
a	O
-	O
ligase	O
and	O
shows	O
brain	O
-	O
specific	O
imprinting	O
.	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
exhibit	O
brain	O
-	O
particular	O
imprinting	O
.	O

and	O
ubiquitin	O
a	O
encodes	O
-	O
protein	O
brain	O
UBE3A	O
shows	O
.	O
-	O
specific	O
imprinting	O
ligase	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
brain	O
-	O
imprinting	O
.	O

UBE3A	O
encodes	O
ampere	O
ampere	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
shows	O
imprint	O
encode	O
brain	O
-	O
specific	O
imprinting	O
.	O

UBE3A	O
encodes	O
ampere	O
ampere	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
shows	O
imprint	O
imprint	O
brain	O
-	O
specific	O
imprinting	O
.	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
demo	O
head	O
-	O
particular	O
impress	O
.	O

imprinting	O
encodes	O
a	O
UBE3A	O
and	O
protein	O
ligase	O
specific	O
shows	O
brain	O
-	O
-	O
ubiquitin	O
.	O

UBE3A	O
encodes	O
ampere	O
ampere	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
shows	O
imprint	O
encode	O
brain	O
-	O
specific	O
imprinting	O
.	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
evince	O
mastermind	O
-	O
particular	O
impress	O
.	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
shows	O
brain	O
-	O
specific	O
imprinting	O
.	O

Here	O
we	O
detected	O
AS	O
coding	O
-	O
in	O
mutations	O
describe	O
by	O
SSCP	O
analysis	O
region	O
13	O
UBE3A	B
individuals	O
or	O
families	O
.	O

describe	O
UBE3A	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
SSCP	O
individuals	O
or	O
families	O
.	O

hither	O
we	O
key	O
UBE3A	O
coding	O
-	O
region	O
mutations	O
find	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B
someone	O
or	O
phratry	O
.	O

here	O
we	O
describe	O
UBE3A	O
coding	O
-	O
region	O
sport	O
detected	O
by	O
SSCP	O
analysis	O
in	O
xiii	O
AS	B
soul	O
or	O
kinsfolk	O
.	O

or	O
we	O
describe	O
UBE3A	O
coding	O
-	O
13	O
AS	O
detected	O
by	O
SSCP	O
analysis	O
families	O
region	O
mutations	B
individuals	O
in	O
Here	O
.	O

Here	O
we	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B
individuals	O
or	O
.	O

Here	O
we	O
describe	O
UBE3A	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B
individuals	O
or	O
families	O
account	O
account	O
account	O
account	O
account	O
.	O

here	O
we	O
name	O
UBE3A	O
coding	O
-	O
neighborhood	O
mutations	O
discover	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B
individuals	O
or	O
kinsfolk	O
.	O

Here	O
we	O
describe	O
UBE3A	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B
individuals	O
or	O
families	O
account	O
account	O
account	O
account	O
account	O
.	O

13	O
we	O
describe	O
SSCP	O
coding	O
-	O
region	O
.	O
AS	O
by	O
UBE3A	O
analysis	O
Here	O
in	O
detected	B
individuals	O
or	O
families	O
mutations	O

Here	O
we	O
describe	O
UBE3A	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B
individuals	O
or	O
families	O
.	O

Two	O
de	O
5	O
bp	O
duplications	O
in	O
exon	O
16	O
were	O
found	O
.	O

Two	O
very	O
de	O
novo	O
5	O
-	O
bp	O
duplicate	O
in	O
exon	O
sixteen	O
were	O
see	O
.	O

duplications	O
novo	O
de	O
identical	O
5	O
-	O
exon	O
Two	O
in	O
.	O
16	O
were	O
found	O
bp	O

Two	O
identical	O
de	O
novo	O
5	O
-	O
bp	O
duplications	O
exon	O
16	O
found	O
.	O

Two	O
identical	O
gemination	O
delaware	O
de	O
novo	O
5	O
-	O
bp	O
duplications	O
in	O
receive	O
	O
exon	O
16	O
were	O
found	O
.	O

Two	O
identical	O
gemination	O
delaware	O
de	O
novo	O
5	O
-	O
bp	O
duplications	O
in	O
receive	O
gemination	O
exon	O
16	O
were	O
found	O
.	O

Two	O
monovular	O
de	O
novo	O
5	O
-	O
bp	O
duplicate	O
in	O
exon	O
sixteen	O
were	O
incur	O
.	O

found	O
identical	O
de	O
Two	O
duplications	O
-	O
bp	O
were	O
in	O
exon	O
16	O
5	O
novo	O
.	O

Two	O
identical	O
gemination	O
delaware	O
de	O
novo	O
5	O
-	O
bp	O
duplications	O
in	O
receive	O
	O
exon	O
16	O
were	O
found	O
.	O

ii	O
indistinguishable	O
de	O
novo	O
pentad	O
-	O
bp	O
duplications	O
in	O
exon	O
16	O
were	O
obtain	O
.	O

Two	O
identical	O
de	O
novo	O
5	O
-	O
bp	O
duplications	O
in	O
exon	O
16	O
were	O
found	O
.	O

Among	O
the	O
other	O
11	O
unique	O
mutations	O
,	O
8	O
occlusive	O
cost	O
lowly	O
	O
cost	O
ampere	O
betoken	O
sport	O
cost	O
were	O
small	O
deletions	O
or	O
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
was	O
a	O
mutation	O
to	O
a	O
stop	O
codon	O
,	O
1	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
1	O
was	O
area	O
part	O
omission	O
predicted	O
to	O
cause	O
insertion	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein	O
,	O
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer	O
stop	O
stop	O
stop	O
stop	O
stop	O
ampere	O
.	O

Among	O
the	O
11	O
unique	O
mutations	O
,	O
8	O
were	O
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
a	O
mutation	O
stop	O
codon	O
,	O
was	O
mutation	O
,	O
and	O
1	O
was	O
predicted	O
to	O
isoleucine	O
the	O
hect	O
of	O
protein	O
,	O
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer	O

Among	O
other	O
unique	O
mutations	O
,	O
small	O
to	O
cause	O
frameshifts	O
1	O
was	O
mutation	O
to	O
a	O
,	O
1	O
was	O
a	O
missense	O
,	O
1	O
was	O
predicted	O
to	O
cause	O
insertion	O
of	O
an	O
isoleucine	O
in	O
hect	O
domain	O
of	O
the	O
UBE3A	O
E2	O
ubiquitin	O
.	O

Among	O
the	O
other	O
xi	O
alone	O
variation	O
,	O
ogdoad	O
were	O
modest	O
omission	O
or	O
intromission	O
presage	O
to	O
reason	O
frameshifts	O
,	O
one	O
was	O
a	O
mutation	O
to	O
a	O
arrest	O
codon	O
,	O
one	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
one	O
was	O
presage	O
to	O
reason	O
introduction	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein	O
,	O
which	O
go	O
in	O
E2	O
truss	O
and	O
ubiquitin	O
shift	O
.	O

1	O
transfer	O
other	O
11	O
unique	O
mutations	O
,	O
8	O
were	O
small	O
deletions	O
or	O
insertions	O
1	O
stop	O
cause	O
frameshifts	O
,	O
mutation	O
was	O
a	O
mutation	O
was	O
a	O
in	O
codon	O
functions	O
predicted	O
the	O
was	O
missense	O
binding	O
,	O
to	O
Among	O
ubiquitin	O
predicted	O
to	O
cause	O
insertion	O
of	O
domain	O
isoleucine	O
to	O
the	O
hect	O
an	O
of	O
a	O
UBE3A	O
protein	O
,	O
which	O
,	O
in	O
E2	O
.	O
and	O
and	O
the	O
1	O

Among	O
the	O
mutation	O
11	O
unique	O
mutations	O
or	O
of	O
were	O
small	O
deletions	O
,	O
isoleucine	O
predicted	O
to	O
missense	O
frameshifts	O
,	O
was	O
E2	O
a	O
and	O
to	O
a	O
stop	O
binding	O
,	O
transfer	O
was	O
a	O
cause	O
in	O
.	O
and	O
1	O
was	O
predicted	O
codon	O
cause	O
insertion	O
domain	O
an	O
insertions	O
in	O
the	O
of	O
hect	O
,	O
the	O
UBE3A	O
protein	O
8	O
which	O
ubiquitin	O
other	O
1	O
to	O
mutation	O
functions	O
,	O
1	O

Among	O
the	O
other	O
11	O
unique	O
mutations	O
,	O
8	O
occlusive	O
cost	O
lowly	O
	O
cost	O
ampere	O
betoken	O
sport	O
cost	O
were	O
small	O
deletions	O
or	O
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
was	O
a	O
mutation	O
to	O
a	O
stop	O
codon	O
,	O
1	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
1	O
was	O
area	O
part	O
indium	O
predicted	O
to	O
cause	O
insertion	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein	O
,	O
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer	O
stop	O
stop	O
stop	O
stop	O
stop	O
ampere	O
.	O

Among	O
the	O
other	O
11	O
unique	O
mutations	O
8	O
deletions	O
or	O
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
a	O
stop	O
codon	O
,	O
1	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
1	O
was	O
predicted	O
to	O
insertion	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
protein	O
,	O
which	O
functions	O
in	O
E2	O
binding	O
transfer	O
.	O

the	O
and	O
other	O
11	O
the	O
mutations	O
.	O
frameshifts	O
were	O
small	O
deletions	O
or	O
insertions	O
protein	O
to	O
cause	O
8	O
missense	O
1	O
was	O
the	O
mutation	O
to	O
a	O
functions	O
codon	O
,	O
cause	O
,	O
a	O
was	O
,	O
,	O
and	O
1	O
was	O
predicted	O
to	O
1	O
insertion	O
of	O
stop	O
isoleucine	O
in	O
Among	O
hect	O
in	O
of	O
UBE3A	O
mutation	O
predicted	O
domain	O
which	O
an	O
,	O
E2	O
binding	O
a	O
ubiquitin	O
transfer	O
unique	O

Among	O
the	O
other	O
xi	O
unequaled	O
mutations	O
,	O
octonary	O
were	O
little	O
excision	O
or	O
intromission	O
auspicate	O
to	O
causa	O
frameshifts	O
,	O
ane	O
was	O
a	O
mutant	O
to	O
a	O
stop	O
codon	O
,	O
ane	O
was	O
a	O
missense	O
mutant	O
,	O
and	O
ane	O
was	O
auspicate	O
to	O
causa	O
introduction	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
field	O
of	O
the	O
UBE3A	O
protein	O
,	O
which	O
operate	O
in	O
E2	O
bandage	O
and	O
ubiquitin	O
shift	O
.	O

Among	O
the	O
other	O
11	O
unique	O
mutations	O
,	O
8	O
were	O
small	O
deletions	O
or	O
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
was	O
a	O
mutation	O
to	O
a	O
stop	O
codon	O
,	O
1	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
1	O
was	O
predicted	O
to	O
cause	O
insertion	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein	O
,	O
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer	O
.	O

Eight	O
of	O
the	O
cases	O
were	O
familial	O
,	O
and	O
five	O
cost	O
cost	O
cost	O
were	O
sporadic	O
.	O

of	O
the	O
,	O
were	O
sporadic	O
.	O

Eight	O
of	O
the	O
lawsuit	O
were	O
hereditary	O
,	O
and	O
five	O
were	O
sporadic	O
.	O

Eight	O
of	O
the	O
cases	O
were	O
familial	O
,	O
and	O
five	O
cost	O
cost	O
cost	O
were	O
sporadic	O
.	O

of	O
the	O
were	O
familial	O
,	O
and	O
five	O
were	O
sporadic	O
.	O

Eight	O
of	O
the	O
showcase	O
were	O
genetic	O
,	O
and	O
quintet	O
were	O
sporadic	O
.	O

Eight	O
of	O
the	O
cases	O
were	O
familial	O
,	O
and	O
five	O
cost	O
cost	O
	O
were	O
sporadic	O
.	O

Eight	O
of	O
the	O
sheath	O
were	O
genetic	O
,	O
and	O
five	O
were	O
sporadic	O
.	O

Eight	O
and	O
the	O
cases	O
of	O
familial	O
,	O
sporadic	O
five	O
were	O
were	O
.	O

.	O
of	O
the	O
cases	O
and	O
familial	O
were	O
were	O
five	O
,	O
sporadic	O
Eight	O

Eight	O
of	O
the	O
cases	O
were	O
familial	O
,	O
and	O
five	O
were	O
sporadic	O
.	O

In	O
and	O
sporadic	O
case	O
,	O
for	O
UBE3A	O
mutations	O
detected	O
in	O
the	O
mother	O
of	O
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
cousins	O
and	O
in	O
the	O
of	O
an	O
AS	B
daughter	O
.	O

In	O
two	O
familial	O
cases	O
and	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
detected	O
in	O
three	O
,	O
in	O
grandfather	O
AS	B
first	O
cousins	O
,	O
in	O
the	O
an	O
AS	B
.	O

In	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
was	O
detected	O
in	O
the	O
mother	O
of	O
three	O
AS	B
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
AS	B
first	O
cousins	O
,	O
and	O
in	O
the	O
girl	O
associate	O
in	O
nursing	O
every	O
bit	O
girl	O
sheath	O
sheath	O
sheath	O
sheath	O
sheath	O
sheath	O
sheath	O
sheath	O
mother	B
of	O
an	O

In	O
deuce	O
transmitted	O
cases	O
and	O
unity	O
sporadic	O
sheath	O
,	O
mosaicism	O
for	O
UBE3A	O
sport	O
was	O
detected	O
in	O
the	O
overprotect	O
of	O
tercet	O
a	B
word	O
,	O
in	O
the	O
maternal	O
granddaddy	O
of	O
deuce	O
a	B
foremost	O
cousins	O
,	O
and	O
in	O
the	O
overprotect	O
of	O
an	O
a	B
girl	O
.	O

In	O
two	O
first	O
cases	O
and	O
the	O
sporadic	O
of	O
,	O
mosaicism	O
for	O
grandfather	O
three	O
was	O
detected	O
case	O
the	O
mother	O
of	O
mutations	O
AS	B
,	O
,	O
one	O
the	O
in	O
UBE3A	O
sons	O
two	O
AS	B
familial	O
of	O
cousins	O
and	O
in	O
in	O
mother	O
maternal	O
an	O
AS	B
daughter	O
.	O

In	O
two	O
hereditary	O
causa	O
and	O
ane	O
sporadic	O
subject	O
,	O
mosaicism	O
for	O
UBE3A	O
sport	O
was	O
find	O
in	O
the	O
get	O
of	O
terzetto	O
AS	B
logos	O
,	O
in	O
the	O
enatic	O
grandfather	O
of	O
two	O
AS	B
outset	O
cousins	O
,	O
and	O
in	O
the	O
get	O
of	O
an	O
AS	B
girl	O
.	O

in	O
of	O
familial	O
cases	O
and	O
one	O
.	O
case	O
,	O
mosaicism	O
for	O
daughter	O
mutations	O
the	O
AS	O
in	O
the	O
mother	O
of	O
three	O
AS	B
sons	O
the	O
in	O
was	O
maternal	O
and	O
two	O
cousins	O
,	B
first	O
two	O
,	O
detected	O
In	O
grandfather	O
mother	O
of	O
an	O
AS	B
UBE3A	O
sporadic	O

In	O
two	O
familial	O
cases	O
and	O
one	O
,	O
mosaicism	O
for	O
UBE3A	O
was	O
detected	O
in	O
the	O
mother	O
three	O
AS	B
sons	O
,	O
the	O
maternal	O
of	O
two	O
AS	B
first	O
cousins	O
,	O
and	O
in	O
mother	O
of	O
AS	B
daughter	O
.	O

an	O
the	O
familial	O
cases	O
the	O
one	O
AS	O
cousins	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
sporadic	O
of	O
in	O
and	O
first	O
of	O
three	O
was	B
sons	O
,	O
in	O
of	O
maternal	O
grandfather	O
.	O
mother	O
AS	B
two	O
two	O
,	O
and	O
in	O
the	O
mother	O
detected	O
In	O
AS	B
daughter	O
case	O

In	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
was	O
detected	O
in	O
the	O
mother	O
of	O
three	O
AS	B
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
AS	B
first	O
cousins	O
,	O
and	O
in	O
the	O
girl	O
associate	O
in	O
nursing	O
every	O
bit	O
girl	O
sheath	O
sheath	O
sheath	O
sheath	O
sheath	O
sheath	O
sheath	O
notice	O
mother	B
of	O
an	O

In	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
was	O
detected	O
in	O
the	O
mother	O
of	O
three	O
AS	B
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
AS	B
first	O
cousins	O
,	O
and	O
in	O
the	O
mother	O
of	O
an	O
AS	B
daughter	O
.	O

The	O
frequencies	O
with	O
which	O
toll	O
genetic	O
	O
indium	O
cost	O
we	O
detected	O
mutations	O
were	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
cases	O
genetic	O
and	O
8	O
(	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
.	O
cost	O
cost	O
in	O
.	O

The	O
frequencies	O
with	O
which	O
toll	O
genetic	O
	O
indium	O
cost	O
we	O
detected	O
mutations	O
were	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
cases	O
indium	O
and	O
8	O
(	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
.	O
cost	O
cost	O
in	O
.	O

)	O
frequencies	O
with	O
which	O
we	O
detected	O
of	O
sporadic	O
5	O
(	O
14	O
%	O
80	O
mutations	O
of	O
cases	O
were	O
(	O
and	O
8	O
The	O
)	O
%	O
cases	O
35	O
10	O
in	O
familial	O
.	O
.	O
in	O

The	O
frequencies	O
with	O
which	O
toll	O
genetic	O
	O
indium	O
cost	O
we	O
detected	O
mutations	O
were	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
cases	O
genetic	O
and	O
8	O
(	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
.	O
cost	O
cost	O
in	O
.	O

The	O
frequencies	O
with	O
which	O
detected	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
.	O
.	O

The	O
frequencies	O
with	O
which	O
we	O
detected	O
sport	O
were	O
5	O
(	O
xiv	O
%	O
)	O
of	O
xxxv	O
in	O
sporadic	O
event	O
and	O
eight	O
(	O
80	O
%	O
)	O
of	O
x	O
in	O
genetic	O
event	O
.	O
.	O

cases	O
frequencies	O
of	O
35	O
we	O
detected	O
familial	O
were	O
which	O
(	O
14	O
%	O
(	O
of	O
with	O
5	O
sporadic	O
cases	O
and	O
8	O
)	O
80	O
%	O
)	O
in	O
mutations	O
in	O
10	O
The	O
.	O
.	O

The	O
frequencies	O
with	O
which	O
we	O
detected	O
mutations	O
were	O
5	O
14	O
%	O
of	O
35	O
in	O
sporadic	O
cases	O
and	O
8	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
.	O
.	O

14	O
frequencies	O
with	O
cases	O
we	O
detected	O
mutations	O
10	O
)	O
(	O
of	O
%	O
in	O
8	O
%	O
in	O
sporadic	O
cases	O
.	O
of	O
(	O
80	O
35	O
5	O
The	O
were	O
)	O
familial	O
which	O
.	O
and	O

The	O
frequencies	O
with	O
which	O
we	O
notice	O
mutations	O
were	O
pentad	O
(	O
xiv	O
%	O
)	O
of	O
xxxv	O
in	O
sporadic	O
example	O
and	O
eighter	O
(	O
eighty	O
%	O
)	O
of	O
10	O
in	O
transmissible	O
example	O
.	O
.	O

The	O
frequencies	O
with	O
which	O
we	O
detected	O
mutations	O
were	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
cases	O
and	O
8	O
(	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
.	O
.	O

The	O
hemochromatosis	B
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
:	O
prevalence	O
caucasian	O
language	O
population	O
caucasian	O
language	O
population	O
population	O
g	O
bronzed	O
diabetes	O
in	O
non	O
-	O

845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
:	O
in	O
-	O
Caucasian	O
populations	O
.	O

The	O
hemochromatosis	B
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
carbon	O
-	O
-	O
>	O
G	O
mutant	O
:	O
preponderance	O
in	O
not	O
-	O
caucasian	O
universe	O
.	O

The	O
hemochromatosis	B
845	O
G	O
-	O
-	O
>	O
and	O
187	O
-	O
-	O
>	O
G	O
mutations	O
:	O
prevalence	O
-	O
Caucasian	O
populations	O
.	O

The	O
hemochromatosis	B
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
:	O
prevalence	O
caucasian	O
language	O
population	O
caucasian	O
language	O
population	O
population	O
g	O
g	O
in	O
non	O
-	O
Caucasian	O

The	O
hemochromatosis	B
845	O
thou	O
-	O
-	O
>	O
a	O
and	O
187	O
C	O
-	O
-	O
>	O
thou	O
mutations	O
:	O
preponderance	O
in	O
not	O
-	O
Caucasian	O
universe	O
.	O

The	O
hemochromatosis	B
845	O
gee	O
-	O
-	O
>	O
A	O
and	O
187	O
coulomb	O
-	O
-	O
>	O
gee	O
mutant	O
:	O
preponderance	O
in	O
not	O
-	O
caucasic	O
populations	O
.	O

The	O
hemochromatosis	B
845	O
G	O
-	O
-	O
>	O
A	O
and	O
C	O
>	O
G	O
mutations	O
:	O
prevalence	O
in	O
non	O
-	O
Caucasian	O

The	O
hemochromatosis	B
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
:	O
prevalence	O
caucasian	O
language	O
population	O
caucasian	O
language	O
population	O
population	O
g	O
g	O
in	O
non	O
-	O
Caucasian	O

prevalence	O
hemochromatosis	B
845	O
C	O
-	O
-	O
>	O
in	O
.	O
187	O
G	O
-	O
-	O
>	O
populations	O
mutations	O
:	O
-	O
A	O
The	O
non	O
Caucasian	O
G	O
and	O

The	O
hemochromatosis	B
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
:	O
prevalence	O
in	O
non	O
-	O
Caucasian	O
populations	O
.	O

death	B
,	O
the	O
,	B
disorder	I
of	I
iron	I
and	I
to	O
leads	O
inherited	O
if	O
,	O
untreated	O
,	O
progressive	O
iron	B
overload	I
metabolism	O
Hemochromatosis	B
premature	I
.	O

Hemochromatosis	B
,	O
the	O
inherited	B
disorder	I
of	I
iron	I
metabolism	I
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B
overload	I
demise	O
demise	I
genetic	O
genetic	I
genetic	O
genetic	I
and	O
premature	B
death	I
.	O

Hemochromatosis	B
,	O
the	O
inherited	B
disorder	I
of	I
iron	I
metabolism	I
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B
overload	I
demise	O
demise	I
genetic	O
genetic	I
genetic	O
genetic	I
and	O
premature	B
death	I
.	O

Hemochromatosis	B
,	O
the	O
inherited	B
cark	I
of	I
fe	I
metamorphosis	I
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
liberalist	O
fe	B
overload	I
and	O
previous	B
demise	I
.	O

Hemochromatosis	B
,	O
the	O
disorder	I
of	I
iron	I
metabolism	I
,	O
,	O
if	O
untreated	O
,	O
progressive	O
iron	B
and	O
premature	B
death	I
.	O

inherited	B
iron	I
metabolism	I
,	O
,	O
if	O
,	O
to	O
progressive	O
iron	B
overload	I
and	O
premature	B
death	I
.	O

hemochromatosis	B
,	O
the	O
transmitted	B
cark	I
of	I
iron	I
metabolism	I
,	O
leash	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B
overcharge	I
and	O
untimely	B
death	I
.	O

to	B
,	O
,	O
iron	B
disorder	I
of	I
progressive	I
metabolism	I
the	O
leads	O
,	O
if	O
death	O
,	O
inherited	O
Hemochromatosis	O
iron	B
overload	I
and	O
premature	B
untreated	I
.	O

Hemochromatosis	B
,	O
the	O
inherited	B
disorder	I
of	I
iron	I
metabolism	I
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B
overload	I
demise	O
demise	I
genetic	O
genetic	I
genetic	O
fe	I
and	O
premature	B
death	I
.	O

Hemochromatosis	B
,	O
the	O
inherited	B
iron	I
metabolism	I
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B
overload	I
and	O
.	O

Hemochromatosis	B
,	O
the	O
inherited	B
disorder	I
of	I
iron	I
metabolism	I
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B
overload	I
and	O
premature	B
death	I
.	O

The	O
,	O
HFE	O
,	O
has	O
identified	O
,	O
and	O
this	O
it	O
contains	O
two	O
that	O
result	O
amino	O
acid	O
substitutions	O
nucleotides	O
845	O
G	O
-	O
-	O
A	O
C282Y	O
)	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
(	O
)	O
.	O

The	O
hemochromatosis	B
gene	O
,	O
HFE	O
,	O
recently	O
has	O
complementary	O
dna	O
nucleotide	O
cost	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G	O
-	O
-	O
	O
receive	O
receive	O
	O
g	O
receive	O
	O
g	O
receive	O
receive	O
g	O
	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
(	O
H63D	O
)	O

The	O
hemochromatosis	B
gene	O
,	O
HFE	O
,	O
recently	O
has	O
complementary	O
dna	O
nucleotide	O
cost	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G	O
-	O
-	O
	O
receive	O
receive	O
	O
g	O
receive	O
	O
g	O
receive	O
receive	O
g	O
receive	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
(	O
H63D	O
)	O

-	O
amino	B
gene	O
,	O
HFE	O
,	O
and	O
has	O
been	O
identified	O
,	O
recently	O
characterization	O
acid	O
substitutions	O
gene	O
has	O
shown	O
-	O
it	O
contains	O
two	O
G	O
that	O
C	O
in	O
>	O
of	O
(	O
that	O
cDNA	O
-	O
845	O
this	O
The	O
and	O
>	O
A	O
(	O
C282Y	O
hemochromatosis	O
nucleotides	O
187	O
mutations	O
-	O
-	O
)	O
G	O
result	O
H63D	O
)	O
.	O

-	O
result	B
gene	O
,	O
HFE	O
,	O
contains	O
has	O
been	O
identified	O
,	O
and	O
characterization	O
)	O
A	O
gene	O
has	O
cDNA	O
that	O
it	O
(	O
two	O
mutations	O
that	O
hemochromatosis	O
in	O
amino	O
(	O
shown	O
-	O
substitutions	O
recently	O
845	O
G	O
-	O
-	O
>	O
this	O
acid	O
C282Y	O
)	O
and	O
187	O
C	O
The	O
-	O
.	O
G	O
H63D	O
nucleotides	O
of	O
>	O

The	O
hemochromatosis	B
gene	O
,	O
HFE	O
,	O
recently	O
has	O
complementary	O
dna	O
nucleotide	O
cost	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G	O
-	O
-	O
	O
receive	O
receive	O
	O
g	O
receive	O
	O
g	O
receive	O
receive	O
g	O
receive	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
(	O
H63D	O
)	O

The	O
hemochromatosis	B
,	O
recently	O
has	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G	O
-	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C	O
-	O
>	O
G	O
(	O
H63D	O
)	O
.	O

The	O
hemochromatosis	B
cDNA	O
,	O
HFE	O
,	O
recently	O
that	O
been	O
identified	O
,	O
that	O
it	O
of	O
this	O
two	O
has	O
shown	O
A	O
characterization	O
contains	O
G	O
mutations	O
and	O
result	O
.	O
acid	O
845	O
substitutions	O
-	O
gene	O
187	O
nucleotides	O
G	O
-	O
-	O
>	O
in	O
(	O
C282Y	O
)	O
and	O
amino	O
C	O
-	O
>	O
-	O
gene	O
(	O
H63D	O
)	O
has	O

The	O
hemochromatosis	B
cistron	O
,	O
HFE	O
,	O
late	O
has	O
been	O
identify	O
,	O
and	O
personation	O
of	O
this	O
cistron	O
has	O
read	O
that	O
it	O
arrest	O
deuce	O
mutations	O
that	O
effect	O
in	O
aminic	O
sulfurous	O
replacement	O
-	O
cDNA	O
base	O
845	O
gib	O
-	O
-	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
coulomb	O
-	O
-	O
>	O
gib	O
(	O
H63D	O
)	O
.	O

The	O
hemochromatosis	B
gene	O
been	O
and	O
of	O
this	O
gene	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
-	O
-	O
(	O
C282Y	O
)	O
187	O
-	O
>	O
G	O
(	O
H63D	O
)	O
.	O

The	O
hemochromatosis	B
gene	O
,	O
HFE	O
,	O
recently	O
has	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G	O
-	O
-	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
(	O
H63D	O
)	O
.	O

Although	O
is	O
common	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
of	O
northern	O
European	O
origin	O
it	O
has	O
not	O
been	O
recognized	O
other	O
populations	O
.	O

Although	O
is	O
common	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
of	O
northern	O
origin	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O

Although	O
hemochromatosis	B
is	O
common	O
somebody	O
caucasian	O
language	O
northerly	O
indium	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
European	O
origin	O
indium	O
former	O
population	O
parentage	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O

has	O
hemochromatosis	B
is	O
,	O
in	O
Caucasians	O
,	O
other	O
recognized	O
=	O
it	O
/	O
300	O
individuals	O
been	O
northern	O
European	O
origin	O
common	O
in	O
1	O
not	O
of	O
>	O
Although	O
affecting	O
populations	O
.	O

populations	O
hemochromatosis	B
is	O
of	O
in	O
Caucasians	O
other	O
affecting	O
common	O
=	O
1	O
/	O
individuals	O
has	O
in	O
>	O
European	O
origin	O
,	O
it	O
300	O
not	O
been	O
recognized	O
northern	O
,	O
Although	O
.	O

Although	O
hemochromatosis	B
is	O
common	O
somebody	O
caucasian	O
language	O
northerly	O
indium	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
European	O
origin	O
indium	O
former	O
population	O
uncouth	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O

Although	O
hemochromatosis	B
is	O
unwashed	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
one	O
/	O
300	O
individuals	O
of	O
northerly	O
european	O
extraction	O
,	O
it	O
has	O
not	O
been	O
realise	O
in	O
other	O
populations	O
.	O

Although	O
hemochromatosis	B
is	O
common	O
somebody	O
caucasian	O
language	O
northerly	O
indium	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
European	O
origin	O
indium	O
former	O
population	O
uncouth	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O

recognized	O
hemochromatosis	B
is	O
common	O
in	O
Caucasians	O
individuals	O
/	O
>	O
=	O
1	O
European	O
not	O
,	O
in	O
Although	O
affecting	O
northern	O
,	O
it	O
has	O
300	O
been	O
origin	O
of	O
other	O
populations	O
.	O

Although	O
hemochromatosis	B
is	O
park	O
in	O
white	O
,	O
impress	O
>	O
=	O
ace	O
/	O
300	O
individuals	O
of	O
northerly	O
european	O
inception	O
,	O
it	O
has	O
not	O
been	O
spot	O
in	O
other	O
populations	O
.	O

Although	O
hemochromatosis	B
is	O
common	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
European	O
origin	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O
.	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
to	O
analyze	O
the	O
frequency	O
the	O
845	O
G	O
-	O
-	O
A	O
and	O
187	O
C	O
-	O
>	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
non	O
Caucasian	O
populations	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O
,	O
and	O
Pacific	O

,	O
C	O
study	O
used	O
PCR	O
and	O
-	O
845	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
.	O
,	O
the	O
-	O
in	O
-	O
-	O
comprising	O
A	O
and	O
187	O
present	O
-	O
-	O
Caucasian	O
G	O
mutations	O
G	O
restriction	O
-	O
typed	O
samples	O
from	O
non	O
Pacific	O
>	O
populations	O
,	O
>	O
Australian	O
Aboriginal	O
The	O
Chinese	O
of	O
and	O
Islanders	O
HLA	O
frequency	O

The	O
present	O
subject	O
practice	O
PCR	O
and	O
confinement	O
-	O
enzyme	O
digestion	O
to	O
dissect	O
the	O
oftenness	O
of	O
the	O
845	O
gram	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
gram	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
not	O
-	O
Caucasian	O
populations	O
,	O
consist	O
Australian	O
Aboriginal	O
,	O
chinese	O
,	O
and	O
pacific	O
Islanders	O
.	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
expend	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
frequency	O
of	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
aussie	O
primeval	O
incorporate	O
chinese	O
primeval	O
incorporate	O
pacific	O
ocean	O
island	O
dweller	O
g	O
pacific	O
ocean	O
island	O
dweller	O
g	O
pacific	O
ocean	O
non	O
-	O
Caucasian	O
populations	O
,	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
expend	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
frequency	O
of	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
aussie	O
primeval	O
incorporate	O
chinese	O
primeval	O
incorporate	O
pacific	O
ocean	O
island	O
dweller	O
g	O
pacific	O
ocean	O
island	O
dweller	O
g	O
pacific	O
ocean	O
non	O
-	O
Caucasian	O
populations	O
,	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O

present	O
study	O
used	O
PCR	O
and	O
-	O
enzyme	O
the	O
the	O
845	O
-	O
and	O
187	O
C	O
-	O
>	O
G	O
HLA	O
-	O
samples	O
from	O
populations	O
comprising	O
Australian	O
Aboriginal	O
Chinese	O
,	O
and	O
Islanders	O
.	O

The	O
present	O
study	O
and	O
restriction	O
-	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
the	O
G	O
-	O
-	O
A	O
and	O
187	O
C	O
-	O
-	O
G	O
mutations	O
-	O
samples	O
from	O
non	O
-	O
,	O
comprising	O
Australian	O
Aboriginal	O
Chinese	O
,	O
and	O
Pacific	O
Islanders	O
.	O

The	O
submit	O
learn	O
victimized	O
PCR	O
and	O
confinement	O
-	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
oftenness	O
of	O
the	O
845	O
thousand	O
-	O
-	O
>	O
ampere	O
and	O
187	O
C	O
-	O
-	O
>	O
thousand	O
mutant	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
not	O
-	O
white	O
universe	O
,	O
comprise	O
aussie	O
Aboriginal	O
,	O
formosan	O
,	O
and	O
pacific	O
Islanders	O
.	O

The	O
demonstrate	O
study	O
used	O
PCR	O
and	O
limitation	O
-	O
enzyme	O
digestion	O
to	O
study	O
the	O
frequency	O
of	O
the	O
845	O
guanine	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
guanine	O
sport	O
in	O
HLA	O
-	O
typewrite	O
samples	O
from	O
not	O
-	O
caucasoid	O
universe	O
,	O
be	O
Australian	O
native	O
,	O
formosan	O
,	O
and	O
Pacific	O
Islanders	O
.	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
expend	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
frequency	O
of	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
aussie	O
primeval	O
incorporate	O
chinese	O
primeval	O
incorporate	O
pacific	O
ocean	O
island	O
dweller	O
g	O
pacific	O
ocean	O
island	O
dweller	O
g	O
island	O
dweller	O
non	O
-	O
Caucasian	O
populations	O
,	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
frequency	O
of	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
non	O
-	O
Caucasian	O
populations	O
,	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O
,	O
and	O
Pacific	O
Islanders	O
.	O

Results	O
showed	O
that	O
the	O
845	O
G	O
-	O
-	O
lookout	O
man	O
put	O
in	O
ampere	O
what	O
is	O
more	O
cost	O
information	O
technology	O
cost	O
ever	O
watch	O
>	O
A	O
mutation	O
was	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
0	O
.	O
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
always	O
seen	O
in	O
conjunction	O
with	O
cost	O
put	O
in	O
watch	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
845	O
G	O
-	O
-	O
>	O
A	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
by	O
Caucasian	O
admixture	O
of	O

Results	O
showed	O
the	O
845	O
G	O
-	O
-	O
>	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
.	O
32	O
,	O
and	O
,	O
,	O
always	O
seen	O
in	O
conjunction	O
with	O
HLA	O
haplotypes	O
suggesting	O
845	O
G	O
-	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
by	O
Caucasian	O
admixture	O

Results	O
that	O
845	O
G	O
-	O
A	O
these	O
populations	O
(	O
frequency	O
0	O
32	O
%	O
)	O
,	O
furthermore	O
,	O
it	O
was	O
seen	O
conjunction	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
G	O
-	O
-	O
>	O
A	O
these	O
Caucasian	O
.	O

outcome	O
showed	O
that	O
the	O
845	O
gee	O
-	O
-	O
>	O
ampere	O
mutation	O
was	O
acquaint	O
in	O
these	O
universe	O
(	O
allelomorph	O
frequence	O
0	O
.	O
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
constantly	O
seen	O
in	O
concurrence	O
with	O
HLA	O
haplotypes	O
uncouth	O
in	O
Caucasians	O
,	O
hint	O
that	O
845	O
gee	O
-	O
-	O
>	O
ampere	O
may	O
have	O
been	O
inclose	O
into	O
these	O
universe	O
by	O
caucasic	O
intermixture	O
.	O

conjunction	O
admixture	O
that	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
was	O
present	O
furthermore	O
,	O
populations	O
(	O
allele	O
always	O
0	O
.	O
32	O
with	O
)	O
that	O
and	O
introduced	O
in	O
>	O
,	O
was	O
populations	O
seen	O
these	O
Results	O
Caucasian	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
-	O
suggesting	O
%	O
845	O
G	O
,	O
-	O
it	O
A	O
may	O
have	O
been	O
,	O
into	O
these	O
.	O
by	O
in	O
showed	O
frequency	O

Results	O
showed	O
always	O
the	O
845	O
G	O
was	O
-	O
>	O
A	O
mutation	O
-	O
suggesting	O
in	O
these	O
was	O
(	O
allele	O
0	O
these	O
.	O
by	O
%	O
)	O
,	O
populations	O
,	O
admixture	O
,	O
it	O
populations	O
into	O
.	O
in	O
conjunction	O
with	O
HLA	O
and	O
common	O
in	O
-	O
,	O
present	O
that	O
845	O
Caucasians	O
G	O
have	O
>	O
A	O
may	O
-	O
been	O
Caucasian	O
that	O
frequency	O
haplotypes	O
32	O
introduced	O
seen	O
furthermore	O

Results	O
showed	O
that	O
the	O
845	O
G	O
-	O
-	O
lookout	O
man	O
put	O
in	O
ampere	O
what	O
is	O
more	O
cost	O
information	O
technology	O
cost	O
ever	O
watch	O
>	O
A	O
mutation	O
was	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
0	O
.	O
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
always	O
seen	O
in	O
conjunction	O
with	O
cost	O
put	O
in	O
receive	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
845	O
G	O
-	O
-	O
>	O
A	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
by	O
Caucasian	O
admixture	O
of	O

Results	O
showed	O
that	O
the	O
845	O
G	O
-	O
mutation	O
was	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
always	O
seen	O
in	O
conjunction	O
with	O
HLA	O
haplotypes	O
in	O
,	O
suggesting	O
that	O
845	O
G	O
-	O
-	O
>	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
admixture	O
.	O

845	O
by	O
that	O
the	O
>	O
G	O
.	O
(	O
>	O
A	O
mutation	O
was	O
present	O
may	O
haplotypes	O
populations	O
-	O
was	O
frequency	O
0	O
showed	O
32	O
%	O
)	O
introduced	O
and	O
,	O
common	O
allele	O
it	O
,	O
-	O
seen	O
in	O
conjunction	O
with	O
HLA	O
these	O
furthermore	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
Results	O
G	O
into	O
-	O
A	O
always	O
in	O
-	O
been	O
,	O
have	O
these	O
populations	O
.	O
Caucasian	O
admixture	O
845	O

termination	O
demo	O
that	O
the	O
845	O
gigabyte	O
-	O
-	O
>	O
a	O
variation	O
was	O
confront	O
in	O
these	O
universe	O
(	O
allelomorph	O
oftenness	O
0	O
.	O
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
invariably	O
realise	O
in	O
colligation	O
with	O
HLA	O
haplotypes	O
vernacular	O
in	O
caucasian	O
,	O
suggesting	O
that	O
845	O
gigabyte	O
-	O
-	O
>	O
a	O
may	O
have	O
been	O
acquaint	O
into	O
these	O
universe	O
by	O
Caucasian	O
admixture	O
.	O

Results	O
showed	O
that	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
was	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
0	O
.	O
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
always	O
seen	O
in	O
conjunction	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
845	O
G	O
-	O
-	O
>	O
A	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
by	O
Caucasian	O
admixture	O
.	O

187	O
>	O
-	O
-	O
C	O
G	O
present	O
allele	O
at	O
an	O
of	O
frequency	O
was	O
2	O
.	O

187	O
C	O
cost	O
introduce	O
atomic	O
number	O
	O
-	O
-	O
>	O
G	O
was	O
present	O
at	O
g	O
an	O
allele	O
frequency	O
of	O

187	O
blow	O
-	O
-	O
>	O
gee	O
was	O
introduce	O
at	O
an	O
allelomorph	O
frequency	O
of	O
2	O
.	O

of	O
C	O
-	O
187	O
present	O
G	O
was	O
frequency	O
at	O
an	O
allele	O
>	O
-	O
2	O
.	O

187	O
C	O
-	O
-	O
>	O
gibibyte	O
was	O
give	O
at	O
an	O
allelomorph	O
frequence	O
of	O
2	O
.	O

187	O
C	O
cost	O
introduce	O
atomic	O
number	O
	O
-	O
-	O
>	O
G	O
was	O
present	O
at	O
	O
an	O
allele	O
frequency	O
of	O

187	O
-	O
>	O
was	O
present	O
at	O
an	O
allele	O
frequency	O
of	O
2	O
.	O

present	O
-	O
-	O
C	O
>	O
G	O
an	O
187	O
at	O
was	O
allele	O
frequency	O
of	O
.	O
2	O

187	O
C	O
-	O
-	O
>	O
thousand	O
was	O
show	O
at	O
an	O
allelomorph	O
frequency	O
of	O
deuce	O
.	O

187	O
C	O
cost	O
introduce	O
atomic	O
number	O
	O
-	O
-	O
>	O
G	O
was	O
present	O
at	O
	O
an	O
allele	O
frequency	O
of	O

187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
at	O
an	O
allele	O
frequency	O
of	O
2	O
.	O

68	O
in	O
two	O
analyzed	O
(	O
Australian	O
Aboriginal	O
and	O
Chinese	O
)	O
.	O

68	O
%	O
in	O
the	O
two	O
populations	O
examine	O
(	O
australian	O
aborigine	O
and	O
formosan	O
)	O
.	O

(	O
the	O
in	O
%	O
two	O
populations	O
Aboriginal	O
68	O
Australian	O
.	O
and	O
Chinese	O
)	O
analyzed	O

68	O
%	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Aboriginal	O
and	O
)	O
.	O

68	O
%	O
indium	O
indium	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Australian	O
chinese	O
	O
Aboriginal	O
and	O
Chinese	O
)	O
.	O

68	O
%	O
indium	O
indium	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Australian	O
chinese	O
	O
Aboriginal	O
and	O
Chinese	O
)	O
.	O

lxviii	O
%	O
in	O
the	O
two	O
populations	O
examine	O
(	O
Australian	O
native	O
and	O
chinese	O
)	O
.	O

)	O
%	O
in	O
68	O
(	O
populations	O
analyzed	O
Chinese	O
Australian	O
Aboriginal	O
and	O
two	O
the	O
.	O

68	O
%	O
indium	O
indium	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Australian	O
chinese	O
	O
Aboriginal	O
and	O
Chinese	O
)	O
.	O

68	O
%	O
in	O
the	O
two	O
universe	O
canvas	O
(	O
australian	O
Aboriginal	O
and	O
taiwanese	O
)	O
.	O

68	O
%	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Australian	O
Aboriginal	O
and	O
Chinese	O
)	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
receive	O
past	O
beryllium	O
sample	O
distribution	O
samples	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
invite	O
invite	O
invite	O
invite	O
cost	O

In	O
the	O
Australian	O
,	O
>	O
G	O
was	O
to	O
be	O
with	O
HLA	O
haplotypes	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
introduced	O
recent	O
admixture	O
.	O

In	O
the	O
aussie	O
indigene	O
samples	O
,	O
187	O
C	O
-	O
-	O
>	O
thou	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
uncouth	O
in	O
caucasian	O
,	O
hint	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
commixture	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
-	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
cytosine	O
-	O
-	O
>	O
gram	O
was	O
feel	O
to	O
be	O
relate	O
with	O
HLA	O
haplotypes	O
usual	O
in	O
Caucasians	O
,	O
propose	O
that	O
it	O
was	O
preface	O
by	O
late	O
intermixture	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
receive	O
past	O
beryllium	O
sample	O
distribution	O
samples	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
invite	O
invite	O
invite	O
invite	O
cost	O

inch	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
c	O
-	O
-	O
>	O
G	O
was	O
found	O
to	O
be	O
colligate	O
with	O
HLA	O
haplotypes	O
unwashed	O
inch	O
Caucasians	O
,	O
intimate	O
that	O
it	O
was	O
innovate	O
by	O
holocene	O
alloy	O
.	O

common	O
HLA	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
suggesting	O
by	O
be	O
associated	O
with	O
was	O
haplotypes	O
the	O
in	O
admixture	O
,	O
found	O
that	O
it	O
In	O
to	O
Caucasians	O
recent	O
introduced	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
C	O
-	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
was	O
introduced	O
by	O
admixture	O

In	O
the	O
Australian	O
Aboriginal	O
receive	O
past	O
beryllium	O
aussie	O
samples	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
invite	O
invite	O
invite	O
invite	O
cost	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
.	O

In	O
the	O
and	O
samples	O
analyzed	O
,	O
187	O
wide	O
-	O
-	O
>	O
,	O
variety	O
present	O
in	O
C	O
with	O
a	O
restricted	O
was	O
of	O
.	O
haplotypes	O
G	O
showing	O
association	O
to	O
to	O
be	O
widespread	O
Chinese	O
>	O
likely	O
predate	O
the	O
mutation	O
genetically	O
this	O
845	O
G	O
-	O
-	O
mutation	O
A	O
more	O
HLA	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
in	O
association	O
with	O
a	O
wide	O
variety	O
of	O
HLA	O
haplotypes	O
,	O
showing	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
predate	O
the	O
more	O
g	O
ampere	O
sport	O
g	O
ampere	O
sport	O
psychoanalyze	O
ampere	O
sport	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
genetically	O
restricted	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
in	O
association	O
with	O
a	O
wide	O
variety	O
of	O
HLA	O
haplotypes	O
,	O
showing	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
predate	O
the	O
more	O
g	O
ampere	O
sport	O
g	O
ampere	O
sport	O
psychoanalyze	O
ampere	O
sport	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
cost	O
genetically	O
restricted	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
-	O
>	O
G	O
present	O
association	O
with	O
a	O
of	O
this	O
mutation	O
to	O
widespread	O
and	O
to	O
predate	O
the	O
restricted	O
845	O
G	O
-	O
-	O
A	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C	O
-	O
>	O
G	O
was	O
present	O
in	O
of	O
,	O
this	O
mutation	O
to	O
widespread	O
and	O
likely	O
to	O
predate	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O

the	O
wide	O
Chinese	O
samples	O
analyzed	O
,	O
-	O
C	O
-	O
-	O
>	O
-	O
was	O
to	O
widespread	O
association	O
with	O
a	O
predate	O
variety	O
of	O
HLA	O
be	O
,	O
A	O
this	O
likely	O
present	O
in	O
showing	O
and	O
more	O
to	O
the	O
In	O
mutation	O
genetically	O
restricted	O
845	O
G	O
G	O
187	O
>	O
haplotypes	O
mutation	O
.	O

in	O
the	O
chinese	O
sampling	O
analyse	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
acquaint	O
in	O
connexion	O
with	O
a	O
blanket	O
miscellany	O
of	O
HLA	O
haplotypes	O
,	O
prove	O
this	O
sport	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
prey	O
the	O
more	O
genetically	O
curtail	O
845	O
G	O
-	O
-	O
>	O
A	O
sport	O
.	O

inch	O
the	O
chinese	O
samples	O
study	O
,	O
187	O
blow	O
-	O
-	O
>	O
k	O
was	O
confront	O
inch	O
tie	O
with	O
a	O
wide	O
multifariousness	O
of	O
HLA	O
haplotypes	O
,	O
evidence	O
this	O
variation	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
forgo	O
the	O
more	O
genetically	O
bound	O
845	O
k	O
-	O
-	O
>	O
a	O
variation	O
.	O

inch	O
the	O
taiwanese	O
sampling	O
examine	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
submit	O
inch	O
connexion	O
with	O
a	O
astray	O
miscellany	O
of	O
HLA	O
haplotypes	O
,	O
designate	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
probably	O
to	O
antedate	O
the	O
more	O
genetically	O
curtail	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
in	O
association	O
with	O
a	O
wide	O
variety	O
of	O
HLA	O
haplotypes	O
,	O
showing	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
predate	O
the	O
more	O
g	O
ampere	O
sport	O
g	O
ampere	O
sport	O
psychoanalyze	O
ampere	O
sport	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
genetically	O
restricted	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
in	O
association	O
with	O
a	O
wide	O
variety	O
of	O
HLA	O
haplotypes	O
,	O
showing	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
predate	O
the	O
more	O
genetically	O
restricted	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
.	O

Genotype	O
-	O
phenotype	O
correlativity	O
in	O
weakened	B
adenomatous	I
polyposis	I
coli	I
.	O

genotype	O
-	O
phenotype	O
correlations	O
in	O
weakened	B
adenomatous	I
polyposis	I
coli	I
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
indium	O
indium	O
weakened	O
.	O

Genotype	O
polyposis	O
phenotype	O
correlations	O
-	O
attenuated	B
in	I
adenomatous	I
coli	I
.	O

polyposis	O
correlations	O
phenotype	O
-	O
in	O
attenuated	B
.	I
Genotype	I
coli	I
adenomatous	O

Genotype	O
-	O
attenuated	B
coli	I
.	O

polyposis	O
.	O
phenotype	O
in	O
correlations	O
attenuated	B
adenomatous	I
Genotype	I
coli	I
-	O

Genotype	O
correlations	O
in	O
attenuated	B
polyposis	I

Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
indium	O
indium	O
indium	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
indium	O
indium	O
indium	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
.	O

Germ	O
-	O
line	O
mutations	O
weakened	O
genetic	O
ampere	O
neoplasm	O
suppresser	O
of	O
the	O
tumor	B
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
genetic	O
parentage	O
)	O
,	O
a	O
variant	O
of	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
countermine	O
indium	O
.	O

Germ	O
-	O
line	O
mutations	O
weakened	O
genetic	O
ampere	O
neoplasm	O
suppresser	O
of	O
the	O
tumor	B
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
genetic	O
indium	O
)	O
,	O
a	O
variant	O
of	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
countermine	O
indium	O
.	O

)	O
-	O
adenomatous	O
polyposis	O
of	O
the	O
FAP	B
suppressor	O
mutations	O
are	O
implicated	O
in	O
a	B
adenomatous	I
line	I
APC	I
(	O
AAPC	B
)	O
,	O
attenuated	O
variant	O
of	O
familial	B
coli	I
tumor	I
(	O
polyposis	B
Germ	O
.	O

Germ	O
-	O
line	O
mutations	O
weakened	O
genetic	O
ampere	O
neoplasm	O
suppresser	O
of	O
the	O
tumor	B
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
genetic	O
parentage	O
)	O
,	O
a	O
variant	O
of	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
countermine	O
indium	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
tumor	B
APC	O
are	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
a	O
variant	O
of	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

source	O
-	O
line	O
mutant	O
of	O
the	O
neoplasm	B
suppresser	O
apc	O
are	O
concerned	O
in	O
faded	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
,	O
a	O
variant	O
of	O
genetic	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

(	O
-	O
line	O
mutations	O
of	O
the	O
variant	B
in	O
APC	O
are	O
implicated	O
Germ	O
)	B
familial	I
coli	I
polyposis	I
AAPC	O
adenomatous	B
)	O
,	O
a	O
tumor	O
of	O
adenomatous	B
suppressor	I
polyposis	I
(	O
FAP	B
attenuated	O
.	O

a	O
-	O
line	O
)	O
of	O
the	O
tumor	B
polyposis	O
familial	O
are	O
)	O
in	O
(	B
,	I
of	I
coli	I
(	O
AAPC	B
mutations	O
adenomatous	O
adenomatous	O
variant	O
polyposis	O
APC	B
Germ	I
suppressor	I
attenuated	O
FAP	B
implicated	O
.	O

microbe	O
-	O
line	O
mutations	O
of	O
the	O
neoplasm	B
suppressor	O
apc	O
are	O
implicated	O
in	O
rarefy	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
,	O
a	O
edition	O
of	O
transmitted	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
tumor	B
APC	O
are	O
implicated	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
AAPC	B
)	O
,	O
a	O
variant	O
of	O
familial	B
(	O
FAP	B
)	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
tumor	B
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
,	O
a	O
variant	O
of	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

AAPC	B
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
adenomas	I
and	O
a	O
later	O
onset	O
of	O
colorectal	B
cancer	I
	O
yr	O
	O
yr	O
yr	O
recognise	O
past	O
(	O
age	O
>	O
40	O
years	O
)	O
.	O

by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
adenomas	I
and	O
a	O
later	O
onset	O
of	O
colorectal	B
cancer	I
age	O
40	O
years	O
)	O
.	O

AAPC	B
is	O
discern	O
by	O
the	O
happening	O
of	O
<	O
c	O
colonic	B
adenomas	I
and	O
a	O
later	O
onrush	O
of	O
colorectal	B
cancer	I
(	O
eld	O
>	O
xl	O
years	O
)	O
.	O

AAPC	B
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
and	O
a	O
onset	O
of	O
colorectal	B
cancer	I
(	O
age	O
>	O
)	O
.	O

AAPC	B
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
adenomas	I
and	O
a	O
later	O
onset	O
of	O
colorectal	B
cancer	I
	O
yr	O
	O
yr	O
yr	O
recognise	O
recognise	O
(	O
age	O
>	O
40	O
years	O
)	O
.	O

AAPC	B
is	O
recognized	O
by	O
the	O
happening	O
of	O
<	O
hundred	O
colonic	B
adenomas	I
and	O
a	O
ulterior	O
oncoming	O
of	O
colorectal	B
crab	I
(	O
age	O
>	O
twoscore	O
years	O
)	O
.	O

AAPC	B
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
adenomas	I
and	O
a	O
later	O
onslaught	O
of	O
colorectal	B
cancer	I
(	O
age	O
>	O
twoscore	O
years	O
)	O
.	O

AAPC	B
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
adenomas	I
a	O
of	O
colorectal	B
cancer	I
(	O
age	O
>	O
40	O
years	O
)	O

AAPC	B
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
adenomas	I
and	O
a	O
later	O
onset	O
of	O
colorectal	B
cancer	I
	O
yr	O
	O
yr	O
yr	O
recognise	O
recognise	O
(	O
age	O
>	O
40	O
years	O
)	O
.	O

age	B
is	O
recognized	O
adenomas	O
the	O
occurrence	O
of	O
(	O
)	O
colonic	B
by	I
and	O
later	O
a	O
years	O
of	O
colorectal	B
cancer	I
<	O
.	O
>	O
40	O
onset	O
100	O
AAPC	O

AAPC	B
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
adenomas	I
and	O
a	O
later	O
onset	O
of	O
colorectal	B
cancer	I
(	O
age	O
>	O
40	O
years	O
)	O
.	O

The	O
aim	O
indium	O
valuate	O
genetic	O
constitution	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	B
AAPC	O
families	O
cost	O

AAPC	O
aim	O
of	O
.	O
study	O
was	O
to	O
assess	O
families	O
-	O
phenotype	O
correlations	O
The	O
in	B
genotype	O
this	O

The	O
aim	O
value	O
valuate	O
valuate	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
AAPC	B
families	O
cost	O
.	O

The	O
object	O
of	O
this	O
field	O
was	O
to	O
tush	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
AAPC	B
house	O
.	O

in	O
aim	O
of	O
assess	O
study	O
was	O
AAPC	O
this	O
genotype	O
-	O
The	O
correlations	O
phenotype	O
to	B
families	O
.	O

The	O
aim	O
indium	O
valuate	O
genetic	O
constitution	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	B
AAPC	O
families	O
cost	O

The	O
direct	O
of	O
this	O
bailiwick	O
was	O
to	O
fundament	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
AAPC	B
syndicate	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
fuck	O
genotype	O
-	O
phenotype	O
correlativity	O
in	O
AAPC	B
fellowship	O
.	O

The	O
aim	O
genotype	O
.	O
study	O
was	O
in	O
assess	O
of	O
-	O
phenotype	O
correlations	O
to	O
AAPC	B
this	O
families	O

aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
phenotype	O
correlations	O
in	O
AAPC	B
families	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
AAPC	B
families	O
.	O

-	O
(	O
PTT	O
)	O
assay	O
the	O
entire	O
of	O
the	O
gene	O
was	O
individuals	O
11	O
AAPC	B
kindreds	O
and	O
their	O
phenotypic	O
were	O
examined	O
.	O

By	O
protein	O
-	O
truncation	O
phenotypical	O
sieve	O
test	O
(	O
PTT	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	B
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	O
AAPC	B
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined	O
phenotypic	O
phenotypic	O
phenotypic	O
phenotypic	O
phenotypic	O
phenotypic	O
phenotypic	O
kin	O
group	O

11	O
was	O
-	O
truncation	O
test	O
(	O
kindreds	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
,	O
their	O
the	O
APC	B
gene	O
examined	O
screened	O
in	O
affected	O
differences	O
from	O
By	O
AAPC	B
PTT	O
region	O
of	O
individuals	O
phenotypic	O
and	O
were	O
.	O
protein	O

By	O
protein	O
-	O
truncation	O
prove	O
(	O
PTT	O
)	O
try	O
,	O
the	O
intact	O
cypher	O
part	O
of	O
the	O
APC	B
cistron	O
was	O
screened	O
in	O
unnatural	O
somebody	O
from	O
11	O
AAPC	B
clan	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
prove	O
.	O

By	O
protein	O
AAPC	O
truncation	O
test	O
(	O
PTT	O
affected	O
assay	O
,	O
the	O
from	O
,	O
region	O
of	O
phenotypic	O
APC	B
gene	O
screened	O
entire	O
in	O
)	O
individuals	O
was	O
11	O
kindreds	B
-	O
were	O
and	O
their	O
the	O
coding	O
differences	O
examined	O
.	O

By	O
protein	O
-	O
truncation	O
test	O
(	O
PTT	O
)	O
assay	O
,	O
coding	O
region	O
of	O
the	O
gene	O
was	O
screened	O
in	O
affected	O
from	O
11	O
AAPC	B
kindreds	O
and	O
their	O
differences	O
were	O
examined	O
.	O

aside	O
protein	O
-	O
shortness	O
test	O
(	O
PTT	O
)	O
try	O
,	O
the	O
integral	O
steganography	O
realm	O
of	O
the	O
APC	B
factor	O
was	O
test	O
in	O
affected	O
person	O
from	O
xi	O
AAPC	B
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined	O
.	O

By	O
protein	O
-	O
truncation	O
phenotypical	O
mental	O
testing	O
test	O
(	O
PTT	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
region	O
of	O
the	B
APC	O
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	B
AAPC	O
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined	O
phenotypic	O
phenotypic	O
phenotypic	O
phenotypic	O
phenotypic	O
phenotypic	O
phenotypic	O
kin	O

aside	O
protein	O
-	O
shortness	O
test	O
(	O
PTT	O
)	O
seek	O
,	O
the	O
intact	O
tantalise	O
realm	O
of	O
the	O
APC	B
factor	O
was	O
sieve	O
in	O
affected	O
individuals	O
from	O
eleven	O
AAPC	B
kindreds	O
,	O
and	O
their	O
phenotypic	O
divergence	O
were	O
examined	O
.	O

,	O
in	O
-	O
truncation	O
APC	O
(	O
of	O
differences	O
assay	O
,	O
the	O
entire	O
coding	O
11	O
)	O
the	O
test	B
phenotypic	O
was	O
screened	O
region	O
affected	O
individuals	O
from	O
protein	O
AAPC	B
kindreds	O
By	O
gene	O
their	O
and	O
PTT	O
were	O
examined	O
.	O

By	O
protein	O
-	O
truncation	O
test	O
(	O
PTT	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	B
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	O
AAPC	B
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined	O
.	O

Five	O
germ	O
-	O
APC	B
were	O
in	O
seven	O
kindreds	O
.	O

Five	O
novel	O
germ	O
-	O
line	O
APC	B
mutations	O
were	O
identified	O
in	O
seven	O
kindreds	O

Five	O
fresh	O
source	O
-	O
line	O
APC	B
mutations	O
were	O
name	O
in	O
seven	O
kindreds	O
.	O

Five	O
novel	O
germ	O
-	O
line	O
APC	B
mutations	O
were	O
identified	O
kin	O
group	O
kin	O
group	O
fresh	O
in	O
seven	O

Five	O
novel	O
germ	O
-	O
line	O
APC	B
mutations	O
were	O
identified	O
kin	O
group	O
kin	O
group	O
indium	O
in	O
seven	O

Five	O
novel	O
germ	O
-	O
line	O
APC	B
mutations	O
were	O
identified	O
kin	O
group	O
kin	O
group	O
fresh	O
in	O
seven	O

Five	O
novel	O
germ	O
-	O
line	O
apc	B
sport	O
were	O
identified	O
in	O
septenary	O
kindreds	O
.	O

Five	O
novel	O
-	O
line	O
APC	B
mutations	O
were	O
identified	O
in	O
.	O

Five	O
fresh	O
microbe	O
-	O
line	O
APC	B
mutations	O
were	O
discover	O
in	O
seven	O
kindreds	O
.	O

Five	O
line	O
germ	O
-	O
.	O
APC	B
mutations	O
novel	O
identified	O
in	O
seven	O
kindreds	O
were	O

Five	O
novel	O
germ	O
-	O
line	O
APC	B
mutations	O
were	O
identified	O
in	O
seven	O
kindreds	O
.	O

Mutations	O
were	O
site	O
in	O
three	O
dissimilar	O
part	O
of	O
the	O
APC	B
cistron	O
(	O
ane	O
)	O
at	O
the	O
phoebe	O
remainder	O
spanning	O
exons	O
4	O
and	O
phoebe	O
,	O
(	O
2	O
)	O
inside	O
exon	O
9	O
,	O
and	O
(	O
tercet	O
)	O
at	O
the	O
tercet	O
distal	O
remainder	O
of	O
the	O
cistron	O
.	O

Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	B
gene	O
(	O
1	O
)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	O
factor	O
	O
	O
factor	O
	O
	O
factor	O
	O
	O
	O
	O
	O
	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene	O
.	O

Mutations	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	B
gene	O
(	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
(	O
)	O
at	O
the	O
3	O
distal	O
end	O
of	O
the	O
.	O

Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	B
(	O
1	O
)	O
at	O
the	O
and	O
(	O
)	O
within	O
exon	O
,	O
and	O
(	O
3	O
)	O
at	O
end	O
of	O
the	O
gene	O
.	O

Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	B
gene	O
(	O
1	O
)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	O
factor	O
	O
	O
factor	O
	O
	O
factor	O
	O
	O
	O
	O
	O
coding	O
dna	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene	O

Mutations	O
were	O
located	O
in	O
three	O
different	O
the	O
APC	B
gene	O
1	O
at	O
the	O
5	O
exons	O
(	O
2	O
)	O
exon	O
9	O
and	O
(	O
3	O
the	O
3	O
distal	O
end	O
of	O
gene	O

sport	O
were	O
located	O
in	O
troika	O
unlike	O
area	O
of	O
the	O
APC	B
cistron	O
(	O
1	O
)	O
at	O
the	O
5	O
stop	O
spanning	O
exons	O
quadruplet	O
and	O
5	O
,	O
(	O
2	O
)	O
inside	O
exon	O
ix	O
,	O
and	O
(	O
terzetto	O
)	O
at	O
the	O
terzetto	O
distal	O
stop	O
of	O
the	O
cistron	O
.	O

mutant	O
were	O
site	O
in	O
three	O
dissimilar	O
neighborhood	O
of	O
the	O
APC	B
factor	O
(	O
i	O
)	O
at	O
the	O
five	O
destruction	O
cross	O
exons	O
quatern	O
and	O
five	O
,	O
(	O
ii	O
)	O
inside	O
exon	O
9	O
,	O
and	O
(	O
troika	O
)	O
at	O
the	O
troika	O
distal	O
destruction	O
of	O
the	O
factor	O
.	O

Mutations	O
spanning	O
located	O
in	O
three	O
different	O
the	O
3	O
the	O
APC	B
gene	O
of	O
1	O
within	O
9	O
the	O
5	O
end	O
of	O
exons	O
4	O
and	O
exon	O
,	O
.	O
2	O
and	O
)	O
at	O
(	O
,	O
at	O
(	O
were	O
)	O
)	O
the	O
3	O
distal	O
end	O
(	O
regions	O
gene	O
5	O

Mutations	O
were	O
and	O
in	O
three	O
exon	O
regions	O
of	O
the	O
APC	B
gene	O
1	O
gene	O
)	O
at	O
,	O
5	O
end	O
exons	O
spanning	O
4	O
(	O
5	O
.	O
(	O
)	O
within	O
and	O
different	O
9	O
the	O
3	O
2	O
3	O
)	O
,	O
the	O
located	O
distal	O
end	O
of	O
the	O
(	O
at	O

Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	B
gene	O
(	O
1	O
)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene	O
.	O

unevenness	O
in	O
the	O
total	O
of	O
colorectal	B
adenomas	I
was	O
most	O
unmistakable	O
in	O
individuals	O
with	O
mutations	O
in	O
realm	O
1	O
,	O
and	O
amphetamine	O
-	O
gi	O
reflexion	O
were	O
more	O
grievous	O
in	O
them	O
.	O

Variability	O
in	O
the	O
number	O
of	O
adenomas	I
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
manifestations	O
were	O
more	O
severe	O
in	O
them	O
.	O

-	O
in	O
the	O
and	O
of	O
colorectal	B
adenomas	I
severe	O
were	O
apparent	O
.	O
individuals	O
with	O
upper	O
manifestations	O
region	O
1	O
,	O
number	O
mutations	O
more	O
gastrointestinal	O
in	O
most	O
Variability	O
was	O
in	O
them	O
in	O

Variability	O
in	O
the	O
number	O
sir	O
thomas	O
more	O
sport	O
indium	O
part	O
	B
of	I
colorectal	O
adenomas	O
was	O
most	O
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
terrible	O
indium	O
virtually	O
and	O
upper	O
-	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O

Variability	O
in	O
the	O
number	O
sir	O
thomas	O
more	O
sport	O
indium	O
part	O
	B
of	I
colorectal	O
adenomas	O
was	O
most	O
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
terrible	O
indium	O
unevenness	O
and	O
upper	O
-	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O

Variability	O
in	O
the	O
number	O
of	O
colorectal	B
adenomas	I
was	O
apparent	O
in	O
with	O
mutations	O
in	O
region	O
1	O
,	O
and	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O
them	O
.	O

.	O
in	O
the	O
in	O
of	O
colorectal	B
severe	I
was	O
number	O
apparent	O
in	O
individuals	O
in	O
mutations	O
more	O
most	O
1	O
,	O
and	O
upper	O
with	O
gastrointestinal	O
manifestations	O
were	O
region	O
adenomas	O
-	O
them	O
Variability	O

Variability	O
in	O
the	O
number	O
of	O
colorectal	B
adenomas	I
was	O
apparent	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
and	O
-	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O

unevenness	O
in	O
the	O
come	O
of	O
colorectal	B
adenomas	I
was	O
most	O
patent	O
in	O
individuals	O
with	O
mutations	O
in	O
neighborhood	O
i	O
,	O
and	O
amphetamine	O
-	O
gi	O
manifestations	O
were	O
more	O
grave	O
in	O
them	O
.	O

variance	O
in	O
the	O
numeral	O
of	O
colorectal	B
adenomas	I
was	O
most	O
patent	O
in	O
person	O
with	O
mutations	O
in	O
area	O
one	O
,	O
and	O
upper	O
-	O
gi	O
manifestations	O
were	O
more	O
serious	O
in	O
them	O
.	O

Variability	O
in	O
the	O
number	O
of	O
colorectal	B
adenomas	I
was	O
most	O
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
and	O
upper	O
-	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O
them	O
.	O

In	O
mortal	O
with	O
variation	O
in	O
either	O
realm	O
2	O
or	O
realm	O
tierce	O
,	O
the	O
middling	O
enumerate	O
of	O
adenomas	B
incline	O
to	O
be	O
grim	O
than	O
those	O
in	O
mortal	O
with	O
variation	O
in	O
realm	O
single	O
,	O
although	O
age	O
at	O
diagnosing	O
was	O
like	O
.	O

individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
the	O
average	O
number	O
of	O
adenomas	B
to	O
be	O
in	O
mutations	O
in	O
,	O
at	O
diagnosis	O
was	O
similar	O

in	O
diagnosis	O
with	O
mutations	O
adenomas	O
either	O
lower	O
although	O
or	O
region	O
3	O
,	O
the	O
individuals	O
.	O
of	O
in	B
,	O
to	O
be	O
2	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
In	O
tended	O
1	O
region	O
region	O
age	O
at	O
average	O
was	O
similar	O
number	O

In	O
individuals	O
with	O
mutations	O
in	O
either	O
or	O
region	O
3	O
,	O
average	O
number	O
of	O
adenomas	B
tended	O
be	O
lower	O
than	O
those	O
individuals	O
with	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
similar	O
.	O

In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	B
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
similar	O
.	O

In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	B
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
similar	O
.	O

indium	O
somebody	O
with	O
mutations	O
indium	O
either	O
realm	O
ii	O
or	O
realm	O
3	O
,	O
the	O
ordinary	O
number	O
of	O
adenomas	B
tended	O
to	O
be	O
miserable	O
than	O
those	O
indium	O
somebody	O
with	O
mutations	O
indium	O
realm	O
1	O
,	O
although	O
maturate	O
at	O
diagnosing	O
was	O
exchangeable	O
.	O

individuals	O
to	O
with	O
mutations	O
in	O
either	O
,	O
at	O
or	O
region	O
3	O
region	O
the	O
in	O
1	O
of	O
adenomas	B
tended	O
2	O
be	O
lower	O
than	O
region	O
in	O
In	O
with	O
although	O
average	O
number	O
those	O
,	O
was	O
age	O
individuals	O
diagnosis	O
mutations	O
similar	O
.	O

In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	B
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
somebody	O
similar	O
.	O

In	O
individuals	O
in	O
either	O
2	O
or	O
the	O
number	O
of	O
adenomas	B
to	O
be	O
lower	O
those	O
in	O
individuals	O
with	O
mutations	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
similar	O

In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	B
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
similar	O
.	O

inch	O
all	O
AAPC	B
clan	O
,	O
a	O
predomination	O
of	O
right	O
-	O
sided	O
colorectal	B
adenomas	I
and	O
rectal	B
polyp	I
scotch	O
was	O
follow	O
.	O

In	O
all	O
AAPC	B
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B
adenomas	I
and	O
rectal	B
polyp	I
sparing	O
was	O
right	O
on	O
right	O
on	O
right	O
on	O
right	O
on	O

In	O
all	O
AAPC	B
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B
adenomas	I
and	O
rectal	B
polyp	I
sparing	O
was	O
right	O
on	O
right	O
on	O
right	O
on	O
right	O
on	O

AAPC	B
a	O
predominance	O
of	O
-	O
sided	O
adenomas	I
and	O
rectal	B
polyp	I
sparing	O
was	O
observed	O
.	O

In	O
all	O
AAPC	B
kindreds	O
,	O
of	O
right	O
sided	O
colorectal	B
adenomas	I
and	O
rectal	B
polyp	I
sparing	O
was	O
observed	O
.	O

AAPC	B
kindreds	O
,	O
a	O
of	O
right	O
-	O
sided	O
colorectal	B
and	O
rectal	B
polyp	I
sparing	O
observed	O
.	O

was	O
all	O
AAPC	B
observed	O
,	O
a	O
predominance	O
right	O
of	O
-	O
rectal	O
colorectal	B
adenomas	I
.	O
In	B
polyp	I
sparing	O
sided	O
kindreds	O
and	O

In	O
all	O
AAPC	B
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B
adenomas	I
and	O
rectal	B
polyp	I
sparing	O
was	O
right	O
on	O
right	O
on	O
right	O
on	O
right	O
on	O

indium	O
all	O
AAPC	B
clan	O
,	O
a	O
prepotency	O
of	O
right	O
-	O
sided	O
colorectal	B
adenomas	I
and	O
rectal	B
polyp	I
sparing	O
was	O
celebrate	O
.	O

sparing	O
all	O
AAPC	B
kindreds	O
,	O
a	O
and	O
colorectal	O
right	O
-	O
sided	O
rectal	B
In	I
predominance	O
of	B
was	I
adenomas	O
polyp	O
observed	O
.	O

In	O
all	O
AAPC	B
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B
adenomas	I
and	O
rectal	B
polyp	I
sparing	O
was	O
observed	O
.	O

No	O
desmoid	B
tumors	I
were	O
notice	O
in	O
these	O
kindreds	O
.	O

No	O
kin	O
group	B
desmoid	I
tumors	O
were	O
found	O
in	O
these	O
kindreds	O
cost	O

No	O
were	B
tumors	I
desmoid	O
found	O
in	O
kindreds	O
these	O
.	O

no	O
desmoid	B
neoplasm	I
were	O
found	O
in	O
these	O
kindreds	O
.	O

No	O
tumors	I
were	O
in	O
kindreds	O

these	O
desmoid	B
tumors	I
were	O
found	O
in	O
kindreds	O
No	O
.	O

No	O
desmoid	B
tumors	I
were	O
found	O
in	O
these	O
.	O

No	O
kindreds	B
tumors	I
were	O
desmoid	O
in	O
these	O
found	O
.	O

No	O
receive	O
desmoid	B
tumors	I
were	O
found	O
in	O
these	O
kindreds	O
cost	O
.	O

no	O
desmoid	B
tumors	I
were	O
launch	O
in	O
these	O
kindreds	O
.	O

No	O
desmoid	B
tumors	I
were	O
found	O
in	O
these	O
kindreds	O
.	O

expression	O
data	O
suggest	O
location	O
,	O
in	O
AAPC	B
specific	O
mutation	O
the	O
that	O
of	O
APC	O
the	B
,	O
may	O
partially	O
predict	O
families	O
Our	O
phenotypic	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	B
families	O
,	O
the	O
location	O
of	O
the	O
APC	B
mutation	O
may	O
partially	O
predict	O
reflexion	O
reflexion	O
propose	O
propose	O
propose	O
propose	O
specific	O
phenotypic	O
expression	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	B
families	O
,	O
the	O
location	O
of	O
the	O
APC	B
mutation	O
may	O
partially	O
predict	O
reflexion	O
reflexion	O
propose	O
propose	O
propose	O
propose	O
specific	O
phenotypic	O
expression	O
.	O

Our	O
information	O
suggest	O
that	O
,	O
in	O
AAPC	B
mob	O
,	O
the	O
placement	O
of	O
the	O
APC	B
mutant	O
may	O
partially	O
presage	O
particular	O
phenotypic	O
expression	O
.	O

Our	O
data	O
suggest	O
,	O
in	O
AAPC	B
families	O
,	O
location	O
of	O
the	O
APC	B
may	O
partially	O
specific	O
phenotypic	O
expression	O
.	O

that	O
AAPC	B
families	O
,	O
location	O
of	O
APC	B
mutation	O
may	O
partially	O
predict	O
specific	O
phenotypic	O
expression	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	B
household	O
,	O
the	O
localization	O
of	O
the	O
apc	B
mutation	O
may	O
partly	O
predict	O
particular	O
phenotypic	O
saying	O
.	O

mutation	O
data	O
,	O
AAPC	O
,	O
in	O
may	B
families	O
suggest	O
the	O
location	O
of	O
expression	O
APC	B
that	O
Our	O
partially	O
predict	O
specific	O
phenotypic	O
the	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	B
families	O
,	O
the	O
location	O
of	O
the	O
APC	B
mutation	O
may	O
partially	O
predict	O
reflexion	O
reflexion	O
propose	O
propose	O
propose	O
family	O
line	O
specific	O
phenotypic	O
expression	O

Our	O
data	O
suggest	O
that	O
AAPC	B
families	O
the	O
location	O
of	O
the	O
APC	B
mutation	O
may	O
partially	O
predict	O
specific	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	B
families	O
,	O
the	O
location	O
of	O
the	O
APC	B
mutation	O
may	O
partially	O
predict	O
specific	O
phenotypic	O
expression	O
.	O

This	O
should	O
supporter	O
in	O
the	O
invention	O
of	O
tailored	O
clinical	O
-	O
direction	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
.	O
.	O

This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
facilitate	O
facilitate	O
facilitate	O
facilitate	O
facilitate	O
facilitate	O
.	O
.	O

This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
facilitate	O
facilitate	O
facilitate	O
facilitate	O
facilitate	O
facilitate	O
.	O
.	O

help	O
design	O
of	O
tailored	O
-	O
management	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
.	O
.	O

This	O
should	O
help	O
in	O
the	O
tailored	O
clinical	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
.	O
.	O

help	O
in	O
the	O
design	O
tailored	O
clinical	O
-	O
management	O
protocols	O
this	O
subset	O
of	O
FAP	B
.	O
.	O

patients	O
should	O
help	O
.	O
the	O
design	O
of	O
clinical	O
tailored	O
-	O
subset	O
protocols	O
in	O
.	O
This	O
of	O
FAP	B
management	O
in	O
this	O

This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
facilitate	O
facilitate	O
facilitate	O
facilitate	O
facilitate	O
direction	O
.	O
.	O

This	O
should	O
assistant	O
in	O
the	O
invention	O
of	O
bespoken	O
clinical	O
-	O
direction	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
.	O
.	O

FAP	O
should	O
help	O
in	O
the	O
design	O
this	O
protocols	O
clinical	O
-	O
management	O
subset	O
This	O
of	O
tailored	O
patients	O
in	B
of	O
.	O
.	O

This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
.	O
.	O

Wilms	B
'	I
tumor	I
1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
SF	O
-	O
1	O
in	O
sex	O
-	O
specific	O
gene	O
expression	O

Wilms	B
'	I
tumor	I
1	O
and	O
Dax	O
-	O
1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
-	O
sex	O
-	O
specific	O
gene	O
expression	O
.	O

Wilms	B
'	I
tumor	I
1	O
and	O
Dax	O
-	O
1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
SF	O
-	O
1	O
in	O
sex	O
factor	O
reflexion	O
reflexion	O
neoplasm	O
neoplasm	O
neoplasm	O
-	O
specific	O
gene	O
expression	O
.	O

Wilms	B
'	I
tumour	I
ace	O
and	O
Dax	O
-	O
ace	O
regulate	O
the	O
orphan	O
atomic	O
receptor	O
SF	O
-	O
ace	O
in	O
sex	O
-	O
particular	O
factor	O
expression	O
.	O

Wilms	B
'	I
tumor	I
1	O
and	O
Dax	O
-	O
1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
SF	O
-	O
1	O
in	O
sex	O
factor	O
reflexion	O
reflexion	O
neoplasm	O
neoplasm	O
neoplasm	O
-	O
specific	O
gene	O
expression	O
.	O

Wilms	B
'	I
neoplasm	I
ane	O
and	O
Dax	O
-	O
ane	O
modulate	O
the	O
orphan	O
atomic	O
receptor	O
SF	O
-	O
ane	O
in	O
sex	O
-	O
particular	O
factor	O
reflexion	O
.	O

Wilms	B
'	I
tumor	I
1	O
and	O
Dax	O
-	O
1	O
modulate	O
the	O
nuclear	O
receptor	O
-	O
1	O
in	O
sex	O
-	O
specific	O
gene	O

orphan	B
'	I
tumor	I
-	O
and	O
Dax	O
-	O
modulate	O
1	O
the	O
specific	O
nuclear	O
SF	O
receptor	O
.	O
1	O
in	O
sex	O
1	O
Wilms	O
gene	O
expression	O
-	O

Wilms	B
'	I
neoplasm	I
ane	O
and	O
Dax	O
-	O
ane	O
tone	O
the	O
orphan	O
atomic	O
receptor	O
SF	O
-	O
ane	O
in	O
sex	O
-	O
specific	O
factor	O
construction	O
.	O

-	B
'	I
modulate	I
-	O
and	O
Dax	O
1	O
1	O
tumor	O
the	O
orphan	O
nuclear	O
gene	O
SF	O
1	O
Wilms	O
in	O
sex	O
-	O
specific	O
receptor	O
expression	O
.	O

Wilms	B
'	I
tumor	I
1	O
and	O
Dax	O
-	O
1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
SF	O
-	O
1	O
in	O
sex	O
-	O
specific	O
gene	O
expression	O
.	O

Products	O
steroidogenic	O
factor	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B
(	O
WT1	O
)	O
genes	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
sexual	O
differentiation	O
.	O

Products	O
steroidogenic	O
factor	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B
tumor	I
(	O
WT1	O
genes	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O

Products	O
of	O
steroidogenic	O
factor	O
	O
intimate	O
specialisation	O
	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B
tumor	I
1	O
(	O
WT1	O
)	O
genes	O
mammal	O
intimate	O
specialisation	O
	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O

for	O
of	O
steroidogenic	O
are	O
1	O
(	O
SF	O
sexual	O
prior	O
)	O
essential	O
Wilms	B
tumor	I
1	O
gonadogenesis	O
WT1	O
)	O
genes	O
factor	O
to	O
and	O
mammalian	O
(	O
1	O
Products	O
-	O
differentiation	O
.	O

differentiation	O
of	O
steroidogenic	O
(	O
1	O
(	O
sexual	O
-	O
factor	O
)	O
and	O
Wilms	B
1	I
for	O
to	O
1	O
)	O
genes	O
are	O
essential	O
tumor	O
mammalian	O
gonadogenesis	O
prior	O
WT1	O
SF	O
Products	O
.	O

Products	O
of	O
steroidogenic	O
factor	O
	O
intimate	O
specialisation	O
	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B
tumor	I
1	O
(	O
WT1	O
)	O
genes	O
mammal	O
intimate	O
specialisation	O
	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O

ware	O
of	O
steroidogenic	O
constituent	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B
tumour	I
1	O
(	O
WT1	O
)	O
factor	O
are	O
necessary	O
for	O
mammalian	O
gonadogenesis	O
anterior	O
to	O
intimate	O
distinction	O
.	O

Products	O
of	O
steroidogenic	O
factor	O
	O
intimate	O
specialisation	O
	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B
tumor	I
1	O
(	O
WT1	O
)	O
genes	O
mammal	O
intimate	O
specialisation	O
	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O

prior	O
of	O
steroidogenic	O
factor	O
1	O
(	O
1	O
Wilms	O
1	O
)	O
and	O
)	B
mammalian	I
SF	O
to	O
Products	O
-	O
WT1	O
are	O
essential	O
for	O
tumor	O
gonadogenesis	O
genes	O
(	O
sexual	O
differentiation	O
.	O

Products	O
of	O
steroidogenic	O
broker	O
ane	O
(	O
SF	O
-	O
ane	O
)	O
and	O
Wilms	B
tumour	I
ane	O
(	O
WT1	O
)	O
broker	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
anterior	O
to	O
intimate	O
specialisation	O
.	O

Products	O
of	O
steroidogenic	O
factor	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B
tumor	I
1	O
(	O
WT1	O
)	O
genes	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O

In	O
males	O
,	O
SF	O
-	O
1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
mile	O
content	O
mile	O
mile	O
intimate	O
intimate	O
content	O
inhibiting	O
substance	O
(	O
MIS	O
)	O
.	O

,	O
SF	O
-	O
1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
inhibiting	O
(	O
MIS	O
)	O
.	O

indium	O
males	O
,	O
SF	O
-	O
1	O
participates	O
indium	O
intimate	O
ontogenesis	O
by	O
mold	O
formula	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
meat	O
(	O
michigan	O
)	O
.	O

In	O
males	O
,	O
SF	O
-	O
1	O
participates	O
sexual	O
development	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
(	O
MIS	O
)	O
.	O

In	O
males	O
,	O
SF	O
-	O
1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
mile	O
content	O
mile	O
mile	O
intimate	O
intimate	O
intimate	O
inhibiting	O
substance	O
(	O
MIS	O
)	O
.	O

inch	O
males	O
,	O
SF	O
-	O
single	O
enter	O
inch	O
intimate	O
exploitation	O
by	O
regulating	O
face	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
sum	O
(	O
MIS	O
)	O
.	O

inward	O
males	O
,	O
SF	O
-	O
1	O
enter	O
inward	O
sexual	O
development	O
by	O
regulation	O
construction	O
of	O
the	O
polypeptide	O
endocrine	O
Mullerian	O
suppress	O
heart	O
(	O
MIS	O
)	O
.	O

In	O
males	O
,	O
SF	O
-	O
1	O
participates	O
in	O
sexual	O
by	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
substance	O
(	O
MIS	O

In	O
males	O
,	O
SF	O
-	O
1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
mile	O
content	O
mile	O
mile	O
intimate	O
intimate	O
intimate	O
inhibiting	O
substance	O
(	O
MIS	O
)	O
.	O

Mullerian	O
males	O
,	O
by	O
-	O
1	O
participates	O
inhibiting	O
.	O
development	O
SF	O
regulating	O
expression	O
of	O
)	O
polypeptide	O
hormone	O
(	O
in	O
In	O
substance	O
MIS	O
the	O
sexual	O

In	O
males	O
,	O
SF	O
-	O
1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
substance	O
(	O
MIS	O
)	O
.	O

hera	O
,	O
we	O
register	O
that	O
WT1	O
-	O
kt	O
isoforms	O
link	O
and	O
synergize	O
with	O
SF	O
-	O
ace	O
to	O
boost	O
MIS	O
expression	O
.	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-	O
KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF	O
-	O
1	O
to	O
promote	O
reflexion	O
display	O
display	O
display	O
display	O
display	O
MIS	O
expression	O
.	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-	O
KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF	O
-	O
1	O
to	O
promote	O
reflexion	O
display	O
display	O
display	O
display	O
display	O
MIS	O
expression	O
.	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-	O
KTS	O
associate	O
and	O
with	O
SF	O
-	O
1	O
to	O
promote	O
MIS	O

-	O
,	O
isoforms	O
-	O
that	O
WT1	O
1	O
KTS	O
we	O
associate	O
and	O
synergize	O
.	O
SF	O
show	O
Here	O
to	O
promote	O
MIS	O
expression	O
with	O

hera	O
,	O
we	O
display	O
that	O
WT1	O
-	O
karat	O
isoforms	O
consociate	O
and	O
synergize	O
with	O
SF	O
-	O
1	O
to	O
raise	O
MIS	O
construction	O
.	O

.	O
,	O
we	O
and	O
that	O
WT1	O
-	O
MIS	O
-	O
associate	O
show	O
synergize	O
SF	O
with	O
isoforms	O
1	O
to	O
promote	O
KTS	O
Here	O
expression	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-	O
KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF	O
-	O
1	O
to	O
promote	O
reflexion	O
display	O
display	O
display	O
display	O
elevate	O
MIS	O
expression	O
.	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-	O
KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
-	O
promote	O
MIS	O
expression	O
.	O

hera	O
,	O
we	O
show	O
that	O
WT1	O
-	O
kt	O
isoforms	O
familiar	O
and	O
synergize	O
with	O
SF	O
-	O
1	O
to	O
further	O
mile	O
manifestation	O
.	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-	O
KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF	O
-	O
1	O
to	O
promote	O
MIS	O
expression	O
.	O

In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B
pseudohermaphroditism	I
in	O
Denys	B
-	I
Drash	I
syndrome	I
,	O
fail	O
	O
subsume	O
	O
	O
colligate	O
to	O
synergize	O
with	O
SF	O
-	O
1	O
.	O

In	O
contrast	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B
pseudohermaphroditism	I
in	O
Denys	B
syndrome	I
,	O
fail	O
to	O
with	O
SF	O
-	O
1	O
.	O

In	O
counterpoint	O
,	O
WT1	O
missense	O
mutations	O
,	O
relate	O
with	O
manlike	B
pseudohermaphroditism	I
in	O
refuse	B
-	I
Drash	I
syndrome	I
,	O
go	O
to	O
synergize	O
with	O
SF	O
-	O
ane	O
.	O

synergize	O
contrast	O
,	O
,	O
missense	O
mutations	O
WT1	O
associated	O
with	O
male	B
pseudohermaphroditism	I
in	O
-	B
with	I
-	I
In	I
,	O
fail	O
to	O
.	O
Denys	O
SF	O
Drash	O
1	O
syndrome	O

inwards	O
demarcation	O
,	O
WT1	O
missense	O
mutations	O
,	O
colligate	O
with	O
male	B
pseudohermaphroditism	I
inwards	O
deny	B
-	I
Drash	I
syndrome	I
,	O
neglect	O
to	O
synergize	O
with	O
SF	O
-	O
i	O
.	O

inch	O
contrast	O
,	O
WT1	O
missense	O
sport	O
,	O
consociate	O
with	O
manlike	B
pseudohermaphroditism	I
inch	O
traverse	B
-	I
Drash	I
syndrome	I
,	O
fail	O
to	O
synergize	O
with	O
SF	O
-	O
i	O
.	O

In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B
pseudohermaphroditism	I
in	O
Denys	B
-	I
Drash	I
syndrome	I
,	O
fail	O
	O
deny	O
	O
	O
abnegate	O
to	O
synergize	O
with	O
SF	O
-	O
1	O
.	O

fail	O
contrast	O
,	O
pseudohermaphroditism	O
missense	O
mutations	O
-	O
to	O
1	O
male	B
WT1	I
in	O
SF	B
,	I
Drash	I
syndrome	I
,	O
with	O
associated	O
synergize	O
In	O
Denys	O
-	O
with	O
.	O

In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B
pseudohermaphroditism	I
in	O
Denys	B
-	I
Drash	I
syndrome	I
,	O
fail	O
	O
deny	O
	O
	O
abnegate	O
to	O
synergize	O
with	O
SF	O
-	O
1	O
.	O

In	O
WT1	O
missense	O
mutations	O
associated	O
with	O
pseudohermaphroditism	I
in	O
Denys	B
-	I
Drash	I
syndrome	I
,	O
fail	O
to	O
synergize	O
with	O
SF	O
-	O

In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B
pseudohermaphroditism	I
in	O
Denys	B
-	I
Drash	I
syndrome	I
,	O
fail	O
to	O
synergize	O
with	O
SF	O
-	O
1	O
.	O

Additionally	O
,	O
the	O
X	O
-	O
linked	O
,	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
-	O
reversal	O
gene	O
,	O
Dax	O
-	O
1	O
,	O
antagonizes	O
synergy	O
between	O
SF	O
-	O
1	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
direct	O
interaction	O
with	O
campaigner	O
	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
SF	O
-	O
1	O
.	O

Additionally	O
,	O
the	O
X	O
-	O
linked	O
,	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
-	O
reversal	O
gene	O
,	O
Dax	O
-	O
1	O
,	O
antagonizes	O
synergy	O
between	O
SF	O
-	O
1	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
direct	O
interaction	O
with	O
campaigner	O
	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
through	O
and	O
through	O
SF	O
-	O

Additionally	O
,	O
the	O
X	O
-	O
linked	O
,	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
-	O
reversal	O
gene	O
,	O
Dax	O
-	O
1	O
,	O
antagonizes	O
synergy	O
between	O
SF	O
-	O
1	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
direct	O
interaction	O
with	O
campaigner	O
	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
campaigner	O
SF	O
-	O
1	O
.	O

-	O
1	O
the	O
X	O
-	O
linked	O
sex	O
direct	O
dosage	O
-	O
sensitive	O
,	O
-	O
WT1	O
most	O
,	O
Dax	O
-	O
candidate	O
,	O
antagonizes	O
a	O
,	O
SF	O
Additionally	O
1	O
through	O
reversal	O
gene	O
between	O
likely	O
with	O
synergy	O
,	O
interaction	O
and	O
SF	O
-	O
1	O
.	O

Additionally	O
,	O
the	O
X	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
reversal	O
gene	O
1	O
synergy	O
between	O
1	O
,	O
most	O
likely	O
through	O
direct	O
interaction	O
-	O
1	O

Additionally	O
,	O
the	O
xtc	O
-	O
associate	O
,	O
campaigner	O
dose	O
-	O
medium	O
excite	O
-	O
blow	O
factor	O
,	O
Dax	O
-	O
unity	O
,	O
antagonise	O
synergism	O
between	O
SF	O
-	O
unity	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
manoeuvre	O
interaction	O
with	O
SF	O
-	O
unity	O
.	O

Additionally	O
,	O
the	O
ecstasy	O
-	O
associate	O
,	O
prospect	O
dose	O
-	O
spiritualist	O
excite	O
-	O
reversal	O
factor	O
,	O
Dax	O
-	O
unity	O
,	O
antagonise	O
synergism	O
between	O
SF	O
-	O
unity	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
head	O
interaction	O
with	O
SF	O
-	O
unity	O
.	O

likely	O
interaction	O
the	O
X	O
Dax	O
linked	O
-	O
through	O
dosage	O
-	O
sensitive	O
sex	O
-	O
-	O
-	O
,	O
-	O
gene	O
1	O
,	O
reversal	O
synergy	O
between	O
SF	O
,	O
1	O
and	O
1	O
Additionally	O
most	O
,	O
,	O
a	O
direct	O
antagonizes	O
with	O
SF	O
candidate	O
WT1	O
.	O

additionally	O
,	O
the	O
ten	O
-	O
linked	O
,	O
nominee	O
dose	O
-	O
raw	O
arouse	O
-	O
reversal	O
cistron	O
,	O
Dax	O
-	O
ace	O
,	O
counteract	O
synergism	O
between	O
SF	O
-	O
ace	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
address	O
interaction	O
with	O
SF	O
-	O
ace	O
.	O

Additionally	O
,	O
likely	O
X	O
-	O
with	O
sensitive	O
candidate	O
dosage	O
-	O
,	O
and	O
,	O
reversal	O
gene	O
1	O
Dax	O
-	O
-	O
-	O
antagonizes	O
synergy	O
between	O
linked	O
-	O
,	O
sex	O
a	O
through	O
most	O
the	O
WT1	O
,	O
direct	O
interaction	O
SF	O
SF	O
1	O
1	O
.	O

Additionally	O
,	O
the	O
X	O
-	O
linked	O
,	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
-	O
reversal	O
gene	O
,	O
Dax	O
-	O
1	O
,	O
antagonizes	O
synergy	O
between	O
SF	O
-	O
1	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
direct	O
interaction	O
with	O
SF	O
-	O
1	O
.	O

We	O
propose	O
that	O
WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF	O
intercede	O
	O
intercede	O
intercede	O
past	O
past	O
indium	O
-	O
1	O
-	O
mediated	O
transactivation	O
.	O
.	O

WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF	O
1	O
mediated	O
transactivation	O
.	O
.	O

We	O
purpose	O
that	O
WT1	O
and	O
Dax	O
-	O
unity	O
functionally	O
contradict	O
each	O
other	O
in	O
nut	O
ontogeny	O
by	O
modulate	O
SF	O
-	O
unity	O
-	O
intercede	O
transactivation	O
.	O
.	O

We	O
propose	O
that	O
WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
other	O
in	O
development	O
by	O
modulating	O
SF	O
-	O
1	O
-	O
.	O
.	O

We	O
propose	O
that	O
WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF	O
intercede	O
	O
intercede	O
intercede	O
past	O
past	O
past	O
-	O
1	O
-	O
mediated	O
transactivation	O
.	O
.	O

We	O
offer	O
that	O
WT1	O
and	O
Dax	O
-	O
ane	O
functionally	O
oppose	O
each	O
other	O
in	O
nut	O
ontogeny	O
by	O
tone	O
SF	O
-	O
ane	O
-	O
intermediate	O
transactivation	O
.	O
.	O

We	O
suggest	O
that	O
WT1	O
and	O
Dax	O
-	O
unity	O
functionally	O
oppose	O
each	O
other	O
in	O
bollock	O
ontogeny	O
by	O
modulate	O
SF	O
-	O
unity	O
-	O
intercede	O
transactivation	O
.	O
.	O

We	O
propose	O
that	O
WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
each	O
in	O
by	O
modulating	O
SF	O
-	O
1	O
-	O
mediated	O
transactivation	O
.	O

We	O
propose	O
that	O
WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF	O
intercede	O
	O
intercede	O
intercede	O
past	O
past	O
past	O
-	O
1	O
-	O
mediated	O
transactivation	O
.	O
.	O

1	O
propose	O
that	O
each	O
and	O
Dax	O
-	O
-	O
.	O
oppose	O
WT1	O
other	O
testis	O
in	O
transactivation	O
by	O
modulating	O
SF	O
1	O
.	O
-	O
mediated	O
development	O
functionally	O
We	O

We	O
propose	O
that	O
WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF	O
-	O
1	O
-	O
mediated	O
transactivation	O
.	O
.	O

A	O
model	O
for	O
-	I
syndrome	I
-	O
centre	O
mutations	O
.	O

A	O
mouse	O
model	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
imprinting	O
-	O
centre	O
mutations	O

A	O
creep	O
example	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
form	O
-	O
centre	O
mutations	O
.	O

A	O
mouse	O
model	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
imprinting	O
sport	O
sport	O
black	O
eye	O
-	O
centre	O
mutations	O

A	O
mouse	O
model	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
imprinting	O
sport	O
sport	O
black	O
eye	O
-	O
centre	O
mutations	O

A	O
mouse	O
model	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
imprinting	O
sport	O
sport	O
black	O
eye	O
-	O
centre	O
mutations	O

angstrom	O
creep	O
model	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
impress	O
-	O
centre	O
mutations	O
.	O

A	O
mouse	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
imprinting	O
-	O
.	O

A	O
sneak	O
mould	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
imprinting	O
-	O
centre	O
sport	O
.	O

A	O
Prader	O
model	O
for	O
.	B
-	I
Willi	I
mouse	I
imprinting	O
-	O
centre	O
mutations	O
syndrome	O

A	O
mouse	O
model	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
imprinting	O
-	O
centre	O
mutations	O
.	O

form	O
in	O
the	O
15q11	O
-	O
q13	O
part	O
involves	O
an	O
form	O
centre	O
(	O
ic	O
)	O
,	O
represent	O
in	O
division	O
to	O
the	O
plugger	O
and	O
offset	O
exon	O
of	O
SNRPN	O
.	O

Imprinting	O
in	O
15q11	O
-	O
q13	O
region	O
involves	O
an	O
imprinting	O
centre	O
(	O
IC	O
mapping	O
in	O
part	O
to	O
promoter	O
and	O
first	O
exon	O
of	O
.	O

Imprinting	O
in	O
the	O
15q11	O
coding	O
dna	O
single	O
valued	O
function	O
indium	O
-	O
q13	O
region	O
involves	O
an	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
mapping	O
in	O
part	O
coding	O
dna	O
low	O
coding	O
dna	O
coding	O
dna	O
associate	O
in	O
nursing	O
to	O

promoter	O
in	O
the	O
to	O
-	O
q13	O
region	O
SNRPN	O
exon	O
imprinting	O
the	O
(	O
IC	O
)	O
first	O
mapping	O
in	O
part	O
15q11	O
of	O
centre	O
and	O
,	O
an	O
Imprinting	O
involves	O
.	O

Imprinting	O
in	O
the	O
15q11	O
coding	O
dna	O
single	O
valued	O
function	O
indium	O
-	O
q13	O
region	O
involves	O
an	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
mapping	O
in	O
part	O
coding	O
dna	O
low	O
coding	O
dna	O
coding	O
dna	O
associate	O
in	O
nursing	O
to	O

Imprinting	O
in	O
the	O
-	O
q13	O
involves	O
an	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
in	O
part	O
the	O
promoter	O
and	O
first	O
exon	O
of	O
SNRPN	O
.	O

.	O
in	O
the	O
,	O
-	O
q13	O
SNRPN	O
involves	O
15q11	O
imprinting	O
centre	O
(	O
)	O
promoter	O
of	O
an	O
in	O
part	O
to	O
the	O
IC	O
and	O
first	O
exon	O
mapping	O
region	O
Imprinting	O

the	O
q13	O
region	O
involves	O
imprinting	O
centre	O
IC	O
)	O
,	O
mapping	O
in	O
part	O
to	O
the	O
promoter	O
and	O
first	O
exon	O
of	O

exon	O
in	O
the	O
15q11	O
-	O
q13	O
)	O
(	O
an	O
imprinting	O
centre	O
in	O
and	O
region	O
of	O
Imprinting	O
involves	O
mapping	O
to	O
the	O
promoter	O
IC	O
first	O
part	O
,	O
SNRPN	O
.	O

form	O
in	O
the	O
15q11	O
-	O
q13	O
realm	O
imply	O
an	O
form	O
kernel	O
(	O
IC	O
)	O
,	O
mapping	O
in	O
function	O
to	O
the	O
booster	O
and	O
maiden	O
exon	O
of	O
SNRPN	O
.	O

Imprinting	O
in	O
the	O
15q11	O
-	O
q13	O
region	O
involves	O
an	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
mapping	O
in	O
part	O
to	O
the	O
promoter	O
and	O
first	O
exon	O
of	O
SNRPN	O
.	O

omission	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
gain	O
cistron	O
manifestation	O
and	O
results	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
PWS	B
)	O
.	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
PWS	B
)	O
.	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
expression	O
and	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B

-	O
of	O
gene	O
paternally	O
abolishes	O
local	O
Willi	O
derived	O
this	O
expression	O
and	O
results	O
.	O
Prader	B
IC	I
Deletion	I
syndrome	I
(	O
PWS	B
)	O
in	O

deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
infer	O
cistron	O
formula	O
and	O
results	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

.	O
of	O
this	O
and	O
abolishes	O
local	O
paternally	O
PWS	O
-	O
expression	O
IC	O
results	O
Prader	O
in	B
gene	I
Willi	I
syndrome	I
(	O
derived	B
Deletion	O
)	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
factor	O
factor	O
factor	O
factor	O
factor	O
reflexion	O
PWS	B
)	O
.	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
-	I
(	O
PWS	B
)	O
.	O

excision	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
gain	O
cistron	O
reflexion	O
and	O
solution	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

PWS	O
have	O
created	O
mice	O
deletion	O
mutations	O
in	O
two	O
of	O
understand	O
mechanism	B
and	O
We	O
the	O
to	O
this	O
IC	O
.	O

We	O
have	O
produce	O
deuce	O
excision	O
sport	O
in	O
mice	O
to	O
infer	O
PWS	B
and	O
the	O
mechanism	O
of	O
this	O
IC	O
.	O

We	O
have	O
make	O
deuce	O
excision	O
mutant	O
in	O
mice	O
to	O
realise	O
PWS	B
and	O
the	O
mechanism	O
of	O
this	O
IC	O
.	O

We	O
have	O
created	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	B
and	O
the	O
mechanism	O
of	O
this	O
IC	O
.	O

We	O
have	O
make	O
two	O
deletion	O
sport	O
in	O
mice	O
to	O
sympathise	O
PWS	B
and	O
the	O
mechanics	O
of	O
this	O
ic	O
.	O

We	O
have	O
produce	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	B
and	O
the	O
mechanism	O
of	O
this	O
IC	O
bring	O
on	O
bring	O
on	O
bring	O

We	O
have	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
and	O
the	O
of	O
this	O
IC	O
.	O

We	O
have	O
produce	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	B
and	O
the	O
mechanism	O
of	O
this	O
IC	O
bring	O
on	O
bring	O
on	O
bring	O

have	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	B
and	O
the	O
.	O

We	O
have	O
to	O
of	O
deletion	O
mutations	O
the	O
mice	O
created	O
understand	O
PWS	B
and	O
in	O
mechanism	O
two	O
this	O
IC	O
.	O

We	O
have	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	B
and	O
the	O
mechanism	O
of	O
this	O
IC	O
.	O

Mice	O
harbouring	O
an	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
induce	O
PWS	B

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
of	O
not	O
sufficient	O
to	O
induce	O
PWS	B
.	O

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
stimulate	O
stimulate	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	B
nursing	O

Mice	O
nurse	O
an	O
intragenic	O
omission	O
in	O
Snrpn	O
are	O
phenotypically	O
convention	O
,	O
suggesting	O
that	O
sport	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
have	O
PWS	B
.	O

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
stimulate	O
stimulate	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	B
nursing	O

Mice	O
nurse	O
an	O
intragenic	O
excision	O
in	O
Snrpn	O
are	O
phenotypically	O
formula	O
,	O
advise	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
stimulate	O
PWS	B
.	O

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
suggesting	O
that	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
induce	O

,	O
harbouring	O
an	O
sufficient	O
deletion	O
in	O
Snrpn	O
phenotypically	O
are	O
normal	O
to	O
suggesting	O
mutations	O
that	O
.	O
SNRPN	O
are	O
not	O
intragenic	O
Mice	O
induce	O
PWS	B
of	O

shiner	O
harbouring	O
an	O
intragenic	O
excision	O
in	O
Snrpn	O
are	O
phenotypically	O
rule	O
,	O
propose	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
cause	O
PWS	B
.	O

of	O
harbouring	O
phenotypically	O
Snrpn	O
deletion	O
in	O
SNRPN	O
are	O
an	O
normal	O
,	O
suggesting	O
induce	O
mutations	O
intragenic	O
Mice	O
are	O
not	O
sufficient	O
to	O
that	O
PWS	B
.	O

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
induce	O
PWS	B
.	O

Mice	O
with	O
a	O
orotund	O
cut	O
demand	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
want	O
manifestation	O
of	O
the	O
impress	O
cistron	O
Zfp127	O
(	O
creep	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
evidence	O
respective	O
phenotypes	O
vulgar	O
to	O
PWS	B
babe	O
.	O

Mice	O
with	O
a	O
big	O
cut	O
imply	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
want	O
reflexion	O
of	O
the	O
form	O
factor	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
evident	O
respective	O
phenotypes	O
park	O
to	O
PWS	B
babe	O
.	O

Mice	O
deletion	O
both	O
Snrpn	O
and	O
putative	O
PWS	O
-	O
lack	O
expression	O
of	O
the	O
imprinted	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
,	O
manifest	O
several	O
phenotypes	O
to	O
PWS	B
infants	O
.	O

Mice	O
with	O
,	O
larger	O
deletion	O
Ndn	O
ZNF127	O
Snrpn	O
and	O
the	O
putative	O
homologue	O
,	O
IC	O
lack	O
Ipw	O
of	O
the	O
genes	O
imprinted	O
Zfp127	O
(	O
mouse	O
phenotypes	O
of	O
)	O
-	O
and	O
involving	O
and	O
expression	O
to	O
both	O
manifest	O
several	O
PWS	O
common	O
a	O
PWS	B
infants	O
.	O

of	O
imprinted	O
a	O
larger	O
deletion	O
involving	O
PWS	O
(	O
and	O
the	O
putative	O
both	O
-	O
,	O
and	O
expression	O
of	O
the	O
.	O
genes	O
Zfp127	O
Snrpn	O
Ndn	O
homologue	O
Mice	O
ZNF127	O
,	O
IC	O
lack	O
mouse	O
Ipw	O
phenotypes	O
and	O
with	O
several	O
)	O
common	O
to	O
PWS	B
infants	O
manifest	O

Mice	O
with	O
a	O
larger	O
both	O
Snrpn	O
and	O
the	O
PWS	O
-	O
IC	O
lack	O
expression	O
the	O
imprinted	O
genes	O
Zfp127	O
mouse	O
homologue	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
several	O
phenotypes	O
to	O
PWS	B
infants	O
.	O

Mice	O
with	O
a	O
larger	O
deletion	O
involving	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
manifest	O
several	O
phenotypes	O
omission	O
omission	O
babe	O
omission	O
omission	O
omission	O
omission	O
omission	O
omission	O
omission	O
omission	O
omission	O
common	O
to	O
PWS	B
infants	O
.	O

Mice	O
with	O
a	O
larger	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
IC	O
lack	O
imprinted	O
(	O
mouse	O
ZNF127	O
Ndn	O
and	O
Ipw	O
,	O
manifest	O
several	O
to	O
PWS	B
.	O

shiner	O
with	O
a	O
bombastic	O
cut	O
imply	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
deficiency	O
construction	O
of	O
the	O
impress	O
cistron	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
patent	O
various	O
phenotypes	O
green	O
to	O
PWS	B
infants	O
.	O

Mice	O
with	O
a	O
larger	O
deletion	O
involving	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
manifest	O
several	O
phenotypes	O
omission	O
omission	O
babe	O
omission	O
omission	O
omission	O
omission	O
omission	O
omission	O
omission	O
omission	O
omission	O
common	O
to	O
PWS	B
infants	O
.	O

Mice	O
with	O
a	O
larger	O
deletion	O
involving	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
manifest	O
several	O
phenotypes	O
common	O
to	O
PWS	B
infants	O
.	O

These	O
datum	O
evidence	O
that	O
both	O
the	O
stance	O
of	O
the	O
ic	O
and	O
its	O
office	O
in	O
the	O
organize	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
creep	O
and	O
human	O
,	O
and	O
suggest	O
that	O
the	O
creep	O
is	O
a	O
suited	O
model	O
scheme	O
in	O
which	O
to	O
inquire	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
realm	O
of	O
the	O
genome	O
.	O
.	O

These	O
data	O
that	O
position	O
of	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
system	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
this	O
region	O
of	O
the	O
genome	O
.	O
.	O

These	O
datum	O
establish	O
that	O
both	O
the	O
position	O
of	O
the	O
IC	O
and	O
its	O
function	O
in	O
the	O
organise	O
aspect	O
of	O
cistron	O
is	O
husband	O
between	O
sneak	O
and	O
human	O
,	O
and	O
signal	O
that	O
the	O
sneak	O
is	O
a	O
worthy	O
model	O
system	O
in	O
which	O
to	O
enquire	O
the	O
molecular	O
mechanisms	O
of	O
form	O
in	O
this	O
part	O
of	O
the	O
genome	O
.	O
.	O

model	O
and	O
demonstrate	O
that	O
both	O
the	O
its	O
of	O
the	O
IC	O
and	O
position	O
role	O
indicate	O
that	O
coordinate	O
expression	O
of	O
the	O
is	O
conserved	O
between	O
suitable	O
and	O
of	O
,	O
this	O
in	O
of	O
genes	O
mouse	O
system	O
a	O
the	O
These	O
molecular	O
in	O
which	O
to	O
investigate	O
data	O
is	O
mechanisms	O
mouse	O
imprinting	O
in	O
the	O
region	O
human	O
the	O
genome	O
.	O
.	O

These	O
position	O
IC	O
its	O
role	O
in	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
a	O
suitable	O
in	O
which	O
to	O
the	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O

imprinting	O
human	O
demonstrate	O
that	O
both	O
the	O
conserved	O
expression	O
the	O
IC	O
and	O
its	O
role	O
genome	O
which	O
coordinate	O
of	O
mouse	O
genes	O
is	O
of	O
between	O
mouse	O
and	O
data	O
,	O
and	O
to	O
of	O
the	O
that	O
position	O
a	O
suitable	O
model	O
system	O
in	O
the	O
indicate	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
These	O
in	O
.	O
region	O
the	O
is	O
in	O
this	O
.	O

demonstrate	O
that	O
both	O
position	O
the	O
IC	O
and	O
in	O
genes	O
is	O
conserved	O
mouse	O
and	O
,	O
and	O
indicate	O
mouse	O
is	O
a	O
suitable	O
model	O
in	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
the	O
genome	O
.	O
.	O

These	O
data	O
demonstrate	O
that	O
both	O
the	O
position	O
of	O
part	O
black	O
eye	O
cost	O
ampere	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
model	O
system	O
imprint	O
indium	O
reflexion	O
part	O
indium	O
reflexion	O
part	O
indium	O
reflexion	O
part	O
reflexion	O
in	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O
genome	O
.	O

These	O
data	O
demonstrate	O
that	O
both	O
the	O
position	O
of	O
part	O
black	O
eye	O
cost	O
ampere	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
model	O
system	O
imprint	O
indium	O
reflexion	O
part	O
indium	O
reflexion	O
part	O
indium	O
reflexion	O
part	O
reflexion	O
in	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O
genome	O
.	O

These	O
data	O
demonstrate	O
that	O
both	O
the	O
position	O
of	O
part	O
black	O
eye	O
cost	O
ampere	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
model	O
system	O
imprint	O
indium	O
reflexion	O
part	O
indium	O
reflexion	O
part	O
indium	O
reflexion	O
part	O
reflexion	O
in	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O
genome	O
.	O

These	O
data	O
demonstrate	O
that	O
both	O
the	O
position	O
of	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
model	O
system	O
in	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O
genome	O
.	O
.	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B
-	I
telangiectasia	I
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
sport	O
sport	O
motor	O
ataxia	O
motor	O
ataxia	O
motor	O
ataxia	O
motor	O
ataxia	O
sport	O
founder	O
mutations	O

the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B
-	I
telangiectasia	I
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
founder	O
4612del165	O
and	O
7883del5	O
.	O

sport	O
of	O
the	O
ATM	O
factor	O
detected	O
in	O
Japanese	O
ataxy	B
-	I
telangiectasia	I
patients	O
:	O
potential	O
preponderance	O
of	O
the	O
ii	O
flop	O
sport	O
4612del165	O
and	O
7883del5	O
.	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
ataxia	B
-	I
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
4612del165	O
and	O
7883del5	O
.	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B
-	I
telangiectasia	I
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
sport	O
sport	O
motor	O
ataxia	O
motor	O
ataxia	O
motor	O
ataxia	O
motor	O
ataxia	O
motor	O
ataxia	O
founder	O

variation	O
of	O
the	O
atmosphere	O
factor	O
find	O
in	O
japanese	O
ataxia	B
-	I
telangiectasia	I
patients	O
:	O
potential	O
preponderance	O
of	O
the	O
two	O
founder	O
variation	O
4612del165	O
and	O
7883del5	O
.	O

Mutations	O
of	O
the	O
ATM	O
cistron	O
observe	O
in	O
nipponese	O
dyssynergia	B
-	I
telangiectasia	I
patients	O
:	O
potential	O
prevalence	O
of	O
the	O
deuce	O
founder	O
mutations	O
4612del165	O
and	O
7883del5	O
.	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B
telangiectasia	I
possible	O
preponderance	O
of	O
the	O
two	O
founder	O
mutations	O
4612del165	O
and	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B
-	I
telangiectasia	I
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
sport	O
sport	O
motor	O
ataxia	O
motor	O
ataxia	O
motor	O
ataxia	O
motor	O
ataxia	O
motor	O
ataxia	O
founder	O

two	O
of	O
the	O
telangiectasia	O
gene	O
detected	O
in	O
founder	O
.	B
-	I
ATM	I
patients	O
:	O
possible	O
7883del5	O
of	O
the	O
4612del165	O
Japanese	O
Mutations	O
mutations	O
and	O
preponderance	O
ataxia	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B
-	I
telangiectasia	I
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
founder	O
mutations	O
4612del165	O
and	O
7883del5	O
.	O

The	O
-	O
(	O
A	O
ATM	O
T	O
mutated	O
on	O
)	O
gene	O
chromosome	O
human	O
,	O
11q22	O
.	O

The	O
ATM	O
international	O
ampere	O
mutate	O
ampere	O
(	O
A	O
-	O
T	O
,	O
mutated	O
)	O
homo	O
gene	O
on	O
human	O
chromosome	O
11q22	O

The	O
ATM	O
(	O
A	O
-	O
liothyronine	O
,	O
mutated	O
)	O
factor	O
on	O
human	O
chromosome	O
11q22	O
.	O

chromosome	O
ATM	O
(	O
The	O
mutated	O
T	O
,	O
human	O
)	O
gene	O
on	O
-	O
A	O
11q22	O
.	O

The	O
ATM	O
(	O
axerophthol	O
-	O
t	O
,	O
mutated	O
)	O
factor	O
on	O
homo	O
chromosome	O
11q22	O
.	O

The	O
ATM	O
international	O
ampere	O
mutate	O
ampere	O
(	O
A	O
-	O
T	O
,	O
mutated	O
)	O
cash	O
machine	O
gene	O
on	O
human	O
chromosome	O

The	O
(	O
-	O
,	O
mutated	O
)	O
gene	O
on	O
human	O
chromosome	O
11q22	O
.	O

mutated	O
A	O
(	O
ATM	O
-	O
T	O
gene	O
The	O
)	O
,	O
on	O
human	O
chromosome	O
.	O
11q22	O

The	O
ATM	O
(	O
axerophthol	O
-	O
T	O
,	O
mutated	O
)	O
cistron	O
on	O
human	O
chromosome	O
11q22	O
.	O

The	O
ATM	O
international	O
ampere	O
mutate	O
ampere	O
(	O
A	O
-	O
T	O
,	O
mutated	O
)	O
cash	O
machine	O
gene	O
on	O
human	O
chromosome	O

The	O
ATM	O
(	O
A	O
-	O
T	O
,	O
mutated	O
)	O
gene	O
on	O
human	O
chromosome	O
11q22	O
.	O

3	O
has	O
recently	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B
disease	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B
ataxia	B
(	O
A	B
-	I
T	I
)	O
.	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B
disease	I
ataxia	B
-	I
telangiectasia	I
(	O
mt	O
mt	O
of	O
late	O
of	O
late	O
of	B
late	I
of	I
late	O
A	O

3	O
has	O
latterly	O
been	O
identify	O
as	O
the	O
cistron	O
creditworthy	O
for	O
the	O
human	O
recessive	B
disease	I
dyssynergia	B
-	I
telangiectasia	I
(	O
angstrom	B
-	I
T	I
)	O
.	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B
disease	I
ataxia	B
-	I
telangiectasia	I
(	O
mt	O
mt	O
of	O
late	O
of	O
late	O
of	B
late	I
of	I
late	O
A	O

3	O
has	O
recently	O
been	O
distinguish	O
as	O
the	O
factor	O
creditworthy	O
for	O
the	O
homo	O
recessive	B
disease	I
dyssynergia	B
-	I
telangiectasia	I
(	O
A	B
-	I
tonne	I
)	O
.	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
human	O
recessive	B
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I

the	O
has	O
recently	O
A	O
identified	O
as	O
the	O
responsible	O
gene	O
for	O
-	O
human	O
disease	B
recessive	I
.	B
-	I
telangiectasia	I
(	O
been	B
3	I
T	I
)	O
ataxia	O

triad	O
has	O
recently	O
been	O
identify	O
as	O
the	O
factor	O
creditworthy	O
for	O
the	O
human	O
recessive	B
disease	I
ataxy	B
-	I
telangiectasia	I
(	O
A	B
-	I
tetraiodothyronine	I
)	O
.	O

ataxia	O
has	O
responsible	O
the	O
identified	O
as	O
-	O
gene	O
recently	O
for	O
the	O
human	O
T	B
disease	I
been	B
3	I
telangiectasia	I
(	O
A	B
-	I
recessive	I
)	O
.	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B
disease	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
.	O

by	O
possible	O
to	O
define	O
the	O
types	O
to	O
T	O
-	O
causing	O
ATM	O
mutations	O
in	O
the	O
restriction	B
-	I
disease	I
analyzed	O
as	O
well	O
fingerprinting	O
to	O
look	O
for	O
,	O
mutational	O
hotspots	O
A	O
families	O
-	O
reverse	O
of	O
derived	O
from	O
ten	O
patients	O
belonging	O
mutations	O
RNA	O
unrelated	O
Japanese	O
as	B
-	I
T	I
transcribed	O
was	O
patients	O
for	O
eight	O
In	O
Japanese	O
A	O
endonuclease	O
order	O
method	O
.	O

In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	O
sport	O
hot	O
spot	O
cash	O
machine	O
change	O
by	O
reversal	O
indium	O
canned	O
rna	O
deduct	O
-	O
causing	O
ATM	B
mutations	I
in	I
Japanese	O
A	O
-	O
T	O
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
from	O
ten	O
patients	O
family	O
line	O
sport	O
past	O
family	O
line	O
limitation	O
past	O
fingerprint	O
mt	B
belonging	I
to	I
eight	O
unrelated	O
Japanese	O
A	O
-	O
T	O
families	O
was	O
analyzed	O
for	O
mutations	O
by	O

In	O
order	O
to	O
the	O
of	O
disease	O
-	O
mutations	O
T	I
patients	O
as	O
as	O
to	O
for	O
possible	O
mutational	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
ten	O
belonging	O
to	O
eight	O
unrelated	O
Japanese	O
A	B
-	I
T	I
families	O
was	O
for	O
mutations	O
by	O
the	O
restriction	O

In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	O
sport	O
hot	O
spot	O
cash	O
machine	O
change	O
by	O
reversal	O
indium	O
canned	O
rna	O
deduct	O
-	O
causing	O
ATM	B
mutations	I
in	I
Japanese	O
A	O
-	O
T	O
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
from	O
ten	O
patients	O
family	O
line	O
sport	O
past	O
family	O
line	O
limitation	O
past	O
fingerprint	O
mt	B
belonging	I
to	I
eight	O
unrelated	O
Japanese	O
A	O
-	O
T	O
families	O
was	O
analyzed	O
for	O
mutations	O
by	O

order	O
the	O
of	O
disease	O
-	O
ATM	O
mutations	O
in	O
Japanese	O
A	B
-	I
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
,	O
reverse	O
RNA	O
derived	O
from	O
patients	O
eight	O
unrelated	O
Japanese	O
A	B
-	I
T	I
families	O
by	O
restriction	O
endonuclease	O
method	O

In	O
grade	O
to	O
delimit	O
the	O
typewrite	O
of	O
disease	O
-	O
cause	O
atm	O
mutations	O
in	O
nipponese	O
axerophthol	B
-	I
t	I
patients	O
as	O
easily	O
as	O
to	O
reckon	O
for	O
possible	O
mutational	O
hotspots	O
,	O
verso	O
-	O
transcribed	O
rna	O
infer	O
from	O
ten	O
patients	O
belonging	O
to	O
eight	O
unrelated	O
nipponese	O
axerophthol	B
-	I
t	I
mob	O
was	O
analyse	O
for	O
mutations	O
by	O
the	O
confinement	O
endonuclease	O
fingerprinting	O
method	O
.	O

In	O
order	O
fingerprinting	O
define	O
the	O
types	O
of	O
as	O
-	O
causing	O
ATM	O
in	O
-	O
Japanese	O
A	B
transcribed	I
T	I
patients	O
well	O
disease	O
as	O
for	O
look	O
patients	O
possible	O
hotspots	O
RNA	O
derived	O
reverse	O
-	O
-	O
to	O
method	O
from	O
ten	O
for	O
belonging	O
mutational	O
eight	O
unrelated	O
Japanese	O
A	B
mutations	I
T	I
families	O
analyzed	O
was	O
restriction	O
mutations	O
by	O
the	O
to	O
endonuclease	O
,	O
to	O
.	O

inwards	O
rescript	O
to	O
limit	O
the	O
typecast	O
of	O
disease	O
-	O
have	O
ATM	O
mutant	O
inwards	O
Japanese	O
amp	B
-	I
T	I
patients	O
as	O
intimately	O
as	O
to	O
see	O
for	O
potential	O
mutational	O
hotspots	O
,	O
lift	O
-	O
canned	O
RNA	O
descend	O
from	O
ten	O
patients	O
go	O
to	O
octet	O
unrelated	O
Japanese	O
amp	B
-	I
T	I
families	O
was	O
canvass	O
for	O
mutant	O
by	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
method	O
.	O

indiana	O
order	O
to	O
determine	O
the	O
eccentric	O
of	O
disease	O
-	O
stimulate	O
ATM	O
mutant	O
indiana	O
japanese	O
angstrom	B
-	I
t	I
patients	O
as	O
advantageously	O
as	O
to	O
feel	O
for	O
possible	O
mutational	O
hotspots	O
,	O
turn	O
-	O
transcribed	O
rna	O
come	O
from	O
ten	O
patients	O
belonging	O
to	O
octet	O
unrelated	O
japanese	O
angstrom	B
-	I
t	I
kinsfolk	O
was	O
analyse	O
for	O
mutant	O
by	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
method	O
.	O

ten	O
hotspots	O
to	O
define	O
the	O
types	O
A	O
disease	O
-	O
causing	O
ATM	O
Japanese	O
in	O
,	O
reverse	B
-	I
T	I
patients	O
-	O
well	O
as	O
to	O
from	O
for	O
T	O
mutational	O
analyzed	O
Japanese	O
mutations	O
as	O
transcribed	O
patients	O
derived	O
A	O
In	O
fingerprinting	O
belonging	O
to	O
eight	O
unrelated	O
mutations	O
of	B
-	I
look	I
families	O
was	O
.	O
for	O
possible	O
by	O
the	O
restriction	O
endonuclease	O
RNA	O
method	O
order	O

In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	O
-	O
causing	O
ATM	O
mutations	O
in	O
Japanese	O
A	B
-	I
T	I
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
from	O
ten	O
patients	O
belonging	O
to	O
eight	O
unrelated	O
Japanese	O
A	B
-	I
T	I
families	O
was	O
analyzed	O
for	O
mutations	O
by	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
method	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
paramount	O
sport	O
indium	O
sport	O
sport	O
cost	O
sport	O
also	O
predominant	O
in	O
our	O
mutants	O
.	O

been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
also	O
in	O
our	O
mutants	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
chair	O
to	O
exon	O
jump	O
or	O
untimely	O
protein	O
shortness	O
were	O
likewise	O
rife	O
in	O
our	O
mutants	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
that	O
lead	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
in	O
our	O
mutants	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
paramount	O
sport	O
indium	O
sport	O
sport	O
cost	O
cost	O
also	O
predominant	O
in	O
our	O
mutants	O
.	O

amp	O
has	O
been	O
cover	O
by	O
others	O
,	O
mutations	O
that	O
contribute	O
to	O
exon	O
vamoose	O
or	O
untimely	O
protein	O
truncation	O
were	O
too	O
rife	O
in	O
our	O
mutants	O
.	O

as	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
run	O
to	O
exon	O
skitter	O
or	O
premature	O
protein	O
shortness	O
were	O
too	O
predominate	O
in	O
our	O
mutation	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
to	O
or	O
premature	O
protein	O
truncation	O
were	O
also	O
predominant	O
in	O
our	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
paramount	O
sport	O
indium	O
sport	O
sport	O
cost	O
cost	O
also	O
predominant	O
in	O
our	O
mutants	O
.	O

were	O
has	O
been	O
to	O
by	O
others	O
,	O
also	O
.	O
lead	O
reported	O
exon	O
skipping	O
or	O
mutants	O
protein	O
truncation	O
in	O
mutations	O
As	O
predominant	O
our	O
premature	O
that	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
also	O
predominant	O
in	O
our	O
mutants	O
.	O

Six	O
mutations	O
were	O
on	O
of	O
16	O
alleles	O
examined	O
.	O

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
16	O
alleles	O
examined	O

Six	O
unlike	O
sport	O
were	O
distinguish	O
on	O
12	O
of	O
the	O
16	O
alleles	O
examined	O
.	O

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
prove	O
prove	O
dissimilar	O
16	O
alleles	O
examined	O
.	O

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
prove	O
prove	O
place	O
16	O
alleles	O
examined	O
.	O

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
prove	O
prove	O
dissimilar	O
16	O
alleles	O
examined	O
.	O

Six	O
unlike	O
mutant	O
were	O
identified	O
on	O
12	O
of	O
the	O
sixteen	O
alleles	O
examined	O
.	O

Six	O
different	O
were	O
identified	O
on	O
12	O
of	O
the	O
16	O
.	O

Six	O
dissimilar	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
sixteen	O
alleles	O
prove	O
.	O

Six	O
identified	O
mutations	O
were	O
.	O
on	O
12	O
different	O
the	O
16	O
alleles	O
examined	O
of	O

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
16	O
alleles	O
examined	O
.	O

35	O
were	O
deletions	O
exon	O
a	O
loss	O
of	O
or	O
16	O
exon	O
involving	O
7	O
exon	O
,	O
single	O
,	O
exon	O
33	O
a	O
Four	O
exon	O
.	O

Four	O
were	O
deletions	O
involving	O
a	O
loss	O
of	O
a	O
single	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	O
	O
	O
omission	O
omission	O
omission	O
omission	O
or	O
exon	O
35	O
.	O

Four	O
were	O
deletions	O
involving	O
a	O
loss	O
of	O
a	O
single	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	O
	O
	O
omission	O
omission	O
omission	O
omission	O
or	O
exon	O
35	O
.	O

Four	O
were	O
omission	O
involving	O
a	O
departure	O
of	O
a	O
bingle	O
exon	O
exon	O
heptad	O
,	O
exon	O
xvi	O
,	O
exon	O
xxxiii	O
or	O
exon	O
35	O
.	O

Four	O
were	O
deletions	O
a	O
loss	O
of	O
a	O
single	O
exon	O
7	O
,	O
exon	O
,	O
exon	O
or	O
exon	O
35	O
.	O

involving	O
of	O
a	O
single	O
exon	O
7	O
exon	O
16	O
,	O
exon	O
33	O
or	O
exon	O
35	O
.	O

tetrad	O
were	O
excision	O
ask	O
a	O
deprivation	O
of	O
a	O
single	O
exon	O
exon	O
seven	O
,	O
exon	O
16	O
,	O
exon	O
33	O
or	O
exon	O
35	O
.	O

16	O
were	O
single	O
of	O
a	O
loss	O
,	O
a	O
deletions	O
exon	O
exon	O
7	O
35	O
exon	O
involving	O
Four	O
exon	O
33	O
or	O
exon	O
,	O
.	O

Four	O
were	O
deletions	O
involving	O
a	O
loss	O
of	O
a	O
single	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	O
	O
	O
omission	O
omission	O
omission	O
coding	O
dna	O
or	O
exon	O
35	O

Four	O
were	O
deletions	O
involving	O
of	O
a	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	O
or	O
.	O

Four	O
were	O
deletions	O
involving	O
a	O
loss	O
of	O
a	O
single	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	O
or	O
exon	O
35	O
.	O

The	O
others	O
toll	O
indium	O
cost	O
were	O
minute	O
deletions	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
55	O
in	O
.	O

exon	O
others	O
were	O
.	O
deletions	O
,	O
4649delA	O
in	O
55	O
33	O
and	O
7883del5	O
The	O
in	O
exon	O
minute	O

The	O
others	O
coding	O
dna	O
indium	O
minute	O
of	O
arc	O
were	O
minute	O
deletions	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O

The	O
others	O
were	O
hour	O
excision	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
lv	O
.	O

in	O
others	O
were	O
in	O
deletions	O
,	O
exon	O
minute	O
exon	O
33	O
The	O
7883del5	O
and	O
4649delA	O
55	O
.	O

The	O
others	O
toll	O
indium	O
cost	O
were	O
minute	O
deletions	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
55	O
in	O
.	O

The	O
others	O
were	O
infinitesimal	O
omission	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
55	O
.	O

The	O
others	O
were	O
bit	O
deletions	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
lv	O
.	O

The	O
others	O
exon	O
.	O
deletions	O
,	O
in	O
in	O
were	O
33	O
and	O
7883del5	O
4649delA	O
exon	O
minute	O
55	O

others	O
were	O
minute	O
deletions	O
,	O
4649delA	O
in	O
and	O
7883del5	O
in	O
exon	O
55	O
.	O

The	O
others	O
were	O
minute	O
deletions	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
55	O
.	O

The	O
mutations	O
4612del165	O
and	O
family	O
line	O
receive	O
	O
receive	O
indium	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
7	O
of	O
16	O
)	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
invite	O
invite	O
invite	O
invite	O

The	O
mutations	O
7883del5	O
than	O
two	O
unrelated	O
;	O
44	O
(	O
7	O
of	O
of	O
the	O
mutant	O
alleles	O
had	O
of	O
two	O
mutations	O
.	O

The	O
sport	O
4612del165	O
and	O
7883del5	O
were	O
get	O
in	O
more	O
than	O
deuce	O
unrelated	O
kin	O
;	O
44	O
%	O
(	O
sevener	O
of	O
16	O
)	O
of	O
the	O
mutation	O
allelomorph	O
had	O
unity	O
of	O
the	O
deuce	O
sport	O
.	O

The	O
mutations	O
4612del165	O
and	O
were	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
.	O

The	O
variation	O
4612del165	O
and	O
7883del5	O
were	O
obtain	O
in	O
more	O
than	O
deuce	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
seven	O
of	O
16	O
)	O
of	O
the	O
variation	O
allelomorph	O
had	O
unrivalled	O
of	O
the	O
deuce	O
variation	O
.	O

The	O
mutations	O
4612del165	O
and	O
family	O
line	O
receive	O
	O
receive	O
indium	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
7	O
of	O
16	O
)	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
invite	O
invite	O
invite	O
invite	O

The	O
mutations	O
4612del165	O
and	O
7883del5	O
were	O
launch	O
in	O
more	O
than	O
ii	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
septet	O
of	O
sixteen	O
)	O
of	O
the	O
mutation	O
alleles	O
had	O
i	O
of	O
the	O
ii	O
mutations	O
.	O

)	O
of	O
4612del165	O
and	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
alleles	O
two	O
%	O
(	O
7	O
of	O
16	O
mutations	O
of	O
.	O
mutant	O
;	O
had	O
one	O
The	O
44	O
the	O
mutations	O
the	O

The	O
mutations	O
4612del165	O
and	O
were	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
(	O
7	O
of	O
16	O
)	O
of	O
the	O
had	O
one	O
of	O
two	O
.	O

The	O
mutations	O
4612del165	O
and	O
family	O
line	O
receive	O
	O
receive	O
sport	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
7	O
of	O
16	O
)	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
invite	O
invite	O
invite	O
invite	O

The	O
mutations	O
4612del165	O
and	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
7	O
of	O
16	O
)	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
.	O

The	O
mutations	O
in	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
-	O
-	O
>	O
A	O
at	O
the	O
splice	O
donor	O
site	O
intron	O
33	O
.	O

The	O
mutations	O
in	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
-	O
-	O
A	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O

The	O
4612del165	O
mutations	O
in	O
mt	O
dissimilar	O
family	O
line	O
	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T	O
-	O
-	O
>	O
A	O
indium	O
noncoding	O
dna	O
	O
	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O
intron	O

the	O
4612del165	O
mutations	O
substitution	O
three	O
different	O
families	O
intron	O
site	O
ascribed	O
at	O
the	O
same	O
T	O
donor	O
-	O
>	O
A	O
in	O
in	O
to	O
splice	O
-	O
all	O
The	O
were	O
33	O
.	O

33	O
4612del165	O
mutations	O
-	O
three	O
different	O
intron	O
were	O
in	O
ascribed	O
to	O
the	O
T	O
the	O
in	O
all	O
>	O
A	O
substitution	O
at	O
same	O
splice	O
donor	O
site	O
-	O
families	O
The	O
.	O

The	O
4612del165	O
mutations	O
in	O
mt	O
dissimilar	O
family	O
line	O
	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T	O
-	O
-	O
>	O
A	O
indium	O
noncoding	O
dna	O
	O
whole	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O
intron	O

The	O
4612del165	O
mutations	O
in	O
three	O
unlike	O
house	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
liothyronine	O
-	O
-	O
>	O
A	O
transposition	O
at	O
the	O
marry	O
conferrer	O
site	O
in	O
intron	O
33	O
.	O

The	O
4612del165	O
mutations	O
in	O
mt	O
dissimilar	O
family	O
line	O
	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T	O
-	O
-	O
>	O
A	O
indium	O
noncoding	O
dna	O
	O
whole	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O
intron	O

site	O
4612del165	O
mutations	O
in	O
three	O
different	O
T	O
the	O
all	O
ascribed	O
to	O
>	O
splice	O
families	O
in	O
The	O
were	O
-	O
substitution	O
at	O
the	O
same	O
donor	O
A	O
-	O
intron	O
33	O
.	O

The	O
4612del165	O
mutations	O
in	O
tercet	O
unlike	O
phratry	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
thymine	O
-	O
-	O
>	O
A	O
commutation	O
at	O
the	O
wed	O
conferrer	O
place	O
in	O
intron	O
33	O
.	O

The	O
4612del165	O
mutations	O
in	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T	O
-	O
-	O
>	O
A	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O
intron	O
33	O
.	O

mutations	O
genotyping	O
around	O
common	O
ATM	O
locus	O
also	O
in	O
by	O
a	O
the	O
haplotype	O
shared	O
was	O
that	O
the	O
mutant	O
alleles	O
indicated	O
Microsatellite	O
both	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
ATM	O
locus	O
also	O
indicated	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
sport	O
sport	O
approximately	O
approximately	O
approximately	O
approximately	O
in	O
both	O
mutations	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
ATM	O
locus	O
also	O
indicated	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
sport	O
sport	O
approximately	O
approximately	O
approximately	O
approximately	O
in	O
both	O
mutations	O
.	O

Microsatellite	O
genotyping	O
approximately	O
the	O
ATM	O
locale	O
also	O
argue	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
sport	O
allelomorph	O
in	O
both	O
sport	O
.	O

Microsatellite	O
genotyping	O
around	O
ATM	O
locus	O
also	O
indicated	O
that	O
common	O
haplotype	O
was	O
shared	O
the	O
mutant	O
in	O
both	O
mutations	O
.	O

the	O
also	O
indicated	O
that	O
common	O
haplotype	O
shared	O
by	O
the	O
mutant	O
alleles	O
in	O
both	O
mutations	O
.	O

Microsatellite	O
genotyping	O
roughly	O
the	O
ATM	O
venue	O
likewise	O
point	O
that	O
a	O
coarse	O
haplotype	O
was	O
shared	O
by	O
the	O
variation	O
alleles	O
in	O
both	O
mutations	O
.	O

by	O
genotyping	O
that	O
also	O
ATM	O
locus	O
the	O
indicated	O
around	O
a	O
common	O
haplotype	O
mutations	O
shared	O
the	O
Microsatellite	O
mutant	O
alleles	O
in	O
both	O
was	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
ATM	O
locus	O
also	O
indicated	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
sport	O
sport	O
approximately	O
approximately	O
approximately	O
ampere	O
in	O
both	O
mutations	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
also	O
indicated	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
in	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
ATM	O
locus	O
also	O
indicated	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
in	O
both	O
mutations	O
.	O

This	O
suggests	O
sport	O
crataegus	O
oxycantha	O
beryllium	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
beginner	O

mutant	O
suggests	O
that	O
.	O
two	O
founder	O
mutations	O
may	O
alleles	O
predominant	O
among	O
Japanese	O
This	O
ATM	O
be	O
these	O

This	O
suggests	O
sport	O
crataegus	O
oxycantha	O
sport	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
beginner	O

This	O
hint	O
that	O
these	O
two	O
flop	O
mutations	O
may	O
be	O
rife	O
among	O
Japanese	O
ATM	O
sport	O
alleles	O
.	O

ATM	O
suggests	O
that	O
may	O
two	O
founder	O
mutant	O
these	O
be	O
predominant	O
This	O
Japanese	O
among	O
mutations	O
alleles	O
.	O

This	O
suggests	O
sport	O
crataegus	O
oxycantha	O
beryllium	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
beginner	O

This	O
hint	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
japanese	O
ATM	O
sport	O
allelomorph	O
.	O

This	O
intimate	O
that	O
these	O
two	O
founder	O
sport	O
may	O
be	O
prevalent	O
among	O
Japanese	O
ATM	O
mutation	O
alleles	O
.	O

This	O
suggests	O
be	O
.	O
two	O
founder	O
ATM	O
may	O
that	O
predominant	O
among	O
Japanese	O
mutations	O
mutant	O
these	O
alleles	O

suggests	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
.	O

This	O
suggests	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
.	O

W474C	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
-	O
hexosaminidase	O
A	O
and	O
associated	O
with	O
subacute	O
G	B
(	I
)	I
gangliosidosis	I
.	O

W474C	O
acid	O
substitution	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
-	O
hexosaminidase	O
and	O
is	O
associated	O
with	O
subacute	O
G	B
(	I
M2	I

W474C	O
amino	O
acid	O
substitution	O
genus	O
beta	O
ahead	O
of	O
time	O
work	O
on	O
affect	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
m	O
g	O
m	O
genus	O
beta	B
is	I
associated	I
with	I
subacute	I
G	O

with	O
amino	O
acid	O
is	O
affects	O
early	O
processing	O
)	O
(	O
alpha	O
associated	O
subunit	O
of	O
beta	O
G	O
hexosaminidase	O
A	O
and	O
substitution	O
M2	O
-	O
subacute	O
-	B
the	I
W474C	I
of	I
gangliosidosis	I
.	O

gangliosidosis	O
amino	O
acid	O
-	O
affects	O
early	O
)	O
of	O
substitution	O
alpha	O
-	O
subunit	O
beta	O
with	O
M2	O
the	O
A	O
and	O
is	O
associated	O
of	O
subacute	O
G	B
(	I
hexosaminidase	I
processing	I
W474C	I
.	O

W474C	O
amino	O
acid	O
substitution	O
genus	O
beta	O
ahead	O
of	O
time	O
work	O
on	O
affect	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
m	O
g	O
m	O
exchange	O
is	B
associated	I
with	I
subacute	I
G	I
(	O

W474C	O
amino	O
caustic	O
exchange	O
involve	O
early	O
march	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
angstrom	O
and	O
is	O
consort	O
with	O
subacute	O
G	B
(	I
m	I
)	I
gangliosidosis	I
.	O

W474C	O
amino	O
acid	O
substitution	O
genus	O
beta	O
ahead	O
of	O
time	O
work	O
on	O
affect	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
m	O
g	O
m	O
exchange	O
is	B
associated	I
with	I
subacute	I
G	I
(	O

(	O
amino	O
acid	O
substitution	O
affects	O
early	O
beta	O
subunit	O
the	O
alpha	O
-	O
A	O
subacute	O
processing	O
M2	O
W474C	O
of	O
hexosaminidase	O
is	O
associated	O
with	O
of	O
G	B
and	I
-	I
)	I
gangliosidosis	I
.	O

W474C	O
aminic	O
acid	O
switch	O
strike	O
other	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
is	O
consociate	O
with	O
subacute	O
m	B
(	I
m	I
)	I
gangliosidosis	I
.	O

W474C	O
amino	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
is	O
associated	O
with	O
subacute	O
G	B
(	I
M2	I
)	I
gangliosidosis	I
.	O

mutant	O
in	O
the	O
HEXA	O
cistron	O
,	O
encryption	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
a	O
(	O
enchant	O
a	O
)	O
,	O
that	O
abolish	O
enchant	O
a	O
enzyme	O
activity	O
lawsuit	O
tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
the	O
calamitous	O
childish	B
work	I
of	I
g	I
(	I
m	I
)	I
gangliosidosis	I
,	I
eccentric	I
unity	I
.	O

Mutations	O
in	O
the	O
HEXA	O
factor	O
,	O
encode	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
,	O
that	O
abolish	O
hex	O
A	O
enzyme	O
action	O
have	O
tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
the	O
black	O
childish	B
manikin	I
of	I
gib	I
(	I
m	I
)	I
gangliosidosis	I
,	I
case	I
one	I
.	O

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
-	O
subunit	O
of	O
beta	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
,	O
that	O
abolish	O
Hex	O
enzyme	O
activity	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
fatal	O
infantile	B
of	I
G	I
(	I
M2	I
)	I
gangliosidosis	I
,	I
Type	I

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
ampere	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
g	O
build	O
m	O
g	O
build	O
m	O
typecast	O
	O
m	O
typecast	O
	O
factor	O
typecast	O
	O
the	O
fatal	O
infantile	B
form	I
of	I
G	I
(	I
M2	I
)	I
gangliosidosis	I
,	I
Type	I
1	I
.	O

)	O
A	O
the	O
HEXA	O
gene	O
,	O
,	O
(	O
alpha	O
-	O
subunit	O
of	O
beta	O
encoding	O
fatal	O
A	O
the	O
,	O
A	O
)	O
-	O
that	O
abolish	O
Hex	O
cause	O
enzyme	O
activity	O
G	O
)	B
-	I
Tay	I
in	I
(	O
TSD	B
.	O
,	O
the	O
hexosaminidase	O
disease	B
form	I
of	I
1	I
(	I
M2	I
Sachs	I
gangliosidosis	I
Hex	I
Type	I
infantile	I
Mutations	O

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
ampere	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
g	O
build	O
m	O
g	O
build	O
m	O
typecast	O
	O
m	O
typecast	O
	O
factor	O
typecast	O
	O
the	O
fatal	O
infantile	B
form	I
of	I
G	I
(	I
M2	I
)	I
gangliosidosis	I
,	I
Type	I
1	I
.	O

mutant	O
in	O
the	O
HEXA	O
factor	O
,	O
encryption	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
,	O
that	O
abolish	O
hex	O
A	O
enzyme	O
activity	O
causa	O
tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
the	O
calamitous	O
childish	B
shape	I
of	I
yard	I
(	I
m	I
)	I
gangliosidosis	I
,	I
case	I
i	I
.	O

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
ampere	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
g	O
build	O
m	O
g	O
build	O
m	O
typecast	O
	O
m	O
typecast	O
	O
factor	O
typecast	O
ampere	O
the	O
fatal	O
infantile	B
form	I
of	I
G	I
(	I
M2	I
)	I
gangliosidosis	I
,	I
Type	I
1	I
.	O

Mutations	O
in	O
the	O
HEXA	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
(	O
A	O
)	O
,	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
-	I
Sachs	I
TSD	B
,	O
the	O
fatal	O
infantile	B
G	I
(	I
M2	I
)	I
,	I
Type	I
1	I
.	O

Mutations	O
activity	O
the	O
HEXA	O
gene	O
,	O
of	O
-	O
alpha	O
-	O
subunit	O
encoding	O
beta	O
cause	O
Tay	O
A	O
(	O
Hex	O
the	O
)	O
,	O
that	O
TSD	O
Hex	O
M2	O
enzyme	O
,	O
-	O
1	B
A	I
Sachs	I
,	I
(	O
hexosaminidase	B
)	O
G	O
the	O
fatal	O
infantile	B
form	I
in	I
disease	I
(	I
abolish	I
)	I
gangliosidosis	I
of	I
Type	I
A	I
.	O

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
the	O
fatal	O
infantile	B
form	I
of	I
G	I
(	I
M2	I
)	I
gangliosidosis	I
,	I
Type	I
1	I
.	O

Less	O
spartan	O
,	O
subacute	O
(	O
adolescent	O
-	O
oncoming	O
)	O
and	O
inveterate	O
(	O
grownup	O
-	O
oncoming	O
)	O
variants	O
are	O
qualify	O
by	O
a	O
unsubtle	O
spectrum	O
of	O
clinical	O
demonstration	O
and	O
are	O
connect	O
with	O
remainder	O
levels	O
of	O
bewitch	O
A	O
enzyme	O
activity	O
.	O

severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
adult	O
-	O
onset	O
)	O
variants	O
characterized	O
by	O
of	O
and	O
are	O
residual	O
Hex	O
A	O
enzyme	O
activity	O

are	O
A	O
,	O
subacute	O
variants	O
juvenile	O
a	O
levels	O
)	O
and	O
chronic	O
(	O
adult	O
clinical	O
.	O
)	O
(	O
residual	O
characterized	O
by	O
onset	O
broad	O
spectrum	O
of	O
severe	O
manifestations	O
and	O
Less	O
are	O
with	O
associated	O
-	O
of	O
Hex	O
-	O
enzyme	O
activity	O
onset	O

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
)	O
and	O
chronic	O
(	O
-	O
onset	O
)	O
variants	O
are	O
by	O
a	O
broad	O
spectrum	O
clinical	O
manifestations	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
activity	O
.	O

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
and	O
chronic	O
(	O
adult	O
-	O
onset	O
)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
activity	O
.	O

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
and	O
chronic	O
(	O
adult	O
-	O
onset	O
)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
activity	O
.	O

Less	O
spartan	O
,	O
subacute	O
(	O
adolescent	O
-	O
oncoming	O
)	O
and	O
continuing	O
(	O
big	O
-	O
oncoming	O
)	O
strain	O
are	O
qualify	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
reflexion	O
and	O
are	O
colligate	O
with	O
balance	O
point	O
of	O
Hex	O
A	O
enzyme	O
activity	O
.	O

clinical	O
characterized	O
,	O
subacute	O
(	O
juvenile	O
(	O
Hex	O
)	O
and	O
chronic	O
-	O
adult	O
are	O
with	O
)	O
variants	O
are	O
onset	O
by	O
a	O
broad	O
associated	O
of	O
Less	O
manifestations	O
levels	O
-	O
onset	O
spectrum	O
residual	O
enzyme	O
of	O
severe	O
A	O
and	O
activity	O
.	O

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
and	O
chronic	O
(	O
adult	O
-	O
onset	O
)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
form	O
ampere	O
activity	O
.	O

Less	O
severe	O
(	O
juvenile	O
onset	O
)	O
adult	O
onset	O
)	O
variants	O
characterized	O
by	O
a	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
activity	O

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
and	O
chronic	O
(	O
adult	O
-	O
onset	O
)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
activity	O
.	O

We	O
G	O
-	O
>	O
C	O
amino	O
acid	O
W474C	O
substitution	O
in	O
the	O
first	O
position	O
13	O
of	O
HEXA	O
of	O
a	O
non	O
-	O
Jewish	O
manifested	O
subacute	O
variant	O
of	O
(	I
M2	I
)	I
gangliosidosis	I
.	O

We	O
identified	O
a	O
1422	O
G	O
C	O
(	O
amino	O
acid	O
W474C	O
substitution	O
in	O
of	O
of	O
HEXA	O
non	O
proband	O
who	O
manifested	O
a	O
variant	O
of	O
M2	I
)	I
.	O

We	O
identified	O
a	O
1422	O
G	O
-	O
-	O
>	O
C	O
(	O
amino	O
acid	O
W474C	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non	O
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
g	O
m	O
g	O
g	O
g	O
g	O
g	O
g	O
g	O
g	O
g	O
g	O
G	B
(	I
M2	I
)	I
gangliosidosis	I
.	O

We	O
identified	O
a	O
1422	O
gee	O
-	O
-	O
>	O
cytosine	O
(	O
amino	O
acid	O
W474C	O
)	O
transposition	O
in	O
the	O
initiative	O
stead	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
not	O
-	O
jewish	O
proband	O
who	O
evidence	O
a	O
subacute	O
form	O
of	O
gee	B
(	I
m	I
)	I
gangliosidosis	I
.	O

We	O
identified	O
who	O
1422	O
G	O
of	O
-	O
position	O
C	O
(	O
amino	O
non	O
of	O
)	O
substitution	O
>	O
the	O
first	O
(	O
W474C	O
exon	O
a	O
of	O
-	O
of	O
in	O
acid	O
13	O
Jewish	O
proband	O
a	O
-	O
manifested	O
subacute	O
variant	O
HEXA	O
G	B
a	I
M2	I
)	I
gangliosidosis	I
.	O

We	O
place	O
a	O
1422	O
guanine	O
-	O
-	O
>	O
cytosine	O
(	O
aminic	O
acid	O
W474C	O
)	O
commutation	O
in	O
the	O
first	O
position	O
of	O
exon	O
thirteen	O
of	O
HEXA	O
of	O
a	O
not	O
-	O
jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
guanine	B
(	I
m	I
)	I
gangliosidosis	I
.	O

variant	O
position	O
a	O
1422	O
G	O
-	O
.	O
>	O
C	O
(	O
amino	O
gangliosidosis	O
W474C	O
of	O
proband	O
in	O
the	O
first	O
-	O
of	O
exon	O
13	O
of	O
HEXA	O
)	O
a	O
subacute	O
identified	O
manifested	O
of	O
who	O
Jewish	O
a	O
substitution	O
We	O
non	O
G	B
(	I
M2	I
)	I
acid	I
-	O

We	O
identified	O
a	O
1422	O
G	O
-	O
C	O
(	O
amino	O
acid	O
)	O
substitution	O
in	O
the	O
first	O
of	O
exon	O
13	O
of	O
of	O
a	O
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
G	B
(	I
)	I
gangliosidosis	I
.	O

M2	O
of	O
a	O
1422	O
the	O
-	O
exon	O
manifested	O
C	O
(	O
amino	O
acid	O
W474C	O
-	O
(	O
in	O
G	O
who	O
position	O
of	O
)	O
13	O
of	O
HEXA	O
-	O
a	O
non	O
.	O
first	O
proband	O
Jewish	O
identified	O
a	O
subacute	O
variant	O
of	O
G	B
substitution	I
We	I
)	I
gangliosidosis	I
>	O

We	O
identified	O
a	O
1422	O
G	O
-	O
-	O
>	O
C	O
(	O
amino	O
acid	O
W474C	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non	O
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
g	O
m	O
g	O
g	O
g	O
g	O
g	O
g	O
g	O
g	O
g	O
situation	O
G	B
(	I
M2	I
)	I
gangliosidosis	I
.	O

We	O
identified	O
a	O
1422	O
G	O
-	O
-	O
>	O
C	O
(	O
amino	O
acid	O
W474C	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non	O
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
G	B
(	I
M2	I
)	I
gangliosidosis	I
.	O

On	O
second	O
maternally	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
causing	O
4	O
-	O
bp	O
,	O
+	O
TATC	O
1278	O
,	O
exon	O
11	O
.	O

On	O
second	O
maternally	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
causing	O
4	O
bp	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O

On	O
the	O
second	O
maternally	O
genetic	O
induce	O
	O
genetic	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
-	O
causing	O
4	O
-	O
bp	O
indium	O
coding	O
dna	O
	O
motherly	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
11	O

+	O
the	O
second	O
insertion	O
inherited	O
allele	O
,	O
exon	O
,	O
the	O
,	O
infantile	O
disease	O
-	O
1278	O
4	O
-	O
bp	O
maternally	O
in	O
common	O
TATC	O
causing	O
identified	O
On	O
we	O
11	O
.	O

11	O
the	O
second	O
causing	O
inherited	O
allele	O
exon	O
we	O
maternally	O
the	O
common	O
infantile	O
-	O
+	O
in	O
identified	O
-	O
bp	O
insertion	O
,	O
disease	O
TATC	O
1278	O
,	O
4	O
,	O
On	O
.	O

On	O
the	O
second	O
maternally	O
genetic	O
induce	O
	O
genetic	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
-	O
causing	O
4	O
-	O
bp	O
indium	O
coding	O
dna	O
	O
place	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
11	O

on	O
the	O
second	O
motherly	O
familial	O
allele	O
,	O
we	O
identified	O
the	O
green	O
childish	O
disease	O
-	O
stimulate	O
4	O
-	O
bp	O
intromission	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
eleven	O
.	O

On	O
the	O
second	O
maternally	O
genetic	O
induce	O
	O
genetic	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
-	O
causing	O
4	O
-	O
bp	O
indium	O
coding	O
dna	O
	O
place	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
11	O

,	O
the	O
second	O
maternally	O
inherited	O
allele	O
-	O
infantile	O
identified	O
the	O
common	O
-	O
TATC	O
,	O
in	O
On	O
we	O
4	O
insertion	O
,	O
+	O
disease	O
1278	O
bp	O
causing	O
exon	O
11	O
.	O

on	O
the	O
second	O
maternally	O
familial	O
allelomorph	O
,	O
we	O
name	O
the	O
vernacular	O
childish	O
disease	O
-	O
causing	O
quartet	O
-	O
bp	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
eleven	O
.	O

On	O
the	O
second	O
maternally	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
-	O
causing	O
4	O
-	O
bp	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
11	O
.	O

pulsing	O
-	O
tail	O
analysis	O
use	O
proband	O
fibroblasts	O
break	O
that	O
the	O
W474C	O
-	O
stop	O
alpha	O
-	O
subunit	O
predecessor	O
was	O
usually	O
synthesized	O
,	O
but	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
and	O
the	O
age	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
observe	O
.	O

-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
normally	O
synthesized	O
phosphorylated	O
,	O
and	O
lysosomal	O
subunit	O
was	O
not	O
detected	O

and	O
was	O
chase	O
analysis	O
precursor	O
proband	O
,	O
alpha	O
that	O
the	O
W474C	O
-	O
containing	O
or	O
.	O
subunit	O
using	O
lysosomal	O
normally	O
synthesized	O
revealed	O
but	O
not	O
phosphorylated	O
-	O
secreted	O
,	O
Pulse	O
was	O
mature	O
the	O
fibroblasts	O
-	O
subunit	O
alpha	O
not	O
detected	O
-	O

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
that	O
the	O
W474C	O
-	O
alpha	O
-	O
subunit	O
precursor	O
was	O
synthesized	O
,	O
but	O
not	O
or	O
secreted	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
detected	O
.	O

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
was	O
normally	O
synthesized	O
,	O
but	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
detected	O
.	O

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
was	O
normally	O
synthesized	O
,	O
but	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
detected	O
.	O

beat	O
-	O
chase	O
analysis	O
victimisation	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
moderate	O
alpha	O
-	O
subunit	O
forerunner	O
was	O
ordinarily	O
synthesise	O
,	O
but	O
not	O
phosphorylated	O
or	O
release	O
,	O
and	O
the	O
ripe	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
find	O
.	O

or	O
normally	O
chase	O
analysis	O
using	O
proband	O
-	O
subunit	O
that	O
the	O
W474C	O
fibroblasts	O
containing	O
and	O
mature	O
subunit	O
precursor	O
was	O
revealed	O
synthesized	O
,	O
but	O
the	O
phosphorylated	O
Pulse	O
secreted	O
alpha	O
alpha	O
-	O
not	O
lysosomal	O
not	O
-	O
-	O
was	O
,	O
detected	O
.	O

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
was	O
normally	O
synthesized	O
,	O
but	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
expend	O
release	O
detected	O
.	O

Pulse	O
-	O
using	O
proband	O
revealed	O
that	O
containing	O
-	O
subunit	O
precursor	O
normally	O
synthesized	O
,	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
detected	O

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
was	O
normally	O
synthesized	O
,	O
but	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
detected	O
.	O

When	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
associate	O
in	O
nursing	O
very	O
much	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
COS	O
-	O
7	O
cells	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	B
with	O
infantile	O
TSD	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O

When	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
was	O
transiently	O
co	O
-	O
convey	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
create	O
whammy	O
A	O
(	O
alphabeta	O
)	O
in	O
cosine	O
-	O
septet	O
cellphone	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
demonstrate	O
,	O
but	O
its	O
dismantle	O
was	O
much	O
lower	O
than	O
that	O
from	O
convention	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
eminent	O
than	O
in	O
those	O
cellphone	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
consort	O
with	O
childish	O
TSD	B
.	O

When	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
associate	O
in	O
nursing	O
cost	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
COS	O
-	O
7	O
cells	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	O
with	B
infantile	O
TSD	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O

When	O
the	O
W474C	O
-	O
hold	O
alpha	O
-	O
subunit	O
was	O
transiently	O
co	O
-	O
verbalized	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
acquire	O
witch	O
a	O
(	O
alphabeta	O
)	O
in	O
COS	O
-	O
heptad	O
cells	O
,	O
the	O
ripen	O
alpha	O
-	O
subunit	O
was	O
gift	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
pattern	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
eminent	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
connect	O
with	O
childish	O
TSD	B
.	O

When	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
associate	O
in	O
nursing	O
cost	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
COS	O
-	O
7	O
cells	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	O
with	B
infantile	O
TSD	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O
high	O
pitched	O

When	O
cells	O
W474C	O
an	O
-	O
transfected	O
-	O
subunit	O
was	O
transiently	O
co	O
than	O
expressed	O
subunit	O
the	O
was	O
-	O
subunit	O
to	O
produce	O
associated	O
alpha	O
that	O
present	O
although	O
TSD	O
COS	O
-	O
7	O
the	O
,	O
with	O
mature	O
alpha	O
-	O
subunit	O
,	O
alphabeta	O
was	O
.	O
its	O
level	O
beta	O
much	O
lower	O
than	O
(	O
containing	O
normal	O
alpha	O
but	O
,	O
transfections	O
subunit	O
-	O
higher	O
-	O
in	O
those	O
cells	O
alpha	O
the	O
-	O
)	O
A	O
with	O
Hex	O
with	O
infantile	O
in	B
from	O

higher	O
TSD	O
present	O
although	O
containing	O
alpha	O
-	O
subunit	O
mature	O
transiently	O
co	O
-	O
,	O
cells	O
the	O
alpha	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
normal	O
COS	O
those	O
lower	O
,	O
the	O
was	O
alpha	O
transfected	O
subunit	O
was	O
its	O
,	O
but	O
alpha	O
level	O
was	O
much	O
.	O
than	O
that	O
from	O
-	O
-	O
-	O
subunit	O
transfections	O
an	O
W474C	O
When	O
beta	O
-	O
with	O
cells	O
in	O
with	O
expressed	O
than	O
-	O
subunit	O
associated	O
7	O
infantile	O
the	B
with	O

than	O
the	O
W474C	O
.	O
transiently	O
alpha	O
-	O
with	O
was	O
containing	O
co	O
alphabeta	O
expressed	O
with	O
the	O
beta	O
associated	O
subunit	O
to	O
produce	O
Hex	O
A	O
that	O
-	O
)	O
-	O
although	O
-	O
7	O
-	O
,	O
the	O
(	O
alpha	O
those	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
-	O
much	O
cells	O
,	O
When	O
from	O
normal	O
subunit	O
-	O
subunit	O
an	O
lower	O
COS	O
higher	O
than	O
in	O
was	O
cells	O
transfected	O
subunit	O
transfections	O
alpha	O
in	O
alpha	O
-	O
with	O
TSD	O
infantile	B
mature	O

-	O
-	O
subunit	O
co	O
with	O
the	O
beta	O
-	O
to	O
produce	O
(	O
alphabeta	O
in	O
COS	O
,	O
mature	O
alpha	O
-	O
was	O
present	O
,	O
its	O
level	O
was	O
much	O
lower	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
in	O
cells	O
transfected	O
with	O
alpha	O
-	O
subunit	O
associated	O
with	O
infantile	O
.	O

When	O
containing	O
-	O
subunit	O
was	O
transiently	O
expressed	O
the	O
subunit	O
produce	O
Hex	O
A	O
alphabeta	O
)	O
in	O
7	O
cells	O
,	O
the	O
mature	O
-	O
subunit	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
cells	O
an	O
-	O
subunit	O
associated	O
infantile	O
TSD	B

When	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
COS	O
-	O
7	O
cells	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	O
with	O
infantile	O
TSD	B
.	O

,	O
the	O
precursor	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
accumulate	O
in	O
to	O
normal	O
alpha	O
-	O
subunit	O
precursor	O
levels	O
.	O

subunit	O
,	O
the	O
the	O
level	O
of	O
the	O
.	O
precursor	O
-	O
levels	O
was	O
found	O
normal	O
subunit	O
in	O
comparison	O
to	O
precursor	O
to	O
alpha	O
-	O
accumulate	O
alpha	O
Furthermore	O
W474C	O

moreover	O
,	O
the	O
predecessor	O
raze	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
collect	O
in	O
comparability	O
to	O
the	O
formula	O
alpha	O
-	O
subunit	O
predecessor	O
stage	O
.	O

moreover	O
,	O
the	O
predecessor	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
feel	O
to	O
collect	O
in	O
equivalence	O
to	O
the	O
pattern	O
alpha	O
-	O
subunit	O
predecessor	O
storey	O
.	O

Furthermore	O
,	O
the	O
precursor	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
was	O
found	O
accumulate	O
in	O
comparison	O
to	O
the	O
normal	O
alpha	O
precursor	O
levels	O
.	O

Furthermore	O
,	O
the	O
precursor	O
horizontal	O
surface	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
accumulate	O
in	O
comparison	O
to	O
fractional	O
monetary	O
unit	O
forerunner	O
horizontal	O
surface	O
forerunner	O
horizontal	O
surface	O
forerunner	O
the	O
normal	O
alpha	O

Furthermore	O
,	O
the	O
precursor	O
horizontal	O
surface	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
accumulate	O
in	O
comparison	O
to	O
fractional	O
monetary	O
unit	O
forerunner	O
horizontal	O
surface	O
forerunner	O
horizontal	O
surface	O
horizontal	O
surface	O
the	O
normal	O

Furthermore	O
,	O
the	O
precursor	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
was	O
accumulate	O
in	O
comparison	O
to	O
the	O
normal	O
alpha	O
-	O
subunit	O

precursor	O
,	O
the	O
precursor	O
level	O
of	O
to	O
comparison	O
alpha	O
-	O
subunit	O
was	O
-	O
the	O
levels	O
in	O
W474C	O
alpha	O
the	O
normal	O
Furthermore	O
found	O
subunit	O
to	O
accumulate	O
.	O

moreover	O
,	O
the	O
herald	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
retrieve	O
to	O
compile	O
in	O
equivalence	O
to	O
the	O
rule	O
alpha	O
-	O
subunit	O
herald	O
grade	O
.	O

Furthermore	O
,	O
the	O
precursor	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
accumulate	O
in	O
comparison	O
to	O
the	O
normal	O
alpha	O
-	O
subunit	O
precursor	O
levels	O
.	O

We	O
conclude	O
that	O
-	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	B
A	I
enzyme	I
deficiency	I
in	O
the	O
proband	O

We	O
conclude	O
that	O
the	O
1422	O
G	O
-	O
-	O
>	O
C	O
mutation	O
is	O
the	O
of	O
enzyme	I
deficiency	I
in	O
the	O
proband	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G	O
-	O
-	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	B
A	I
enzyme	I
indium	I
hex	O
hex	I
hex	O
hex	I
hex	O
deficiency	I
in	O
the	O
proband	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G	O
-	O
-	O
>	O
C	O
mutation	O
is	O
the	O
causa	O
of	O
jinx	B
A	I
enzyme	I
want	I
in	O
the	O
proband	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G	O
-	O
-	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	B
A	I
enzyme	I
indium	I
hex	O
hex	I
hex	O
hex	I
hex	O
deficiency	I
in	O
the	O
proband	O
.	O

We	O
resolve	O
that	O
the	O
1422	O
yard	O
-	O
-	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
hexadecimal	B
A	I
enzyme	I
insufficiency	I
in	O
the	O
proband	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G	O
-	O
-	O
>	O
C	O
is	O
the	O
of	O
Hex	B
A	I
enzyme	I
deficiency	I
in	O
the	O

mutation	O
conclude	O
that	O
deficiency	O
1422	O
G	O
-	O
>	O
-	O
C	O
in	O
is	O
cause	O
the	O
.	O
Hex	B
A	I
enzyme	I
the	I
We	O
the	O
proband	O
of	O

We	O
resolve	O
that	O
the	O
1422	O
thou	O
-	O
-	O
>	O
c	O
variation	O
is	O
the	O
cause	O
of	O
whammy	B
A	I
enzyme	I
lack	I
in	O
the	O
proband	O
.	O

of	O
conclude	O
>	O
-	O
1422	O
G	O
Hex	O
-	O
that	O
C	O
mutation	O
is	O
the	O
cause	O
the	O
We	B
A	I
enzyme	I
deficiency	I
in	O
the	O
proband	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G	O
-	O
-	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	B
A	I
enzyme	I
deficiency	I
in	O
the	O
proband	O
.	O

The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
Hex	B
A	I
deficiency	I
in	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
this	O
proband	O
.	O
.	O

The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
Hex	B
A	I
deficiency	I
in	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
situation	O
this	O
proband	O
.	O
.	O

The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
Hex	B
A	I
deficiency	I
in	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
understandably	O
this	O
proband	O
.	O
.	O

13	O
at	O
W474C	O
substitution	O
clearly	O
interferes	O
,	O
A	O
-	O
subunit	O
processing	O
with	O
but	O
splicing	O
also	O
base	O
substitution	O
falls	O
alpha	O
the	O
first	O
Hex	O
may	O
exon	O
The	O
,	O
to	O
because	O
the	O
of	O
contribute	O
in	O
position	B
resulting	I
deficiency	I
aberrant	O
this	O
proband	O
.	O
.	O

The	O
resulting	O
W474C	O
substitution	O
alpha	O
-	O
subunit	O
processing	O
,	O
because	O
the	O
at	O
position	O
of	O
,	O
may	O
also	O
contribute	O
to	O
A	I
deficiency	I
proband	O
.	O

The	O
ensue	O
W474C	O
exchange	O
distinctly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
radix	O
exchange	O
falls	O
at	O
the	O
first	O
put	O
of	O
exon	O
xiii	O
,	O
deviant	O
tie	O
may	O
besides	O
give	O
to	O
Hex	B
a	I
inadequacy	I
in	O
this	O
proband	O
.	O
.	O

The	O
resulting	O
W474C	O
exchange	O
clearly	O
interpose	O
with	O
alpha	O
-	O
subunit	O
sue	O
,	O
but	O
because	O
the	O
ground	O
exchange	O
drop	O
at	O
the	O
maiden	O
berth	O
of	O
exon	O
13	O
,	O
deviate	O
splice	O
may	O
too	O
contribute	O
to	O
jinx	B
A	I
inadequacy	I
in	O
this	O
proband	O
.	O
.	O

contribute	O
deficiency	O
W474C	O
substitution	O
substitution	O
interferes	O
proband	O
to	O
-	O
subunit	O
processing	O
,	O
but	O
13	O
falls	O
base	O
clearly	O
the	O
at	O
the	O
because	O
position	O
of	O
exon	O
resulting	O
,	O
aberrant	O
.	O
The	O
also	O
may	O
with	O
Hex	B
A	I
first	I
in	O
this	O
alpha	O
splicing	O
.	O

The	O
leave	O
W474C	O
permutation	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
action	O
,	O
but	O
because	O
the	O
qaeda	O
permutation	O
falls	O
at	O
the	O
low	O
spot	O
of	O
exon	O
13	O
,	O
deviant	O
tie	O
may	O
also	O
lead	O
to	O
enchant	B
amp	I
lack	I
in	O
this	O
proband	O
.	O
.	O

The	O
resulting	O
contribute	O
substitution	O
clearly	O
in	O
processing	O
alpha	O
-	O
subunit	O
with	O
aberrant	O
the	O
because	O
the	O
at	O
substitution	O
falls	O
proband	O
but	O
first	O
position	O
of	O
interferes	O
13	O
base	O
,	O
Hex	O
to	O
also	O
W474C	O
splicing	O
may	B
A	I
deficiency	I
exon	O
this	O
,	O
.	O
.	O

The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
Hex	B
A	I
deficiency	I
in	O
this	O
proband	O
.	O
.	O

syndrome	O
frequent	O
missense	O
mutations	O
.	O
Pendred	B
Two	I
in	O

Two	O
patronise	O
missense	O
variation	O
in	O
Pendred	B
syndrome	I
.	O

missense	O
Pendred	B
syndrome	I
.	O

Two	O
sport	O
sport	O
frequent	O
missense	O
mutations	O
in	O
Pendred	B
syndrome	I
.	O

Two	O
missense	O
mutations	O
syndrome	I
.	O

Two	O
in	O
missense	O
mutations	O
frequent	O
Pendred	B
.	I
syndrome	O

.	O
mutations	O
missense	O
frequent	O
in	O
Pendred	B
syndrome	I
Two	O

Two	O
sport	O
indium	O
frequent	O
missense	O
mutations	O
in	O
Pendred	B
syndrome	I
.	O

two	O
frequent	O
missense	O
mutant	O
in	O
Pendred	B
syndrome	I
.	O

Two	O
sport	O
indium	O
frequent	O
missense	O
mutations	O
in	O
Pendred	B
syndrome	I
.	O

Two	O
frequent	O
missense	O
mutations	O
in	O
Pendred	B
syndrome	I
.	O

Pendred	B
autosomal	I
is	O
an	O
syndrome	B
recessive	I
characterized	I
childhood	O
by	O
early	O
and	O
deafness	B
disorder	O
goiter	B
.	O

Pendred	B
syndrome	I
disarray	O
characterize	O
cost	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
goitre	O
early	O
childhood	O
deafness	B
and	O
goiter	B
.	O

Pendred	B
syndrome	I
is	O
an	O
autosomal	B
recessionary	I
unhinge	I
characterized	O
by	O
early	O
puerility	O
deafness	B
and	O
struma	B
.	O

and	B
syndrome	I
is	O
Pendred	O
characterized	B
recessive	I
disorder	I
deafness	O
by	O
early	O
childhood	O
autosomal	B
an	O
goiter	B
.	O

Pendred	B
syndrome	I
is	O
an	O
autosomal	B
recessive	I
unhinge	I
characterise	O
by	O
early	O
puerility	O
deafness	B
and	O
thyromegaly	B
.	O

Pendred	B
syndrome	I
disarray	O
characterize	O
cost	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
characterize	O
early	O
childhood	O
deafness	B
and	O
goiter	B
.	O

Pendred	B
is	O
autosomal	B
disorder	I
characterized	O
by	O
early	O
childhood	O
deafness	B
and	O
goiter	B
.	O

characterized	B
an	I
is	O
syndrome	O
autosomal	B
recessive	I
early	I
Pendred	O
by	O
disorder	O
childhood	O
deafness	B
and	O
.	B
goiter	O

Pendred	B
syndrome	I
is	O
an	O
autosomal	B
recessive	I
upset	I
qualify	O
by	O
early	O
puerility	O
deafness	B
and	O
goitre	B
.	O

Pendred	B
syndrome	I
disarray	O
characterize	O
cost	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
characterize	O
early	O
childhood	O
deafness	B
and	O
goiter	B
.	O

Pendred	B
syndrome	I
is	O
an	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
early	O
childhood	O
deafness	B
and	O
goiter	B
.	O

century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	O
gene	O
(	O
)	O
mapped	O
to	O
chromosome	O
7q22	O
-	O
q31	O
.	O

Pendred	O
century	O
after	O
was	O
recognition	O
as	O
a	O
.	O
-	O
Vaughan	O
q31	O
,	O
the	O
mapped	O
7q22	O
(	O
PDS	O
)	O
its	O
disease	O
to	O
chromosome	O
gene	O
by	O
A	O
syndrome	O

ampere	O
century	O
after	O
its	O
acknowledgement	O
as	O
ampere	O
syndrome	O
by	O
vaughan	O
Pendred	O
,	O
the	O
disease	O
cistron	O
(	O
pd	O
)	O
was	O
represent	O
to	O
chromosome	O
7q22	O
-	O
q31	O
.	O

angstrom	O
hundred	O
after	O
its	O
acknowledgment	O
as	O
angstrom	O
syndrome	O
by	O
vaughan	O
Pendred	O
,	O
the	O
disease	O
cistron	O
(	O
pd	O
)	O
was	O
represent	O
to	O
chromosome	O
7q22	O
-	O
q31	O
.	O

A	O
century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
,	O
the	O
gene	O
(	O
PDS	O
)	O
was	O
mapped	O
to	O
-	O
q31	O
.	O

A	O
century	O
after	O
its	O
acknowledgement	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	O
gene	O
(	O
PDS	O
)	O
represent	O
later	O
on	O
later	O
on	O
later	O
on	O
later	O
on	O
past	O
was	O
mapped	O
to	O
chromosome	O

A	O
century	O
after	O
its	O
acknowledgement	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	O
gene	O
(	O
PDS	O
)	O
represent	O
later	O
on	O
later	O
on	O
later	O
on	O
later	O
on	O
information	O
technology	O
was	O
mapped	O
to	O

A	O
century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
,	O
gene	O
(	O
PDS	O
)	O
was	O
mapped	O
to	O
chromosome	O
7q22	O

-	O
century	O
after	O
its	O
recognition	O
as	O
disease	O
PDS	O
by	O
Vaughan	O
Pendred	O
,	O
chromosome	O
a	O
q31	O
(	O
syndrome	O
to	O
was	O
mapped	O
A	O
the	O
7q22	O
)	O
gene	O
.	O

axerophthol	O
hundred	O
after	O
its	O
realization	O
as	O
axerophthol	O
syndrome	O
by	O
vaughan	O
Pendred	O
,	O
the	O
disease	O
cistron	O
(	O
pd	O
)	O
was	O
mapped	O
to	O
chromosome	O
7q22	O
-	O
q31	O
.	O

A	O
century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	O
gene	O
(	O
PDS	O
)	O
was	O
mapped	O
to	O
chromosome	O
7q22	O
-	O
q31	O
.	O

1	O
,	O
recently	O
found	O
encode	O
putative	O
sulfate	O
transporter	O
.	O

1	O
and	O
,	O
recently	O
,	O
found	O
to	O
encode	O
a	O
putative	O
sulfate	O
transporter	O

1	O
and	O
,	O
recently	O
,	O
obtain	O
to	O
encode	O
a	O
putative	O
sulphate	O
transporter	O
.	O

1	O
and	O
,	O
recently	O
,	O
found	O
to	O
encode	O
a	O
conveyor	O
belt	O
of	O
late	O
putative	O
sulfate	O

1	O
and	O
,	O
recently	O
,	O
found	O
to	O
encode	O
a	O
conveyor	O
belt	O
conveyor	O
belt	O
receive	O
putative	O
sulfate	O

1	O
and	O
,	O
recently	O
,	O
found	O
to	O
encode	O
a	O
conveyor	O
belt	O
of	O
late	O
putative	O
sulfate	O

1	O
and	O
,	O
late	O
,	O
found	O
to	O
encode	O
a	O
putative	O
sulphate	O
conveyer	O
.	O

1	O
and	O
recently	O
,	O
found	O
to	O
encode	O
a	O
putative	O
.	O

ane	O
and	O
,	O
latterly	O
,	O
bump	O
to	O
encode	O
a	O
putative	O
sulfate	O
transporter	O
.	O

1	O
,	O
,	O
recently	O
.	O
found	O
to	O
and	O
a	O
putative	O
sulfate	O
transporter	O
encode	O

1	O
and	O
,	O
recently	O
,	O
found	O
to	O
encode	O
a	O
putative	O
sulfate	O
transporter	O
.	O

We	O
performed	O
mutation	O
gene	O
in	O
patients	O
from	O
14	O
Pendred	B
families	O
originating	O
from	O
seven	O
countries	O
and	O
identified	O
all	O
mutations	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	B
gene	O
in	O
patients	O
from	O
14	O
Pendred	B
originating	O
countries	O
and	O
identified	O
all	O
mutations	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	B
gene	O
in	O
patients	O
from	O
14	O
Pendred	B
families	O
originating	O
from	O
seven	O
countries	O
whole	O
sport	O
sport	O
sport	O
sport	O
sport	O
and	O
identified	O
all	O
mutations	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
pd	B
gene	O
in	O
patients	O
from	O
fourteen	O
Pendred	B
mob	O
arise	O
from	O
heptad	O
countries	O
and	O
identified	O
all	O
variation	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	B
gene	O
in	O
patients	O
from	O
14	O
Pendred	B
families	O
originating	O
from	O
seven	O
countries	O
whole	O
sport	O
sport	O
sport	O
sport	O
sport	O
and	O
identified	O
all	O
mutations	O
.	O

We	O
do	O
mutation	O
analysis	O
of	O
the	O
PDS	B
cistron	O
in	O
patients	O
from	O
xiv	O
Pendred	B
families	O
initiate	O
from	O
seven	O
countries	O
and	O
distinguish	O
all	O
sport	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	B
gene	O
in	O
patients	O
14	O
Pendred	B
originating	O
from	O
seven	O
countries	O
and	O
identified	O
all	O

from	O
performed	O
mutation	O
and	O
of	O
the	O
PDS	B
in	O
gene	O
patients	O
identified	O
14	O
families	B
Pendred	O
.	O
from	O
seven	O
countries	O
analysis	O
We	O
all	O
mutations	O
originating	O

We	O
performed	O
mutant	O
analysis	O
of	O
the	O
PDS	B
factor	O
in	O
patients	O
from	O
14	O
Pendred	B
phratry	O
arise	O
from	O
heptad	O
countries	O
and	O
discover	O
all	O
mutations	O
.	O

originating	O
performed	O
in	O
PDS	O
of	O
the	O
from	B
gene	O
mutation	O
patients	O
from	O
14	O
all	B
families	O
analysis	O
We	O
seven	O
countries	O
and	O
identified	O
Pendred	O
mutations	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	B
gene	O
in	O
patients	O
from	O
14	O
Pendred	B
families	O
originating	O
from	O
seven	O
countries	O
and	O
identified	O
all	O
mutations	O
.	O

site	O
mutations	O
include	O
,	O
single	O
base	O
deletions	O
three	O
missense	O
splice	O
10	O
mutation	O
The	O
and	O
one	O
mutations	O
.	O

The	O
mutations	O
include	O
three	O
bingle	O
fundament	O
omission	O
,	O
single	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
.	O

The	O
mutations	O
include	O
three	O
exclusive	O
base	O
cut	O
,	O
nonpareil	O
wed	O
site	O
mutation	O
and	O
tenner	O
missense	O
mutations	O
.	O

The	O
mutations	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
.	O

The	O
mutations	O
admit	O
tierce	O
single	O
base	O
cut	O
,	O
one	O
splice	O
situation	O
mutant	O
and	O
10	O
missense	O
mutations	O
.	O

The	O
mutations	O
let	O
in	O
let	O
in	O
include	O
three	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
omission	O
omission	O

The	O
mutations	O
include	O
three	O
single	O
base	O
deletions	O
,	O
splice	O
site	O
and	O
10	O
missense	O
mutations	O
.	O

The	O
mutations	O
let	O
in	O
let	O
in	O
include	O
three	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
omission	O
omission	O

mutations	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O

The	O
mutations	O
one	O
missense	O
single	O
base	O
and	O
,	O
include	O
splice	O
site	O
mutation	O
deletions	O
10	O
three	O
mutations	O
.	O

The	O
mutations	O
include	O
three	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
.	O

unity	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
deuce	O
akin	O
kinsperson	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
five	O
extra	O
not	O
-	O
akin	O
kinsperson	O
.	O

One	O
missense	O
mutation	O
(	O
L236P	O
was	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
five	O
additional	O
non	O
-	O
consanguineous	O
families	O
.	O

state	O
missense	O
mutation	O
a	O
L236P	O
)	O
was	O
-	O
additional	O
a	O
.	O
state	O
in	O
heterozygous	O
five	O
families	O
and	O
in	O
(	O
two	O
non	O
in	O
consanguineous	O
in	O
One	O
found	O
consanguineous	O
families	O
homozygous	O

One	O
missense	O
mutation	O
(	O
indium	O
	O
blood	O
related	O
family	O
line	O
receive	O
L236P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
extra	O
blood	O
related	O
indium	O
a	O
heterozygous	O
state	O
in	O
five	O
additional	O
non	O
-	O

One	O
missense	O
mutation	O
(	O
indium	O
	O
blood	O
related	O
family	O
line	O
receive	O
L236P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
extra	O
blood	O
related	O
blood	O
related	O
a	O
heterozygous	O
state	O
in	O
five	O
additional	O
non	O

One	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
found	O
a	O
homozygous	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
a	O
in	O
five	O
additional	O
non	O
-	O
consanguineous	O
families	O
.	O

.	O
missense	O
mutation	O
consanguineous	O
L236P	O
)	O
-	O
found	O
(	O
a	O
homozygous	O
state	O
consanguineous	O
two	O
non	O
in	O
and	O
in	O
a	O
heterozygous	O
in	O
in	O
five	O
additional	O
families	O
was	O
state	O
families	O
One	O

One	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
found	O
a	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
a	O
state	O
in	O
five	O
additional	O
non	O
-	O
consanguineous	O

nonpareil	O
missense	O
variation	O
(	O
L236P	O
)	O
was	O
obtain	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineal	O
kinfolk	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
five	O
extra	O
not	O
-	O
consanguineal	O
kinfolk	O
.	O

unitary	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
establish	O
in	O
a	O
homozygous	O
province	O
in	O
ii	O
kin	O
class	O
and	O
in	O
a	O
heterozygous	O
province	O
in	O
five	O
extra	O
not	O
-	O
kin	O
class	O
.	O

One	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
five	O
additional	O
non	O
-	O
consanguineous	O
families	O
.	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
	O
family	O
line	O
	O
family	O
line	O
family	O
line	O
sport	O
ampere	O
heterozygous	O
state	O
in	O

mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
heterozygous	O
in	O
four	O
families	O
.	O

another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
matchless	O
kinfolk	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
quaternity	O
families	O
.	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
in	O
a	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
in	O
four	O
families	O
.	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
	O
family	O
line	O
	O
family	O
line	O
family	O
line	O
sport	O
sport	O
heterozygous	O
state	O
in	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
bump	O
in	O
a	O
homozygous	O
posit	O
in	O
unity	O
folk	O
and	O
in	O
a	O
heterozygous	O
posit	O
in	O
quartet	O
sept	O
.	O

another	O
missense	O
sport	O
(	O
T416P	O
)	O
was	O
constitute	O
in	O
a	O
homozygous	O
state	O
in	O
i	O
folk	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
quartet	O
families	O
.	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
homozygous	O
one	O
family	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
four	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
	O
family	O
line	O
	O
family	O
line	O
family	O
line	O
sport	O
sport	O
heterozygous	O
state	O
in	O

a	O
missense	O
mutation	O
homozygous	O
T416P	O
)	O
was	O
heterozygous	O
.	O
a	O
(	O
state	O
in	O
one	O
families	O
and	O
in	O
in	O
found	O
Another	O
state	O
four	O
family	O
in	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
four	O
families	O
.	O

Pendred	B
patients	O
were	O
for	O
non	O
-	O
compound	O
families	O
in	O
shown	O
to	O
be	O
consanguineous	O
heterozygotes	O
three	O
L236P	O
and	O
T416P	O
.	O

in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
L236P	O
and	O
T416P	O
.	O

Pendred	B
patients	O
in	O
tierce	O
not	O
-	O
consanguineous	O
families	O
were	O
indicate	O
to	O
be	O
colonial	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
.	O

Pendred	B
patients	O
in	O
trinity	O
non	O
-	O
consanguineal	O
folk	O
were	O
evidence	O
to	O
be	O
combine	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
.	O

and	B
patients	O
in	O
three	O
non	O
-	O
heterozygotes	O
for	O
were	O
shown	O
to	O
be	O
T416P	O
consanguineous	O
families	O
L236P	O
compound	O
Pendred	O
.	O

Pendred	B
patients	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
.	O

Pendred	B
patients	O
in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
indium	O
indium	O
indium	O
indium	O
heterozygote	O
.	O

Pendred	B
patients	O
in	O
three	O
not	O
-	O
consanguineous	O
house	O
were	O
demo	O
to	O
be	O
deepen	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
.	O

Pendred	B
patients	O
in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
indium	O
indium	O
indium	O
indium	O
indium	O
.	O

heterozygotes	B
patients	O
in	O
to	O
non	O
-	O
consanguineous	O
.	O
for	O
shown	O
three	O
be	O
Pendred	O
compound	O
were	O
L236P	O
and	O
T416P	O
families	O

Pendred	B
patients	O
in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
.	O

In	O
total	O
mutations	O
the	O
or	O
both	O
nine	O
these	O
,	O
were	O
found	O
in	O
of	O
of	O
one	O
14	O
families	O
analyzed	O
.	O

,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
14	O
families	O
analyzed	O
.	O

In	O
aggregate	O
,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
plant	O
in	O
nine	O
of	O
the	O
xiv	O
family	O
study	O
.	O

inch	O
total	O
,	O
one	O
or	O
both	O
of	O
these	O
sport	O
were	O
determine	O
inch	O
nine	O
of	O
the	O
14	O
families	O
analyzed	O
.	O

families	O
total	O
,	O
one	O
or	O
both	O
of	O
the	O
mutations	O
were	O
found	O
in	O
analyzed	O
of	O
these	O
14	O
nine	O
In	O
.	O

In	O
total	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
.	O

In	O
total	O
,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
analyzed	O
sport	O
sport	O
sport	O
sport	O
receive	O
.	O

In	O
full	O
,	O
unrivalled	O
or	O
both	O
of	O
these	O
sport	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
phratry	O
examine	O
.	O

In	O
total	O
,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
analyzed	O
sport	O
sport	O
sport	O
sport	O
sport	O
.	O

of	O
total	O
,	O
found	O
or	O
both	O
of	O
.	O
the	O
were	O
one	O
in	O
In	O
nine	O
mutations	O
14	O
families	O
analyzed	O
these	O

In	O
total	O
,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
analyzed	O
.	O

The	O
identification	O
sport	O
volition	O
help	O
of	O
two	O
frequent	O
PDS	B
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B
syndrome	I
atomic	O
number	O

Pendred	O
identification	O
of	O
.	O
frequent	O
PDS	B
mutations	O
will	O
syndrome	O
the	O
molecular	O
diagnosis	O
The	O
of	B
facilitate	I
two	O

The	O
identification	O
sport	O
volition	O
	O
of	O
two	O
frequent	O
PDS	B
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B
syndrome	I
atomic	O
number	O

The	O
designation	O
of	O
two	O
patronise	O
PDS	B
mutations	O
will	O
help	O
the	O
molecular	O
diagnosing	O
of	O
Pendred	B
syndrome	I
.	O

of	O
identification	O
of	O
will	O
frequent	O
PDS	B
Pendred	O
two	O
facilitate	O
the	O
The	O
diagnosis	O
molecular	O
mutations	B
syndrome	I
.	O

The	O
identification	O
sport	O
volition	O
help	O
of	O
two	O
frequent	O
PDS	B
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B
syndrome	I
atomic	O
number	O

The	O
identification	O
of	O
two	O
haunt	O
PDS	B
variation	O
will	O
alleviate	O
the	O
molecular	O
diagnosing	O
of	O
Pendred	B
syndrome	I
.	O

The	O
recognition	O
of	O
ii	O
frequent	O
palladium	B
mutations	O
will	O
alleviate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B
syndrome	I
.	O

The	O
identification	O
facilitate	O
.	O
frequent	O
PDS	B
of	O
will	O
of	O
the	O
molecular	O
diagnosis	O
mutations	O
Pendred	B
two	I
syndrome	O

identification	O
of	O
two	O
frequent	O
PDS	B
mutations	O
will	O
molecular	O
diagnosis	O
of	O
Pendred	B
syndrome	I
.	O

The	O
identification	O
of	O
two	O
frequent	O
PDS	B
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B
syndrome	I
.	O

Insertional	O
mutation	O
by	O
permutable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	B
factor	O
solution	O
in	O
X	B
-	I
associate	I
expand	I
myocardiopathy	I
.	O

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	B
gene	O
results	O
in	O
X	B
-	I
linked	I
dilated	I
past	I
past	O
past	I
past	O
past	I
past	O
cardiomyopathy	I
.	O

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	B
gene	O
results	O
in	O
X	B
-	I
linked	I
dilated	I
past	I
past	O
past	I
past	O
past	I
past	O
cardiomyopathy	I
.	O

by	O
,	O
L1	O
,	O
the	O
DMD	B
results	O
in	O
X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
.	O

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
in	O
DMD	B
gene	O
results	O
in	O
X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
.	O

by	O
transposable	O
element	O
,	O
,	O
in	O
the	O
DMD	B
gene	O
in	O
X	B
-	I
linked	I
cardiomyopathy	I
.	O

dilated	O
mutation	O
by	O
cardiomyopathy	O
element	O
,	O
L1	O
in	O
,	O
the	O
X	B
gene	O
results	O
.	O
Insertional	B
-	I
linked	I
DMD	I
transposable	I
in	O

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	B
gene	O
results	O
in	O
X	B
-	I
linked	I
dilated	I
past	I
past	O
past	I
past	O
past	I
permutable	O
cardiomyopathy	I
.	O

Insertional	O
variation	O
by	O
permutable	O
ingredient	O
,	O
L1	O
,	O
in	O
the	O
DMD	B
cistron	O
results	O
in	O
ecstasy	B
-	I
yoke	I
dilated	I
cardiomyopathy	I
.	O

linked	O
mutation	O
by	O
transposable	O
element	O
,	O
in	O
gene	O
in	O
the	O
DMD	B
X	O
Insertional	O
L1	O
,	B
dilated	I
results	I
-	I
cardiomyopathy	I
.	O

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	B
gene	O
results	O
in	O
X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
.	O

X	B
-	I
linked	I
dilated	I
cardiomyopathy	O
myocardiopathy	I
haggard	O
cost	I
myocardiopathy	O
cardiomyopathy	I
(	O
XLDCM	B
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
characterized	O
by	O
open	O
haggard	O
preferential	O
myocardial	B
involvement	I
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B
myopathy	I
myocardiopathy	O
toll	O
.	O

X	B
-	I
linked	I
dilated	I
cardiomyopathy	O
myocardiopathy	I
haggard	O
cost	I
myocardiopathy	O
cardiomyopathy	I
(	O
XLDCM	B
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
characterized	O
by	O
open	O
ampere	O
preferential	O
myocardial	B
involvement	I
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B
myopathy	I
myocardiopathy	O
toll	O
.	O

myopathy	B
-	I
clinical	I
which	I
cardiomyopathy	I
(	O
skeletal	B
)	O
dilated	O
a	O
clinical	O
phenotype	O
involvement	O
dystrophinopathy	B
linked	O
is	O
characterized	O
by	O
preferential	O
myocardial	B
of	I
without	O
any	O
overt	O
is	O
XLDCM	O
of	O
signs	B
X	I
.	O

X	B
-	I
linked	I
dilated	I
cardiomyopathy	O
myocardiopathy	I
haggard	O
cost	I
myocardiopathy	O
cardiomyopathy	I
(	O
XLDCM	B
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
characterized	O
by	O
open	O
haggard	O
preferential	O
myocardial	B
involvement	I
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B
myopathy	I
myocardiopathy	O
toll	O
.	O

X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
(	O
XLDCM	B
is	O
a	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
characterized	O
by	O
involvement	I
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B
myopathy	I
.	O

ten	B
-	I
coupled	I
elaborate	I
myocardiopathy	I
(	O
XLDCM	B
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
qualify	O
by	O
discriminatory	O
myocardial	B
involvement	I
without	O
any	O
open	O
clinical	O
mansion	O
of	O
haggard	B
myopathy	I
.	O

characterized	B
-	I
linked	I
dilated	I
cardiomyopathy	I
(	O
without	B
phenotype	O
is	O
a	O
clinical	O
X	O
myopathy	O
overt	B
is	O
which	O
by	O
clinical	O
preferential	O
myocardial	B
involvement	I
XLDCM	O
any	O
dystrophinopathy	O
)	O
signs	O
of	O
skeletal	B
of	I
.	O

involvement	B
-	I
linked	I
preferential	I
cardiomyopathy	I
(	O
XLDCM	B
signs	O
overt	O
a	O
myopathy	O
phenotype	O
of	O
myocardial	B
any	O
is	O
characterized	O
by	O
dilated	O
dystrophinopathy	B
clinical	I
without	O
which	O
is	O
X	O
)	O
of	O
skeletal	B
clinical	I
.	O

adam	B
-	I
coupled	I
lucubrate	I
myocardiopathy	I
(	O
XLDCM	B
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
characterized	O
by	O
discriminatory	O
myocardial	B
participation	I
without	O
any	O
open	O
clinical	O
signs	O
of	O
wasted	B
myopathy	I
.	O

X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
XLDCM	B
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
by	O
preferential	O
myocardial	B
involvement	I
without	O
any	O
overt	O
of	O
skeletal	B
myopathy	I

X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
(	O
XLDCM	B
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
characterized	O
by	O
preferential	O
myocardial	B
involvement	I
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B
myopathy	I
.	O

To	O
mutations	O
the	O
Duchenne	B
muscular	I
gene	O
,	O
DMD	O
have	O
been	O
identified	O
in	O
patients	O
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
DMD	O
the	O
XLDCM	B
phenotype	O
remained	O
to	O
be	O
elucidated	O
.	O

To	O
date	O
,	O
several	O
mutations	O
muscular	I
dystrophy	I
gene	O
,	O
DMD	O
have	O
been	O
with	O
but	O
a	O
of	O
mutations	O
in	O
DMD	O
with	O
XLDCM	B
phenotype	O
to	O
be	O
.	O

To	O
date	O
,	O
several	O
mutations	O
in	O
the	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
,	O
DMD	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
XLDCM	B
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	B
phenotype	O
shed	O
light	O
on	O
sport	O
beryllium	O
shed	O
light	O
on	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
has	O
remained	O

To	O
date	O
,	O
respective	O
sport	O
in	O
the	O
Duchenne	B
mesomorphic	I
dystrophy	I
factor	O
,	O
DMD	O
,	O
have	O
been	O
distinguish	O
in	O
patients	O
with	O
XLDCM	B
,	O
but	O
a	O
morbific	O
correlation	O
of	O
these	O
cardiospecific	O
sport	O
in	O
DMD	O
with	O
the	O
XLDCM	B
phenotype	O
has	O
remained	O
to	O
be	O
illuminate	O
.	O

To	O
date	O
in	O
several	O
mutations	O
phenotype	O
the	O
patients	B
muscular	I
dystrophy	I
gene	O
of	O
with	O
,	O
have	O
Duchenne	O
identified	O
in	O
remained	O
DMD	O
XLDCM	B
with	O
but	O
in	O
pathogenic	O
been	O
,	O
,	O
cardiospecific	O
mutations	O
,	O
these	O
DMD	O
the	O
XLDCM	B
a	O
has	O
correlation	O
to	O
be	O
elucidated	O
.	O

To	O
appointment	O
,	O
respective	O
mutant	O
in	O
the	O
Duchenne	B
powerful	I
dystrophy	I
factor	O
,	O
DMD	O
,	O
have	O
been	O
identify	O
in	O
patients	O
with	O
XLDCM	B
,	O
but	O
a	O
morbific	O
correlation	O
of	O
these	O
cardiospecific	O
mutant	O
in	O
DMD	O
with	O
the	O
XLDCM	B
phenotype	O
has	O
stay	O
to	O
be	O
elucidated	O
.	O

XLDCM	O
patients	O
,	O
several	O
mutations	O
in	O
.	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
elucidated	O
DMD	O
pathogenic	O
mutations	O
been	O
identified	O
in	O
these	O
with	O
XLDCM	B
,	O
phenotype	O
a	O
,	O
correlation	O
the	O
date	O
DMD	O
but	O
in	O
cardiospecific	O
with	O
have	O
To	B
of	O
has	O
remained	O
to	O
be	O
,	O
the	O

To	O
date	O
,	O
several	O
mutations	O
in	O
muscular	I
dystrophy	I
gene	O
,	O
,	O
have	O
been	O
identified	O
in	O
with	O
XLDCM	B
,	O
but	O
pathogenic	O
correlation	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	B
has	O
remained	O
be	O
elucidated	O
.	O

to	O
pathogenic	O
,	O
several	O
identified	O
in	O
XLDCM	O
DMD	B
muscular	I
dystrophy	I
gene	O
,	O
DMD	O
the	O
remained	O
been	O
mutations	O
in	O
patients	O
with	O
,	B
,	O
but	O
a	O
these	O
correlation	O
of	O
.	O
in	O
mutations	O
cardiospecific	O
date	O
with	O
the	O
XLDCM	B
phenotype	O
has	O
have	O
To	O
be	O
elucidated	O
Duchenne	O

To	O
date	O
,	O
several	O
mutations	O
in	O
the	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
,	O
DMD	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
XLDCM	B
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	B
phenotype	O
shed	O
light	O
on	O
sport	O
beryllium	O
shed	O
light	O
on	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
dmd	O
has	O
remained	O

To	O
date	O
,	O
several	O
mutations	O
in	O
the	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
,	O
DMD	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
XLDCM	B
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	B
phenotype	O
has	O
remained	O
to	O
be	O
elucidated	O
.	O

We	O
report	O
here	O
the	O
designation	O
of	O
a	O
alone	O
de	O
novo	O
L1	O
introduction	O
in	O
the	O
brawniness	O
exon	O
1	O
in	O
dmd	O
in	O
three	O
XLDCM	B
patients	O
from	O
ii	O
unrelated	O
nipponese	O
kin	O
.	O

We	O
report	O
here	O
the	O
identification	O
a	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O
.	O

three	O
report	O
here	O
DMD	O
identification	O
of	O
a	O
unrelated	O
from	O
novo	O
.	O
insertion	O
in	O
in	O
patients	O
exon	O
1	O
in	O
the	O
the	O
two	O
XLDCM	B
muscle	O
de	O
We	O
unique	O
Japanese	O
families	O
L1	O

We	O
report	O
here	O
the	O
indium	O
designation	O
heftiness	O
coding	O
dna	O
designation	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
patient	O
nipponese	O
delaware	O
DMD	O
in	O
three	B
XLDCM	O
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O

We	O
report	O
here	O
the	O
indium	O
designation	O
heftiness	O
coding	O
dna	O
designation	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
patient	O
nipponese	O
heftiness	O
DMD	O
in	O
three	B
XLDCM	O
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
novo	O
L1	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
DMD	O
XLDCM	B
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O
.	O

.	O
report	O
here	O
muscle	O
identification	O
of	O
unrelated	O
unique	O
the	O
novo	O
L1	O
insertion	O
Japanese	O
the	O
two	O
de	O
1	O
in	O
DMD	O
in	O
in	O
XLDCM	B
patients	O
from	O
exon	O
a	O
three	O
families	O
We	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
novo	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
DMD	O
three	O
XLDCM	B
patients	O
from	O
two	O
unrelated	O
Japanese	O

We	O
report	O
here	O
the	O
recognition	O
of	O
a	O
unequalled	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
musculus	O
exon	O
unity	O
in	O
dmd	O
in	O
trey	O
XLDCM	B
patients	O
from	O
ii	O
unrelated	O
nipponese	O
families	O
.	O

We	O
report	O
here	O
the	O
designation	O
of	O
a	O
alone	O
de	O
novo	O
L1	O
introduction	O
in	O
the	O
brawniness	O
exon	O
ane	O
in	O
dmd	O
in	O
three	O
XLDCM	B
patients	O
from	O
two	O
unrelated	O
nipponese	O
category	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
DMD	O
in	O
three	O
XLDCM	B
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O
.	O

The	O
insertion	O
the	O
a	O
5	O
-	O
truncated	O
region	O
of	O
human	O
L1	O
not	O
of	O
in	O
the	O
muscle	O
-	O
untranslated	O
in	O
form	O
the	O
cell	O
exon	O
1	O
,	O
due	O
affected	O
or	O
transcription	O
or	O
was	O
unique	O
which	O
the	O
muscle	O
form	O
of	O
stability	O
transcripts	O
but	O
inversely	O
that	O
integrated	O
the	O
brain	O
of	O
integration	O
5	O
form	O
,	O
probably	O
the	O
to	O
.	O
of	O
Purkinje	O
dystrophin	O
site	O
its	O

The	O
insertion	O
was	O
a	O
5	O
-	O
truncated	O
form	O
credibly	O
referable	O
touched	O
information	O
technology	O
recording	O
operating	O
theatre	O
indium	O
stableness	O
	O
of	O
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
5	O
-	O
untranslated	O
region	O
in	O
the	O
muscle	O
exon	O
1	O
,	O
which	O
affected	O
the	O
transcription	O
or	O
the	O
stability	O
of	O
the	O
muscle	O
form	O
credibly	O
referable	O
jan	O
evangelista	O
purkinje	O
information	O
technology	O
unequaled	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
form	O
,	O
probably	O
due	O
to	O
its	O
unique	O
site	O
of	O

The	O
was	O
a	O
5	O
-	O
truncated	O
form	O
of	O
human	O
L1	O
inversely	O
the	O
5	O
-	O
untranslated	O
in	O
the	O
muscle	O
exon	O
1	O
which	O
affected	O
the	O
transcription	O
the	O
stability	O
the	O
muscle	O
form	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
of	O
the	O
or	O
Purkinje	O
cell	O
form	O
,	O
probably	O
due	O
to	O
of	O
integration	O
.	O

The	O
introduction	O
was	O
a	O
cinque	O
-	O
truncated	O
anatomy	O
of	O
human	O
L1	O
reciprocally	O
merged	O
in	O
the	O
cinque	O
-	O
untranslated	O
realm	O
in	O
the	O
musculus	O
exon	O
1	O
,	O
which	O
unnatural	O
the	O
arranging	O
or	O
the	O
constancy	O
of	O
the	O
musculus	O
anatomy	O
of	O
dystrophin	O
copy	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
anatomy	O
,	O
credibly	O
ascribable	O
to	O
its	O
alone	O
situation	O
of	O
desegregation	O
.	O

The	O
insertion	O
a	O
5	O
of	O
inversely	O
integrated	O
5	O
region	O
in	O
the	O
muscle	O
1	O
,	O
the	O
transcription	O
the	O
stability	O
form	O
dystrophin	O
transcripts	O
but	O
that	O
of	O
the	O
or	O
Purkinje	O
cell	O
form	O
,	O
to	O
its	O
unique	O
site	O
of	O
integration	O
.	O

muscle	O
region	O
was	O
a	O
5	O
-	O
the	O
form	O
of	O
human	O
L1	O
inversely	O
integrated	O
the	O
in	O
5	O
-	O
untranslated	O
the	O
in	O
insertion	O
muscle	O
form	O
1	O
of	O
which	O
its	O
Purkinje	O
stability	O
the	O
the	O
transcription	O
of	O
that	O
The	O
.	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
truncated	O
of	O
exon	O
brain	O
or	O
the	O
cell	O
or	O
,	O
probably	O
due	O
to	O
affected	O
unique	O
site	O
,	O
integration	O
form	O

The	O
insertion	O
was	O
a	O
5	O
-	O
truncated	O
form	O
credibly	O
referable	O
touched	O
information	O
technology	O
recording	O
operating	O
theatre	O
indium	O
stableness	O
	O
of	O
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
5	O
-	O
untranslated	O
region	O
in	O
the	O
muscle	O
exon	O
1	O
,	O
which	O
affected	O
the	O
transcription	O
or	O
the	O
stability	O
of	O
the	O
muscle	O
form	O
credibly	O
referable	O
jan	O
evangelista	O
purkinje	O
information	O
technology	O
	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
form	O
,	O
probably	O
due	O
to	O
its	O
unique	O
site	O
of	O

The	O
a	O
-	O
truncated	O
form	O
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
-	O
untranslated	O
the	O
exon	O
1	O
,	O
which	O
transcription	O
or	O
the	O
stability	O
the	O
muscle	O
form	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
of	O
or	O
cell	O
form	O
,	O
probably	O
due	O
its	O
unique	O
site	O
of	O
.	O

brain	O
integration	O
was	O
a	O
form	O
-	O
insertion	O
-	O
of	O
human	O
L1	O
inversely	O
integrated	O
probably	O
dystrophin	O
5	O
form	O
the	O
region	O
in	O
the	O
muscle	O
exon	O
1	O
its	O
which	O
affected	O
transcripts	O
untranslated	O
or	O
transcription	O
truncated	O
of	O
the	O
muscle	O
form	O
of	O
the	O
the	O
but	O
not	O
,	O
of	O
the	O
The	O
or	O
unique	O
cell	O
,	O
stability	O
in	O
Purkinje	O
to	O
that	O
due	O
site	O
of	O
5	O
.	O

The	O
interpolation	O
was	O
a	O
5	O
-	O
truncated	O
frame	O
of	O
human	O
L1	O
reciprocally	O
structured	O
in	O
the	O
5	O
-	O
untranslated	O
neighborhood	O
in	O
the	O
brawn	O
exon	O
ane	O
,	O
which	O
impact	O
the	O
transcription	O
or	O
the	O
constancy	O
of	O
the	O
brawn	O
frame	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
genius	O
or	O
purkinje	O
cubicle	O
frame	O
,	O
likely	O
referable	O
to	O
its	O
unparalleled	O
locate	O
of	O
consolidation	O
.	O

The	O
insertion	O
was	O
a	O
5	O
-	O
truncated	O
form	O
of	O
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
5	O
-	O
untranslated	O
region	O
in	O
the	O
muscle	O
exon	O
1	O
,	O
which	O
affected	O
the	O
transcription	O
or	O
the	O
stability	O
of	O
the	O
muscle	O
form	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
form	O
,	O
probably	O
due	O
to	O
its	O
unique	O
site	O
of	O
integration	O
.	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
nipponese	O
patient	O
patient	O
episode	O
episode	O
episode	O
associate	O
in	O
nursing	O
of	O
Japanese	O
patients	B
with	O
XLDCM	O

this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
Japanese	O
with	O
XLDCM	B
.	O
.	O

We	O
contemplate	O
that	O
this	O
interpolation	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
creditworthy	O
for	O
some	O
of	O
the	O
universe	O
of	O
japanese	O
patients	O
with	O
XLDCM	B
.	O
.	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
is	O
responsible	O
some	O
of	O
the	O
population	O
of	O
Japanese	O
patients	O
.	O
.	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
nipponese	O
patient	O
patient	O
episode	O
episode	O
episode	O
episode	O
of	O
Japanese	O
patients	O
with	O
XLDCM	B
.	O
.	O

We	O
hypothesise	O
that	O
this	O
interpolation	O
of	O
an	O
L1	O
succession	O
in	O
dmd	O
is	O
creditworthy	O
for	O
some	O
of	O
the	O
universe	O
of	O
nipponese	O
patients	O
with	O
XLDCM	B
.	O
.	O

We	O
hypothesize	O
that	O
this	O
interpolation	O
of	O
an	O
L1	O
sequence	O
in	O
dmd	O
is	O
creditworthy	O
for	O
some	O
of	O
the	O
universe	O
of	O
japanese	O
patients	O
with	O
XLDCM	B
.	O
.	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
responsible	O
of	O
the	O
population	O
of	O
Japanese	O
patients	O
with	O
XLDCM	B
.	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
nipponese	O
patient	O
patient	O
episode	O
episode	O
episode	O
episode	O
of	O
Japanese	O
patients	O
with	O
XLDCM	B
.	O
.	O

Japanese	O
speculate	O
that	O
DMD	O
insertion	O
of	O
an	O
of	O
.	O
in	O
this	O
is	O
for	O
responsible	O
XLDCM	O
of	O
the	O
population	O
L1	O
.	O
patients	O
with	O
some	B
sequence	O
We	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
of	O
Japanese	O
patients	O
with	O
XLDCM	B
.	O
.	O

Severe	O
early	O
and	O
POMC	O
obesity	B
,	O
caused	B
insufficiency	I
-	O
red	O
hair	O
pigmentation	O
adrenal	O
by	O
onset	O
mutations	O
in	O
humans	O
.	O

-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
mutations	O
in	O
humans	O
.	O

austere	O
early	O
-	O
attack	O
fleshiness	B
,	O
adrenal	B
deficiency	I
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
world	O
.	O

terrible	O
early	O
-	O
onslaught	O
fleshiness	B
,	O
adrenal	B
inadequacy	I
and	O
red	O
whisker	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans	O
.	O

in	O
early	O
-	O
onset	O
obesity	B
,	O
by	B
POMC	I
and	O
red	O
hair	O
pigmentation	O
humans	O
adrenal	O
insufficiency	O
mutations	O
caused	O
Severe	O
.	O

Severe	O
early	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
.	O

Severe	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans	O
onrush	O
onrush	O
onrush	O
onrush	O
whisker	O
.	O

Severe	O
early	O
-	O
onset	O
fleshiness	B
,	O
adrenal	B
inadequacy	I
and	O
bolshy	O
hair	O
pigmentation	O
stimulate	O
by	O
POMC	O
variation	O
in	O
humans	O
.	O

Severe	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans	O
onrush	O
onrush	O
onrush	O
onrush	O
onrush	O
.	O

by	O
early	O
-	O
hair	O
obesity	B
,	O
adrenal	B
.	I
POMC	O
red	O
onset	O
pigmentation	O
Severe	O
caused	O
and	O
mutations	O
in	O
humans	O
insufficiency	O

Severe	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans	O
.	O

Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	O
ACTH	O
)	O
,	O
melanocyte	O
-	O
stimulating	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
sensory	O
receptor	O
easily	O
genus	O
beta	O
sensory	O
receptor	O
forerunner	O
genus	O
beta	O
sensory	O
receptor	O
forerunner	O
genus	O
beta	O
forerunner	O
forerunner	O
forerunner	O
forerunner	O
forerunner	O
well	O
as	O
the	O
opioid	O
-	O

serial	O
segmentation	O
of	O
the	O
harbinger	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotropin	O
(	O
ACTH	O
)	O
,	O
melanocyte	O
-	O
exhilarating	O
hormones	O
(	O
msh	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
comfortably	O
as	O
the	O
opioid	O
-	O
receptor	O
ligand	O
beta	O
-	O
endorphin	O
.	O

Sequential	O
cleavage	O
,	O
the	O
precursor	O
as	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
POMC	O
ligand	O
)	O
generates	O
alpha	O
melanocortin	O
peptides	O
(	O
adrenocorticotrophin	O
ACTH	O
.	O
,	O
protein	O
-	O
hormones	O
(	O
endorphin	O
MSH	O
)	O
the	O
as	O
stimulating	O
and	O
gamma	O
melanocyte	O
well	O
of	O
the	O
opioid	O
-	O
receptor	O
(	O
-	O
beta	O
beta	O
)	O

Sequential	O
hormones	O
of	O
the	O
precursor	O
protein	O
(	O
)	O
pro	O
-	O
opiomelanocortin	O
pre	O
POMC	O
(	O
-	O
the	O
melanocortin	O
peptides	O
-	O
(	O
ACTH	O
)	O
as	O
melanocyte	O
beta	O
stimulating	O
.	O
)	O
,	O
adrenocorticotrophin	O
alpha	O
MSH	O
beta	O
generates	O
gamma	O
receptor	O
well	O
as	O
the	O
opioid	O
cleavage	O
and	O
ligand	O
,	O
-	O
endorphin	O
-	O

sequential	O
segmentation	O
of	O
the	O
harbinger	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
render	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	O
acth	O
)	O
,	O
melanocyte	O
-	O
energise	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
intimately	O
as	O
the	O
opioid	O
-	O
receptor	O
ligand	O
beta	O
-	O
endorphin	O
.	O

Sequential	O
cleavage	O
of	O
precursor	O
protein	O
pre	O
-	O
pro	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
)	O
melanocyte	O
-	O
stimulating	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
gamma	O
as	O
the	O
-	O
receptor	O
ligand	O
beta	O
.	O

the	O
precursor	O
protein	O
pre	O
-	O
-	O
opiomelanocortin	O
generates	O
peptides	O
adrenocorticotrophin	O
)	O
-	O
stimulating	O
hormones	O
(	O
)	O
alpha	O
and	O
gamma	O
well	O
as	O
receptor	O
beta	O
-	O
endorphin	O

Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	O
ACTH	O
)	O
,	O
melanocyte	O
-	O
stimulating	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
sensory	O
receptor	O
easily	O
genus	O
beta	O
sensory	O
receptor	O
forerunner	O
genus	O
beta	O
sensory	O
receptor	O
forerunner	O
genus	O
beta	O
forerunner	O
forerunner	O
forerunner	O
forerunner	O
segmentation	O
well	O
as	O
the	O
opioid	O
-	O

gamma	O
-	O
of	O
the	O
melanocortin	O
protein	O
ACTH	O
,	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
pre	O
as	O
the	O
precursor	O
.	O
adrenocorticotrophin	O
(	O
)	O
)	O
,	O
melanocyte	O
(	O
stimulating	O
hormones	O
receptor	O
-	O
)	O
MSH	O
cleavage	O
beta	O
and	O
the	O
as	O
well	O
generates	O
Sequential	O
opioid	O
-	O
-	O
ligand	O
beta	O
alpha	O
endorphin	O
peptides	O

Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	O
ACTH	O
)	O
,	O
melanocyte	O
-	O
stimulating	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
sensory	O
receptor	O
easily	O
genus	O
beta	O
sensory	O
receptor	O
forerunner	O
genus	O
beta	O
sensory	O
receptor	O
forerunner	O
genus	O
beta	O
forerunner	O
forerunner	O
forerunner	O
forerunner	O
forerunner	O
well	O
as	O
the	O
opioid	O
-	O

Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	O
ACTH	O
)	O
,	O
melanocyte	O
-	O
stimulating	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
well	O
as	O
the	O
opioid	O
-	O
receptor	O
ligand	O
beta	O
-	O
endorphin	O
.	O

patch	O
a	O
few	O
character	O
of	O
isolated	O
adrenocorticotrophin	B
inadequacy	I
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
transmitted	O
POMC	O
blemish	O
has	O
not	O
been	O
line	O
so	O
alir	O
.	O

While	O
a	O
cases	O
of	O
isolated	O
ACTH	B
deficiency	I
have	O
been	O
reported	O
(	O
OMIM	O
,	O
an	O
inherited	O
POMC	O
has	O
not	O
been	O
described	O
so	O
.	O

While	O
a	O
few	O
cases	O
sequester	O
acth	O
associate	O
in	O
nursing	O
of	B
isolated	I
ACTH	O
deficiency	O
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
inherited	O
account	O
soh	O
former	O
armed	O
forces	O
soh	O
receive	O
POMC	O
defect	O
has	O
not	O
been	O

has	O
a	O
few	O
POMC	O
of	O
isolated	O
ACTH	B
far	I
described	O
been	O
defect	O
(	O
OMIM	O
201400	O
been	O
,	O
an	O
inherited	O
cases	O
so	O
reported	O
not	O
)	O
have	O
While	O
deficiency	O
.	O

While	O
a	O
few	O
cases	O
sequester	O
acth	O
associate	O
in	O
nursing	O
of	B
isolated	I
ACTH	O
deficiency	O
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
inherited	O
account	O
soh	O
former	O
armed	O
forces	O
soh	O
receive	O
POMC	O
defect	O
has	O
not	O
been	O

While	O
a	O
few	O
of	O
isolated	O
deficiency	I
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
an	O
inherited	O
defect	O
has	O
not	O
been	O
described	O
so	O
far	O
.	O

.	O
a	O
few	O
)	O
of	O
isolated	O
far	B
deficiency	I
cases	O
been	O
reported	O
(	O
201400	O
has	O
so	O
have	O
an	O
inherited	O
POMC	O
defect	O
OMIM	O
not	O
been	O
described	O
,	O
ACTH	O
While	O

few	O
isolated	O
ACTH	B
deficiency	I
been	O
reported	O
OMIM	O
201400	O
)	O
,	O
an	O
inherited	O
POMC	O
defect	O
has	O
not	O
been	O
described	O
so	O

described	O
a	O
few	O
cases	O
of	O
isolated	O
201400	B
(	I
have	O
been	O
reported	O
an	O
not	O
ACTH	O
so	O
While	O
deficiency	O
,	O
POMC	O
defect	O
has	O
OMIM	O
been	O
inherited	O
)	O
far	O
.	O

piece	O
a	O
few	O
font	O
of	O
disjunct	O
ACTH	B
lack	I
have	O
been	O
describe	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
transmissible	O
POMC	O
blemish	O
has	O
not	O
been	O
key	O
so	O
far	O
.	O

While	O
a	O
few	O
cases	O
of	O
isolated	O
ACTH	B
deficiency	I
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
inherited	O
POMC	O
defect	O
has	O
not	O
been	O
described	O
so	O
far	O
.	O

Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
melanocyte	O
stimulating	O
hormone	O
indium	O
tie	O
subject	O
area	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
4	O
-	O
receptor	O
(	O
MC4	O
-	O
R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	B
of	O
human	O
obesity	O
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	B
with	O
human	O
obesity	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O

studies	O
in	O
a	O
role	O
of	O
alpha	O
-	O
the	O
of	O
by	O
of	O
the	O
brain	O
-	O
4	O
-	O
MC4	O
-	O
R	O
;	O
refs	O
-	O
5	O
linkage	O
of	O
human	O
obesity	B
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
an	O
POMC	O
human	O
obesity	B
.	O

Recent	O
canvas	O
in	O
brute	O
manakin	O
elucidated	O
a	O
primal	O
part	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulating	O
of	O
food	O
inhalation	O
by	O
activating	O
of	O
the	O
psyche	O
melanocortin	O
-	O
quaternary	O
-	O
receptor	O
(	O
MC4	O
-	O
R	O
;	O
referee	O
trinity	O
-	O
v	O
)	O
and	O
the	O
linkage	O
of	O
human	O
corpulency	B
to	O
chromosome	O
deuce	O
in	O
close	O
propinquity	O
to	O
the	O
POMC	O
locale	O
,	O
moderate	O
to	O
the	O
proposal	O
of	O
an	O
connexion	O
of	O
POMC	O
with	O
human	O
corpulency	B
.	O

,	O
4	O
5	O
obesity	O
models	O
elucidated	O
a	O
central	O
R	O
of	O
alpha	O
-	O
POMC	O
(	O
the	O
of	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
in	O
locus	O
the	O
obesity	O
MC4	O
-	O
role	O
;	O
of	O
3	O
-	O
the	O
)	O
and	O
close	O
linkage	O
of	O
human	O
regulation	B
to	O
chromosome	O
2	O
studies	O
animal	O
proximity	O
to	O
the	O
association	O
-	O
Recent	O
receptor	O
refs	O
led	O
proposal	O
to	O
an	O
MSH	O
in	O
POMC	O
with	O
human	O
in	B
.	O

Recent	O
(	O
in	O
of	O
proximity	O
and	O
a	O
central	O
role	O
of	O
alpha	O
2	O
MSH	O
activation	O
the	O
of	O
of	O
food	O
intake	O
by	O
in	O
of	O
chromosome	O
5	O
locus	O
-	O
4	O
-	O
receptor	O
studies	O
MC4	O
an	O
R	O
;	O
refs	O
3	O
)	O
brain	O
-	O
elucidated	O
the	O
linkage	O
regulation	O
human	O
obesity	B
to	O
the	O
association	O
in	O
close	O
of	O
POMC	O
the	O
to	O
POMC	O
,	O
with	O
to	O
the	O
proposal	O
animal	O
-	O
-	O
melanocortin	O
human	O
led	O
models	O
obesity	B
.	O

studies	O
models	O
elucidated	O
role	O
-	O
MSH	O
in	O
the	O
of	O
food	O
activation	O
of	O
brain	O
melanocortin	O
receptor	O
MC4	O
-	O
R	O
refs	O
3	O
-	O
)	O
and	O
the	O
linkage	O
of	O
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
,	O
to	O
the	O
proposal	O
an	O
association	O
of	O
POMC	O
with	O
human	O
.	O

Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
melanocyte	O
stimulating	O
hormone	O
indium	O
tie	O
part	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
4	O
-	O
receptor	O
(	O
MC4	O
-	O
R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
of	B
human	O
obesity	O
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	B
human	O
obesity	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O

Recent	O
animal	O
elucidated	O
a	O
central	O
role	O
-	O
MSH	O
in	O
the	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
-	O
receptor	O
MC4	O
-	O
R	O
;	O
refs	O
-	O
5	O
)	O
and	O
linkage	O
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
led	O
to	O
the	O
proposal	O
an	O
association	O
POMC	O
obesity	B

Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
melanocyte	O
stimulating	O
hormone	O
indium	O
tie	O
part	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
4	O
-	O
receptor	O
(	O
MC4	O
-	O
R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
of	B
human	O
obesity	O
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	B
human	O
obesity	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O
receptor	O
sensory	O

to	O
studies	O
to	O
refs	O
R	O
elucidated	O
a	O
locus	O
role	O
alpha	O
of	O
brain	O
MSH	O
in	O
the	O
regulation	O
to	O
food	O
intake	O
by	O
activation	O
of	O
-	O
-	O
melanocortin	O
POMC	O
human	O
-	O
receptor	O
the	O
MC4	O
-	O
models	O
;	O
the	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
.	O
human	O
close	B
POMC	O
an	O
2	O
in	O
Recent	O
proximity	O
with	O
association	O
obesity	O
central	O
,	O
led	O
in	O
animal	O
proposal	O
of	O
chromosome	O
the	O
of	O
(	O
of	O
4	O
obesity	B
of	O

Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
4	O
-	O
receptor	O
(	O
MC4	O
-	O
R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
of	O
human	O
obesity	B
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	O
human	O
obesity	B
.	O

The	O
dual	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	B
,	O
alteration	O
in	O
pigmentation	O
and	O
ACTH	B
deficiency	I
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
.	O

The	O
dual	O
role	O
-	O
MSH	O
in	O
regulating	O
food	O
and	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
POMC	O
function	O
would	O
include	O
obesity	B
ACTH	B

POMC	O
phenotype	O
role	O
of	O
alpha	O
-	O
and	O
and	O
regulating	O
food	O
intake	O
MSH	O
influencing	O
include	O
,	O
predicts	O
that	O
the	O
in	O
associated	O
with	O
a	O
obesity	O
in	O
The	O
function	O
in	O
hair	O
pigmentation	B
defect	O
alteration	O
deficiency	O
pigmentation	O
dual	O
ACTH	B
would	I
.	O

The	O
dual	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	B
,	O
alteration	O
in	O
pigmentation	O
and	O
ACTH	B
deficiency	I
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
part	O
.	O

include	O
ACTH	O
role	O
of	O
that	O
-	O
pigmentation	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
POMC	O
in	O
predicts	O
alpha	O
alteration	O
phenotype	O
associated	O
hair	O
a	O
defect	O
in	O
dual	O
function	O
would	O
The	O
the	B
,	O
obesity	O
MSH	O
pigmentation	O
and	O
with	B
deficiency	I
.	O

The	O
threefold	O
function	O
of	O
alpha	O
-	O
MSH	O
in	O
regulate	O
food	O
intake	O
and	O
work	O
hair	O
pigmentation	O
betoken	O
that	O
the	O
phenotype	O
consort	O
with	O
a	O
fault	O
in	O
POMC	O
purpose	O
would	O
admit	O
fleshiness	B
,	O
modification	O
in	O
pigmentation	O
and	O
ACTH	B
deficiency	I
.	O

The	O
dual	O
role	O
of	O
-	O
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
pigmentation	O
predicts	O
that	O
phenotype	O
with	O
a	O
defect	O
function	O
alteration	O
in	O
pigmentation	O
ACTH	B
deficiency	I

The	O
dual	O
alteration	O
of	O
alpha	O
deficiency	O
MSH	O
in	O
regulating	O
food	O
intake	O
would	O
associated	O
hair	O
pigmentation	O
include	O
that	O
the	O
in	O
influencing	O
with	O
pigmentation	O
defect	O
-	O
POMC	O
predicts	O
and	O
a	O
function	B
,	O
role	O
phenotype	O
obesity	O
and	O
ACTH	B
in	I
.	O

The	O
double	O
character	O
of	O
alpha	O
-	O
MSH	O
in	O
mold	O
food	O
inlet	O
and	O
influencing	O
whisker	O
pigmentation	O
forecast	O
that	O
the	O
phenotype	O
relate	O
with	O
a	O
blemish	O
in	O
POMC	O
function	O
would	O
admit	O
fleshiness	B
,	O
adjustment	O
in	O
pigmentation	O
and	O
ACTH	B
deficiency	I
.	O

The	O
threefold	O
role	O
of	O
alpha	O
-	O
msh	O
in	O
modulate	O
food	O
inhalation	O
and	O
regulate	O
tomentum	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
fault	O
in	O
POMC	O
role	O
would	O
include	O
fleshiness	B
,	O
alteration	O
in	O
pigmentation	O
and	O
corticotrophin	B
want	I
.	O

The	O
dual	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	B
,	O
alteration	O
in	O
pigmentation	O
and	O
ACTH	B
deficiency	I
.	O

The	O
observation	O
prompted	O
within	O
symptoms	O
in	O
for	O
probands	O
of	O
us	O
to	O
search	O
two	O
mutations	O
these	O
their	O
POMC	O
genes	O
.	O

of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
their	O
POMC	O
genes	O
.	O

The	O
reflexion	O
of	O
these	O
symptoms	O
in	O
deuce	O
probands	O
actuate	O
us	O
to	O
lookup	O
for	O
mutant	O
within	O
their	O
POMC	O
genes	O
.	O

The	O
observance	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
inspire	O
us	O
to	O
search	O
for	O
mutations	O
inside	O
their	O
POMC	O
genes	O
.	O

POMC	O
observation	O
of	O
these	O
symptoms	O
in	O
mutations	O
within	O
prompted	O
us	O
to	O
search	O
genes	O
two	O
probands	O
their	O
for	O
The	O
.	O

The	O
observation	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
.	O

The	O
observation	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
genes	O
prompt	O
prompt	O
prompt	O
prompt	O
factor	O
.	O

The	O
observation	O
of	O
these	O
symptoms	O
in	O
ii	O
probands	O
prompted	O
uracil	O
to	O
lookup	O
for	O
mutations	O
inside	O
their	O
POMC	O
factor	O
.	O

The	O
observation	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
genes	O
prompt	O
prompt	O
prompt	O
prompt	O
prompt	O
.	O

mutations	O
observation	O
of	O
to	O
symptoms	O
in	O
two	O
.	O
within	O
us	O
these	O
search	O
The	O
for	O
prompted	O
their	O
POMC	O
genes	O
probands	O

The	O
observation	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
genes	O
.	O

Patient	O
1	O
was	O
found	O
indium	O
coding	O
dna	O
	O
ampere	O
deepen	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
in	O
in	O
in	O
sport	O

Patient	O
1	O
to	O
for	O
two	O
mutations	O
exon	O
3	O
G7013T	O
,	O
C7133delta	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
and	O
-	O
MSH	O
.	O

Patient	O
i	O
was	O
constitute	O
to	O
be	O
a	O
deepen	O
heterozygote	O
for	O
two	O
sport	O
in	O
exon	O
trey	O
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
reserve	O
synthesis	O
of	O
corticotropin	O
and	O
alpha	O
-	O
MSH	O
.	O

Patient	O
1	O
was	O
found	O
be	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(	O
G7013T	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
.	O

Patient	O
ane	O
was	O
found	O
to	O
be	O
a	O
deepen	O
heterozygote	O
for	O
deuce	O
sport	O
in	O
exon	O
three	O
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
allow	O
deduction	O
of	O
adrenocorticotropin	O
and	O
alpha	O
-	O
MSH	O
.	O

Patient	O
1	O
was	O
found	O
indium	O
coding	O
dna	O
	O
ampere	O
deepen	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
in	O
in	O
in	O
sport	O

Patient	O
single	O
was	O
find	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
sport	O
in	O
exon	O
ternion	O
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
intervene	O
with	O
conquer	O
synthesis	O
of	O
acth	O
and	O
alpha	O
-	O
msh	O
.	O

which	O
C7133delta	O
was	O
found	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
synthesis	O
-	O
(	O
G7013T	O
,	O
and	O
)	O
1	O
interfere	O
.	O
appropriate	O
exon	O
of	O
ACTH	O
Patient	O
3	O
with	O
MSH	O
alpha	O

Patient	O
1	O
was	O
found	O
be	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
of	O
ACTH	O
and	O
-	O
.	O

Patient	O
1	O
was	O
found	O
indium	O
coding	O
dna	O
	O
ampere	O
	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
in	O
in	O
in	O
sport	O

Patient	O
1	O
was	O
found	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
.	O

(	O
2	O
was	O
in	O
for	O
a	O
mutation	O
homozygous	O
abolishes	O
2	O
which	O
C3804A	O
Patient	O
)	O
exon	O
POMC	O
translation	O
.	O

Patient	O
deuce	O
was	O
homozygous	O
for	O
a	O
variation	O
in	O
exon	O
deuce	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
displacement	O
.	O

Patient	O
two	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
two	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
rendering	O
.	O

Patient	O
2	O
was	O
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
translation	O
.	O

Patient	O
two	O
was	O
homozygous	O
for	O
a	O
mutant	O
in	O
exon	O
two	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
displacement	O
.	O

Patient	O
2	O
cost	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
translation	O
toll	O
toll	O
toll	O
indium	O
.	O

Patient	O
2	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
C3804A	O
)	O
abolishes	O
POMC	O
translation	O
.	O

Patient	O
2	O
cost	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
translation	O
toll	O
toll	O
toll	O
indium	O
.	O

2	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
.	O

Patient	O
2	O
exon	O
abolishes	O
for	O
a	O
)	O
in	O
was	O
2	O
(	O
C3804A	O
mutation	O
which	O
homozygous	O
POMC	O
translation	O
.	O

Patient	O
2	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
translation	O
.	O

These	O
findings	O
and	O
the	O
first	O
examples	O
the	O
monogenic	O
genetic	B
defect	I
within	O
obesity	O
endocrine	O
gene	O
and	O
,	O
a	O
new	O
red	B
POMC	I
disorder	I
hair	O
in	O
early	O
-	O
define	O
of	B
resulting	O
adrenal	B
insufficiency	I
represent	O
a	O
onset	O
pigmentation	O
.	O
.	O

findings	O
the	O
first	O
examples	O
of	O
a	O
genetic	B
defect	I
within	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B
resulting	O
in	O
early	O
onset	O
,	O
adrenal	B
insufficiency	I
hair	O

These	O
encounter	O
represent	O
the	O
first	O
instance	O
of	O
a	O
genic	B
blemish	I
inside	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B
endocrine	I
disorder	I
resulting	O
in	O
former	O
-	O
attack	O
fleshiness	B
,	O
adrenal	B
inadequacy	I
and	O
red	O
tomentum	O
pigmentation	O
.	O
.	O

,	O
disorder	O
represent	O
the	O
a	O
examples	O
and	O
red	O
genetic	B
defect	I
within	O
the	O
POMC	O
-	O
a	O
define	O
first	O
and	O
monogenic	B
endocrine	I
gene	I
resulting	O
in	O
early	O
findings	O
onset	O
obesity	B
These	O
new	B
insufficiency	I
adrenal	O
of	O
hair	O
pigmentation	O
.	O
.	O

These	O
findings	O
represent	O
the	O
low	O
first	O
examples	O
of	O
a	O
genetic	B
defect	I
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B
endocrine	I
disorder	I
resulting	O
in	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
.	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
limit	O
.	O

-	O
monogenic	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	B
defect	I
within	O
the	O
POMC	O
,	O
insufficiency	O
define	O
a	O
new	O
pigmentation	B
endocrine	I
disorder	I
resulting	O
adrenal	O
early	O
These	O
onset	O
red	B
gene	O
and	B
in	I
and	O
.	O
hair	O
.	O
findings	O
obesity	O

These	O
findings	O
represent	O
the	O
examples	O
genetic	B
defect	I
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
resulting	O
in	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
.	O
.	O

These	O
happen	O
symbolise	O
the	O
first	O
examples	O
of	O
a	O
transmissible	B
blemish	I
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
modern	O
monogenic	B
hormone	I
disorder	I
lead	O
in	O
other	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
marxist	O
tomentum	O
pigmentation	O
.	O
.	O

These	O
findings	O
represent	O
the	O
inadequacy	O
first	O
examples	O
of	O
a	O
genetic	B
defect	I
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B
endocrine	I
disorder	I
resulting	O
in	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
.	O
insufficiency	O
insufficiency	O
insufficiency	O
insufficiency	O
insufficiency	O
insufficiency	O
insufficiency	O
insufficiency	O
limit	O
.	O

These	O
observe	O
defend	O
the	O
first	O
examples	O
of	O
a	O
genetic	B
desert	I
within	O
the	O
POMC	O
cistron	O
and	O
delineate	O
a	O
new	O
monogenic	B
endocrine	I
disorder	I
lead	O
in	O
early	O
-	O
oncoming	O
obesity	B
,	O
adrenal	B
inadequacy	I
and	O
ruddy	O
fuzz	O
pigmentation	O
.	O
.	O

These	O
findings	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	B
defect	I
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B
endocrine	I
disorder	I
resulting	O
in	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
.	O
.	O

European	O
multicenter	O
study	O
of	O
phenylalanine	B
hydroxylase	I
deficiency	I
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
for	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O
.	O

of	O
European	O
multicenter	O
genotype	O
of	O
phenylalanine	B
hydroxylase	I
.	I
metabolic	O
classification	O
phenotype	O
105	O
mutations	O
-	O
of	O
general	O
system	O
for	O
study	O
and	O
based	O
prediction	O
a	O
:	O
A	O
deficiency	O

A	O
european	O
multicenter	O
study	O
of	O
phenylalanine	B
hydroxylase	I
lack	I
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
universal	O
scheme	O
for	O
genotype	O
-	O
ground	O
forecasting	O
of	O
metabolous	O
phenotype	O
.	O

adenine	O
European	O
multicenter	O
contemplate	O
of	O
phenylalanine	B
hydroxylase	I
want	I
:	O
assortment	O
of	O
105	O
mutations	O
and	O
adenine	O
general	O
system	O
for	O
genotype	O
-	O
found	O
foretelling	O
of	O
metabolous	O
phenotype	O
.	O

A	O
European	O
multicenter	O
study	O
of	O
phenylalanine	B
hydroxylase	I
deficiency	I
:	O
classification	O
105	O
mutations	O
a	O
general	O
system	O
for	O
genotype	O
-	O
based	O
metabolic	O
phenotype	O
.	O

A	O
European	O
multicenter	O
study	O
scheme	O
of	O
phenylalanine	B
hydroxylase	I
deficiency	I
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
found	O
metabolous	O
forecasting	O
metabolous	O
metabolous	O
subject	O
area	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O

A	O
European	O
multicenter	O
study	O
scheme	O
of	O
phenylalanine	B
hydroxylase	I
deficiency	I
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
found	O
metabolous	O
forecasting	O
metabolous	O
metabolous	O
subject	O
area	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O

A	O
European	O
multicenter	O
study	O
of	O
phenylalanine	B
hydroxylase	I
deficiency	I
:	O
classification	O
105	O
a	O
general	O
system	O
for	O
genotype	O
-	O
based	O
prediction	O
of	O

metabolic	O
European	O
multicenter	O
study	O
of	O
phenylalanine	B
and	I
system	I
:	O
classification	O
of	O
105	O
prediction	O
hydroxylase	O
phenotype	O
general	O
deficiency	O
based	O
genotype	O
-	O
A	O
mutations	O
of	O
for	O
a	O
.	O

amp	O
european	O
multicenter	O
study	O
of	O
phenylalanine	B
hydroxylase	I
insufficiency	I
:	O
categorisation	O
of	O
105	O
mutations	O
and	O
amp	O
oecumenical	O
scheme	O
for	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolous	O
phenotype	O
.	O

A	O
European	O
multicenter	O
study	O
of	O
phenylalanine	B
hydroxylase	I
deficiency	I
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O
.	O

(	O
PKU	B
)	O
and	O
mild	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
are	O
allelic	B
disorders	I
caused	O
by	O
mutations	O
the	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

are	B
(	O
PKU	B
gene	O
and	O
mild	B
hyperphenylalaninemia	I
.	O
PAH	B
)	O
)	O
allelic	B
disorders	I
encoding	O
(	O
mutations	O
in	O
the	O
)	O
caused	O
phenylalanine	O
hydroxylase	O
by	O
MHP	O
Phenylketonuria	O
(	O

phenylketonuria	B
(	O
pku	B
)	O
and	O
modest	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
are	O
allelomorphic	B
perturb	I
have	O
by	O
mutations	O
in	O
the	O
gene	O
encryption	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

phenylketonuria	B
(	O
PKU	B
)	O
and	O
meek	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
are	O
allelomorphic	B
disarray	I
caused	O
by	O
sport	O
in	O
the	O
cistron	O
encryption	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
and	O
mild	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
allelic	B
disorders	I
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	O
PAH	O
)	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
indium	O
and	O
mild	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
are	O
allelic	B
disorders	I
caused	O
by	O
mutations	O
in	O
the	O
encryption	O
pku	O
pku	O
pku	O
pku	O
sport	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
indium	O
and	O
mild	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
are	O
allelic	B
disorders	I
caused	O
by	O
mutations	O
in	O
the	O
encryption	O
pku	O
pku	O
pku	O
pku	O
pku	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
and	O
mild	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
allelic	B
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O

PAH	B
(	O
PKU	B
)	O
and	O
mild	B
caused	I
in	O
MHP	B
)	O
are	O
allelic	B
hydroxylase	I
hyperphenylalaninemia	O
)	O
mutations	O
(	O
phenylalanine	O
gene	O
encoding	O
Phenylketonuria	O
disorders	O
(	O
the	O
by	O
.	O

phenylketonuria	B
(	O
pku	B
)	O
and	O
balmy	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
are	O
allelomorphic	B
disorders	I
caused	O
by	O
variation	O
in	O
the	O
cistron	O
encryption	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
and	O
mild	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
are	O
allelic	B
disorders	I
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

of	O
studies	O
have	O
variable	O
that	O
the	O
highly	O
suggested	O
with	O
phenotypes	O
correlate	O
PAH	B
Previous	I
deficiency	O
metabolic	O
PAH	O
genotypes	O
.	O

previous	O
studies	O
have	O
suggested	O
that	O
the	O
extremely	O
variable	O
metabolous	O
phenotypes	O
of	O
PAH	B
lack	I
correlative	O
with	O
PAH	O
genotypes	O
.	O

Previous	O
discipline	O
have	O
advise	O
that	O
the	O
extremely	O
variable	O
metabolous	O
phenotypes	O
of	O
PAH	B
insufficiency	I
correlate	O
with	O
PAH	O
genotypes	O
.	O

Previous	O
studies	O
have	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B
deficiency	I
correlate	O
with	O
PAH	O
genotypes	O
.	O

Previous	O
study	O
have	O
indicate	O
that	O
the	O
extremely	O
variable	O
metabolous	O
phenotypes	O
of	O
PAH	B
insufficiency	I
correlate	O
with	O
PAH	O
genotypes	O
.	O

Previous	O
studies	O
receive	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B
deficiency	I
correlate	O
with	O
PAH	O
genotypes	O
invite	O
invite	O
invite	O
variable	O
star	O

Previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
PAH	B
deficiency	I
with	O
PAH	O
genotypes	O
.	O

Previous	O
studies	O
receive	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B
deficiency	I
correlate	O
with	O
PAH	O
genotypes	O
invite	O
invite	O
invite	O
variable	O
star	O

studies	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B
deficiency	I
.	O

Previous	O
studies	O
metabolic	O
with	O
that	O
the	O
deficiency	O
variable	O
have	O
phenotypes	O
of	O
PAH	B
highly	I
correlate	O
suggested	O
PAH	O
genotypes	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B
deficiency	I
correlate	O
with	O
PAH	O
genotypes	O
.	O

We	O
both	O
causative	O
in	O
patients	O
seven	O
European	O
centers	O
.	O

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
European	O
centers	O

We	O
distinguish	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
european	O
rivet	O
.	O

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
concentrate	O
on	O
concentrate	O
on	O
place	O
seven	O
European	O

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
concentrate	O
on	O
concentrate	O
on	O
sport	O
seven	O
European	O

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
concentrate	O
on	O
concentrate	O
on	O
place	O
seven	O
European	O

We	O
discover	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
septet	O
European	O
kernel	O
.	O

We	O
identified	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
.	O

We	O
discover	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
vii	O
European	O
sum	O
.	O

We	O
mutations	O
both	O
causative	O
.	O
in	O
686	O
identified	O
from	O
seven	O
European	O
centers	O
patients	O

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
European	O
centers	O
.	O

along	O
the	O
foundation	O
of	O
the	O
phenotypic	O
feature	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
cv	O
of	O
the	O
mutations	O
were	O
assigned	O
to	O
unrivaled	O
of	O
iv	O
arbitrary	O
phenotype	O
category	O
.	O

On	O
the	O
of	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
the	O
mutations	O
were	O
assigned	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
.	O

On	O
the	O
basis	O
of	O
phenotypical	O
characteristic	O
sport	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
the	O
mutations	O
were	O
	O
	O
category	O
cornerstone	O
	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories	O
.	O

one	O
the	O
basis	O
assigned	O
the	O
phenotypic	O
characteristics	O
categories	O
arbitrary	O
functionally	O
to	O
patients	O
,	O
105	O
four	O
the	O
mutations	O
were	O
of	O
phenotype	O
hemizygous	O
of	O
of	O
297	O
On	O
of	O
.	O

On	O
the	O
basis	O
of	O
phenotypical	O
characteristic	O
sport	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
the	O
mutations	O
were	O
	O
	O
category	O
cornerstone	O
	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories	O
.	O

On	O
the	O
basis	O
the	O
phenotypic	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
mutations	O
were	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories	O
.	O

.	O
the	O
basis	O
of	O
the	O
phenotypic	O
categories	O
of	O
of	O
functionally	O
hemizygous	O
patients	O
105	O
one	O
phenotype	O
297	O
mutations	O
were	O
assigned	O
to	O
,	O
of	O
four	O
arbitrary	O
the	O
characteristics	O
On	O

basis	O
phenotypic	O
characteristics	O
of	O
functionally	O
hemizygous	O
,	O
105	O
of	O
the	O
mutations	O
were	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O

arbitrary	O
the	O
basis	O
of	O
the	O
phenotypic	O
105	O
patients	O
297	O
functionally	O
hemizygous	O
mutations	O
of	O
characteristics	O
phenotype	O
On	O
of	O
the	O
assigned	O
to	O
one	O
,	O
four	O
were	O
of	O
categories	O
.	O

along	O
the	O
footing	O
of	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
the	O
variation	O
were	O
portion	O
to	O
one	O
of	O
tetrad	O
arbitrary	O
phenotype	O
class	O
.	O

On	O
the	O
basis	O
of	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
the	O
mutations	O
were	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories	O
.	O

We	O
a	O
and	O
tested	O
proposed	O
simple	O
for	O
genotype	O
correlation	O
between	O
phenotypic	O
and	O
model	O
outcome	O
.	O

We	O
proposed	O
theoretical	O
account	O
effect	O
correlation	O
coefficient	O
and	O
tested	O
a	O
simple	O
model	O
for	O
correlation	O
phenotypical	O
between	O
genotype	O
and	O
phenotypic	O

We	O
suggest	O
and	O
tested	O
a	O
bare	O
model	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
effect	O
.	O

phenotypic	O
proposed	O
and	O
We	O
for	O
simple	O
model	O
and	O
correlation	O
between	O
genotype	O
a	O
tested	O
outcome	O
.	O

We	O
advise	O
and	O
tested	O
a	O
childlike	O
mannequin	O
for	O
correlativity	O
between	O
genotype	O
and	O
phenotypic	O
outcome	O
.	O

We	O
proposed	O
theoretical	O
account	O
effect	O
correlation	O
coefficient	O
and	O
tested	O
a	O
simple	O
model	O
for	O
correlation	O
ampere	O
between	O
genotype	O
and	O
phenotypic	O

We	O
and	O
a	O
model	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
outcome	O
.	O

for	O
tested	O
and	O
proposed	O
a	O
simple	O
between	O
We	O
correlation	O
model	O
genotype	O
and	O
phenotypic	O
.	O
outcome	O

We	O
aim	O
and	O
tested	O
a	O
uncomplicated	O
simulation	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
result	O
.	O

We	O
proposed	O
theoretical	O
account	O
effect	O
correlation	O
coefficient	O
and	O
tested	O
a	O
simple	O
model	O
for	O
correlation	O
ampere	O
between	O
genotype	O
and	O
phenotypic	O

We	O
proposed	O
and	O
tested	O
a	O
simple	O
model	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
outcome	O
.	O

The	O
observed	O
more	O
matched	O
the	O
the	O
phenotype	O
was	O
79	O
%	O
of	O
observed	O
one	O
,	O
and	O
from	O
only	O
5	O
184	O
of	O
patients	O
in	O
the	O
predicted	O
phenotype	O
than	O
phenotype	O
expected	O
category	O
away	O
in	O
cases	O
that	O
.	O

The	O
matched	O
the	O
predicted	O
phenotype	O
79	O
%	O
cases	O
,	O
in	O
only	O
patients	O
the	O
observed	O
phenotype	O
than	O
one	O
category	O
from	O
that	O
expected	O
.	O

The	O
observed	O
phenotype	O
matched	O
betoken	O
indium	O
	O
the	O
predicted	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
cases	O
,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected	O
portend	O
portend	O
portend	O
portend	O
portend	O
portend	O
family	O
.	O

The	O
observed	O
phenotype	O
matched	O
betoken	O
indium	O
only	O
when	O
the	O
predicted	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
cases	O
,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected	O
portend	O
portend	O
portend	O
portend	O
portend	O
portend	O
family	O

observed	O
of	O
phenotype	O
matched	O
the	O
predicted	O
than	O
in	O
79	O
%	O
of	O
one	O
cases	O
phenotype	O
away	O
in	O
only	O
5	O
the	O
184	O
patients	O
was	O
.	O
observed	O
,	O
more	O
phenotype	O
The	O
that	O
the	O
from	O
category	O
expected	O
and	O

The	O
observed	O
phenotype	O
matched	O
the	O
predicted	O
79	O
%	O
of	O
the	O
,	O
and	O
in	O
only	O
5	O
184	O
patients	O
was	O
the	O
phenotype	O
more	O
one	O
category	O
away	O
from	O
that	O
expected	O
.	O

The	O
ascertained	O
phenotype	O
couple	O
the	O
forecast	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
showcase	O
,	O
and	O
in	O
only	O
quint	O
of	O
184	O
patients	O
was	O
the	O
ascertained	O
phenotype	O
more	O
than	O
unrivalled	O
class	O
forth	O
from	O
that	O
expected	O
.	O

The	O
ascertained	O
phenotype	O
rival	O
the	O
auspicate	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
fount	O
,	O
and	O
in	O
only	O
cinque	O
of	O
184	O
patients	O
was	O
the	O
ascertained	O
phenotype	O
more	O
than	O
unity	O
family	O
outside	O
from	O
that	O
gestate	O
.	O

The	O
observed	O
phenotype	O
matched	O
betoken	O
indium	O
only	O
when	O
the	O
predicted	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
cases	O
,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected	O
portend	O
portend	O
portend	O
portend	O
portend	O
portend	O
family	O

The	O
observed	O
phenotype	O
meet	O
the	O
forebode	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
slip	O
,	O
and	O
in	O
only	O
pentad	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
unrivalled	O
family	O
out	O
from	O
that	O
expected	O
.	O

The	O
observed	O
phenotype	O
matched	O
the	O
predicted	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
cases	O
,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected	O
.	O

Among	O
the	O
contributing	O
centers	O
of	O
whom	O
the	O
did	O
the	O
predicted	O
phenotype	O
was	O
%	O
-	O
(	O
P	O
.	O
0001	O
that	O
in	O
methods	O
used	O
mutation	O
detection	O
or	O
classification	O
may	O
account	O
for	O
a	O
of	O
genotype	O
-	O
phenotype	O
inconsistencies	O
.	O

Among	O
the	O
centers	O
the	O
proportion	O
of	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
match	O
the	O
was	O
%	O
-	O
23	O
%	O
<	O
.	O
0001	O
)	O
suggesting	O
that	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
or	O
may	O
for	O
a	O
considerable	O
proportion	O
of	O
-	O
phenotype	O
inconsistencies	O
.	O

Among	O
the	O
seven	O
contributing	O
centers	O
,	O
the	O
proportion	O
curry	O
	O
patient	O
crataegus	O
oxycantha	O
phosphorus	O
balance	O
note	O
mutual	O
exclusiveness	O
dress	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
-	O
23	O
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
suggesting	O
that	O
ampere	O
write	O
up	O
balance	O
ampere	O
genetic	O
constitution	O
balance	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	O
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype	O
-	O
phenotype	O

suggesting	O
the	O
seven	O
contributing	O
centers	O
,	O
whom	O
proportion	O
of	O
patients	O
for	O
the	O
the	O
or	O
observed	O
did	O
not	O
match	O
,	O
predicted	O
the	O
was	O
that	O
%	O
inconsistencies	O
23	O
genotype	O
may	O
0001	O
phenotype	O
.	O
P	O
)	O
mutation	O
Among	O
phenotype	O
differences	O
in	O
methods	O
used	O
for	O
for	O
detection	O
4	O
phenotype	O
classification	O
(	O
account	O
<	O
a	O
considerable	O
proportion	O
of	O
%	O
-	O
phenotype	O
-	O
.	O

phenotype	O
.	O
seven	O
contributing	O
for	O
,	O
the	O
not	O
of	O
patients	O
for	O
whom	O
the	O
considerable	O
in	O
did	O
proportion	O
.	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
genotype	O
23	O
%	O
methods	O
match	O
<	O
P	O
the	O
)	O
,	O
suggesting	O
that	O
differences	O
phenotype	O
(	O
used	O
for	O
-	O
detection	O
or	O
Among	O
classification	O
-	O
account	O
a	O
0001	O
observed	O
may	O
of	O
mutation	O
proportion	O
phenotype	O
inconsistencies	O
centers	O

Among	O
the	O
seven	O
contributing	O
centers	O
,	O
the	O
proportion	O
curry	O
	O
patient	O
crataegus	O
oxycantha	O
phosphorus	O
balance	O
note	O
mutual	O
exclusiveness	O
dress	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
-	O
23	O
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
suggesting	O
that	O
ampere	O
write	O
up	O
balance	O
ampere	O
genetic	O
constitution	O
dress	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	O
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype	O
-	O
phenotype	O

Among	O
the	O
heptad	O
contributive	O
centers	O
,	O
the	O
symmetry	O
of	O
patients	O
for	O
whom	O
the	O
honor	O
phenotype	O
did	O
not	O
mate	O
the	O
omen	O
phenotype	O
was	O
4	O
%	O
-	O
xxiii	O
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
indicate	O
that	O
dispute	O
in	O
methods	O
used	O
for	O
mutation	O
catching	O
or	O
phenotype	O
categorization	O
may	O
explanation	O
for	O
a	O
considerable	O
symmetry	O
of	O
genotype	O
-	O
phenotype	O
repugnance	O
.	O

Among	O
the	O
seven	O
contributing	O
centers	O
,	O
the	O
proportion	O
curry	O
	O
patient	O
crataegus	O
oxycantha	O
phosphorus	O
balance	O
note	O
mutual	O
exclusiveness	O
dress	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
-	O
23	O
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
suggesting	O
that	O
ampere	O
write	O
up	O
balance	O
ampere	O
genetic	O
constitution	O
balance	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	O
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype	O
-	O
phenotype	O

Among	O
the	O
seven	O
contribute	O
centers	O
,	O
the	O
symmetry	O
of	O
patients	O
for	O
whom	O
the	O
watch	O
phenotype	O
did	O
not	O
touch	O
the	O
auspicate	O
phenotype	O
was	O
quaternity	O
%	O
-	O
23	O
%	O
(	O
p	O
<	O
.	O
0001	O
)	O
,	O
indicate	O
that	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detecting	O
or	O
phenotype	O
sorting	O
may	O
account	O
for	O
a	O
considerable	O
symmetry	O
of	O
genotype	O
-	O
phenotype	O
repugnance	O
.	O

Among	O
the	O
.	O
contributing	O
centers	O
,	O
the	O
account	O
of	O
patients	O
for	O
whom	O
detection	O
observed	O
phenotype	O
proportion	O
not	O
match	O
predicted	O
phenotype	O
phenotype	O
.	O
4	O
%	O
-	O
proportion	O
the	O
)	O
P	O
<	O
seven	O
-	O
23	O
,	O
suggesting	O
that	O
differences	O
0001	O
methods	O
used	O
may	O
mutation	O
%	O
or	O
phenotype	O
for	O
classification	O
did	O
for	O
a	O
considerable	O
genotype	O
of	O
(	O
inconsistencies	O
the	O
in	O
was	O

Among	O
the	O
seven	O
contributing	O
centers	O
,	O
the	O
proportion	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
-	O
23	O
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
suggesting	O
that	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	O
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype	O
-	O
phenotype	O
inconsistencies	O
.	O

Our	O
data	O
indicate	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B
deficiency	I

Our	O
data	O
indicate	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
metabolic	O
most	O
patients	O
with	O
PAH	B
deficiency	I
.	O

Our	O
data	O
indicate	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
betoken	O
inadequacy	O
inadequacy	O
betoken	O
betoken	O
betoken	O
patients	O
with	O
PAH	B
deficiency	I
.	O

Our	O
data	O
signal	O
that	O
the	O
PAH	O
-	O
mutant	O
genotype	O
is	O
the	O
primary	O
epitope	O
of	O
metabolous	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B
insufficiency	I
.	O

Our	O
data	O
indicate	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
betoken	O
inadequacy	O
inadequacy	O
betoken	O
betoken	O
betoken	O
patients	O
with	O
PAH	B
deficiency	I
.	O

Our	O
information	O
show	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
principal	O
determining	O
of	O
metabolous	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B
inadequacy	I
.	O

Our	O
data	O
indicate	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
main	O
determinant	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B

the	O
data	O
indicate	O
patients	O
the	O
PAH	O
-	O
genotype	O
mutation	O
is	O
with	O
main	O
of	O
determinant	O
.	O
phenotype	O
in	O
most	O
that	O
Our	O
PAH	B
deficiency	I
metabolic	O

Our	O
datum	O
signal	O
that	O
the	O
PAH	O
-	O
sport	O
genotype	O
is	O
the	O
primary	O
determinant	O
of	O
metabolous	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B
inadequacy	I
.	O

metabolic	O
data	O
genotype	O
-	O
the	O
PAH	O
phenotype	O
mutation	O
indicate	O
is	O
the	O
main	O
PAH	O
of	O
that	O
Our	O
in	O
most	O
patients	O
with	O
determinant	B
deficiency	I
.	O

Our	O
data	O
indicate	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B
deficiency	I
.	O

In	O
the	O
present	O
study	O
,	O
the	O
categorisation	O
of	O
cv	O
PAH	O
mutant	O
may	O
permit	O
the	O
prevision	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
tenner	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
utile	O
for	O
the	O
direction	O
of	O
hyperphenylalaninemia	B
in	O
newborns	O
.	O

the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
allow	O
the	O
prediction	O
of	O
the	O
phenotype	O
in	O
000	O
which	O
may	O
for	O
of	O
hyperphenylalaninemia	B
in	O
newborns	O

may	O
hyperphenylalaninemia	O
present	O
study	O
the	O
the	O
>	O
the	O
105	O
PAH	O
mutations	O
may	O
allow	O
genotypes	O
.	O
of	O
,	O
for	O
phenotype	O
in	O
of	O
10	O
,	O
000	O
the	O
,	O
which	O
In	O
biochemical	O
useful	O
be	O
classification	O
management	O
of	O
the	B
in	O
newborns	O
prediction	O

In	O
the	O
present	O
study	O
,	O
the	O
105	O
PAH	O
mutations	O
may	O
the	O
prediction	O
of	O
the	O
biochemical	O
in	O
>	O
10	O
,	O
genotypes	O
,	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B
newborns	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B
in	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
newborns	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B
in	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
newborns	O
.	O

indium	O
the	O
present	O
take	O
,	O
the	O
categorisation	O
of	O
105	O
PAH	O
mutant	O
whitethorn	O
leave	O
the	O
prognostication	O
of	O
the	O
biochemical	O
phenotype	O
indium	O
>	O
ten	O
,	O
000	O
genotypes	O
,	O
which	O
whitethorn	O
be	O
utilitarian	O
for	O
the	O
direction	O
of	O
hyperphenylalaninemia	B
indium	O
newborns	O
.	O

genotypes	O
phenotype	O
present	O
study	O
,	O
the	O
may	O
of	O
105	O
PAH	O
mutations	O
classification	O
allow	O
may	O
useful	O
of	O
the	O
biochemical	O
of	O
in	O
>	O
10	O
be	O
000	O
In	O
,	O
the	O
the	O
prediction	O
,	O
for	O
in	O
management	O
the	O
hyperphenylalaninemia	B
which	O
newborns	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B
in	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
take	O
into	O
account	O

In	O
the	O
,	O
the	O
of	O
105	O
allow	O
prediction	O
of	O
the	O
phenotype	O
in	O
>	O
,	O
000	O
genotypes	O
,	O
which	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B
in	O
newborns	O

In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B
in	O
newborns	O
.	O

Somatic	O
instability	O
of	O
the	O
muscular	O
dystrophy	O
part	O
cost	O
years	O
pendent	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	B
myotonic	I
dystrophy	O
region	O
is	O
age	O
dependent	O
but	O
recording	O
horizontal	O
surface	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
yr	O

Somatic	O
instability	O
of	O
the	O
muscular	O
dystrophy	O
part	O
cost	O
years	O
pendent	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	B
myotonic	I
dystrophy	O
region	O
is	O
age	O
dependent	O
but	O
recording	O
indium	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
yr	O
yr	O

capacities	O
instability	O
transcription	O
is	O
CTG	O
repeat	O
proliferative	O
mice	O
the	O
for	O
the	O
myotonic	B
to	I
region	O
of	O
transgenic	O
dependent	O
but	O
not	O
correlated	O
dystrophy	O
the	O
relative	O
intertissue	O
age	O
in	O
and	O
levels	O
Somatic	O
.	O

Somatic	O
instability	O
of	O
the	O
muscular	O
dystrophy	O
part	O
cost	O
years	O
pendent	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	B
myotonic	I
dystrophy	O
region	O
is	O
age	O
dependent	O
but	O
recording	O
horizontal	O
surface	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
yr	O

Somatic	O
instability	O
of	O
the	O
CTG	O
repeat	O
in	O
transgenic	O
for	O
myotonic	B
dystrophy	I
region	O
is	O
age	O
dependent	O
but	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
.	O

corporeal	O
unstableness	O
of	O
the	O
CTG	O
reiterate	O
in	O
shiner	O
transgenic	O
for	O
the	O
myotonic	B
dystrophy	I
region	O
is	O
years	O
dependent	O
but	O
not	O
correlative	O
to	O
the	O
relative	O
intertissue	O
recording	O
layer	O
and	O
proliferative	O
content	O
.	O

dependent	O
instability	O
of	O
the	O
CTG	O
repeat	O
the	O
myotonic	O
transgenic	O
for	O
the	O
Somatic	B
capacities	I
intertissue	O
age	O
is	O
but	O
transcription	O
not	O
correlated	O
to	O
in	O
relative	O
region	O
mice	O
levels	O
and	O
proliferative	O
dystrophy	O
.	O

to	O
instability	O
of	O
not	O
CTG	O
repeat	O
in	O
levels	O
intertissue	O
for	O
capacities	O
myotonic	B
and	I
correlated	O
relative	O
age	O
dependent	O
but	O
the	O
region	O
transcription	O
the	O
is	O
transgenic	O
Somatic	O
mice	O
dystrophy	O
proliferative	O
the	O
.	O

corporal	O
imbalance	O
of	O
the	O
CTG	O
reduplicate	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	B
dystrophy	I
neighborhood	O
is	O
age	O
hooked	O
but	O
not	O
correlated	O
to	O
the	O
congeneric	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capability	O
.	O

Somatic	O
instability	O
of	O
the	O
CTG	O
in	O
transgenic	O
for	O
the	O
myotonic	B
dystrophy	I
region	O
is	O
age	O
but	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
and	O
proliferative	O
capacities	O

Somatic	O
instability	O
of	O
the	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	B
dystrophy	I
region	O
is	O
age	O
dependent	O
but	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
.	O

A	O
(	O
CTG	O
)	O
muscular	O
dystrophy	O
indium	O
dm	O
dm	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
causing	B
myotonic	I
dystrophy	O
(	B
DM	O
)	O
decimetre	O
decimetre	O
decimetre	O
decimetre	O
decimetre	O

A	O
(	O
CTG	O
in	O
region	O
(	O
UTR	O
of	O
the	O
protein	O
kinase	O
gene	O
)	O
is	O
responsible	O
for	O
causing	O
dystrophy	I
DM	B
)	O
.	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
ternion	O
-	O
untranslated	O
realm	O
(	O
UTR	O
)	O
of	O
the	O
dm	O
protein	O
kinase	O
factor	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
have	O
myotonic	B
dystrophy	I
(	O
dm	B
)	O
.	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
-	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
responsible	O
for	O
causing	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
trey	O
-	O
untranslated	O
realm	O
(	O
UTR	O
)	O
of	O
the	O
dm	O
protein	O
kinase	O
cistron	O
(	O
DMPK	O
)	O
is	O
creditworthy	O
for	O
causation	O
myotonic	B
dystrophy	I
(	O
dm	B
)	O
.	O

A	O
(	O
CTG	O
)	O
muscular	O
dystrophy	O
indium	O
dm	O
dm	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
causing	B
myotonic	I
dystrophy	O
(	B
DM	O
)	O
decimetre	O
decimetre	O
decimetre	O
decimetre	O
decimetre	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
trey	O
-	O
untranslated	O
part	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
factor	O
(	O
DMPK	O
)	O
is	O
creditworthy	O
for	O
induce	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

(	O
kinase	O
CTG	O
)	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
responsible	O
(	O
the	O
DM	O
protein	O
myotonic	O
gene	O
(	O
DMPK	O
)	O
is	O
)	O
for	O
causing	O
A	B
of	I
)	O
DM	B
dystrophy	O
.	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
3	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
myotonic	B
dystrophy	I
(	O
)	O

A	O
(	O
CTG	O
)	O
muscular	O
dystrophy	O
indium	O
dm	O
responsible	O
for	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	B
causing	I
myotonic	O
dystrophy	B
(	O
DM	O
)	O
responsible	O
for	O
responsible	O
for	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
causing	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

major	O
unstableness	O
,	O
with	O
very	O
orotund	O
elaboration	O
between	O
generations	O
and	O
high	O
charge	O
of	O
corporeal	O
mosaicism	O
,	O
is	O
observed	O
in	O
patients	O
.	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism	O
,	O
is	O
observed	O
patient	O
generation	O
generation	O
generation	O
generation	O
generation	O
in	O
patients	O
.	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism	O
,	O
is	O
observed	O
patient	O
generation	O
generation	O
generation	O
generation	O
generation	O
in	O
patients	O
.	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
and	O
high	O
of	O
somatic	O
mosaicism	O
,	O
is	O
observed	O
in	O

mosaicism	O
instability	O
generations	O
expansions	O
very	O
large	O
,	O
between	O
,	O
and	O
high	O
levels	O
.	O
somatic	O
with	O
Major	O
is	O
observed	O
in	O
patients	O
of	O

Major	O
instability	O
,	O
with	O
very	O
great	O
enlargement	O
between	O
contemporaries	O
and	O
gamy	O
levels	O
of	O
corporeal	O
mosaicism	O
,	O
is	O
respect	O
in	O
patients	O
.	O

.	O
instability	O
,	O
high	O
very	O
large	O
expansions	O
in	O
mosaicism	O
and	O
with	O
levels	O
somatic	O
of	O
generations	O
,	O
is	O
observed	O
between	O
Major	O
patients	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism	O
,	O
is	O
observed	O
patient	O
generation	O
generation	O
generation	O
generation	O
note	O
in	O
patients	O
.	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
mosaicism	O
observed	O
in	O
patients	O
.	O

Major	O
unstableness	O
,	O
with	O
very	O
large	O
enlargement	O
between	O
propagation	O
and	O
high	O
storey	O
of	O
bodily	O
mosaicism	O
,	O
is	O
discovered	O
in	O
patients	O
.	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism	O
,	O
is	O
observed	O
in	O
patients	O
.	O

onset	O
is	O
a	O
least	O
correlation	O
between	O
repeat	O
age	O
,	O
at	O
good	O
in	O
)	O
leucocytes	O
(	O
clinical	O
severity	O
and	O
size	O
There	O
of	O
.	O

There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
onrush	O
onrush	O
ampere	O
ampere	O
ampere	O
ampere	O
age	O
of	O
onset	O
.	O

There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
onrush	O
onrush	O
ampere	O
ampere	O
ampere	O
ampere	O
age	O
of	O
onset	O
.	O

There	O
is	O
a	O
good	O
correlativity	O
between	O
double	O
sizing	O
(	O
at	O
least	O
in	O
leukocyte	O
)	O
,	O
clinical	O
austereness	O
and	O
age	O
of	O
onslaught	O
.	O

There	O
is	O
a	O
correlation	O
between	O
repeat	O
size	O
(	O
least	O
in	O
leucocytes	O
)	O
clinical	O
severity	O
age	O
of	O
onset	O
.	O

good	O
repeat	O
size	O
(	O
least	O
in	O
)	O
,	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

There	O
is	O
a	O
soundly	O
correlation	O
between	O
reprise	O
sizing	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
hardness	O
and	O
geezerhood	O
of	O
onrush	O
.	O

,	O
is	O
(	O
repeat	O
correlation	O
between	O
clinical	O
size	O
a	O
at	O
least	O
in	O
onset	O
)	O
good	O
There	O
severity	O
and	O
age	O
of	O
leucocytes	O
.	O

There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
onrush	O
onrush	O
ampere	O
ampere	O
ampere	O
hardship	O
age	O
of	O
onset	O
.	O

There	O
is	O
a	O
good	O
repeat	O
size	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
age	O
.	O

There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
trinucleotide	O
indium	O
dm	O
iterate	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B
and	O
other	O
human	O
genetic	B
diseases	I
are	O
unknown	O
need	O
.	O

are	O
trinucleotide	O
repeat	O
.	O
mechanisms	O
involved	O
in	O
DM	B
unknown	O
other	O
human	O
genetic	B
The	I
diseases	O
and	O
instability	O

The	O
trinucleotide	O
indium	O
dm	O
indium	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B
and	O
other	O
human	O
genetic	B
diseases	I
are	O
unknown	O
need	O
.	O

The	O
trinucleotide	O
repeat	O
imbalance	O
mechanisms	O
involved	O
in	O
decimetre	B
and	O
other	O
human	O
transmissible	B
diseases	I
are	O
unidentified	O
.	O

diseases	O
trinucleotide	O
repeat	O
DM	O
mechanisms	O
involved	O
are	O
instability	B
and	O
other	O
The	O
genetic	B
human	I
in	O
unknown	O
.	O

The	O
trinucleotide	O
indium	O
dm	O
iterate	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B
and	O
other	O
human	O
genetic	B
diseases	I
are	O
unknown	O
need	O
.	O

The	O
trinucleotide	O
recur	O
unbalance	O
mechanisms	O
involved	O
in	O
DM	B
and	O
other	O
homo	O
inherited	B
diseases	I
are	O
unknown	O
.	O

The	O
trinucleotide	O
repeat	O
unstableness	O
mechanisms	O
necessitate	O
in	O
DM	B
and	O
other	O
human	O
transmitted	B
diseases	I
are	O
unidentified	O
.	O

The	O
trinucleotide	O
and	O
.	O
mechanisms	O
involved	O
diseases	O
DM	B
repeat	O
other	O
human	O
genetic	B
in	I
are	O
instability	O
unknown	O

trinucleotide	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B
human	O
genetic	B
diseases	I
are	O
unknown	O
.	O

The	O
trinucleotide	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B
and	O
other	O
human	O
genetic	B
diseases	I
are	O
unknown	O
.	O

We	O
study	O
bodily	O
instability	O
by	O
measurement	O
the	O
CTG	O
reprize	O
distance	O
at	O
respective	O
years	O
in	O
respective	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
dm	B
region	O
,	O
utilize	O
low	O
-	O
consortium	O
PCR	O
.	O

We	O
studied	O
somatic	O
imbalance	O
by	O
valuate	O
the	O
CTG	O
iterate	O
distance	O
at	O
assorted	O
years	O
in	O
assorted	O
tissues	O
of	O
transgenic	O
mice	O
channel	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B
part	O
,	O
victimization	O
diminished	O
-	O
syndicate	O
PCR	O
.	O

We	O
by	O
the	O
CTG	O
repeat	O
at	O
several	O
ages	O
various	O
tissues	O
of	O
transgenic	O
mice	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
human	O
region	O
,	O
using	O
-	O
pool	O
PCR	O
.	O

We	O
studied	O
human	O
instability	O
by	O
kb	O
surrounded	O
CTG	O
repeat	O
length	O
at	O
)	O
45	O
in	O
various	O
the	O
of	O
transgenic	O
carrying	O
mice	O
a	O
(	O
CTG	O
using	O
55expansion	O
by	O
ages	O
DM	O
measuring	O
of	O
tissues	O
-	O
the	B
region	O
,	O
several	O
small	O
somatic	O
pool	O
PCR	O
.	O

55expansion	O
mice	O
somatic	O
instability	O
by	O
measuring	O
several	O
(	O
repeat	O
length	O
at	O
the	O
ages	O
45	O
of	O
tissues	O
of	O
transgenic	O
.	O
carrying	O
a	O
CTG	O
kb	O
)	O
We	O
surrounded	O
human	O
in	O
various	O
CTG	O
the	O
using	O
DM	B
studied	O
,	O
by	O
small	O
-	O
pool	O
PCR	O
region	O

We	O
studied	O
somatic	O
instability	O
the	O
CTG	O
repeat	O
length	O
several	O
ages	O
in	O
various	O
tissues	O
transgenic	O
mice	O
carrying	O
a	O
CTG	O
)	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B
,	O
using	O
-	O
pool	O
PCR	O
.	O

We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	O
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B
region	O
,	O
using	O
past	O
consortium	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
small	O
-	O
pool	O
PCR	O
.	O

We	O
studied	O
somatic	O
instability	O
CTG	O
repeat	O
length	O
at	O
several	O
in	O
various	O
mice	O
(	O
CTG	O
surrounded	O
kb	O
of	O
the	O
human	O
region	O
,	O
-	O
pool	O
.	O

We	O
studied	O
corporal	O
instability	O
by	O
appraise	O
the	O
CTG	O
iterate	O
length	O
at	O
respective	O
ages	O
in	O
versatile	O
tissues	O
of	O
transgenic	O
mice	O
pack	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kilobit	O
of	O
the	O
homo	O
decimetre	B
part	O
,	O
using	O
minuscule	O
-	O
pond	O
PCR	O
.	O

We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	O
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B
region	O
,	O
using	O
past	O
consortium	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
past	O
small	O
-	O
pool	O
PCR	O
.	O

We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	O
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B
region	O
,	O
using	O
small	O
-	O
pool	O
PCR	O
.	O

These	O
mice	O
have	O
been	O
ussher	O
usher	O
	O
procreate	O
usher	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
indium	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
usher	O
usher	O
unbalance	O
.	O

These	O
mice	O
have	O
been	O
ussher	O
usher	O
	O
procreate	O
usher	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
need	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
usher	O
usher	O
unbalance	O
.	O

chromatin	O
mice	O
have	O
been	O
shown	O
to	O
the	O
repeat	O
intergenerational	O
and	O
somatic	O
instability	O
and	O
reproduce	O
environment	O
instability	O
the	O
sequences	O
that	O
surrounding	O
These	O
of	O
the	O
suggesting	O
55	O
are	O
involved	O
in	O
.	O
mechanisms	O
CTG	O

These	O
mice	O
have	O
been	O
ussher	O
usher	O
	O
procreate	O
usher	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
indium	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
usher	O
usher	O
unbalance	O
.	O

These	O
mice	O
have	O
been	O
to	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
.	O

These	O
mouse	O
have	O
been	O
shown	O
to	O
regurgitate	O
the	O
intergenerational	O
and	O
somatic	O
imbalance	O
of	O
the	O
55	O
CTG	O
reiterate	O
propose	O
that	O
beleaguer	O
episode	O
and	O
the	O
chromatin	O
surroundings	O
are	O
ask	O
in	O
imbalance	O
mechanisms	O
.	O

instability	O
mice	O
environment	O
55	O
shown	O
to	O
in	O
the	O
been	O
and	O
somatic	O
instability	O
sequences	O
the	O
have	O
intergenerational	O
repeat	O
suggesting	O
that	O
surrounding	O
of	O
and	O
the	O
chromatin	O
CTG	O
reproduce	O
involved	O
are	O
These	O
mechanisms	O
.	O

These	O
mice	O
have	O
been	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
somatic	O
instability	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
that	O
surrounding	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
.	O

somatic	O
mice	O
have	O
instability	O
shown	O
to	O
reproduce	O
are	O
chromatin	O
and	O
environment	O
instability	O
involved	O
surrounding	O
the	O
CTG	O
repeat	O
suggesting	O
.	O
the	O
sequences	O
and	O
55	O
intergenerational	O
These	O
the	O
of	O
in	O
been	O
mechanisms	O
that	O

These	O
shiner	O
have	O
been	O
shown	O
to	O
regurgitate	O
the	O
intergenerational	O
and	O
corporal	O
unbalance	O
of	O
the	O
55	O
CTG	O
reprize	O
suggesting	O
that	O
wall	O
successiveness	O
and	O
the	O
chromatin	O
environs	O
are	O
involved	O
in	O
unbalance	O
mechanics	O
.	O

These	O
mice	O
have	O
been	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
.	O

As	O
observed	O
in	O
some	O
cost	O
ampere	O
trend	O
weave	O
iterate	O
of	O
the	O
tissues	O
of	O
DM	B
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
indium	O
years	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
toll	O
in	O
that	O

As	O
observed	O
in	O
some	O
cost	O
ampere	O
trend	O
weave	O
iterate	O
of	O
the	O
tissues	O
of	O
DM	B
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
indium	O
cost	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
toll	O
in	O
that	O

mouse	O
observed	O
the	O
tendency	O
of	O
the	O
the	O
of	O
some	B
patients	O
,	O
there	O
mosaicism	O
a	O
in	O
DM	O
repeat	O
length	O
and	O
somatic	O
is	O
to	O
increase	O
with	O
for	O
tissues	O
of	O
age	O
As	O
.	O

As	O
observed	O
in	O
some	O
cost	O
ampere	O
trend	O
weave	O
iterate	O
of	O
the	O
tissues	O
of	O
DM	B
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
indium	O
years	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
toll	O
in	O
that	O

As	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
DM	B
patients	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
.	O

As	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
of	O
dm	B
patients	O
,	O
there	O
is	O
a	O
propensity	O
for	O
iterate	O
distance	O
and	O
corporeal	O
mosaicism	O
to	O
addition	O
with	O
the	O
age	O
of	O
the	O
sneak	O
.	O

repeat	O
observed	O
in	O
some	O
of	O
the	O
to	O
there	O
DM	B
patients	O
,	O
As	O
mouse	O
with	O
for	O
tendency	O
length	O
the	O
and	O
somatic	O
mosaicism	O
tissues	O
increase	O
a	O
of	O
age	O
of	O
the	O
is	O
.	O

mosaicism	O
observed	O
in	O
and	O
of	O
the	O
tissues	O
age	O
with	B
patients	O
mouse	O
there	O
of	O
somatic	O
increase	O
for	O
repeat	O
length	O
some	O
a	O
the	O
to	O
tendency	O
DM	O
As	O
of	O
is	O
the	O
,	O
.	O

equally	O
discovered	O
in	O
some	O
of	O
the	O
tissues	O
of	O
decimeter	B
patients	O
,	O
there	O
is	O
a	O
trend	O
for	O
repeat	O
distance	O
and	O
corporal	O
mosaicism	O
to	O
addition	O
with	O
the	O
senesce	O
of	O
the	O
shiner	O
.	O

As	O
observed	O
in	O
some	O
of	O
tissues	O
DM	B
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
length	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
of	O
the	O
mouse	O

As	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
of	O
DM	B
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
.	O

Furthermore	O
,	O
tween	O
content	O
corporal	O
we	O
observed	O
no	O
correlation	O
between	O
the	O
somatic	O
mutation	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
correlation	O
coefficient	O

proliferation	O
,	O
we	O
.	O
no	O
correlation	O
between	O
the	O
capacity	O
mutation	O
rate	O
and	O
Furthermore	O
tissue	O
somatic	O
observed	O

Furthermore	O
,	O
tween	O
content	O
sport	O
we	O
observed	O
no	O
correlation	O
between	O
the	O
somatic	O
mutation	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
correlation	O
coefficient	O

moreover	O
,	O
we	O
observed	O
no	O
correlativity	O
between	O
the	O
somatic	O
mutation	O
rank	O
and	O
tissue	O
proliferation	O
capacitance	O
.	O

tissue	O
,	O
we	O
the	O
no	O
correlation	O
proliferation	O
observed	O
somatic	O
mutation	O
Furthermore	O
and	O
rate	O
between	O
capacity	O
.	O

Furthermore	O
,	O
tween	O
content	O
corporal	O
we	O
observed	O
no	O
correlation	O
between	O
the	O
somatic	O
mutation	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
correlation	O
coefficient	O

Furthermore	O
,	O
we	O
note	O
no	O
correlation	O
between	O
the	O
corporal	O
mutation	O
order	O
and	O
weave	O
proliferation	O
capacity	O
.	O

Furthermore	O
,	O
we	O
honour	O
no	O
correlation	O
between	O
the	O
bodily	O
variation	O
range	O
and	O
tissue	O
proliferation	O
capacity	O
.	O

Furthermore	O
,	O
somatic	O
.	O
no	O
correlation	O
tissue	O
the	O
we	O
mutation	O
rate	O
and	O
between	O
proliferation	O
observed	O
capacity	O

,	O
we	O
observed	O
no	O
correlation	O
between	O
the	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
.	O

Furthermore	O
,	O
we	O
observed	O
no	O
correlation	O
between	O
the	O
somatic	O
mutation	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
.	O

The	O
somatic	O
mutation	O
rates	O
in	O
different	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
relative	O
inter	O
-	O
tissue	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
three	O
genes	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
surrounding	O
the	O
repeat	O
.	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
.	O

The	O
somatic	O
mutation	O
different	O
tissues	O
were	O
also	O
not	O
to	O
relative	O
inter	O
-	O
tissue	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
genes	O
(	O
DMAHP	O
,	O
DMPK	O
repeat	O

genes	O
in	O
mutation	O
rates	O
in	O
different	O
to	O
the	O
also	O
not	O
correlated	O
tissues	O
the	O
,	O
and	O
-	O
tissue	O
difference	O
were	O
transcriptional	O
levels	O
of	O
DMPK	O
three	O
The	O
(	O
)	O
relative	O
inter	O
the	O
59	O
.	O
surrounding	O
somatic	O
repeat	O
DMAHP	O
.	O

The	O
somatic	O
mutation	O
rates	O
in	O
different	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
relative	O
inter	O
-	O
tissue	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
three	O
genes	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
surrounding	O
the	O
repeat	O
.	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
too	O
.	O

,	O
repeat	O
mutation	O
rates	O
tissue	O
different	O
inter	O
)	O
also	O
not	O
correlated	O
to	O
the	O
genes	O
were	O
-	O
in	O
59	O
in	O
transcriptional	O
relative	O
of	O
the	O
three	O
somatic	O
(	O
DMAHP	O
The	O
difference	O
and	O
DMPK	O
tissues	O
surrounding	O
the	O
levels	O
.	O
.	O

The	O
bodily	O
mutation	O
rates	O
in	O
dissimilar	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
congener	O
entomb	O
-	O
tissue	O
dispute	O
in	O
transcriptional	O
layer	O
of	O
the	O
three	O
cistron	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
fence	O
the	O
echo	O
.	O
.	O

The	O
somatic	O
mutation	O
rates	O
different	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
inter	O
-	O
tissue	O
in	O
levels	O
of	O
the	O
(	O
59	O
)	O
surrounding	O
repeat	O
.	O

The	O
somatic	O
59	O
rates	O
in	O
.	O
tissues	O
were	O
also	O
not	O
correlated	O
DMAHP	O
transcriptional	O
relative	O
inter	O
,	O
tissue	O
difference	O
)	O
the	O
levels	O
surrounding	O
the	O
different	O
genes	O
-	O
to	O
of	O
(	O
and	O
mutation	O
in	O
DMPK	O
the	O
repeat	O
three	O
.	O

The	O
bodily	O
mutation	O
betray	O
in	O
unlike	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
proportional	O
inter	O
-	O
weave	O
divergence	O
in	O
transcriptional	O
levels	O
of	O
the	O
trine	O
cistron	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
ilx	O
)	O
beleaguer	O
the	O
ingeminate	O
.	O
.	O

The	O
corporal	O
variation	O
rank	O
in	O
unlike	O
tissues	O
were	O
also	O
not	O
correlative	O
to	O
the	O
relation	O
entomb	O
-	O
weave	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
three	O
factor	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
wall	O
the	O
double	O
.	O
.	O

The	O
somatic	O
mutation	O
rates	O
in	O
different	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
relative	O
inter	O
-	O
tissue	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
three	O
genes	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
surrounding	O
the	O
repeat	O
.	O
.	O

A	O
novel	O
retinoblastoma	O
of	O
in	O
patients	O
mild	O
a	O
missense	B
pedigree	O
showing	O
only	O
from	O
expression	O
mutation	O
the	O
tumor	B
phenotype	O
.	O

missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B
pedigree	O
showing	O
the	O
tumor	B
phenotype	O
.	O

A	O
new	O
missense	O
variation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B
pedigree	O
read	O
only	O
mild	O
locution	O
of	O
the	O
tumour	B
phenotype	O
.	O

angstrom	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
angstrom	O
retinoblastoma	B
bloodline	O
demo	O
only	O
soft	O
expression	O
of	O
the	O
neoplasm	B
phenotype	O
.	O

tumor	O
novel	O
missense	O
mutation	O
in	O
patients	O
expression	O
of	O
retinoblastoma	B
pedigree	O
showing	O
only	O
phenotype	O
from	O
a	O
the	O
mild	B
A	O
.	O

A	O
novel	O
in	O
patients	O
from	O
a	O
retinoblastoma	B
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B
.	O

A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B
phenotype	O
sport	O
sport	O
sport	O
sport	O
indium	O
.	O

A	O
refreshing	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B
bloodline	O
establish	O
only	O
mild	O
reflection	O
of	O
the	O
neoplasm	B
phenotype	O
.	O

A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B
phenotype	O
sport	O
sport	O
sport	O
sport	O
sport	O
.	O

expression	O
novel	O
missense	O
showing	O
in	O
patients	O
from	O
.	O
of	B
pedigree	O
mutation	O
only	O
A	O
mild	O
retinoblastoma	O
the	O
tumor	B
phenotype	O
a	O

A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B
phenotype	O
.	O

We	O
have	O
used	O
single	O
coding	O
dna	O
ground	O
form	O
pleomorphism	O
ground	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
reflexion	O
reflexion	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	B
retinoblastoma	O
phenotype	O
twenty	O
seven	O

We	O
have	O
used	O
single	O
coding	O
dna	O
ground	O
form	O
pleomorphism	O
ground	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
reflexion	O
depth	O
psychology	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	B
the	O
retinoblastoma	O
phenotype	O
twenty	O

phenotype	O
have	O
expression	O
the	O
strand	O
conformation	O
retinoblastoma	O
analysis	O
single	O
study	O
the	O
27	O
a	O
of	O
used	O
to	O
gene	O
in	O
individuals	O
from	O
exons	O
family	O
showing	O
mild	O
RB1	O
polymorphism	O
the	O
of	B
We	O
.	O

We	O
have	O
used	O
single	O
coding	O
dna	O
ground	O
form	O
pleomorphism	O
ground	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
reflexion	O
reflexion	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	B
retinoblastoma	O
phenotype	O
twenty	O
seven	O

We	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
to	O
study	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B
phenotype	O
.	O

We	O
have	O
practice	O
single	O
filament	O
conformation	O
pleomorphism	O
analysis	O
to	O
discipline	O
the	O
xxvii	O
exons	O
of	O
the	O
RB1	O
cistron	O
in	O
individuals	O
from	O
a	O
phratry	O
picture	O
soft	O
expression	O
of	O
the	O
retinoblastoma	B
phenotype	O
.	O

gene	O
have	O
used	O
single	O
strand	O
conformation	O
family	O
27	O
to	O
study	O
the	O
We	O
phenotype	O
mild	O
RB1	O
the	O
in	O
expression	O
individuals	O
from	O
a	O
polymorphism	O
showing	O
of	O
analysis	O
of	O
the	O
retinoblastoma	B
exons	O
.	O

a	O
have	O
used	O
individuals	O
strand	O
conformation	O
polymorphism	O
of	O
mild	O
study	O
phenotype	O
27	O
the	O
from	O
showing	O
RB1	O
gene	O
in	O
single	O
of	O
expression	O
family	O
the	O
to	O
We	O
analysis	O
exons	O
retinoblastoma	B
the	O
.	O

We	O
have	O
exploited	O
single	O
ground	O
conformation	O
pleomorphism	O
analysis	O
to	O
take	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
factor	O
in	O
somebody	O
from	O
a	O
home	O
display	O
soft	O
expression	O
of	O
the	O
retinoblastoma	B
phenotype	O
.	O

We	O
have	O
used	O
single	O
strand	O
polymorphism	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
in	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
the	O
retinoblastoma	B
phenotype	O

We	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B
phenotype	O
.	O

In	O
this	O
family	O
strike	O
person	O
modernize	O
unilateral	B
neoplasm	I
and	O
,	O
as	O
a	O
consequence	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
mutation	O
toter	O
were	O
besides	O
identified	O
inside	O
the	O
pedigree	O
.	O

In	O
this	O
affected	O
individuals	O
developed	O
unilateral	B
tumors	I
and	O
,	O
as	O
a	O
result	O
analysis	O
,	O
unaffected	O
mutation	O
were	O
also	O
identified	O
within	O
the	O
.	O

In	O
this	O
family	O
affected	O
gene	O
linkage	O
depth	O
psychology	O
somebody	O
individuals	B
developed	I
unilateral	O
tumors	O
and	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
inside	O
place	O
line	O
of	O
descent	O
inside	O
touched	O
mutation	O
carriers	O
were	O
also	O
identified	O

were	O
this	O
family	O
mutation	O
individuals	O
developed	O
unilateral	B
pedigree	I
within	O
,	O
carriers	O
a	O
result	O
of	O
identified	O
analysis	O
,	O
unaffected	O
affected	O
the	O
as	O
also	O
linkage	O
and	O
In	O
tumors	O
.	O

In	O
this	O
family	O
affected	O
gene	O
linkage	O
depth	O
psychology	O
somebody	O
individuals	B
developed	I
unilateral	O
tumors	O
and	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
inside	O
place	O
line	O
of	O
descent	O
inside	O
touched	O
mutation	O
carriers	O
were	O
also	O
identified	O

In	O
this	O
family	O
individuals	O
developed	O
tumors	I
and	O
,	O
as	O
a	O
result	O
of	O
linkage	O
,	O
unaffected	O
carriers	O
were	O
also	O
identified	O
within	O
the	O
pedigree	O
.	O

.	O
this	O
family	O
linkage	O
individuals	O
developed	O
pedigree	B
tumors	I
affected	O
,	O
as	O
a	O
of	O
were	O
the	O
and	O
,	O
unaffected	O
mutation	O
carriers	O
result	O
also	O
identified	O
within	O
analysis	O
unilateral	O
In	O

family	O
developed	O
unilateral	B
tumors	I
,	O
as	O
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
mutation	O
carriers	O
were	O
also	O
identified	O
within	O
the	O

within	O
this	O
family	O
affected	O
individuals	O
developed	O
of	B
a	I
and	O
,	O
as	O
,	O
also	O
unilateral	O
the	O
In	O
tumors	O
analysis	O
mutation	O
carriers	O
were	O
result	O
identified	O
unaffected	O
linkage	O
pedigree	O
.	O

In	O
this	O
phratry	O
dissemble	O
individuals	O
developed	O
unilateral	B
tumors	I
and	O
,	O
as	O
a	O
answer	O
of	O
linkage	O
analysis	O
,	O
insensible	O
mutation	O
mailman	O
were	O
also	O
discover	O
inside	O
the	O
thoroughbred	O
.	O

In	O
this	O
family	O
affected	O
individuals	O
developed	O
unilateral	B
tumors	I
and	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
mutation	O
carriers	O
were	O
also	O
identified	O
within	O
the	O
pedigree	O
.	O

A	O
single	O
band	O
shift	O
lead	O
indium	O
ampere	O
cost	O
expend	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
trail	O
trail	O
trail	O
toll	O
.	O

A	O
single	O
using	O
exon	O
21	O
which	O
in	O
a	O
mutation	O
converting	O
a	O
-	O
>	O
arg	O
at	O
nucleotide	O
28	O
the	O
exon	O
.	O

A	O
ace	O
band	O
fracture	O
use	O
SSCP	O
was	O
identify	O
in	O
exon	O
xxi	O
which	O
ensue	O
in	O
a	O
missense	O
mutation	O
commute	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
base	O
put	O
28	O
in	O
the	O
exon	O
.	O

A	O
single	O
band	O
shift	O
SSCP	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
-	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
.	O

A	O
exclusive	O
ring	O
shift	O
expend	O
SSCP	O
was	O
identified	O
in	O
exon	O
xxi	O
which	O
leave	O
in	O
a	O
missense	O
variation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
base	O
place	O
xxviii	O
in	O
the	O
exon	O
.	O

A	O
single	O
band	O
shift	O
lead	O
indium	O
ampere	O
cost	O
expend	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
trail	O
trail	O
trail	O
toll	O
.	O

A	O
single	O
isthmus	O
chemise	O
victimisation	O
SSCP	O
was	O
place	O
in	O
exon	O
xxi	O
which	O
ensue	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
base	O
put	O
xxviii	O
in	O
the	O
exon	O
.	O

-	O
a	O
band	O
shift	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
at	O
the	O
missense	O
mutation	O
converting	O
28	O
cys	O
single	O
-	O
.	O
arg	O
in	O
nucleotide	O
position	O
A	O
a	O
>	O
exon	O
in	O

A	O
single	O
band	O
shift	O
SSCP	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
mutation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
nucleotide	O
position	O
28	O
the	O
.	O

A	O
single	O
band	O
shift	O
lead	O
indium	O
ampere	O
cost	O
	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
trail	O
trail	O
trail	O
toll	O
.	O

A	O
single	O
band	O
shift	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
.	O

The	O
mutation	O
destruct	O
an	O
NdeI	O
limitation	O
enzyme	O
site	O
.	O

The	O
associate	O
in	O
nursing	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
site	O

The	O
an	O
destroyed	O
mutation	O
NdeI	O
restriction	O
site	O
enzyme	O
.	O

The	O
sport	O
destroyed	O
an	O
NdeI	O
confinement	O
enzyme	O
site	O
.	O

The	O
destroyed	O
an	O
restriction	O
site	O

enzyme	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
site	O
The	O
.	O

The	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
.	O

The	O
site	O
destroyed	O
an	O
mutation	O
restriction	O
enzyme	O
NdeI	O
.	O

The	O
sport	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
site	O
associate	O
in	O

The	O
mutant	O
destroyed	O
an	O
NdeI	O
limitation	O
enzyme	O
site	O
.	O

The	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
site	O
.	O

all	O
demonstrated	O
that	O
the	O
missense	O
co	O
-	O
patients	O
with	O
or	O
who	O
result	O
linkage	O
analysis	O
had	O
predicted	O
to	O
carry	O
predisposing	O
mutation	O
.	O

Analysis	O
of	O
all	O
family	O
comport	O
carbon	O
monoxide	O
gas	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
with	O
patients	B
with	O
tumors	O
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
carry	O
the	O
predisposing	O
mutation	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O

linkage	O
who	O
all	O
family	O
members	O
demonstrated	O
had	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
been	O
to	O
with	O
tumors	B
or	O
mutation	O
,	O
as	O
a	O
the	O
of	O
Analysis	O
analysis	O
that	O
with	O
patients	O
result	O
carry	O
predicted	O
predisposing	O
.	O
of	O

Analysis	O
of	O
all	O
category	O
members	O
demonstrated	O
that	O
the	O
missense	O
sport	O
co	O
-	O
segregated	O
with	O
patients	O
with	O
tumors	B
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
anticipate	O
to	O
channel	O
the	O
predispose	O
sport	O
.	O

Analysis	O
of	O
analysis	O
family	O
members	O
demonstrated	O
that	O
a	O
missense	O
mutation	O
co	O
of	O
been	O
with	O
patients	O
carry	O
tumors	B
or	O
,	O
-	O
as	O
the	O
result	O
who	O
linkage	O
had	O
all	O
predisposing	O
predicted	O
to	O
with	O
segregated	O
the	O
mutation	O
.	O

Analysis	O
of	O
all	O
family	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
segregated	O
with	O
patients	O
with	O
or	O
who	O
,	O
as	O
a	O
of	O
linkage	O
analysis	O
had	O
predicted	O
to	O
the	O
predisposing	O
mutation	O
.	O

Analysis	O
of	O
all	O
home	O
phallus	O
attest	O
that	O
the	O
missense	O
variation	O
co	O
-	O
unintegrated	O
with	O
patients	O
with	O
tumour	B
or	O
who	O
,	O
as	O
a	O
answer	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
expect	O
the	O
predispose	O
variation	O
.	O

Analysis	O
of	O
all	O
family	O
comport	O
member	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
with	O
patients	O
with	O
tumors	B
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
carry	O
the	O
predisposing	O
mutation	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
patient	O
.	O

Analysis	O
of	O
all	O
family	O
penis	O
shew	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
unintegrated	O
with	O
patients	O
with	O
tumour	B
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
betoken	O
to	O
persuade	O
the	O
predispose	O
mutation	O
.	O

been	O
as	O
all	O
family	O
tumors	O
demonstrated	O
patients	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
linkage	O
the	O
with	O
members	B
carry	O
who	O
,	O
with	O
a	O
result	O
of	O
of	O
analysis	O
had	O
Analysis	O
or	O
to	O
predicted	O
that	O
predisposing	O
mutation	O
.	O

Analysis	O
of	O
all	O
family	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
with	O
patients	O
with	O
tumors	B
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
carry	O
the	O
predisposing	O
mutation	O
.	O

These	O
observations	O
counseling	O
to	O
another	O
mutations	O
of	O
important	O
RB1	O
gene	O
where	O
for	O
families	O
modify	O
the	O
distinctive	O
of	O
the	O
and	O
gene	O
raise	O
the	O
questions	O
region	O
genetic	O
in	O
point	O
.	O
with	O
these	O
function	O
only	O
phenotypes	O
.	O

These	O
to	O
another	O
region	O
of	O
RB1	O
gene	O
only	O
modify	O
function	O
of	O
raise	O
questions	O
for	O
genetic	O
in	O
families	O
with	O
distinctive	O
phenotypes	O
.	O
.	O

These	O
observations	O
point	O
to	O
part	O
part	O
part	O
another	O
region	O
of	O
the	O
RB1	O
gene	O
where	O
mutations	O
only	O
modify	O
the	O
function	O
of	O
the	O
gene	O
and	O
raise	O
important	O
questions	O
for	O
genetic	O
counseling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
.	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O

These	O
observations	O
point	O
to	O
part	O
part	O
some	O
other	O
another	O
region	O
of	O
the	O
RB1	O
gene	O
where	O
mutations	O
only	O
modify	O
the	O
function	O
of	O
the	O
gene	O
and	O
raise	O
important	O
questions	O
for	O
genetic	O
counseling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
.	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O

observations	O
gene	O
point	O
to	O
another	O
region	O
in	O
the	O
RB1	O
gene	O
where	O
families	O
only	O
genetic	O
these	O
function	O
of	O
the	O
mutations	O
and	O
raise	O
important	O
.	O
for	O
modify	O
counseling	O
of	O
These	O
phenotypes	O
questions	O
distinctive	O
with	O
.	O
the	O

These	O
observations	O
point	O
to	O
another	O
region	O
RB1	O
gene	O
where	O
mutations	O
modify	O
the	O
function	O
of	O
the	O
and	O
raise	O
important	O
questions	O
genetic	O
counseling	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
.	O
.	O

These	O
notice	O
direct	O
to	O
another	O
region	O
of	O
the	O
RB1	O
factor	O
where	O
mutant	O
only	O
change	O
the	O
function	O
of	O
the	O
factor	O
and	O
rear	O
authoritative	O
query	O
for	O
familial	O
counselling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
.	O
.	O

These	O
observations	O
point	O
to	O
another	O
area	O
of	O
the	O
RB1	O
factor	O
where	O
mutations	O
only	O
alter	O
the	O
affair	O
of	O
the	O
factor	O
and	O
resurrect	O
significant	O
interview	O
for	O
genetic	O
rede	O
in	O
home	O
with	O
these	O
typical	O
phenotypes	O
.	O
.	O

These	O
observations	O
point	O
to	O
part	O
part	O
some	O
other	O
another	O
region	O
of	O
the	O
RB1	O
gene	O
where	O
mutations	O
only	O
modify	O
the	O
function	O
of	O
the	O
gene	O
and	O
raise	O
important	O
questions	O
for	O
genetic	O
counseling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
.	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O
role	O
theatrical	O

These	O
notice	O
point	O
to	O
another	O
realm	O
of	O
the	O
RB1	O
factor	O
where	O
mutations	O
only	O
qualify	O
the	O
purpose	O
of	O
the	O
factor	O
and	O
enhance	O
important	O
motion	O
for	O
genic	O
rede	O
in	O
families	O
with	O
these	O
typical	O
phenotypes	O
.	O
.	O

These	O
observations	O
point	O
to	O
another	O
region	O
of	O
the	O
RB1	O
gene	O
where	O
mutations	O
only	O
modify	O
the	O
function	O
of	O
the	O
gene	O
and	O
raise	O
important	O
questions	O
for	O
genetic	O
counseling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
.	O
.	O

Maternal	B
disomy	I
and	O
Prader	B
ampere	B
sheath	B
	B
genetic	B
uniform	B
-	I
Willi	I
syndrome	I
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
genetic	O
	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
international	O
ampere	O
indium	O

Maternal	B
disomy	I
and	O
Prader	B
ampere	B
sheath	B
	B
genetic	B
uniform	B
-	I
Willi	I
syndrome	I
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
genetic	O
ampere	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
international	O
ampere	O
indium	O

)	B
disomy	I
;	O
of	B
-	I
Willi	I
2	I
consistent	O
Prader	O
gamete	O
complementation	O
in	O
15	O
case	O
and	O
with	O
translocation	O
(	O
3	O
;	O
a	O
)	O
(	O
p25	O
familial	O
syndrome	O
.	O
q11	O
Maternal	O
.	O

Maternal	B
disomy	I
and	O
Prader	B
ampere	B
sheath	B
	B
genetic	B
uniform	B
-	I
Willi	I
syndrome	I
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
genetic	O
	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
international	O
ampere	O
indium	O

Maternal	B
disomy	I
and	O
Prader	B
-	I
Willi	I
syndrome	I
with	O
gamete	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
.	O

paternal	B
disomy	I
and	O
Prader	B
-	I
Willi	I
syndrome	I
logical	O
with	O
gamete	O
complementation	O
in	O
a	O
casing	O
of	O
hereditary	O
translocation	O
(	O
ternion	O
;	O
xv	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
.	O

translocation	B
disomy	I
and	O
Prader	B
-	I
Willi	I
)	I
in	O
with	O
gamete	O
complementation	O
Maternal	O
)	O
p25	O
familial	O
of	O
(	O
;	O
3	O
;	O
15	O
syndrome	O
(	O
case	O
consistent	O
q11	O
.	O
2	O
a	O
.	O

15	B
disomy	I
and	O
3	B
-	I
Willi	I
syndrome	I
q11	O
p25	O
gamete	O
)	O
in	O
.	O
;	O
(	O
familial	O
translocation	O
(	O
Prader	O
case	O
;	O
)	O
of	O
with	O
Maternal	O
consistent	O
a	O
2	O
complementation	O
.	O

maternal	B
disomy	I
and	O
Prader	B
-	I
Willi	I
syndrome	I
reproducible	O
with	O
gamete	O
complementation	O
in	O
a	O
character	O
of	O
transmitted	O
translocation	O
(	O
iii	O
;	O
xv	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
.	O

Maternal	B
disomy	I
and	O
Prader	B
-	I
syndrome	I
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
.	O
2	O
)	O

Maternal	B
disomy	I
and	O
Prader	B
-	I
Willi	I
syndrome	I
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
.	O

parental	B
uniparental	I
disomy	I
(	I
UPD	I
)	I
for	I
chromosome	I
fifteen	I
is	O
creditworthy	O
for	O
an	O
judge	O
30	O
%	O
of	O
cases	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

Maternal	B
uniparental	I
(	I
UPD	I
)	I
for	I
chromosome	I
15	I
is	O
responsible	O
for	O
an	O
%	O
of	O
cases	O
of	O
-	I
Willi	I
syndrome	I
(	O
PWS	B
.	O

Maternal	B
uniparental	I
disomy	I
(	I
	I
associate	I
in	I
nursing	I
guess	I
UPD	I
)	I
for	I
chromosome	O
15	O
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
	O
	O
	O
	O
	B
of	I
Prader	I
-	I
Willi	O
syndrome	B
(	O
PWS	O

-	B
uniparental	I
disomy	I
of	I
UPD	I
)	I
for	I
)	I
(	I
is	O
Prader	O
for	O
an	O
estimated	O
syndrome	O
%	O
of	O
cases	O
(	O
PWS	B
responsible	I
Willi	I
30	I
15	O
Maternal	B
chromosome	O
.	O

Maternal	B
uniparental	I
disomy	I
(	I
	I
associate	I
in	I
nursing	I
guess	I
UPD	I
)	I
for	I
chromosome	O
15	O
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
	O
	O
	O
	O
	B
of	I
Prader	I
-	I
Willi	O
syndrome	B
(	O
PWS	O

Maternal	B
uniparental	I
disomy	I
UPD	I
)	I
chromosome	I
15	I
is	O
responsible	O
for	O
an	O
estimated	O
30	O
of	O
cases	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

.	B
uniparental	I
disomy	I
30	I
UPD	I
)	I
)	I
chromosome	I
(	I
is	O
responsible	O
for	O
estimated	O
-	O
PWS	O
15	O
of	O
cases	O
of	O
Prader	B
an	I
Willi	I
syndrome	I
(	O
%	B
for	O
Maternal	O

disomy	I
)	I
for	I
chromosome	I
is	O
responsible	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B

(	B
uniparental	I
disomy	I
(	I
UPD	I
)	I
estimated	I
for	I
15	I
is	O
responsible	O
of	O
Willi	O
for	O
PWS	O
Maternal	O
chromosome	O
%	O
of	O
Prader	B
-	I
an	I
syndrome	I
cases	O
30	B
)	O
.	O

enate	B
uniparental	I
disomy	I
(	I
UPD	I
)	I
for	I
chromosome	I
fifteen	I
is	O
responsible	O
for	O
an	O
calculate	O
xxx	O
%	O
of	O
lawsuit	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

Maternal	B
uniparental	I
disomy	I
(	I
UPD	I
)	I
for	I
chromosome	I
15	I
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
report	O
(	O
an	O
unusual	O
case	O
of	O
-	B
disomy	I
15	I
in	O
paternal	B
1	O
is	O
most	O
maternal	O
with	O
adjacent	O
with	O
that	O
segregation	O
.	O
a	O
PWS	O
t	O
consistent	O
;	O
;	O
15	O
)	O
on	O
for	O
p25	O
q11	O
.	O
15	O
)	O
(	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
3	O
chromosome	O
2	O
of	O

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B
disomy	I
15	I
in	O
PWS	B
that	O
is	O
most	O
consistent	O
with	O
adjacent	O
-	O
1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
paternal	O
strange	O
	O
paternal	O
strange	O
	O
strange	O
strange	O
	O
strange	O
strange	O
strange	O
strange	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B
disomy	I
15	I
in	O
PWS	B
that	O
is	O
most	O
consistent	O
with	O
adjacent	O
-	O
1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
paternal	O
strange	O
	O
paternal	O
strange	O
	O
strange	O
strange	O
	O
strange	O
strange	O
strange	O
cost	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
15	I
in	O
PWS	B
is	O
consistent	O
with	O
adjacent	O
segregation	O
(	O
3	O
;	O
)	O
(	O
;	O
q11	O
.	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
chromosome	O
.	O

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B
disomy	I
in	O
PWS	B
that	O
is	O
most	O
segregation	O
paternal	O
(	O
3	O
;	O
)	O
(	O
p25	O
;	O
q11	O
.	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O

.	O
-	O
on	O
an	O
unusual	O
case	O
nondisjunction	O
maternal	B
disomy	I
15	I
in	O
meiotic	B
that	O
;	O
)	O
consistent	O
with	O
adjacent	O
q11	O
1	O
segregation	O
of	O
15	O
paternal	O
chromosome	O
(	O
p25	O
is	O
most	O
t	O
(	O
2	O
;	O
report	O
We	O
3	O
)	O
with	O
simultaneous	O
maternal	O
PWS	O
of	O
for	O
a	O
15	O
.	O

We	O
cover	O
on	O
an	O
strange	O
cause	O
of	O
enate	B
disomy	I
fifteen	I
in	O
PWS	B
that	O
is	O
most	O
uniform	O
with	O
conterminous	O
-	O
one	O
sequestration	O
of	O
a	O
parental	O
t	O
(	O
3	O
;	O
fifteen	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
with	O
cooccurring	O
enate	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
fifteen	O
.	O

We	O
report	O
on	O
an	O
strange	O
case	O
of	O
parental	B
disomy	I
xv	I
in	O
PWS	B
that	O
is	O
most	O
logical	O
with	O
contiguous	O
-	O
ane	O
separatism	O
of	O
a	O
parental	O
t	O
(	O
triplet	O
;	O
xv	O
)	O
(	O
p25	O
;	O
q11	O
.	O
two	O
)	O
with	O
simultaneous	O
parental	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
xv	O
.	O

We	O
reputation	O
on	O
an	O
strange	O
sheath	O
of	O
enate	B
disomy	I
xv	I
in	O
PWS	B
that	O
is	O
most	O
uniform	O
with	O
conterminous	O
-	O
one	O
separatism	O
of	O
a	O
parental	O
t	O
(	O
trinity	O
;	O
xv	O
)	O
(	O
p25	O
;	O
q11	O
.	O
deuce	O
)	O
with	O
cooccurring	O
enate	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
xv	O
.	O

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B
disomy	I
15	I
in	O
PWS	B
that	O
is	O
most	O
consistent	O
with	O
adjacent	O
-	O
1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
paternal	O
strange	O
	O
paternal	O
strange	O
	O
strange	O
strange	O
	O
strange	O
strange	O
strange	O
strange	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B
disomy	I
15	I
in	O
PWS	B
that	O
is	O
most	O
consistent	O
with	O
adjacent	O
-	O
1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O

The	O
patient	O
(	O
.	O
.	O
)	O
,	O
-	O
male	O
with	O
PWS	B
was	O
found	O
have	O
47	O
chromosomes	O
supernumerary	O
,	O
paternal	O
der	O
(	O
)	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
15	O
,	O
and	O
distal	O
chromosome	O

The	O
patient	O
(	O
j	O
.	O
barn	O
.	O
)	O
,	O
a	O
seventeen	O
-	O
yr	O
-	O
old	O
white	O
male	O
with	O
PWS	B
,	O
was	O
get	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
surplus	O
,	O
agnate	O
der	O
(	O
fifteen	O
)	O
dwell	O
of	O
the	O
short	O
subdivision	O
and	O
the	O
proximal	O
farsighted	O
subdivision	O
of	O
chromosome	O
fifteen	O
,	O
and	O
distal	O
chromosome	O
subdivision	O
3p	O
.	O

The	O
patient	O
(	O
j	O
.	O
B	O
.	O
)	O
,	O
a	O
17	O
-	O
yr	O
-	O
erstwhile	O
white	O
manful	O
with	O
PWS	B
,	O
was	O
ground	O
to	O
have	O
xlvii	O
chromosomes	O
with	O
a	O
spare	O
,	O
agnatic	O
der	O
(	O
15	O
)	O
comprise	O
of	O
the	O
brusque	O
arm	O
and	O
the	O
proximal	O
hanker	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O
3p	O
.	O

The	O
patient	O
J	O
.	O
)	O
,	O
a	O
17	O
-	O
year	O
-	O
old	O
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
consisting	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O

)	O
with	O
(	O
J	O
.	O
B	O
the	O
)	O
,	O
a	O
17	O
and	O
year	O
a	O
supernumerary	O
white	O
male	O
with	O
patient	B
,	O
was	O
found	O
15	O
have	O
long	O
chromosomes	O
chromosome	O
-	O
,	O
PWS	O
paternal	O
consisting	O
(	O
old	O
The	O
3p	O
of	O
the	O
short	O
arm	O
-	O
.	O
proximal	O
to	O
arm	O
of	O
,	O
15	O
47	O
and	O
distal	O
chromosome	O
arm	O
der	O
.	O

The	O
patient	O
paternal	O
J	O
.	O
B	O
.	O
15	O
,	O
a	O
17	O
have	O
,	O
-	O
old	O
)	O
male	O
with	O
the	B
year	O
was	O
chromosome	O
to	O
-	O
47	O
chromosome	O
3p	O
of	O
supernumerary	O
,	O
(	O
.	O
chromosomes	O
15	O
)	O
arm	O
of	O
der	O
short	O
arm	O
and	O
the	O
with	O
long	O
consisting	O
(	O
found	O
white	O
,	O
and	O
distal	O
a	O
arm	O
proximal	O
PWS	O

and	O
47	O
(	O
J	O
.	O
B	O
the	O
male	O
,	O
a	O
17	O
-	O
year	O
distal	O
chromosome	O
white	O
)	O
chromosome	O
PWS	B
,	O
3p	O
found	O
to	O
have	O
a	O
chromosomes	O
with	O
the	O
arm	O
,	O
supernumerary	O
.	O
(	O
15	O
)	O
consisting	O
of	O
,	O
der	O
arm	O
and	O
was	O
proximal	O
long	O
paternal	O
of	O
with	O
15	O
short	O
The	O
-	O
old	O
arm	O
patient	O
.	O

The	O
patient	O
(	O
J	O
.	O
B	O
.	O
)	O
ampere	O
ampere	O
excess	O
yr	O
agnatic	O
	O
edward	O
white	O
,	O
a	O
17	O
-	O
year	O
-	O
old	O
white	O
male	O
with	B
PWS	O
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
recollective	O
	O
manlike	O
recollective	O
	O
manlike	O
build	O
up	O
	O
consist	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O

The	O
patient	O
(	O
J	O
.	O
B	O
.	O
)	O
ampere	O
ampere	O
excess	O
yr	O
agnatic	O
	O
edward	O
white	O
,	O
a	O
17	O
-	O
year	O
-	O
old	O
white	O
male	O
with	B
PWS	O
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
recollective	O
	O
manlike	O
recollective	O
	O
manlike	O
build	O
up	O
	O
manlike	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O

The	O
patient	O
(	O
joule	O
.	O
boron	O
.	O
)	O
,	O
a	O
17	O
-	O
twelvemonth	O
-	O
old	O
white	O
male	O
with	O
PWS	B
,	O
was	O
ground	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
excess	O
,	O
maternal	O
der	O
(	O
xv	O
)	O
consisting	O
of	O
the	O
little	O
branch	O
and	O
the	O
proximal	O
farseeing	O
branch	O
of	O
chromosome	O
xv	O
,	O
and	O
distal	O
chromosome	O
branch	O
3p	O
.	O

The	O
patient	O
(	O
J	O
.	O
B	O
.	O
)	O
,	O
a	O
17	O
-	O
year	O
-	O
old	O
white	O
male	O
with	O
PWS	B
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O
3p	O
.	O

The	O
t	O
(	O
tierce	O
;	O
15	O
)	O
was	O
give	O
in	O
the	O
equilibrize	O
dos	O
in	O
the	O
patients	O
father	O
and	O
a	O
sister	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
sis	O
introduce	O
introduce	O
introduce	O
introduce	O
introduce	O
a	O
sister	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
sis	O
introduce	O
introduce	O
introduce	O
introduce	O
introduce	O
a	O
sister	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
in	O
the	O
state	O
in	O
the	O
patients	O
father	O
and	O
a	O

the	O
t	O
present	O
)	O
;	O
15	O
patients	O
was	O
(	O
in	O
the	O
balanced	O
.	O
in	O
3	O
The	O
father	O
and	O
a	O
sister	O
state	O

The	O
t	O
(	O
terzetto	O
;	O
fifteen	O
)	O
was	O
demonstrate	O
in	O
the	O
equilibrize	O
commonwealth	O
in	O
the	O
patients	O
father	O
and	O
a	O
sister	O
.	O

.	O
t	O
(	O
the	O
;	O
15	O
)	O
a	O
the	O
in	O
3	O
balanced	O
in	O
state	O
present	O
patients	O
father	O
and	O
was	O
The	O
sister	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
sis	O
introduce	O
introduce	O
introduce	O
introduce	O
mt	O
a	O
sister	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
the	O
and	O
a	O
sister	O
.	O

The	O
t	O
(	O
troika	O
;	O
xv	O
)	O
was	O
nowadays	O
in	O
the	O
poise	O
state	O
in	O
the	O
patients	O
father	O
and	O
a	O
babe	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
a	O
sister	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	B
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
of	O
the	O
PWS	B
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
J	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

Fluorescent	O
in	O
situ	O
demonstrated	O
that	O
the	O
PWS	B
critical	O
resided	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
the	O
PWS	B
region	O
on	O
the	O
in	O

the	O
that	O
situ	O
hybridization	O
analysis	O
demonstrated	O
resided	O
present	O
PWS	B
critical	O
region	O
that	O
on	O
on	O
normal	O
chromosome	O
3	O
and	O
the	O
there	O
was	O
no	O
the	O
of	O
Fluorescent	O
PWS	B
of	O
the	O
derivative	O
deletion	O
pair	O
J	O
15s	O
in	O
in	O
region	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	B
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
of	O
the	O
PWS	B
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
J	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

on	O
in	O
situ	O
hybridization	O
3	O
demonstrated	O
derivative	O
of	O
PWS	B
critical	O
region	O
resided	O
on	O
the	O
the	O
chromosome	O
analysis	O
pair	O
that	O
there	O
the	O
no	O
deletion	O
of	O
in	O
PWS	B
region	O
Fluorescent	O
and	O
normal	O
the	O
that	O
15s	O
present	O
was	O
J	O
.	O

fluorescent	O
in	O
situ	O
hybridisation	O
analysis	O
certify	O
that	O
the	O
PWS	B
critical	O
part	O
domicile	O
on	O
the	O
derivative	O
chromosome	O
tercet	O
and	O
that	O
there	O
was	O
no	O
excision	O
of	O
the	O
PWS	B
part	O
on	O
the	O
formula	O
duad	O
of	O
15s	O
introduce	O
in	O
j	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
demonstrated	O
that	O
the	O
PWS	B
critical	O
region	O
resided	O
derivative	O
chromosome	O
3	O
that	O
was	O
no	O
deletion	O
PWS	B
pair	O
of	O
15s	O
in	O
J	O

Fluorescent	O
in	O
pair	O
hybridization	O
analysis	O
J	O
that	O
the	O
PWS	B
critical	O
region	O
region	O
there	O
the	O
derivative	O
on	O
3	O
and	O
of	O
on	O
was	O
15s	O
deletion	O
demonstrated	O
the	O
chromosome	B
resided	O
no	O
PWS	O
normal	O
situ	O
that	O
the	O
present	O
in	O
of	O
.	O

Fluorescent	O
in	O
situ	O
hybridisation	O
analysis	O
show	O
that	O
the	O
PWS	B
vital	O
part	O
occupy	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
omission	O
of	O
the	O
PWS	B
part	O
on	O
the	O
convention	O
duet	O
of	O
xv	O
confront	O
in	O
j	O
.	O

fluorescent	O
in	O
situ	O
crossing	O
analysis	O
establish	O
that	O
the	O
PWS	B
critical	O
region	O
domiciliate	O
on	O
the	O
differential	O
chromosome	O
trey	O
and	O
that	O
there	O
was	O
no	O
omission	O
of	O
the	O
PWS	B
region	O
on	O
the	O
rule	O
geminate	O
of	O
fifteen	O
gift	O
in	O
J	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	B
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
of	O
the	O
PWS	B
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
J	O
.	O

.	O

.	O

.	O
B	O

b	O
complex	O
B	O

.	O
B	O

b	O
.	O

b	O
complex	O
B	O

barn	O
.	O

b	O
complex	O
B	O

B	O
.	O

Methylation	O
analysis	O
at	O
exon	O
baseborn	O
newton	O
indium	O
j	O
lowly	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J	O
lowly	O
lowly	O
colligate	O
.	O

Methylation	O
analysis	O
at	O
exon	O
baseborn	O
newton	O
indium	O
j	O
lowly	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
paternal	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J	O
lowly	O
lowly	O
colligate	O
.	O

only	O
analysis	O
at	O
exon	O
alpha	O
of	O
N	O
)	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
characteristic	O
the	O
the	O
in	O
small	O
pattern	O
showed	O
a	O
Methylation	O
polypeptide	O
of	O
gene	O
(	O
maternal	O
chromosome	O
15	O
.	O
J	O
SNRPN	O

Methylation	O
analysis	O
at	O
exon	O
baseborn	O
newton	O
indium	O
j	O
lowly	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J	O
lowly	O
lowly	O
colligate	O
.	O

Methylation	O
analysis	O
at	O
exon	O
of	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J	O
.	O

Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
atomic	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
newton	O
(	O
SNRPN	O
)	O
factor	O
showed	O
a	O
figure	O
characteristic	O
of	O
only	O
the	O
parental	O
chromosome	O
15	O
in	O
J	O
.	O

in	O
analysis	O
the	O
(	O
alpha	O
of	O
15	O
small	O
exon	O
ribonucleoprotein	O
-	O
associated	O
pattern	O
N	O
at	O
nuclear	O
)	O
gene	O
showed	O
a	O
polypeptide	O
characteristic	O
of	O
only	O
SNRPN	O
the	O
chromosome	O
maternal	O
Methylation	O
J	O
.	O

Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
nuclear	O
-	O
associated	O
N	O
(	O
SNRPN	O
)	O
gene	O
showed	O
a	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J	O
.	O

-	O
analysis	O
at	O
in	O
alpha	O
of	O
the	O
maternal	O
only	O
ribonucleoprotein	O
the	O
associated	O
chromosome	O
a	O
of	O
SNRPN	O
)	O
gene	O
.	O
N	O
pattern	O
characteristic	O
(	O
nuclear	O
Methylation	O
small	O
polypeptide	O
15	O
exon	O
J	O
showed	O

Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
atomic	O
ribonucleoprotein	O
-	O
affiliate	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
cistron	O
point	O
a	O
shape	O
characteristic	O
of	O
only	O
the	O
parental	O
chromosome	O
xv	O
in	O
joule	O
.	O

Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J	O
.	O

b	O
complex	O
B	O

.	O
B	O

.	O

b	O
complex	O
B	O

.	O
B	O

b	O
complex	O
B	O

.	O

B	O
.	O

disomy	I
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
acid	O
beta3	O
subunit	O
(	O
GABRB3	O
)	O
locus	O
.	O

microsatellite	B
disomy	I
was	O
receptor	O
by	O
polymerase	O
chain	O
.	O
)	O
of	O
locus	O
repeats	O
at	O
beta3	O
GABRB3	O
-	O
aminobutyric	O
acid	O
confirmed	O
the	O
subunit	O
(	O
gamma	O
analysis	O
Maternal	O
reaction	O

enate	B
disomy	I
was	O
sustain	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
ingeminate	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
caustic	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O
)	O
locale	O
.	O

maternal	B
disomy	I
was	O
substantiate	O
by	O
polymerase	O
strand	O
response	O
analysis	O
of	O
microsatellite	O
iterate	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
dot	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O
)	O
venue	O
.	O

Maternal	B
disomy	I
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
repeats	O
at	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
)	O
locus	O
.	O

Maternal	B
disomy	I
was	O
confirmed	O
past	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
fractional	O
monetary	O
unit	O
fractional	O
monetary	O
unit	O
locale	O
cost	O
locale	O
depth	O
psychology	O
receptor	O
beta3	O
subunit	O

Maternal	B
disomy	I
was	O
confirmed	O
past	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
fractional	O
monetary	O
unit	O
fractional	O
monetary	O
unit	O
locale	O
cost	O
locale	O
iterate	O
receptor	O
beta3	O
subunit	O
(	O

Maternal	B
disomy	I
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
repeats	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O

)	B
disomy	I
was	O
confirmed	O
by	O
polymerase	O
the	O
aminobutyric	O
analysis	O
of	O
microsatellite	O
repeats	O
(	O
chain	O
locus	O
-	O
reaction	O
subunit	O
receptor	O
beta3	O
Maternal	O
at	O
GABRB3	O
acid	O
gamma	O
.	O

maternal	B
disomy	I
was	O
confirmed	O
by	O
polymerase	O
range	O
response	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O
)	O
venue	O
.	O

Maternal	B
disomy	I
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O
)	O
locus	O
.	O

A	O
niece	O
haploinsufficiency	O
B	O
.	O
B	O
and	O
der	O
with	O
45	O
chromosomes	O
with	O
(	O
derivative	O
3	O
that	O
without	O
the	O
of	O
the	O
15	O
distal	O
demonstrated	O
a	O
phenotype	O
but	O
.	O
)	O
reported	O
for	O
(	O
)	O
consistent	O
3	O
p	O
.	O

niece	O
B	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
)	O
demonstrated	O
a	O
consistent	O
that	O
reported	O
for	O
distal	O

A	O
niece	O
(	O
boron	O
.	O
boron	O
.	O
)	O
with	O
xlv	O
chromosomes	O
and	O
the	O
derivative	O
trio	O
but	O
without	O
the	O
der	O
(	O
fifteen	O
)	O
exhibit	O
a	O
phenotype	O
coherent	O
with	O
that	O
describe	O
for	O
haploinsufficiency	O
of	O
distal	O
trio	O
p	O
.	O

that	O
15	O
(	O
B	O
without	O
B	O
3	O
of	O
with	O
45	O
chromosomes	O
and	O
the	O
phenotype	O
)	O
but	O
.	O
haploinsufficiency	O
der	O
(	O
derivative	O
)	O
demonstrated	O
a	O
niece	O
consistent	O
with	O
A	O
the	O
for	O
reported	O
.	O
distal	O
3	O
p	O
.	O

A	O
niece	O
(	O
B	O
account	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(	O
15	O
)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p	O
write	O
up	O
write	O
up	O
write	O
up	O
write	O
up	O
write	O
up	O

phenotype	O
der	O
(	O
B	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
that	O
for	O
but	O
without	O
the	O
3	O
(	O
15	O
)	O
reported	O
a	O
A	O
consistent	O
of	O
derivative	O
3	O
demonstrated	O
haploinsufficiency	O
.	O
distal	O
p	O
niece	O
with	O

A	O
niece	O
(	O
B	O
B	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p	O
.	O

A	O
niece	O
(	O
B	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
differential	O
terzetto	O
but	O
without	O
the	O
der	O
(	O
xv	O
)	O
establish	O
a	O
phenotype	O
logical	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
terzetto	O
p	O
.	O

A	O
niece	O
(	O
B	O
chromosome	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(	O
15	O
)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p	O
merely	O
merely	O
merely	O
merely	O
merely	O
merely	O
merely	O
merely	O
merely	O
.	O

A	O
niece	O
(	O
B	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(	O
fifteen	O
)	O
demonstrated	O
a	O
phenotype	O
coherent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p	O
.	O

A	O
niece	O
(	O
B	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(	O
15	O
)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p	O
.	O

Uniparental	B
disomy	I
associated	O
with	O
cost	O
account	O
antecedently	O
merely	O
brainsick	O
unbalanced	O
segregation	O
of	O
non	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
sheath	O
,	O
to	O
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B
toll	O
toll	O
receive	O
.	O

Uniparental	B
disomy	I
associated	O
with	O
cost	O
account	O
antecedently	O
merely	O
brainsick	O
unbalanced	O
segregation	O
of	O
non	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
ampere	O
,	O
to	O
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B
toll	O
toll	O
receive	O
.	O

been	B
disomy	I
associated	O
with	O
unbalanced	O
segregation	O
reported	O
has	O
-	O
Robertsonian	O
translocations	O
has	O
knowledge	O
of	O
observed	O
of	O
non	O
our	O
,	O
to	O
Uniparental	O
been	O
,	O
not	O
previously	O
in	O
a	O
case	O
.	O
PWS	B
but	O

Uniparental	B
disomy	I
associated	O
with	O
cost	O
account	O
antecedently	O
merely	O
brainsick	O
unbalanced	O
segregation	O
of	O
non	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
sheath	O
,	O
to	O
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B
toll	O
toll	O
receive	O
.	O

Uniparental	B
disomy	I
associated	O
with	O
segregation	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B
.	O

Uniparental	B
disomy	I
link	O
with	O
demented	O
sequestration	O
of	O
not	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
account	O
antecedently	O
but	O
has	O
not	O
,	O
to	O
our	O
cognition	O
,	O
been	O
observed	O
in	O
a	O
casing	O
of	O
PWS	B
.	O

of	B
disomy	I
observed	O
previously	O
unbalanced	O
segregation	O
case	O
non	O
with	O
Robertsonian	O
translocations	O
has	O
our	O
reported	O
associated	O
-	O
has	O
not	O
,	O
to	O
been	O
knowledge	O
,	O
been	O
but	O
of	O
a	O
in	O
Uniparental	O
PWS	B
.	O

Uniparental	B
disomy	I
associated	O
with	O
unbalanced	O
segregation	O
of	O
non	O
-	O
translocations	O
has	O
reported	O
previously	O
but	O
has	O
not	O
,	O
to	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B
.	O

translocations	B
disomy	I
associated	O
of	O
unbalanced	O
segregation	O
of	O
in	O
been	O
Robertsonian	O
observed	O
has	O
a	O
to	O
,	O
but	O
has	O
not	O
.	O
reported	O
our	O
knowledge	O
previously	O
-	O
Uniparental	O
non	O
been	O
case	O
with	O
PWS	B
,	O

Uniparental	B
disomy	I
associated	O
with	O
unhinged	O
separatism	O
of	O
not	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
antecedently	O
but	O
has	O
not	O
,	O
to	O
our	O
cognition	O
,	O
been	O
respect	O
in	O
a	O
instance	O
of	O
PWS	B
.	O

Uniparental	B
disomy	I
associated	O
with	O
unbalanced	O
segregation	O
of	O
non	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
,	O
to	O
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B
.	O

complementation	O
,	O
our	O
as	O
are	O
best	O
interpreted	O
findings	O
UPD	O
gamete	O
maternal	O
resulting	O
Furthermore	O
in	B
true	I
15	I
and	O
PWS	B

furthermore	O
,	O
our	O
findings	O
are	O
unspoiled	O
interpreted	O
as	O
truthful	O
gamete	O
complementation	O
lead	O
in	O
parental	B
UPD	I
15	I
and	O
PWS	B

furthermore	O
,	O
our	O
findings	O
are	O
well	O
interpreted	O
as	O
honest	O
gamete	O
complementation	O
ensue	O
in	O
parental	B
UPD	I
15	I
and	O
PWS	B

Furthermore	O
,	O
our	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B
UPD	I
15	I
and	O
PWS	B

Furthermore	O
,	O
our	O
incur	O
are	O
right	O
render	O
as	O
admittedly	O
gamete	O
complementation	O
resulting	O
in	O
enatic	B
UPD	I
15	I
and	O
PWS	B

Furthermore	O
,	O
honest	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B
UPD	I
15	I
and	O
true	O
true	O
true	O
every	O
bit	B

Furthermore	O
,	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
resulting	O
in	O
UPD	I
15	I
and	O
PWS	B

Furthermore	O
,	O
honest	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B
UPD	I
15	I
and	O
true	O
true	O
true	O
every	O
bit	B

,	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
PWS	B

Furthermore	O
,	O
true	O
UPD	O
are	O
best	O
in	O
as	O
our	O
gamete	O
complementation	O
resulting	O
interpreted	O
maternal	B
findings	I
15	I
and	O
PWS	B

Furthermore	O
,	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B
UPD	I
15	I
and	O
PWS	B

Schwartz	B
-	I
-	I
for	I
type	I
2	I
a	O
Stuve	B
Jampel	I
Wiedemann	I
syndrome	I
:	O
and	O
case	O
syndrome	O
"	O
lumping	O
"	O
.	O

Jampel	I
syndrome	I
type	I
2	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
"	O
lumping	O
"	O
.	O

Schwartz	B
-	I
Jampel	I
syndrome	I
eccentric	I
ii	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
:	O
a	O
fount	O
for	O
"	O
collocate	O
"	O
.	O

Schwartz	B
-	I
Jampel	I
syndrome	I
type	I
two	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
:	O
a	O
casing	O
for	O
"	O
collocate	O
"	O
.	O

lumping	B
-	I
Jampel	I
syndrome	I
type	I
2	I
case	O
for	B
-	I
Wiedemann	I
syndrome	I
:	O
"	O
and	O
Stuve	O
"	O
a	O
Schwartz	O
.	O

Schwartz	B
-	I
type	I
2	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
:	O
a	O
case	O
for	O
"	O
lumping	O
.	O

Schwartz	B
-	I
Jampel	I
syndrome	I
type	I
2	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
:	O
a	O
case	O
for	O
"	O
lumping	O
"	O
international	O
ampere	O
ampere	O
ampere	O
ampere	O
	O

Schwartz	B
-	I
Jampel	I
syndrome	I
case	I
deuce	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
:	O
a	O
case	O
for	O
"	O
lumping	O
"	O
.	O

Schwartz	B
-	I
Jampel	I
syndrome	I
type	I
2	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
:	O
a	O
case	O
for	O
"	O
lumping	O
"	O
international	O
ampere	O
international	O
ampere	O
ampere	O
ampere	O

case	B
-	I
Jampel	I
syndrome	I
type	I
2	I
and	O
.	B
for	I
Wiedemann	I
syndrome	I
:	O
Schwartz	O
a	O
-	O
"	O
lumping	O
"	O
Stuve	O

Schwartz	B
-	I
Jampel	I
syndrome	I
type	I
2	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
:	O
a	O
case	O
for	O
"	O
lumping	O
"	O
.	O

demonstrated	O
of	O
a	O
genetically	O
distinct	O
usually	O
lethal	O
the	O
Schwartz	B
Jampel	I
syndrome	I
of	O
and	O
skeletal	B
dysplasia	I
which	O
we	O
called	O
type	I
2	I
.	O

Recent	O
studies	O
demonstrated	O
the	O
ampere	O
trenchant	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
)	O
of	O
myotonia	B
and	O
skeletal	B
dysplasia	I
,	O
which	O
we	O
called	O
SJS	B
type	I
2	I
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O
international	O

and	O
syndrome	O
demonstrated	O
the	O
existence	O
of	O
dysplasia	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
,	O
we	O
Schwartz	B
-	I
Jampel	I
2	I
(	O
SJS	B
)	O
SJS	O
myotonia	B
Recent	O
skeletal	B
a	I
of	O
the	O
of	O
called	O
which	B
type	I
.	I
studies	O

recent	O
canvas	O
demonstrated	O
the	O
creation	O
of	O
a	O
genetically	O
distinct	O
,	O
unremarkably	O
deadly	O
bod	O
of	O
the	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
)	O
of	O
myotonia	B
and	O
haggard	B
dysplasia	I
,	O
which	O
we	O
called	O
SJS	B
type	I
deuce	I
.	O

Recent	O
studies	O
skeletal	O
the	O
existence	O
of	O
a	O
)	O
distinct	O
,	O
usually	O
myotonia	O
,	O
of	O
the	O
called	B
-	I
Jampel	I
(	I
lethal	O
SJS	B
genetically	O
of	O
syndrome	B
and	O
dysplasia	B
demonstrated	I
type	O
which	O
we	O
Schwartz	O
form	B
SJS	I
2	I
.	O

Recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
form	O
of	O
the	O
Schwartz	B
Jampel	I
syndrome	I
(	O
SJS	B
)	O
myotonia	B
and	O
skeletal	B
dysplasia	I
which	O
we	O
SJS	B
type	I
2	I
.	O

holocene	O
analyse	O
present	O
the	O
existence	O
of	O
a	O
genetically	O
discrete	O
,	O
ordinarily	O
deadly	O
soma	O
of	O
the	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
)	O
of	O
myotonia	B
and	O
wasted	B
dysplasia	I
,	O
which	O
we	O
visit	O
SJS	B
type	I
ii	I
.	O

Recent	O
studies	O
demonstrated	O
the	O
ampere	O
macrocosm	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
)	O
of	O
myotonia	B
and	O
skeletal	B
dysplasia	I
,	O
which	O
we	O
called	O
SJS	B
type	I
2	I
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O
international	O

recent	O
study	O
prove	O
the	O
being	O
of	O
a	O
genetically	O
discrete	O
,	O
normally	O
deadly	O
phase	O
of	O
the	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
)	O
of	O
myotonia	B
and	O
gaunt	B
dysplasia	I
,	O
which	O
we	O
called	O
SJS	B
type	I
deuce	I
.	O

,	O
SJS	O
demonstrated	O
the	O
-	O
of	O
the	O
SJS	O
distinct	O
,	O
usually	O
lethal	O
form	O
and	O
genetically	O
Schwartz	B
existence	I
called	I
syndrome	I
(	O
of	B
)	O
of	O
myotonia	B
studies	O
skeletal	B
dysplasia	I
Recent	O
Jampel	O
we	O
which	O
a	B
type	I
2	I
.	O

Recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
)	O
of	O
myotonia	B
and	O
skeletal	B
dysplasia	I
,	O
which	O
we	O
called	O
SJS	B
type	I
2	I
.	O

This	O
disorder	O
is	O
reminiscent	O
contracture	O
some	O
other	O
southwestward	O
status	O
of	O
another	O
rare	O
condition	O
,	O
the	B
Stuve	I
-	I
Wiedemann	I
syndrome	O
(	B
SWS	O
)	O
,	O
which	O
comprises	B
campomelia	O
at	O
birth	O
with	B
skeletal	I
dysplasia	O
,	B
contractures	O
,	O
and	B
early	I
death	O
position	O
position	O
position	O
position	O
position	O

This	O
disorder	O
is	O
another	O
Stuve	B
-	I
Wiedemann	I
(	O
SWS	B
,	O
which	O
comprises	O
birth	O
with	O
skeletal	B
dysplasia	I
,	O
,	O
early	B
death	I
.	O

This	O
unhinge	O
is	O
redolent	O
of	O
another	O
uncommon	O
condition	O
,	O
the	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
(	O
southwestward	B
)	O
,	O
which	O
be	O
campomelia	B
at	O
nascency	O
with	O
emaciated	B
dysplasia	I
,	O
contractures	B
,	O
and	O
betimes	B
dying	I
.	O

This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
,	O
-	I
Wiedemann	I
syndrome	I
(	O
SWS	B
)	O
,	O
which	O
comprises	O
skeletal	B
dysplasia	I
,	O
contractures	B
,	O
and	O
early	B
death	I
.	O

This	O
disquiet	O
is	O
remindful	O
of	O
another	O
uncommon	O
circumstance	O
,	O
the	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
(	O
SWS	B
)	O
,	O
which	O
be	O
campomelia	B
at	O
bear	O
with	O
wasted	B
dysplasia	I
,	O
contractures	B
,	O
and	O
early	B
last	I
.	O

This	O
disorder	O
is	O
reminiscent	O
contracture	O
some	O
other	O
southwestward	O
status	O
of	O
another	O
rare	O
condition	O
,	O
the	B
Stuve	I
-	I
Wiedemann	I
syndrome	O
(	B
SWS	O
)	O
,	O
which	O
comprises	B
campomelia	O
at	O
birth	O
with	B
skeletal	I
dysplasia	O
,	B
contractures	O
,	O
and	B
early	I
death	O
position	O
position	O
position	O
position	O
position	O

This	O
disorder	O
is	O
redolent	O
of	O
another	O
uncommon	O
condition	O
,	O
the	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
(	O
southwestward	B
)	O
,	O
which	O
consist	O
campomelia	B
at	O
nascency	O
with	O
gaunt	B
dysplasia	I
,	O
contractures	B
,	O
and	O
other	B
destruction	I
.	O

campomelia	O
which	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition	O
,	O
the	O
Stuve	B
-	I
Wiedemann	I
skeletal	I
and	O
SWS	B
)	O
,	O
contractures	O
comprises	O
disorder	B
at	O
death	O
with	O
syndrome	B
dysplasia	I
,	O
This	B
(	O
birth	O
early	B
,	I
.	O

This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
condition	O
the	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
(	O
SWS	B
)	O
which	O
comprises	O
campomelia	B
at	O
birth	O
with	O
skeletal	B
contractures	B
,	O
and	O
death	I

This	O
disorder	O
is	O
reminiscent	O
contracture	O
some	O
other	O
southwestward	O
status	O
of	O
another	O
rare	O
condition	O
,	O
the	B
Stuve	I
-	I
Wiedemann	I
syndrome	O
(	B
SWS	O
)	O
,	O
which	O
comprises	B
campomelia	O
at	O
birth	O
with	B
skeletal	I
dysplasia	O
,	B
contractures	O
,	O
and	B
early	I
death	O
position	O
position	O
position	O
position	O
position	O

This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition	O
,	O
the	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
(	O
SWS	B
)	O
,	O
which	O
comprises	O
campomelia	B
at	O
birth	O
with	O
skeletal	B
dysplasia	I
,	O
contractures	B
,	O
and	O
early	B
death	I
.	O

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
,	O
we	O
reviewed	O
literature	O
obtained	O
a	O
follow	O
of	O
patients	O
,	O
one	O
SJS	B
type	I
at	O
age	O
10	O
another	O
with	O
SWS	B
at	O
age	O
years	O

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
reviewed	O
the	O
literature	O
and	O
obtained	O
the	O
surviving	O
,	O
one	O
with	O
type	I
2	I
at	O
age	O
10	O
years	O
SWS	B
at	O
age	O
7	O
years	O
.	O

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	B
type	I
2	I
at	O
age	O
10	O
years	O
	O
yr	O
years	O
	O
yr	O
years	O
	O
yr	O
ampere	O
ampere	O
ampere	O
ampere	O
yr	O
and	O
another	O
with	O
SWS	B
at	O
age	O
7	O
years	O
.	O

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	B
type	I
2	I
at	O
age	O
10	O
years	O
	O
yr	O
years	O
	O
yr	O
years	O
	O
yr	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
and	O
another	O
with	O
SWS	B
at	O
age	O
7	O
years	O
.	O

To	O
test	O
for	O
potential	O
nosologic	O
identity	O
between	O
these	O
upset	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
incur	O
a	O
postdate	O
-	O
up	O
of	O
the	O
only	O
two	O
go	O
patients	O
,	O
unity	O
with	O
SJS	B
type	I
ii	I
at	O
age	O
tenner	O
age	O
and	O
another	O
with	O
SWS	B
at	O
age	O
seven	O
age	O
.	O

To	O
for	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	B
type	I
2	I
at	O
10	O
and	O
another	O
with	O
SWS	B
at	O
age	O
7	O
years	O

To	O
screen	O
for	O
potential	O
nosologic	O
identity	O
between	O
these	O
disorderliness	O
,	O
we	O
critique	O
the	O
literature	O
and	O
receive	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
live	O
patients	O
,	O
one	O
with	O
SJS	B
eccentric	I
2	I
at	O
years	O
ten	O
class	O
and	O
another	O
with	O
sw	B
at	O
years	O
7	O
class	O
.	O

with	O
surviving	O
for	O
possible	O
a	O
identity	O
another	O
2	O
disorders	O
,	O
we	O
reviewed	O
the	O
between	O
follow	O
obtained	O
nosologic	O
and	O
-	O
up	O
these	O
the	O
only	O
two	O
one	O
patients	O
,	O
age	O
.	O
SJS	B
with	I
test	I
at	O
age	O
10	O
years	O
and	O
literature	O
To	O
SWS	B
at	O
of	O
7	O
years	O
type	O

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	B
type	I
2	I
at	O
age	O
10	O
years	O
	O
yr	O
years	O
	O
yr	O
years	O
	O
yr	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
and	O
another	O
with	O
SWS	B
at	O
age	O
7	O
years	O
.	O

To	O
test	O
for	O
potential	O
nosologic	O
identity	O
between	O
these	O
disquiet	O
,	O
we	O
critique	O
the	O
literature	O
and	O
prevail	O
a	O
observe	O
-	O
up	O
of	O
the	O
only	O
deuce	O
surviving	O
patients	O
,	O
unmatched	O
with	O
SJS	B
type	I
deuce	I
at	O
age	O
x	O
age	O
and	O
another	O
with	O
southwest	B
at	O
age	O
heptad	O
age	O
.	O

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	B
type	I
2	I
at	O
age	O
10	O
years	O
and	O
another	O
with	O
SWS	B
at	O
age	O
7	O
years	O
.	O

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
a	O
combination	O
of	O
a	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B
(	O
with	O
congenital	B
joint	I
,	O
respiratory	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B
,	O
and	O
death	O
in	O
)	O
with	O
a	O
distinct	O
campomelic	B
-	I
metaphyseal	I
skeletal	I

distinct	O
joint	O
as	O
having	O
either	O
neonatal	O
frequent	B
prenatal	O
SWS	B
presented	O
a	O
combination	O
of	O
.	O
-	O
,	O
or	O
difficulties	O
onset	O
neuromuscular	B
)	I
(	O
with	O
congenital	B
reported	I
contractures	I
,	O
death	O
-	O
feeding	O
and	O
SJS	O
tendency	O
to	O
hyperthermia	B
,	O
and	O
skeletal	O
respiratory	O
in	O
infancy	O
disorder	O
with	O
a	O
Patients	O
campomelic	B
severe	I
metaphyseal	I
dysplasia	I
,	I
a	O

patient	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
SWS	B
salute	O
a	O
compounding	O
of	O
a	O
austere	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B
trouble	I
(	O
with	O
inborn	B
roast	I
contractures	I
,	O
respiratory	O
and	O
fertilise	O
difficultness	O
,	O
leaning	O
to	O
hyperthermy	B
,	O
and	O
patronize	O
destruction	O
in	O
infancy	O
)	O
with	O
a	O
discrete	O
campomelic	B
-	I
metaphyseal	I
gaunt	I
dysplasia	I
.	O

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
terrible	O
southwestward	O
SWS	B
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B
disorder	I
(	O
with	O
congenital	B
joint	I
contractures	I
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B
,	O
indium	O
ampere	O
trenchant	O
indium	O
ampere	O
trenchant	O
haggard	O
ampere	O
trenchant	O
haggard	O
antepartum	O
antepartum	O
antepartum	O
and	O
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B
-	I
metaphyseal	I
skeletal	I
dysplasia	I
.	O

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
terrible	O
southwestward	O
SWS	B
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B
disorder	I
(	O
with	O
congenital	B
joint	I
contractures	I
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B
,	O
indium	O
ampere	O
trenchant	O
indium	O
ampere	O
trenchant	O
haggard	O
ampere	O
trenchant	O
haggard	O
antepartum	O
antepartum	O
antepartum	O
and	O
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B
-	I
metaphyseal	I
skeletal	I
dysplasia	I
.	O

reported	O
as	O
having	O
either	O
neonatal	O
or	O
SWS	B
of	O
,	O
prenatal	O
neuromuscular	B
with	O
congenital	B
joint	I
contractures	I
respiratory	O
and	O
,	O
tendency	O
hyperthermia	B
,	O
in	O
)	O
with	O
a	O
campomelic	B
-	I
metaphyseal	I
dysplasia	I
.	O

Patients	O
reported	O
as	O
neonatal	O
SJS	B
or	O
SWS	B
presented	O
a	O
combination	O
of	O
,	O
-	O
onset	O
neuromuscular	B
(	O
with	O
congenital	B
joint	I
contractures	I
,	O
and	O
feeding	O
tendency	O
hyperthermia	B
,	O
and	O
frequent	O
infancy	O
)	O
with	O
a	O
campomelic	B
-	I
metaphyseal	I
skeletal	I
dysplasia	I
.	O

Patients	O
account	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
southwest	B
presented	O
a	O
combining	O
of	O
a	O
severe	O
,	O
antepartum	O
-	O
attack	O
neuromuscular	B
upset	I
(	O
with	O
inborn	B
joint	I
contractures	I
,	O
respiratory	O
and	O
prey	O
trouble	O
,	O
disposition	O
to	O
hyperthermy	B
,	O
and	O
frequent	O
dying	O
in	O
babyhood	O
)	O
with	O
a	O
trenchant	O
campomelic	B
-	I
metaphyseal	I
haggard	I
dysplasia	I
.	O

Patients	O
cover	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
southwestward	B
salute	O
a	O
combination	O
of	O
a	O
grievous	O
,	O
antepartum	O
-	O
onset	O
neuromuscular	B
unhinge	I
(	O
with	O
inborn	B
juncture	I
contractures	I
,	O
respiratory	O
and	O
feeding	O
difficultness	O
,	O
trend	O
to	O
hyperthermy	B
,	O
and	O
frequent	O
decease	O
in	O
babyhood	O
)	O
with	O
a	O
trenchant	O
campomelic	B
-	I
metaphyseal	I
bony	I
dysplasia	I
.	O

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
terrible	O
southwestward	O
SWS	B
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B
disorder	I
(	O
with	O
congenital	B
joint	I
contractures	I
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B
,	O
indium	O
ampere	O
trenchant	O
indium	O
ampere	O
trenchant	O
haggard	O
ampere	O
trenchant	O
haggard	O
antepartum	O
antepartum	O
account	O
and	O
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B
-	I
metaphyseal	I
skeletal	I
dysplasia	I
.	O

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
SWS	B
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B
disorder	I
(	O
with	O
congenital	B
joint	I
contractures	I
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B
,	O
and	O
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B
-	I
metaphyseal	I
skeletal	I
dysplasia	I
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorderliness	O
seem	O
to	O
be	O
a	O
exclusive	O
entity	O
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
single	O
entity	O
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
single	O
entity	O
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
so	O
extensive	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
single	O

appear	O
similarity	O
is	O
radiographic	O
clinical	O
and	O
to	O
findings	O
of	O
so	O
extensive	O
that	O
.	O
disorders	O
the	O
The	O
be	O
a	O
single	O
entity	O
these	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
encounter	O
is	O
so	O
wide	O
that	O
these	O
disarray	O
seem	O
to	O
be	O
a	O
bingle	O
entity	O
.	O

.	O
similarity	O
of	O
extensive	O
clinical	O
and	O
radiographic	O
single	O
appear	O
so	O
the	O
that	O
disorders	O
these	O
is	O
to	O
be	O
a	O
findings	O
The	O
entity	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
cost	O
cost	O
cost	O
cost	O
cost	O
receive	O
single	O
entity	O
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
appear	O
a	O
single	O
entity	O
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
see	O
is	O
so	O
extensive	O
that	O
these	O
trouble	O
seem	O
to	O
be	O
a	O
ace	O
entity	O
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
single	O
entity	O
.	O

The	O
observation	O
an	O
identical	O
and	O
pattern	O
of	O
progressive	O
dysplasia	I
in	O
the	O
two	O
patients	O
with	O
SJS	B
type	I
2	I
,	O
one	O
with	O
SWS	B
beyond	O
adds	O
to	O
the	O
in	O
favor	O
of	O
identity	O
.	O

The	O
follow	O
-	O
up	O
observation	O
and	O
unique	O
pattern	O
of	O
progressive	O
dysplasia	I
in	O
(	O
SJS	B
type	I
one	O
)	O
surviving	O
beyond	O
infancy	O
to	O
the	O
favor	O
of	O
.	O

The	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B
dysplasia	I
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
SJS	B
type	I
2	I
,	O
one	O
with	O
SWS	B
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
indistinguishability	O
party	O
favour	O
reflexion	O
indistinguishability	O
reflexion	O
reflexion	O
reflexion	O
reflexion	O
reflexion	O
reflexion	O
reflexion	O
reflexion	O
evidence	O
in	O
favor	O
of	O
identity	O

The	O
follow	O
-	O
up	O
notice	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
imperfect	O
bone	B
dysplasia	I
in	O
the	O
two	O
patients	O
(	O
nonpareil	O
with	O
SJS	B
case	I
deuce	I
,	O
nonpareil	O
with	O
southwestward	B
)	O
survive	O
beyond	O
babyhood	O
impart	O
to	O
the	O
manifest	O
in	O
favour	O
of	O
indistinguishability	O
.	O

The	O
follow	O
surviving	O
up	O
observation	O
the	O
an	O
patients	O
and	O
unique	O
pattern	O
one	O
(	O
bone	B
dysplasia	I
identical	O
the	O
two	O
in	O
progressive	O
one	O
infancy	O
SJS	B
of	I
2	I
in	O
of	O
with	O
SWS	B
)	O
-	O
with	O
beyond	O
adds	O
to	O
type	O
evidence	O
,	O
favor	O
of	O
identity	O
.	O

The	O
follow	O
-	O
up	O
reflexion	O
of	O
an	O
monovular	O
and	O
singular	O
normal	O
of	O
progressive	O
bone	B
dysplasia	I
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
SJS	B
eccentric	I
two	I
,	O
one	O
with	O
sw	B
)	O
surviving	O
beyond	O
babyhood	O
summate	O
to	O
the	O
grounds	O
in	O
favour	O
of	O
identity	O
.	O

to	O
patients	O
-	O
up	O
observation	O
of	O
.	O
identical	O
and	O
unique	O
pattern	O
identity	O
progressive	O
2	B
)	I
in	O
the	O
two	O
with	O
(	O
one	O
with	O
the	B
type	I
bone	I
,	O
adds	O
follow	O
beyond	B
SJS	O
surviving	O
SWS	O
infancy	O
dysplasia	O
The	O
one	O
evidence	O
in	O
favor	O
of	O
of	O
an	O

The	O
follow	O
-	O
up	O
observation	O
of	O
and	O
unique	O
pattern	O
of	O
bone	B
dysplasia	I
in	O
the	O
two	O
(	O
one	O
with	O
SJS	B
2	I
,	O
with	O
SWS	B
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
evidence	O
in	O
of	O
identity	O
.	O

favor	O
2	O
-	O
up	O
the	O
of	O
one	O
beyond	O
and	O
unique	O
pattern	O
of	O
progressive	O
an	B
in	I
in	O
observation	O
surviving	O
patients	O
(	O
bone	O
with	O
SJS	B
type	I
with	I
,	O
one	O
.	O
two	B
)	O
SWS	O
follow	O
infancy	O
adds	O
to	O
the	O
evidence	O
dysplasia	O
The	O
of	O
identity	O
identical	O

The	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B
dysplasia	I
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
SJS	B
type	I
2	I
,	O
one	O
with	O
SWS	B
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
indistinguishability	O
party	O
favour	O
reflexion	O
indistinguishability	O
reflexion	O
reflexion	O
reflexion	O
reflexion	O
reflexion	O
reflexion	O
reflexion	O
continuous	O
tense	O
evidence	O
in	O
favor	O
of	O

The	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B
dysplasia	I
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
SJS	B
type	I
2	I
,	O
one	O
with	O
SWS	B
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
evidence	O
in	O
favor	O
of	O
identity	O
.	O

The	O
surmisal	O
that	O
SWS	B
and	O
SJS	B
eccentric	I
two	I
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
.	O
.	O

The	O
hypothesis	O
that	O
SWS	B
and	O
SJS	B
type	I
2	I
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
.	O
.	O

The	O
hypothesis	O
that	O
SWS	B
and	O
SJS	B
type	I
2	I
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
.	O
.	O

that	O
SJS	B
type	I
2	I
the	O
same	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
.	O
.	O

The	O
hypothesis	O
that	O
SWS	B
and	O
2	I
are	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
.	O
.	O

that	O
SWS	B
and	O
SJS	B
2	I
are	O
the	O
same	O
disorder	O
be	O
testable	O
by	O
molecular	O
.	O
.	O

methods	O
hypothesis	O
that	O
.	B
and	O
SJS	B
type	I
are	I
2	O
the	O
testable	O
disorder	O
should	O
.	O
The	O
by	O
molecular	O
same	O
SWS	O
be	O

The	O
hypothesis	O
that	O
SWS	B
and	O
SJS	B
type	I
2	I
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
cost	O
cost	O
cost	O
cost	O
cost	O
saami	O
.	O
.	O

The	O
supposition	O
that	O
sw	B
and	O
SJS	B
type	I
two	I
are	O
the	O
same	O
unhinge	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
.	O
.	O

molecular	O
hypothesis	O
that	O
SWS	B
and	O
SJS	B
be	I
disorder	I
are	O
the	O
same	O
testable	O
The	O
type	O
2	O
methods	O
should	O
by	O
.	O
.	O

The	O
hypothesis	O
that	O
SWS	B
and	O
SJS	B
type	I
2	I
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
.	O
.	O

A	O
severe	O
model	O
of	O
mouse	O
von	B
disease	I
in	I
:	O
defects	O
and	O
hemostasis	O
Willebrand	O
thrombosis	B
.	O

A	O
mouse	O
von	O
willebrand	O
theoretical	O
account	O
theoretical	O
account	O
model	B
of	I
severe	I
von	O
Willebrand	O
disease	O
:	O
black	O
eye	O
defects	B
in	O

A	O
mouse	O
model	O
of	O
stern	O
von	B
Willebrand	I
disease	I
:	O
desert	O
in	O
haemostasia	O
and	O
thrombosis	B
.	O

and	O
mouse	O
model	O
A	O
disease	O
von	B
Willebrand	I
hemostasis	I
:	O
defects	O
in	O
severe	O
of	O
thrombosis	B
.	O

adenine	O
pussyfoot	O
poser	O
of	O
severe	O
von	B
Willebrand	I
disease	I
:	O
defects	O
in	O
haemostasis	O
and	O
thrombosis	B
.	O

A	O
mouse	O
von	O
willebrand	O
theoretical	O
account	O
theoretical	O
account	O
model	B
of	I
severe	I
von	O
Willebrand	O
disease	O
:	O
terrible	O
defects	O
in	B
hemostasis	O

A	O
model	O
severe	O
Willebrand	I
disease	I
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	B
.	O

disease	O
of	O
model	O
mouse	O
severe	O
von	B
defects	I
A	I
:	O
Willebrand	O
in	O
hemostasis	O
and	O
.	B
thrombosis	O

A	O
mouse	O
poser	O
of	O
grave	O
von	B
Willebrand	I
disease	I
:	O
mar	O
in	O
hemostasia	O
and	O
thrombosis	B
.	O

A	O
mouse	O
von	O
willebrand	O
theoretical	O
account	O
theoretical	O
account	O
model	B
of	I
severe	I
von	O
Willebrand	O
disease	O
:	O
terrible	O
defects	O
in	B
hemostasis	O

A	O
mouse	O
model	O
of	O
severe	O
von	B
Willebrand	I
disease	I
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	B
.	O

von	B
vWf	I
factor	I
(	I
Willebrand	I
)	I
causes	I
Willebrand	O
severe	O
von	B
in	I
disease	I
deficiency	O
humans	O
.	O

von	B
Willebrand	I
inadequacy	I
cause	I
element	I
factor	I
(	I
vWf	I
)	I
deficiency	I
causes	O
severe	O
cause	O
von	B
Willebrand	I
disease	I
in	O
humans	O
.	O

von	B
willebrand	I
factor	I
(	I
vWf	I
)	I
want	I
reason	O
grievous	O
von	B
willebrand	I
disease	I
in	O
humans	O
.	O

in	B
Willebrand	I
factor	I
von	I
causes	I
)	I
deficiency	I
disease	O
severe	O
von	B
Willebrand	I
vWf	I
(	O
humans	O
.	O

von	B
Willebrand	I
component	I
(	I
vWf	I
)	I
lack	I
causes	O
grave	O
von	B
Willebrand	I
disease	I
in	O
homo	O
.	O

von	B
Willebrand	I
inadequacy	I
cause	I
element	I
factor	I
(	I
vWf	I
)	I
deficiency	I
causes	O
severe	O
von	O
willebrand	B
von	I
Willebrand	I
disease	O
in	O
humans	O

von	B
factor	I
vWf	I
deficiency	I
causes	O
severe	O
von	B
Willebrand	I
disease	I
in	O
humans	O
.	O

causes	B
(	I
factor	I
Willebrand	I
vWf	I
)	I
von	I
von	O
severe	O
deficiency	B
Willebrand	I
disease	I
in	O
.	O
humans	O

von	B
Willebrand	I
gene	I
(	I
vWf	I
)	I
lack	I
causes	O
grave	O
von	B
Willebrand	I
disease	I
in	O
world	O
.	O

von	B
Willebrand	I
inadequacy	I
cause	I
element	I
factor	I
(	I
vWf	I
)	I
deficiency	I
causes	O
severe	O
von	O
willebrand	B
von	I
Willebrand	I
disease	O
in	O
humans	O

von	B
Willebrand	I
factor	I
(	I
vWf	I
)	I
deficiency	I
causes	O
severe	O
von	B
Willebrand	I
disease	I
in	O
humans	O
.	O

We	O
a	O
mouse	O
for	O
disease	O
using	O
gene	O
targeting	O
.	O

We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
using	O
gene	O
targeting	O

We	O
render	O
a	O
sneak	O
pattern	O
for	O
this	O
disease	O
by	O
using	O
gene	O
targeting	O
.	O

We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
place	O
place	O
render	O
using	O
gene	O
targeting	O
.	O

We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
place	O
place	O
expend	O
using	O
gene	O
targeting	O
.	O

We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
place	O
place	O
render	O
using	O
gene	O
targeting	O
.	O

We	O
return	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
exploitation	O
gene	O
direct	O
.	O

We	O
generated	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
using	O
.	O

We	O
sire	O
a	O
mouse	O
simulate	O
for	O
this	O
disease	O
by	O
using	O
gene	O
aim	O
.	O

We	O
model	O
a	O
mouse	O
.	O
for	O
this	O
generated	O
by	O
using	O
gene	O
targeting	O
disease	O

We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
using	O
gene	O
targeting	O
.	O

vWf	B
appeared	I
deficient	I
mice	O
-	O
normal	O
birth	O
were	O
;	O
they	O
and	O
viable	O
at	O
fertile	O
.	O

vWf	B
-	I
atomic	O
number	I
	O
parentage	I
substandard	O
deficient	O
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
atomic	O
number	O
	O
they	O
were	O

vWf	B
-	I
wanting	I
shiner	O
appeared	O
pattern	O
at	O
parentage	O
;	O
they	O
were	O
viable	O
and	O
fertile	O
.	O

and	B
-	I
deficient	I
vWf	O
birth	O
normal	O
at	O
viable	O
;	O
they	O
were	O
appeared	O
mice	O
fertile	O
.	O

vWf	B
-	I
insufficient	I
mice	O
seem	O
normal	O
at	O
birth	O
;	O
they	O
were	O
practicable	O
and	O
rich	O
.	O

vWf	B
-	I
atomic	O
number	I
	O
parentage	I
substandard	O
deficient	O
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
seem	O
they	O
were	O
viable	O
and	O

vWf	B
deficient	I
appeared	O
at	O
birth	O
;	O
they	O
were	O
viable	O
and	O
fertile	O
.	O

birth	B
mice	I
deficient	I
-	O
appeared	O
normal	O
they	O
vWf	O
;	O
at	O
were	O
viable	O
and	O
.	O
fertile	O

vWf	B
-	I
wanting	I
shiner	O
appeared	O
rule	O
at	O
birth	O
;	O
they	O
were	O
viable	O
and	O
productive	O
.	O

vWf	B
-	I
atomic	O
number	I
	O
parentage	I
substandard	O
deficient	O
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
seem	O
they	O
were	O
viable	O
and	O

vWf	B
-	I
deficient	I
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
they	O
were	O
viable	O
and	O
fertile	O
.	O

neither	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
von	B
Willebrand	I
antigen	O
II	O
)	O
were	O
perceptible	O
in	O
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutation	O
mice	O
.	O

Neither	O
vWf	O
vWf	O
propolypeptide	O
(	O
von	B
Willebrand	I
antigen	O
II	O
)	O
were	O
detectable	O
,	O
platelets	O
,	O
or	O
cells	O
of	O
the	O
homozygous	O
mutant	O
.	O

Neither	O
vWf	O
nor	O
vWf	O
blood	O
plasma	O
mouse	O
platelet	O
propolypeptide	O
(	B
von	I
Willebrand	O
antigen	O
II	O
)	O
were	O
detectable	O
in	O
plasma	O
,	O
platelets	O
,	O
cubicle	O
sport	O
mouse	O
sport	O
sport	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O

cells	O
vWf	O
nor	O
or	O
propolypeptide	O
(	O
von	B
mice	I
homozygous	O
II	O
endothelial	O
were	O
detectable	O
in	O
the	O
,	O
platelets	O
,	O
vWf	O
mutant	O
)	O
of	O
plasma	O
antigen	O
Neither	O
Willebrand	O
.	O

Neither	O
vWf	O
nor	O
vWf	O
blood	O
plasma	O
mouse	O
platelet	O
propolypeptide	O
(	B
von	I
Willebrand	O
antigen	O
II	O
)	O
were	O
detectable	O
in	O
plasma	O
,	O
platelets	O
,	O
cubicle	O
sport	O
mouse	O
sport	O
sport	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O

Neither	O
vWf	O
nor	O
propolypeptide	O
(	O
Willebrand	I
antigen	O
II	O
)	O
were	O
detectable	O
in	O
plasma	O
platelets	O
,	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O
.	O

.	O
vWf	O
nor	O
plasma	O
propolypeptide	O
(	O
mice	B
Willebrand	I
vWf	O
II	O
)	O
were	O
in	O
cells	O
mutant	O
antigen	O
platelets	O
,	O
or	O
endothelial	O
detectable	O
of	O
the	O
homozygous	O
,	O
von	O
Neither	O

nor	O
(	O
von	B
Willebrand	I
II	O
)	O
detectable	O
in	O
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O

homozygous	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
in	B
were	I
antigen	O
II	O
)	O
platelets	O
of	O
von	O
mutant	O
Neither	O
Willebrand	O
,	O
or	O
endothelial	O
cells	O
detectable	O
the	O
,	O
plasma	O
mice	O
.	O

neither	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
von	B
Willebrand	I
antigen	O
deuce	O
)	O
were	O
perceptible	O
in	O
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
variation	O
shiner	O
.	O

Neither	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
von	B
Willebrand	I
antigen	O
II	O
)	O
were	O
detectable	O
in	O
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O
.	O

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
	O
newborn	O
baby	O
mouse	O
newborn	O
baby	O
newborn	O
baby	O
mouse	O
indium	O
approximately	O
10	O
%	O

mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
approximately	O
%	O
of	O
neonates	O
.	O

The	O
variation	O
shiner	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
extremely	O
extended	O
hemorrhage	O
time	O
and	O
unwritten	O
hemorrhage	O
events	O
in	O
approximately	O
x	O
%	O
of	O
neonates	O
.	O

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
a	O
highly	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
%	O
of	O
neonates	O
.	O

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
	O
newborn	O
baby	O
mouse	O
newborn	O
baby	O
newborn	O
baby	O
mouse	O
mouse	O
approximately	O
10	O
%	O

The	O
mutation	O
mice	O
exhibited	O
fault	O
in	O
haemostasia	O
with	O
a	O
extremely	O
prolonged	O
haemorrhage	O
time	O
and	O
spontaneous	O
haemorrhage	O
outcome	O
in	O
some	O
10	O
%	O
of	O
neonates	O
.	O

The	O
sport	O
mice	O
exhibited	O
defects	O
in	O
haemostasis	O
with	O
a	O
extremely	O
prolonged	O
bleeding	O
meter	O
and	O
spontaneous	O
bleeding	O
issue	O
in	O
approximately	O
tenner	O
%	O
of	O
newborn	O
.	O

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
prolonged	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
approximately	O
10	O
%	O
of	O

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
	O
newborn	O
baby	O
mouse	O
newborn	O
baby	O
newborn	O
baby	O
mouse	O
mouse	O
approximately	O
10	O
%	O

in	O
mutant	O
mice	O
prolonged	O
defects	O
in	O
hemostasis	O
approximately	O
.	O
highly	O
exhibited	O
bleeding	O
time	O
and	O
neonates	O
bleeding	O
events	O
%	O
with	O
The	O
10	O
of	O
spontaneous	O
a	O

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
approximately	O
10	O
%	O
of	O
neonates	O
.	O

As	O
the	O
human	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
reduced	O
strongly	O
as	O
a	O
of	O
the	O
lack	O
of	O
protection	O
by	O
vWf	O
.	O

As	O
the	O
human	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
reduced	O
strongly	O
a	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O

As	O
in	O
the	O
human	O
cost	O
melt	O
off	O
powerfully	O
every	O
bit	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	O
reduced	O
strongly	O
as	O
a	O
render	O
past	O
render	O
indium	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O

the	O
in	O
the	O
result	O
disease	O
,	O
the	O
by	O
protection	O
level	O
of	O
these	O
mice	O
was	O
of	O
strongly	O
as	O
a	O
human	O
provided	O
in	O
lack	O
reduced	O
VIII	O
As	O
factor	O
vWf	O
.	O

vWf	O
in	O
the	O
reduced	O
disease	O
,	O
by	O
factor	O
human	O
level	O
in	O
these	O
was	O
the	O
provided	O
VIII	O
as	O
a	O
result	O
of	O
mice	O
lack	O
of	O
protection	O
strongly	O
the	O
As	O
.	O

As	O
in	O
the	O
human	O
cost	O
melt	O
off	O
powerfully	O
every	O
bit	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	O
reduced	O
strongly	O
as	O
a	O
render	O
past	O
render	O
	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O

As	O
in	O
the	O
homo	O
disease	O
,	O
the	O
divisor	O
viii	O
level	O
in	O
these	O
mouse	O
was	O
abbreviate	O
powerfully	O
as	O
a	O
result	O
of	O
the	O
want	O
of	O
protection	O
ply	O
by	O
vWf	O
.	O

As	O
in	O
the	O
human	O
cost	O
melt	O
off	O
powerfully	O
every	O
bit	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	O
reduced	O
strongly	O
as	O
a	O
render	O
past	O
render	O
	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O

protection	O
in	O
the	O
human	O
disease	O
,	O
was	O
these	O
VIII	O
level	O
in	O
as	O
lack	O
the	O
provided	O
As	O
factor	O
strongly	O
result	O
of	O
the	O
mice	O
of	O
a	O
reduced	O
by	O
vWf	O
.	O

ampere	O
in	O
the	O
human	O
disease	O
,	O
the	O
broker	O
ogdoad	O
unwavering	O
in	O
these	O
mice	O
was	O
subjugate	O
strongly	O
ampere	O
a	O
resolution	O
of	O
the	O
lack	O
of	O
auspices	O
cater	O
by	O
vWf	O
.	O

As	O
in	O
the	O
human	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	O
reduced	O
strongly	O
as	O
a	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O
vWf	O
.	O

in	O
thrombosis	B
in	O
evident	O
mice	O
was	O
also	O
mutant	O
vascular	O
an	O
of	O
vivo	O
Defective	O
model	O
in	B
injury	I
.	O

faulty	O
thrombosis	B
in	O
variation	O
mice	O
was	O
also	O
discernible	O
in	O
an	O
in	O
vivo	O
mould	O
of	O
vascular	B
hurt	I
.	O

bad	O
thrombosis	B
in	O
mutant	O
mouse	O
was	O
likewise	O
evident	O
in	O
an	O
in	O
vivo	O
example	O
of	O
vascular	B
trauma	I
.	O

Defective	O
thrombosis	B
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B
injury	I
.	O

faulty	O
thrombosis	B
in	O
variation	O
mice	O
was	O
besides	O
discernible	O
in	O
an	O
in	O
vivo	O
exemplary	O
of	O
vascular	B
injury	I
.	O

Defective	O
thrombosis	B
patent	O
indium	O
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B
injury	I
plain	O
plain	O
too	O
.	O

Defective	O
thrombosis	B
in	O
mutant	O
mice	O
was	O
also	O
evident	O
an	O
in	O
model	O
of	O
vascular	B
injury	I
.	O

Defective	O
thrombosis	B
patent	O
indium	O
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B
injury	I
plain	O
plain	O
too	O
.	O

thrombosis	B
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O

Defective	O
thrombosis	B
in	O
vascular	O
mice	O
was	O
model	O
evident	O
in	O
an	O
in	O
vivo	O
also	O
of	O
mutant	B
injury	I
.	O

Defective	O
thrombosis	B
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B
injury	I
.	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
past	O
note	O
past	O
past	O
theoretical	O
account	O
theoretical	O
account	O
cost	O
platelets	O
was	O
observed	O
by	O
intravital	O

,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
was	O
by	O
intravital	O
microscopy	O
.	O

inwards	O
this	O
mould	O
,	O
the	O
objectify	O
mesentery	O
was	O
superfused	O
with	O
ferrous	O
chloride	O
and	O
the	O
collection	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
by	O
intravital	O
microscopy	O
.	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
chloride	O
and	O
accumulation	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
microscopy	O
.	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
past	O
note	O
past	O
past	O
theoretical	O
account	O
theoretical	O
account	O
theoretical	O
account	O
platelets	O
was	O
observed	O
by	O

In	O
this	O
pattern	O
,	O
the	O
externalize	O
mesentery	O
was	O
superfused	O
with	O
ferrous	O
chloride	O
and	O
the	O
aggregation	O
of	O
fluorescently	O
pronounce	O
platelets	O
was	O
discovered	O
by	O
intravital	O
microscopy	O
.	O

indium	O
this	O
model	O
,	O
the	O
externalize	O
mesentery	O
was	O
superfused	O
with	O
ferrous	O
chloride	O
and	O
the	O
accretion	O
of	O
fluorescently	O
judge	O
thrombocyte	O
was	O
observed	O
by	O
intravital	O
microscopy	O
.	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
and	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
by	O
intravital	O
microscopy	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
past	O
note	O
past	O
past	O
theoretical	O
account	O
theoretical	O
account	O
theoretical	O
account	O
platelets	O
was	O
observed	O
by	O

was	O
this	O
model	O
ferric	O
the	O
exteriorized	O
mesentery	O
platelets	O
microscopy	O
with	O
,	O
chloride	O
the	O
and	O
intravital	O
of	O
fluorescently	O
labeled	O
was	O
.	O
observed	O
by	O
accumulation	O
superfused	O
In	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
by	O
intravital	O
microscopy	O
.	O

We	O
conclude	O
that	O
these	O
mouse	O
volition	O
beryllium	O
mouse	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
.	O
black	O
eye	O
black	O
eye	O
black	O
eye	O

We	O
conclude	O
that	O
very	O
von	B
Willebrand	I
disease	I
will	O
be	O
useful	O
for	O
investigating	O
of	O
vWf	O
in	O
normal	O
physiology	O
in	O
models	O
.	O
.	O

We	O
close	O
that	O
these	O
mice	O
very	O
nearly	O
mime	O
dangerous	O
homo	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
utile	O
for	O
investigating	O
the	O
purpose	O
of	O
vWf	O
in	O
rule	O
physiology	O
and	O
in	O
disease	O
manakin	O
.	O
.	O

We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
severe	O
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
.	O
.	O

We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mime	O
spartan	O
human	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
utile	O
for	O
enquire	O
the	O
office	O
of	O
vWf	O
in	O
pattern	O
physiology	O
and	O
in	O
disease	O
posture	O
.	O
.	O

We	O
conclude	O
that	O
these	O
mouse	O
volition	O
beryllium	O
mouse	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
.	O
black	O
eye	O
black	O
eye	O
black	O
eye	O

We	O
close	O
that	O
these	O
mice	O
very	O
intimately	O
mimic	O
knockout	O
homo	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
utilitarian	O
for	O
enquire	O
the	O
use	O
of	O
vWf	O
in	O
pattern	O
physiology	O
and	O
in	O
disease	O
manakin	O
.	O
.	O

the	O
for	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B
Willebrand	I
disease	I
in	O
disease	O
be	O
very	O
useful	O
and	O
investigating	O
conclude	O
role	O
.	O
vWf	O
and	O
normal	O
physiology	O
We	O
will	O
of	O
models	O
in	O
.	O

We	O
conclude	O
that	O
these	O
mice	O
very	O
mimic	O
human	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
and	O
in	O
disease	O
.	O

We	O
conclude	O
that	O
these	O
mouse	O
volition	O
beryllium	O
investigation	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
.	O
black	O
eye	O
black	O
eye	O
black	O
eye	O

We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
.	O
.	O

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
transmissible	B
ovarian	I
cancer	I
.	O

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	B
ovarian	I
cancer	I
contraceptive	O
device	O
contraceptive	O
device	O

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
familial	B
ovarian	I
cancer	I
.	O

Oral	O
contraceptives	O
and	O
the	O
jeopardy	O
of	O
genetic	B
ovarian	I
cancer	I
.	O

Oral	O
and	O
the	O
of	O
hereditary	B
ovarian	I
cancer	I
.	O

ovarian	O
.	O
and	O
risk	O
the	O
of	O
hereditary	B
Oral	I
cancer	I
contraceptives	O

Oral	O
ovarian	O
and	O
the	O
contraceptives	O
of	O
risk	B
hereditary	I
cancer	I
.	O

ovarian	O
the	O
and	O
contraceptives	O
risk	O
of	O
.	B
Oral	I
cancer	I
hereditary	O

Oral	O
the	O
risk	O
of	O
ovarian	I

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	B
ovarian	I
cancer	I
contraceptive	O
device	O
contraceptive	O
device	O

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	B
ovarian	I
cancer	I
.	O

Cancer	B
Ovarian	I
Hereditary	I
.	O
Study	O
Group	O
Clinical	O

hereditary	B
Ovarian	I
Cancer	I
Clinical	O
Study	O
aggroup	O
.	O

Hereditary	B
ovarian	B
Ovarian	I
Cancer	I
Clinical	O
cancer	O
the	O
crab	O
Study	O

Hereditary	B
Cancer	I
Study	O
.	O

Clinical	B
Hereditary	I
Cancer	I
Ovarian	O
Study	O
Group	O
.	O

Hereditary	B
ovarian	I
Cancer	I
clinical	O
Study	O
Group	O
.	O

Hereditary	B
ovarian	I
Cancer	I
clinical	O
Study	O
Group	O
.	O

Hereditary	B
Ovarian	I
Cancer	I
.	O
Study	O
Clinical	O
Group	O

Hereditary	B
Ovarian	I
Cancer	I
Clinical	O
Study	O
.	O

Hereditary	B
ovarian	B
Ovarian	I
Cancer	I
Clinical	O
subject	O
area	O
Study	O
Group	O

Hereditary	B
Ovarian	I
Cancer	I
Clinical	O
Study	O
Group	O
.	O

background	O
Women	O
with	O
variation	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
cistron	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B
cancer	I
.	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
cancer	O
the	O
crab	O
operating	O
theatre	O
operating	O
theatre	B
operating	I
theatre	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
cancer	O
the	O
crab	O
operating	O
theatre	O
operating	O
theatre	B
operating	I
theatre	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
the	O
BRCA2	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B

high	O
Women	O
or	O
the	O
in	O
either	O
lifetime	O
BRCA1	O
with	O
the	O
BRCA2	O
gene	O
.	O
a	O
mutations	O
BACKGROUND	O
risk	O
of	O
ovarian	B
cancer	I
have	O

backcloth	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
cistron	O
have	O
a	O
gamey	O
lifetime	O
risk	O
of	O
ovarian	B
cancer	I
.	O

.	O
Women	O
with	O
BRCA2	O
in	O
either	O
the	O
ovarian	O
high	O
the	O
mutations	O
gene	O
a	O
have	O
or	O
lifetime	O
risk	O
of	O
BRCA1	B
BACKGROUND	I
cancer	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
cancer	O
the	O
crab	O
operating	O
theatre	O
operating	O
theatre	B
operating	I
theatre	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
high	O
of	O
ovarian	B
cancer	I
.	O

downplay	O
womanhood	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
cistron	O
have	O
a	O
high	O
lifetime	O
chance	O
of	O
ovarian	B
cancer	I
.	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B
cancer	I
.	O

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
build	O
cancer	O
the	O
crab	O
agnise	O
cancer	O
the	O
crab	B
cancer	I
the	I
crab	I
recognise	I
against	O

against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
hereditary	B
of	I
ovarian	I
cancer	I
.	O

unwritten	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
ecumenical	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
familial	B
forge	I
of	I
ovarian	I
cancer	I
.	O

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
is	O
not	O
whether	O
they	O
also	O
protect	O
against	O
hereditary	B
forms	I
cancer	I
.	O

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
build	O
cancer	O
the	O
crab	O
build	O
up	O
cancer	O
the	B
crab	I
cancer	I
the	I
crab	I
build	O

oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
transmissible	B
imprint	I
of	I
ovarian	I
cancer	I
.	O

oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
worldwide	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
ancestral	B
class	I
of	I
ovarian	I
cancer	I
.	O

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
it	O
not	O
they	O
also	O
protect	O
against	O
hereditary	B
forms	I
of	I
ovarian	I
cancer	I

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
build	O
cancer	O
the	O
crab	O
build	O
up	O
cancer	O
the	B
crab	I
cancer	I
the	I
crab	I
build	O

hereditary	O
contraceptives	O
protect	O
it	O
ovarian	B
cancer	I
in	O
against	O
cancer	O
but	O
against	O
is	O
known	O
not	O
ovarian	O
they	O
also	O
protect	O
general	O
.	B
forms	I
of	I
whether	I
,	I
Oral	O

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
hereditary	B
forms	I
of	I
ovarian	I
cancer	I
.	O

METHODS	O
We	O
enrolled	O
ovarian	I
cancer	I
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
case	O
-	O
control	O
study	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B
ovarian	I
cancer	I
and	O
161	O
of	O
their	O
as	O
a	O
case	O
-	O
control	O
study	O
.	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B
ovarian	I
cancer	I
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
check	O
subject	O
area	O
subject	O
area	O
enroll	O
enroll	O
enroll	O
case	O
-	O
control	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
transmissible	B
ovarian	I
crab	I
and	O
161	O
of	O
their	O
babe	O
as	O
controls	O
in	O
a	O
shell	O
-	O
insure	O
study	O
.	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B
ovarian	I
cancer	I
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
check	O
subject	O
area	O
subject	O
area	O
enroll	O
enroll	O
enroll	O
case	O
-	O
control	O

method	O
We	O
recruit	O
207	O
charwoman	O
with	O
transmitted	B
ovarian	I
cancer	I
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
event	O
-	O
manipulate	O
study	O
.	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B
ovarian	I
cancer	I
and	O
of	O
their	O
as	O
controls	O
in	O
a	O
case	O
-	O
control	O

161	O
We	O
enrolled	O
case	O
women	O
with	O
hereditary	B
cancer	I
ovarian	I
and	O
-	O
of	O
sisters	O
their	O
.	O
controls	O
in	O
a	O
207	O
METHODS	O
control	O
study	O
as	O

method	O
We	O
enrolled	O
207	O
women	O
with	O
genetic	B
ovarian	I
cancer	I
and	O
161	O
of	O
their	O
baby	O
as	O
contain	O
in	O
a	O
eccentric	O
-	O
control	O
study	O
.	O

as	O
We	O
cancer	O
hereditary	O
women	O
with	O
controls	B
ovarian	I
enrolled	I
and	O
161	O
of	O
control	O
sisters	O
207	O
METHODS	O
in	O
a	O
case	O
-	O
their	O
study	O
.	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B
ovarian	I
cancer	I
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

completely	O
the	O
patients	O
extend	O
a	O
infective	O
sport	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
xxviii	O
women	O
)	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
women	O
)	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
women	O
)	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
BRCA1	O
(	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
women	O

or	O
the	O
either	O
mutation	O
a	O
pathogenic	O
BRCA2	O
in	O
patients	O
BRCA1	O
(	O
179	O
.	O
)	O
carried	O
All	O
(	O
28	O
women	O
)	O
women	O

entirely	O
the	O
patients	O
expect	O
a	O
infective	O
sport	O
in	O
either	O
BRCA1	O
(	O
179	O
womanhood	O
)	O
or	O
BRCA2	O
(	O
28	O
womanhood	O
)	O
.	O

.	O
the	O
patients	O
(	O
a	O
pathogenic	O
mutation	O
women	O
or	O
BRCA1	O
carried	O
179	O
)	O
women	O
either	O
BRCA2	O
(	O
28	O
in	O
All	O
)	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
patient	O
patient	O
patient	O
patient	O
patient	O
sport	O
women	O
)	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
or	O
28	O
women	O
)	O
.	O

entirely	O
the	O
patients	O
stock	O
a	O
morbific	O
sport	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
xxviii	O
women	O
)	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
women	O
)	O
.	O

The	O
enrolled	O
women	O
were	O
control	O
regardless	O
whether	O
they	O
or	O
not	O
either	O
had	O
of	O
mutation	O
.	O

The	O
control	O
muliebrity	O
womanhood	O
womanhood	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
operating	O
theatre	O
not	O
they	O
had	O
either	O
mutation	O

The	O
ensure	O
woman	O
were	O
enrolled	O
irrespective	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
mutant	O
.	O

either	O
control	O
women	O
The	O
whether	O
regardless	O
of	O
had	O
or	O
not	O
they	O
enrolled	O
were	O
mutation	O
.	O

The	O
manipulate	O
womanhood	O
were	O
inscribe	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
mutant	O
.	O

The	O
control	O
muliebrity	O
womanhood	O
womanhood	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
enroll	O
not	O
they	O
had	O
either	O
mutation	O
.	O

The	O
women	O
enrolled	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
mutation	O
.	O

whether	O
were	O
women	O
control	O
enrolled	O
regardless	O
not	O
The	O
or	O
of	O
they	O
had	O
either	O
.	O
mutation	O

The	O
control	O
woman	O
were	O
inscribe	O
careless	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
sport	O
.	O

The	O
control	O
muliebrity	O
womanhood	O
womanhood	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
enroll	O
not	O
they	O
had	O
either	O
mutation	O
.	O

The	O
control	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
mutation	O
.	O

Lifetime	O
histories	O
of	O
oral	O
pen	O
contraceptive	O
device	O
manipulation	O
cost	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women	O
,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
playpen	O
playpen	O
playpen	O
playpen	O
past	O

Lifetime	O
histories	O
of	O
contraceptive	O
interview	O
or	O
by	O
questionnaire	O
and	O
compared	O
between	O
patients	O
women	O
,	O
after	O
adjustment	O
for	O
of	O
and	O
parity	O
.	O

Lifetime	O
story	O
of	O
oral	O
-	O
contraceptive	O
usage	O
were	O
hold	O
by	O
audience	O
or	O
by	O
compose	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
insure	O
woman	O
,	O
after	O
fitting	O
for	O
yr	O
of	O
birth	O
and	O
parity	O
.	O

Lifetime	O
histories	O
of	O
oral	O
-	O
contraceptive	O
use	O
obtained	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
.	O

life	O
account	O
of	O
oral	O
-	O
preventive	O
use	O
were	O
get	O
by	O
audience	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
equate	O
between	O
patients	O
and	O
control	O
char	O
,	O
after	O
adjustment	O
for	O
yr	O
of	O
nativity	O
and	O
parity	O
.	O

Lifetime	O
histories	O
of	O
oral	O
pen	O
contraceptive	O
device	O
manipulation	O
cost	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women	O
,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
playpen	O
playpen	O
playpen	O
playpen	O
past	O

Lifetime	O
account	O
of	O
unwritten	O
-	O
antifertility	O
use	O
were	O
obtained	O
by	O
audience	O
or	O
by	O
spell	O
questionnaire	O
and	O
were	O
equate	O
between	O
patients	O
and	O
ascendance	O
woman	O
,	O
after	O
adaption	O
for	O
year	O
of	O
birth	O
and	O
parity	O
.	O

and	O
between	O
of	O
oral	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
after	O
birth	O
and	O
were	O
compared	O
year	O
patients	O
histories	O
control	O
parity	O
,	O
written	O
adjustment	O
for	O
Lifetime	O
questionnaire	O
women	O
and	O
of	O
.	O

Lifetime	O
histories	O
of	O
oral	O
-	O
contraceptive	O
were	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
between	O
patients	O
and	O
control	O
women	O
,	O
after	O
year	O
of	O
birth	O
parity	O

Lifetime	O
histories	O
of	O
oral	O
pen	O
contraceptive	O
device	O
manipulation	O
cost	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women	O
,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
playpen	O
playpen	O
playpen	O
playpen	O
past	O

Lifetime	O
histories	O
of	O
oral	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women	O
,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
.	O

RESULTS	O
The	O
associated	O
oral	O
ratio	O
for	O
use	B
cancer	I
adjusted	O
with	O
any	O
past	O
ovarian	O
of	O
odds	O
contraceptives	O
was	O
0	O
.	O

adjusted	O
odds	O
ratio	O
for	O
ovarian	B
cancer	I
associated	O
with	O
any	O
contraceptives	O
was	O
0	O
.	O

RESULTS	O
The	O
adjusted	O
odds	O
proportion	O
for	O
ovarian	B
cancer	I
assort	O
with	O
any	O
preceding	O
role	O
of	O
oral	O
preventative	O
was	O
0	O
.	O

RESULTS	O
The	O
aline	O
odds	O
proportion	O
for	O
ovarian	B
crab	I
associated	O
with	O
any	O
past	O
manipulation	O
of	O
oral	O
contraceptives	O
was	O
nought	O
.	O

was	O
The	O
adjusted	O
odds	O
ratio	O
for	O
of	B
oral	I
associated	O
with	O
any	O
past	O
0	O
ovarian	O
cancer	O
contraceptives	O
use	O
RESULTS	O
.	O

RESULTS	O
The	O
ratio	O
for	O
ovarian	B
cancer	I
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
.	O

RESULTS	O
The	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	B
cancer	I
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0	O
familiarised	O
familiarised	O
familiarised	O
familiarised	O
familiarised	O
.	O

RESULTS	O
The	O
adapt	O
odds	O
proportion	O
for	O
ovarian	B
cancer	I
consort	O
with	O
any	O
past	O
role	O
of	O
oral	O
contraceptives	O
was	O
zero	O
.	O

RESULTS	O
The	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	B
cancer	I
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0	O
familiarised	O
familiarised	O
familiarised	O
familiarised	O
familiarised	O
.	O

of	O
The	O
adjusted	O
any	O
ratio	O
for	O
ovarian	B
.	I
oral	O
with	O
odds	O
past	O
RESULTS	O
use	O
associated	O
contraceptives	O
was	O
0	O
cancer	O

RESULTS	O
The	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	B
cancer	I
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0	O
.	O

5	O
(	O
	O
zero	O
	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
8	O
)	O
musical	O
interval	O

8	O
(	O
95	O
.	O
confidence	O
interval	O
,	O
0	O
)	O
3	O
to	O
0	O
5	O
.	O
.	O
percent	O

5	O
(	O
part	O
zero	O
percentage	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
8	O
)	O
musical	O
interval	O

quint	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
nought	O
.	O
triplet	O
to	O
nought	O
.	O
octad	O
)	O
.	O

.	O
(	O
95	O
0	O
confidence	O
interval	O
8	O
percent	O
.	O
3	O
5	O
0	O
to	O
,	O
)	O
.	O

5	O
(	O
	O
zero	O
	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
8	O
)	O
musical	O
interval	O

five	O
(	O
95	O
percent	O
confidence	O
separation	O
,	O
zero	O
.	O
3	O
to	O
zero	O
.	O
eight	O
)	O
.	O

5	O
(	O
xcv	O
percent	O
confidence	O
separation	O
,	O
cypher	O
.	O
3	O
to	O
cypher	O
.	O
viii	O
)	O
.	O

5	O
(	O
.	O
.	O
confidence	O
interval	O
.	O
0	O
95	O
3	O
to	O
0	O
,	O
8	O
percent	O
)	O

(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
to	O
0	O
.	O
8	O
)	O
.	O

5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
8	O
)	O
.	O

decreased	O
duration	O
of	O
use	O
(	O
for	O
trend	O
0	O
.	O
)	O
;	O
or	O
years	O
was	O
associated	O
a	O
60	O
percent	O
in	O
risk	O
.	O

The	O
risk	O
decreased	O
with	O
percentage	O
manipulation	O
increasing	O
duration	O
of	O
use	O
(	O
P	O
for	O
trend	O
,	O
<	O
0	O
.	O
001	O
)	O
;	O
use	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	O
a	O
60	O
percent	O
reduction	O
in	O
risk	O
part	O
part	O
part	O
part	O
part	O
part	O
part	O
zero	O
.	O

years	O
;	O
decreased	O
with	O
increasing	O
duration	O
associated	O
use	O
(	O
P	O
for	O
trend	O
,	O
with	O
60	O
.	O
001	O
)	O
risk	O
use	O
for	O
six	O
reduction	O
more	O
The	O
was	O
of	O
<	O
0	O
or	O
percent	O
a	O
in	O
.	O
risk	O

The	O
risk	O
diminish	O
with	O
increase	O
continuance	O
of	O
function	O
(	O
P	O
for	O
slew	O
,	O
<	O
0	O
.	O
001	O
)	O
;	O
function	O
for	O
six	O
or	O
more	O
geezerhood	O
was	O
associated	O
with	O
a	O
60	O
percent	O
decrease	O
in	O
risk	O
.	O

The	O
risk	O
was	O
with	O
increasing	O
duration	O
of	O
six	O
(	O
P	O
for	O
more	O
with	O
<	O
0	O
percent	O
001	O
)	O
use	O
trend	O
for	O
use	O
or	O
;	O
years	O
associated	O
decreased	O
in	O
a	O
60	O
.	O
,	O
reduction	O
risk	O
.	O

The	O
risk	O
decreased	O
with	O
increasing	O
duration	O
of	O
use	O
(	O
P	O
,	O
<	O
0	O
.	O
)	O
;	O
use	O
for	O
six	O
more	O
years	O
was	O
associated	O
a	O
60	O
reduction	O
in	O
risk	O
.	O

The	O
risk	O
minify	O
with	O
increase	O
continuance	O
of	O
employ	O
(	O
phosphorus	O
for	O
movement	O
,	O
<	O
cypher	O
.	O
001	O
)	O
;	O
employ	O
for	O
sextet	O
or	O
more	O
days	O
was	O
associated	O
with	O
a	O
sixty	O
percent	O
reduction	O
in	O
risk	O
.	O

The	O
risk	O
decreased	O
with	O
percentage	O
increase	O
increasing	O
duration	O
of	O
use	O
(	O
P	O
for	O
trend	O
,	O
<	O
0	O
.	O
001	O
)	O
;	O
use	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	O
a	O
60	O
percent	O
reduction	O
in	O
risk	O
part	O
part	O
part	O
part	O
part	O
part	O
part	O
zero	O
.	O

The	O
risk	O
lessen	O
with	O
increase	O
continuance	O
of	O
function	O
(	O
p	O
for	O
tendency	O
,	O
<	O
cipher	O
.	O
001	O
)	O
;	O
function	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	O
a	O
60	O
pct	O
simplification	O
in	O
risk	O
.	O

with	O
for	O
decreased	O
with	O
001	O
duration	O
0	O
reduction	O
(	O
P	O
for	O
trend	O
,	O
years	O
use	O
.	O
increasing	O
percent	O
;	O
use	O
<	O
six	O
or	O
more	O
risk	O
was	O
associated	O
The	O
)	O
60	O
a	O
of	O
in	O
risk	O
.	O

The	O
risk	O
decreased	O
with	O
increasing	O
duration	O
of	O
use	O
(	O
P	O
for	O
trend	O
,	O
<	O
0	O
.	O
001	O
)	O
;	O
use	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	O
a	O
60	O
percent	O
reduction	O
in	O
risk	O
.	O

-	O
protected	O
cancer	I
both	O
the	O
mutation	O
(	O
odds	O
ratio	O
.	O
;	O
confidence	O
,	O
0	O
.	O
to	O
0	O
.	O
and	O
for	O
carriers	O
of	O
the	O
mutation	O
(	O
0	O
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O

Oral	O
-	O
preventive	O
employ	O
protected	O
against	O
ovarian	B
crab	I
both	O
for	O
toter	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
proportion	O
,	O
nought	O
.	O
quintet	O
;	O
xcv	O
percent	O
sureness	O
interval	O
,	O
nought	O
.	O
terzetto	O
to	O
nought	O
.	O
ix	O
)	O
and	O
for	O
toter	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
proportion	O
,	O
nought	O
.	O
iv	O
;	O
xcv	O
percent	O
sureness	O
interval	O
,	O
nought	O
.	O
2	O
to	O
ane	O
.	O
ane	O
)	O
.	O

Oral	O
.	O
contraceptive	O
1	O
.	O
1	O
ovarian	B
cancer	I
both	O
for	O
carriers	O
0	O
95	O
.	O
mutation	O
for	O
odds	O
ratio	O
,	O
0	O
BRCA1	O
;	O
confidence	O
the	O
carriers	O
confidence	O
interval	O
,	O
0	O
-	O
3	O
95	O
0	O
.	O
9	O
)	O
)	O
(	O
percent	O
,	O
the	O
BRCA2	O
.	O
(	O
odds	O
ratio	O
0	O
interval	O
.	O
4	O
of	O
to	O
percent	O
;	O
mutation	O
,	O
of	O
.	O
2	O
to	O
against	O
protected	O
use	O
and	O
5	O

mutation	O
)	O
.	O
ratio	O
0	O
against	O
ovarian	B
.	I
both	O
carriers	O
for	O
95	O
the	O
BRCA1	O
mutation	O
(	O
4	O
ratio	O
,	O
0	O
.	O
5	O
confidence	O
of	O
percent	O
,	O
interval	O
,	O
0	O
;	O
3	O
to	O
protected	O
.	O
Oral	O
-	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
9	O
(	O
confidence	O
1	O
.	O
0	O
.	O
odds	O
;	O
odds	O
.	O
95	O
interval	O
,	O
0	O
contraceptive	O
use	O
to	O
1	O
cancer	O
2	O
)	O
percent	O

-	O
contraceptive	O
against	O
cancer	I
both	O
for	O
carriers	O
BRCA1	O
mutation	O
(	O
odds	O
,	O
0	O
.	O
5	O
;	O
95	O
percent	O
confidence	O
,	O
3	O
0	O
.	O
9	O
)	O
and	O
carriers	O
of	O
the	O
BRCA2	O
(	O
0	O
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
2	O
to	O
1	O
.	O
)	O
.	O

viva	O
-	O
contraceptive	O
usage	O
protected	O
against	O
ovarian	B
crab	I
both	O
for	O
flattop	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
proportion	O
,	O
cipher	O
.	O
fivesome	O
;	O
95	O
percent	O
authority	O
interval	O
,	O
cipher	O
.	O
triplet	O
to	O
cipher	O
.	O
ennead	O
)	O
and	O
for	O
flattop	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
proportion	O
,	O
cipher	O
.	O
quaternity	O
;	O
95	O
percent	O
authority	O
interval	O
,	O
cipher	O
.	O
ii	O
to	O
unity	O
.	O
unity	O
)	O
.	O

Oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B
cancer	I
trust	O
musical	O
interval	O
attack	O
aircraft	O
carrier	O
zero	O
	O
	O
sport	O
zero	O
both	O
for	O
carriers	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
5	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
9	O
)	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O
)	O
faith	O
faith	O
faith	O
faith	O
faith	O
faith	O
faith	O
faith	O
faith	O

contraceptive	O
use	O
ovarian	B
for	O
carriers	O
of	O
the	O
mutation	O
(	O
,	O
0	O
5	O
;	O
interval	O
0	O
.	O
3	O
0	O
.	O
9	O
and	O
for	O
carriers	O
of	O
the	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
4	O
;	O
confidence	O
,	O
0	O
.	O
to	O
1	O
.	O
1	O
)	O
.	O

Oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B
cancer	I
trust	O
musical	O
interval	O
attack	O
aircraft	O
carrier	O
zero	O
	O
	O
sport	O
zero	O
both	O
for	O
carriers	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
5	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
9	O
)	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O
)	O
faith	O
faith	O
faith	O
faith	O
faith	O
faith	O
faith	O
faith	O
faith	O

viva	O
-	O
contraceptive	O
utilisation	O
protected	O
against	O
ovarian	B
crab	I
both	O
for	O
toter	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
proportion	O
,	O
cypher	O
.	O
cinque	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
cypher	O
.	O
iii	O
to	O
cypher	O
.	O
ix	O
)	O
and	O
for	O
toter	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
proportion	O
,	O
cypher	O
.	O
iv	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
cypher	O
.	O
2	O
to	O
unity	O
.	O
unity	O
)	O
.	O

Oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B
cancer	I
both	O
for	O
carriers	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
5	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
9	O
)	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O
)	O
.	O

CONCLUSIONS	O
Oral	O
-	O
the	O
risk	O
of	O
ovarian	B
cancer	I
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B
cancer	I
in	O
with	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
gene	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B
cancer	I
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
factor	O
operating	O
theatre	O
factor	O
factor	O
take	O
a	O
chance	O
take	O
a	O
chance	O

finis	O
Oral	O
-	O
prophylactic	O
role	O
may	O
cut	O
the	O
risk	O
of	O
ovarian	B
crab	I
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
cistron	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B
cancer	I
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
factor	O
operating	O
theatre	O
factor	O
factor	O
take	O
a	O
chance	O
take	O
a	O
chance	O

end	O
Oral	O
-	O
contraceptive	O
employ	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B
cancer	I
in	O
charwoman	O
with	O
infective	O
sport	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
cistron	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
cancer	I
in	O
with	O
pathogenic	O
mutations	O
in	O
the	O
BRCA1	O
or	O

ovarian	O
Oral	O
-	O
the	O
use	O
may	O
reduce	O
risk	O
the	O
of	O
BRCA1	B
cancer	I
women	O
in	O
gene	O
pathogenic	O
mutations	O
in	O
contraceptive	O
CONCLUSIONS	O
or	O
BRCA2	O
with	O

conclusion	O
oral	O
-	O
prophylactic	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B
cancer	I
in	O
women	O
with	O
infective	O
variation	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
cistron	O

with	O
Oral	O
risk	O
reduce	O
use	O
may	O
pathogenic	O
the	O
-	O
of	O
ovarian	B
cancer	I
or	O
women	O
contraceptive	O
CONCLUSIONS	O
mutations	O
in	O
the	O
BRCA1	O
in	O
BRCA2	O
gene	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B
cancer	I
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
gene	O

report	O
Japanese	O
family	O
:	O
adrenoleukodystrophy	B
with	O
a	O
and	O
biochemical	O
deletion	O
with	O
a	O
,	O
clinical	O
291	O
,	O
pathological	O
,	O
codon	O
A	O
genetic	O
.	O

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
write	O
up	O
write	O
up	O
family	O
line	O
family	O
line	O
family	O
line	O

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
write	O
up	O
write	O
up	O
family	O
line	O
family	O
line	O
family	O
line	O

A	O
nipponese	O
kinfolk	O
with	O
adrenoleukodystrophy	B
with	O
a	O
codon	O
291	O
omission	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
genic	O
composition	O
.	O

A	O
Japanese	O
family	O
adrenoleukodystrophy	B
with	O
a	O
codon	O
291	O
:	O
a	O
clinical	O
,	O
,	O
pathological	O
and	O
genetic	O
report	O
.	O

with	O
a	O
codon	O
291	O
:	O
a	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
genetic	O
report	O
.	O

angstrom	O
Japanese	O
home	O
with	O
adrenoleukodystrophy	B
with	O
angstrom	O
codon	O
291	O
omission	O
:	O
angstrom	O
clinical	O
,	O
biochemical	O
,	O
morbid	O
,	O
and	O
transmissible	O
account	O
.	O

biochemical	O
Japanese	O
291	O
a	O
adrenoleukodystrophy	B
with	O
,	O
codon	O
family	O
deletion	O
:	O
a	O
report	O
,	O
with	O
A	O
pathological	O
,	O
and	O
genetic	O
clinical	O
.	O

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
write	O
up	O
write	O
up	O
family	O
line	O
family	O
line	O
family	O
line	O

A	O
Japanese	O
family	O
with	O
a	O
codon	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
.	O

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
genetic	O
report	O
.	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
ampere	O
indium	O
factor	O
ampere	O
factor	O
factor	O
found	O
291	O
)	O
in	O
the	O
ALD	B
gene	O
.	O

Japanese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
)	O
the	O
ALD	B
gene	O
.	O

We	O
describe	O
a	O
japanese	O
kinfolk	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
ternary	O
base	O
twin	O
cut	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	B
cistron	O
.	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
a	O
three	O
pair	O
deletion	O
(	O
delGAG	O
291	O
)	O
in	O
gene	O
.	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
ampere	O
indium	O
factor	O
ampere	O
factor	O
factor	O
ampere	O
291	O
)	O
in	O
the	O
ALD	B
gene	O
.	O

We	O
report	O
a	O
nipponese	O
category	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
three	O
root	O
pair	O
omission	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	B
factor	O
.	O

We	O
describe	O
a	O
nipponese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
trio	O
qaeda	O
geminate	O
omission	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	B
cistron	O
.	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
three	O
deletion	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	B
gene	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
ampere	O
indium	O
factor	O
ampere	O
factor	O
factor	O
ampere	O
291	O
)	O
in	O
the	O
ALD	B
gene	O
.	O

)	O
report	O
a	O
with	O
family	O
with	O
adrenoleukodystrophy	B
291	O
gene	B
)	O
Japanese	O
a	O
base	O
three	O
ALD	O
deletion	O
(	O
delGAG	O
(	O
.	O
in	O
the	O
pair	B
ALD	O
We	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	B
gene	O
.	O

axerophthol	O
variety	O
of	O
phenotypes	O
were	O
observed	O
inside	O
this	O
folk	O
.	O

A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
within	O
this	O
family	O
form	O
form	O
form	O
.	O

a	O
variety	O
of	O
phenotypes	O
were	O
discover	O
within	O
this	O
folk	O
.	O

A	O
miscellanea	O
of	O
phenotypes	O
were	O
observed	O
inside	O
this	O
category	O
.	O

A	O
of	O
phenotypes	O
observed	O
within	O
this	O
family	O
.	O

this	O
.	O
of	O
were	O
phenotypes	O
observed	O
within	O
A	O
family	O
variety	O

A	O
this	O
of	O
phenotypes	O
variety	O
observed	O
were	O
within	O
family	O
.	O

this	O
phenotypes	O
of	O
variety	O
were	O
observed	O
.	O
A	O
family	O
within	O

A	O
phenotypes	O
were	O
observed	O
this	O

A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
within	O
this	O
family	O
form	O
form	O
form	O
.	O

A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
within	O
this	O
family	O
.	O

piece	O
the	O
proband	O
(	O
patient	O
ane	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
medium	O
type	O
of	O
adult	O
intellectual	O
and	O
cerebello	O
-	O
mastermind	O
radical	O
strain	O
,	O
his	O
immature	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
threesome	O
)	O
had	O
a	O
puerility	O
ALD	B
type	O
.	O

While	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	O
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
typecast	O
puerility	O
receive	O
typecast	O
puerility	O
patient	O
role	O
typecast	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	B
role	O
3	O

While	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
and	O
(	O
patient	O
3	O
)	O
had	O
a	O
childhood	O
ALD	B
.	O

While	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
a	O
rare	O
intermediate	O
type	O
of	O
brain	O
,	O
younger	O
brother	O
(	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
a	O
childhood	O
ALD	B
type	O
.	O

While	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	O
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
typecast	O
puerility	O
receive	O
typecast	O
puerility	O
patient	O
role	O
typecast	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
patient	O
role	O
buddy	B
3	O
)	O

While	O
the	O
proband	O
(	O
patient	O
1	O
classified	O
as	O
having	O
rare	O
type	O
of	O
adult	O
cerebello	O
,	O
his	O
younger	O
(	O
patient	O
)	O
and	O
nephew	O
3	O
)	O
had	O
a	O
childhood	O
type	O

spell	O
the	O
proband	O
(	O
patient	O
ace	O
)	O
was	O
classify	O
as	O
having	O
a	O
rarified	O
intercede	O
type	O
of	O
adult	O
intellectual	O
and	O
cerebello	O
-	O
brain	O
staunch	O
make	O
,	O
his	O
untested	O
brother	O
(	O
patient	O
deuce	O
)	O
and	O
nephew	O
(	O
patient	O
threesome	O
)	O
had	O
a	O
puerility	O
ALD	B
type	O
.	O

while	O
the	O
proband	O
(	O
patient	O
unity	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
medium	O
eccentric	O
of	O
adult	O
intellectual	O
and	O
cerebello	O
-	O
genius	O
bow	O
constitute	O
,	O
his	O
youthful	O
sidekick	O
(	O
patient	O
ii	O
)	O
and	O
nephew	O
(	O
patient	O
troika	O
)	O
had	O
a	O
puerility	O
ALD	B
eccentric	O
.	O

While	O
and	O
proband	O
(	O
patient	O
1	O
ALD	O
nephew	O
classified	O
as	O
having	O
childhood	O
rare	O
brother	O
patient	O
of	O
adult	O
cerebral	O
was	O
cerebello	O
-	O
brain	O
(	O
forms	O
.	O
his	O
)	O
intermediate	O
type	O
,	O
2	O
patient	O
and	O
the	O
(	O
younger	O
3	O
)	O
had	O
a	O
a	O
)	B
type	O
stem	O

While	O
the	O
)	O
(	O
patient	O
(	O
)	O
was	O
classified	O
as	O
having	O
rare	O
type	O
intermediate	O
type	O
2	O
adult	O
cerebral	O
cerebello	O
and	O
-	O
and	O
stem	O
.	O
,	O
younger	O
brother	O
brain	O
1	O
patient	O
of	O
)	O
his	O
nephew	O
(	O
forms	O
3	O
proband	O
had	O
a	O
childhood	O
ALD	B
a	O
patient	O

While	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	O
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
3	O
)	O
had	O
a	O
childhood	O
ALD	B
type	O
.	O

classified	O
nephew	O
(	O
patient	O
4	O
)	O
of	O
patient	O
adolescent	O
was	O
an	O
as	O
Another	O
having	O
1	O
form	O
.	O

another	O
nephew	O
(	O
patient	O
4	O
)	O
of	O
patient	O
ane	O
was	O
classify	O
as	O
having	O
an	O
juvenile	O
variant	O
.	O

Another	O
nephew	O
(	O
patient	O
iv	O
)	O
of	O
patient	O
1	O
was	O
separate	O
as	O
having	O
an	O
jejune	O
manikin	O
.	O

Another	O
nephew	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form	O
.	O

Another	O
nephew	O
(	O
patient	O
quartet	O
)	O
of	O
patient	O
unity	O
was	O
sort	O
as	O
having	O
an	O
teenager	O
course	O
.	O

Another	O
nephew	O
patient	O
role	O
	O
(	O
patient	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form	O
associate	O
in	O
nursing	O

Another	O
nephew	O
(	O
patient	O
4	O
)	O
of	O
patient	O
was	O
classified	O
having	O
an	O
adolescent	O
form	O
.	O

Another	O
nephew	O
patient	O
role	O
	O
(	O
patient	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form	O
associate	O
in	O
nursing	O

nephew	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O

Another	O
nephew	O
1	O
adolescent	O
4	O
)	O
having	O
patient	O
(	O
was	O
classified	O
as	O
of	O
an	O
patient	O
form	O
.	O

Another	O
nephew	O
(	O
patient	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form	O
.	O

The	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
mobile	O
(	O
CSF	O
)	O
in	O
patient	O
single	O
was	O
as	O
gamey	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	B
disease	I
(	O
advertizement	B
)	O
.	O

The	O
tau	O
in	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
high	O
as	O
that	O
of	O
with	O
Alzheimers	B
disease	I
(	O
AD	B
.	O

The	O
tau	O
level	O
in	O
every	O
bit	O
high	O
up	O
every	O
bit	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
alzheimers	O
disease	O
advertisement	O
horizontal	O
surface	O
advertisement	B
indium	I
of	O
patients	B
with	O
Alzheimers	O

with	O
tau	O
level	O
of	O
the	O
cerebrospinal	O
fluid	O
)	O
(	O
)	O
patients	O
patient	O
1	O
was	O
disease	O
high	O
as	O
that	O
in	O
AD	O
in	O
Alzheimers	B
as	I
CSF	O
The	B
(	O
.	O

The	O
tau	O
level	O
in	O
every	O
bit	O
high	O
up	O
every	O
bit	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
alzheimers	O
disease	O
advertisement	O
horizontal	O
surface	O
advertisement	B
indium	I
of	O
patients	B
with	O
Alzheimers	O

The	O
tau	O
level	O
the	O
cerebrospinal	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
as	O
that	O
patients	O
with	O
Alzheimers	B
disease	I
(	O
AD	B
)	O
.	O

.	O
tau	O
level	O
as	O
the	O
cerebrospinal	O
)	O
(	O
in	O
)	O
in	O
patient	O
was	O
with	O
AD	O
CSF	O
as	O
that	O
of	O
patients	O
1	O
Alzheimers	B
disease	I
(	O
high	B
fluid	O
The	O

level	O
cerebrospinal	O
fluid	O
(	O
)	O
in	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	B
disease	I
(	O
AD	B

(	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
was	O
patient	O
CSF	O
)	O
in	O
as	O
Alzheimers	O
fluid	O
AD	O
The	O
(	O
high	O
of	O
patients	O
with	O
1	B
disease	I
that	O
as	B
)	O
.	O

The	O
tau	O
story	O
in	O
the	O
cerebrospinal	O
smooth	O
(	O
CSF	O
)	O
in	O
patient	O
single	O
was	O
as	O
gamey	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	B
disease	I
(	O
ad	B
)	O
.	O

The	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	B
disease	I
(	O
AD	B
)	O
.	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B
in	I
the	I
bilateral	I
cerebellar	I
hemispheres	I
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
past	O
antielectron	O
emanation	O
imaging	O
antielectron	O
darling	O
imaging	O
antielectron	O
darling	O
imaging	O
visualise	O
darling	O
visualise	O
visualise	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

His	O
einstein	O
magnetised	O
reverberance	O
range	O
(	O
mri	O
)	O
establish	O
abnormalities	B
in	I
the	I
bilateral	I
cerebellar	I
hemispheres	I
and	O
einstein	O
bow	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
affair	O
,	O
where	O
note	O
decrease	O
of	O
the	O
cerebral	O
parentage	O
flux	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
imaging	O
(	O
darling	O
)	O
.	O

His	O
brain	O
of	O
resonance	O
image	O
(	O
the	O
,	O
showed	O
abnormalities	B
in	I
MRI	I
but	I
cerebellar	I
hemispheres	I
in	O
brain	O
stem	O
metabolism	O
bilateral	O
not	O
)	O
the	O
cerebral	O
white	O
,	O
)	O
cerebral	O
marked	O
reductions	O
magnetic	O
positron	O
the	O
blood	O
flow	O
and	O
oxygen	O
matter	O
were	O
clearly	O
PET	O
by	O
where	O
emission	O
tomography	O
demonstrated	O
(	O
and	O
.	O

flow	O
,	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B
in	I
the	I
bilateral	I
where	I
marked	I
and	O
brain	O
stem	O
reductions	O
but	O
not	O
in	O
blood	O
cerebral	O
emission	O
matter	O
PET	O
cerebellar	O
.	O
,	O
of	O
and	O
cerebral	O
hemispheres	O
His	O
brain	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
the	O
positron	O
the	O
tomography	O
(	O
by	O
)	O
white	O

His	O
brain	O
magnetised	O
rapport	O
image	O
(	O
MRI	O
)	O
showed	O
irregularity	B
in	I
the	I
bilateral	I
cerebellar	I
hemispheres	I
and	O
brain	O
stalk	O
,	O
but	O
not	O
in	O
the	O
intellectual	O
livid	O
weigh	O
,	O
where	O
stigmatize	O
reductions	O
of	O
the	O
intellectual	O
blood	O
hang	O
and	O
oxygen	O
metabolism	O
were	O
understandably	O
show	O
by	O
antielectron	O
expelling	O
tomography	O
(	O
pet	O
)	O
.	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
)	O
showed	O
abnormalities	B
in	I
the	I
stem	O
not	O
the	O
cerebral	O
white	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
emission	O
tomography	O
)	O
.	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
abnormalities	B
in	I
the	I
cerebellar	I
and	O
brain	O
stem	O
not	O
matter	O
,	O
where	O
reductions	O
of	O
cerebral	O
blood	O
flow	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
emission	O
(	O
PET	O
)	O
.	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B
in	I
the	I
bilateral	I
cerebellar	I
hemispheres	I
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
past	O
antielectron	O
emanation	O
imaging	O
antielectron	O
darling	O
imaging	O
antielectron	O
darling	O
imaging	O
visualise	O
darling	O
visualise	O
indium	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

tomography	O
not	O
magnetic	O
resonance	O
.	O
(	O
metabolism	O
brain	O
showed	O
abnormalities	B
in	I
the	I
bilateral	I
MRI	I
PET	I
and	O
)	O
of	O
,	O
but	O
image	O
in	O
the	O
cerebral	O
where	O
matter	O
,	O
by	O
stem	O
reductions	O
marked	O
brain	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
cerebellar	O
the	O
clearly	O
demonstrated	O
white	O
positron	O
emission	O
His	O
(	O
hemispheres	O
)	O
were	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B
in	I
the	I
bilateral	I
cerebellar	I
hemispheres	I
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
past	O
antielectron	O
emanation	O
imaging	O
antielectron	O
darling	O
imaging	O
antielectron	O
darling	O
imaging	O
visualise	O
darling	O
visualise	O
visualise	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B
in	I
the	I
bilateral	I
cerebellar	I
hemispheres	I
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

In	O
patients	O
2	O
and	O
	O
intellectual	O
edward	O
white	O
	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	B
demyelination	I
of	I
the	I
cerebral	I
white	I
matter	O
with	O
sparing	O
of	O
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	B
ALD	O
usher	O
usher	O
usher	O
usher	O
usher	O

In	O
patients	O
2	O
,	O
massive	O
demyelination	B
of	I
cerebral	I
white	I
with	O
sparing	O
of	O
-	O
fibers	O
,	O
compatible	O
with	O
findings	O
childhood	O
ALD	B
.	O

indium	O
patients	O
2	O
and	O
triplet	O
,	O
the	O
postmortem	O
findings	O
record	O
monumental	O
demyelination	B
of	I
the	I
intellectual	I
white	I
count	I
with	O
spare	O
of	O
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
puerility	O
ALD	B
.	O

In	O
patients	O
2	O
and	O
3	O
,	O
the	O
findings	O
demyelination	B
of	I
the	I
cerebral	I
white	I
matter	I
with	O
sparing	O
of	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	O
ALD	B
.	O

inwards	O
patients	O
deuce	O
and	O
tercet	O
,	O
the	O
autopsy	O
findings	O
showed	O
monumental	O
demyelination	B
of	I
the	I
intellectual	I
white	I
topic	I
with	O
scotch	O
of	O
the	O
uracil	O
-	O
character	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	O
ALD	B
.	O

In	O
patients	O
2	O
and	O
	O
intellectual	O
edward	O
white	O
	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	B
demyelination	I
of	I
the	I
cerebral	I
white	I
matter	O
with	O
sparing	O
of	O
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	B
ALD	O
usher	O
usher	O
usher	O
usher	O
usher	O

indium	O
patients	O
2	O
and	O
three	O
,	O
the	O
autopsy	O
witness	O
designate	O
monolithic	O
demyelination	B
of	I
the	I
cerebral	I
blank	I
weigh	I
with	O
sparing	O
of	O
the	O
uranium	O
-	O
character	O
,	O
compatible	O
with	O
the	O
witness	O
of	O
childhood	O
ALD	B
.	O

the	O
sparing	O
2	O
and	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	O
demyelination	B
of	I
,	I
of	I
white	I
matter	I
with	O
the	O
of	O
patients	O
U	O
ALD	O
fibers	O
the	O
compatible	O
with	O
In	O
cerebral	O
-	O
childhood	O
findings	B
.	O

In	O
patients	O
2	O
and	O
3	O
,	O
autopsy	O
showed	O
massive	O
demyelination	B
of	I
the	I
cerebral	I
white	I
matter	I
sparing	O
of	O
the	O
U	O
-	O
fibers	O
,	O
the	O
findings	O
of	O
ALD	B

In	O
patients	O
2	O
and	O
	O
intellectual	O
edward	O
white	O
	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	B
demyelination	I
of	I
the	I
cerebral	I
white	I
matter	O
with	O
sparing	O
of	O
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	B
ALD	O
usher	O
usher	O
usher	O
usher	O
usher	O

In	O
patients	O
2	O
and	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	O
demyelination	B
of	I
the	I
cerebral	I
white	I
matter	I
with	O
sparing	O
of	O
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	O
ALD	B
.	O

Oleic	O
and	O
erucic	O
)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4	O
,	O
but	O
sufficient	O
effectiveness	O
was	O
not	O
obtained	O

Oleic	O
and	O
erucic	O
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
to	O
patients	O
1	O
4	O
sufficient	O
effectiveness	O
was	O
not	O
obtained	O
.	O

Oleic	O
and	O
erucic	O
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4	O
,	O
but	O
sufficient	O
non	O
hold	O
hold	O
cost	O
cost	O
cost	O
effectiveness	O
was	O
not	O
obtained	O
.	O

Oleic	O
and	O
erucic	O
zen	O
(	O
Lorenzos	O
petroleum	O
)	O
were	O
administered	O
to	O
patients	O
single	O
and	O
tetrad	O
,	O
but	O
sufficient	O
potency	O
was	O
not	O
hold	O
.	O

Oleic	O
and	O
erucic	O
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4	O
,	O
but	O
sufficient	O
non	O
hold	O
hold	O
cost	O
cost	O
cost	O
effectiveness	O
was	O
not	O
obtained	O
.	O

Oleic	O
and	O
erucic	O
superman	O
(	O
Lorenzos	O
anoint	O
)	O
were	O
administered	O
to	O
patients	O
ace	O
and	O
quartet	O
,	O
but	O
sufficient	O
strength	O
was	O
not	O
get	O
.	O

Oleic	O
and	O
erucic	O
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
patients	O
1	O
4	O
,	O
but	O
sufficient	O
effectiveness	O
was	O
not	O

to	O
and	O
erucic	O
effectiveness	O
(	O
Lorenzos	O
Oil	O
were	O
)	O
administered	O
was	O
patients	O
and	O
1	O
.	O
,	O
but	O
sufficient	O
acids	O
Oleic	O
not	O
obtained	O
4	O

Oleic	O
and	O
erucic	O
elvis	O
(	O
Lorenzos	O
crude	O
)	O
were	O
deal	O
to	O
patients	O
i	O
and	O
4	O
,	O
but	O
sufficient	O
strength	O
was	O
not	O
receive	O
.	O

4	O
and	O
were	O
Oil	O
(	O
Lorenzos	O
,	O
)	O
erucic	O
administered	O
to	O
patients	O
not	O
and	O
acids	O
Oleic	O
but	O
sufficient	O
effectiveness	O
was	O
1	O
obtained	O
.	O

Oleic	O
and	O
erucic	O
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4	O
,	O
but	O
sufficient	O
effectiveness	O
was	O
not	O
obtained	O
.	O

The	O
happen	O
in	O
this	O
folk	O
intimate	O
that	O
delGAG291	O
is	O
function	O
of	O
the	O
grounds	O
of	O
nipponese	O
ALD	B
with	O
phenotypic	O
variations	O
.	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	O
part	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	B
with	O
phenotypic	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
variations	O
.	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	O
part	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	B
with	O
phenotypic	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
variations	O
.	O

in	O
suggest	O
that	O
delGAG291	O
part	O
of	O
cause	O
of	O
Japanese	O
ALD	B
with	O
phenotypic	O
variations	O
.	O

The	O
findings	O
in	O
this	O
family	O
delGAG291	O
is	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	B
with	O
phenotypic	O
variations	O
.	O

in	O
this	O
family	O
suggest	O
delGAG291	O
is	O
part	O
of	O
the	O
of	O
Japanese	O
ALD	B
with	O
variations	O
.	O

phenotypic	O
findings	O
in	O
variations	O
family	O
suggest	O
that	O
is	O
delGAG291	O
part	O
Japanese	O
the	O
cause	O
.	O
The	O
ALD	B
with	O
of	O
this	O
of	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	O
part	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	B
with	O
phenotypic	O
indium	O
indium	O
indium	O
indium	O
indium	O
cost	O
variations	O
.	O

The	O
obtain	O
in	O
this	O
family	O
intimate	O
that	O
delGAG291	O
is	O
role	O
of	O
the	O
case	O
of	O
japanese	O
ALD	B
with	O
phenotypic	O
variance	O
.	O

with	O
findings	O
in	O
this	O
family	O
suggest	O
of	O
the	O
is	O
part	O
of	O
Japanese	O
The	O
that	O
delGAG291	O
phenotypic	B
cause	O
ALD	O
variations	O
.	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	O
part	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	B
with	O
phenotypic	O
variations	O
.	O

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
,	O
there	O
is	O
a	O
that	O
PET	O
can	O
detect	O
an	O
lesion	I
which	O
is	O
undetectable	O
computed	O
tomogram	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
that	O
higher	O
level	O
tau	O
reflects	O
the	O
process	O
of	O
neuronal	B
degeneration	I
in	O

process	O
undetectable	O
although	O
the	O
scale	O
of	O
the	O
PET	O
is	O
limited	O
,	O
there	O
is	O
.	O
neuronal	O
that	O
study	O
)	O
detect	O
an	O
tau	B
lesion	I
which	O
is	O
,	O
by	O
computed	O
higher	O
can	O
CT	O
(	O
the	O
MRI	O
analysis	O
,	O
and	O
that	O
in	O
tomogram	O
level	O
of	O
insidious	O
reflects	O
the	O
Moreover	O
of	O
possibility	B
degeneration	I
ALD	O
or	B
a	O

moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
take	O
is	O
circumscribed	O
,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
find	O
an	O
pernicious	B
wound	I
which	O
is	O
indiscernible	O
by	O
cypher	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
that	O
the	O
gamey	O
storey	O
of	O
tau	O
contemplate	O
the	O
appendage	O
of	O
neural	B
degeneracy	I
in	O
ALD	B
.	O

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
operating	O
theatre	O
cost	O
is	O
limited	O
,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	B
insidious	I
lesion	O
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
reverberate	O
scurf	O
treat	O
reverberate	O
neural	O
degeneracy	O
indium	O
neural	O
degeneracy	O
indium	O
neural	O
degeneracy	O
darling	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	B
neuronal	I
degeneration	O
in	B
ALD	O

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
operating	O
theatre	O
cost	O
is	O
limited	O
,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	B
insidious	I
lesion	O
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
reverberate	O
scurf	O
treat	O
reverberate	O
neural	O
degeneracy	O
indium	O
neural	O
degeneracy	O
indium	O
neural	O
degeneracy	O
darling	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	B
neuronal	I
degeneration	O
in	B
ALD	O

,	O
although	O
the	O
scale	O
of	O
study	O
is	O
is	O
that	O
PET	O
an	O
which	O
is	O
undetectable	O
by	O
tomogram	O
(	O
or	O
MRI	O
,	O
and	O
level	O
tau	O
reflects	O
the	O
of	O
neuronal	B
degeneration	I
ALD	B
.	O

Moreover	O
,	O
although	O
of	O
the	O
study	O
is	O
limited	O
,	O
there	O
is	O
that	O
can	O
detect	O
an	O
lesion	I
which	O
is	O
undetectable	O
by	O
computed	O
(	O
CT	O
MRI	O
,	O
and	O
that	O
the	O
of	O
tau	O
reflects	O
the	O
of	O
neuronal	B
degeneration	I
in	O
ALD	B
.	O

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
read	O
is	O
fix	O
,	O
there	O
is	O
a	O
hypothesis	O
that	O
preferent	O
can	O
observe	O
an	O
subtle	B
wound	I
which	O
is	O
insensible	O
by	O
figure	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
that	O
the	O
gamy	O
tier	O
of	O
tau	O
speculate	O
the	O
operation	O
of	O
neuronic	B
decadency	I
in	O
ALD	B
.	O

Moreover	O
,	O
although	O
the	O
scurf	O
of	O
the	O
examine	O
is	O
throttle	O
,	O
there	O
is	O
a	O
possibleness	O
that	O
PET	O
can	O
find	O
an	O
subtle	B
wound	I
which	O
is	O
indiscernible	O
by	O
cypher	O
tomogram	O
(	O
CT	O
)	O
or	O
mri	O
analysis	O
,	O
and	O
that	O
the	O
higher	O
layer	O
of	O
tau	O
speculate	O
the	O
litigate	O
of	O
neural	B
decadence	I
in	O
ALD	B
.	O

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
operating	O
theatre	O
cost	O
is	O
limited	O
,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	B
insidious	I
lesion	O
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
reverberate	O
scurf	O
treat	O
reverberate	O
neural	O
degeneracy	O
indium	O
neural	O
degeneracy	O
indium	O
neural	O
degeneracy	O
scurf	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	B
neuronal	I
degeneration	O
in	B
ALD	O

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
is	O
limited	O
,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	O
insidious	B
lesion	I
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	O
neuronal	B
degeneration	I
in	O
ALD	B
.	O

Lorenzos	O
Oil	O
should	O
be	O
render	O
in	O
the	O
betimes	O
arrange	O
.	O
.	O

Lorenzos	O
Oil	O
should	O
be	O
given	O
in	O
the	O
early	O
stage	O
crude	O
crude	O
crude	O
.	O
.	O

Lorenzos	O
crude	O
should	O
be	O
pass	O
in	O
the	O
early	O
arrange	O
.	O
.	O

Lorenzos	O
embrocate	O
should	O
be	O
open	O
in	O
the	O
early	O
stage	O
.	O
.	O

Oil	O
should	O
given	O
in	O
the	O
early	O
stage	O
.	O
.	O

early	O
Oil	O
should	O
given	O
be	O
in	O
.	O
Lorenzos	O
stage	O
the	O
.	O

Lorenzos	O
early	O
should	O
be	O
Oil	O
in	O
the	O
.	O
stage	O
.	O
given	O

be	O
early	O
should	O
the	O
given	O
in	O
Lorenzos	O
Oil	O
stage	O
.	O
.	O

Lorenzos	O
should	O
given	O
the	O
early	O
stage	O
.	O
.	O

Lorenzos	O
Oil	O
should	O
be	O
given	O
in	O
the	O
early	O
stage	O
crude	O
crude	O
crude	O
.	O
.	O

Lorenzos	O
Oil	O
should	O
be	O
given	O
in	O
the	O
early	O
stage	O
.	O
.	O

falderol	O
mutation	O
in	O
exon	O
quaternary	O
of	O
human	O
complement	O
C9	O
factor	O
is	O
the	O
major	O
campaign	O
of	O
nipponese	O
complement	B
C9	I
insufficiency	I
.	O

Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B
C9	I
indium	I
indium	O
indium	I
indium	O
indium	I
indium	O
deficiency	I
.	O

Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B
C9	I
indium	I
indium	O
indium	I
indium	O
indium	I
indium	O
deficiency	I
.	O

in	O
of	O
human	O
complement	O
gene	O
is	O
major	O
cause	O
of	O
Japanese	O
complement	B
C9	I
deficiency	I
.	O

Nonsense	O
mutation	O
in	O
exon	O
4	O
complement	O
C9	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B
C9	I
deficiency	I
.	O

in	O
exon	O
4	O
of	O
complement	O
C9	O
gene	O
is	O
the	O
cause	O
of	O
Japanese	O
complement	B
deficiency	I
.	O

C9	O
mutation	O
in	O
deficiency	O
4	O
of	O
human	O
C9	O
complement	O
gene	O
of	O
the	O
major	O
.	O
Nonsense	O
Japanese	O
complement	B
is	I
exon	I
cause	O

Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B
C9	I
indium	I
indium	O
indium	I
indium	O
indium	I
indium	O
deficiency	I
.	O

bunk	O
mutation	O
in	O
exon	O
quadruplet	O
of	O
human	O
complement	O
C9	O
factor	O
is	O
the	O
major	O
campaign	O
of	O
japanese	O
complement	B
C9	I
inadequacy	I
.	O

complement	O
mutation	O
in	O
exon	O
4	O
of	O
cause	O
the	O
C9	O
gene	O
is	O
of	O
Nonsense	O
human	O
complement	O
C9	O
major	B
Japanese	I
deficiency	I
.	O

Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B
C9	I
deficiency	I
.	O

of	I
the	I
ninth	I
component	I
of	I
human	I
complement	I
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B
in	O
but	O
is	O
rare	O
in	O
other	O
countries	O
.	O

)	B
of	I
the	I
Japan	I
component	I
of	I
human	I
.	I
other	O
C9	O
countries	O
is	O
the	O
but	O
in	O
complement	B
deficiency	I
in	O
ninth	O
most	O
is	O
rare	O
common	O
(	O
Deficiency	O
complement	O

insufficiency	B
of	I
the	I
ninth	I
element	I
of	I
homo	I
complement	I
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B
insufficiency	I
in	O
nihon	O
but	O
is	O
rarified	O
in	O
other	O
country	O
.	O

lack	B
of	I
the	I
ninth	I
factor	I
of	I
human	I
accompaniment	I
(	O
C9	O
)	O
is	O
the	O
most	O
coarse	O
accompaniment	B
lack	I
in	O
japan	O
but	O
is	O
rare	O
in	O
other	O
state	O
.	O

Deficiency	B
of	I
the	I
ninth	I
component	I
of	I
human	I
complement	I
(	O
C9	O
is	O
the	O
common	O
complement	B
deficiency	I
in	O
Japan	O
but	O
is	O
other	O
countries	O
.	O

Deficiency	B
of	I
the	I
ninth	I
element	I
component	I
of	I
human	I
complement	I
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B
deficiency	I
in	O
indium	O
former	O
res	O
publica	O
former	O
res	O
publica	O
th	O
Japan	O
but	O
is	O
rare	O
in	O
other	O

Deficiency	B
of	I
the	I
ninth	I
element	I
component	I
of	I
human	I
complement	I
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B
deficiency	I
in	O
indium	O
former	O
res	O
publica	O
former	O
res	O
publica	O
former	O
Japan	O
but	O
is	O
rare	O
in	O
other	O

Deficiency	B
of	I
the	I
ninth	I
component	I
of	I
human	I
complement	I
(	O
C9	O
is	O
common	O
complement	B
deficiency	I
in	O
Japan	O
but	O
is	O
rare	O
in	O

other	B
of	I
the	I
ninth	I
component	I
of	I
most	I
deficiency	I
(	O
C9	O
)	O
is	O
rare	O
human	O
countries	O
complement	B
complement	I
is	O
Japan	O
but	O
Deficiency	O
the	O
in	O
in	O
common	O
.	O

lack	B
of	I
the	I
ninth	I
component	I
of	I
human	I
accompaniment	I
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
accompaniment	B
lack	I
in	O
Japan	O
but	O
is	O
rarified	O
in	O
other	O
countries	O
.	O

Deficiency	B
of	I
the	I
ninth	I
component	I
of	I
human	I
complement	I
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B
deficiency	I
in	O
Japan	O
but	O
is	O
rare	O
in	O
other	O
countries	O
.	O

meningitis	O
studied	O
the	O
Japanese	O
basis	O
of	O
C9	B
from	I
patients	O
four	O
molecular	O
C9	B
deficient	I
-	I
in	O
who	O
had	O
suffered	O
deficiency	O
We	B
meningococcal	I
.	O

We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B
deficiency	I
in	O
four	O
Japanese	O
C9	B
-	I
deficient	I
patients	O
who	O
had	O
suffered	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
from	O
meningococcal	B
meningitis	I
.	O

We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B
deficiency	I
in	O
four	O
Japanese	O
C9	B
-	I
deficient	I
patients	O
who	O
had	O
suffered	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
from	O
meningococcal	B
meningitis	I
.	O

We	O
canvass	O
the	O
molecular	O
base	O
of	O
C9	B
want	I
in	O
four	O
japanese	O
C9	B
-	I
wanting	I
patients	O
who	O
had	O
get	O
from	O
meningococcal	B
meningitis	I
.	O

We	O
studied	O
the	O
basis	O
of	O
C9	B
deficiency	I
in	O
Japanese	O
C9	B
-	I
deficient	I
who	O
had	O
from	O
meningococcal	B
meningitis	I
.	O

molecular	O
C9	B
deficiency	I
in	O
Japanese	O
C9	B
deficient	I
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	B
meningitis	I
.	O

We	O
canvass	O
the	O
molecular	O
base	O
of	O
C9	B
inadequacy	I
in	O
iv	O
nipponese	O
C9	B
-	I
deficient	I
patients	O
who	O
had	O
stomach	O
from	O
meningococcal	B
meningitis	I
.	O

patients	O
studied	O
in	O
C9	O
basis	O
of	O
who	B
deficiency	I
the	O
four	O
Japanese	O
C9	B
meningitis	I
deficient	I
molecular	O
We	O
had	O
suffered	O
from	O
meningococcal	B
-	I
.	O

We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B
deficiency	I
in	O
four	O
Japanese	O
C9	B
-	I
deficient	I
patients	O
who	O
had	O
suffered	O
indium	O
indium	O
indium	O
indium	O
indium	O
inadequacy	O
from	O
meningococcal	B
meningitis	I
.	O

We	O
studied	O
the	O
molecular	O
C9	B
deficiency	I
four	O
Japanese	O
C9	B
-	I
deficient	I
patients	O
who	O
had	O
suffered	O
from	O
.	O

We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B
deficiency	I
in	O
four	O
Japanese	O
C9	B
-	I
deficient	I
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	B
meningitis	I
.	O

Direct	O
sequencing	O
of	O
amplified	O
indium	O
complementary	O
dna	O
substandard	O
dna	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	B
C9	I
-	I
deficient	O
individuals	O
in	O
in	O
in	O
in	O
desoxyribonucleic	O

Direct	O
sequencing	O
of	O
cDNA	O
nonsense	O
substitution	O
(	O
-	O
-	O
TGA	O
)	O
at	O
in	O
exon	O
4	O
in	O
the	O
C9	B
deficient	I
individuals	O
.	O

point	O
sequence	O
of	O
amplified	O
C9	O
cdna	O
and	O
dna	O
unwrap	O
a	O
hokum	O
commutation	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
quaternity	O
C9	B
-	I
substandard	I
individuals	O
.	O

Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
and	O
revealed	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
4	O
in	O
the	O
four	O
C9	B
-	I
deficient	I
individuals	O
.	O

unmediated	O
sequence	O
of	O
hyperbolize	O
C9	O
cDNA	O
and	O
dna	O
unveil	O
a	O
nonsense	O
permutation	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
quaternary	O
C9	B
-	I
wanting	I
someone	O
.	O

Direct	O
sequencing	O
of	O
amplified	O
indium	O
complementary	O
dna	O
substandard	O
dna	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	B
C9	I
-	I
deficient	O
individuals	O
in	O
in	O
in	O
in	O
desoxyribonucleic	O

Direct	O
sequence	O
of	O
overdraw	O
C9	O
cDNA	O
and	O
dna	O
divulge	O
a	O
hokum	O
exchange	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
quatern	O
in	O
the	O
four	O
C9	B
-	I
substandard	I
soul	O
.	O

codon	O
)	O
of	O
amplified	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
4	O
-	O
-	O
>	O
TGA	O
four	O
at	O
sequencing	O
95	O
individuals	O
exon	O
CGA	O
in	O
the	O
Direct	O
-	B
in	I
deficient	I
C9	O
.	O

Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
DNA	O
a	O
nonsense	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
four	O
C9	B
-	I
individuals	O

Direct	O
sequencing	O
of	O
amplified	O
indium	O
complementary	O
dna	O
substandard	O
organise	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	B
C9	I
-	I
deficient	O
individuals	O
in	O
in	O
in	O
in	O
machinate	O

Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	O
C9	B
-	I
deficient	I
individuals	O
.	O

An	O
allelomorph	O
-	O
particular	O
polymerase	O
chain	O
reaction	O
arrangement	O
designed	O
to	O
find	O
only	O
only	O
unity	O
of	O
the	O
rule	O
and	O
sport	O
allelomorph	O
suggest	O
that	O
all	O
the	O
quaternion	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
quadruplet	O
and	O
that	O
the	O
parents	O
of	O
patient	O
2	O
were	O
heterozygous	O
.	O

An	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
patient	O
role	O
	O
cost	O
patient	O
role	O
	O
cost	O
convention	O
convention	O
convention	O
convention	O
convention	O
convention	O
convention	O
the	O
parents	O
of	O
patient	O
2	O
were	O

An	O
specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
exon	O
and	O
that	O
the	O
parents	O
of	O
patient	O
2	O
were	O
.	O

An	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
exclusively	O
only	O
one	O
of	O
the	O
that	O
four	O
were	O
homozygous	O
for	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
patient	O
2	O
were	O
heterozygous	O
.	O

An	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
patient	O
role	O
	O
cost	O
patient	O
role	O
	O
cost	O
convention	O
convention	O
convention	O
convention	O
convention	O
convention	O
sport	O
the	O
parents	O
of	O
patient	O
2	O
were	O

An	O
allele	O
-	O
specific	O
polymerase	O
chain	O
designed	O
to	O
detect	O
only	O
of	O
the	O
normal	O
alleles	O
four	O
patients	O
were	O
for	O
the	O
in	O
exon	O
4	O
the	O
parents	O
of	O
patient	O
2	O
heterozygous	O

An	O
allelomorph	O
-	O
particular	O
polymerase	O
chain	O
reaction	O
scheme	O
project	O
to	O
notice	O
only	O
only	O
unmatchable	O
of	O
the	O
pattern	O
and	O
sport	O
alleles	O
bespeak	O
that	O
all	O
the	O
quaternion	O
patients	O
were	O
homozygous	O
for	O
the	O
mutant	O
in	O
exon	O
4	O
and	O
that	O
the	O
parents	O
of	O
patient	O
deuce	O
were	O
heterozygous	O
.	O

An	O
allelomorph	O
-	O
particular	O
polymerase	O
chain	O
response	O
system	O
project	O
to	O
observe	O
alone	O
only	O
one	O
of	O
the	O
formula	O
and	O
variation	O
alleles	O
indicated	O
that	O
all	O
the	O
quatern	O
patients	O
were	O
homozygous	O
for	O
the	O
variation	O
in	O
exon	O
quadruplet	O
and	O
that	O
the	O
raise	O
of	O
patient	O
ii	O
were	O
heterozygous	O
.	O

An	O
mutant	O
-	O
specific	O
polymerase	O
chain	O
were	O
4	O
designed	O
to	O
detect	O
2	O
only	O
homozygous	O
the	O
the	O
normal	O
and	O
system	O
alleles	O
indicated	O
that	O
for	O
the	O
.	O
patients	O
in	O
one	O
of	O
four	O
mutation	O
that	O
exon	O
allele	O
and	O
were	O
the	O
parents	O
of	O
patient	O
exclusively	O
reaction	O
heterozygous	O
all	O

An	O
allele	O
in	O
specific	O
polymerase	O
for	O
reaction	O
system	O
designed	O
to	O
detect	O
only	O
heterozygous	O
one	O
of	O
mutation	O
normal	O
and	O
alleles	O
mutant	O
indicated	O
exon	O
all	O
.	O
four	O
were	O
homozygous	O
that	O
chain	O
the	O
the	O
parents	O
patients	O
4	O
and	O
the	O
the	O
-	O
of	O
patient	O
2	O
were	O
exclusively	O
that	O

An	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
the	O
parents	O
of	O
patient	O
2	O
were	O
heterozygous	O
.	O

The	O
common	O
4	O
Japanese	O
codon	O
95	O
for	O
exon	O
mutation	O
might	O
be	O
responsible	O
in	O
most	O
at	O
C9	B
deficiency	I
.	O
.	O

mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
C9	B
deficiency	I
.	O
.	O

The	O
common	O
variation	O
at	O
codon	O
xcv	O
in	O
exon	O
four	O
might	O
be	O
creditworthy	O
for	O
most	O
Japanese	O
C9	B
want	I
.	O
.	O

The	O
unwashed	O
mutant	O
at	O
codon	O
95	O
in	O
exon	O
iv	O
might	O
be	O
responsible	O
for	O
most	O
nipponese	O
C9	B
want	I
.	O
.	O

deficiency	O
common	O
mutation	O
at	O
codon	O
95	O
most	O
Japanese	O
4	O
might	O
be	O
responsible	O
.	O
in	O
exon	O
C9	B
for	I
The	O
.	O

The	O
common	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B
deficiency	I
.	O

The	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B
deficiency	I
.	O
sport	O
sport	O
sport	O
sport	O
atomic	O
number	O

The	O
green	O
mutation	O
at	O
codon	O
xcv	O
in	O
exon	O
quartet	O
might	O
be	O
creditworthy	O
for	O
most	O
nipponese	O
C9	B
deficiency	I
.	O
.	O

The	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B
deficiency	I
.	O
sport	O
sport	O
sport	O
sport	O
sport	O
.	O

most	O
common	O
mutation	O
be	O
codon	O
95	O
in	O
.	O
Japanese	O
might	O
at	O
responsible	O
The	O
for	O
4	O
C9	B
deficiency	I
.	O
exon	O

The	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B
deficiency	I
.	O
.	O

BRCA1	O
required	O
for	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
legal	O
injury	O
ask	O
ask	O
DNA	O
damage	O

required	O
for	O
repair	O
DNA	O
damage	O
.	O

BRCA1	O
need	O
for	O
transcription	O
-	O
coupled	O
hangout	O
of	O
oxidative	O
dna	O
damage	O
.	O

BRCA1	O
required	O
for	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
legal	O
injury	O
ask	O
ask	O
DNA	O
damage	O

required	O
for	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O

BRCA1	O
compulsory	O
for	O
transcription	O
-	O
coupled	O
remediate	O
of	O
oxidative	O
DNA	O
scathe	O
.	O

BRCA1	O
required	O
for	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
legal	O
injury	O
ask	O
ask	O
DNA	O
damage	O

BRCA1	O
command	O
for	O
transcription	O
-	O
coupled	O
recompense	O
of	O
oxidative	O
dna	O
damage	O
.	O

BRCA1	O
of	O
for	O
transcription	O
required	O
coupled	O
repair	O
damage	O
oxidative	O
DNA	O
-	O
.	O

.	O
required	O
for	O
transcription	O
of	O
coupled	O
DNA	O
-	O
oxidative	O
repair	O
damage	O
BRCA1	O

BRCA1	O
required	O
for	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O

zinc	O
breast	B
and	I
BRCA1	I
cancer	I
susceptibility	O
gene	O
ovarian	O
unknown	O
a	O
of	O
finger	O
The	O
protein	O
encodes	O
function	O
.	O

The	O
summit	B
and	I
ovarian	I
cancer	I
susceptibleness	O
gene	O
BRCA1	O
encodes	O
a	O
zn	O
finger	O
protein	O
of	O
strange	O
operate	O
.	O

The	O
boob	B
and	I
ovarian	I
cancer	I
susceptibleness	O
cistron	O
BRCA1	O
encodes	O
a	O
zinc	O
digit	O
protein	O
of	O
stranger	O
function	O
.	O

The	O
breast	B
cancer	I
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

The	O
bosom	B
and	I
ovarian	I
crab	I
susceptibility	O
factor	O
BRCA1	O
encodes	O
a	O
zinc	O
feel	O
protein	O
of	O
unsung	O
function	O
.	O

The	O
breast	B
unknown	B
quantity	B
encode	I
and	I
ovarian	I
cancer	O
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
factor	O
factor	O
factor	O

The	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
a	O
zinc	O
protein	O
of	O
unknown	O
function	O
.	O

The	O
breast	B
unknown	B
quantity	B
encode	I
and	I
ovarian	I
cancer	O
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
factor	O
factor	O
factor	O

breast	B
cancer	I
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O

The	O
breast	B
encodes	I
unknown	I
cancer	I
susceptibility	O
protein	O
BRCA1	O
and	O
a	O
zinc	O
finger	O
gene	O
of	O
ovarian	O
function	O
.	O

The	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

Association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA	O
-	O
damaging	O
agents	O
are	O
consistent	O
with	O
a	O
role	O
for	O
BRCA1	O
dna	O
hangout	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
in	O
DNA	O
repair	O
.	O

Association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA	O
-	O
damaging	O
agents	O
are	O
consistent	O
with	O
a	O
role	O
for	O
BRCA1	O
dna	O
hangout	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
in	O
DNA	O
repair	O
.	O

Association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA	O
-	O
damaging	O
agents	O
are	O
consistent	O
with	O
a	O
role	O
for	O
BRCA1	O
dna	O
hangout	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O
in	O
DNA	O
repair	O
.	O

to	O
localization	O
the	O
BRCA1	O
protein	O
with	O
and	O
role	O
repair	O
protein	O
Rad51	O
the	O
changes	O
damaging	O
are	O
phosphorylation	O
and	O
cellular	O
DNA	O
of	O
the	O
a	O
agents	O
exposure	O
Association	O
DNA	O
with	O
in	O
the	O
after	O
consistent	O
BRCA1	O
protein	O
of	O
for	O
-	O
in	O
DNA	O
repair	O
.	O

Association	O
of	O
the	O
BRCA1	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
in	O
the	O
localization	O
protein	O
after	O
DNA	O
agents	O
are	O
consistent	O
with	O
role	O
for	O
DNA	O
repair	O

tie	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
dna	O
repair	O
protein	O
Rad51	O
and	O
switch	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
fix	O
of	O
the	O
protein	O
after	O
picture	O
to	O
dna	O
-	O
negative	O
agents	O
are	O
uniform	O
with	O
a	O
office	O
for	O
BRCA1	O
in	O
dna	O
repair	O
.	O

association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
remediate	O
protein	O
Rad51	O
and	O
transfer	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localisation	O
of	O
the	O
protein	O
after	O
photo	O
to	O
DNA	O
-	O
damage	O
agents	O
are	O
uniform	O
with	O
a	O
office	O
for	O
BRCA1	O
in	O
DNA	O
remediate	O
.	O

consistent	O
for	O
the	O
BRCA1	O
and	O
with	O
DNA	O
with	O
repair	O
protein	O
Rad51	O
and	O
changes	O
to	O
cellular	O
phosphorylation	O
protein	O
the	O
localization	O
of	O
in	O
protein	O
after	O
exposure	O
of	O
DNA	O
-	O
repair	O
Association	O
are	O
agents	O
the	O
a	O
role	O
the	O
BRCA1	O
in	O
DNA	O
damaging	O
.	O

tie	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
hangout	O
protein	O
Rad51	O
and	O
modify	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
locating	O
of	O
the	O
protein	O
after	O
pic	O
to	O
DNA	O
-	O
prejudicious	O
agents	O
are	O
coherent	O
with	O
a	O
character	O
for	O
BRCA1	O
in	O
DNA	O
hangout	O
.	O

Association	O
of	O
consistent	O
BRCA1	O
protein	O
BRCA1	O
Rad51	O
DNA	O
repair	O
protein	O
the	O
-	O
of	O
in	O
the	O
localization	O
and	O
cellular	O
DNA	O
changes	O
the	O
protein	O
after	O
with	O
to	O
phosphorylation	O
and	O
a	O
with	O
are	O
the	O
damaging	O
agents	O
role	O
for	O
exposure	O
in	O
DNA	O
repair	O
.	O

Association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA	O
-	O
damaging	O
agents	O
are	O
consistent	O
with	O
a	O
role	O
for	O
BRCA1	O
in	O
DNA	O
repair	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	B
in	I
BRCA1	I
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionizing	O
radiation	O
atomic	O
number	O
	O
hydrogen	O
peroxide	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
and	O

Here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	B
in	I
BRCA1	I
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionizing	O
radiation	O
atomic	O
number	O
	O
hydrogen	O
peroxide	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
and	O

Here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	B
in	I
BRCA1	I
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionizing	O
radiation	O
atomic	O
number	O
	O
hydrogen	O
peroxide	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
and	O

repair	O
to	O
it	O
is	O
shown	O
that	O
in	O
to	O
stem	O
cells	O
deficient	B
mouse	I
BRCA1	I
DNA	O
,	O
in	O
the	O
ability	O
embryonic	O
carry	O
out	O
hypersensitive	O
damage	O
coupled	O
Here	O
of	O
are	O
are	O
defective	O
-	O
and	O
radiation	O
transcription	O
,	O
ionizing	O
oxidative	O
and	O
hydrogen	O
peroxide	O
.	O

Here	O
,	O
it	O
is	O
embryonic	O
stem	O
cells	O
deficient	B
in	I
are	O
defective	O
to	O
transcription	O
-	O
of	O
damage	O
,	O
and	O
are	O
to	O
ionizing	O
hydrogen	O
peroxide	O

hither	O
,	O
it	O
is	O
picture	O
that	O
mouse	O
embryonal	O
stalk	O
cells	O
deficient	B
in	I
BRCA1	I
are	O
faulty	O
in	O
the	O
power	O
to	O
comport	O
out	O
arranging	O
-	O
coupled	O
quicken	O
of	O
oxidative	O
dna	O
impairment	O
,	O
and	O
are	O
supersensitized	O
to	O
ionizing	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O

here	O
,	O
it	O
is	O
usher	O
that	O
mouse	O
embryonal	O
stem	O
cellphone	O
wanting	B
in	I
BRCA1	I
are	O
faulty	O
in	O
the	O
power	O
to	O
carry	O
out	O
arranging	O
-	O
conjugate	O
repair	O
of	O
oxidative	O
DNA	O
scathe	O
,	O
and	O
are	O
supersensitized	O
to	O
ionize	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O

and	O
ionizing	O
it	O
is	O
the	O
that	O
hydrogen	O
are	O
stem	O
cells	O
deficient	B
in	I
BRCA1	I
repair	O
ability	O
in	O
shown	O
defective	O
to	O
carry	O
are	O
transcription	O
-	O
coupled	O
,	O
of	O
oxidative	O
peroxide	O
Here	O
,	O
damage	O
mouse	O
hypersensitive	O
to	O
out	O
radiation	O
and	O
embryonic	O
DNA	O
.	O

hera	O
,	O
it	O
is	O
read	O
that	O
creep	O
embryotic	O
stem	O
cells	O
lacking	B
in	I
BRCA1	I
are	O
bad	O
in	O
the	O
power	O
to	O
stockpile	O
out	O
arranging	O
-	O
conjugated	O
remediate	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionise	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O

Here	O
,	O
and	O
is	O
shown	O
radiation	O
deficient	O
embryonic	O
stem	O
cells	O
mouse	B
oxidative	I
carry	I
are	O
defective	O
to	O
the	O
ability	O
hydrogen	O
BRCA1	O
out	O
transcription	O
-	O
that	O
repair	O
in	O
in	O
hypersensitive	O
are	O
,	O
it	O
DNA	O
damage	O
to	O
ionizing	O
coupled	O
and	O
of	O
peroxide	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	B
in	I
BRCA1	I
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionizing	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O

.	O
results	O
suggest	O
,	O
BRCA1	O
participates	O
,	O
DNA	O
coupled	O
indirectly	O
that	O
in	O
-	O
transcription	O
or	O
repair	O
of	O
oxidative	O
directly	O
These	O
damage	O
.	O

These	O
results	O
suggest	O
that	O
BRCA1	O
participates	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
legal	O
injury	O
propose	O
propose	O
propose	O
propose	O
propose	O
DNA	O
damage	O
.	O

These	O
results	O
suggest	O
that	O
BRCA1	O
participates	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
legal	O
injury	O
propose	O
propose	O
propose	O
propose	O
propose	O
DNA	O
damage	O
.	O

These	O
termination	O
indicate	O
that	O
BRCA1	O
participates	O
,	O
forthwith	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
twin	O
remediate	O
of	O
oxidative	O
DNA	O
scathe	O
.	O
.	O

These	O
results	O
suggest	O
BRCA1	O
participates	O
,	O
directly	O
or	O
,	O
in	O
transcription	O
-	O
repair	O
of	O
DNA	O
damage	O
.	O
.	O

that	O
,	O
directly	O
or	O
,	O
in	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O
.	O

These	O
resolution	O
intimate	O
that	O
BRCA1	O
participates	O
,	O
straightaway	O
or	O
indirectly	O
,	O
in	O
arranging	O
-	O
coupled	O
vivify	O
of	O
oxidative	O
DNA	O
damage	O
.	O
.	O

coupled	O
results	O
or	O
,	O
BRCA1	O
participates	O
repair	O
directly	O
suggest	O
indirectly	O
,	O
in	O
.	O
-	O
that	O
These	O
of	O
oxidative	O
DNA	O
damage	O
transcription	O
.	O

These	O
results	O
suggest	O
that	O
BRCA1	O
participates	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
legal	O
injury	O
propose	O
propose	O
propose	O
propose	O
recording	O
DNA	O
damage	O
.	O

These	O
results	O
suggest	O
that	O
,	O
directly	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
.	O

These	O
results	O
suggest	O
that	O
BRCA1	O
participates	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O
.	O

Truncation	O
transactivation	O
in	O
the	O
mutations	O
region	O
PAX6	O
dominant	O
result	O
in	O
negative	O
-	O
of	O
mutants	O
.	O

Truncation	O
mutations	O
in	O
indium	O
indium	O
in	O
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
part	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O

truncation	O
sport	O
in	O
the	O
transactivation	O
realm	O
of	O
PAX6	O
result	O
in	O
dominant	O
-	O
negative	O
variation	O
.	O

negative	O
mutations	O
in	O
Truncation	O
PAX6	O
region	O
of	O
-	O
result	O
in	O
dominant	O
transactivation	O
the	O
mutants	O
.	O

shortness	O
mutations	O
in	O
the	O
transactivation	O
area	O
of	O
PAX6	O
solvent	O
in	O
rife	O
-	O
negative	O
mutants	O
.	O

Truncation	O
mutations	O
in	O
indium	O
indium	O
in	O
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
sport	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O

Truncation	O
in	O
transactivation	O
of	O
PAX6	O
result	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O

PAX6	O
the	O
in	O
mutations	O
transactivation	O
region	O
in	O
Truncation	O
result	O
of	O
dominant	O
-	O
negative	O
.	O
mutants	O

Truncation	O
mutations	O
in	O
the	O
transactivation	O
area	O
of	O
PAX6	O
upshot	O
in	O
dominant	O
-	O
blackball	O
mutation	O
.	O

Truncation	O
mutations	O
in	O
indium	O
indium	O
in	O
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
sport	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O

Truncation	O
mutations	O
in	O
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O

PAX6	O
is	O
a	O
transcription	O
partner	O
off	O
loge	O
robust	O
homeobox	O
gene	O
element	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
rich	O
transactivation	O
domain	O
pst	O
pst	O
pst	O

PAX6	O
is	O
factor	O
binding	O
domains	O
(	O
box	O
and	O
)	O
and	O
a	O
serine	O
-	O
threonine	O
(	O
PST	O
-	O
transactivation	O
domain	O
.	O

PAX6	O
is	O
a	O
transcription	O
factor	O
with	O
two	O
DNA	O
-	O
cover	O
domains	O
(	O
geminate	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
robust	O
transactivation	O
field	O
.	O

PAX6	O
is	O
a	O
transcription	O
with	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
homeobox	O
)	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
rich	O
transactivation	O
domain	O
.	O

PAX6	O
is	O
a	O
arranging	O
divisor	O
with	O
deuce	O
DNA	O
-	O
stick	O
domains	O
(	O
twin	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
fertile	O
transactivation	O
area	O
.	O

PAX6	O
is	O
a	O
transcription	O
partner	O
off	O
loge	O
robust	O
homeobox	O
gene	O
element	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
rich	O
transactivation	O
domain	O
pst	O
pst	O
pst	O

PAX6	O
is	O
a	O
arrangement	O
divisor	O
with	O
ii	O
dna	O
-	O
binding	O
domains	O
(	O
opposite	O
package	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
robust	O
transactivation	O
domain	O
.	O

-	O
a	O
a	O
transcription	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
(	O
transactivation	O
homeobox	O
)	O
and	O
-	O
proline	O
is	O
serine	O
.	O
threonine	O
box	O
PST	O
)	O
PAX6	O
and	O
-	O
domain	O
rich	O

PAX6	O
is	O
a	O
transcription	O
with	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
PST	O
)	O
-	O
transactivation	O
.	O

PAX6	O
is	O
a	O
transcription	O
partner	O
off	O
loge	O
robust	O
homeobox	O
gene	O
partner	O
off	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
rich	O
transactivation	O
domain	O
pst	O
pst	O

PAX6	O
is	O
a	O
transcription	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
rich	O
transactivation	O
domain	O
.	O

PAX6	O
eye	O
in	O
ranging	O
from	O
jellyfish	O
to	O
Drosophila	O
to	O
humans	O
.	O

PAX6	O
shape	O
eye	O
development	O
in	O
animals	O
drift	O
from	O
jellyfish	O
to	O
drosophila	O
to	O
homo	O
.	O

from	O
development	O
eye	O
regulates	O
in	O
animals	O
to	O
PAX6	O
jellyfish	O
.	O
Drosophila	O
to	O
humans	O
ranging	O

PAX6	O
regulates	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
to	O
Drosophila	O
humans	O
.	O

PAX6	O
regulates	O
oculus	O
oculus	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
human	O
indium	O
to	O
Drosophila	O
to	O
humans	O
.	O

PAX6	O
regulates	O
oculus	O
oculus	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
human	O
animal	O
to	O
Drosophila	O
to	O
humans	O
.	O

PAX6	O
regularise	O
eye	O
developing	O
in	O
animals	O
rank	O
from	O
jellyfish	O
to	O
Drosophila	O
to	O
humanity	O
.	O

humans	O
regulates	O
eye	O
PAX6	O
from	O
animals	O
ranging	O
to	O
jellyfish	O
to	O
Drosophila	O
in	O
development	O
.	O

PAX6	O
regulates	O
oculus	O
oculus	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
human	O
indium	O
to	O
Drosophila	O
to	O
humans	O
.	O

PAX6	O
regulates	O
oculus	O
growth	O
in	O
fauna	O
ranging	O
from	O
jellyfish	O
to	O
drosophila	O
to	O
humans	O
.	O

PAX6	O
regulates	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
to	O
Drosophila	O
to	O
humans	O
.	O

heterozygous	O
sport	O
in	O
the	O
human	O
PAX6	O
gene	O
solvent	O
in	O
assorted	O
phenotypes	O
,	O
include	O
aniridia	B
,	O
cock	B
anomaly	I
,	O
autosomal	B
prevailing	I
keratitis	I
,	O
and	O
hereditary	B
foveal	I
dysplasia	I
.	O

Heterozygous	O
mutations	O
the	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
Peters	B
anomaly	I
,	O
autosomal	B
keratitis	I
,	O
and	O
familial	B
foveal	I
.	O

Heterozygous	O
mutations	O
in	O
the	O
genetic	O
cock	O
homo	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B
,	O
Peters	B
anomaly	I
,	O
genetic	O
indium	O
genetic	O
genetic	O
indium	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
familial	B
foveal	I
dysplasia	I
.	O

keratitis	O
mutations	O
in	O
autosomal	O
human	O
PAX6	O
gene	O
dysplasia	O
familial	O
various	O
dominant	O
,	O
including	O
aniridia	B
and	O
Peters	B
anomaly	I
,	O
the	B
foveal	I
phenotypes	I
,	O
,	O
in	B
Heterozygous	I
result	I
.	O

Heterozygous	O
mutations	O
in	O
the	O
genetic	O
cock	O
homo	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B
,	O
Peters	B
anomaly	I
,	O
genetic	O
indium	O
genetic	O
genetic	O
indium	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
familial	B
foveal	I
dysplasia	I
.	O

Heterozygous	O
mutations	O
in	O
human	O
PAX6	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B
,	O
anomaly	I
,	O
dominant	I
keratitis	I
,	O
and	O
familial	B
foveal	I
dysplasia	I
.	O

.	O
mutations	O
in	O
,	O
human	O
PAX6	O
dysplasia	O
result	O
the	O
various	O
phenotypes	O
,	O
aniridia	O
keratitis	B
foveal	O
in	B
anomaly	I
,	O
autosomal	B
dominant	I
including	I
,	O
and	O
familial	B
Peters	I
gene	I
Heterozygous	O

in	O
PAX6	O
gene	O
result	O
various	O
phenotypes	O
including	O
aniridia	B
,	O
Peters	B
anomaly	I
,	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
familial	B
foveal	I

familial	O
mutations	O
in	O
the	O
human	O
PAX6	O
aniridia	O
,	O
in	O
various	O
phenotypes	O
anomaly	O
,	O
gene	B
foveal	O
Heterozygous	B
result	I
Peters	O
autosomal	B
dominant	I
keratitis	I
including	O
and	O
,	B
,	I
dysplasia	I
.	O

heterozygous	O
variation	O
in	O
the	O
human	O
PAX6	O
factor	O
ensue	O
in	O
assorted	O
phenotypes	O
,	O
admit	O
aniridia	B
,	O
Peters	B
anomalousness	I
,	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
hereditary	B
foveal	I
dysplasia	I
.	O

Heterozygous	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B
,	O
Peters	B
anomaly	I
,	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
familial	B
foveal	I
dysplasia	I
.	O

haploinsufficiency	O
is	O
believed	O
an	O
the	O
mutated	O
allele	O
to	O
aniridia	O
produces	O
that	O
inactive	O
and	O
protein	O
PAX6	B
is	O
caused	O
due	O
of	O
It	O
genetic	O
.	O

It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B
is	O
caused	O
due	O
familial	O
believe	O
believe	O
believe	O
believe	O
believe	O
to	O
genetic	O
haploinsufficiency	O
.	O

It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B
is	O
caused	O
due	O
familial	O
believe	O
believe	O
believe	O
believe	O
believe	O
to	O
genetic	O
haploinsufficiency	O
.	O

it	O
is	O
believed	O
that	O
the	O
mutated	O
allelomorph	O
of	O
PAX6	O
get	O
an	O
motionless	O
protein	O
and	O
aniridia	B
is	O
caused	O
imputable	O
to	O
genic	O
haploinsufficiency	O
.	O

It	O
is	O
believed	O
the	O
mutated	O
allele	O
of	O
PAX6	O
an	O
inactive	O
protein	O
and	O
is	O
caused	O
to	O
genetic	O
haploinsufficiency	O
.	O

that	O
allele	O
of	O
PAX6	O
an	O
inactive	O
and	O
aniridia	B
is	O
caused	O
due	O
to	O
genetic	O
haploinsufficiency	O
.	O

It	O
is	O
consider	O
that	O
the	O
mutated	O
allelomorph	O
of	O
PAX6	O
produces	O
an	O
still	O
protein	O
and	O
aniridia	B
is	O
get	O
referable	O
to	O
transmitted	O
haploinsufficiency	O
.	O

aniridia	O
is	O
PAX6	O
allele	O
the	O
mutated	O
is	O
of	O
believed	O
produces	O
an	O
inactive	O
haploinsufficiency	O
and	O
that	B
It	O
caused	O
due	O
to	O
genetic	O
protein	O
.	O

It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B
is	O
caused	O
due	O
familial	O
believe	O
believe	O
believe	O
believe	O
allelomorph	O
to	O
genetic	O
haploinsufficiency	O
.	O

It	O
is	O
believed	O
that	O
allele	O
of	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B
is	O
caused	O
due	O
to	O
.	O

It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B
is	O
caused	O
due	O
to	O
genetic	O
haploinsufficiency	O
.	O

However	O
mutations	O
been	O
found	O
to	O
in	O
the	O
C	O
terminal	O
half	O
of	O
PAX6	O
in	O
Aniridia	B
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
binding	O
but	O
have	O
lost	O
of	O
the	O
transactivation	O
domain	O
.	O

However	O
,	O
several	O
truncation	O
mutations	O
to	O
occur	O
in	O
the	O
C	O
terminal	O
half	O
patients	O
resulting	O
in	O
that	O
DNA	O
-	O
binding	O
domains	O
have	O
lost	O
the	O
transactivation	O
.	O

However	O
,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	B
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
DNA	O
-	O
binding	O
domains	O
but	O
have	O
lost	O
area	O
sport	O
sport	O
area	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
most	O
of	O
the	O
transactivation	O
domain	O
.	O

still	O
,	O
respective	O
shortness	O
sport	O
have	O
been	O
get	O
to	O
occur	O
in	O
the	O
C	O
-	O
final	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	B
resulting	O
in	O
variation	O
proteins	O
that	O
continue	O
the	O
DNA	O
-	O
binding	O
domains	O
but	O
have	O
bewildered	O
most	O
of	O
the	O
transactivation	O
sphere	O
.	O

However	O
,	O
-	O
truncation	O
mutations	O
lost	O
been	O
in	O
to	O
occur	O
in	O
that	O
patients	O
-	O
terminal	O
found	O
of	O
PAX6	O
of	O
C	O
with	O
domains	B
resulting	O
have	O
mutant	O
half	O
the	O
Aniridia	O
the	O
DNA	O
several	O
retain	O
binding	O
but	O
have	O
in	O
most	O
proteins	O
the	O
transactivation	O
domain	O
.	O

yet	O
,	O
various	O
shortness	O
variation	O
have	O
been	O
detect	O
to	O
happen	O
in	O
the	O
C	O
-	O
concluding	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	B
leave	O
in	O
mutation	O
proteins	O
that	O
retain	O
the	O
DNA	O
-	O
tie	O
orbit	O
but	O
have	O
mazed	O
most	O
of	O
the	O
transactivation	O
domain	O
.	O

have	O
in	O
several	O
truncation	O
mutations	O
have	O
.	O
found	O
to	O
occur	O
in	O
domain	O
C	O
mutant	O
DNA	O
half	O
of	O
PAX6	O
retain	O
patients	O
with	O
Aniridia	B
lost	O
in	O
-	O
proteins	O
but	O
,	O
binding	O
resulting	O
-	O
the	O
domains	O
terminal	O
However	O
that	O
most	O
of	O
the	O
transactivation	O
the	O
been	O

However	O
,	O
several	O
truncation	O
mutations	O
have	O
to	O
occur	O
in	O
the	O
-	O
terminal	O
half	O
of	O
PAX6	O
patients	O
with	O
Aniridia	B
resulting	O
mutant	O
proteins	O
retain	O
the	O
DNA	O
-	O
binding	O
domains	O
but	O
have	O
most	O
of	O
transactivation	O
domain	O
.	O

the	O
mutant	O
several	O
truncation	O
of	O
have	O
with	O
binding	O
to	O
occur	O
in	O
the	O
C	O
been	O
of	O
half	O
mutations	O
-	O
in	O
patients	O
-	O
Aniridia	B
resulting	O
in	O
retain	O
proteins	O
that	O
.	O
PAX6	O
DNA	O
the	O
,	O
domains	O
but	O
have	O
lost	O
most	O
terminal	O
However	O
transactivation	O
domain	O
found	O

However	O
,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	B
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
DNA	O
-	O
binding	O
domains	O
but	O
have	O
lost	O
area	O
sport	O
sport	O
area	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
protein	O
most	O
of	O
the	O
transactivation	O
domain	O
.	O

However	O
,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	B
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
DNA	O
-	O
binding	O
domains	O
but	O
have	O
lost	O
most	O
of	O
the	O
transactivation	O
domain	O
.	O

it	O
is	O
not	O
pass	O
whether	O
such	O
mutants	O
truly	O
deport	O
as	O
loss	O
-	O
of	O
-	O
work	O
mutants	O
as	O
omen	O
by	O
haploinsufficiency	O
.	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
non	O
non	O
non	O
non	O
non	O
non	O
by	O
haploinsufficiency	O
.	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
non	O
non	O
non	O
non	O
non	O
non	O
by	O
haploinsufficiency	O
.	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
as	O
loss	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
by	O

function	O
is	O
behave	O
mutants	O
whether	O
such	O
mutants	O
really	O
not	O
as	O
loss	O
-	O
.	O
-	O
clear	O
It	O
as	O
predicted	O
by	O
haploinsufficiency	O
of	O

it	O
is	O
not	O
exculpate	O
whether	O
such	O
mutation	O
really	O
deport	O
as	O
red	O
-	O
of	O
-	O
function	O
mutation	O
as	O
prognosticate	O
by	O
haploinsufficiency	O
.	O

.	O
is	O
not	O
loss	O
whether	O
such	O
mutants	O
by	O
function	O
as	O
clear	O
-	O
-	O
of	O
behave	O
mutants	O
as	O
predicted	O
really	O
It	O
haploinsufficiency	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
non	O
non	O
non	O
non	O
non	O
release	O
by	O
haploinsufficiency	O
.	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss	O
-	O
of	O
function	O
predicted	O
by	O
haploinsufficiency	O
.	O

it	O
is	O
not	O
crystalise	O
whether	O
such	O
mutants	O
truly	O
conduct	O
as	O
loss	O
-	O
of	O
-	O
office	O
mutants	O
as	O
foretell	O
by	O
haploinsufficiency	O
.	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
by	O
haploinsufficiency	O
.	O

reverse	O
to	O
this	O
possibility	O
,	O
our	O
datum	O
establish	O
that	O
these	O
variation	O
are	O
prevailing	O
-	O
negative	O
in	O
transeunt	O
transfection	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
wild	O
-	O
eccentric	O
PAX6	O
.	O

Contrary	O
to	O
this	O
theory	O
,	O
data	O
these	O
mutants	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
coexpressed	O
with	O
wild	O
-	O
type	O
PAX6	O
.	O

they	O
to	O
this	O
assays	O
,	O
our	O
data	O
-	O
with	O
these	O
.	O
are	O
dominant	O
when	O
coexpressed	O
in	O
transient	O
transfection	O
theory	O
-	O
wild	O
are	O
negative	O
that	O
Contrary	O
showed	O
type	O
PAX6	O
mutants	O

Contrary	O
to	O
this	O
theory	O
prevailing	O
waste	O
negatively	O
charged	O
indium	O
ephemeral	O
,	O
our	O
data	O
showed	O
that	O
these	O
mutants	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
possibility	O
typecast	O
possibility	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
wild	O
-	O
type	O
PAX6	O

Contrary	O
to	O
this	O
theory	O
prevailing	O
waste	O
negatively	O
charged	O
indium	O
ephemeral	O
,	O
our	O
data	O
showed	O
that	O
these	O
mutants	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
possibility	O
typecast	O
ephemeral	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
wild	O
-	O
type	O
PAX6	O

Contrary	O
to	O
this	O
theory	O
,	O
our	O
data	O
showed	O
these	O
mutants	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
assays	O
are	O
coexpressed	O
with	O
wild	O
-	O
type	O
PAX6	O
.	O

.	O
to	O
this	O
negative	O
,	O
our	O
-	O
showed	O
theory	O
these	O
mutants	O
are	O
type	O
-	O
wild	O
that	O
transient	O
transfection	O
assays	O
when	O
dominant	O
are	O
coexpressed	O
with	O
in	O
data	O
they	O
PAX6	O
Contrary	O

Contrary	O
to	O
this	O
theory	O
,	O
our	O
data	O
showed	O
these	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
assays	O
they	O
are	O
coexpressed	O
with	O
wild	O
-	O
type	O

opposite	O
to	O
this	O
theory	O
,	O
our	O
data	O
present	O
that	O
these	O
mutation	O
are	O
rife	O
-	O
blackball	O
in	O
fugacious	O
transfection	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
gaga	O
-	O
eccentric	O
PAX6	O
.	O

perverse	O
to	O
this	O
theory	O
,	O
our	O
datum	O
showed	O
that	O
these	O
sport	O
are	O
rife	O
-	O
disconfirming	O
in	O
ephemeral	O
transfection	O
try	O
when	O
they	O
are	O
coexpressed	O
with	O
idle	O
-	O
type	O
PAX6	O
.	O

Contrary	O
to	O
this	O
theory	O
,	O
our	O
data	O
showed	O
that	O
these	O
mutants	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
wild	O
-	O
type	O
PAX6	O
.	O

We	O
found	O
result	O
ability	O
dominant	O
-	O
DNA	O
effects	O
that	O
from	O
the	O
enhanced	O
negative	O
binding	O
the	O
of	O
these	O
mutants	O
.	O

that	O
the	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
of	O
these	O
mutants	O
.	O

We	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
essence	O
result	O
from	O
the	O
heighten	O
DNA	O
obligate	O
power	O
of	O
these	O
mutation	O
.	O

We	O
found	O
that	O
the	O
rife	O
-	O
minus	O
impression	O
termination	O
from	O
the	O
enhanced	O
DNA	O
binding	O
power	O
of	O
these	O
mutants	O
.	O

these	O
found	O
that	O
the	O
dominant	O
-	O
binding	O
ability	O
result	O
from	O
the	O
enhanced	O
mutants	O
negative	O
effects	O
of	O
DNA	O
We	O
.	O

We	O
found	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
.	O

We	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
mutants	O
effect	O
effect	O
effect	O
effect	O
prevailing	O
.	O

We	O
found	O
that	O
the	O
dominant	O
-	O
blackball	O
effects	O
leave	O
from	O
the	O
heighten	O
DNA	O
binding	O
power	O
of	O
these	O
mutation	O
.	O

We	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
mutants	O
effect	O
effect	O
effect	O
effect	O
effect	O
.	O

binding	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
.	O
ability	O
from	O
the	O
enhanced	O
We	O
DNA	O
result	O
of	O
these	O
mutants	O
effects	O

We	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
mutants	O
.	O

Kinetic	O
studies	O
when	O
binding	O
and	O
have	O
revealed	O
DNA	O
various	O
truncation	O
mutants	O
binding	O
with	O
-	O
5	O
-	O
fold	O
higher	O
to	O
affinity	O
various	O
that	O
-	O
dissociation	O
sites	O
compared	O
of	O
PAX6	O
the	O
wild	O
-	O
3	O
type	O
.	O

Kinetic	O
binding	O
and	O
dissociation	O
revealed	O
various	O
truncation	O
3	O
-	O
-	O
fold	O
various	O
-	O
binding	O
sites	O
compared	O
with	O
the	O
-	O
type	O
PAX6	O
.	O

Kinetic	O
studies	O
of	O
binding	O
	O
unveil	O
sport	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	O
mutants	O
have	O
3	O
-	O
5	O
-	O
fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
binding	O
sites	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
desoxyribonucleic	O
acid	O
dna	O
dna	O
dna	O
dna	O
dna	O
dna	O

Kinetic	O
studies	O
of	O
binding	O
	O
unveil	O
fold	O
up	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	O
mutants	O
have	O
3	O
-	O
5	O
-	O
fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
binding	O
sites	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
desoxyribonucleic	O
acid	O
dna	O
dna	O
dna	O
dna	O
dna	O

studies	O
affinity	O
of	O
binding	O
and	O
dissociation	O
compared	O
that	O
various	O
truncation	O
mutants	O
with	O
3	O
sites	O
wild	O
-	O
fold	O
higher	O
have	O
to	O
various	O
DNA	O
.	O
binding	O
-	O
when	O
revealed	O
Kinetic	O
type	O
-	O
-	O
the	O
PAX6	O
5	O

Kinetic	O
studies	O
of	O
binding	O
and	O
dissociation	O
various	O
truncation	O
mutants	O
have	O
-	O
5	O
-	O
fold	O
higher	O
to	O
various	O
DNA	O
-	O
sites	O
when	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
.	O

Kinetic	O
studies	O
of	O
hold	O
and	O
disassociation	O
discover	O
that	O
diverse	O
shortness	O
sport	O
have	O
3	O
-	O
pentad	O
-	O
fold	O
eminent	O
affinity	O
to	O
diverse	O
DNA	O
-	O
hold	O
sites	O
when	O
liken	O
with	O
the	O
unwarranted	O
-	O
type	O
PAX6	O
.	O

energizing	O
analyze	O
of	O
binding	O
and	O
disassociation	O
discover	O
that	O
versatile	O
shortness	O
mutation	O
have	O
3	O
-	O
phoebe	O
-	O
fold	O
higher	O
kinship	O
to	O
versatile	O
DNA	O
-	O
binding	O
sites	O
when	O
compared	O
with	O
the	O
unfounded	O
-	O
type	O
PAX6	O
.	O

Kinetic	O
studies	O
of	O
binding	O
	O
unveil	O
fold	O
up	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	O
mutants	O
have	O
3	O
-	O
5	O
-	O
fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
binding	O
sites	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
desoxyribonucleic	O
acid	O
dna	O
dna	O
dna	O
dna	O
dna	O

kinetic	O
field	O
of	O
oblige	O
and	O
disassociation	O
unwrap	O
that	O
various	O
shortness	O
mutation	O
have	O
3	O
-	O
5	O
-	O
fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
oblige	O
model	O
when	O
equate	O
with	O
the	O
barbarian	O
-	O
type	O
PAX6	O
.	O

Kinetic	O
studies	O
of	O
binding	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	O
mutants	O
have	O
3	O
-	O
5	O
-	O
fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
binding	O
sites	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
.	O

mutant	O
results	O
provide	O
the	O
new	O
insight	O
into	O
a	O
aniridia	O
of	O
causing	O
PAX6	O
These	O
in	O
role	B
.	O
.	O

These	O
resultant	O
provide	O
a	O
young	O
perceptivity	O
into	O
the	O
purpose	O
of	O
variation	O
PAX6	O
in	O
causing	O
aniridia	B
.	O
.	O

These	O
issue	O
allow	O
a	O
young	O
insight	O
into	O
the	O
role	O
of	O
mutation	O
PAX6	O
in	O
cause	O
aniridia	B
.	O
.	O

These	O
results	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	B
.	O
.	O

These	O
termination	O
leave	O
a	O
raw	O
insight	O
into	O
the	O
role	O
of	O
mutation	O
PAX6	O
in	O
get	O
aniridia	B
.	O
.	O

These	O
results	O
render	O
render	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	B
.	O
fork	O
out	O
fork	O
out	O

These	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
of	O
mutant	O
in	O
causing	O
aniridia	B
.	O
.	O

These	O
results	O
render	O
render	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	B
.	O
fork	O
out	O
fork	O
out	O

results	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O

These	O
results	O
role	O
aniridia	O
new	O
insight	O
in	O
the	O
provide	O
of	O
mutant	O
PAX6	O
into	O
causing	O
a	B
.	O
.	O

These	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	B
.	O
.	O

deficiency	O
of	O
severe	O
very	B
cardiomyopathy	I
and	O
excellent	O
A	O
chain	O
in	O
hypertrophic	B
-	I
-	I
long	I
outcome	I
acyl	I
-	I
coenzyme	I
neuropsychologic	I
Reversal	I
dehydrogenase	I
.	O

Reversal	O
of	O
severe	O
hypertrophic	B
cardiomyopathy	I
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
inadequacy	I
inadequacy	I
terrible	I
terrible	I
terrible	I
terrible	I
A	I
dehydrogenase	I
deficiency	I
.	O

Reversal	O
of	O
severe	O
hypertrophic	B
cardiomyopathy	I
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
inadequacy	I
inadequacy	I
terrible	I
terrible	I
terrible	I
terrible	I
A	I
dehydrogenase	I
deficiency	I
.	O

Reversal	O
of	O
terrible	O
hypertrophic	B
myocardiopathy	I
and	O
splendid	O
neuropsychologic	O
outcome	O
in	O
very	B
-	I
farsighted	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
ampere	I
dehydrogenase	I
lack	I
.	O

Reversal	O
of	O
severe	O
cardiomyopathy	I
and	O
excellent	O
neuropsychologic	O
outcome	O
very	B
-	I
long	I
-	I
acyl	I
-	I
A	I
dehydrogenase	I
deficiency	I
.	O

hypertrophic	B
excellent	O
neuropsychologic	O
outcome	O
very	B
-	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
deficiency	I
.	O

transposition	O
of	O
grievous	O
hypertrophic	B
myocardiopathy	I
and	O
excellent	O
neuropsychologic	O
issue	O
in	O
very	B
-	I
foresighted	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
inadequacy	I
.	O

chain	O
of	O
outcome	O
excellent	B
cardiomyopathy	I
and	O
acyl	O
neuropsychologic	O
severe	O
in	O
very	B
-	I
deficiency	I
-	I
hypertrophic	I
Reversal	I
-	I
coenzyme	I
A	I
dehydrogenase	I
long	I
.	O

Reversal	O
of	O
severe	O
hypertrophic	B
cardiomyopathy	I
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
inadequacy	I
inadequacy	I
terrible	I
terrible	I
terrible	I
first	I
class	I
A	I
dehydrogenase	I
deficiency	O

Reversal	O
of	O
severe	O
hypertrophic	B
excellent	O
neuropsychologic	O
in	O
very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
.	O

Reversal	O
of	O
severe	O
hypertrophic	B
cardiomyopathy	I
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
deficiency	I
.	O

Very	B
-	I
long	I
-	I
receive	I
inadequacy	I
cost	I
ampere	I
sir	I
ernst	I
boris	I
chain	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	O
)	O
deficiency	O
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
invite	O
invite	O

Very	B
-	I
chain	I
dehydrogenase	I
(	I
VLCAD	I
deficiency	I
is	O
disorder	O
of	O
fatty	O
oxidation	O
that	O
reportedly	O
has	O
high	O
of	O
and	O
mortality	O
.	O

very	B
-	I
farsighted	I
-	I
strand	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	I
)	I
inadequacy	I
is	O
a	O
distract	O
of	O
fatso	O
acid	O
beta	O
oxidization	O
that	O
reportedly	O
has	O
high	O
grade	O
of	O
morbidness	O
and	O
mortality	O
.	O

Very	B
-	I
long	I
-	I
acyl	I
A	I
dehydrogenase	I
(	I
VLCAD	I
)	I
deficiency	I
is	O
a	O
disorder	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
.	O

selfsame	B
-	I
retentive	I
-	I
concatenation	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	I
)	I
want	I
is	O
a	O
distract	O
of	O
fatty	O
acid	O
beta	O
oxidization	O
that	O
reportedly	O
has	O
high	O
grade	O
of	O
unwholesomeness	O
and	O
mortality	O
.	O

Very	B
-	I
long	I
-	I
receive	I
inadequacy	I
cost	I
ampere	I
sir	I
ernst	I
boris	I
chain	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	O
)	O
deficiency	O
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
invite	O
invite	O

rattling	B
-	I
foresightful	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
ampere	I
dehydrogenase	I
(	I
VLCAD	I
)	I
deficiency	I
is	O
ampere	O
perturb	O
of	O
fatso	O
blistering	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
mellow	O
value	O
of	O
unwholesomeness	O
and	O
mortality	O
.	O

beta	B
fatty	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	I
)	I
has	I
and	O
a	O
disorder	O
of	O
of	O
acid	O
-	O
oxidation	O
.	O
reportedly	O
deficiency	O
high	O
rates	O
Very	O
is	O
that	O
mortality	O
morbidity	O

Very	B
-	I
long	I
-	I
acyl	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	I
)	I
deficiency	I
is	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
high	O
rates	O
of	O
and	O
.	O

Very	B
-	I
long	I
-	I
tenacious	I
inadequacy	I
cost	I
ampere	I
recollective	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	I
)	I
deficiency	I
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
recollective	O
recollective	O
recollective	O
international	O
ampere	O

Very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	I
)	I
deficiency	I
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
.	O

We	O
describe	O
,	O
outcome	O
of	O
a	O
girl	O
seen	O
year	O
-	O
old	O
hypertrophic	O
at	O
VLCAD	B
deficiency	I
cardiomyopathy	O
was	O
first	O
encephalopathy	O
with	O
5	O
,	O
of	O
age	O
with	O
who	O
5	B
months	I
,	O
hepatomegaly	B
the	O
-	B
severe	O
and	O
hypotonia	B
.	O

describe	O
outcome	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
with	O
VLCAD	B
deficiency	I
who	O
was	O
first	O
seen	O
months	O
of	O
age	O
severe	O
cardiomyopathy	I
,	O
hepatomegaly	B
,	O

We	O
name	O
the	O
result	O
of	O
a	O
quintuplet	O
-	O
class	O
-	O
old	O
girl	O
with	O
VLCAD	B
insufficiency	I
who	O
was	O
offset	O
discover	O
at	O
quintuplet	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B
myocardiopathy	I
,	O
megalohepatia	B
,	O
encephalopathy	B
,	O
and	O
hypotonus	B
.	O

cardiomyopathy	O
5	O
the	O
outcome	O
was	O
a	O
deficiency	O
encephalopathy	O
year	O
-	O
old	O
girl	O
with	O
with	B
-	I
who	O
of	O
,	O
seen	O
at	O
VLCAD	O
months	O
of	O
age	O
describe	O
severe	O
hypertrophic	B
We	I
first	O
hepatomegaly	B
,	O
5	B
,	O
and	O
hypotonia	B
.	O

We	O
describe	O
the	O
outcome	O
cost	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
VLCAD	B
deficiency	I
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B
cardiomyopathy	I
,	O
hepatomegaly	B
,	O
encephalopathy	B
,	O
and	O
hypotonia	B
toll	O
toll	O
toll	O
toll	O
toll	O
toll	O
toll	O
toll	O
world	O
health	O

with	O
seen	O
the	O
outcome	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
cardiomyopathy	B
hepatomegaly	I
who	O
was	O
first	O
and	O
at	O
5	O
months	O
,	O
age	O
We	O
severe	O
encephalopathy	B
VLCAD	I
deficiency	O
of	B
,	O
.	B
,	O
hypotonia	O
describe	B
hypertrophic	O

We	O
describe	O
the	O
outcome	O
a	O
year	O
-	O
old	O
girl	O
with	O
VLCAD	B
deficiency	I
who	O
was	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B
cardiomyopathy	I
,	O
hepatomegaly	B
,	O
encephalopathy	B
,	O
and	O
hypotonia	B
.	O

We	O
delineate	O
the	O
upshot	O
of	O
a	O
quint	O
-	O
class	O
-	O
old	O
girl	O
with	O
VLCAD	B
insufficiency	I
who	O
was	O
showtime	O
seen	O
at	O
quint	O
months	O
of	O
age	O
with	O
grave	O
hypertrophic	B
myocardiopathy	I
,	O
megalohepatia	B
,	O
encephalopathy	B
,	O
and	O
hypotonicity	B
.	O

We	O
describe	O
the	O
outcome	O
yr	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
VLCAD	B
deficiency	I
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B
cardiomyopathy	I
,	O
hepatomegaly	B
,	O
encephalopathy	B
,	O
and	O
hypotonia	B
year	O
year	O
year	O
year	O
year	O
year	O
year	O
year	O
world	O
health	O

We	O
draw	O
the	O
issue	O
of	O
a	O
cinque	O
-	O
year	O
-	O
previous	O
miss	O
with	O
VLCAD	B
deficiency	I
who	O
was	O
first	O
seen	O
at	O
cinque	O
months	O
of	O
years	O
with	O
hard	O
hypertrophic	B
myocardiopathy	I
,	O
megalohepatia	B
,	O
encephalopathy	B
,	O
and	O
hypotonicity	B
.	O

We	O
describe	O
the	O
outcome	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
VLCAD	B
deficiency	I
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B
cardiomyopathy	I
,	O
hepatomegaly	B
,	O
encephalopathy	B
,	O
and	O
hypotonia	B
.	O

Biochemical	O
indicated	O
VLCAD	B
caused	O
a	O
yet	O
inactive	O
enzyme	O
.	O

Biochemical	O
studies	O
indicated	O
VLCAD	B
deficiency	I
caused	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme	O

biochemical	O
studies	O
argue	O
VLCAD	B
deficiency	I
do	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme	O
.	O

Biochemical	O
studies	O
indicated	O
VLCAD	B
deficiency	I
caused	O
by	O
a	O
stable	O
motionless	O
subject	O
area	O
subject	O
area	O
yet	O
inactive	O

Biochemical	O
studies	O
indicated	O
VLCAD	B
deficiency	I
caused	O
by	O
a	O
stable	O
motionless	O
subject	O
area	O
past	O
yet	O
inactive	O
enzyme	O

Biochemical	O
studies	O
indicated	O
VLCAD	B
deficiency	I
caused	O
by	O
a	O
stable	O
motionless	O
subject	O
area	O
subject	O
area	O
yet	O
inactive	O

Biochemical	O
studies	O
indicated	O
VLCAD	B
deficiency	I
do	O
by	O
a	O
stable	O
hitherto	O
still	O
enzyme	O
.	O

Biochemical	O
studies	O
VLCAD	B
deficiency	I
caused	O
by	O
a	O
stable	O
yet	O
.	O

Biochemical	O
report	O
indicated	O
VLCAD	B
inadequacy	I
caused	O
by	O
a	O
unchanging	O
yet	O
inactive	O
enzyme	O
.	O

Biochemical	O
deficiency	O
indicated	O
VLCAD	B
.	I
caused	O
by	O
studies	O
stable	O
yet	O
inactive	O
enzyme	O
a	O

Biochemical	O
studies	O
indicated	O
VLCAD	B
deficiency	I
caused	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
internet	O
site	O
sport	O
internet	O
site	O
sport	O
sport	O
depth	O
psychology	O
unveil	O
ACAG	O
1669	O
splice	O

analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
ACAG	O
splice	O
site	O
mutation	O
.	O

molecular	O
transmitted	O
analysis	O
of	O
her	O
VLCAD	O
cistron	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
sport	O
and	O
a	O
1668	O
ACAG	O
1669	O
splicing	O
site	O
sport	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
a	O
T1372C	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
splice	O
site	O
mutation	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
internet	O
site	O
sport	O
internet	O
site	O
sport	O
sport	O
depth	O
psychology	O
depth	O
psychology	O
ACAG	O
1669	O

molecular	O
genic	O
analysis	O
of	O
her	O
VLCAD	O
factor	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutant	O
and	O
a	O
1668	O
ACAG	O
1669	O
marry	O
situation	O
mutant	O
.	O

molecular	O
transmitted	O
analysis	O
of	O
her	O
VLCAD	O
factor	O
unveil	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
variation	O
and	O
a	O
1668	O
ACAG	O
1669	O
splice	O
site	O
variation	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
(	O
missense	O
mutation	O
and	O
a	O
1668	O
ACAG	O
1669	O
splice	O
site	O

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
internet	O
site	O
sport	O
internet	O
site	O
sport	O
sport	O
depth	O
psychology	O
depth	O
psychology	O
ACAG	O
1669	O

1668	O
genetic	O
analysis	O
(	O
her	O
VLCAD	O
gene	O
ACAG	O
.	O
T1372C	O
of	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
splice	O
revealed	O
Molecular	O
1669	O
site	O
mutation	O
a	O

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
ACAG	O
1669	O
splice	O
site	O
mutation	O
.	O

After	O
initial	O
treatment	O
with	O
along	O
ampere	O
humiliated	O
endovenous	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
on	O
on	O
on	O
on	O
boom	O
.	O

After	O
initial	O
treatment	O
glucose	O
patient	O
has	O
thrived	O
a	O
low	O
fat	O
diet	O
supplemented	O
-	O
chain	O
triglyceride	O
oil	O
and	O
and	O
of	O
fasting	O
.	O

after	O
initial	O
handling	O
with	O
endovenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
flourish	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
strand	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
.	O

After	O
initial	O
treatment	O
with	O
intravenous	O
glucose	O
and	O
,	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
.	O

later	O
initial	O
intervention	O
with	O
endovenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
expand	O
on	O
a	O
down	O
-	O
fertile	O
diet	O
supplemented	O
with	O
sensitive	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
.	O

After	O
initial	O
treatment	O
with	O
along	O
ampere	O
humiliated	O
endovenous	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
on	O
on	O
on	O
on	O
boom	O
.	O

after	O
initial	O
handling	O
with	O
endovenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
prosper	O
on	O
a	O
humbled	O
-	O
fat	O
diet	O
affix	O
with	O
intermediate	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
dodging	O
of	O
fasting	O
.	O

with	O
diet	O
treatment	O
with	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
triglyceride	O
avoidance	O
low	O
-	O
fat	O
carnitine	O
supplemented	O
initial	O
medium	O
fasting	O
chain	O
on	O
oil	O
and	O
After	O
a	O
-	O
of	O
and	O
.	O

After	O
initial	O
treatment	O
with	O
intravenous	O
glucose	O
carnitine	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
carnitine	O
and	O
avoidance	O
fasting	O

After	O
initial	O
treatment	O
with	O
along	O
ampere	O
humiliated	O
boom	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
on	O
on	O
on	O
on	O
boom	O
.	O

After	O
initial	O
treatment	O
with	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
.	O

Her	O
ventricular	O
hypertrophy	O
conclude	O
importantly	O
over	O
1	O
class	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superscript	O
order	O
for	O
mature	O
.	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superior	O
range	O
years	O
solve	O
solve	O
solve	O
solve	O
solve	O
for	O
age	O
.	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superior	O
range	O
years	O
solve	O
solve	O
solve	O
solve	O
solve	O
for	O
age	O
.	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
and	O
cognitively	O
she	O
is	O
in	O
the	O
superior	O
range	O
for	O

in	O
ventricular	O
,	O
1	O
significantly	O
over	O
the	O
year	O
hypertrophy	O
and	O
cognitively	O
,	O
.	O
is	O
resolved	O
Her	O
superior	O
range	O
for	O
age	O
she	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
importantly	O
over	O
single	O
class	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
ranking	O
rove	O
for	O
maturate	O
.	O

.	O
ventricular	O
hypertrophy	O
cognitively	O
significantly	O
over	O
1	O
for	O
in	O
and	O
resolved	O
,	O
is	O
she	O
,	O
the	O
superior	O
range	O
year	O
Her	O
age	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superior	O
range	O
years	O
solve	O
solve	O
solve	O
solve	O
	O
for	O
age	O
.	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
in	O
range	O
for	O
age	O
.	O

Her	O
ventricular	O
hypertrophy	O
answer	O
importantly	O
over	O
one	O
twelvemonth	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superscript	O
order	O
for	O
age	O
.	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superior	O
range	O
for	O
age	O
.	O

Clinical	O
recognition	O
of	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	B
in	O
children	O
.	O

Clinical	O
recognition	O
of	O
VLCAD	B
deficiency	I
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
directly	O
of	O
cardiomyopathy	B
in	O
children	O
.	O
.	O

Clinical	O
recognition	O
of	O
VLCAD	B
deficiency	I
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
child	O
child	O
information	O
technology	O
information	O
technology	O
information	B
technology	O
information	O
technology	O
cardiomyopathy	O

Clinical	O
acknowledgement	O
of	O
VLCAD	B
want	I
is	O
crucial	O
because	O
it	O
is	O
unity	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
myocardiopathy	B
in	O
minor	O
.	O
.	O

Clinical	O
recognition	O
of	O
VLCAD	B
deficiency	I
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
child	O
child	O
information	O
technology	O
information	O
technology	O
information	B
technology	O
information	O
technology	O
cardiomyopathy	O

clinical	O
recognition	O
of	O
VLCAD	B
insufficiency	I
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
now	O
treatable	O
induce	O
of	O
myocardiopathy	B
in	O
kid	O
.	O
.	O

Clinical	O
recognition	O
of	O
VLCAD	B
deficiency	I
is	O
important	O
because	O
it	O
is	O
of	O
the	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	B
in	O
children	O

one	O
recognition	O
of	O
cardiomyopathy	B
deficiency	I
is	O
important	O
it	O
because	O
is	O
in	O
of	O
few	O
the	O
.	O
treatable	O
causes	O
of	O
VLCAD	B
Clinical	O
children	O
.	O
directly	O

Clinical	O
credit	O
of	O
VLCAD	B
lack	I
is	O
important	O
because	O
it	O
is	O
unitary	O
of	O
the	O
few	O
straightaway	O
treatable	O
causes	O
of	O
myocardiopathy	B
in	O
minor	O
.	O
.	O

directly	O
recognition	O
it	O
important	B
deficiency	I
is	O
treatable	O
because	O
of	O
is	O
one	O
of	O
children	O
few	O
VLCAD	O
Clinical	O
causes	O
of	O
cardiomyopathy	B
in	O
the	O
.	O
.	O

Clinical	O
recognition	O
of	O
VLCAD	B
deficiency	I
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	B
in	O
children	O
.	O
.	O

Cloning	O
a	O
member	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
family	O
.	O

cloning	O
of	O
a	O
new	O
extremity	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
fellowship	O
.	O

low	O
novel	O
a	O
of	O
member	O
of	O
density	O
Cloning	O
-	O
.	O
lipoprotein	O
receptor	O
family	O
the	O

Cloning	O
of	O
a	O
novel	O
member	O
of	O
the	O
low	O
density	O
lipoprotein	O
family	O
.	O

Cloning	O
of	O
humiliated	O
ampere	O
a	O
novel	O
member	O
of	O
the	O
low	O
-	O
family	O
line	O
extremity	O
density	O
lipoprotein	O
receptor	O
family	O

Cloning	O
of	O
humiliated	O
ampere	O
a	O
novel	O
member	O
of	O
the	O
low	O
-	O
family	O
line	O
humiliated	O
density	O
lipoprotein	O
receptor	O
family	O

Cloning	O
of	O
a	O
refreshing	O
appendage	O
of	O
the	O
low	O
-	O
compactness	O
lipoprotein	O
receptor	O
category	O
.	O

family	O
of	O
a	O
Cloning	O
low	O
of	O
the	O
receptor	O
-	O
density	O
lipoprotein	O
member	O
novel	O
.	O

Cloning	O
of	O
humiliated	O
ampere	O
a	O
novel	O
member	O
of	O
the	O
low	O
-	O
family	O
line	O
extremity	O
density	O
lipoprotein	O
receptor	O
family	O

clone	O
of	O
a	O
novel	O
phallus	O
of	O
the	O
low	O
-	O
concentration	O
lipoprotein	O
receptor	O
syndicate	O
.	O

Cloning	O
of	O
a	O
novel	O
member	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
family	O
.	O

A	O
factor	O
encode	O
a	O
fresh	O
transmembrane	O
protein	O
was	O
discover	O
by	O
DNA	O
episode	O
analysis	O
inside	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
(	O
IDDM	B
)	O
locale	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

A	O
gene	O
encoding	O
a	O
novel	O
protein	O
by	O
DNA	O
sequence	O
analysis	O
within	O
the	O
insulin	B
-	I
dependent	I
)	O
locus	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

(	O
gene	O
encoding	O
diabetes	O
novel	O
transmembrane	O
protein	O
on	O
locus	O
by	O
.	O
sequence	O
analysis	O
mellitus	O
)	O
insulin	B
-	I
dependent	I
a	I
within	I
IDDM4	O
IDDM	B
the	O
identified	O
A	O
was	O
chromosome	O
11q13	O
DNA	O

A	O
gene	O
encoding	O
a	O
depth	O
psychology	O
inside	O
locale	O
depth	O
psychology	O
fresh	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	B
the	I
insulin	I
-	I
dependent	I
along	I
locale	I
place	I
diabetes	O
mellitus	B
(	O
IDDM	O
)	O
locus	O
IDDM4	O
on	O
chromosome	O

A	O
gene	O
encoding	O
a	O
depth	O
psychology	O
inside	O
locale	O
depth	O
psychology	O
fresh	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	B
the	I
insulin	I
-	I
dependent	I
along	I
locale	I
locale	I
diabetes	O
mellitus	B
(	O
IDDM	O
)	O
locus	O
IDDM4	O
on	O
chromosome	O

A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
by	O
DNA	O
analysis	O
within	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
IDDM	B
)	O
locus	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

.	O
gene	O
encoding	O
the	O
novel	O
transmembrane	O
on	O
was	O
a	O
by	O
DNA	O
sequence	O
chromosome	O
within	O
IDDM4	O
identified	B
-	I
dependent	I
diabetes	I
mellitus	I
analysis	O
IDDM	B
)	O
locus	O
insulin	O
protein	O
(	O
11q13	O
A	O

A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
by	O
sequence	O
analysis	O
within	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
(	O
IDDM	B
)	O
locus	O
IDDM4	O
on	O
chromosome	O

A	O
factor	O
encryption	O
a	O
fresh	O
transmembrane	O
protein	O
was	O
distinguish	O
by	O
DNA	O
sequence	O
analysis	O
inside	O
the	O
insulin	B
-	I
pendant	I
diabetes	I
mellitus	I
(	O
iddm	B
)	O
locale	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

A	O
cistron	O
encryption	O
a	O
refreshing	O
transmembrane	O
protein	O
was	O
identify	O
by	O
DNA	O
sequence	O
analysis	O
inside	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
(	O
iddm	B
)	O
venue	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
(	O
IDDM	B
)	O
locus	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

candidate	O
on	O
its	O
gene	O
position	O
,	O
this	O
chromosomal	O
to	O
a	O
susceptibility	O
for	O
Based	O
conferring	O
is	O
diabetes	B
.	O

establish	O
on	O
its	O
chromosomal	O
position	O
,	O
this	O
factor	O
is	O
a	O
nominee	O
for	O
consult	O
susceptibleness	O
to	O
diabetes	B
.	O

Based	O
on	O
its	O
chromosomal	O
view	O
,	O
this	O
factor	O
is	O
a	O
nominee	O
for	O
consult	O
susceptibleness	O
to	O
diabetes	B
.	O

Based	O
on	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	B
.	O

ground	O
on	O
its	O
chromosomal	O
spot	O
,	O
this	O
gene	O
is	O
a	O
nominee	O
for	O
consult	O
susceptibleness	O
to	O
diabetes	B
.	O

Based	O
on	O
factor	O
information	O
technology	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	B
diabetes	O
element	O
element	O
susceptibleness	O

Based	O
on	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
a	O
candidate	O
conferring	O
susceptibility	O
to	O
diabetes	B
.	O

Based	O
on	O
factor	O
information	O
technology	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	B
diabetes	O
element	O
element	O
susceptibleness	O

on	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O

Based	O
on	O
is	O
to	O
position	O
,	O
conferring	O
gene	O
its	O
a	O
candidate	O
for	O
this	O
susceptibility	O
chromosomal	O
diabetes	B
.	O

Based	O
on	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	B
.	O

The	O
low	O
density	O
lipoprotein	O
receptor	O
protein	O
5	O
(	O
)	O
,	O
encodes	O
a	O
protein	O
amino	O
acids	O
that	O
contains	O
conserved	O
modules	O
which	O
are	O
the	O
-	O
density	O
lipoprotein	O
LDL	O
)	O
receptor	O
family	O
.	O

The	O
gene	O
,	O
termed	O
low	O
receptor	O
related	O
protein	O
5	O
(	O
)	O
,	O
of	O
acids	O
that	O
modules	O
characteristic	O
of	O
the	O
low	O
density	O
lipoprotein	O
)	O
receptor	O
.	O

The	O
gene	O
,	O
termed	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
related	O
protein	O
5	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
amino	O
acids	O
that	O
contains	O
conserved	O
modules	O
which	O
are	O
characteristic	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
family	O
line	O
humiliated	O
sensory	O
receptor	O
family	O
line	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
(	O
LDL	O
)	O

The	O
factor	O
,	O
termed	O
downcast	O
-	O
compactness	O
lipoprotein	O
receptor	O
associate	O
protein	O
fin	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
amino	O
acids	O
that	O
control	O
conserved	O
modules	O
which	O
are	O
feature	O
of	O
the	O
downcast	O
-	O
compactness	O
lipoprotein	O
(	O
LDL	O
)	O
receptor	O
menage	O
.	O

The	O
gene	O
of	O
termed	O
low	O
lipoprotein	O
density	O
protein	O
receptor	O
related	O
protein	O
modules	O
of	O
LRP5	O
)	O
lipoprotein	O
encodes	O
a	O
LDL	O
(	O
1615	O
low	O
acids	O
-	O
contains	O
,	O
5	O
amino	O
are	O
characteristic	O
,	O
which	O
the	O
-	O
density	O
that	O
(	O
conserved	O
)	O
receptor	O
family	O
.	O

The	O
factor	O
,	O
termed	O
low	O
-	O
concentration	O
lipoprotein	O
receptor	O
colligate	O
protein	O
5	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
aminic	O
acids	O
that	O
control	O
husband	O
modules	O
which	O
are	O
feature	O
of	O
the	O
low	O
-	O
concentration	O
lipoprotein	O
(	O
LDL	O
)	O
receptor	O
category	O
.	O

density	O
protein	O
,	O
termed	O
low	O
-	O
.	O
lipoprotein	O
receptor	O
related	O
protein	O
family	O
(	O
contains	O
characteristic	O
,	O
encodes	O
a	O
which	O
of	O
1615	O
amino	O
lipoprotein	O
that	O
LRP5	O
conserved	O
-	O
gene	O
the	O
acids	O
of	O
are	O
low	O
)	O
The	O
modules	O
(	O
LDL	O
)	O
receptor	O
5	O
density	O

The	O
gene	O
,	O
termed	O
low	O
-	O
receptor	O
related	O
protein	O
5	O
LRP5	O
)	O
,	O
encodes	O
a	O
of	O
1615	O
amino	O
acids	O
contains	O
conserved	O
which	O
are	O
characteristic	O
of	O
the	O
low	O
-	O
density	O
(	O
LDL	O
receptor	O
family	O
.	O

)	O
contains	O
,	O
termed	O
encodes	O
-	O
1615	O
the	O
receptor	O
related	O
protein	O
5	O
(	O
density	O
LDL	O
,	O
low	O
of	O
protein	O
of	O
LRP5	O
amino	O
acids	O
that	O
which	O
conserved	O
modules	O
.	O
a	O
characteristic	O
are	O
gene	O
low	O
-	O
density	O
lipoprotein	O
(	O
)	O
The	O
receptor	O
family	O
lipoprotein	O

The	O
gene	O
,	O
termed	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
related	O
protein	O
5	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
amino	O
acids	O
that	O
contains	O
conserved	O
modules	O
which	O
are	O
characteristic	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
family	O
line	O
humiliated	O
sensory	O
receptor	O
family	O
line	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
humiliated	O
incorporate	O
(	O
LDL	O
)	O

The	O
gene	O
,	O
termed	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
related	O
protein	O
5	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
amino	O
acids	O
that	O
contains	O
conserved	O
modules	O
which	O
are	O
characteristic	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
receptor	O
family	O
.	O

These	O
faculty	O
include	O
a	O
putative	O
indicate	O
peptide	O
for	O
protein	O
export	O
,	O
quadruplet	O
epidermal	O
growth	O
agent	O
(	O
EGF	O
)	O
restate	O
with	O
consort	O
spacer	O
domains	O
,	O
terzetto	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
restate	O
,	O
a	O
ace	O
transmembrane	O
cross	O
orbit	O
,	O
and	O
a	O
cytoplasmatic	O
orbit	O
.	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
four	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
domains	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
repeats	O
,	O
a	O
single	O
transmembrane	O
area	O
ampere	O
cytoplasmatic	O
area	O
ampere	O
cytoplasmatic	O
area	O
iterate	O
iterate	O
iterate	O
iterate	O
iterate	O
iterate	O
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

These	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
four	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
domains	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
,	O
single	O
transmembrane	O
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
.	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
four	O
epidermal	O
growth	O
factor	O
(	O
spacer	O
three	O
-	O
receptor	O
(	O
)	O
repeats	O
,	O
a	O
single	O
transmembrane	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
four	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
domains	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
repeats	O
,	O
a	O
single	O
transmembrane	O
area	O
ampere	O
cytoplasmatic	O
area	O
ampere	O
cytoplasmatic	O
area	O
iterate	O
iterate	O
iterate	O
iterate	O
iterate	O
	O
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
protein	O
export	O
,	O
epidermal	O
factor	O
(	O
EGF	O
with	O
three	O
LDL	O
-	O
(	O
LDLR	O
repeats	O
,	O
a	O
spanning	O
domain	O
,	O
and	O
a	O
domain	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
quartet	O
epidermal	O
maturation	O
constituent	O
(	O
EGF	O
)	O
recur	O
with	O
associated	O
spacer	O
arena	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
recur	O
,	O
a	O
one	O
transmembrane	O
traverse	O
arena	O
,	O
and	O
a	O
cytoplasmatic	O
arena	O
.	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
quaternity	O
epidermic	O
ontogeny	O
factor	O
(	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
field	O
,	O
trinity	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
repeats	O
,	O
a	O
one	O
transmembrane	O
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmatic	O
domain	O
.	O

These	O
repeats	O
include	O
a	O
putative	O
signal	O
cytoplasmic	O
a	O
protein	O
export	O
,	O
a	O
epidermal	O
receptor	O
LDLR	O
(	O
EGF	O
)	O
for	O
with	O
associated	O
spacer	O
(	O
,	O
.	O
LDL	O
repeats	O
growth	O
factor	O
three	O
)	O
transmembrane	O
,	O
modules	O
single	O
-	O
spanning	O
domain	O
,	O
and	O
four	O
peptide	O
domain	O
domains	O

These	O
modules	O
repeats	O
a	O
putative	O
(	O
peptide	O
for	O
protein	O
export	O
,	O
epidermal	O
domain	O
growth	O
factor	O
)	O
EGF	O
)	O
with	O
repeats	O
associated	O
,	O
domains	O
.	O
three	O
-	O
receptor	O
spacer	O
signal	O
LDLR	O
(	O
domain	O
LDL	O
a	O
single	O
,	O
spanning	O
include	O
,	O
and	O
a	O
cytoplasmic	O
four	O
transmembrane	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
four	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
domains	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
repeats	O
,	O
a	O
single	O
transmembrane	O
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

encoded	O
protein	O
has	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
represents	O
new	O
category	O
of	O
the	O
LDLR	O
family	O
.	O

LDLR	O
encoded	O
protein	O
a	O
a	O
unique	O
organization	O
.	O
LDLR	O
and	O
family	O
repeats	O
;	O
new	O
the	O
LRP5	O
likely	O
represents	O
has	O
therefore	O
category	O
of	O
,	O
EGF	O
The	O
of	O

The	O
encoded	O
protein	O
has	O
a	O
unequaled	O
arrangement	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
belike	O
defend	O
a	O
unexampled	O
fellowship	O
of	O
the	O
LDLR	O
fellowship	O
.	O

The	O
encoded	O
protein	O
has	O
a	O
alone	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
so	O
,	O
LRP5	O
probable	O
defend	O
a	O
novel	O
family	O
of	O
the	O
LDLR	O
kinsfolk	O
.	O

The	O
encoded	O
protein	O
has	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
repeats	O
;	O
,	O
LRP5	O
likely	O
represents	O
a	O
new	O
category	O
LDLR	O
family	O
.	O

The	O
encoded	O
protein	O
has	O
ampere	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
likely	O
represents	O
family	O
family	O
family	O
line	O
receive	O
family	O
line	O
receive	O
a	O
new	O
category	O
of	O
the	O
LDLR	O

The	O
encoded	O
protein	O
has	O
ampere	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
likely	O
represents	O
family	O
family	O
family	O
line	O
receive	O
family	O
line	O
unequaled	O
a	O
new	O
category	O
of	O
the	O
LDLR	O

The	O
encoded	O
protein	O
has	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
repeats	O
,	O
LRP5	O
likely	O
represents	O
a	O
new	O
category	O
of	O
the	O

LDLR	O
encoded	O
protein	O
has	O
a	O
unique	O
therefore	O
likely	O
EGF	O
and	O
LDLR	O
repeats	O
of	O
organization	O
family	O
LRP5	O
of	O
category	O
a	O
new	O
The	O
;	O
the	O
represents	O
,	O
.	O

The	O
encoded	O
protein	O
has	O
a	O
unequaled	O
organization	O
of	O
EGF	O
and	O
LDLR	O
restate	O
;	O
hence	O
,	O
LRP5	O
likely	O
symbolize	O
a	O
modern	O
class	O
of	O
the	O
LDLR	O
family	O
.	O

The	O
encoded	O
protein	O
has	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
likely	O
represents	O
a	O
new	O
category	O
of	O
the	O
LDLR	O
family	O
.	O

Both	O
and	O
mouse	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
are	O
95	O
%	O
identical	O
indicating	O
a	O
high	O
degree	O
of	O
conservation	O
.	O
.	O

Both	O
and	O
mouse	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
are	O
95	O
identical	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O

Both	O
human	O
and	O
mouse	O
protein	O
cost	O
	O
cost	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
identical	O
stage	O
preservation	O
sequester	O
receive	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O
conservation	O
.	O
.	O

a	O
human	O
and	O
,	O
LRP5	O
cDNAs	O
have	O
conservation	O
of	O
and	O
indicating	O
encoded	O
mature	O
proteins	O
degree	O
95	O
%	O
identical	O
mouse	O
evolutionary	O
the	O
high	O
are	O
isolated	O
Both	O
been	O
.	O
.	O

.	O
human	O
and	O
are	O
LRP5	O
cDNAs	O
conservation	O
been	O
mouse	O
and	O
the	O
encoded	O
proteins	O
a	O
evolutionary	O
isolated	O
%	O
identical	O
,	O
indicating	O
mature	O
high	O
degree	O
of	O
95	O
have	O
Both	O
.	O

Both	O
human	O
and	O
mouse	O
protein	O
cost	O
	O
cost	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
identical	O
stage	O
preservation	O
sequester	O
sequester	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O
conservation	O
.	O
.	O

both	O
homo	O
and	O
sneak	O
LRP5	O
cdna	O
have	O
been	O
detached	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
selfsame	O
,	O
signal	O
a	O
high	O
degree	O
of	O
evolutionary	O
preservation	O
.	O
.	O

Both	O
human	O
and	O
mouse	O
protein	O
cost	O
	O
cost	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
identical	O
stage	O
preservation	O
sequester	O
sequester	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O
conservation	O
.	O
.	O

of	O
human	O
and	O
mouse	O
LRP5	O
cDNAs	O
proteins	O
encoded	O
isolated	O
and	O
the	O
%	O
high	O
have	O
evolutionary	O
Both	O
been	O
95	O
,	O
indicating	O
a	O
mature	O
degree	O
identical	O
are	O
conservation	O
.	O
.	O

both	O
human	O
and	O
creep	O
LRP5	O
cdna	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
ripen	O
proteins	O
are	O
95	O
%	O
very	O
,	O
show	O
a	O
mellow	O
degree	O
of	O
evolutionary	O
preservation	O
.	O
.	O

Both	O
human	O
and	O
mouse	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
identical	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O
conservation	O
.	O
.	O

The	O
apc	B
variation	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B
tumors	I
,	O
but	O
not	O
perpetually	O
with	O
a	O
syndicate	O
chronicle	O
.	O

The	O
APC	B
variants	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B
tumors	I
,	O
but	O
not	O
always	O
with	O
a	O
family	O
form	O
form	O
form	O
form	O
form	O
form	O
history	O
.	O

The	O
APC	B
variants	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B
tumors	I
,	O
but	O
not	O
always	O
with	O
a	O
family	O
form	O
form	O
form	O
form	O
form	O
form	O
history	O
.	O

variants	O
E1317Q	O
are	O
associated	O
colorectal	B
tumors	I
but	O
not	O
always	O
with	O
a	O
family	O
history	O
.	O

The	O
APC	B
variants	O
I1307K	O
and	O
associated	O
with	O
tumors	I
,	O
but	O
not	O
always	O
with	O
a	O
family	O
history	O
.	O

variants	O
I1307K	O
and	O
E1317Q	O
associated	O
with	O
colorectal	B
tumors	I
,	O
not	O
always	O
with	O
a	O
history	O
.	O

family	O
APC	B
variants	O
history	O
and	O
E1317Q	O
are	O
with	O
associated	O
colorectal	B
always	I
,	O
but	O
.	O
The	O
with	O
a	O
tumors	O
I1307K	O
not	O

The	O
APC	B
variants	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B
tumors	I
,	O
but	O
not	O
always	O
with	O
a	O
family	O
form	O
form	O
form	O
form	O
form	O
ever	O
history	O
.	O

The	O
APC	B
variate	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B
tumors	I
,	O
but	O
not	O
constantly	O
with	O
a	O
home	O
account	O
.	O

a	O
APC	B
variants	O
I1307K	O
and	O
E1317Q	O
not	O
,	O
with	O
colorectal	B
tumors	I
always	O
The	O
are	O
associated	O
family	O
but	O
with	O
history	O
.	O

The	O
APC	B
variants	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B
tumors	I
,	O
but	O
not	O
always	O
with	O
a	O
family	O
history	O
.	O

Classical	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B
dominant	I
disease	I
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B
adenomas	I
and	I
carcinoma	I
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	B
gene	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
.	O

Classical	O
familial	B
adenomatous	I
FAP	B
)	O
is	O
a	O
high	O
penetrance	O
dominant	I
disease	I
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B
and	I
carcinoma	I
and	O
that	O
results	O
APC	B

and	O
hundreds	B
adenomatous	I
polyposis	I
(	O
FAP	B
penetrance	O
the	O
a	O
high	O
-	O
)	O
autosomal	B
that	I
from	I
that	O
predisposes	O
to	O
is	O
or	O
thousands	O
of	O
results	B
adenomas	I
Classical	I
carcinoma	I
mutations	O
dominant	O
disease	O
colorectal	O
truncating	O
gene	O
in	O
familial	O
APC	B
and	O
.	O

Classical	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B
dominant	I
disease	I
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B
adenomas	I
and	I
carcinoma	I
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	B
gene	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
predispose	O
prevailing	O
.	O

that	O
APC	B
adenomatous	I
polyposis	I
predisposes	O
FAP	B
disease	O
mutations	O
a	O
high	O
-	O
penetrance	O
autosomal	B
and	I
is	I
that	O
(	O
truncating	O
hundreds	O
or	O
dominant	O
of	O
colorectal	B
adenomas	I
familial	I
carcinoma	I
and	O
Classical	O
to	O
from	O
results	O
)	O
in	O
the	O
thousands	B
gene	O
.	O

classical	O
transmissible	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
a	O
richly	O
-	O
penetrance	O
autosomal	B
prevailing	I
disease	I
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B
adenomas	I
and	I
carcinoma	I
and	O
that	O
effect	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	B
factor	O
.	O

Classical	O
familial	B
adenomatous	I
polyposis	I
FAP	B
)	O
is	O
a	O
high	O
-	O
penetrance	O
disease	I
that	O
predisposes	O
hundreds	O
thousands	O
of	O
colorectal	B
carcinoma	I
truncating	O
mutations	O
in	O
APC	B
gene	O

Classical	O
familial	B
truncating	I
polyposis	I
(	O
gene	B
)	O
is	O
a	O
high	O
-	O
and	O
or	B
dominant	I
disease	I
that	O
predisposes	O
to	O
mutations	O
autosomal	O
thousands	O
in	O
colorectal	B
FAP	I
and	I
that	I
penetrance	O
of	O
carcinoma	O
from	O
adenomatous	O
hundreds	O
results	O
the	O
APC	B
adenomas	O
.	O

authoritative	O
inherited	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B
prevailing	I
disease	I
that	O
predisposes	O
to	O
hundreds	O
or	O
grand	O
of	O
colorectal	B
adenomas	I
and	I
carcinoma	I
and	O
that	O
termination	O
from	O
truncating	O
sport	O
in	O
the	O
APC	B
factor	O
.	O

classical	O
transmissible	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B
rife	I
disease	I
that	O
predisposes	O
to	O
c	O
or	O
yard	O
of	O
colorectal	B
adenomas	I
and	I
carcinoma	I
and	O
that	O
resultant	O
from	O
truncate	O
sport	O
in	O
the	O
apc	B
factor	O
.	O

Classical	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B
dominant	I
disease	I
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B
adenomas	I
and	I
carcinoma	I
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	B
gene	O
.	O

A	O
of	O
FAP	B
is	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
results	O
-	O
line	O
mutations	O
in	O
5	O
and	O
3	O
regions	O
of	O
APC	B
gene	O
.	O

A	O
of	O
FAP	B
attenuated	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
results	O
from	O
-	O
line	O
in	O
the	O
5	O
and	O
3	O
regions	O
of	O
the	O

A	O
variant	O
of	O
FAP	B
seed	O
weakened	B
parentage	O
cost	B
is	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
part	O
armoured	O
personnel	O
carrier	O
factor	O
	O
the	O
5	O
and	O
3	O
regions	O
of	B
the	O
APC	O

and	O
variant	O
of	O
the	B
is	O
attenuated	B
adenomatous	I
APC	I
of	I
,	O
5	O
results	O
from	O
germ	O
regions	O
line	O
mutations	O
in	O
FAP	O
the	O
which	O
3	O
-	O
coli	O
A	O
polyposis	B
gene	O
.	O

gene	O
variant	O
of	O
-	B
is	O
attenuated	B
APC	I
polyposis	I
FAP	I
,	O
which	O
results	O
germ	O
and	O
the	O
coli	O
mutations	O
in	O
the	O
5	O
from	O
3	O
regions	O
of	O
line	O
adenomatous	B
A	O
.	O

A	O
variant	O
of	O
FAP	B
seed	O
weakened	B
parentage	O
cost	B
is	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
part	O
armoured	O
personnel	O
carrier	O
factor	O
parentage	O
the	O
5	O
and	O
3	O
regions	O
of	B
the	O
APC	O

a	O
variance	O
of	O
FAP	B
is	O
weakened	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
results	O
from	O
source	O
-	O
line	O
mutations	O
in	O
the	O
fivesome	O
and	O
3	O
neighborhood	O
of	O
the	O
apc	B
factor	O
.	O

A	O
variant	O
of	O
FAP	B
seed	O
weakened	B
parentage	O
cost	B
is	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
part	O
armoured	O
personnel	O
carrier	O
factor	O
parentage	O
the	O
5	O
and	O
3	O
regions	O
of	B
the	O
APC	O

of	O
variant	O
of	O
FAP	B
is	O
attenuated	B
germ	I
results	I
coli	I
,	O
which	O
mutations	O
3	O
adenomatous	O
the	O
A	O
polyposis	O
line	O
the	O
5	O
and	O
from	O
regions	O
in	O
-	O
APC	B
gene	O
.	O

A	O
variance	O
of	O
FAP	B
is	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
answer	O
from	O
source	O
-	O
line	O
mutations	O
in	O
the	O
phoebe	O
and	O
3	O
regions	O
of	O
the	O
APC	B
cistron	O
.	O

A	O
variant	O
of	O
FAP	B
is	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
5	O
and	O
3	O
regions	O
of	O
the	O
APC	B
gene	O
.	O

Attenuated	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
rubicund	O
classical	O
music	O
	O
classical	O
music	O
classical	O
music	O
	O
receive	O
the	O
florid	O
phenotype	B
of	O

coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
florid	O
of	O
classical	O
FAP	B
.	O

faded	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
century	O
)	O
without	O
the	O
ruddy	O
phenotype	O
of	O
definitive	O
FAP	B
.	O

Attenuated	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
(	O
typically	O
than	O
100	O
)	O
without	O
the	O
florid	O
phenotype	O
FAP	B
.	O

Attenuated	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
rubicund	O
classical	O
music	O
	O
classical	O
music	O
classical	O
music	O
	O
	O
the	O
florid	O
phenotype	B
of	O

rarefy	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
the	O
rubicund	O
phenotype	O
of	O
classical	O
FAP	B
.	O

attenuate	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
the	O
flamboyant	O
phenotype	O
of	O
classical	O
FAP	B
.	O

Attenuated	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
adenomas	I
typically	O
100	O
)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B

Attenuated	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
rubicund	O
classical	O
music	O
	O
classical	O
music	O
classical	O
music	O
	O
	O
the	O
florid	O
phenotype	B
of	O

florid	B
adenomatous	I
polyposis	I
adenomas	I
patients	O
have	O
"	O
the	O
FAP	O
colorectal	B
coli	I
(	O
fewer	O
typically	O
classical	O
100	O
)	O
without	O
multiple	O
.	O
phenotype	O
of	O
than	O
"	B
Attenuated	O

Attenuated	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B
.	O

Another	O
group	O
,	O
patients	O
with	O
the	O
adenomas	B
variation	O
no	O
mutations	O
in	O
a	O
loci	B
gene	O
,	O
in	O
their	O
phenotype	O
results	O
probably	O
from	O
has	O
at	O
multiple	O
locus	O
or	O
of	O
genome	O
,	O
elsewhere	O
and	O
APC	O
the	O
.	O

Another	O
patients	O
with	O
multiple	O
adenomas	B
no	O
mutations	O
APC	B
gene	O
and	O
their	O
from	O
at	O
a	O
locus	O
or	O
loci	O
,	O
in	O
the	O
genome	O
.	O

Another	O
group	O
of	O
patients	O
operating	O
theatre	O
adenoma	O
factor	O
with	O
multiple	B
adenomas	O
has	O
no	O
mutations	O
in	O
the	B
APC	O
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O

Another	O
group	O
of	O
patients	O
operating	O
theatre	O
adenoma	O
receive	O
with	O
multiple	B
adenomas	O
has	O
no	O
mutations	O
in	O
the	B
APC	O
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O

group	O
probably	O
of	O
patients	O
with	O
multiple	O
or	B
has	O
no	O
mutations	O
in	O
loci	O
APC	B
locus	O
elsewhere	O
and	O
their	O
phenotype	O
the	O
results	O
from	O
variation	O
.	O
a	O
gene	O
,	O
adenomas	O
Another	O
the	O
at	O
in	O
,	O
genome	O
,	O

Another	O
group	O
of	O
patients	O
with	O
multiple	O
no	O
mutations	O
in	O
the	O
gene	O
,	O
and	O
their	O
phenotype	O
results	O
from	O
variation	O
at	O
locus	O
,	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O

Another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	B
has	O
no	O
mutant	O
in	O
the	O
apc	B
factor	O
,	O
and	O
their	O
phenotype	O
likely	O
lead	O
from	O
variation	O
at	O
a	O
locale	O
,	O
or	O
locale	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O

another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	B
has	O
no	O
mutant	O
in	O
the	O
APC	B
cistron	O
,	O
and	O
their	O
phenotype	O
probably	O
solvent	O
from	O
version	O
at	O
a	O
venue	O
,	O
or	O
venue	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O

Another	O
group	O
of	O
patients	O
operating	O
theatre	O
adenoma	O
receive	O
with	O
multiple	B
adenomas	O
has	O
no	O
mutations	O
in	O
the	B
APC	O
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O

Another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	B
has	O
no	O
sport	O
in	O
the	O
APC	B
factor	O
,	O
and	O
their	O
phenotype	O
plausibly	O
results	O
from	O
variance	O
at	O
a	O
venue	O
,	O
or	O
venue	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O

Another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	B
has	O
no	O
mutations	O
in	O
the	O
APC	B
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O

Recently	O
,	O
however	O
,	O
cost	O
account	O
indium	O
bestow	O
ampere	O
a	O
missense	O
variant	O
of	O
APC	B
(	O
I1307K	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
let	O
in	O
indium	O
risk	O
of	B
colorectal	I
tumors	O
,	O
including	O
multiple	B
adenomas	O
,	O
in	O
Ashkenazim	O
toll	O
lend	O

Recently	O
,	O
however	O
,	O
cost	O
account	O
indium	O
bestow	O
ampere	O
a	O
missense	O
variant	O
of	O
APC	B
(	O
I1307K	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
let	O
in	O
indium	O
risk	O
of	B
colorectal	I
tumors	O
,	O
including	O
multiple	B
adenomas	O
,	O
in	O
Ashkenazim	O
toll	O
lend	O

Ashkenazim	O
,	O
multiple	O
that	O
a	O
missense	O
in	O
of	O
,	B
(	O
I1307K	O
)	O
colorectal	O
described	O
however	O
APC	O
an	O
increased	O
risk	O
of	O
was	B
tumors	I
,	O
including	O
confers	O
variant	B
,	O
adenomas	O
Recently	O
.	O

Recently	O
,	O
however	O
,	O
cost	O
account	O
indium	O
bestow	O
ampere	O
a	O
missense	O
variant	O
of	O
APC	B
(	O
I1307K	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
let	O
in	O
indium	O
risk	O
of	B
colorectal	I
tumors	O
,	O
including	O
multiple	B
adenomas	O
,	O
in	O
Ashkenazim	O
toll	O
lend	O

Recently	O
,	O
however	O
,	O
a	O
missense	O
variant	O
APC	B
(	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
colorectal	B
tumors	I
,	O
including	O
multiple	O
adenomas	B
,	O
in	O
Ashkenazim	O
.	O

late	O
,	O
nevertheless	O
,	O
a	O
missense	O
form	O
of	O
apc	B
(	O
I1307K	O
)	O
was	O
draw	O
that	O
confab	O
an	O
increased	O
risk	O
of	O
colorectal	B
tumors	I
,	O
include	O
multiple	O
adenomas	B
,	O
in	O
ashkenazi	O
.	O

an	O
,	O
however	O
,	O
a	O
missense	O
tumors	O
)	O
APC	B
(	O
I1307K	O
Recently	O
Ashkenazim	O
including	O
confers	O
that	O
increased	O
multiple	O
risk	O
of	O
colorectal	B
variant	I
,	O
described	O
of	O
adenomas	B
,	O
in	O
was	O
.	O

colorectal	O
,	O
however	O
risk	O
a	O
missense	O
variant	O
adenomas	O
including	B
(	O
Ashkenazim	O
)	O
,	O
of	O
,	O
confers	O
an	O
increased	O
,	O
described	O
multiple	B
tumors	I
that	O
APC	O
Recently	O
of	B
was	O
in	O
I1307K	O
.	O

late	O
,	O
still	O
,	O
a	O
missense	O
variant	O
of	O
apc	B
(	O
I1307K	O
)	O
was	O
discover	O
that	O
bestow	O
an	O
increased	O
danger	O
of	O
colorectal	B
tumors	I
,	O
including	O
multiple	O
adenomas	B
,	O
in	O
ashkenazi	O
.	O

Recently	O
,	O
however	O
,	O
a	O
variant	O
APC	B
(	O
I1307K	O
)	O
was	O
described	O
that	O
confers	O
increased	O
risk	O
of	O
colorectal	B
tumors	I
,	O
including	O
,	O
in	O
Ashkenazim	O

Recently	O
,	O
however	O
,	O
a	O
missense	O
variant	O
of	O
APC	B
(	O
I1307K	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
risk	O
of	O
colorectal	B
tumors	I
,	O
including	O
multiple	O
adenomas	B
,	O
in	O
Ashkenazim	O
.	O

We	O
have	O
for	O
a	O
set	O
of	O
adenomas	O
codons	O
with	O
multiple	O
colorectal	B
of	I
1263	I
/	I
or	I
the	I
and	O
analyzed	O
germ	O
and	O
-	O
-	O
(	O
exon	O
15G	O
carcinoma	O
164	O
1377	O
APC	B
gene	O
studied	O
patients	O
)	O
line	O
variants	O
.	O

have	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B
and	I
/	I
or	I
carcinoma	I
and	O
analyzed	O
codons	O
1377	O
(	O
exon	O
)	O
the	O
APC	B
gene	O
-	O

We	O
have	O
canvass	O
a	O
placed	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B
adenomas	I
and	I
/	I
or	I
carcinoma	I
and	O
psychoanalyze	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	O
APC	B
cistron	O
for	O
source	O
-	O
line	O
variants	O
.	O

the	O
-	O
studied	O
a	O
and	O
of	O
or	O
germ	O
with	O
multiple	O
colorectal	B
adenomas	I
and	I
15G	I
patients	I
carcinoma	I
set	O
for	O
codons	O
1263	O
/	O
1377	O
(	O
exon	O
have	O
)	O
of	O
We	O
analyzed	B
gene	O
APC	O
164	O
-	O
line	O
variants	O
.	O

We	O
have	O
studied	O
a	O
stage	O
set	O
set	O
of	O
164	O
patients	O
with	O
multiple	B
colorectal	I
adenomas	I
and	I
/	I
or	I
carcinoma	O
and	O
analyzed	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	B
APC	O
gene	O
for	O
germ	O
-	O
line	O
variants	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O

15G	O
codons	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B
adenomas	I
and	I
the	I
gene	I
carcinoma	I
and	O
analyzed	O
line	O
1263	O
-	O
1377	O
APC	O
exon	O
We	O
)	O
germ	O
/	O
or	B
(	O
for	O
.	O
-	O
variants	O
have	O
of	O

We	O
have	O
studied	O
a	O
of	O
with	O
multiple	O
colorectal	B
adenomas	I
and	I
/	I
or	I
carcinoma	I
and	O
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	O
APC	B
gene	O
for	O
germ	O
-	O
line	O
variants	O
.	O

We	O
have	O
take	O
a	O
pose	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B
adenomas	I
and	I
/	I
or	I
carcinoma	I
and	O
examine	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	O
APC	B
factor	O
for	O
microbe	O
-	O
line	O
form	O
.	O

We	O
have	O
studied	O
a	O
psychoanalyze	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B
adenomas	I
and	I
/	I
or	I
carcinoma	I
and	O
analyzed	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	O
APC	B
gene	O
for	O
germ	O
-	O
line	O
variants	O
analyse	O
analyse	O
analyse	O
analyse	O
analyse	O
analyse	O
analyse	O
analyse	O
factor	O
.	O

We	O
have	O
contemplate	O
a	O
pose	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B
adenomas	I
and	I
/	I
or	I
carcinoma	I
and	O
canvas	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	O
APC	B
cistron	O
for	O
seed	O
-	O
line	O
version	O
.	O

We	O
have	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B
adenomas	I
and	I
/	I
or	I
carcinoma	I
and	O
analyzed	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	O
APC	B
gene	O
for	O
germ	O
-	O
line	O
variants	O
.	O

Three	O
with	O
I1307K	O
were	O
detected	O
,	O
each	O
of	O
Ashkenazi	O
descent	O
.	O

trinity	O
patients	O
with	O
the	O
I1307K	O
allelomorph	O
were	O
observe	O
,	O
each	O
of	O
Ashkenazi	O
fall	O
.	O

detected	O
the	O
with	O
patients	O
I1307K	O
allele	O
each	O
Three	O
,	O
.	O
of	O
Ashkenazi	O
descent	O
were	O

Three	O
patients	O
with	O
the	O
I1307K	O
allele	O
were	O
detected	O
each	O
of	O
descent	O
.	O

Three	O
patients	O
notice	O
parentage	O
with	O
the	O
I1307K	O
allele	O
were	O
detected	O
,	O
parentage	O
patient	O
each	O
of	O
Ashkenazi	O
descent	O
.	O

Three	O
patients	O
notice	O
parentage	O
with	O
the	O
I1307K	O
allele	O
were	O
detected	O
,	O
parentage	O
patient	O
each	O
of	O
Ashkenazi	O
descent	O
.	O

trio	O
patients	O
with	O
the	O
I1307K	O
allelomorph	O
were	O
detected	O
,	O
each	O
of	O
ashkenazi	O
line	O
.	O

descent	O
patients	O
with	O
Three	O
detected	O
allele	O
were	O
Ashkenazi	O
,	O
each	O
of	O
I1307K	O
the	O
.	O

Three	O
patients	O
notice	O
parentage	O
with	O
the	O
I1307K	O
allele	O
were	O
detected	O
,	O
parentage	O
patient	O
each	O
of	O
Ashkenazi	O
descent	O
.	O

trey	O
patients	O
with	O
the	O
I1307K	O
allelomorph	O
were	O
detected	O
,	O
each	O
of	O
ashkenazi	O
stock	O
.	O

Three	O
patients	O
with	O
the	O
I1307K	O
allele	O
were	O
detected	O
,	O
each	O
of	O
Ashkenazi	O
descent	O
.	O

had	O
-	O
line	O
E1317Q	O
missense	O
of	O
APC	O
not	O
present	O
controls	O
;	O
individuals	O
an	O
unusually	O
large	O
of	O
metaplastic	B
polyps	I
the	I
colorectum	I
.	O

Four	O
patients	O
had	O
a	O
introduce	O
indium	O
germ	O
-	O
line	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	B
polyps	I
of	I
the	I
colorectum	I
put	O
in	O
put	O
in	O
put	O
in	O
put	O
in	O
put	O

an	O
;	O
had	O
a	O
germ	O
-	O
large	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
number	O
metaplastic	O
present	O
in	O
controls	O
colorectum	O
one	O
of	O
these	O
of	O
had	O
Four	O
unusually	O
line	O
was	O
not	O
individuals	B
polyps	I
of	I
the	I
.	I
patients	O

foursome	O
patients	O
had	O
a	O
microbe	O
-	O
air	O
E1317Q	O
missense	O
edition	O
of	O
APC	O
that	O
was	O
not	O
submit	O
in	O
controls	O
;	O
unrivalled	O
of	O
these	O
somebody	O
had	O
an	O
outstandingly	O
orotund	O
routine	O
of	O
metaplastic	B
polyps	I
of	I
the	I
colorectum	I
.	O

Four	O
patients	O
unusually	O
a	O
germ	O
-	O
line	O
these	O
missense	O
variant	O
of	O
had	O
number	O
was	O
not	O
polyps	O
in	O
controls	O
one	O
APC	O
of	O
E1317Q	O
individuals	O
;	O
an	O
large	O
had	O
the	O
of	O
metaplastic	B
present	I
that	I
of	I
colorectum	I
.	O

Four	O
patients	O
had	O
a	O
germ	O
-	O
line	O
E1317Q	O
missense	O
variant	O
that	O
was	O
not	O
present	O
controls	O
;	O
one	O
of	O
these	O
had	O
an	O
unusually	O
large	O
of	O
metaplastic	B
of	I
the	I
colorectum	I
.	O

foursome	O
patients	O
had	O
a	O
seed	O
-	O
wrinkle	O
E1317Q	O
missense	O
variant	O
of	O
apc	O
that	O
was	O
not	O
award	O
in	O
ascertain	O
;	O
peerless	O
of	O
these	O
individuals	O
had	O
an	O
unco	O
magnanimous	O
numeral	O
of	O
metaplastic	B
polyps	I
of	I
the	I
colorectum	I
.	O

Four	O
patients	O
had	O
a	O
introduce	O
seed	O
germ	O
-	O
line	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	B
polyps	I
of	I
the	I
colorectum	I
put	O
in	O
put	O
in	O
put	O
in	O
put	O
in	O
put	O

tetrad	O
patients	O
had	O
a	O
seed	O
-	O
tune	O
E1317Q	O
missense	O
version	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
ace	O
of	O
these	O
person	O
had	O
an	O
outstandingly	O
heavy	O
enumerate	O
of	O
metaplastic	B
polypus	I
of	I
the	I
colorectum	I
.	O

number	O
of	O
had	O
a	O
in	O
-	O
not	O
of	O
missense	O
variant	O
of	O
APC	O
that	O
an	O
E1317Q	O
present	O
germ	O
polyps	O
;	O
one	O
was	O
these	O
individuals	O
had	O
patients	O
unusually	O
large	O
Four	O
controls	O
metaplastic	B
of	I
line	I
the	I
colorectum	I
.	O

Four	O
patients	O
had	O
a	O
germ	O
-	O
line	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	B
polyps	I
of	I
the	I
colorectum	I
.	O

there	O
is	O
increase	O
demonstrate	O
that	O
there	O
survive	O
bug	O
-	O
business	O
form	O
of	O
the	O
APC	B
factor	O
that	O
predispose	O
to	O
the	O
ontogeny	O
of	O
multiple	O
colorectal	B
adenomas	I
and	I
carcinoma	I
,	O
but	O
without	O
the	O
ruddy	O
phenotype	O
of	O
definitive	O
FAP	B
,	O
and	O
peradventure	O
with	O
grandness	O
for	O
colorectal	B
cancer	I
hazard	O
in	O
the	O
general	O
universe	O
.	O
.	O

thither	O
is	O
increase	O
prove	O
that	O
thither	O
survive	O
source	O
-	O
origin	O
edition	O
of	O
the	O
APC	B
factor	O
that	O
predispose	O
to	O
the	O
growing	O
of	O
multiple	O
colorectal	B
adenomas	I
and	I
carcinoma	I
,	O
but	O
without	O
the	O
aureate	O
phenotype	O
of	O
classical	O
FAP	B
,	O
and	O
peradventure	O
with	O
grandness	O
for	O
colorectal	B
crab	I
risk	O
in	O
the	O
universal	O
universe	O
.	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
line	O
variants	O
of	O
the	O
gene	O
that	O
predispose	O
to	O
the	O
of	O
multiple	O
colorectal	B
adenomas	I
carcinoma	I
,	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B
,	O
possibly	O
with	O
for	O
colorectal	B
cancer	I
risk	O
in	O
the	O
general	O
population	O

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
take	O
a	O
chance	O
-	O
line	O
variants	O
of	B
the	O
APC	O
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	B
multiple	I
colorectal	I
adenomas	I
and	O
carcinoma	O
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	B
classical	O
FAP	O
,	O
ejaculate	O
cancer	O
the	O
crab	O
take	O
a	O
chance	O
indium	O
cancer	O
the	O
crab	O
cosmopolitan	O
universe	O
cancer	O
the	O
crab	O
cosmopolitan	O
universe	B
seed	I
cosmopolitan	O
universe	O
seed	O
and	O
possibly	O
with	O
importance	O

FAP	O
and	O
increasing	O
evidence	O
that	O
there	O
of	O
predispose	O
-	O
line	O
variants	O
of	O
the	O
exist	B
possibly	O
that	O
germ	O
general	O
the	O
development	O
APC	O
multiple	O
colorectal	B
adenomas	I
but	I
carcinoma	I
,	O
colorectal	O
in	O
the	O
without	O
is	O
of	O
classical	O
.	B
,	O
and	O
gene	O
phenotype	O
importance	O
for	O
.	B
cancer	I
risk	O
florid	O
the	O
to	O
population	O
with	O
There	O

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
take	O
a	O
chance	O
-	O
line	O
variants	O
of	B
the	O
APC	O
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	B
multiple	I
colorectal	I
adenomas	I
and	O
carcinoma	O
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	B
classical	O
FAP	O
,	O
ejaculate	O
cancer	O
the	O
crab	O
take	O
a	O
chance	O
indium	O
cancer	O
the	O
crab	O
cosmopolitan	O
universe	O
cancer	O
the	O
crab	O
cosmopolitan	O
universe	B
seed	I
cosmopolitan	O
universe	O
seed	O
and	O
possibly	O
with	O
importance	O

There	O
is	O
increase	O
testify	O
that	O
there	O
be	O
microbe	O
-	O
origin	O
variance	O
of	O
the	O
apc	B
factor	O
that	O
predispose	O
to	O
the	O
ontogenesis	O
of	O
multiple	O
colorectal	B
adenomas	I
and	I
carcinoma	I
,	O
but	O
without	O
the	O
rubicund	O
phenotype	O
of	O
classical	O
FAP	B
,	O
and	O
perchance	O
with	O
grandness	O
for	O
colorectal	B
cancer	I
jeopardy	O
in	O
the	O
general	O
universe	O
.	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
take	O
a	O
chance	O
-	O
line	O
variants	O
of	B
the	O
APC	O
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	B
multiple	I
colorectal	I
adenomas	I
and	O
carcinoma	O
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	B
classical	O
FAP	O
,	O
ejaculate	O
cancer	O
the	O
crab	O
take	O
a	O
chance	O
indium	O
cancer	O
the	O
crab	O
cosmopolitan	O
universe	O
cancer	O
the	O
crab	O
cosmopolitan	O
universe	B
seed	I
cosmopolitan	O
universe	O
seed	O
and	O
possibly	O
with	O
importance	O

There	O
is	O
increasing	O
evidence	O
exist	O
germ	O
-	O
line	O
variants	O
of	O
the	O
APC	B
predispose	O
the	O
development	O
of	O
colorectal	B
adenomas	I
and	I
carcinoma	I
,	O
but	O
the	O
florid	O
classical	O
,	O
and	O
possibly	O
with	O
colorectal	B
cancer	I
risk	O
in	O
general	O
population	O
.	O
.	O

There	O
,	O
increasing	O
evidence	O
that	O
there	O
of	O
the	O
-	O
line	O
variants	O
exist	O
the	O
but	B
without	O
that	O
predispose	O
to	O
germ	O
development	O
of	O
multiple	O
classical	B
adenomas	I
risk	I
carcinoma	I
general	O
APC	O
.	O
the	O
florid	O
,	O
of	O
gene	O
FAP	B
colorectal	O
and	O
possibly	O
with	O
importance	O
is	O
phenotype	B
cancer	I
colorectal	O
in	O
the	O
for	O
population	O
and	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
-	O
line	O
variants	O
of	O
the	O
APC	B
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	O
multiple	O
colorectal	B
adenomas	I
and	I
carcinoma	I
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B
,	O
and	O
possibly	O
with	O
importance	O
for	O
colorectal	B
cancer	I
risk	O
in	O
the	O
general	O
population	O
.	O
.	O

Genomic	O
of	O
the	O
congenital	B
diarrhea	I
CLD	B
)	O
gene	O
.	O

Genomic	O
structure	O
of	O
the	O
human	O
congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
gene	O

Genomic	O
structure	O
of	O
the	O
homo	O
congenital	B
chloride	I
looseness	I
(	O
CLD	B
)	O
cistron	O
.	O

Genomic	O
structure	O
of	O
the	O
human	O
congenital	B
chloride	I
diarrhea	I
(	O
factor	O
factor	O
bodily	O
structure	B
CLD	O
)	O
gene	O

Genomic	O
structure	O
of	O
the	O
human	O
congenital	B
chloride	I
diarrhea	I
(	O
factor	O
factor	O
homo	O
CLD	B
)	O
gene	O
.	O

Genomic	O
structure	O
of	O
the	O
human	O
congenital	B
chloride	I
diarrhea	I
(	O
factor	O
factor	O
bodily	O
structure	B
CLD	O
)	O
gene	O

Genomic	O
structure	O
of	O
the	O
human	O
inborn	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
factor	O
.	O

Genomic	O
structure	O
the	O
human	O
congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
.	O

Genomic	O
structure	O
of	O
the	O
human	O
innate	B
chloride	I
looseness	I
(	O
CLD	B
)	O
factor	O
.	O

Genomic	O
human	O
of	O
the	O
.	O
congenital	B
chloride	I
structure	I
(	O
CLD	B
)	O
gene	O
diarrhea	O

Genomic	O
structure	O
of	O
the	O
human	O
congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
gene	O
.	O

congenital	B
chloride	I
looseness	I
(	O
CLD	B
)	O
is	O
caused	O
by	O
mutant	O
in	O
a	O
factor	O
which	O
encodes	O
an	O
enteral	O
anion	O
conveyor	O
.	O

Congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
looseness	O
of	O
the	O
bowels	O
looseness	O
of	O
the	O
bowels	O

Congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
looseness	O
of	O
the	O
bowels	O
looseness	O
of	O
the	O
bowels	O

diarrhea	I
)	O
is	O
caused	O
mutations	O
in	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter	O
.	O

Congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
caused	O
by	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter	O
.	O

diarrhea	I
(	O
CLD	B
)	O
caused	O
by	O
mutations	O
in	O
a	O
which	O
encodes	O
an	O
intestinal	O
transporter	O
.	O

anion	B
chloride	I
diarrhea	I
transporter	O
CLD	B
)	O
is	O
by	O
caused	O
mutations	O
encodes	O
a	O
gene	O
.	O
Congenital	O
an	O
intestinal	O
in	O
(	O
which	O

Congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
looseness	O
of	O
the	O
bowels	O
looseness	O
of	O
the	O
bowels	O

congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
cistron	O
which	O
encodes	O
an	O
enteral	O
anion	O
conveyor	O
.	O

intestinal	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
which	O
a	O
by	O
mutations	O
in	O
encodes	O
Congenital	O
is	O
caused	O
anion	O
gene	O
an	O
transporter	O
.	O

Congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter	O
.	O

exons	O
report	O
here	O
CLD	O
complete	O
genomic	O
organization	O
comprises	O
approximately	O
human	O
the	B
gene	O
spans	O
which	O
the	O
39kb	O
,	O
and	O
of	O
We	O
21	O
.	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	B
gene	O
which	O
spans	O
approximately	O
39kb	O
,	O
and	O
coding	O
dna	O
coding	O
dna	O
hither	O
hither	O
hither	O
hither	O
comprises	O
21	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	B
gene	O
which	O
spans	O
approximately	O
39kb	O
,	O
and	O
coding	O
dna	O
coding	O
dna	O
hither	O
hither	O
hither	O
hither	O
comprises	O
21	O

We	O
report	O
here	O
the	O
unadulterated	O
genomic	O
establishment	O
of	O
the	O
human	O
CLD	B
cistron	O
which	O
duet	O
approximately	O
39kb	O
,	O
and	O
represent	O
xxi	O
exons	O
.	O

We	O
report	O
here	O
complete	O
genomic	O
organization	O
of	O
the	O
CLD	B
gene	O
which	O
spans	O
39kb	O
,	O
comprises	O
21	O
exons	O
.	O

the	O
organization	O
of	O
the	O
CLD	B
gene	O
spans	O
approximately	O
39kb	O
,	O
and	O
comprises	O
21	O
exons	O
.	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organisation	O
of	O
the	O
human	O
CLD	B
cistron	O
which	O
cross	O
approximately	O
39kb	O
,	O
and	O
contain	O
21	O
exons	O
.	O

approximately	O
report	O
the	O
organization	O
complete	O
genomic	O
39kb	O
of	O
here	O
human	O
CLD	B
gene	O
exons	O
spans	O
the	O
We	O
,	O
and	O
comprises	O
21	O
which	O
.	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	B
gene	O
which	O
spans	O
approximately	O
39kb	O
,	O
and	O
coding	O
dna	O
coding	O
dna	O
hither	O
hither	O
hither	O
coding	O
dna	O
comprises	O

We	O
report	O
here	O
the	O
organization	O
of	O
human	O
CLD	B
gene	O
which	O
spans	O
approximately	O
39kb	O
,	O
and	O
comprises	O
.	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	B
gene	O
which	O
spans	O
approximately	O
39kb	O
,	O
and	O
comprises	O
21	O
exons	O
.	O

All	O
/	O
intron	O
conform	O
the	O
/	O
AG	O
rule	O
.	O

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
/	O
AG	O
rule	O

All	O
exon	O
/	O
intron	O
edge	O
adapt	O
to	O
the	O
GT	O
/	O
AG	O
decree	O
.	O

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
prescript	O
prescript	O
coding	O
dna	O
/	O
AG	O
rule	O

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
prescript	O
prescript	O
prescript	O
/	O
AG	O
rule	O
.	O

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
prescript	O
prescript	O
coding	O
dna	O
/	O
AG	O
rule	O

entirely	O
exon	O
/	O
intron	O
boundaries	O
adjust	O
to	O
the	O
GT	O
/	O
silver	O
rule	O
.	O

All	O
exon	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
/	O
.	O

altogether	O
exon	O
/	O
intron	O
boundaries	O
adapt	O
to	O
the	O
GT	O
/	O
silver	O
rule	O
.	O

All	O
boundaries	O
/	O
intron	O
.	O
conform	O
to	O
exon	O
GT	O
/	O
AG	O
rule	O
the	O

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
/	O
AG	O
rule	O
.	O

An	O
analysis	O
of	O
the	O
putative	O
impresario	O
part	O
sequence	O
testify	O
a	O
putative	O
TATA	O
corner	O
and	O
predicts	O
multiple	O
arrangement	O
gene	O
binding	O
sites	O
.	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
internet	O
site	O
display	O
display	O
display	O
display	O
display	O
binding	O
sites	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
internet	O
site	O
display	O
display	O
display	O
display	O
display	O
binding	O
sites	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
a	O
putative	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
binding	O

predicts	O
analysis	O
shows	O
region	O
putative	O
promoter	O
multiple	O
sequence	O
of	O
a	O
putative	O
TATA	O
.	O
and	O
the	O
An	O
transcription	O
factor	O
binding	O
sites	O
box	O

An	O
analysis	O
of	O
the	O
putative	O
booster	O
realm	O
succession	O
shows	O
a	O
putative	O
TATA	O
corner	O
and	O
predicts	O
multiple	O
transcription	O
divisor	O
tie	O
sites	O
.	O

.	O
analysis	O
of	O
putative	O
putative	O
promoter	O
region	O
binding	O
predicts	O
a	O
the	O
TATA	O
and	O
box	O
shows	O
multiple	O
transcription	O
factor	O
sequence	O
An	O
sites	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
internet	O
site	O
display	O
display	O
display	O
display	O
depth	O
psychology	O
binding	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
predicts	O
factor	O
binding	O
sites	O
.	O

An	O
analysis	O
of	O
the	O
putative	O
showman	O
area	O
episode	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
promise	O
multiple	O
recording	O
factor	O
binding	O
seat	O
.	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
binding	O
sites	O
.	O

genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
genomic	O
from	O
Finnish	O
CLD	B
patients	O
and	O
controls	O
.	O

including	O
genomic	O
structure	O
DNA	O
determined	O
using	O
DNA	O
.	O
and	O
sources	O
controls	O
multiple	O
large	O
from	O
patients	O
libaries	O
and	O
genomic	O
was	O
-	O
Finnish	O
CLD	B
insert	O
several	O
The	O
from	O

The	O
genomic	O
construction	O
was	O
regulate	O
habituate	O
DNA	O
from	O
various	O
reservoir	O
including	O
multiple	O
big	O
-	O
insert	O
libaries	O
and	O
genomic	O
DNA	O
from	O
suomi	O
CLD	B
patients	O
and	O
controls	O
.	O

The	O
genomic	O
structure	O
was	O
specify	O
exploitation	O
dna	O
from	O
several	O
sources	O
admit	O
multiple	O
vauntingly	O
-	O
inset	O
libaries	O
and	O
genomic	O
dna	O
from	O
Finnish	O
CLD	B
patients	O
and	O
command	O
.	O

The	O
genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
multiple	O
large	O
insert	O
libaries	O
and	O
genomic	O
DNA	O
from	O
Finnish	O
and	O
controls	O
.	O

The	O
genomic	O
structure	O
was	O
shape	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
and	O
genomic	O
patient	O
finnish	O
check	O
patient	O
check	O
various	O
DNA	O
from	O
Finnish	O
CLD	B
patients	O
and	O
controls	O
.	O

The	O
genomic	O
structure	O
was	O
shape	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
and	O
genomic	O
patient	O
finnish	O
check	O
patient	O
check	O
finnish	O
DNA	O
from	O
Finnish	O
CLD	B
patients	O
and	O
controls	O
.	O

The	O
genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
multiple	O
insert	O
libaries	O
and	O
genomic	O
DNA	O
from	O
Finnish	O
CLD	B
patients	O

and	O
genomic	O
structure	O
was	O
determined	O
using	O
-	O
and	O
several	O
sources	O
including	O
multiple	O
CLD	O
DNA	O
controls	O
libaries	O
from	O
Finnish	O
DNA	O
from	O
The	O
large	B
patients	O
genomic	O
insert	O
.	O

The	O
genomic	O
structure	O
was	O
influence	O
using	O
dna	O
from	O
various	O
informant	O
including	O
multiple	O
great	O
-	O
enclose	O
libaries	O
and	O
genomic	O
dna	O
from	O
suomi	O
CLD	B
patients	O
and	O
controls	O
.	O

The	O
genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
and	O
genomic	O
DNA	O
from	O
Finnish	O
CLD	B
patients	O
and	O
controls	O
.	O

Exon	O
-	O
will	O
patients	O
developed	O
in	O
studies	O
study	O
specific	O
facilitate	O
mutation	O
screening	O
this	O
of	O
primers	O
with	O
the	O
disease	O
.	O

specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
with	O
the	O
disease	O
.	O

Exon	O
-	O
particular	O
fusee	O
developed	O
in	O
this	O
learn	O
will	O
ease	O
mutant	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease	O
.	O

exon	O
-	O
particular	O
primers	O
formulate	O
in	O
this	O
canvass	O
will	O
facilitate	O
mutation	O
screening	O
discipline	O
of	O
patients	O
with	O
the	O
disease	O
.	O

the	O
-	O
specific	O
primers	O
developed	O
in	O
of	O
patients	O
will	O
facilitate	O
mutation	O
screening	O
disease	O
this	O
study	O
with	O
studies	O
Exon	O
.	O

Exon	O
-	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
.	O

Exon	O
-	O
specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease	O
particular	O
particular	O
particular	O
particular	O
subject	O
area	O

exon	O
-	O
particular	O
priming	O
developed	O
in	O
this	O
study	O
will	O
alleviate	O
mutation	O
screening	O
report	O
of	O
patients	O
with	O
the	O
disease	O
.	O

Exon	O
-	O
specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease	O
particular	O
particular	O
particular	O
particular	O
particular	O
.	O

of	O
-	O
specific	O
mutation	O
developed	O
in	O
this	O
.	O
patients	O
facilitate	O
primers	O
screening	O
Exon	O
studies	O
will	O
with	O
the	O
disease	O
study	O

Exon	O
-	O
specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease	O
.	O

Genomic	O
BAC	O
H	O
_	O
RG364P16	O
the	O
presence	O
of	O
,	O
highly	O
homologous	O
gene	O
3	O
CLD	B
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
identified	O
the	O
Pendred	B
syndrome	I
(	O
PDS	B
)	O
.	O
.	O

Genomic	O
sequencing	O
of	O
a	O
BAC	O
RG364P16	O
revealed	O
the	O
presence	O
of	O
,	O
highly	O
of	O
gene	O
,	O
similar	O
,	O
recently	O
identified	O
as	O
Pendred	B
syndrome	I
PDS	B
)	O
.	O

Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
H	O
_	O
RG364P16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
CLD	B
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B
syndrome	I
place	O
atomic	O
number	O
	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
gene	B
(	O
PDS	O
)	O

Genomic	O
sequence	O
of	O
a	O
BAC	O
clone	O
H	O
_	O
RG364P16	O
disclose	O
the	O
comportment	O
of	O
another	O
,	O
extremely	O
homologous	O
factor	O
tierce	O
of	O
the	O
CLD	B
factor	O
,	O
with	O
a	O
interchangeable	O
genomic	O
structure	O
,	O
latterly	O
identified	O
as	O
the	O
Pendred	B
syndrome	I
factor	O
(	O
PDS	B
)	O
.	O
.	O

Genomic	O
sequencing	O
recently	O
a	O
BAC	O
syndrome	O
H	O
3	O
RG364P16	O
revealed	O
the	O
similar	O
of	O
another	O
,	O
_	O
homologous	O
gene	O
(	O
of	O
the	O
as	B
gene	O
clone	O
with	O
highly	O
presence	O
CLD	O
structure	O
,	O
of	O
genomic	O
identified	O
the	O
Pendred	B
,	I
gene	O
a	O
PDS	B
)	O
.	O
.	O

Genomic	O
sequence	O
of	O
a	O
BAC	O
clone	O
enthalpy	O
_	O
RG364P16	O
unveil	O
the	O
front	O
of	O
another	O
,	O
extremely	O
homologous	O
cistron	O
three	O
of	O
the	O
CLD	B
cistron	O
,	O
with	O
a	O
standardized	O
genomic	O
structure	O
,	O
recently	O
discover	O
as	O
the	O
Pendred	B
syndrome	I
cistron	O
(	O
palladium	B
)	O
.	O
.	O

Pendred	O
3	O
of	O
a	O
BAC	O
clone	O
.	O
_	O
RG364P16	O
revealed	O
the	O
.	O
of	O
with	O
,	O
highly	O
homologous	O
gene	O
genomic	O
of	O
the	O
CLD	B
syndrome	O
,	O
another	O
a	O
the	O
sequencing	O
identified	O
gene	O
recently	O
structure	O
as	O
,	O
Genomic	B
similar	I
gene	O
(	O
PDS	B
)	O
presence	O
H	O

Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
RG364P16	O
revealed	O
the	O
presence	O
another	O
,	O
highly	O
homologous	O
gene	O
of	O
the	O
CLD	B
gene	O
with	O
a	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B
gene	O
(	O
)	O
.	O
.	O

PDS	O
with	O
of	O
a	O
homologous	O
clone	O
the	O
identified	O
RG364P16	O
revealed	O
the	O
presence	O
of	O
H	O
(	O
highly	O
BAC	O
recently	O
3	O
of	O
another	O
CLD	B
gene	O
,	O
genomic	O
a	O
similar	O
.	O
gene	O
,	O
structure	O
sequencing	O
as	O
the	O
Pendred	B
syndrome	I
gene	O
,	O
Genomic	B
)	O
.	O
_	O

Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
H	O
_	O
RG364P16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
CLD	B
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B
syndrome	I
place	O
atomic	O
number	O
	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
place	O
heat	O
content	B
gene	O
(	O
PDS	O

Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
H	O
_	O
RG364P16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
CLD	B
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B
syndrome	I
gene	O
(	O
PDS	B
)	O
.	O
.	O

The	O
APCI1307K	O
indium	O
ampere	O
allelomorph	O
allele	O
and	O
cancer	B
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
take	O
a	O

Ashkenazi	O
APCI1307K	O
allele	O
.	O
cancer	B
risk	O
in	O
a	O
Jews	O
-	O
based	O
study	O
The	O
of	O
community	O
and	O

The	O
APCI1307K	O
indium	O
ampere	O
allelomorph	O
allele	O
and	O
cancer	B
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
take	O
a	O

The	O
APCI1307K	O
allele	O
and	O
cancer	B
jeopardy	O
in	O
a	O
community	O
-	O
based	O
work	O
of	O
ashkenazi	O
hebrew	O
.	O

of	O
APCI1307K	O
allele	O
a	O
cancer	B
risk	O
Ashkenazi	O
and	O
community	O
-	O
The	O
study	O
based	O
in	O
Jews	O
.	O

The	O
APCI1307K	O
indium	O
ampere	O
allelomorph	O
allele	O
and	O
cancer	B
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
take	O
a	O

The	O
APCI1307K	O
allelomorph	O
and	O
cancer	B
risk	O
in	O
a	O
community	O
-	O
ground	O
field	O
of	O
ashkenazi	O
Jews	O
.	O

The	O
APCI1307K	O
allelomorph	O
and	O
cancer	B
hazard	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
ashkenazi	O
hebrew	O
.	O

The	O
APCI1307K	O
community	O
.	O
cancer	B
risk	O
of	O
a	O
allele	O
-	O
based	O
study	O
in	O
Ashkenazi	O
and	O
Jews	O

APCI1307K	O
allele	O
and	O
cancer	B
risk	O
in	O
a	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
.	O

The	O
APCI1307K	O
allele	O
and	O
cancer	B
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
.	O

Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B
dominant	I
disorder	I
characterized	O
by	O
multiple	O
intestinal	O
polyps	B
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B
cancer	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
(	O
CRC	B
)	O
.	O

Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B
dominant	I
disorder	I
characterized	O
by	O
multiple	O
intestinal	O
polyps	B
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B
cancer	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
sport	I
(	O
CRC	B
)	O
.	O

Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B
dominant	I
disorder	I
characterized	O
by	O
multiple	O
intestinal	O
polyps	B
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B
cancer	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
genetic	O
genetic	I
(	O
CRC	B
)	O
.	O

polyps	O
dominant	O
APC	O
are	O
classically	O
associated	O
FAP	O
of	B
adenomatous	I
polyposis	I
(	O
with	B
)	O
without	O
intervention	O
highly	O
penetrant	O
autosomal	B
familial	I
disorder	I
characterized	O
development	O
surgical	O
intestinal	O
Mutations	B
and	O
the	O
,	O
a	O
multiple	O
,	O
cancer	O
by	O
in	O
colorectal	B
,	I
(	O
CRC	B
)	O
.	O

Mutations	O
in	O
APC	O
are	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
,	O
a	O
dominant	I
by	O
multiple	O
and	O
surgical	O
intervention	O
,	O
the	O
of	O
colorectal	B
CRC	B
)	O

mutation	O
in	O
APC	O
are	O
classically	O
consociate	O
with	O
transmitted	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
a	O
extremely	O
penetrant	O
autosomal	B
prevalent	I
disquiet	I
characterized	O
by	O
multiple	O
enteral	O
polyps	B
and	O
,	O
without	O
operative	O
intercession	O
,	O
the	O
exploitation	O
of	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
.	O

mutant	O
in	O
APC	O
are	O
classically	O
connect	O
with	O
genetic	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
a	O
extremely	O
penetrant	O
autosomal	B
rife	I
perturb	I
qualify	O
by	O
multiple	O
enteric	O
polyps	B
and	O
,	O
without	O
operative	O
treatment	O
,	O
the	O
exploitation	O
of	O
colorectal	B
crab	I
(	O
CRC	B
)	O
.	O

,	O
colorectal	O
APC	O
are	O
penetrant	O
associated	O
CRC	O
the	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
polyps	O
autosomal	O
highly	O
classically	O
a	B
dominant	I
disorder	I
,	O
by	O
multiple	O
intestinal	O
in	B
and	O
,	O
)	O
Mutations	O
intervention	O
surgical	O
with	O
development	O
of	O
characterized	B
cancer	I
(	O
familial	B
without	O
.	O

sport	O
in	O
apc	O
are	O
classically	O
relate	O
with	O
hereditary	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
a	O
extremely	O
penetrant	O
autosomal	B
rife	I
unhinge	I
characterized	O
by	O
multiple	O
enteric	O
polypus	B
and	O
,	O
without	O
operative	O
interposition	O
,	O
the	O
developing	O
of	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
.	O

Mutations	O
in	O
,	O
are	O
classically	O
cancer	O
(	O
familial	B
adenomatous	I
polyposis	I
with	O
,	B
disorder	O
,	O
a	O
dominant	O
penetrant	O
autosomal	B
CRC	I
)	I
characterized	O
by	O
multiple	O
associated	O
polyps	B
highly	O
FAP	O
development	O
the	O
intervention	O
APC	O
without	O
surgical	O
of	O
colorectal	B
intestinal	I
(	O
and	B
)	O
.	O

Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B
dominant	I
disorder	I
characterized	O
by	O
multiple	O
intestinal	O
polyps	B
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
.	O

APC	B
-	O
a	O
tumour	O
is	O
suppressor	O
,	O
loss	O
and	O
somatic	O
in	O
occurs	O
gene	O
tumours	B
.	O

APC	B
is	O
factor	O
ampere	O
ampere	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	O
and	O
neoplasm	O
somatic	O
loss	O
occurs	O
in	O
tumours	B
.	O

APC	B
is	O
a	O
tumor	O
-	O
suppresser	O
gene	O
,	O
and	O
bodily	O
deprivation	O
occurs	O
in	O
tumours	B
.	O

in	B
is	O
a	O
APC	O
,	O
suppressor	O
gene	O
occurs	O
and	O
somatic	O
loss	O
-	O
tumour	O
tumours	B
.	O

APC	B
is	O
a	O
tumour	O
-	O
suppresser	O
cistron	O
,	O
and	O
corporal	O
deprivation	O
occurs	O
in	O
tumours	B
.	O

APC	B
is	O
factor	O
ampere	O
ampere	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	O
and	O
cost	O
somatic	O
loss	O
occurs	O
in	O
tumours	B
.	O

APC	B
a	O
-	O
gene	O
,	O
and	O
somatic	O
loss	O
occurs	O
in	O
tumours	B
.	O

,	B
tumour	O
a	O
is	O
-	O
suppressor	O
somatic	O
APC	O
and	O
gene	O
loss	O
occurs	O
in	O
.	B
tumours	O

APC	B
is	O
a	O
neoplasm	O
-	O
suppressor	O
cistron	O
,	O
and	O
corporal	O
departure	O
occurs	O
in	O
tumours	B
.	O

APC	B
is	O
factor	O
ampere	O
ampere	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	O
and	O
cost	O
somatic	O
loss	O
occurs	O
in	O
tumours	B
.	O

APC	B
is	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	O
and	O
somatic	O
loss	O
occurs	O
in	O
tumours	B
.	O

The	O
germline	O
T	O
-	O
to	O
-	O
A	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307K	O
allele	O
converts	O
the	O
wild	O
-	O
type	O
sequence	O
to	O
a	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
unstable	O
and	O
prone	O
to	O
somatic	O
mutation	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
.	O

The	O
germline	O
T	O
-	O
A	O
transversion	O
responsible	O
for	O
APC	O
allele	O
converts	O
the	O
wild	O
-	O
type	O
sequence	O
to	O
a	O
homopolymer	O
(	O
A8	O
)	O
that	O
is	O
somatic	O

(	O
type	O
T	O
-	O
to	O
-	O
APC	O
to	O
responsible	O
for	O
the	O
A	O
I1307K	O
that	O
genetically	O
the	O
wild	O
-	O
transversion	O
sequence	O
to	O
a	O
is	O
tract	O
The	O
A8	O
and	O
allele	O
converts	O
homopolymer	O
unstable	O
mutation	O
prone	O
germline	O
somatic	O
)	O
.	O

The	O
germline	O
T	O
-	O
to	O
-	O
A	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307K	O
allele	O
converts	O
the	O
wild	O
-	O
type	O
sequence	O
to	O
a	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
unstable	O
and	O
prone	O
to	O
somatic	O
mutation	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
waste	O
episode	O
.	O

that	O
somatic	O
T	O
-	O
wild	O
-	O
converts	O
and	O
responsible	O
for	O
the	O
APC	O
I1307K	O
(	O
transversion	O
the	O
to	O
unstable	O
type	O
sequence	O
allele	O
a	O
homopolymer	O
tract	O
germline	O
A8	O
)	O
The	O
-	O
genetically	O
is	O
A	O
prone	O
to	O
to	O
mutation	O
.	O

The	O
germline	O
t	O
-	O
to	O
-	O
ampere	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307K	O
allelomorph	O
exchange	O
the	O
hazardous	O
-	O
type	O
sequence	O
to	O
ampere	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
fluid	O
and	O
prostrate	O
to	O
corporal	O
sport	O
.	O

The	O
germline	O
T	O
-	O
-	O
A	O
transversion	O
responsible	O
for	O
the	O
APC	O
converts	O
the	O
wild	O
type	O
to	O
a	O
homopolymer	O
A8	O
unstable	O
and	O
prone	O
somatic	O
mutation	O

The	O
germline	O
unstable	O
-	O
to	O
mutation	O
A	O
transversion	O
responsible	O
for	O
the	O
)	O
sequence	O
allele	O
converts	O
that	O
wild	O
-	O
and	O
I1307K	O
to	O
prone	O
homopolymer	O
-	O
(	O
the	O
APC	O
a	O
A8	O
genetically	O
T	O
type	O
is	O
to	O
somatic	O
tract	O
.	O

The	O
germline	O
tetraiodothyronine	O
-	O
to	O
-	O
A	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307K	O
allelomorph	O
converts	O
the	O
unfounded	O
-	O
character	O
episode	O
to	O
a	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
unsound	O
and	O
prostrate	O
to	O
corporeal	O
mutation	O
.	O

The	O
germline	O
mt	O
-	O
to	O
-	O
A	O
transversion	O
creditworthy	O
for	O
the	O
APC	O
I1307K	O
allelomorph	O
converts	O
the	O
barbarian	O
-	O
type	O
successiveness	O
to	O
a	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
precarious	O
and	O
prostrate	O
to	O
corporal	O
mutation	O
.	O

The	O
germline	O
T	O
-	O
to	O
-	O
A	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307K	O
allele	O
converts	O
the	O
wild	O
-	O
type	O
sequence	O
to	O
a	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
unstable	O
and	O
prone	O
to	O
somatic	O
mutation	O
.	O

6	O
I1307K	O
allele	O
was	O
.	O
in	O
The	O
found	O

The	O
I1307K	O
allele	O
was	O
retrieve	O
in	O
six	O
.	O

allele	O
in	O
6	O
.	O

The	O
cost	O
allelomorph	O
I1307K	O
allele	O
was	O
found	O
in	O
6	O
.	O

The	O
allele	O
was	O
6	O
.	O

The	O
found	O
allele	O
was	O
I1307K	O
in	O
.	O
6	O

.	O
was	O
allele	O
I1307K	O
found	O
in	O
6	O
The	O

The	O
cost	O
receive	O
I1307K	O
allele	O
was	O
found	O
in	O
6	O
.	O

The	O
I1307K	O
allelomorph	O
was	O
found	O
in	O
sextet	O
.	O

The	O
cost	O
receive	O
I1307K	O
allele	O
was	O
found	O
in	O
6	O
.	O

The	O
I1307K	O
allele	O
was	O
found	O
in	O
6	O
.	O

1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	B
	O
referee	O
	O
	O
proportion	O
proportion	O
proportion	O
(	O
ref	O
.	O
2	O
)	O
.	O

of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
(	O
.	O
2	O
)	O
.	O

i	O
%	O
of	O
unselected	O
ashkenazi	O
Jews	O
and	O
mellow	O
ratio	O
of	O
ashkenazi	O
with	O
family	O
or	O
personal	O
story	O
of	O
CRC	B
(	O
ref	O
.	O
ii	O
)	O
.	O

1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
proportions	O
of	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	B
.	O
2	O
)	O
.	O

1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	B
	O
referee	O
	O
	O
proportion	O
proportion	O
proportion	O
(	O
ref	O
.	O
2	O
)	O
.	O

1	O
%	O
of	O
unselected	O
ashkenazi	O
Jews	O
and	O
gamey	O
dimension	O
of	O
ashkenazi	O
with	O
category	O
or	O
personal	O
chronicle	O
of	O
CRC	B
(	O
ref	O
.	O
deuce	O
)	O
.	O

unity	O
%	O
of	O
unselected	O
ashkenazi	O
Jews	O
and	O
higher	O
proportionality	O
of	O
ashkenazi	O
with	O
kinfolk	O
or	O
personal	O
history	O
of	O
CRC	B
(	O
ref	O
.	O
two	O
)	O
.	O

1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
Ashkenazim	O
or	O
personal	O
histories	O
of	O
CRC	B
(	O
ref	O
.	O
2	O

1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	B
	O
referee	O
	O
	O
proportion	O
proportion	O
proportion	O
(	O
ref	O
.	O
2	O
)	O
.	O

CRC	O
%	O
of	O
Ashkenazim	O
Ashkenazi	O
Jews	O
and	O
(	O
.	O
of	O
unselected	O
with	O
family	O
or	O
)	O
histories	O
of	O
.	B
higher	O
1	O
ref	O
2	O
personal	O
proportions	O

1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	B
(	O
ref	O
.	O
2	O
)	O
.	O

To	O
judge	O
the	O
character	O
of	O
I1307K	O
in	O
cancer	B
,	O
we	O
genotyped	O
5	O
,	O
081	O
ashkenazi	O
tennessean	O
in	O
a	O
community	O
sketch	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	B
,	O
we	O
genotyped	O
5	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
sight	O
part	O
part	O
part	O
part	O
part	O
community	O
survey	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	B
,	O
we	O
genotyped	O
5	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
sight	O
part	O
part	O
part	O
part	O
part	O
community	O
survey	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	B
we	O
genotyped	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
community	O

Ashkenazi	O
evaluate	O
,	O
in	O
of	O
I1307K	O
volunteers	O
cancer	B
the	O
we	O
genotyped	O
5	O
.	O
081	O
role	O
To	O
in	O
a	O
community	O
survey	O
,	O

To	O
value	O
the	O
office	O
of	O
I1307K	O
in	O
cancer	B
,	O
we	O
genotyped	O
quintet	O
,	O
081	O
ashkenazi	O
tennessean	O
in	O
a	O
community	O
sight	O
.	O

.	O
evaluate	O
the	O
genotyped	O
of	O
I1307K	O
in	O
community	B
Ashkenazi	O
we	O
role	O
5	O
081	O
,	O
,	O
volunteers	O
in	O
a	O
cancer	O
To	O
survey	O

To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	B
,	O
we	O
genotyped	O
5	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
sight	O
part	O
part	O
part	O
part	O
indium	O
community	O
survey	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	B
,	O
we	O
genotyped	O
5	O
,	O
Ashkenazi	O
a	O
community	O
survey	O
.	O

To	O
evaluate	O
the	O
purpose	O
of	O
I1307K	O
in	O
cancer	B
,	O
we	O
genotyped	O
phoebe	O
,	O
081	O
ashkenazi	O
volunteers	O
in	O
a	O
community	O
sight	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	B
,	O
we	O
genotyped	O
5	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
community	O
survey	O
.	O

of	O
developing	O
colorectal	B
,	I
breast	I
and	I
other	I
cancers	I
were	O
compared	O
between	O
genotyped	O
I1307K	O
carriers	O
and	O
-	O
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

compared	O
of	O
developing	O
carriers	B
,	I
breast	I
and	I
.	I
degree	I
were	O
relatives	O
between	O
genotyped	O
and	O
-	O
and	O
non	O
-	O
colorectal	O
I1307K	O
their	O
first	O
carriers	O
cancers	O
Risk	O
other	O

Risk	O
of	O
prepare	O
colorectal	B
,	I
breast	I
and	I
other	I
crab	I
were	O
equate	O
between	O
genotyped	O
I1307K	O
carriers	O
and	O
not	O
-	O
carriers	O
and	O
their	O
first	O
-	O
point	O
congener	O
.	O

Risk	O
of	O
developing	O
colorectal	B
,	I
bosom	I
and	I
other	I
cancers	I
were	O
equate	O
between	O
genotyped	O
I1307K	O
mailman	O
and	O
not	O
-	O
mailman	O
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

Risk	O
of	O
developing	O
colorectal	B
,	I
breast	I
and	I
other	I
cancers	I
were	O
between	O
genotyped	O
carriers	O
and	O
non	O
-	O
carriers	O
and	O
their	O
degree	O
relatives	O
.	O

Risk	O
of	O
developing	O
colorectal	B
not	B
,	I
breast	I
and	I
other	I
cancers	I
were	O
compared	O
between	O
genotyped	O
I1307K	O
carriers	O
and	O
non	O
-	O
build	O
up	O
stage	O
congeneric	O
stage	O
congeneric	O
cancer	O
the	O
crab	O
carriers	O
and	O
their	O
first	O
-	O

Risk	O
of	O
developing	O
colorectal	B
not	B
,	I
breast	I
and	I
other	I
cancers	I
were	O
compared	O
between	O
genotyped	O
I1307K	O
carriers	O
and	O
non	O
-	O
build	O
up	O
stage	O
congeneric	O
stage	O
congeneric	O
not	O
carriers	O
and	O
their	O
first	O
-	O
degree	O
relatives	O

Risk	O
of	O
developing	O
colorectal	B
,	I
breast	I
and	I
other	I
cancers	I
were	O
between	O
carriers	O
and	O
non	O
-	O
carriers	O
and	O
their	O
first	O
-	O

degree	O
of	O
developing	O
colorectal	B
,	I
breast	I
I1307K	I
non	I
cancers	I
were	O
compared	O
between	O
first	O
and	O
relatives	O
and	O
other	O
their	O
carriers	O
and	O
Risk	O
genotyped	O
-	O
-	O
carriers	O
.	O

Risk	O
of	O
prepare	O
colorectal	B
,	I
summit	I
and	I
other	I
cancers	I
were	O
equate	O
between	O
genotyped	O
I1307K	O
carriers	O
and	O
not	O
-	O
carriers	O
and	O
their	O
first	O
-	O
degree	O
relation	O
.	O

Risk	O
of	O
developing	O
colorectal	B
,	I
breast	I
and	I
other	I
cancers	I
were	O
compared	O
between	O
genotyped	O
I1307K	O
carriers	O
and	O
non	O
-	O
carriers	O
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B
ataxia	I
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
enlargement	O
in	O
the	O
FRDA	B
factor	O
.	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B
ataxia	I
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B
ataxia	I
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

analysis	O
Friedreich	B
ataxia	I
premutation	O
suggests	O
both	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B
gene	O
.	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
premutation	O
carrier	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B
gene	O
.	O

analysis	O
in	O
a	O
Friedreich	B
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
mitotic	O
expansion	O
in	O
the	O
gene	O
.	O

FRDA	O
DNA	O
analysis	O
gene	O
a	O
Friedreich	B
ataxia	I
carrier	O
premutation	O
suggests	O
expansion	O
meiotic	O
and	O
.	O
Sperm	O
in	O
the	O
both	B
in	O
mitotic	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B
ataxia	I
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B
ataxy	I
premutation	O
carrier	O
evoke	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B
factor	O
.	O

the	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B
mitotic	I
meiotic	O
carrier	O
suggests	O
both	O
expansion	O
Sperm	O
ataxia	O
premutation	O
FRDA	O
and	O
in	B
gene	O
.	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B
ataxia	I
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B
gene	O
.	O

Friedreich	B
dyssynergia	I
is	O
unremarkably	O
caused	O
by	O
an	O
elaboration	O
of	O
a	O
GAA	O
trinucleotide	O
recur	O
in	O
intron	O
single	O
of	O
the	O
FRDA	B
cistron	O
.	O

Friedreich	B
ataxia	I
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
factor	O
cost	O
cost	O
cost	O
cost	O
cost	O
FRDA	B
gene	O
.	O

Friedreich	B
ataxia	I
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
factor	O
cost	O
cost	O
cost	O
cost	O
cost	O
FRDA	B
gene	O
.	O

Friedreich	B
ataxia	I
is	O
usually	O
caused	O
by	O
an	O
expansion	O
a	O
GAA	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
FRDA	B

intron	B
ataxia	I
of	O
an	O
caused	O
by	O
1	O
expansion	O
is	O
a	O
GAA	O
trinucleotide	O
.	O
in	O
usually	O
Friedreich	O
of	O
the	O
FRDA	B
gene	O
repeat	O

Friedreich	B
dyssynergia	I
is	O
normally	O
get	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
recur	O
in	O
intron	O
ane	O
of	O
the	O
FRDA	B
factor	O
.	O

.	B
ataxia	I
is	O
GAA	O
caused	O
by	O
an	O
FRDA	O
intron	O
a	O
usually	O
trinucleotide	O
in	O
repeat	O
of	O
1	O
of	O
the	O
expansion	B
Friedreich	O
gene	O

Friedreich	B
ataxia	I
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
factor	O
cost	O
cost	O
cost	O
cost	O
associate	O
in	B
nursing	O
FRDA	O

Friedreich	B
ataxia	I
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
intron	O
the	O
FRDA	B
gene	O
.	O

Friedreich	B
ataxia	I
is	O
unremarkably	O
do	O
by	O
an	O
enlargement	O
of	O
a	O
GAA	O
trinucleotide	O
reiterate	O
in	O
intron	O
single	O
of	O
the	O
FRDA	B
cistron	O
.	O

Friedreich	B
ataxia	I
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
FRDA	B
gene	O
.	O

occasionally	O
,	O
a	O
fully	O
elaborate	O
allelomorph	O
has	O
been	O
detect	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
three	O
reprise	O
.	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
iterate	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
triplet	O
repeats	O
.	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
iterate	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
triplet	O
repeats	O
.	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
to	O
arise	O
a	O
premutation	O
of	O
100	O
or	O
less	O
triplet	O

of	O
,	O
found	O
has	O
expanded	O
allele	O
100	O
been	O
a	O
to	O
arise	O
from	O
.	O
premutation	O
fully	O
Occasionally	O
or	O
less	O
triplet	O
repeats	O
a	O

Occasionally	O
,	O
a	O
fully	O
boom	O
allelomorph	O
has	O
been	O
encounter	O
to	O
rebel	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
tercet	O
retell	O
.	O

.	O
,	O
a	O
arise	O
expanded	O
allele	O
has	O
triplet	O
of	O
to	O
fully	O
from	O
premutation	O
a	O
found	O
100	O
or	O
less	O
been	O
Occasionally	O
repeats	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
iterate	O
ampere	O
ampere	O
ampere	O
ampere	O
operating	O
theatre	O
triplet	O
repeats	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
of	O
less	O
triplet	O
repeats	O
.	O

Occasionally	O
,	O
a	O
fully	O
enlarge	O
allelomorph	O
has	O
been	O
chance	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
iii	O
reprize	O
.	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
triplet	O
repeats	O
.	O

We	O
have	O
prove	O
the	O
sperm	O
dna	O
of	O
a	O
premutation	O
carrier	O
.	O

We	O
have	O
examined	O
the	O
sperm	O
DNA	O
of	O
a	O
premutation	O
receive	O
receive	O
receive	O
carrier	O
.	O

We	O
have	O
study	O
the	O
sperm	O
dna	O
of	O
a	O
premutation	O
carrier	O
.	O

We	O
have	O
probe	O
the	O
sperm	O
DNA	O
of	O
a	O
premutation	O
carrier	O
.	O

have	O
examined	O
sperm	O
DNA	O
of	O
a	O
premutation	O
carrier	O
.	O

a	O
have	O
examined	O
sperm	O
the	O
DNA	O
carrier	O
We	O
premutation	O
of	O
.	O

We	O
a	O
examined	O
the	O
have	O
DNA	O
of	O
.	O
premutation	O
carrier	O
sperm	O

the	O
a	O
examined	O
of	O
sperm	O
DNA	O
We	O
have	O
premutation	O
carrier	O
.	O

We	O
examined	O
sperm	O
of	O
a	O
premutation	O
carrier	O
.	O

We	O
have	O
examined	O
the	O
sperm	O
DNA	O
of	O
a	O
premutation	O
receive	O
receive	O
receive	O
carrier	O
.	O

We	O
have	O
examined	O
the	O
sperm	O
DNA	O
of	O
a	O
premutation	O
carrier	O
.	O

This	O
mans	O
convention	O
allelomorph	O
white	O
cell	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
and	O
one	O
allele	O
of	O
approximately	O
100	O
repeats	O
	O

100	O
mans	O
leucocyte	O
.	O
showed	O
one	O
normal	O
allele	O
repeats	O
one	O
allele	O
of	O
This	O
approximately	O
and	O
DNA	O

This	O
mans	O
convention	O
allelomorph	O
convention	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
and	O
one	O
allele	O
of	O
approximately	O
100	O
repeats	O
	O
.	O

This	O
mans	O
wbc	O
DNA	O
demonstrate	O
peerless	O
normal	O
allele	O
and	O
peerless	O
allele	O
of	O
approximately	O
100	O
echo	O
.	O

approximately	O
mans	O
leucocyte	O
allele	O
showed	O
one	O
100	O
DNA	O
and	O
one	O
This	O
of	O
allele	O
normal	O
repeats	O
.	O

This	O
mans	O
convention	O
allelomorph	O
white	O
cell	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
and	O
one	O
allele	O
of	O
approximately	O
100	O
repeats	O
	O

This	O
mans	O
leucocyte	O
DNA	O
usher	O
single	O
pattern	O
allelomorph	O
and	O
single	O
allelomorph	O
of	O
approximately	O
100	O
repeats	O
.	O

This	O
mans	O
leucocyte	O
DNA	O
demonstrate	O
ane	O
normal	O
allele	O
and	O
ane	O
allele	O
of	O
about	O
100	O
repetition	O
.	O

This	O
mans	O
and	O
.	O
showed	O
one	O
approximately	O
allele	O
leucocyte	O
one	O
allele	O
of	O
normal	O
100	O
DNA	O
repeats	O

mans	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
allele	O
of	O
approximately	O
100	O
repeats	O
.	O

This	O
mans	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
and	O
one	O
allele	O
of	O
approximately	O
100	O
repeats	O
.	O

His	O
sperm	O
showed	O
an	O
amplify	O
allele	O
in	O
a	O
wet	O
roam	O
pore	O
on	O
a	O
sizing	O
of	O
approximately	O
320	O
trinucleotide	O
retell	O
.	O

His	O
sperm	O
showed	O
an	O
expanded	O
allele	O
in	O
a	O
tight	O
range	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
repeats	O
.	O

His	O
sperm	O
showed	O
an	O
expanded	O
allele	O
in	O
a	O
tight	O
range	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
repeats	O
.	O

showed	O
allele	O
in	O
a	O
range	O
centering	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
repeats	O
.	O

His	O
sperm	O
showed	O
an	O
expanded	O
a	O
tight	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
repeats	O
.	O

showed	O
an	O
expanded	O
allele	O
a	O
tight	O
range	O
centering	O
on	O
size	O
of	O
approximately	O
320	O
repeats	O
.	O

trinucleotide	O
sperm	O
showed	O
repeats	O
expanded	O
allele	O
in	O
tight	O
a	O
range	O
of	O
on	O
a	O
.	O
His	O
approximately	O
320	O
centering	O
an	O
size	O

His	O
sperm	O
showed	O
an	O
expanded	O
allele	O
in	O
a	O
tight	O
range	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
usher	O
usher	O
usher	O
usher	O
usher	O
roll	O
repeats	O
.	O

His	O
sperm	O
read	O
an	O
elaborate	O
allelomorph	O
in	O
a	O
plastered	O
range	O
pore	O
on	O
a	O
size	O
of	O
around	O
320	O
trinucleotide	O
repeats	O
.	O

320	O
sperm	O
showed	O
an	O
expanded	O
allele	O
size	O
on	O
tight	O
range	O
centering	O
of	O
His	O
in	O
a	O
trinucleotide	O
a	O
approximately	O
repeats	O
.	O

His	O
sperm	O
showed	O
an	O
expanded	O
allele	O
in	O
a	O
tight	O
range	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
repeats	O
.	O

His	O
affected	O
boy	O
has	O
recur	O
sizes	O
of	O
1040	O
and	O
540	O
.	O

His	O
affected	O
son	O
has	O
repeat	O
sizes	O
of	O
1040	O
and	O
touched	O
touched	O
touched	O
540	O
.	O

His	O
strike	O
logos	O
has	O
retell	O
sizes	O
of	O
1040	O
and	O
540	O
.	O

His	O
impact	O
logos	O
has	O
ingeminate	O
sizes	O
of	O
1040	O
and	O
540	O
.	O

affected	O
son	O
repeat	O
sizes	O
of	O
1040	O
and	O
540	O
.	O

1040	O
affected	O
son	O
repeat	O
has	O
sizes	O
540	O
His	O
and	O
of	O
.	O

His	O
1040	O
son	O
has	O
affected	O
sizes	O
of	O
.	O
and	O
540	O
repeat	O

has	O
1040	O
son	O
of	O
repeat	O
sizes	O
His	O
affected	O
and	O
540	O
.	O

His	O
son	O
repeat	O
of	O
1040	O
and	O
540	O
.	O

His	O
affected	O
son	O
has	O
repeat	O
sizes	O
of	O
1040	O
and	O
touched	O
touched	O
touched	O
540	O
.	O

His	O
affected	O
son	O
has	O
repeat	O
sizes	O
of	O
1040	O
and	O
540	O
.	O

These	O
data	O
advise	O
that	O
expansion	O
happen	O
in	O
ii	O
stages	O
,	O
the	O
offset	O
during	O
miosis	O
adopt	O
by	O
a	O
second	O
mitotic	O
expansion	O
.	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
elaboration	O
propose	O
propose	O
propose	O
propose	O
propose	O
mitotic	O
expansion	O
.	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
elaboration	O
propose	O
propose	O
propose	O
propose	O
propose	O
mitotic	O
expansion	O
.	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
,	O
the	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
mitotic	O

followed	O
data	O
stages	O
in	O
expansion	O
occurs	O
by	O
two	O
suggest	O
,	O
the	O
first	O
.	O
meiosis	O
that	O
These	O
a	O
second	O
mitotic	O
expansion	O
during	O

These	O
information	O
propose	O
that	O
enlargement	O
occurs	O
in	O
deuce	O
shop	O
,	O
the	O
first	O
during	O
miosis	O
followed	O
by	O
a	O
second	O
mitotic	O
enlargement	O
.	O

.	O
data	O
suggest	O
the	O
expansion	O
occurs	O
in	O
mitotic	O
followed	O
,	O
that	O
first	O
meiosis	O
during	O
stages	O
by	O
a	O
second	O
two	O
These	O
expansion	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
elaboration	O
propose	O
propose	O
propose	O
propose	O
litotes	O
mitotic	O
expansion	O
.	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
followed	O
second	O
mitotic	O
expansion	O
.	O

These	O
datum	O
suggest	O
that	O
enlargement	O
occurs	O
in	O
ii	O
snoop	O
,	O
the	O
first	O
during	O
meiosis	O
be	O
by	O
a	O
indorsement	O
mitotic	O
enlargement	O
.	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
mitotic	O
expansion	O
.	O

We	O
also	O
register	O
that	O
in	O
all	O
informatory	O
carrier	O
father	O
to	O
moved	O
tyke	O
transmissions	O
,	O
with	O
the	O
noted	O
elision	O
of	O
the	O
premutation	O
carrier	O
,	O
the	O
elaboration	O
size	O
lessen	O
.	O
.	O

We	O
also	O
show	O
that	O
in	O
informative	O
to	O
affected	O
child	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
,	O
the	O
expansion	O
size	O
decreases	O
.	O
.	O

premutation	O
also	O
show	O
of	O
in	O
all	O
informative	O
size	O
the	O
to	O
.	O
child	O
transmissions	O
the	O
,	O
the	O
notable	O
exception	O
that	O
,	O
expansion	O
carrier	O
with	O
father	O
We	O
carrier	O
decreases	O
.	O
affected	O

We	O
also	O
show	O
that	O
transmitting	O
indium	O
whole	O
instructive	O
indium	O
in	O
all	O
informative	O
carrier	O
father	O
to	O
affected	O
child	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
sizing	O
lessen	O
beginner	O
of	O
the	O
premutation	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O
.	O
.	O

We	O
also	O
show	O
that	O
transmitting	O
indium	O
whole	O
instructive	O
indium	O
in	O
all	O
informative	O
carrier	O
father	O
to	O
affected	O
child	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
sizing	O
lessen	O
attack	O
aircraft	O
carrier	O
of	O
the	O
premutation	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O

We	O
also	O
show	O
that	O
in	O
all	O
informative	O
carrier	O
to	O
affected	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
of	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O
.	O
.	O

.	O
also	O
show	O
with	O
in	O
all	O
size	O
carrier	O
that	O
to	O
affected	O
child	O
decreases	O
,	O
expansion	O
father	O
notable	O
exception	O
of	O
the	O
transmissions	O
carrier	O
,	O
the	O
the	O
informative	O
premutation	O
.	O
We	O

We	O
also	O
show	O
that	O
in	O
all	O
informative	O
carrier	O
to	O
child	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
of	O
premutation	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O

We	O
also	O
show	O
that	O
in	O
all	O
illuminating	O
newsboy	O
get	O
to	O
sham	O
fry	O
transmittal	O
,	O
with	O
the	O
celebrated	O
exception	O
of	O
the	O
premutation	O
newsboy	O
,	O
the	O
expansion	O
size	O
lessening	O
.	O
.	O

We	O
too	O
show	O
that	O
in	O
all	O
enlightening	O
flattop	O
beget	O
to	O
affected	O
child	O
transmitting	O
,	O
with	O
the	O
notable	O
exclusion	O
of	O
the	O
premutation	O
flattop	O
,	O
the	O
expansion	O
sizing	O
fall	O
.	O
.	O

We	O
also	O
show	O
that	O
in	O
all	O
informative	O
carrier	O
father	O
to	O
affected	O
child	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
of	O
the	O
premutation	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O
.	O
.	O

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
non	O
non	O
non	O
metachromatic	B
leukodystrophy	I
.	O

R496H	O
mutation	O
does	O
metachromatic	B
leukodystrophy	I
.	O

The	O
R496H	O
variation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
metachromatic	B
leukodystrophy	I
.	O

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
non	O
non	O
non	O
metachromatic	B
leukodystrophy	I
.	O

R496H	O
mutation	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
metachromatic	B
leukodystrophy	I
.	O

The	O
R496H	O
sport	O
of	O
arylsulfatase	O
axerophthol	O
does	O
not	O
effort	O
metachromatic	B
leukodystrophy	I
.	O

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
non	O
non	O
dress	O
metachromatic	B
leukodystrophy	I
.	O

The	O
R496H	O
mutant	O
of	O
arylsulfatase	O
A	O
does	O
not	O
grounds	O
metachromatic	B
leukodystrophy	I
.	O

The	O
not	O
mutation	O
of	O
R496H	O
A	O
does	O
leukodystrophy	O
cause	O
metachromatic	B
arylsulfatase	I
.	O

.	O
R496H	O
mutation	O
of	O
not	O
A	O
metachromatic	O
arylsulfatase	O
cause	O
does	B
leukodystrophy	I
The	O

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
metachromatic	B
leukodystrophy	I
.	O

Deficiency	B
of	I
arylsulfatase	I
A	I
(	O
ARSA	O
activity	O
causes	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

enzyme	B
of	I
arylsulfatase	I
metachromatic	I
(	O
ARSA	O
MLD	O
Deficiency	O
activity	O
causes	O
A	B
leukodystrophy	I
(	O
)	B
)	O
.	O

)	B
of	I
arylsulfatase	I
A	I
(	O
ARSA	O
)	O
activity	O
enzyme	O
causes	O
metachromatic	B
leukodystrophy	I
MLD	O
(	B
.	O
Deficiency	O

Deficiency	B
of	I
carry	I
out	I
inadequacy	I
action	I
arylsulfatase	I
A	O
(	O
ARSA	O
)	O
enzyme	O
activity	O
causes	B
metachromatic	I
leukodystrophy	O
(	B
MLD	O
)	O

Deficiency	B
of	I
carry	I
out	I
inadequacy	I
action	I
arylsulfatase	I
A	O
(	O
ARSA	O
)	O
enzyme	O
activity	O
causes	B
metachromatic	I
leukodystrophy	O
(	B
MLD	O
)	O

deficiency	B
of	I
arylsulfatase	I
angstrom	I
(	O
ARSA	O
)	O
enzyme	O
activity	O
suit	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

deficiency	B
of	I
arylsulfatase	I
A	I
(	O
ARSA	O
)	O
enzyme	O
action	O
drive	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

Deficiency	B
of	I
insufficiency	I
inadequacy	I
inadequacy	I
arylsulfatase	I
A	I
(	O
ARSA	O
)	O
enzyme	O
activity	O
causes	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

Deficiency	B
of	I
arylsulfatase	I
A	I
(	O
)	O
causes	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

want	B
of	I
arylsulfatase	I
ampere	I
(	O
ARSA	O
)	O
enzyme	O
activity	O
drive	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

Deficiency	B
of	I
arylsulfatase	I
A	I
(	O
ARSA	O
)	O
enzyme	O
activity	O
causes	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

A	O
of	O
ARSA	O
mutations	O
for	O
have	O
been	O
identified	O
.	O

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B
have	O
been	O
identified	O

A	O
number	O
of	O
ARSA	O
factor	O
mutations	O
creditworthy	O
for	O
MLD	B
have	O
been	O
name	O
.	O

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B
place	O
place	O
numerate	O
have	O
been	O
identified	O
.	O

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B
place	O
place	O
ampere	O
have	O
been	O
identified	O
.	O

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B
place	O
place	O
numerate	O
have	O
been	O
identified	O
.	O

axerophthol	O
act	O
of	O
ARSA	O
cistron	O
mutations	O
responsible	O
for	O
MLD	B
have	O
been	O
identified	O
.	O

A	O
number	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B
have	O
.	O

A	O
numeral	O
of	O
ARSA	O
factor	O
mutations	O
creditworthy	O
for	O
MLD	B
have	O
been	O
identified	O
.	O

A	O
gene	O
of	O
ARSA	O
.	O
mutations	O
responsible	O
number	O
MLD	B
have	O
been	O
identified	O
for	O

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B
(	O
Draghia	O
et	O
camellia	O
state	O
declare	O
oneself	O
declare	O
oneself	O
declare	O
oneself	O
declare	O
oneself	O
declare	O
oneself	O
ampere	O

the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B
(	O
Draghia	O
al	O
,	O
1997	O
)	O
.	O

latterly	O
,	O
the	O
R496H	O
variation	O
of	O
ARSA	O
was	O
aim	O
to	O
be	O
a	O
reason	O
of	O
MLD	B
(	O
Draghia	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
proposed	O
to	O
a	O
cause	O
of	O
MLD	B
(	O
Draghia	O
et	O
,	O
1997	O
)	O
.	O

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B
(	O
Draghia	O
et	O
camellia	O
state	O
declare	O
oneself	O
declare	O
oneself	O
declare	O
oneself	O
declare	O
oneself	O
declare	O
oneself	O
declare	O

lately	O
,	O
the	O
R496H	O
sport	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
reason	O
of	O
MLD	B
(	O
Draghia	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

lately	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B
(	O
Draghia	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
be	O
of	O
MLD	B
(	O
Draghia	O
et	O
al	O
.	O
,	O
1997	O

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B
(	O
Draghia	O
et	O
camellia	O
state	O
declare	O
oneself	O
declare	O
oneself	O
declare	O
oneself	O
declare	O
oneself	O
declare	O
oneself	O
declare	O

et	O
,	O
the	O
be	O
mutation	O
of	O
ARSA	O
al	O
.	O
to	O
R496H	O
a	O
cause	O
of	O
)	B
(	O
Draghia	O
,	O
was	O
Recently	O
.	O
1997	O
MLD	O
proposed	O

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B
(	O
Draghia	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

We	O
have	O
investigated	O
the	O
high	O
up	O
frequence	O
indium	O
associate	O
in	O
nursing	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
09	O
,	O
n	O
=	O
61	O
subjects	O
)	O
comparatively	O
comparatively	O
comparatively	O

We	O
have	O
investigated	O
mutation	O
at	O
a	O
relatively	O
frequency	O
in	O
African	O
American	O
population	O
=	O
0	O
.	O
09	O
,	O
=	O
subjects	O
)	O
.	O

We	O
have	O
investigated	O
the	O
R496H	O
mutant	O
and	O
found	O
this	O
mutant	O
at	O
a	O
comparatively	O
high	O
frequence	O
in	O
an	O
african	O
American	O
universe	O
(	O
f	O
=	O
nought	O
.	O
09	O
,	O
n	O
=	O
61	O
field	O
)	O
.	O

We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
and	O
this	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
.	O
09	O
,	O
n	O
=	O
61	O
subjects	O
)	O
.	O

We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
and	O
witness	O
this	O
mutation	O
at	O
a	O
comparatively	O
high	O
oftenness	O
in	O
an	O
african	O
American	O
universe	O
(	O
f	O
=	O
nought	O
.	O
09	O
,	O
n	O
=	O
61	O
discipline	O
)	O
.	O

We	O
have	O
investigated	O
the	O
high	O
up	O
frequence	O
indium	O
associate	O
in	O
nursing	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
09	O
,	O
n	O
=	O
61	O
subjects	O
)	O
comparatively	O
comparatively	O
comparatively	O

We	O
have	O
enquire	O
the	O
R496H	O
mutation	O
and	O
ground	O
this	O
mutation	O
at	O
a	O
comparatively	O
mellow	O
frequency	O
in	O
an	O
african	O
American	O
universe	O
(	O
f	O
=	O
nought	O
.	O
09	O
,	O
n	O
=	O
61	O
matter	O
)	O
.	O

(	O
American	O
investigated	O
the	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
.	O
61	O
in	O
an	O
African	O
n	O
population	O
have	O
f	O
)	O
0	O
high	O
09	O
,	O
We	O
frequency	O
=	O
subjects	O
=	O
.	O

We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
found	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
n	O
=	O
61	O
)	O

We	O
have	O
investigated	O
the	O
high	O
up	O
frequence	O
indium	O
comparatively	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
09	O
,	O
n	O
=	O
61	O
subjects	O
)	O
comparatively	O
comparatively	O
comparatively	O
comparatively	O
comparatively	O

We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
09	O
,	O
n	O
=	O
61	O
subjects	O
)	O
.	O

The	O
ARSA	O
enzyme	O
action	O
in	O
theme	O
with	O
and	O
without	O
the	O
R496H	O
variation	O
was	O
determined	O
and	O
base	O
to	O
be	O
pattern	O
.	O

The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
action	O
action	O
action	O
action	O
action	O
action	O
normal	O
.	O

The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
action	O
action	O
action	O
action	O
action	O
action	O
normal	O
.	O

enzyme	O
subjects	O
with	O
and	O
the	O
R496H	O
was	O
determined	O
and	O
found	O
to	O
be	O
normal	O
.	O

The	O
ARSA	O
enzyme	O
activity	O
in	O
and	O
without	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
normal	O
.	O

enzyme	O
activity	O
in	O
subjects	O
and	O
without	O
the	O
R496H	O
mutation	O
determined	O
and	O
found	O
to	O
normal	O
.	O

be	O
ARSA	O
enzyme	O
normal	O
in	O
subjects	O
with	O
without	O
and	O
the	O
and	O
mutation	O
was	O
.	O
The	O
found	O
to	O
R496H	O
activity	O
determined	O

The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
action	O
action	O
action	O
action	O
action	O
shape	O
normal	O
.	O

The	O
ARSA	O
enzyme	O
activeness	O
in	O
bailiwick	O
with	O
and	O
without	O
the	O
R496H	O
mutant	O
was	O
determined	O
and	O
feel	O
to	O
be	O
pattern	O
.	O

to	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
determined	O
mutation	O
without	O
the	O
R496H	O
and	O
The	O
with	O
and	O
be	O
was	O
found	O
normal	O
.	O

The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
normal	O
.	O

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
ampere	O
causal	O
agent	O
ampere	O
causal	O
agent	O
causal	O
agent	O
consequently	O
shape	O
and	O
is	O
not	O
a	B

concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
is	O
a	O
cause	O
of	O
MLD	B

It	O
is	O
thus	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
regulate	O
the	O
action	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
causa	O
of	O
MLD	B

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
not	O
negatively	O
the	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
of	O
MLD	B

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
ampere	O
causal	O
agent	O
ampere	O
causal	O
agent	O
causal	O
agent	O
consequently	O
consequently	O
and	O
is	O
not	O
a	B

It	O
is	O
so	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
work	O
the	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
make	O
of	O
MLD	B

it	O
is	O
thence	O
ended	O
that	O
the	O
R496H	O
sport	O
of	O
ARSA	O
does	O
not	O
negatively	O
mold	O
the	O
action	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
do	O
of	O
MLD	B

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
negatively	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
cause	O
of	O

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
ampere	O
causal	O
agent	O
ampere	O
causal	O
agent	O
causal	O
agent	O
consequently	O
consequently	O
and	O
is	O
not	O
a	B

is	O
is	O
therefore	O
does	O
that	O
the	O
R496H	O
and	O
of	O
ARSA	O
concluded	O
not	O
influence	O
negatively	O
cause	O
activity	O
of	O
ARSA	O
mutation	O
MLD	O
not	O
a	O
the	O
of	O
It	B

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
cause	O
of	O
MLD	B

Down	O
-	O
regulation	O
in	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B
Hippel	I
-	I
Lindau	I
transgenes	O

Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
wild	O
von	B
Hippel	I
-	I
Lindau	I
transgenes	O
.	O

Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B
regulating	B
transgene	B
transgene	B
regulating	B
regulating	B
regulating	B
Hippel	I
-	I
Lindau	I
transgenes	O
.	O

downhearted	O
-	O
regulating	O
of	O
transmembrane	O
carbonaceous	O
anhydrases	O
in	O
nephritic	B
cell	I
carcinoma	I
cell	O
crinkle	O
by	O
wild	O
-	O
eccentric	O
von	B
Hippel	I
-	I
Lindau	I
transgenes	O
.	O

Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B
regulating	B
transgene	B
transgene	B
regulating	B
regulating	B
regulating	B
Hippel	I
-	I
Lindau	I
transgenes	O
.	O

Down	O
-	O
regulating	O
of	O
transmembrane	O
carbonaceous	O
anhydrases	O
in	O
nephritic	B
cell	I
carcinoma	I
cell	O
describe	O
by	O
hazardous	O
-	O
type	O
von	B
Hippel	I
-	I
Lindau	I
transgenes	O
.	O

Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B
cell	I
cell	O
lines	O
wild	O
-	O
type	O
von	B
Hippel	I
-	I
Lindau	I

carcinoma	O
-	O
regulation	O
Hippel	O
transmembrane	O
carbonic	O
anhydrases	O
renal	O
in	B
cell	I
-	I
cell	O
by	O
lines	O
.	O
-	O
type	O
von	B
of	I
Down	I
Lindau	I
transgenes	O
wild	O

devour	O
-	O
regularization	O
of	O
transmembrane	O
carboniferous	O
anhydrases	O
in	O
nephritic	B
cell	I
carcinoma	I
cell	O
lines	O
by	O
unwarranted	O
-	O
eccentric	O
von	B
Hippel	I
-	I
Lindau	I
transgenes	O
.	O

wild	O
-	O
renal	O
anhydrases	O
transmembrane	O
carbonic	O
-	O
in	O
regulation	B
cell	I
carcinoma	I
cell	O
Lindau	O
by	O
of	O
Down	O
type	O
von	B
Hippel	I
-	I
lines	I
transgenes	O
.	O

Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B
Hippel	I
-	I
Lindau	I
transgenes	O
.	O

To	O
discover	O
with	O
involved	O
in	O
)	B
Hippel	I
cell	I
Lindau	I
(	O
VHL	B
stably	O
-	O
mediated	O
carcinogenesis	O
-	O
we	O
used	O
cell	B
renal	I
carcinoma	I
-	O
lines	O
von	O
transfected	O
wild	O
genes	O
transgenes	O
type	O
VHL	O
,	O
-	O
expressing	O
.	O

To	O
involved	O
in	O
von	B
Hippel	I
Lindau	I
(	O
-	O
mediated	O
,	O
we	O
carcinoma	I
lines	O
stably	O
transfected	O
wild	O
-	O
type	O
-	O
expressing	O
transgenes	O
.	O

To	O
discover	O
genes	O
involved	O
waste	O
waste	O
parentage	O
in	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
-	O
mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
stably	O
transfected	O
with	O
wild	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
consume	O
consume	O
consume	O
consume	O
consume	O
intercede	O
.	O

To	O
discover	O
genes	O
involved	O
waste	O
waste	O
indium	O
in	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
-	O
mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
stably	O
transfected	O
with	O
wild	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
consume	O
consume	O
consume	O
consume	O
consume	O
intercede	O
.	O

discover	O
renal	O
genes	O
involved	O
in	O
von	B
wild	I
-	I
Lindau	I
(	O
VHL	B
-	O
-	O
transfected	O
VHL	O
,	O
we	O
used	O
)	B
cell	I
carcinoma	I
cell	O
.	O
stably	O
mediated	O
with	O
Hippel	O
To	O
expressing	O
lines	O
-	O
type	O
transgenes	O
carcinogenesis	O

To	O
discover	O
genes	O
involved	O
in	O
von	B
Lindau	I
(	O
VHL	B
)	O
mediated	O
carcinogenesis	O
,	O
we	O
used	O
cell	I
carcinoma	I
cell	O
lines	O
transfected	O
with	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
.	O

To	O
strike	O
factor	O
knotty	O
in	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
-	O
intercede	O
carcinogenesis	O
,	O
we	O
habituate	O
nephritic	B
cell	I
carcinoma	I
cell	O
lines	O
stably	O
transfected	O
with	O
waste	O
-	O
case	O
VHL	O
-	O
show	O
transgenes	O
.	O

To	O
discover	O
factor	O
regard	O
in	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
-	O
arbitrate	O
carcinogenesis	O
,	O
we	O
apply	O
nephritic	B
cell	I
carcinoma	I
cell	O
furrow	O
stably	O
transfected	O
with	O
waste	O
-	O
character	O
VHL	O
-	O
extract	O
transgenes	O
.	O

To	O
discover	O
genes	O
involved	O
waste	O
waste	O
indium	O
in	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
-	O
mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
stably	O
transfected	O
with	O
wild	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
consume	O
consume	O
consume	O
consume	O
consume	O
intercede	O
.	O

To	O
discover	O
factor	O
byzantine	O
in	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
-	O
intercede	O
carcinogenesis	O
,	O
we	O
victimized	O
nephritic	B
cell	I
carcinoma	I
cell	O
seam	O
stably	O
transfected	O
with	O
baseless	O
-	O
character	O
VHL	O
-	O
utter	O
transgenes	O
.	O

To	O
discover	O
genes	O
involved	O
in	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
-	O
mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
stably	O
transfected	O
with	O
wild	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
.	O

Large	O
scale	O
RNA	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
differentially	O
expressed	O
genes	O
,	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
termed	O
CA12	O
.	O

Large	O
scale	O
RNA	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
differentially	O
expressed	O
,	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O

Large	O
-	O
scale	O
RNA	O
various	O
video	O
display	O
verbalize	O
first	O
derivative	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes	O
,	O
carbonaceous	O
term	O
factor	O
go	O
for	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O

alpha	O
-	O
scale	O
including	O
differential	O
display	O
technology	O
termed	O
gene	O
these	O
an	O
lines	O
identified	O
several	O
anhydrase	O
expressed	O
genes	O
,	O
RNA	O
,	O
cell	O
carbonic	O
differentially	O
to	O
Large	O
applied	O
CA12	O
.	O

CA12	O
-	O
scale	O
differentially	O
differential	O
display	O
termed	O
applied	O
RNA	O
these	O
cell	O
lines	O
several	O
alpha	O
,	O
to	O
genes	O
,	O
including	O
an	O
identified	O
carbonic	O
anhydrase	O
gene	O
expressed	O
technology	O
Large	O
.	O

Large	O
-	O
scale	O
RNA	O
various	O
video	O
display	O
verbalize	O
first	O
derivative	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes	O
,	O
carbonaceous	O
term	O
factor	O
rna	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O
termed	O

expectant	O
-	O
scale	O
RNA	O
differential	O
showing	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
various	O
differentially	O
evince	O
cistron	O
,	O
admit	O
an	O
alpha	O
carbonaceous	O
anhydrase	O
factor	O
,	O
termed	O
CA12	O
.	O

Large	O
-	O
scale	O
RNA	O
various	O
video	O
display	O
verbalize	O
first	O
derivative	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes	O
,	O
carbonaceous	O
term	O
factor	O
rna	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O
termed	O

gene	O
-	O
scale	O
RNA	O
differential	O
display	O
several	O
lines	O
to	O
these	O
cell	O
genes	O
carbonic	O
technology	O
,	O
Large	O
applied	O
expressed	O
including	O
an	O
alpha	O
identified	O
anhydrase	O
,	O
differentially	O
termed	O
CA12	O
.	O

boastfully	O
-	O
exfoliation	O
rna	O
derivative	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
respective	O
differentially	O
expressed	O
genes	O
,	O
admit	O
an	O
alpha	O
carbonaceous	O
anhydrase	O
cistron	O
,	O
termed	O
CA12	O
.	O

Large	O
-	O
scale	O
RNA	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes	O
,	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O
termed	O
CA12	O
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
indium	O
california	O
faculty	O
california	O
faculty	O
faculty	O
area	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	O
.	O

sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
in	O
extracellular	O
CA	O
module	O
.	O

The	O
deduct	O
protein	O
successiveness	O
was	O
classify	O
as	O
a	O
nonpareil	O
-	O
toss	O
transmembrane	O
calcium	O
own	O
an	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
calcium	O
module	O
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
transmembrane	O
CA	O
an	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
module	O
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
indium	O
california	O
faculty	O
california	O
faculty	O
faculty	O
	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	O
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
unmatched	O
-	O
overhaul	O
transmembrane	O
calcium	O
possessing	O
an	O
ostensibly	O
inviolate	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
calcium	O
module	O
.	O

The	O
deduced	O
protein	O
successiveness	O
was	O
classified	O
as	O
a	O
unmatchable	O
-	O
clear	O
transmembrane	O
CA	O
possessing	O
an	O
plain	O
inviolate	O
catalytic	O
orbit	O
in	O
the	O
extracellular	O
CA	O
faculty	O
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
CA	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
indium	O
california	O
faculty	O
california	O
faculty	O
faculty	O
	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	O
.	O

in	O
deduced	O
protein	O
pass	O
was	O
classified	O
as	O
domain	O
module	O
-	O
sequence	O
transmembrane	O
possessing	O
CA	O
CA	O
apparently	O
intact	O
catalytic	O
a	O
.	O
the	O
extracellular	O
an	O
one	O
The	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	O
.	O

lines	O
wild	O
-	O
the	O
VHL	B
strongly	O
inhibited	O
carcinoma	O
the	O
of	O
type	O
CA12	O
in	O
gene	O
overexpression	O
parental	O
renal	B
cell	I
the	I
Reintroduced	O
cell	O
.	O

Reintroduced	O
wild	O
-	O
type	O
VHL	B
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B
cell	I
parentage	I
parentage	O
typecast	I
typecast	O
typecast	I
typecast	O
carcinoma	I
cell	O
lines	O
.	O

Reintroduced	O
wild	O
-	O
type	O
VHL	B
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B
cell	I
parentage	I
parentage	O
typecast	I
typecast	O
typecast	I
typecast	O
carcinoma	I
cell	O
lines	O
.	O

Reintroduced	O
hazardous	O
-	O
type	O
VHL	B
powerfully	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
factor	O
in	O
the	O
maternal	O
nephritic	B
cell	I
carcinoma	I
cell	O
air	O
.	O

Reintroduced	O
wild	O
-	O
VHL	B
strongly	O
inhibited	O
the	O
overexpression	O
the	O
CA12	O
gene	O
in	O
parental	O
renal	B
carcinoma	I
cell	O
lines	O
.	O

type	O
inhibited	O
the	O
overexpression	O
the	O
CA12	O
in	O
the	O
parental	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
.	O

Reintroduced	O
wild	O
-	O
character	O
VHL	B
powerfully	O
subdue	O
the	O
overexpression	O
of	O
the	O
CA12	O
cistron	O
in	O
the	O
paternal	O
nephritic	B
cell	I
carcinoma	I
cell	O
lines	O
.	O

the	O
wild	O
overexpression	O
inhibited	O
VHL	B
strongly	O
parental	O
the	O
-	O
of	O
the	O
CA12	O
lines	O
in	O
type	O
Reintroduced	O
renal	B
cell	I
carcinoma	I
cell	O
gene	O
.	O

Reintroduced	O
wild	O
-	O
type	O
VHL	B
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B
cell	I
parentage	I
parentage	O
typecast	I
typecast	O
typecast	I
parentage	O
carcinoma	I
cell	O
lines	O
.	O

Reintroduced	O
wild	O
-	O
type	O
inhibited	O
the	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B
cell	I
carcinoma	I
.	O

Reintroduced	O
wild	O
-	O
type	O
VHL	B
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
.	O

CA	O
results	O
were	O
encoding	O
with	O
CA9	O
,	O
obtained	O
catalytic	O
transmembrane	O
intact	O
with	O
Similar	O
an	O
another	O
domain	O
.	O

alike	O
solvent	O
were	O
hold	O
with	O
CA9	O
,	O
encode	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
world	O
.	O

interchangeable	O
results	O
were	O
receive	O
with	O
CA9	O
,	O
encryption	O
another	O
transmembrane	O
CA	O
with	O
an	O
inviolate	O
catalytic	O
field	O
.	O

Similar	O
results	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain	O
.	O

Similar	O
resolution	O
were	O
prevail	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
calcium	O
with	O
an	O
inviolate	O
catalytic	O
sphere	O
.	O

Similar	O
results	O
encryption	O
cost	O
were	O
obtained	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain	O
encoding	O
encoding	O
toll	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
CA9	O
,	O
encoding	O
transmembrane	O
CA	O
an	O
intact	O
catalytic	O
domain	O
.	O

Similar	O
results	O
encryption	O
cost	O
were	O
obtained	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain	O
encoding	O
encoding	O
toll	O
.	O

results	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O

Similar	O
results	O
another	O
catalytic	O
with	O
CA9	O
an	O
encoding	O
were	O
transmembrane	O
CA	O
with	O
,	O
intact	O
obtained	O
domain	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain	O
.	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
order	O
in	O
effect	O
reflexion	O
order	O
reflexion	O
reflexion	O
bestow	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O

of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
could	O
regulate	O
CA9	O
expression	O
.	O

Although	O
both	O
orbit	O
of	O
the	O
VHL	B
protein	O
lead	O
to	O
regulating	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
field	O
solo	O
could	O
effectively	O
regularize	O
CA9	O
expression	O
.	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regulation	O
CA12	O
expression	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
expression	O
.	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
order	O
in	O
effect	O
reflexion	O
order	O
reflexion	O
reflexion	O
area	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
add	O
to	O
ordinance	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
efficaciously	O
order	O
CA9	O
expression	O
.	O

Although	O
both	O
arena	O
of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regularization	O
of	O
CA12	O
aspect	O
,	O
the	O
elongin	O
constipate	O
domain	O
unequalled	O
could	O
efficaciously	O
modulate	O
CA9	O
aspect	O
.	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regulation	O
of	O
expression	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
order	O
in	O
effect	O
reflexion	O
order	O
reflexion	O
reflexion	O
area	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O

could	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
alone	O
expression	O
regulation	O
of	O
CA12	O
,	O
expression	O
CA9	O
elongin	O
binding	O
domain	O
contribute	O
.	O
effectively	O
regulate	O
the	O
to	O
Although	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O
.	O

We	O
CA12	O
and	O
loci	O
chromosome	O
15q22	O
and	O
17q21	O
.	O

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21	O

We	O
represent	O
CA12	O
and	O
CA9	O
venue	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21	O
.	O

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
represent	O
represent	O
represent	O
15q22	O
and	O
17q21	O
.	O

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
represent	O
represent	O
locale	O
15q22	O
and	O
17q21	O
.	O

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
represent	O
represent	O
represent	O
15q22	O
and	O
17q21	O
.	O

We	O
represent	O
CA12	O
and	O
CA9	O
locale	O
to	O
chromosome	O
stripe	O
15q22	O
and	O
17q21	O
.	O

We	O
mapped	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
15q22	O
.	O

We	O
represent	O
CA12	O
and	O
CA9	O
venue	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21	O
.	O

We	O
CA9	O
CA12	O
and	O
.	O
loci	O
to	O
mapped	O
bands	O
15q22	O
and	O
17q21	O
chromosome	O

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21	O
.	O

2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
cancer	O
the	O
crab	O
severally	O
severally	B
human	O

respectively	O
,	O
amplification	O
human	O
cancers	B
.	O

deuce	O
severally	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
crab	B
.	O

2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
cancer	O
the	O
crab	O
severally	O
severally	B
human	O

respectively	O
,	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	B
.	O

two	O
respectively	O
,	O
part	O
prostrate	O
to	O
amplification	O
in	O
some	O
human	O
cancers	B
.	O

2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
cancer	O
the	O
crab	O
severally	O
approximately	B
human	O

deuce	O
severally	O
,	O
regions	O
prone	O
to	O
elaboration	O
in	O
some	O
human	O
cancers	B
.	O

2	O
in	O
,	O
regions	O
respectively	O
to	O
amplification	O
cancers	O
some	O
human	O
prone	B
.	O

.	O
respectively	O
,	O
regions	O
in	O
to	O
human	O
prone	O
some	O
amplification	O
cancers	B
2	O

2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	B
.	O

Additional	O
experiments	O
are	O
needed	O
	O
enzyme	O
indium	O
part	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B
cell	O
growth	O
california	O
california	O
california	O
california	O
california	O
.	O

Additional	O
experiments	O
are	O
define	O
IX	O
and	O
CA	O
enzymes	O
in	O
regulation	O
of	O
pH	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
on	O
cell	O
growth	O
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
delineate	O
the	O
office	O
of	O
calcium	O
nine	O
and	O
calcium	O
twelve	O
enzymes	O
in	O
the	O
ordinance	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
possible	O
shock	O
on	O
cancer	B
cell	O
maturation	O
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
of	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B
cell	O
growth	O
.	O

additional	O
experimentation	O
are	O
needed	O
to	O
specify	O
the	O
use	O
of	O
CA	O
IX	O
and	O
CA	O
twelve	O
enzymes	O
in	O
the	O
rule	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B
cadre	O
emergence	O
.	O

Additional	O
experiments	O
are	O
needed	O
	O
enzyme	O
indium	O
part	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B
cell	O
growth	O
california	O
california	O
california	O
california	O
california	O
.	O

additional	O
experiments	O
are	O
want	O
to	O
define	O
the	O
role	O
of	O
california	O
ennead	O
and	O
california	O
xii	O
enzymes	O
in	O
the	O
ordinance	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
likely	O
impingement	O
on	O
cancer	B
cell	O
growing	O
.	O

in	O
of	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
and	O
cancer	O
in	O
the	O
regulation	O
impact	O
pH	O
experiments	O
the	O
growth	O
microenvironment	O
XII	O
its	O
potential	O
Additional	O
enzymes	O
extracellular	B
cell	O
on	O
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
define	O
role	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
impact	O
on	O
cancer	B
growth	O

Additional	O
experiments	O
are	O
needed	O
	O
enzyme	O
indium	O
california	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B
cell	O
growth	O
california	O
california	O
california	O
california	O
california	O
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B
cell	O
growth	O
.	O

axerophthol	O
factor	O
encode	O
axerophthol	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
and	O
ocular	B
atrophy	I
(	O
Wolfram	B
syndrome	I
)	O
.	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
and	O
optic	B
atrophy	I
(	O
Wolfram	B
encryption	B
encryption	O
encryption	B
encryption	O
encryption	B
encryption	O
syndrome	I
)	O
.	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
and	O
optic	B
atrophy	I
(	O
Wolfram	B
encryption	B
encryption	O
encryption	B
encryption	O
encryption	B
encryption	O
syndrome	I
)	O
.	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
patients	O
with	O
mellitus	I
and	O
optic	B
atrophy	I
(	O
Wolfram	B
syndrome	I

optic	O
gene	O
in	O
is	O
transmembrane	O
protein	O
atrophy	O
mutated	O
encoding	O
patients	O
with	O
diabetes	B
.	I
and	O
a	B
A	I
(	O
Wolfram	B
syndrome	I
)	O
mellitus	O

angstrom	O
cistron	O
encryption	O
angstrom	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
and	O
ocular	B
atrophy	I
(	O
w	B
syndrome	I
)	O
.	O

.	O
gene	O
encoding	O
with	O
transmembrane	O
protein	O
is	O
syndrome	O
optic	O
patients	O
a	O
diabetes	B
and	I
mellitus	O
in	B
atrophy	I
(	O
Wolfram	B
mutated	I
A	O
)	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
and	O
optic	B
atrophy	I
(	O
Wolfram	B
encryption	B
encryption	O
encryption	B
encryption	O
encryption	B
mutate	O
syndrome	I
)	O
.	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
optic	B
Wolfram	B
syndrome	I
)	O
.	O

A	O
cistron	O
encryption	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
and	O
opthalmic	B
withering	I
(	O
w	B
syndrome	I
)	O
.	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
and	O
optic	B
atrophy	I
(	O
Wolfram	B
syndrome	I
)	O
.	O

Wolfram	B
syndrome	I
(	O
WFS	B
spring	O
chicken	O
disarray	O
limit	O
past	O
youth	O
;	O
OMIM	O
222300	O
)	O
is	O
an	B
autosomal	I
recessive	I
neurodegenerative	I
disorder	O
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	B
insulin	I
-	I
dependent	I
diabetes	I
mellitus	O
and	O
progressive	B
optic	I
atrophy	O
recessionary	O
recessionary	O
recessionary	O
recessionary	O

Wolfram	B
syndrome	I
;	O
an	O
autosomal	B
recessive	I
disorder	I
defined	O
young	O
-	O
onset	O
immune	O
insulin	B
-	I
dependent	I
diabetes	I
and	O
optic	B
atrophy	I
.	O

tungsten	B
syndrome	I
(	O
WFS	B
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B
recessionary	I
neurodegenerative	I
upset	I
outlined	O
by	O
young	O
-	O
onrush	O
not	O
-	O
resistant	O
insulin	B
-	I
dependant	I
diabetes	I
mellitus	I
and	O
progressive	O
oculus	B
atrophy	I
.	O

Wolfram	B
syndrome	I
(	O
WFS	B
OMIM	O
is	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
disorder	I
defined	O
by	O
young	O
immune	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
and	O
progressive	O
optic	B
atrophy	I
.	O

tungsten	B
syndrome	I
(	O
WFS	B
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B
recessionary	I
neurodegenerative	I
distract	I
outlined	O
by	O
young	O
-	O
onset	O
not	O
-	O
resistant	O
insulin	B
-	I
subject	I
diabetes	I
mellitus	I
and	O
progressive	O
oculus	B
wasting	I
.	O

Wolfram	B
syndrome	I
(	O
WFS	B
spring	O
chicken	O
disarray	O
limit	O
past	O
youth	O
;	O
OMIM	O
222300	O
)	O
is	O
an	B
autosomal	I
recessive	I
neurodegenerative	I
disorder	O
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	B
insulin	I
-	I
dependent	I
diabetes	I
mellitus	O
and	O
progressive	B
optic	I
atrophy	O
recessionary	O
recessionary	O
recessionary	O
recessionary	O

Wolfram	B
syndrome	I
(	O
WFS	B
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
upset	I
outlined	O
by	O
youth	O
-	O
onrush	O
not	O
-	O
resistant	O
insulin	B
-	I
hooked	I
diabetes	I
mellitus	I
and	O
progressive	O
ocular	B
wasting	I
.	O

-	B
onset	I
(	O
WFS	B
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
dependent	I
optic	O
by	O
young	O
-	O
and	O
non	O
syndrome	O
immune	O
.	B
-	I
disorder	I
diabetes	I
mellitus	I
Wolfram	O
defined	O
insulin	B
atrophy	I
progressive	O

Wolfram	B
syndrome	I
(	O
WFS	B
OMIM	O
)	O
is	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
disorder	I
defined	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	B
diabetes	I
mellitus	I
and	O
optic	B
.	O

Wolfram	B
syndrome	I
(	O
WFS	B
confusedness	O
disarray	O
limit	O
past	O
disarray	O
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
disorder	I
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
and	O
progressive	O
optic	B
atrophy	I
disarray	O
disarray	O
disarray	O
recessionary	O
.	O

Wolfram	B
syndrome	I
(	O
WFS	B
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
disorder	I
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
and	O
progressive	O
optic	B
atrophy	I
.	O

Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
family	O
line	O
affirm	O
affirm	O
five	O
families	O

to	O
markers	O
was	O
five	O
families	O
.	O

linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
affirm	O
in	O
quintet	O
families	O
.	O

Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
family	O
line	O
affirm	O
affirm	O
five	O
families	O

to	O
markers	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
five	O
families	O
.	O

Linkage	O
to	O
marking	O
on	O
chromosome	O
4p	O
was	O
sustain	O
in	O
five	O
home	O
.	O

Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
family	O
line	O
affirm	O
	O
five	O
families	O

linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
support	O
in	O
five	O
category	O
.	O

Linkage	O
confirmed	O
markers	O
on	O
to	O
4p	O
was	O
families	O
in	O
five	O
chromosome	O
.	O

.	O
to	O
markers	O
on	O
confirmed	O
4p	O
five	O
chromosome	O
in	O
was	O
families	O
Linkage	O

Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
five	O
families	O
.	O

along	O
the	O
foundation	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	O
,	O
the	O
WFS	B
factor	O
was	O
localised	O
to	O
a	O
BAC	O
/	O
P1	O
contig	O
of	O
less	O
than	O
250	O
kibibyte	O
.	O

On	O
the	O
basis	O
of	O
meiotic	O
and	O
associated	O
haplotypes	O
,	O
the	O
WFS	B
gene	O
was	O
localized	O
to	O
contig	O
of	O
less	O
than	O
250	O
kb	O
.	O

/	O
the	O
basis	O
a	O
meiotic	O
recombinants	O
and	O
than	O
of	O
associated	O
.	O
,	O
the	O
BAC	B
contig	O
was	O
localized	O
to	O
of	O
WFS	O
less	O
P1	O
gene	O
-	O
On	O
disease	O
250	O
kb	O
haplotypes	O

On	O
the	O
basis	O
of	O
situation	O
to	O
a	O
lesser	O
extent	O
factor	O
cost	O
place	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	B
,	O
the	O
WFS	O
gene	O
was	O
localized	O
to	O
cornerstone	O
to	O
a	O
lesser	O
extent	O
cost	O
a	O
BAC	O
/	O
P1	O
contig	O

On	O
the	O
basis	O
of	O
situation	O
to	O
a	O
lesser	O
extent	O
factor	O
cost	O
place	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	B
,	O
the	O
WFS	O
gene	O
was	O
localized	O
to	O
cornerstone	O
to	O
a	O
lesser	O
extent	O
colligate	O
a	O
BAC	O
/	O
P1	O
contig	O

On	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
associated	O
haplotypes	O
the	O
WFS	B
gene	O
was	O
localized	O
to	O
a	O
P1	O
contig	O
of	O
less	O
than	O
250	O
kb	O
.	O

.	O
the	O
basis	O
gene	O
meiotic	O
recombinants	O
than	O
disease	O
of	O
associated	O
haplotypes	O
,	O
250	O
WFS	B
less	O
-	O
localized	O
to	O
a	O
BAC	O
the	O
P1	O
contig	O
of	O
was	O
and	O
/	O
kb	O
On	O

On	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
associated	O
,	O
the	O
WFS	B
gene	O
was	O
localized	O
to	O
a	O
/	O
P1	O
contig	O
of	O
less	O
than	O
250	O

along	O
the	O
foundation	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
affiliate	O
haplotypes	O
,	O
the	O
WFS	B
factor	O
was	O
localised	O
to	O
a	O
BAC	O
/	O
P1	O
contig	O
of	O
less	O
than	O
250	O
kb	O
.	O

along	O
the	O
fundament	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
colligate	O
haplotypes	O
,	O
the	O
WFS	B
factor	O
was	O
focalise	O
to	O
a	O
BAC	O
/	O
P1	O
contig	O
of	O
less	O
than	O
250	O
kib	O
.	O

On	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	O
,	O
the	O
WFS	B
gene	O
was	O
localized	O
to	O
a	O
BAC	O
/	O
P1	O
contig	O
of	O
less	O
than	O
250	O
kb	O
.	O

Mutations	O
in	O
these	O
novel	O
gene	O
transmembrane	O
WFS1	O
WFS	O
encoding	O
a	O
putative	O
,	O
were	O
were	O
found	O
the	O
all	O
affected	O
in	O
individuals	O
six	O
)	B
families	O
(	O
and	O
mutations	O
a	O
phenotype	O
associated	O
with	O
in	O
protein	O
disease	O
.	O

Mutations	O
novel	O
gene	O
(	O
WFS1	O
encoding	O
a	O
protein	O
were	O
in	O
all	O
six	O
families	O
,	O
and	O
mutations	O
were	O
associated	O
the	O
disease	O
phenotype	O
.	O

Mutations	O
in	O
a	O
novel	O
receive	O
indium	O
somebody	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	B
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
invite	O
invite	O
invite	O
invite	O
invite	O
invite	O
cost	O
.	O

Mutations	O
in	O
a	O
novel	O
receive	O
indium	O
factor	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	B
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
invite	O
invite	O
invite	O
invite	O
invite	O
invite	O
cost	O
.	O

in	O
individuals	O
a	O
novel	O
gene	O
(	O
mutations	O
)	O
encoding	O
a	O
putative	O
were	O
protein	O
and	O
with	O
in	O
all	O
affected	O
transmembrane	O
in	O
six	O
WFS	B
.	O
,	O
were	O
these	O
WFS1	O
Mutations	O
disease	O
families	O
the	O
associated	O
phenotype	O
found	O

Mutations	O
in	O
a	O
novel	O
gene	O
(	O
encoding	O
a	O
putative	O
transmembrane	O
were	O
found	O
in	O
all	O
affected	O
in	O
six	O
WFS	B
families	O
and	O
these	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
.	O

mutation	O
in	O
a	O
refreshing	O
cistron	O
(	O
WFS1	O
)	O
encode	O
a	O
putative	O
transmembrane	O
protein	O
were	O
institute	O
in	O
all	O
affected	O
mortal	O
in	O
sestet	O
WFS	B
families	O
,	O
and	O
these	O
mutation	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
.	O

Mutations	O
in	O
a	O
fresh	O
factor	O
(	O
WFS1	O
)	O
encode	O
a	O
putative	O
transmembrane	O
protein	O
were	O
retrieve	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	B
sept	O
,	O
and	O
these	O
mutations	O
were	O
consort	O
with	O
the	O
disease	O
phenotype	O
.	O

Mutations	O
in	O
a	O
novel	O
receive	O
indium	O
factor	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	B
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
invite	O
invite	O
invite	O
invite	O
invite	O
invite	O
cost	O
.	O

variation	O
in	O
a	O
new	O
factor	O
(	O
WFS1	O
)	O
encode	O
a	O
putative	O
transmembrane	O
protein	O
were	O
constitute	O
in	O
all	O
affected	O
mortal	O
in	O
vi	O
WFS	B
mob	O
,	O
and	O
these	O
variation	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
.	O

Mutations	O
in	O
a	O
novel	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	B
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
.	O

islet	O
function	O
to	O
appears	O
in	O
survival	O
-	O
WFS1	O
beta	O
of	O
cells	O
and	O
neurons	O
.	O
.	O

WFS1	O
appears	O
nerve	O
cell	O
isle	O
genus	O
beta	O
to	O
function	O
in	O
survival	O
of	O
islet	O
beta	O
indium	O
-	O
cells	O
and	O
neurons	O

WFS1	O
appears	O
nerve	O
cell	O
isle	O
genus	O
beta	O
to	O
function	O
in	O
survival	O
of	O
islet	O
beta	O
genus	O
beta	O
-	O
cells	O
and	O

WFS1	O
to	O
in	O
of	O
islet	O
beta	O
-	O
cells	O
and	O
neurons	O
.	O
.	O

WFS1	O
appears	O
to	O
part	O
in	O
survival	O
of	O
islet	O
beta	O
-	O
cells	O
and	O
neurons	O
.	O
.	O

WFS1	O
appears	O
nerve	O
cell	O
isle	O
genus	O
beta	O
to	O
function	O
in	O
survival	O
of	O
islet	O
beta	O
indium	O
-	O
cells	O
and	O
neurons	O

WFS1	O
appears	O
to	O
function	O
in	O
survival	O
of	O
beta	O
-	O
and	O
neurons	O
.	O
.	O

neurons	O
appears	O
to	O
WFS1	O
islet	O
survival	O
of	O
and	O
beta	O
-	O
cells	O
in	O
function	O
.	O
.	O

WFS1	O
appears	O
to	O
function	O
in	O
selection	O
of	O
islet	O
beta	O
-	O
cells	O
and	O
neurons	O
.	O
.	O

WFS1	O
in	O
to	O
function	O
appears	O
survival	O
islet	O
cells	O
beta	O
-	O
neurons	O
and	O
of	O
.	O
.	O

WFS1	O
appears	O
to	O
function	O
in	O
survival	O
of	O
islet	O
beta	O
-	O
cells	O
and	O
neurons	O
.	O
.	O

Stable	O
interaction	O
and	O
mitotic	O
products	O
of	O
genes	O
BRCA1	O
between	O
BRCA2	O
tumor	B
suppressor	O
the	O
in	O
the	O
and	O
meiotic	O
cells	O
.	O

between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B
and	O
meiotic	O
cells	O
.	O

unchanging	O
interaction	O
between	O
the	O
intersection	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
neoplasm	B
suppressor	O
factor	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O

stalls	O
interaction	O
between	O
the	O
merchandise	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumour	B
suppressor	O
cistron	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O

meiotic	O
interaction	O
between	O
the	O
products	O
of	O
in	O
mitotic	O
and	O
BRCA2	O
tumor	B
suppressor	O
cells	O
the	O
BRCA1	O
and	O
genes	O
Stable	O
.	O

Stable	O
interaction	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
.	O

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
tween	O
tween	O
tween	O
tween	O
fundamental	O
interaction	O

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
neoplasm	B
suppresser	O
factor	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
tween	O
tween	O
tween	O
tween	O
tween	O
.	O

in	O
interaction	O
between	O
tumor	O
products	O
of	O
the	O
.	O
mitotic	O
BRCA2	O
the	B
suppressor	O
Stable	O
genes	O
and	O
and	O
meiotic	O
cells	O
BRCA1	O

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O

BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
lawsuit	O
of	O
transmitted	O
,	O
early	O
oncoming	O
boob	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51	O
.	O

BRCA1	O
and	O
account	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	O
breast	B
or	I
ovarian	I
cancer	I
and	O
products	O
that	O
each	O
interact	O
with	O
.	O

BRCA1	O
and	O
BRCA2	O
account	O
virtually	O
operating	O
theatre	O
sheath	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	B
breast	I
and	I
/	I
or	I
ovarian	I
cancer	O
production	O
for	O
each	O
one	O
for	O
each	O
one	O
genetic	O
genetic	O
and	O
encode	O
products	O
that	O

products	O
and	O
BRCA2	O
and	O
for	O
most	O
cases	O
hRAD51	O
interact	O
,	O
encode	O
onset	O
breast	B
and	I
each	I
or	I
ovarian	I
cancer	I
account	O
with	O
early	O
that	O
/	O
familial	O
BRCA1	O
of	O
.	O

BRCA1	O
and	O
BRCA2	O
account	O
virtually	O
operating	O
theatre	O
sheath	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	B
breast	I
and	I
/	I
or	I
ovarian	I
cancer	O
production	O
for	O
each	O
one	O
for	O
each	O
one	O
genetic	O
genetic	O
and	O
encode	O
products	O
that	O

BRCA1	O
and	O
BRCA2	O
for	O
most	O
of	O
familial	O
,	O
early	O
onset	O
breast	B
and	I
/	I
ovarian	I
cancer	I
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51	O
.	O

.	O
and	O
BRCA2	O
/	O
for	O
most	O
hRAD51	O
of	O
account	O
,	O
early	O
onset	O
and	B
products	I
with	I
familial	I
ovarian	I
cancer	I
and	O
encode	O
breast	O
that	O
each	O
interact	O
or	O
cases	O
BRCA1	O

BRCA2	O
most	O
cases	O
of	O
,	O
early	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O

interact	O
and	O
BRCA2	O
account	O
for	O
most	O
and	O
onset	O
familial	O
,	O
early	O
ovarian	O
that	B
cases	I
with	I
BRCA1	I
of	I
or	I
and	O
encode	O
products	O
breast	O
each	O
cancer	O
/	O
hRAD51	O
.	O

BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
cases	O
of	O
genetic	O
,	O
early	O
attack	O
knocker	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51	O
.	O

BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51	O
.	O

Results	O
presented	O
here	O
show	O
coordination	O
compound	O
build	O
up	O
element	O
indium	O
build	O
up	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
build	O
up	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O

Results	O
presented	O
here	O
show	O
coordination	O
compound	O
build	O
up	O
element	O
indium	O
build	O
up	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
coordination	O
compound	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O

the	O
presented	O
here	O
show	O
that	O
BRCA1	O
and	O
subnuclear	O
coexist	O
in	O
a	O
biochemical	O
and	O
and	O
axial	O
synaptonemal	O
BRCA2	O
cells	O
in	O
somatic	O
Results	O
complex	O
on	O
foci	O
colocalize	O
elements	O
of	O
developing	O
.	O
complexes	O
in	O

Results	O
presented	O
here	O
show	O
coordination	O
compound	O
build	O
up	O
element	O
indium	O
build	O
up	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
build	O
up	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O

Results	O
presented	O
here	O
show	O
BRCA1	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O
.	O

solution	O
submit	O
here	O
display	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
composite	O
and	O
colocalize	O
in	O
subnuclear	O
focussing	O
in	O
corporal	O
cells	O
and	O
on	O
the	O
axile	O
ingredient	O
of	O
evolve	O
synaptonemal	O
complexes	O
.	O

synaptonemal	O
presented	O
axial	O
colocalize	O
that	O
BRCA1	O
developing	O
BRCA2	O
show	O
in	O
a	O
biochemical	O
cells	O
and	O
here	O
coexist	O
subnuclear	O
foci	O
in	O
somatic	O
complex	O
and	O
on	O
the	O
in	O
and	O
of	O
elements	O
Results	O
complexes	O
.	O

Results	O
presented	O
here	O
show	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
a	O
biochemical	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
in	O
somatic	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O
.	O

a	O
presented	O
here	O
synaptonemal	O
that	O
BRCA1	O
and	O
elements	O
the	O
in	O
axial	O
biochemical	O
of	O
somatic	O
on	O
in	O
subnuclear	O
foci	O
.	O
and	O
cells	O
and	O
colocalize	O
coexist	O
Results	O
BRCA2	O
complex	O
developing	O
show	O
complexes	O
in	O

termination	O
face	O
here	O
depict	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
composite	O
and	O
colocalize	O
in	O
subnuclear	O
focus	O
in	O
bodily	O
cells	O
and	O
on	O
the	O
axile	O
elements	O
of	O
developing	O
synaptonemal	O
composite	O
.	O

Results	O
presented	O
here	O
show	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O
.	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
uv	O
beam	O
of	O
light	O
uv	O
beam	O
of	O
light	O
beam	O
of	O
light	O
entropy	O
uv	O

and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
to	O
or	O
UV	O
irradiation	O
.	O

same	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
reproduction	O
sites	O
following	O
photo	O
of	O
S	O
stage	O
cadre	O
to	O
hydroxyurea	O
or	O
UV	O
ray	O
.	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
PCNA	O
+	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
or	O
UV	O
irradiation	O
.	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
uv	O
beam	O
of	O
light	O
uv	O
beam	O
of	O
light	O
beam	O
of	O
light	O
entropy	O
entropy	O

corresponding	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
counter	O
pose	O
following	O
vulnerability	O
of	O
south	O
form	O
cells	O
to	O
hydroxyurea	O
or	O
UV	O
irradiation	O
.	O

similar	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
reproduction	O
pose	O
surveil	O
picture	O
of	O
S	O
phase	O
cells	O
to	O
hydroxyurea	O
or	O
ultraviolet	O
shaft	O
.	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
replication	O
exposure	O
of	O
S	O
phase	O
cells	O
to	O
hydroxyurea	O
or	O
UV	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
uv	O
beam	O
of	O
light	O
uv	O
beam	O
of	O
light	O
beam	O
of	O
light	O
entropy	O
entropy	O

cells	O
BRCA1	O
and	O
replication	O
,	O
BRCA2	O
relocates	O
to	O
.	O
+	O
RAD51	O
sites	O
following	O
exposure	O
irradiation	O
S	O
phase	O
or	O
to	O
Like	O
hydroxyurea	O
UV	O
of	O
PCNA	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
to	O
hydroxyurea	O
or	O
UV	O
irradiation	O
.	O

Thus	O
,	O
BRCA1	O
and	O
together	O
entropy	O
enter	O
colligate	O
unitedly	O
BRCA2	O
participate	O
,	O
together	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
the	O
operating	O
theatre	O
activation	O
of	O
double	O
-	O
strand	O
break	O
repair	O
and	O
/	O
or	O
homologous	O
recombination	O
unitedly	O
unitedly	O
nerve	O

Thus	O
,	O
BRCA1	O
and	O
together	O
entropy	O
enter	O
colligate	O
unitedly	O
BRCA2	O
participate	O
,	O
together	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
the	O
therefore	O
activation	O
of	O
double	O
-	O
strand	O
break	O
repair	O
and	O
/	O
or	O
homologous	O
recombination	O
unitedly	O
unitedly	O
nerve	O
tract	O

break	O
,	O
BRCA1	O
and	O
BRCA2	O
participate	O
s	O
with	O
,	O
in	O
a	O
pathway	O
-	O
,	O
repair	O
homologous	O
together	O
double	O
activation	O
of	O
Thus	O
(	O
strand	O
the	O
)	O
and	O
/	O
or	O
.	O
recombination	O
associated	O

Thus	O
,	O
BRCA1	O
and	O
together	O
entropy	O
enter	O
colligate	O
unitedly	O
BRCA2	O
participate	O
,	O
together	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
the	O
operating	O
theatre	O
activation	O
of	O
double	O
-	O
strand	O
break	O
repair	O
and	O
/	O
or	O
homologous	O
recombination	O
unitedly	O
unitedly	O
nerve	O

Thus	O
,	O
BRCA1	O
and	O
participate	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
-	O
strand	O
break	O
repair	O
and	O
/	O
or	O
homologous	O
recombination	O
.	O

thence	O
,	O
BRCA1	O
and	O
BRCA2	O
enter	O
,	O
unitedly	O
,	O
in	O
a	O
footpath	O
(	O
s	O
)	O
connect	O
with	O
the	O
energizing	O
of	O
double	O
-	O
string	O
break	O
remedy	O
and	O
/	O
or	O
homologous	O
recombination	O
.	O

homologous	O
,	O
repair	O
)	O
BRCA2	O
participate	O
or	O
together	O
and	O
in	O
a	O
pathway	O
double	O
s	O
BRCA1	O
,	O
with	O
the	O
activation	O
of	O
(	O
-	O
strand	O
break	O
associated	O
,	O
/	O
and	O
Thus	O
recombination	O
.	O

Thus	O
,	O
BRCA1	O
and	O
BRCA2	O
participate	O
,	O
together	O
,	O
a	O
pathway	O
s	O
)	O
associated	O
with	O
the	O
activation	O
of	O
strand	O
break	O
repair	O
and	O
/	O
or	O
homologous	O
recombination	O
.	O

a	O
,	O
BRCA1	O
homologous	O
BRCA2	O
participate	O
,	O
and	O
break	O
in	O
repair	O
pathway	O
/	O
of	O
strand	O
associated	O
with	O
the	O
.	O
s	O
double	O
-	O
)	O
,	O
Thus	O
together	O
(	O
or	O
and	O
recombination	O
activation	O

thence	O
,	O
BRCA1	O
and	O
BRCA2	O
participate	O
,	O
unitedly	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
connect	O
with	O
the	O
activating	O
of	O
doubly	O
-	O
string	O
collapse	O
fix	O
and	O
/	O
or	O
homologous	O
recombination	O
.	O

Thus	O
,	O
BRCA1	O
and	O
BRCA2	O
participate	O
,	O
together	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
the	O
activation	O
of	O
double	O
-	O
strand	O
break	O
repair	O
and	O
/	O
or	O
homologous	O
recombination	O
.	O

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B
breast	I
and	I
cancer	I
the	I
crab	I
operating	I
theatre	I
cancer	I
the	I
crab	I
cancer	I
the	I
crab	I
nerve	O
tract	O

this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B
breast	I
/	I
ovarian	I
cancer	I
.	O
.	O

disfunction	O
of	O
this	O
pathway	O
whitethorn	O
be	O
a	O
universal	O
phenomenon	O
in	O
the	O
majority	O
of	O
type	O
of	O
transmitted	B
titty	I
and	I
/	I
or	I
ovarian	I
cancer	I
.	O
.	O

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
phenomenon	O
in	O
majority	O
of	O
cases	O
of	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
.	O
.	O

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B
breast	I
and	I
cancer	I
the	I
crab	I
operating	I
theatre	I
cancer	I
the	I
crab	I
cancer	I
the	I
crab	I
nerve	O
tract	O

dysfunction	O
of	O
this	O
footpath	O
may	O
be	O
a	O
universal	O
phenomenon	O
in	O
the	O
bulk	O
of	O
event	O
of	O
patrimonial	B
breast	I
and	I
/	I
or	I
ovarian	I
crab	I
.	O
.	O

disfunction	O
of	O
this	O
tract	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
showcase	O
of	O
transmissible	B
titty	I
and	I
/	I
or	I
ovarian	I
cancer	I
.	O
.	O

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
the	O
cases	O
of	O
hereditary	B
breast	I
and	I
/	I
or	I
ovarian	I
cancer	I

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B
breast	I
and	I
cancer	I
the	I
crab	I
operating	I
theatre	I
cancer	I
the	I
crab	I
cancer	I
the	I
crab	I
nerve	O
tract	O

and	O
of	O
this	O
the	O
may	O
be	O
a	O
/	O
.	O
in	O
pathway	O
majority	O
of	O
cases	O
.	O
hereditary	B
breast	I
ovarian	I
general	I
Dysfunction	I
or	I
cancer	I
of	O
phenomenon	O

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B
breast	I
and	I
/	I
or	I
ovarian	I
cancer	I
.	O
.	O

novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
:	O
its	O
on	O
-	O
mRNA	O
splicing	O
and	O
enzyme	O
activity	O
.	O

gene	O
novel	O
Arg362Ser	O
pre	O
in	O
the	O
sterol	O
.	O
enzyme	O
hydroxylase	O
activity	O
(	O
CYP27	O
-	O
and	O
its	O
effects	O
on	O
mutation	O
)	O
mRNA	O
splicing	O
:	O
-	O
A	O
27	O

A	O
new	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
cistron	O
(	O
CYP27	O
)	O
:	O
its	O
consequence	O
on	O
pre	O
-	O
mRNA	O
marry	O
and	O
enzyme	O
activeness	O
.	O

A	O
fresh	O
Arg362Ser	O
sport	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
cistron	O
(	O
CYP27	O
)	O
:	O
its	O
force	O
on	O
pre	O
-	O
mRNA	O
splice	O
and	O
enzyme	O
activity	O
.	O

A	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
(	O
CYP27	O
:	O
its	O
effects	O
on	O
pre	O
-	O
mRNA	O
enzyme	O
activity	O
.	O

A	O
novel	O
Arg362Ser	O
mutation	O
indium	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
:	O
its	O
effects	O
on	O
template	O
rna	O
tie	O
action	O
sport	O
action	O
sport	O
pre	O
-	O
mRNA	O
splicing	O
and	O
enzyme	O
activity	O

A	O
novel	O
Arg362Ser	O
mutation	O
indium	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
:	O
its	O
effects	O
on	O
template	O
rna	O
tie	O
action	O
sport	O
action	O
ampere	O
pre	O
-	O
mRNA	O
splicing	O
and	O
enzyme	O
activity	O

A	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
(	O
:	O
its	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
and	O

enzyme	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
)	O
effects	O
-	O
hydroxylase	O
gene	O
(	O
splicing	O
sterol	O
activity	O
its	O
27	O
mRNA	O
pre	O
-	O
A	O
CYP27	O
and	O
on	O
:	O
.	O

A	O
refreshing	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
factor	O
(	O
CYP27	O
)	O
:	O
its	O
consequence	O
on	O
pre	O
-	O
mrna	O
marry	O
and	O
enzyme	O
activeness	O
.	O

A	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
:	O
its	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
and	O
enzyme	O
activity	O
.	O

A	O
novel	O
a	O
to	O
A	O
hydroxylase	O
in	O
CYP27	O
sterol	O
27	O
-	O
products	O
with	O
(	O
CYP27	O
(	O
was	O
identified	O
sequencing	O
by	O
amplified	O
the	O
gene	O
mutation	O
from	O
patient	O
C	O
)	O
cerebrotendinous	B
xanthomatosis	I
)	O
gene	B
CTX	O
.	O

A	O
to	O
A	O
mutation	O
in	O
sterol	O
27	O
gene	O
(	O
)	O
was	O
amplified	O
gene	O
products	O
from	O
patient	O
with	O
cerebrotendinous	B
(	O
CTX	B
)	O
.	O

A	O
novel	O
C	O
to	O
sport	O
indium	O
factor	O
A	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
ampere	O
.	O

A	O
novel	O
C	O
to	O
sport	O
indium	O
ampere	O
A	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
ampere	O
.	O

novel	O
by	O
C	O
to	O
A	O
mutation	O
patient	O
the	O
sterol	O
27	O
-	O
with	O
gene	O
from	O
xanthomatosis	O
)	O
was	O
identified	O
hydroxylase	O
sequencing	O
amplified	O
CYP27	O
.	O
products	O
(	O
a	O
in	O
A	O
CTX	B
gene	I
(	O
cerebrotendinous	B
)	O
CYP27	O

A	O
novel	O
C	O
to	O
A	O
mutation	O
sterol	O
27	O
-	O
hydroxylase	O
(	O
CYP27	O
)	O
was	O
identified	O
sequencing	O
amplified	O
CYP27	O
gene	O
from	O
a	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

A	O
fresh	O
C	O
to	O
A	O
mutant	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
cistron	O
(	O
CYP27	O
)	O
was	O
place	O
by	O
sequence	O
hyperbolise	O
CYP27	O
cistron	O
merchandise	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

A	O
refreshing	O
C	O
to	O
A	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
factor	O
(	O
CYP27	O
)	O
was	O
distinguish	O
by	O
sequence	O
amplify	O
CYP27	O
factor	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

A	O
novel	O
C	O
to	O
sport	O
indium	O
ampere	O
A	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
mutant	O
ampere	O
.	O

A	O
refreshing	O
carbon	O
to	O
A	O
variation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
cistron	O
(	O
CYP27	O
)	O
was	O
distinguish	O
by	O
sequence	O
hyperbolise	O
CYP27	O
cistron	O
intersection	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

A	O
novel	O
C	O
to	O
A	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
to	O
362Ser	O
(	O
362Arg	O
AGT	O
362Ser	O
)	O
was	O
the	O
sterol	O
27	O
hydroxylase	O
activity	O
as	O
confirmed	O
by	O
mutant	O
cDNA	O
into	O
COS	O
-	O
cells	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
responsible	O
in	O
sterol	O
27	O
-	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
into	O
COS	O
-	O
1	O
cells	O
.	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
	O
cubicle	O
complementary	O
dna	O
	O
cubicle	O
remainder	O
	O
cubicle	O
remainder	O
remainder	O
remainder	O
remainder	O
twenty	O
seven	O
of	O
mutant	O
cDNA	O
into	O
COS	O
-	O
1	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
	O
cubicle	O
complementary	O
dna	O
	O
cubicle	O
remainder	O
	O
cubicle	O
remainder	O
remainder	O
remainder	O
remainder	O
remainder	O
of	O
mutant	O
cDNA	O
into	O
COS	O
-	O
1	O
cells	O

The	O
mutation	O
transfer	O
the	O
adrenodoxin	O
cofactor	O
binding	O
rest	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
inadequacy	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
action	O
,	O
as	O
reassert	O
by	O
reflection	O
of	O
sport	O
cDNA	O
into	O
colorado	O
-	O
single	O
cells	O
.	O

The	O
changed	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
by	O
of	O
mutant	O
cDNA	O
into	O
COS	O
-	O
1	O
cells	O

The	O
sport	O
interchange	O
the	O
adrenodoxin	O
cofactor	O
constipate	O
balance	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
creditworthy	O
for	O
insufficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
affirm	O
by	O
locution	O
of	O
sport	O
cDNA	O
into	O
COS	O
-	O
one	O
cells	O
.	O

cDNA	O
in	O
changed	O
the	O
362Ser	O
cofactor	O
mutant	O
,	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
binding	O
)	O
AGT	O
adrenodoxin	O
to	O
,	O
and	O
residue	O
responsible	O
for	O
deficiency	O
27	O
the	O
sterol	O
-	O
.	O
hydroxylase	O
-	O
mutation	O
as	O
confirmed	O
by	O
expression	O
of	O
362Arg	O
The	O
into	O
COS	O
was	O
1	O
cells	O
activity	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
	O
cubicle	O
complementary	O
dna	O
	O
cubicle	O
remainder	O
	O
cubicle	O
remainder	O
remainder	O
remainder	O
remainder	O
remainder	O
of	O
mutant	O
cDNA	O
into	O
COS	O
-	O
1	O
cells	O

The	O
variation	O
modify	O
the	O
adrenodoxin	O
cofactor	O
cover	O
residuum	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
creditworthy	O
for	O
insufficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
sustain	O
by	O
aspect	O
of	O
variation	O
cdna	O
into	O
cos	O
-	O
one	O
cells	O
.	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
of	O
mutant	O
cDNA	O
into	O
COS	O
-	O
1	O
cells	O
.	O

Quantitative	O
analysis	O
ussher	O
usher	O
usher	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52	O
reflexion	O
.	O

represented	O
analysis	O
showed	O
.	O
the	O
expression	O
of	O
CYP27	O
52	O
mRNA	O
in	O
the	O
Quantitative	O
patient	O
gene	O
that	O

Quantitative	O
analysis	O
stand	O
for	O
usher	O
template	O
rna	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52	O

quantitative	O
analysis	O
shew	O
that	O
the	O
expression	O
of	O
CYP27	O
factor	O
mRNA	O
in	O
the	O
patient	O
symbolise	O
52	O
.	O

patient	O
analysis	O
showed	O
CYP27	O
the	O
expression	O
represented	O
that	O
gene	O
mRNA	O
Quantitative	O
the	O
in	O
of	O
52	O
.	O

Quantitative	O
analysis	O
ussher	O
usher	O
usher	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52	O
reflexion	O
.	O

quantitative	O
analysis	O
picture	O
that	O
the	O
aspect	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
interpret	O
52	O
.	O

quantitative	O
analysis	O
showed	O
that	O
the	O
reflection	O
of	O
CYP27	O
gene	O
mrna	O
in	O
the	O
patient	O
interpret	O
52	O
.	O

Quantitative	O
analysis	O
gene	O
.	O
the	O
expression	O
patient	O
CYP27	O
showed	O
mRNA	O
in	O
the	O
of	O
represented	O
that	O
52	O

analysis	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
in	O
the	O
patient	O
represented	O
52	O
.	O

Quantitative	O
analysis	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52	O
.	O

of	O
%	O
5	O
.	O
normal	O
level	O
the	O

5	O
%	O
of	O
the	O
formula	O
dismantle	O
.	O

5	O
horizontal	O
surface	O
%	O
of	O
the	O
	O
normal	O
level	O

5	O
of	O
normal	O
.	O

the	O
5	O
of	O
%	O
normal	O
level	O
.	O

5	O
%	O
of	O
the	O
convention	O
unwavering	O
.	O

cinque	O
%	O
of	O
the	O
formula	O
level	O
.	O

5	O
%	O
of	O
.	O
normal	O
the	O
level	O

5	O
%	O
of	O
the	O
normal	O
.	O

5	O
horizontal	O
surface	O
%	O
of	O
the	O
	O
normal	O
level	O

5	O
%	O
of	O
the	O
normal	O
level	O
.	O

As	O
the	O
occurred	O
at	O
of	O
(	O
-	O
of	O
-	O
intron	O
6	O
splice	O
)	O
of	O
,	O
we	O
that	O
the	O
affect	O
normal	O
splicing	O
efficiency	O
exon	O
6	O
and	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
decreased	O
transcript	O
in	O
the	O
patient	O
.	O

As	O
the	O
at	O
penultimate	O
nucleotide	O
of	O
6	O
(	O
-	O
2	O
position	O
of	O
6	O
-	O
splice	O
)	O
of	O
the	O
gene	O
hypothesized	O
that	O
the	O
mutation	O
partially	O
affect	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
and	O
splicing	O
,	O
which	O
resulted	O
in	O
decreased	O
in	O
the	O
patient	O
.	O

As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
mutant	O
lead	O
factor	O
	O
copy	O
hypothesise	O
	O
situation	O
sport	O
of	O
exon	O
6	O
(	O
-	O
2	O
position	O
of	O
exon	O
6	O
-	O
intron	O
6	O
splice	O
site	O
)	O
of	O
the	O
gene	O
,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
tie	O
lead	O
indium	O
decrease	O
copy	O
indium	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient	O
sport	O
place	O
.	O

partially	O
-	O
mutation	O
occurred	O
at	O
the	O
(	O
nucleotide	O
of	O
exon	O
6	O
penultimate	O
-	O
and	O
2	O
of	O
exon	O
6	O
may	O
intron	O
the	O
splice	O
affect	O
)	O
patient	O
the	O
transcript	O
splicing	O
the	O
position	O
that	O
we	O
mutation	O
exon	O
As	O
6	O
the	O
normal	O
splicing	O
efficiency	O
in	O
,	O
6	O
site	O
cause	O
alternative	O
,	O
elsewhere	O
hypothesized	O
which	O
resulted	O
in	O
decreased	O
gene	O
in	O
the	O
of	O
.	O

cause	O
.	O
mutation	O
occurred	O
,	O
the	O
the	O
exon	O
of	O
exon	O
6	O
(	O
-	O
resulted	O
normal	O
of	O
nucleotide	O
that	O
-	O
intron	O
6	O
splice	O
site	O
)	O
transcript	O
the	O
gene	O
splicing	O
6	O
hypothesized	O
we	O
penultimate	O
mutation	O
may	O
partially	O
affect	O
the	O
position	O
,	O
efficiency	O
in	O
of	O
6	O
and	O
As	O
alternative	O
in	O
elsewhere	O
which	O
the	O
2	O
splicing	O
decreased	O
exon	O
in	O
the	O
patient	O
at	O

As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
mutant	O
lead	O
factor	O
	O
copy	O
hypothesise	O
	O
situation	O
sport	O
of	O
exon	O
6	O
(	O
-	O
2	O
position	O
of	O
exon	O
6	O
-	O
intron	O
6	O
splice	O
site	O
)	O
of	O
the	O
gene	O
,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
tie	O
lead	O
indium	O
decrease	O
copy	O
factor	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient	O
sport	O
place	O
.	O

As	O
the	O
mutation	O
come	O
at	O
the	O
penultimate	O
base	O
of	O
exon	O
vi	O
(	O
-	O
2	O
stance	O
of	O
exon	O
vi	O
-	O
intron	O
vi	O
wed	O
situation	O
)	O
of	O
the	O
factor	O
,	O
we	O
hypothesise	O
that	O
the	O
mutation	O
may	O
partly	O
affect	O
the	O
pattern	O
tie	O
efficiency	O
in	O
exon	O
vi	O
and	O
movement	O
option	O
tie	O
elsewhere	O
,	O
which	O
resulted	O
in	O
minify	O
copy	O
in	O
the	O
patient	O
.	O

As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
mutant	O
lead	O
factor	O
	O
copy	O
hypothesise	O
	O
situation	O
sport	O
of	O
exon	O
6	O
(	O
-	O
2	O
position	O
of	O
exon	O
6	O
-	O
intron	O
6	O
splice	O
site	O
)	O
of	O
the	O
gene	O
,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
tie	O
lead	O
indium	O
decrease	O
copy	O
indium	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient	O
sport	O
place	O
.	O

as	O
the	O
sport	O
occurred	O
at	O
the	O
penultimate	O
base	O
of	O
exon	O
six	O
(	O
-	O
2	O
lieu	O
of	O
exon	O
six	O
-	O
intron	O
six	O
wed	O
site	O
)	O
of	O
the	O
factor	O
,	O
we	O
hypothesized	O
that	O
the	O
sport	O
whitethorn	O
partially	O
affect	O
the	O
convention	O
wed	O
efficiency	O
in	O
exon	O
six	O
and	O
make	O
choice	O
wed	O
elsewhere	O
,	O
which	O
leave	O
in	O
diminish	O
copy	O
in	O
the	O
patient	O
.	O

As	O
the	O
that	O
occurred	O
at	O
the	O
penultimate	O
elsewhere	O
of	O
exon	O
6	O
(	O
6	O
2	O
position	O
nucleotide	O
exon	O
6	O
intron	O
the	O
6	O
.	O
site	O
)	O
of	O
in	O
-	O
mutation	O
we	O
hypothesized	O
mutation	O
in	O
the	O
may	O
partially	O
affect	O
the	O
the	O
splicing	O
efficiency	O
splicing	O
exon	O
gene	O
and	O
cause	O
in	O
alternative	O
of	O
,	O
which	O
resulted	O
transcript	O
decreased	O
,	O
patient	O
-	O
normal	O
splice	O

As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
(	O
-	O
2	O
position	O
of	O
exon	O
6	O
-	O
intron	O
6	O
splice	O
site	O
)	O
of	O
the	O
gene	O
,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient	O
.	O

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS	O
-	O
1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
	O
close	O
affirm	O
coding	O
dna	O
	O
affirm	O
coding	O
dna	O
	O
affirm	O
coding	O
dna	O
	O
affirm	O
affirm	O
affirm	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O
of	O

Transfection	O
of	O
retrace	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutant	O
,	O
into	O
COS	O
-	O
ane	O
cells	O
affirm	O
that	O
the	O
sport	O
minigene	O
was	O
creditworthy	O
for	O
a	O
mrna	O
species	O
instead	O
tie	O
at	O
an	O
excited	O
cryptic	O
phoebe	O
wed	O
place	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
remnant	O
of	O
exon	O
6	O
.	O

Transfection	O
of	O
activated	O
minigenes	O
,	O
site	O
or	O
without	O
the	O
mutation	O
,	O
COS	O
end	O
-	O
1	O
an	O
confirmed	O
that	O
mutant	O
the	O
minigene	O
.	O
responsible	O
with	O
a	O
species	O
alternatively	O
6	O
spliced	O
at	O
cells	O
bp	O
mRNA	O
5	O
splice	O
for	O
88	O
constructed	O
upstream	O
from	O
the	O
3	O
into	O
exon	O
of	O
cryptic	O
was	O

Transfection	O
species	O
constructed	O
minigenes	O
,	O
with	O
into	O
at	O
the	O
mutation	O
,	O
or	O
COS	O
alternatively	O
a	O
cells	O
confirmed	O
that	O
without	O
mutant	O
minigene	O
was	O
site	O
for	O
of	O
mRNA	O
.	O
-	O
activated	O
the	O
an	O
spliced	O
cryptic	O
1	O
splice	O
3	O
88	O
bp	O
upstream	O
from	O
of	O
5	O
end	O
responsible	O
exon	O
6	O
the	O

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
cos	O
-	O
unity	O
cells	O
corroborate	O
that	O
the	O
mutation	O
minigene	O
was	O
responsible	O
for	O
a	O
mrna	O
species	O
alternatively	O
tie	O
at	O
an	O
activated	O
kabbalistic	O
5	O
tie	O
situation	O
88	O
bp	O
upriver	O
from	O
the	O
ternion	O
destruction	O
of	O
exon	O
6	O
.	O

Transfection	O
of	O
constructed	O
,	O
with	O
or	O
without	O
the	O
into	O
COS	O
-	O
1	O
cells	O
confirmed	O
that	O
the	O
was	O
for	O
a	O
mRNA	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
splice	O
site	O
upstream	O
the	O
3	O
end	O
of	O
.	O

minigenes	O
,	O
with	O
or	O
without	O
mutation	O
,	O
1	O
that	O
the	O
was	O
a	O
mRNA	O
species	O
alternatively	O
at	O
an	O
5	O
splice	O
88	O
bp	O
3	O
of	O
exon	O
6	O

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS	O
-	O
1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
	O
close	O
affirm	O
coding	O
dna	O
	O
affirm	O
coding	O
dna	O
	O
affirm	O
coding	O
dna	O
	O
affirm	O
affirm	O
internet	O
site	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O

splice	O
a	O
constructed	O
minigenes	O
confirmed	O
with	O
minigene	O
activated	O
the	O
mutation	O
,	O
into	O
COS	O
or	O
bp	O
cells	O
,	O
.	O
the	O
mutant	O
-	O
was	O
responsible	O
for	O
alternatively	O
mRNA	O
species	O
3	O
exon	O
at	O
spliced	O
of	O
cryptic	O
5	O
upstream	O
site	O
88	O
1	O
Transfection	O
from	O
the	O
without	O
end	O
of	O
an	O
6	O
that	O

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS	O
-	O
1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
	O
close	O
affirm	O
coding	O
dna	O
	O
affirm	O
coding	O
dna	O
	O
affirm	O
coding	O
dna	O
	O
affirm	O
affirm	O
affirm	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O
of	O

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS	O
-	O
1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O
of	O
exon	O
6	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	B
in	I
the	I
sterol	I
27	I
-	I
hydroxylase	I
activity	I
,	O
but	O
also	O
partially	O
template	O
rna	O
tie	O
ampere	O
template	O
rna	O
factor	O
ampere	O
template	O
rna	O
factor	O
ampere	O
ampere	O
factor	O
ampere	O
ampere	O
ampere	O
leads	O
to	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
of	O

Our	O
data	O
hint	O
that	O
the	O
C	O
to	O
A	O
mutant	O
at	O
the	O
penultimate	O
base	O
of	O
exon	O
sextuplet	O
of	O
the	O
CYP27	O
cistron	O
not	O
only	O
suit	O
the	O
inadequacy	B
in	I
the	I
sterol	I
xxvii	I
-	I
hydroxylase	I
activity	I
,	O
but	O
too	O
partly	O
contribute	O
to	O
substitute	O
pre	O
-	O
mRNA	O
marry	O
of	O
the	O
cistron	O
.	O

Our	O
data	O
activity	O
that	O
the	O
partially	O
to	O
A	O
mutation	O
at	O
the	O
nucleotide	O
splicing	O
of	O
exon	O
hydroxylase	O
of	O
the	O
gene	O
CYP27	O
not	O
.	O
causes	O
C	O
deficiency	B
the	I
sterol	I
gene	I
27	I
-	I
6	I
to	I
in	O
but	O
also	O
the	O
leads	O
suggest	O
alternative	O
pre	O
-	O
mRNA	O
penultimate	O
the	O
of	O
,	O
only	O

Our	O
the	O
suggest	O
that	O
the	O
C	O
penultimate	O
-	O
mutation	O
at	O
the	O
to	O
nucleotide	O
sterol	O
deficiency	O
6	O
of	O
the	O
A	O
gene	O
not	O
only	O
partially	O
the	O
of	B
in	I
.	I
of	I
activity	I
CYP27	I
hydroxylase	I
27	I
,	O
exon	O
also	O
mRNA	O
leads	O
to	O
alternative	O
pre	O
data	O
but	O
splicing	O
causes	O
the	O
gene	O
-	O

Our	O
data	O
advise	O
that	O
the	O
C	O
to	O
A	O
variation	O
at	O
the	O
penultimate	O
base	O
of	O
exon	O
sextuplet	O
of	O
the	O
CYP27	O
factor	O
not	O
only	O
campaign	O
the	O
insufficiency	B
in	I
the	I
sterol	I
27	I
-	I
hydroxylase	I
activeness	I
,	O
but	O
too	O
partially	O
leading	O
to	O
choice	O
pre	O
-	O
mRNA	O
splice	O
of	O
the	O
factor	O
.	O

Our	O
data	O
suggest	O
the	O
C	O
to	O
A	O
mutation	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
only	O
the	O
deficiency	B
in	I
sterol	I
27	I
-	I
hydroxylase	I
activity	I
,	O
also	O
partially	O
alternative	O
-	O
mRNA	O
splicing	O
of	O
.	O

that	O
the	O
C	O
to	O
A	O
at	O
the	O
exon	O
the	O
CYP27	O
only	O
deficiency	B
in	I
the	I
sterol	I
-	I
hydroxylase	I
but	O
also	O
leads	O
to	O
mRNA	O
of	O
the	O
gene	O

Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	B
in	I
the	I
sterol	I
27	I
-	I
hydroxylase	I
activity	I
,	O
but	O
also	O
partially	O
template	O
rna	O
tie	O
ampere	O
template	O
rna	O
factor	O
ampere	O
template	O
rna	O
factor	O
ampere	O
ampere	O
factor	O
ampere	O
ampere	O
part	O
leads	O
to	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
of	O

also	O
deficiency	O
suggest	O
that	O
of	O
C	O
not	O
activity	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
to	O
to	O
6	O
the	O
.	O
CYP27	O
gene	O
of	O
only	O
causes	O
the	O
sterol	B
in	I
the	I
mRNA	I
the	I
-	I
27	I
data	I
,	O
but	O
alternative	O
partially	O
leads	O
exon	O
Our	O
pre	O
-	O
A	O
splicing	O
of	O
hydroxylase	O
gene	O
the	O

Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	B
in	I
the	I
sterol	I
27	I
-	I
hydroxylase	I
activity	I
,	O
but	O
also	O
partially	O
template	O
rna	O
tie	O
ampere	O
template	O
rna	O
factor	O
ampere	O
template	O
rna	O
factor	O
ampere	O
ampere	O
factor	O
ampere	O
ampere	O
ampere	O
leads	O
to	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
of	O

Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	B
in	I
the	I
sterol	I
27	I
-	I
hydroxylase	I
activity	I
,	O
but	O
also	O
partially	O
leads	O
to	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
of	O
the	O
gene	O
.	O

To	O
our	O
knowledge	O
,	O
humiliated	O
	O
template	O
rna	O
tie	O
low	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
	O
lap	O
joint	O
mutation	O
at	O
the	O
-	O
2	O
position	O
of	O
a	O
5	O
splice	O
site	O
broken	O

To	O
our	O
knowledge	O
,	O
humiliated	O
	O
template	O
rna	O
tie	O
low	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
	O
ampere	O
mutation	O
at	O
the	O
-	O
2	O
position	O
of	O
a	O
5	O
splice	O
site	O
broken	O
along	O

site	O
our	O
of	O
mRNA	O
this	O
is	O
splice	O
first	O
,	O
regarding	O
effects	O
on	O
the	O
-	O
knowledge	O
report	O
of	O
a	O
mutation	O
at	O
pre	O
-	O
2	O
position	O
splicing	O
the	O
5	O
a	O
To	O
.	O

To	O
our	O
knowledge	O
,	O
humiliated	O
	O
template	O
rna	O
tie	O
low	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
	O
lap	O
joint	O
mutation	O
at	O
the	O
-	O
2	O
position	O
of	O
a	O
5	O
splice	O
site	O
broken	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
report	O
regarding	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
the	O
-	O
2	O
position	O
of	O
a	O
5	O
splice	O
site	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
describe	O
regarding	O
gist	O
on	O
pre	O
-	O
mrna	O
marry	O
of	O
a	O
mutation	O
at	O
the	O
-	O
ii	O
posture	O
of	O
a	O
phoebe	O
wed	O
locate	O
.	O

of	O
our	O
knowledge	O
,	O
this	O
is	O
-	O
on	O
report	O
regarding	O
effects	O
To	O
site	O
position	O
splicing	O
mRNA	O
a	O
of	O
mutation	O
at	O
the	O
the	O
2	O
-	O
first	O
a	O
5	O
splice	O
pre	O
.	O

the	O
our	O
knowledge	O
mutation	O
this	O
is	O
the	O
a	O
position	O
regarding	O
site	O
on	O
5	O
at	O
2	O
splicing	O
of	O
a	O
,	O
-	O
of	O
-	O
mRNA	O
report	O
To	O
first	O
pre	O
splice	O
effects	O
.	O

To	O
our	O
cognition	O
,	O
this	O
is	O
the	O
first	O
reputation	O
regarding	O
event	O
on	O
pre	O
-	O
mRNA	O
tie	O
of	O
a	O
mutation	O
at	O
the	O
-	O
two	O
billet	O
of	O
a	O
cinque	O
splice	O
site	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
the	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
a	O
mutation	O
at	O
the	O
-	O
2	O
position	O
5	O
splice	O
site	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
mutation	O
at	O
the	O
-	O
2	O
position	O
of	O
a	O
5	O
splice	O
site	O
.	O

ATM	O
mutations	O
classical	O
-	I
telangiectasia	I
patients	O
in	O
the	O
Dutch	O
population	O
.	O

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B
-	I
telangiectasia	I
patients	O
in	O
the	O
dutch	O
universe	O
.	O

telangiectasia	O
in	O
mutations	O
germline	O
classical	O
ataxia	B
in	I
ATM	I
patients	O
.	O
the	O
Dutch	O
population	O
-	O

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B
-	I
telangiectasia	I
in	O
the	O
population	O
.	O

ATM	O
germline	O
sport	O
sport	O
mutations	O
in	O
classical	O
ataxia	B
-	I
telangiectasia	I
patients	O
universe	O
classical	O
music	O
in	O
the	O
Dutch	O
population	O

ATM	O
germline	O
sport	O
sport	O
mutations	O
in	O
classical	O
ataxia	B
-	I
telangiectasia	I
patients	O
universe	O
dutch	O
in	O
the	O
Dutch	O
population	O
.	O

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B
-	I
telangiectasia	I
patients	O
in	O
the	O
Dutch	O
universe	O
.	O

population	O
germline	O
mutations	O
ATM	O
telangiectasia	O
ataxia	B
-	I
Dutch	I
patients	O
in	O
the	O
classical	O
in	O
.	O

ATM	O
germline	O
sport	O
sport	O
mutations	O
in	O
classical	O
ataxia	B
-	I
telangiectasia	I
patients	O
universe	O
classical	O
music	O
in	O
the	O
Dutch	O
population	O

ATM	O
germline	O
mutations	O
in	O
hellenic	O
dyssynergia	B
-	I
telangiectasia	I
patients	O
in	O
the	O
dutch	O
universe	O
.	O

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B
-	I
telangiectasia	I
patients	O
in	O
the	O
Dutch	O
population	O
.	O

)	O
mutations	O
in	O
autosomal	O
ATM	O
gene	O
are	O
-	O
-	O
the	O
the	B
recessive	I
ataxia	I
disorder	B
for	I
telangiectasia	I
(	O
A	B
responsible	I
Germline	I
T	O
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
mt	B
indium	B
indium	B
indium	B
indium	B
indium	B
-	I
T	I
)	O
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
mt	B
indium	B
indium	B
indium	B
indium	B
indium	B
-	I
T	I
)	O
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
cistron	O
are	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
dyssynergia	B
-	I
telangiectasia	I
(	O
a	B
-	I
tetraiodothyronine	I
)	O
.	O

Germline	O
mutations	O
in	O
ATM	O
gene	O
are	O
responsible	O
for	O
autosomal	B
recessive	I
disorder	I
ataxia	B
telangiectasia	I
(	O
-	I
T	I
)	O
.	O

the	O
are	O
responsible	O
for	O
autosomal	B
recessive	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
cistron	O
are	O
creditworthy	O
for	O
the	O
autosomal	B
recessive	I
disarray	I
dyssynergia	B
-	I
telangiectasia	I
(	O
adenine	B
-	I
thymine	I
)	O
.	O

-	O
mutations	O
for	O
are	O
ATM	O
gene	O
telangiectasia	O
responsible	O
in	O
the	O
autosomal	B
recessive	I
)	I
ataxia	B
the	I
Germline	I
(	O
A	B
-	I
T	I
disorder	O
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
mt	B
indium	B
indium	B
indium	B
indium	B
mt	B
-	I
T	I
)	O
.	O

Germline	O
mutations	O
in	O
the	O
are	O
responsible	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
.	O

In	O
our	O
study	O
,	O
classical	O
music	O
ampere	O
shape	O
mt	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
classical	B
A	I
-	I
T	O
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
nineteen	O
nineteen	O
nineteen	O
nineteen	O
nineteen	O

In	O
our	O
study	O
have	O
spectrum	O
in	O
19	O
A	B
-	I
patients	O
,	O
including	O
populations	O
,	O
as	O
well	O
as	O
of	O
ethnic	O
origin	O
.	O

In	O
our	O
examine	O
,	O
we	O
have	O
check	O
the	O
ATM	O
sport	O
spectrum	O
in	O
nineteen	O
authoritative	O
A	B
-	I
thymine	I
patients	O
,	O
include	O
some	O
immigrant	O
populations	O
,	O
as	O
intimately	O
as	O
12	O
of	O
Dutch	O
ethnic	O
source	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
determined	O
ATM	O
in	O
19	O
classical	O
A	B
-	I
T	I
patients	O
,	O
including	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
.	O

inch	O
our	O
field	O
,	O
we	O
have	O
influence	O
the	O
ATM	O
sport	O
spectrum	O
inch	O
nineteen	O
hellenic	O
axerophthol	B
-	I
T	I
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
considerably	O
as	O
xii	O
of	O
Dutch	O
ethnic	O
origin	O
.	O

In	O
our	O
study	O
,	O
classical	O
music	O
ampere	O
shape	O
mt	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
classical	B
A	I
-	I
T	O
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
nineteen	O
nineteen	O
nineteen	O
nineteen	O
nineteen	O

in	O
our	O
contemplate	O
,	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
xix	O
definitive	O
A	B
-	I
triiodothyronine	I
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
considerably	O
as	O
xii	O
of	O
Dutch	O
pagan	O
parentage	O
.	O

some	O
,	O
study	O
,	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
as	O
Dutch	B
-	I
T	I
patients	O
12	O
including	O
our	O
immigrant	O
origin	O
,	O
classical	O
well	O
as	O
In	O
A	O
populations	O
ethnic	O
of	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
the	O
mutation	O
spectrum	O
in	O
19	O
classical	O
A	B
-	I
T	I
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
12	O
of	O
Dutch	O
origin	O

In	O
our	O
study	O
,	O
classical	O
music	O
ampere	O
shape	O
classical	O
music	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	B
classical	I
A	I
-	O
T	O
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
nineteen	O
nineteen	O
nineteen	O
nineteen	O

In	O
our	O
study	O
,	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
classical	O
A	B
-	I
T	I
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
.	O

both	O
the	O
protein	O
shortness	O
screen	O
(	O
PTT	O
)	O
and	O
the	O
confinement	O
endonuclease	O
fingerprinting	O
(	O
referee	O
)	O
method	O
were	O
exploited	O
and	O
compared	O
for	O
their	O
detecting	O
efficiency	O
,	O
describe	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
severally	O
.	O

the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
and	O
fingerprinting	O
(	O
REF	O
)	O
method	O
used	O
and	O
detection	O
identifying	O
76	O
60	O
the	O
mutations	O
,	O
respectively	O

76	O
mutations	O
protein	O
truncation	O
method	O
(	O
compared	O
%	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
efficiency	O
.	O
)	O
test	O
60	O
used	O
and	O
)	O
for	O
their	O
detection	O
the	O
,	O
identifying	O
Both	O
were	O
and	O
%	O
PTT	O
of	O
the	O
(	O
,	O
respectively	O
REF	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
and	O
the	O
restriction	O
endonuclease	O
(	O
REF	O
)	O
method	O
were	O
and	O
compared	O
for	O
their	O
efficiency	O
,	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
respectively	O
.	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
(	O
REF	O
)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	O
efficiency	O
,	O
identifying	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
(	O
REF	O
)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	O
efficiency	O
,	O
identifying	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O

Both	O
the	O
protein	O
shortness	O
essay	O
(	O
PTT	O
)	O
and	O
the	O
limitation	O
endonuclease	O
fingerprinting	O
(	O
referee	O
)	O
method	O
were	O
utilize	O
and	O
liken	O
for	O
their	O
espial	O
efficiency	O
,	O
describe	O
lxxvi	O
%	O
and	O
sixty	O
%	O
of	O
the	O
mutations	O
,	O
severally	O
.	O

efficiency	O
used	O
protein	O
truncation	O
test	O
(	O
endonuclease	O
the	O
and	O
the	O
restriction	O
PTT	O
fingerprinting	O
76	O
and	O
)	O
method	O
were	O
)	O
and	O
compared	O
for	O
%	O
detection	O
Both	O
,	O
%	O
(	O
REF	O
their	O
60	O
,	O
of	O
the	O
mutations	O
identifying	O
respectively	O
.	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
(	O
REF	O
)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	O
efficiency	O
,	O
identifying	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O
testing	O
mental	O

Both	O
the	O
test	O
(	O
)	O
and	O
fingerprinting	O
REF	O
)	O
method	O
used	O
and	O
compared	O
their	O
detection	O
efficiency	O
,	O
identifying	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
respectively	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
(	O
REF	O
)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	O
efficiency	O
,	O
identifying	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
respectively	O
.	O

nearly	O
patients	O
were	O
obtain	O
to	O
be	O
compound	O
heterozygote	O
.	O

Most	O
receive	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote	O
receive	O
.	O

Most	O
found	O
were	O
patients	O
to	O
be	O
heterozygote	O
compound	O
.	O

most	O
patients	O
were	O
retrieve	O
to	O
be	O
compound	O
heterozygote	O
.	O

Most	O
were	O
found	O
be	O
heterozygote	O

compound	O
patients	O
were	O
found	O
to	O
be	O
heterozygote	O
Most	O
.	O

Most	O
patients	O
were	O
found	O
to	O
be	O
compound	O
.	O

Most	O
heterozygote	O
were	O
found	O
patients	O
be	O
compound	O
to	O
.	O

Most	O
patient	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote	O
receive	O
.	O

virtually	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote	O
.	O

Most	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote	O
.	O

Seventeen	O
were	O
distinct	O
of	O
10	O
not	O
reported	O
previously	O
.	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
not	O
reported	O
previously	O

seventeen	O
mutations	O
were	O
trenchant	O
,	O
of	O
which	O
10	O
were	O
not	O
reported	O
antecedently	O
.	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
antecedently	O
antecedently	O
sport	O
not	O
reported	O
previously	O
.	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
antecedently	O
antecedently	O
cost	O
not	O
reported	O
previously	O
.	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
antecedently	O
antecedently	O
sport	O
not	O
reported	O
previously	O
.	O

seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
x	O
were	O
not	O
cover	O
previously	O
.	O

Seventeen	O
mutations	O
distinct	O
,	O
of	O
which	O
10	O
were	O
not	O
.	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
decade	O
were	O
not	O
cover	O
antecedently	O
.	O

Seventeen	O
,	O
were	O
distinct	O
.	O
of	O
which	O
mutations	O
were	O
not	O
reported	O
previously	O
10	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
not	O
reported	O
previously	O
.	O

Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
internet	O
site	O
cost	O
cost	O
splice	O
sites	O

are	O
small	O
mutations	O
splice	O
sites	O
.	O

mutation	O
are	O
small	O
excision	O
or	O
point	O
mutation	O
frequently	O
affecting	O
splice	O
sites	O
.	O

Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
internet	O
site	O
cost	O
cost	O
splice	O
sites	O

are	O
small	O
or	O
point	O
mutations	O
frequently	O
affecting	O
splice	O
sites	O
.	O

Mutations	O
are	O
belittled	O
deletions	O
or	O
point	O
mutations	O
oftentimes	O
affecting	O
marry	O
sites	O
.	O

Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
internet	O
site	O
cost	O
ofttimes	O
splice	O
sites	O

mutation	O
are	O
small	O
deletions	O
or	O
point	O
mutation	O
frequently	O
pretend	O
splice	O
website	O
.	O

Mutations	O
frequently	O
small	O
deletions	O
are	O
point	O
mutations	O
sites	O
affecting	O
splice	O
or	O
.	O

.	O
are	O
small	O
deletions	O
frequently	O
point	O
splice	O
or	O
affecting	O
mutations	O
sites	O
Mutations	O

Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
splice	O
sites	O
.	O

a	O
,	O
Moreover	O
16	O
.	O

Moreover	O
16	O
a	O
,	O
.	O

Moreover	O
,	O
a	O
16	O
sixteen	O
.	O

a	O
16	O
.	O

,	O
a	O
.	O

moreover	O
,	O
a	O
16	O
.	O

Moreover	O
,	O
a	O
16	O
what	O
is	O

furthermore	O
,	O
a	O
16	O
.	O

Moreover	O
16	O
.	O

Moreover	O
,	O
a	O
16	O
what	O
is	O

Moreover	O
,	O
a	O
16	O
.	O

7	O
-	O
kb	O
genomic	O
omission	O
of	O
the	O
trine	O
oddment	O
of	O
the	O
factor	O
,	O
most	O
likely	O
a	O
leave	O
of	O
recombination	O
between	O
deuce	O
contrast	O
component	O
,	O
was	O
identified	O
.	O

7	O
-	O
genomic	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene	O
,	O
a	O
result	O
of	O
recombination	O
two	O
LINE	O
elements	O
,	O
was	O
.	O

7	O
-	O
kb	O
genomic	O
probable	O
ampere	O
omission	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene	O
,	O
most	O
likely	O
a	O
result	O
of	O
parentage	O
cost	O
place	O
cost	O
close	O
recombination	O
between	O
two	O
LINE	O
elements	O
,	O
was	O
identified	O
.	O

two	O
-	O
kb	O
recombination	O
deletion	O
of	O
the	O
identified	O
,	O
of	O
between	O
gene	O
,	O
most	O
elements	O
a	O
result	O
of	O
genomic	O
was	O
the	O
LINE	O
likely	O
end	O
7	O
3	O
.	O

7	O
-	O
kb	O
genomic	O
probable	O
ampere	O
omission	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene	O
,	O
most	O
likely	O
a	O
result	O
of	O
parentage	O
cost	O
place	O
cost	O
close	O
recombination	O
between	O
two	O
LINE	O
elements	O
,	O
was	O
identified	O
.	O

7	O
-	O
kb	O
deletion	O
of	O
3	O
end	O
of	O
the	O
gene	O
,	O
most	O
likely	O
result	O
of	O
between	O
two	O
LINE	O
elements	O
,	O
was	O
identified	O
.	O

.	O
-	O
kb	O
likely	O
deletion	O
of	O
identified	O
3	O
genomic	O
of	O
the	O
gene	O
most	O
two	O
was	O
end	O
result	O
of	O
recombination	O
between	O
,	O
LINE	O
elements	O
,	O
a	O
the	O
7	O

kb	O
of	O
the	O
3	O
of	O
the	O
,	O
most	O
likely	O
a	O
result	O
of	O
recombination	O
between	O
two	O
LINE	O
elements	O
,	O
was	O

,	O
-	O
kb	O
genomic	O
deletion	O
of	O
most	O
gene	O
end	O
of	O
the	O
result	O
LINE	O
the	O
was	O
7	O
3	O
a	O
recombination	O
between	O
two	O
,	O
elements	O
of	O
likely	O
identified	O
.	O

sevener	O
-	O
kb	O
genomic	O
cut	O
of	O
the	O
troika	O
finish	O
of	O
the	O
cistron	O
,	O
most	O
likely	O
a	O
effect	O
of	O
recombination	O
between	O
deuce	O
LINE	O
elements	O
,	O
was	O
name	O
.	O

7	O
-	O
kb	O
genomic	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene	O
,	O
most	O
likely	O
a	O
result	O
of	O
recombination	O
between	O
two	O
LINE	O
elements	O
,	O
was	O
identified	O
.	O

The	O
most	O
ofttimes	O
found	O
mutant	O
,	O
identified	O
in	O
triad	O
unrelated	O
turkish	O
A	B
-	I
T	I
somebody	O
,	O
was	O
antecedently	O
key	O
to	O
be	O
a	O
turkish	O
A	B
-	I
T	I
give	O
mutant	O
.	O

The	O
most	O
frequently	O
found	O
mutation	O
identified	O
unrelated	O
Turkish	O
A	B
-	I
T	I
individuals	O
,	O
was	O
previously	O
Turkish	O
A	B
-	I
T	I
founder	O
mutation	O
.	O

be	O
most	O
frequently	O
described	O
mutation	O
,	O
identified	O
T	O
A	O
unrelated	O
.	O
A	B
-	I
to	I
Turkish	O
,	O
was	O
previously	O
found	O
T	O
-	O
a	O
individuals	O
three	B
The	I
in	I
founder	O
mutation	O
Turkish	O

The	O
most	O
frequently	O
found	O
mutant	O
mt	O
somebody	O
place	O
sport	O
mutation	O
,	O
identified	O
in	O
three	O
unrelated	O
Turkish	O
A	B
-	I
T	I
individuals	O
,	O
was	O
previously	O
mt	O
beginner	O
	O
described	O
to	O
be	O
a	O
Turkish	O
A	B
-	I
T	I
founder	O
mutation	O
.	O

The	O
most	O
frequently	O
found	O
mutant	O
mt	O
somebody	O
place	O
sport	O
mutation	O
,	O
identified	O
in	O
three	O
unrelated	O
Turkish	O
A	B
-	I
T	I
individuals	O
,	O
was	O
previously	O
mt	O
beginner	O
account	O
described	O
to	O
be	O
a	O
Turkish	O
A	B
-	I
T	I
founder	O
mutation	O
.	O

The	O
most	O
frequently	O
found	O
mutation	O
,	O
identified	O
in	O
unrelated	O
Turkish	O
-	I
T	I
individuals	O
,	O
was	O
previously	O
described	O
a	O
Turkish	O
A	B
-	I
T	I
founder	O
mutation	O
.	O

.	O
most	O
frequently	O
individuals	O
mutation	O
,	O
T	O
in	O
found	O
unrelated	O
Turkish	O
A	B
founder	I
T	I
-	O
three	O
was	O
previously	O
described	O
to	O
-	O
a	O
Turkish	O
A	B
,	I
identified	I
be	O
mutation	O
The	O

The	O
most	O
frequently	O
found	O
mutation	O
,	O
identified	O
in	O
unrelated	O
A	B
-	I
T	I
individuals	O
,	O
was	O
previously	O
described	O
be	O
a	O
Turkish	O
A	B
-	I
T	I
founder	O

The	O
most	O
oftentimes	O
found	O
mutation	O
,	O
identified	O
in	O
terzetto	O
unrelated	O
turkish	O
angstrom	B
-	I
mt	I
person	O
,	O
was	O
antecedently	O
key	O
to	O
be	O
angstrom	O
turkish	O
angstrom	B
-	I
mt	I
founder	O
mutation	O
.	O

The	O
most	O
often	O
bump	O
mutation	O
,	O
distinguish	O
in	O
trinity	O
unrelated	O
turkish	O
A	B
-	I
t	I
individuals	O
,	O
was	O
antecedently	O
discover	O
to	O
be	O
a	O
turkish	O
A	B
-	I
t	I
founder	O
mutation	O
.	O

The	O
most	O
frequently	O
found	O
mutation	O
,	O
identified	O
in	O
three	O
unrelated	O
Turkish	O
A	B
-	I
T	I
individuals	O
,	O
was	O
previously	O
described	O
to	O
be	O
a	O
Turkish	O
A	B
-	I
T	I
founder	O
mutation	O
.	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
indium	O
frequence	O
residential	O
district	O
indium	O
residential	O
district	O
residential	O
district	O
chemical	O
group	O
high	O
carrier	O
frequency	O

a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
carrier	O
in	O
such	O
communities	O
.	O

The	O
comportment	O
of	O
a	O
break	O
mutation	O
among	O
comparatively	O
little	O
ethnic	O
population	O
groups	O
in	O
Western	O
eu	O
could	O
suggest	O
a	O
high	O
carrier	O
frequence	O
in	O
such	O
communities	O
.	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
groups	O
in	O
Europe	O
could	O
indicate	O
a	O
high	O
carrier	O
frequency	O
communities	O
.	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
indium	O
frequence	O
residential	O
district	O
indium	O
residential	O
district	O
residential	O
district	O
lowly	O
high	O
carrier	O
frequency	O
in	O

The	O
front	O
of	O
a	O
founder	O
mutation	O
among	O
comparatively	O
small	O
ethnic	O
universe	O
groups	O
in	O
Western	O
Europe	O
could	O
bespeak	O
a	O
gamey	O
bearer	O
frequence	O
in	O
such	O
communities	O
.	O

The	O
presence	O
of	O
a	O
founder	O
mutant	O
among	O
comparatively	O
lowly	O
heathenish	O
universe	O
groups	O
in	O
Western	O
Europe	O
could	O
argue	O
a	O
high	O
carrier	O
frequence	O
in	O
such	O
communities	O
.	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
in	O
could	O
indicate	O
a	O
high	O
carrier	O
frequency	O
in	O
such	O
communities	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
indium	O
frequence	O
residential	O
district	O
indium	O
residential	O
district	O
residential	O
district	O
lowly	O
high	O
carrier	O
frequency	O
in	O

carrier	O
presence	O
of	O
population	O
founder	O
mutation	O
among	O
high	O
communities	O
ethnic	O
a	O
groups	O
Western	O
in	O
such	O
could	O
indicate	O
a	O
relatively	O
.	O
frequency	O
in	O
Europe	O
small	O
The	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
high	O
carrier	O
frequency	O
in	O
such	O
communities	O
.	O

significant	O
patients	O
of	O
however	O
ethnic	O
origin	O
,	O
Dutch	O
be	O
no	O
could	O
founder	O
In	O
effect	O
,	O
identified	O
.	O

indium	O
patients	O
of	O
Dutch	O
pagan	O
origin	O
,	O
notwithstanding	O
,	O
no	O
pregnant	O
flop	O
effect	O
could	O
be	O
identified	O
.	O

inwards	O
patients	O
of	O
Dutch	O
ethnic	O
source	O
,	O
however	O
,	O
no	O
meaning	O
flop	O
issue	O
could	O
be	O
identified	O
.	O

In	O
patients	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified	O
.	O

indium	O
patients	O
of	O
dutch	O
ethnic	O
origin	O
,	O
still	O
,	O
no	O
significant	O
founder	O
upshot	O
could	O
be	O
place	O
.	O

In	O
patients	O
notwithstanding	O
dutch	O
of	O
Dutch	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified	O
nevertheless	O
nevertheless	O
dutch	O
people	O

In	O
patients	O
of	O
Dutch	O
ethnic	O
origin	O
,	O
however	O
no	O
significant	O
effect	O
could	O
be	O
identified	O
.	O

In	O
patients	O
notwithstanding	O
dutch	O
of	O
Dutch	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified	O
nevertheless	O
nevertheless	O
dutch	O
people	O

patients	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O

In	O
patients	O
,	O
be	O
ethnic	O
origin	O
effect	O
however	O
of	O
no	O
significant	O
founder	O
,	O
could	O
Dutch	O
identified	O
.	O

In	O
patients	O
of	O
Dutch	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified	O
.	O

The	O
observed	O
genetic	O
heterogeneousness	O
include	O
the	O
comparative	O
luxuriously	O
part	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflectivity	O
on	O
the	O
phenotype	O
.	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflection	O
on	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
the	O
phenotype	O
.	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflection	O
on	O
familial	O
familial	O
familial	O
familial	O
familial	O
familial	O
the	O
phenotype	O
.	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
of	O
splice	O
site	O
mutations	O
had	O
no	O
reflection	O
on	O
the	O

had	O
observed	O
percentage	O
relative	O
including	O
the	O
no	O
high	O
genetic	O
of	O
splice	O
-	O
.	O
mutations	O
heterogeneity	O
The	O
reflection	O
on	O
the	O
phenotype	O
site	O

The	O
observed	O
transmissible	O
heterogeneousness	O
including	O
the	O
congeneric	O
high	O
share	O
of	O
wed	O
-	O
site	O
mutations	O
had	O
no	O
contemplation	O
on	O
the	O
phenotype	O
.	O

.	O
observed	O
genetic	O
splice	O
including	O
the	O
relative	O
the	O
had	O
of	O
heterogeneity	O
-	O
mutations	O
site	O
percentage	O
no	O
reflection	O
on	O
high	O
The	O
phenotype	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflection	O
on	O
familial	O
familial	O
familial	O
familial	O
familial	O
no	O
more	O
the	O
phenotype	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
had	O
on	O
the	O
phenotype	O
.	O

The	O
find	O
genetic	O
heterogeneousness	O
including	O
the	O
congener	O
high	O
percentage	O
of	O
wed	O
-	O
locate	O
mutations	O
had	O
no	O
contemplation	O
on	O
the	O
phenotype	O
.	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflection	O
on	O
the	O
phenotype	O
.	O

All	O
manifested	O
A	B
T	I
and	O
increased	O
cellular	O
radioresistant	O
DNA	O
synthesis	O
.	O

altogether	O
patients	O
evidence	O
classical	O
A	B
-	I
T	I
and	O
increased	O
cellular	O
radioresistant	O
dna	O
synthesis	O
.	O

and	O
classical	O
manifested	O
patients	O
A	B
-	I
cellular	I
All	O
increased	O
.	O
radioresistant	O
DNA	O
synthesis	O
T	O

All	O
patients	O
manifested	O
classical	O
A	B
-	I
T	I
and	O
cellular	O
radioresistant	O
synthesis	O
.	O

All	O
patients	O
demonstrate	O
demonstrate	O
manifested	O
classical	O
A	B
-	I
T	I
and	O
increased	O
synthetic	O
thinking	O
ampere	O
cellular	O
radioresistant	O
DNA	O
synthesis	O

All	O
patients	O
demonstrate	O
demonstrate	O
manifested	O
classical	O
A	B
-	I
T	I
and	O
increased	O
synthetic	O
thinking	O
dna	O
cellular	O
radioresistant	O
DNA	O
synthesis	O

altogether	O
patients	O
manifested	O
classical	O
A	B
-	I
liothyronine	I
and	O
increased	O
cellular	O
radioresistant	O
DNA	O
deduction	O
.	O

synthesis	O
patients	O
manifested	O
All	O
and	B
-	I
T	I
DNA	O
increased	O
cellular	O
radioresistant	O
A	O
classical	O
.	O

All	O
patients	O
demonstrate	O
demonstrate	O
manifested	O
classical	O
A	B
-	I
T	I
and	O
increased	O
synthetic	O
thinking	O
ampere	O
cellular	O
radioresistant	O
DNA	O
synthesis	O

totally	O
patients	O
manifested	O
definitive	O
A	B
-	I
t	I
and	O
increased	O
cellular	O
radioresistant	O
dna	O
synthesis	O
.	O

All	O
patients	O
manifested	O
classical	O
A	B
-	I
T	I
and	O
increased	O
cellular	O
radioresistant	O
DNA	O
synthesis	O
.	O

Determination	O
of	O
gene	O
autosomal	O
structure	O
of	O
mutations	O
COL4A4	O
the	O
and	O
of	O
novel	O
the	O
causing	O
genomic	B
recessive	I
Alport	I
syndrome	I
.	O

the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
recessive	I
Alport	I
syndrome	I
.	O

conclusion	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
factor	O
and	O
of	O
refreshing	O
mutations	O
induce	O
autosomal	B
recessive	I
Alport	I
syndrome	I
.	O

finding	O
of	O
the	O
genomic	O
construction	O
of	O
the	O
COL4A4	O
cistron	O
and	O
of	O
fresh	O
mutations	O
causing	O
autosomal	B
recessionary	I
Alport	I
syndrome	I
.	O

Alport	O
of	O
the	O
genomic	O
structure	O
of	O
causing	O
autosomal	O
gene	O
and	O
of	O
novel	O
syndrome	O
the	O
COL4A4	B
recessive	I
mutations	I
Determination	I
.	O

Determination	O
of	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B
recessive	I
Alport	I
.	O

Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B
recessive	I
Alport	I
syndrome	I
factor	O
factor	O
factor	O
factor	O
factor	O
.	O

conclusion	O
of	O
the	O
genomic	O
construction	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
fresh	O
mutations	O
causation	O
autosomal	B
recessionary	I
Alport	I
syndrome	I
.	O

Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B
recessive	I
Alport	I
syndrome	I
factor	O
factor	O
factor	O
factor	O
factor	O
.	O

causing	O
of	O
the	O
of	O
structure	O
of	O
the	O
.	O
autosomal	O
and	O
genomic	O
novel	O
Determination	O
mutations	O
gene	B
recessive	I
Alport	I
syndrome	I
COL4A4	O

Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B
recessive	I
Alport	I
syndrome	I
.	O

autosomal	B
recessionary	I
Alport	I
syndrome	I
is	O
a	O
liberalist	O
hematuric	B
glomerulonephritis	I
characterized	O
by	O
glomerular	B
cellar	I
membrane	I
abnormalities	I
and	O
relate	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
factor	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
case	O
quaternion	O
collagen	O
chains	O
,	O
severally	O
.	O

autosomal	B
recessive	I
Alport	I
syndrome	I
is	O
a	O
imperfect	O
hematuric	B
glomerulonephritis	I
qualify	O
by	O
glomerular	B
cellar	I
membrane	I
abnormalcy	I
and	O
associated	O
with	O
sport	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
cistron	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
collagen	O
strand	O
,	O
severally	O
.	O

Autosomal	B
is	O
progressive	O
hematuric	B
glomerulonephritis	I
by	O
glomerular	B
basement	I
abnormalities	I
and	O
associated	O
with	O
mutations	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene	O
,	O
which	O
alpha3	O
alpha4	O
type	O
IV	O
chains	O
,	O
respectively	O
.	O

Autosomal	B
recessive	I
alpha3	I
syndrome	I
is	O
which	O
COL4A4	O
hematuric	B
glomerulonephritis	I
characterized	O
by	O
or	B
,	I
membrane	I
abnormalities	I
the	O
associated	O
with	O
in	O
mutations	O
either	O
the	O
COL4A3	O
IV	O
the	O
gene	O
basement	O
and	O
a	O
encode	O
and	O
chains	O
progressive	O
alpha4	O
type	O
glomerular	O
collagen	O
Alport	O
,	O
respectively	O
.	O

the	B
mutations	I
Alport	I
syndrome	I
is	O
a	O
glomerular	O
the	B
glomerulonephritis	I
characterized	O
by	O
progressive	B
basement	I
,	I
encode	I
and	O
associated	O
with	O
.	O
in	O
either	O
hematuric	O
which	O
or	O
Autosomal	O
COL4A4	O
alpha3	O
membrane	O
abnormalities	O
COL4A3	O
the	O
IV	O
and	O
recessive	O
type	O
gene	O
collagen	O
chains	O
,	O
respectively	O
alpha4	O

Autosomal	B
recessive	I
Alport	I
syndrome	I
progressive	O
hematuric	B
glomerulonephritis	I
characterized	O
glomerular	B
basement	I
membrane	I
abnormalities	I
and	O
with	O
mutations	O
in	O
either	O
COL4A3	O
or	O
COL4A4	O
gene	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
type	O
IV	O
chains	O
,	O
respectively	O
.	O

Autosomal	B
recessive	I
Alport	I
syndrome	I
is	O
a	O
progressive	O
hematuric	B
glomerulonephritis	I
characterized	O
by	O
glomerular	B
basement	I
membrane	I
abnormalities	I
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
sir	O
ernst	O
boris	O
chain	O
cost	O
severally	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
collagen	O
chains	O

Autosomal	B
recessive	I
Alport	I
syndrome	I
hematuric	B
glomerulonephritis	I
characterized	O
by	O
glomerular	B
membrane	I
abnormalities	I
mutations	O
the	O
COL4A3	O
COL4A4	O
which	O
encode	O
the	O
alpha3	O
alpha4	O
type	O
chains	O
,	O
.	O

autosomal	B
recessive	I
Alport	I
syndrome	I
is	O
a	O
progressive	O
hematuric	B
glomerulonephritis	I
characterized	O
by	O
glomerular	B
cellar	I
membrane	I
abnormalcy	I
and	O
associated	O
with	O
sport	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
factor	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
eccentric	O
tetrad	O
collagen	O
chains	O
,	O
severally	O
.	O

Autosomal	B
recessive	I
Alport	I
syndrome	I
is	O
a	O
progressive	O
hematuric	B
glomerulonephritis	I
characterized	O
by	O
glomerular	B
basement	I
membrane	I
abnormalities	I
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
sir	O
ernst	O
boris	O
chain	O
cost	O
severally	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
collagen	O
chains	O

Autosomal	B
recessive	I
Alport	I
syndrome	I
is	O
a	O
progressive	O
hematuric	B
glomerulonephritis	I
characterized	O
by	O
glomerular	B
basement	I
membrane	I
abnormalities	I
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
collagen	O
chains	O
,	O
respectively	O
.	O

To	O
engagement	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
factor	O
has	O
been	O
hinder	O
by	O
the	O
deficiency	O
of	O
genomic	O
construction	O
information	O
.	O

To	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
information	O
.	O

To	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
information	O
.	O

,	O
in	O
the	O
two	O
has	O
been	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
information	O
.	O

To	O
date	O
,	O
mutation	O
screening	O
two	O
genes	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
information	O
.	O

,	O
mutation	O
screening	O
in	O
two	O
genes	O
has	O
been	O
hampered	O
the	O
lack	O
of	O
genomic	O
information	O
.	O

structure	O
date	O
,	O
information	O
screening	O
in	O
the	O
genes	O
two	O
has	O
lack	O
hampered	O
by	O
.	O
To	O
of	O
genomic	O
been	O
mutation	O
the	O

To	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
factor	O
factor	O
factor	O
factor	O
factor	O
sport	O
information	O
.	O

To	O
date	O
,	O
mutant	O
masking	O
in	O
the	O
ii	O
factor	O
has	O
been	O
hampered	O
by	O
the	O
want	O
of	O
genomic	O
structure	O
entropy	O
.	O

genomic	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
hampered	O
genes	O
has	O
been	O
lack	O
To	O
the	O
two	O
structure	O
by	O
of	O
information	O
.	O

To	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
information	O
.	O

We	O
account	O
here	O
the	O
unadulterated	O
delineation	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
factor	O
,	O
a	O
comprehensive	O
factor	O
test	O
,	O
and	O
the	O
subsequent	O
sensing	O
of	O
tenner	O
fresh	O
mutations	O
in	O
ogdoad	O
patients	O
diagnosed	O
with	O
autosomal	B
recessive	I
Alport	I
syndrome	I
.	O

report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
screen	O
,	O
detection	O
novel	O
mutations	O
patients	O
autosomal	B
recessive	I
Alport	I
syndrome	I

mutations	O
recessive	O
here	O
the	O
comprehensive	O
characterization	O
and	O
diagnosed	O
48	O
exons	O
of	O
the	O
COL4A4	O
of	O
.	O
a	O
complete	O
patients	O
screen	O
,	O
the	O
the	O
subsequent	O
detection	O
report	O
10	O
novel	O
We	O
gene	O
eight	O
in	O
of	O
with	O
autosomal	B
gene	I
Alport	I
syndrome	I
,	O

We	O
report	O
here	O
the	O
complete	O
characterization	O
48	O
exons	O
of	O
the	O
gene	O
,	O
a	O
comprehensive	O
gene	O
,	O
and	O
the	O
subsequent	O
of	O
10	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B
recessive	I
syndrome	I
.	O

We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B
recessive	I
Alport	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
syndrome	I
.	O

We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B
recessive	I
Alport	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
syndrome	I
.	O

We	O
report	O
here	O
the	O
discharge	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
factor	O
,	O
a	O
comprehensive	O
factor	O
concealment	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
x	O
new	O
mutations	O
in	O
eight	O
patients	O
name	O
with	O
autosomal	B
recessionary	I
Alport	I
syndrome	I
.	O

of	O
screen	O
here	O
the	O
complete	O
characterization	O
the	O
autosomal	O
48	O
exons	O
of	O
of	O
COL4A4	O
mutations	O
eight	O
a	O
comprehensive	O
gene	O
the	O
,	O
and	O
the	O
in	O
detection	O
We	O
10	O
diagnosed	O
gene	O
,	O
subsequent	O
patients	O
Alport	O
with	O
report	B
recessive	I
novel	I
syndrome	I
.	O

We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B
recessive	I
Alport	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
terminated	I
terminated	O
terminated	I
blind	O
syndrome	I
.	O

We	O
report	O
complete	O
characterization	O
the	O
48	O
COL4A4	O
,	O
a	O
comprehensive	O
screen	O
,	O
and	O
subsequent	O
detection	O
of	O
10	O
novel	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B
recessive	I
Alport	I
syndrome	I

We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B
recessive	I
Alport	I
syndrome	I
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
exchange	O
indium	O
	O
indium	O
	O
	O
place	O
the	O
heterozygous	O
carriers	O
,	O
in	O
11	O
.	O

identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
heterozygous	O
,	O
in	O
11	O
.	O

Furthermore	O
,	O
we	O
distinguish	O
a	O
glycine	O
to	O
alanine	O
permutation	O
in	O
the	O
collagenic	O
arena	O
that	O
is	O
obviously	O
mum	O
in	O
the	O
heterozygous	O
carriers	O
,	O
in	O
eleven	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
collagenous	O
domain	O
is	O
apparently	O
silent	O
in	O
the	O
heterozygous	O
carriers	O
11	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
exchange	O
indium	O
	O
indium	O
	O
	O
exchange	O
the	O
heterozygous	O
carriers	O
,	O
in	O
11	O
.	O

Furthermore	O
,	O
we	O
identify	O
a	O
glycine	O
to	O
alanine	O
switch	O
in	O
the	O
collagenic	O
sphere	O
that	O
is	O
ostensibly	O
tacit	O
in	O
the	O
heterozygous	O
flattop	O
,	O
in	O
11	O
.	O

furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
exchange	O
in	O
the	O
collagenic	O
orbit	O
that	O
is	O
apparently	O
mum	O
in	O
the	O
heterozygous	O
postman	O
,	O
in	O
xi	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
domain	O
apparently	O
silent	O
in	O
the	O
heterozygous	O
carriers	O
,	O
in	O
11	O

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
exchange	O
indium	O
	O
indium	O
	O
	O
exchange	O
the	O
heterozygous	O
carriers	O
,	O
in	O
11	O
.	O

heterozygous	O
,	O
we	O
the	O
a	O
glycine	O
to	O
the	O
11	O
in	O
identified	O
collagenous	O
that	O
domain	O
in	O
apparently	O
silent	O
in	O
alanine	O
.	O
carriers	O
,	O
is	O
substitution	O
Furthermore	O

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
the	O
heterozygous	O
carriers	O
,	O
in	O
11	O
.	O

control	O
%	O
of	O
and	O
control	O
individuals	O
,	O
all	O
this	O
one	O
for	O
individual	O
5	O
homozygous	O
in	O
glycine	O
substitution	O
.	O

five	O
%	O
of	O
all	O
ascendancy	O
individuals	O
,	O
and	O
in	O
i	O
ascendancy	O
somebody	O
homozygous	O
for	O
this	O
glycine	O
replacement	O
.	O

5	O
%	O
of	O
all	O
verify	O
person	O
,	O
and	O
in	O
unrivalled	O
verify	O
private	O
homozygous	O
for	O
this	O
glycine	O
replacement	O
.	O

5	O
%	O
of	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
for	O
this	O
glycine	O
substitution	O
.	O

pentad	O
%	O
of	O
all	O
ensure	O
individuals	O
,	O
and	O
in	O
i	O
ensure	O
person	O
homozygous	O
for	O
this	O
glycine	O
replacement	O
.	O

5	O
%	O
indium	O
of	O
all	O
control	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
for	O
this	O
glycine	O
substitution	O
in	O
in	O
in	O
somebody	O
.	O

5	O
%	O
of	O
all	O
control	O
individuals	O
,	O
and	O
in	O
one	O
individual	O
homozygous	O
this	O
glycine	O
substitution	O
.	O

5	O
%	O
indium	O
of	O
all	O
control	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
for	O
this	O
glycine	O
substitution	O
in	O
in	O
in	O
somebody	O
.	O

%	O
control	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
.	O

5	O
%	O
in	O
this	O
control	O
individuals	O
homozygous	O
and	O
of	O
one	O
control	O
individual	O
,	O
for	O
all	O
glycine	O
substitution	O
.	O

5	O
%	O
of	O
all	O
control	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
for	O
this	O
glycine	O
substitution	O
.	O

individuals	O
has	O
been	O
that	O
previous	O
finding	O
of	O
in	O
with	O
substitution	O
no	O
is	O
associated	O
not	O
glycine	O
any	O
obvious	O
phenotype	O
a	O
There	O
homozygous	O
.	O

There	O
has	O
been	O
no	O
previous	O
finding	O
of	O
a	O
glycine	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
somebody	O
somebody	O
cost	O
cost	O
cost	O
cost	O
in	O
homozygous	O
individuals	O
.	O

There	O
has	O
been	O
no	O
previous	O
finding	O
of	O
a	O
glycine	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
somebody	O
somebody	O
cost	O
cost	O
cost	O
cost	O
in	O
homozygous	O
individuals	O
.	O

there	O
has	O
been	O
no	O
old	O
finding	O
of	O
a	O
glycine	O
switch	O
that	O
is	O
not	O
relate	O
with	O
any	O
obvious	O
phenotype	O
in	O
homozygous	O
somebody	O
.	O

There	O
has	O
been	O
previous	O
finding	O
of	O
a	O
glycine	O
that	O
is	O
not	O
associated	O
any	O
obvious	O
in	O
homozygous	O
individuals	O
.	O

no	O
of	O
a	O
glycine	O
that	O
is	O
associated	O
with	O
any	O
obvious	O
phenotype	O
in	O
homozygous	O
individuals	O
.	O

there	O
has	O
been	O
no	O
late	O
rule	O
of	O
a	O
glycine	O
replacement	O
that	O
is	O
not	O
relate	O
with	O
any	O
obvious	O
phenotype	O
in	O
homozygous	O
someone	O
.	O

with	O
has	O
glycine	O
of	O
previous	O
finding	O
any	O
a	O
been	O
substitution	O
that	O
is	O
individuals	O
associated	O
no	O
There	O
obvious	O
phenotype	O
in	O
homozygous	O
not	O
.	O

There	O
has	O
been	O
no	O
previous	O
finding	O
of	O
a	O
glycine	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
somebody	O
somebody	O
cost	O
cost	O
cost	O
somebody	O
in	O
homozygous	O
individuals	O
.	O

There	O
has	O
been	O
no	O
of	O
a	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
in	O
.	O

There	O
has	O
been	O
no	O
previous	O
finding	O
of	O
a	O
glycine	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
in	O
homozygous	O
individuals	O
.	O

Founder	O
and	O
mutations	O
French	O
Canadian	O
breast	B
and	I
ovarian	I
cancer	I
families	O
.	O

founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
gallic	O
Canadian	O
front	B
and	I
ovarian	I
cancer	I
fellowship	O
.	O

Canadian	O
BRCA2	O
and	O
BRCA1	O
mutations	O
in	O
and	O
Founder	O
breast	B
.	I
ovarian	I
cancer	I
families	O
French	O

Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
and	I
ovarian	I
families	O
.	O

Founder	O
BRCA1	O
canadian	O
summit	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	B
family	B
line	B
sport	I
and	I
ovarian	I
cancer	O
families	O

Founder	O
BRCA1	O
canadian	O
summit	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	B
family	B
line	B
sport	I
and	I
ovarian	I
cancer	O
families	O

Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
canadian	O
titty	B
and	I
ovarian	I
cancer	I
phratry	O
.	O

families	O
BRCA1	O
and	O
Founder	O
Canadian	O
in	O
French	O
cancer	O
breast	B
and	I
ovarian	I
mutations	I
BRCA2	O
.	O

Founder	O
BRCA1	O
canadian	O
summit	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	B
family	B
line	B
sport	I
and	I
ovarian	I
cancer	O
families	O

collapse	O
BRCA1	O
and	O
BRCA2	O
sport	O
in	O
french	O
canadian	O
breast	B
and	I
ovarian	I
cancer	I
families	O
.	O

Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	B
and	I
ovarian	I
cancer	I
families	O
.	O

We	O
have	O
identified	O
four	O
factor	O
indium	O
for	O
each	O
one	O
sport	O
mutations	O
in	O
each	O
of	B
the	I
breast	O
cancer	O
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	B
Canadian	I
breast	O
cancer	B
and	I
breast	I
/	I
ovarian	O
cancer	O
families	O
from	O
Quebec	O
element	O
element	O
element	O
element	O

We	O
have	O
identified	O
in	O
cancer	I
-	O
susceptibility	O
,	O
BRCA1	O
BRCA2	O
,	O
in	O
breast	B
cancer	I
and	O
breast	B
/	I
cancer	I
from	O
Quebec	O
.	O

We	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
front	B
cancer	I
-	O
susceptibleness	O
factor	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
french	O
Canadian	O
front	B
cancer	I
and	O
front	B
/	I
ovarian	I
cancer	I
folk	O
from	O
Quebec	O
.	O

We	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
the	O
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
and	O
breast	B
/	I
ovarian	I
cancer	I
families	O
from	O
Quebec	O
.	O

We	O
have	O
discover	O
four	O
mutations	O
in	O
each	O
of	O
the	O
boob	B
crab	I
-	O
susceptibleness	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	O
Canadian	O
boob	B
crab	I
and	O
boob	B
/	I
ovarian	I
crab	I
house	O
from	O
Quebec	O
.	O

We	O
have	O
identified	O
four	O
factor	O
indium	O
for	O
each	O
one	O
sport	O
mutations	O
in	O
each	O
of	B
the	I
breast	O
cancer	O
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	B
Canadian	I
breast	O
cancer	B
and	I
breast	I
/	I
ovarian	O
cancer	O
families	O
from	O
Quebec	O
element	O
element	O
element	O
element	O

We	O
have	O
distinguish	O
quartet	O
sport	O
in	O
each	O
of	O
the	O
titty	B
cancer	I
-	O
susceptibleness	O
cistron	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
gallic	O
Canadian	O
titty	B
cancer	I
and	O
titty	B
/	I
ovarian	I
cancer	I
category	O
from	O
Quebec	O
.	O

French	O
,	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
breast	B
cancer	I
-	O
susceptibility	O
and	O
families	O
BRCA1	O
and	O
BRCA2	O
ovarian	O
in	O
have	O
Canadian	O
Quebec	B
cancer	I
genes	O
breast	B
/	I
We	I
,	I
breast	O
from	O
cancer	O
.	O

We	O
have	O
identified	O
four	O
mutations	O
in	O
of	O
breast	B
cancer	I
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
,	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
ovarian	I
cancer	I
families	O
Quebec	O

We	O
have	O
identified	O
four	O
factor	O
indium	O
for	O
each	O
one	O
susceptibleness	O
mutations	O
in	O
each	O
of	B
the	I
breast	O
cancer	O
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	B
Canadian	I
breast	O
cancer	B
and	I
breast	I
/	I
ovarian	O
cancer	O
families	O
from	O
Quebec	O
element	O
element	O
element	O
element	O

We	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
breast	B
cancer	I
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
breast	B
/	I
ovarian	I
cancer	I
families	O
from	O
Quebec	O
.	O

To	O
identify	O
give	O
effects	O
,	O
we	O
study	O
severally	O
learn	O
French	O
Canadian	O
crab	B
fellowship	O
for	O
the	O
distribution	O
of	O
these	O
eight	O
mutations	O
.	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	B
families	O
for	O
the	O
distribution	O
of	O
these	O
sport	O
beginner	O
beginner	O
beginner	O
beginner	O
beginner	O
eight	O
mutations	O
.	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	B
families	O
for	O
the	O
distribution	O
of	O
these	O
sport	O
beginner	O
beginner	O
beginner	O
beginner	O
beginner	O
eight	O
mutations	O
.	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
French	O
Canadian	O
families	O
for	O
the	O
distribution	O
of	O
these	O
eight	O

the	O
identify	O
ascertained	O
examined	O
,	O
we	O
distribution	O
independently	O
founder	O
French	O
Canadian	O
cancer	B
.	O
for	O
effects	O
To	O
of	O
these	O
eight	O
mutations	O
families	O

To	O
describe	O
founder	O
effects	O
,	O
we	O
analyze	O
severally	O
insure	O
French	O
canadian	O
crab	B
families	O
for	O
the	O
distribution	O
of	O
these	O
eight	O
mutations	O
.	O

.	O
identify	O
founder	O
Canadian	O
,	O
we	O
examined	O
eight	O
the	O
French	O
effects	O
cancer	B
for	O
families	O
ascertained	O
distribution	O
of	O
these	O
independently	O
To	O
mutations	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	B
families	O
for	O
the	O
distribution	O
of	O
these	O
sport	O
beginner	O
beginner	O
beginner	O
beginner	O
prove	O
eight	O
mutations	O
.	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	B
families	O
the	O
these	O
eight	O
mutations	O
.	O

To	O
distinguish	O
founder	O
event	O
,	O
we	O
test	O
severally	O
ascertained	O
French	O
Canadian	O
cancer	B
families	O
for	O
the	O
dispersion	O
of	O
these	O
eight	O
mutant	O
.	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	B
families	O
for	O
the	O
distribution	O
of	O
these	O
eight	O
mutations	O
.	O

sport	O
were	O
notice	O
in	O
41	O
of	O
97	O
families	O
.	O

Mutations	O
sport	O
were	O
found	O
in	O
41	O
of	O
97	O
families	O
indium	O
.	O

Mutations	O
in	O
found	O
were	O
41	O
of	O
families	O
97	O
.	O

Mutations	O
were	O
found	O
in	O
41	O
of	O
xcvii	O
category	O
.	O

Mutations	O
found	O
in	O
of	O
families	O

97	O
were	O
found	O
in	O
41	O
of	O
families	O
Mutations	O
.	O

Mutations	O
were	O
found	O
in	O
41	O
of	O
97	O
.	O

Mutations	O
families	O
found	O
in	O
were	O
of	O
97	O
41	O
.	O

Mutations	O
cost	O
were	O
found	O
in	O
41	O
of	O
97	O
families	O
indium	O
.	O

Mutations	O
were	O
launch	O
in	O
41	O
of	O
97	O
home	O
.	O

Mutations	O
were	O
found	O
in	O
41	O
of	O
97	O
families	O
.	O

sixer	O
of	O
eight	O
mutant	O
were	O
detect	O
at	O
least	O
twice	O
.	O

Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	O
least	O
twice	O
cost	O
cost	O
cost	O
.	O

Six	O
of	O
eight	O
mutations	O
were	O
note	O
at	O
least	O
double	O
.	O

Six	O
of	O
ogdoad	O
mutations	O
were	O
follow	O
at	O
least	O
doubly	O
.	O

Six	O
eight	O
mutations	O
observed	O
at	O
least	O
twice	O
.	O

least	O
.	O
eight	O
were	O
mutations	O
observed	O
at	O
Six	O
twice	O
of	O

Six	O
least	O
eight	O
mutations	O
of	O
observed	O
were	O
at	O
twice	O
.	O

least	O
mutations	O
eight	O
of	O
were	O
observed	O
.	O
Six	O
twice	O
at	O

Six	O
mutations	O
were	O
observed	O
least	O

Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	O
least	O
twice	O
cost	O
cost	O
cost	O
.	O

Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	O
least	O
twice	O
.	O

,	O
BRCA1	O
C4446T	O
common	O
was	O
the	O
most	O
mutation	O
BRCA2	O
found	O
the	O
followed	O
The	O
by	O
mutation	O
8765delAG	O
mutation	O
.	O

The	O
BRCA1	O
C4446T	O
variation	O
was	O
the	O
most	O
plebeian	O
variation	O
found	O
,	O
be	O
by	O
the	O
BRCA2	O
8765delAG	O
variation	O
.	O

The	O
BRCA1	O
C4446T	O
mutant	O
was	O
the	O
most	O
green	O
mutant	O
receive	O
,	O
be	O
by	O
the	O
BRCA2	O
8765delAG	O
mutant	O
.	O

The	O
BRCA1	O
C4446T	O
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
.	O

The	O
BRCA1	O
C4446T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
receive	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
.	O

The	O
BRCA1	O
sport	O
C4446T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
mutant	O
mutant	O
mutant	O
uncouth	O
.	O

The	O
BRCA1	O
C4446T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
found	O
followed	O
by	O
BRCA2	O
8765delAG	O
mutation	O
.	O

The	O
BRCA1	O
sport	O
C4446T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
mutant	O
mutant	O
mutant	O
uncouth	O
.	O

BRCA1	O
was	O
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
.	O

The	O
BRCA1	O
mutation	O
BRCA2	O
was	O
the	O
by	O
common	O
C4446T	O
found	O
,	O
followed	O
most	O
the	O
mutation	O
8765delAG	O
mutation	O
.	O

The	O
BRCA1	O
C4446T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
.	O

families	O
,	O
these	O
28	O
were	O
found	O
in	O
mutations	O
a	O
41	O
have	O
identified	O
Together	O
to	O
of	O
mutation	O
.	O

together	O
,	O
these	O
variation	O
were	O
found	O
in	O
xxviii	O
of	O
41	O
sept	O
discover	O
to	O
have	O
a	O
mutation	O
.	O

unitedly	O
,	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
xli	O
category	O
describe	O
to	O
have	O
a	O
sport	O
.	O

Together	O
,	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation	O
.	O

unitedly	O
,	O
these	O
variation	O
were	O
find	O
in	O
28	O
of	O
41	O
families	O
name	O
to	O
have	O
a	O
variation	O
.	O

Together	O
,	O
	O
sport	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation	O
indium	O
indium	O
indium	O
.	O

Together	O
,	O
these	O
mutations	O
were	O
found	O
in	O
28	O
41	O
families	O
to	O
have	O
a	O
mutation	O
.	O

Together	O
,	O
	O
sport	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation	O
indium	O
indium	O
indium	O
.	O

,	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O

Together	O
,	O
of	O
a	O
were	O
found	O
to	O
28	O
these	O
41	O
families	O
identified	O
in	O
have	O
mutations	O
mutation	O
.	O

Together	O
,	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation	O
.	O

The	O
of	O
of	O
of	O
the	O
four	O
BRCA1	O
mutations	O
was	O
18	O
.	O

The	O
odds	O
of	O
sleuthing	O
of	O
any	O
of	O
the	O
tetrad	O
BRCA1	O
mutations	O
was	O
eighteen	O
.	O

the	O
detection	O
of	O
odds	O
of	O
any	O
BRCA1	O
The	O
four	O
.	O
mutations	O
was	O
18	O
of	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
BRCA1	O
mutations	O
18	O
.	O

The	O
odds	O
	O
	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
	O
betting	O
odds	O
BRCA1	O
mutations	O
was	O
18	O

The	O
odds	O
	O
	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
	O
	O
BRCA1	O
mutations	O
was	O
18	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
iv	O
BRCA1	O
mutations	O
was	O
18	O
.	O

18	O
odds	O
of	O
The	O
the	O
any	O
of	O
was	O
four	O
BRCA1	O
mutations	O
of	O
detection	O
.	O

The	O
odds	O
	O
	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
	O
betting	O
odds	O
BRCA1	O
mutations	O
was	O
18	O

The	O
odds	O
of	O
sleuthing	O
of	O
any	O
of	O
the	O
quartet	O
BRCA1	O
mutations	O
was	O
18	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA1	O
mutations	O
was	O
18	O
.	O

were	O
greater	O
if	O
of	O
or	O
more	O
cases	O
one	O
the	B
cancer	I
in	O
also	O
7x	O
present	O
ovarian	O
family	O
.	O

7x	O
greater	O
if	O
ane	O
or	O
more	O
pillowcase	O
of	O
ovarian	B
cancer	I
were	O
also	O
show	O
in	O
the	O
home	O
.	O

7x	O
heavy	O
if	O
peerless	O
or	O
more	O
suit	O
of	O
ovarian	B
cancer	I
were	O
also	O
award	O
in	O
the	O
family	O
.	O

7x	O
greater	O
or	O
more	O
cases	O
of	O
ovarian	B
cancer	I
were	O
also	O
present	O
in	O
the	O
family	O
.	O

7x	O
greater	O
if	O
matchless	O
or	O
more	O
cases	O
of	O
ovarian	B
cancer	I
were	O
too	O
present	O
in	O
the	O
class	O
.	O

7x	O
greater	O
indium	O
	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B
cancer	I
were	O
also	O
present	O
in	O
the	O
family	O
in	O
in	O
sheath	O
.	O

7x	O
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
cancer	I
were	O
present	O
in	O
the	O
family	O
.	O

7x	O
greater	O
indium	O
	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B
cancer	I
were	O
also	O
present	O
in	O
the	O
family	O
in	O
in	O
sheath	O
.	O

greater	O
or	O
more	O
cases	O
of	O
ovarian	B
cancer	I
were	O
also	O
present	O

7x	O
greater	O
ovarian	O
the	O
or	O
more	O
present	O
of	O
if	B
cancer	I
were	O
also	O
cases	O
in	O
one	O
family	O
.	O

7x	O
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B
cancer	I
were	O
also	O
present	O
in	O
the	O
family	O
.	O

The	O
of	O
of	O
of	O
the	O
four	O
BRCA2	O
mutations	O
was	O
5	O
.	O

The	O
odds	O
of	O
sleuthing	O
of	O
any	O
of	O
the	O
quaternary	O
BRCA2	O
sport	O
was	O
5	O
.	O

the	O
detection	O
of	O
odds	O
of	O
any	O
BRCA2	O
The	O
four	O
.	O
mutations	O
was	O
5	O
of	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
BRCA2	O
mutations	O
5	O
.	O

The	O
odds	O
	O
	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
	O
betting	O
odds	O
BRCA2	O
mutations	O
was	O
5	O

The	O
odds	O
	O
	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
	O
	O
BRCA2	O
mutations	O
was	O
5	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
iv	O
BRCA2	O
mutations	O
was	O
5	O
.	O

5	O
odds	O
of	O
The	O
the	O
any	O
of	O
was	O
four	O
BRCA2	O
mutations	O
of	O
detection	O
.	O

The	O
odds	O
	O
	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
	O
betting	O
odds	O
BRCA2	O
mutations	O
was	O
5	O

The	O
odds	O
of	O
detecting	O
of	O
any	O
of	O
the	O
four	O
BRCA2	O
mutations	O
was	O
5	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA2	O
mutations	O
was	O
5	O
.	O

3x	O
greater	O
to	O
the	O
lowest	O
degree	O
	O
sheath	O
if	O
there	O
were	O
at	O
least	O
five	B
cases	I
of	O
breast	O
cancer	O
in	O
the	O

the	O
greater	O
if	O
.	O
were	O
at	O
least	O
five	O
family	O
of	O
breast	B
cancer	I
3x	O
in	O
cases	O
there	O

3x	O
greater	O
to	O
the	O
lowest	O
degree	O
	O
summit	O
if	O
there	O
were	O
at	O
least	O
five	B
cases	I
of	O
breast	O
cancer	O
in	O
the	O

3x	O
majuscule	O
if	O
there	O
were	O
at	O
least	O
five	O
lawsuit	O
of	O
chest	B
cancer	I
in	O
the	O
kin	O
.	O

in	O
greater	O
if	O
five	O
were	O
at	O
the	O
there	O
cases	O
of	O
3x	B
cancer	I
breast	O
least	O
family	O
.	O

3x	O
greater	O
to	O
the	O
lowest	O
degree	O
	O
sheath	O
if	O
there	O
were	O
at	O
least	O
five	B
cases	I
of	O
breast	O
cancer	O
in	O
the	O

3x	O
dandy	O
if	O
there	O
were	O
at	O
least	O
five	O
font	O
of	O
titty	B
cancer	I
in	O
the	O
phratry	O
.	O

3x	O
majuscule	O
if	O
there	O
were	O
at	O
least	O
cinque	O
cases	O
of	O
bosom	B
cancer	I
in	O
the	O
house	O
.	O

3x	O
greater	O
cases	O
.	O
were	O
at	O
in	O
five	O
if	O
of	O
breast	B
cancer	I
least	O
the	O
there	O
family	O

greater	O
if	O
there	O
were	O
at	O
least	O
five	O
breast	B
cancer	I
in	O
the	O
family	O
.	O

3x	O
greater	O
if	O
there	O
were	O
at	O
least	O
five	O
cases	O
of	O
breast	B
cancer	I
in	O
the	O
family	O
.	O

Interestingly	O
the	O
presence	O
of	O
a	O
breast	B
cancer	I
case	O
<	O
36	O
years	O
was	O
strongly	O
predictive	O
of	O
presence	O
of	O
any	O
of	O
the	O
mutations	O
screened	O
.	O

Interestingly	O
the	O
presence	O
a	O
breast	B
cancer	I
case	O
<	O
36	O
years	O
of	O
was	O
strongly	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O

Interestingly	O
,	O
the	O
presence	O
years	O
cost	O
powerfully	O
prognostic	O
of	O
a	O
breast	B
cancer	I
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
	O
sport	O
sieve	O
sport	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O

of	O
,	O
the	O
the	O
of	O
a	O
breast	B
mutations	I
the	O
<	O
presence	O
years	O
of	O
age	O
of	O
strongly	O
predictive	O
of	O
presence	O
eight	O
36	O
any	O
was	O
case	O
Interestingly	O
cancer	O
screened	O
.	O

screened	O
,	O
the	O
was	O
of	O
a	O
mutations	B
cancer	I
presence	O
<	O
36	O
years	O
age	O
of	O
eight	O
case	O
predictive	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
strongly	O
breast	O
Interestingly	O
.	O

Interestingly	O
,	O
the	O
presence	O
years	O
cost	O
powerfully	O
prognostic	O
of	O
a	O
breast	B
cancer	I
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
	O
sport	O
sieve	O
sheath	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O

interestingly	O
,	O
the	O
bearing	O
of	O
a	O
bosom	B
cancer	I
suit	O
<	O
xxxvi	O
days	O
of	O
maturate	O
was	O
powerfully	O
predictive	O
of	O
the	O
bearing	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O

Interestingly	O
,	O
the	O
presence	O
years	O
cost	O
powerfully	O
prognostic	O
of	O
a	O
breast	B
cancer	I
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
	O
sport	O
sieve	O
sheath	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O

the	O
,	O
the	O
presence	O
of	O
a	O
age	B
years	I
case	O
<	O
36	O
predictive	O
any	O
breast	O
eight	O
Interestingly	O
cancer	O
strongly	O
the	O
presence	O
of	O
of	O
of	O
of	O
was	O
mutations	O
screened	O
.	O

interestingly	O
,	O
the	O
presence	O
of	O
a	O
front	B
cancer	I
casing	O
<	O
xxxvi	O
years	O
of	O
age	O
was	O
powerfully	O
prognosticative	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
sport	O
test	O
.	O

Interestingly	O
,	O
the	O
presence	O
of	O
a	O
breast	B
cancer	I
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O

Carriers	O
of	O
descent	O
same	O
mutation	O
similar	O
from	O
to	O
families	O
,	O
shared	O
identical	O
a	O
,	O
indicating	O
the	O
the	O
mutant	O
were	O
alleles	O
likely	O
different	O
be	O
,	O
by	O
for	O
the	O
population	O
mutation	O
in	O
that	O
haplotypes	O
founder	O
.	O

Carriers	O
same	O
mutation	O
,	O
from	O
families	O
,	O
haplotypes	O
,	O
that	O
the	O
likely	O
be	O
identical	O
by	O
for	O
a	O
mutation	O
the	O
founder	O
population	O
.	O

Carriers	O
of	O
the	O
same	O
betoken	O
ampere	O
haplotype	O
mutation	O
,	O
from	O
different	O
families	O
,	O
shared	O
similar	O
haplotypes	O
,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
portend	O
portend	O
portend	O
portend	O
portend	O
portend	O
sport	O
.	O

Carriers	O
of	O
the	O
same	O
betoken	O
ampere	O
sport	O
mutation	O
,	O
from	O
different	O
families	O
,	O
shared	O
similar	O
haplotypes	O
,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
portend	O
portend	O
portend	O
portend	O
portend	O
portend	O
sport	O
.	O

of	O
alleles	O
the	O
same	O
mutation	O
,	O
for	O
different	O
families	O
,	O
shared	O
a	O
haplotypes	O
by	O
in	O
that	O
the	O
mutant	O
similar	O
were	O
likely	O
to	O
.	O
identical	O
,	O
descent	O
from	O
Carriers	O
founder	O
be	O
the	O
mutation	O
population	O
indicating	O

Carriers	O
of	O
the	O
same	O
mutation	O
,	O
families	O
,	O
shared	O
similar	O
,	O
indicating	O
that	O
the	O
mutant	O
were	O
likely	O
to	O
be	O
by	O
descent	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
.	O

Carriers	O
of	O
the	O
same	O
mutation	O
,	O
from	O
unlike	O
families	O
,	O
deal	O
interchangeable	O
haplotypes	O
,	O
indicate	O
that	O
the	O
variation	O
allelomorph	O
were	O
likely	O
to	O
be	O
monovular	O
by	O
declivity	O
for	O
a	O
mutation	O
in	O
the	O
beginner	O
universe	O
.	O

Carriers	O
of	O
the	O
same	O
sport	O
,	O
from	O
dissimilar	O
kin	O
,	O
shared	O
standardized	O
haplotypes	O
,	O
show	O
that	O
the	O
variation	O
allelomorph	O
were	O
probably	O
to	O
be	O
identical	O
by	O
origin	O
for	O
a	O
sport	O
in	O
the	O
founder	O
universe	O
.	O

Carriers	O
of	O
the	O
same	O
betoken	O
ampere	O
sport	O
mutation	O
,	O
from	O
different	O
families	O
,	O
shared	O
similar	O
haplotypes	O
,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
portend	O
portend	O
portend	O
portend	O
portend	O
portend	O
sport	O
.	O

Carriers	O
of	O
the	O
same	O
mutation	O
,	O
from	O
unlike	O
family	O
,	O
divided	O
like	O
haplotypes	O
,	O
indicating	O
that	O
the	O
sport	O
allelomorph	O
were	O
probably	O
to	O
be	O
superposable	O
by	O
declension	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
universe	O
.	O

Carriers	O
of	O
the	O
same	O
mutation	O
,	O
from	O
different	O
families	O
,	O
shared	O
similar	O
haplotypes	O
,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
.	O

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
cancer	O
the	O
crab	O
family	O
line	O
cancer	O
the	O
crab	B
family	I
line	I
family	I
line	O
volition	O

of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B
cancer	I
breast	B
ovarian	I
cancer	I
families	O
.	O

The	O
designation	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
help	O
flattop	O
catching	O
in	O
french	O
Canadian	O
tit	B
cancer	I
and	O
tit	B
/	I
ovarian	I
cancer	I
phratry	O
.	O

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
will	O
facilitate	O
detection	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
ovarian	I
cancer	I
families	O
.	O

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
cancer	O
the	O
crab	O
family	O
line	O
cancer	O
the	O
crab	B
family	I
line	I
family	I
line	O
volition	O

The	O
recognition	O
of	O
unwashed	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
alleviate	O
carrier	O
catching	O
in	O
french	O
canadian	O
chest	B
cancer	I
and	O
chest	B
/	I
ovarian	I
cancer	I
families	O
.	O

The	O
designation	O
of	O
plebeian	O
BRCA1	O
and	O
BRCA2	O
variation	O
will	O
help	O
carrier	O
detection	O
in	O
French	O
canadian	O
breast	B
crab	I
and	O
breast	B
/	I
ovarian	I
crab	I
category	O
.	O

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
carrier	O
French	O
Canadian	O
breast	B
cancer	I
and	O
breast	B
/	I
ovarian	I
cancer	I

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
cancer	O
the	O
crab	O
family	O
line	O
cancer	O
the	O
crab	B
family	I
line	I
family	I
line	O
volition	O

and	O
identification	O
of	O
carrier	O
BRCA1	O
and	O
BRCA2	O
breast	O
.	O
facilitate	O
common	O
detection	O
in	O
French	O
families	O
breast	B
cancer	I
ovarian	O
mutations	B
The	I
/	I
cancer	I
Canadian	O
will	O

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

Are	O
Dp71	O
sinewy	O
colligate	O
muscular	O
dystrophy	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	B
cognitive	I
impairment	O
in	B
Duchenne	I
muscular	I
dystrophy	O
subsume	O

muscular	O
Dp71	O
and	O
?	O
brain	O
dystrophin	O
isoforms	O
related	O
dystrophy	O
cognitive	B
impairment	I
in	O
Are	B
Duchenne	I
to	I
Dp140	O

Are	O
Dp71	O
idea	O
colligate	O
mind	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B
impairment	I
in	O
Duchenne	B
muscular	I
dystrophy	I
subsume	O
?	O

constitute	O
Dp71	O
and	O
Dp140	O
mind	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B
deterioration	I
in	O
Duchenne	B
sinewy	I
dystrophy	I
?	O

Duchenne	O
Dp71	O
and	O
related	O
brain	O
dystrophin	O
muscular	O
Dp140	O
to	O
cognitive	B
Are	I
in	O
impairment	B
isoforms	I
dystrophy	I
?	O

Are	O
Dp71	O
sinewy	O
colligate	O
muscular	O
dystrophy	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	B
cognitive	I
impairment	O
in	B
Duchenne	I
muscular	I
dystrophy	O
subsume	O

exist	O
Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B
disability	I
in	O
Duchenne	B
brawny	I
dystrophy	I
?	O

live	O
Dp71	O
and	O
Dp140	O
mind	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B
harm	I
in	O
Duchenne	B
hefty	I
dystrophy	I
?	O

Are	O
Dp71	O
to	O
?	O
brain	O
dystrophin	O
Duchenne	O
related	O
and	O
cognitive	B
impairment	I
in	O
isoforms	B
muscular	I
Dp140	I
dystrophy	O

Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
impairment	I
in	O
Duchenne	B
muscular	I
dystrophy	I
?	O

Are	O
Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B
impairment	I
in	O
Duchenne	B
muscular	I
dystrophy	I
?	O

and	O
were	O
performed	O
concurrently	O
on	O
patients	O
with	O
dystrophy	I
(	O
)	O
in	O
a	O
explanation	O
for	O
the	O
impairment	I
observed	O
in	O
DMD	B
patients	O
.	O

Molecular	O
study	O
and	O
neuropsychological	O
perform	O
regularise	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	B
impairment	I
observed	O
in	O
most	O
DMD	B
patients	O
execute	O
execute	O
execute	O
execute	O
execute	O
execute	O
execute	O
muscular	O
dystrophy	O

explanation	O
in	O
and	O
neuropsychological	O
analysis	O
were	O
the	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B
cognitive	I
observed	I
(	O
DMD	B
)	O
patients	O
order	O
to	O
find	O
most	O
molecular	O
Molecular	O
for	O
performed	O
muscular	B
dystrophy	I
a	O
in	O
impairment	O
DMD	B
.	O
study	O

molecular	O
survey	O
and	O
neuropsychological	O
analysis	O
were	O
execute	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B
hefty	I
dystrophy	I
(	O
DMD	B
)	O
in	O
govern	O
to	O
regain	O
a	O
molecular	O
account	O
for	O
the	O
cognitive	B
handicap	I
honor	O
in	O
most	O
DMD	B
patients	O
.	O

Molecular	O
study	O
for	O
neuropsychological	O
analysis	O
were	O
performed	O
find	O
on	O
49	O
patients	O
molecular	O
cognitive	B
muscular	I
dystrophy	I
in	O
DMD	B
)	O
order	O
with	O
to	O
concurrently	O
a	O
in	O
explanation	O
the	O
and	O
DMD	B
impairment	I
observed	O
(	O
Duchenne	O
most	B
patients	O
.	O

Molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
Duchenne	B
muscular	I
dystrophy	I
(	O
)	O
in	O
order	O
to	O
find	O
molecular	O
explanation	O
for	O
the	O
impairment	I
observed	O
most	O
DMD	B
patients	O
.	O

molecular	O
analyse	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
il	O
patients	O
with	O
Duchenne	B
sinewy	I
dystrophy	I
(	O
DMD	B
)	O
in	O
lodge	O
to	O
happen	O
a	O
molecular	O
account	O
for	O
the	O
cognitive	B
disablement	I
observed	O
in	O
most	O
DMD	B
patients	O
.	O

Molecular	O
study	O
and	O
neuropsychological	O
perform	O
depth	O
psychology	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	B
Duchenne	I
muscular	I
dystrophy	O
(	B
DMD	O
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	B
cognitive	I
impairment	O
observed	O
in	O
most	B
DMD	O
patients	O
execute	O
execute	O
execute	O
execute	O
execute	O
execute	O
execute	O
muscular	O

molecular	O
bailiwick	O
and	O
neuropsychological	O
analysis	O
were	O
do	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B
powerful	I
dystrophy	I
(	O
dmd	B
)	O
in	O
fiat	O
to	O
breakthrough	O
a	O
molecular	O
account	O
for	O
the	O
cognitive	B
damage	I
remark	O
in	O
most	O
dmd	B
patients	O
.	O

cognitive	O
to	O
and	O
neuropsychological	O
DMD	O
were	O
dystrophy	O
most	O
on	O
49	O
patients	O
with	O
Duchenne	B
explanation	I
concurrently	I
(	O
analysis	B
in	O
in	O
order	O
muscular	O
find	O
a	O
molecular	O
study	O
for	O
the	O
Molecular	B
)	I
observed	O
impairment	O
performed	O
DMD	B
patients	O
.	O

Molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	B
impairment	I
observed	O
in	O
most	O
DMD	B
patients	O
.	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
dmd	O
booster	O
dmd	O
booster	O
booster	O
gemination	O
limit	O
to	O
the	O
different	O
DMD	B
promoters	O
.	O

of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
to	O
different	O
DMD	B
promoters	O
.	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
factor	O
was	O
execute	O
to	O
define	O
the	O
fix	O
of	O
omission	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
dissimilar	O
dmd	B
impresario	O
.	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
to	O
define	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
different	O
DMD	B
promoters	O
.	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
dmd	O
booster	O
dmd	O
booster	O
booster	O
gemination	O
gemination	O
to	O
the	O
different	O
DMD	B
promoters	O
.	O

thoroughgoing	O
analysis	O
of	O
the	O
dystrophin	O
factor	O
was	O
performed	O
to	O
determine	O
the	O
localization	O
of	O
omission	O
and	O
duplicate	O
in	O
relation	O
to	O
the	O
unlike	O
DMD	B
plugger	O
.	O

unadulterated	O
analysis	O
of	O
the	O
dystrophin	O
factor	O
was	O
do	O
to	O
set	O
the	O
locating	O
of	O
deletions	O
and	O
duplicate	O
in	O
relation	O
to	O
the	O
dissimilar	O
DMD	B
promoters	O
.	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
the	O
deletions	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
different	O
DMD	B

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
dmd	O
booster	O
dmd	O
booster	O
booster	O
gemination	O
gemination	O
to	O
the	O
different	O
DMD	B
promoters	O
.	O

relation	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
to	O
.	O
define	O
the	O
localization	O
of	O
deletions	O
promoters	O
duplications	O
in	O
different	O
performed	O
Complete	O
the	O
DMD	B
and	O
to	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
different	O
DMD	B
promoters	O
.	O

qualitative	O
analysis	O
of	O
the	O
Dp71	O
copy	O
and	O
essay	O
for	O
the	O
particular	O
low	O
exon	O
of	O
Dp140	O
were	O
likewise	O
carried	O
out	O
.	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
out	O
.	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
cost	O
cost	O
cost	O
cost	O
cost	O
cost	O
out	O
.	O

of	O
transcript	O
and	O
testing	O
the	O
specific	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
out	O
.	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
testing	O
for	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
out	O
.	O

of	O
the	O
Dp71	O
transcript	O
testing	O
for	O
the	O
specific	O
first	O
of	O
Dp140	O
were	O
also	O
out	O
.	O

carried	O
analysis	O
of	O
out	O
Dp71	O
transcript	O
and	O
for	O
testing	O
the	O
Dp140	O
first	O
exon	O
.	O
Qualitative	O
were	O
also	O
specific	O
the	O
of	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
cost	O
cost	O
cost	O
cost	O
cost	O
too	O
out	O
.	O

qualitative	O
analysis	O
of	O
the	O
Dp71	O
copy	O
and	O
quiz	O
for	O
the	O
particular	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
convey	O
out	O
.	O

also	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
of	O
first	O
for	O
the	O
specific	O
Dp140	O
Qualitative	O
and	O
testing	O
carried	O
exon	O
were	O
out	O
.	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
out	O
.	O

Neuropsychological	O
and	O
assessed	O
verbal	O
analysis	O
visuospatial	O
,	O
,	O
verbal	O
memory	O
reading	O
and	O
intelligence	O
skills	O
.	O

Neuropsychological	O
analysis	O
intelligence	O
agency	O
valuate	O
valuate	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
depth	O
psychology	O
memory	O
,	O
and	O
reading	O

neuropsychological	O
analysis	O
assessed	O
verbal	O
and	O
visuospatial	O
news	O
,	O
verbal	O
store	O
,	O
and	O
reading	O
accomplishment	O
.	O

reading	O
analysis	O
assessed	O
Neuropsychological	O
,	O
visuospatial	O
intelligence	O
and	O
verbal	O
memory	O
,	O
and	O
verbal	O
skills	O
.	O

neuropsychological	O
analysis	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
remembering	O
,	O
and	O
scan	O
skills	O
.	O

Neuropsychological	O
analysis	O
intelligence	O
agency	O
valuate	O
valuate	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
depth	O
psychology	O
memory	O
,	O
and	O
reading	O

Neuropsychological	O
assessed	O
and	O
intelligence	O
,	O
verbal	O
memory	O
,	O
and	O
reading	O
skills	O
.	O

,	O
verbal	O
assessed	O
analysis	O
and	O
visuospatial	O
memory	O
Neuropsychological	O
verbal	O
intelligence	O
,	O
and	O
reading	O
.	O
skills	O

neuropsychological	O
analysis	O
valuate	O
verbal	O
and	O
visuospatial	O
tidings	O
,	O
verbal	O
memory	O
,	O
and	O
reading	O
science	O
.	O

Neuropsychological	O
analysis	O
intelligence	O
agency	O
valuate	O
valuate	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
depth	O
psychology	O
memory	O
,	O
and	O
reading	O

Neuropsychological	O
analysis	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
memory	O
,	O
and	O
reading	O
skills	O
.	O

Comparison	O
of	O
molecular	O
and	O
cost	O
place	O
indium	O
prove	O
deadening	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
beryllium	O
colligate	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B
impairment	I
toll	O
turn	O
up	O

Comparison	O
of	O
molecular	O
and	O
cost	O
place	O
indium	O
prove	O
deadening	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
beryllium	O
receive	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B
impairment	I
toll	O
turn	O
up	O

impairment	O
of	O
preferentially	O
in	O
psychometric	O
findings	O
cognitive	O
that	O
and	O
and	O
duplications	O
that	O
gene	O
localized	O
molecular	O
deletions	O
distal	O
part	O
of	O
the	O
were	O
seemed	O
to	O
be	O
the	O
demonstrated	O
with	O
associated	B
Comparison	I
.	O

Comparison	O
of	O
molecular	O
and	O
cost	O
place	O
indium	O
prove	O
deadening	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
beryllium	O
colligate	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B
impairment	I
toll	O
turn	O
up	O

Comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
deletions	O
and	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B
impairment	I
.	O

Comparison	O
of	O
molecular	O
and	O
psychometric	O
discover	O
certify	O
that	O
excision	O
and	O
gemination	O
that	O
were	O
place	O
in	O
the	O
distal	O
break	O
of	O
the	O
gene	O
appear	O
to	O
be	O
preferentially	O
connect	O
with	O
cognitive	B
deterioration	I
.	O

distal	O
of	O
molecular	O
and	O
psychometric	O
findings	O
seemed	O
that	O
deletions	O
and	O
duplications	O
Comparison	O
impairment	O
be	O
the	O
in	O
part	O
preferentially	O
of	O
the	O
gene	O
demonstrated	O
to	O
localized	O
that	O
associated	O
with	O
cognitive	B
were	I
.	O

gene	O
of	O
molecular	O
of	O
psychometric	O
findings	O
demonstrated	O
associated	O
be	O
and	O
impairment	O
that	O
with	O
the	O
to	O
the	O
distal	O
part	O
and	O
localized	O
preferentially	O
seemed	O
in	O
deletions	O
Comparison	O
that	O
were	O
cognitive	B
duplications	I
.	O

Comparison	O
of	O
molecular	O
and	O
psychometric	O
notice	O
certify	O
that	O
omission	O
and	O
duplicate	O
that	O
were	O
set	O
in	O
the	O
distal	O
constituent	O
of	O
the	O
cistron	O
seemed	O
to	O
be	O
preferentially	O
affiliate	O
with	O
cognitive	B
handicap	I
.	O

Comparison	O
of	O
molecular	O
and	O
psychometric	O
demonstrated	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
with	O
cognitive	B
impairment	I

Comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B
impairment	I
.	O

deuce	O
modify	O
Dp71	O
copy	O
and	O
deuce	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
tetrad	O
patients	O
with	O
grievous	O
intellectual	B
dysfunction	I
.	O

Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B
dna	B
dna	O
dna	B
dna	O
dna	B
dna	O
dysfunction	I
.	O

Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B
dna	B
dna	O
dna	B
dna	O
dna	B
dna	O
dysfunction	I
.	O

Dp71	O
two	O
deleted	O
Dp140	O
sequences	O
were	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B
dysfunction	I
.	O

Two	O
altered	O
Dp71	O
transcripts	O
and	O
Dp140	O
DNA	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B
dysfunction	I
.	O

Dp71	O
transcripts	O
and	O
two	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
four	O
patients	O
with	O
severe	O
dysfunction	I
.	O

cerebral	O
altered	O
Dp71	O
dysfunction	O
and	O
two	O
deleted	O
DNA	O
Dp140	O
sequences	O
patients	O
found	O
in	O
.	O
Two	O
with	O
severe	O
were	B
transcripts	I
four	O

Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B
dna	B
dna	O
dna	B
dna	O
dna	B
dna	O
dysfunction	I
.	O

deuce	O
altered	O
Dp71	O
copy	O
and	O
deuce	O
cancel	O
Dp140	O
dna	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
intellectual	B
dysfunction	I
.	O

severe	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
four	O
found	O
DNA	O
sequences	O
were	O
patients	O
Two	O
deleted	O
Dp140	O
cerebral	O
in	O
with	B
dysfunction	I
.	O

Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B
dysfunction	I
.	O

These	O
get	O
suggest	O
that	O
some	O
sequences	O
placed	O
in	O
the	O
distal	O
break	O
of	O
the	O
factor	O
and	O
,	O
in	O
particular	O
,	O
some	O
dmd	B
isoforms	O
carry	O
in	O
the	O
wit	O
may	O
be	O
concern	O
to	O
the	O
cognitive	B
deadening	I
consociate	O
with	O
dmd	B
.	O
.	O

findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
the	O
gene	O
and	O
,	O
in	O
,	O
some	O
in	O
may	O
be	O
the	O
associated	O
with	O
DMD	B
.	O

be	O
with	O
suggest	O
that	O
in	O
sequences	O
DMD	O
cognitive	O
the	O
distal	O
part	O
of	O
the	O
the	O
.	O
,	O
some	O
the	O
,	O
some	O
in	B
isoforms	O
expressed	O
in	O
findings	O
brain	O
may	O
These	O
particular	O
to	O
related	O
located	B
impairment	I
associated	O
gene	O
DMD	B
.	O
and	O

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
the	O
distal	O
part	O
of	O
gene	O
and	O
,	O
in	O
particular	O
some	O
DMD	B
isoforms	O
expressed	O
the	O
brain	O
be	O
related	O
to	O
the	O
cognitive	B
impairment	I
associated	O
with	O
.	O
.	O

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	B
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B
impairment	I
associated	O
with	O
DMD	B
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
.	O
.	O

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	B
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B
impairment	I
associated	O
with	O
DMD	B
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
.	O
.	O

These	O
findings	O
evoke	O
that	O
some	O
sequences	O
site	O
in	O
the	O
distal	O
split	O
of	O
the	O
cistron	O
and	O
,	O
in	O
particular	O
,	O
some	O
dmd	B
isoforms	O
expressed	O
in	O
the	O
mentality	O
may	O
be	O
related	O
to	O
the	O
cognitive	B
disablement	I
colligate	O
with	O
dmd	B
.	O
.	O

the	O
,	O
suggest	O
that	O
some	O
sequences	O
of	O
associated	O
the	O
distal	O
part	O
located	O
the	O
be	O
to	O
,	O
in	O
particular	O
in	O
some	O
DMD	B
isoforms	O
related	O
in	O
These	O
brain	O
cognitive	O
gene	O
and	O
expressed	O
the	O
DMD	B
impairment	I
findings	O
with	O
may	B
.	O
.	O

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	B
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B
impairment	I
associated	O
with	O
DMD	B
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
approximately	O
crataegus	O
oxycantha	O
.	O

These	O
findings	O
some	O
sequences	O
in	O
the	O
the	O
and	O
,	O
in	O
,	O
some	O
DMD	B
expressed	O
in	O
the	O
brain	O
may	O
to	O
the	O
cognitive	B
impairment	I
associated	O
with	O
DMD	B
.	O

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	B
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B
impairment	I
associated	O
with	O
DMD	B
.	O
.	O

I1307K	O
APC	O
-	O
-	O
mutations	O
in	O
hereditary	O
non	O
and	O
Jewish	O
family	O
with	O
a	B
non	I
hMLH1	I
polyposis	I
colorectal	I
cancer	I
.	O

and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
polyposis	I
colorectal	I
cancer	I
.	O

I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
not	O
-	O
judaic	O
kinsfolk	O
with	O
familial	B
not	I
-	I
polyposis	I
colorectal	I
crab	I
.	O

I1307K	O
apc	O
and	O
hMLH1	O
mutations	O
in	O
a	O
not	O
-	O
judaic	O
family	O
with	O
familial	B
not	I
-	I
polyposis	I
colorectal	I
cancer	I
.	O

colorectal	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
non	O
-	O
-	O
Jewish	O
family	O
with	O
cancer	B
a	I
non	I
polyposis	I
hereditary	I
I1307K	I
.	O

I1307K	O
APC	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
.	O

I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
familial	O
genetic	O
genetic	O
genetic	O
cancer	O
the	O

I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
not	O
-	O
judaic	O
family	O
with	O
patrimonial	B
not	I
-	I
polyposis	I
colorectal	I
cancer	I
.	O

I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
familial	O
familial	O
genetic	O
genetic	O
genetic	O
.	O

non	O
APC	O
and	O
family	O
mutations	O
in	O
a	O
.	O
-	O
Jewish	O
hMLH1	O
with	O
I1307K	B
hereditary	I
-	I
polyposis	I
colorectal	I
cancer	I
non	O

I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
.	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
carries	O
a	O
indium	O
sport	O
indium	O
indium	O
ampere	O
ampere	O
canadian	O
novel	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O

a	O
French	O
Canadian	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
carries	O
novel	O
mutation	O
in	O
hMLH1	O
.	O

We	O
draw	O
a	O
french	O
Canadian	O
genetic	B
not	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
stock	O
a	O
new	O
truncating	O
sport	O
in	O
hMLH1	O
.	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B
non	I
polyposis	I
colorectal	I
(	O
HNPCC	B
)	O
kindred	O
which	O
carries	O
a	O
mutation	O
in	O
hMLH1	O
.	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
carries	O
a	O
indium	O
sport	O
indium	O
indium	O
ampere	O
ampere	O
ampere	O
novel	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O

We	O
report	O
a	O
French	O
Canadian	O
genetic	B
not	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
comport	O
a	O
refreshing	O
truncate	O
sport	O
in	O
hMLH1	O
.	O

We	O
name	O
a	O
french	O
Canadian	O
ancestral	B
not	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
carry	O
a	O
refreshing	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B
non	I
-	I
polyposis	I
cancer	I
)	O
kindred	O
which	O
carries	O
a	O
novel	O
truncating	O
mutation	O
in	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
carries	O
a	O
indium	O
sport	O
indium	O
indium	O
ampere	O
ampere	O
ampere	O
novel	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O

a	O
describe	O
a	O
cancer	O
Canadian	O
hereditary	B
non	I
novel	I
.	I
colorectal	I
French	I
(	O
HNPCC	B
)	O
hMLH1	O
which	O
carries	O
mutation	O
-	O
We	O
truncating	O
in	O
kindred	O
polyposis	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
carries	O
a	O
novel	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O

Interestingly	O
,	O
the	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B
cancer	I
,	O
is	O
also	O
present	O
in	O
this	O
family	O

Interestingly	O
,	O
the	O
I1307K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cancer	I
also	O
present	O
in	O
this	O
family	O
.	O

Interestingly	O
,	O
the	O
I1307K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B
cancer	I
,	O
is	O
also	O
indium	O
family	O
line	O
family	O
line	O
cancer	O
the	O
crab	O
cancer	O
the	O
crab	O

interestingly	O
,	O
the	O
I1307K	O
apc	O
pleomorphism	O
,	O
consociate	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B
cancer	I
,	O
is	O
likewise	O
nowadays	O
in	O
this	O
family	O
.	O

Interestingly	O
,	O
the	O
I1307K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B
cancer	I
,	O
is	O
also	O
indium	O
family	O
line	O
family	O
line	O
cancer	O
the	O
crab	O
cancer	O
the	O
crab	O

interestingly	O
,	O
the	O
I1307K	O
APC	O
pleomorphism	O
,	O
colligate	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B
cancer	I
,	O
is	O
besides	O
stage	O
in	O
this	O
family	O
.	O

Interestingly	O
,	O
the	O
I1307K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
risk	O
of	O
cancer	I
,	O
is	O
also	O
present	O
in	O
this	O

increased	O
,	O
the	O
present	O
APC	O
polymorphism	O
,	O
with	O
associated	O
an	O
in	O
risk	O
colorectal	O
of	B
.	I
,	O
is	O
also	O
I1307K	O
Interestingly	O
this	O
family	O
cancer	O

interestingly	O
,	O
the	O
I1307K	O
APC	O
pleomorphism	O
,	O
connect	O
with	O
an	O
increased	O
peril	O
of	O
colorectal	B
cancer	I
,	O
is	O
besides	O
gift	O
in	O
this	O
family	O
.	O

cancer	O
,	O
with	O
,	O
APC	O
polymorphism	O
,	O
associated	O
the	O
an	O
increased	O
risk	O
this	O
colorectal	B
I1307K	I
Interestingly	O
is	O
also	O
present	O
in	O
of	O
family	O
.	O

Interestingly	O
,	O
the	O
I1307K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B
cancer	I
,	O
is	O
also	O
present	O
in	O
this	O
family	O
.	O

of	O
I1307K	O
polymorphism	O
identified	O
previously	O
only	O
been	O
has	O
Ashkenazi	O
individuals	O
reported	O
self	O
The	O
-	O
in	O
Jewish	O
origins	O
.	O

The	O
I1307K	O
pleomorphism	O
has	O
antecedently	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
cover	O
Ashkenazi	O
judaic	O
extraction	O
.	O

The	O
I1307K	O
polymorphism	O
has	O
antecedently	O
only	O
been	O
distinguish	O
in	O
individuals	O
of	O
self	O
-	O
reported	O
ashkenazi	O
judaic	O
beginning	O
.	O

The	O
I1307K	O
polymorphism	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
reported	O
Ashkenazi	O
Jewish	O
origins	O
.	O

The	O
I1307K	O
polymorphism	O
has	O
antecedently	O
only	O
been	O
identified	O
in	O
mortal	O
of	O
self	O
-	O
account	O
ashkenazi	O
jewish	O
origins	O
.	O

The	O
I1307K	O
pleomorphism	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
reported	O
Ashkenazi	O
Jewish	O
origins	O
polymorphism	O
polymorphism	O
polymorphism	O
place	O
.	O

The	O
I1307K	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
self	O
-	O
Ashkenazi	O
Jewish	O
origins	O
.	O

The	O
I1307K	O
pleomorphism	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
reported	O
Ashkenazi	O
Jewish	O
origins	O
polymorphism	O
polymorphism	O
polymorphism	O
place	O
.	O

I1307K	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
.	O

The	O
I1307K	O
in	O
Ashkenazi	O
previously	O
only	O
-	O
identified	O
polymorphism	O
individuals	O
of	O
self	O
been	O
reported	O
has	O
Jewish	O
origins	O
.	O

The	O
I1307K	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
reported	O
Ashkenazi	O
Jewish	O
origins	O
.	O

addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
and	O
presence	O
or	O
absence	O
of	O
cancer	B
.	O
.	O

be	O
addition	O
,	O
the	O
this	O
family	O
,	O
.	O
cancer	O
to	O
.	O
no	O
relationship	O
presence	O
of	O
I1307K	O
polymorphism	O
and	O
in	O
between	O
or	O
absence	O
the	O
appears	B
In	O
there	O

inwards	O
accession	O
,	O
inwards	O
this	O
mob	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
pleomorphism	O
and	O
the	O
comportment	O
or	O
absence	O
of	O
crab	B
.	O
.	O

inwards	O
increase	O
,	O
inwards	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
pleomorphism	O
and	O
the	O
front	O
or	O
absence	O
of	O
cancer	B
.	O
.	O

In	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
no	O
relationship	O
the	O
I1307K	O
polymorphism	O
and	O
the	O
presence	O
or	O
cancer	B
.	O
.	O

In	O
addition	O
,	O
in	O
pleomorphism	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
polymorphism	O
and	O
operating	O
theatre	O
cancer	O
the	O
crab	O
absence	O
seizure	O
cancer	O
the	O
crab	O
cancer	O
the	B
crab	O
seem	O

In	O
addition	O
,	O
in	O
pleomorphism	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
polymorphism	O
and	O
operating	O
theatre	O
cancer	O
the	O
crab	O
absence	O
seizure	O
cancer	O
the	O
crab	O
cancer	O
the	B
crab	O
beryllium	O

In	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
no	O
the	O
I1307K	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O

cancer	O
addition	O
,	O
in	O
this	O
family	O
between	O
polymorphism	O
appears	O
to	O
be	O
no	O
absence	O
,	O
.	O
I1307K	O
there	O
or	O
the	O
presence	O
In	O
relationship	O
of	O
and	B
the	O
.	O

In	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
kinship	O
between	O
the	O
I1307K	O
pleomorphism	O
and	O
the	O
mien	O
or	O
absence	O
of	O
cancer	B
.	O
.	O

In	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O
cancer	B
.	O
.	O

Identification	O
of	O
international	O
ampere	O
ampere	O
ampere	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	B
hereditary	I
coproporphyria	O
family	O
international	O

coproporphyria	O
of	O
a	O
.	O
mutation	O
of	O
the	O
CPO	O
family	O
in	O
a	O
Japanese	O
Identification	B
hereditary	I
gene	O
novel	O

Identification	O
of	O
element	O
ampere	O
factor	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
hereditary	B
coproporphyria	I
family	O
international	O
ampere	O

designation	O
of	O
a	O
novel	O
sport	O
of	O
the	O
CPO	O
factor	O
in	O
a	O
Japanese	O
transmitted	B
coproporphyria	I
family	O
.	O

hereditary	O
of	O
a	O
CPO	O
mutation	O
of	O
coproporphyria	O
novel	O
gene	O
in	O
Identification	O
Japanese	O
a	B
the	I
family	O
.	O

Identification	O
of	O
international	O
ampere	O
ampere	O
ampere	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	B
hereditary	I
coproporphyria	O
family	O
international	O

designation	O
of	O
a	O
new	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
familial	B
coproporphyria	I
kinfolk	O
.	O

Identification	O
of	O
a	O
new	O
mutant	O
of	O
the	O
CPO	O
cistron	O
in	O
a	O
Japanese	O
transmitted	B
coproporphyria	I
family	O
.	O

Identification	O
of	O
gene	O
.	O
mutation	O
of	O
hereditary	O
CPO	O
a	O
in	O
a	O
Japanese	O
the	B
coproporphyria	I
novel	O
family	O

of	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
a	O
Japanese	O
hereditary	B
coproporphyria	I
family	O
.	O

Identification	O
of	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
hereditary	B
coproporphyria	I
family	O
.	O

inherited	B
coproporphyria	I
(	O
HCP	B
)	O
is	O
an	O
autosomal	B
prevalent	I
disease	I
characterized	O
by	O
a	O
lack	B
of	I
coproporphyrinogen	I
oxidase	I
(	O
CPO	O
)	O
have	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
cistron	O
.	O

Hereditary	B
coproporphyria	I
(	O
HCP	B
)	O
an	O
disease	I
characterized	O
by	O
a	O
deficiency	B
of	I
coproporphyrinogen	I
oxidase	I
(	O
a	O
mutation	O
in	O
the	O
CPO	O
gene	O
.	O

caused	B
coproporphyria	I
(	O
CPO	B
)	O
is	O
an	O
the	B
mutation	I
disease	I
.	O
by	O
a	O
)	B
a	I
coproporphyrinogen	I
oxidase	I
(	O
HCP	O
deficiency	O
in	O
by	O
of	O
dominant	O
Hereditary	O
autosomal	O
CPO	O
gene	O
characterized	O

Hereditary	B
coproporphyria	I
(	O
HCP	B
ampere	O
inadequacy	O
cost	O
associate	O
in	O
nursing	O
factor	O
)	O
is	B
an	I
autosomal	I
dominant	O
disease	O
characterized	O
by	B
a	I
deficiency	I
of	I
coproporphyrinogen	O
oxidase	O
(	O
sport	O
indium	O
prevailing	O
CPO	O
)	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O

Hereditary	B
coproporphyria	I
(	O
HCP	B
ampere	O
inadequacy	O
cost	O
associate	O
in	O
nursing	O
factor	O
)	O
is	B
an	I
autosomal	I
dominant	O
disease	O
characterized	O
by	B
a	I
deficiency	I
of	I
coproporphyrinogen	O
oxidase	O
(	O
sport	O
indium	O
induce	O
CPO	O
)	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O

Hereditary	B
coproporphyria	I
(	O
HCP	B
)	O
is	O
an	O
autosomal	B
disease	I
characterized	O
a	O
deficiency	B
of	I
coproporphyrinogen	I
oxidase	I
(	O
CPO	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
gene	O
.	O

.	B
coproporphyria	I
(	O
of	B
)	O
is	O
the	O
autosomal	B
HCP	I
disease	I
characterized	O
by	O
CPO	O
deficiency	B
in	I
dominant	I
oxidase	I
(	O
CPO	O
)	O
a	O
by	O
a	O
mutation	O
coproporphyrinogen	O
an	O
caused	O
gene	O
Hereditary	O

Hereditary	B
coproporphyria	I
(	O
HCP	B
)	O
is	O
an	O
autosomal	B
disease	I
by	O
a	O
deficiency	B
of	I
coproporphyrinogen	I
oxidase	I
(	O
CPO	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O

inherited	B
coproporphyria	I
(	O
HCP	B
)	O
is	O
an	O
autosomal	B
rife	I
disease	I
characterise	O
by	O
a	O
lack	B
of	I
coproporphyrinogen	I
oxidase	I
(	O
CPO	O
)	O
induce	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
factor	O
.	O

genetic	B
coproporphyria	I
(	O
HCP	B
)	O
is	O
an	O
autosomal	B
rife	I
disease	I
qualify	O
by	O
a	O
lack	B
of	I
coproporphyrinogen	I
oxidase	I
(	O
CPO	O
)	O
get	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
cistron	O
.	O

Hereditary	B
coproporphyria	I
(	O
HCP	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
characterized	O
by	O
a	O
deficiency	B
of	I
coproporphyrinogen	I
oxidase	I
(	O
CPO	O
)	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
gene	O
.	O

Only	O
mutations	O
of	O
gene	O
been	O
in	O
HCP	B
patients	O
.	O

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
HCP	B
patients	O

Only	O
xi	O
mutations	O
of	O
the	O
factor	O
have	O
been	O
reported	O
in	O
HCP	B
patients	O
.	O

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
patient	O
patient	O
	O
in	O
HCP	B
patients	O
.	O

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
patient	O
patient	O
sport	O
in	O
HCP	B
patients	O
.	O

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
patient	O
patient	O
	O
in	O
HCP	B
patients	O
.	O

Only	O
xi	O
mutations	O
of	O
the	O
cistron	O
have	O
been	O
account	O
in	O
HCP	B
patients	O
.	O

Only	O
11	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
.	O

Only	O
11	O
mutations	O
of	O
the	O
factor	O
have	O
been	O
cover	O
in	O
HCP	B
patients	O
.	O

Only	O
the	O
mutations	O
of	O
.	O
gene	O
have	O
11	O
reported	O
in	O
HCP	B
patients	O
been	O

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
HCP	B
patients	O
.	O

We	O
report	O
another	O
mutation	O
in	O
a	O
japanese	O
kinfolk	O
.	O

We	O
nipponese	O
report	O
another	O
mutation	O
in	O
a	O
Japanese	O
family	O
sport	O
.	O

We	O
mutation	O
another	O
report	O
in	O
a	O
family	O
Japanese	O
.	O

We	O
study	O
another	O
mutation	O
in	O
a	O
nipponese	O
family	O
.	O

We	O
another	O
mutation	O
a	O
family	O

Japanese	O
report	O
another	O
mutation	O
in	O
a	O
family	O
We	O
.	O

We	O
report	O
another	O
mutation	O
in	O
a	O
Japanese	O
.	O

We	O
family	O
another	O
mutation	O
report	O
a	O
Japanese	O
in	O
.	O

We	O
write	O
up	O
report	O
another	O
mutation	O
in	O
a	O
Japanese	O
family	O
sport	O

We	O
theme	O
another	O
mutation	O
in	O
a	O
Japanese	O
menage	O
.	O

We	O
report	O
another	O
mutation	O
in	O
a	O
Japanese	O
family	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
unity	O
ground	O
conformational	O
polymorphism	O
and	O
manoeuver	O
episode	O
dissect	O
certify	O
a	O
C	O
to	O
thyroxine	O
switch	O
in	O
exon	O
1	O
of	O
the	O
CPO	O
cistron	O
at	O
base	O
emplacement	O
85	O
,	O
which	O
lies	O
in	O
the	O
putative	O
presequence	O
for	O
targeting	O
to	O
chondriosome	O
.	O

polymerase	O
chain	O
reaction	O
-	O
ace	O
strand	O
conformational	O
pleomorphism	O
and	O
guide	O
sequence	O
analyses	O
demonstrated	O
a	O
c	O
to	O
T	O
permutation	O
in	O
exon	O
one	O
of	O
the	O
CPO	O
factor	O
at	O
base	O
locating	O
85	O
,	O
which	O
lies	O
in	O
the	O
putative	O
presequence	O
for	O
point	O
to	O
chondriosome	O
.	O

Polymerase	O
single	O
conformational	O
polymorphism	O
and	O
sequence	O
analyses	O
demonstrated	O
C	O
to	O
T	O
substitution	O
in	O
of	O
the	O
CPO	O
gene	O
at	O
nucleotide	O
position	O
85	O
lies	O
the	O
putative	O
presequence	O
targeting	O
to	O
mitochondria	O
.	O

Polymerase	O
chain	O
lies	O
-	O
single	O
85	O
at	O
polymorphism	O
and	O
direct	O
sequence	O
CPO	O
position	O
a	O
C	O
which	O
T	O
substitution	O
exon	O
in	O
1	O
of	O
the	O
presequence	O
gene	O
nucleotide	O
demonstrated	O
in	O
strand	O
,	O
to	O
targeting	O
conformational	O
the	O
putative	O
analyses	O
for	O
reaction	O
to	O
mitochondria	O
.	O

gene	O
in	O
reaction	O
-	O
single	O
strand	O
analyses	O
of	O
and	O
direct	O
sequence	O
conformational	O
demonstrated	O
position	O
,	O
to	O
T	O
substitution	O
.	O
exon	O
1	O
polymorphism	O
85	O
CPO	O
Polymerase	O
at	O
lies	O
a	O
C	O
the	O
which	O
presequence	O
in	O
chain	O
putative	O
nucleotide	O
for	O
targeting	O
to	O
mitochondria	O
the	O

Polymerase	O
chain	O
reaction	O
-	O
conformational	O
polymorphism	O
and	O
direct	O
analyses	O
demonstrated	O
a	O
C	O
to	O
substitution	O
in	O
exon	O
1	O
the	O
CPO	O
at	O
nucleotide	O
position	O
85	O
,	O
which	O
lies	O
in	O
putative	O
presequence	O
targeting	O
to	O
mitochondria	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
and	O
direct	O
sequence	O
analyses	O
demonstrated	O
a	O
C	O
to	O
T	O
substitution	O
in	O
exon	O
1	O
of	O
the	O
CPO	O
gene	O
at	O
nucleotide	O
position	O
85	O
,	O
which	O
lies	O
in	O
the	O
putative	O
presequence	O
place	O
	O
chondriosome	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
for	O
targeting	O
to	O
mitochondria	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
polymorphism	O
and	O
direct	O
sequence	O
analyses	O
a	O
C	O
in	O
of	O
the	O
at	O
85	O
,	O
which	O
lies	O
the	O
putative	O
targeting	O
to	O
.	O

polymerase	O
strand	O
reaction	O
-	O
single	O
strand	O
conformational	O
pleomorphism	O
and	O
direct	O
episode	O
psychoanalysis	O
demonstrated	O
a	O
cytosine	O
to	O
T	O
commutation	O
in	O
exon	O
ane	O
of	O
the	O
CPO	O
factor	O
at	O
nucleotide	O
position	O
85	O
,	O
which	O
dwell	O
in	O
the	O
putative	O
presequence	O
for	O
aim	O
to	O
chondriosome	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
and	O
direct	O
sequence	O
analyses	O
demonstrated	O
a	O
C	O
to	O
T	O
substitution	O
in	O
exon	O
1	O
of	O
the	O
CPO	O
gene	O
at	O
nucleotide	O
position	O
85	O
,	O
which	O
lies	O
in	O
the	O
putative	O
presequence	O
place	O
	O
chondriosome	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
for	O
targeting	O
to	O
mitochondria	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
and	O
direct	O
sequence	O
analyses	O
demonstrated	O
a	O
C	O
to	O
T	O
substitution	O
in	O
exon	O
1	O
of	O
the	O
CPO	O
gene	O
at	O
nucleotide	O
position	O
85	O
,	O
which	O
lies	O
in	O
the	O
putative	O
presequence	O
for	O
targeting	O
to	O
mitochondria	O
.	O

codon	O
mutation	O
changes	O
to	O
codon	O
for	O
glutamine	O
the	O
position	O
termination	O
acid	O
at	O
This	O
amino	O
a	O
29	O
.	O

This	O
mutation	O
convert	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
expiration	O
codon	O
at	O
aminic	O
acid	O
pose	O
xxix	O
.	O

This	O
mutation	O
deepen	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
expiry	O
codon	O
at	O
aminic	O
zen	O
post	O
29	O
.	O

This	O
mutation	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
29	O
.	O

This	O
mutant	O
transfer	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
endpoint	O
codon	O
at	O
amino	O
acid	O
placement	O
xxix	O
.	O

This	O
mutation	O
deepen	O
deepen	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
29	O
compound	O
compound	O
compound	O
.	O

This	O
mutation	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
termination	O
codon	O
amino	O
acid	O
position	O
29	O
.	O

This	O
mutation	O
deepen	O
deepen	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
29	O
compound	O
compound	O
compound	O
.	O

mutation	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O

This	O
mutation	O
a	O
position	O
codon	O
for	O
amino	O
to	O
changes	O
termination	O
codon	O
at	O
glutamine	O
acid	O
the	O
29	O
.	O

This	O
mutation	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
29	O
.	O

MaeI	O
limitation	O
analysis	O
register	O
two	O
other	O
mailman	O
in	O
the	O
family	O
.	O

MaeI	O
restriction	O
analysis	O
showed	O
two	O
other	O
carriers	O
in	O
the	O
limitation	O
limitation	O
limitation	O
family	O
.	O

MaeI	O
confinement	O
analysis	O
picture	O
two	O
other	O
carriers	O
in	O
the	O
family	O
.	O

MaeI	O
confinement	O
analysis	O
testify	O
ii	O
other	O
carriers	O
in	O
the	O
family	O
.	O

restriction	O
analysis	O
two	O
other	O
carriers	O
in	O
the	O
family	O
.	O

in	O
restriction	O
analysis	O
two	O
showed	O
other	O
family	O
MaeI	O
the	O
carriers	O
.	O

MaeI	O
in	O
analysis	O
showed	O
restriction	O
other	O
carriers	O
.	O
the	O
family	O
two	O

showed	O
in	O
analysis	O
carriers	O
two	O
other	O
MaeI	O
restriction	O
the	O
family	O
.	O

MaeI	O
analysis	O
two	O
carriers	O
in	O
the	O
family	O
.	O

MaeI	O
restriction	O
analysis	O
showed	O
two	O
other	O
carriers	O
in	O
the	O
limitation	O
limitation	O
limitation	O
family	O
.	O

MaeI	O
restriction	O
analysis	O
showed	O
two	O
other	O
carriers	O
in	O
the	O
family	O
.	O

The	O
C	O
-	O
t	O
mutant	O
is	O
placed	O
inside	O
a	O
recently	O
suggest	O
putative	O
alternative	O
rendering	O
innovation	O
codon	O
(	O
tic	O
-	O
1	O
)	O
,	O
supporting	O
that	O
tic	O
-	O
1	O
is	O
the	O
substantial	O
tic	O
sooner	O
than	O
tic	O
-	O
ii	O
.	O
.	O

C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	O
alternative	O
translation	O
initiation	O
codon	O
(	O
-	O
1	O
that	O
1	O
is	O
TIC	O
TIC	O
-	O
2	O
.	O

is	O
-	O
-	O
T	O
(	O
is	O
)	O
rather	O
a	O
recently	O
proposed	O
putative	O
alternative	O
TIC	O
.	O
codon	O
mutation	O
TIC	O
-	O
1	O
within	O
,	O
supporting	O
that	O
C	O
-	O
1	O
The	O
TIC	O
real	O
the	O
located	O
than	O
TIC	O
translation	O
2	O
.	O
initiation	O

The	O
C	O
-	O
T	O
mutation	O
is	O
a	O
recently	O
proposed	O
putative	O
translation	O
initiation	O
codon	O
(	O
TIC	O
1	O
)	O
,	O
supporting	O
TIC	O
-	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC	O
-	O
.	O
.	O

The	O
C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	O
recently	O
proposed	O
putative	O
alternative	O
translation	O
initiation	O
codon	O
(	O
TIC	O
-	O
1	O
)	O
,	O
supporting	O
that	O
TIC	O
-	O
1	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC	O
-	O
2	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
.	O
.	O

The	O
C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	O
recently	O
proposed	O
putative	O
alternative	O
translation	O
initiation	O
codon	O
(	O
TIC	O
-	O
1	O
)	O
,	O
supporting	O
that	O
TIC	O
-	O
1	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC	O
-	O
2	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
.	O
.	O

The	O
cytosine	O
-	O
T	O
sport	O
is	O
located	O
inside	O
a	O
recently	O
suggest	O
putative	O
substitute	O
displacement	O
induction	O
codon	O
(	O
tic	O
-	O
single	O
)	O
,	O
supporting	O
that	O
tic	O
-	O
single	O
is	O
the	O
veridical	O
tic	O
rather	O
than	O
tic	O
-	O
ii	O
.	O
.	O

TIC	O
-	O
-	O
T	O
mutation	O
is	O
putative	O
TIC	O
a	O
recently	O
proposed	O
located	O
alternative	O
is	O
real	O
codon	O
(	O
TIC	O
within	O
1	O
)	O
,	O
the	O
that	O
The	O
-	O
rather	O
translation	O
initiation	O
supporting	O
TIC	O
2	O
than	O
C	O
-	O
1	O
.	O
.	O

The	O
C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	O
recently	O
proposed	O
putative	O
alternative	O
translation	O
initiation	O
codon	O
(	O
TIC	O
-	O
1	O
)	O
,	O
supporting	O
that	O
TIC	O
-	O
1	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC	O
-	O
2	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
sport	O
interlingual	O
rendition	O
.	O

The	O
C	O
mutation	O
is	O
within	O
a	O
alternative	O
initiation	O
codon	O
(	O
-	O
1	O
)	O
supporting	O
that	O
TIC	O
-	O
1	O
real	O
TIC	O
rather	O
than	O
TIC	O
-	O
2	O
.	O

The	O
C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	O
recently	O
proposed	O
putative	O
alternative	O
translation	O
initiation	O
codon	O
(	O
TIC	O
-	O
1	O
)	O
,	O
supporting	O
that	O
TIC	O
-	O
1	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC	O
-	O
2	O
.	O
.	O

Human	B
complement	I
factor	I
H	I
lack	I
associated	O
with	O
haemolytic	B
uraemic	I
syndrome	I
.	O

Human	B
complement	I
factor	I
H	I
deficiency	I
associated	O
with	O
hemolytic	B
uremic	I
full	O
complement	I
full	O
complement	I
full	O

Human	B
accompaniment	I
factor	I
H	I
want	I
associated	O
with	O
hemolytic	B
uraemic	I
syndrome	I
.	O

Human	B
accompaniment	I
factor	I
H	I
insufficiency	I
associated	O
with	O
hemolytic	B
azotemic	I
syndrome	I
.	O

complement	I
factor	I
deficiency	I
associated	O
with	O
hemolytic	B
uremic	I
syndrome	I
.	O

hemolytic	B
complement	I
factor	I
deficiency	I
H	I
associated	O
syndrome	O
Human	B
uremic	I
with	I
.	O

Human	B
hemolytic	I
factor	I
H	I
complement	I
associated	O
with	O
.	B
uremic	I
syndrome	I
deficiency	O

H	B
hemolytic	I
factor	I
with	I
deficiency	I
associated	O
Human	O
complement	B
uremic	I
syndrome	I
.	O

Human	B
factor	I
deficiency	I
with	O
hemolytic	B
uremic	I
syndrome	I
.	O

Human	B
complement	I
factor	I
H	I
deficiency	I
associated	O
with	O
hemolytic	B
uremic	I
full	O
complement	I
full	O
complement	I
full	O

Human	B
complement	I
factor	I
H	I
deficiency	I
associated	O
with	O
hemolytic	B
uremic	I
syndrome	I
.	O

This	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	B
in	I
the	I
human	I
complement	I
Factor	I
H	I
(	O
FH	O
in	O
the	O
context	O
of	O
an	O
renal	I
disease	I
.	O

This	O
reports	O
on	O
cases	O
of	O
deficiency	B
in	I
the	I
human	I
complement	I
regulatory	I
Factor	I
H	I
FH	O
)	O
in	O
the	O
context	O
of	O
an	O
acute	B

This	O
study	O
reports	O
on	O
	O
element	O
heat	O
content	O
	O
six	O
cases	O
of	B
deficiency	I
in	I
the	I
human	I
complement	I
regulatory	I
protein	I
Factor	I
H	O
(	O
FH	O
penetrative	O
nephritic	O
penetrative	O
homo	O
)	O
in	O
the	O
context	O
of	O
an	B
acute	I
renal	I
disease	O

the	O
study	O
reports	O
)	O
six	O
cases	O
of	O
renal	B
an	I
the	I
in	I
complement	I
regulatory	I
protein	I
of	I
H	I
(	O
FH	O
on	O
acute	O
human	O
context	O
Factor	O
in	O
This	B
deficiency	I
disease	I
.	O

disease	O
study	O
reports	O
Factor	O
six	O
cases	O
renal	O
deficiency	B
on	I
the	I
human	I
complement	I
protein	I
the	I
acute	I
in	I
(	O
FH	O
)	O
in	O
regulatory	O
context	O
of	O
an	O
H	B
of	I
This	I
.	O

This	O
study	O
reports	O
on	O
	O
element	O
heat	O
content	O
	O
six	O
cases	O
of	B
deficiency	I
in	I
the	I
human	I
complement	I
regulatory	I
protein	I
Factor	I
H	O
(	O
FH	O
penetrative	O
nephritic	O
penetrative	O
indium	O
)	O
in	O
the	O
context	O
of	O
an	B
acute	I
renal	I
disease	O

This	O
study	O
reports	O
on	O
six	O
vitrine	O
of	O
lack	B
in	I
the	I
human	I
accompaniment	I
regulative	I
protein	I
Factor	I
hydrogen	I
(	O
FH	O
)	O
in	O
the	O
context	O
of	O
an	O
intense	B
nephritic	I
disease	I
.	O

This	O
study	O
reports	O
on	O
	O
element	O
heat	O
content	O
	O
six	O
cases	O
of	B
deficiency	I
in	I
the	I
human	I
complement	I
regulatory	I
protein	I
Factor	I
H	O
(	O
FH	O
penetrative	O
nephritic	O
penetrative	O
indium	O
)	O
in	O
the	O
context	O
of	O
an	B
acute	I
renal	I
disease	O

an	O
study	O
reports	O
on	O
six	O
cases	O
protein	O
complement	B
in	I
the	I
human	I
(	I
context	I
of	I
acute	I
This	I
deficiency	O
H	O
)	O
in	O
the	O
regulatory	O
of	O
FH	O
Factor	B
renal	I
disease	I
.	O

This	O
study	O
describe	O
on	O
six	O
cases	O
of	O
insufficiency	B
in	I
the	I
human	I
accompaniment	I
regulative	I
protein	I
broker	I
henry	I
(	O
FH	O
)	O
in	O
the	O
context	O
of	O
an	O
acuate	B
nephritic	I
disease	I
.	O

This	O
study	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	B
in	I
the	I
human	I
complement	I
regulatory	I
protein	I
Factor	I
H	I
(	O
FH	O
)	O
in	O
the	O
context	O
of	O
an	O
acute	B
renal	I
disease	I
.	O

idiopathic	O
of	O
the	O
children	O
were	O
observed	O
in	O
cases	O
(	O
with	O
syndrome	O
hemolytic	B
Five	I
uremic	I
presenting	O
HUS	B
)	O
.	O

cinque	O
of	O
the	O
example	O
were	O
observed	O
in	O
tike	O
presenting	O
with	O
idiopathic	O
haemolytic	B
uremic	I
syndrome	I
(	O
huss	B
)	O
.	O

five	O
of	O
the	O
encase	O
were	O
observed	O
in	O
shaver	O
confront	O
with	O
idiopathic	O
hemolytic	B
uremic	I
syndrome	I
(	O
huss	B
)	O
.	O

Five	O
of	O
the	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B
uremic	I
syndrome	I
(	O
HUS	B
)	O
.	O

quint	O
of	O
the	O
cases	O
were	O
honour	O
in	O
children	O
stage	O
with	O
idiopathic	O
haemolytic	B
azotemic	I
syndrome	I
(	O
HUS	B
)	O
.	O

Five	O
of	O
introduce	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B
uremic	I
syndrome	I
(	O
HUS	B
)	O
put	O
in	O
put	O
in	O
put	O

Five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
hemolytic	B
uremic	I
(	O
HUS	B
)	O
.	O

Five	O
of	O
introduce	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B
uremic	I
syndrome	I
(	O
HUS	B
)	O
put	O
in	O
put	O
in	O
put	O

of	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B
uremic	I
.	O

Five	O
of	O
presenting	O
(	O
were	O
observed	O
uremic	O
children	O
the	O
with	O
idiopathic	O
hemolytic	B
in	I
syndrome	I
cases	O
HUS	B
)	O
.	O

Five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B
uremic	I
syndrome	I
(	O
HUS	B
)	O
.	O

Two	O
of	O
the	O
exhibited	O
homozygous	O
deficiency	O
characterized	O
absence	O
kD	O
form	O
of	O
H	O
and	O
presence	O
,	O
upon	O
of	O
the	O
42	O
-	O
kD	O
H	O
like	O
protein	O
1	O
(	O
FHL	O
-	O
1	O
)	O
and	O
other	O
-	O
related	O
protein	O
(	O
FHR	O

ii	O
of	O
the	O
kid	O
demonstrate	O
a	O
homozygous	O
inadequacy	O
qualify	O
by	O
the	O
absence	O
of	O
the	O
150	O
-	O
kD	O
kind	O
of	O
cistron	O
H	O
and	O
the	O
front	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
xlii	O
-	O
kD	O
cistron	O
H	O
-	O
wish	O
protein	O
ane	O
(	O
FHL	O
-	O
ane	O
)	O
and	O
other	O
FH	O
-	O
refer	O
protein	O
(	O
FHR	O
)	O
isthmus	O
.	O

two	O
of	O
the	O
tyke	O
present	O
a	O
homozygous	O
insufficiency	O
characterise	O
by	O
the	O
absence	O
of	O
the	O
150	O
-	O
kD	O
descriptor	O
of	O
constituent	O
H	O
and	O
the	O
comportment	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
constituent	O
H	O
-	O
care	O
protein	O
unity	O
(	O
FHL	O
-	O
unity	O
)	O
and	O
other	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O
circle	O
.	O

Two	O
of	O
children	O
homozygous	O
deficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
Factor	O
-	O
protein	O
1	O
(	O
FHL	O
-	O
1	O
)	O
and	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O

H	O
immunoblotting	O
the	O
children	O
exhibited	O
a	O
-	O
deficiency	O
characterized	O
by	O
the	O
FHL	O
of	O
,	O
of	O
-	O
kD	O
form	O
of	O
Factor	O
H	O
and	O
Factor	O
presence	O
)	O
upon	O
FH	O
the	O
related	O
of	O
42	O
-	O
kD	O
150	O
Two	O
bands	O
like	O
protein	O
1	O
(	O
absence	O
homozygous	O
1	O
the	O
and	O
other	O
the	O
-	O
,	O
protein	O
(	O
FHR	O
)	O
-	O
.	O

Two	O
of	O
42	O
children	O
exhibited	O
a	O
homozygous	O
-	O
characterized	O
by	O
the	O
presence	O
Factor	O
the	O
150	O
deficiency	O
kD	O
form	O
protein	O
of	O
H	O
FH	O
the	O
absence	O
,	O
FHR	O
bands	O
other	O
of	O
the	O
the	O
.	O
upon	O
Factor	O
H	O
and	O
like	O
-	O
1	O
(	O
FHL	O
-	O
immunoblotting	O
)	O
-	O
kD	O
and	O
-	O
related	O
protein	O
(	O
,	O
)	O
1	O
of	O

protein	O
,	O
the	O
children	O
exhibited	O
a	O
protein	O
kD	O
characterized	O
by	O
the	O
absence	O
of	O
(	O
FHR	O
-	O
deficiency	O
FH	O
of	O
Factor	O
bands	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
-	O
and	O
the	O
of	O
homozygous	O
kD	O
Factor	O
H	O
-	O
like	O
related	O
-	O
(	O
FHL	O
H	O
1	O
)	O
42	O
other	O
form	O
-	O
1	O
Two	O
the	O
150	O
)	O
of	O
.	O

Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	O
deficiency	O
past	O
band	O
absence	O
seizure	O
former	O
	O
	O
characterize	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150	O
-	O
kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
Factor	O
H	O
-	O
demo	O
demo	O
colligate	O
demo	O
demo	O
colligate	O
demo	O
isthmus	O
	O
like	O
protein	O
1	O
(	O
FHL	O
-	O
1	O
)	O
and	O
other	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O
bands	O

Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	O
deficiency	O
past	O
band	O
absence	O
seizure	O
former	O
	O
	O
characterize	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150	O
-	O
kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
Factor	O
H	O
-	O
demo	O
demo	O
colligate	O
demo	O
demo	O
colligate	O
demo	O
isthmus	O
inadequacy	O
like	O
protein	O
1	O
(	O
FHL	O
-	O
1	O
)	O
and	O
other	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O
bands	O

deuce	O
of	O
the	O
children	O
show	O
a	O
homozygous	O
insufficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
cl	O
-	O
kD	O
organize	O
of	O
cistron	O
H	O
and	O
the	O
bearing	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
cistron	O
H	O
-	O
ilk	O
protein	O
ace	O
(	O
FHL	O
-	O
ace	O
)	O
and	O
other	O
FH	O
-	O
colligate	O
protein	O
(	O
FHR	O
)	O
set	O
.	O

Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	O
deficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150	O
-	O
kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
Factor	O
H	O
-	O
like	O
protein	O
1	O
(	O
FHL	O
-	O
1	O
)	O
and	O
other	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O
bands	O
.	O

Southern	O
blot	O
and	O
PCR	O
dominate	O
proscribed	O
dna	O
depth	O
psychology	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
eclipse	O
eclipse	O
eclipse	O
eclipse	O
inadequacy	O

Southern	O
blot	O
and	O
of	O
with	O
homozygous	O
deficiency	O
out	O
the	O
of	O
a	O
large	O
the	O
FH	O
gene	O
as	O
the	O
defect	O
the	O
deficiency	O
.	O

southerly	O
blob	O
and	O
PCR	O
analysis	O
of	O
dna	O
of	O
unrivalled	O
patient	O
with	O
homozygous	O
lack	O
find	O
out	O
the	O
bearing	O
of	O
a	O
large	O
omission	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
mar	O
for	O
the	O
lack	O
.	O

Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
one	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
.	O

southerly	O
smudge	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
harness	O
out	O
the	O
mien	O
of	O
a	O
expectant	O
excision	O
of	O
the	O
FH	O
factor	O
as	O
the	O
fundamental	O
blemish	O
for	O
the	O
deficiency	O
.	O

Southern	O
blot	O
and	O
PCR	O
dominate	O
proscribed	O
dna	O
depth	O
psychology	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
eclipse	O
eclipse	O
eclipse	O
eclipse	O
inadequacy	O

southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
i	O
patient	O
with	O
homozygous	O
want	O
rein	O
out	O
the	O
mien	O
of	O
a	O
orotund	O
cut	O
of	O
the	O
FH	O
cistron	O
as	O
the	O
rudimentary	O
defect	O
for	O
the	O
want	O
.	O

deletion	O
a	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
gene	O
for	O
the	O
presence	O
of	O
underlying	O
large	O
blot	O
of	O
deficiency	O
FH	O
ruled	O
as	O
the	O
Southern	O
out	O
the	O
the	O
defect	O
.	O

Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
of	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
underlying	O
defect	O
for	O
deficiency	O

Southern	O
blot	O
and	O
PCR	O
dominate	O
proscribed	O
dna	O
blemish	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
eclipse	O
eclipse	O
eclipse	O
eclipse	O
inadequacy	O
.	O

Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
.	O

The	O
other	O
tetrad	O
baby	O
presented	O
with	O
heterozygous	O
lack	O
and	O
demonstrate	O
a	O
convention	O
immunoblotting	O
blueprint	O
of	O
proteins	O
of	O
the	O
FH	O
family	O
.	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
family	O
line	O
	O
	O
	O
	O
	O
FH	O
family	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
family	O
line	O
	O
	O
	O
	O
	O
FH	O
family	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
exhibited	O
a	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	O

of	O
other	O
and	O
heterozygous	O
presented	O
with	O
proteins	O
deficiency	O
four	O
exhibited	O
a	O
normal	O
.	O
pattern	O
children	O
The	O
of	O
the	O
FH	O
family	O
immunoblotting	O

The	O
other	O
quaternity	O
baby	O
introduce	O
with	O
heterozygous	O
inadequacy	O
and	O
exhibited	O
a	O
formula	O
immunoblotting	O
formula	O
of	O
proteins	O
of	O
the	O
FH	O
family	O
.	O

.	O
other	O
four	O
a	O
presented	O
with	O
heterozygous	O
FH	O
of	O
exhibited	O
children	O
normal	O
pattern	O
immunoblotting	O
and	O
proteins	O
of	O
the	O
deficiency	O
The	O
family	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
family	O
line	O
	O
	O
	O
	O
inadequacy	O
FH	O
family	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
of	O
the	O
FH	O
family	O
.	O

The	O
other	O
four	O
fry	O
demo	O
with	O
heterozygous	O
insufficiency	O
and	O
show	O
a	O
pattern	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	O
fellowship	O
.	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	O
family	O
.	O

Factor	B
H	I
deficiency	I
is	O
the	O
only	O
complement	B
deficiency	I
associated	O
hus	O
heat	O
content	O
heat	O
content	B
with	O

H	I
deficiency	I
complement	B
with	O
HUS	B
.	O

Factor	B
H	I
lack	I
is	O
the	O
only	O
complement	B
lack	I
connect	O
with	O
HUS	B
.	O

Factor	B
H	I
deficiency	I
is	O
the	O
only	O
complement	B
deficiency	I
associated	O
hus	O
heat	O
content	O
heat	O
content	B
with	O

H	I
deficiency	I
the	O
only	O
complement	B
deficiency	I
associated	O
with	O
HUS	B
.	O

cistron	B
H	I
inadequacy	I
is	O
the	O
only	O
complement	B
inadequacy	I
relate	O
with	O
HUS	B
.	O

Factor	B
H	I
deficiency	I
is	O
the	O
only	O
complement	B
deficiency	I
associated	O
hus	O
heat	O
content	O
inadequacy	O
with	B
HUS	O

element	B
hydrogen	I
deficiency	I
is	O
the	O
only	O
complement	B
deficiency	I
relate	O
with	O
HUS	B
.	O

Factor	B
deficiency	I
deficiency	I
is	O
H	O
only	O
complement	B
HUS	I
associated	O
with	O
the	B
.	O

.	B
H	I
deficiency	I
is	O
deficiency	O
only	O
with	B
the	I
associated	O
complement	O
HUS	B
Factor	O

Factor	B
H	I
deficiency	I
is	O
the	O
only	O
complement	B
deficiency	I
associated	O
with	O
HUS	B
.	O

These	O
reflection	O
hint	O
a	O
function	O
for	O
FH	O
and	O
/	O
or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
.	O
.	O

These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and	O
/	O
or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
propose	O
propose	O
propose	O
propose	O
propose	O
propose	O
.	O
.	O

These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and	O
/	O
or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
propose	O
propose	O
propose	O
propose	O
propose	O
propose	O
.	O
.	O

suggest	O
for	O
FH	O
and	O
or	O
FH	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
.	O
.	O

These	O
observations	O
suggest	O
a	O
role	O
and	O
/	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
.	O
.	O

suggest	O
a	O
role	O
for	O
and	O
/	O
or	O
FH	O
receptors	O
the	O
pathogenesis	O
of	O
idiopathic	O
.	O
.	O

HUS	O
observations	O
suggest	O
.	O
role	O
for	O
FH	O
/	O
and	O
or	O
pathogenesis	O
receptors	O
in	O
.	O
These	O
of	O
idiopathic	O
FH	B
a	O
the	O

These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and	O
/	O
or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
propose	O
propose	O
propose	O
propose	O
propose	O
hus	O
.	O
.	O

These	O
notice	O
propose	O
a	O
persona	O
for	O
FH	O
and	O
/	O
or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
.	O
.	O

idiopathic	O
observations	O
suggest	O
a	O
role	O
for	O
the	O
receptors	O
/	O
or	O
FH	O
pathogenesis	O
These	O
FH	O
and	O
HUS	O
in	O
of	B
.	O
.	O

These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and	O
/	O
or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
.	O
.	O

Further	O
evidence	O
myotonic	O
in	O
major	O
ancient	O
disequilibrium	O
underlying	O
for	B
dystrophy	I
from	O
linkage	O
mutation	O
studies	O
a	O
the	O
Japanese	O
population	O
.	O

for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B
dystrophy	I
from	O
the	O
Japanese	O
population	O
.	O

Further	O
evidence	O
for	O
a	O
major	O
antediluvian	O
variation	O
inherent	O
myotonic	B
dystrophy	I
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
nipponese	O
universe	O
.	O

further	O
grounds	O
for	O
a	O
major	O
ancient	O
mutant	O
underlying	O
myotonic	B
dystrophy	I
from	O
linkage	O
disequilibrium	O
contemplate	O
in	O
the	O
Japanese	O
universe	O
.	O

Japanese	O
evidence	O
for	O
a	O
major	O
ancient	O
studies	O
in	O
myotonic	B
dystrophy	I
from	O
linkage	O
population	O
mutation	O
underlying	O
the	O
disequilibrium	O
Further	O
.	O

Further	O
evidence	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B
dystrophy	I
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
.	O

Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B
dystrophy	I
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
population	O
ampere	O
ampere	O
ampere	O
ampere	O
john	O
major	O

Further	O
certify	O
for	O
a	O
major	O
antediluvian	O
mutation	O
underlying	O
myotonic	B
dystrophy	I
from	O
linkage	O
disequilibrium	O
subject	O
in	O
the	O
nipponese	O
universe	O
.	O

Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B
dystrophy	I
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
population	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
.	O

studies	O
evidence	O
for	O
from	O
major	O
ancient	O
mutation	O
.	O
in	B
dystrophy	I
a	O
linkage	O
Further	O
disequilibrium	O
myotonic	O
the	O
Japanese	O
population	O
underlying	O

Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B
dystrophy	I
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
dm	O
chromosome	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
on	O
DM	B
chromosomes	O
.	O

The	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
dm	O
chromosome	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
	O
on	O
DM	B
chromosomes	O
.	O

The	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
dm	O
chromosome	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
dm	O
on	O
DM	B
chromosomes	O
.	O

37	O
a	B
dystrophy	I
(	O
DM	B
)	O
CTG	O
-	O
an	O
unstable	O
(	O
mutation	O
)	O
normal	O
but	O
,	O
present	O
at	O
is	O
copy	O
number	O
50	O
chromosomes	O
-	O
The	O
repeats	O
to	O
n	O
repeat	O
5	O
amplified	O
copies	O
of	O
myotonic	O
3000	O
on	O
on	O
DM	B
chromosomes	O
.	O

The	O
myotonic	B
dystrophy	I
(	O
is	O
an	O
unstable	O
(	O
CTG	O
n	O
repeat	O
a	O
of	O
5	O
repeats	O
chromosomes	O
but	O
amplified	O
to	O
-	O
3000	O
DM	B
chromosomes	O

The	O
myotonic	B
dystrophy	I
(	O
dm	B
)	O
mutant	O
is	O
an	O
precarious	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
demonstrate	O
at	O
a	O
copy	O
routine	O
of	O
v	O
-	O
37	O
reprize	O
on	O
convention	O
chromosomes	O
but	O
hyperbolize	O
to	O
50	O
-	O
3000	O
replicate	O
on	O
dm	B
chromosomes	O
.	O

The	O
myotonic	B
dystrophy	I
(	O
decimeter	B
)	O
mutation	O
is	O
an	O
unsound	O
(	O
CTG	O
)	O
n	O
iterate	O
,	O
award	O
at	O
a	O
transcript	O
turn	O
of	O
5	O
-	O
37	O
reiterate	O
on	O
convention	O
chromosomes	O
but	O
exaggerate	O
to	O
l	O
-	O
3000	O
simulate	O
on	O
decimeter	B
chromosomes	O
.	O

amplified	O
3000	B
dystrophy	I
(	O
present	B
)	O
DM	O
to	O
an	O
unstable	O
(	O
CTG	O
)	O
37	O
at	O
,	O
DM	O
repeat	O
a	O
copy	O
n	O
of	O
5	O
-	O
myotonic	O
repeats	O
on	O
chromosomes	O
The	O
but	O
chromosomes	O
mutation	O
50	O
-	O
number	O
copies	O
on	O
is	B
normal	O
.	O

The	O
myotonic	B
dystrophy	I
(	O
dm	B
)	O
variation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
iterate	O
,	O
gift	O
at	O
a	O
replicate	O
count	O
of	O
5	O
-	O
xxxvii	O
restate	O
on	O
convention	O
chromosomes	O
but	O
hyperbolise	O
to	O
l	O
-	O
3000	O
transcript	O
on	O
dm	B
chromosomes	O
.	O

The	O
myotonic	B
amplified	I
(	O
DM	B
copies	O
(	O
is	O
an	O
unstable	O
mutation	O
on	O
copy	O
n	O
repeat	O
a	O
present	O
at	O
DM	O
)	O
number	O
of	O
5	O
)	O
37	O
,	O
CTG	O
50	O
to	O
but	O
dystrophy	O
normal	O
chromosomes	O
-	O
3000	O
-	O
on	O
repeats	B
chromosomes	O
.	O

The	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
on	O
DM	B
chromosomes	O
.	O

Previous	O
findings	O
in	O
DM	B
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
in	O
the	O
expansion	O
mutation	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B
founder	O
chromosome	O
raise	O
a	O
question	O
the	O
involved	O
in	O
the	O
expansion	O
mutation	O
.	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
elaboration	O
sport	O
sport	O
indium	O
indium	O
indium	O
in	O
the	O
expansion	O
mutation	O
.	O

Previous	O
happen	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B
father	O
chromosome	O
raise	O
a	O
wonder	O
about	O
the	O
molecular	O
events	O
demand	O
in	O
the	O
enlargement	O
variation	O
.	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
elaboration	O
sport	O
sport	O
indium	O
indium	O
indium	O
in	O
the	O
expansion	O
mutation	O
.	O

premature	O
encounter	O
in	O
white	O
populations	O
of	O
a	O
DM	B
beginner	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
issue	O
involved	O
in	O
the	O
elaboration	O
mutation	O
.	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B
founder	O
chromosome	O
a	O
question	O
the	O
molecular	O
events	O
involved	O
in	O
the	O
expansion	O

raise	O
findings	O
in	O
in	O
populations	O
of	O
a	O
founder	B
DM	O
chromosome	O
the	O
a	O
about	O
question	O
.	O
molecular	O
events	O
involved	O
Caucasian	O
Previous	O
expansion	O
mutation	O
the	O

Previous	O
detect	O
in	O
Caucasian	O
populations	O
of	O
a	O
decimeter	B
founder	O
chromosome	O
kindle	O
a	O
doubt	O
about	O
the	O
molecular	O
case	O
convoluted	O
in	O
the	O
expansion	O
mutation	O
.	O

the	O
findings	O
founder	O
a	O
populations	O
of	O
molecular	O
DM	B
in	O
chromosome	O
raise	O
a	O
expansion	O
about	O
Caucasian	O
Previous	O
events	O
involved	O
in	O
the	O
question	O
mutation	O
.	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
in	O
the	O
expansion	O
mutation	O
.	O

To	O
investigate	O
CTG	O
a	O
founder	O
in	O
for	O
markers	O
DM	B
mutation	O
exists	O
the	O
n	O
Japanese	O
population	O
and	O
we	O
genotyped	O
using	O
families	O
polymorphic	O
the	O
near	O
chromosome	O
(	O
)	O
whether	O
haplotypes	O
repeat	O
region	O
,	O
the	O
constructed	O
.	O

To	O
a	O
founder	O
chromosome	O
for	O
DM	B
mutation	O
the	O
Japanese	O
,	O
we	O
polymorphic	O
near	O
the	O
(	O
)	O
n	O
repeat	O
and	O
constructed	O
haplotypes	O
.	O

To	O
investigate	O
whether	O
a	O
universe	O
newton	O
build	O
founder	O
chromosome	O
for	O
the	O
DM	B
mutation	O
exists	O
in	O
the	O
Japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
macrocosm	O
macrocosm	O
macrocosm	O
macrocosm	O
macrocosm	O
macrocosm	O
nipponese	O
.	O

To	O
investigate	O
whether	O
a	O
universe	O
newton	O
beginner	O
founder	O
chromosome	O
for	O
the	O
DM	B
mutation	O
exists	O
in	O
the	O
Japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
macrocosm	O
macrocosm	O
macrocosm	O
macrocosm	O
macrocosm	O
macrocosm	O
nipponese	O
.	O

investigate	O
families	O
whether	O
a	O
founder	O
chromosome	O
)	O
the	O
DM	B
mutation	O
exists	O
n	O
the	O
(	O
region	O
,	O
we	O
genotyped	O
in	O
using	O
polymorphic	O
markers	O
.	O
the	O
Japanese	O
CTG	O
for	O
To	O
constructed	O
near	O
and	O
repeat	O
haplotypes	O
population	O

To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
DM	B
mutation	O
exists	O
in	O
Japanese	O
population	O
,	O
we	O
genotyped	O
using	O
polymorphic	O
markers	O
near	O
(	O
CTG	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
.	O

To	O
inquire	O
whether	O
a	O
laminitis	O
chromosome	O
for	O
the	O
DM	B
mutant	O
survive	O
in	O
the	O
nipponese	O
universe	O
,	O
we	O
genotyped	O
mob	O
habituate	O
polymorphous	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
build	O
haplotypes	O
.	O

To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
decimetre	B
mutation	O
be	O
in	O
the	O
nipponese	O
universe	O
,	O
we	O
genotyped	O
fellowship	O
using	O
polymorphous	O
markers	O
good	O
the	O
(	O
CTG	O
)	O
n	O
duplicate	O
area	O
and	O
make	O
haplotypes	O
.	O

To	O
investigate	O
whether	O
a	O
universe	O
newton	O
beginner	O
founder	O
chromosome	O
for	O
the	O
DM	B
mutation	O
exists	O
in	O
the	O
Japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
macrocosm	O
macrocosm	O
macrocosm	O
macrocosm	O
macrocosm	O
macrocosm	O
nipponese	O
.	O

To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
DM	B
mutant	O
live	O
in	O
the	O
japanese	O
universe	O
,	O
we	O
genotyped	O
fellowship	O
utilize	O
polymorphous	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
recur	O
realm	O
and	O
make	O
haplotypes	O
.	O

To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
DM	B
mutation	O
exists	O
in	O
the	O
Japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
.	O

Six	O
haplotypes	O
were	O
and	O
alleles	O
always	O
haplotype	O
A	O
.	O

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B
alleles	O
were	O
always	O
haplotype	O
A	O

Six	O
dissimilar	O
haplotypes	O
were	O
found	O
and	O
DM	B
allelomorph	O
were	O
always	O
haplotype	O
amp	O
.	O

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B
alleles	O
were	O
ampere	O
ampere	O
dissimilar	O
always	O
haplotype	O
A	O
.	O

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B
alleles	O
were	O
ampere	O
ampere	O
dm	O
always	O
haplotype	O
A	O
.	O

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B
alleles	O
were	O
ampere	O
ampere	O
dissimilar	O
always	O
haplotype	O
A	O
.	O

Six	O
unlike	O
haplotypes	O
were	O
witness	O
and	O
DM	B
alleles	O
were	O
always	O
haplotype	O
angstrom	O
.	O

Six	O
different	O
were	O
found	O
and	O
DM	B
alleles	O
were	O
always	O
.	O

six	O
unlike	O
haplotypes	O
were	O
found	O
and	O
decimetre	B
alleles	O
were	O
always	O
haplotype	O
A	O
.	O

Six	O
found	O
haplotypes	O
were	O
.	O
and	O
DM	B
different	O
were	O
always	O
haplotype	O
A	O
alleles	O

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B
alleles	O
were	O
always	O
haplotype	O
A	O
.	O

To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	B
families	O
comprising	O
190	O
affected	O
and	O
unmoved	O
member	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O

To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	B
families	O
comprising	O
190	O
affected	O
and	O
unmoved	O
member	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O

To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	B
families	O
comprising	O
190	O
affected	O
and	O
unmoved	O
member	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O

population	O
the	O
an	O
origin	O
of	O
the	O
mutation	O
190	O
)	O
n	O
repeat	O
(	O
and	O
studied	O
Japanese	O
the	O
mechanism	O
of	O
CTG	O
expansion	O
mutation	O
comprising	O
90	O
Japanese	O
To	O
we	O
families	O
to	O
investigate	O
the	O
DM	B
and	O
in	O
find	O
affected	O
have	O
130	O
unaffected	O
members	O
.	O

To	O
find	O
an	O
origin	O
CTG	O
)	O
n	O
repeat	O
mutation	O
to	O
investigate	O
the	O
in	O
the	O
we	O
90	O
Japanese	O
DM	B
families	O
190	O
affected	O
unaffected	O
members	O

To	O
get	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
echo	O
variation	O
and	O
to	O
enquire	O
the	O
mechanism	O
of	O
the	O
elaboration	O
variation	O
in	O
the	O
nipponese	O
universe	O
we	O
have	O
contemplate	O
90	O
nipponese	O
dm	B
kinfolk	O
be	O
190	O
affected	O
and	O
130	O
insensible	O
members	O
.	O

To	O
find	O
an	O
stemma	O
of	O
the	O
(	O
CTG	O
)	O
n	O
iterate	O
mutant	O
and	O
to	O
enquire	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutant	O
in	O
the	O
japanese	O
universe	O
we	O
have	O
analyse	O
90	O
japanese	O
dm	B
class	O
contain	O
190	O
affected	O
and	O
130	O
untouched	O
phallus	O
.	O

DM	O
affected	O
an	O
origin	O
mechanism	O
the	O
unaffected	O
families	O
)	O
n	O
repeat	O
mutation	O
and	O
population	O
of	O
the	O
of	O
investigate	O
the	O
expansion	O
to	O
in	O
the	O
Japanese	O
find	O
we	O
have	O
members	O
To	O
Japanese	O
90	B
(	O
comprising	O
190	O
mutation	O
and	O
130	O
CTG	O
studied	O
.	O

To	O
breakthrough	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
ingeminate	O
sport	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
sport	O
in	O
the	O
japanese	O
universe	O
we	O
have	O
read	O
ninety	O
japanese	O
decimeter	B
syndicate	O
comprise	O
190	O
feign	O
and	O
130	O
unmoved	O
members	O
.	O

To	O
find	O
DM	O
origin	O
of	O
and	O
repeat	O
CTG	O
)	O
n	O
(	O
have	O
expansion	O
to	O
investigate	O
the	O
mechanism	O
of	O
unaffected	O
and	O
mutation	O
in	O
the	O
the	O
population	O
the	O
mutation	O
comprising	O
families	O
Japanese	O
an	B
studied	O
90	O
190	O
affected	O
Japanese	O
130	O
we	O
members	O
.	O

To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	B
families	O
comprising	O
190	O
affected	O
and	O
130	O
unaffected	O
members	O
.	O

The	O
results	O
repeat	O
that	O
a	O
Caucasian	O
common	O
ancestral	O
mutations	O
in	O
both	O
=	O
n	O
Japanese	O
populations	O
-	O
originated	O
by	O
of	O
expansion	O
an	O
ancestral	O
n	O
few	O
5	O
to	O
suggest	O
copies	O
=	O
19	O
have	O
and	O
37	O
.	O

The	O
that	O
a	O
few	O
common	O
mutations	O
in	O
and	O
Japanese	O
have	O
originated	O
an	O
n	O
=	O
5	O
to	O
n	O
=	O
-	O
37	O
copies	O
.	O

The	O
results	O
suggest	O
that	O
population	O
receive	O
receive	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	O
to	O
n	O
=	O
19	O
-	O
37	O
copies	O
universe	O
universe	O
universe	O
universe	O
universe	O
universe	O
nipponese	O
.	O

The	O
results	O
suggest	O
that	O
population	O
receive	O
ampere	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	O
to	O
n	O
=	O
19	O
-	O
37	O
copies	O
universe	O
universe	O
universe	O
universe	O
universe	O
universe	O
nipponese	O
.	O

results	O
expansion	O
suggest	O
that	O
a	O
few	O
to	O
ancestral	O
mutations	O
in	O
both	O
n	O
and	O
5	O
19	O
have	O
originated	O
by	O
Caucasian	O
of	O
an	O
ancestral	O
.	O
=	O
Japanese	O
repeat	O
common	O
The	O
37	O
n	O
-	O
=	O
copies	O
populations	O

The	O
results	O
suggest	O
that	O
a	O
few	O
mutations	O
in	O
both	O
Caucasian	O
Japanese	O
populations	O
have	O
originated	O
by	O
of	O
an	O
ancestral	O
n	O
5	O
repeat	O
n	O
=	O
19	O
-	O
37	O
copies	O
.	O

The	O
leave	O
suggest	O
that	O
a	O
few	O
plebeian	O
hereditary	O
mutations	O
in	O
both	O
caucasian	O
and	O
japanese	O
populations	O
have	O
uprise	O
by	O
expansion	O
of	O
an	O
hereditary	O
n	O
=	O
fin	O
reiterate	O
to	O
n	O
=	O
nineteen	O
-	O
37	O
transcript	O
.	O

The	O
solution	O
evoke	O
that	O
a	O
few	O
uncouth	O
hereditary	O
mutant	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
uprise	O
by	O
elaboration	O
of	O
an	O
hereditary	O
n	O
=	O
quintet	O
replicate	O
to	O
n	O
=	O
19	O
-	O
xxxvii	O
copies	O
.	O

The	O
results	O
suggest	O
that	O
population	O
receive	O
ampere	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	O
to	O
n	O
=	O
19	O
-	O
37	O
copies	O
universe	O
universe	O
universe	O
universe	O
universe	O
universe	O
nipponese	O
.	O

The	O
results	O
suggest	O
that	O
a	O
few	O
common	O
ancestral	O
mutant	O
in	O
both	O
Caucasian	O
and	O
japanese	O
universe	O
have	O
arise	O
by	O
elaboration	O
of	O
an	O
ancestral	O
n	O
=	O
phoebe	O
reprize	O
to	O
n	O
=	O
xix	O
-	O
xxxvii	O
copy	O
.	O

The	O
results	O
suggest	O
that	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	O
to	O
n	O
=	O
19	O
-	O
37	O
copies	O
.	O

These	O
information	O
accompaniment	O
multistep	O
models	O
of	O
iii	O
double	O
enlargement	O
that	O
have	O
been	O
proposed	O
for	O
both	O
decimetre	B
and	O
Friedreichs	B
ataxia	I
.	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	B
and	O
Friedreichs	B
subscribe	B
subscribe	O
subscribe	B
subscribe	O
subscribe	B
subscribe	O
ataxia	I
.	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	B
and	O
Friedreichs	B
subscribe	B
subscribe	O
subscribe	B
subscribe	O
subscribe	B
subscribe	O
ataxia	I
.	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
that	O
have	O
proposed	O
for	O
both	O
DM	B
and	O
Friedreichs	B
ataxia	I

both	O
data	O
expansion	O
triplet	O
models	O
of	O
DM	O
repeat	O
support	O
that	O
have	O
been	O
.	O
for	O
multistep	O
These	B
and	O
Friedreichs	B
ataxia	I
.	O
proposed	O

These	O
datum	O
support	O
multistep	O
models	O
of	O
triplet	O
repetition	O
enlargement	O
that	O
have	O
been	O
purport	O
for	O
both	O
dm	B
and	O
Friedreichs	B
dyssynergia	I
.	O
.	O

.	O
data	O
support	O
have	O
models	O
of	O
triplet	O
ataxia	O
both	O
that	O
multistep	O
been	O
for	O
proposed	O
expansion	O
DM	B
and	O
Friedreichs	B
repeat	I
These	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	B
and	O
Friedreichs	B
subscribe	B
subscribe	O
subscribe	B
subscribe	O
subscribe	B
	O
ataxia	I
.	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
both	O
Friedreichs	B
ataxia	I
.	O
.	O

These	O
data	O
support	O
multistep	O
pattern	O
of	O
tercet	O
retell	O
expansion	O
that	O
have	O
been	O
nominate	O
for	O
both	O
decimetre	B
and	O
Friedreichs	B
ataxia	I
.	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	B
and	O
Friedreichs	B
ataxia	I
.	O
.	O

The	O
basis	O
C6	B
in	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

The	O
molecular	O
base	O
of	O
C6	B
want	I
in	O
the	O
western	O
ness	O
,	O
South	O
africa	O
.	O

the	O
of	O
basis	O
molecular	O
C6	B
deficiency	I
Cape	O
The	O
western	O
.	O
,	O
South	O
Africa	O
in	O

The	O
molecular	O
basis	O
of	O
C6	B
deficiency	I
in	O
the	O
Cape	O
,	O
Africa	O
.	O

The	O
molecular	O
cornerstone	O
cornerstone	O
basis	O
of	O
C6	B
deficiency	I
in	O
the	O
western	O
africa	O
africa	O
Cape	O
,	O
South	O
Africa	O
.	O

The	O
molecular	O
cornerstone	O
cornerstone	O
basis	O
of	O
C6	B
deficiency	I
in	O
the	O
western	O
africa	O
dixieland	O
Cape	O
,	O
South	O
Africa	O
.	O

The	O
molecular	O
basis	O
of	O
C6	B
deficiency	I
in	O
the	O
westerly	O
ness	O
,	O
confederacy	O
africa	O
.	O

Africa	O
molecular	O
basis	O
The	O
the	B
deficiency	I
in	O
South	O
western	O
Cape	O
,	O
C6	O
of	O
.	O

The	O
molecular	O
cornerstone	O
cornerstone	O
basis	O
of	O
C6	B
deficiency	I
in	O
the	O
western	O
africa	O
africa	O
Cape	O
,	O
South	O
Africa	O
.	O

The	O
molecular	O
fundament	O
of	O
C6	B
want	I
in	O
the	O
western	O
mantle	O
,	O
South	O
africa	O
.	O

The	O
molecular	O
basis	O
of	O
C6	B
deficiency	I
in	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

lack	B
of	I
the	I
sixth	I
element	I
of	I
homo	I
complement	I
(	O
C6	O
)	O
has	O
been	O
describe	O
in	O
a	O
come	O
of	O
phratry	O
from	O
the	O
western	O
Cape	O
,	O
southward	O
africa	O
.	O

Deficiency	B
of	I
sixth	I
component	I
of	I
human	I
complement	I
(	O
C6	O
)	O
has	O
been	O
a	O
number	O
of	O
families	O
the	O
western	O
Cape	O
,	O
South	O
.	O

Deficiency	B
of	I
the	I
sixth	I
indium	I
ampere	I
element	I
component	I
of	I
human	I
complement	I
(	O
C6	O
)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
horse	O
opera	O
dixieland	O
africa	O
dixieland	O
th	O
families	O
from	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O

the	B
of	I
the	I
families	I
component	I
of	I
human	I
Africa	I
,	O
C6	O
from	O
has	O
been	O
reported	O
Cape	O
a	O
number	O
of	O
sixth	O
South	O
)	O
western	O
in	O
(	O
Deficiency	O
complement	O
.	O

Deficiency	B
of	I
the	I
sixth	I
indium	I
ampere	I
element	I
component	I
of	I
human	I
complement	I
(	O
C6	O
)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
horse	O
opera	O
dixieland	O
africa	O
dixieland	O
th	O
families	O
from	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O

Deficiency	B
of	I
the	I
component	I
of	I
complement	I
(	O
C6	O
)	O
has	O
been	O
reported	O
in	O
number	O
of	O
from	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

.	B
of	I
the	I
in	I
component	I
of	I
Africa	I
complement	I
sixth	O
C6	O
)	O
has	O
reported	O
the	O
South	O
(	O
number	O
of	O
families	O
from	O
been	O
western	O
Cape	O
,	O
a	O
human	O
Deficiency	O

the	I
of	I
human	I
complement	I
C6	O
)	O
been	O
reported	O
in	O
a	O
number	O
of	O
families	O
from	O
the	O
western	O
Cape	O
,	O
South	O

,	B
of	I
the	I
sixth	I
component	I
of	I
reported	I
has	I
(	O
C6	O
)	O
number	O
western	O
human	O
South	O
Deficiency	O
complement	O
a	O
families	O
from	O
the	O
been	O
Cape	O
of	O
in	O
Africa	O
.	O

lack	B
of	I
the	I
sixth	I
part	I
of	I
human	I
accompaniment	I
(	O
C6	O
)	O
has	O
been	O
cover	O
in	O
a	O
total	O
of	O
families	O
from	O
the	O
westerly	O
ness	O
,	O
South	O
africa	O
.	O

Deficiency	B
of	I
the	I
sixth	I
component	I
of	I
human	I
complement	I
(	O
C6	O
)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
families	O
from	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

disease	I
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	B
deficiency	I
(	O
)	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O

pedigrees	B
disease	I
is	O
have	O
in	O
the	O
Cape	O
.	O
recurrent	O
all	O
disease	O
of	O
total	O
been	B
of	I
(	O
C6Q0	O
)	O
endemic	O
C6	O
ascertained	O
because	O
deficiency	O
almost	O
Meningococcal	O
and	O

Meningococcal	B
disease	I
is	O
autochthonic	O
in	O
the	O
cape	O
and	O
almost	O
all	O
line	O
of	O
add	O
C6	B
inadequacy	I
(	O
C6Q0	O
)	O
have	O
been	O
see	O
because	O
of	O
repeated	O
disease	O
.	O

Meningococcal	B
disease	I
is	O
autochthonous	O
in	O
the	O
cape	O
and	O
almost	O
all	O
origin	O
of	O
come	O
C6	B
want	I
(	O
C6Q0	O
)	O
have	O
been	O
discovered	O
because	O
of	O
repeated	O
disease	O
.	O

Meningococcal	B
disease	I
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
of	O
total	O
deficiency	I
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
recurrent	O
disease	O
.	O

Meningococcal	B
disease	I
is	O
endemic	O
indium	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	B
deficiency	I
(	O
C6Q0	O
)	O
learn	O
perennial	O
cost	O
perennial	O
perennial	O
virtually	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O

Meningococcal	B
disease	I
is	O
endemic	O
indium	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	B
deficiency	I
(	O
C6Q0	O
)	O
learn	O
perennial	O
cost	O
perennial	O
perennial	O
whole	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O

Meningococcal	B
disease	I
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
of	O
deficiency	I
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O

recurrent	B
disease	I
is	O
endemic	O
in	O
the	O
C6	O
C6Q0	O
almost	O
all	O
pedigrees	O
of	O
because	O
Cape	B
disease	I
(	O
and	O
ascertained	O
have	O
been	O
Meningococcal	O
total	O
of	O
)	O
deficiency	O
.	O

Meningococcal	B
disease	I
is	O
endemic	O
in	O
the	O
cape	O
and	O
almost	O
all	O
lineage	O
of	O
number	O
C6	B
lack	I
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O
repeated	O
disease	O
.	O

Meningococcal	B
disease	I
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	B
deficiency	I
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O

We	O
the	O
expressed	O
exons	O
the	O
gene	O
from	O
selected	O
have	O
leading	O
to	O
total	O
879delG	O
,	O
is	O
the	O
common	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
and	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
Americans	O
.	O

We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
indium	O
receive	O
ness	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
receive	O
cost	O
antecedently	O
account	O
indium	O
african	O
account	O
american	O
african	O
account	O
american	O
ness	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
indium	O
receive	O
ness	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
receive	O
cost	O
antecedently	O
account	O
indium	O
african	O
account	O
american	O
african	O
account	O
american	O
	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

hitherto	O
is	O
sequenced	O
the	O
expressed	O
exons	O
selected	O
the	O
C6	O
gene	O
from	O
of	O
cases	O
the	O
common	O
found	O
three	O
molecular	O
defect	O
leading	O
to	O
total	O
and	O
879delG	O
have	O
which	O
reported	O
and	O
African	O
defects	O
in	O
unreported	O
Cape	O
have	O
We	O
,	O
,	O
and	O
1195delC	O
and	O
have	O
the	O
which	O
deficiency	O
been	O
previously	O
1936delG	O
in	O
,	O
-	O
Americans	O
.	O

been	O
,	O
sequenced	O
the	O
expressed	O
exons	O
to	O
three	O
C6	O
gene	O
from	O
selected	O
cases	O
Americans	O
and	O
found	O
the	O
in	O
defects	O
leading	O
African	O
total	O
deficiency	O
879delG	O
have	O
which	O
is	O
1195delC	O
molecular	O
defect	O
common	O
of	O
Cape	O
and	O
hitherto	O
unreported	O
,	O
have	O
the	O
and	O
1936delG	O
,	O
which	O
have	O
We	O
previously	O
.	O
in	O
-	O
the	O
and	O
reported	O

We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
indium	O
receive	O
ness	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
receive	O
cost	O
antecedently	O
account	O
indium	O
african	O
account	O
american	O
african	O
account	O
american	O
	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

We	O
have	O
the	O
of	O
the	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
unreported	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

We	O
have	O
in	O
the	O
expressed	O
exons	O
of	O
defects	O
C6	O
gene	O
from	O
879delG	O
leading	O
and	O
have	O
total	O
three	O
molecular	O
and	O
cases	O
to	O
in	O
deficiency	O
selected	O
,	O
.	O
the	O
Cape	O
common	O
defect	O
sequenced	O
which	O
the	O
and	O
hitherto	O
been	O
,	O
which	O
1195delC	O
and	O
1936delG	O
,	O
is	O
have	O
unreported	O
reported	O
previously	O
found	O
African	O
-	O
Americans	O
the	O

We	O
have	O
sequenced	O
the	O
verbalized	O
exons	O
of	O
the	O
C6	O
factor	O
from	O
selected	O
subject	O
and	O
have	O
incur	O
tierce	O
molecular	O
defects	O
leadership	O
to	O
total	O
want	O
879delG	O
,	O
which	O
is	O
the	O
usual	O
blemish	O
in	O
the	O
cape	O
and	O
hitherto	O
unreported	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
antecedently	O
reported	O
in	O
african	O
-	O
Americans	O
.	O

We	O
have	O
sequenced	O
C6	O
selected	O
and	O
have	O
found	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
hitherto	O
unreported	O
1195delC	O
and	O
1936delG	O
which	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
879delG	O
and	O
1195delC	O
fault	O
are	O
link	O
with	O
characteristic	O
C6	O
/	O
C7	O
area	O
dna	O
marking	O
haplotypes	O
,	O
although	O
little	O
variations	O
were	O
observed	O
.	O

We	O
also	O
that	O
the	O
879delG	O
and	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C7	O
region	O
DNA	O
marker	O
,	O
although	O
small	O
variations	O
were	O
.	O

We	O
also	O
show	O
that	O
cost	O
note	O
part	O
the	O
879delG	O
and	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C6	O
/	O
C7	O
region	O
DNA	O
sport	O
cost	O
note	O
cost	O
blemish	O
marker	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O
observed	O
.	O

,	O
also	O
show	O
marker	O
the	O
879delG	O
and	O
observed	O
variations	O
are	O
haplotypes	O
with	O
characteristic	O
C6	O
small	O
C7	O
region	O
DNA	O
that	O
were	O
associated	O
although	O
/	O
defects	O
We	O
1195delC	O
.	O

We	O
also	O
show	O
that	O
cost	O
note	O
part	O
the	O
879delG	O
and	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C6	O
/	O
C7	O
region	O
DNA	O
sport	O
cost	O
note	O
cost	O
blemish	O
marker	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O
observed	O
.	O

We	O
also	O
show	O
the	O
879delG	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C6	O
/	O
region	O
DNA	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O
observed	O
.	O

.	O
also	O
show	O
/	O
the	O
879delG	O
observed	O
1195delC	O
that	O
are	O
associated	O
with	O
C6	O
,	O
were	O
defects	O
region	O
DNA	O
marker	O
haplotypes	O
characteristic	O
although	O
small	O
variations	O
C7	O
and	O
We	O

show	O
879delG	O
and	O
1195delC	O
are	O
associated	O
characteristic	O
C6	O
/	O
C7	O
region	O
DNA	O
marker	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O

variations	O
also	O
show	O
that	O
the	O
879delG	O
C6	O
with	O
defects	O
are	O
associated	O
region	O
although	O
and	O
were	O
We	O
1195delC	O
C7	O
marker	O
haplotypes	O
,	O
characteristic	O
small	O
DNA	O
/	O
observed	O
.	O

We	O
also	O
read	O
that	O
the	O
879delG	O
and	O
1195delC	O
shortcoming	O
are	O
connect	O
with	O
feature	O
C6	O
/	O
C7	O
neighborhood	O
DNA	O
marker	O
haplotypes	O
,	O
although	O
minuscule	O
variance	O
were	O
maintain	O
.	O

We	O
also	O
show	O
that	O
the	O
879delG	O
and	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C6	O
/	O
C7	O
region	O
DNA	O
marker	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O
observed	O
.	O

The	O
1936delG	O
the	O
haplotype	O
observed	O
only	O
its	O
in	O
defect	O
Cape	O
,	O
but	O
once	O
associated	O
was	O
could	O
be	O
deduced	O
.	O

defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
could	O
be	O
deduced	O
.	O

The	O
1936delG	O
blemish	O
was	O
note	O
only	O
once	O
in	O
the	O
mantle	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduct	O
.	O

The	O
1936delG	O
mar	O
was	O
observed	O
only	O
once	O
in	O
the	O
ness	O
,	O
but	O
its	O
affiliate	O
haplotype	O
could	O
be	O
infer	O
.	O

be	O
1936delG	O
defect	O
was	O
observed	O
only	O
associated	O
haplotype	O
the	O
Cape	O
,	O
but	O
deduced	O
once	O
in	O
could	O
its	O
The	O
.	O

The	O
1936delG	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
.	O

The	O
1936delG	O
defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduced	O
blemish	O
blemish	O
blemish	O
blemish	O
only	O
when	O

The	O
1936delG	O
mar	O
was	O
observed	O
only	O
once	O
in	O
the	O
ness	O
,	O
but	O
its	O
link	O
haplotype	O
could	O
be	O
deduced	O
.	O

The	O
1936delG	O
defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduced	O
blemish	O
blemish	O
blemish	O
blemish	O
blemish	O
.	O

associated	O
1936delG	O
defect	O
,	O
observed	O
only	O
once	O
.	O
haplotype	O
Cape	O
was	O
but	O
The	O
its	O
the	O
could	O
be	O
deduced	O
in	O

The	O
1936delG	O
defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduced	O
.	O

The	O
information	O
from	O
the	O
haplotypes	O
point	O
that	O
these	O
three	O
molecular	O
fault	O
account	O
for	O
the	O
fault	O
in	O
all	O
the	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
contemplate	O
from	O
the	O
ness	O
.	O

The	O
data	O
from	O
the	O
haplotypes	O
that	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O

C6Q0	O
data	O
from	O
38	O
haplotypes	O
indicate	O
that	O
from	O
have	O
molecular	O
.	O
account	O
for	O
unrelated	O
we	O
in	O
all	O
the	O
the	O
the	O
studied	O
individuals	O
defects	O
three	O
The	O
these	O
the	O
Cape	O
defects	O

The	O
data	O
from	O
the	O
analyse	O
haplotype	O
blemish	O
indium	O
haplotype	O
haplotypes	O
indicate	O
that	O
these	O
three	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
receive	O
analyse	O
	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O

The	O
data	O
from	O
the	O
analyse	O
haplotype	O
blemish	O
indium	O
haplotype	O
haplotypes	O
indicate	O
that	O
these	O
three	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
receive	O
analyse	O
haplotype	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O

The	O
data	O
from	O
the	O
haplotypes	O
indicate	O
that	O
these	O
molecular	O
defects	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O

.	O
data	O
from	O
defects	O
haplotypes	O
indicate	O
from	O
these	O
the	O
molecular	O
defects	O
account	O
the	O
the	O
studied	O
three	O
all	O
the	O
38	O
unrelated	O
for	O
individuals	O
we	O
have	O
in	O
that	O
C6Q0	O
Cape	O
The	O

The	O
data	O
from	O
the	O
haplotypes	O
indicate	O
that	O
these	O
molecular	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O

The	O
datum	O
from	O
the	O
haplotypes	O
argue	O
that	O
these	O
triplet	O
molecular	O
blemish	O
history	O
for	O
the	O
blemish	O
in	O
all	O
the	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
read	O
from	O
the	O
ness	O
.	O

The	O
data	O
from	O
the	O
haplotypes	O
betoken	O
that	O
these	O
tierce	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	O
unrelated	O
C6Q0	O
somebody	O
we	O
have	O
studied	O
from	O
the	O
cape	O
.	O

The	O
data	O
from	O
the	O
haplotypes	O
indicate	O
that	O
these	O
three	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O

We	O
have	O
also	O
observed	O
substandard	O
kin	O
group	O
the	O
netherlands	O
merely	O
indium	O
the	O
879delG	O
defect	O
in	O
two	B
Dutch	I
C6	I
-	O
deficient	O
kindreds	O
,	O
but	O
the	O
879delG	O
occur	O
defect	O
in	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
.	O
deficient	O
deficient	O

We	O
have	O
also	O
observed	O
substandard	O
kin	O
group	O
the	O
netherlands	O
merely	O
indium	O
the	O
879delG	O
defect	O
in	O
two	B
Dutch	I
C6	I
-	O
deficient	O
kindreds	O
,	O
but	O
the	O
879delG	O
note	O
defect	O
in	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
.	O
deficient	O
deficient	O

did	O
have	O
also	O
observed	O
the	O
879delG	O
kindreds	O
the	O
two	O
Dutch	O
C6	B
-	I
Cape	I
defect	O
not	O
Netherlands	O
in	O
the	O
defect	O
in	O
We	O
deficient	O
probably	O
879delG	O
,	O
come	O
from	O
The	O
.	O
.	O
but	O

We	O
have	O
also	O
observed	O
substandard	O
kin	O
group	O
the	O
netherlands	O
merely	O
indium	O
the	O
879delG	O
defect	O
in	O
two	B
Dutch	I
C6	I
-	O
deficient	O
kindreds	O
,	O
but	O
the	O
879delG	O
occur	O
defect	O
in	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
.	O
deficient	O
deficient	O

We	O
have	O
also	O
observed	O
879delG	O
two	O
Dutch	O
C6	B
-	I
deficient	I
kindreds	O
,	O
but	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
.	O
.	O

We	O
have	O
also	O
observed	O
the	O
879delG	O
flaw	O
in	O
deuce	O
dutch	O
C6	B
-	I
insufficient	I
kindreds	O
,	O
but	O
the	O
879delG	O
flaw	O
in	O
the	O
mantle	O
likely	O
did	O
not	O
seed	O
from	O
The	O
Netherlands	O
.	O
.	O

Netherlands	O
have	O
not	O
,	O
the	O
879delG	O
The	O
in	O
observed	O
Dutch	O
C6	B
-	I
the	I
kindreds	O
also	O
two	O
the	O
879delG	O
defect	O
in	O
deficient	O
Cape	O
probably	O
did	O
but	O
defect	O
from	O
come	O
We	O
.	O
.	O

We	O
have	O
also	O
observed	O
the	O
879delG	O
defect	O
in	O
two	O
C6	B
-	I
kindreds	O
,	O
but	O
the	O
879delG	O
defect	O
in	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
.	O
.	O

C6	O
have	O
also	O
Netherlands	O
the	O
879delG	O
defect	O
come	O
did	O
Dutch	O
not	B
-	I
from	I
in	O
probably	O
but	O
the	O
879delG	O
.	O
kindreds	O
the	O
Cape	O
,	O
two	O
We	O
in	O
deficient	O
The	O
observed	O
.	O
defect	O

We	O
have	O
besides	O
note	O
the	O
879delG	O
shortcoming	O
in	O
ii	O
Dutch	O
C6	B
-	I
insufficient	I
kindreds	O
,	O
but	O
the	O
879delG	O
shortcoming	O
in	O
the	O
mantle	O
probably	O
did	O
not	O
number	O
from	O
The	O
Netherlands	O
.	O
.	O

We	O
have	O
also	O
observed	O
the	O
879delG	O
defect	O
in	O
two	O
Dutch	O
C6	B
-	I
deficient	I
kindreds	O
,	O
but	O
the	O
879delG	O
defect	O
in	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
.	O
.	O

Complement	B
deficiency	I
seven	O
molecular	O
defects	O
and	O
their	O
associated	O
marker	O
haplotypes	O
.	O

accompaniment	B
C7	I
lack	I
:	O
seven	O
further	O
molecular	O
blemish	O
and	O
their	O
colligate	O
marker	O
haplotypes	O
.	O

defects	B
:	I
deficiency	I
C7	O
seven	O
further	O
their	O
Complement	O
and	O
.	O
associated	O
marker	O
haplotypes	O
molecular	O

Complement	B
C7	I
deficiency	I
:	O
seven	O
further	O
molecular	O
defects	O
their	O
associated	O
haplotypes	O
.	O

Complement	B
C7	I
blemish	I
inadequacy	O
deficiency	I
:	O
seven	O
further	O
molecular	O
defects	O
and	O
haplotype	O
	O
their	O
associated	O
marker	O
haplotypes	O
.	O

Complement	B
C7	I
blemish	I
inadequacy	O
deficiency	I
:	O
seven	O
further	O
molecular	O
defects	O
and	O
haplotype	O
colligate	O
their	O
associated	O
marker	O
haplotypes	O
.	O

Complement	B
C7	I
want	I
:	O
heptad	O
further	O
molecular	O
desert	O
and	O
their	O
affiliate	O
marker	O
haplotypes	O
.	O

haplotypes	B
C7	I
deficiency	I
Complement	O
defects	O
further	O
molecular	O
marker	O
and	O
their	O
associated	O
seven	O
:	O
.	O

Complement	B
C7	I
blemish	I
inadequacy	O
deficiency	I
:	O
seven	O
further	O
molecular	O
defects	O
and	O
haplotype	O
	O
their	O
associated	O
marker	O
haplotypes	O
.	O

accompaniment	B
C7	I
insufficiency	I
:	O
heptad	O
further	O
molecular	O
defects	O
and	O
their	O
associated	O
marking	O
haplotypes	O
.	O

Complement	B
C7	I
deficiency	I
:	O
seven	O
further	O
molecular	O
defects	O
and	O
their	O
associated	O
marker	O
haplotypes	O
.	O

septet	O
further	O
molecular	O
bases	O
of	O
C7	B
lack	I
are	O
name	O
.	O

Seven	O
further	O
molecular	O
bases	O
of	O
C7	B
deficiency	I
are	O
described	O
far	O
far	O
far	O
.	O

Seven	O
further	O
molecular	O
theme	O
of	O
C7	B
want	I
are	O
identify	O
.	O

septet	O
further	O
molecular	O
bases	O
of	O
C7	B
lack	I
are	O
name	O
.	O

Seven	O
molecular	O
bases	O
C7	B
deficiency	I
are	O
described	O
.	O

are	O
.	O
molecular	O
of	O
bases	O
C7	B
deficiency	I
Seven	O
described	O
further	O

Seven	O
are	O
molecular	O
bases	O
further	O
C7	B
of	I
deficiency	O
described	O
.	O

are	O
bases	O
molecular	O
further	O
of	O
C7	B
.	I
Seven	O
described	O
deficiency	O

Seven	O
bases	O
of	O
C7	B
are	O

Seven	O
further	O
molecular	O
bases	O
of	O
C7	B
deficiency	I
are	O
described	O
far	O
far	O
far	O
.	O

Seven	O
further	O
molecular	O
bases	O
of	O
C7	B
deficiency	I
are	O
described	O
.	O

these	O
new	O
molecular	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
which	O
splice	O
sites	O
,	O
and	O
others	O
codons	O
.	O

,	O
these	O
new	O
alter	O
defects	O
involve	O
single	O
.	O
others	O
events	O
codons	O
deletions	O
and	O
splice	O
and	O
some	O
of	O
which	O
molecular	O
substitutions	O
sites	O
,	O
,	O
nucleotide	O
All	O
-	O

entirely	O
these	O
modern	O
molecular	O
blemish	O
involve	O
one	O
-	O
base	O
events	O
,	O
deletions	O
and	O
commutation	O
,	O
some	O
of	O
which	O
alter	O
splice	O
seat	O
,	O
and	O
others	O
codons	O
.	O

entirely	O
these	O
raw	O
molecular	O
shortcoming	O
need	O
single	O
-	O
base	O
effect	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
of	O
which	O
modify	O
splice	O
sites	O
,	O
and	O
others	O
codons	O
.	O

All	O
these	O
new	O
molecular	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
deletions	O
and	O
,	O
some	O
of	O
which	O
alter	O
splice	O
sites	O
others	O
codons	O
.	O

All	O
these	O
new	O
molecular	O
blemish	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
of	O
which	O
internet	O
site	O
internet	O
site	O
codon	O
young	O
codon	O
base	O
alter	O
splice	O
sites	O
,	O
and	O
others	O

All	O
these	O
new	O
molecular	O
blemish	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
of	O
which	O
internet	O
site	O
internet	O
site	O
codon	O
young	O
codon	O
whole	O
alter	O
splice	O
sites	O
,	O
and	O
others	O

All	O
these	O
new	O
molecular	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
deletions	O
,	O
some	O
of	O
which	O
alter	O
splice	O
sites	O
,	O
and	O

others	O
these	O
new	O
molecular	O
defects	O
involve	O
substitutions	O
of	O
nucleotide	O
events	O
,	O
deletions	O
,	O
single	O
codons	O
some	O
-	O
sites	O
alter	O
splice	O
All	O
and	O
and	O
which	O
,	O
.	O

altogether	O
these	O
young	O
molecular	O
shortcoming	O
involve	O
single	O
-	O
base	O
consequence	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
of	O
which	O
alter	O
marry	O
posture	O
,	O
and	O
others	O
codons	O
.	O

All	O
these	O
new	O
molecular	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
of	O
which	O
alter	O
splice	O
sites	O
,	O
and	O
others	O
codons	O
.	O

They	O
the	O
distributed	O
along	O
are	O
C7	O
,	O
towards	O
but	O
predominantly	O
3	O
the	O
gene	O
end	O
.	O

They	O
are	O
factor	O
parcel	O
out	O
parcel	O
out	O
distributed	O
along	O
the	O
C7	O
gene	O
,	O
but	O
on	O
predominantly	O
towards	O
the	O
3	O

They	O
are	O
distributed	O
along	O
the	O
C7	O
factor	O
,	O
but	O
preponderantly	O
towards	O
the	O
trinity	O
end	O
.	O

3	O
are	O
distributed	O
They	O
,	O
C7	O
gene	O
the	O
but	O
predominantly	O
towards	O
the	O
along	O
end	O
.	O

They	O
are	O
distributed	O
along	O
the	O
C7	O
factor	O
,	O
but	O
preponderantly	O
towards	O
the	O
tercet	O
remnant	O
.	O

They	O
are	O
factor	O
parcel	O
out	O
parcel	O
out	O
distributed	O
along	O
the	O
C7	O
gene	O
,	O
but	O
cost	O
predominantly	O
towards	O
the	O
3	O

They	O
distributed	O
the	O
gene	O
,	O
but	O
predominantly	O
towards	O
the	O
3	O
end	O
.	O

,	O
along	O
distributed	O
are	O
the	O
C7	O
predominantly	O
They	O
but	O
gene	O
towards	O
the	O
3	O
.	O
end	O

They	O
are	O
broadcast	O
along	O
the	O
C7	O
gene	O
,	O
but	O
preponderantly	O
towards	O
the	O
triad	O
cease	O
.	O

They	O
are	O
factor	O
parcel	O
out	O
parcel	O
out	O
distributed	O
along	O
the	O
C7	O
gene	O
,	O
but	O
cost	O
predominantly	O
towards	O
the	O
3	O

They	O
are	O
distributed	O
along	O
the	O
C7	O
gene	O
,	O
but	O
predominantly	O
towards	O
the	O
3	O
end	O
.	O

individuals	O
were	O
found	O
in	O
.	O
heterozygous	O
All	O
compound	O

altogether	O
were	O
found	O
in	O
compound	O
heterozygous	O
person	O
.	O

found	O
heterozygous	O
individuals	O
.	O

All	O
indium	O
receive	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals	O
.	O

All	O
found	O
in	O
individuals	O
.	O

All	O
compound	O
found	O
in	O
were	O
heterozygous	O
.	O
individuals	O

.	O
in	O
found	O
were	O
compound	O
heterozygous	O
individuals	O
All	O

All	O
indium	O
deepen	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals	O
.	O

All	O
were	O
encounter	O
in	O
combine	O
heterozygous	O
individuals	O
.	O

All	O
indium	O
deepen	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals	O
.	O

All	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals	O
.	O

The	O
marker	O
/	O
C7	O
C6	O
haplotypes	O
with	O
defects	O
most	O
C7	B
tabulated	I
are	O
associated	O
.	O
.	O

The	O
C6	O
colligate	O
tabularise	O
virtually	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
marking	O
C7	B
defects	I
are	O
tabulated	O
.	O
.	O

The	O
C6	O
/	O
C7	O
marker	O
haplotypes	O
consort	O
with	O
most	O
C7	B
desert	I
are	O
tabularize	O
.	O
.	O

tabulated	O
C6	O
/	O
The	O
with	O
haplotypes	O
associated	O
are	O
most	O
C7	B
defects	I
marker	O
C7	O
.	O
.	O

The	O
C6	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
C7	B
desert	I
are	O
table	O
.	O
.	O

The	O
C6	O
colligate	O
tabularise	O
virtually	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
marking	O
C7	B
defects	I
are	O
tabulated	O
.	O
.	O

The	O
/	O
marker	O
associated	O
with	O
most	O
C7	B
defects	I
are	O
tabulated	O
.	O
.	O

with	O
C7	O
/	O
C6	O
marker	O
haplotypes	O
C7	O
The	O
most	O
associated	B
defects	I
are	O
tabulated	O
.	O
.	O

The	O
C6	O
/	O
C7	O
marker	O
haplotypes	O
affiliate	O
with	O
most	O
C7	B
blemish	I
are	O
tabulated	O
.	O
.	O

The	O
C6	O
colligate	O
tabularise	O
virtually	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
marking	O
C7	B
defects	I
are	O
tabulated	O
.	O
.	O

The	O
C6	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
C7	B
defects	I
are	O
tabulated	O
.	O
.	O

A	O
-	O
wide	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
relatives	O
at	O
high	O
risk	O
bipolar	B
affective	I
disorder	I
among	O
the	O
Order	O
Amish	O
.	O

A	O
-	O
wide	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
relatives	O
at	O
risk	O
for	O
bipolar	B
affective	I
disorder	I
among	O
the	O
Old	O

A	O
genome	O
-	O
wide	O
indium	O
congeneric	O
atomic	O
number	O
	O
look	O
for	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
onetime	O
regularise	O
amish	B
indium	I
for	I
bipolar	O
affective	O
disorder	O
among	O
the	O
Old	O

affective	O
genome	O
-	O
for	O
search	O
for	O
chromosomal	O
Order	O
the	O
to	O
bipolar	O
health	O
wellness	O
in	O
among	O
at	O
high	O
risk	O
wide	O
Old	B
mental	I
disorder	I
relatives	O
linked	O
A	O
loci	O
Amish	O
.	O

Amish	O
genome	O
-	O
relatives	O
search	O
for	O
Order	O
loci	O
wide	O
to	O
mental	O
health	O
in	O
affective	O
Old	O
linked	O
high	O
risk	O
for	O
bipolar	B
wellness	I
disorder	I
among	O
the	O
at	O
chromosomal	O
A	O
.	O

A	O
genome	O
-	O
wide	O
indium	O
congeneric	O
atomic	O
number	O
	O
look	O
for	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
onetime	O
regularise	O
amish	B
colligate	I
for	I
bipolar	O
affective	O
disorder	O
among	O
the	O
Old	O

angstrom	O
genome	O
-	O
wide	O
search	O
for	O
chromosomal	O
locus	O
linked	O
to	O
mental	O
wellness	O
wellness	O
in	O
relatives	O
at	O
gamy	O
risk	O
for	O
bipolar	B
affective	I
disorder	I
among	O
the	O
quondam	O
society	O
amish	O
.	O

A	O
genome	O
-	O
wide	O
indium	O
congeneric	O
atomic	O
number	O
	O
look	O
for	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
onetime	O
regularise	O
amish	B
colligate	I
for	I
bipolar	O
affective	O
disorder	O
among	O
the	O
Old	O

the	O
genome	O
-	O
wide	O
search	O
for	O
in	O
health	O
linked	O
to	O
mental	O
high	O
disorder	O
chromosomal	O
Old	O
A	O
loci	O
at	O
for	O
bipolar	B
affective	I
wellness	I
among	O
risk	O
relatives	O
Order	O
Amish	O
.	O

A	O
genome	O
-	O
wide	O
search	O
for	O
chromosomal	O
locale	O
coupled	O
to	O
genial	O
wellness	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
for	O
bipolar	B
affectional	I
disorder	I
among	O
the	O
onetime	O
orderliness	O
amish	O
.	O

A	O
genome	O
-	O
wide	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
for	O
bipolar	B
affective	I
disorder	I
among	O
the	O
Old	O
Order	O
Amish	O
.	O

bipolar	B
affectional	I
disorder	I
(	O
BPAD	B
;	O
frenzied	B
-	I
depressive	I
unwellness	I
)	O
is	O
characterized	O
by	O
installment	O
of	O
passion	B
and	O
/	O
or	O
hypomania	B
interlard	O
with	O
menstruum	O
of	O
depression	B
.	O

Bipolar	B
affective	I
(	O
BPAD	B
;	O
manic	B
-	I
depressive	I
illness	I
)	O
is	O
characterized	O
of	O
mania	B
and	O
/	O
hypomania	B
interspersed	O
with	O
periods	O
of	O
.	O

Bipolar	B
affective	I
disorder	I
(	O
installment	O
frenzied	O
cacoethes	O
BPAD	B
;	O
manic	B
-	I
depressive	I
illness	I
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	B
and	O
full	O
stop	O
intersperse	O
imprint	O
full	O
stop	O
installment	O
/	B
or	O
hypomania	O
interspersed	O
with	O
periods	B
of	O

hypomania	B
affective	I
disorder	I
/	O
BPAD	B
;	O
manic	B
depression	I
periods	I
illness	I
or	O
is	O
characterized	O
by	O
with	O
of	O
mania	B
and	O
(	O
of	O
)	B
interspersed	O
episodes	O
depressive	O
Bipolar	O
-	B
.	O

Bipolar	B
affective	I
disorder	I
(	O
installment	O
frenzied	O
cacoethes	O
BPAD	B
;	O
manic	B
-	I
depressive	I
illness	I
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	B
and	O
full	O
stop	O
intersperse	O
imprint	O
full	O
stop	O
installment	O
/	B
or	O
hypomania	O
interspersed	O
with	O
periods	B
of	O

Bipolar	B
affective	I
disorder	I
BPAD	B
;	O
-	I
depressive	I
illness	I
)	O
is	O
characterized	O
by	O
episodes	O
mania	B
and	O
or	O
hypomania	B
interspersed	O
with	O
periods	O
of	O
depression	B
.	O

.	B
affective	I
disorder	I
episodes	O
BPAD	B
;	O
depression	B
-	I
(	I
illness	I
)	O
is	O
by	O
hypomania	O
of	O
depressive	O
mania	B
and	O
/	O
or	O
characterized	B
interspersed	O
with	O
periods	O
of	O
manic	B
Bipolar	O

disorder	I
;	O
manic	B
-	I
illness	I
)	O
characterized	O
by	O
episodes	O
of	O
mania	B
and	O
/	O
or	O
hypomania	B
interspersed	O
with	O
periods	O
of	O

periods	B
affective	I
disorder	I
(	O
BPAD	B
;	O
by	B
is	I
depressive	I
illness	I
)	O
mania	O
interspersed	O
manic	O
of	O
Bipolar	O
-	B
of	O
/	O
or	O
hypomania	B
characterized	O
with	O
and	O
episodes	O
depression	B
.	O

bipolar	B
affectional	I
cark	I
(	O
BPAD	B
;	O
frenzied	B
-	I
depressive	I
sickness	I
)	O
is	O
characterized	O
by	O
sequence	O
of	O
mania	B
and	O
/	O
or	O
hypomania	B
interspersed	O
with	O
catamenia	O
of	O
depression	B
.	O

Bipolar	B
affective	I
disorder	I
(	O
BPAD	B
;	O
manic	B
-	I
depressive	I
illness	I
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	B
and	O
/	O
or	O
hypomania	B
interspersed	O
with	O
periods	O
of	O
depression	B
.	O

Compelling	O
supports	O
significant	O
component	O
in	O
the	O
susceptibility	O
to	O
develop	O
BPAD	B
.	O

oblige	O
evidence	O
supports	O
a	O
significant	O
transmitted	O
component	O
in	O
the	O
susceptibleness	O
to	O
formulate	O
BPAD	B
.	O

in	O
a	O
supports	O
evidence	O
significant	O
genetic	O
susceptibility	O
Compelling	O
the	O
.	O
to	O
develop	O
BPAD	B
component	O

Compelling	O
evidence	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
susceptibility	O
to	O
BPAD	B
.	O

Compelling	O
evidence	O
indium	O
subscribe	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
build	O
up	O
important	O
susceptibility	O
to	O
develop	B
BPAD	O

Compelling	O
evidence	O
indium	O
subscribe	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
build	O
up	O
element	O
susceptibility	O
to	O
develop	B
BPAD	O

compel	O
evidence	O
documentation	O
a	O
substantial	O
genetic	O
part	O
in	O
the	O
susceptibility	O
to	O
develop	O
BPAD	B
.	O

BPAD	O
evidence	O
supports	O
Compelling	O
in	O
genetic	O
component	O
develop	O
the	O
susceptibility	O
to	O
significant	O
a	B
.	O

Compelling	O
evidence	O
indium	O
subscribe	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
build	O
up	O
important	O
susceptibility	O
to	O
develop	B
BPAD	O

Compelling	O
evidence	O
hold	O
a	O
significant	O
genic	O
portion	O
in	O
the	O
susceptibleness	O
to	O
develop	O
BPAD	B
.	O

Compelling	O
evidence	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
susceptibility	O
to	O
develop	O
BPAD	B
.	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
build	O
up	O
take	O
a	O
chance	O
build	O
up	O
build	O
up	O
essay	O
essay	O
gene	B
linkage	O

,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
the	O
of	O
developing	O
BPAD	B
.	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
discover	O
chromosomal	O
locale	O
that	O
suit	O
or	O
increment	O
the	O
adventure	O
of	O
developing	O
BPAD	B
.	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
attempted	O
only	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
of	O
developing	O
BPAD	B
.	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
build	O
up	O
take	O
a	O
chance	O
build	O
up	O
build	O
up	O
essay	O
essay	O
essay	B
the	O

To	O
appointment	O
,	O
nonetheless	O
,	O
linkage	O
studies	O
have	O
essay	O
only	O
to	O
describe	O
chromosomal	O
locus	O
that	O
drive	O
or	O
addition	O
the	O
risk	O
of	O
developing	O
BPAD	B
.	O

To	O
date	O
,	O
nevertheless	O
,	O
linkage	O
survey	O
have	O
assay	O
only	O
to	O
distinguish	O
chromosomal	O
locus	O
that	O
suit	O
or	O
addition	O
the	O
risk	O
of	O
developing	O
BPAD	B
.	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
to	O
loci	O
that	O
cause	O
or	O
increase	O
the	O
risk	O
of	O
developing	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
build	O
up	O
take	O
a	O
chance	O
build	O
up	O
build	O
up	O
essay	O
essay	O
essay	B
the	O

increase	O
date	O
,	O
to	O
,	O
linkage	O
studies	O
the	O
.	O
only	O
however	O
identify	O
chromosomal	O
loci	O
BPAD	O
cause	O
or	O
of	O
have	O
To	O
risk	O
developing	O
that	B
attempted	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
the	O
risk	O
of	O
developing	O
BPAD	B
.	O

whether	O
could	O
be	O
protective	O
that	O
prevent	O
reduce	O
the	O
of	O
developing	O
BPAD	B
,	O
similar	O
to	O
what	O
is	O
observed	O
other	O
disorders	I
,	O
we	O
used	O
mental	O
health	O
(	O
absence	O
of	O
psychiatric	B
disorder	I
)	O
as	O
the	O
phenotype	O
-	O
wide	O
scan	O
several	O
large	O
Old	O
pedigrees	O
exhibiting	O
an	O
incidence	O
of	O

To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
allelomorph	O
that	O
keep	O
or	O
subdue	O
the	O
endangerment	O
of	O
developing	O
BPAD	B
,	O
standardized	O
to	O
what	O
is	O
observed	O
in	O
other	O
transmitted	B
trouble	I
,	O
we	O
used	O
genial	O
health	O
health	O
(	O
absence	O
of	O
any	O
psychiatric	B
distract	I
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
spacious	O
linkage	O
scan	O
of	O
various	O
large	O
multigeneration	O
onetime	O
gild	O
amish	O
pedigrees	O
display	O
an	O
passing	O
mellow	O
incidence	O
of	O
BPAD	B
.	O

To	O
determine	O
whether	O
extremely	O
high	O
)	O
protective	O
alleles	O
that	O
prevent	O
or	O
Amish	O
in	O
.	O
of	O
psychiatric	O
BPAD	B
,	O
similar	O
to	O
Old	O
of	O
multigeneration	O
the	O
disorder	O
genetic	B
disorders	I
,	O
we	O
used	O
mental	O
several	O
wellness	O
(	O
absence	O
of	O
of	O
developing	B
other	I
be	O
as	O
the	O
BPAD	O
in	O
our	O
genome	O
wide	O
incidence	O
linkage	O
scan	O
is	O
health	O
large	O
observed	O
phenotype	O
Order	O
reduce	O
pedigrees	O
exhibiting	O
an	O
there	O
could	O
-	O
any	O
what	B
risk	O

phenotype	O
used	O
whether	O
absence	O
wellness	O
be	O
protective	O
high	O
that	O
or	O
prevent	O
in	O
the	O
risk	O
of	O
developing	O
several	B
,	O
similar	O
to	O
what	O
is	O
genetic	O
reduce	O
other	O
-	B
Old	I
,	O
we	O
observed	O
mental	O
health	O
could	O
(	O
exhibiting	O
of	O
any	O
psychiatric	B
disorder	I
)	O
as	O
the	O
scan	O
in	O
multigeneration	O
incidence	O
determine	O
wide	O
linkage	O
To	O
of	O
.	O
BPAD	O
genome	O
disorders	O
Order	O
Amish	O
pedigrees	O
there	O
an	O
extremely	O
alleles	O
our	O
of	O
large	B
BPAD	O

there	O
could	O
be	O
protective	O
alleles	O
that	O
prevent	O
reduce	O
the	O
developing	O
BPAD	B
,	O
to	O
observed	O
in	O
other	O
genetic	B
disorders	I
,	O
we	O
(	O
of	O
any	O
disorder	I
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
Old	O
Order	O
pedigrees	O
exhibiting	O
an	O
extremely	O
incidence	O
BPAD	B

To	O
influence	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
preclude	O
or	O
reduce	O
the	O
adventure	O
of	O
recrudesce	O
BPAD	B
,	O
standardised	O
to	O
what	O
is	O
honor	O
in	O
other	O
hereditary	B
perturb	I
,	O
we	O
used	O
genial	O
health	O
health	O
(	O
absence	O
of	O
any	O
psychiatric	B
upset	I
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
various	O
expectant	O
multigeneration	O
Old	O
grade	O
amish	O
pedigrees	O
exhibiting	O
an	O
highly	O
high	O
incidence	O
of	O
BPAD	B
.	O

To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
disarray	O
operating	O
theatre	O
melt	O
off	O
expend	O
genial	O
wellness	O
health	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	B
developing	O
BPAD	O
,	O
similar	O
to	O
what	O
is	O
observed	O
in	B
other	I
genetic	O
disorders	O
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	B
any	I
psychiatric	O
disorder	O
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
Old	O
Order	O
Amish	O
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	B
of	O
BPAD	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O

To	O
determine	O
whether	O
be	O
or	O
reduce	O
the	O
of	O
developing	O
,	O
similar	O
to	O
observed	O
in	O
other	O
genetic	B
disorders	I
we	O
mental	O
health	O
wellness	O
(	O
absence	O
of	O
any	O
psychiatric	B
disorder	I
)	O
the	O
phenotype	O
in	O
our	O
genome	O
several	O
Old	O
Amish	O
pedigrees	O
exhibiting	O
extremely	O
high	O
incidence	O
of	O
BPAD	B
.	O

To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
disarray	O
operating	O
theatre	O
melt	O
off	O
expend	O
genial	O
wellness	O
health	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	B
developing	O
BPAD	O
,	O
similar	O
to	O
what	O
is	O
observed	O
in	B
other	I
genetic	O
disorders	O
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	B
any	I
psychiatric	O
disorder	O
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
Old	O
Order	O
Amish	O
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	B
of	O
BPAD	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O
confusedness	O

To	O
settle	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
keep	O
or	O
reduce	O
the	O
chance	O
of	O
get	O
BPAD	B
,	O
similar	O
to	O
what	O
is	O
find	O
in	O
other	O
genic	B
upset	I
,	O
we	O
used	O
genial	O
health	O
health	O
(	O
absence	O
of	O
any	O
psychiatric	B
distract	I
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
full	O
linkage	O
scan	O
of	O
respective	O
prominent	O
multigeneration	O
Old	O
ordering	O
amish	O
pedigrees	O
expose	O
an	O
highly	O
luxuriously	O
incidence	O
of	O
BPAD	B
.	O

To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	O
developing	O
BPAD	B
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
other	O
genetic	B
disorders	I
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	O
any	O
psychiatric	B
disorder	I
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
Old	O
Order	O
Amish	O
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	O
of	O
BPAD	B
.	O

score	O
have	O
found	O
2	O
evidence	O
for	O
a	O
a	O
on	O
chromosome	O
4p	O
.	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
health	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
(	O
at	O
05	O
-	O
.	O
=	O
5	O
mental	O
22	O
x	O
10	O
(	O
4q	O
4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
-	O
x	O
for	O
wellness	O
(	O
5	O
)	O
We	O
and	O
.	O
maximum	O
PLUS	O
locus	O
locus	O
on	O
chromosome	O
3	O
at	O
D4S397	O
-	O
evidence	O
GENEHUNTER	O
,	O
-	O
are	O
linkage	O
)	O
x	O
suggestive	O
P	O
)	O
(	O
29	O
=	O
strong	O
(	O
.	O
3	O
10	O
4	O
-	O
3	O
=	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
.	O
10	O
3	O
)	O
)	O
that	O
nonparametric	O
57	O
to	O
,	O
-	O
P	O
linked	O

We	O
have	O
found	O
unattackable	O
certify	O
for	O
a	O
venue	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
utmost	O
GENEHUNTER	O
-	O
asset	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
,	O
p	O
=	O
5	O
.	O
22	O
ten	O
ten	O
(	O
-	O
4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
triplet	O
ten	O
ten	O
(	O
-	O
5	O
)	O
)	O
and	O
revelatory	O
certify	O
for	O
a	O
venue	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
utmost	O
GENEHUNTER	O
-	O
asset	O
nonparametric	O
linkage	O
score	O
=	O
triplet	O
.	O
xxix	O
,	O
p	O
=	O
ii	O
.	O
lvii	O
ten	O
ten	O
(	O
-	O
triplet	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
ane	O
ten	O
ten	O
(	O
-	O
triplet	O
)	O
)	O
that	O
are	O
join	O
to	O
genial	O
wellness	O
wellness	O
.	O

We	O
have	O
found	O
strong	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
	O
	O
atomic	O
number	O
	O
cost	O
phosphorus	O
upper	O
limit	O
	O
wellness	O
summation	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
,	O
P	O
=	O
5	O
.	O
22	O
x	O
10	O
(	O
-	O
4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3	O
.	O
	O
valuate	O
	O
	O
	O
	O
along	O
valuate	O
	O
	O
	O
	O
cost	O
colligate	O
	O
genial	O
wellness	O
health	O
cost	O
colligate	O
along	O
	O
29	O
,	O
P	O
=	O
2	O
.	O
57	O
x	O
10	O
(	O
-	O
3	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
(	O
-	O
3	O
)	O
)	O
that	O
are	O
linked	O
to	O
mental	O

We	O
found	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
nonparametric	O
linkage	O
=	O
4	O
.	O
05	O
P	O
5	O
10	O
-	O
4	O
)	O
SIBPAL	O
Pempirical	O
<	O
3	O
10	O
(	O
-	O
5	O
)	O
)	O
and	O
suggestive	O
evidence	O
a	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
GENEHUNTER	O
-	O
PLUS	O
linkage	O
score	O
=	O
3	O
.	O
29	O
2	O
.	O
x	O
(	O
-	O
)	O
Pempirical	O
value	O
<	O
10	O
(	O
)	O
)	O
are	O
linked	O
health	O
wellness	O
.	O

<	O
=	O
for	O
mental	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
.	O
value	O
maximum	O
10	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
maximum	O
05	O
,	O
linked	O
a	O
on	O
SIBPAL	O
22	O
x	O
GENEHUNTER	O
(	O
D4S397	O
4	O
)	O
4q	O
SIBPAL	O
Pempirical	O
(	O
<	O
3	O
x	O
=	O
(	O
-	O
5	O
Pempirical	O
strong	O
and	O
suggestive	O
evidence	O
)	O
=	O
.	O
that	O
-	O
;	O
at	O
chromosome	O
(	O
D4S2949	O
3	O
-	O
PLUS	O
nonparametric	O
5	O
score	O
have	O
)	O
-	O
29	O
,	O
P	O
.	O
2	O
locus	O
57	O
x	O
)	O
(	O
.	O
found	O
)	O
;	O
10	O
3	O
value	O
We	O
1	O
x	O
10	O
(	O
-	O
3	O
)	O
linkage	O
GENEHUNTER	O
are	O
P	O
to	O
10	O
health	O
wellness	O
.	O

We	O
.	O
found	O
D4S397	O
(	O
Pempirical	O
a	O
locus	O
on	O
chromosome	O
4p	O
on	O
D4S2949	O
SIBPAL	O
maximum	O
;	O
-	O
PLUS	O
nonparametric	O
linkage	O
nonparametric	O
GENEHUNTER	O
-	O
.	O
SIBPAL	O
that	O
P	O
=	O
5	O
have	O
22	O
3	O
10	O
(	O
-	O
4	O
=	O
GENEHUNTER	O
05	O
for	O
value	O
<	O
3	O
x	O
10	O
(	O
4	O
)	O
)	O
)	O
-	O
mental	O
evidence	O
a	O
-	O
locus	O
at	O
chromosome	O
4q	O
at	O
strong	O
evidence	O
(	O
;	O
=	O
)	O
score	O
linkage	O
score	O
=	O
<	O
.	O
29	O
,	O
and	O
P	O
2	O
.	O
1	O
x	O
10	O
(	O
-	O
3	O
PLUS	O
for	O
are	O
Pempirical	O
value	O
3	O
57	O
10	O
x	O
maximum	O
5	O
x	O
)	O
)	O
,	O
(	O
linked	O
to	O
suggestive	O
health	O
wellness	O
.	O

We	O
have	O
found	O
strong	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
	O
	O
atomic	O
number	O
	O
cost	O
phosphorus	O
upper	O
limit	O
	O
wellness	O
summation	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
,	O
P	O
=	O
5	O
.	O
22	O
x	O
10	O
(	O
-	O
4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3	O
.	O
	O
valuate	O
	O
	O
	O
	O
along	O
valuate	O
	O
	O
	O
	O
cost	O
colligate	O
	O
genial	O
wellness	O
health	O
cost	O
colligate	O
along	O
gene	O
linkage	O
29	O
,	O
P	O
=	O
2	O
.	O
57	O
x	O
10	O
(	O
-	O
3	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
(	O
-	O
3	O
)	O
)	O
that	O
are	O
linked	O
to	O

We	O
found	O
evidence	O
for	O
a	O
chromosome	O
maximum	O
GENEHUNTER	O
-	O
nonparametric	O
linkage	O
=	O
4	O
.	O
P	O
=	O
5	O
.	O
22	O
10	O
-	O
4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
(	O
-	O
5	O
)	O
)	O
locus	O
4q	O
D4S397	O
(	O
maximum	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
,	O
P	O
=	O
2	O
.	O
57	O
x	O
(	O
-	O
;	O
SIBPAL	O
Pempirical	O
<	O
10	O
(	O
-	O
3	O
)	O
)	O
that	O
health	O
.	O

We	O
have	O
observe	O
substantial	O
grounds	O
for	O
a	O
locale	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
-	O
addition	O
nonparametric	O
linkage	O
score	O
=	O
quadruplet	O
.	O
05	O
,	O
P	O
=	O
5	O
.	O
22	O
ecstasy	O
10	O
(	O
-	O
quadruplet	O
)	O
;	O
SIBPAL	O
Pempirical	O
appreciate	O
<	O
trey	O
ecstasy	O
10	O
(	O
-	O
5	O
)	O
)	O
and	O
indicative	O
grounds	O
for	O
a	O
locale	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
maximum	O
GENEHUNTER	O
-	O
addition	O
nonparametric	O
linkage	O
score	O
=	O
trey	O
.	O
29	O
,	O
P	O
=	O
ii	O
.	O
lvii	O
ecstasy	O
10	O
(	O
-	O
trey	O
)	O
;	O
SIBPAL	O
Pempirical	O
appreciate	O
<	O
single	O
ecstasy	O
10	O
(	O
-	O
trey	O
)	O
)	O
that	O
are	O
joined	O
to	O
genial	O
wellness	O
wellness	O
.	O

We	O
found	O
strong	O
evidence	O
for	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
=	O
.	O
x	O
10	O
(	O
-	O
)	O
;	O
Pempirical	O
<	O
3	O
x	O
10	O
-	O
5	O
)	O
and	O
evidence	O
locus	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3	O
.	O
,	O
P	O
=	O
2	O
.	O
57	O
-	O
)	O
;	O
value	O
<	O
1	O
10	O
(	O
-	O
3	O
)	O
)	O
that	O
are	O
linked	O
to	O
mental	O
health	O

We	O
have	O
found	O
strong	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
,	O
P	O
=	O
5	O
.	O
22	O
x	O
10	O
(	O
-	O
4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3	O
.	O
29	O
,	O
P	O
=	O
2	O
.	O
57	O
x	O
10	O
(	O
-	O
3	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
(	O
-	O
3	O
)	O
)	O
that	O
are	O
linked	O
to	O
mental	O
health	O
wellness	O
.	O

findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
of	O
and	O
perhaps	O
other	O
related	O
affective	B
disorders	I
.	O

could	O
findings	O
are	O
BPAD	O
with	O
the	O
hypothesis	O
.	O
affective	O
alleles	O
disorders	O
prevent	O
or	O
and	O
related	O
clinical	O
manifestations	O
of	O
consistent	B
modify	O
perhaps	O
other	O
the	O
certain	B
These	I
that	O

These	O
findings	O
are	O
ordered	O
with	O
the	O
guess	O
that	O
sure	O
allelomorph	O
could	O
foreclose	O
or	O
modify	O
the	O
clinical	O
reflection	O
of	O
BPAD	B
and	O
possibly	O
other	O
related	O
affective	B
disorders	I
.	O

These	O
detect	O
are	O
consistent	O
with	O
the	O
speculation	O
that	O
sealed	O
allelomorph	O
could	O
foreclose	O
or	O
alter	O
the	O
clinical	O
manifestations	O
of	O
BPAD	B
and	O
perhaps	O
other	O
related	O
affectional	B
disorders	I
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
prevent	O
or	O
the	O
clinical	O
manifestations	O
of	O
BPAD	B
and	O
perhaps	O
affective	B
disorders	I
.	O

These	O
findings	O
are	O
consistent	O
reflexion	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
colligate	O
emotive	O
disarray	O
emotive	O
disarray	O
sealed	O
BPAD	B
and	O
perhaps	O
other	O
related	O
affective	B
disorders	I
.	O

These	O
findings	O
are	O
consistent	O
reflexion	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
colligate	O
emotive	O
disarray	O
emotive	O
disarray	O
operating	O
theatre	B
BPAD	O
and	O
perhaps	O
other	O
related	B
affective	I
disorders	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
prevent	O
the	O
clinical	O
manifestations	O
of	O
BPAD	B
and	O
perhaps	O
other	O
related	O

affective	O
findings	O
are	O
consistent	O
with	O
the	O
modify	O
manifestations	O
certain	O
alleles	O
could	O
prevent	O
other	O
hypothesis	O
disorders	O
clinical	O
that	O
perhaps	O
BPAD	B
and	O
These	O
or	O
related	O
of	B
the	I
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
speculation	O
that	O
sealed	O
alleles	O
could	O
forbid	O
or	O
qualify	O
the	O
clinical	O
manifestations	O
of	O
BPAD	B
and	O
perhaps	O
other	O
colligate	O
affectional	B
cark	I
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
BPAD	B
and	O
perhaps	O
other	O
related	O
affective	B
disorders	I
.	O

Segregation	O
distortion	O
in	O
myotonic	B
sequestration	O
dystrophy	I
.	O

Segregation	O
in	O
dystrophy	I
.	O

Segregation	O
distortion	O
myotonic	B
dystrophy	I

Segregation	O
torture	O
in	O
myotonic	B
dystrophy	I
.	O

sequestration	O
distortion	O
in	O
myotonic	B
dystrophy	I
.	O

Segregation	O
distortion	O
in	O
myotonic	B
sequestration	O
dystrophy	I
.	O

Segregation	O
in	O
myotonic	B
dystrophy	I
.	O

myotonic	O
distortion	O
in	O
Segregation	B
dystrophy	I
.	O

Segregation	O
distortion	O
in	O
myotonic	B
indium	O
dystrophy	I
.	O

Segregation	O
distortion	O
in	O
.	B
dystrophy	I
myotonic	O

Segregation	O
distortion	O
in	O
myotonic	B
dystrophy	I
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
prediction	O
cascade	O
down	O
prediction	O
cascade	O
down	O
cascade	O
down	O
prevailing	O
line	O
of	O
descent	O
a	O

(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
a	O
generation	O
anticipation	O
cascade	O
.	O

myotonic	B
dystrophy	I
(	O
decimetre	B
)	O
is	O
an	O
autosomal	B
prevalent	I
disease	I
which	O
,	O
in	O
the	O
distinctive	O
pedigree	O
,	O
render	O
a	O
tierce	O
propagation	O
anticipation	O
cascade	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
dominant	I
disease	I
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
generation	O
anticipation	O
cascade	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
prediction	O
cascade	O
down	O
prediction	O
cascade	O
down	O
cascade	O
down	O
prevailing	O
prevailing	O
a	O
three	O
generation	O

myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
which	O
,	O
in	O
the	O
distinctive	O
pedigree	O
,	O
testify	O
a	O
terzetto	O
contemporaries	O
expectation	O
shower	O
.	O

myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
rife	I
disease	I
which	O
,	O
in	O
the	O
typical	O
descent	O
,	O
express	O
a	O
tercet	O
propagation	O
anticipation	O
shower	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
which	O
the	O
typical	O
pedigree	O
,	O
shows	O
a	O
three	O
generation	O
anticipation	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
prediction	O
cascade	O
down	O
prediction	O
cascade	O
down	O
cascade	O
down	O
prevailing	O
prevailing	O
a	O
three	O
generation	O

shows	B
dystrophy	I
(	O
which	B
)	O
is	O
an	O
a	B
.	I
disease	I
DM	O
,	O
in	O
the	O
cascade	O
pedigree	O
,	O
generation	O
autosomal	O
Myotonic	O
three	O
anticipation	O
typical	O
dominant	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
a	O
three	O
generation	O
anticipation	O
cascade	O
.	O

This	O
ensue	O
in	O
sterility	B
and	O
inborn	B
myotonic	I
dystrophy	I
(	O
CDM	B
)	O
with	O
the	O
fade	O
of	O
decimeter	B
in	O
that	O
blood	O
.	O

This	O
results	O
in	O
infertility	B
and	O
congenital	B
myotonic	I
dystrophy	I
(	O
CDM	B
)	O
with	O
the	O
disappearance	O
of	O
DM	B
in	O
that	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
pedigree	O
.	O

This	O
results	O
in	O
infertility	B
and	O
congenital	B
myotonic	I
dystrophy	I
(	O
CDM	B
)	O
with	O
the	O
disappearance	O
of	O
DM	B
in	O
that	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
pedigree	O
.	O

in	O
congenital	B
myotonic	I
dystrophy	I
CDM	B
)	O
the	O
disappearance	O
of	O
DM	B
in	O
that	O
pedigree	O
.	O

This	O
results	O
in	O
infertility	B
and	O
dystrophy	I
(	O
)	O
with	O
the	O
disappearance	O
of	O
DM	B
in	O
that	O
pedigree	O
.	O

in	O
infertility	B
and	O
congenital	B
dystrophy	I
(	O
CDM	B
)	O
with	O
disappearance	O
of	O
DM	B
in	O
pedigree	O
.	O

that	O
results	O
in	O
pedigree	B
and	O
congenital	B
myotonic	I
(	I
dystrophy	O
CDM	B
of	O
with	O
the	O
.	O
This	O
DM	B
in	O
)	O
infertility	O
disappearance	O

This	O
results	O
in	O
infertility	B
and	O
congenital	B
myotonic	I
dystrophy	I
(	O
CDM	B
)	O
with	O
the	O
disappearance	O
of	O
DM	B
in	O
that	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
pedigree	O
.	O

This	O
effect	O
in	O
sterility	B
and	O
innate	B
myotonic	I
dystrophy	I
(	O
CDM	B
)	O
with	O
the	O
fade	O
of	O
dm	B
in	O
that	O
pureblood	O
.	O

in	O
results	O
in	O
infertility	B
and	O
congenital	B
disappearance	I
with	I
(	O
CDM	B
)	O
of	O
This	O
myotonic	O
dystrophy	O
that	B
the	O
DM	O
pedigree	O
.	O

This	O
results	O
in	O
infertility	B
and	O
congenital	B
myotonic	I
dystrophy	I
(	O
CDM	B
)	O
with	O
the	O
disappearance	O
of	O
DM	B
in	O
that	O
pedigree	O
.	O

of	O
,	O
where	O
there	O
is	O
transmission	O
of	O
allele	O
at	O
DM	B
locus	O
put	O
to	O
explain	O
partially	O
maintenance	O
of	O
DM	B
the	O
population	O
.	O

The	O
concept	O
of	O
segregation	O
atomic	O
number	O
	O
overrefinement	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	B
the	O
DM	O
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	B
of	O
DM	O
in	O
the	O
population	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O

to	O
locus	O
of	O
segregation	O
distortion	O
,	O
partially	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
the	O
of	O
at	O
the	O
DM	B
population	O
,	O
has	O
been	O
in	O
forward	O
The	O
explain	O
where	O
larger	O
allele	O
put	O
DM	B
maintenance	O
the	O
.	O
concept	O

The	O
concept	O
of	O
sequestration	O
overrefinement	O
,	O
where	O
there	O
is	O
discriminatory	O
transmission	O
of	O
the	O
tumid	O
allelomorph	O
at	O
the	O
decimeter	B
locale	O
,	O
has	O
been	O
redact	O
forrader	O
to	O
excuse	O
partially	O
the	O
maintenance	O
of	O
decimeter	B
in	O
the	O
population	O
.	O

The	O
concept	O
explain	O
segregation	O
distortion	O
,	O
where	O
been	O
is	O
preferential	O
transmission	O
forward	O
the	O
larger	O
allele	O
DM	O
the	O
DM	B
,	O
of	O
has	O
there	O
put	O
locus	O
to	O
partially	O
of	O
the	O
maintenance	O
of	O
at	B
the	O
in	O
population	O
.	O

The	O
concept	O
of	O
segregation	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
the	O
larger	O
allele	O
at	O
DM	B
locus	O
,	O
has	O
been	O
forward	O
to	O
explain	O
partially	O
maintenance	O
of	O
in	O
the	O
population	O
.	O

The	O
concept	O
of	O
sequestration	O
twisting	O
,	O
where	O
there	O
is	O
discriminatory	O
transmission	O
of	O
the	O
declamatory	O
allelomorph	O
at	O
the	O
decimeter	B
locus	O
,	O
has	O
been	O
set	O
frontward	O
to	O
explain	O
partially	O
the	O
sustentation	O
of	O
decimeter	B
in	O
the	O
universe	O
.	O

The	O
concept	O
of	O
segregation	O
atomic	O
number	O
	O
overrefinement	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	B
the	O
DM	O
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	B
of	O
DM	O
in	O
the	O
population	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O

The	O
construct	O
of	O
sequestration	O
aberration	O
,	O
where	O
there	O
is	O
preferential	O
transmitting	O
of	O
the	O
big	O
allele	O
at	O
the	O
DM	B
locale	O
,	O
has	O
been	O
put	O
frontward	O
to	O
excuse	O
partially	O
the	O
care	O
of	O
DM	B
in	O
the	O
universe	O
.	O

the	O
has	O
of	O
segregation	O
the	O
,	O
allele	O
in	O
is	O
preferential	O
transmission	O
of	O
the	O
to	O
there	O
at	O
distortion	O
DM	B
locus	O
,	O
larger	O
been	O
put	O
forward	O
concept	O
explain	O
partially	O
The	O
DM	O
of	O
maintenance	B
where	O
the	O
population	O
.	O

The	O
concept	O
of	O
segregation	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	O
of	O
DM	B
in	O
the	O
population	O
.	O

In	O
survey	O
DM	B
Northern	O
Ireland	O
,	O
59	O
pedigrees	O
were	O
ascertained	O
.	O

indiana	O
a	O
sketch	O
of	O
DM	B
indiana	O
Northern	O
Ireland	O
,	O
59	O
descent	O
were	O
ensure	O
.	O

Ireland	O
of	O
survey	O
a	O
DM	B
in	O
59	O
In	O
,	O
.	O
pedigrees	O
were	O
ascertained	O
Northern	O

In	O
a	O
survey	O
of	O
DM	B
in	O
Northern	O
Ireland	O
59	O
pedigrees	O
ascertained	O
.	O

In	O
a	O
ireland	O
sight	O
survey	O
of	O
DM	B
in	O
Northern	O
Ireland	O
,	O
learn	O
dm	O
59	O
pedigrees	O
were	O
ascertained	O
.	O

In	O
a	O
ireland	O
sight	O
survey	O
of	O
DM	B
in	O
Northern	O
Ireland	O
,	O
learn	O
line	O
of	O
descent	O
59	O
pedigrees	O
were	O

indiana	O
a	O
survey	O
of	O
DM	B
indiana	O
Northern	O
eire	O
,	O
59	O
stemma	O
were	O
insure	O
.	O

ascertained	O
a	O
survey	O
In	O
Ireland	B
in	O
Northern	O
were	O
,	O
59	O
pedigrees	O
DM	O
of	O
.	O

In	O
a	O
ireland	O
sight	O
survey	O
of	O
DM	B
in	O
Northern	O
Ireland	O
,	O
learn	O
dm	O
59	O
pedigrees	O
were	O
ascertained	O
.	O

In	O
a	O
study	O
of	O
DM	B
in	O
northern	O
Ireland	O
,	O
59	O
ancestry	O
were	O
watch	O
.	O

In	O
a	O
survey	O
of	O
DM	B
in	O
Northern	O
Ireland	O
,	O
59	O
pedigrees	O
were	O
ascertained	O
.	O

Sibships	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
determine	O
the	O
transmission	O
of	O
DM	B
expansion	O
from	O
affected	O
parents	O
their	O
offspring	O
.	O

Sibships	O
the	O
status	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
determine	O
the	O
of	O
the	O
DM	B
expansion	O
from	O
affected	O
parents	O
to	O

Sibships	O
where	O
the	O
status	O
raise	O
shape	O
young	O
transmitting	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
touched	O
raise	O
young	O
shape	O
the	O
DM	B
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O

expansion	O
where	O
the	O
the	O
of	O
all	O
the	O
their	O
parents	O
been	O
DM	O
were	O
examined	O
to	O
affected	O
the	O
transmission	O
of	O
status	O
to	B
identified	O
from	O
determine	O
had	O
Sibships	O
members	O
offspring	O
.	O

offspring	O
where	O
the	O
determine	O
of	O
all	O
their	O
members	O
status	O
been	O
identified	O
were	O
to	O
expansion	O
to	O
had	O
transmission	O
of	O
the	O
DM	B
examined	O
from	O
affected	O
parents	O
the	O
the	O
Sibships	O
.	O

Sibships	O
where	O
the	O
status	O
raise	O
shape	O
young	O
transmitting	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
touched	O
raise	O
young	O
receive	O
the	O
DM	B
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O

Sibships	O
where	O
the	O
position	O
of	O
all	O
the	O
extremity	O
had	O
been	O
discover	O
were	O
probe	O
to	O
mold	O
the	O
transmission	O
of	O
the	O
DM	B
expansion	O
from	O
touched	O
nurture	O
to	O
their	O
progeny	O
.	O

Sibships	O
where	O
the	O
status	O
raise	O
shape	O
young	O
transmitting	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
touched	O
raise	O
young	O
receive	O
the	O
DM	B
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O

parents	O
where	O
the	O
status	O
of	O
all	O
to	O
were	O
had	O
been	O
identified	O
transmission	O
from	O
the	O
to	O
Sibships	O
members	O
the	O
the	O
DM	B
expansion	O
examined	O
affected	O
of	O
determine	O
their	O
offspring	O
.	O

Sibships	O
where	O
the	O
position	O
of	O
all	O
the	O
penis	O
had	O
been	O
key	O
were	O
examined	O
to	O
learn	O
the	O
transmission	O
of	O
the	O
decimetre	B
expansion	O
from	O
touch	O
raise	O
to	O
their	O
materialisation	O
.	O

Sibships	O
where	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
the	O
DM	B
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O

Where	O
the	O
channelize	O
raise	O
was	O
male	O
,	O
58	O
.	O

Where	O
cost	O
the	O
transmitting	O
parent	O
was	O
male	O
,	O
58	O
raise	O
.	O

Where	O
parent	O
transmitting	O
the	O
was	O
male	O
58	O
,	O
.	O

Where	O
the	O
channel	O
parent	O
was	O
manly	O
,	O
58	O
.	O

Where	O
transmitting	O
parent	O
male	O
58	O

,	O
the	O
transmitting	O
parent	O
was	O
male	O
58	O
Where	O
.	O

Where	O
the	O
transmitting	O
parent	O
was	O
male	O
,	O
.	O

Where	O
58	O
transmitting	O
parent	O
the	O
male	O
,	O
was	O
.	O

Where	O
cost	O
the	O
transmitting	O
parent	O
was	O
male	O
,	O
58	O
raise	O
.	O

Where	O
the	O
transmitting	O
rear	O
was	O
male	O
,	O
58	O
.	O

Where	O
the	O
transmitting	O
parent	O
was	O
male	O
,	O
58	O
.	O

tercet	O
%	O
of	O
the	O
offspring	O
were	O
touched	O
,	O
and	O
in	O
the	O
example	O
of	O
a	O
distaff	O
communicate	O
parent	O
,	O
lxviii	O
.	O

3	O
%	O
of	O
the	O
offspring	O
were	O
affected	O
,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
68	O
.	O

3	O
%	O
of	O
the	O
offspring	O
were	O
affected	O
,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
68	O
.	O

of	O
were	O
affected	O
,	O
in	O
the	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
68	O
.	O

3	O
%	O
of	O
the	O
offspring	O
,	O
and	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
68	O
.	O

of	O
the	O
offspring	O
were	O
,	O
and	O
in	O
the	O
case	O
a	O
female	O
transmitting	O
parent	O
68	O
.	O

,	O
%	O
of	O
68	O
offspring	O
were	O
affected	O
and	O
,	O
in	O
female	O
case	O
of	O
.	O
3	O
transmitting	O
parent	O
the	O
the	O
a	O

3	O
%	O
of	O
the	O
offspring	O
were	O
affected	O
,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
conduct	O
conduct	O
conduct	O
conduct	O
conduct	O
touched	O
68	O
.	O

trinity	O
%	O
of	O
the	O
materialization	O
were	O
affected	O
,	O
and	O
in	O
the	O
character	O
of	O
a	O
distaff	O
carry	O
rear	O
,	O
68	O
.	O

parent	O
%	O
of	O
the	O
offspring	O
were	O
a	O
case	O
and	O
in	O
the	O
female	O
3	O
affected	O
,	O
,	O
of	O
transmitting	O
68	O
.	O

3	O
%	O
of	O
the	O
offspring	O
were	O
affected	O
,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
68	O
.	O

7	O
%	O
were	O
affected	O
	O
.	O

affected	O
%	O
were	O
7	O
.	O

heptad	O
%	O
were	O
affected	O
.	O

7	O
affected	O
were	O
%	O
.	O

were	O
affected	O
.	O

sevener	O
%	O
were	O
affected	O
.	O

7	O
%	O
were	O
affected	O
	O
.	O

septenary	O
%	O
were	O
affected	O
.	O

7	O
affected	O
.	O

7	O
%	O
were	O
affected	O
	O
.	O

7	O
%	O
were	O
affected	O
.	O

on	O
meiotic	O
drive	O
in	O
DM	B
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
locus	O
non	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O

of	O
on	O
meiotic	O
in	O
in	O
DM	B
have	O
.	O
for	O
transmission	O
CTGn	O
the	O
larger	O
non	O
heterozygotes	O
the	O
DM	B
locus	O
drive	O
allele	O
-	O
DM	O
at	O
increased	O
Studies	O
shown	O

study	O
on	O
meiotic	O
drive	O
in	O
dm	B
have	O
point	O
increased	O
transmittal	O
of	O
the	O
larger	O
allelomorph	O
at	O
the	O
dm	B
venue	O
in	O
not	O
-	O
dm	O
heterozygotes	O
for	O
CTGn	O
.	O

discipline	O
on	O
meiotic	O
crusade	O
in	O
decimeter	B
have	O
read	O
increased	O
transmission	O
of	O
the	O
larger	O
allelomorph	O
at	O
the	O
decimeter	B
venue	O
in	O
not	O
-	O
decimeter	O
heterozygotes	O
for	O
CTGn	O
.	O

Studies	O
on	O
meiotic	O
drive	O
in	O
DM	B
have	O
shown	O
increased	O
transmission	O
the	O
larger	O
at	O
the	O
DM	B
locus	O
in	O
non	O
-	O
for	O
CTGn	O
.	O

Studies	O
on	O
meiotic	O
drive	O
indium	O
in	O
DM	B
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B
locus	O
heterozygote	O
dm	O
heterozygote	O
heterozygote	O
increase	O
increase	O
in	O
non	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O

Studies	O
on	O
meiotic	O
drive	O
indium	O
in	O
DM	B
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B
locus	O
heterozygote	O
dm	O
heterozygote	O
heterozygote	O
increase	O
dm	O
in	O
non	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O

Studies	O
on	O
meiotic	O
drive	O
in	O
DM	B
have	O
shown	O
increased	O
transmission	O
the	O
at	O
the	O
DM	B
locus	O
in	O
non	O
-	O
DM	O
heterozygotes	O

for	O
on	O
meiotic	O
drive	O
in	O
DM	B
allele	O
DM	O
increased	O
transmission	O
of	O
the	O
DM	O
have	O
CTGn	O
the	O
shown	B
-	O
in	O
non	O
Studies	O
larger	O
heterozygotes	O
locus	O
at	O
.	O

learn	O
on	O
meiotic	O
drive	O
in	O
DM	B
have	O
demonstrate	O
increased	O
infection	O
of	O
the	O
tumid	O
allelomorph	O
at	O
the	O
DM	B
venue	O
in	O
not	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O

Studies	O
on	O
meiotic	O
drive	O
in	O
DM	B
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B
locus	O
in	O
non	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O

This	O
evidence	O
provides	O
further	O
study	O
that	O
DM	O
to	B
expansion	O
tends	O
transmitted	O
be	O
the	O
preferentially	O
.	O

This	O
study	O
fork	O
out	O
dm	O
render	O
provides	O
further	O
evidence	O
that	O
the	B
DM	O
expansion	O
transfer	O
tends	O
to	O
be	O
transmitted	O
preferentially	O

This	O
work	O
furnish	O
further	O
evidence	O
that	O
the	O
DM	B
expansion	O
incline	O
to	O
be	O
familial	O
preferentially	O
.	O

transmitted	O
study	O
provides	O
This	O
DM	O
that	O
the	O
be	B
expansion	O
tends	O
to	O
evidence	O
further	O
preferentially	O
.	O

This	O
study	O
render	O
further	O
testify	O
that	O
the	O
dm	B
elaboration	O
tends	O
to	O
be	O
transmitted	O
preferentially	O
.	O

This	O
study	O
fork	O
out	O
dm	O
render	O
provides	O
further	O
evidence	O
that	O
the	B
DM	O
expansion	O
prove	O
tends	O
to	O
be	O
transmitted	O
preferentially	O

This	O
provides	O
evidence	O
the	O
DM	B
expansion	O
tends	O
to	O
be	O
transmitted	O
preferentially	O
.	O

DM	O
further	O
provides	O
study	O
evidence	O
that	O
tends	O
This	B
expansion	O
the	O
to	O
be	O
transmitted	O
.	O
preferentially	O

This	O
analyse	O
provides	O
further	O
evidence	O
that	O
the	O
decimetre	B
expansion	O
incline	O
to	O
be	O
genetic	O
preferentially	O
.	O

This	O
study	O
fork	O
out	O
dm	O
render	O
provides	O
further	O
evidence	O
that	O
the	B
DM	O
expansion	O
prove	O
tends	O
to	O
be	O
transmitted	O
preferentially	O

This	O
study	O
provides	O
further	O
evidence	O
that	O
the	O
DM	B
expansion	O
tends	O
to	O
be	O
transmitted	O
preferentially	O
.	O

bronzed	O
diabetes	O
Diagnosis	O
of	B
hemochromatosis	O

diagnosis	O
of	O
hemochromatosis	B
.	O

Diagnosis	O
of	O

diagnosing	O
of	O
hemochromatosis	B
.	O

of	O
hemochromatosis	B

bronzed	O
diabetes	O
Diagnosis	O
of	B
hemochromatosis	O

.	O
of	O
hemochromatosis	B
Diagnosis	O

diagnosis	O
Diagnosis	O
of	O
hemochromatosis	B
.	O

hemochromatosis	O
of	O
Diagnosis	B
.	O

diagnosis	O
of	O
hemochromatosis	B
.	O

Diagnosis	O
of	O
hemochromatosis	B
.	O

diagnosed	O
untreated	O
,	O
death	B
can	O
cause	O
serious	O
under	O
disease	O
early	B
hemochromatosis	I
,	O
the	O
but	O
and	O
is	O
still	O
substantially	O
illness	O
If	O
-	O
.	O

If	O
untreated	O
,	O
hemochromatosis	B
can	O
cause	O
serious	O
illness	O
and	O
early	B
death	I
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
diagnose	O
diagnose	O
bronzed	O
diabetes	O
bronzed	O
diabetes	O
bronzed	O
diabetes	O
bronzed	O
diabetes	O

If	O
untreated	O
,	O
hemochromatosis	B
can	O
cause	O
serious	O
illness	O
and	O
early	B
death	I
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
diagnose	O
diagnose	O
bronzed	O
diabetes	O
bronzed	O
diabetes	O
bronzed	O
diabetes	O
bronzed	O
diabetes	O

If	O
untreated	O
,	O
hemochromatosis	B
can	O
cause	O
sober	O
malady	O
and	O
early	B
dying	I
,	O
but	O
the	O
disease	O
is	O
yet	O
well	O
under	O
-	O
name	O
.	O

If	O
untreated	O
,	O
can	O
cause	O
serious	O
illness	O
and	O
death	I
,	O
but	O
the	O
is	O
still	O
under	O
-	O
diagnosed	O
.	O

hemochromatosis	B
serious	O
illness	O
and	O
death	I
,	O
the	O
disease	O
is	O
still	O
substantially	O
under	O
-	O
diagnosed	O
.	O

If	O
untreated	O
,	O
hemochromatosis	B
can	O
cause	O
unplayful	O
sickness	O
and	O
former	B
expiry	I
,	O
but	O
the	O
disease	O
is	O
nonetheless	O
substantially	O
under	O
-	O
name	O
.	O

disease	O
untreated	O
and	O
serious	B
can	O
cause	O
is	O
illness	O
,	O
early	B
death	I
,	O
diagnosed	O
the	O
hemochromatosis	O
If	O
still	O
substantially	O
under	O
-	O
but	O
.	O

If	O
untreated	O
,	O
hemochromatosis	B
can	O
cause	O
serious	O
illness	O
and	O
early	B
death	I
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
diagnose	O
diagnose	O
bronzed	O
diabetes	O
bronzed	O
diabetes	O
bronzed	O
diabetes	O
nevertheless	O
under	O

If	O
untreated	O
,	O
hemochromatosis	B
serious	O
illness	O
early	B
death	I
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
under	O
.	O

If	O
untreated	O
,	O
hemochromatosis	B
can	O
cause	O
serious	O
illness	O
and	O
early	B
death	I
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
under	O
-	O
diagnosed	O
.	O

The	O
foundation	O
of	O
masking	O
and	O
eccentric	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
impregnation	O
and	O
the	O
serum	O
ferritin	O
level	O
.	O

The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
level	O
.	O

The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
level	O
.	O

of	O
case	O
detection	O
is	O
measurement	O
of	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
level	O
.	O

The	O
cornerstone	O
of	O
screening	O
and	O
is	O
the	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
level	O
.	O

of	O
screening	O
and	O
case	O
is	O
the	O
measurement	O
of	O
serum	O
saturation	O
and	O
the	O
serum	O
level	O
.	O

ferritin	O
cornerstone	O
of	O
level	O
and	O
case	O
detection	O
the	O
is	O
measurement	O
and	O
serum	O
transferrin	O
.	O
The	O
the	O
serum	O
of	O
screening	O
saturation	O

The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
sieve	O
sieve	O
sieve	O
sieve	O
sieve	O
blood	O
serum	O
level	O

The	O
basis	O
of	O
sort	O
and	O
instance	O
detection	O
is	O
the	O
measuring	O
of	O
serum	O
siderophilin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
unwavering	O
.	O

serum	O
cornerstone	O
of	O
screening	O
and	O
case	O
saturation	O
serum	O
the	O
measurement	O
of	O
and	O
The	O
detection	O
is	O
ferritin	O
transferrin	O
the	O
level	O
.	O

The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
level	O
.	O

Once	O
the	O
diagnosis	O
is	O
misgiving	O
liverwort	O
fe	O
storage	O
distrust	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
diagnosing	O
fe	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B
overload	I
qualm	O
horizontal	O
surface	O

Once	O
the	O
diagnosis	O
is	O
misgiving	O
liverwort	O
fe	O
storage	O
distrust	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
diagnosing	O
manipulation	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B
overload	I
qualm	O
horizontal	O
surface	O

overload	O
the	O
the	O
iron	O
suspected	O
,	O
iron	O
must	O
is	O
serum	O
ferritin	O
levels	O
to	O
hepatic	O
diagnosis	O
use	O
on	O
liver	O
biopsy	O
specimens	O
and	O
assess	O
patients	O
for	O
stores	O
physicians	O
of	O
presence	B
Once	I
.	O

Once	O
the	O
diagnosis	O
is	O
misgiving	O
liverwort	O
fe	O
storage	O
distrust	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
diagnosing	O
fe	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B
overload	I
qualm	O
horizontal	O
surface	O

Once	O
the	O
diagnosis	O
is	O
suspected	O
,	O
physicians	O
use	O
serum	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B
overload	I
.	O

once	O
the	O
diagnosing	O
is	O
suspected	O
,	O
doctor	O
moldiness	O
exercise	O
serum	O
ferritin	O
levels	O
and	O
liverwort	O
iron	O
stores	O
on	O
liver	O
biopsy	O
specimens	O
to	O
buttocks	O
patients	O
for	O
the	O
comportment	O
of	O
iron	B
surcharge	I
.	O

on	O
the	O
diagnosis	O
is	O
suspected	O
,	O
assess	O
levels	O
use	O
serum	O
ferritin	O
Once	O
overload	O
for	O
stores	O
iron	O
liver	O
the	O
biopsy	O
specimens	O
to	O
physicians	O
patients	O
hepatic	O
must	O
presence	O
of	O
iron	B
and	I
.	O

to	O
the	O
diagnosis	O
biopsy	O
suspected	O
,	O
physicians	O
presence	O
for	O
serum	O
overload	O
levels	O
of	O
specimens	O
patients	O
stores	O
on	O
liver	O
is	O
hepatic	O
the	O
assess	O
iron	O
use	O
Once	O
must	O
and	O
iron	B
ferritin	I
.	O

Once	O
the	O
diagnosing	O
is	O
distrust	O
,	O
physicians	O
moldiness	O
use	O
serum	O
ferritin	O
storey	O
and	O
liverwort	O
iron	O
memory	O
on	O
liver	O
biopsy	O
specimens	O
to	O
posterior	O
patients	O
for	O
the	O
mien	O
of	O
iron	B
clog	I
.	O

Once	O
the	O
diagnosis	O
is	O
suspected	O
physicians	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
liver	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
of	O
iron	B
overload	I

Once	O
the	O
diagnosis	O
is	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B
overload	I
.	O

Liver	O
biopsy	O
is	O
also	O
utilize	O
to	O
found	O
the	O
mien	O
or	O
absence	O
of	O
cirrhosis	B
,	O
which	O
can	O
touch	O
prognosis	O
and	O
direction	O
.	O

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B
,	O
which	O
can	O
affect	O
prognosis	O
direction	O
cost	O
cost	O
cost	O
cost	O
cost	O
and	O
management	O
.	O

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B
,	O
which	O
can	O
affect	O
prognosis	O
direction	O
cost	O
cost	O
cost	O
cost	O
cost	O
and	O
management	O
.	O

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
or	O
absence	O
cirrhosis	B
,	O
which	O
can	O
affect	O
prognosis	O
and	O

which	O
biopsy	O
presence	O
establish	O
used	O
to	O
can	O
the	O
is	O
or	O
absence	O
of	O
.	B
,	O
also	O
Liver	O
affect	O
prognosis	O
and	O
management	O
cirrhosis	O

Liver	O
biopsy	O
is	O
besides	O
victimized	O
to	O
ground	O
the	O
mien	O
or	O
absence	O
of	O
cirrhosis	B
,	O
which	O
can	O
feign	O
prospect	O
and	O
management	O
.	O

.	O
biopsy	O
is	O
absence	O
used	O
to	O
establish	O
and	O
which	O
or	O
also	O
of	O
,	B
cirrhosis	O
presence	O
can	O
affect	O
prognosis	O
the	O
Liver	O
management	O

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B
,	O
which	O
can	O
affect	O
prognosis	O
direction	O
cost	O
cost	O
cost	O
cost	O
mien	O
and	O
management	O
.	O

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B
which	O
prognosis	O
and	O
management	O
.	O

Liver	O
biopsy	O
is	O
too	O
used	O
to	O
base	O
the	O
front	O
or	O
absence	O
of	O
cirrhosis	B
,	O
which	O
can	O
affect	O
prospect	O
and	O
direction	O
.	O

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B
,	O
which	O
can	O
affect	O
prognosis	O
and	O
management	O
.	O

DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
the	O
of	O
hemochromatosis	B
is	O
still	O
being	O
evaluated	O
.	O

commercially	O
DNA	O
-	O
diagnosis	O
test	O
for	O
the	O
.	O
being	O
is	O
evaluated	O
available	O
,	O
of	O
still	O
place	O
in	O
the	O
based	O
but	O
hemochromatosis	B
is	O
its	O
gene	O
A	O
HFE	O

A	O
DNA	O
-	O
establish	O
quiz	O
for	O
the	O
HFE	O
factor	O
is	O
commercially	O
useable	O
,	O
but	O
its	O
shoes	O
in	O
the	O
diagnosing	O
of	O
hemochromatosis	B
is	O
still	O
being	O
measure	O
.	O

A	O
DNA	O
-	O
ground	O
screen	O
for	O
the	O
HFE	O
cistron	O
is	O
commercially	O
uncommitted	O
,	O
but	O
its	O
position	O
in	O
the	O
diagnosing	O
of	O
hemochromatosis	B
is	O
tranquillise	O
being	O
evaluated	O
.	O

A	O
DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
available	O
,	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	B
being	O
evaluated	O
.	O

A	O
DNA	O
-	O
based	O
mental	O
testing	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
nevertheless	O
cost	O
valuate	O
cost	O
valuate	O
factor	O
diagnosis	O
of	B
hemochromatosis	O
is	O
still	O
being	O
evaluated	O

A	O
DNA	O
-	O
based	O
mental	O
testing	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
nevertheless	O
cost	O
valuate	O
cost	O
valuate	O
indium	O
diagnosis	O
of	B
hemochromatosis	O
is	O
still	O
being	O
evaluated	O

A	O
DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
available	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	B
is	O
still	O

being	O
DNA	O
-	O
based	O
test	O
for	O
but	O
in	O
gene	O
is	O
commercially	O
available	O
is	O
the	O
evaluated	O
place	O
HFE	O
hemochromatosis	O
diagnosis	O
of	O
A	B
,	O
still	O
the	O
its	O
.	O

ampere	O
DNA	O
-	O
found	O
tryout	O
for	O
the	O
HFE	O
cistron	O
is	O
commercially	O
uncommitted	O
,	O
but	O
its	O
point	O
in	O
the	O
diagnosing	O
of	O
hemochromatosis	B
is	O
still	O
being	O
evaluated	O
.	O

A	O
DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	B
is	O
still	O
being	O
evaluated	O
.	O

presently	O
,	O
the	O
most	O
utilitarian	O
use	O
for	O
this	O
try	O
is	O
in	O
the	O
catching	O
of	O
hemochromatosis	B
in	O
the	O
phratry	O
phallus	O
of	O
patients	O
with	O
a	O
proven	O
causa	O
of	O
the	O
disease	O
.	O

Currently	O
,	O
the	O
most	O
useful	O
for	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	B
in	O
the	O
family	O
a	O
proven	O
case	O
of	O
the	O
disease	O
.	O

patients	O
,	O
the	O
members	O
useful	O
role	O
for	O
of	O
proven	O
is	O
.	O
the	O
detection	O
of	O
a	B
in	O
the	O
family	O
most	O
of	O
case	O
with	O
hemochromatosis	O
test	O
Currently	O
this	O
the	O
disease	O
in	O

Currently	O
,	O
the	O
most	O
sleuthing	O
utilitarian	O
bronzed	O
diabetes	O
indium	O
utilitarian	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	B
hemochromatosis	O
in	O
the	O
family	O
try	O
out	O
sheath	O
mental	O
testing	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O

Currently	O
,	O
the	O
most	O
sleuthing	O
utilitarian	O
bronzed	O
diabetes	O
indium	O
utilitarian	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	B
hemochromatosis	O
in	O
the	O
family	O
try	O
out	O
sheath	O
try	O
out	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O

Currently	O
,	O
the	O
most	O
useful	O
role	O
for	O
this	O
is	O
in	O
detection	O
of	O
hemochromatosis	B
in	O
the	O
family	O
members	O
with	O
a	O
proven	O
case	O
of	O
the	O
disease	O
.	O

.	O
,	O
the	O
hemochromatosis	O
useful	O
role	O
of	O
this	O
most	O
is	O
in	O
the	O
the	O
of	O
case	B
test	O
the	O
family	O
members	O
of	O
detection	O
with	O
a	O
proven	O
in	O
for	O
patients	O
disease	O
Currently	O

Currently	O
,	O
the	O
most	O
useful	O
role	O
for	O
this	O
is	O
the	O
detection	O
of	O
hemochromatosis	B
in	O
the	O
family	O
members	O
patients	O
with	O
a	O
proven	O
case	O
of	O
the	O

presently	O
,	O
the	O
most	O
utilitarian	O
office	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	B
in	O
the	O
kin	O
penis	O
of	O
patients	O
with	O
a	O
show	O
shell	O
of	O
the	O
disease	O
.	O

currently	O
,	O
the	O
most	O
utilitarian	O
function	O
for	O
this	O
test	O
is	O
in	O
the	O
spying	O
of	O
hemochromatosis	B
in	O
the	O
kinfolk	O
appendage	O
of	O
patients	O
with	O
a	O
proved	O
shell	O
of	O
the	O
disease	O
.	O

Currently	O
,	O
the	O
most	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	B
in	O
the	O
family	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O
the	O
disease	O
.	O

It	O
crucial	O
to	O
diagnose	O
hemochromatosis	B
before	O
hepatic	B
cirrhosis	I
develops	O
because	O
phlebotomy	O
avert	O
serious	O
chronic	O
disease	O
can	O
even	O
lead	O
to	O
normal	O
expectancy	O
.	O
.	O

It	O
crucial	O
to	O
hemochromatosis	B
before	O
hepatic	B
cirrhosis	I
develops	O
because	O
phlebotomy	O
therapy	O
avert	O
serious	O
disease	O
and	O
can	O
even	O
lead	O
to	O
normal	O
life	O

It	O
is	O
crucial	O
to	O
give	O
the	O
axe	O
forefend	O
life	O
threatening	B
name	O
diagnose	B
hemochromatosis	I
before	O
hepatic	O
cirrhosis	O
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
spirit	O
anticipation	O
spirit	O
build	O
up	O
and	O
can	O
even	O
lead	O
to	O
normal	O

even	O
is	O
crucial	O
and	O
diagnose	O
hemochromatosis	B
before	O
expectancy	B
normal	I
develops	O
can	O
phlebotomy	O
therapy	O
can	O
to	O
serious	O
chronic	O
disease	O
to	O
life	O
because	O
lead	O
avert	O
cirrhosis	O
It	O
hepatic	O
.	O
.	O

.	O
is	O
crucial	O
avert	O
diagnose	O
hemochromatosis	B
expectancy	O
hepatic	B
to	I
develops	O
because	O
phlebotomy	O
can	O
even	O
life	O
cirrhosis	O
chronic	O
disease	O
and	O
can	O
therapy	O
lead	O
to	O
normal	O
serious	O
before	O
It	O
.	O

It	O
is	O
crucial	O
to	O
give	O
the	O
axe	O
forefend	O
life	O
threatening	B
name	O
diagnose	B
hemochromatosis	I
before	O
hepatic	O
cirrhosis	O
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
spirit	O
anticipation	O
spirit	O
cirrhosis	O
of	O
the	O
liver	O
and	O
can	O
even	O
lead	O

It	O
is	O
crucial	O
to	O
name	O
hemochromatosis	B
before	O
liverwort	B
cirrhosis	I
uprise	O
because	O
phlebotomy	O
therapy	O
can	O
obviate	O
good	O
continuing	O
disease	O
and	O
can	O
even	O
lead	O
to	O
formula	O
life	O
anticipation	O
.	O
.	O

It	O
is	O
crucial	O
to	O
give	O
the	O
axe	O
forefend	O
life	O
threatening	B
name	O
diagnose	B
hemochromatosis	I
before	O
hepatic	O
cirrhosis	O
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
spirit	O
anticipation	O
spirit	O
cirrhosis	O
of	O
the	O
liver	O
and	O
can	O
even	O
lead	O

normal	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	B
can	O
phlebotomy	B
cirrhosis	I
develops	O
because	O
chronic	O
lead	O
before	O
life	O
It	O
hepatic	O
serious	O
and	O
can	O
even	O
therapy	O
to	O
disease	O
avert	O
expectancy	O
.	O
.	O

It	O
is	O
crucial	O
to	O
name	O
hemochromatosis	B
before	O
liverwort	B
cirrhosis	I
develops	O
because	O
venesection	O
therapy	O
can	O
obviate	O
grievous	O
continuing	O
disease	O
and	O
can	O
even	O
lead	O
to	O
normal	O
animation	O
anticipation	O
.	O
.	O

It	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	B
before	O
hepatic	B
cirrhosis	I
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
and	O
can	O
even	O
lead	O
to	O
normal	O
life	O
expectancy	O
.	O
.	O

prevalence	O
of	O
the	O
I1307K	O
APC	B
cistron	O
variant	O
in	O
israeli	O
israelite	O
of	O
differing	O
heathenish	O
bloodline	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

Prevalence	O
of	O
the	O
I1307K	O
APC	B
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
israeli	B
israeli	O
israeli	B
israeli	O
israeli	B
israeli	O
cancer	I
.	O

Prevalence	O
of	O
the	O
I1307K	O
APC	B
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
israeli	B
israeli	O
israeli	B
israeli	O
israeli	B
israeli	O
cancer	I
.	O

the	O
gene	O
variant	O
in	O
Jews	O
of	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

Prevalence	O
of	O
the	O
I1307K	O
APC	B
in	O
Israeli	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

the	O
I1307K	O
APC	B
gene	O
in	O
Israeli	O
Jews	O
of	O
differing	O
origin	O
and	O
risk	O
for	O
cancer	I
.	O

colorectal	O
of	O
the	O
cancer	O
APC	B
gene	O
variant	O
Israeli	O
in	O
Jews	O
and	O
differing	O
ethnic	O
.	O
Prevalence	O
risk	O
for	O
of	B
I1307K	I
origin	O

Prevalence	O
of	O
the	O
I1307K	O
APC	B
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
israeli	B
israeli	O
israeli	B
israeli	O
israeli	B
israelite	O
cancer	I
.	O

Prevalence	O
of	O
the	O
I1307K	O
APC	B
cistron	O
strain	O
in	O
israeli	O
israelite	O
of	O
differing	O
cultural	O
root	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

for	O
of	O
the	O
I1307K	O
APC	B
gene	O
origin	O
differing	O
Israeli	O
Jews	O
of	O
and	O
Prevalence	O
variant	O
in	O
colorectal	O
ethnic	O
risk	B
cancer	I
.	O

Prevalence	O
of	O
the	O
I1307K	O
APC	B
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

BACKGROUND	O
AIMS	O
Israeli	O
Jews	O
of	O
European	O
birth	O
,	O
i	O
.	O
e	O
Ashkenazim	O
,	O
have	O
the	O
colorectal	B
cancer	I
incidence	O
of	O
any	O
ethnic	O
group	O
.	O

BACKGROUND	O
AIMS	O
Israeli	O
of	O
European	O
birth	O
,	O
i	O
.	O
e	O
.	O
Ashkenazim	O
,	O
the	O
highest	O
colorectal	B
cancer	I
incidence	O
of	O
any	O
Israeli	O

BACKGROUND	O
&	O
AIMS	O
Israeli	O
israelite	O
ashkenazi	O
european	O
israelite	O
Jews	O
of	O
European	O
birth	O
,	O
i	O
.	O
e	O
.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
israeli	O
ethnical	O
chemical	O
group	O
whatever	O
highest	B
colorectal	I
cancer	O
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group	O

cancer	O
&	O
AIMS	O
highest	O
Jews	O
of	O
European	O
ethnic	O
any	O
i	O
colorectal	O
e	O
.	O
,	O
of	O
,	O
have	O
the	O
Israeli	O
Israeli	B
.	I
incidence	O
Ashkenazim	O
,	O
BACKGROUND	O
birth	O
group	O
.	O

group	O
&	O
AIMS	O
Ashkenazim	O
Jews	O
of	O
ethnic	O
birth	O
Israeli	O
i	O
.	O
e	O
,	O
cancer	O
Israeli	O
,	O
have	O
the	O
highest	O
colorectal	B
.	I
incidence	O
of	O
any	O
,	O
European	O
BACKGROUND	O
.	O

BACKGROUND	O
&	O
AIMS	O
Israeli	O
israelite	O
ashkenazi	O
european	O
israelite	O
Jews	O
of	O
European	O
birth	O
,	O
i	O
.	O
e	O
.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
israeli	O
ethnical	O
chemical	O
group	O
israeli	O
highest	B
colorectal	I
cancer	O
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group	O

scope	O
&	O
aim	O
israeli	O
israelite	O
of	O
european	O
parentage	O
,	O
i	O
.	O
e	O
.	O
,	O
ashkenazi	O
,	O
have	O
the	O
gamy	O
colorectal	B
cancer	I
incidence	O
of	O
any	O
israeli	O
ethnic	O
group	O
.	O

BACKGROUND	O
&	O
AIMS	O
Israeli	O
israelite	O
ashkenazi	O
european	O
israelite	O
Jews	O
of	O
European	O
birth	O
,	O
i	O
.	O
e	O
.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
israeli	O
ethnical	O
chemical	O
group	O
israeli	O
highest	B
colorectal	I
cancer	O
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group	O

any	O
&	O
AIMS	O
Israeli	O
Jews	O
of	O
,	O
e	O
,	O
i	O
.	O
have	O
incidence	O
European	O
Israeli	O
BACKGROUND	O
birth	O
,	O
highest	O
colorectal	B
cancer	I
.	O
of	O
the	O
Ashkenazim	O
ethnic	O
group	O
.	O

backcloth	O
&	O
intent	O
israeli	O
hebrew	O
of	O
european	O
nascence	O
,	O
i	O
.	O
e	O
.	O
,	O
ashkenazi	O
,	O
have	O
the	O
highest	O
colorectal	B
cancer	I
incidence	O
of	O
any	O
israeli	O
ethnic	O
group	O
.	O

BACKGROUND	O
&	O
AIMS	O
Israeli	O
Jews	O
of	O
European	O
birth	O
,	O
i	O
.	O
e	O
.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
highest	O
colorectal	B
cancer	I
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group	O
.	O

The	O
I1307K	O
apc	B
gene	O
version	O
was	O
find	O
in	O
6	O
.	O

The	O
I1307K	O
APC	B
gene	O
variant	O
was	O
found	O
in	O
6	O
form	O
form	O
form	O
.	O

The	O
I1307K	O
APC	B
cistron	O
form	O
was	O
obtain	O
in	O
6	O
.	O

The	O
I1307K	O
APC	B
cistron	O
variant	O
was	O
found	O
in	O
6	O
.	O

The	O
APC	B
gene	O
was	O
found	O
in	O
6	O
.	O

in	O
.	O
APC	B
variant	O
gene	O
was	O
found	O
The	O
6	O
I1307K	O

The	O
in	O
APC	B
gene	O
I1307K	O
was	O
variant	O
found	O
6	O
.	O

in	O
gene	O
APC	B
I1307K	O
variant	O
was	O
.	O
The	O
6	O
found	O

The	O
gene	O
variant	O
was	O
in	O

The	O
I1307K	O
APC	B
gene	O
variant	O
was	O
found	O
in	O
6	O
form	O
form	O
form	O
.	O

The	O
I1307K	O
APC	B
gene	O
variant	O
was	O
found	O
in	O
6	O
.	O

Jews	O
%	O
of	O
familial	O
Jews	O
,	O
28	O
non	O
,	O
their	O
American	O
colorectal	B
cases	I
cancer	O
of	O
but	O
not	O
in	O
%	O
1	O
-	O
.	O

1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B
cancer	I
cases	O
,	O
but	O
not	O
in	O
israelite	O
israelite	O
american	O
american	O
american	O
american	O
non	O
-	O
Jews	O
.	O

1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B
cancer	I
cases	O
,	O
but	O
not	O
in	O
israelite	O
israelite	O
american	O
american	O
american	O
american	O
non	O
-	O
Jews	O
.	O

ane	O
%	O
of	O
American	O
jew	O
,	O
xxviii	O
%	O
of	O
their	O
inherited	O
colorectal	B
cancer	I
sheath	O
,	O
but	O
not	O
in	O
not	O
-	O
jew	O
.	O

1	O
%	O
of	O
Jews	O
,	O
28	O
%	O
of	O
familial	O
colorectal	B
cancer	I
cases	O
but	O
not	O
non	O
-	O
Jews	O
.	O

American	O
28	O
%	O
of	O
familial	O
colorectal	B
cases	O
,	O
but	O
not	O
in	O
non	O
-	O
Jews	O
.	O

ace	O
%	O
of	O
American	O
israelite	O
,	O
xxviii	O
%	O
of	O
their	O
hereditary	O
colorectal	B
cancer	I
causa	O
,	O
but	O
not	O
in	O
not	O
-	O
israelite	O
.	O

,	O
%	O
of	O
28	O
Jews	O
,	O
but	O
%	O
of	O
their	O
familial	O
colorectal	B
Jews	I
cases	O
American	O
1	O
not	O
in	O
non	O
-	O
cancer	O
.	O

1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B
cancer	I
cases	O
,	O
but	O
not	O
in	O
israelite	O
israelite	O
american	O
american	O
american	O
	O
non	O
-	O
Jews	O
.	O

1	O
%	O
of	O
American	O
28	O
%	O
their	O
familial	O
colorectal	B
cancer	I
cases	O
,	O
but	O
not	O
in	O
non	O
.	O

1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B
cancer	I
cases	O
,	O
but	O
not	O
in	O
non	O
-	O
Jews	O
.	O

ethnic	O
assessed	O
the	O
Jews	O
prevalence	O
in	O
Israeli	O
I1307K	O
for	O
differing	O
risk	O
origin	O
We	O
and	O
of	O
colorectal	B
cancer	I
.	O

We	O
assessed	O
the	O
I1307K	O
preponderance	O
in	O
israeli	O
jew	O
of	O
differing	O
pagan	O
line	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

We	O
appraise	O
the	O
I1307K	O
prevalence	O
in	O
israeli	O
Jews	O
of	O
differing	O
pagan	O
source	O
and	O
endangerment	O
for	O
colorectal	B
cancer	I
.	O

We	O
assessed	O
the	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

We	O
appraise	O
the	O
I1307K	O
preponderance	O
in	O
israeli	O
Jews	O
of	O
differing	O
heathen	O
beginning	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

We	O
assessed	O
israeli	O
the	O
I1307K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
israelite	O
israelite	O
israelite	O
israelite	O
.	O

We	O
assessed	O
the	O
I1307K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
origin	O
and	O
for	O
colorectal	B
cancer	I
.	O

We	O
assessed	O
israeli	O
the	O
I1307K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
israelite	O
israelite	O
israelite	O
israelite	O
.	O

assessed	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
.	O

We	O
assessed	O
of	O
for	O
prevalence	O
in	O
and	O
Jews	O
the	O
differing	O
ethnic	O
origin	O
Israeli	O
risk	O
I1307K	O
colorectal	B
cancer	I
.	O

We	O
assessed	O
the	O
I1307K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
or	O
non	O
-	O
origin	O
with	O
or	O
without	O
and	O
of	O
neoplasia	B
,	O
examined	O
for	O
I1307K	O
variant	O
by	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O
method	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
-	O
European	O
origin	O
,	O
with	O
/	O
history	O
neoplasia	B
,	O
were	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
neoplasia	B
,	O
were	O
examined	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
allelomorph	O
method	O
acting	O
particular	O
	O
method	O
acting	O
	O
	O
method	O
acting	O
	O
	O
	O
	O
israelite	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
neoplasia	B
,	O
were	O
examined	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
allelomorph	O
method	O
acting	O
particular	O
	O
method	O
acting	O
	O
	O
method	O
acting	O
	O
	O
	O
	O
	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O

method	O
dna	O
taste	O
from	O
500	O
unrelated	O
hebrew	O
of	O
european	O
or	O
not	O
-	O
european	O
beginning	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
house	O
account	O
of	O
neoplasia	B
,	O
were	O
examined	O
for	O
the	O
I1307K	O
variate	O
by	O
the	O
allelomorph	O
-	O
particular	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O

METHODS	O
samples	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
a	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
neoplasia	B
,	O
were	O
examined	O
for	O
the	O
I1307K	O
by	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O

method	O
dna	O
taste	O
from	O
500	O
unrelated	O
hebrew	O
of	O
european	O
or	O
not	O
-	O
european	O
beginning	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
phratry	O
chronicle	O
of	O
neoplasia	B
,	O
were	O
analyze	O
for	O
the	O
I1307K	O
variance	O
by	O
the	O
allelomorph	O
-	O
particular	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O

specific	O
history	O
samples	O
from	O
or	O
unrelated	O
-	O
the	O
European	O
or	O
non	O
-	O
European	O
Jews	O
without	O
with	O
500	O
,	O
a	O
personal	O
of	O
/	O
or	O
family	O
,	O
of	O
neoplasia	B
ASO	O
.	O
examined	O
were	O
DNA	O
I1307K	O
variant	O
by	O
the	O
allele	O
origin	O
METHODS	O
oligonucleotide	O
(	O
and	O
)	O
method	O
for	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
neoplasia	B
,	O
were	O
examined	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
allelomorph	O
method	O
acting	O
particular	O
	O
method	O
acting	O
	O
	O
method	O
acting	O
	O
	O
	O
	O
	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O

method	O
DNA	O
sampling	O
from	O
d	O
unrelated	O
israelite	O
of	O
european	O
or	O
not	O
-	O
european	O
line	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
syndicate	O
chronicle	O
of	O
neoplasia	B
,	O
were	O
analyse	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
allelomorph	O
-	O
particular	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
neoplasia	B
,	O
were	O
examined	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O

RESULTS	O
In	O
mortal	O
somebody	O
somebody	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B
cancer	I
,	O
I1307K	O
was	O
found	O
in	O
5	O
take	O
a	O

in	O
In	O
persons	O
.	O
average	O
risk	O
for	O
colorectal	B
5	I
,	O
I1307K	O
was	O
RESULTS	O
found	O
cancer	O
at	O

RESULTS	O
In	O
mortal	O
somebody	O
somebody	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B
cancer	I
,	O
I1307K	O
was	O
found	O
in	O
5	O
take	O
a	O

solution	O
indiana	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B
cancer	I
,	O
I1307K	O
was	O
incur	O
indiana	O
quintet	O
.	O

found	O
In	O
persons	O
colorectal	O
average	O
risk	O
in	O
at	B
cancer	I
,	O
RESULTS	O
was	O
I1307K	O
for	O
5	O
.	O

RESULTS	O
In	O
mortal	O
somebody	O
somebody	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B
cancer	I
,	O
I1307K	O
was	O
found	O
in	O
5	O
take	O
a	O

RESULTS	O
inch	O
someone	O
at	O
average	O
jeopardy	O
for	O
colorectal	B
cancer	I
,	O
I1307K	O
was	O
rule	O
inch	O
5	O
.	O

issue	O
In	O
individual	O
at	O
ordinary	O
risk	O
for	O
colorectal	B
cancer	I
,	O
I1307K	O
was	O
rule	O
in	O
5	O
.	O

RESULTS	O
In	O
cancer	O
.	O
average	O
risk	O
found	O
colorectal	B
persons	I
,	O
I1307K	O
was	O
for	O
in	O
at	O
5	O

In	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B
I1307K	O
was	O
found	O
in	O
5	O
.	O

RESULTS	O
In	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B
cancer	I
,	O
I1307K	O
was	O
found	O
in	O
5	O
.	O

1	O
%	O
of	O
120	O
.	O
and	O
0	O
European	O

cipher	O
%	O
of	O
120	O
european	O
and	O
1	O
.	O

of	O
and	O
1	O
.	O

0	O
	O
	O
%	O
of	O
120	O
European	O
and	O
1	O
.	O

0	O
of	O
120	O
1	O
.	O

0	O
European	O
of	O
120	O
%	O
and	O
.	O
1	O

.	O
120	O
of	O
%	O
European	O
and	O
1	O
0	O

0	O
	O
european	O
%	O
of	O
120	O
European	O
and	O
1	O
.	O

zero	O
%	O
of	O
120	O
european	O
and	O
1	O
.	O

0	O
	O
european	O
%	O
of	O
120	O
European	O
and	O
1	O
.	O

0	O
%	O
of	O
120	O
European	O
and	O
1	O
.	O

6	O
%	O
european	O
israelite	O
european	O
of	O
188	O
non	O
-	O
European	O
Jews	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
hebrew	O
.	O

08	O
%	O
of	O
.	O
non	O
-	O
European	O
Jews	O
)	O
P	O
=	O
0	O
6	O
.	O
(	O
188	O

6	O
%	O
european	O
israelite	O
european	O
of	O
188	O
non	O
-	O
European	O
Jews	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
hebrew	O
.	O

sise	O
%	O
of	O
188	O
non	O
-	O
European	O
jew	O
(	O
p	O
=	O
cypher	O
.	O
08	O
)	O
.	O

.	O
%	O
of	O
Jews	O
non	O
-	O
08	O
188	O
(	O
P	O
6	O
0	O
=	O
European	O
)	O
.	O

6	O
%	O
european	O
israelite	O
european	O
of	O
188	O
non	O
-	O
European	O
Jews	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
hebrew	O
.	O

6	O
%	O
of	O
188	O
not	O
-	O
european	O
jew	O
(	O
phosphorus	O
=	O
0	O
.	O
08	O
)	O
.	O

hexad	O
%	O
of	O
188	O
not	O
-	O
european	O
israelite	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

6	O
%	O
(	O
.	O
non	O
-	O
.	O
Jews	O
of	O
P	O
=	O
0	O
European	O
08	O
188	O
)	O

%	O
of	O
188	O
non	O
-	O
European	O
Jews	O
=	O
0	O
.	O
08	O
)	O
.	O

6	O
%	O
of	O
188	O
non	O
-	O
European	O
Jews	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

It	O
occurred	O
in	O
15	O
information	O
technology	O

15	O
occurred	O
in	O
It	O
.	O

It	O
happen	O
in	O
15	O
.	O

It	O
15	O
in	O
occurred	O
.	O

in	O
15	O
.	O

It	O
occurred	O
in	O
xv	O
.	O

It	O
occurred	O
in	O
15	O
information	O
technology	O

it	O
occurred	O
in	O
15	O
.	O

It	O
15	O
.	O

It	O
occurred	O
in	O
15	O
information	O
technology	O

It	O
occurred	O
in	O
15	O
.	O

4	O
%	O
of	O
52	O
zero	O
ashkenazi	O
israeli	O
take	O
a	O
chance	O
ashkenazi	O
Ashkenazi	O
Israelis	O
with	B
familial	O
cancer	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
increase	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	B
increased	O
cancer	O
risk	O
null	O
null	O

4	O
%	O
of	O
52	O
zero	O
ashkenazi	O
israeli	O
take	O
a	O
chance	O
ashkenazi	O
Ashkenazi	O
Israelis	O
with	B
familial	O
cancer	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
increase	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	B
increased	O
cancer	O
risk	O
null	O
null	O

-	O
%	O
of	O
52	O
Ashkenazi	O
Israelis	O
.	O
and	O
cancer	B
(	O
P	O
=	O
51	O
with	O
European	O
cancer	O
familial	O
in	O
not	O
detected	O
4	O
0	O
non	O
was	O
02	O
Jews	O
at	O
increased	O
.	B
risk	O
)	O

4	O
%	O
of	O
52	O
zero	O
ashkenazi	O
israeli	O
take	O
a	O
chance	O
ashkenazi	O
Ashkenazi	O
Israelis	O
with	B
familial	O
cancer	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
increase	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	B
increased	O
cancer	O
risk	O
null	O
null	O

4	O
%	O
of	O
52	O
Israelis	O
cancer	B
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
51	O
non	O
-	O
European	O
Jews	O
at	O
increased	O
cancer	B
risk	O
.	O

quaternion	O
%	O
of	O
lii	O
ashkenazi	O
israeli	O
with	O
transmissible	O
cancer	B
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
not	O
observe	O
in	O
51	O
non	O
-	O
european	O
jew	O
at	O
increased	O
cancer	B
adventure	O
.	O

cancer	O
%	O
European	O
02	O
Ashkenazi	O
Israelis	O
increased	O
familial	O
52	B
(	O
P	O
=	O
in	O
.	O
of	O
cancer	O
and	O
was	O
not	O
detected	O
0	O
51	O
non	O
-	O
)	O
with	O
at	O
Jews	O
4	B
risk	O
.	O

4	O
%	O
of	O
52	O
Ashkenazi	O
Israelis	O
with	O
familial	O
cancer	B
P	O
=	O
.	O
02	O
)	O
and	O
was	O
not	O
detected	O
non	O
-	O
European	O
Jews	O
at	O
increased	O
cancer	B
risk	O
.	O

P	O
%	O
of	O
cancer	O
Ashkenazi	O
Israelis	O
with	O
Jews	O
-	B
(	O
European	O
=	O
at	O
detected	O
non	O
)	O
and	O
was	O
.	O
.	O
in	O
51	O
02	O
cancer	O
4	O
familial	O
0	O
increased	O
52	B
risk	O
not	O

four	O
%	O
of	O
52	O
ashkenazi	O
Israelis	O
with	O
hereditary	O
crab	B
(	O
p	O
=	O
cipher	O
.	O
02	O
)	O
and	O
was	O
not	O
detected	O
in	O
51	O
not	O
-	O
european	O
jew	O
at	O
increased	O
crab	B
risk	O
.	O

4	O
%	O
of	O
52	O
Ashkenazi	O
Israelis	O
with	O
familial	O
cancer	B
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	O
increased	O
cancer	B
risk	O
.	O

Colorectal	B
neoplasia	I
occurred	O
personally	O
ashkenazi	O
operating	O
theatre	O
attack	O
aircraft	O
carrier	O
chronicle	O
operating	O
theatre	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307K	O
carriers	O
,	O
8	O
of	O
family	O
line	O
chronicle	O
whom	O
also	O
had	O
a	O
personal	O
or	B
family	O
history	O
of	O

Colorectal	B
neoplasia	I
occurred	O
personally	O
ashkenazi	O
operating	O
theatre	O
attack	O
aircraft	O
carrier	O
chronicle	O
operating	O
theatre	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307K	O
carriers	O
,	O
8	O
of	O
family	O
line	O
ashkenazi	O
whom	O
also	O
had	O
a	O
personal	O
or	B
family	O
history	O
of	O

neoplasia	B
neoplasia	I
family	O
carriers	O
or	O
in	O
noncolonic	O
families	O
personally	O
13	O
of	O
20	O
had	O
I1307K	O
occurred	O
of	O
8	O
of	O
whom	O
also	O
Ashkenazi	O
a	O
personal	O
or	O
,	O
the	O
of	O
history	O
Colorectal	B
.	O

Colorectal	B
neoplasia	I
occurred	O
personally	O
ashkenazi	O
operating	O
theatre	O
attack	O
aircraft	O
carrier	O
chronicle	O
operating	O
theatre	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307K	O
carriers	O
,	O
8	O
of	O
family	O
line	O
chronicle	O
whom	O
also	O
had	O
a	O
personal	O
or	B
family	O
history	O
of	O

Colorectal	B
neoplasia	I
occurred	O
personally	O
or	O
in	O
the	O
of	O
13	O
20	O
Ashkenazi	O
I1307K	O
carriers	O
,	O
8	O
of	O
had	O
a	O
personal	O
or	O
family	O
history	O
of	O
noncolonic	O
neoplasia	B
.	O

colorectal	B
neoplasia	I
pass	O
personally	O
or	O
in	O
the	O
sept	O
of	O
13	O
of	O
xx	O
ashkenazi	O
I1307K	O
carriers	O
,	O
octad	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
household	O
account	O
of	O
noncolonic	O
neoplasia	B
.	O

8	B
neoplasia	I
occurred	O
personally	O
or	O
in	O
a	O
20	O
of	O
13	O
of	O
Colorectal	O
neoplasia	O
or	O
,	O
carriers	O
of	O
family	O
whom	O
also	O
had	O
the	O
personal	O
I1307K	O
families	O
history	O
of	O
noncolonic	O
Ashkenazi	B
.	O

had	B
neoplasia	I
occurred	O
whom	O
or	O
in	O
the	O
history	O
or	O
13	O
neoplasia	O
20	O
of	O
also	O
personal	O
,	O
8	O
of	O
personally	O
I1307K	O
family	O
a	O
carriers	O
of	O
Colorectal	O
families	O
Ashkenazi	O
noncolonic	O
of	B
.	O

colorectal	B
neoplasia	I
occurred	O
personally	O
or	O
in	O
the	O
folk	O
of	O
13	O
of	O
xx	O
ashkenazi	O
I1307K	O
mailman	O
,	O
viii	O
of	O
whom	O
besides	O
had	O
a	O
personal	O
or	O
syndicate	O
chronicle	O
of	O
noncolonic	O
neoplasia	B
.	O

Colorectal	B
neoplasia	I
occurred	O
personally	O
or	O
the	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307K	O
carriers	O
,	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
of	O
noncolonic	O
neoplasia	B

Colorectal	B
neoplasia	I
occurred	O
personally	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307K	O
carriers	O
,	O
8	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
family	O
history	O
of	O
noncolonic	O
neoplasia	B
.	O

CONCLUSIONS	O
The	O
higher	O
APC	O
variant	O
colorectal	O
represent	O
and	O
susceptibility	O
gene	O
for	O
explains	B
of	I
or	I
other	I
in	I
cancers	I
in	O
Jews	O
Ashkenazi	O
,	O
a	O
partially	O
may	O
the	O
incidence	O
I1307K	O
Israelis	O
colorectal	B
cancer	I
,	O
,	O
European	O
.	O

CONCLUSIONS	O
APC	O
variant	O
may	O
represent	O
susceptibility	O
gene	O
,	I
or	I
,	I
cancers	I
,	O
partially	O
explains	O
the	O
incidence	O
of	O
colorectal	B
in	O
European	O
Israelis	O
.	O

CONCLUSIONS	O
The	O
I1307K	O
APC	O
former	O
stand	O
for	O
part	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	B
colorectal	I
,	I
or	I
other	I
,	I
cancers	O
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	B
colorectal	I
cancer	O
in	O
European	O
Israelis	O
onetime	O
onetime	O
onetime	O
onetime	O
onetime	O
onetime	O
operating	O

CONCLUSIONS	O
The	O
I1307K	O
APC	O
former	O
stand	O
for	O
form	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	B
colorectal	I
,	I
or	I
other	I
,	I
cancers	O
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	B
colorectal	I
cancer	O
in	O
European	O
Israelis	O
onetime	O
onetime	O
onetime	O
onetime	O
onetime	O
onetime	O
operating	O

The	O
Ashkenazi	O
I1307K	O
APC	O
variant	O
may	O
incidence	O
a	O
susceptibility	O
gene	O
for	O
of	B
,	I
the	I
cancer	I
,	I
cancers	I
in	O
colorectal	O
Jews	O
,	O
and	O
.	O
explains	O
or	O
higher	O
represent	O
CONCLUSIONS	O
European	B
partially	I
in	O
colorectal	O
Israelis	O
other	O

CONCLUSIONS	O
The	O
I1307K	O
APC	O
variant	O
may	O
susceptibility	O
gene	O
for	O
colorectal	B
or	I
other	I
,	I
cancers	I
in	O
Jews	O
,	O
and	O
partially	O
the	O
higher	O
of	O
colorectal	B
cancer	I
in	O
European	O
Israelis	O
.	O

determination	O
The	O
I1307K	O
apc	O
edition	O
may	O
represent	O
a	O
susceptibleness	O
factor	O
for	O
colorectal	B
,	I
or	I
other	I
,	I
cancers	I
in	O
ashkenazi	O
israelite	O
,	O
and	O
partially	O
excuse	O
the	O
higher	O
incidence	O
of	O
colorectal	B
cancer	I
in	O
european	O
israeli	O
.	O

decision	O
The	O
I1307K	O
apc	O
variant	O
may	O
be	O
a	O
susceptibleness	O
factor	O
for	O
colorectal	B
,	I
or	I
other	I
,	I
cancers	I
in	O
Ashkenazi	O
hebrew	O
,	O
and	O
partially	O
explains	O
the	O
gamy	O
incidence	O
of	O
colorectal	B
crab	I
in	O
european	O
israeli	O
.	O

CONCLUSIONS	O
The	O
I1307K	O
APC	O
former	O
stand	O
for	O
form	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	B
colorectal	I
,	I
or	I
other	I
,	I
cancers	O
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	B
colorectal	I
cancer	O
in	O
European	O
Israelis	O
onetime	O
onetime	O
onetime	O
onetime	O
onetime	O
onetime	O
operating	O

finish	O
The	O
I1307K	O
APC	O
strain	O
may	O
represent	O
a	O
susceptibility	O
factor	O
for	O
colorectal	B
,	I
or	I
other	I
,	I
cancers	I
in	O
ashkenazi	O
jew	O
,	O
and	O
partially	O
explicate	O
the	O
gamy	O
incidence	O
of	O
colorectal	B
crab	I
in	O
european	O
israeli	O
.	O

CONCLUSIONS	O
The	O
I1307K	O
APC	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	O
colorectal	B
,	I
or	I
other	I
,	I
cancers	I
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	O
colorectal	B
cancer	I
in	O
European	O
Israelis	O
.	O

Systematic	O
of	O
oxidase	O
defects	O
in	O
hereditary	B
coproporphyria	I
and	O
mutation	O
update	O
.	O

taxonomic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
factor	O
flaw	O
in	O
transmitted	B
coproporphyria	I
and	O
mutation	O
update	O
.	O

in	O
coproporphyrinogen	O
of	O
analysis	O
oxidase	O
gene	O
coproporphyria	O
Systematic	O
hereditary	B
.	I
and	O
mutation	O
update	O
defects	O

Systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
coproporphyria	I
and	O
update	O
.	O

Systematic	O
analysis	O
indium	O
genetic	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B
sport	B
depth	O
psychology	I
coproporphyria	O
and	O
mutation	O
update	O

Systematic	O
analysis	O
indium	O
genetic	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B
sport	B
factor	O
coproporphyria	I
and	O
mutation	O
update	O
.	O

taxonomic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
cistron	O
defects	O
in	O
transmissible	B
coproporphyria	I
and	O
mutant	O
update	O
.	O

update	O
analysis	O
of	O
Systematic	O
in	O
gene	O
defects	O
mutation	O
hereditary	B
coproporphyria	I
and	O
oxidase	O
coproporphyrinogen	O
.	O

Systematic	O
analysis	O
indium	O
genetic	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B
sport	B
depth	O
psychology	I
coproporphyria	O
and	O
mutation	O
update	O

systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
factor	O
defects	O
in	O
familial	B
coproporphyria	I
and	O
variation	O
update	O
.	O

Systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B
coproporphyria	I
and	O
mutation	O
update	O
.	O

coproporphyria	I
(	O
HC	B
)	O
is	O
an	O
acute	O
hepatic	B
porphyria	I
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
activity	I
coproporphyrinogen	I
III	I
oxidase	I
(	O
CPO	O
)	O
.	O

with	B
coproporphyria	I
(	O
of	B
)	O
is	O
an	O
.	O
CPO	B
porphyria	I
)	O
autosomal	O
dominant	O
coproporphyrinogen	O
(	O
by	O
deficient	B
activity	I
HC	I
inheritance	I
III	I
oxidase	I
caused	O
hepatic	O
Hereditary	O
acute	O

hereditary	B
coproporphyria	I
(	O
HC	B
)	O
is	O
an	O
discriminating	O
liverwort	B
porphyria	I
with	O
autosomal	O
rife	O
heritage	O
make	O
by	O
inferior	B
activity	I
of	I
coproporphyrinogen	I
III	I
oxidase	I
(	O
CPO	O
)	O
.	O

hereditary	B
coproporphyria	I
(	O
HC	B
)	O
is	O
an	O
ague	O
liverwort	B
porphyria	I
with	O
autosomal	O
prevailing	O
inheritance	O
do	O
by	O
lacking	B
activity	I
of	I
coproporphyrinogen	I
III	I
oxidase	I
(	O
CPO	O
)	O
.	O

Hereditary	B
coproporphyria	I
(	O
HC	B
)	O
is	O
an	O
acute	O
hepatic	B
porphyria	I
autosomal	O
dominant	O
caused	O
by	O
deficient	B
activity	I
of	I
coproporphyrinogen	I
III	I
CPO	O
)	O
.	O

Hereditary	B
coproporphyria	I
(	O
HC	B
substandard	O
)	O
is	O
an	O
acute	O
hepatic	B
porphyria	I
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
deficient	B
activity	I
	I
	I
liverwort	I
liverwort	I
liverwort	I
liverwort	I
of	I
coproporphyrinogen	I
III	I
oxidase	I
(	O
CPO	O
)	O
.	O

Hereditary	B
coproporphyria	I
(	O
HC	B
substandard	O
)	O
is	O
an	O
acute	O
hepatic	B
porphyria	I
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
deficient	B
activity	I
	I
	I
liverwort	I
liverwort	I
liverwort	I
cost	I
of	I
coproporphyrinogen	I
III	I
oxidase	I
(	O
CPO	O
)	O
.	O

Hereditary	B
coproporphyria	I
(	O
HC	B
)	O
is	O
an	O
acute	O
hepatic	B
porphyria	I
autosomal	O
caused	O
by	O
deficient	B
activity	I
of	I
coproporphyrinogen	I
III	I
oxidase	I
(	O

CPO	B
coproporphyria	I
(	O
HC	B
)	O
is	O
inheritance	O
deficient	O
hepatic	B
porphyria	I
with	O
autosomal	O
oxidase	O
an	O
)	O
by	O
acute	B
III	I
of	I
coproporphyrinogen	I
Hereditary	I
dominant	I
(	O
activity	O
caused	O
.	O

transmissible	B
coproporphyria	I
(	O
HC	B
)	O
is	O
an	O
knifelike	O
liverwort	B
porphyria	I
with	O
autosomal	O
rife	O
inheritance	O
have	O
by	O
wanting	B
activity	I
of	I
coproporphyrinogen	I
trine	I
oxidase	I
(	O
CPO	O
)	O
.	O

Hereditary	B
coproporphyria	I
(	O
HC	B
)	O
is	O
an	O
acute	O
hepatic	B
porphyria	I
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
deficient	B
activity	I
of	I
coproporphyrinogen	I
III	I
oxidase	I
(	O
CPO	O
)	O
.	O

Clinical	O
of	O
the	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B
precipitated	O
by	O
drugs	O
,	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
infectious	B
diseases	I
.	O

Clinical	O
of	O
the	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B
dysfunction	I
precipitated	O
by	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O

Clinical	O
manifestations	O
of	O
the	O
ofttimes	O
precipitate	O
past	O
drug	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B
dysfunction	I
often	O
precipitated	O
by	O
drugs	O
,	O
operating	O
theatre	O
infective	O
disease	O
disfunction	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	B
infectious	I
diseases	O

cyclical	O
manifestations	O
of	O
fasting	O
disease	O
are	O
characterized	O
infectious	O
,	O
attacks	O
,	O
neurological	B
dysfunction	I
often	O
changes	O
by	O
drugs	O
,	O
the	O
or	O
of	O
hormonal	O
precipitated	O
acute	O
Clinical	O
by	B
diseases	I
.	O

diseases	O
manifestations	O
of	O
precipitated	O
disease	O
are	O
infectious	O
by	O
the	O
attacks	O
of	O
neurological	B
often	I
cyclical	O
or	O
acute	O
drugs	O
,	O
fasting	O
,	O
dysfunction	O
hormonal	O
changes	O
,	O
by	O
characterized	B
Clinical	I
.	O

Clinical	O
manifestations	O
of	O
the	O
ofttimes	O
precipitate	O
past	O
drug	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B
dysfunction	I
often	O
precipitated	O
by	O
drugs	O
,	O
operating	O
theatre	O
infective	O
disease	O
penetrative	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	B
infectious	I
diseases	O

clinical	O
reflection	O
of	O
the	O
disease	O
are	O
qualify	O
by	O
acuate	O
approach	O
of	O
neurological	B
disfunction	I
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
deepen	O
,	O
or	O
infective	B
diseases	I
.	O

Clinical	O
manifestations	O
of	O
the	O
ofttimes	O
precipitate	O
past	O
drug	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B
dysfunction	I
often	O
precipitated	O
by	O
drugs	O
,	O
operating	O
theatre	O
infective	O
disease	O
penetrative	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	B
infectious	I
diseases	O

,	O
manifestations	O
of	O
the	O
disease	O
are	O
often	O
neurological	O
acute	O
attacks	O
of	O
drugs	B
hormonal	I
characterized	O
or	O
Clinical	O
by	O
by	O
fasting	O
,	O
cyclical	O
dysfunction	O
changes	O
,	O
precipitated	O
infectious	B
diseases	I
.	O

clinical	O
materialization	O
of	O
the	O
disease	O
are	O
characterise	O
by	O
acuate	O
attacks	O
of	O
neurological	B
disfunction	I
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O
infective	B
diseases	I
.	O

Clinical	O
manifestations	O
of	O
the	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B
dysfunction	I
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O
infectious	B
diseases	I
.	O

may	O
photosensitivity	O
Skin	O
.	O
be	O
present	O
also	O

Skin	O
radiosensitivity	O
may	O
also	O
be	O
acquaint	O
.	O

Skin	O
radiosensitivity	O
photosensitivity	O
may	O
also	O
crataegus	O
oxycantha	O
be	O
present	O

Skin	O
may	O
be	O
.	O

also	O
Skin	O
may	O
photosensitivity	O
be	O
present	O
.	O

scramble	O
radiosensitivity	O
may	O
also	O
be	O
present	O
.	O

Skin	O
radiosensitivity	O
may	O
likewise	O
be	O
present	O
.	O

Skin	O
photosensitivity	O
may	O
.	O
be	O
also	O
present	O

Skin	O
photosensitivity	O
may	O
also	O
be	O
.	O

Skin	O
radiosensitivity	O
photosensitivity	O
may	O
also	O
crataegus	O
oxycantha	O
be	O
present	O

Skin	O
photosensitivity	O
may	O
also	O
be	O
present	O
.	O

,	O
exon	O
exons	O
,	O
the	O
exon	O
followed	O
the	O
boundaries	O
and	O
part	O
of	O
3	O
Holland	O
,	O
of	O
intron	O
patients	O
gene	O
were	O
Czech	O
analyzed	O
by	O
an	O
-	O
-	O
by	O
in	O
heterozygous	O
denaturing	O
exon	O
/	O
electrophoresis	O
(	O
DGGE	O
)	O
strategy	O
France	O
gel	O
direct	O
sequencing	O
systematically	O
seven	O
unrelated	O
gradient	O
HC	B
CPO	O
from	O
by	O
The	O
noncoding	O
sequence	O
and	O
seven	O
Republic	O
.	O

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundary	O
past	O
theatrical	O
role	O
coding	O
dna	O
denature	O
slope	O
colloidal	O
gel	O
boundary	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
gene	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
indium	O
french	O
republic	O
patient	O
the	O
netherlands	O
french	O
republic	O
patient	O
czechoslovakian	O
noncoding	O
dna	O
strategy	O
followed	O
by	B
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	O
patients	O
from	O
France	O

The	O
seven	O
exons	O
the	O
/	O
intron	O
boundaries	O
of	O
the	O
CPO	O
gene	O
systematically	O
analyzed	O
an	O
exon	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
DGGE	O
strategy	O
followed	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	B
from	O
France	O
,	O
Holland	O
,	O

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundary	O
past	O
theatrical	O
role	O
coding	O
dna	O
denature	O
slope	O
colloidal	O
gel	O
boundary	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
gene	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
indium	O
french	O
republic	O
patient	O
the	O
netherlands	O
french	O
republic	O
patient	O
czechoslovakian	O
noncoding	O
dna	O
strategy	O
followed	O
by	B
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	O
patients	O
from	O
France	O

seven	O
the	O
/	O
intron	O
boundaries	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
-	O
exon	O
gel	O
electrophoresis	O
(	O
)	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
,	O
,	O
and	O
Republic	O

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
bounds	O
and	O
part	O
of	O
triad	O
noncoding	O
successiveness	O
of	O
the	O
CPO	O
factor	O
were	O
consistently	O
examine	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
slope	O
mousse	O
ionophoresis	O
(	O
DGGE	O
)	O
scheme	O
followed	O
by	O
organise	O
sequence	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	B
patients	O
from	O
france	O
,	O
holland	O
,	O
and	O
czechoslovakian	O
democracy	O
.	O

The	O
seven	O
Czech	O
,	O
the	O
exon	O
/	O
gene	O
boundaries	O
and	O
part	O
3	O
seven	O
noncoding	O
sequence	O
gradient	O
the	O
CPO	O
were	O
intron	O
systematically	O
from	O
by	O
)	O
exon	O
by	O
gel	O
electrophoresis	O
exon	O
denaturing	O
of	O
followed	O
Republic	O
(	O
DGGE	O
an	O
strategy	O
-	O
by	O
direct	O
sequencing	O
in	O
of	O
unrelated	O
heterozygous	O
patients	B
HC	O
,	O
France	O
,	O
Holland	O
analyzed	O
and	O
-	O
exons	O
.	O

The	O
septet	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
edge	O
and	O
break	O
of	O
trinity	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
cistron	O
were	O
consistently	O
canvass	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denature	O
slope	O
gel	O
dielectrolysis	O
(	O
DGGE	O
)	O
scheme	O
followed	O
by	O
maneuver	O
sequence	O
in	O
septet	O
unrelated	O
heterozygous	O
HC	B
patients	O
from	O
France	O
,	O
Holland	O
,	O
and	O
czechoslovakian	O
commonwealth	O
.	O

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundary	O
and	O
break	O
of	O
trey	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
cistron	O
were	O
consistently	O
dissect	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denature	O
slope	O
gel	O
ionophoresis	O
(	O
DGGE	O
)	O
scheme	O
followed	O
by	O
maneuver	O
sequence	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	B
patients	O
from	O
France	O
,	O
Holland	O
,	O
and	O
czechoslovak	O
republic	O
.	O

DGGE	O
by	O
exons	O
,	O
the	O
exon	O
in	O
intron	O
boundaries	O
and	O
part	O
sequencing	O
3	O
-	O
exon	O
of	O
the	O
CPO	O
denaturing	O
were	O
systematically	O
analyzed	O
(	O
an	O
unrelated	O
-	O
patients	O
noncoding	O
France	O
gene	O
gradient	O
)	O
electrophoresis	O
sequence	O
The	O
Czech	O
strategy	O
followed	O
by	O
direct	O
of	O
/	O
seven	O
by	O
heterozygous	O
HC	B
.	O
from	O
exon	O
,	O
Holland	O
,	O
and	O
gel	O
Republic	O
seven	O

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
gene	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
strategy	O
followed	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	B
patients	O
from	O
France	O
,	O
Holland	O
,	O
and	O
Czech	O
Republic	O
.	O

Seven	O
refreshing	O
mutations	O
and	O
two	O
new	O
pleomorphism	O
were	O
observe	O
.	O

Seven	O
novel	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
detected	O
fresh	O
fresh	O
fresh	O
.	O

seven	O
fresh	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
find	O
.	O

heptad	O
novel	O
variation	O
and	O
two	O
modern	O
polymorphisms	O
were	O
detected	O
.	O

Seven	O
mutations	O
and	O
new	O
polymorphisms	O
were	O
detected	O
.	O

were	O
.	O
mutations	O
two	O
and	O
new	O
polymorphisms	O
Seven	O
detected	O
novel	O

Seven	O
were	O
mutations	O
and	O
novel	O
new	O
two	O
polymorphisms	O
detected	O
.	O

were	O
and	O
mutations	O
novel	O
two	O
new	O
.	O
Seven	O
detected	O
polymorphisms	O

Seven	O
and	O
two	O
new	O
were	O

Seven	O
novel	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
detected	O
fresh	O
fresh	O
fresh	O
.	O

Seven	O
novel	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
detected	O
.	O

Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
omission	O
international	O
ampere	O
produce	O
ampere	O
young	O
remove	O
ampere	O
genus	O
glycine	O
atomic	O
number	O
	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
cost	O
cost	O
produce	O
internet	O
site	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	O
15c	O
-	O
-	O
>	O
g	O
)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site	O
skip	O

390	O
662de14bp	O
mutations	O
two	O
are	O
missense	O
these	O
G197W	O
,	O
W427R	O
)	O
a	O
two	O
(	O
are	O
(	O
Q306X	O
,	O
.	O
)	O
,	O
two	O
)	O
small	O
acceptor	O
(	O
position	O
15c	O
glycine	O
nonsense	O
a	O
1168del3bp	O
at	O
splicing	O
Among	O
Q385X	O
,	O
and	O
one	O
is	O
,	O
(	O
mutation	O
are	O
IVS1	O
-	O
;	O
-	O
removing	O
>	O
g	O
)	O
which	O
site	O
a	O
new	O
deletions	O
splice	O
creates	O
-	O

these	O
two	O
are	O
missense	O
,	O
are	O
nonsense	O
(	O
,	O
Q385X	O
,	O
two	O
are	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
glycine	O
position	O
390	O
)	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
IVS1	O
-	O
15c	O
-	O
-	O
a	O
splice	O
.	O

Among	O
these	O
creates	O
two	O
are	O
missense	O
(	O
Q385X	O
,	O
W427R	O
)	O
site	O
)	O
are	O
nonsense	O
a	O
Q306X	O
,	O
and	O
two	O
,	O
-	O
are	O
small	O
deletions	O
662de14bp	O
G197W	O
.	O
1168del3bp	O
removing	O
(	O
acceptor	O
a	O
position	O
390	O
)	O
,	O
(	O
one	O
is	O
a	O
splicing	O
,	O
(	O
IVS1	O
at	O
splice	O
)	O
-	O
>	O
g	O
two	O
which	O
-	O
mutations	O
15c	O
glycine	O
new	O
mutation	O
;	O

Among	O
these	O
mutations	O
two	O
missense	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
and	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	O
15c	O
-	O
>	O
g	O
)	O
which	O
creates	O
a	O
splice	O
site	O
.	O

Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
omission	O
international	O
ampere	O
produce	O
ampere	O
young	O
remove	O
ampere	O
genus	O
glycine	O
atomic	O
number	O
	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
cost	O
cost	O
produce	O
ampere	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	O
15c	O
-	O
-	O
>	O
g	O
)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site	O
skip	O
skip	O

Among	O
these	O
mutations	O
deuce	O
are	O
missense	O
(	O
G197W	O
,	O
W427R	O
)	O
,	O
deuce	O
are	O
frill	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
deuce	O
are	O
humble	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
set	O
390	O
)	O
,	O
and	O
i	O
is	O
a	O
tie	O
mutation	O
(	O
IVS1	O
-	O
15c	O
-	O
-	O
>	O
g	O
)	O
which	O
make	O
a	O
raw	O
acceptor	O
tie	O
locate	O
.	O

IVS1	O
,	O
mutations	O
two	O
-	O
missense	O
these	O
Q306X	O
,	O
W427R	O
)	O
,	O
two	O
g	O
and	O
(	O
G197W	O
a	O
Q385X	O
)	O
splice	O
two	O
are	O
small	O
creates	O
(	O
662de14bp	O
one	O
,	O
removing	O
1168del3bp	O
(	O
at	O
position	O
390	O
)	O
,	O
nonsense	O
;	O
is	O
a	O
deletions	O
mutation	O
(	O
Among	O
-	O
a	O
-	O
>	O
glycine	O
are	O
15c	O
which	O
splicing	O
)	O
new	O
acceptor	O
are	O
site	O
.	O

Among	O
these	O
variation	O
deuce	O
are	O
missense	O
(	O
G197W	O
,	O
W427R	O
)	O
,	O
deuce	O
are	O
bunk	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
deuce	O
are	O
low	O
omission	O
(	O
662de14bp	O
;	O
1168del3bp	O
take	O
a	O
glycine	O
at	O
lay	O
390	O
)	O
,	O
and	O
single	O
is	O
a	O
marry	O
sport	O
(	O
IVS1	O
-	O
15c	O
-	O
-	O
>	O
g	O
)	O
which	O
make	O
a	O
new	O
acceptor	O
marry	O
place	O
.	O

Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
omission	O
international	O
ampere	O
produce	O
ampere	O
young	O
remove	O
ampere	O
genus	O
glycine	O
atomic	O
number	O
	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
cost	O
cost	O
produce	O
ampere	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	O
15c	O
-	O
-	O
>	O
g	O
)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site	O
skip	O
skip	O

Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	O
15c	O
-	O
-	O
>	O
g	O
)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site	O
.	O

The	O
pathological	O
a	O
of	O
the	O
and	O
mutations	O
their	O
,	O
W427R	O
,	O
expression	O
system	O
in	O
-	O
-	O
deletion	O
390delGly	O
assessed	O
were	O
by	O
G197W	O
respective	O
point	O
in	O
prokaryotic	O
significance	O
mutagenesis	O
using	O
site	O
frame	O
the	O
directed	O
.	O

The	O
of	O
the	O
point	O
mutations	O
,	O
W427R	O
the	O
in	O
frame	O
deletion	O
by	O
respective	O
expression	O
in	O
prokaryotic	O
system	O
using	O
-	O
directed	O
mutagenesis	O
.	O

The	O
pathological	O
significance	O
of	O
luff	O
build	O
diseased	O
the	O
point	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	O
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
point	O
point	O
point	O
point	O
point	O
point	O
indium	O
.	O

The	O
pathological	O
significance	O
of	O
luff	O
build	O
omission	O
the	O
point	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	O
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
point	O
point	O
point	O
point	O
point	O
point	O
indium	O
.	O

pathological	O
were	O
significance	O
of	O
the	O
point	O
prokaryotic	O
G197W	O
,	O
W427R	O
,	O
system	O
the	O
in	O
site	O
frame	O
deletion	O
390delGly	O
and	O
assessed	O
by	O
their	O
.	O
expression	O
in	O
a	O
mutations	O
The	O
directed	O
respective	O
-	O
using	O
mutagenesis	O
-	O

The	O
pathological	O
significance	O
of	O
the	O
point	O
,	O
W427R	O
,	O
and	O
in	O
-	O
frame	O
deletion	O
390delGly	O
assessed	O
by	O
their	O
respective	O
in	O
a	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
.	O

The	O
morbid	O
significance	O
of	O
the	O
designate	O
variation	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
cut	O
390delGly	O
were	O
measure	O
by	O
their	O
several	O
face	O
in	O
a	O
procaryotic	O
system	O
use	O
site	O
-	O
conduct	O
mutagenesis	O
.	O

The	O
morbid	O
import	O
of	O
the	O
aim	O
sport	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
flesh	O
omission	O
390delGly	O
were	O
evaluate	O
by	O
their	O
respective	O
reflection	O
in	O
a	O
procaryotic	O
system	O
exploitation	O
site	O
-	O
directed	O
mutagenesis	O
.	O

The	O
pathological	O
significance	O
of	O
luff	O
build	O
omission	O
the	O
point	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	O
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
point	O
point	O
point	O
point	O
point	O
point	O
indium	O
.	O

The	O
diseased	O
significance	O
of	O
the	O
target	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
bod	O
cut	O
390delGly	O
were	O
value	O
by	O
their	O
respective	O
formula	O
in	O
a	O
procaryotic	O
arrangement	O
utilise	O
situation	O
-	O
directed	O
mutagenesis	O
.	O

The	O
pathological	O
significance	O
of	O
the	O
point	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	O
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
.	O

These	O
resulted	O
the	O
or	O
a	O
dramatic	O
decrease	O
of	O
CPO	O
activity	O
.	O

These	O
sport	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
striking	O
lessen	O
of	O
CPO	O
activity	O
.	O

a	O
in	O
resulted	O
mutations	O
the	O
absence	O
decrease	O
These	O
dramatic	O
.	O
of	O
CPO	O
activity	O
or	O

These	O
mutations	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
decrease	O
of	O
activity	O
.	O

These	O
mutations	O
ampere	O
lead	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
action	O
sport	O
decrease	O
of	O
CPO	O
activity	O
.	O

These	O
mutations	O
ampere	O
lead	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
action	O
operating	O
theatre	O
decrease	O
of	O
CPO	O
activity	O

These	O
mutations	O
lead	O
in	O
the	O
absence	O
or	O
a	O
striking	O
minify	O
of	O
CPO	O
activity	O
.	O

activity	O
mutations	O
resulted	O
These	O
a	O
absence	O
or	O
CPO	O
dramatic	O
decrease	O
of	O
the	O
in	O
.	O

These	O
mutations	O
ampere	O
lead	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
action	O
sport	O
decrease	O
of	O
CPO	O
activity	O
.	O

These	O
mutations	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
spectacular	O
decrement	O
of	O
CPO	O
activeness	O
.	O

These	O
mutations	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
decrease	O
of	O
CPO	O
activity	O
.	O

The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
gene	O
1	O
)	O
a	O
C	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
,	O
142	O
bp	O
upstream	O
from	O
the	O
transcriptional	O
initiation	O
site	O
(	O
-	O
142C	O
/	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
6	O
bp	O
deletion	O
polymorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
gene	O
,	O
574	O
bp	O
downstream	O
of	O
the	O
last	O
base	O
of	O
the	O
normal	O
termination	O
codon	O
(	O
+	O
574	O
delATTCTT	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
)	O
.	O

The	O
two	O
were	O
localized	O
part	O
of	O
the	O
1	O
C	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
upstream	O
the	O
transcriptional	O
site	O
142C	O
/	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
6	O
in	O
the	O
noncoding	O
part	O
of	O
the	O
gene	O
574	O
the	O
base	O
of	O
the	O
termination	O
codon	O
+	O
574	O
)	O
.	O

The	O
initiation	O
polymorphisms	O
the	O
last	O
2	O
noncoding	O
part	O
of	O
the	O
gene	O
the	O
)	O
promotor	O
C	O
,	O
G	O
polymorphism	O
in	O
the	O
a	O
part	O
CPO	O
142	O
and	O
+	O
from	O
the	O
transcriptional	O
in	O
site	O
of	O
-	O
142C	O
/	O
G	O
of	O
/	O
bp	O
in	O
)	O
a	O
the	O
bp	O
deletion	O
polymorphism	O
574	O
base	O
3	O
noncoding	O
region	O
(	O
the	O
,	O
6	O
,	O
normal	O
bp	O
downstream	O
of	O
were	O
localized	O
1	O
)	O
termination	O
574	O
gene	O
codon	O
(	O
upstream	O
two	O
delATTCTT	O
)	O
.	O

The	O
deuce	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
factor	O
i	O
)	O
a	O
C	O
/	O
g	O
pleomorphism	O
in	O
the	O
promotor	O
neighborhood	O
,	O
142	O
bp	O
upriver	O
from	O
the	O
transcriptional	O
induction	O
locate	O
(	O
-	O
142C	O
/	O
g	O
)	O
,	O
and	O
2	O
)	O
a	O
sextuplet	O
bp	O
cut	O
pleomorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
factor	O
,	O
574	O
bp	O
downriver	O
of	O
the	O
go	O
meanspirited	O
of	O
the	O
formula	O
expiry	O
codon	O
(	O
+	O
574	O
delATTCTT	O
)	O
.	O

The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
gene	O
1	O
)	O
a	O
C	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
,	O
142	O
bp	O
upstream	O
from	O
the	O
transcriptional	O
initiation	O
site	O
(	O
-	O
142C	O
/	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
6	O
bp	O
deletion	O
polymorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
gene	O
,	O
574	O
bp	O
downstream	O
of	O
the	O
last	O
base	O
of	O
the	O
normal	O
termination	O
codon	O
(	O
+	O
574	O
delATTCTT	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
)	O
.	O

The	O
two	O
polymorphisms	O
in	O
gene	O
1	O
)	O
C	O
/	O
polymorphism	O
in	O
the	O
,	O
142	O
bp	O
upstream	O
from	O
transcriptional	O
site	O
(	O
-	O
142C	O
/	O
G	O
)	O
,	O
and	O
2	O
a	O
6	O
bp	O
deletion	O
polymorphism	O
of	O
gene	O
574	O
bp	O
downstream	O
the	O
last	O
base	O
of	O
the	O
normal	O
+	O
574	O
delATTCTT	O
)	O
.	O

,	O
+	O
,	O
gene	O
localized	O
in	O
noncoding	O
part	O
-	O
the	O
gene	O
1	O
142	O
initiation	O
C	O
of	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
,	O
base	O
bp	O
upstream	O
3	O
from	O
downstream	O
deletion	O
site	O
(	O
of	O
142C	O
the	O
G	O
)	O
)	O
and	O
2	O
noncoding	O
a	O
6	O
bp	O
574	O
polymorphism	O
in	O
the	O
the	O
were	O
part	O
of	O
the	O
delATTCTT	O
polymorphisms	O
The	O
/	O
/	O
codon	O
of	O
bp	O
last	O
)	O
574	O
the	O
normal	O
termination	O
transcriptional	O
(	O
two	O
a	O
CPO	O
)	O
.	O

The	O
deuce	O
pleomorphism	O
were	O
focalize	O
in	O
noncoding	O
part	O
of	O
the	O
factor	O
unity	O
)	O
a	O
c	O
/	O
g	O
pleomorphism	O
in	O
the	O
promotor	O
realm	O
,	O
142	O
bp	O
upriver	O
from	O
the	O
transcriptional	O
foundation	O
site	O
(	O
-	O
142C	O
/	O
g	O
)	O
,	O
and	O
deuce	O
)	O
a	O
6	O
bp	O
excision	O
pleomorphism	O
in	O
the	O
troika	O
noncoding	O
part	O
of	O
the	O
CPO	O
factor	O
,	O
574	O
bp	O
downriver	O
of	O
the	O
finale	O
groundwork	O
of	O
the	O
pattern	O
conclusion	O
codon	O
(	O
+	O
574	O
delATTCTT	O
)	O
.	O

(	O
two	O
polymorphisms	O
polymorphism	O
-	O
in	O
noncoding	O
last	O
of	O
gene	O
the	O
142	O
)	O
a	O
C	O
/	O
of	O
polymorphism	O
in	O
the	O
promotor	O
region	O
initiation	O
upstream	O
bp	O
/	O
gene	O
the	O
transcriptional	O
,	O
site	O
(	O
localized	O
142C	O
574	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
+	O
bp	O
CPO	O
base	O
)	O
the	O
3	O
The	O
part	O
normal	O
the	O
.	O
from	O
,	O
574	O
bp	O
were	O
of	O
the	O
part	O
downstream	O
of	O
the	O
G	O
delATTCTT	O
codon	O
noncoding	O
6	O
1	O
termination	O
in	O
deletion	O

The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
of	O
gene	O
1	O
)	O
a	O
C	O
/	O
polymorphism	O
in	O
the	O
region	O
,	O
142	O
bp	O
upstream	O
from	O
site	O
(	O
142C	O
G	O
)	O
and	O
a	O
6	O
bp	O
in	O
the	O
part	O
of	O
CPO	O
gene	O
bp	O
downstream	O
of	O
the	O
base	O
of	O
the	O
normal	O
+	O
574	O
delATTCTT	O
)	O
.	O

The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
gene	O
1	O
)	O
a	O
C	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
,	O
142	O
bp	O
upstream	O
from	O
the	O
transcriptional	O
initiation	O
site	O
(	O
-	O
142C	O
/	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
6	O
bp	O
deletion	O
polymorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
gene	O
,	O
574	O
bp	O
downstream	O
of	O
the	O
last	O
base	O
of	O
the	O
normal	O
termination	O
codon	O
(	O
+	O
574	O
delATTCTT	O
)	O
.	O

Five	O
intragenic	O
defects	O
are	O
now	O
well	O
of	O
with	O
the	O
high	O
degree	O
of	O
seven	O
heterogeneity	O
in	O
nineteen	B
is	O
demonstrated	O
reported	O
allelic	O
new	O
so	O
mutations	O
making	O
a	O
HC	O
characterized	O
different	O
CPO	O
gene	B
dimorphisms	I
and	O
total	O
far	O
.	O
.	O

intragenic	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
allelic	O
heterogeneity	O
in	O
HC	B
is	O
demonstrated	O
with	O
different	O
mutations	O
making	O
total	O
nineteen	O
CPO	O
gene	B
so	O

quintuplet	O
intragenic	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelomorphic	O
heterogeneousness	O
in	O
HC	B
is	O
exhibit	O
with	O
seven	O
new	O
dissimilar	O
mutations	O
attain	O
a	O
tally	O
of	O
xix	O
CPO	O
gene	B
defects	I
cover	O
so	O
alir	O
.	O
.	O

nineteen	O
new	O
dimorphisms	O
are	O
is	O
well	O
in	O
reported	O
the	O
high	O
degree	O
of	O
allelic	O
a	O
and	O
HC	B
now	O
defects	O
with	O
seven	O
heterogeneity	O
different	O
mutations	O
making	O
intragenic	O
total	O
of	O
Five	O
demonstrated	O
gene	B
CPO	I
characterized	O
so	O
far	O
.	O
.	O

Five	O
intragenic	O
dimorphisms	O
are	O
immediately	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	B
is	O
demonstrated	O
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
CPO	O
gene	B
defects	I
reported	O
so	O
far	O
.	O
at	O
once	O
at	O
once	O
at	O
once	O
at	O
once	O
at	O
once	O

a	O
with	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
nineteen	O
gene	O
HC	B
is	O
demonstrated	O
far	O
seven	O
new	O
different	O
CPO	O
making	O
Five	O
total	O
reported	O
heterogeneity	O
in	O
mutations	B
defects	I
.	O
so	O
.	O
intragenic	O
of	O

Five	O
intragenic	O
dimorphisms	O
are	O
well	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	B
is	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
CPO	O
gene	B
defects	I
reported	O
so	O
far	O
.	O
.	O

Five	O
intragenic	O
dimorphisms	O
are	O
now	O
fountainhead	O
characterise	O
and	O
the	O
high	O
degree	O
of	O
allelomorphic	O
heterogeneousness	O
in	O
HC	B
is	O
demonstrated	O
with	O
vii	O
new	O
dissimilar	O
mutations	O
making	O
a	O
total	O
of	O
xix	O
CPO	O
factor	B
blemish	I
reported	O
so	O
alir	O
.	O
.	O

Five	O
intragenic	O
dimorphisms	O
are	O
tot	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	B
is	O
demonstrated	O
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
CPO	O
gene	B
defects	I
reported	O
so	O
far	O
.	O
add	O
together	O
add	O
together	O
add	O
together	O
add	O
together	O
add	O
together	O

fivesome	O
intragenic	O
dimorphisms	O
are	O
now	O
comfortably	O
characterized	O
and	O
the	O
high	O
point	O
of	O
allelomorphic	O
heterogeneity	O
in	O
HC	B
is	O
show	O
with	O
heptad	O
new	O
dissimilar	O
mutations	O
hit	O
a	O
total	O
of	O
xix	O
CPO	O
gene	B
defects	I
cover	O
so	O
far	O
.	O
.	O

Five	O
intragenic	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	B
is	O
demonstrated	O
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
CPO	O
gene	B
defects	I
reported	O
so	O
far	O
.	O
.	O

Coincidence	O
of	O
deuce	O
fresh	O
arylsulfatase	O
a	O
allelomorph	O
and	O
sport	O
459	O
+	O
1G	O
>	O
a	O
inside	O
a	O
family	O
with	O
metachromatic	B
leukodystrophy	I
:	O
molecular	O
ground	O
of	O
phenotypic	O
heterogeneousness	O
.	O

Coincidence	O
of	O
novel	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
a	O
family	O
with	O
metachromatic	B
:	O
molecular	O
basis	O
of	O
phenotypic	O
.	O

Coincidence	O
of	O
two	O
novel	O
inside	O
ampere	O
family	O
line	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
a	O
family	O
with	O
	O
phenotypical	O
heterogeneousness	O
phenotypical	O
sport	B
metachromatic	I
leukodystrophy	O
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O

:	O
of	O
two	O
metachromatic	O
arylsulfatase	O
A	O
alleles	O
heterogeneity	O
of	O
459	O
leukodystrophy	O
1G	O
>	O
A	O
basis	O
a	O
family	O
with	O
novel	B
phenotypic	I
+	O
molecular	O
within	O
mutation	O
Coincidence	O
and	O
.	O

Coincidence	O
of	O
two	O
novel	O
inside	O
ampere	O
family	O
line	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
a	O
family	O
with	O
	O
phenotypical	O
heterogeneousness	O
phenotypical	O
sport	B
metachromatic	I
leukodystrophy	O
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O

Coincidence	O
of	O
two	O
arylsulfatase	O
A	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
family	O
with	O
leukodystrophy	I
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O
.	O

.	O
of	O
two	O
within	O
arylsulfatase	O
A	O
heterogeneity	O
and	O
novel	O
459	O
+	O
1G	O
A	O
:	O
phenotypic	O
mutation	O
family	O
with	O
metachromatic	B
leukodystrophy	I
>	O
molecular	O
basis	O
of	O
a	O
alleles	O
Coincidence	O

two	O
A	O
alleles	O
and	O
459	O
+	O
>	O
A	O
within	O
a	O
family	O
with	O
metachromatic	B
leukodystrophy	I
:	O
molecular	O
basis	O
of	O
phenotypic	O

of	O
of	O
two	O
novel	O
arylsulfatase	O
A	O
A	O
1G	O
mutation	O
459	O
+	O
family	O
molecular	O
alleles	O
phenotypic	O
Coincidence	O
and	O
a	O
metachromatic	B
leukodystrophy	I
:	O
>	O
basis	O
with	O
within	O
heterogeneity	O
.	O

conjunction	O
of	O
deuce	O
new	O
arylsulfatase	O
A	O
alleles	O
and	O
variation	O
459	O
+	O
1G	O
>	O
A	O
inside	O
a	O
menage	O
with	O
metachromatic	B
leukodystrophy	I
:	O
molecular	O
ground	O
of	O
phenotypic	O
heterogeneousness	O
.	O

Coincidence	O
of	O
two	O
novel	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
a	O
family	O
with	O
metachromatic	B
leukodystrophy	I
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O
.	O

In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
,	O
fatal	O
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
	O
excreting	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
GS	O
)	O
excretion	O
.	O

In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
,	O
fatal	O
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
	O
excreting	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
GS	O
)	O
excretion	O
.	O

In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
,	O
fatal	O
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
	O
excreting	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
GS	O
)	O
excretion	O
.	O

with	O
fatal	O
family	O
with	O
three	O
siblings	O
infantile	O
increased	O
developed	O
classical	O
late	O
,	O
metachromatic	B
A	I
ARSA	O
MLD	B
)	O
,	O
one	O
at	O
age	O
and	O
(	O
,	O
In	O
deficient	O
activity	O
leukodystrophy	O
(	O
years	O
)	O
(	O
5	O
a	O
galactosylsulfatide	O
arylsulfatase	O
GS	O
)	O
excretion	O
.	O

In	O
a	O
family	O
with	O
one	O
developed	O
classical	O
late	O
infantile	O
leukodystrophy	I
(	O
fatal	O
5	O
years	O
deficient	O
(	O
ARSA	O
)	O
activity	O
increased	O
galactosylsulfatide	O
)	O
excretion	O

inch	O
a	O
kin	O
with	O
three	O
siblings	O
,	O
unmatched	O
get	O
hellenic	O
tardily	O
childish	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
,	O
disastrous	O
at	O
age	O
quint	O
years	O
,	O
with	O
lacking	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
thousand	O
)	O
evacuation	O
.	O

inwards	O
a	O
kin	O
with	O
leash	O
siblings	O
,	O
one	O
originate	O
classical	O
late	O
childish	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
,	O
fateful	O
at	O
eld	O
fin	O
twelvemonth	O
,	O
with	O
wanting	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
GS	O
)	O
excretion	O
.	O

)	O
galactosylsulfatide	O
family	O
with	O
)	O
siblings	O
)	O
activity	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B
with	I
,	O
MLD	B
three	O
(	O
fatal	O
at	O
leukodystrophy	O
5	O
years	O
,	O
a	O
deficient	O
arylsulfatase	O
excretion	O
In	O
ARSA	O
(	O
,	O
and	O
increased	O
age	O
(	O
GS	O
one	O
A	O
.	O

in	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
educate	O
definitive	O
late	O
childish	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
,	O
calamitous	O
at	O
age	O
fin	O
geezerhood	O
,	O
with	O
insufficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
GS	O
)	O
excreting	O
.	O

In	O
a	O
)	O
with	O
three	O
(	O
late	O
one	O
developed	O
classical	O
,	O
arylsulfatase	O
at	B
leukodystrophy	I
(	O
fatal	B
)	O
,	O
)	O
metachromatic	O
age	O
5	O
years	O
siblings	O
with	O
MLD	O
infantile	O
and	O
activity	O
ARSA	O
family	O
A	O
(	O
increased	O
galactosylsulfatide	O
,	O
GS	O
deficient	O
excretion	O
.	O

In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
,	O
fatal	O
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
GS	O
)	O
excretion	O
.	O

The	O
two	O
other	O
siblings	O
,	O
plainly	O
healthy	O
at	O
dozen	O
(	O
ace	O
/	O
ii	O
)	O
and	O
15	O
years	O
,	O
severally	O
,	O
and	O
their	O
beginner	O
,	O
plainly	O
healthy	O
as	O
advantageously	O
,	O
introduce	O
ARSA	O
and	O
GS	O
measure	O
inside	O
the	O
compass	O
of	O
MLD	B
patients	O
.	O

The	O
two	O
other	O
siblings	O
,	O
seemingly	O
goodly	O
at	O
xii	O
(	O
single	O
/	O
2	O
)	O
and	O
fifteen	O
geezerhood	O
,	O
severally	O
,	O
and	O
their	O
begetter	O
,	O
seemingly	O
goodly	O
as	O
easily	O
,	O
presented	O
ARSA	O
and	O
thousand	O
appraise	O
inside	O
the	O
range	O
of	O
MLD	B
patients	O
.	O

The	O
,	O
healthy	O
at	O
12	O
1	O
/	O
2	O
and	O
15	O
years	O
,	O
respectively	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
and	O
values	O
within	O
the	O
of	O
MLD	B
patients	O
.	O

The	O
two	O
and	O
siblings	O
,	O
,	O
healthy	O
at	O
12	O
(	O
1	O
,	O
well	O
)	O
and	O
ARSA	O
years	O
,	O
,	O
respectively	O
and	O
their	O
father	O
the	O
apparently	O
as	O
2	O
GS	O
apparently	O
presented	O
15	O
of	O
healthy	O
values	O
within	O
/	O
range	O
other	O
MLD	B
patients	O
.	O

apparently	O
respectively	O
other	O
siblings	O
,	O
apparently	O
/	O
their	O
12	O
(	O
1	O
healthy	O
2	O
well	O
presented	O
15	O
years	O
,	O
.	O
,	O
and	O
at	O
,	O
,	O
The	O
healthy	O
and	O
)	O
and	O
father	O
ARSA	O
the	O
GS	O
two	O
within	O
as	O
range	O
of	O
MLD	B
patients	O
values	O

The	O
two	O
other	O
siblings	O
healthy	O
at	O
12	O
(	O
/	O
2	O
)	O
and	O
15	O
,	O
respectively	O
,	O
and	O
father	O
,	O
healthy	O
as	O
well	O
,	O
presented	O
ARSA	O
and	O
GS	O
within	O
the	O
of	O
MLD	B
patients	O
.	O

The	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	O
12	O
(	O
1	O
/	O
2	O
)	O
and	O
15	O
years	O
,	O
respectively	O
,	O
and	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
presented	O
ARSA	O
and	O
GS	O
values	O
within	O
the	O
yr	O
yr	O
patient	O
yr	O
yr	O
yr	O
yr	O
yr	O
yr	O
yr	O
yr	O
yr	O
range	O
of	O
MLD	B
patients	O
.	O

The	O
two	O
other	O
siblings	O
at	O
12	O
(	O
1	O
/	O
)	O
and	O
respectively	O
their	O
father	O
healthy	O
,	O
presented	O
ARSA	O
and	O
values	O
within	O
of	O
MLD	B
.	O

The	O
two	O
other	O
siblings	O
,	O
plain	O
goodish	O
at	O
twelve	O
(	O
1	O
/	O
deuce	O
)	O
and	O
fifteen	O
years	O
,	O
severally	O
,	O
and	O
their	O
father	O
,	O
plain	O
goodish	O
as	O
fountainhead	O
,	O
demonstrate	O
ARSA	O
and	O
GS	O
values	O
inside	O
the	O
range	O
of	O
MLD	B
patients	O
.	O

The	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	O
12	O
(	O
1	O
/	O
2	O
)	O
and	O
15	O
years	O
,	O
respectively	O
,	O
and	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
presented	O
ARSA	O
and	O
GS	O
values	O
within	O
the	O
yr	O
yr	O
patient	O
yr	O
yr	O
yr	O
yr	O
yr	O
yr	O
yr	O
yr	O
yr	O
range	O
of	O
MLD	B
patients	O
.	O

The	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	O
12	O
(	O
1	O
/	O
2	O
)	O
and	O
15	O
years	O
,	O
respectively	O
,	O
and	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
presented	O
ARSA	O
and	O
GS	O
values	O
within	O
the	O
range	O
of	O
MLD	B
patients	O
.	O

heterogeneity	O
screening	O
and	O
different	O
analysis	O
disclosed	O
the	O
intrafamilial	O
the	O
three	O
sequence	O
ARSA	O
being	O
mutations	O
of	O
molecular	O
basis	O
of	O
involvement	O
Mutation	O
phenotypic	O
.	O

Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
heterogeneousness	O
heterogeneousness	O
episode	O
episode	O
episode	O
episode	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
heterogeneousness	O
heterogeneousness	O
episode	O
episode	O
episode	O
episode	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

sport	O
masking	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
amour	O
of	O
trinity	O
unlike	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
phenotypic	O
heterogeneousness	O
.	O

Mutation	O
screening	O
and	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
different	O
ARSA	O
mutations	O
being	O
molecular	O
basis	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

sequence	O
the	O
involvement	O
of	O
different	O
ARSA	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

Mutation	O
sort	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
interest	O
of	O
ternary	O
unlike	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
base	O
of	O
intrafamilial	O
phenotypic	O
heterogeneousness	O
.	O

the	O
screening	O
of	O
the	O
analysis	O
disclosed	O
molecular	O
involvement	O
and	O
three	O
different	O
ARSA	O
heterogeneity	O
being	O
sequence	O
Mutation	O
basis	O
of	O
intrafamilial	O
phenotypic	O
mutations	O
.	O

Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
heterogeneousness	O
heterogeneousness	O
episode	O
episode	O
episode	O
sport	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

Mutation	O
screening	O
and	O
sequence	O
the	O
involvement	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
.	O

Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

The	O
inherited	O
his	O
mother	O
the	O
0	O
-	O
type	O
459	O
+	O
1G	O
>	O
A	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
guanine	O
nucleotide	O
7	O
in	O
1	O
(	O
7delG	O
)	O
.	O

The	O
late	O
infantile	O
patient	O
inherited	O
the	O
frequent	O
0	O
-	O
type	O
459	O
+	O
,	O
his	O
father	O
,	O
microdeletion	O
of	O
guanine	O
at	O
7	O
in	O
(	O
7delG	O
.	O

The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	O
mother	O
the	O
frequent	O
0	O
-	O
type	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
in	O
	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
exon	O
1	O
(	O
7delG	O
)	O
.	O

The	O
late	O
childish	O
patient	O
genetic	O
from	O
his	O
sire	O
the	O
shop	O
cipher	O
-	O
case	O
variation	O
459	O
+	O
1G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
new	O
,	O
bingle	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
base	O
heptad	O
in	O
exon	O
one	O
(	O
7delG	O
)	O
.	O

The	O
late	O
of	O
patient	O
inherited	O
in	O
his	O
A	O
the	O
frequent	O
0	O
,	O
,	O
mutation	O
459	O
mother	O
1G	O
>	O
1	O
type	O
and	O
at	O
his	O
from	O
a	O
+	O
-	O
from	O
basepair	O
microdeletion	O
infantile	O
single	O
guanine	O
nucleotide	O
7	O
father	O
exon	O
novel	O
(	O
7delG	O
)	O
.	O

The	O
latterly	O
childish	O
patient	O
genetic	O
from	O
his	O
beget	O
the	O
patronize	O
cypher	O
-	O
type	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
refreshing	O
,	O
unmarried	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
base	O
septenary	O
in	O
exon	O
ane	O
(	O
7delG	O
)	O
.	O

7	O
A	O
infantile	O
patient	O
inherited	O
from	O
.	O
mother	O
the	O
frequent	O
0	O
)	O
type	O
a	O
microdeletion	O
+	O
1G	O
>	O
single	O
,	O
and	O
from	O
in	O
father	O
mutation	O
novel	O
nucleotide	O
late	O
guanine	O
his	O
of	O
basepair	O
at	O
459	O
The	O
,	O
exon	O
1	O
(	O
7delG	O
-	O
his	O

The	O
late	O
infantile	O
patient	O
inherited	O
from	O
the	O
frequent	O
0	O
-	O
mutation	O
459	O
+	O
1G	O
>	O
,	O
and	O
from	O
his	O
a	O
novel	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
exon	O
1	O
7delG	O
)	O
.	O

(	O
a	O
infantile	O
patient	O
1G	O
from	O
and	O
guanine	O
the	O
frequent	O
0	O
-	O
type	O
his	O
1	O
+	O
inherited	O
of	O
A	O
,	O
mutation	O
from	O
his	O
father	O
single	O
novel	O
,	O
.	O
>	O
microdeletion	O
basepair	O
late	O
at	O
nucleotide	O
7	O
in	O
exon	O
459	O
The	O
7delG	O
)	O
mother	O

The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	O
mother	O
the	O
frequent	O
0	O
-	O
type	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
in	O
	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
genetic	O
indium	O
exon	O
1	O
(	O
7delG	O
)	O
.	O

The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	O
mother	O
the	O
frequent	O
0	O
-	O
type	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
in	O
exon	O
1	O
(	O
7delG	O
)	O
.	O

The	O
two	O
in	O
unaffected	O
siblings	O
carried	O
the	O
paternal	O
mutation	O
459	O
+	O
cytosine	O
allele	O
A	O
and	O
maternal	O
on	O
their	O
of	O
>	O
,	O
.	O
novel	O
1G	O
to	O
,	O
at	O
8	O
nucleotide	O
2435	O
clinically	O
(	O
exon	O
,	O
resulting	O
)	O
substitution	O
thymidine	O
alanine	O
464	O
by	O
valine	O
transition	O
A464V	O
in	O
a	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
exchange	O
past	O
sib	O
sib	O
past	O
sib	O
sib	O
sib	O
sib	O
sib	O
sib	O
sib	O
sib	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
exchange	O
past	O
sib	O
sib	O
past	O
sib	O
sib	O
sib	O
sib	O
sib	O
sib	O
sib	O
allelomorph	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
459	O
+	O
1G	O
A	O
,	O
on	O
their	O
,	O
thymidine	O
transition	O
at	O
2435	O
in	O
8	O
,	O
resulting	O
of	O
alanine	O
464	O
by	O
valine	O
A464V	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
+	O
1G	O
>	O
A	O
and	O
,	O
cytosine	O
thymidine	O
transition	O
at	O
2435	O
in	O
exon	O
8	O
,	O
resulting	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O

resulting	O
paternal	O
clinically	O
unaffected	O
siblings	O
carried	O
valine	O
maternal	O
mutation	O
459	O
+	O
by	O
>	O
at	O
2435	O
,	O
on	O
their	O
,	O
allele	O
,	O
a	O
nucleotide	O
cytosine	O
A464V	O
thymidine	O
exon	O
A	O
and	O
to	O
in	O
in	O
8	O
two	O
The	O
transition	O
substitution	O
of	O
alanine	O
464	O
1G	O
the	O
(	O
novel	O
)	O
.	O

The	O
ii	O
clinically	O
unmoved	O
siblings	O
extend	O
the	O
parental	O
sport	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
parental	O
allelomorph	O
,	O
a	O
refreshing	O
cytosine	O
to	O
thymidine	O
modulation	O
at	O
base	O
2435	O
in	O
exon	O
8	O
,	O
lead	O
in	O
transposition	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
two	O
clinically	O
insensible	O
siblings	O
stockpile	O
the	O
enate	O
variation	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
agnate	O
allelomorph	O
,	O
a	O
fresh	O
cytosine	O
to	O
thymidine	O
passage	O
at	O
base	O
2435	O
in	O
exon	O
8	O
,	O
leave	O
in	O
permutation	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
deuce	O
clinically	O
untouched	O
siblings	O
sway	O
the	O
enatic	O
mutant	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
agnate	O
allelomorph	O
,	O
a	O
refreshing	O
cytosine	O
to	O
thymidine	O
passage	O
at	O
base	O
2435	O
in	O
exon	O
viii	O
,	O
leave	O
in	O
transposition	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
exchange	O
past	O
sib	O
sib	O
past	O
sib	O
sib	O
sib	O
sib	O
sib	O
sib	O
sib	O
sib	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
genotype	O
thus	O
7delG	O
A464V	O

The	O
fathers	O
genotype	O
olibanum	O
was	O
7delG	O
/	O
A464V	O
.	O

The	O
beginner	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
A464V	O
therefore	O
.	O

The	O
beginner	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
A464V	O
therefore	O
.	O

The	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
.	O

The	O
thus	O
genotype	O
fathers	O
was	O
7delG	O
A464V	O
/	O
.	O

/	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
A464V	O
The	O
.	O

The	O
A464V	O
genotype	O
thus	O
fathers	O
7delG	O
/	O
was	O
.	O

The	O
fathers	O
genotype	O
hence	O
was	O
7delG	O
/	O
A464V	O
.	O

The	O
beginner	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
A464V	O
therefore	O
.	O

The	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
A464V	O
.	O

Mutation	O
was	O
found	O
18	O
unrelated	O
MLD	B
patients	O
and	O
50	O
controls	O
.	O

mutation	O
A464V	O
was	O
not	O
bump	O
in	O
18	O
unrelated	O
MLD	B
patients	O
and	O
l	O
restraint	O
.	O

unrelated	O
not	O
was	O
A464V	O
found	O
in	O
patients	O
Mutation	O
MLD	B
.	O
and	O
50	O
controls	O
18	O

Mutation	O
A464V	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
patients	O
and	O
controls	O
.	O

Mutation	O
A464V	O
cost	O
cost	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	B
check	O
receive	O
patients	O
and	O
50	O
controls	O
.	O

Mutation	O
A464V	O
cost	O
cost	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	B
check	O
receive	O
patients	O
and	O
50	O
controls	O
.	O

Mutation	O
A464V	O
was	O
not	O
establish	O
in	O
xviii	O
unrelated	O
MLD	B
patients	O
and	O
50	O
controls	O
.	O

controls	O
A464V	O
was	O
Mutation	O
unrelated	O
in	O
18	O
50	O
MLD	B
patients	O
and	O
found	O
not	O
.	O

Mutation	O
A464V	O
cost	O
cost	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	B
check	O
receive	O
patients	O
and	O
50	O
controls	O
.	O

variation	O
A464V	O
was	O
not	O
notice	O
in	O
xviii	O
unrelated	O
MLD	B
patients	O
and	O
l	O
controls	O
.	O

Mutation	O
A464V	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	B
patients	O
and	O
50	O
controls	O
.	O

A464V	O
,	O
although	O
distinctly	O
modifying	O
ARSA	O
and	O
gigabyte	O
grade	O
,	O
apparently	O
deliver	O
short	O
import	O
for	O
clinical	O
manifestation	O
of	O
MLD	B
,	O
mimicking	O
the	O
shop	O
ARSA	O
pseudodeficiency	O
allelomorph	O
.	O

A464V	O
,	O
clearly	O
modifying	O
ARSA	O
and	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
clinical	O
manifestation	O
of	O
MLD	B
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O
.	O

A464V	O
,	O
although	O
clearly	O
assume	O
allelomorph	O
alter	O
modifying	O
ARSA	O
and	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
mime	O
haunt	O
allelomorph	O
horizontal	O
surface	O
horizontal	B
surface	O
MLD	O
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O

mimicking	O
,	O
although	O
MLD	O
modifying	O
ARSA	O
and	O
allele	O
ARSA	O
,	O
,	O
bears	O
little	O
significance	O
frequent	O
clinical	O
manifestation	O
of	O
clearly	B
pseudodeficiency	O
apparently	O
the	O
for	O
levels	O
A464V	O
GS	O
.	O

A464V	O
,	O
although	O
clearly	O
assume	O
allelomorph	O
alter	O
modifying	O
ARSA	O
and	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
mime	O
haunt	O
allelomorph	O
horizontal	O
surface	O
horizontal	B
surface	O
MLD	O
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O

A464V	O
,	O
although	O
modifying	O
ARSA	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
manifestation	O
of	O
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O
allele	O
.	O

.	O
,	O
although	O
for	O
modifying	O
ARSA	O
allele	O
GS	O
clearly	O
,	O
apparently	O
bears	O
significance	O
mimicking	O
pseudodeficiency	O
levels	O
manifestation	O
of	O
MLD	B
,	O
little	O
the	O
frequent	O
ARSA	O
clinical	O
and	O
A464V	O

although	O
ARSA	O
and	O
GS	O
,	O
apparently	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
MLD	B
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O

ARSA	O
,	O
although	O
clearly	O
modifying	O
ARSA	O
significance	O
bears	O
levels	O
,	O
apparently	O
manifestation	O
the	O
and	O
pseudodeficiency	O
A464V	O
GS	O
clinical	O
MLD	B
,	O
mimicking	O
little	O
frequent	O
of	O
for	O
allele	O
.	O

A464V	O
,	O
although	O
clearly	O
alter	O
ARSA	O
and	O
GS	O
layer	O
,	O
plain	O
bears	O
footling	O
meaning	O
for	O
clinical	O
demonstration	O
of	O
MLD	B
,	O
mimicking	O
the	O
patronise	O
ARSA	O
pseudodeficiency	O
allelomorph	O
.	O

A464V	O
,	O
although	O
clearly	O
modifying	O
ARSA	O
and	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
MLD	B
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O
allele	O
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
g	O
valuate	O
pauperism	O
indium	O
in	O
certain	O
genetic	O
conditions	O
MLD	B
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
indium	O
indium	O
indium	O
penury	O
.	O

Our	O
results	O
in	O
-	O
like	O
ARSA	O
GS	O
values	O
not	O
be	O
paralleled	O
disease	O
,	O
a	O
finding	O
with	O
diagnostic	O
prognostic	O
implications	O
.	O

Our	O
upshot	O
exhibit	O
that	O
in	O
sure	O
genetic	O
status	O
MLD	B
-	O
comparable	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
feel	O
with	O
severe	O
symptomatic	O
and	O
prognostic	O
deduction	O
.	O

Our	O
results	O
demonstrate	O
that	O
certain	O
MLD	B
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
.	O

Our	O
effect	O
march	O
that	O
in	O
sure	O
genetic	O
term	O
MLD	B
-	O
like	O
ARSA	O
and	O
gee	O
values	O
motivation	O
not	O
be	O
collimate	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
symptomatic	O
and	O
predictive	O
implications	O
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
g	O
valuate	O
pauperism	O
indium	O
in	O
certain	O
genetic	O
conditions	O
MLD	B
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
indium	O
indium	O
indium	O
penury	O
.	O

Our	O
results	O
evidence	O
that	O
in	O
sure	O
hereditary	O
shape	O
MLD	B
-	O
ilk	O
ARSA	O
and	O
GS	O
values	O
pauperization	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
determination	O
with	O
serious	O
symptomatic	O
and	O
omen	O
implications	O
.	O

clinical	O
paralleled	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	O
MLD	B
-	O
like	O
ARSA	O
and	O
finding	O
prognostic	O
need	O
not	O
be	O
diagnostic	O
by	O
results	O
disease	O
.	O
a	O
GS	O
with	O
serious	O
Our	O
values	O
,	O
implications	O
and	O

Our	O
results	O
demonstrate	O
that	O
certain	O
conditions	O
MLD	B
-	O
like	O
ARSA	O
and	O
GS	O
values	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
with	O
serious	O
diagnostic	O
prognostic	O
.	O

Our	O
results	O
demonstrate	O
that	O
invite	O
g	O
valuate	O
pauperism	O
receive	O
in	O
certain	O
genetic	O
conditions	O
MLD	B
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
call	O
for	O
call	O
for	O
call	O

Our	O
results	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	O
MLD	B
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
.	O

Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
,	O
together	O
with	O
0	O
-	O
type	O
mutations	O
,	O
may	O
cause	O
pathological	O
ARSA	O
and	O
GS	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	O
.	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
.	O

Moreover	O
,	O
further	O
functionally	O
similar	O
to	O
A464V	O
might	O
which	O
together	O
with	O
0	O
-	O
type	O
mutations	O
,	O
may	O
cause	O
pathological	O
and	O
GS	O
levels	O
,	O
but	O
disease	O

and	O
mutations	O
further	O
ARSA	O
alleles	O
functionally	O
which	O
the	O
A464V	O
might	O
exist	O
similar	O
,	O
,	O
not	O
0	O
-	O
type	O
to	O
,	O
may	O
cause	O
but	O
ARSA	O
Moreover	O
GS	O
outbreak	O
together	O
with	O
pathological	O
clinical	O
.	O
of	O
,	O
disease	O
levels	O
.	O

Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
,	O
together	O
with	O
0	O
-	O
type	O
mutations	O
,	O
may	O
cause	O
pathological	O
ARSA	O
and	O
GS	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	O
.	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
allele	O
non	O
.	O

,	O
disease	O
further	O
ARSA	O
-	O
functionally	O
with	O
outbreak	O
A464V	O
might	O
exist	O
which	O
,	O
and	O
to	O
0	O
alleles	O
clinical	O
mutations	O
,	O
together	O
cause	O
pathological	O
ARSA	O
,	O
GS	O
levels	O
Moreover	O
type	O
not	O
but	O
similar	O
of	O
the	O
may	O
.	O
.	O

furthermore	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
standardised	O
to	O
A464V	O
might	O
survive	O
which	O
,	O
unitedly	O
with	O
zero	O
-	O
character	O
mutant	O
,	O
whitethorn	O
campaign	O
pathological	O
ARSA	O
and	O
m	O
levels	O
,	O
but	O
not	O
clinical	O
eruption	O
of	O
the	O
disease	O
.	O
.	O

Moreover	O
,	O
further	O
ARSA	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
with	O
0	O
-	O
mutations	O
may	O
cause	O
pathological	O
GS	O
clinical	O
outbreak	O
of	O
disease	O
.	O

Moreover	O
,	O
clinical	O
ARSA	O
alleles	O
.	O
similar	O
to	O
A464V	O
might	O
exist	O
levels	O
,	O
together	O
with	O
,	O
-	O
type	O
outbreak	O
,	O
may	O
of	O
pathological	O
functionally	O
and	O
0	O
which	O
cause	O
GS	O
not	O
further	O
mutations	O
but	O
the	O
disease	O
ARSA	O
.	O

Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
standardised	O
to	O
A464V	O
power	O
be	O
which	O
,	O
together	O
with	O
0	O
-	O
type	O
mutant	O
,	O
whitethorn	O
stimulate	O
pathological	O
ARSA	O
and	O
grand	O
charge	O
,	O
but	O
not	O
clinical	O
irruption	O
of	O
the	O
disease	O
.	O
.	O

furthermore	O
,	O
further	O
ARSA	O
allelomorph	O
functionally	O
standardised	O
to	O
A464V	O
power	O
subsist	O
which	O
,	O
unitedly	O
with	O
nought	O
-	O
character	O
variation	O
,	O
may	O
make	O
pathological	O
ARSA	O
and	O
thou	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	O
.	O
.	O

Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
,	O
together	O
with	O
0	O
-	O
type	O
mutations	O
,	O
may	O
cause	O
pathological	O
ARSA	O
and	O
GS	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	O
.	O
.	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B
malignancy	I
and	O
neurofibromatosis	B
malignance	B
	B
type	I
1	I
.	O

MLH1	O
deficiency	O
malignancy	I
type	I
1	I
.	O

Human	O
MLH1	O
inadequacy	O
predisposes	O
to	O
hematological	B
malignance	I
and	O
neurofibromatosis	B
character	I
1	I
.	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B
malignancy	I
and	O
neurofibromatosis	B
malignance	B
	B
type	I
1	I
.	O

MLH1	O
deficiency	O
to	O
hematological	B
malignancy	I
and	O
neurofibromatosis	B
type	I
1	I
.	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B
malignance	I
and	O
neurofibromatosis	B
eccentric	I
one	I
.	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B
malignancy	I
and	O
neurofibromatosis	B
malignance	B
inadequacy	B
type	I
1	I
.	O

Human	O
MLH1	O
insufficiency	O
predisposes	O
to	O
haematological	B
malignance	I
and	O
neurofibromatosis	B
type	I
1	I
.	O

Human	O
and	O
deficiency	O
predisposes	O
MLH1	O
hematological	B
malignancy	I
1	O
neurofibromatosis	B
type	I
to	I
.	O

.	O
MLH1	O
deficiency	O
predisposes	O
and	O
hematological	B
type	I
to	O
neurofibromatosis	B
malignancy	I
1	I
Human	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B
malignancy	I
and	O
neurofibromatosis	B
type	I
1	I
.	O

genes	O
germ	O
-	O
DNA	O
mutations	O
in	O
the	O
line	O
nonpolyposis	O
repair	O
hereditary	O
lead	O
Heterozygous	O
to	B
mismatch	I
colorectal	I
cancer	I
.	O

Heterozygous	O
germ	O
-	O
line	O
sport	O
in	O
the	O
DNA	O
mismatch	O
haunt	O
cistron	O
wind	O
to	O
transmitted	B
nonpolyposis	I
colorectal	I
cancer	I
.	O

heterozygous	O
bug	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
cistron	O
conduce	O
to	O
inherited	B
nonpolyposis	I
colorectal	I
cancer	I
.	O

Heterozygous	O
germ	O
-	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
.	O

heterozygous	O
bug	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
reanimate	O
factor	O
result	O
to	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
.	O

Heterozygous	O
germ	O
parentage	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
line	O
of	O
descent	O
line	O
of	O

Heterozygous	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
lead	O
to	O
nonpolyposis	I
colorectal	I
cancer	I
.	O

Heterozygous	O
germ	O
parentage	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
line	O
of	O
descent	O
line	O
of	O

germ	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
.	O

Heterozygous	O
germ	O
mismatch	O
nonpolyposis	O
mutations	O
in	O
to	O
DNA	O
-	O
repair	O
genes	O
lead	O
the	O
hereditary	B
line	I
colorectal	I
cancer	I
.	O

Heterozygous	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
.	O

The	O
disease	O
susceptibility	O
deficiency	O
susceptibleness	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild	O
-	O
type	O
alleles	O
is	O
unknown	O
world	O
health	O

is	O
disease	O
susceptibility	O
.	O
individuals	O
who	O
constitutionally	O
lack	O
unknown	O
wild	O
-	O
type	O
The	O
alleles	O
both	O
of	O

The	O
disease	O
cost	O
deficiency	O
world	O
health	O
organization	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild	O
-	O
type	O
alleles	O
is	O
unknown	O

The	O
disease	O
susceptibleness	O
of	O
individuals	O
who	O
constitutionally	O
want	O
both	O
wild	O
-	O
character	O
alleles	O
is	O
unsung	O
.	O

alleles	O
disease	O
susceptibility	O
lack	O
individuals	O
who	O
is	O
of	O
both	O
wild	O
The	O
type	O
-	O
constitutionally	O
unknown	O
.	O

The	O
disease	O
susceptibility	O
deficiency	O
susceptibleness	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild	O
-	O
type	O
alleles	O
is	O
unknown	O
world	O
health	O

The	O
disease	O
susceptibility	O
of	O
someone	O
who	O
constitutionally	O
deficiency	O
both	O
uncivilized	O
-	O
type	O
alleles	O
is	O
obscure	O
.	O

The	O
disease	O
susceptibility	O
of	O
someone	O
who	O
constitutionally	O
lack	O
both	O
baseless	O
-	O
eccentric	O
alleles	O
is	O
stranger	O
.	O

The	O
disease	O
both	O
.	O
individuals	O
who	O
alleles	O
lack	O
susceptibility	O
wild	O
-	O
type	O
constitutionally	O
is	O
of	O
unknown	O

disease	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
-	O
type	O
alleles	O
is	O
unknown	O
.	O

The	O
disease	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild	O
-	O
type	O
alleles	O
is	O
unknown	O
.	O

We	O
have	O
distinguish	O
three	O
materialization	O
in	O
a	O
genetic	B
nonpolyposis	I
colorectal	I
cancer	I
family	O
who	O
acquire	O
hematological	B
malignance	I
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
exhibit	O
ratify	O
of	O
neurofibromatosis	B
type	I
ace	I
(	O
NF1	B
)	O
.	O

have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B
nonpolyposis	I
who	O
developed	O
hematological	B
malignancy	I
at	O
very	O
early	O
at	O
of	O
them	O
of	O
1	I
(	O
NF1	B
)	O

them	O
(	O
identified	O
three	O
at	O
in	O
age	O
neurofibromatosis	B
nonpolyposis	I
colorectal	I
cancer	I
family	O
who	O
least	O
.	B
malignancy	I
offspring	O
of	O
very	O
early	O
hereditary	O
,	O
and	O
at	O
have	O
two	O
of	O
We	O
a	O
signs	O
displayed	O
a	B
type	I
1	I
developed	O
NF1	B
)	O
hematological	O

We	O
have	O
identified	O
three	O
offspring	O
in	O
nonpolyposis	I
colorectal	I
cancer	I
family	O
developed	O
hematological	B
malignancy	I
at	O
a	O
early	O
age	O
,	O
and	O
least	O
two	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B
type	I
1	I
(	O
)	O
.	O

We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
family	O
who	O
developed	O
hematological	B
malignancy	I
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B
type	I
1	I
(	O
NF1	B
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
)	O
.	O

We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
family	O
who	O
developed	O
hematological	B
malignancy	I
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B
type	I
1	I
(	O
NF1	B
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
)	O
.	O

We	O
have	O
identified	O
leash	O
progeny	O
in	O
a	O
ancestral	B
nonpolyposis	I
colorectal	I
crab	I
kinsfolk	O
who	O
developed	O
haematological	B
malignity	I
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
ii	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B
character	I
i	I
(	O
NF1	B
)	O
.	O

least	O
very	O
identified	O
three	O
offspring	O
in	O
family	O
1	B
nonpolyposis	I
colorectal	I
cancer	I
a	O
who	O
them	O
signs	B
malignancy	I
at	O
a	O
hereditary	O
early	O
age	O
,	O
displayed	O
at	O
We	O
two	O
neurofibromatosis	O
developed	O
hematological	O
and	O
of	O
NF1	B
type	I
have	I
(	O
of	B
)	O
.	O

We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
family	O
who	O
developed	O
hematological	B
malignancy	I
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B
type	I
1	I
(	O
NF1	B
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
young	O
build	O
up	O
)	O

We	O
have	O
offspring	O
in	O
hereditary	B
nonpolyposis	I
who	O
hematological	B
malignancy	I
at	O
very	O
early	O
age	O
and	O
at	O
least	O
two	O
of	O
signs	O
of	O
neurofibromatosis	B
type	I
1	I
(	O
NF1	B
)	O

We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
family	O
who	O
developed	O
hematological	B
malignancy	I
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B
type	I
1	I
(	O
NF1	B
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
dna	O

analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
-	O
>	O
Arg226Stop	O
)	O
.	O

dna	O
sequence	O
analysis	O
and	O
allelomorph	O
-	O
particular	O
gain	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
-	O
-	O
>	O
Arg226Stop	O
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
in	O
two	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
>	O
Arg226Stop	O
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O

DNA	O
successiveness	O
analysis	O
and	O
allelomorph	O
-	O
particular	O
gain	O
in	O
two	O
siblings	O
disclose	O
a	O
homozygous	O
MLH1	O
mutant	O
(	O
C676T	O
-	O
-	O
>	O
Arg226Stop	O
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allelomorph	O
-	O
particular	O
elaboration	O
in	O
ii	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
variation	O
(	O
C676T	O
-	O
-	O
>	O
Arg226Stop	O
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
siblings	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
-	O
-	O
>	O
Arg226Stop	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O

C676T	O
sequence	O
analysis	O
siblings	O
allele	O
-	O
specific	O
-	O
.	O
two	O
and	O
revealed	O
a	O
homozygous	O
)	O
mutation	O
(	O
>	O
amplification	O
DNA	O
-	O
Arg226Stop	O
MLH1	O
in	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
-	O
-	O
>	O
Arg226Stop	O
)	O
.	O

Thus	O
,	O
a	O
homozygous	O
inadequacy	O
effect	O
indium	O
seed	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B
and	O
/	O
or	O
lymphoma	B
associated	O
with	O
neurofibromatosis	B
type	I
1	I
.	O
insufficiency	O
insufficiency	O
insufficiency	O
insufficiency	O
hangout	O
.	O

Thus	O
,	O
a	O
-	O
consequent	O
mismatch	O
repair	O
results	O
in	O
mutator	O
phenotype	O
characterized	O
and	O
/	O
or	O
lymphoma	B
associated	O
neurofibromatosis	B
1	I
.	O
.	O

hence	O
,	O
a	O
homozygous	O
germ	O
-	O
furrow	O
MLH1	O
mutation	O
and	O
accompanying	O
mismatch	O
fix	O
inadequacy	O
lead	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B
and	O
/	O
or	O
lymphoma	B
consort	O
with	O
neurofibromatosis	B
character	I
one	I
.	O
.	O

Thus	O
,	O
a	O
homozygous	O
germ	O
-	O
line	O
mutation	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
or	O
lymphoma	B
associated	O
with	O
neurofibromatosis	B
type	I
1	I
.	O
.	O

olibanum	O
,	O
a	O
homozygous	O
source	O
-	O
line	O
MLH1	O
mutation	O
and	O
resultant	O
mismatch	O
remediate	O
want	O
results	O
in	O
a	O
mutator	O
phenotype	O
qualify	O
by	O
leukaemia	B
and	O
/	O
or	O
lymphoma	B
consociate	O
with	O
neurofibromatosis	B
type	I
i	I
.	O
.	O

Thus	O
,	O
a	O
homozygous	O
inadequacy	O
effect	O
indium	O
seed	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B
and	O
/	O
or	O
lymphoma	B
associated	O
with	O
neurofibromatosis	B
type	I
1	I
.	O
insufficiency	O
insufficiency	O
insufficiency	O
insufficiency	O
hangout	O
.	O

Thus	O
,	O
a	O
homozygous	O
microbe	O
-	O
line	O
MLH1	O
mutation	O
and	O
resultant	O
mismatch	O
fixture	O
want	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterise	O
by	O
leukemia	B
and	O
/	O
or	O
lymphoma	B
associated	O
with	O
neurofibromatosis	B
character	I
i	I
.	O
.	O

by	O
phenotype	O
a	O
homozygous	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
or	O
type	O
in	O
a	O
mutator	O
with	O
characterized	O
,	O
leukemia	B
.	O
/	O
deficiency	O
lymphoma	B
associated	O
Thus	O
results	B
and	I
1	I
neurofibromatosis	O
.	O

Thus	O
,	O
a	O
homozygous	O
germ	O
-	O
MLH1	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
phenotype	O
characterized	O
by	O
leukemia	B
and	O
/	O
or	O
with	O
neurofibromatosis	B
type	I
.	O

Thus	O
,	O
a	O
homozygous	O
inadequacy	O
effect	O
indium	O
hangout	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B
and	O
/	O
or	O
lymphoma	B
associated	O
with	O
neurofibromatosis	B
type	I
1	I
.	O
insufficiency	O
insufficiency	O
insufficiency	O
insufficiency	O
hangout	O
.	O

Thus	O
,	O
a	O
homozygous	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B
and	O
/	O
or	O
lymphoma	B
associated	O
with	O
neurofibromatosis	B
type	I
1	I
.	O
.	O

Missense	O
mutations	O
in	O
the	O
most	O
antediluvian	O
rest	O
of	O
the	O
PAX6	O
twin	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
inborn	B
oculus	I
malformations	I
.	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B
misshapenness	B
indium	B
indium	B
indium	B
indium	B
indium	B
eye	I
malformations	I
.	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B
misshapenness	B
indium	B
indium	B
indium	B
indium	B
indium	B
eye	I
malformations	I
.	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
PAX6	O
paired	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B
eye	I

spectrum	O
mutations	O
the	O
residues	O
most	O
ancient	O
of	O
of	O
in	O
PAX6	O
paired	O
domain	O
.	O
a	O
the	O
Missense	O
human	O
congenital	B
eye	I
malformations	I
underlie	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
balance	O
of	O
the	O
PAX6	O
mated	O
world	O
underlie	O
a	O
spectrum	O
of	O
homo	O
inborn	B
eye	I
misshapenness	I
.	O

.	O
mutations	O
in	O
paired	O
most	O
ancient	O
residues	O
eye	O
spectrum	O
PAX6	O
the	O
domain	O
a	O
underlie	O
the	O
of	O
human	O
congenital	B
of	I
Missense	I
malformations	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B
misshapenness	B
indium	B
indium	B
indium	B
indium	B
indium	B
eye	I
malformations	I
.	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
spectrum	O
congenital	B
eye	I
malformations	I
.	O

Missense	O
mutations	O
in	O
the	O
most	O
antediluvian	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
innate	B
center	I
deformity	I
.	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B
eye	I
malformations	I
.	O

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B
(	O
congenital	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
rare	O
misshapenness	O
oculus	O
homo	O
oculus	O
oculus	O
homo	O
oculus	O
dominant	O
malformation	B
of	I
the	I
eye	I
.	O

the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B
(	O
congenital	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
dominant	O
of	I
the	I
eye	I
.	O

sport	O
of	O
the	O
homo	O
PAX6	O
cistron	O
underlie	O
aniridia	B
(	O
inborn	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
rare	O
dominant	O
miscreation	B
of	I
the	I
middle	I
.	O

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
(	O
congenital	B
of	I
the	I
iris	I
)	O
,	O
a	O
rare	O
of	I
the	I
eye	I
.	O

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B
(	O
congenital	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
rare	O
misshapenness	O
oculus	O
homo	O
oculus	O
oculus	O
homo	O
homo	O
dominant	O
malformation	B
of	I
the	I
eye	I
.	O

Mutations	O
of	O
the	O
human	O
PAX6	O
cistron	O
underlie	O
aniridia	B
(	O
innate	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
rarified	O
dominant	O
misshapenness	B
of	I
the	I
oculus	I
.	O

Mutations	O
of	O
the	O
homo	O
PAX6	O
factor	O
underlie	O
aniridia	B
(	O
inborn	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
uncommon	O
rife	O
deformity	B
of	I
the	I
eye	I
.	O

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B
(	O
absence	I
iris	I
)	O
,	O
a	O
rare	O
dominant	O
malformation	B
of	I
the	I

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B
(	O
congenital	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
rare	O
misshapenness	O
oculus	O
homo	O
oculus	O
oculus	O
homo	O
homo	O
dominant	O
malformation	B
of	I
the	I
eye	I
.	O

rare	O
of	O
the	O
absence	O
PAX6	O
gene	O
underlie	O
dominant	B
.	O
congenital	B
human	I
of	I
the	I
iris	I
eye	O
,	O
a	O
of	O
aniridia	O
Mutations	B
malformation	I
the	I
)	I
(	O

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B
(	O
congenital	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
rare	O
dominant	O
malformation	B
of	I
the	I
eye	I
.	O

The	O
PAX6	O
mutations	O
in	O
patients	O
highly	O
biased	O
,	O
%	O
leading	O
to	O
premature	O
of	O
the	O
(	O
nonsense	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
2	O
leading	O
to	O
substitution	O
of	O
one	O
amino	O
acid	O
by	O
another	O
(	O
)	O
.	O

The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	B
patients	O
	O
insertion	O
cost	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
past	O
some	O
other	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
past	O
some	O
other	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
past	O
some	O

The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	B
patients	O
	O
insertion	O
cost	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
past	O
some	O
other	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
past	O
some	O
other	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
past	O
some	O

)	O
(	O
of	O
PAX6	O
mutations	O
in	O
,	B
patients	O
is	O
highly	O
biased	O
aniridia	O
with	O
nonsense	O
,	O
of	O
all	O
reported	O
splicing	O
leading	O
to	O
premature	O
deletions	O
of	O
one	O
protein	O
by	O
92	O
(	O
mutations	O
,	O
and	O
and	O
%	O
The	O
substitution	O
just	O
2	O
%	O
leading	O
spectrum	O
insertions	O
of	O
truncation	O
amino	O
acid	O
to	O
another	O
the	O
missense	O
)	O
.	O

amino	O
the	O
of	O
PAX6	O
mutations	O
in	O
to	B
all	O
is	O
highly	O
biased	O
,	O
with	O
)	O
2	O
of	O
patients	O
,	O
mutations	O
leading	O
(	O
premature	O
truncation	O
of	O
spectrum	O
protein	O
(	O
%	O
reported	O
splicing	O
,	O
aniridia	O
and	O
deletions	O
)	O
and	O
just	O
%	O
nonsense	O
leading	O
to	O
substitution	O
of	O
one	O
The	O
acid	O
.	O
another	O
missense	O
insertions	O
92	O
by	O

The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	B
patients	O
	O
insertion	O
cost	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
past	O
some	O
other	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
past	O
some	O
other	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
past	O
some	O

The	O
spectrum	O
PAX6	O
aniridia	B
patients	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
and	O
2	O
%	O
leading	O
to	O
substitution	O
of	O
one	O
amino	O
by	O
another	O
(	O
missense	O
)	O
.	O

The	O
spectrum	O
,	O
PAX6	O
mutations	O
in	O
aniridia	B
mutations	O
is	O
highly	O
biased	O
of	O
leading	O
92	O
%	O
premature	O
all	O
reported	O
2	O
with	O
to	O
another	O
truncation	O
,	O
the	O
.	O
nonsense	O
and	O
,	O
splicing	O
of	O
of	O
insertions	O
deletions	O
)	O
amino	O
just	O
protein	O
%	O
leading	O
to	O
substitution	O
(	O
one	O
and	O
by	O
acid	O
of	O
(	O
missense	O
)	O
patients	O

The	O
spectrum	O
of	O
PAX6	O
mutant	O
in	O
aniridia	B
patients	O
is	O
extremely	O
colored	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutant	O
leadership	O
to	O
previous	O
shortness	O
of	O
the	O
protein	O
(	O
gimcrackery	O
,	O
marry	O
,	O
interpolation	O
and	O
cut	O
)	O
and	O
just	O
2	O
%	O
leadership	O
to	O
commutation	O
of	O
single	O
aminic	O
virulent	O
by	O
another	O
(	O
missense	O
)	O
.	O

The	O
spectrum	O
of	O
is	O
,	O
92	O
%	O
of	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
)	O
and	O
%	O
leading	O
to	O
of	O
acid	O
by	O
another	O
(	O
missense	O
)	O
.	O

The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	B
patients	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
just	O
2	O
%	O
leading	O
to	O
substitution	O
of	O
one	O
amino	O
acid	O
by	O
another	O
(	O
missense	O
)	O
.	O

conservation	O
PAX6	O
protein	O
at	O
the	O
acid	O
level	O
predicts	O
that	O
missense	O
mutations	O
be	O
even	O
though	O
they	O
hardly	O
ever	O
seen	O
aniridia	B
patients	O
.	O

The	O
extraordinary	O
conservation	O
of	O
watch	O
indium	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	B
patients	O
lookout	O
man	O
lookout	O
man	O
lookout	O
man	O
lookout	O
man	O
lookout	O

even	O
mutations	O
conservation	O
of	O
the	O
PAX6	O
they	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
are	O
ever	O
that	O
pathological	O
missense	O
patients	O
should	O
in	O
fact	O
in	O
common	O
The	O
though	O
protein	O
vertebrates	O
predicts	O
be	O
seen	O
hardly	O
aniridia	B
.	O
extraordinary	O

The	O
sinful	O
preservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
aminic	O
zen	O
level	O
amongst	O
craniate	O
foretell	O
that	O
diseased	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
plebeian	O
even	O
though	O
they	O
are	O
just	O
ever	O
hear	O
in	O
aniridia	B
patients	O
.	O

The	O
extraordinary	O
though	O
of	O
the	O
PAX6	O
protein	O
fact	O
the	O
amino	O
acid	O
common	O
are	O
vertebrates	O
predicts	O
seen	O
pathological	O
missense	O
should	O
level	O
in	O
at	O
be	O
mutations	O
even	O
they	O
conservation	O
aniridia	O
hardly	O
ever	O
that	O
amongst	O
in	B
patients	O
.	O

The	O
extraordinary	O
conservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
amongst	O
vertebrates	O
predicts	O
that	O
missense	O
mutations	O
should	O
in	O
fact	O
common	O
even	O
though	O
they	O
hardly	O
ever	O
in	O
aniridia	B
patients	O
.	O

The	O
extraordinary	O
preservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
aminic	O
acid	O
level	O
amongst	O
craniate	O
foretell	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
vernacular	O
still	O
though	O
they	O
are	O
just	O
ever	O
consider	O
in	O
aniridia	B
patients	O
.	O

The	O
extraordinary	O
conservation	O
of	O
watch	O
diseased	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	B
patients	O
lookout	O
man	O
lookout	O
man	O
lookout	O
man	O
lookout	O
man	O
lookout	O

The	O
extraordinary	O
preservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
superman	O
plane	O
amongst	O
craniate	O
betoken	O
that	O
pathological	O
missense	O
variation	O
should	O
in	O
fact	O
be	O
vulgar	O
even	O
though	O
they	O
are	O
barely	O
ever	O
experience	O
in	O
aniridia	B
patients	O
.	O

are	O
in	O
conservation	O
of	O
pathological	O
PAX6	O
predicts	O
in	O
the	O
amino	O
acid	O
level	O
amongst	O
even	O
at	O
that	O
the	O
seen	O
mutations	O
should	O
vertebrates	O
fact	O
be	O
common	O
extraordinary	O
though	O
they	O
The	O
missense	O
ever	O
hardly	O
protein	O
aniridia	B
patients	O
.	O

The	O
extraordinary	O
conservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	B
patients	O
.	O

This	O
indicates	O
frequently	O
there	O
is	O
selection	O
heavy	O
missing	O
bias	O
in	O
the	O
missense	O
underlie	O
patients	O
for	O
from	O
mutation	O
analysis	O
that	O
and	O
the	O
ascertainment	O
PAX6	O
a	O
mutations	O
may	O
that	O
aniridia	O
phenotypes	O
distinct	O
PAX6	O
of	O
textbook	B
.	O

This	O
there	O
is	O
a	O
heavy	O
bias	O
in	O
of	O
patients	O
PAX6	O
mutation	O
the	O
PAX6	O
missense	O
mutations	O
may	O
underlie	O
phenotypes	O
from	O
textbook	O
aniridia	B
.	O

This	O
indicates	O
that	O
there	O
ampere	O
backbreaking	O
trenchant	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O

This	O
indicates	O
that	O
there	O
ampere	O
backbreaking	O
cost	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O

indicates	O
and	O
that	O
there	O
is	O
a	O
may	O
ascertainment	O
bias	O
in	O
the	O
underlie	O
of	O
mutations	O
distinct	O
PAX6	O
mutation	O
analysis	O
selection	O
that	O
the	O
missing	O
.	O
missense	O
patients	O
frequently	O
heavy	O
This	O
textbook	O
PAX6	O
from	O
phenotypes	O
aniridia	B
for	O

This	O
indicates	O
that	O
there	O
is	O
a	O
bias	O
in	O
the	O
selection	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
that	O
the	O
missing	O
PAX6	O
mutations	O
frequently	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B
.	O

This	O
bespeak	O
that	O
there	O
is	O
a	O
laborious	O
ascertainment	O
prejudice	O
in	O
the	O
excerption	O
of	O
patients	O
for	O
PAX6	O
mutant	O
analysis	O
and	O
that	O
the	O
neglect	O
PAX6	O
missense	O
mutations	O
ofttimes	O
may	O
underlie	O
phenotypes	O
discrete	O
from	O
textbook	O
aniridia	B
.	O

This	O
indicates	O
that	O
there	O
is	O
a	O
hard	O
ascertainment	O
predetermine	O
in	O
the	O
survival	O
of	O
patients	O
for	O
PAX6	O
mutant	O
analysis	O
and	O
that	O
the	O
overlook	O
PAX6	O
missense	O
variation	O
ofttimes	O
whitethorn	O
underlie	O
phenotypes	O
discrete	O
from	O
casebook	O
aniridia	B
.	O

This	O
indicates	O
that	O
there	O
ampere	O
backbreaking	O
cost	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O
international	O
ampere	O

This	O
indicates	O
that	O
there	O
is	O
a	O
large	O
ascertainment	O
diagonal	O
in	O
the	O
option	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
pretermit	O
PAX6	O
missense	O
mutations	O
oftentimes	O
may	O
underlie	O
phenotypes	O
trenchant	O
from	O
textbook	O
aniridia	B
.	O

This	O
indicates	O
that	O
there	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B
.	O

we	O
present	O
four	O
missense	O
mutations	O
,	O
two	O
in	O
with	O
phenotypes	O
ectopia	B
pupillae	I
(	O
displaced	B
pupils	I
)	O
and	O
congenital	B
nystagmus	I
searching	B
gaze	I
)	O
,	O
and	O
recognizable	O
.	O

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B
pupillae	I
(	O
displaced	B
pupils	I
)	O
and	O
congenital	B
nystagmus	I
(	O
searching	B
gaze	I
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
aniridia	B
phenotypes	O
.	O

two	O
)	O
present	O
four	O
pupillae	O
PAX6	O
phenotypes	O
in	O
,	O
two	O
in	O
association	O
with	O
(	O
(	O
ectopia	B
novel	I
phenotypes	O
displaced	B
pupils	I
atypical	O
and	O
congenital	B
nystagmus	I
we	O
searching	B
gaze	I
.	O
Here	O
and	O
,	O
missense	O
association	O
with	O
more	O
recognizable	O
aniridia	B
mutations	O
)	O

Here	O
we	O
present	O
novel	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B
)	O
and	O
congenital	B
nystagmus	I
(	O
searching	B
gaze	I
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
aniridia	B
.	O

here	O
we	O
acquaint	O
four	O
new	O
PAX6	O
missense	O
variation	O
,	O
ii	O
in	O
connexion	O
with	O
atypical	O
phenotypes	O
ectopia	B
pupillae	I
(	O
dismiss	B
schoolchild	I
)	O
and	O
innate	B
nystagmus	I
(	O
seek	B
gaze	I
)	O
,	O
and	O
ii	O
in	O
connexion	O
with	O
more	O
placeable	O
aniridia	B
phenotypes	O
.	O

(	O
displaced	O
present	O
four	O
novel	O
PAX6	O
association	O
mutations	O
,	O
two	O
in	O
missense	O
with	O
)	O
and	O
ectopia	B
pupillae	I
(	O
with	B
pupils	I
)	O
and	O
,	B
nystagmus	I
Here	O
searching	B
in	I
atypical	O
phenotypes	O
congenital	O
two	O
recognizable	O
association	O
more	O
we	O
gaze	O
aniridia	B
phenotypes	O
.	O

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B
pupillae	I
(	O
displaced	B
pupils	I
)	O
and	O
congenital	B
nystagmus	I
(	O
searching	B
gaze	I
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
aniridia	B
phenotypes	O
.	O

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B
pupillae	I
(	O
displaced	B
pupils	I
)	O
and	O
congenital	B
nystagmus	I
(	O
searching	B
gaze	I
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
fresh	O
sport	O
aniridia	B
phenotypes	O
.	O

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
(	O
displaced	B
pupils	I
and	O
nystagmus	I
(	O
searching	B
,	O
with	O
more	O
recognizable	O
phenotypes	O
.	O

Here	O
we	O
two	O
four	O
novel	O
PAX6	O
missense	O
displaced	O
,	O
two	O
in	O
gaze	O
pupils	O
atypical	O
phenotypes	O
mutations	B
pupillae	I
(	O
phenotypes	B
with	I
)	O
association	O
congenital	B
recognizable	I
(	O
ectopia	B
association	I
and	O
,	O
and	O
present	O
)	O
in	O
with	O
more	O
nystagmus	O
aniridia	B
searching	O
.	O

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B
pupillae	I
(	O
displaced	B
pupils	I
)	O
and	O
congenital	B
nystagmus	I
(	O
searching	B
gaze	I
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
aniridia	B
phenotypes	O
.	O

strikingly	O
,	O
all	O
four	O
mutations	O
are	O
placed	O
inside	O
the	O
PAX6	O
twin	O
field	O
and	O
sham	O
amino	O
acids	O
which	O
are	O
extremely	O
economize	O
in	O
all	O
known	O
twin	O
field	O
proteins	O
.	O

Strikingly	O
,	O
four	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
acids	O
which	O
are	O
highly	O
in	O
all	O
known	O
paired	O
domain	O
.	O

Strikingly	O
,	O
all	O
four	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
sport	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
partner	O
off	O
area	O
protein	O
area	O
	O
highly	O
conserved	O
in	O

in	O
,	O
all	O
highly	O
mutations	O
are	O
located	O
proteins	O
paired	O
PAX6	O
conserved	O
domain	O
and	O
affect	O
known	O
acids	O
which	O
are	O
four	O
domain	O
paired	O
all	O
amino	O
the	O
Strikingly	O
within	O
.	O

Strikingly	O
,	O
all	O
four	O
aminic	O
lucy	O
in	O
the	O
sky	O
with	O
diamonds	O
sport	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
partner	O
off	O
area	O
protein	O
area	O
	O
highly	O
conserved	O
in	O

Strikingly	O
,	O
all	O
mutations	O
are	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
which	O
are	O
conserved	O
in	O
all	O
known	O
paired	O
domain	O
proteins	O
.	O

.	O
,	O
all	O
amino	O
mutations	O
are	O
proteins	O
within	O
four	O
PAX6	O
paired	O
domain	O
affect	O
in	O
domain	O
the	O
which	O
are	O
highly	O
conserved	O
and	O
all	O
known	O
paired	O
acids	O
located	O
Strikingly	O

all	O
are	O
located	O
within	O
PAX6	O
paired	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
highly	O
conserved	O
in	O
all	O
known	O
paired	O
domain	O

paired	O
,	O
all	O
four	O
mutations	O
are	O
affect	O
domain	O
the	O
PAX6	O
paired	O
which	O
all	O
located	O
domain	O
Strikingly	O
within	O
acids	O
highly	O
conserved	O
in	O
and	O
known	O
are	O
amino	O
proteins	O
.	O

Strikingly	O
,	O
all	O
quartet	O
mutations	O
are	O
situated	O
inside	O
the	O
PAX6	O
paired	O
world	O
and	O
touch	O
amino	O
acids	O
which	O
are	O
extremely	O
maintain	O
in	O
all	O
cognize	O
paired	O
world	O
proteins	O
.	O

Strikingly	O
,	O
all	O
four	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
highly	O
conserved	O
in	O
all	O
known	O
paired	O
domain	O
proteins	O
.	O

support	O
that	O
the	O
under	O
-	O
of	O
missense	O
caused	O
by	O
bias	O
and	O
substantial	O
of	O
PAX6	B
-	I
disease	I
remains	O
to	O
uncovered	O
.	O
.	O

Our	O
results	O
support	O
the	O
past	O
sport	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	B
-	I
related	I
disease	I
remains	O
to	O
be	O
uncovered	O
.	O
preceding	O
preceding	O
preceding	O
preceding	O
preceding	O
preceding	O
preceding	O
induce	O
.	O

of	O
and	O
support	O
the	O
hypothesis	O
that	O
-	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
related	O
remains	O
by	O
ascertainment	O
bias	O
.	O
suggest	O
that	O
a	O
be	O
burden	O
Our	O
PAX6	B
the	I
is	I
caused	I
substantial	O
to	O
disease	O
uncovered	O
.	O
results	O

Our	O
answer	O
keep	O
the	O
guess	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutant	O
is	O
get	O
by	O
ascertainment	O
diagonal	O
and	O
advise	O
that	O
a	O
material	O
core	O
of	O
PAX6	B
-	I
related	I
disease	I
stiff	O
to	O
be	O
uncovered	O
.	O
.	O

Our	O
results	O
PAX6	O
the	O
hypothesis	O
that	O
the	O
a	O
-	O
representation	O
of	O
burden	O
related	O
is	O
caused	O
to	O
ascertainment	O
bias	O
suggest	O
missense	O
that	O
under	O
substantial	O
and	O
of	O
-	B
support	I
uncovered	I
disease	I
remains	O
by	O
mutations	O
be	O
.	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
mutations	O
is	O
caused	O
by	O
bias	O
and	O
suggest	O
that	O
a	O
burden	O
of	O
PAX6	B
-	I
disease	I
remains	O
be	O
uncovered	O
.	O
.	O

Our	O
answer	O
support	O
the	O
speculation	O
that	O
the	O
under	O
-	O
theatrical	O
of	O
missense	O
mutations	O
is	O
induce	O
by	O
ascertainment	O
diagonal	O
and	O
advise	O
that	O
a	O
real	O
essence	O
of	O
PAX6	B
-	I
pertain	I
disease	I
remains	O
to	O
be	O
expose	O
.	O
.	O

Our	O
results	O
support	O
the	O
past	O
guess	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	B
-	I
related	I
disease	I
remains	O
to	O
be	O
uncovered	O
.	O
preceding	O
preceding	O
preceding	O
preceding	O
preceding	O
preceding	O
preceding	O
induce	O
.	O

Our	O
results	O
hold	O
the	O
conjecture	O
that	O
the	O
under	O
-	O
theatrical	O
of	O
missense	O
sport	O
is	O
do	O
by	O
ascertainment	O
predetermine	O
and	O
intimate	O
that	O
a	O
material	O
gist	O
of	O
PAX6	B
-	I
related	I
disease	I
remains	O
to	O
be	O
reveal	O
.	O
.	O

related	O
that	O
support	O
the	O
ascertainment	O
that	O
caused	O
be	O
-	O
representation	O
of	O
missense	O
mutations	O
of	O
under	O
by	O
hypothesis	O
to	O
and	O
suggest	O
is	O
a	O
substantial	O
burden	O
results	O
PAX6	B
-	I
Our	I
bias	I
remains	O
disease	O
the	O
uncovered	O
.	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	B
-	I
related	I
disease	I
remains	O
to	O
be	O
uncovered	O
.	O
.	O

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B
of	I
secondly	I
full	I
complement	I
element	I
full	I
complement	I
full	I
complement	I
regularise	I
b	I
complex	I
the	I
second	O

order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B
the	I
component	I
of	I
complement	I
.	O

The	O
chromosomal	O
fiat	O
of	O
cistron	O
controlling	O
the	O
major	O
histocompatibility	O
composite	O
,	O
properdin	O
gene	O
B	O
,	O
and	O
want	B
of	I
the	I
second	I
element	I
of	I
accompaniment	I
.	O

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
histocompatibility	O
complex	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B
of	I
component	I
of	I
complement	I
.	O

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B
of	I
secondly	I
full	I
complement	I
element	I
full	I
complement	I
full	I
complement	I
regularise	I
regularise	I
the	I
second	I
component	O

The	O
chromosomal	O
rescript	O
of	O
agent	O
operate	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
agent	O
B	O
,	O
and	O
insufficiency	B
of	I
the	I
second	I
portion	I
of	I
accompaniment	I
.	O

The	O
chromosomal	O
tell	O
of	O
factor	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
cistron	O
b	O
,	O
and	O
inadequacy	B
of	I
the	I
second	I
part	I
of	I
complement	I
.	O

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
,	O
B	O
,	O
and	O
deficiency	B
of	I
the	I
second	I
component	I
of	I

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B
of	I
secondly	I
full	I
complement	I
element	I
full	I
complement	I
full	I
complement	I
regularise	I
regularise	I
the	I
second	I
component	O

of	O
chromosomal	O
order	O
,	O
genes	O
controlling	O
the	O
the	O
.	O
complex	O
of	O
properdin	O
factor	O
B	O
complement	O
and	O
deficiency	B
component	I
major	I
The	I
second	I
of	I
,	I
histocompatibility	O

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
complement	I
.	O

relationship	O
of	O
the	O
for	O
HLA	O
to	O
those	O
coding	O
properdin	O
B	O
allotypes	O
and	O
for	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
(	O
C2	O
)	O
was	O
studied	O
connective	O
.	O

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
complement	I
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
tissue	O
disorders	O
.	O

in	O
the	O
of	O
the	O
and	O
coding	O
disorders	O
families	O
to	O
those	O
coding	O
for	O
properdin	O
complement	O
for	O
allotypes	O
genes	O
B	O
deficiency	B
of	I
Factor	I
second	I
component	I
of	I
relationship	I
(	O
C2	O
.	O
The	O
studied	O
was	O
for	O
of	O
patients	O
with	O
connective	O
tissue	O
HLA	O
)	O

The	O
relationship	O
of	O
genes	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
the	I
second	I
component	I
of	I
complement	I
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
tissue	O
.	O

The	O
relationship	O
of	O
the	O
cistron	O
rally	O
for	O
HLA	O
to	O
those	O
rally	O
for	O
properdin	O
cistron	O
B	O
allotypes	O
and	O
for	O
inadequacy	B
of	I
the	I
indorse	I
element	I
of	I
accompaniment	I
(	O
C2	O
)	O
was	O
studied	O
in	O
class	O
of	O
patients	O
with	O
connecter	O
weave	O
cark	O
.	O

complement	O
deficiency	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
)	O
studied	O
allotypes	O
and	O
for	O
patients	B
of	I
the	I
second	I
was	I
of	I
The	I
(	O
families	O
Factor	O
B	O
component	O
in	O
connective	O
of	O
with	O
relationship	O
C2	O
tissue	O
disorders	O
.	O

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
complement	I
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
tissue	O
disorders	O
.	O

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
complement	I
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
family	O
line	O
tissue	O
disorders	O

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
for	O
deficiency	B
of	I
second	I
of	I
complement	I
(	O
was	O
patients	O
with	O
connective	O
disorders	O
.	O

The	O
relationship	O
in	O
the	O
genes	O
coding	O
for	O
deficiency	O
to	O
those	O
coding	O
C2	O
of	O
Factor	O
B	O
HLA	O
and	O
for	O
disorders	B
properdin	I
the	I
of	I
component	I
connective	I
complement	I
allotypes	O
for	O
second	O
was	O
studied	O
of	O
)	O
families	O
patients	O
with	O
of	O
tissue	O
(	O
.	O

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
complement	I
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
tissue	O
disorders	O
.	O

Patients	O
selected	O
because	O
were	O
or	O
for	O
C2	B
deficiency	I
.	O

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B
deficiency	I

patient	O
were	O
choose	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B
want	I
.	O

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
inadequacy	O
inadequacy	O
cost	O
for	O
C2	B
deficiency	I
.	O

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
inadequacy	O
inadequacy	O
cost	O
for	O
C2	B
deficiency	I
.	O

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
inadequacy	O
inadequacy	O
cost	O
for	O
C2	B
deficiency	I
.	O

patient	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B
insufficiency	I
.	O

Patients	O
were	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
.	O

Patients	O
were	O
choose	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B
insufficiency	I
.	O

Patients	O
they	O
selected	O
because	O
.	O
were	O
heterozygous	O
were	O
homozygous	O
for	O
C2	B
deficiency	I
or	O

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B
deficiency	I
.	O

12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	B
deficiency	I
receive	O
family	O
line	O
family	O
line	O
were	O

families	O
with	O
for	O
were	O
found	O
.	O

xii	O
families	O
with	O
xv	O
matings	O
illuminating	O
for	O
C2	B
deficiency	I
were	O
found	O
.	O

12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	B
deficiency	I
receive	O
family	O
line	O
family	O
line	O
were	O

families	O
with	O
matings	O
informative	O
for	O
C2	B
deficiency	I
were	O
found	O
.	O

12	O
kinfolk	O
with	O
15	O
matings	O
illuminating	O
for	O
C2	B
lack	I
were	O
found	O
.	O

12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	B
deficiency	I
receive	O
family	O
line	O
	O
were	O
found	O

12	O
families	O
with	O
xv	O
conjugation	O
informatory	O
for	O
C2	B
deficiency	I
were	O
found	O
.	O

12	O
C2	O
with	O
15	O
families	O
informative	O
for	O
found	B
deficiency	I
were	O
matings	O
.	O

.	O
families	O
with	O
15	O
C2	O
informative	O
were	O
matings	B
deficiency	I
for	O
found	O
12	O

12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	B
deficiency	I
were	O
found	O
.	O

Of	O
informative	O
meioses	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B
and	O
the	O
HLA	O
-	O
gene	O
,	O
with	O
a	O
recombinant	O
of	O
0	O
.	O

Of	O
informative	O
meioses	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B
deficiency	I
and	O
the	O
-	O
B	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O

Of	O
57	O
informative	O
meioses	O
factor	O
	O
crossing	O
cost	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B
deficiency	I
gene	O
and	O
the	O
HLA	O
-	O
divide	O
ampere	O
zero	O
take	O
note	O
B	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0	O

,	O
57	O
informative	O
B	O
,	O
two	O
crossovers	O
of	O
recombinant	O
between	O
gene	O
C2	B
deficiency	I
gene	O
a	O
the	O
HLA	O
-	O
meioses	O
fraction	O
the	O
with	O
and	O
noted	O
Of	O
were	O
0	O
.	O

0	O
57	O
informative	O
and	O
,	O
two	O
of	O
were	O
meioses	O
between	O
the	O
C2	B
gene	I
,	O
fraction	O
noted	O
HLA	O
-	O
B	O
gene	O
deficiency	O
with	O
a	O
recombinant	O
the	O
crossovers	O
Of	O
.	O

Of	O
57	O
informative	O
meioses	O
factor	O
	O
crossing	O
cost	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B
deficiency	I
gene	O
and	O
the	O
HLA	O
-	O
divide	O
ampere	O
zero	O
take	O
note	O
B	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0	O

Of	O
lvii	O
instructive	O
miosis	O
,	O
deuce	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B
insufficiency	I
factor	O
and	O
the	O
HLA	O
-	O
bel	O
factor	O
,	O
with	O
a	O
recombinant	O
divide	O
of	O
0	O
.	O

Of	O
57	O
informative	O
meioses	O
factor	O
	O
crossing	O
cost	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B
deficiency	I
gene	O
and	O
the	O
HLA	O
-	O
divide	O
ampere	O
zero	O
take	O
note	O
B	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0	O

recombinant	O
57	O
informative	O
meioses	O
,	O
two	O
gene	O
C2	O
noted	O
between	O
the	O
HLA	B
with	I
crossovers	O
fraction	O
Of	O
were	O
the	O
B	O
gene	O
,	O
deficiency	O
a	O
-	O
and	O
of	O
0	O
.	O

Of	O
57	O
informatory	O
meiosis	O
,	O
ii	O
crossovers	O
were	O
mention	O
between	O
the	O
C2	B
lack	I
cistron	O
and	O
the	O
HLA	O
-	O
B	O
cistron	O
,	O
with	O
a	O
recombinant	O
divide	O
of	O
zero	O
.	O

Of	O
57	O
informative	O
meioses	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B
deficiency	I
gene	O
and	O
the	O
HLA	O
-	O
B	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O

.	O
035	O

.	O
035	O

035	O

.	O
035	O

035	O
.	O

A	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B
deficiency	I
-	O
B	O
at	O
a	O
likelihood	O
value	O
of	O
the	O
recombinant	O
of	O
0	O
.	O

A	O
score	O
of	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B
deficiency	I
and	O
-	O
B	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O

A	O
lod	O
score	O
of	O
	O
cost	O
b	O
complex	O
	O
13	O
was	O
calculated	O
for	O
linkage	O
between	B
C2	I
deficiency	O
and	O
HLA	O
-	O
B	O
at	O
a	O
divide	O
scotch	O
zero	O
scotch	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O

value	O
lod	O
score	O
maximum	O
13	O
was	O
calculated	O
of	O
recombinant	O
between	O
likelihood	B
deficiency	I
and	O
HLA	O
the	O
B	O
at	O
a	O
of	O
fraction	O
C2	O
of	O
-	O
linkage	O
A	O
for	O
0	O
.	O

0	O
lod	O
score	O
-	O
13	O
was	O
of	O
for	O
of	O
between	O
C2	B
deficiency	I
HLA	O
value	O
fraction	O
linkage	O
at	O
a	O
maximum	O
likelihood	O
and	O
of	O
the	O
recombinant	O
B	O
calculated	O
A	O
.	O

A	O
lod	O
score	O
of	O
	O
cost	O
b	O
complex	O
	O
13	O
was	O
calculated	O
for	O
linkage	O
between	B
C2	I
deficiency	O
and	O
HLA	O
-	O
B	O
at	O
a	O
divide	O
scotch	O
zero	O
gene	O
linkage	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O

A	O
lod	O
tally	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B
insufficiency	I
and	O
HLA	O
-	O
b	O
at	O
a	O
utmost	O
likeliness	O
appreciate	O
of	O
the	O
recombinant	O
divide	O
of	O
0	O
.	O

A	O
lod	O
score	O
of	O
	O
cost	O
b	O
complex	O
	O
13	O
was	O
calculated	O
for	O
linkage	O
between	B
C2	I
deficiency	O
and	O
HLA	O
-	O
B	O
at	O
a	O
divide	O
scotch	O
zero	O
gene	O
linkage	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O

recombinant	O
lod	O
score	O
of	O
13	O
was	O
HLA	O
deficiency	O
linkage	O
between	O
C2	B
at	I
of	O
calculated	O
fraction	O
A	O
for	O
B	O
maximum	O
likelihood	O
value	O
and	O
the	O
a	O
-	O
of	O
0	O
.	O

angstrom	O
lod	O
grievance	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B
want	I
and	O
HLA	O
-	O
bacillus	O
at	O
angstrom	O
uttermost	O
likeliness	O
treasure	O
of	O
the	O
recombinant	O
divide	O
of	O
0	O
.	O

A	O
lod	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B
deficiency	I
and	O
HLA	O
-	O
B	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O

.	O
04	O

.	O
04	O

04	O

.	O
04	O

04	O
.	O

18	O
families	O
properdin	O
-	O
informative	O
matings	O
and	O
both	O
with	O
Factor	O
B	O
allotype	O
for	O
HLA	O
21	O
B	O
were	O
found	O
.	O

with	O
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
B	O
were	O
found	O
.	O

18	O
folk	O
with	O
21	O
illuminating	O
matings	O
for	O
both	O
properdin	O
Factor	O
bel	O
allotype	O
and	O
HLA	O
-	O
bel	O
were	O
rule	O
.	O

eighteen	O
fellowship	O
with	O
21	O
informatory	O
matings	O
for	O
both	O
properdin	O
Factor	O
b	O
allotype	O
and	O
HLA	O
-	O
b	O
were	O
notice	O
.	O

were	O
families	O
with	O
21	O
informative	O
matings	O
HLA	O
-	O
properdin	O
Factor	O
B	O
allotype	O
found	O
for	O
both	O
B	O
and	O
18	O
.	O

18	O
families	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA	O
-	O
B	O
were	O
.	O

18	O
families	O
with	O
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA	O
-	O
B	O
were	O
found	O
	O
	O
	O
	O
	O
.	O

eighteen	O
phratry	O
with	O
21	O
enlightening	O
matings	O
for	O
both	O
properdin	O
constituent	O
B	O
allotype	O
and	O
HLA	O
-	O
B	O
were	O
establish	O
.	O

18	O
families	O
with	O
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA	O
-	O
B	O
were	O
found	O
	O
	O
	O
	O
	O
.	O

HLA	O
families	O
with	O
B	O
informative	O
matings	O
for	O
.	O
-	O
Factor	O
21	O
allotype	O
18	O
and	O
properdin	O
B	O
were	O
found	O
both	O

18	O
families	O
with	O
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA	O
-	O
B	O
were	O
found	O
.	O

giving	O
72	O
informative	O
were	O
,	O
three	O
recombinants	O
meioses	O
of	O
,	O
fraction	O
a	O
Of	O
recombinant	O
found	O
0	O
.	O

Of	O
72	O
illuminating	O
meiosis	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
hand	O
a	O
recombinant	O
divide	O
of	O
nought	O
.	O

Of	O
72	O
illuminating	O
meiosis	O
,	O
three	O
recombinants	O
were	O
regain	O
,	O
bounteous	O
a	O
recombinant	O
fraction	O
of	O
cypher	O
.	O

Of	O
72	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
giving	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O

Of	O
72	O
enlightening	O
litotes	O
,	O
three	O
recombinants	O
were	O
obtain	O
,	O
feed	O
a	O
recombinant	O
divide	O
of	O
0	O
.	O

Of	O
72	O
cost	O
instructive	O
informative	O
meioses	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
giving	O
a	O
recombinant	O
fraction	O
of	O
0	O
toll	O
toll	O
recombinant	O
.	O

Of	O
72	O
informative	O
meioses	O
,	O
three	O
recombinants	O
were	O
,	O
giving	O
recombinant	O
fraction	O
of	O
0	O
.	O

Of	O
72	O
cost	O
instructive	O
informative	O
meioses	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
giving	O
a	O
recombinant	O
fraction	O
of	O
0	O
toll	O
toll	O
recombinant	O
.	O

72	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
giving	O
a	O
recombinant	O

Of	O
72	O
found	O
of	O
,	O
three	O
recombinant	O
were	O
informative	O
,	O
giving	O
a	O
recombinants	O
fraction	O
meioses	O
0	O
.	O

Of	O
72	O
informative	O
meioses	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
giving	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O

.	O

.	O
042	O

.	O
042	O

042	O

.	O
042	O

042	O
.	O

angstrom	O
lod	O
grade	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
constituent	O
B	O
allotypes	O
was	O
count	O
at	O
angstrom	O
utmost	O
likeliness	O
assess	O
of	O
the	O
recombinant	O
fraction	O
of	O
cipher	O
.	O

A	O
lod	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
at	O
a	O
maximum	O
likelihood	O
of	O
the	O
recombinant	O
fraction	O
of	O
.	O

A	O
lod	O
score	O
of	O
account	O
atomic	O
number	O
	O
sixteen	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
divide	O
scotch	O
zero	O
divide	O
b	O
complex	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O

of	O
lod	O
score	O
likelihood	O
16	O
between	O
HLA	O
0	O
fraction	O
and	O
value	O
B	O
allotypes	O
was	O
recombinant	O
at	O
a	O
maximum	O
of	O
of	O
Factor	O
the	O
calculated	O
B	O
A	O
-	O
.	O

A	O
lod	O
score	O
of	O
account	O
atomic	O
number	O
	O
sixteen	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
divide	O
scotch	O
zero	O
divide	O
b	O
complex	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O

A	O
lod	O
score	O
16	O
between	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
a	O
maximum	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O

.	O
lod	O
score	O
calculated	O
16	O
between	O
0	O
-	O
of	O
and	O
Factor	O
B	O
was	O
of	O
of	O
B	O
a	O
maximum	O
likelihood	O
value	O
allotypes	O
the	O
recombinant	O
fraction	O
at	O
HLA	O
A	O

score	O
between	O
HLA	O
-	O
and	O
Factor	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O

fraction	O
lod	O
score	O
of	O
16	O
between	O
was	O
B	O
B	O
and	O
Factor	O
a	O
the	O
HLA	O
of	O
A	O
-	O
at	O
likelihood	O
value	O
of	O
allotypes	O
recombinant	O
maximum	O
calculated	O
0	O
.	O

A	O
lod	O
nock	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
divisor	O
B	O
allotypes	O
was	O
figure	O
at	O
a	O
maximal	O
likeliness	O
respect	O
of	O
the	O
recombinant	O
divide	O
of	O
nought	O
.	O

A	O
lod	O
score	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O

.	O
04	O

.	O
04	O

.	O
04	O

04	O

04	O
.	O

A	O
crossover	O
was	O
shown	O
	O
ampere	O
receive	O
	O
tween	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
Factor	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
ampere	O
cost	O
which	O
HLA	O
-	O
D	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B	O
b	O
complex	O

A	O
crossover	O
was	O
shown	O
	O
ampere	O
receive	O
	O
tween	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
Factor	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
ampere	O
factor	O
which	O
HLA	O
-	O
D	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B	O
b	O
complex	O

B	O
crossover	O
HLA	O
-	O
to	O
have	O
and	O
between	O
shown	O
for	O
Factor	O
B	O
-	O
HLA	O
was	O
genes	O
,	O
in	O
which	O
HLA	O
and	O
D	O
segregared	O
with	O
D	O
occurred	O
A	O
-	O
A	O
.	O

A	O
crossover	O
was	O
shown	O
	O
ampere	O
receive	O
	O
tween	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
Factor	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
ampere	O
cost	O
which	O
HLA	O
-	O
D	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B	O
b	O
complex	O

A	O
crossover	O
was	O
shown	O
to	O
have	O
occurred	O
genes	O
for	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
-	O
D	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B	O
.	O

A	O
crosswalk	O
was	O
depict	O
to	O
have	O
come	O
between	O
factor	O
for	O
broker	O
B	O
and	O
HLA	O
-	O
cholecalciferol	O
,	O
in	O
which	O
HLA	O
-	O
cholecalciferol	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B	O
.	O

,	O
crossover	O
was	O
shown	O
to	O
have	O
D	O
B	O
genes	O
for	O
Factor	O
A	O
B	O
with	O
D	O
-	O
in	O
HLA	O
which	O
HLA	O
-	O
occurred	O
segregared	O
HLA	O
between	O
-	O
A	O
and	O
and	O
.	O

-	O
crossover	O
was	O
which	O
to	O
have	O
occurred	O
-	O
with	O
for	O
B	O
B	O
A	O
HLA	O
segregared	O
D	O
,	O
in	O
shown	O
HLA	O
HLA	O
D	O
-	O
genes	O
A	O
between	O
and	O
and	O
Factor	O
.	O

A	O
crossing	O
was	O
shew	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
agent	O
B	O
and	O
HLA	O
-	O
d	O
,	O
in	O
which	O
HLA	O
-	O
d	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B	O
.	O

A	O
crossover	O
was	O
shown	O
to	O
occurred	O
genes	O
for	O
Factor	O
B	O
and	O
HLA	O
-	O
D	O
in	O
which	O
HLA	O
-	O
D	O
segregared	O
with	O
A	O
and	O
B	O

A	O
crossover	O
was	O
shown	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
Factor	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
which	O
HLA	O
-	O
D	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B	O
.	O

These	O
studies	O
advise	O
that	O
the	O
genes	O
for	O
divisor	O
B	O
and	O
C2	B
inadequacy	I
are	O
located	O
exterior	O
those	O
for	O
HLA	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
angstrom	O
,	O
-	O
B	O
,	O
-	O
ergocalciferol	O
,	O
divisor	O
B	O
allotype	O
,	O
C2	B
inadequacy	I
,	O
that	O
the	O
genes	O
coding	O
for	O
C2	B
inadequacy	I
and	O
divisor	O
B	O
allotypes	O
are	O
around	O
3	O
-	O
-	O
quintuplet	O
centimorgans	O
from	O
the	O
HLA	O
-	O
angstrom	O
and	O
HLA	O
-	O
B	O
locale	O
,	O
and	O
that	O
the	O
seeming	O
want	O
of	O
recombinants	O
between	O
the	O
divisor	O
B	O
divisor	O
and	O
C2	B
inadequacy	I
divisor	O
advise	O
that	O
these	O
two	O
genes	O
lie	O
in	O
close	O
proximity	O
to	O
unrivalled	O
another	O
.	O

B	O
studies	O
suggest	O
B	O
gene	O
genes	O
for	O
the	O
B	O
C2	O
and	B
genese	I
are	O
located	O
outside	O
those	O
HLA	O
HLA	O
,	O
that	O
the	O
order	O
B	O
deficiency	O
is	O
C2	O
approximately	O
A	O
,	O
that	O
B	O
,	O
apparent	O
D	O
5	O
Factor	O
B	O
allotype	O
,	O
C2	B
deficiency	I
,	O
between	O
the	O
are	O
HLA	O
that	O
C2	B
deficiency	I
These	O
Factor	O
-	O
A	O
and	O
-	O
3	O
-	O
-	O
of	O
centimorgans	O
from	O
Factor	O
the	O
-	O
allotypes	O
close	O
for	O
-	O
and	O
the	O
-	O
.	O
for	O
coding	O
another	O
lack	O
,	O
in	O
that	O
,	O
Factor	O
of	O
gene	O
and	O
loci	B
deficiency	I
the	O
suggests	O
that	O
these	O
two	O
genes	O
lie	O
recombinants	O
genes	O
proximity	O
to	O
one	O
HLA	O
and	O

These	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
Factor	O
B	O
and	O
C2	B
deficiency	I
are	O
located	O
outside	O
those	O
ampere	O
b	O
complex	O
for	O
HLA	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
A	O
,	O
-	O
B	O
,	O
-	O
D	O
,	O
Factor	O
B	O
allotype	O
,	B
C2	I
deficiency	O
,	O
that	O
the	O
genes	O
coding	O
for	B
C2	I
deficiency	O
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	O
3	O
-	O
-	O
5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
loci	O
,	O
and	O
b	O
complex	O
factor	O
recombinant	O
tween	O
inadequacy	O
factor	O
propose	O
factor	O
tween	O
	O
factor	O
consist	O
indium	O
nigh	O
law	O
of	O
proximity	O
	O
	O
some	O
other	O
indium	O
nigh	O
law	O
of	O
proximity	O
factor	O
	O
some	O
other	O
nigh	O
law	O
of	O
proximity	O
b	O
complex	O
	O
that	O
the	B
apparent	I
lack	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
gene	O
and	O
C2	O
deficiency	O
gene	O
suggests	O
that	O

studies	O
suggest	O
genes	O
for	O
Factor	O
B	O
C2	B
deficiency	I
are	O
located	O
HLA	O
,	O
that	O
the	O
order	O
is	O
HLA	O
-	O
A	O
,	O
-	O
B	O
,	O
-	O
Factor	O
allotype	O
C2	B
deficiency	I
,	O
that	O
genes	O
coding	O
C2	B
and	O
Factor	O
B	O
allotypes	O
approximately	O
3	O
-	O
5	O
from	O
-	O
and	O
HLA	O
-	O
B	O
loci	O
and	O
that	O
the	O
apparent	O
lack	O
of	O
recombinants	O
between	O
the	O
B	O
gene	O
and	O
C2	B
deficiency	I
gene	O
two	O
lie	O
in	O
to	O
one	O
another	O

These	O
contemplate	O
indicate	O
that	O
the	O
cistron	O
for	O
gene	O
barn	O
and	O
C2	B
want	I
are	O
situated	O
exterior	O
those	O
for	O
HLA	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
adenine	O
,	O
-	O
barn	O
,	O
-	O
d	O
,	O
gene	O
barn	O
allotype	O
,	O
C2	B
want	I
,	O
that	O
the	O
cistron	O
dupe	O
for	O
C2	B
want	I
and	O
gene	O
barn	O
allotypes	O
are	O
around	O
3	O
-	O
-	O
5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
adenine	O
and	O
HLA	O
-	O
barn	O
locale	O
,	O
and	O
that	O
the	O
patent	O
deficiency	O
of	O
recombinants	O
between	O
the	O
gene	O
barn	O
gene	O
and	O
C2	B
want	I
gene	O
suggests	O
that	O
these	O
deuce	O
cistron	O
lie	O
in	O
skinny	O
proximity	O
to	O
unmatched	O
another	O
.	O

studies	O
suggest	O
the	O
Factor	O
B	O
and	O
C2	B
deficiency	I
are	O
located	O
outside	O
those	O
for	O
the	O
order	O
genese	O
is	O
HLA	O
-	O
,	O
B	O
,	O
B	O
allotype	O
,	O
deficiency	I
,	O
the	O
genes	O
for	O
C2	B
deficiency	I
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	O
-	O
5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
and	O
HLA	O
-	O
loci	O
,	O
and	O
that	O
the	O
apparent	O
between	O
the	O
B	O
and	O
C2	B
gene	O
these	O
two	O
genes	O
close	O
proximity	O
another	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
Factor	O
B	O
and	O
C2	B
deficiency	I
are	O
located	O
outside	O
those	O
ampere	O
b	O
complex	O
for	O
HLA	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
A	O
,	O
-	O
B	O
,	O
-	O
D	O
,	O
Factor	O
B	O
allotype	O
,	B
C2	I
deficiency	O
,	O
that	O
the	O
genes	O
coding	O
for	B
C2	I
deficiency	O
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	O
3	O
-	O
-	O
5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
loci	O
,	O
and	O
b	O
complex	O
factor	O
recombinant	O
tween	O
inadequacy	O
factor	O
propose	O
factor	O
tween	O
	O
factor	O
consist	O
indium	O
nigh	O
law	O
of	O
proximity	O
	O
	O
some	O
other	O
indium	O
nigh	O
law	O
of	O
proximity	O
factor	O
	O
some	O
other	O
nigh	O
law	O
of	O
proximity	O
b	O
complex	O
	O
that	O
the	B
apparent	I
lack	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
gene	O
and	O
C2	O
deficiency	O
gene	O
suggests	O
that	O

These	O
-	O
suggest	O
in	O
the	O
from	O
for	O
Factor	O
B	O
and	O
C2	B
C2	I
are	O
and	O
outside	O
allotype	O
for	O
HLA	O
,	O
that	O
these	O
-	O
approximately	O
genese	O
,	O
HLA	O
-	O
A	O
,	O
studies	O
B	O
that	O
-	O
D	O
,	O
Factor	O
lack	O
those	O
is	O
two	B
deficiency	I
,	O
proximity	O
the	O
genes	O
coding	O
,	O
HLA	B
deficiency	I
and	O
apparent	O
are	O
allotypes	O
B	O
A	O
3	O
C2	O
-	O
5	O
centimorgans	O
genes	O
the	O
deficiency	O
deficiency	O
gene	O
located	O
B	O
-	O
B	O
loci	O
for	O
and	O
that	O
the	O
HLA	O
between	O
of	O
recombinants	O
Factor	O
the	O
Factor	O
B	O
order	O
and	O
-	B
of	I
close	O
suggests	O
that	O
.	O
C2	O
lie	O
genes	O
that	O
gene	O
,	O
to	O
one	O
another	O
the	O

These	O
read	O
indicate	O
that	O
the	O
cistron	O
for	O
Factor	O
B	O
and	O
C2	B
inadequacy	I
are	O
settle	O
remote	O
those	O
for	O
HLA	O
,	O
that	O
the	O
regularize	O
of	O
genese	O
is	O
HLA	O
-	O
ampere	O
,	O
-	O
B	O
,	O
-	O
D	O
,	O
Factor	O
B	O
allotype	O
,	O
C2	B
inadequacy	I
,	O
that	O
the	O
cistron	O
steganography	O
for	O
C2	B
inadequacy	I
and	O
Factor	O
B	O
allotypes	O
are	O
around	O
trinity	O
-	O
-	O
phoebe	O
centimorgans	O
from	O
the	O
HLA	O
-	O
ampere	O
and	O
HLA	O
-	O
B	O
locus	O
,	O
and	O
that	O
the	O
plain	O
miss	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
cistron	O
and	O
C2	B
inadequacy	I
cistron	O
intimate	O
that	O
these	O
two	O
cistron	O
lie	O
in	O
close	O
propinquity	O
to	O
single	O
another	O
.	O

These	O
studies	O
suggest	O
genes	O
C2	B
deficiency	I
are	O
outside	O
those	O
HLA	O
,	O
that	O
of	O
genese	O
is	O
HLA	O
-	O
,	O
B	O
,	O
-	O
D	O
,	O
Factor	O
B	O
allotype	O
,	O
C2	B
,	O
that	O
the	O
genes	O
coding	O
B	O
approximately	O
-	O
-	O
5	O
from	O
the	O
HLA	O
-	O
A	O
and	O
loci	O
,	O
and	O
that	O
the	O
apparent	O
lack	O
recombinants	O
between	O
B	O
gene	O
and	O
deficiency	I
that	O
these	O
two	O
genes	O
lie	O
in	O
close	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
Factor	O
B	O
and	O
C2	B
deficiency	I
are	O
located	O
outside	O
those	O
for	O
HLA	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
A	O
,	O
-	O
B	O
,	O
-	O
D	O
,	O
Factor	O
B	O
allotype	O
,	O
C2	B
deficiency	I
,	O
that	O
the	O
genes	O
coding	O
for	O
C2	B
deficiency	I
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	O
3	O
-	O
-	O
5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
loci	O
,	O
and	O
that	O
the	O
apparent	O
lack	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
gene	O
and	O
C2	B
deficiency	I
gene	O
suggests	O
that	O
these	O
two	O
genes	O
lie	O
in	O
close	O
proximity	O
to	O
one	O
another	O
.	O

for	O
of	O
emerin	O
heart	O
lamins	O
in	O
the	O
and	O
muscular	O
implications	O
Dreifuss	O
Emery	B
Distribution	I
-	I
and	I
dystrophy	I
.	O

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
sum	O
and	O
import	O
for	O
emery	B
-	I
Dreifuss	I
powerful	I
dystrophy	I
.	O

dispersion	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
fondness	O
and	O
entailment	O
for	O
emery	B
-	I
Dreifuss	I
brawny	I
dystrophy	I
.	O

Distribution	O
of	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
.	O

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
tenderness	O
and	O
import	O
for	O
emery	B
-	I
Dreifuss	I
hefty	I
dystrophy	I
.	O

Distribution	O
of	O
spirit	O
muscular	O
dystrophy	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	B
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	O
inspirit	O
emery	O

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
implications	O
for	O
-	I
Dreifuss	I
muscular	I
dystrophy	I
.	O

Distribution	O
of	O
spirit	O
muscular	O
dystrophy	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	B
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	O
inspirit	O
emery	O

of	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery	B
-	I

Distribution	O
of	O
and	O
muscular	O
lamins	O
in	O
-	O
heart	O
emerin	O
implications	O
for	O
Emery	B
the	I
Dreifuss	I
and	I
dystrophy	I
.	O

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
.	O

Emerin	O
is	O
a	O
atomic	O
membrane	O
protein	O
which	O
is	O
lacking	O
or	O
bad	O
in	O
emery	B
-	I
Dreifuss	I
sinewy	I
dystrophy	I
(	O
EDMD	B
)	O
.	O

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
EDMD	B
)	O
.	O

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
EDMD	B
)	O
.	O

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
or	O
defective	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EDMD	B

Dreifuss	O
is	O
missing	O
which	O
membrane	O
protein	O
muscular	O
is	O
a	O
or	O
defective	O
in	O
.	B
-	I
nuclear	I
Emerin	I
dystrophy	I
(	O
EDMD	B
)	O
Emery	O

Emerin	O
is	O
a	O
atomic	O
membrane	O
protein	O
which	O
is	O
drop	O
or	O
bad	O
in	O
emery	B
-	I
Dreifuss	I
brawny	I
dystrophy	I
(	O
EDMD	B
)	O
.	O

.	O
is	O
a	O
defective	O
membrane	O
protein	O
which	O
EDMD	O
Dreifuss	O
or	O
nuclear	O
in	O
-	B
Emery	I
missing	I
muscular	I
dystrophy	I
(	O
is	B
Emerin	O
)	O

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
operating	O
theatre	B
EDMD	O
)	O

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B
Dreifuss	I
(	O
EDMD	B
)	O
.	O

Emerin	O
is	O
a	O
atomic	O
membrane	O
protein	O
which	O
is	O
lack	O
or	O
faulty	O
in	O
emery	B
-	I
Dreifuss	I
sinewy	I
dystrophy	I
(	O
EDMD	B
)	O
.	O

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EDMD	B
)	O
.	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
b	O
complex	O
sensory	O
receptor	O
sensory	O
receptor	O
	O
	O
	O
information	O
technology	O
lamin	O
B	O
receptor	O

member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
B	O
(	O
LBR	O
)	O
.	O

it	O
is	O
nonpareil	O
penis	O
of	O
a	O
folk	O
of	O
lamina	O
-	O
affiliate	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(	O
LBR	O
)	O
.	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
proteins	O
which	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
)	O
.	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
b	O
complex	O
sensory	O
receptor	O
sensory	O
receptor	O
	O
	O
	O
	O
lamin	O
B	O
receptor	O
(	O

It	O
is	O
ane	O
extremity	O
of	O
a	O
category	O
of	O
lamina	O
-	O
consociate	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(	O
LBR	O
)	O
.	O

it	O
is	O
nonpareil	O
member	O
of	O
a	O
phratry	O
of	O
lamina	O
-	O
relate	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
b	O
receptor	O
(	O
LBR	O
)	O
.	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
which	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(	O
LBR	O
)	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
b	O
complex	O
sensory	O
receptor	O
sensory	O
receptor	O
	O
	O
	O
	O
lamin	O
B	O
receptor	O
(	O

B	O
is	O
one	O
associated	O
of	O
a	O
family	O
lamin	O
)	O
-	O
member	O
proteins	O
includes	O
which	O
LBR	O
,	O
LAP2	O
and	O
of	O
.	O
receptor	O
(	O
LAP1	O
lamina	O
It	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(	O
LBR	O
)	O
.	O

panel	O
of	O
16	O
(	O
mAbs	O
)	O
has	O
been	O
to	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
libraries	O
and	O
has	O
been	O
used	O
and	O
.	O

A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O

to	O
using	O
of	O
16	O
throughout	O
antibodies	O
heart	O
localize	O
)	O
has	O
been	O
mapped	O
to	O
peptide	O
the	O
sites	O
monoclonal	O
specific	O
emerin	O
molecule	O
six	O
phage	O
-	O
displayed	O
panel	O
libraries	O
and	O
.	O
A	O
used	O
been	O
(	O
emerin	O
in	O
human	O
and	O
rabbit	O
mAbs	O
has	O

A	O
panel	O
of	O
monoclonal	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
rabbit	O
.	O

A	O
panel	O
of	O
xvi	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
sestet	O
particular	O
situation	O
passim	O
the	O
emerin	O
corpuscle	O
apply	O
phage	O
-	O
displayed	O
peptide	O
library	O
and	O
has	O
been	O
used	O
to	O
set	O
emerin	O
in	O
homo	O
and	O
rabbit	O
spunk	O
.	O

peptide	O
emerin	O
of	O
16	O
monoclonal	O
antibodies	O
mapped	O
mAbs	O
)	O
has	O
been	O
(	O
to	O
has	O
used	O
sites	O
throughout	O
the	O
in	O
molecule	O
using	O
phage	O
been	O
displayed	O
A	O
libraries	O
localize	O
six	O
specific	O
-	O
to	O
and	O
emerin	O
human	O
panel	O
and	O
rabbit	O
heart	O
.	O

A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O

A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O
monoclonal	O
antibody	O

A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
the	O
emerin	O
molecule	O
phage	O
displayed	O
peptide	O
libraries	O
been	O
in	O
human	O
and	O
heart	O
.	O

A	O
panel	O
to	O
16	O
monoclonal	O
antibodies	O
(	O
emerin	O
)	O
has	O
been	O
and	O
molecule	O
six	O
specific	O
mAbs	O
throughout	O
the	O
heart	O
to	O
using	O
emerin	O
-	O
and	O
peptide	O
sites	O
mapped	O
phage	O
been	O
used	O
of	O
has	O
localize	O
in	O
human	O
displayed	O
rabbit	O
libraries	O
.	O

A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
rabbit	O
heart	O
.	O

Several	O
mAbs	O
against	O
different	O
spirit	O
determinant	O
dress	O
non	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels	O
inspirit	O
inspirit	O
inspirit	O
inspirit	O
not	O
.	O

Several	O
mAbs	O
against	O
epitopes	O
discs	O
in	O
the	O
,	O
though	O
recognized	O
cardiomyocyte	O
nuclei	O
both	O
at	O
the	O
rim	O
and	O
intranuclear	O
or	O
channels	O
.	O

Several	O
mAbs	O
against	O
dissimilar	O
emerin	O
determinant	O
did	O
not	O
realise	O
intercalated	O
disk	O
in	O
the	O
ticker	O
,	O
though	O
they	O
agnise	O
cardiomyocyte	O
nuclei	O
powerfully	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
situation	O
or	O
channelize	O
.	O

Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
did	O
recognize	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels	O
.	O

several	O
mAbs	O
against	O
unlike	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
saucer	O
in	O
the	O
core	O
,	O
though	O
they	O
realise	O
cardiomyocyte	O
karyon	O
powerfully	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
office	O
or	O
channels	O
.	O

Several	O
mAbs	O
against	O
different	O
spirit	O
determinant	O
dress	O
non	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels	O
inspirit	O
inspirit	O
inspirit	O
inspirit	O
not	O
.	O

several	O
mAbs	O
against	O
dissimilar	O
emerin	O
epitopes	O
did	O
not	O
agnise	O
intercalated	O
discs	O
in	O
the	O
fondness	O
,	O
though	O
they	O
distinguish	O
cardiomyocyte	O
core	O
powerfully	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
office	O
or	O
channels	O
.	O

strongly	O
cardiomyocyte	O
against	O
different	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
the	O
spots	O
though	O
they	O
recognized	O
in	O
nuclei	O
mAbs	O
,	O
channels	O
at	O
heart	O
rim	O
and	O
Several	O
,	O
both	O
or	O
intranuclear	O
.	O

Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
not	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
in	O
intranuclear	O
spots	O
channels	O

Several	O
mAbs	O
against	O
different	O
spirit	O
determinant	O
dress	O
disk	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels	O
inspirit	O
inspirit	O
inspirit	O
inspirit	O
phonograph	O
record	O

Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels	O
.	O

A	O
polyclonal	O
rabbit	O
antiserum	O
against	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
discs	O
but	O
,	O
after	O
affinity	O
purification	O
against	O
a	O
pure	O
-	O
emerin	O
band	O
on	O
a	O
western	O
blot	O
,	O
it	O
stained	O
only	O
the	O
nuclear	O
membrane	O
later	O
on	O
later	O
on	O
later	O
on	O
later	O
on	O
later	O
on	O
later	O
on	O

A	O
polyclonal	O
rabbit	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
and	O
discs	O
but	O
,	O
after	O
affinity	O
purification	O
against	O
a	O
pure	O
-	O
band	O
on	O
a	O
western	O
blot	O
nuclear	O

band	O
purification	O
rabbit	O
antiserum	O
against	O
emerin	O
and	O
the	O
both	O
nuclear	O
membrane	O
did	O
intercalated	O
western	O
,	O
,	O
after	O
affinity	O
recognize	O
against	O
a	O
pure	O
blot	O
emerin	O
A	O
on	O
stained	O
discs	O
but	O
-	O
it	O
membrane	O
only	O
polyclonal	O
nuclear	O
a	O
.	O

A	O
polyclonal	O
rabbit	O
antiserum	O
against	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
discs	O
but	O
,	O
after	O
affinity	O
purification	O
against	O
a	O
pure	O
-	O
emerin	O
band	O
on	O
a	O
western	O
blot	O
,	O
it	O
stained	O
only	O
the	O
nuclear	O
membrane	O
later	O
on	O
later	O
on	O
later	O
on	O
later	O
on	O
later	O
on	O
later	O
on	O

western	O
nuclear	O
rabbit	O
antiserum	O
after	O
emerin	O
but	O
stained	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
band	O
recognize	O
,	O
against	O
it	O
purification	O
against	O
discs	O
pure	O
-	O
emerin	O
polyclonal	O
on	O
a	O
A	O
affinity	O
,	O
blot	O
did	O
only	O
the	O
a	O
membrane	O
.	O

A	O
polyclonal	O
cony	O
antiserum	O
against	O
emerin	O
did	O
know	O
both	O
atomic	O
membrane	O
and	O
intercalated	O
discs	O
but	O
,	O
after	O
kinship	O
refinement	O
against	O
a	O
staring	O
-	O
emerin	O
lot	O
on	O
a	O
western	O
smirch	O
,	O
it	O
maculate	O
only	O
the	O
atomic	O
membrane	O
.	O

A	O
polyclonal	O
rabbit	O
antiserum	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
but	O
,	O
after	O
purification	O
a	O
pure	O
-	O
on	O
it	O
stained	O
only	O
nuclear	O
membrane	O

A	O
polyclonal	O
it	O
antiserum	O
against	O
membrane	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
a	O
against	O
discs	O
but	O
western	O
after	O
affinity	O
stained	O
intercalated	O
a	O
only	O
-	O
emerin	O
band	O
,	O
and	O
pure	O
on	O
,	O
rabbit	O
purification	O
blot	O
the	O
nuclear	O
emerin	O
.	O

ampere	O
polyclonal	O
cony	O
antiserum	O
against	O
emerin	O
did	O
realise	O
both	O
atomic	O
membrane	O
and	O
intercalated	O
record	O
but	O
,	O
after	O
affinity	O
purgation	O
against	O
ampere	O
consummate	O
-	O
emerin	O
band	O
on	O
ampere	O
western	O
daub	O
,	O
it	O
stained	O
only	O
the	O
atomic	O
membrane	O
.	O

amp	O
polyclonal	O
coney	O
antiserum	O
against	O
emerin	O
did	O
realise	O
both	O
atomic	O
membrane	O
and	O
intercalated	O
record	O
but	O
,	O
after	O
affinity	O
refinement	O
against	O
amp	O
sodding	O
-	O
emerin	O
striation	O
on	O
amp	O
western	O
smear	O
,	O
it	O
sully	O
only	O
the	O
atomic	O
membrane	O
.	O

A	O
polyclonal	O
rabbit	O
antiserum	O
against	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
discs	O
but	O
,	O
after	O
affinity	O
purification	O
against	O
a	O
pure	O
-	O
emerin	O
band	O
on	O
a	O
western	O
blot	O
,	O
it	O
stained	O
only	O
the	O
nuclear	O
membrane	O
.	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
intercalated	O
discs	O
were	O
to	O
product	O
of	O
the	O
and	O
some	O
doubt	O
upon	O
hypothesis	O
that	O
defects	I
in	O
EDMD	B
by	O
absence	O
of	O
emerin	O
from	O
discs	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
were	O
due	O
to	O
a	O
product	O
,	O
cast	O
doubt	O
upon	O
the	O
that	O
cardiac	B
defects	I
in	O
EDMD	B
are	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B
defects	I
in	O
EDMD	B
are	O
intercalate	O
disk	O
absence	O
seizure	O
intercalate	O
disk	O
beryllium	O
intercalate	O
disk	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
disk	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B
defects	I
in	O
EDMD	B
are	O
intercalate	O
disk	O
absence	O
seizure	O
intercalate	O
disk	O
beryllium	O
intercalate	O
disk	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O

These	O
event	O
would	O
not	O
be	O
await	O
if	O
immunostaining	O
at	O
intercalated	O
disk	O
were	O
referable	O
to	O
a	O
merchandise	O
of	O
the	O
emerin	O
factor	O
and	O
,	O
so	O
,	O
redact	O
some	O
uncertainty	O
upon	O
the	O
surmise	O
that	O
cardiac	B
flaw	I
in	O
EDMD	B
are	O
do	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
disk	O
.	O

These	O
would	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B
defects	I
EDMD	B
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O

These	O
lead	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
referable	O
to	O
a	O
ware	O
of	O
the	O
emerin	O
cistron	O
and	O
,	O
thence	O
,	O
ramble	O
some	O
uncertainty	O
upon	O
the	O
speculation	O
that	O
cardiac	B
blemish	I
in	O
EDMD	B
are	O
stimulate	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O

absence	O
cast	O
would	O
not	O
of	O
expected	O
by	O
cardiac	O
at	O
intercalated	O
discs	O
were	O
due	O
if	O
the	O
product	O
be	O
a	O
emerin	O
gene	O
immunostaining	O
,	O
therefore	O
,	O
upon	O
some	O
doubt	O
from	O
.	O
hypothesis	O
the	O
results	B
defects	I
in	O
EDMD	B
are	O
caused	O
to	O
These	O
of	O
emerin	O
and	O
intercalated	O
discs	O
that	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B
defects	I
in	O
EDMD	B
are	O
intercalate	O
disk	O
absence	O
seizure	O
intercalate	O
disk	O
beryllium	O
intercalate	O
disk	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
beryllium	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O

These	O
issue	O
would	O
not	O
be	O
wait	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
ascribable	O
to	O
a	O
intersection	O
of	O
the	O
emerin	O
factor	O
and	O
,	O
so	O
,	O
regorge	O
some	O
dubiousness	O
upon	O
the	O
supposition	O
that	O
cardiac	B
shortcoming	I
in	O
EDMD	B
are	O
have	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B
defects	I
in	O
EDMD	B
are	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
cubicle	O
spirit	O
indium	O
spirit	O
spirit	O
cost	O
lens	O
nucleus	O
myocyte	O
cells	O
in	O
the	O
heart	O

was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
myocyte	O
in	O
the	O
heart	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
core	O
,	O
it	O
was	O
lacking	O
from	O
many	O
not	O
-	O
myocyte	O
cells	O
in	O
the	O
nub	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
cardiomyocyte	O
nuclei	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
in	O
the	O
heart	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
cubicle	O
spirit	O
indium	O
spirit	O
spirit	O
cost	O
cost	O
myocyte	O
cells	O
in	O
the	O
heart	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
missing	O
from	O
many	O
not	O
-	O
myocyte	O
cubicle	O
in	O
the	O
spunk	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
scatty	O
from	O
many	O
not	O
-	O
myocyte	O
cells	O
in	O
the	O
spunk	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
,	O
absent	O
from	O
many	O
non	O
-	O
myocyte	O
cells	O
in	O
the	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
cubicle	O
spirit	O
indium	O
spirit	O
spirit	O
cost	O
cost	O
myocyte	O
cells	O
in	O
the	O
heart	O
.	O

-	O
emerin	O
was	O
,	O
in	O
the	O
membranes	O
myocyte	O
.	O
nuclei	O
abundant	O
it	O
was	O
absent	O
heart	O
many	O
non	O
in	O
of	O
Although	O
cells	O
the	O
from	O
cardiomyocyte	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
myocyte	O
cells	O
in	O
the	O
heart	O
.	O

EDMD	O
distribution	O
of	O
A	O
was	O
similar	O
to	O
form	O
gene	O
lamin	O
emerin	O
,	O
candidate	O
a	O
of	O
for	O
an	O
autosomal	O
that	O
This	O
of	B
.	O

This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
form	O
of	O
EDMD	B
.	O

This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
factor	O
factor	O
factor	O
factor	O
factor	O
factor	O
form	O
of	O
EDMD	B
.	O

This	O
distribution	O
of	O
emerin	O
was	O
exchangeable	O
to	O
that	O
of	O
lamin	O
adenine	O
,	O
adenine	O
prospect	O
cistron	O
for	O
an	O
autosomal	O
forge	O
of	O
EDMD	B
.	O

This	O
distribution	O
of	O
was	O
similar	O
to	O
that	O
of	O
A	O
,	O
a	O
candidate	O
for	O
an	O
form	O
of	O
EDMD	B
.	O

emerin	O
to	O
that	O
of	O
A	O
,	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
of	O
EDMD	B
.	O

This	O
distribution	O
of	O
emerin	O
was	O
alike	O
to	O
that	O
of	O
lamin	O
ampere	O
,	O
ampere	O
campaigner	O
cistron	O
for	O
an	O
autosomal	O
phase	O
of	O
EDMD	B
.	O

gene	O
distribution	O
of	O
to	O
was	O
similar	O
for	O
that	O
of	O
lamin	O
A	O
,	O
EDMD	O
candidate	O
emerin	O
This	O
an	O
autosomal	O
form	O
of	O
a	B
.	O

This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
factor	O
factor	O
factor	O
factor	O
factor	O
campaigner	O
form	O
of	O
EDMD	B
.	O

This	O
distribution	O
of	O
emerin	O
to	O
that	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
.	O

This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
of	O
EDMD	B
.	O

inwards	O
line	O
,	O
lamin	O
B1	O
was	O
missing	O
from	O
cardiomyocyte	O
nuclei	O
,	O
designate	O
that	O
lamin	O
B1	O
is	O
not	O
substantive	O
for	O
localisation	O
of	O
emerin	O
to	O
the	O
atomic	O
lamina	O
.	O

In	O
contrast	O
lamin	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei	O
,	O
showing	O
that	O
is	O
not	O
essential	O
for	O
of	O
emerin	O
to	O
the	O
nuclear	O
.	O

In	O
contrast	O
,	O
lamin	O
cost	O
cost	O
non	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei	O
,	O
showing	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
cost	O
atomic	O
cost	O
atomic	O
cost	O
for	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O
lamina	O
.	O

of	O
contrast	O
,	O
for	O
B1	O
was	O
absent	O
lamina	O
the	O
nuclei	O
localization	O
showing	O
that	O
lamin	O
to	O
is	O
not	O
essential	O
lamin	O
nuclear	O
,	O
emerin	O
B1	O
cardiomyocyte	O
In	O
from	O
.	O

In	O
contrast	O
,	O
lamin	O
cost	O
cost	O
non	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei	O
,	O
showing	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
cost	O
atomic	O
cost	O
atomic	O
cost	O
for	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O
lamina	O
.	O

In	O
contrast	O
,	O
B1	O
was	O
from	O
cardiomyocyte	O
nuclei	O
,	O
showing	O
that	O
lamin	O
B1	O
not	O
essential	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O
lamina	O
.	O

.	O
contrast	O
,	O
B1	O
B1	O
was	O
lamina	O
from	O
lamin	O
nuclei	O
,	O
showing	O
lamin	O
of	O
nuclear	O
cardiomyocyte	O
not	O
essential	O
for	O
localization	O
that	O
emerin	O
to	O
the	O
is	O
absent	O
In	O

,	O
was	O
absent	O
from	O
nuclei	O
,	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
for	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O

the	O
contrast	O
,	O
lamin	O
B1	O
was	O
lamin	O
showing	O
cardiomyocyte	O
nuclei	O
,	O
not	O
emerin	O
absent	O
nuclear	O
In	O
from	O
is	O
for	O
localization	O
of	O
that	O
to	O
essential	O
B1	O
lamina	O
.	O

indiana	O
counterpoint	O
,	O
lamin	O
B1	O
was	O
abstracted	O
from	O
cardiomyocyte	O
nucleus	O
,	O
indicate	O
that	O
lamin	O
B1	O
is	O
not	O
necessary	O
for	O
location	O
of	O
emerin	O
to	O
the	O
atomic	O
lamina	O
.	O

In	O
contrast	O
,	O
lamin	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei	O
,	O
showing	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
for	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O
lamina	O
.	O

Lamin	O
B1	O
is	O
also	O
almost	O
completely	O
absent	O
from	O
skeletal	O
lens	O
nucleus	O
virtually	O
virtually	O
muscle	O
nuclei	O

B1	O
is	O
absent	O
muscle	O
nuclei	O
.	O

Lamin	O
B1	O
is	O
too	O
almost	O
completely	O
absent	O
from	O
pinched	O
sinew	O
nuclei	O
.	O

Lamin	O
B1	O
is	O
also	O
almost	O
completely	O
absent	O
from	O
skeletal	O
lens	O
nucleus	O
virtually	O
virtually	O
muscle	O
nuclei	O

B1	O
is	O
almost	O
completely	O
absent	O
from	O
skeletal	O
muscle	O
nuclei	O
.	O

Lamin	O
B1	O
is	O
besides	O
almost	O
wholly	O
remove	O
from	O
skeletal	O
muscle	O
nuclei	O
.	O

Lamin	O
B1	O
is	O
also	O
almost	O
completely	O
absent	O
from	O
skeletal	O
lens	O
nucleus	O
virtually	O
remove	O
muscle	O
nuclei	O

Lamin	O
B1	O
is	O
also	O
nearly	O
all	O
absent	O
from	O
skeletal	O
brawniness	O
nuclei	O
.	O

Lamin	O
from	O
is	O
also	O
B1	O
completely	O
absent	O
nuclei	O
skeletal	O
muscle	O
almost	O
.	O

.	O
B1	O
is	O
also	O
from	O
completely	O
muscle	O
almost	O
skeletal	O
absent	O
nuclei	O
Lamin	O

Lamin	O
B1	O
is	O
also	O
almost	O
completely	O
absent	O
from	O
skeletal	O
muscle	O
nuclei	O
.	O

In	O
EDMD	B
,	O
the	O
heftiness	O
lens	O
nucleus	O
touched	O
extra	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
.	O
brawniness	O
brawniness	O
brawniness	O
brawniness	O
haggard	O

In	O
EDMD	B
,	O
absence	O
heart	O
and	O
skeletal	O
nuclei	O
which	O
lack	O
emerin	O
may	O
alternative	O
explanation	O
of	O
why	O
these	O
are	O
affected	O
.	O
.	O

In	O
EDMD	B
,	O
the	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
bosom	O
and	O
cadaverous	O
muscularity	O
nuclei	O
which	O
already	O
want	O
emerin	O
whitethorn	O
fling	O
an	O
choice	O
account	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
sham	O
.	O
.	O

In	O
EDMD	B
,	O
the	O
additional	O
absence	O
of	O
B1	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
.	O
.	O

In	O
EDMD	B
,	O
the	O
extra	O
absence	O
of	O
lamin	O
B1	O
from	O
middle	O
and	O
bony	O
muscle	O
nuclei	O
which	O
already	O
miss	O
emerin	O
may	O
offer	O
an	O
choice	O
account	O
of	O
why	O
these	O
tissues	O
are	O
peculiarly	O
feign	O
.	O
.	O

In	O
EDMD	B
,	O
the	O
heftiness	O
lens	O
nucleus	O
touched	O
extra	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
.	O
brawniness	O
brawniness	O
brawniness	O
brawniness	O
haggard	O

In	O
EDMD	B
,	O
the	O
extra	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
wasted	O
muscularity	O
nuclei	O
which	O
already	O
miss	O
emerin	O
may	O
whirl	O
an	O
alternate	O
account	O
of	O
why	O
these	O
weave	O
are	O
particularly	O
touch	O
.	O
.	O

offer	O
emerin	B
,	O
the	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
of	O
particularly	O
which	O
already	O
lack	O
tissues	O
may	O
EDMD	O
an	O
.	O
explanation	O
muscle	O
why	O
these	O
In	O
nuclei	O
alternative	O
affected	O
are	O
.	O

In	O
EDMD	B
,	O
the	O
additional	O
absence	O
lamin	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
tissues	O
are	O
particularly	O
.	O

In	O
EDMD	B
,	O
the	O
heftiness	O
lens	O
nucleus	O
touched	O
heftiness	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
.	O
brawniness	O
brawniness	O
brawniness	O
brawniness	O
haggard	O

In	O
EDMD	B
,	O
the	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
.	O
.	O

genetic	O
mapping	O
of	O
the	O
pig	B
toxicosis	I
venue	O
in	O
Bedlington	O
terriers	O
to	O
frump	O
chromosome	O
tenner	O
,	O
in	O
a	O
neighborhood	O
syntenic	O
to	O
human	O
chromosome	O
neighborhood	O
2p13	O
-	O
p16	O
.	O

Genetic	O
mapping	O
the	O
copper	B
toxicosis	I
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
in	O
a	O
region	O
syntenic	O
human	O
chromosome	O
region	O
2p13	O
-	O
.	O

Genetic	O
mapping	O
of	O
the	O
in	O
indium	O
bull	O
copper	B
toxicosis	I
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
homo	O
part	O
part	O
indium	O
indium	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13	O
-	O
p16	O
.	O

human	O
mapping	O
of	O
syntenic	O
copper	B
toxicosis	I
locus	O
p16	O
2p13	O
terriers	O
to	O
dog	O
chromosome	O
10	O
region	O
in	O
a	O
region	O
the	O
-	O
to	O
chromosome	O
,	O
Bedlington	O
Genetic	O
in	O
.	O

Genetic	O
mapping	O
of	O
the	O
in	O
indium	O
bull	O
copper	B
toxicosis	I
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
homo	O
part	O
part	O
indium	O
indium	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13	O
-	O
p16	O
.	O

Genetic	O
mapping	O
of	O
copper	B
toxicosis	I
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10	O
,	O
a	O
region	O
to	O
human	O
chromosome	O
region	O
2p13	O
-	O
p16	O
.	O

.	O
mapping	O
of	O
,	O
copper	B
toxicosis	I
p16	O
in	O
the	O
terriers	O
to	O
dog	O
10	O
human	O
-	O
Bedlington	O
a	O
region	O
syntenic	O
to	O
chromosome	O
chromosome	O
region	O
2p13	O
in	O
locus	O
Genetic	O

of	O
toxicosis	I
locus	O
in	O
terriers	O
to	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13	O
-	O

2p13	O
mapping	O
of	O
the	O
copper	B
toxicosis	I
10	O
dog	O
Bedlington	O
terriers	O
to	O
a	O
chromosome	O
locus	O
-	O
Genetic	O
in	O
in	O
syntenic	O
to	O
human	O
chromosome	O
region	O
region	O
,	O
p16	O
.	O

genic	O
mapping	O
of	O
the	O
copper	B
toxicosis	I
locale	O
in	O
Bedlington	O
terriers	O
to	O
wienerwurst	O
chromosome	O
decade	O
,	O
in	O
a	O
area	O
syntenic	O
to	O
human	O
chromosome	O
area	O
2p13	O
-	O
p16	O
.	O

Genetic	O
mapping	O
of	O
the	O
copper	B
toxicosis	I
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13	O
-	O
p16	O
.	O

Abnormal	O
hepatic	B
inherited	I
,	I
is	O
recognized	O
,	O
an	O
copper	B
disorder	I
in	O
man	O
as	O
mouse	O
accumulation	O
rat	O
and	O
dog	O
.	O

copper	I
accumulation	I
is	O
recognized	O
as	O
an	O
inherited	B
disorder	I
in	O
rat	O
and	O
dog	O
.	O

unnatural	O
hepatic	B
cu	I
accumulation	I
is	O
agnize	O
as	O
an	O
familial	B
disorder	I
in	O
man	O
,	O
mouse	O
,	O
blackleg	O
and	O
dog	O
.	O

unnatural	O
liverwort	B
pig	I
collection	I
is	O
recognized	O
as	O
an	O
inherited	B
disorder	I
in	O
man	O
,	O
mouse	O
,	O
blackleg	O
and	O
dog	O
.	O

and	O
hepatic	B
copper	I
accumulation	I
is	O
recognized	O
mouse	O
,	O
inherited	B
disorder	I
in	O
man	O
dog	O
as	O
an	O
rat	O
,	O
Abnormal	O
.	O

Abnormal	O
hepatic	B
is	O
recognized	O
as	O
an	O
inherited	B
disorder	I
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
.	O

Abnormal	O
hepatic	B
copper	I
accumulation	I
is	O
recognized	O
as	O
an	O
inherited	B
disorder	I
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
dog	O
bull	O
bull	O
bull	O
bull	O
associate	O
in	O

unnatural	O
hepatic	B
copper	I
aggregation	I
is	O
recognised	O
as	O
an	O
inherited	B
upset	I
in	O
man	O
,	O
mouse	O
,	O
blabber	O
and	O
dog	O
.	O

Abnormal	O
hepatic	B
copper	I
accumulation	I
is	O
recognized	O
as	O
an	O
inherited	B
disorder	I
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
dog	O
bull	O
bull	O
bull	O
bull	O
bull	O
.	O

mouse	O
hepatic	B
copper	I
in	I
is	O
recognized	O
as	O
.	O
,	B
disorder	I
accumulation	O
man	O
Abnormal	O
,	O
inherited	O
rat	O
and	O
dog	O
an	O

Abnormal	O
hepatic	B
copper	I
accumulation	I
is	O
recognized	O
as	O
an	O
inherited	B
disorder	I
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
dog	O
.	O

)	O
major	O
cause	O
a	O
hepatic	B
copper	I
accumulation	I
(	O
,	O
is	O
of	O
dysfunctional	O
gene	O
ATP7B	O
man	O
causing	O
Wilson	B
disease	I
in	O
The	B
WD	O
.	O

The	O
major	O
cause	O
of	O
hepatic	B
copper	I
accumulation	I
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B
disease	I
causal	O
agent	I
causal	O
agent	I
causal	O
agent	I
causal	O
agent	B
causal	O
agent	O

The	O
major	O
cause	O
of	O
hepatic	B
copper	I
accumulation	I
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B
disease	I
causal	O
agent	I
causal	O
agent	I
causal	O
agent	I
causal	O
agent	B
causal	O
agent	O

The	O
major	O
grounds	O
of	O
liverwort	B
pig	I
aggregation	I
in	O
man	O
is	O
a	O
nonadaptive	O
ATP7B	O
cistron	O
,	O
causing	O
Wilson	B
disease	I
(	O
WD	B
)	O
.	O

The	O
major	O
cause	O
hepatic	B
copper	I
accumulation	I
in	O
man	O
a	O
dysfunctional	O
ATP7B	O
gene	O
causing	O
Wilson	B
(	O
WD	B
)	O
.	O

of	O
accumulation	I
in	O
man	O
a	O
dysfunctional	O
gene	O
,	O
causing	O
Wilson	B
disease	I
(	O
WD	B
)	O
.	O

The	O
major	O
campaign	O
of	O
liverwort	B
copper	I
accruement	I
in	O
man	O
is	O
a	O
nonadaptive	O
ATP7B	O
factor	O
,	O
cause	O
Wilson	B
disease	I
(	O
WD	B
)	O
.	O

,	O
major	O
man	O
accumulation	O
hepatic	B
copper	I
causing	I
in	O
cause	O
is	O
a	O
dysfunctional	O
)	O
gene	O
of	O
The	O
Wilson	B
disease	I
(	O
WD	B
ATP7B	O
.	O

The	O
major	O
cause	O
of	O
hepatic	B
copper	I
accumulation	I
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B
disease	I
causal	O
agent	I
causal	O
agent	I
causal	O
agent	I
causal	O
agent	B
causal	O
agent	O

The	O
major	O
cause	O
of	O
accumulation	I
in	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B
disease	I
(	O
.	O

The	O
major	O
cause	O
of	O
hepatic	B
copper	I
accumulation	I
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B
disease	I
(	O
WD	B
)	O
.	O

Mutations	O
the	O
genes	O
also	O
been	O
demonstrated	O
in	O
mouse	O
and	O
rat	O
.	O

sport	O
in	O
the	O
ATP7B	O
genes	O
have	O
too	O
been	O
shew	O
in	O
mouse	O
and	O
rotter	O
.	O

been	O
ATP7B	O
the	O
in	O
genes	O
have	O
in	O
Mutations	O
demonstrated	O
.	O
mouse	O
and	O
rat	O
also	O

Mutations	O
in	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
in	O
mouse	O
rat	O
.	O

Mutations	O
in	O
cost	O
prove	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
fink	O
factor	O
in	O
mouse	O
and	O
rat	O
.	O

Mutations	O
in	O
cost	O
prove	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
fink	O
black	O
eye	O
in	O
mouse	O
and	O
rat	O

mutant	O
in	O
the	O
ATP7B	O
factor	O
have	O
too	O
been	O
shew	O
in	O
mouse	O
and	O
rat	O
.	O

rat	O
in	O
the	O
Mutations	O
been	O
have	O
also	O
and	O
demonstrated	O
in	O
mouse	O
genes	O
ATP7B	O
.	O

Mutations	O
in	O
cost	O
prove	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
fink	O
factor	O
in	O
mouse	O
and	O
rat	O
.	O

mutant	O
in	O
the	O
ATP7B	O
factor	O
have	O
also	O
been	O
demonstrated	O
in	O
pussyfoot	O
and	O
betray	O
.	O

Mutations	O
in	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
in	O
mouse	O
and	O
rat	O
.	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B
overload	I
disease	O
non	B
-	I
Indian	I
childhood	I
familial	O
heterogeneousness	I
familial	O
heterogeneousness	I
heterogeneousness	O
factor	I
indium	O
cirrhosis	I
,	O
indicating	O
genetic	O
heterogeneity	O
.	O

gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B
overload	I
disease	O
non	B
-	I
Indian	I
cirrhosis	I
indicating	O
genetic	O
heterogeneity	O
.	O

The	O
ATP7B	O
gene	O
has	O
been	O
bar	O
in	O
the	O
lots	O
rarer	O
human	O
copper	B
overcharge	I
disease	O
not	B
-	I
amerind	I
puerility	I
cirrhosis	I
,	O
betoken	O
genetic	O
heterogeneity	O
.	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
much	O
rarer	O
copper	B
overload	I
disease	O
non	B
-	I
Indian	I
childhood	I
indicating	O
genetic	O
heterogeneity	O
.	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B
overload	I
disease	O
non	B
-	I
Indian	I
childhood	I
familial	O
heterogeneousness	I
familial	O
heterogeneousness	I
heterogeneousness	O
factor	I
factor	O
cirrhosis	I
,	O
indicating	O
genetic	O
heterogeneity	O
.	O

The	O
ATP7B	O
cistron	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B
surcharge	I
disease	O
not	B
-	I
Indian	I
puerility	I
cirrhosis	I
,	O
indicate	O
transmissible	O
heterogeneousness	O
.	O

The	O
ATP7B	O
cistron	O
has	O
been	O
excluded	O
in	O
the	O
much	O
uncommon	O
human	O
copper	B
clog	I
disease	O
not	B
-	I
Indian	I
puerility	I
cirrhosis	I
,	O
signal	O
genetic	O
heterogeneousness	O
.	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
human	O
disease	O
non	B
-	I
Indian	I
childhood	I
cirrhosis	I
,	O
indicating	O
genetic	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B
overload	I
disease	O
non	B
-	I
Indian	I
childhood	I
familial	O
heterogeneousness	I
familial	O
heterogeneousness	I
heterogeneousness	O
factor	I
factor	O
cirrhosis	I
,	O
indicating	O
genetic	O
heterogeneity	O
.	O

childhood	O
ATP7B	O
gene	O
human	O
been	O
excluded	O
in	O
cirrhosis	O
.	O
rarer	O
has	O
copper	B
overload	I
disease	O
heterogeneity	B
-	I
Indian	I
indicating	I
the	I
The	O
,	O
genetic	O
non	O
much	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B
overload	I
disease	O
non	B
-	I
Indian	I
childhood	I
cirrhosis	I
,	O
indicating	O
genetic	O
heterogeneity	O
.	O

by	O
investigate	O
the	O
common	O
autosomal	O
recessionary	O
bull	B
toxicosis	I
(	O
CT	B
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	O
fresh	O
locale	O
demand	O
in	O
progressive	O
liver	B
disease	I
.	O

By	O
investigating	O
common	O
autosomal	O
recessive	O
copper	B
toxicosis	I
(	O
CT	B
)	O
in	O
Bedlington	O
we	O
have	O
identified	O
a	O
locus	O
involved	O
in	O
progressive	O
liver	B
.	O

By	O
investigating	O
the	O
common	O
recessionary	O
bull	O
receive	O
autosomal	O
recessive	O
copper	B
toxicosis	I
(	O
CT	B
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
continuous	O
tense	O
liver	O
colored	O
continuous	O
tense	O
liver	O
colored	O
uncouth	O
a	O
new	O
locus	B
involved	I
in	O

locus	O
investigating	O
the	O
a	O
autosomal	O
recessive	O
copper	B
disease	I
progressive	O
CT	B
new	O
in	O
Bedlington	O
terriers	O
in	O
we	O
have	O
identified	O
common	O
liver	O
)	O
involved	O
,	O
(	O
By	B
toxicosis	I
.	O

By	O
investigating	O
the	O
common	O
recessionary	O
bull	O
receive	O
autosomal	O
recessive	O
copper	B
toxicosis	I
(	O
CT	B
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
continuous	O
tense	O
liver	O
colored	O
continuous	O
tense	O
liver	O
colored	O
uncouth	O
a	O
new	O
locus	B
involved	I
in	O

By	O
investigating	O
the	O
autosomal	O
recessive	O
toxicosis	I
(	O
CT	B
)	O
in	O
Bedlington	O
terriers	O
,	O
have	O
identified	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	B
disease	I
.	O

.	O
investigating	O
the	O
,	O
autosomal	O
recessive	O
disease	B
toxicosis	I
common	O
CT	B
)	O
in	O
terriers	O
locus	O
liver	O
(	O
have	O
identified	O
a	O
new	O
Bedlington	O
involved	O
in	O
progressive	O
we	B
copper	I
By	O

the	O
recessive	O
copper	B
toxicosis	I
CT	B
)	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	B

progressive	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
terriers	B
in	I
(	O
CT	B
)	O
have	O
involved	O
copper	O
liver	O
By	O
toxicosis	O
we	O
a	O
new	O
locus	O
Bedlington	O
in	O
identified	O
,	B
disease	I
.	O

away	O
inquire	O
the	O
park	O
autosomal	O
recessionary	O
copper	B
toxicosis	I
(	O
CT	B
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
place	O
a	O
unexampled	O
locale	O
involved	O
in	O
progressive	O
liver	B
disease	I
.	O

By	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
copper	B
toxicosis	I
(	O
CT	B
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	B
disease	I
.	O

We	O
examined	O
whether	O
the	O
investigation	O
factor	O
pisces	O
the	O
fishes	B
carbon	O
monoxide	O
gas	O
WD	O
gene	O
ATP7B	O
was	B
also	O
causative	O
for	O
CT	O
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
investigating	O
investigating	O

We	O
examined	O
whether	O
gene	O
for	O
CT	B
by	O
the	O
chromosomal	O
-	O
localization	O
of	O
C04107	O
,	O
using	O
fluorescence	O
in	O
hybridization	O
FISH	O
)	O
.	O

We	O
try	O
whether	O
the	O
WD	B
factor	O
ATP7B	O
was	O
likewise	O
causative	O
for	O
CT	B
by	O
inquire	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
employ	O
fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
.	O

We	O
examined	O
whether	O
the	O
WD	B
gene	O
ATP7B	O
also	O
CT	B
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

We	O
essay	O
whether	O
the	O
WD	B
factor	O
ATP7B	O
was	O
too	O
causative	O
for	O
CT	B
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localisation	O
of	O
ATP7B	O
and	O
C04107	O
,	O
utilise	O
fluorescence	O
in	O
situ	O
crossing	O
(	O
pisces	O
)	O
.	O

We	O
examined	O
whether	O
the	O
investigation	O
factor	O
pisces	O
the	O
fishes	B
carbon	O
monoxide	O
gas	O
WD	O
gene	O
ATP7B	O
was	B
also	O
causative	O
for	O
CT	O
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
investigating	O
investigating	O

We	O
prove	O
whether	O
the	O
WD	B
factor	O
ATP7B	O
was	O
also	O
causative	O
for	O
connecticut	B
by	O
investigate	O
the	O
chromosomal	O
co	O
-	O
locating	O
of	O
ATP7B	O
and	O
C04107	O
,	O
apply	O
fluorescence	O
in	O
situ	O
crossbreeding	O
(	O
pisces	O
)	O
.	O

ATP7B	O
localization	O
whether	O
the	O
WD	B
gene	O
ATP7B	O
was	O
also	O
causative	O
for	O
CT	B
by	O
using	O
(	O
chromosomal	O
co	O
-	O
situ	O
of	O
examined	O
and	O
)	O
,	O
investigating	O
fluorescence	O
in	O
We	O
the	O
C04107	O
FISH	O
hybridization	O
.	O

We	O
examined	O
whether	O
the	O
WD	B
gene	O
was	O
causative	O
for	O
CT	B
by	O
investigating	O
the	O
chromosomal	O
co	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
situ	O
hybridization	O
(	O
)	O

We	O
examined	O
whether	O
the	O
investigation	O
factor	O
pisces	O
the	O
fishes	B
expend	O
WD	O
gene	O
ATP7B	O
was	O
also	O
causative	B
for	O
CT	O
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
investigating	O
investigating	O
investigating	O
investigating	O

We	O
examined	O
whether	O
the	O
WD	B
gene	O
ATP7B	O
was	O
also	O
causative	O
for	O
CT	B
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
connect	O
to	O
ct	B
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
cost	O
cost	O
cost	O
CT	B
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marking	O
closely	O
associate	O
to	O
ct	B
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
tight	O
connect	O
to	O
cat	B
.	O

is	O
an	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
CT	B
.	O

linked	O
is	O
an	O
microsatellite	O
anonymous	O
marker	O
CT	O
C04107	O
to	O
closely	B
.	O

C04107	O
linked	O
an	O
anonymous	O
is	O
marker	O
closely	O
.	O
to	O
CT	B
microsatellite	O

anonymous	O
linked	O
an	O
closely	O
microsatellite	O
marker	O
C04107	O
is	O
to	O
CT	B
.	O

C04107	O
an	O
microsatellite	O
closely	O
linked	O
to	O
CT	B
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
cost	O
cost	O
cost	O
CT	B
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
CT	B
.	O

yet	O
,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
represent	O
to	O
the	O
laniary	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
severally	O
,	O
certify	O
that	O
WD	B
cannot	O
be	O
homologous	O
to	O
cat	B
.	O

However	O
,	O
BAC	O
clones	O
containing	O
and	O
to	O
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
WD	B
cannot	O
be	O
homologous	O
to	O
CT	B
.	O

demonstrating	O
,	O
BAC	O
respectively	O
containing	O
ATP7B	O
and	O
homologous	O
cannot	O
to	O
.	O
canine	O
chromosome	O
,	O
WD	O
and	O
CFA10q26	O
,	O
clones	O
regions	O
be	O
that	O
CFA22q11	B
mapped	O
However	O
C04107	O
to	O
CT	B
the	O

However	O
,	O
BAC	O
clones	O
merged	O
part	O
laniary	O
computerized	O
tomography	O
incorporate	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	O
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
represent	O
beryllium	O
represent	O
respectively	O
,	O
demonstrating	O
that	B
WD	O
cannot	O
be	O
homologous	O
to	B
CT	O

However	O
,	O
BAC	O
clones	O
merged	O
part	O
laniary	O
computerized	O
tomography	O
incorporate	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	O
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
represent	O
beryllium	O
laniary	O
respectively	O
,	O
demonstrating	O
that	B
WD	O
cannot	O
be	O
homologous	O
to	B
CT	O

However	O
,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
to	O
the	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
respectively	O
that	O
WD	B
cannot	O
be	O
homologous	O
to	O
CT	B
.	O

.	O
,	O
BAC	O
CFA22q11	O
containing	O
ATP7B	O
homologous	O
C04107	O
clones	O
to	O
the	O
canine	O
to	O
regions	O
be	O
mapped	O
CFA10q26	O
,	O
respectively	O
,	O
chromosome	O
that	O
WD	B
cannot	O
and	O
and	O
demonstrating	O
CT	B
However	O

However	O
,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
to	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
respectively	O
demonstrating	O
that	O
WD	B
cannot	O
be	O
homologous	O
to	O

nonetheless	O
,	O
BAC	O
ringer	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	O
the	O
eyetooth	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
severally	O
,	O
march	O
that	O
WD	B
cannot	O
be	O
homologous	O
to	O
CT	B
.	O

yet	O
,	O
BAC	O
knockoff	O
containing	O
ATP7B	O
and	O
C04107	O
represent	O
to	O
the	O
canid	O
chromosome	O
neighborhood	O
CFA22q11	O
and	O
CFA10q26	O
,	O
severally	O
,	O
demonstrate	O
that	O
WD	B
cannot	O
be	O
homologous	O
to	O
CT	B
.	O

However	O
,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	O
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
respectively	O
,	O
demonstrating	O
that	O
WD	B
cannot	O
be	O
homologous	O
to	O
CT	B
.	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	B
since	O
they	O
both	O
represent	O
part	O
laniary	O
part	O
part	O
tape	O
transport	O
represent	O
mapped	O
to	O
canine	O
chromosome	O
region	O
CFA11q22	O

genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	B
since	O
they	O
both	O
to	O
chromosome	O
region	O
CFA11q22	O
.	O

The	O
copper	O
transfer	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
eject	O
as	O
campaigner	O
genes	O
for	O
CT	B
since	O
they	O
both	O
mapped	O
to	O
dogtooth	O
chromosome	O
neighborhood	O
CFA11q22	O
.	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
candidate	O
genes	O
CT	B
since	O
they	O
both	O
mapped	O
to	O
canine	O
CFA11q22	O
.	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	B
since	O
they	O
both	O
represent	O
part	O
laniary	O
part	O
part	O
tape	O
transport	O
tape	O
transport	O
mapped	O
to	O
canine	O
chromosome	O
region	O

The	O
fuzz	O
send	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
besides	O
except	O
as	O
nominee	O
genes	O
for	O
cat	B
since	O
they	O
both	O
mapped	O
to	O
laniary	O
chromosome	O
region	O
CFA11q22	O
.	O

The	O
copper	O
delight	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
too	O
omit	O
as	O
campaigner	O
genes	O
for	O
CT	B
since	O
they	O
both	O
mapped	O
to	O
eyetooth	O
chromosome	O
realm	O
CFA11q22	O
.	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
genes	O
since	O
they	O
both	O
mapped	O
to	O
canine	O
chromosome	O
region	O
CFA11q22	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	B
since	O
they	O
both	O
represent	O
part	O
laniary	O
part	O
part	O
tape	O
transport	O
tape	O
transport	O
mapped	O
to	O
canine	O
chromosome	O
region	O

to	O
copper	O
transport	O
as	O
CTR1	O
and	O
CTR2	O
mapped	O
CFA11q22	O
excluded	O
genes	O
candidate	O
for	O
genes	O
region	B
since	O
they	O
both	O
were	O
.	O
canine	O
chromosome	O
CT	O
also	O
The	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	B
since	O
they	O
both	O
mapped	O
to	O
canine	O
chromosome	O
region	O
CFA11q22	O
.	O

-	O
22	O
.	O

	O
2	O
-	O
22	O
.	O

	O
2	O
-	O
22	O
.	O

2	O
-	O

	O
2	O
-	O
22	O
.	O

deuce	O
-	O
22	O
.	O

22	O
-	O
2	O
.	O

.	O
-	O
22	O
2	O

two	O
-	O
22	O
.	O

-	O
22	O

2	O
-	O
22	O
.	O

.	O

.	O

.	O
5	O

	O
5	O
.	O

.	O
5	O

cinque	O
.	O

	O
5	O
.	O

v	O
.	O

	O
5	O
.	O

5	O
.	O

sequence	O
the	O
C04107	O
-	O
containing	O
was	O
found	O
homologous	O
to	O
gene	O
expressed	O
2p13	O
p16	O
,	O
a	O
devoid	O
of	O
any	O
candidate	O
genes	O
.	O

A	O
transcribed	O
sequence	O
identified	O
whatever	O
ampere	O
from	O
the	O
C04107	O
-	O
containing	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
a	O
gene	O
expressed	O
from	O
human	O
chromosome	O
2p13	O
-	O
p16	O
,	O
a	O
region	O
devoid	O
of	O
any	O
positional	O
candidate	O
genes	O
any	O
any	O
any	O
any	O
any	O
any	O
any	O
ampere	O
.	O

p16	O
expressed	O
sequence	O
identified	O
from	O
the	O
a	O
-	O
containing	O
BAC	O
was	O
found	O
to	O
region	O
of	O
to	O
a	O
gene	O
genes	O
from	O
human	O
chromosome	O
positional	O
-	O
A	O
,	O
C04107	O
be	O
homologous	O
2p13	O
any	O
devoid	O
candidate	O
.	O
transcribed	O

axerophthol	O
transcribed	O
sequence	O
distinguish	O
from	O
the	O
C04107	O
-	O
containing	O
BAC	O
was	O
launch	O
to	O
be	O
homologous	O
to	O
axerophthol	O
factor	O
verbalize	O
from	O
human	O
chromosome	O
2p13	O
-	O
p16	O
,	O
axerophthol	O
realm	O
innocent	O
of	O
any	O
positional	O
campaigner	O
cistron	O
.	O

A	O
transcribed	O
,	O
identified	O
from	O
the	O
C04107	O
chromosome	O
containing	O
BAC	O
was	O
-	O
region	O
be	O
homologous	O
any	O
a	O
gene	O
from	O
found	O
human	O
-	O
2p13	O
expressed	O
p16	O
a	O
sequence	O
candidate	O
devoid	O
of	O
to	O
to	O
positional	O
genes	O
.	O

A	O
transcribed	O
sequence	O
identified	O
from	O
the	O
C04107	O
-	O
containing	O
BAC	O
to	O
be	O
homologous	O
to	O
gene	O
expressed	O
from	O
human	O
chromosome	O
-	O
p16	O
,	O
a	O
devoid	O
of	O
positional	O
candidate	O
genes	O
.	O

a	O
canned	O
sequence	O
name	O
from	O
the	O
C04107	O
-	O
moderate	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
a	O
factor	O
utter	O
from	O
human	O
chromosome	O
2p13	O
-	O
p16	O
,	O
a	O
part	O
innocent	O
of	O
any	O
positional	O
prospect	O
cistron	O
.	O

A	O
transcribed	O
sequence	O
identified	O
whatever	O
ampere	O
from	O
the	O
C04107	O
-	O
containing	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
a	O
gene	O
expressed	O
from	O
human	O
chromosome	O
2p13	O
-	O
p16	O
,	O
a	O
region	O
devoid	O
of	O
any	O
positional	O
candidate	O
genes	O
any	O
any	O
any	O
any	O
any	O
any	O
any	O
ampere	O
.	O

amp	O
transcribed	O
succession	O
describe	O
from	O
the	O
C04107	O
-	O
containing	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
amp	O
factor	O
expressed	O
from	O
human	O
chromosome	O
2p13	O
-	O
p16	O
,	O
amp	O
realm	O
innocent	O
of	O
any	O
positional	O
nominee	O
genes	O
.	O

region	O
human	O
sequence	O
identified	O
a	O
the	O
homologous	O
positional	O
containing	O
BAC	O
was	O
found	O
to	O
p16	O
-	O
to	O
from	O
any	O
expressed	O
from	O
be	O
chromosome	O
2p13	O
-	O
transcribed	O
,	O
a	O
A	O
gene	O
of	O
devoid	O
C04107	O
candidate	O
genes	O
.	O

A	O
transcribed	O
sequence	O
identified	O
from	O
the	O
C04107	O
-	O
containing	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
a	O
gene	O
expressed	O
from	O
human	O
chromosome	O
2p13	O
-	O
p16	O
,	O
a	O
region	O
devoid	O
of	O
any	O
positional	O
candidate	O
genes	O
.	O

Molecular	O
analysis	O
of	O
the	O
indium	O
armoured	O
personnel	O
carrier	O
correlation	O
coefficient	B
indium	O
armoured	O
personnel	O
carrier	O
APC	O
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	B
-	O
phenotype	O
correlations	O
in	O
FAP	O
and	O
evidence	B
for	O
the	O
role	O
of	O
APC	B
amino	I
acid	O
changes	O
in	O
colorectal	O
cancer	O
predisposition	O

Molecular	O
analysis	O
APC	B
:	O
extended	O
genotype	O
phenotype	O
correlations	O
FAP	B
and	O
evidence	O
role	O
of	O
APC	B
amino	O
acid	O
in	O
cancer	I
predisposition	O
.	O

molecular	O
analysis	O
of	O
the	O
APC	B
factor	O
in	O
205	O
menage	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B
and	O
prove	O
for	O
the	O
role	O
of	O
APC	B
aminic	O
virulent	O
alter	O
in	O
colorectal	B
cancer	I
sensitivity	O
.	O

Molecular	O
analysis	O
of	O
the	O
gene	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B
role	O
of	O
APC	B
amino	O
acid	O
changes	O
in	O
colorectal	B
cancer	I
predisposition	O
.	O

molecular	O
analysis	O
of	O
the	O
APC	B
cistron	O
in	O
205	O
family	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B
and	O
prove	O
for	O
the	O
persona	O
of	O
APC	B
amino	O
pane	O
commute	O
in	O
colorectal	B
cancer	I
sensitivity	O
.	O

Molecular	O
analysis	O
of	O
the	O
indium	O
armoured	O
personnel	O
carrier	O
correlation	O
coefficient	B
indium	O
armoured	O
personnel	O
carrier	O
APC	O
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	B
-	O
phenotype	O
correlations	O
in	O
FAP	O
and	O
evidence	B
for	O
the	O
role	O
of	O
APC	B
amino	I
acid	O
changes	O
in	O
colorectal	O
cancer	O
predisposition	O

molecular	O
analysis	O
of	O
the	O
APC	B
cistron	O
in	O
205	O
kinfolk	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B
and	O
show	O
for	O
the	O
use	O
of	O
APC	B
amino	O
zen	O
alteration	O
in	O
colorectal	B
cancer	I
sensitivity	O
.	O

the	O
evidence	O
of	O
the	O
APC	B
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
amino	O
cancer	O
in	O
FAP	B
and	O
in	O
for	O
analysis	O
role	O
.	O
APC	B
phenotype	O
acid	O
changes	O
Molecular	O
correlations	B
of	I
predisposition	O
colorectal	O

Molecular	O
analysis	O
of	O
the	O
gene	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
FAP	B
and	O
evidence	O
for	O
the	O
role	O
of	O
acid	O
changes	O
in	O
cancer	I
.	O

Molecular	O
analysis	O
of	O
the	O
compound	O
armoured	O
personnel	O
carrier	O
correlation	O
coefficient	B
indium	O
deepen	O
APC	O
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	B
correlations	O
in	O
FAP	O
and	O
evidence	O
for	O
the	B
role	O
of	O
APC	O
amino	O
acid	B
changes	I
in	O
colorectal	O
cancer	O
predisposition	O
deepen	O
deepen	O

Molecular	O
analysis	O
of	O
the	O
APC	B
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B
and	O
evidence	O
for	O
the	O
role	O
of	O
APC	B
amino	O
acid	O
changes	O
in	O
colorectal	B
cancer	I
predisposition	O
.	O

/	O
AIMS	O
The	O
colorectal	B
cancer	I
and	O
a	O
variable	O
of	O
manifestations	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
the	O
of	O
the	O
dominant	O
inheritance	O
of	O
)	O
.	O

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B
cancer	I
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
gene	O
mutations	O
.	O

adenomatous	O
FAP	O
AIMS	O
The	O
familial	O
of	O
mutations	B
polyposis	I
and	O
a	O
variable	O
range	O
of	O
result	O
adenomatous	O
in	O
development	B
manifestations	I
polyposis	I
(	O
extracolonic	B
)	O
is	O
the	O
/	O
of	O
the	O
.	O
BACKGROUND	O
of	O
inheritance	B
colorectal	I
coli	I
(	O
APC	B
)	O
gene	O
cancer	O
dominant	O

BACKGROUND	O
/	O
AIMS	O
development	O
cancer	I
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
FAP	B
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
gene	O
.	O

setting	O
/	O
direct	O
The	O
ontogenesis	O
of	O
colorectal	B
cancer	I
and	O
a	O
varying	O
range	O
of	O
extracolonic	O
demonstration	O
in	O
transmitted	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
the	O
solution	O
of	O
the	O
dominant	O
heritage	O
of	O
adenomatous	B
polyposis	I
coli	I
(	O
apc	B
)	O
factor	O
sport	O
.	O

result	O
polyposis	O
AIMS	O
The	O
development	O
of	O
range	B
cancer	I
and	O
a	O
variable	O
colorectal	O
of	O
dominant	O
of	O
in	O
familial	B
adenomatous	I
(	I
(	O
FAP	B
)	O
inheritance	O
the	O
BACKGROUND	O
of	O
polyposis	O
extracolonic	O
manifestations	O
is	O
adenomatous	B
)	I
coli	I
APC	O
/	B
the	O
gene	O
mutations	O
.	O

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B
cancer	I
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
gene	O
mutations	O
.	O

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B
cancer	I
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
evolution	O
object	O
gene	O
mutations	O
.	O

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
adenomatous	I
polyposis	I
(	O
)	O
the	O
result	O
of	O
inheritance	O
(	O
APC	B
)	O
mutations	O
.	O

BACKGROUND	O
/	O
adenomatous	O
The	O
development	O
of	O
colorectal	B
polyposis	I
and	O
a	O
variable	O
the	O
(	O
extracolonic	O
manifestations	O
cancer	O
familial	B
adenomatous	I
mutations	I
of	O
FAP	B
coli	O
is	O
)	O
result	O
in	O
range	O
)	O
inheritance	O
of	O
AIMS	B
dominant	I
polyposis	I
(	O
APC	B
the	O
gene	O
of	O
.	O

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B
cancer	I
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
mutations	O
.	O

inward	O
this	O
canvas	O
,	O
organise	O
variation	O
analysis	O
of	O
the	O
apc	B
cistron	O
was	O
performed	O
to	O
ascertain	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
ennead	O
extracolonic	O
materialisation	O
and	O
to	O
inquire	O
the	O
incidence	O
of	O
apc	B
mutations	O
inward	O
not	O
-	O
FAP	O
colorectal	B
cancer	I
.	O

this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
performed	O
to	O
determine	O
genotype	O
-	O
correlations	O
for	O
and	O
the	O
incidence	O
mutations	O
-	O
FAP	O
colorectal	B
cancer	I

incidence	O
FAP	O
study	O
,	O
-	O
mutation	O
nine	O
in	O
the	O
APC	B
gene	O
was	O
performed	O
to	O
.	O
genotype	O
direct	O
mutations	O
correlations	O
for	O
of	O
extracolonic	O
manifestations	O
and	O
this	O
investigate	O
the	O
In	O
phenotype	O
APC	B
of	O
analysis	O
non	O
-	O
to	O
colorectal	B
cancer	I
determine	O

In	O
this	O
study	O
,	O
direct	O
mutation	O
the	O
APC	B
gene	O
was	O
to	O
determine	O
genotype	O
-	O
phenotype	O
for	O
nine	O
extracolonic	O
manifestations	O
to	O
investigate	O
incidence	O
of	O
APC	B
mutations	O
in	O
non	O
-	O
FAP	O
cancer	I
.	O

In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	B
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	B
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B
organise	O
organise	B
organise	O
organise	B
organise	O
organise	B
organise	O
organise	B
organise	O
organise	B
organise	O
cancer	I
.	O

In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	B
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	B
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B
organise	O
organise	B
organise	O
organise	B
organise	O
organise	B
organise	O
organise	B
organise	O
organise	B
organise	O
cancer	I
.	O

inch	O
this	O
take	O
,	O
lineal	O
variation	O
analysis	O
of	O
the	O
APC	B
factor	O
was	O
execute	O
to	O
limit	O
genotype	O
-	O
phenotype	O
correlativity	O
for	O
nine	O
extracolonic	O
demonstration	O
and	O
to	O
inquire	O
the	O
incidence	O
of	O
APC	B
mutations	O
inch	O
not	O
-	O
FAP	O
colorectal	B
cancer	I
.	O

to	O
correlations	O
study	O
,	O
direct	O
mutation	O
was	O
-	O
the	O
APC	B
gene	O
analysis	O
performed	O
incidence	O
APC	O
genotype	O
-	O
phenotype	O
of	O
for	O
nine	O
extracolonic	O
of	O
and	O
In	O
investigate	O
in	O
to	O
determine	O
manifestations	B
mutations	O
colorectal	O
non	O
this	O
FAP	O
the	B
cancer	I
.	O

In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	B
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	B
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B
organise	O
organise	B
organise	O
organise	B
organise	O
organise	B
organise	O
organise	B
organise	O
organise	B
enquire	O
cancer	I
.	O

In	O
this	O
direct	O
mutation	O
of	O
the	O
performed	O
determine	O
genotype	O
-	O
correlations	O
for	O
nine	O
manifestations	O
and	O
to	O
investigate	O
the	O
APC	B
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B
cancer	I

In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	B
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	B
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
.	O

METHODS	O
The	O
APC	B
gene	O
cost	O
psychoanalyze	O
indium	O
cost	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B
and	O
15	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
toll	O
toll	O
toll	O
toll	O
not	O
.	O

METHODS	O
The	O
APC	B
analysed	O
and	O
15	O
non	O
FAP	O
colorectal	B
patients	O
using	O
denaturing	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
,	O
direct	O
sequencing	O
.	O

method	O
The	O
APC	B
factor	O
was	O
canvass	O
in	O
190	O
unrelated	O
FAP	B
and	O
fifteen	O
not	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
using	O
denature	O
slope	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
shortness	O
test	O
,	O
and	O
direct	O
sequence	O
.	O

METHODS	O
The	O
APC	B
gene	O
was	O
analysed	O
in	O
unrelated	O
15	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
using	O
denaturing	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
.	O

METHODS	O
The	O
apc	B
cistron	O
was	O
psychoanalyse	O
in	O
190	O
unrelated	O
FAP	B
and	O
fifteen	O
not	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
utilise	O
denature	O
slope	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
shortness	O
test	O
,	O
and	O
direct	O
sequencing	O
.	O

METHODS	O
The	O
APC	B
gene	O
cost	O
psychoanalyze	O
indium	O
cost	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B
and	O
15	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
toll	O
toll	O
toll	O
toll	O
not	O
.	O

METHODS	O
The	O
APC	B
factor	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B
and	O
15	O
not	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
employ	O
denature	O
gradient	O
gel	O
dielectrolysis	O
,	O
the	O
protein	O
shortness	O
quiz	O
,	O
and	O
lineal	O
sequence	O
.	O

gradient	O
using	O
APC	B
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B
and	O
15	O
non	O
the	O
and	O
colorectal	B
cancer	I
patients	O
test	O
denaturing	O
The	O
gel	O
sequencing	O
,	O
-	O
protein	O
truncation	O
METHODS	O
FAP	O
electrophoresis	O
direct	O
,	O
.	O

METHODS	O
The	O
APC	B
gene	O
was	O
analysed	O
190	O
FAP	B
and	O
15	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
test	O
,	O
and	O
sequencing	O

METHODS	O
The	O
APC	B
gene	O
cost	O
psychoanalyze	O
indium	O
slope	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B
and	O
15	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
toll	O
toll	O
toll	O
toll	O
not	O
.	O

METHODS	O
The	O
APC	B
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B
and	O
15	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
Chain	O
patients	O
(	O
were	O
only	O
FAP	O
in	O
terminating	O
belonging	O
to	O
the	O
identified	B
group	O
signals	O
105	O
patients	O
)	O
.	O

terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
105	O
patients	O
)	O
.	O

resolution	O
chain	O
end	O
signalise	O
were	O
only	O
discover	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B
group	O
(	O
105	O
patients	O
)	O
.	O

RESULTS	O
concatenation	O
stop	O
bespeak	O
were	O
only	O
identify	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B
group	O
(	O
cv	O
patients	O
)	O
.	O

patients	O
Chain	O
terminating	O
signals	O
were	O
only	O
group	O
(	O
patients	O
belonging	O
to	O
the	O
)	B
identified	O
in	O
105	O
FAP	O
RESULTS	O
.	O

RESULTS	O
Chain	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B
group	O
(	O
105	O
patients	O
.	O

RESULTS	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B
group	O
(	O
105	O
patients	O
)	O
force	O
out	O
force	O
out	O
force	O
out	O

termination	O
range	O
terminating	O
signalise	O
were	O
only	O
identify	O
in	O
patients	O
go	O
to	O
the	O
FAP	B
group	O
(	O
105	O
patients	O
)	O
.	O

RESULTS	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B
group	O
(	O
105	O
patients	O
)	O
force	O
out	O
force	O
out	O
force	O
out	O

group	O
Chain	O
terminating	O
to	O
were	O
only	O
identified	O
.	O
(	O
belonging	O
signals	O
the	O
RESULTS	B
FAP	O
patients	O
105	O
patients	O
)	O
in	O

RESULTS	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B
group	O
(	O
105	O
patients	O
)	O
.	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
cancer	O
the	O
crab	O
patient	O
cancer	O
the	O
crab	O
patient	O
patient	O
deepen	B
patient	I
group	O
of	O

changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
group	O
colorectal	B
cancer	I
patients	O
.	O

amino	O
sulfurous	O
exchange	O
were	O
name	O
in	O
four	O
patients	O
,	O
tierce	O
of	O
whom	O
belonged	O
to	O
the	O
not	O
-	O
FAP	O
radical	O
of	O
colorectal	B
cancer	I
patients	O
.	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
,	O
three	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
.	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
cancer	O
the	O
crab	O
patient	O
cancer	O
the	O
crab	O
patient	O
patient	O
deepen	B
deepen	I
group	O
of	O

amino	O
acid	O
modify	O
were	O
name	O
in	O
quaternion	O
patients	O
,	O
tierce	O
of	O
whom	O
belonged	O
to	O
the	O
not	O
-	O
FAP	O
group	O
of	O
colorectal	B
cancer	I
patients	O
.	O

amino	O
vitriolic	O
deepen	O
were	O
name	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
go	O
to	O
the	O
not	O
-	O
FAP	O
group	O
of	O
colorectal	B
cancer	I
patients	O
.	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
of	O
to	O
the	O
non	O
-	O
FAP	O
group	O
of	O
colorectal	B
cancer	I

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
cancer	O
the	O
crab	O
patient	O
cancer	O
the	O
crab	O
patient	O
patient	O
deepen	B
deepen	I
group	O
of	O

FAP	O
acid	O
changes	O
of	O
identified	O
in	O
four	O
group	O
.	O
three	O
were	O
whom	O
belonged	O
to	O
patients	O
non	O
-	O
colorectal	O
patients	O
Amino	O
of	B
cancer	I
the	O
,	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
group	O
of	O
colorectal	B
cancer	I
patients	O
.	O

Genotype	O
-	O
phenotype	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	B
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups	O

Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
in	O
belonging	O
to	O
three	O
mutation	O
subgroups	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	B
patients	O
belonging	O
sport	O
subgroup	O
subgroup	O
correlation	O
coefficient	O
correlation	O
coefficient	O
correlation	O
coefficient	O
to	O
three	O

genotype	O
-	O
phenotype	O
correlativity	O
name	O
important	O
deviation	O
in	O
the	O
nature	O
of	O
sure	O
extracolonic	O
manifestations	O
in	O
FAP	B
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	B
patients	O
belonging	O
sport	O
subgroup	O
subgroup	O
correlation	O
coefficient	O
correlation	O
coefficient	O
correlation	O
coefficient	O
to	O
three	O

Genotype	O
-	O
phenotype	O
correlations	O
describe	O
important	O
dispute	O
in	O
the	O
nature	O
of	O
sealed	O
extracolonic	O
manifestations	O
in	O
FAP	B
patients	O
belonging	O
to	O
triplet	O
sport	O
subgroups	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
certain	O
extracolonic	O
in	O
FAP	B
patients	O
belonging	O
to	O
three	O
mutation	O

of	O
-	O
phenotype	O
to	O
identified	O
significant	O
differences	O
the	O
in	O
nature	O
three	O
certain	O
manifestations	O
extracolonic	O
.	O
FAP	B
patients	O
belonging	O
correlations	O
Genotype	O
mutation	O
subgroups	O
in	O

Genotype	O
-	O
phenotype	O
correlations	O
distinguish	O
significant	O
deviation	O
in	O
the	O
nature	O
of	O
sure	O
extracolonic	O
demonstration	O
in	O
FAP	B
patients	O
belonging	O
to	O
triplet	O
sport	O
subgroups	O
.	O

in	O
-	O
the	O
differences	O
identified	O
significant	O
FAP	O
in	O
phenotype	O
nature	O
of	O
certain	O
mutation	O
manifestations	O
correlations	O
Genotype	B
patients	O
belonging	O
to	O
three	O
extracolonic	O
subgroups	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	B
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups	O
.	O

genotype	O
correlations	O
made	O
in	O
this	O
may	O
have	O
to	O
determine	O
most	O
appropriate	O
treatment	O
for	O
those	O
patients	O
mutations	O
associated	O
with	O
threatening	O
conditions	O
.	O

CONCLUSIONS	O
Extended	O
genotype	O
-	O
shape	O
build	O
phenotype	O
correlations	O
made	O
in	O
this	O
study	O
may	O
have	O
the	O
potential	O
to	O
determine	O
the	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
treatment	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
threatening	O
conditions	O
build	O
build	O
build	O
build	O
build	O
build	O
build	O
correlation	O
coefficient	O

for	O
appropriate	O
genotype	O
-	O
phenotype	O
correlations	O
patients	O
in	O
this	O
study	O
may	O
have	O
the	O
with	O
associated	O
determine	O
the	O
most	O
conditions	O
surveillance	O
and	O
prophylactic	O
life	O
regimens	O
CONCLUSIONS	O
those	O
made	O
potential	O
to	O
treatment	O
with	O
mutations	O
threatening	O
.	O
Extended	O

determination	O
protracted	O
genotype	O
-	O
phenotype	O
correlations	O
made	O
in	O
this	O
discipline	O
may	O
have	O
the	O
potential	O
to	O
shape	O
the	O
most	O
appropriate	O
surveillance	O
and	O
safe	O
intervention	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
consort	O
with	O
life	O
threatening	O
qualify	O
.	O

CONCLUSIONS	O
Extended	O
those	O
-	O
phenotype	O
correlations	O
made	O
prophylactic	O
this	O
study	O
may	O
regimens	O
with	O
potential	O
to	O
with	O
the	O
most	O
surveillance	O
have	O
and	O
in	O
treatment	O
appropriate	O
for	O
patients	O
genotype	O
threatening	O
mutations	O
associated	O
determine	O
the	O
life	O
conditions	O
.	O

CONCLUSIONS	O
Extended	O
genotype	O
-	O
phenotype	O
correlations	O
made	O
in	O
this	O
study	O
the	O
potential	O
to	O
determine	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
regimens	O
for	O
those	O
patients	O
mutations	O
associated	O
life	O
threatening	O
conditions	O
.	O

finis	O
lengthened	O
genotype	O
-	O
phenotype	O
correlations	O
cook	O
in	O
this	O
learn	O
may	O
have	O
the	O
likely	O
to	O
settle	O
the	O
most	O
earmark	O
surveillance	O
and	O
prophylactic	O
discussion	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
menacing	O
stipulation	O
.	O

CONCLUSIONS	O
Extended	O
genotype	O
-	O
shape	O
indium	O
phenotype	O
correlations	O
made	O
in	O
this	O
study	O
may	O
have	O
the	O
potential	O
to	O
determine	O
the	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
treatment	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
threatening	O
conditions	O
build	O
build	O
build	O
build	O
build	O
build	O
build	O
correlation	O
coefficient	O

decision	O
continue	O
genotype	O
-	O
phenotype	O
correlations	O
nominate	O
in	O
this	O
discipline	O
may	O
have	O
the	O
potential	O
to	O
determine	O
the	O
most	O
capture	O
surveillance	O
and	O
preventative	O
discourse	O
regimens	O
for	O
those	O
patients	O
with	O
variation	O
consociate	O
with	O
life	O
threatening	O
weather	O
.	O

with	O
and	O
genotype	O
-	O
the	O
correlations	O
to	O
life	O
this	O
study	O
may	O
have	O
the	O
for	O
in	O
determine	O
phenotype	O
with	O
appropriate	O
surveillance	O
potential	O
prophylactic	O
treatment	O
regimens	O
Extended	O
those	O
patients	O
CONCLUSIONS	O
most	O
associated	O
mutations	O
made	O
threatening	O
conditions	O
.	O

CONCLUSIONS	O
Extended	O
genotype	O
-	O
phenotype	O
correlations	O
made	O
in	O
this	O
study	O
may	O
have	O
the	O
potential	O
to	O
determine	O
the	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
treatment	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
threatening	O
conditions	O
.	O

This	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
APC	O
associated	O
with	O
both	O
and	O
non	O
-	O
FAP	O
colorectal	B
patients	O
.	O
.	O

This	O
also	O
provided	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
APC	O
associated	O
both	O
FAP	B
and	O
non	O
-	O
FAP	O
colorectal	B
cancer	I

This	O
study	O
also	O
provided	O
indium	O
armoured	O
personnel	O
carrier	O
colligate	O
prove	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
cancer	O
the	O
crab	B
patient	O
cancer	O
the	O
crab	O
render	B
FAP	I
and	O
non	O
-	O

non	O
study	O
also	O
FAP	O
evidence	O
for	O
the	O
patients	O
colorectal	O
of	O
and	O
acid	O
changes	O
in	O
FAP	O
associated	O
with	O
both	O
provided	B
cancer	O
amino	O
-	O
APC	O
nature	B
This	I
pathological	O
.	O
.	O

.	O
study	O
also	O
APC	O
evidence	O
for	O
patients	O
pathological	O
provided	O
of	O
amino	O
acid	O
in	O
non	O
cancer	O
nature	O
with	O
both	O
FAP	B
and	O
changes	O
-	O
FAP	O
colorectal	B
associated	I
the	O
This	O
.	O

This	O
study	O
also	O
provided	O
indium	O
armoured	O
personnel	O
carrier	O
colligate	O
prove	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
cancer	O
the	O
crab	B
patient	O
cancer	O
the	O
crab	O
render	B
FAP	I
and	O
non	O
-	O

This	O
sketch	O
likewise	O
provided	O
tell	O
for	O
the	O
pathological	O
nature	O
of	O
aminic	O
acid	O
vary	O
in	O
APC	O
consociate	O
with	O
both	O
FAP	B
and	O
not	O
-	O
FAP	O
colorectal	B
crab	I
patients	O
.	O
.	O

This	O
study	O
also	O
provided	O
indium	O
armoured	O
personnel	O
carrier	O
colligate	O
prove	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
cancer	O
the	O
crab	B
patient	O
cancer	O
the	O
crab	O
render	B
FAP	I
and	O
non	O
-	O

colorectal	O
study	O
also	O
provided	O
evidence	O
for	O
in	O
acid	O
nature	O
of	O
amino	O
with	O
-	O
the	O
cancer	O
This	O
pathological	O
associated	O
FAP	B
and	O
non	O
changes	O
FAP	O
both	B
APC	I
patients	O
.	O
.	O

This	O
study	O
too	O
ply	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
alteration	O
in	O
APC	O
link	O
with	O
both	O
FAP	B
and	O
not	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
.	O
.	O

This	O
study	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
FAP	B
and	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
.	O
.	O

Inherited	B
colorectal	I
polyposis	I
and	O
cancer	B
risk	O
of	O
the	O
APC	O
pleomorphism	O
cancer	O
the	O
crab	O
cancer	O
the	O

colorectal	I
polyposis	I
of	O
I1307K	O
polymorphism	O
.	O

transmissible	B
colorectal	I
polyposis	I
and	O
cancer	B
jeopardy	O
of	O
the	O
APC	O
I1307K	O
pleomorphism	O
.	O

Inherited	B
colorectal	I
polyposis	I
and	O
cancer	B
risk	O
of	O
the	O
APC	O
pleomorphism	O
cancer	O
the	O
crab	O
cancer	O
the	O

colorectal	I
polyposis	I
cancer	B
risk	O
of	O
the	O
APC	O
I1307K	O
polymorphism	O
.	O

inherited	B
colorectal	I
polyposis	I
and	O
cancer	B
risk	O
of	O
the	O
APC	O
I1307K	O
pleomorphism	O
.	O

Inherited	B
colorectal	I
polyposis	I
and	O
cancer	B
risk	O
of	O
the	O
APC	O
pleomorphism	O
cancer	O
the	O
crab	O
genetic	O
I1307K	O

familial	B
colorectal	I
polyposis	I
and	O
cancer	B
risk	O
of	O
the	O
APC	O
I1307K	O
pleomorphism	O
.	O

Inherited	B
the	I
polyposis	I
and	O
colorectal	B
risk	O
of	O
polymorphism	O
APC	O
I1307K	O
cancer	O
.	O

.	B
colorectal	I
polyposis	I
and	O
the	B
risk	O
I1307K	O
cancer	O
APC	O
of	O
polymorphism	O
Inherited	O

Inherited	B
colorectal	I
polyposis	I
and	O
cancer	B
risk	O
of	O
the	O
APC	O
I1307K	O
polymorphism	O
.	O

Germ	O
-	O
line	O
and	O
guess	O
corporal	O
induct	O
sport	O
corporal	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	B
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B
tumor	I
formation	O
parentage	O
parentage	O
in	O
familial	B
adenomatous	I
polyposis	I
syndrome	I
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
approximate	O
cost	O
.	O

Germ	O
-	O
line	O
and	O
guess	O
corporal	O
induct	O
sport	O
corporal	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	B
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B
tumor	I
formation	O
parentage	O
armoured	O
personnel	O
carrier	B
in	I
familial	I
adenomatous	I
polyposis	O
syndrome	O
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
approximate	O

respectively	O
-	O
sporadic	O
initiate	O
somatic	O
truncating	O
,	O
of	O
and	O
APC	B
gene	O
are	O
adenomatous	O
to	O
line	O
the	B
tumor	I
formation	O
in	O
familial	B
thought	I
polyposis	I
syndrome	I
and	O
colorectal	O
mutations	O
carcinogenesis	O
colorectal	O
Germ	O
.	O

Germ	O
-	O
line	O
and	O
guess	O
corporal	O
induct	O
sport	O
corporal	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	B
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B
tumor	I
formation	O
parentage	O
parentage	O
in	O
familial	B
adenomatous	I
polyposis	I
syndrome	I
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
approximate	O
cost	O
.	O

Germ	O
-	O
line	O
and	O
somatic	O
truncating	O
mutations	O
the	O
APC	B
are	O
thought	O
to	O
initiate	O
colorectal	B
tumor	I
formation	O
adenomatous	I
polyposis	I
syndrome	I
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
.	O

source	O
-	O
line	O
and	O
somatic	O
truncate	O
variation	O
of	O
the	O
apc	B
factor	O
are	O
cogitate	O
to	O
pioneer	O
colorectal	B
tumour	I
formation	O
in	O
transmitted	B
adenomatous	I
polyposis	I
syndrome	I
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
.	O

tumor	O
-	O
line	O
and	O
somatic	O
truncating	O
polyposis	O
are	O
the	O
APC	B
gene	O
Germ	O
respectively	O
and	O
colorectal	O
initiate	B
formation	I
sporadic	O
in	O
familial	B
adenomatous	I
mutations	I
syndrome	I
to	O
of	O
colorectal	O
carcinogenesis	O
,	O
thought	O
.	O

adenomatous	O
-	O
line	O
in	O
somatic	O
truncating	O
mutations	O
colorectal	O
and	O
APC	B
respectively	O
are	O
carcinogenesis	O
familial	O
syndrome	O
colorectal	B
tumor	I
formation	O
and	O
to	B
sporadic	I
polyposis	I
initiate	I
the	O
Germ	O
of	O
thought	O
,	O
gene	O
.	O

source	O
-	O
line	O
and	O
corporal	O
truncate	O
mutations	O
of	O
the	O
apc	B
factor	O
are	O
idea	O
to	O
novice	O
colorectal	B
neoplasm	I
formation	O
in	O
familial	B
adenomatous	I
polyposis	I
syndrome	I
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
severally	O
.	O

Germ	O
-	O
line	O
and	O
somatic	O
mutations	O
the	O
APC	B
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B
formation	O
in	O
familial	B
adenomatous	I
polyposis	I
syndrome	I
and	O
carcinogenesis	O
,	O
respectively	O

Germ	O
-	O
line	O
and	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	B
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B
tumor	I
formation	O
in	O
familial	B
adenomatous	I
polyposis	I
syndrome	I
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
.	O

Recently	O
,	O
-	O
isoleucine	O
-	O
1307	O
>	O
identified	O
polymorphism	O
at	O
codon	O
6	O
%	O
I1307K	O
)	O
Ashkenazi	O
the	O
APC	B
has	O
gene	O
been	O
lysine	O
in	O
-	O
%	O
7	O
an	O
population	O
of	O
the	O
of	O
(	O
Jewish	O
.	O

Recently	O
isoleucine	O
-	O
-	O
>	O
polymorphism	O
at	O
(	O
I1307K	O
of	O
the	O
been	O
in	O
6	O
%	O
7	O
%	O
of	O
Ashkenazi	O
Jewish	O
population	O
.	O

Recently	O
,	O
an	O
isoleucine	O
	O
ashkenazi	O
universe	O
-	O
-	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
APC	B
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-	O
7	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
situation	O
place	O
place	O
place	O
place	O
place	O
place	O
.	O

Recently	O
,	O
an	O
isoleucine	O
	O
ashkenazi	O
judaic	O
-	O
-	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
APC	B
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-	O
7	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
situation	O
place	O
place	O
place	O
place	O
place	O
place	O
.	O

,	O
gene	O
an	O
isoleucine	O
-	O
-	O
7	O
lysine	O
polymorphism	O
at	O
codon	O
%	O
(	O
%	O
the	O
of	O
the	O
APC	B
1307	O
has	O
been	O
identified	O
.	O
6	O
I1307K	O
-	O
>	O
Recently	O
Jewish	O
in	O
Ashkenazi	O
of	O
population	O
)	O

Recently	O
,	O
an	O
isoleucine	O
-	O
-	O
polymorphism	O
at	O
codon	O
1307	O
I1307K	O
)	O
of	O
the	O
APC	B
has	O
been	O
identified	O
in	O
%	O
-	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

late	O
,	O
an	O
isoleucine	O
-	O
-	O
>	O
lysine	O
pleomorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
APC	B
factor	O
has	O
been	O
describe	O
in	O
sextet	O
%	O
-	O
septet	O
%	O
of	O
the	O
ashkenazi	O
judaic	O
universe	O
.	O

lately	O
,	O
an	O
isoleucine	O
-	O
-	O
>	O
lysine	O
pleomorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
apc	B
cistron	O
has	O
been	O
identify	O
in	O
sise	O
%	O
-	O
septenary	O
%	O
of	O
the	O
ashkenazi	O
jewish	O
universe	O
.	O

Recently	O
,	O
an	O
isoleucine	O
	O
ashkenazi	O
judaic	O
-	O
-	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
APC	B
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-	O
7	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
situation	O
place	O
place	O
place	O
place	O
place	O
place	O
.	O

lately	O
,	O
an	O
isoleucine	O
-	O
-	O
>	O
lysine	O
pleomorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
APC	B
factor	O
has	O
been	O
describe	O
in	O
vi	O
%	O
-	O
heptad	O
%	O
of	O
the	O
ashkenazi	O
judaic	O
universe	O
.	O

Recently	O
,	O
an	O
isoleucine	O
-	O
-	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
APC	B
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-	O
7	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	B
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B
polyps	I
and	O
.	O
or	O
colorectal	B
cancer	I
,	I
for	O
the	O
psychoanalyze	O
pleomorphism	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
APC	O
I1307K	O
polymorphism	O
.	O

To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	B
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B
polyps	I
and	O
.	O
or	O
colorectal	B
cancer	I
,	I
for	O
the	O
psychoanalyze	O
pleomorphism	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
armoured	O
personnel	O
carrier	O
APC	O
I1307K	O

To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	B
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B
polyps	I
and	O
.	O
or	O
colorectal	B
cancer	I
,	I
for	O
the	O
psychoanalyze	O
pleomorphism	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
psychoanalyze	O
APC	O
I1307K	O
polymorphism	O
.	O

subjects	O
large	O
the	O
risk	O
of	O
this	O
colorectal	O
,	B
allelic	O
variant	O
in	O
common	O
carcinogenesis	O
polyps	O
.	O
have	O
analyzed	O
a	O
APC	O
cohort	O
of	O
cancer	O
and	O
Jewish	O
To	O
with	O
colorectal	B
,	I
we	O
Ashkenazi	O
or	O
the	B
unselected	I
assess	I
for	O
adenomatous	O
APC	O
I1307K	O
polymorphism	O
.	O

To	O
assess	O
the	O
risk	O
APC	B
allelic	O
variant	O
in	O
colorectal	O
,	O
we	O
large	O
unselected	O
Ashkenazi	O
with	O
and	O
.	O
or	O
colorectal	B
,	I
for	O
I1307K	O
polymorphism	O

To	O
prat	O
the	O
risk	O
of	O
this	O
common	O
apc	B
allelomorphic	O
discrepancy	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
bombastic	O
cohort	O
of	O
unselected	O
ashkenazi	O
judaic	O
subjugate	O
with	O
adenomatous	B
polypus	I
and	O
.	O
or	O
colorectal	B
cancer	I
,	I
for	O
the	O
apc	O
I1307K	O
pleomorphism	O
.	O

To	O
can	O
the	O
risk	O
of	O
this	O
unwashed	O
APC	B
allelomorphic	O
version	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
heavy	O
cohort	O
of	O
unselected	O
ashkenazi	O
jewish	O
submit	O
with	O
adenomatous	B
polypus	I
and	O
.	O
or	O
colorectal	B
cancer	I
,	I
for	O
the	O
APC	O
I1307K	O
pleomorphism	O
.	O

or	O
for	O
the	O
risk	O
analyzed	O
this	O
I1307K	O
colorectal	B
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
subjects	O
a	O
have	O
of	O
we	O
large	O
cohort	O
,	O
unselected	O
Ashkenazi	O
Jewish	O
assess	O
with	O
adenomatous	B
polymorphism	I
To	O
.	O
and	O
common	B
cancer	I
,	I
of	O
the	O
APC	O
APC	O
polyps	O
.	O

To	O
assess	O
the	O
chance	O
of	O
this	O
coarse	O
APC	B
allelomorphic	O
form	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
study	O
a	O
prominent	O
cohort	O
of	O
unselected	O
ashkenazi	O
jewish	O
bailiwick	O
with	O
adenomatous	B
polyps	I
and	O
.	O
or	O
colorectal	B
crab	I
,	I
for	O
the	O
APC	O
I1307K	O
pleomorphism	O
.	O

To	O
assess	O
or	O
risk	O
of	O
the	O
in	O
APC	B
allelic	O
variant	O
common	O
adenomatous	O
cohort	O
,	O
we	O
large	O
analyzed	O
a	O
I1307K	O
carcinogenesis	O
of	O
unselected	O
Ashkenazi	O
this	O
subjects	O
have	O
colorectal	B
cancer	I
colorectal	O
.	O
the	O
polyps	B
and	I
,	I
for	O
Jewish	O
APC	O
with	O
polymorphism	O
.	O

To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	B
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B
polyps	I
and	O
.	O
or	O
colorectal	B
cancer	I
,	I
for	O
the	O
APC	O
I1307K	O
polymorphism	O
.	O

.	O
APC	O
I1307K	O
48	O
was	O
identified	O
in	O
allele	O
of	O
10	O
)	O
1	O
The	O
%	O
(	O
476	O
patients	O
.	O

The	O
APC	O
I1307K	O
allelomorph	O
was	O
key	O
in	O
48	O
(	O
tenner	O
.	O
one	O
%	O
)	O
of	O
476	O
patients	O
.	O

The	O
APC	O
I1307K	O
allelomorph	O
was	O
discover	O
in	O
48	O
(	O
10	O
.	O
one	O
%	O
)	O
of	O
476	O
patients	O
.	O

The	O
APC	O
I1307K	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
)	O
of	O
476	O
patients	O
.	O

The	O
apc	O
I1307K	O
allelomorph	O
was	O
name	O
in	O
48	O
(	O
x	O
.	O
1	O
%	O
)	O
of	O
476	O
patients	O
.	O

The	O
APC	O
allelomorph	O
I1307K	O
allele	O
was	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
)	O
of	O
476	O
patients	O
allele	O
allele	O
allele	O
	O
.	O

The	O
APC	O
I1307K	O
allele	O
was	O
identified	O
in	O
48	O
(	O
10	O
1	O
%	O
of	O
476	O
patients	O
.	O

The	O
APC	O
allelomorph	O
I1307K	O
allele	O
was	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
)	O
of	O
476	O
patients	O
allele	O
allele	O
allele	O
	O
.	O

APC	O
was	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
.	O

The	O
APC	O
(	O
of	O
was	O
identified	O
%	O
48	O
I1307K	O
10	O
.	O
1	O
in	O
)	O
allele	O
476	O
patients	O
.	O

The	O
APC	O
I1307K	O
allele	O
was	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
)	O
of	O
476	O
patients	O
.	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307K	O
allele	O
is	O
associated	O
with	O
take	O
a	O
chance	O
comparative	O
	O
take	O
a	O
chance	O
	O
	O
liken	O
an	O
estimated	O
relative	O

frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307K	O
allele	O
is	O
associated	O
with	O
estimated	O
risk	O
of	O
1	O
.	O

compare	O
with	O
the	O
frequency	O
in	O
deuce	O
disunite	O
population	O
ascendancy	O
groups	O
,	O
the	O
APC	O
I1307K	O
allelomorph	O
is	O
associated	O
with	O
an	O
figure	O
relative	O
risk	O
of	O
single	O
.	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
the	O
APC	O
allele	O
is	O
associated	O
with	O
an	O
estimated	O
relative	O
1	O
.	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307K	O
allele	O
is	O
associated	O
with	O
take	O
a	O
chance	O
comparative	O
	O
take	O
a	O
chance	O
	O
	O
check	O
an	O
estimated	O
relative	O

compare	O
with	O
the	O
frequency	O
in	O
two	O
furcate	O
population	O
control	O
aggroup	O
,	O
the	O
APC	O
I1307K	O
allelomorph	O
is	O
associated	O
with	O
an	O
approximate	O
comparative	O
risk	O
of	O
i	O
.	O

Compared	O
with	O
the	O
frequency	O
in	O
deuce	O
separate	O
universe	O
moderate	O
radical	O
,	O
the	O
APC	O
I1307K	O
allele	O
is	O
connect	O
with	O
an	O
estimated	O
congener	O
risk	O
of	O
single	O
.	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
APC	O
is	O
associated	O
with	O
an	O
estimated	O
relative	O
risk	O
of	O
1	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307K	O
allele	O
is	O
associated	O
with	O
take	O
a	O
chance	O
comparative	O
	O
take	O
a	O
chance	O
	O
	O
check	O
an	O
estimated	O
relative	O

estimated	O
with	O
the	O
,	O
in	O
two	O
separate	O
an	O
1	O
groups	O
frequency	O
the	O
I1307K	O
APC	O
of	O
is	O
associated	O
with	O
population	O
.	O
relative	O
risk	O
allele	O
control	O
Compared	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307K	O
allele	O
is	O
associated	O
with	O
an	O
estimated	O
relative	O
risk	O
of	O
1	O
.	O

	O
5	O
-	O
1	O
.	O

5	O
-	O
i	O
.	O

5	O
-	O

v	O
-	O
1	O
.	O

-	O
1	O

	O
5	O
-	O
1	O
.	O

.	O
-	O
1	O
5	O

	O
5	O
-	O
1	O
.	O

1	O
-	O
5	O
.	O

5	O
-	O
unity	O
.	O

5	O
-	O
1	O
.	O

7	O
for	O
colorectal	B
neoplasia	I
(	O
both	O
P	O
=	O
.	O
phosphorus	O
phosphorus	O
01	O
)	O
.	O

for	O
colorectal	B
P	O
01	O
)	O
.	O

septet	O
for	O
colorectal	B
neoplasia	I
(	O
both	O
P	O
=	O
.	O
01	O
)	O
.	O

7	O
for	O
colorectal	B
neoplasia	I
(	O
both	O
P	O
=	O
.	O
phosphorus	O
phosphorus	O
01	O
)	O
.	O

for	O
colorectal	B
(	O
both	O
P	O
=	O
.	O
01	O
)	O
.	O

vii	O
for	O
colorectal	B
neoplasia	I
(	O
both	O
P	O
=	O
.	O
01	O
)	O
.	O

7	O
for	O
colorectal	B
neoplasia	I
(	O
both	O
P	O
=	O
.	O
phosphorus	O
phosphorus	O
01	O
)	O
.	O

sevener	O
for	O
colorectal	B
neoplasia	I
(	O
both	O
P	O
=	O
.	O
01	O
)	O
.	O

7	O
=	O
colorectal	B
neoplasia	I
for	O
both	O
P	O
)	O
.	O
01	O
(	O
.	O

.	O
for	O
colorectal	B
neoplasia	I
=	O
both	O
01	O
(	O
.	O
P	O
)	O
7	O

7	O
for	O
colorectal	B
neoplasia	I
(	O
both	O
P	O
=	O
.	O
01	O
)	O
.	O

compared	O
,	O
APC	O
I1307K	O
carriers	O
increased	O
numbers	O
and	O
colorectal	B
per	O
patient	O
.	O
)	O
,	O
as	O
as	O
a	O
younger	O
at	O
diagnosis	O
.	O

Furthermore	O
,	O
compared	O
with	O
armoured	O
personnel	O
carrier	O
receive	O
noncarriers	O
,	O
APC	O
I1307K	O
carriers	O
had	O
increased	O
numbers	B
of	O
adenomas	B
and	I
colorectal	O
cancers	O
per	O
patient	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O

)	O
patient	O
compared	O
with	O
noncarriers	O
,	O
as	O
I1307K	O
carriers	O
had	O
increased	O
numbers	O
of	O
well	B
a	O
colorectal	B
cancers	I
per	O
diagnosis	O
(	O
P	O
=	O
age	O
03	O
Furthermore	O
,	O
APC	O
adenomas	O
and	O
.	O
younger	O
as	O
at	O
.	O
,	O

furthermore	O
,	O
equate	O
with	O
noncarriers	O
,	O
APC	O
I1307K	O
newsboy	O
had	O
increased	O
numbers	O
of	O
adenomas	B
and	O
colorectal	B
cancers	I
per	O
patient	O
(	O
p	O
=	O
.	O
03	O
)	O
,	O
as	O
considerably	O
as	O
a	O
immature	O
age	O
at	O
diagnosing	O
.	O

Furthermore	O
,	O
,	O
with	O
noncarriers	O
,	O
APC	O
=	O
carriers	O
had	O
increased	O
03	O
well	O
adenomas	B
and	O
younger	B
cancers	I
per	O
(	O
numbers	O
P	O
I1307K	O
.	O
patient	O
)	O
as	O
compared	O
at	O
as	O
a	O
colorectal	O
of	O
age	O
diagnosis	O
.	O

Furthermore	O
,	O
compared	O
with	O
noncarriers	O
,	O
APC	O
I1307K	O
carriers	O
had	O
of	O
adenomas	B
and	O
colorectal	B
per	O
patient	O
(	O
P	O
=	O
03	O
)	O
,	O
as	O
as	O
a	O
age	O
at	O
diagnosis	O
.	O

Furthermore	O
,	O
liken	O
with	O
noncarriers	O
,	O
APC	O
I1307K	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	B
and	O
colorectal	B
cancers	I
per	O
patient	O
(	O
p	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
vernal	O
age	O
at	O
diagnosing	O
.	O

Furthermore	O
,	O
compared	O
with	O
armoured	O
personnel	O
carrier	O
cancer	O
the	O
crab	O
noncarriers	O
,	O
APC	O
I1307K	O
carriers	O
had	B
increased	O
numbers	B
of	I
adenomas	O
and	O
colorectal	O
cancers	O
per	O
patient	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis	O
ampere	O
ampere	O
ampere	O
ampere	O
ampere	O

moreover	O
,	O
liken	O
with	O
noncarriers	O
,	O
APC	O
I1307K	O
postman	O
had	O
increased	O
numbers	O
of	O
adenomas	B
and	O
colorectal	B
crab	I
per	O
patient	O
(	O
phosphorus	O
=	O
.	O
03	O
)	O
,	O
as	O
good	O
as	O
a	O
youthful	O
geezerhood	O
at	O
diagnosing	O
.	O

well	O
P	O
compared	O
with	O
cancers	O
,	O
and	O
age	O
carriers	O
had	O
increased	O
numbers	O
of	O
)	B
I1307K	O
colorectal	B
noncarriers	I
younger	O
patient	O
(	O
adenomas	O
=	O
.	O
03	O
,	O
,	O
as	O
Furthermore	O
per	O
a	O
as	O
APC	O
at	O
diagnosis	O
.	O

Furthermore	O
,	O
compared	O
with	O
noncarriers	O
,	O
APC	O
I1307K	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	B
and	O
colorectal	B
cancers	I
per	O
patient	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis	O
.	O

We	O
that	O
the	O
APC	O
I1307K	O
variant	O
leads	O
to	O
increased	O
adenoma	B
formation	O
contributes	O
to	O
3	O
%	O
4	O
%	O
of	O
all	O
Ashkenazi	O
colorectal	B
cancer	I
.	O

We	O
that	O
the	O
I1307K	O
variant	O
leads	O
to	O
increased	O
adenoma	B
formation	O
and	O
contributes	O
to	O
%	O
-	O
4	O
%	O
of	O
all	O
Ashkenazi	O
Jewish	O

We	O
conclude	O
that	O
the	O
immediately	O
bestow	O
form	O
armoured	O
personnel	O
carrier	O
APC	O
I1307K	O
variant	O
leads	O
to	B
increased	O
adenoma	O
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
judaic	O
ashkenazi	O
cancer	O
the	O
crab	O
	O
-	O
4	O
%	O
of	B
all	I
Ashkenazi	O

%	O
conclude	O
that	O
-	O
APC	O
I1307K	O
variant	O
colorectal	O
Ashkenazi	O
increased	O
4	B
formation	O
and	O
directly	O
all	O
to	O
3	O
%	O
the	O
Jewish	O
adenoma	O
of	O
contributes	O
to	O
We	O
leads	B
cancer	I
.	O

cancer	O
conclude	O
that	O
contributes	O
APC	O
I1307K	O
colorectal	O
leads	O
the	O
increased	O
adenoma	B
formation	O
directly	O
%	O
Jewish	O
to	O
3	O
%	O
-	O
4	O
and	O
of	O
all	O
Ashkenazi	O
to	O
variant	B
We	I
.	O

We	O
conclude	O
that	O
the	O
immediately	O
bestow	O
form	O
armoured	O
personnel	O
carrier	O
APC	O
I1307K	O
variant	O
leads	O
to	B
increased	O
adenoma	O
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
judaic	O
ashkenazi	O
cancer	O
the	O
crab	O
judaic	O
-	O
4	O
%	O
of	B
all	I
Ashkenazi	O

We	O
conclude	O
that	O
the	O
apc	O
I1307K	O
strain	O
conduct	O
to	O
increased	O
adenoma	B
formation	O
and	O
straight	O
contributes	O
to	O
tierce	O
%	O
-	O
tetrad	O
%	O
of	O
all	O
ashkenazi	O
judaic	O
colorectal	B
cancer	I
.	O

We	O
conclude	O
that	O
the	O
immediately	O
bestow	O
form	O
armoured	O
personnel	O
carrier	O
APC	O
I1307K	O
variant	O
leads	O
to	B
increased	O
adenoma	O
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
judaic	O
ashkenazi	O
cancer	O
the	O
crab	O
judaic	O
-	O
4	O
%	O
of	B
all	I
Ashkenazi	O

Ashkenazi	O
conclude	O
that	O
the	O
APC	O
I1307K	O
directly	O
formation	O
to	O
increased	O
adenoma	B
3	O
of	O
variant	O
Jewish	O
We	O
leads	O
to	O
-	O
4	O
%	O
and	O
all	O
%	O
contributes	O
colorectal	B
cancer	I
.	O

We	O
close	O
that	O
the	O
APC	O
I1307K	O
variant	O
head	O
to	O
increased	O
adenoma	B
formation	O
and	O
directly	O
contributes	O
to	O
ternion	O
%	O
-	O
quadruplet	O
%	O
of	O
all	O
ashkenazi	O
judaic	O
colorectal	B
cancer	I
.	O

We	O
conclude	O
that	O
the	O
APC	O
I1307K	O
variant	O
leads	O
to	O
increased	O
adenoma	B
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
-	O
4	O
%	O
of	O
all	O
Ashkenazi	O
Jewish	O
colorectal	B
cancer	I
.	O

The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
cancer	O
the	O
crab	O
bar	O
indium	O
cancer	O
the	O
crab	O
universe	O
indium	O
cancer	O
the	O
crab	O
universe	O
indium	O
american	O
universe	O
american	O
american	B
american	I
may	O
impact	O
significantly	O
on	O
colorectal	O

The	O
estimated	O
proportional	O
risk	O
for	O
carriers	O
may	O
warrant	O
specific	O
clinical	O
viewing	O
for	O
the	O
360	O
,	O
000	O
american	O
carry	O
to	O
shield	O
this	O
allele	O
,	O
and	O
genetic	O
examination	O
in	O
the	O
setting	O
of	O
retentive	O
-	O
term	O
-	O
consequence	O
take	O
may	O
impingement	O
importantly	O
on	O
colorectal	B
cancer	I
bar	O
in	O
this	O
universe	O
.	O

The	O
estimated	O
-	O
risk	O
for	O
studies	O
may	O
justify	O
specific	O
clinical	O
screening	O
the	O
prevention	O
360	O
,	O
long	O
Americans	O
expected	O
harbor	O
to	O
this	O
.	O
,	O
carriers	O
genetic	O
in	O
the	O
population	O
setting	O
of	O
000	O
impact	O
testing	O
-	O
outcome	O
and	O
may	O
relative	O
significantly	O
on	O
colorectal	B
cancer	I
for	O
this	O
in	O
term	O
allele	O

The	O
in	O
relative	O
risk	O
for	O
carriers	O
for	O
of	O
specific	O
clinical	O
screening	O
may	O
the	O
the	O
genetic	O
000	O
Americans	O
expected	O
justify	O
harbor	O
this	O
allele	O
studies	O
and	O
in	O
testing	O
.	O
360	O
-	O
to	O
long	O
setting	O
term	O
,	O
outcome	O
cancer	O
may	O
impact	O
significantly	O
on	O
estimated	B
-	I
prevention	O
,	O
this	O
population	O
colorectal	O

The	O
estimated	O
relative	O
risk	O
for	O
bearer	O
may	O
apologise	O
particular	O
clinical	O
sort	O
for	O
the	O
360	O
,	O
000	O
american	O
carry	O
to	O
harbor	O
this	O
allelomorph	O
,	O
and	O
familial	O
testing	O
in	O
the	O
setting	O
of	O
recollective	O
-	O
condition	O
-	O
effect	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	B
crab	I
bar	O
in	O
this	O
universe	O
.	O

The	O
estimated	O
relative	O
for	O
carriers	O
may	O
justify	O
specific	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
allele	O
and	O
genetic	O
testing	O
the	O
setting	O
of	O
long	O
-	O
term	O
outcome	O
studies	O
significantly	O
colorectal	B
cancer	I
prevention	O
in	O
.	O

risk	O
for	O
carriers	O
may	O
justify	O
clinical	O
screening	O
,	O
expected	O
to	O
allele	O
genetic	O
testing	O
in	O
the	O
of	O
long	O
-	O
outcome	O
may	O
impact	O
cancer	I
in	O
this	O
population	O

The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
cancer	O
the	O
crab	O
bar	O
indium	O
cancer	O
the	O
crab	O
universe	O
indium	O
cancer	O
the	O
crab	O
universe	O
indium	O
american	O
universe	O
american	O
american	B
impingement	I
may	O
impact	O
significantly	O
on	O
colorectal	O

outcome	O
genetic	O
relative	O
risk	O
Americans	O
carriers	O
this	O
-	O
specific	O
clinical	O
screening	O
for	O
the	O
may	O
impact	O
000	O
for	O
.	O
to	O
harbor	O
360	O
allele	O
,	O
and	O
the	O
testing	O
in	O
cancer	O
this	O
of	O
setting	O
estimated	O
term	O
-	O
significantly	O
studies	O
may	O
,	O
The	O
on	O
colorectal	B
justify	I
prevention	O
in	O
long	O
population	O
expected	O

The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
cancer	O
the	O
crab	O
bar	O
indium	O
cancer	O
the	O
crab	O
universe	O
indium	O
cancer	O
the	O
crab	O
universe	O
indium	O
american	O
universe	O
american	O
american	B
american	I
may	O
impact	O
significantly	O
on	O
colorectal	O

The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	B
cancer	I
prevention	O
in	O
this	O
population	O
.	O

grade	O
of	O
human	O
in	O
and	O
its	O
loss	O
BRCA1	O
inherited	O
-	O
-	O
,	O
Localization	B
non	I
high	I
breast	I
carcinomas	I
.	O

localisation	O
of	O
human	O
BRCA1	O
and	O
its	O
exit	O
in	O
high	O
-	O
grade	O
,	O
not	B
-	I
transmitted	I
bosom	I
carcinomas	I
.	O

locating	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
form	O
,	O
not	B
-	I
genetic	I
bosom	I
carcinomas	I
.	O

Localization	O
of	O
human	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B
-	I
inherited	I
breast	I
carcinomas	I
.	O

localization	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
luxuriously	O
-	O
rank	O
,	O
not	B
-	I
inherited	I
breast	I
carcinomas	I
.	O

Localization	O
of	O
homo	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B
-	I
inherited	I
breast	I
carcinomas	I
human	O
human	O
human	O
indium	O
.	O

Localization	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
,	O
non	B
inherited	I
breast	I
carcinomas	I
.	O

Localization	O
of	O
homo	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B
-	I
inherited	I
breast	I
carcinomas	I
human	O
human	O
human	O
indium	O
.	O

of	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B
.	O

Localization	O
of	O
high	O
inherited	O
and	O
its	O
non	O
in	O
human	O
-	O
grade	O
,	O
loss	B
-	I
BRCA1	I
breast	I
carcinomas	I
.	O

Localization	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B
-	I
inherited	I
breast	I
carcinomas	I
.	O

link	O
BRCA1	O
tumour	B
-	O
suppressor	O
and	O
hereditary	B
ovarian	I
cancer	I
established	O
,	O
if	O
,	O
of	O
BRCA1	O
non	B
-	I
familial	I
is	O
unclear	O
.	O

Although	O
the	O
link	O
between	O
cancer	O
the	O
crab	O
suppresser	O
the	B
BRCA1	O
tumour	O
-	O
suppressor	O
gene	B
and	I
hereditary	I
breast	I
and	I
ovarian	O
cancer	O
is	O
established	O
,	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
BRCA1	B
in	I
non	I
-	I
familial	O
cancers	O
is	O
unclear	O
not	O
not	O
not	O
not	O
not	O
not	O
not	O

,	O
,	O
link	O
between	O
the	O
BRCA1	O
BRCA1	B
-	O
suppressor	O
gene	O
and	O
hereditary	B
breast	I
in	I
-	I
cancer	I
is	O
established	O
unclear	O
the	O
role	O
,	O
cancers	O
any	O
Although	O
of	O
tumour	O
and	O
ovarian	B
if	I
familial	I
non	I
is	O
.	O
the	O

Although	O
the	O
link	O
between	O
the	O
BRCA1	O
tumor	B
-	O
suppressor	O
factor	O
and	O
ancestral	B
breast	I
and	I
ovarian	I
cancer	I
is	O
show	O
,	O
the	O
use	O
,	O
if	O
any	O
,	O
of	O
BRCA1	O
in	O
not	B
-	I
ancestral	I
cancers	I
is	O
indecipherable	O
.	O

Although	O
the	O
of	O
between	O
the	O
BRCA1	O
tumour	B
,	O
suppressor	O
gene	O
and	O
any	B
in	I
and	I
ovarian	I
familial	I
is	O
established	O
the	O
hereditary	O
role	O
-	O
if	O
,	O
,	O
BRCA1	O
link	O
is	O
non	B
-	I
cancer	I
breast	I
cancers	O
unclear	O
.	O

Although	O
the	O
link	O
between	O
the	O
BRCA1	O
tumour	B
-	O
suppressor	O
gene	O
breast	I
and	I
ovarian	I
cancer	I
established	O
,	O
the	O
role	O
,	O
any	O
,	O
of	O
BRCA1	O
non	B
-	I
cancers	I
is	O
unclear	O
.	O

Although	O
the	O
nexus	O
between	O
the	O
BRCA1	O
neoplasm	B
-	O
suppressor	O
cistron	O
and	O
transmissible	B
front	I
and	I
ovarian	I
crab	I
is	O
established	O
,	O
the	O
character	O
,	O
if	O
any	O
,	O
of	O
BRCA1	O
in	O
not	B
-	I
genetic	I
cancers	I
is	O
indecipherable	O
.	O

Although	O
the	O
link	O
between	O
cancer	O
the	O
crab	O
cost	O
the	B
BRCA1	O
tumour	O
-	O
suppressor	O
gene	B
and	I
hereditary	I
breast	I
and	I
ovarian	O
cancer	O
is	O
established	O
,	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
BRCA1	B
in	I
non	I
-	I
familial	O
cancers	O
is	O
unclear	O
not	O
not	O
not	O
not	O
not	O
not	O
not	O

Although	O
the	O
join	O
between	O
the	O
BRCA1	O
tumor	B
-	O
suppressor	O
factor	O
and	O
transmitted	B
tit	I
and	I
ovarian	I
cancer	I
is	O
build	O
,	O
the	O
use	O
,	O
if	O
any	O
,	O
of	O
BRCA1	O
in	O
not	B
-	I
transmitted	I
cancers	I
is	O
unreadable	O
.	O

in	O
role	O
link	O
between	O
is	O
BRCA1	O
ovarian	B
cancers	O
suppressor	O
gene	O
and	O
hereditary	B
breast	I
,	I
-	I
cancer	I
the	O
familial	O
,	O
the	O
and	O
,	O
if	O
any	O
the	O
of	O
BRCA1	O
Although	O
established	B
-	I
non	I
tumour	I
is	O
unclear	O
.	O

Although	O
the	O
link	O
between	O
the	O
BRCA1	O
tumour	B
-	O
suppressor	O
gene	O
and	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
is	O
established	O
,	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
BRCA1	O
in	O
non	B
-	I
familial	I
cancers	I
is	O
unclear	O
.	O

BRCA1	O
mutations	O
in	O
rare	O
in	O
BRCA1	B
cancers	I
postulated	O
but	O
loss	O
of	O
be	O
-	O
from	O
reduced	O
and	O
or	O
incorrect	O
localization	O
subcellular	O
is	O
,	O
to	O
sporadic	O
important	O
non	O
are	B
cancers	I
familial	I
breast	I
expression	I
resulting	I
ovarian	I
.	O

BRCA1	O
rare	O
in	O
sporadic	B
cancers	I
but	O
loss	O
resulting	O
from	O
expression	O
or	O
is	O
to	O
be	O
important	O
non	B
-	I
familial	I
and	I
ovarian	I
cancers	I
.	O

BRCA1	O
mutations	O
are	O
rare	O
melt	O
off	O
reflexion	O
summit	O
in	B
sporadic	I
cancers	O
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	B
non	I
-	I
familial	I
breast	I
and	I
ovarian	I
cancers	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O

BRCA1	O
mutations	O
are	O
rare	O
melt	O
off	O
reflexion	O
indium	O
in	B
sporadic	I
cancers	O
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	B
non	I
-	I
familial	I
breast	I
and	I
ovarian	I
cancers	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O

mutations	O
subcellular	O
are	O
rare	O
in	O
sporadic	B
non	I
,	O
but	O
loss	O
of	O
-	O
resulting	O
important	O
breast	O
expression	O
or	O
incorrect	O
BRCA1	O
localization	O
is	O
postulated	O
.	O
be	O
from	O
in	O
cancers	B
BRCA1	I
ovarian	I
to	I
and	I
familial	I
cancers	I
reduced	O

BRCA1	O
mutations	O
are	O
rare	O
in	O
sporadic	B
but	O
loss	O
of	O
BRCA1	O
from	O
reduced	O
expression	O
or	O
incorrect	O
localization	O
is	O
postulated	O
to	O
important	O
in	O
-	I
familial	I
breast	I
and	I
ovarian	I
cancers	I
.	O

BRCA1	O
variation	O
are	O
uncommon	O
in	O
sporadic	B
cancers	I
,	O
but	O
red	O
of	O
BRCA1	O
resulting	O
from	O
shrink	O
expression	O
or	O
wrong	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
significant	O
in	O
not	B
-	I
genetic	I
boob	I
and	I
ovarian	I
cancers	I
.	O

BRCA1	O
mutations	O
are	O
uncommon	O
in	O
sporadic	B
cancers	I
,	O
but	O
deprivation	O
of	O
BRCA1	O
lead	O
from	O
trim	O
locution	O
or	O
wrong	O
subcellular	O
localization	O
is	O
necessitate	O
to	O
be	O
important	O
in	O
not	B
-	I
inherited	I
front	I
and	I
ovarian	I
cancers	I
.	O

BRCA1	O
mutations	O
are	O
rare	O
melt	O
off	O
reflexion	O
indium	O
in	B
sporadic	I
cancers	O
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	B
non	I
-	I
familial	I
breast	I
and	I
ovarian	I
cancers	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O
indium	O

BRCA1	O
sport	O
are	O
rare	O
in	O
sporadic	B
cancers	I
,	O
but	O
red	O
of	O
BRCA1	O
resulting	O
from	O
slim	O
manifestation	O
or	O
faulty	O
subcellular	O
localization	O
is	O
require	O
to	O
be	O
crucial	O
in	O
not	B
-	I
hereditary	I
boob	I
and	I
ovarian	I
cancers	I
.	O

BRCA1	O
mutations	O
are	O
rare	O
in	O
sporadic	B
cancers	I
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	O
non	B
-	I
familial	I
breast	I
and	I
ovarian	I
cancers	I
.	O

Epigenetic	O
loss	O
,	O
however	O
,	O
has	O
not	O
received	O
general	O
acceptance	O
due	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins	O
,	O
reports	O
of	O
which	O
have	O
ranged	O
from	O
exclusively	O
nuclear	O
,	O
to	O
conditionally	O
nuclear	O
,	O
to	O
the	O
cytoplasmatic	O
intussusception	O
location	O
cytoplasmatic	O
lens	O
nucleus	O
location	O
cytoplasmatic	O
lens	O
nucleus	O
location	O
location	O
lens	O
nucleus	O
location	O
location	O
location	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmic	O
invaginations	O
into	O

Epigenetic	O
expiration	O
,	O
nonetheless	O
,	O
has	O
not	O
experience	O
general	O
espousal	O
ascribable	O
to	O
argument	O
reckon	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins	O
,	O
reports	O
of	O
which	O
have	O
straddle	O
from	O
solely	O
atomic	O
,	O
to	O
conditionally	O
atomic	O
,	O
to	O
the	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmatic	O
infolding	O
into	O
the	O
nucleus	O
.	O

Epigenetic	O
loss	O
conditionally	O
however	O
,	O
the	O
not	O
received	O
general	O
acceptance	O
due	O
controversy	O
invaginations	O
regarding	O
the	O
to	O
localization	O
of	O
proteins	O
BRCA1	O
,	O
.	O
of	O
has	O
have	O
from	O
exclusively	O
nucleus	O
nuclear	O
,	O
subcellular	O
/	O
ranged	O
,	O
to	O
which	O
ER	O
,	O
golgi	O
,	O
to	O
cytoplasmic	O
to	O
the	O
into	O
nuclear	O
reports	O

Epigenetic	O
from	O
,	O
however	O
,	O
has	O
to	O
,	O
general	O
acceptance	O
due	O
not	O
controversy	O
exclusively	O
have	O
subcellular	O
localization	O
of	O
received	O
proteins	O
,	O
reports	O
the	O
which	O
into	O
ranged	O
.	O
regarding	O
conditionally	O
BRCA1	O
to	O
nuclear	O
nuclear	O
the	O
to	O
cytoplasmic	O
ER	O
/	O
golgi	O
,	O
loss	O
,	O
invaginations	O
of	O
the	O
nucleus	O
to	O

Epigenetic	O
loss	O
,	O
nonetheless	O
,	O
has	O
not	O
welcome	O
general	O
acceptation	O
ascribable	O
to	O
contention	O
regarding	O
the	O
subcellular	O
location	O
of	O
BRCA1	O
proteins	O
,	O
story	O
of	O
which	O
have	O
stray	O
from	O
alone	O
atomic	O
,	O
to	O
conditionally	O
atomic	O
,	O
to	O
the	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmatic	O
infolding	O
into	O
the	O
nucleus	O
.	O

Epigenetic	O
loss	O
,	O
,	O
has	O
not	O
received	O
general	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
reports	O
which	O
have	O
ranged	O
exclusively	O
nuclear	O
,	O
to	O
conditionally	O
nuclear	O
to	O
the	O
golgi	O
to	O
cytoplasmic	O
invaginations	O
into	O
.	O

however	O
,	O
has	O
not	O
received	O
acceptance	O
due	O
the	O
of	O
BRCA1	O
reports	O
have	O
ranged	O
from	O
exclusively	O
,	O
to	O
,	O
to	O
ER	O
/	O
cytoplasmic	O
into	O
the	O
nucleus	O

Epigenetic	O
loss	O
,	O
however	O
,	O
has	O
not	O
received	O
general	O
acceptance	O
due	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins	O
,	O
reports	O
of	O
which	O
have	O
ranged	O
from	O
exclusively	O
nuclear	O
,	O
to	O
conditionally	O
nuclear	O
,	O
to	O
the	O
cytoplasmatic	O
intussusception	O
location	O
cytoplasmatic	O
lens	O
nucleus	O
location	O
cytoplasmatic	O
lens	O
nucleus	O
location	O
location	O
lens	O
nucleus	O
location	O
location	O
location	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmic	O
invaginations	O
into	O

to	O
have	O
,	O
however	O
localization	O
has	O
,	O
conditionally	O
general	O
acceptance	O
due	O
to	O
controversy	O
not	O
/	O
subcellular	O
,	O
.	O
BRCA1	O
proteins	O
regarding	O
reports	O
of	O
which	O
exclusively	O
ranged	O
from	O
cytoplasmic	O
the	O
,	O
nuclear	O
loss	O
nuclear	O
,	O
golgi	O
the	O
ER	O
the	O
Epigenetic	O
,	O
to	O
received	O
invaginations	O
into	O
to	O
nucleus	O
of	O

Epigenetic	O
loss	O
,	O
however	O
,	O
has	O
not	O
received	O
general	O
acceptance	O
due	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins	O
,	O
reports	O
of	O
which	O
have	O
ranged	O
from	O
exclusively	O
nuclear	O
,	O
to	O
conditionally	O
nuclear	O
,	O
to	O
the	O
cytoplasmatic	O
intussusception	O
location	O
cytoplasmatic	O
lens	O
nucleus	O
location	O
cytoplasmatic	O
lens	O
nucleus	O
location	O
location	O
lens	O
nucleus	O
location	O
location	O
location	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmic	O
invaginations	O
into	O

Epigenetic	O
loss	O
,	O
however	O
,	O
has	O
not	O
received	O
general	O
acceptance	O
due	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins	O
,	O
reports	O
of	O
which	O
have	O
ranged	O
from	O
exclusively	O
nuclear	O
,	O
to	O
conditionally	O
nuclear	O
,	O
to	O
the	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmic	O
invaginations	O
into	O
the	O
nucleus	O
.	O

comprehensively	O
an	O
attempt	O
,	O
resolve	O
this	O
issue	O
to	O
-	O
have	O
anti	O
characterized	O
In	O
19	O
we	O
BRCA1	O
antibodies	O
.	O

In	O
an	O
attempt	O
to	O
resolution	O
this	O
egress	O
,	O
we	O
have	O
comprehensively	O
qualify	O
nineteen	O
anti	O
-	O
BRCA1	O
antibody	O
.	O

in	O
an	O
attempt	O
to	O
dissolve	O
this	O
progeny	O
,	O
we	O
have	O
comprehensively	O
characterized	O
nineteen	O
anti	O
-	O
BRCA1	O
antibody	O
.	O

In	O
an	O
attempt	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
anti	O
-	O
BRCA1	O
antibodies	O
.	O

inward	O
an	O
seek	O
to	O
conclude	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterise	O
19	O
anti	O
-	O
BRCA1	O
antibody	O
.	O

In	O
an	O
endeavor	O
attempt	O
to	O
resolve	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
anti	O
-	O
BRCA1	O
antibodies	O
attempt	O
attempt	O
attempt	O
endeavor	O
.	O

In	O
an	O
attempt	O
to	O
resolve	O
this	O
issue	O
,	O
we	O
have	O
characterized	O
19	O
-	O
BRCA1	O
antibodies	O
.	O

In	O
an	O
endeavor	O
attempt	O
to	O
resolve	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
anti	O
-	O
BRCA1	O
antibodies	O
attempt	O
attempt	O
attempt	O
endeavor	O
.	O

an	O
resolve	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
.	O

In	O
an	O
we	O
-	O
resolve	O
this	O
19	O
,	O
attempt	O
have	O
comprehensively	O
characterized	O
issue	O
anti	O
to	O
BRCA1	O
antibodies	O
.	O

In	O
an	O
attempt	O
to	O
resolve	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
anti	O
-	O
BRCA1	O
antibodies	O
.	O

reagents	O
detect	O
a	O
220	O
-	O
kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
lines	O
including	O
those	O
derived	O
from	O
breast	B
malignancies	I
.	O

discrete	O
reagents	O
detect	O
,	O
220	O
-	O
kD	O
.	O
breast	O
in	O
malignancies	O
nuclear	O
foci	O
including	O
from	O
epithelial	O
cell	O
lines	O
a	O
in	O
those	O
derived	O
all	O
localized	B
These	I
protein	O

These	O
reagents	O
find	O
a	O
220	O
-	O
kD	O
protein	O
localise	O
in	O
distinct	O
atomic	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
deduct	O
from	O
boob	B
malignancy	I
.	O

These	O
reagents	O
find	O
a	O
220	O
-	O
kD	O
protein	O
place	O
in	O
distinct	O
atomic	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
include	O
those	O
derived	O
from	O
summit	B
malignancy	I
.	O

These	O
reagents	O
detect	O
a	O
220	O
-	O
kD	O
protein	O
localized	O
in	O
nuclear	O
foci	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
breast	B
malignancies	I
.	O

These	O
reagents	O
detect	O
a	O
cubicle	O
220	O
-	O
kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
let	O
in	O
summit	O
malignance	O
summit	O
malignance	O
place	O
,	O
including	O
those	O
derived	O
from	B
breast	I
malignancies	O

These	O
reagents	O
detect	O
a	O
cubicle	O
220	O
-	O
kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
let	O
in	O
summit	O
malignance	O
summit	O
malignance	O
deduct	O
,	O
including	O
those	O
derived	O
from	B
breast	I
malignancies	O

These	O
reagents	O
detect	O
a	O
220	O
-	O
kD	O
protein	O
localized	O
in	O
nuclear	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
derived	O
from	O

breast	O
reagents	O
detect	O
a	O
220	O
-	O
in	O
cell	O
localized	O
in	O
discrete	O
nuclear	O
derived	O
kD	O
malignancies	O
epithelial	O
protein	O
those	O
,	O
including	O
These	O
foci	O
from	O
lines	B
all	I
.	O

These	O
reagents	O
notice	O
a	O
220	O
-	O
kD	O
protein	O
set	O
in	O
distinct	O
atomic	O
stress	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
descend	O
from	O
breast	B
malignity	I
.	O

These	O
reagents	O
detect	O
a	O
220	O
-	O
kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
derived	O
from	O
breast	B
malignancies	I
.	O

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B
lobular	I
cancers	I
order	I
humiliated	O
carcinoma	I
order	O
carcinoma	I
carcinoma	O
invading	I
and	O
low	B
-	I
grade	I
ductal	I
carcinomas	I
.	O

human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B
lobular	I
cancers	I
low	B
grade	I
ductal	I
carcinomas	I
.	O

Immunohistochemical	O
tarnish	O
of	O
human	O
titty	O
specimens	O
besides	O
break	O
BRCA1	O
atomic	O
foci	O
in	O
benign	O
titty	O
,	O
trespassing	B
lobular	I
crab	I
and	O
low	B
-	I
grade	I
ductal	I
carcinomas	I
.	O

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
in	O
benign	O
,	O
invasive	B
lobular	I
cancers	I
and	O
low	B
-	I
carcinomas	I
.	O

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B
lobular	I
cancers	I
order	I
humiliated	O
carcinoma	I
order	O
carcinoma	I
carcinoma	O
homo	I
and	O
low	B
-	I
grade	I
ductal	I
carcinomas	I
.	O

Immunohistochemical	O
maculation	O
of	O
human	O
breast	O
specimens	O
likewise	O
break	O
BRCA1	O
atomic	O
focus	O
in	O
benign	O
breast	O
,	O
invasive	B
lobular	I
cancers	I
and	O
miserable	B
-	I
place	I
ductal	I
carcinomas	I
.	O

Immunohistochemical	O
defile	O
of	O
human	O
boob	O
specimens	O
besides	O
unwrap	O
BRCA1	O
atomic	O
focusing	O
in	O
benign	O
boob	O
,	O
invasive	B
lobular	I
cancers	I
and	O
low	B
-	I
rank	I
ductal	I
carcinomas	I
.	O

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
benign	O
invasive	B
lobular	I
cancers	I
and	O
low	B
-	I
grade	I
ductal	I
carcinomas	I

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B
lobular	I
cancers	I
order	I
humiliated	O
carcinoma	I
order	O
carcinoma	I
carcinoma	O
homo	I
and	O
low	B
-	I
grade	I
ductal	I
carcinomas	I
.	O

low	O
staining	O
of	O
foci	O
breast	O
specimens	O
also	O
and	O
carcinomas	O
nuclear	O
human	O
in	O
breast	O
benign	O
ductal	O
invasive	B
lobular	I
cancers	I
revealed	O
.	B
-	I
grade	I
,	I
BRCA1	I
Immunohistochemical	O

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B
lobular	I
cancers	I
and	O
low	B
-	I
grade	I
ductal	I
carcinomas	I
.	O

,	O
BRCA1	O
expression	O
or	O
undetectable	O
in	O
the	O
majority	O
high	O
grade	O
,	O
ductal	B
carcinomas	I
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
breast	I
.	O

Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	B
carcinomas	I
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B
breast	I
cost	O
cost	I
cost	O
cost	I
cost	O
cost	I
cost	O
cost	I
cost	O
cost	I
cost	O
cancers	I
.	O
.	O

a	O
that	O
BRCA1	O
expression	O
ductal	O
reduced	O
.	O
significant	O
in	O
the	O
majority	O
of	O
high	O
may	O
carcinomas	O
,	O
was	B
grade	I
,	O
suggesting	O
-	O
absence	O
of	O
BRCA1	O
,	O
contribute	O
to	O
.	O
Conversely	O
of	O
pathogenesis	O
or	O
percentage	O
of	O
sporadic	B
breast	I
cancers	I
undetectable	O
the	O

Conversely	O
,	O
BRCA1	O
was	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B
cancers	I
.	O

conversely	O
,	O
BRCA1	O
formula	O
was	O
thin	O
or	O
insensible	O
in	O
the	O
majority	O
of	O
heights	O
-	O
tier	O
,	O
ductal	B
carcinomas	I
,	O
propose	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
pregnant	O
pct	O
of	O
sporadic	B
boob	I
cancers	I
.	O
.	O

may	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
of	O
undetectable	O
in	O
the	O
majority	O
or	O
high	O
the	O
of	O
,	O
ductal	B
carcinomas	I
of	O
suggesting	O
that	O
absence	O
pathogenesis	O
BRCA1	O
Conversely	O
contribute	O
significant	O
-	O
grade	O
of	O
a	O
breast	O
percentage	O
sporadic	O
,	B
to	I
cancers	I
.	O
.	O

Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	B
carcinomas	I
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B
breast	I
cost	O
cost	I
cost	O
cost	I
cost	O
cost	I
cost	O
cost	I
cost	O
cost	I
cost	O
cancers	I
.	O
.	O

Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	B
carcinomas	I
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B
breast	I
cost	O
cost	I
cost	O
cost	I
cost	O
cost	I
cost	O
cost	I
cost	O
cost	I
important	O
cancers	I
.	O
.	O

Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
carcinomas	I
,	O
suggesting	O
absence	O
BRCA1	O
may	O
contribute	O
pathogenesis	O
of	O
sporadic	B
breast	I
.	O
.	O

Conversely	O
,	O
a	O
expression	O
was	O
reduced	O
or	O
,	O
in	O
the	O
majority	O
to	O
suggesting	O
-	O
grade	O
undetectable	O
ductal	B
carcinomas	I
.	O
high	O
that	O
percentage	O
of	O
breast	O
may	O
,	O
of	O
absence	O
pathogenesis	O
of	O
BRCA1	O
the	O
significant	O
of	O
sporadic	B
BRCA1	I
cancers	I
contribute	O
.	O

Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	B
carcinomas	I
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B
breast	I
cancers	I
.	O
.	O

